0001370368-18-000005.txt : 20180124 0001370368-18-000005.hdr.sgml : 20180124 20180124085059 ACCESSION NUMBER: 0001370368-18-000005 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 256 CONFORMED PERIOD OF REPORT: 20171231 FILED AS OF DATE: 20180124 DATE AS OF CHANGE: 20180124 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NOVARTIS AG CENTRAL INDEX KEY: 0001114448 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-15024 FILM NUMBER: 18544088 BUSINESS ADDRESS: STREET 1: LICHTSTRASSE 35 CITY: BASEL STATE: V8 ZIP: CH 4056 BUSINESS PHONE: 01141613241111 MAIL ADDRESS: STREET 1: LICHTSTRASSE 35 CITY: BASEL STATE: V8 ZIP: CH 4056 6-K 1 a180124-6k.htm 6-K 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
Form 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
 
Report on Form 6-K dated January 24, 2018
(Commission File No. 1-15024)
 
Novartis AG
(Name of Registrant)
 
Lichtstrasse 35
4056 Basel
Switzerland
(Address of Principal Executive Offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
   Form 20-F   x   Form 40-F   o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
   Yes   o   No   x
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):
   Yes   o   No   x
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
   Yes   o   No   x
Exhibits:
101.INS XBRL Instance Document
101.SCH XBRL Taxonomy Extension Schema Document
101.CAL XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF XBRL Taxonomy Extension Definition Linkbase Document
101.LAB XBRL Taxonomy Extension Label Linkbase Document
101.PRE XBRL Taxonomy Extension Presentation Linkbase Document
SIGNATURES
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
Date: January 24, 2018
 
Novartis AG
 
By: /s/ HARRY KIRSCH
Name: Harry Kirsch
Title: Chief Financial Officer, Novartis Group
 
By: /s/ FELIX R. EHRAT
Name: Felix R. Ehrat
Title: General Counsel, Novartis Group
EX-99 2 a180124-99_1.htm 99.1 EXCERPTS FROM NOVARTIS ANNUAL REPORT 2017 99.1 Excerpts from Novartis Annual Report 2017


Corporate governance


Contents

Letter from the Chairman


Dear shareholder,
2017 was an important and successful year for our company and our Board. We made good progress in pursuing our mission, managed the selection of the new CEO, reinforced the Board’s membership, increased our strategic focus on digital technology, accelerated our corporate culture change, and further improved our corporate governance.
Progress in pursuing our mission
At a time of big geopolitical uncertainties and increasing regulatory, pricing and enforcement pressure, we achieved a solid business performance, launched important new products, and made further efficiency gains.
Strong and diverse Board
We have a strong, diverse and independent Board. A key to our achievements is the excellent collaboration between our Board and our CEO and his Executive Committee.
The diversity of our Board was further strengthened when Ton Buechner and Liz Doherty joined in February 2016, and Frans van Houten in February 2017, reinforcing our expertise in finance and accounting, in digital health solutions, as well as in leadership and management. With their arrival, we have substantially refreshed our Board. Two-thirds of our members have a tenure of less than six years, balancing the benefits of continuity and experience with new perspectives.
We appointed new members of the Audit and Compliance Committee; the Risk Committee; and the Governance, Nomination and Corporate Responsibilities Committee, benefiting from the experience and knowledge of new Board members.
At the 2018 Annual General Meeting (AGM), Pierre Landolt will leave our Board, having reached the statutory retirement age of 70. I would like to thank Pierre for his many contributions over the years, including his chairmanship of the Governance, Nomination and Corporate Responsibilities Committee. During his chairmanship, the committee extended its mandate to also cover corporate responsibility, and Pierre was instrumental in driving the Novartis corporate responsibility strategy as well as the Board’s oversight of the many corporate responsibility programs at Novartis.
At the end of 2017, we initiated a performance and effectiveness evaluation of the Board’s work by an independent expert. The outcome is encouraging. We have made significant progress over the last few years in our efforts to continuously improve our performance.
82
CEO succession
One of the most important tasks of a Board is selecting the right CEO. After Joe Jimenez informed us that he was considering stepping down, we conducted a thorough evaluation of internal and external candidates with the help of an executive search firm, building on our CEO succession plan. We concluded that Vas Narasimhan is the right choice to build on Joe’s heritage and lead Novartis in our next growth phase. It is a phase that we expect will be characterized by new technologies that transform science, our business, and our interactions with people and societies. Vas will take the helm from Joe on February 1, 2018, completing a smooth transition facilitated by the strong leadership team that Joe built. I sincerely thank Joe for his dedication to our company and for his achievements, which span a period of 10 years.
Strategy and culture
Other key areas for our Board are the strategy and culture of Novartis. During our strategy retreat in August, one of the conclusions was that we should strengthen our strategic focus on digital technologies to improve how we use data in drug discovery and development; how we engage with patients, doctors and other stakeholders; and how we automate business processes. Our Chief Digital Officer, a newly created role, will lead the companywide implementation of our digital strategy.
In 2017, we also accelerated our corporate culture change. The Executive Committee took action to further improve collaboration, reduce bureaucracy, speed up decision-making, support smart risk-taking, increase empowerment and trust throughout the organization, and reinforce our interactions with the external world and society at large.
Auditor rotation
In 2017, we discussed the question of changing our long-standing auditor. While the Board is open to a change in the foreseeable future, we concluded that it is in the best interest of Novartis, our investors and other stakeholders to continue with our current auditor. We will, of course, continue with the yearly assessments of PricewaterhouseCoopers’ effectiveness and independence, and with the regular rotation of the audit partner in charge. The matter remains high on our agenda and will be continuously reassessed.
Shareholder engagement
Let me end by addressing our engagement with you, our shareholders. As you know, shareholder engagement is an important aspect of our corporate governance framework. Although I believe our engagement program has in many instances aligned the views of the Board with those of our shareholders, we recognize that a significant number of you did not support at our 2017 AGM the advisory vote on the 2016 Compensation Report. As a result, we have intensified our engagement with you and we are confident that we can further align our views. I encourage you to actively participate and share your perspectives.
While we achieved quite a lot in 2017, I believe there is more work to be done. Our Board and our Executive Committee must continue to sharpen our strategy, strengthen our corporate culture, and accelerate the evolution of our business model. I am very confident that with your support, we will continue to make progress.
Joerg Reinhardt
Chairman of the Board of Directors
83

Our corporate governance approach

Governance bodies General Meeting of ShareholdersApproves operating and financial review, Novartis Group consolidated financial statements and financial statements of Novartis AG; decides appropriation of available earnings and dividend; approves compensation of Board and Executive Committee; elects Board members, Chairman, Compensation Committee members, Independent Proxy and external auditors; adopts and modifies Articles of IncorporationExternal auditorProvides opinion on compliance of Novartis Group consolidated financial statements and the financial statements of Novartis AG with applicable standards and Swiss law, on compliance of the Compensation Report with applicable law, on effectiveness of internal control over financial reporting, and on the corporate responsibility reporting of NovartisBoard of DirectorsAudit and Compliance CommitteeCompensation CommitteeGovernance, Nomi­nation and Corporate Responsibilities CommitteeResearch & Development CommitteeRisk CommitteeSets strategic direction of Novartis, appoints and oversees key executives, approves major transactions and investmentsExecutive CommitteeResponsible for operational management of Novartis
Leadership structure
Independent, non-executive Chairman and separate CEO
Board governance
Structure
All Board members are non-executive and independent, as defined by our rules. The Board has assigned responsibilities to five committees:
• Audit and Compliance Committee
• Compensation Committee
• Governance, Nomination and Corporate Responsibilities Committee
• Research & Development Committee
• Risk Committee
Composition
Board members have diverse education, experience, nationalities and interpersonal skills. Their biographies (beginning on page 102) describe their specific qualifications.
Processes
The Board’s processes significantly influence its effectiveness. The Board has implemented best practices for all such processes. Important elements include Board meeting agendas (to address all important topics), information submitted to the Board (to ensure the Board receives sufficient information from management to perform its supervisory duty and to make decisions that are reserved for it), and boardroom behavior (to promote an efficient and balanced decision-making process).
Board and Executive Committee compensation
Information on Board and Executive Committee compensation is outlined in our Compensation Report, beginning on page 118.
84

Our shares and our shareholders

Our shares
Share capital of Novartis AG
As of December 31, 2017, the share capital of Novartis AG is CHF 1 308 422 410 fully paid-in and divided into 2 616 844 820 registered shares, each with a nominal value of CHF 0.50 (Novartis share). Novartis AG has neither authorized nor conditional capital. There are no preferential voting shares; all Novartis shares have equal voting rights. No participation certificates, non-voting equity securities (Genussscheine), or profit-sharing certificates have been issued.
Novartis shares are listed on the SIX Swiss Exchange (ISIN CH0012005267, symbol: NOVN) and on the New York Stock Exchange (NYSE) in the form of American depositary receipts (ADRs) representing Novartis American depositary shares (ADSs) (ISIN US66987V1098, symbol: NVS).
The holder of an ADR has the rights enumerated in the deposit agreement (such as the right to give voting instructions and to receive dividends). The ADS depositary of Novartis AG – JPMorgan Chase Bank, N.A., New York – holds the Novartis shares underlying the ADRs and is registered as a shareholder in the Novartis Share Register. An ADR is not a Novartis share and an ADR holder is not a Novartis AG shareholder. ADR holders exercise their voting rights by instructing the depositary to exercise their voting rights. Each ADR represents one Novartis share.
Changes in share capital
During the last three years, the following changes were made to the share capital of Novartis AG:
In 2015, Novartis AG reduced its share capital by CHF 14.6 million (from CHF 1 353 096 500 to CHF 1 338 496 500) by canceling 29.2 million Novartis shares repurchased on the second trading line during 2013 and 2014. In 2016, Novartis AG reduced its share capital by CHF 24.9 million (from CHF 1 338 496 500 to CHF 1 313 557 410) by canceling 49.9 million Novartis shares repurchased on the second trading line during 2015. In 2017, Novartis AG reduced its share capital by CHF 5.1 million (from CHF 1 313 557 410 to CHF 1 308 422 410) by canceling 10.3 million Novartis shares repurchased on the second trading line during 2016.
Capital changes
Number of shares

Year

As of Jan 1
Changes
in shares

As of Dec 31
Changes
in CHF
2015
2 706 193 000
– 29 200 000
2 676 993 000
– 14 600 000
2016
2 676 993 000
– 49 878 180
2 627 114 820
– 24 939 090
2017
2 627 114 820
– 10 270 000
2 616 844 820
– 5 135 000
A table with additional information on changes in the Novartis AG share capital can be found in Note 7 to the financial statements of Novartis AG.
Convertible or exchangeable securities
Novartis AG has not issued convertible or exchangeable bonds, warrants, options or other securities granting rights to Novartis shares, other than options (or similar instruments such as stock appreciation rights) granted under or in connection with equity-based participation plans of Novartis associates. Novartis AG does not grant any new stock options under these plans.
Share repurchase programs
In 2015, Novartis repurchased under the sixth share repurchase program 49 878 180 Novartis shares at an average price of CHF 93.24 per Novartis share, and canceled them in 2016. With those repurchases, the sixth share repurchase program was completed.
At the 2016 AGM, shareholders approved the seventh share repurchase program authorizing the Board to repurchase Novartis shares up to a maximum of CHF 10 billion. In 2016, a total of 10 270 000 Novartis shares were repurchased at an average price of CHF 74.67 per Novartis share, and canceled in 2017. In 2017, a total of 66 220 000 Novartis shares were repurchased at an average price of CHF 78.34 per Novartis share. The Board will propose the cancellation of the Novartis shares repurchased in 2017 to its shareholders at the AGM 2018.
85
Share developments
Share developments in 2017
• Swiss-listed Novartis shares increased 11.2% to CHF 82.40
• ADRs increased 15.3% to USD 83.96
Novartis shares finished at CHF 82.40, an increase of 11.2% from the 2016 year-end closing price of CHF 74.10. Novartis ADRs increased in 2017 by 15.3% to USD 83.96 from USD 72.84. The Swiss Market Index (SMI), in comparison, increased by 14.1% in 2017, whereas the world pharmaceutical index (MSCI) increased by 10.8% during the year. Total shareholder return for Novartis shares in 2017 was + 15.2% in CHF and + 20.4% in USD, including an increased dividend. Over a longer-term period, Novartis AG has consistently delivered a solid performance, providing a 9.2% compounded annual total shareholder return between January 1, 1996 and December 31, 2017, exceeding the 9.0% compounded returns of its large pharmaceutical peers, or the returns of 8.5% of the world pharmaceutical index (MSCI).
The market capitalization of Novartis AG based on the number of Novartis shares outstanding (excluding Novartis treasury shares) amounted to USD 195.5 billion as of December 31, 2017, compared to USD 172 billion as of December 31, 2016.
Continuously rising dividend since 1996
The Board proposes a 2% increase in the dividend payment for 2017 to CHF 2.80 per Novartis share (2016: CHF 2.75) for approval at the AGM on March 2, 2018. This represents the 21st consecutive increase in the dividend paid per share since the creation of Novartis AG in December 1996. If the 2017 dividend proposal is approved by shareholders, dividends to be paid out will total approximately USD 6.7 billion (2016: USD 6.5 billion). This will result in an expected payout ratio of 87% of net income attributable to shareholders of Novartis AG (2016: 97%). Based on the 2017 year-end share price of CHF 82.40, the dividend yield will be 3.4% (2016: 3.7%). The dividend payment date has been set for March 8, 2018.
Novartis 2017 share price movement(based on USD amounts)120115110105100 95Jan Feb Mar Apr May Jun Jul Aug Sept Oct Nov DecNovartisPeersMSCI World MarketsMSCI World PharmaSource: Bloomberg; data are converted into US dollars and re-based to 100 at January 1, 2017. Currency fluctuations have an influence on the representation of the relative performance of Novartis vs. indices and peers. Peers include Abbott, AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, GSK, J&J, Merck&Co, Pfizer, Roche, Sanofi.
Novartis 1996–2017 total shareholder return(based on USD amounts)800700600500400300200100  096 97 98 99 00 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17NovartisPeersMSCI World MarketsMSCI World PharmaSource: Datastream, Bloomberg; data are converted into US dollars and re-based to 100 at January 1, 1996. Currency fluctuations have an influence on the representation of the relative performance of Novartis vs. indices and peers. Peers include Abbott, AbbVie, Amgen, AstraZeneca, BMS, Eli Lilly, GSK, J&J, Merck&Co, Pfizer, Roche, Sanofi.
86
Key Novartis share data
2017
2016
2015
Issued shares
2 616 844 820
2 627 114 820
2 676 993 000
Treasury shares 1
299 388 321
253 055 807
303 098 183
Outstanding shares at December 31
2 317 456 499
2 374 059 013
2 373 894 817
Weighted average number of shares outstanding
2 345 783 843
2 378 474 555
2 402 806 352
 1  Approximately 131 million treasury shares (2016: 135 million; 2015: 137 million) are held in Novartis entities that restrict their availability for use.
Per-share information1
2017
2016
2015
Basic earnings per share (USD) from continuing operations
3.28
2.82
2.92
Basic earnings per share (USD) from discontinued operations
4.48
Total basic earnings per share (USD)
3.28
2.82
7.40
Diluted earnings per share (USD) from continuing operations
3.25
2.80
2.88
Diluted earnings per share (USD) from discontinued operations
4.41
Total diluted earnings per share
3.25
2.80
7.29
Operating cash flow (USD) from continuing operations
5.38
4.82
5.03
Year-end equity for Novartis AG shareholders (USD)
32.00
31.52
32.46
Dividend (CHF) 2
2.80
2.75
2.70
 1  Calculated on the weighted average number of shares outstanding, except year-end equity
 2  2017: proposal to shareholders for approval at the Annual General Meeting on March 2, 2018
Key ratios – December 31
2017
2016
2015
Price/earnings ratio 1
25.7
25.7
11.9
Price/earnings ratio from continuing operations 1
25.7
25.7
30.1
Enterprise value/EBITDA from continuing operations
15
13
16
Dividend yield (%) 1
3.4
3.7
3.1
 1  Based on the Novartis share price at December 31 of each year
Key data on ADRs issued in the US
2017
2016
2015
Year-end ADR price (USD)
83.96
72.84
86.04
High 1
86.65
86.21
106.12
Low 1
70.03
67.59
83.96
Number of ADRs outstanding 2
320 833 039
315 349 314
299 578 398
 1  Based on the daily closing prices
 2  The depositary, JPMorgan Chase Bank, N.A., holds one Novartis AG share for every ADR issued.
Share price (CHF)
2017
2016
2015
Year-end share price
82.40
74.10
86.80
High 1
85.15
86.45
102.30
Low 1
69.55
68.15
82.20
Year-end market capitalization (USD billions) 2
195.5
172.0
208.3
Year-end market capitalization (CHF billions) 2
191.0
175.9
206.1
 1  Based on the daily closing prices
 2  Market capitalization is calculated based on the number of shares outstanding (excluding treasury shares). Market capitalization in USD is based on the market capitalization in CHF converted at the year-end CHF/USD exchange rate.
87
Our shareholders
Significant shareholders
According to the Novartis Share Register, as of December 31, 2017, the following registered shareholders (including nominees and the ADS depositary) held more than 2% of the total share capital of Novartis AG, with the right to vote all their Novartis shares based on an exemption granted by the Board (see page 90):1
• Shareholders: Novartis Foundation for Employee Participation, with its registered office in Basel, holding 2.5%; Emasan AG, with its registered office in Basel, holding 3.4%; and UBS Fund Management (Switzerland) AG, with its registered office in Basel, holding 2.0%
• Nominees: Chase Nominees Ltd., London, holding 7.8%; Nortrust Nominees Ltd., London, holding 3.8%; and The Bank of New York Mellon, New York, holding 4.3% through its nominees, The Bank of New York Mellon, Everett, holding 2.0%, and The Bank of New York Mellon, SA/NV, Brussels, holding 2.3%
• ADS depositary: JPMorgan Chase Bank, N.A., New York, holding 12.3%
According to a disclosure notification filed with Novartis AG, Norges Bank (Central Bank of Norway), Oslo, held 2.1% of the share capital of Novartis AG but was not registered in the Novartis Share Register as of December 31, 2017.
According to a disclosure notification filed with Novartis AG and the SIX Swiss Exchange, BlackRock, Inc., New York, held between 3% and 5% of the share capital of Novartis AG but was registered with less than 2% of the share capital as of December 31, 2017 in the Novartis Share Register.
Disclosure notifications pertaining to shareholdings in Novartis AG that were filed with Novartis AG and the SIX Swiss Exchange are published on the latter’s electronic publication platform, and can be accessed via:
https://www.six-exchange-regulation.com/en/home/publications/significant-shareholders.html.
Cross shareholdings
Novartis AG has no cross shareholdings in excess of 5% of capital, or voting rights with any other company.
Distribution of Novartis shares
The information in the following tables relates only to registered shareholders and does not include holders of unregistered shares. Also, the information provided in the tables cannot be assumed to represent the entire Novartis AG investor base because nominees and JPMorgan Chase Bank, N.A., as ADS depositary, are registered as shareholders for a large number of beneficial owners.
As of December 31, 2017, Novartis AG had approximately 167 000 registered shareholders.
1 Excluding 6.4% of the share capital held as treasury shares by Novartis AG and its subsidiaries
Number of shares held

As of December 31, 2017
Number of
registered
shareholders

% of registered
share capital
1–100
24 970
0.06
101–1'000
101 722
1.62
1'001–10'000
36 938
3.93
10'001–100'000
3 244
3.21
100'001–1'000'000
463
5.25
1'000'001–5'000'000
72
5.58
5'000'001 or more 1
32
50.24
Total registered shareholders/shares
167 441
69.89
Unregistered shares
30.11
Total
100.00
 1  Including significant registered shareholders as listed above
Registered shareholders by type
As of December 31, 2017
Shareholders in %
Shares in %
Individual shareholders
96.31
13.36
Legal entities 1
3.63
35.25
Nominees, fiduciaries and ADS depositary
0.06
51.39
Total
100.00
100.00
 1  Excluding 6.4% of the share capital held as treasury shares by Novartis AG and its subsidiaries
Registered shareholders by country
As of December 31, 2017
Shareholders in %
Shares in %
Belgium
0.13
3.82
France
2.23
0.38
Germany
5.35
2.13
Japan
0.18
0.71
Switzerland 1
88.42
42.56
United Kingdom
0.49
22.22
United States
0.34
25.82
Other countries
2.86
2.36
Total
100.00
100.00
Registered shares held by nominees are shown in the country where the company/affiliate entered in the Novartis Share Register as shareholder has its registered seat.
 1  Excluding 6.4% of the share capital held as treasury shares by Novartis AG and its subsidiaries
88
Shareholder rights
Shareholders have the right to receive dividends, to vote and to execute all other rights as granted under Swiss law and the Articles of Incorporation (see in particular articles 17 and 18 of the Articles of Incorporation:
www.novartis.com/investors/company-overview/corporate-governance).
Right to vote
Each Novartis share registered with the right to vote entitles the holder to one vote at General Meetings of Shareholders (General Meetings). Novartis shares can only be voted if they are registered with voting rights in the Novartis Share Register by the third business day before the General Meeting (for shareholder registration and voting restrictions, see page 90).
ADR holders may vote by instructing JPMorgan Chase Bank, N.A., the ADS depositary, to exercise the voting rights attached to the registered Novartis shares underlying the ADRs. JPMorgan Chase Bank, N.A., exercises the voting rights for registered Novartis shares underlying ADRs for which no voting instructions have been given by providing a discretionary proxy to an uninstructed independent designee. Such designee has to be a Novartis AG shareholder.
Powers of General Meetings of Shareholders
The following powers are vested exclusively in the General Meeting:
• Adoption and amendment of the Articles of Incorporation
• Election and removal of the Chairman of the Board, Board and Compensation Committee members, the Independent Proxy and external auditors
• Approval of the management report (if required) and of the consolidated financial statements
• Approval of the financial statements of Novartis AG, and decision on the appropriation of available earnings shown on the balance sheet, including dividends
• Approval of the maximum aggregate amounts of compensation of the Board (for the period from an AGM until the next AGM) and of the Executive Committee (for the financial year following the AGM)
• Grant of discharge to Board and Executive Committee members
• Decision of other matters that are reserved by law or by the Articles of Incorporation (e.g. advisory vote on the compensation report) to the General Meeting of Shareholders
Resolutions and elections at General Meetings
The General Meeting passes resolutions and elections with the absolute majority of the votes represented at the meeting. However, under article 18 of the Articles of Incorporation (www.novartis.com/investors/company-overview/corporate-governance), the approval of two-thirds of the votes represented at the meeting is required for:
• Alteration of the purpose of Novartis AG
• Creation of shares with increased voting powers
• Implementation of restrictions on the transfer of registered shares, and the removal of such restrictions
• Authorized or conditional increase of the share capital
• Increase of the share capital out of equity, by contribution in kind, for the purpose of an acquisition of property or the grant of special rights
• Restriction or suspension of rights or options to subscribe
• Change of location of the registered office of Novartis AG
• Dissolution of Novartis AG
In addition, the law provides for a qualified majority for other resolutions, such as a merger or spin-off.
Other shareholder rights
Shareholders representing at least 10% of the Novartis share capital may request that an extraordinary General Meeting be convened. Shareholders representing Novartis shares with an aggregate nominal value of at least CHF 1 million may request that an item be included in a General Meeting agenda. Such requests must be made in writing at least 45 days before the meeting, specify the agenda item to be included, and contain the proposal on which the shareholder requests a vote.
Shareholders can vote their Novartis shares by themselves or appoint another shareholder or the Independent Proxy to vote on their behalf. All shareholders (who are not yet registered on the online platform; see below) receive a General Meeting invitation letter with a proxy appointment form for the appointment of the Independent Proxy. On this form, shareholders can instruct the Independent Proxy to vote on alternative or additional motions related to the agenda items either (i) following the recommendations of the Board for such alternative or additional motions, or (ii) against such alternative or additional motions. They can also abstain from voting.
Novartis AG offers shareholders the opportunity to use an online platform (the Sherpany Platform) to receive invitations to future General Meetings exclusively by email and to electronically give their instructions to the Independent Proxy, grant powers of attorney to other shareholders, and order their admission cards online. The General Meeting registration form enables shareholders who are not yet registered on the Sherpany Platform to order detailed documents related to opening a Sherpany account. They may also do so by contacting the Novartis Share Registry. Shareholders can deactivate their online account at any time and again receive invitations in paper form.
Other rights associated with a registered Novartis share may only be exercised by the shareholder, its legal representative, another shareholder with the right to vote, the Independent Proxy, an usufructuary (a person who is not the owner of the share but who is entitled to exercise shareholder rights), or a nominee who is registered in the Novartis Share Register.
89
Shareholder registration
Only shareholders, usufructuaries or nominees registered in the Novartis Share Register with voting rights may exercise their voting rights. To be registered with voting rights, a shareholder must declare that he or she acquired the shares in his or her own name and for his or her own account. According to article 5, paragraph 3 of the Articles of Incorporation (www.novartis.com/investors/company-overview/corporate-governance), the Board may register nominees with the right to vote. For restrictions on the registration of nominees, please see below.
The Articles of Incorporation provide that no shareholder shall be registered with the right to vote for more than 2% of the registered share capital. The Board may, upon request, grant an exemption from this restriction. Considerations include whether the shareholder supports the Novartis goal of creating sustainable value and has a long-term investment horizon. Exemptions are in force for the registered significant shareholders listed on page 88 under Our Shareholders – Significant Shareholders, and for Norges Bank (Central Bank of Norway), Oslo, which as of December 31, 2017, was not registered in the share register but according to a disclosure notification filed with Novartis AG, held 2.1% of the share capital of Novartis AG. No further exemptions were requested in 2017.
The same registration and voting restrictions indirectly apply to holders of ADRs.
Given that shareholder representation at General Meetings traditionally has been rather low in Switzerland, Novartis AG considers registration restrictions necessary to prevent a minority shareholder from dominating a General Meeting.
The Articles of Incorporation provide that no nominee shall be registered with the right to vote for more than 0.5% of the registered share capital. The Board may, upon request, grant an exemption from this restriction if the nominee discloses the names, addresses and number of shares of the individuals for whose account it holds 0.5% or more of the registered share capital. Exemptions are in force for the nominees listed on page 88 under Our Shareholders – Significant Shareholders, and for the nominee Citibank, London, which in 2015 requested an exemption, but as of December 31, 2017, was not registered in the Novartis Share Register.
The same restrictions indirectly apply to holders of ADRs.
Registration restrictions in the Articles of Incorporation may only be removed through a resolution of the General Meeting, with approval of at least two-thirds of the votes represented at the meeting (see article 18 lit. c of the Articles of Incorporation: www.novartis.com/investors/company-overview/corporate-governance).
Shareholders, ADR holders, or nominees who are linked to each other or who act in concert to circumvent registration restrictions are treated as one person or nominee for the purposes of the restrictions on registration.
No restrictions on trading of shares
No restrictions are imposed on the transferability of Novartis shares. The registration of shareholders in the Novartis Share Register or in the ADR register kept by JPMorgan Chase Bank, N.A., does not affect the tradability of Novartis shares or ADRs. Registered Novartis shareholders or ADR holders may therefore purchase or sell their Novartis shares or ADRs at any time, including before a General Meeting, regardless of the record date. The record date serves only to determine the right to vote at a General Meeting.
Change-of-control provisions
No opting up, no opting out
According to the Swiss Federal Act on Financial Infrastructures, anyone who – directly, indirectly or acting in concert with third parties – acquires equity securities exceeding 33 1/3% of the voting rights of a company (whether or not such rights are exercisable) is required to make an offer to acquire all listed equity securities of that company. A company may raise this threshold up to 49% of the voting rights (“opting up”) or may, under certain circumstances, waive the threshold (“opting out”). Novartis AG has not adopted any such measures.
Change-of-control clauses
In accordance with good corporate governance and the rules of the Ordinance against Excessive Compensation in Listed Companies, there are no change-of-control clauses and “golden parachute” agreements benefiting Board members, Executive Committee members, or other members of senior management. Furthermore, employment contracts with Executive Committee members are either for a fixed term not exceeding one year or for an indefinite period of time with a notice period not exceeding 12 months, and do not contain commissions for the acquisition or transfer of enterprises or severance payments.
90
General compensation provisions
Non-executive members of the Board of Directors
Compensation of non-executive members of the Board includes fixed compensation elements only. In particular, non-executive members of the Board shall receive no company contributions to any pension plan, no performance-related elements, and no financial instruments (e.g., options).
Members of the Executive Committee
The members of the Executive Committee receive fixed and variable, performance-related compensation. Fixed compensation is comprised of the base salary and may include other elements and benefits such as contributions to pension plans. Variable compensation may be structured into short-term and long-term compensation elements. Short-term variable compensation elements shall be governed by performance metrics that take into account the performance of Novartis and/or parts thereof, and/or individual targets. Achievements are generally measured based on the one-year period to which the short-term compensation relates. The long-term compensation plans are based on performance metrics that take into account strategic objectives of Novartis (such as financial, innovation, shareholder return and/or other metrics). Achievements are generally measured based on a period of not less than three years.
Additional Amount
If the maximum aggregate amount of compensation already approved by the General Meeting is not sufficient to cover the compensation of newly appointed or promoted Executive Committee members, Novartis may pay out compensation, in a total amount up to 40% of the total maximum aggregate amount last approved for the Executive Committee per compensation period, to newly appointed or promoted Executive Committee members.
For detailed information on the compensation of the Board and the Executive Committee, see articles 29-35 of the Articles of Incorporation (www.novartis.com/investors/company-overview/corporate-governance) and the Compensation Report, beginning on page 118.
91

Our Board of Directors

Composition of the Board of Directors and its committees (as per December 31, 2017)Board of DirectorsChairman: J. ReinhardtVice Chairman: E. VanniN. AndrewsD. AzarT. BuechnerS. DatarE. DohertyA. FudgeF. van HoutenP. Landolt 1A. von PlantaC. SawyersW. WintersAudit and Compliance CommitteeE. Doherty (Chairman)D. Azar 2S. DatarA. von PlantaE. VanniCompensation CommitteeE. Vanni (Chairman)S. DatarA. FudgeW. WintersGovernance, Nomination and Corporate Responsibilities CommitteeA. von Planta (Chairman)A. FudgeP. LandoltC. SawyersE. VanniResearch & Development CommitteeJ. Reinhardt (Chairman)N. AndrewsD. AzarC. SawyersRisk CommitteeS. Datar (Chairman)N. AndrewsT. BuechnerE. DohertyA. FudgeA. von Planta1P. Landolt will reach the statutory retirement age at the AGM 2018.2D. Azar will step down as member of the Audit and Compliance Committee as per the AGM 2018 and will be replaced by T. Buechner, subject to his re-election.
Election and term of office
Board members, the Chairman, and Compensation Committee members are elected annually and individually as a matter of law by the shareholders at the General Meeting. Board members whose term of office has expired are immediately eligible for re-election.
The average tenure of Board members is six years, with two-thirds of Board members having a tenure of less than six years. A Board member must retire after reaching age 70. Under special circumstances, shareholders may grant an exemption from this rule and re-elect a Board member for additional terms of office. There is no mandatory term limit for Board members, enabling the company to benefit from the insight and knowledge that long-serving Board members have developed about the company’s operations and practices.

Name

Nationality

Year of birth
First election
at AGM
Joerg Reinhardt, Ph.D.
D
1956
2013
Enrico Vanni, Ph.D.
CH
1951
2011
Nancy C. Andrews, M.D., Ph.D.
US
1958
2015
Dimitri Azar, M.D.
US
1959
2012
Ton Buechner
NLD
1965
2016
Srikant Datar, Ph.D.
US
1953
2003
Elizabeth Doherty
GB
1957
2016
Ann Fudge
US
1951
2008
Frans van Houten
NLD
1960
2017
Pierre Landolt, Ph.D.
CH
1947
1996
Andreas von Planta, Ph.D.
CH
1955
2006
Charles L. Sawyers, M.D.
US
1959
2013
William T. Winters
GB/US
1961
2013
92
Board profile
Board composition
The composition of the Board should align with our status as a listed company as well as our business portfolio, geographic reach and culture. The Board should be diverse in all aspects, as set-out below.
Profile of individual Board members
Board members should have the following personal qualities:
• Interact with other Board members to build an effective and complementary Board
• Establish trusting relationships
• Apply independence of thought and judgment
• Be challenging but supportive in the boardroom
• Influence without creating conflict by applying a constructive, non-confrontational style
• Listen well and offer advice based on sound judgment
• Be able and willing to commit adequate time to Board and committee responsibilities
• Be open to personal feedback and seek to be responsive
• Do not have existing board memberships or hold other positions that could lead to a permanent conflict of interest
• Understand and respect the boundaries of the role, leaving the operational management of the company to the CEO and the Executive Committee
Board members’ biographies (pages 102–105) highlight the specific qualifications that led the Board to conclude members are qualified to serve on the Board, which is diverse in terms of background, credentials, interests and skills.
Board diversity
The diversity of a Board is critical to its effectiveness. When the Governance, Nomination and Corporate Responsibilities Committee (GNCRC) of Novartis identifies new Board member candidates to be proposed to shareholders for election, the maintenance and improvement of the Board’s diversity is an important criterion. The Board’s aspiration is to have a diverse Board in all aspects. This includes nationality, gender, background and experience, age, tenure, viewpoints, interests, and technical and interpersonal skills. Background and experience in the following fields should be represented on the Board: leadership and management; healthcare, life sciences and medicine; research and development; engineering and technology; marketing; banking, finance and accounting; human resources; legal and public affairs; and risk management.
DiversityNationalityAmerican38 %Swiss24 %British15 %German8 %Dutch15 %GenderMale77 %Female23 %Background/ExperienceLeadership management22 %Medicine/healthcare/R&D28 %Finance/accounting17 %Engineering/technology17 %Law11 %Marketing5 %Age<558 %556046 %616523 %>6623 %Tenure<3y31 %36y38 %79y8 %>9y23 %
93
Succession planning
The Chairman, supported by the GNCRC, ensures effective succession plans for the Board, the CEO and the Executive Committee. These plans are discussed by the Board in private meetings without management, and, in a meeting without the Chairman, the succession plan for the Chairman is discussed.
The GNCRC determines the target profile for a new Board member, with the aim of strengthening the overall Board composition to meet knowledge and experience requirements in all essential fields. Factors considered include skills and knowledge; diversity; professional background and expertise; business and other experience relevant to the business of Novartis; the ability and willingness to commit adequate time and effort to Board and committee responsibilities; the extent to which personality, background, expertise, knowledge and experience will help build an effective and complementary Board; and whether existing board memberships or other positions held by a candidate could lead to a potential conflict of interest or an independence issue.
The search for a new Board member is then launched – normally with the support of a professional executive search company – based on the target profile. Candidates are interviewed by the Chairman and other Board members, and evaluated by the GNCRC. The GNCRC then makes a recommendation to the entire Board, and the Board ultimately decides who should be proposed to shareholders for election at the upcoming AGM.
Role of the Board and its committees
The Board is responsible for the overall direction and supervision of management, and holds the ultimate decision-making authority for Novartis AG, with the exception of decisions reserved for shareholders.
The Board has delegated certain of its responsibilities to five committees, as set out on the next pages. In some cases, these responsibilities are of an advisory or preparatory nature (A/P). In other cases, they have been fully delegated to the committee (FD), or the committee has decision-making power that is subject to final Board approval (FBA). The committees enable the Board to work in an efficient and effective manner, ensuring a thorough review and discussion of issues, while giving the Board more time for deliberation and decision-making. Moreover, committees ensure that only Board members who are independent oversee audit and compliance, governance and compensation – as only independent Board members are delegated in the respective committees.
94
ResponsibilitiesMembersNumber of meetingsheld in 2017/approximate averageduration (hrs)of each meeting/attendanceDocuments/linkBoard of Directors9/6:00The primary responsibilities of the Board of Directors include:—Setting the strategic direction of the Group—Appointing, overseeing and dismissing key executives, and planning their succession —Approving transactions and investments of fundamental importance to Novartis and all in excess of USD 500 Mio—Determining the organizational structure and governance of the Group—Determining and overseeing financial planning, accounting, reporting and controlling—Approving annual financial statements and corresponding financial results releasesJoerg Reinhardt1Enrico VanniNancy C. AndrewsDimitri AzarTon BuechnerSrikant Datar Elizabeth DohertyAnn FudgeFrans van Houten2Pierre Landolt Andreas von Planta Charles L. SawyersWilliam T. Winters9999899959998Articles of Incorporation of Novartis AG Regulations of the Board of Directors, its Committees and the Executive Committee of Novartis AG (Board regulations)www.novartis.com/investors/company-overview/corporate-governanceAudit and Compliance Committee7/3:00The primary responsibilities of this committee include:—Supervising external auditors (FD)**, and selecting and nominating external auditors for election by the meeting of shareholders (FBA)***—Overseeing internal auditors (FD)**—Overseeing accounting policies, financial controls, and compliance with accounting and internal control standards (FD)**—Approving quarterly financial statements and financial results releases (FBA)***—Overseeing internal control and compliance processes and procedures (FD)**—Overseeing compliance with laws, and external and internal regulations (FD)**The Audit and Compliance Committee has the authority to retainexternal consultants and other advisors.Elizabeth Doherty1,3Dimitri Azar4Srikant Datar3Andreas von PlantaEnrico Vanni77777Charter of the Audit and Compliance Committee www.novartis.com/investors/company-overview/corporate-governanceCompensation Committee6/2:30The primary responsibilities of this committee include:—Designing, reviewing and recommending to the Board the compensation policies and programs (FBA)***—Advising the Board on the compensation of Board members and the CEO (A/P)*—Deciding on the compensation of Executive Committee members (FD)**—Preparing the Compensation Report and submitting it to the Boardfor approval (FBA)***The Compensation Committee has the authority to retain external consultants and other advisors.Enrico Vanni1Srikant DatarAnn FudgeWilliam T. Winters6666Charter of the Compensation Committeewww.novartis.com/investors/company-overview/corporate-governance1Chairman2Elected new Board member at AGM 2017; see also page 97.3Audit Committee Financial Expert4Will step down as per AGM 2018, replaced by T. Buechner, subject to his re-election.*A/P = advisory or preparatory task**FD = fully delegated task***FBA = task subject to final Board approval
95
ResponsibilitiesMembersNumber of meetingsheld in 2017/approximate averageduration (hrs)of each meeting/attendanceDocuments/linkGovernance, Nomination andCorporate Responsibilities Committee3/1:30The primary responsibilities of this committee include:—Designing, reviewing and recommending to the Board corporate governance principles (FBA)***—Identifying candidates for election as Board members (FBA)***—Assessing existing Board members and recommending to the Board whether they should stand for re-election (FBA)***—Preparing and reviewing the succession plan for the CEO (FBA)***—Developing and reviewing an onboarding program for new Board members, and an ongoing education plan for existing Board members (FD)**—Reviewing on a regular basis the Articles of Incorporation, with a view to reinforcing shareholder rights (FD)**—Reviewing on a regular basis the composition and size of the Board and its committees (FBA)***—Reviewing annually the independence status of each Board member (FBA)***—Reviewing directorships and agreements of Board members forconflicts of interest, and dealing with conflicts of interest (FD)**—Overseeing the company's strategy and governance on corporateresponsibility (FBA)***The Governance, Nomination and Corporate Responsibilities Committeehas the authority to retain external consultants and other advisors.Andreas von Planta1Ann FudgePierre LandoltCharles L. SawyersEnrico Vanni33333Charter of the Governance, Nomination and Corporate Responsibilities Committee www.novartis.com/investors/company-overview/corporate-governanceResearch & Development Committee3/7:00The primary responsibilities of this committee include:—Monitoring research and development, and bringing recommendations to the Board (FBA)***—Assisting the Board with oversight and evaluation related to research and development (FD)**—Informing the Board on a periodic basis about the research and development strategy, the effectiveness and competitiveness of the research and development function, emerging scientific trends and activities critical to the success of research and development,and the pipeline (A/P)*—Advising the Board on scientific, technological, and research and development matters (A/P)*—Providing counsel and know-how to management in the area of research and development (A/P)*—Reviewing such other matters in relation to the company's research and development as the committee may, in its own discretion, deem desirable in connection with its responsibilities (A/P)*The Research & Development Committee has the authority to retainexternal consultants and other advisors. Joerg Reinhardt1Nancy C. AndrewsDimitri AzarCharles L. Sawyers3333Charter of the Research & Development Committeewww.novartis.com/investors/company-overview/corporate-governanceRisk Committee5/2:00The primary responsibilities of this committee include:—Ensuring that Novartis has implemented an appropriate and effective risk management system and process (FBA)***—Ensuring that all necessary steps are taken to foster a cultureof risk-adjusted decision-making without constraining reasonable risk-taking and innovation (FBA)***—Approving guidelines and reviewing policies and processes (FBA)***—Reviewing with management, internal auditors and external auditors the identification, prioritization and management of risks; theaccountabilities and roles of the functions involved in riskmanagement; the risk portfolio; and the related actions implemented by management (FBA)***The Risk Committee has the authority to retain external consultantsand other advisors. Srikant Datar1Nancy C. AndrewsTon BuechnerElizabeth DohertyAnn FudgeAndreas von Planta553455Charter of the Risk Committee www.novartis.com/investors/company-overview/corporate-governance1Chairman*A/P = advisory or preparatory task**FD = fully delegated task***FBA = task subject to final Board approval
96
All Board members except Frans van Houten attended more than 75% of all Board meetings and the meetings of their Board committees.
Mr. van Houten has an overall meeting attendance of 71% due to scheduling conflicts with Royal Philips board meetings, which he is required to attend as CEO of the company. In 2017, he could not resolve all of these conflicts following his election to the Novartis Board at the 2017 AGM. He informed the GNCRC about this issue prior to his election.
The Novartis corporate culture and role of the Board
The corporate culture of Novartis is a key focus of the Board. The Board works to ensure that the Novartis strategy, operating model and compensation system are aligned with Novartis Values and Behaviors, as endorsed by the Board, and that the Novartis compensation system supports the desired corporate culture of Novartis. The Board also reviews the regular evaluation of the corporate culture throughout Novartis.
Functioning of the Board
The Board takes decisions as a whole, supported by its five committees. Each committee has a written charter outlining its duties and responsibilities, and is led by a Board-elected Chairman.
The Board and its committees meet regularly throughout the year. The Chairmen set their meeting agendas. Any Board member may request a Board or committee meeting, and the inclusion of an agenda item. Before meetings, Board members receive materials to help them prepare the discussions and decision-making.
Chairman
Joerg Reinhardt has been the independent, non-executive Chairman since August 1, 2013. He has both industry and Novartis experience, and meets the company’s independence criteria. As independent Chairman, he can lead the Board to represent the interests of all stakeholders, being accountable to them and creating sustainable value through effective governance, the right strategy, and delivery of the expected level of performance. The independent chairmanship also ensures an appropriate balance of power between the Board and the Executive Committee.
In this role, Mr. Reinhardt:
• Provides leadership to the Board
• Supports and mentors the CEO
• Supported by the GNCRC, ensures effective succession plans for the Board and the Executive Committee
• Ensures that the Board and its committees work effectively
• Sets the agenda, style and tone of Board discussions, promoting constructive dialogue and effective decision-making
• Supported by the GNCRC, ensures that all Board committees are properly established, composed and operated
• Ensures that the Board’s performance is annually evaluated
• Ensures onboarding programs for new Board members, and continuing education and specialization for all Board members
• Ensures effective communication with the company’s shareholders
• Promotes effective relationships and communication between Board and Executive Committee members
Vice Chairman
Enrico Vanni has been the independent, non-executive Vice Chairman since February 22, 2013.
In this role, Mr. Vanni:
• Leads the Board in case and as long as the Chairman is incapacitated
• Chairs the sessions of independent Board members, and leads independent Board members if and as long as the Chairman is not independent
• Leads the yearly session of the Board members evaluating the performance of the Chairman, during which the Chairman is not present
97
Board meetings
The Board has meetings with Executive Committee members, as well as private meetings without them. Because all Board members are independent, no separate meetings of the independent Board members were held in 2017. Subject to additional special meetings, the Board and Board committee meetings take place in January, April, June, August, October and December. Typically these meetings last two days, with the first day allocated to Board committee meetings, and the second day allocated to the meeting of the full Board.
Full Board meetings include separate sessions of the Board without the CEO and the other Executive Committee members, of the Board with the CEO, and of the Board with the CEO and the other Executive Committee members.
Occasionally, other members of management and/or external advisors are invited to attend and/or present a specific topic at a Board meeting. The independent advisor of the Compensation Committee is regularly invited to attend portions of the meetings of the Compensation Committee. For more information, see Information and Control Systems of the Board vis-à-vis Management, beginning on page 100, and our Compensation Report, beginning on page 118.
Key activities of our Board and committees in 2017
In 2017, the Board addressed in its meetings among others the following key standard topics: strategy; Group targets; mergers and acquisitions, business development and licensing review; financial and business reviews; major projects; investments and transactions; corporate governance; and culture. Topics addressed during private meetings included Board self-evaluation and the performance assessment of the Executive Committee members, as well as CEO and Executive Committee succession planning.
In addition, in 2017 our Board and its committees focused on a number of special topics, including:
Board of Directors:
CEO succession; strategic options for Alcon; the Novartis digital strategy; the results of the Global Engagement Survey 2017; and AGM analysis
Audit and Compliance Committee:
Accounting and compliance questions related to new reporting requirements and guidelines; matters of accounting judgement; tax strategy as well as questions; compensation disclosure; potential rotation of the external auditors; and satisfactory resolution of high rated internal audit observations
Compensation Committee:
Compensation decisions related to the CEO succession; review of the compensation system of the Executive Committee and potential changes to the Annual Incentive and Long-Term Relative Performance Plan; review of the Board and committee fees and related potential changes; review of shareholder feedback from the roadshows; and potential enhanced disclosures in the 2017 Compensation Report
Governance, Nomination and Corporate Responsibilities Committee:
Shareholder feedback from our corporate governance roadshow; emerging corporate governance practices and whether to adopt them; succession planning for the Board, Board committees and committee Chairmen; CEO succession; reviews of our corporate responsibility activities; Novartis access-to-medicine portfolio; and the company’s performance in Environmental, Social and Governance (ESG) ratings and indices
Research & Development Committee:
The Novartis portfolio of research and development projects in ophthalmology, translational medicine, chemical biology and therapeutics, hepatology, non-malignant hematology and immuno-oncology, as well as innovation-related incentives
Risk Committee:
Data privacy; management of people risk related to the changed operating model; main risks and mitigations at Alcon, Novartis Technical Operations and in IT; and oversight of medical and patient activities
Honorary Chairmen
Dr. Alex Krauer and Dr. Daniel Vasella have been appointed Honorary Chairmen in recognition of their significant achievements on behalf of Novartis. They are not provided with Board documents and do not attend Board meetings.
98
Independence of Board members
The independence of Board members is a key corporate governance issue. An independent Board member is one who is independent of management and has no business or relationship that could materially interfere with the exercise of objective, unfettered and independent judgment. Only with a majority of Board members being independent can the Board fulfill its obligation to represent the interests of shareholders, being accountable to them and creating sustainable value through the effective governance of Novartis. Accordingly, Novartis established independence criteria based on international best practice standards as outlined on the Novartis website:
https://www.novartis.com/sites/www.novartis.com/files/independence-criteria-board-of-directors-and-its-committees.pdf
• The majority of Board members and any member of the Audit and Compliance Committee, the Compensation Committee, and the GNCRC must meet the company’s independence criteria. These include, inter alia, (i) a Board member not having received direct compensation of more than USD 120 000 per year from Novartis, except for dividends or Board compensation, within the last three years; (ii) a Board member not having been an employee of Novartis within the last three years; (iii) a family member not having been an executive officer of Novartis within the last three years; (iv) a Board member or family member not being employed by the external auditor of Novartis; (v) a Board member or family member not being a board member, employee or 10% shareholder of an enterprise that has made payments to, or received payments from, Novartis in excess of the greater of USD 1 million or 2% of that enterprise’s gross revenues. For members of the Audit and Compliance Committee and the Compensation Committee, even stricter rules apply.
• In addition, Board members are bound by the Novartis Conflict of Interest Policy, which prevents a Board member’s potential personal interests from influencing the decision-making of the Board.
• The GNCRC annually submits to the Board a proposal concerning the determination of the independence of each Board member. For this assessment, the committee considers all relevant facts and circumstances of which it is aware – not only the explicit formal independence criteria. This includes an assessment of whether a Board member is truly independent, in character and judgment, from any member of senior management and from any of his/her current or former colleagues.
In its meeting on December 14, 2017, the Board determined that all of its members are independent.
Relationship of non-executive Board members with Novartis
No Board member is or was a member of the management of Novartis AG or of any other Novartis Group company in the last three financial years up to December 31, 2017. There are no significant business relationships of any Board member with Novartis AG or with any other Novartis Group company.
Mandates outside the Novartis Group
According to article 34 of the Articles of Incorporation (www.novartis.com/investors/company-overview/corporate-governance), no Board member may hold more than 10 additional mandates in other companies, of which no more than four shall be in other listed companies. Chairmanships of the boards of directors of other listed companies count as two mandates. Each of these mandates is subject to Board approval.
The following mandates are not subject to these limitations:
a) Mandates in companies that are controlled by Novartis AG
b) Mandates that a Board member holds at the request of Novartis AG or companies controlled by it. No Board member shall hold more than five such mandates.
c) Mandates in associations, charitable organizations, foundations, trusts and employee welfare foundations. No Board member may hold more than 10 such mandates.
“Mandates” means those in the supreme governing body of a legal entity that is required to be registered in the commercial register or a comparable foreign register. Mandates in different legal entities that are under joint control are deemed one mandate.
The Board may issue regulations that determine additional restrictions, taking into account the position of the respective member.
Loans and credits
No loans or credits are granted to members of the Board.
99
Board performance and effectiveness evaluation
Process
The Board conducts an annual review to evaluate its performance, the performance of the committees and of Board members. As part of this process, each Board member completes a questionnaire on the performance and effectiveness of the Board and the Chairman, and on his/her committees, which lays the groundwork for a qualitative review led by the Chairman. The Chairman has discussions with each Board member and then with the entire Board. Also, the Board, without its Chairman, discusses the performance of the Chairman. Any suggestion for improvement is recorded and actions are agreed upon.
Periodically, this process is conducted by an independent consultant. In 2017, an independent performance and effectiveness evaluation of the Board and its committees, including an assessment of individual Board members, was conducted by the independent expert company Egon Zehnder.
Board memberscomplete ­questionnaireResults are collected and evaluated by Board officeChairman has discussion with each Board memberFull Board discusses results and agrees on actions
Content and results
The performance review examines the performance and effectiveness, strengths and weaknesses of individual Board members and of the full Board and each Board committee.
This review covers topics including Board composition; purpose, scope and responsibilities; processes and governance of the Board and its committees; meetings and pre-reading material; team effectiveness; and leadership and culture.
The review also evaluates the ability and willingness of each Board member to commit adequate time and effort to his/her responsibilities as provided for in the charter of the GNCRC.
The results were discussed at the January 2018 meetings. It was concluded that the Board and its committees operate effectively.
Information and control systems of the Board vis-à-vis management
Information on management
The Board ensures that it receives sufficient information from the Executive Committee to perform its supervisory duty and to make decisions that are reserved for it. The Board obtains this information through several means:
• The CEO informs the Board regularly about current developments.
• Executive Committee meeting minutes are made available to the Board.
• Meetings or teleconferences are held as required between Board members and the CEO.
• The Board regularly meets with all Executive Committee members.
• The Board receives detailed quarterly updates from each division and business unit head.
• By invitation, other members of management attend Board meetings to report on areas of the business for which they are responsible.
• Board members are entitled to request information from Executive Committee members or any other Novartis associate, and they may visit any Novartis site.
Board committees
Board committees regularly meet with management and, at times, external consultants to review the business, better understand applicable laws and policies affecting the Group, and support the Board and management in meeting the requirements and expectations of stakeholders and shareholders.
In particular, the Chief Financial Officer (CFO), the Group General Counsel, and representatives of the external auditors are invited to partly attend each Audit and Compliance Committee meeting. Additionally, the heads of Internal Audit, Financial Reporting & Accounting, Integrity and Compliance, and Quality, as well as the Head of the Global Business Practices Office, report on a regular basis to the Audit and Compliance Committee. This committee reviews financial reporting processes on behalf of the Board. For each quarterly and annual release of financial information, the Disclosure Review Committee is responsible for ensuring the accuracy and completeness of disclosures. The Disclosure Review Committee, which is a management committee, is chaired by the CFO and includes the CEO; the Group General Counsel; the heads of the divisions, business units, Novartis Operations, Novartis Technical Operations, Global Drug Development, and the Novartis Institutes for BioMedical Research (NIBR), as well as their finance heads; and the heads of the following corporate functions: Treasury, Tax, Financial Reporting & Accounting, Internal Audit and Investor Relations. The Audit and Compliance Committee reviews decisions made by the Disclosure Review Committee before the quarterly and annual releases are published.
100
The Risk Committee oversees the risk management system and processes, and also reviews the risk portfolio of the Group to ensure appropriate and professional risk management. For this purpose, the Group Risk Office and the risk owners of the divisions report on a regular basis to the Risk Committee. The Group General Counsel, the Head of Group Risk, the Head of Internal Audit, the Chief Ethics and Compliance Officer, and other senior executives are invited to these meetings on a regular basis.
Novartis management information system
Novartis produces comprehensive, consolidated (unaudited) financial statements on a monthly basis for the total Group and its operating divisions. These are typically available within 10 days of the end of the month, and include the following:
• Consolidated income statement of the month, quarter-to-date and year-to-date in accordance with International Financial Reporting Standards (IFRS), as well as adjustments to arrive at core results, as defined by Novartis (see page 179). The IFRS and core figures are compared to the prior-year period and targets in both USD and on a constant currency basis
• Consolidated balance sheet as of the month-end in accordance with IFRS in USD
• Consolidated cash flow on a monthly, quarter-to-date and year-to-date basis in accordance with IFRS in USD
• Supplementary data on a monthly, quarterly and year-to-date basis such as free cash flow, gross and net debt, headcount, personnel costs, working capital, and earnings per share on a USD basis where applicable
Constant currencies, core results, free cash flow, net debt and related target figures are non-IFRS measures. An explanation of non-IFRS measures can be found on pages 179-183 of the operating and financial review 2017.
This information is made available to Board members on a monthly basis. An analysis of key deviations from the prior year or target is also provided.
Prior to the release of each quarter’s results, the Board receives the actual consolidated financial statement information and an outlook of the full-year results in accordance with IFRS and “core” results (as defined by Novartis), together with related commentary.
On an annual basis, in the fourth quarter of the year, the Board receives and approves the operating and financial targets for the following year.
In the middle of the year, the Board also reviews and approves the strategic plan for the next five years, which includes a projected consolidated income statement in USD prepared in accordance with IFRS and non-IFRS measures as defined by Novartis (“core results”).
The Board does not have direct access to the company’s financial and management reporting systems but can, at any time, request more detailed financial information on any aspect that is presented to it.
Internal audit
The Internal Audit function carries out operational and system audits in accordance with an audit plan approved by the Audit and Compliance Committee. This function helps organizational units accomplish objectives by providing an independent approach to the evaluation, improvement and effectiveness of their internal control framework. It prepares reports on the audits it has performed, and reports actual or suspected irregularities to the Audit and Compliance Committee and to the CEO. The Audit and Compliance Committee regularly invites the Head of Internal Audit to its meetings to review the internal audit scope, audit plans and results. In 2017, the Head of Internal Audit attended four meetings of the Audit and Compliance Committee.
Risk management
The Group Risk Office is overseen by the Board’s independent Risk Committee. The Compensation Committee works closely with the Risk Committee to ensure that the compensation system does not lead to excessive risk-taking by management (for details, see our Compensation Report, beginning on page 118).
Organizational and process measures have been designed to identify and mitigate risks at an early stage. Organizationally, the responsibility for risk assessment and management is allocated to the divisions, organizational units and functions, with specialized corporate functions – such as Group Finance; Group Legal; Group Quality Assurance; Corporate Health, Safety and Environment; Business Continuity Management; Integrity and Compliance; and the Business Practices Office – providing support and controlling the effectiveness of the risk management in these respective areas.
101

Board of Directors

Joerg Reinhardt, Ph.D.
Chairman of the Board of Directors | Nationality: German | Year of Birth: 1956
Joerg Reinhardt, Ph.D., has been Chairman of the Board of Directors since 2013. He is also Chairman of the Research & Development Committee and Chairman of the Board of Trustees of the Novartis Foundation.
From 2010 to mid-2013, Mr. Reinhardt was chairman of the board of management and the executive committee of Bayer HealthCare, Germany. Prior to that, he was Chief Operating Officer of Novartis from 2008 to 2010, and Head of the Vaccines and Diagnostics Division of Novartis from 2006 to 2008. Since 2017, Mr. Reinhardt has been a non-executive board member of Swiss Re, Switzerland. Additionally, he was a member of the board of directors of Lonza Group AG in Switzerland from 2012 to 2013, Chairman of the Board of the Genomics Institute of the Novartis Research Foundation in the United States from 2000 to 2010, and a member of the supervisory board of MorphoSys AG in Germany from 2001 to 2004.
Mr. Reinhardt graduated with a doctorate in pharmaceutical sciences from Saarland University in Germany. He joined Sandoz Pharma Ltd. in 1982 and held various positions at Sandoz and later Novartis, including Head of Development.
Enrico Vanni, Ph.D.
Vice Chairman of the Board of Directors | Nationality: Swiss | Year of Birth: 1951
Enrico Vanni, Ph.D., has been a member of the Board of Directors since 2011 and qualifies as an independent Non-Executive Director. He is Vice Chairman of the Board of Directors and Chairman of the Compensation Committee. He is also a member of the Audit and Compliance Committee and the Governance, Nomination and Corporate Responsibilities Committee.
Mr. Vanni retired as director of McKinsey & Company in 2007. He is a board member of several companies in industries from healthcare to private banking, including Advanced Oncotherapy PLC in the United Kingdom, and non-listed companies such as Lombard Odier SA, Banque Privée BCP (Suisse) SA, and Denzler & Partners SA – all based in Switzerland. He previously served on the boards of Eclosion2 in Switzerland from 2009 to 2017, of Alcon Inc. in Switzerland from 2010 to 2011, and of Actavis PLC in Ireland in 2010.
Mr. Vanni holds an engineering degree in chemistry from the Federal Polytechnic School of Lausanne, Switzerland; a doctorate in chemistry from the University of Lausanne; and a Master of Business Administration from INSEAD in Fontainebleau, France. He began his career as a research engineer at the International Business Machines Corp. (IBM) in California, United States, and joined McKinsey in Zurich in 1980. He managed the Geneva office for McKinsey from 1988 to 2004, and consulted for companies in the pharmaceutical, consumer and finance sectors. He led McKinsey’s European pharmaceutical practice and served as a member of the firm’s partner review committee prior to his retirement. From 2008 to 2015, he was an independent consultant, supporting leaders of pharmaceutical and biotechnology companies on core strategic challenges facing the healthcare industry.
Nancy C. Andrews, M.D., Ph.D.
Member of the Board of Directors | Nationality: American | Year of Birth: 1958
Nancy C. Andrews, M.D., Ph.D., has been a member of the Board of Directors since 2015. She qualifies as an independent Non-Executive Director and is a member of the Research & Development Committee and the Risk Committee.
Dr. Andrews is dean emerita of the Duke University School of Medicine and vice chancellor emerita for academic affairs at Duke University in the United States. She served as dean and vice chancellor from 2007 to 2017. She is a professor of pediatrics, pharmacology and cancer biology at Duke, and was elected as a fellow of the American Association for the Advancement of Science and to membership in the US National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. She is chair of the board of directors of the American Academy of Arts and Sciences and of the Burroughs Wellcome Fund, a member of the Massachusetts Institute of Technology (MIT) Corporation, and former president of the American Society for Clinical Investigation. Additionally, she serves on the council of the National Academy of Medicine and on the Scientific Management Review Board of the US National Institutes of Health.
Dr. Andrews holds a doctorate in biology from MIT and a doctor of medicine from Harvard Medical School, both in the US. She completed her residency and fellowship trainings in pediatrics and hematology/oncology at Boston Children’s Hospital and the Dana-Farber Cancer Institute, also in the US, and served as an attending physician at Boston Children’s Hospital. Prior to joining Duke, Dr. Andrews was director of the Harvard/MIT M.D.-Ph.D. Program, and dean of basic sciences and graduate studies as well as professor of pediatrics at Harvard Medical School. From 1993 to 2006, she was a biomedical research investigator at the Howard Hughes Medical Institute in the US. Her research expertise is in iron homeostasis and mouse models of human diseases.
102
Dimitri Azar, M.D.
Member of the Board of Directors | Nationality: American | Year of Birth: 1959
Dimitri Azar, M.D., has been a member of the Board of Directors since 2012. He qualifies as an independent Non-Executive Director and is a member of the Audit and Compliance Committee and the Research & Development Committee.
Dr. Azar is senior director of ophthalmological innovation at Verily Life Sciences. He has also served as dean of the University of Illinois at Chicago (UIC) College of Medicine in the United States since 2011, and as professor of ophthalmology, bioengineering and pharmacology at UIC since 2006. From 2006 to 2011, he was head of the Department of Ophthalmology and Visual Sciences at UIC. He is a member of the American Ophthalmological Society, former president of the Chicago Ophthalmological Society, and president-elect of the Chicago Medical Society. Additionally, he is on the board of the Tear Film and Ocular Surface Society, the board of Verb Surgical Inc., and the scientific board of Verily – all based in the US.
Dr. Azar began his career at the American University of Beirut Medical Center in Lebanon, and completed his fellowship and residency training at the Massachusetts Eye and Ear Infirmary at Harvard Medical School in the US. His research on matrix metalloproteinases in corneal wound healing and angiogenesis has been funded by the US National Institutes of Health since 1993. Dr. Azar practiced at the Wilmer Eye Institute at the Johns Hopkins Hospital School of Medicine in the US, and then returned to the Massachusetts Eye and Ear Infirmary as director of cornea and external disease. He became professor of ophthalmology with tenure at Harvard Medical School in 2003. Dr. Azar holds a master’s degree from Harvard and an Executive Master of Business Administration from the University of Chicago Booth School of Business in the US.
Ton Buechner
Member of the Board of Directors | Nationality: Dutch | Year of Birth: 1965
Ton Buechner has been a member of the Board of Directors since February 2016. He qualifies as an independent Non-Executive Director and is a member of the Risk Committee.
Mr. Buechner most recently served as chairman and CEO of the executive board of Dutch multinational AkzoNobel from 2012 to 2017. Prior to joining AkzoNobel, he spent almost two decades at the Sulzer Corporation in Switzerland, where he was appointed divisional president in 2001 and served as president and CEO from 2007 to 2011. Mr. Buechner’s early career was spent in the oil and gas construction industry, and included roles at Allseas Engineering in the Netherlands and at Aker Kvaerner in Singapore. He is a member of the supervisory board of Voith GmbH in Germany.
Mr. Buechner is an engineer by training. He received his master’s degree in civil engineering from Delft University of Technology in the Netherlands in 1988, specializing in offshore construction technology and coastal engineering. Mr. Buechner holds a Master of Business Administration from IMD business school in Lausanne, Switzerland.
Srikant Datar, Ph.D.
Member of the Board of Directors | Nationality: American | Year of Birth: 1953
Srikant Datar, Ph.D., has been a member of the Board of Directors since 2003 and qualifies as an independent Non-Executive Director. He is Chairman of the Risk Committee, as well as a member of the Audit and Compliance Committee and the Compensation Committee. The Board of Directors has appointed him as Audit Committee Financial Expert.
Since 1996, Mr. Datar has been the Arthur Lowes Dickinson professor of business administration at Harvard Business School in the United States. Additionally, since 2015, he has been faculty chair of the Harvard Innovation Lab and senior associate dean for university affairs at Harvard Business School. He is a member of the boards of directors of ICF International Inc., Stryker Corp. and T-Mobile US, all in the US. He previously served on the boards of HCL Technologies Ltd. (2012 to 2014) and KPIT Cummins Infosystems Ltd (2007 to 2012), both based in India.
Mr. Datar graduated in 1973 with distinction in mathematics and economics from the University of Bombay in India. He is a chartered accountant, and holds two master’s degrees and a doctorate from Stanford University in the US. Mr. Datar has worked as an accountant and planner in industry, and as a professor at Carnegie Mellon University, Stanford University and Harvard University, all in the US. His research interests are in the areas of cost management, measurement of productivity, new product development, innovation, time-based competition, incentives and performance evaluation. He is the author of many scientific publications and has received several academic awards and honors. Mr. Datar has also advised and worked with numerous companies in research, development and training.
103

Board of Directors (continued)

Elizabeth (Liz) Doherty
Member of the Board of Directors | Nationality: British | Year of Birth: 1957
Elizabeth (Liz) Doherty has been a member of the Board of Directors since February 2016. She qualifies as an independent Non-Executive Director and is the Chairman of the Audit and Compliance Committee and a member of the Risk Committee. The Board of Directors has appointed her as Audit Committee Financial Expert.
Ms. Doherty is a non-executive director and chairman of the audit committee of Dunelm Group PLC in the United Kingdom, and a member of the supervisory board and audit committee of Corbion NV in the Netherlands. She is a fellow of the Chartered Institute of Management Accountants; a non-executive board member of the UK Ministry of Justice; a non-executive board member of Her Majesty’s Courts and Tribunals Service in the UK; and an advisor to GBfoods and Affinity Petcare SA, subsidiaries of Agrolimen SA. She previously served as a non-executive director and audit committee member at Delhaize Group in Belgium and Nokia Corp. in Finland, and as a non-executive director at SABMiller PLC in the UK.
Ms. Doherty received her bachelor’s degree in liberal studies in science (physics) from the University of Manchester in the UK. She began her career as an auditor and has held senior finance and accounting roles at Unilever PLC and Tesco PLC. Her previous positions also include interim chief financial officer (CFO) of Cognita Schools Ltd. from 2014 to 2015, CFO and board member of Reckitt Benckiser Group PLC from 2011 to 2013, interim CFO of City Inn in 2010, and CFO of Brambles Ltd. from 2007 to 2009.
Ann Fudge
Member of the Board of Directors | Nationality: American | Year of Birth: 1951
Ann Fudge has been a member of the Board of Directors since 2008. She qualifies as an independent Non-Executive Director and is a member of the Risk Committee; the Compensation Committee; and the Governance, Nomination and Corporate Responsibilities Committee.
Ms. Fudge is vice chairman and senior independent director of Unilever NV, London and Rotterdam. She is also chair of the United States Program Advisory Panel of the Bill & Melinda Gates Foundation; a director of Northrop Grumman Corporation in the US; a trustee of Boston-based WGBH public media; and a member of the visiting committee of Harvard Business School in the US. She served on the board of General Electric Co. in the US from 1999 to 2015.
Ms. Fudge received her bachelor’s degree from Simmons College in the US and her Master of Business Administration from Harvard Business School. She is former chairman and CEO of Young & Rubicam Brands, New York. Before that, she served as president of the Beverages, Desserts and Post Division of Kraft Foods Inc.
Frans van Houten
Member of the Board of Directors | Nationality: Dutch | Year of Birth: 1960
Frans van Houten has been a member of the Board of Directors since February 28, 2017. He qualifies as an independent Non-Executive Director.
Mr. van Houten is CEO and chairman of the executive committee and the board of management of Royal Philips, a position he has held since 2011. Under his leadership, Philips has transformed itself into a focused health technology company. In May 2016, he also became vice chairman and a member of the supervisory board of Philips Lighting.
Mr. van Houten holds a master’s degree in economics and business management from Erasmus University in Rotterdam, the Netherlands. He joined Philips in 1986 and has held multiple global senior leadership positions. From 2009 to 2010, he was a consultant to the boards of companies including ING Group NV and ASM International NV. Before that, he was CEO of NXP Semiconductors (a Philips spinoff) from 2004 to 2009.
Pierre Landolt, Ph.D.
Member of the Board of Directors | Nationality: Swiss | Year of Birth: 1947
Pierre Landolt, Ph.D., has been a member of the Board of Directors since 1996. He qualifies as an independent Non-Executive Director and is a member of the Governance, Nomination and Corporate Responsibilities Committee.
Mr. Landolt is chairman of the Sandoz Family Foundation, overseeing its development in several investment fields. He is also chairman of the Swiss private bank Landolt & Cie SA. In Switzerland, he is chairman of Emasan AG and Vaucher Manufacture Fleurier SA, and vice chairman of Parmigiani Fleurier SA. Additionally, he is vice chairman of the Montreux Jazz Festival Foundation and a board member of Amazentis SA, Switzerland, and the Eneas Fund, Cayman Islands. In Brazil, Mr. Landolt is president of AxialPar Ltda. and Moco Agropecuaria Ltda., the Instituto Fazenda Tamanduá and the Instituto Estrela de Fomento ao Microcrédito.
Mr. Landolt graduated with a bachelor’s degree in law from the University of Paris-Assas. From 1974 to 1976, he worked for Sandoz Brazil. In 1977, he acquired an agricultural estate in the semi-arid Northeast Region of Brazil, and within several years he converted it into a model farm in organic and biodynamic production. Since 1997, Mr. Landolt has been associate and chairman of AxialPar Ltda., Brazil, an investment company focused on sustainable development. In 2007, he co-founded Amazentis SA, a startup company active in the convergence space of medication and nutrition. In 2011, Mr. Landolt received the title of Docteur des Sciences Économiques Honoris Causa from the University of Lausanne in Switzerland.
104
Andreas von Planta, Ph.D.
Member of the Board of Directors | Nationality: Swiss | Year of Birth: 1955
Andreas von Planta, Ph.D., has been a member of the Board of Directors since 2006. He qualifies as an independent Non-Executive Director and is Chairman of the Governance, Nomination and Corporate Responsibilities Committee. He is also a member of the Risk Committee and the Audit and Compliance Committee.
Mr. von Planta provides counsel to the law firm Lenz & Staehelin AG, where he was a partner from 1988 through 2017. He is a board member of Helvetia Holding AG in Switzerland, and also serves on the boards of various Swiss subsidiaries of foreign companies and other non-listed Swiss companies, including Burberry (Suisse) SA, Lenz & Staehelin, A.P. Moller Finance SA, HSBC Private Bank (Suisse) SA, Socotab Frana SA and Raymond Weil SA. Additionally, he is chairman of the regulatory board of the SIX Swiss Exchange AG.
Mr. von Planta holds a doctorate in law from the University of Basel in Switzerland, and a Master of Laws from Columbia Law School in the United States. He passed his bar examinations in Basel in 1982, and specializes in corporate law, corporate governance, corporate finance, company reorganizations, and mergers and acquisitions. He previously served as chairman of Clinique Générale-Beaulieu SA from 2011 to 2016, and as a director there from 2008 to 2016. Additionally, he was chairman of Swiss National Insurance Company Ltd. (Nationale Suisse) from 2011 to 2015, a director at Nationale Suisse from 1997 to 2015, and a director at Holcim Ltd. from 2003 to 2014.
Charles L. Sawyers, M.D.
Member of the Board of Directors | Nationality: American | Year of Birth: 1959
Charles L. Sawyers, M.D., has been a member of the Board of Directors since 2013. He qualifies as an independent Non-Executive Director and is a member of the Research & Development Committee and the Governance, Nomination and Corporate Responsibilities Committee.
In the United States, Dr. Sawyers is chair of the Human Oncology and Pathogenesis Program at Memorial Sloan Kettering Cancer Center, professor of medicine and of cell and developmental biology at the Weill Cornell Graduate School of Medical Sciences, and an investigator at the Howard Hughes Medical Institute. He was appointed to the US National Cancer Advisory Board, and is former president of the American Association for Cancer Research and of the American Society for Clinical Investigation. He is also a member of the US National Academy of Sciences, the National Academy of Medicine, and the American Academy of Arts and Sciences. He serves as a science advisor for the following companies: Agios Pharmaceuticals Inc., Housey Pharmaceutical Research Laboratories, Nextech Invest Ltd., Blueprint Medicines Corporation, BeiGene Ltd., The Column Group, ORIC Pharmaceuticals Inc., KSQ Therapeutics Inc., Foghorn Therapeutics Inc., and PMV Pharmaceuticals Inc.
Dr. Sawyers received his doctor of medicine from the Johns Hopkins University School of Medicine in the US, and worked at the Jonsson Comprehensive Cancer Center at the University of California, Los Angeles, for nearly 18 years before joining Memorial Sloan Kettering in 2006. An internationally acclaimed cancer researcher, he co-developed the Novartis cancer drug Gleevec/Glivec and has received numerous honors and awards, including the Lasker-DeBakey Clinical Medical Research Award in 2009.
William T. Winters
Member of the Board of Directors | Nationality: British/American | Year of Birth: 1961
William T. Winters has been a member of the Board of Directors since 2013. He qualifies as an independent Non-Executive Director and is a member of the Compensation Committee.
Mr. Winters is CEO and a board member of Standard Chartered, based in London. He also serves on the board of Colgate University in the United States, and on the boards of the International Rescue Committee and the Print Room theater in the United Kingdom.
Mr. Winters received his bachelor’s degree from Colgate University and his Master of Business Administration from the Wharton School of the University of Pennsylvania in the US. From 2011 to 2015, he was chairman and CEO of Renshaw Bay, an alternative asset management firm. Prior to that, he was co-CEO of JPMorgan’s investment bank from 2003 to 2010. He joined JPMorgan in 1983 and has held management roles across several market areas and in corporate finance. Additionally, he was a commissioner on the UK Independent Commission on Banking in 2010 and 2011, and was awarded the title of Commander of the Order of the British Empire in 2013.
Honorary Chairmen
Alex Krauer, Ph.D.
Daniel Vasella, M.D.
Corporate Secretary
Charlotte Pamer-Wieser, Ph.D.
105

Our management

Composition of the Executive CommitteeJoseph JimenezChief Executive Officer(until January 31, 2018)Steven BaertHuman ResourcesFelix R. EhratGroup General CounselHarry KirschChief Financial OfficerAndré WyssNovartis OperationsJames BradnerBiomedical ResearchVasant NarasimhanGlobal Drug Development(CEO as per February 1, 2018) 1Paul HudsonInnovative Medicines:PharmaceuticalsBruno StriginiInnovative Medicines:Oncology(until December 31, 2017) 2F. Michael BallAlconRichard FrancisSandoz1Search for new Head Global Drug Development is ongoing; an interim Head has been appointed, who is not a member of the Executive Committee.2Elizabeth Barrett appointed CEO Novartis Oncology and member of the Executive Committee, effective February 1, 2018.
Executive Committee composition
The Executive Committee is headed by the CEO. Its members are appointed by the Board.
There are no contracts between Novartis and third parties whereby Novartis would delegate any business management tasks to such third parties.
Executive Committee role and functioning
The Board has delegated to the Executive Committee overall responsibility for and oversight of the operational management of Novartis. This includes:
• Recruiting, appointing and promoting senior management
• Ensuring the efficient operation of the Group and the achievement of optimal results
• Promoting an active internal and external communications policy
• Developing policies and strategic plans for Board approval, and implementing those approved
• Submitting the following to the Board for approval: investments, divestments, transactions, contracts and litigations with a value exceeding USD 500 million, important capital market and other financing transactions, as well as all (other) matters of fundamental significance for the Novartis Group
• Preparing and submitting quarterly and annual reports to the Board and its committees
• Informing the Board of all matters of fundamental significance to the businesses
• Dealing with any other matters delegated by the Board
The Executive Committee is supported by a sub-committee: The Disclosure Committee (members are the CEO, CFO and Group General Counsel) determines whether an event constitutes information that is material to the Group, determines the appropriate disclosure and update of such information, and reviews media releases concerning such information.
106
CEO
In addition to other Board-assigned duties, the CEO leads the Executive Committee, building and maintaining an effective executive team. With the support of the Executive Committee, the CEO:
• Is responsible for the operational management of Novartis
• Develops strategy proposals to be recommended to the Board, and ensures that approved strategies are implemented
• Plans human resourcing to ensure that Novartis has the capabilities and means to achieve its plans, and that robust management succession and management development plans are in place and presented to the Board
• Develops an organizational structure, and establishes processes and systems to ensure the efficient organization of resources
• Ensures that financial results, business strategies and, when appropriate, targets and milestones are communicated to the investment community – and generally develops and promotes effective communication with shareholders and other stakeholders
• Ensures that the business performance is consistent with business principles as well as high legal and ethical standards, and that the culture of Novartis is consistent with the Novartis Values and Behaviors
• Leads the Innovative Medicines Division
• Develops processes and structures to ensure that capital investment proposals are reviewed thoroughly, that associated risks are identified, and that appropriate steps are taken to manage these risks
• Develops and maintains an effective framework of internal controls over risk in relation to all business activities of the company
• Ensures that the flow of information to the Board is accurate, timely and clear
Mandates outside the Novartis Group
According to article 34 of the Articles of Incorporation (www.novartis.com/investors/company-overview/corporate-governance), no Executive Committee member may hold more than six additional mandates in other companies, of which no more than two additional mandates shall be in other listed companies. Each of these mandates is subject to Board approval. Executive Committee members are not allowed to hold chairmanships of the boards of directors of other listed companies.
The following mandates are not subject to these limitations:
a) Mandates in companies that are controlled by Novartis AG.
b) Mandates that an Executive Committee member holds at the request of Novartis AG or companies controlled by it. No Executive Committee member shall hold more than five such mandates.
c) Mandates in associations, charitable organizations, foundations, trusts and employee welfare foundations. No Executive Committee member may hold more than 10 such mandates.
“Mandates” means those in the supreme governing body of a legal entity that is required to be registered in the commercial register or a comparable foreign register. Mandates in different legal entities that are under joint control are deemed one mandate.
The Board may issue regulations that determine additional restrictions, taking into account the position of the respective member.
Loans and credits
No loans or credits shall be granted to members of the Executive Committee.
107

Executive Committee

Joseph Jimenez
Chief Executive Officer of Novartis | Nationality: American | Year of Birth: 1959
Joseph Jimenez has been Chief Executive Officer (CEO) of Novartis since 2010. Effective February 1, 2018, Mr. Jimenez will step down as CEO.
Mr. Jimenez previously held the position of Division Head, Novartis Pharmaceuticals. He joined Novartis in 2007 as Division Head, Novartis Consumer Health. Before that, from 1998 to 2006, he served as president and CEO of the North American and European businesses for the H.J. Heinz Company. He also served on the board of directors of Colgate-Palmolive Co. from 2009 to 2015, and of AstraZeneca PLC from 2002 to 2007.
Mr. Jimenez is a member of the board of directors of General Motors Co. He graduated in 1982 with a bachelor’s degree from Stanford University and in 1984 with a Master of Business Administration from the University of California, Berkeley, both in the United States.
Steven Baert
Head of Human Resources of Novartis | Nationality: Belgian | Year of Birth: 1974
Steven Baert has been Head of Human Resources (CHRO) of Novartis since 2014. He is a member of the Executive Committee of Novartis.
Mr. Baert joined Novartis in 2006 as Head of Human Resources Global Functions in Switzerland. He has held several other senior HR roles, including Head of Human Resources for Emerging Growth Markets, and Global Head, Human Resources, Oncology. Mr. Baert also served as Head of Human Resources, United States and Canada, for Novartis Pharmaceuticals Corporation. Prior to joining Novartis, he held HR positions at Bristol-Myers Squibb Co. and Unilever.
Mr. Baert represents Novartis on the board of the GSK Consumer Healthcare joint venture. He holds a Master of Business Administration from the Vlerick Business School in Belgium and a Master of Laws from the Katholieke Universiteit Leuven, also in Belgium. Additionally, he has a Bachelor of Laws from the Katholieke Universiteit Brussels.
F. Michael (Mike) Ball
CEO, Alcon | Nationality: American | Year of Birth: 1955
F. Michael (Mike) Ball was appointed CEO of Alcon in February 2016. He is a member of the Executive Committee of Novartis.
Mr. Ball previously served as CEO of Hospira Inc. from 2011 to 2015. Prior to that, he held a number of senior leadership positions at Allergan Inc., including president from 2006 to 2011. Before joining Allergan in 1995, Mr. Ball held roles of increasing responsibility in marketing and sales at Syntex Corporation and Eli Lilly & Co. He began his career in the healthcare industry in 1981.
Mr. Ball has served on the boards of several companies based in the United States, including Kythera Biopharmaceuticals Inc. (2013 to 2015), Hospira (2011 to 2015), IntraLase Corp. (2005 to 2006), and sTec Inc. (2000 to 2013). He holds a Bachelor of Science and a Master of Business Administration from Queen’s University in Canada.
James (Jay) Bradner, M.D.
President of the Novartis Institutes for BioMedical Research (NIBR) | Nationality: American | Year of Birth: 1972
James (Jay) Bradner, M.D., joined Novartis in January 2016 and became President of the Novartis Institutes for BioMedical Research (NIBR) in March 2016. He is a member of the Executive Committee of Novartis.
Prior to joining Novartis, Dr. Bradner was on the faculty of Harvard Medical School in the Department of Medical Oncology at the Dana-Farber Cancer Institute in the United States from 2005 through 2015. He is a co-founder of five biotechnology companies and has authored more than 180 scientific publications and 30 US patent applications.
Dr. Bradner is a graduate of Harvard University and the University of Chicago Medical School in the US. He completed his residency in medicine at Brigham and Women’s Hospital and his fellowship in medical oncology and hematology at the Dana-Farber Cancer Institute. He has been honored with many awards and was elected into the American Society for Clinical Investigation in 2011 and the Alpha Omega Alpha Honor Medical Society in 2013.
108
Felix R. Ehrat, Ph.D.
Group General Counsel of Novartis | Nationality: Swiss | Year of Birth: 1957
Felix R. Ehrat, Ph.D., has been Group General Counsel of Novartis since 2011. He is a member of the Executive Committee of Novartis.
Mr. Ehrat is a leading practitioner of corporate, banking, and mergers and acquisitions law, as well as an expert in corporate governance and arbitration. He started his career as an associate at Bär & Karrer Ltd. in Zurich in 1987, and served as senior partner from 2003 to 2011, and as executive chairman of the board from 2007 to 2011. Since 2011, he has also held various other leadership positions at the Novartis Group level, including in compliance and country management. He is chairman of Globalance Bank AG and a board member of Geberit AG and Avenir Suisse (a think tank for economic and social issues), all headquartered in Switzerland. He previously served as chairman and board member of several listed and non-listed companies based in Switzerland and elsewhere.
After being admitted to the bar, Mr. Ehrat received his Master of Laws from McGeorge School of Law in the United States in 1986, and his doctorate in law from the University of Zurich in Switzerland in 1990. He has held leadership roles at international legal organizations including the International Bar Association and Association Internationale des Jeunes Avocats.
Richard Francis
CEO, Sandoz | Nationality: British | Year of Birth: 1968
Richard Francis has been CEO of Sandoz since 2014. He is a member of the Executive Committee of Novartis.
Mr. Francis joined Novartis from Biogen Idec, where he held global and country leadership positions during his 13-year career with the company. Most recently, he was senior vice president of the company’s United States commercial organization. From 1998 to 2001, he was at Sanofi in the United Kingdom, and held various marketing roles across the company’s urology, analgesics and cardiovascular products. He also held sales and marketing positions at Lorex Synthélabo and Wyeth.
Mr. Francis is a member of the board of directors of Mettler-Toledo International Inc., based in the US. He received a Bachelor of Arts in economics from Manchester Metropolitan University in the UK.
Paul Hudson
CEO, Novartis Pharmaceuticals | Nationality: British | Year of Birth: 1967
Paul Hudson has been CEO of Novartis Pharmaceuticals since July 2016. He is a member of the Executive Committee of Novartis.
Mr. Hudson joined Novartis from AstraZeneca PLC, where he most recently was president, AstraZeneca United States and executive vice president, North America. He also served as representative director and president of AstraZeneca K.K. in Japan; as president of AstraZeneca’s business in Spain; and as vice president and primary care director, United Kingdom. Before joining AstraZeneca in 2006, Mr. Hudson held roles of increasing responsibility at Schering-Plough, including leading biologics global marketing. He began his career in sales and marketing roles at GlaxoSmithKline UK and Sanofi-Synthélabo UK.
Mr. Hudson holds a degree in economics from Manchester Metropolitan University in the UK and a diploma in marketing from the Chartered Institute of Marketing, also in the UK.
Harry Kirsch
Chief Financial Officer of Novartis | Nationality: Swiss, German | Year of Birth: 1965
Harry Kirsch has been Chief Financial Officer (CFO) of Novartis since 2013. He is a member of the Executive Committee of Novartis.
Mr. Kirsch joined Novartis in 2003 and, prior to his current position, served as CFO of the company’s Pharmaceuticals Division. Under his leadership, the division’s core operating income margin increased, in constant currencies, every quarter of 2011 and 2012 despite patent expirations. At Novartis, he also served as CFO of Pharma Europe, and as Head of Business Planning & Analysis and Financial Operations for the Pharmaceuticals Division. Mr. Kirsch joined Novartis from Procter & Gamble (P&G) in the United States, where he was CFO of P&G’s global pharmaceutical business. Prior to that, he held finance positions in various categories of P&G’s consumer goods business, technical operations, and Global Business Services organization.
Mr. Kirsch represents Novartis on the board of the GSK Consumer Healthcare joint venture. He holds a diploma degree in industrial engineering and economics from the University of Karlsruhe in Germany.
109

Executive Committee (continued)

Vasant (Vas) Narasimhan, M.D.
Global Head of Drug Development and Chief Medical Officer for Novartis | Nationality: American | Year of Birth: 1976
Vasant (Vas) Narasimhan, M.D., has been Global Head of Drug Development and Chief Medical Officer for Novartis since February 2016. He is a member of the Executive Committee of Novartis, and effective February 1, 2018, will become Chief Executive Officer of the company.
Dr. Narasimhan previously was Global Head of Development for Novartis Pharmaceuticals, overseeing the entire general medicines pipeline. He has also served as Global Head of the Sandoz Biopharmaceuticals and Oncology Injectables business unit, Global Head of Development for Novartis Vaccines, North America Region Head for Novartis Vaccines, and United States Country President for Novartis Vaccines and Diagnostics. Before joining Novartis in 2005, he worked at McKinsey & Company.
Dr. Narasimhan received his medical degree from Harvard Medical School in the US, a master’s degree in public policy from Harvard’s John F. Kennedy School of Government, and a bachelor’s degree in biological sciences from the University of Chicago in the US. During and after his medical studies, he worked extensively on a range of public health issues in developing countries. He is an elected member of the US National Academy of Medicine and serves on the board of fellows of Harvard Medical School.
Bruno Strigini
CEO, Novartis Oncology | Nationality: French | Year of Birth: 1961
Bruno Strigini has been CEO of Novartis Oncology since July 2016. On December 31, 2017, he stepped back from the Executive Committee of Novartis, and he will step down as CEO of Novartis Oncology in early 2018.
Mr. Strigini joined Novartis in 2014 as President of Oncology. Prior to Novartis, he was President of MSD for Europe and Canada (Merck & Co. in the United States and Canada) from 2009 to 2014. He previously worked at Schering-Plough from 2006 to 2009 as group vice president and president of EUCAN Region II (encompassing Austria, Belgium, Greece, the Netherlands, Portugal, Switzerland, Central and Eastern Europe, the Middle East and Africa). Before that, he held positions at UCB Celltech and SmithKline Beecham.
Mr. Strigini holds a Master of Business Administration from IMD business school in Switzerland, a doctorate in pharmacy from the University of Montpellier in France, and a master’s degree in microbiology from Heriot-Watt University in the United Kingdom. He is an elected member of the French National Academy of Pharmacy, and in 2014, he was awarded a doctor honoris causa from Universidad Internacional Menéndez Pelayo in Spain.
André Wyss
President of Novartis Operations and Country President for Switzerland | Nationality: Swiss | Year of Birth: 1967
André Wyss has been President of Novartis Operations since February 2016, and is responsible for manufacturing, shared services and corporate affairs. He is also Country President for Switzerland and a member of the Executive Committee of Novartis.
Mr. Wyss has been with Novartis since 1984 when he was a chemistry apprentice in manufacturing at Sandoz. Before being appointed President of Novartis Operations, he served as Head of Novartis Business Services, building and implementing a shared services organization across Novartis. Prior to that, he held several other leadership positions, including US Country Head and President of Novartis Pharmaceuticals Corporation; Head of the Pharmaceuticals Division for the AMAC region (Asia-Pacific, Middle East and African countries); Group Emerging Markets Head; and Country President and Head of Pharmaceuticals, Greece.
Mr. Wyss received a graduate degree in economics from the School of Economics and Business Administration (HWV) in Switzerland in 1995. He is a member of the board of economiesuisse.
Secretary
Bruno Heynen
110

Our independent external auditors

Duration of the mandate and terms of office of the auditors
Based on a recommendation by the Audit and Compliance Committee, the Board nominates an independent auditor for election at the AGM. PricewaterhouseCoopers (PwC) assumed its existing auditing mandate for Novartis in 1996. Martin Kennard, auditor in charge, began serving in his role in 2017, and Stephen Johnson, global relationship partner, began serving in his role in 2014. The Audit and Compliance Committee together with PwC ensures that these partners are rotated at least every five years.
Information to the Board and the Audit and Compliance Committee
PwC is responsible for providing an opinion on whether the consolidated financial statements comply with IFRS and Swiss law, and whether the separate parent company financial statements of Novartis AG comply with Swiss law. Additionally, PwC is responsible for opining on the effectiveness of internal control over financial reporting, on the Compensation Report and on the corporate responsibility reporting of Novartis.
The Audit and Compliance Committee, acting on behalf of the Board, is responsible for overseeing the activities of PwC. In 2017, this committee held seven meetings. PwC was invited to six of these meetings to attend during the discussion of agenda items that dealt with accounting, financial reporting or auditing matters, and any other matters relevant to its audit.
On an annual basis, PwC provides the Audit and Compliance Committee with written disclosures required by the US Public Company Accounting Oversight Board, and the committee and PwC discuss PwC’s independence from Novartis.
The Audit and Compliance Committee recommended to the Board to approve the audited consolidated financial statements and the separate parent company financial statements of Novartis AG for the year ended December 31, 2017. The Board proposed the acceptance of these financial statements for approval by the shareholders at the next AGM.
The Audit and Compliance Committee regularly evaluates the performance of PwC and, based on this, once a year determines whether PwC should be proposed to the shareholders for election. Also once a year, the auditor in charge and the global relationship partner report to the Board on PwC’s activities during the current year and on the audit plan for the coming year. They also answer any questions or concerns that Board members have about the performance of PwC, or about the work it has conducted or is planning to conduct.
To assess the performance of PwC, the Audit and Compliance Committee holds private meetings with the CFO and the Head of Internal Audit and, if necessary, obtains an independent external assessment. Criteria applied for the performance assessment of PwC include an evaluation of its technical and operational competence; its independence and objectivity; the sufficiency of the resources it has employed; its focus on areas of significant risk to Novartis; its willingness to probe and challenge; its ability to provide effective, practical recommendations; and the openness and effectiveness of its communications and coordination with the Audit and Compliance Committee, the Internal Audit function, and management.
Approval of audit and non-audit services
The Audit and Compliance Committee approves a budget for audit services, whether recurring or non-recurring in nature, and for audit-related services not associated with internal control over financial reporting. PwC reports quarterly to the Audit and Compliance Committee regarding the extent of services provided in accordance with the applicable pre-approval, and the fees for services performed to date. The Audit and Compliance Committee individually approves all audit-related services associated with internal control over financial reporting, tax services and other services prior to the start of work.
111
Audit and additional fees
PwC fees for professional services related to the 12-month periods ended December 31, 2017 and December 31, 2016 are as follows:
2017
USD million
2016
USD million
Audit services
24.6
26.7
Audit-related services
7.2
2.9
Tax services
0.8
0.7
Other services
1.4
1.3
Total
34.0
31.6
 
Audit services include work performed to issue opinions on consolidated financial statements and parent company financial statements of Novartis AG, to issue opinions related to the effectiveness of the Group’s internal control over financial reporting, and to issue reports on local statutory financial statements. Also included are audit services that generally can only be provided by the statutory auditor, such as the audit of the Compensation Report, audits of non-recurring transactions, audits of the adoption of new accounting policies, audits of information systems and the related control environment, reviews of quarterly financial results, as well as procedures required to issue consents and comfort letters.
Audit-related services include other assurance services provided by the independent auditor but not restricted to those that can only be provided by the statutory auditor. They include services such as audits of pension and other employee benefit plans, contract audits of third-party arrangements, corporate responsibility assurance, other audit-related services, and in 2017 audit services related to the Alcon strategic review.
Tax services represent tax compliance, assistance with historical tax matters, and other tax-related services.
Other services include procedures related to corporate integrity agreements, training in the finance area, benchmarking studies, and license fees for use of accounting and other reporting guidance databases.
112

Our corporate governance framework

Laws and regulations
Novartis AG is subject to the laws of Switzerland, in particular Swiss company and securities laws, and to the securities laws of the US as applicable to foreign private issuers of securities.
In addition, Novartis AG is subject to the rules of the SIX Swiss Exchange, including the Directive on Information Relating to Corporate Governance.
Novartis AG is also subject to the rules of the NYSE as applicable to foreign private issuers of securities. The NYSE requires Novartis AG to describe any material ways in which its corporate governance differs from that of domestic US companies listed on the exchange. These differences are:
• Novartis AG shareholders do not receive written reports directly from Board committees.
• External auditors are appointed by shareholders at the AGM, as opposed to being appointed by the Audit and Compliance Committee.
• While shareholders cannot vote on all equity compensation plans, they are entitled to hold separate, yearly binding shareholder votes on Board and Executive Committee compensation.
• The Board has set up a separate Risk Committee that is responsible for business risk oversight, as opposed to delegating this responsibility to the Audit and Compliance Committee.
• The full Board is responsible for overseeing the performance evaluation of the Board and Executive Committee.
• The full Board is responsible for setting objectives relevant to the CEO’s compensation and for evaluating his performance.
Swiss Code of Best Practice for Corporate Governance
Novartis applies the Swiss Code of Best Practice for Corporate Governance.
Novartis corporate governance standards
Novartis has incorporated the aforementioned corporate governance standards into the Articles of Incorporation and the Regulations of the Board of Directors, its Committees and the Executive Committee of Novartis AG
(www.novartis.com/investors/company-overview/corporate-governance).
The GNCRC regularly reviews these standards and principles, taking into account best practices, and recommends improvements to the corporate governance framework for consideration by the full Board.
Additional corporate governance information can be found on the Novartis website: www.novartis.com/investors/company-overview/corporate-governance
Printed copies of the Novartis Articles of Incorporation as well as the Regulations of the Board, including the charters of Board committees (in English), can be obtained by writing to: Novartis AG, Attn: Corporate Secretary, Lichtstrasse 35, CH-4056 Basel, Switzerland. Electronic copies are available at: www.novartis.com/investors/company-overview/corporate-governance.
113

Further information

Group structure of Novartis
Novartis AG and Group companies
Under Swiss company law, Novartis AG is organized as a corporation that has issued shares of common stock to investors. The registered office of Novartis AG is Lichtstrasse 35, CH-4056 Basel, Switzerland.
Business operations are conducted through Novartis Group companies. Novartis AG, a holding company, owns or controls directly or indirectly all entities worldwide belonging to the Novartis Group. Except as described below, the shares of these companies are not publicly traded. The principal Novartis subsidiaries and associated companies are listed in Note 31 to the Group’s consolidated financial statements.
Divisions
The businesses of Novartis are divided on a worldwide basis into three operating divisions: Innovative Medicines, with the two business units Novartis Pharmaceuticals and Novartis Oncology; Sandoz (generics); and Alcon (eye care). These businesses are supported by a number of global organizations including NIBR, which focuses on discovering new drugs; the Global Drug Development organization, which oversees the clinical development of new medicines; and Novartis Operations, which includes Novartis Technical Operations (the global manufacturing organization) and Novartis Business Services (which consolidates support services across Novartis).
Majority holdings in publicly traded Group companies
The Novartis Group owns 73.4% of Novartis India Ltd., with its registered office in Mumbai, India, and listed on the Bombay Stock Exchange (ISIN INE234A01025, symbol: HCBA). The total market value of the 26.6% free float of Novartis India Ltd. was USD 75.3 million at December 31, 2017, using the quoted market share price at year-end. Applying this share price to all the shares of the company, the market capitalization of the whole company was USD 283.2 million, and that of the shares owned by Novartis was USD 207.9 million.
Significant minority shareholding owned by the Novartis Group 
The Novartis Group owns 33.3% of the bearer shares of Roche Holding AG, with its registered office in Basel, Switzerland, and listed on the SIX Swiss Exchange (ISIN CH0012032113, symbol: RO). The market value of the Group’s interest in Roche Holding AG, as of December 31, 2017, was USD 13.4 billion. The total market value of Roche Holding AG was USD 217.6 billion. Novartis does not exercise control over Roche Holding AG, which is independently governed, managed and operated.
The Novartis Group owns a 36.5% share of a joint venture created by GlaxoSmithKline PLC (GSK) and Novartis, which combined the Novartis OTC and GSK Consumer Healthcare businesses. Novartis holds four of the 11 seats on the joint venture’s board. Furthermore, Novartis has certain minority rights and exit rights, including a put option that is exercisable as of March 2, 2018 until latest 2035.
Political contributions and lobbying
Novartis makes political contributions to support political dialogue on issues of relevance to the company.
Political contributions made by Novartis are not intended to give rise to any obligations of the party receiving it, or with the expectation of a direct or immediate return for Novartis. Such contributions are fully compliant with applicable laws, regulations and industry codes. Novartis only makes political contributions in countries where such contributions from corporations are considered to reflect good corporate citizenship. Moreover, Novartis only makes modest political contributions so as to not create any dependency from the political parties receiving these contributions.
In 2017, Novartis made political contributions totaling approximately USD 2.0 million, thereof approximately USD 600 000 in Switzerland, USD 1 365 000 in the US, and USD 65 000 in Australia. In addition, in the US, a political action committee established by Novartis used funds received from Novartis employees (but not from the company) to make political contributions totaling approximately USD 220 000.
In Switzerland, Novartis supports political parties that have a political agenda and that hold positions supporting the strategic interests of Novartis, its shareholders and other stakeholders. Swiss political parties are completely privately financed, and the contributions of companies are a crucial part thereof. This private financing of parties is a deeply rooted trait of the Swiss political culture, and contributing to that system is an important element of being a good corporate citizen.
In 2016, Novartis issued a guideline on responsible lobbying, describing the overarching principles of transparency in lobbying activities. For more information on responsible lobbying, see the public policy and advocacy section of the Novartis website (www.novartis.com/our-company/corporate-responsibility/doingbusiness-responsibly/transparency-disclosure/public-policy-advocacy).
114
Shareholder relations
The CEO, with the CFO and Investor Relations team, supported by the Chairman, are responsible for ensuring effective communication with shareholders to keep them informed of the company’s strategy, prospects, business operations and governance. Through communication, the Board also learns about and addresses shareholders’ expectations and concerns.
Novartis communicates with its shareholders through the AGM, meetings with groups of shareholders and individual shareholders, and written and electronic communications.
At the AGM, the Chairman and other Board members, the CEO and other Executive Committee members, and representatives of the external auditors are present and can answer shareholders’ questions. Other meetings with shareholders may be attended by the Chairman, CEO, CFO, Executive Committee members, and other members of senior management.
Topics discussed with shareholders may include strategy, business performance and corporate governance, while fully respecting all applicable laws and stock exchange rules.
Information for our stakeholders
Introduction
Novartis is committed to open and transparent communication with shareholders, financial analysts, customers, suppliers and other stakeholders. Novartis aims to disseminate material developments in its businesses in a broad and timely manner that complies with the rules of the SIX Swiss Exchange and the NYSE.
Communications
Novartis publishes this Annual Report to provide information on the Group’s results and operations. In addition, Novartis prepares an annual report on Form 20-F that is filed with the US Securities and Exchange Commission (SEC). Novartis discloses financial results in accordance with IFRS on a quarterly basis, and issues press releases from time to time regarding business developments.
Novartis furnishes press releases related to financial results and material events to the SEC via Form 6-K. An archive containing recent Annual Reports, annual reports on Form 20-F, quarterly results releases, and all related materials – including presentations and conference call webcasts – is on the Novartis website at www.novartis.com/investors.
Novartis also publishes a consolidated Corporate Responsibility Performance Report, available on the Novartis website at www.novartis.com/our-company/corporate-responsibility, which details progress and demonstrates the company’s commitment to be a leader in corporate responsibility. This report reflects the best-in-class reporting standard, the Global Reporting Initiative’s G4 guidelines, and fulfills the company’s reporting requirement as a signatory of the UN Global Compact.
Information contained in reports and releases issued by Novartis is only correct and accurate at the time of release. Novartis does not update past releases to reflect subsequent events, and advises against relying on them for current information.
Investor Relations program
An Investor Relations team manages the Group’s interactions with the international financial community. Several events are held each year to provide institutional investors and analysts with various opportunities to learn more about Novartis.
Investor Relations is based at the Group’s headquarters in Basel. Part of the team is located in the US to coordinate interaction with US investors. More information is available on the Novartis website:
www.novartis.com/investors. Investors are also welcome to subscribe to a free email service on this site.
Website information
Topic
Information
Share capital
Articles of Incorporation of Novartis AG
www.novartis.com/investors/company-overview/corporate-governance
Novartis key share data
www.novartis.com/key-share-data
Shareholder rights
Articles of Incorporation of Novartis AG
www.novartis.com/investors/company-overview/corporate-governance
Investor Relations information
www.novartis.com/investors
Board regulations
Board regulations
www.novartis.com/investors/company-overview/corporate-governance
Executive Committee
Executive Committee
www.novartis.com/our-company/executive-committee
Novartis code for senior financial officers
Novartis Code of Ethical Conduct for CEO and Senior Financial Officers
www.novartis.com/investors/company-overview/corporate-governance
Additional information
Novartis Investor Relations
www.novartis.com/investors
115
Compensation Report


Contents

Compensation Committee Chairman’s letter


Dear Shareholder,

As Chairman of the Compensation Committee, I am pleased to present the 2017 Compensation Report of Novartis AG. 
This report includes an “at a glance” management summary of key information, followed by full details of our Executive Committee and Board compensation for 2017, including changes that will apply from 2018.
During the year, we engaged in dialogue with many of our major shareholders and proxy advisors to gather feedback on our compensation systems and disclosures, and we considered this feedback when making decisions on both topics. Through these discussions, we also addressed concerns of some shareholders who opposed the 2016 Compensation Report at the 2017 Annual General Meeting (AGM).
2017 company performance
Novartis delivered strong performance in 2017, with Group sales, net income and free cash flow ahead of target in constant currencies. Growth drivers in the Innovative Medicines division, including Cosentyx, Entresto, Promacta/Revolade, and Tafinlar + Mekinist, more than offset the loss of exclusivity of Gleevec/Glivec. Sandoz experienced a small decline in sales but gained market share and outperformed peers in a challenging market. Alcon returned to growth and made good progress toward becoming a leaner and more agile medical devices company.
Novartis achieved or surpassed pipeline milestone targets, including a number of positive readouts of major studies. Access to healthcare programs were expanded. Talent has been strengthened in key leadership positions in many parts of the organization. Culture, particularly collaboration, has been further improved.
Shareholders benefited from an annual total shareholder return (TSR) in USD of 20.4%, including an increased dividend.
2017 CEO realized pay
The Board determined that the CEO met or exceeded his financial targets and strategic objectives set at the beginning of the year, and that he role modeled the Novartis Values and Behaviors. When determining his compensation, the Board also considered other factors such as the external business environment and competition. The CEO was awarded a 2017 Annual Incentive of 125% of target, i.e. CHF 3 937 542.
The first of the two Long-Term Incentives, the Long-Term Performance Plan (LTPP) for the 2015-2017 ­performance cycle, based on a cumulative three-year Novartis Cash Value Added target and long-term ­innovation milestones, vested at 114% of target, i.e. CHF 5 068 337.
The second Long-Term Incentive, the Long-Term Relative Performance Plan (LTRPP) for the 2015-2017 performance cycle, based on three-year relative TSR compared to the global healthcare peer group, did not vest due to our rank at No. 12 out of 13 companies, i.e. no payout.
In light of the company’s performance, the 2017 total realized compensation for the CEO was CHF 11 344 462, (compared with CHF 10 556 685 in 2016), and includes his base salary and benefits, his Annual Incentive for the
118
2017 performance year, and the vesting of his LTPP award for the 2015-2017 performance cycle, including dividend equivalents.
Compensation Report transparency
To provide greater transparency, we have enhanced the disclosures in this Compensation Report, including:
• Prospective disclosure of the retirement conditions of the outgoing CEO, Joseph Jimenez, as well as the target compensation of the newly appointed CEO, Vasant Narasimhan.
• Prospective disclosure of any 2018 increases in Executive Committee members’ target compensation, as well as the policy for setting compensation of newly appointed Executive Committee members.
• Realized compensation of the CEO – and for the first time, on an aggregated basis – the other members of the Executive Committee.
• An interim update on the one-off three-year performance award granted in 2016 to the Alcon CEO for the 2016-2018 performance cycle.
Changes to our executive compensation system
During the year, the Compensation Committee conducted a review of the Executive Committee compensation system, considering business needs, feedback from dialogue with shareholders and developments in compensation best practices. After the review, the Board and Compensation Committee approved the following changes:
• A simplified Annual Incentive balanced scorecard will be introduced that places additional weighting on financial performance (60% weighting) and that also focuses on key strategic objectives in the areas of innovation, access to healthcare, people and culture, data and digital (40% weighting). Values and Behaviors remain a key component of the Annual Incentive and are embedded in our culture. As such, members of the Executive Committee are expected to demonstrate these to the highest standard.
• The performance condition for the LTRPP has been made more stringent from the 2018-2020 performance cycle onward. Going forward, Executive Committee members will receive no payout if relative TSR is below the median of the companies in our global healthcare peer group.
• Finally, in line with evolving governance practices, we have revised our Long-Term Incentive plan rules for retiring Executive Committee members. From grants made in 2019 onwards, members who fulfill the retirement conditions under the plan rules will receive pro-rata vesting, rather than full vesting, of outstanding Long-Term Incentives. The timing of this change respects the one-year notice period required per Executive Committee employment contracts. Two members who have already met the conditions to retire with full vesting will be grandfathered under the current rules. These incentives will continue to have performance conditions applied and will vest at the end of the cycle on the normal vesting date.
Changes to our Board compensation system from the 2018 AGM
Board and committee membership fees have remained unchanged since the reduction that took place at the 2014 AGM. The Board has decided to rebalance its fee structure from the 2018 AGM to better recognize the responsibilities and time commitment of the committees, both of which have increased as a result of the evolving governance and regulatory environment. In particular, developments in compensation governance requirements have, over the last few years, resulted in a greater number of interactions between the Compensation Committee and shareholders and other external stakeholders.
The Board membership fee will decrease, and the committee membership fees will increase. The Board took into consideration external benchmarking information in the Swiss market as well as independent advice. The change is cost-neutral for the company, as the new fee structure results in the same average fee per Board member, excluding the Chairman.
In addition, following a review of practices among our peer group companies, the share ownership requirement for Board members will be increased from 4 000 to 5 000 shares, effective from the 2018 AGM. This minimum share ownership increase will strengthen the alignment of interests with those of shareholders. To allow sufficient time for Board members to achieve the increased requirement, they will have four years from appointment to acquire the minimum 5 000 shares under the new policy.
This change excludes the Chairman of the Board, whose share ownership requirement of 30 000 shares remains the same. In addition, all Board members will continue to be required to hold these shares for 12 months after retiring from the Board.
2018 CEO succession
Mr. Jimenez steps down as CEO on January 31, 2018, and will continue to support the Board and new CEO until his retirement date and the end of his notice period on August 31, 2018. He will retire in full compliance with the terms of his employment contract and the Novartis incentive plan rules. He will receive his annual base salary and pro-rated Annual Incentive until August 31, 2018. No new Long-Term Incentive awards will be made in January 2018. There will be no accelerated vesting of outstanding Long-Term Incentives, which will remain subject to performance over their full term. There will be no severance or non-compete payments.
Dr. Narasimhan will become CEO effective February 1, 2018. The Board determined Dr. Narasimhan’s compensation by taking into account the fact that this is his first Group CEO role. He will receive an annual base salary of CHF 1.55 million, with a view to increasing this over a period of three to four years, dependent on strong performance and proven ability in the role. Total performance-based variable compensation at target will be 475% of base salary split into his Annual Incentive (150%) and his two Long-Term Incentives (325%). This will result in an initial total annual compensation at target of CHF 8.91 million, 26% lower than that of Mr. Jimenez.
On behalf of Novartis and the Compensation Committee, thank you for your continued support and feedback, which we consider extremely valuable in driving improvements in our compensation systems and practices.
I invite you to send your comments to me at the following email address: investor.relations@novartis.com.
Respectfully,
Enrico Vanni, Ph.D.
Chairman of the Compensation Committee
119

Executive Committee compensation at a glance (pages 127 to 142)

2017 Executive Committee compensation system
Reflecting a strong focus on pay for performance and alignment with shareholder interest, variable pay represents a significant proportion of the package. Outcomes from variable pay elements can vary significantly (from 0% to 200% of the target level), depending on the level of performance achieved.
Fixed pay and benefitsAnnual base salaryPension and other benefitsVariable pay performance-relatedAnnual IncentiveLong-term share awardsLTPP1LTRPP2PurposeReflects responsibilities, experience and skill setsTailored to local market practices / regulationsRewards for performance against key short-term targets and Values and BehaviorsRewards long-term shareholder value creation and innovation in line with our strategyForm of paymentCashCountry / individual specific50% cash50% equity3 deferredfor three yearsEquityPerformance measuresPerformance matrix based on:•Individual balanced scorecard, including financial targets and individual objectives•Values and Behaviors•Novartis Cash Value Added•Innovation milestones•Relative TSR vs. global sector peers1LTPP = Long-Term Performance Plan 2LTRPP = Long-Term Relative Performance Plan3Executive Committee members may elect to receive more of their Annual Incentive in equity instead of cash.
The CEO’s Annual Incentive at target is 150% of base salary, his target LTPP is 200% of base salary and his target LTRPP is 125% of base salary. Based on Novartis’ compensation guidelines, the other members of the Executive Committee have Annual Incentive targets that range from 90% to 120% of base salary, and have Long-Term ­Incentives (LTPP and LTRPP) in total that range from 170% to 270% of base salary.
2017 CEO pay for performance – outcomes
2017 Annual Incentive Novartis performanceDeliver financial results•Group net sales, net income and free cash flow as a % of sales above target Ensure world-class commercial execution•Innovative Medicines delivered strong performance; Cosentyx well ahead of target, Entresto in line with expectations, Oncology sales slightly below target•Sandoz sales below target due to pricing pressure in the USTransform Alcon into an agile medicaldevicecompany•Alcon returned to growth with sales and core operating income results ahead of target, andall seven key approvals in innovation projects achievedStrengthen R&D•Pipeline milestone targets either achieved or surpassed, including 16 major approvals, 16major submissions and six FDA breakthrough therapy designationsImprove access to healthcare•Novartis access to healthcare programs expanded, with agreements now signed in sixcountries, delivering a portfolio of 15 products for USD 1 per treatment, per monthCreate a stronger company for the future•NTO, NBS and GDD delivered or over-delivered on productivity targets•Compliance, reputation and culture further improvedOverall performance outcome•Overall performance of the CEO was determined to be above expectations, based on achievements versus the targets set by the Board, and demonstration of the Novartis Values and Behaviors Overall outcome of 125% of target20152017 Long-Term IncentivesLong-Term Performance Plan (LTPP)•Novartis Cash Value Added outcome of 113% of target (75% weighting)•Key innovation milestones outcome of 115% of target (25% weighting) Overall outcome of 114% of targetLong-Term Relative Performance Plan (LTRPP)•Annual Total Shareholder Return (TSR) in USD was 20.4%. Absolute TSR growth in USD was 0.1% over the last three years. Relative performance in USD over the three-year performance cycle compared to peers was rank No. 12 out of 13 companiesOverall outcome of 0% of target
120
2017 total realized pay for the CEO
The 2017 total realized pay for the CEO was CHF 11 344 462 (compared with CHF 10 556 685 in 2016), and includes the payouts of the Annual Incentive, LTPP and LTRPP based on actual performance assessed for cycles concluding in 2017.
CHF 000sAnnual basesalaryPension and other benefits2017 Annual IncentiveLTPP 2015–20171LTRPP 2015–20171Total realizedcompensationJoseph Jimenez (CEO)2100239393750680113441The shown amounts represent the underlying share value of the total number of shares vested (including dividend equivalents) to the CEO for the LTPP and LTRPP performance cycle 2015-2017.
CEO succession – compensation elements
In September 2017, Novartis announced that Mr. Jimenez will retire following eight years as CEO and will be succeeded by Dr. Narasimhan effective February 1, 2018. An overview of the key compensation elements of the CEO succession is provided below. All terms are fully in line with the Swiss Ordinance against Excessive Compensation in Listed ­Companies.
Key compensation termsJoseph Jimenez(retiring CEO)All retirement terms are consistent with employment contract and incentive plan rules•12-month notice period ending August 31, 2018•No compensation increase in 2018 •Annual base salary, pension and other benefits, and Annual Incentive will be paid pro-rata in 2018•No new Long-Term Incentive grants in January 2018•Outstanding equity awards:No accelerated vesting Payout subject to achievement of performance conditions, share price movement and dividend equivalents •Incentives fully at risk, and subject to malus and clawback Vasant Narasimhan(appointed CEO)Target annual compensationCHF 000sp Salary1550p Annual Incentive (150% of salary)2325p LTPP (200% of salary; three-year cycle)3100p LTRPP (125% of salary; three-year cycle)1938Total at target8913•83% of total target compensation is variable performance-related pay•26% reduction versus his predecessor •Base salary will be kept under review, with any increases based on development and performance as CEO, consistent with the Executive Committee appointments compensation policy (details on page 124)
121

Board compensation at a glance (pages 146 to 150)

2017 Board compensation system
The compensation system applicable to the Board is shown below. All fees to Board members are delivered at least 50% in equity and the remainder in cash.

CHF 000s
AGM 2017-2018
annual fee
Chairman of the Board
3 800
Board membership
300
Vice Chairman
50
Chair of the Audit and Compliance Committee
120
Chair of the following committees:
• Compensation Committee
• Governance, Nomination and Corporate Responsibilities Committee
• Research & Development Committee
• Risk Committee




60
Membership of the Audit and Compliance Committee
60
Membership of the following committees:
• Compensation Committee
• Governance, Nomination and Corporate Responsibilities Committee
• Research & Development Committee
• Risk Committee




30
2017 Board compensation
Total actual compensation paid to Board members in the 2017 financial year is shown in the table below.

CHF 000s
2017
total compensation 1
Chairman of the Board
3 805
Other 12 members of the Board
4 591
Total
8 396
 1  Includes an amount of CHF 15 622 for mandatory employer contributions for all Board members paid by Novartis to Swiss governmental social security systems. This amount is out of total employer contributions of CHF 298 206, and provides a right to the maximum future insured government pension benefit for the Board member.

Compensation governance at a glance

(page 152)
A summary of the compensation decision authorization levels within the parameters set by the AGM is shown below, along with an overview of the risk management principles.
Decision on
Decision-making authority
Compensation of Chairman and other Board members
Board of Directors
Compensation of CEO
Board of Directors
Compensation of other Executive Committee members
Compensation Committee
Executive Committee compensation risk management principles
• Rigorous performance management process
• Balanced mix of short-term and long-term variable compensation elements
• Performance evaluation under the Annual Incentive includes an individual balanced scorecard and assessed Values and Behaviors
• Performance-based Long-Term Incentives only, with three-year overlapping cycles
• All variable compensation is capped at 200% of target
• Contractual notice period of 12 months
• Post-contractual non-compete limited to a maximum of 12 months from the end of employment (annual base salary and Annual Incentive of the prior year only) as per contract, if applicable
• Good and bad leaver provisions apply to variable compensation of leavers
• No severance payments or change-­of-control clauses
• Clawback and malus principles apply to all elements of variable compensation
• Share ownership requirements; no hedging or pledging of Novartis share ownership position
122

Executive Committee compensation philosophy and principles

Novartis compensation philosophy
Our compensation philosophy aims to ensure that Executive Committee members are rewarded according to their success in implementing the company strategy as well as their contribution to company performance and long-term value creation.
Pay for performance•Variable compensation is tied directly to the achievement of strategic company targetsShareholderalignment•Our incentives are significantly weighted toward long-term, equity-based plans•Measures under the Long-Term Incentives are calibrated to promote the creation of shareholder value •Executive Committee members are expected to build and maintain substantial shareholdings Balanced rewards•Balanced set of measures to create sustainable value•Mix of targets based on financial metrics, innovation, individual objectives, Values and Behaviors, and performance vs. competitorsBusiness ethics•The Values and Behaviors are an integral part of our compensation system•Forms part of the assessment of the individual objectives for the Annual IncentiveCompetitive compensation•Total compensation must be sufficient to attract and retain key global talent•Overarching emphasis on pay for performance
Alignment with company strategy
The Novartis strategy is to use science-based innovation to deliver better patient outcomes. We aim to lead in growing areas of pharmaceuticals and oncology medicines, generics and biosimilars, and eye care.
To align the compensation system with this strategy and to ensure that Novartis is a high-performing organization, the company operates both a short-term Annual Incentive and two Long-Term Incentive plans with a balanced set of measures and targets.
The Board determines specific, measurable and time-bound performance metrics for the Annual Incentive and the two Long-Term Incentive plans.
Executive Committee compensation
There is fierce competition within the pharmaceutical and biotechnology industries for top executive talent with deep expertise, competencies and proven performance. The Board and the Compensation Committee determine compensation for appointed Executive Committee members in line with the appointments compensation policy outlined on page 124.
Approach to benchmarking
Novartis takes a rigorous approach to peer group construction and maintenance. In recent years, the Compensation Committee has solicited feedback from shareholders and the Compensation Committee’s independent advisor in selecting peer companies for executive compensation comparison purposes. External peer data is one of the elements considered by the Board and the Compensation Committee when making decisions on executive pay and helps ensure the system and levels at Novartis remain competitive.
The Compensation Committee considers executive compensation among the peer group of 15 global healthcare companies set out in the table below, as communicated in last year’s Compensation Report. The companies in this peer group were selected based on a number of criteria that reflect our industry, as well as the size and scope of operations. Target compensation is generally positioned around the market median benchmark for comparable roles within this group.
Global healthcare peer groupAbbVieBiogenEli Lilly & Co.Johnson & JohnsonPfizerAmgenBristol-Myers SquibbGilead SciencesMerck & Co.RocheAstraZenecaCelgeneGlaxoSmithKlineNovo NordiskSanofi
The Compensation Committee believes that using a consistent set of peers that have a similar scope and size enables shareholders to evaluate the compensation year on year and make pay-for-performance comparisons. Novartis therefore makes the commitment to shareholders to confirm benchmarking practices, including the peer group, each year.
Although Novartis is headquartered in Switzerland, more than a third of sales come from the US market, and the US remains a significant talent pool for the recruitment of executives by the company. All current Executive Committee members have either worked in or have extensive experience with the US. It is therefore critical that Novartis is able to attract and retain key talent globally, especially from the US.
For consideration of European and local practices, the Compensation Committee also references a cross-industry peer group of Europe-headquartered multinational companies selected on the basis of comparability in size, scale, global scope of operations, and economic influence to Novartis. Five of these companies focus exclusively on healthcare: AstraZeneca, GlaxoSmithKline, Novo Nordisk, Roche and Sanofi. Ten companies are selected from the STOXX® All Europe 100 Index representing multiple sectors: Anheuser-Busch InBev, Bayer, BMW, Daimler, Danone, Heineken, L’Oréal, Merck KgaA, Nestlé and Unilever.
While the global healthcare peer group remains the primary comparator group for pay decisions, this second cross-industry group, which remains unchanged since last year, is used as an additional reference point to assess wider market pay practices and to minimize any distortions in Novartis compensation practices and systems.
123

Executive Committee compensation policies

Executive Committee appointments compensation policy
The Compensation Committee takes a prudent approach to setting compensation. Consistent with that philosophy, when determining the compensation arrangements for a newly appointed Executive Committee member, the ­following principles are applied:
Element of compensationPolicyLevelThe overall package should be market-competitive to facilitate the recruitment of global executive talent with deep expertise and competencies. The Compensation Committee will always intend to pay no more than it believes is necessary to secure the required individual. Annual base salaryThe Compensation Committee may appoint individuals who are new to a role on an annual base salary that is below the market level, with a view to increasing this toward a market level over a period of three to four years as an individual develops in the role. This prudent approach ensures pay levels are merit-based, with increases dependent on strong performance and proven ability in the role over a sustained period.IncentivesThe ongoing compensation package will normally include the key compensation elements and incentive opportunities in line with those offered to current Executive Committee members. In exceptional circumstances, higher Long-Term Incentive opportunities than those offered to current Executive Committee members may be provided, at the Compensation Committee’s discretion. Performance measures may include business-specific measures tailored to the specific role.Pension and other benefitsNewly appointed Executive Committee members are eligible for local market pension and other benefits in line with the wider senior employee group.Buy-outsThe Compensation Committee seeks to balance the need to offer competitive compensation opportunities to acquire the talent required by the business with the principle of maintaining a strong focus on pay for performance. As such, when an individual forfeits variable compensation as a result of appointment at Novartis, the Compensation Committee may offer replacement awards in such form as the Compensation Committee considers appropriate, taking into account relevant factors. Relevant factors include the replacement vehicle (i.e. cash, restricted share units, restricted shares or performance share units), whether the award is contingent on meeting performance conditions or not, the expected value of the forfeited award, the timing of forfeiture (i.e. Novartis mirrors the blocking or vesting period of the forfeited award) and the leaver conditions, in case the recruited individual leaves Novartis prior to the end of the blocking or vesting period. The Compensation Committee will seek to pay no more than is required to match the commercial value or fair value of payments and awards forfeited by the individual.International mobility If individuals are required to relocate or be assigned from their home location to take up their position, relocation support may be provided in line with our global mobility policies (e.g., relocation support, tax equalization).
124
Treatment of variable compensation for Executive Committee member leavers
The following table sets out the treatment of variable compensation for associates (including Executive Committee members) who leave Novartis during the performance or vesting period. All variable compensation is subject to malus and clawback provisions, including after termination of employment.
Element of compensationPolicyAnnual Incentive cash elementRetirement, termination by the company (for reasons other than performance or conduct), change of control, disability, deathPro-rata Annual Incentive is paid to reflect the portion of the year the individual was employed.Any other reasonNo Annual IncentiveAnnual Incentive mandatory deferral into restricted shares / RSUsIf a participant leaves employment due to voluntary resignation or misconduct, unvested restricted shares and restricted share units (RSUs) are forfeited. All awards are subject to non-compete terms until the end of the three-year blocking date, starting from the date of grant.Annual Incentive voluntary restricted shares / RSUs / ADRs (US associates only)Awards are not subject to forfeiture during the deferral period. Long-Term Incentives (LTPP / LTRPP)Voluntary resignation or termination by the company for misconductAll of the award will be forfeited.Terminated by the company for reasons other than performance or conduct, and change in control due to divestmentAwards vest on the regular vesting date, subject to performance, on a pro-rata basis for time spent with the company during the performance cycle. There is no accelerated vesting.Retirement For grants made until the end of 2018, awards vest on the normal vesting date, subject to performance, without the application of time pro-rating. For grants made to members of the Executive Committee from 2019 onward, awards will vest on the normal vesting date, subject to performance, with the application of time pro-rating. The timing of this change respects the one-year notice period required in the Executive Committee employment contracts.Death or long-term disability Accelerated vesting at target will be applied in the case of death and long-term disability.Non-compete agreementAll awards are subject to non-compete terms against the healthcare peer group until the vesting date.
Malus and clawback
Any incentive compensation paid to Executive Committee members is subject to malus and clawback rules. This means that the Board for the CEO, and the Compensation Committee for the other Executive Committee members, may decide – subject to applicable law – to retain any unpaid or unvested incentive compensation (malus), or to recover incentive compensation that has been paid or has vested in the past (clawback). This applies in cases where the payout conflicts with internal management standards, including company and accounting policies, or violates laws.
This principle applies to both the short-term Annual Incentive and the Long-Term Incentive plans.
In 2017, malus or clawback for current or former Executive Committee members was not required.
125

Executive Committee performance management process

To foster a high-performance culture, the company applies a uniform performance management process worldwide based on quantitative and qualitative criteria, including our Values and Behaviors. All Novartis associates, including the CEO and other Executive Committee members, are subject to a formal three-step process: objective setting, performance evaluation and compensation determination. This process is explained below.
Performance targets are generally set before the start of the relevant performance cycle. There is a rigorous framework in place for establishing targets to ensure they are suitably robust and challenging, and align with the strategic priorities of the Group. The key factors taken into account when setting targets include:
• Novartis strategic priorities.
• Internal and external market expectations.
• Regulatory factors (e.g., new launches, patent expiries).
• Investment in capital expenditure.
• Values and Behaviors.
The targets are challenged at multiple stages before they are ultimately approved by the Board. In line with good governance practices, the Compensation Committee works to set targets that are ambitious and challenging but that do not encourage undue risk taking.
Following the end of the performance cycle, the Board and the Compensation Committee consider performance against the targets originally set. The CEO and Executive Committee members are not present while the Board and Compensation Committee discuss their individual performance evaluations. Prior to determining the final outcome, related factors – such as performance relative to peers, wider market conditions and general industry trends – are used to inform the overall performance assessment.
Objective setting•The CEO discusses his targets with the Chairman of the Board; they are then reviewed and approved by the Board of Directors, based on input from the Compensation Committee. •For other Executive Committee members, targets for their division or unit are initially discussed with the CEO and subsequently approved by the Board and Compensation Committee. Performance evaluation•The CEO’s performance is assessed by the Board.•For Executive Committee members, the CEO discusses performance for each individual with the Chairman before making recommendations to the Board.•Periodic assessments, including at the mid-year stage, ensure progress is suitably tracked.Compensation determination •A recommendation for the CEO’s variable pay is made by the Compensation Committee to the Board for final determination.•The CEO’s recommendations for other Executive Committee members are considered and approved by the Compensation Committee, after which the Board is notified of the outcomes.
126

2017 Executive Committee compensation

System and performance outcomes
Annual base salary
Overview•The annual base salary is reviewed each year, taking into account the individual’s role, performance and experience; business performance and the external environment; increases across the Group; and market movements.2017 annual base salariesAnnual base salary (effective March 1, 2017):•CEO: CHF 2100000 (no increase awarded during the year)•Other Executive Committee members: see details on page 138Pension and other benefitsOverview•Pension and other benefits do not constitute a significant proportion of total compensation and are provided to Executive Committee members on the same terms as all other associates, based on country practices and regulations.•The company operates both defined benefit and defined contribution pension plans (see also Note 24 to the Group’s consolidated financial statements). •Novartis may provide other benefits according to local market practice. These include company car provision, tax and financial planning, and insurance benefits. •Executive Committee members who are required to relocate internationally may also receive additional benefits (including tax equalization), in line with the company’s global mobility policies.
127
Annual Incentive – 2017
PLAN OVERVIEWGrant formula On-target opportunities•CEO: 150% of annual base salary•Other Executive Committee members: 90% to 120% of annual base salary Performance measures•Performance is measured against a balanced scorecard of quantitative targets and individual objectives; behavior is assessed against the Novartis Values and Behaviors. Balanced scorecard•The 2017 balanced scorecard targets and achievements of the CEO are detailed on the next page. •Balanced scorecards for the other Executive Committee members have quantitative objectives (weighted 60%) specific to their division or business unit. For Group function heads, these are the same as the Group financial targets of the CEO. The individual objectives (weighted 40%) differ by role. They may include additional financial and strategic targets, such as EPS; growth, productivity and development initiatives; leadership; diversity; quality; and corporate responsibility initiatives, including access to medicine. They also include managing company reputational risk.Values and Behaviors•The Annual Incentive also takes into account an assessment of the following six Values and Behaviors: innovation, quality, collaboration, performance, courage and integrity. •The Executive Committee members are expected to demonstrate these at the highest level. Further details on the Values and Behaviors can be found on page 18.Payout matrix•The payout matrix equally recognizes performance against the balanced scorecard of financial and non-financial targets, and demonstration of our Values and Behaviors. The payout range is 0200% of on-target opportunity based on performance, as shown below:Form of award•At the end of the performance period, 50% is paid in cash and the remaining 50% is paid in Novartis restricted shares or RSUs, deferred for three years (see table on page 125 for details on leaver treatment).•Executives may choose to receive all or part of the cash portion of their Annual Incentive in Novartis shares or American Depositary Receipts (ADRs; US only) that will not be subject to forfeiture conditions. In the US, awards may also be delivered in cash under the US-deferred compensation plan.•Clawback and malus provisions apply to all Annual Incentive awards.Dividend rights, voting rights and settlement•Restricted shares carry voting rights and dividends during vesting period. RSUs are of equivalent value but do not carry voting rights and dividends during vesting period. •Following the vesting period, settlement of RSUs is made in unrestricted Novartis shares or ADRs. Annual base salaryxTarget incentive %=Target Annual Incentive% PayoutPerformance vs. balanced scorecardExceedingexpectations60  90%130  160%170  200%Meeting expectations0  70%90  120%130  160%Partially meeting expectations0%0  70%60  90%Partially meeting expectationsMeeting expectationsExceedingexpectationsValues and Behaviors assessment
disclosure of CEO Annual incentive PrinciplesTargets and achievements of the Annual Incentive are disclosed in arrears due to commercial sensitivity of the targets. However, to ensure that shareholders can understand the basis for CEO Annual Incentive awards, a detailed balanced scorecard is disclosed annually after the end of the performance cycle.
128
2017 ceo Balanced Scorecard Balanced scorecard performance is measured in constant currencies to reflect operational performance that can be influenced. The Board uses a stringent process to set ambitious financial targets and incentivize superior performance.AchievementCEO achievements 2017Targetvs. targetGroupfinancial targets(60%)Group net sales|USD 48.4 billion|AboveCorporate net result|USD -1.5 billion|AboveGroup net income|USD 7.0 billion|Above Group free cash flow as a % of sales|19%|Strongly aboveOverall assessment of Group financial targets in constant currencies|AboveIndividualobjectives(40%)Additional financial targetsAboveIn constant currencies, operating income and earnings per share, as well as core operating income and core earnings per share, were above target. Annual total shareholder return in USD was 20.4%. Pharmaceuticals, Alcon and Sandoz exceeded their market share growth targets, while Oncology was slightly below target. Ensure world-class commercial execution|Largely metThe Innovative Medicines Division delivered strong performance. Cosentyx was well ahead of target, while Entresto was in line with expectations. Oncology sales were slightly below target, mainly due to a slower launch uptake of Kisqali. Sandoz sales were below target, impacted by industry pricing pressure in the US, partly offset by continued strong growth outside the US. Strong sales in biosimilars reinforced global leadership in the field. Transform Alcon into an agile medical device company|MetAlcon made good progress and returned to growth in 2017, with four quarters of successive growth. Sales and core operating income results were ahead of target. Seven key approvals were achieved (e.g., AcrySof IQ ReSTOR +2.5 D Multifocal Toric IOL launched in the US, CyPass Micro-Stent launched in the EU), and fundamentals in both the commercial organization and the supply chain were significantly improved.Strengthen R&D |Strongly above Pipeline milestone targets were achieved or surpassed, including 16 major approvals and 16 major submissions. Novartis received six breakthrough therapy designations from the FDA. 15 positive readouts from major studies were delivered (e.g., CAR-T 19, RTH258, CANTOS and BAF312). Sandoz had five key filings of biosimilars. The Novartis Institutes for BioMedical Research launched an initiative to better explore new targets, showing positive results, and Global Drug Development efficacy improved significantly.Expand access to healthcare, and corporate responsibility|MetAccess to healthcare programs were expanded, with agreements now signed in six countries to bring a portfolio of 15 products to participating governments and organizations for the price of USD 1 per treatment, per month. Over USD 530000 of such treatments were delivered in 2017. Global endorsement of a new action plan to accelerate leprosy elimination was reached. Novartis reached new milestones in efforts to eliminate malaria. USD 850 million in treatments have now been delivered since 2001, and Novartis initiated clinical trials for KAF156, a novel compound against multidrug-resistant malaria. Novartis signed its first US windfarm power purchase agreement to offset carbon emissions.Create a stronger company for the future|Met NTO, NBS and GDD delivered or over-delivered on productivity targets. Compliance and integrity were strengthened. The global compliance program Step Change was fully transitioned and embedded into the organization. Novartis announced the acquisition of Advanced Accelerator Applications SA in Oncology and invested in a number of digital technologies in R&D, commercial and operations. 99% of health authority quality inspections were deemed good or acceptable. Reputation improved further, with good progress in a number of important industry rankings. Culture, particularly collaboration across the organization, further improved. Talent was upgraded in all divisions, and diversity targets for leadership were met. Overall assessment of individual objectives|Above Overall assessment of CEO balanced scorecardAbove target
ANNUAL INCENTIVE PAYOUT FOR the 2017 performance yearCEO payout In reaching its recommendation to the Board on the CEO’s 2017 Annual Incentive payout factor, the Compensation Committee recognized that overall, he exceeded expectations. Overall, the Board approved an Annual Incentive payout of 125% of target, i.e. CHF 3 937 542 for the CEO.
129
Long-Term Performance Plan – 2015-2017 cycle
The Long-Term Performance Plan (LTPP) is the first of two Long-Term Incentive plans, which rewards creation of long-term value and innovation, in line with our business strategy.
Plan overview Grant formula At the start of the performance cycle, performance share units (PSUs) are granted under each of the Long-Term Incentive plans, as follows:On-target opportunity and payout rangeOn-target opportunities:•CEO: 200% of annual base salary•Other Executive Committee members: between 140% and 190% of annual base salaryPayout range: from 0% to 200% of the on-target amount based on performanceForm of awardPSUs granted at the beginning of the cycle will vest at the end of the three-year performance cycle and are converted into Novartis shares.PSUs carry dividend equivalents that are paid in shares at the end of the cycle to the extent that performance conditions have been met.Payout formula:Policy information on page 125 provides details on the treatment of Long-Term Incentive awards for leavers.Step 1Annual base salaryxTarget incentive %=Grant valueStep 2Grant value/Share price=Target number of PSUsTarget number of PSUsxPerformance factor+Dividend equivalents=Realized PSUs
For the 2015-2017 cycle, the tables below provide details on the achievements and payouts for each of the two performance measures of the LTPP. The Novartis Cash Value Added performance measure (75% weighting) applies equally for the CEO and the other Executive Committee members. The innovation performance measure (25% weighting) is specific to the respective head of the division or unit, and is a weighted average of the divisions or units for the CEO and Group function heads.
Performance measure 1: Novartis Cash Value Added (ncva) for 2015-2017 cycle (75% of LTPP)DescriptionNCVA incentivizes sales growth and margin improvement as well as asset efficiency. It is calculated as follows:1 WACC = weighted average cost of capital2 NCVA = (cash flow return on investment % WACC) x gross operational assets in constant currenciesThe NCVA performance factor is based on a 1:3 payout curve, where a 1% deviation in realization versus target leads to a 3% change in payout (for example, a realization of 105% leads to a payout factor of 115%). Accordingly, if performance over the three-year vesting period falls below 67% of target, no payout is made for this portion of the LTPP. If performance over the three-year vesting period is above 133% of target, payout for this portion of the LTPP is capped at 200% of target.Group performance outcome for the 2015-2017 cycleDuring the 2015-2017 cycle, Novartis delivered an NCVA of USD 8.3 billion, 4.4% ahead of a target of USD 7.9 billion in constant currencies. This was mainly due to a much stronger operational performance in 2017, driven especially by Cosentyx and Entresto, and Alcon returning to growth. Following the application of the 1:3 payout curve, the 104.4% achievement versus target generates a performance factor of 113% of target for this part of the LTPP. When determining the NCVA target for 2015-2017 in comparison to the 2014-2016 cycle, the Board took into account predominantly the loss of exclusivity of Glivec/Gleevec, a total of USD 2.8 billion of sales in 2017 compared to 2014. They also considered the impact of the negative currency effects (strengthening of the US dollar), which were partly offset by lower costs of capital resulting from lower interest rates.Operating income+Amortization, impairments, and adjusting for gains / losses from non-operating assetsTaxesCapital charge (based on WACC1) on gross operational assets=NCVA2
130
Performance measure 2: Innovation measure for cycle 2015-2017 (25% of LTPP)DescriptionInnovation is a key value driver for shareholders and is critical to our future. At the beginning of the cycle, the Research & Development Committee determines the most important target milestones, considering the following:•The expected future potential revenue•The potential qualitative impact of research and development on science and medicine•The potential impact of research and development on the treatment or care of patientsAt the end of the cycle, the Compensation Committee determines the payout factor based on the performance assessment made by the Research & Development Committee.Payout range 0150% based on achievement of target milestones; payout range 150200% for truly exceptional performance.Group performance outcome for the 2015-2017 cycleDuring the 2015-2017 performance cycle, Novartis delivered solid performance versus target on innovation, which accelerated over the three-year performance period. Some of the successes in the Innovative Medicines Division included approvals of Cosentyx (ankylosing spondylitis and psoriatic arthritis) and Kisqali (metastatic breast cancer), as well as the AMG 334 (migraine) submission. The serelaxin (acute heart failure) pivotal study readout was disappointing. Sandoz achievements included the rituximab US and EU filings, as well as epoetin alfa EU approval. Sandoz did not achieve approval in the US and EU for pegfilgrastim. Alcon achieved EU approval for the Clareon IOL with AutonoMe pre-loaded delivery system, and EU approval for Dailies Total1 Multifocal. NIBR discovered several unanticipated targets using shRNA/CRISPR and phenotypic screens, translational clinical research and integrative genomics. The achievements made over the three-year performance cycle will have a positive impact on Novartis, the scientific and medical community, and patient outcomes. Following input from the Research and Development Committee, the Board approved an innovation performance factor for the Group of 115% of target.
LTPP PAYOUT for the 2015-2017 performance cycle CEO payoutOverall, the Board approved an LTPP payout of 114% of target for the CEO, i.e. CHF 5 068 337 (including CHF 446 250 of dividend equivalents accrued and CHF -66 618 in share price evolution over the performance cycle).
disclosure of LTPP targetsPrinciplesLTPP targets (NCVA and long-term innovation) are considered commercially sensitive at the time of setting and therefore are not disclosed on a prospective basis. However, to ensure that shareholders are able to understand the link between pay and performance, we will disclose the targets, achievements and payout after the end of the performance cycle.
131
Long-Term Relative Performance Plan – 2015-2017 cycle
The Long-Term Relative Performance Plan (LTRPP) is the second of two Long-Term Incentive plans, which rewards competitive shareholder return relative to the global healthcare peer group.
plan overview Grant formula At the start of the performance cycle, PSUs are granted under each of the Long-Term Incentive plans, as follows:On-target opportunity and payout rangeOn-target opportunities:•CEO: 125% of annual base salary •Other Executive Committee members: between 30% and 80% of annual base salaryPayout range: from 0% to 200% of the on-target amount based on performanceForm of awardPSUs granted at the beginning of the cycle will vest at the end of the three-year performance cycle and are converted into Novartis shares.PSUs carry dividend equivalents that paid in shares at the end of the cycle to the extent that performance conditions have been met.Payout formula:Policy information on page 125 provides details on the treatment of Long-Term Incentive awards for leavers.Step 1Annual base salaryxTarget incentive %=Grant valueStep 2Grant value/Share price=Target number of PSUsTarget number of PSUsxPerformance factor+Dividend equivalents=Realized PSUs
Relative TSR performance for cycle 2015-2017 (100% of LTRPP)DescriptionPerformance is based on our TSR relative to a global healthcare peer group. Outperformance of this peer group is a key indicator of the extent to which Novartis is delivering long-term value for shareholders.The peer group and payout matrix for the 2015-2017 performance cycle are as follows:1From the LTRPP 2017-2019 performance cycle onward, a revised peer group of 15 global healthcare companies applies, as listed on page 123.2 From the LTRPP 2018-2020 performance cycle onward, there will be no vesting for below median performance.The payout matrix includes a significant reduction (including scope to reduce to nil) when Novartis does not outperform the majority of the companies in the group.At the end of the performance cycle, all companies are ranked in order of highest to lowest TSR in USD. The Compensation Committee uses its discretion to determine the payout factor within the ranges shown above, and takes into consideration factors such as absolute TSR, overall economic conditions, currency fluctuations and other unforeseeable economic situations. Group performance outcomefor the 2015-2017 cycleAbsolute annual TSR in USD was 20.4%. Absolute TSR over the three-year cycle was 0.1% in USD (-1.4% in CHF). Relative TSR performance in USD was rank number 12 out of 13 companies (rank number four among five European comparators).The Board awarded a performance factor of 0%.2015-2017 peer group (12 companies, excluding Novartis)1AbbotAstraZenecaGlaxoSmithKlinePfizerAbbVieBristol-Myers SquibbJohnson & JohnsonRocheAmgenEli Lilly & Co.Merck & Co.SanofiNovartis position Payout range2in the peer group(% of target)Position 1 3Position 4 6Position 7 10Position 11 13160 200% 100 140%20 80%0%
LTRPP PAYOUT for the 2015-2017 performance cycle CEO payout Overall, the Board approved an LTRPP payout of 0% of target for the CEO, i.e. no payout.
132
Realized compensation
To aid shareholders’ understanding of the link between pay and short-term and long-term performance, the ­Compensation Committee has decided to disclose the realized compensation for the CEO individually and, for the first time, the other members of the Executive Committee on an aggregated basis. Disclosing realized compensation means that the Annual Incentive and the Long-Term Incentives are disclosed at the end of their respective ­performance cycles, reflecting actual payouts based on performance.
The total actual payout may vary year-on-year depending on multiple factors, including the composition of the Executive Committee and the tenure of its members (as new members may not have vested Long-Term Incentives), compensation increases, payout of variable compensation based on actual performance, share price fluctuations of Long-Term Incentives, and dividend equivalents.
2017 realized compensation for the CEO and other Executive Committee members
The table below reports the fixed and other compensation for the year, including the Annual Incentive for the 2017 performance year, as well as the realized Long-Term Incentives for the 2015-2017 performance cycle. The portion of the Annual Incentive paid in shares for the year 2017 is disclosed using the underlying value of Novartis shares at the date of grant, while the realized value of the LTPP and LTRPP payouts (including dividend equivalents) is ­calculated using the share price on the date of vesting.
2017 annual base salary
2017 pension benefits
2017 Annual Incentive1
Long-Term Incentives
Other 2017 Compensation2
LTPP 2015–2017 cycle
LTRPP 2015–2017 cycle



Currency



Cash (amount)



Amount



Cash



Equity 1


Equity (value
at vesting date) 2


Equity (value
at vesting date) 2



Amount 3
Total realized
compensation
(incl. Share
price movement) 4
Executive Committee members active on December 31, 2017
Joseph Jimenez (CEO)
CHF
2 100 000
166 397
1 968 750
1 968 792
5 068 337
0
72 186
11 344 462
Aggregate realized compensation of the other 10 ECN members
CHF
9 310 740
1 675 398
5 841 107
7 743 069
8 355 739
0
3 248 419
36 174 472
Total 5
CHF
11 410 740
1 841 795
7 809 857
9 711 861
13 424 076
0
3 320 605
47 518 934
See page 134 for 2016 comparative figures.
  1  The portion of the Annual Incentive delivered in equity is rounded up to the nearest share, based on the closing share price on the grant date (January 18, 2018) of CHF 82.90 per Novartis share and USD 86.41 per ADR.
  2  The amounts represent the underlying share value of the 160 733 PSUs vesting on January 21, 2018 to the CEO and other Executive Committee members for the performance cycle 2015-2017, inclusive of earned dividend equivalents for the three-year cycle. The value is determined using the closing share price on the last trading day (January 19, 2018) before the vesting date of CHF 83.38 per Novartis share and USD 86.94 per ADR. For two members of the Executive Committee, the vesting value is reported pro-rata based on the period they were an Executive Committee member during the performance cycle.
  3  Includes any other perquisites, benefits in kind, international assignment benefits as per the global mobility policy (e.g., housing, international health insurance, children's school fees, tax equalization).
  4  All amounts are before deduction of the social security contribution and income tax due by the Executive Committee member.
  5  Amounts for Executive Committee members paid in USD were converted at a rate of CHF 1.00 = USD 1.015, which is the same average exchange rate used in the Group's 2017 consolidated financial statements.
The aggregate amount of realized compensation for the members of the Executive Committee shown in the table above is CHF 47 518 934 million. This figure is below past and expected future levels, despite the fact that the Annual Incentive and the LTPP paid out above target on average for the members, mainly due to the following factors:
• There was no payout for the LTRPP for any of the Executive Committee members in 2017, due to relative TSR over the 2015-2017 performance cycle.
• Five members of the Executive Committee either did not receive LTPP vesting or received limited LTPP vesting in 2017. This is because they were either recent external hires who did not receive a grant three years earlier, or internal promotions who received lower Long-Term Incentive grants based on their compensation prior to ­Executive Committee appointment.
At the start of the 2015-2017 performance cycle, the CEO was granted 48 626 target performance share units under the LTPP at a share price of CHF 84.75, for a total target grant value of CHF 4 121 054. As shown in the table above, the realized value of the LTPP for the CEO was CHF 5 068 337. Compared to the target value at the grant date, this includes CHF 567 651 relating to the performance over the cycle, CHF -66 618 due to share price movement and CHF 446 250 of dividend equivalents.
At the start of the 2015-2017 performance cycle, the other members of the Executive Committee were granted 80 325 target performance share units under the LTPP at a share price of CHF 84.75 (ADR price of USD 98.75 for Executive Committee members on a US employment contract at an exchange rate of CHF 1 = USD 1.040 at grant), for a total target grant value of CHF 6 887 395 (which is pro-rated for two Executive Committee members based on the period they were an Executive Committee member during the performance cycle). As shown in the table
133
above, the realized value of the LTPP for the other members of the Executive Committee was CHF 8 355 739. Compared to the target value at the grant date, this includes CHF 931 727 relating to the performance over the cycle, CHF -195 650 due to share price and foreign exchange movements and CHF 732 267 of dividend equivalents.
The column titled “Other 2017 Compensation” in the 2017 total realized compensation of the Executive Committee includes the following amounts:
• CHF 470 925 relating to the vesting of a buy-out award made to Richard Francis when he joined Novartis in 2014 to replace a time-vesting long-term incentive that he lost by leaving his previous employer upon joining Novartis.
• CHF 40 174 relating to the vesting of a buy-out award made to Paul Hudson to replace a time-vesting long-term incentive he lost upon joining Novartis in 2016, and CHF 729 047 relating to the vesting of a buy-out award made to him to replace a performance-vesting long-term incentive that he lost with his previous employer upon joining Novartis. This latter award was granted with performance conditions attached, to mirror the forfeited award. The performance conditions applied were the same as those for the LTPP for the 2014-2016 performance cycle (NCVA and long-term innovation).
All abovementioned buy-out awards were disclosed at the time of grant in previous Compensation Reports.
2016 realized compensation for the CEO and other Executive Committee members (comparative information)
For comparative purposes, 2016 realized compensation is provided below. The main reason for the higher aggregate realized pay in 2016 was the overlap in compensation for outgoing and newly appointed Executive Committee members in 2016. Three members who stepped down in 2016 received ongoing contractual payments during their notice periods while their successors were already in place.
2016 annual base salary
2016 pension benefits
2016 Annual Incentive1
Long-Term Incentives
Other 2016 Compensation2
LTPP 2014–2016 cycle
LTRPP 2014–2016 cycle



Currency



Cash (amount)



Amount



Cash



Equity 1


Equity (value
at vesting date) 2


Equity (value
at vesting date) 2



Amount 3
Total realized
compensation
(incl. Share
price movement) 4
Executive Committee members active on December 31, 2016 and members who stepped down during financial year 2016
Joseph Jimenez (CEO)
CHF
2 093 417
160 283
1 417 500
1 417 510
4 950 334
442 013
75 628
10 556 685
Aggregate realized compensation of the other 13 ECN members 5
CHF
8 778 483
1 675 484
4 825 680
6 516 148
12 190 674
733 656
9 684 126
44 404 251
Total 6
CHF
10 871 900
1 835 767
6 243 180
7 933 658
17 141 008
1 175 669
9 759 754
54 960 936
  1  The portion of the Annual Incentive delivered in equity is rounded up to the nearest share, based on the closing share price on the grant date (January 17, 2017) of CHF 71.35 per Novartis share and USD 71.99 per ADR.
  2  The amounts represent the underlying share value of the PSUs vesting to Executive Committee members for the performance cycle 2014-2016, based on the closing share price on the vesting date (January 17, 2017) of CHF 71.35 per Novartis share and USD 71.99 per ADR, plus earned dividend equivalents during the three-year cycle.
  3  Includes any other perquisites, benefits in kind, international assignment benefits as per the global mobility policy (e.g., housing, international health insurance, children's school fees, tax equalization). In addition, for the three Executive Committee members who stepped down during 2016, it includes, inter alia, their pro-rata compensation from the date they stepped down from the Executive Committee to December 31, 2016.
  4  All amounts are before deduction of the social security contribution and income tax due by the Executive Committee member.
  5  This represents realized compensation of ten Executive Committee members who were active on December 31, 2016 as well as three members who stepped down during 2016.
  6  Amounts for Executive Committee members paid in USD were converted at a rate of CHF 1.00 = USD 1.015, which is the same average exchange rate used in the Group's 2016 consolidated financial statements.
The column titled “Other 2016 Compensation” 2016 total realized compensation of the Executive Committee includes the following amounts:
• CHF 1 059 750 relating to the vesting of a buy-out award made to Richard Francis when he joined Novartis in 2014 to replace a time-vesting long-term incentive that he lost by leaving his previous employer.
• CHF 191 300 relating to a cash buy-out award made to Paul Hudson when he joined Novartis in 2016 to replace a short-term incentive that he lost by leaving his previous employer.
• USD 844 250 relating to a cash buy-out award made to James Bradner when he joined Novartis in 2016 to replace lost entitlements at one of his former scientific companies.
All abovementioned buy-out awards were disclosed at the time of grant in previous Compensation Reports.
134
Compensation at grant value
In accordance with the Swiss Ordinance against Excessive Compensation in Listed Companies, Novartis continues to disclose total compensation at grant value for the CEO and other Executive Committee members. The tables below disclose for the CEO and other Executive Committee members:
• Fixed 2017 compensation (base salary and benefits).
• The actual cash portion and the deferred portion granted in equity of the 2017 Annual Incentive.
• LTPP and LTRPP 2017-2019 performance cycle awards, which are reported at target value at grant date under the assumption that the awards will vest at 100% achievement and excluding any share price movement and ­dividend equivalents that may be accrued over the performance cycle. The future payout will only be determined after the performance cycle concludes in three years (i.e., end of 2019), with a payout range of 0–200% of the target value.
• Other compensation for 2017, which includes other benefits and the full amount of compensation for lost ­entitlements from former employers, either paid in cash or granted in equity in the year.
To assess CEO pay for performance in 2017, including the Annual Incentive payout for the 2017 performance year and the Long-Term Incentive payouts for the 2015-2017 performance cycle, shareholders should refer to the 2017 realized compensation table on page 133.
2017 compensation at grant value for the CEO and other Executive Committee members
Fixed compensation and pension benefits
Variable compensation
Actual compensation paid or granted for 2017
Long-Term Incentive 2017-2019 cycle grants at target
2017 annual base salary
2017 pension benefits
2017 Annual Incentive (performance achieved)
LTPP 2017–2019 cycle
LTRPP 2017–2019 cycle
Other 2017 compensation
Total compensation paid, promised or granted 2017


Currency

Cash
(amount)


Amount 1


Cash
Equity
(value at
grant date) 2
PSUs
(target value
at grant date) 3
PSUs
(target value
at grant date) 3


Amount 4


Amount 5
Executive Committee members active on December 31, 2017
Joseph Jimenez (CEO)
CHF
2 100 000
166 397
1 968 750
1 968 792
4 200 018
2 625 038
72 186
13 101 181
Steven Baert
CHF
775 000
154 652
663 000
663 034
1 170 069
468 056
119 218
4 013 029
F. Michael Ball
USD
1 120 000
203 546
873 600
873 605
1 792 047
784 043
293 289
5 940 130
James Bradner
USD
1 066 385
117 394
898 800
898 837
1 819 043
856 033
45 855
5 702 347
Felix R. Ehrat
CHF
928 333
137 334
223 200
892 833
1 581 045
558 028
15 034
4 335 807
Richard Francis
CHF
841 667
176 362
425 000
425 028
1 360 002
510 010
1 112 948
4 851 017
Paul Hudson
CHF
958 333
203 485
950 400
950 449
1 536 023
672 046
197 101
5 467 837
Harry Kirsch
CHF
1 038 333
153 854
800 800
800 814
1 768 053
832 012
58 710
5 452 576
Vasant Narasimhan
CHF
841 667
168 562
807 500
807 529
1 360 002
510 010
50 603
4 545 873
Bruno Strigini (until December 31, 2017) 6
CHF
898 333
210 613
225 000
225 074
1 440 057
540 048
50 000
3 589 125
André Wyss
CHF
875 000
154 339
0
1 232 060
1 408 021
528 061
70 526
4 268 007
Total 7
CHF
11 410 740
1 841 795
7 809 857
9 711 861
19 381 014
8 859 147
2 080 458
61 094 873
      
      
      
      
      
      
      
      
      
      
      
 Based on assumption of 100% payout at target. Actual payout (0-200% of target) will be known at  the end of the three-year cycle in January 2020.
      
      
      
      
      
See page 136 for 2016 comparative figures.
  1  Includes mandatory employer contributions of CHF 4 336 for the CEO and CHF 50 227 for the other Executive Committee members paid by Novartis to governmental social security systems. This amount is out of total employer contributions of CHF 2 710 445 paid in 2017 for all Executive Committee members, and provides a right to the maximum future insured government pension benefit for the Executive Committee member.
  2  The portion of the Annual Incentive delivered in equity is rounded up to the nearest share, based on the closing share price on the grant date (January 18, 2018) of CHF 82.90 per Novartis share and USD 86.41 per ADR.
  3  The amounts represent the underlying share value of the target number of PSUs granted to Executive Committee members for the performance cycle 2017-2019, based on the closing share price on the grant date (January 17, 2017) of CHF 71.35 per Novartis share and USD 71.99 per ADR.
  4  Includes any other perquisites, benefits in kind, and international assignment benefits as per the global mobility policy (e.g., housing, international health insurance, children's school fees, tax equalization).
  5  All amounts are before deduction of the social security contribution and income tax due by the Executive Committee member.
  6  Bruno Strigini stepped down from the Executive Committee at the end of the 2017 business year. The LTPP and LTRPP grants for the 2017-19 performance cycle, included in the table above, will vest at the end of the performance cycle on a pro-rata basis per his contractual agreement and subject to the plan rules .
  7  Amounts in USD for F. Michael Ball and James Bradner were converted at a rate of CHF 1.00 = USD 1.015, which is the same average exchange rate used in the Group's 2017 consolidated financial statements.
135
When comparing the Executive Committee compensation at grant in 2017 to the compensation at grant in 2016, it may be noted that the two members of the Executive Committee who joined in July 2016, Mr. Hudson and Mr. ­Strigini, were compensated in 2017 for the first time on a full year basis, including their Annual Incentive based on 2017 ­performance and full Long-Term Incentive grants.
2016 compensation at grant value for the CEO and other Executive Committee members
For comparative purposes, the table below provides the compensation at grant value for 2016.
Fixed compensation and pension benefits
Variable compensation
Actual compensation paid or granted for 2016
Long-Term Incentive 2016-2018 cycle grants at target
2016 annual base salary
2016 pension benefits
2016 Annual Incentive (performance achieved)
LTPP 2016–2018 cycle
LTRPP 2016–2018 cycle
Other 2016 compensation
Total compensation paid, promised or granted 2016


Currency

Cash
(amount)


Amount 1


Cash
Equity
(value at
grant date) 2
PSUs
(target value
at grant date) 3
PSUs
(target value
at grant date) 3


Amount 4


Amount 5
Executive Committee members active on December 31, 2016 6
Joseph Jimenez (CEO)
CHF
2 093 417
160 283
1 417 500
1 417 510
4 200 031
2 625 079
75 628
11 989 448
Steven Baert
CHF
721 667
147 442
554 730
554 746
1 050 048
350 042
139 159
3 517 834
F. Michael Ball (from February 1, 2016)
USD
1 012 308
60 574
553 574
553 603
1 742 284
762 269
4 040 748
8 725 360
James Bradner (from March 1, 2016)
USD
888 462
58 859
579 393
579 448
1 687 473
794 195
1 155 169
5 742 999
Felix R. Ehrat
CHF
915 833
148 122
202 400
809 680
1 564 033
552 002
14 852
4 206 922
Richard Francis
CHF
786 667
188 738
520 000
520 070
1 280 062
480 033
1 116 054
4 891 624
Paul Hudson (from July 1, 2016)
CHF
475 000
108 818
288 945
288 968
0
0
3 090 313
4 252 044
Harry Kirsch
CHF
1 025 000
141 510
736 450
736 475
1 751 009
824 018
51 361
5 265 823
Vasant Narasimhan (from February 1, 2016)
CHF
764 993
157 348
537 531
537 551
1 093 245
364 468
102 868
3 558 004
Bruno Strigini (from July 1, 2016)
CHF
445 000
109 057
211 863
211 910
1 074 442
268 670
45 696
2 366 638
André Wyss
CHF
830 834
146 289
0
1 275 025
1 360 001
425 040
95 595
4 132 784
Subtotal 7
CHF
9 931 091
1 425 275
5 585 643
7 468 241
16 751 942
7 422 814
9 850 656
58 435 662
Executive Committee members who stepped down during 2016 8
David Epstein (until June 30, 2016)
USD
699 767
290 385
428 400
428 412
1 285 264
642 632
4 529 809
8 304 669
Mark C. Fishman (until February 29, 2016)
USD
175 154
107 706
195 000
0
0
0
126 454
604 314
Jeff George (until January 31, 2016)
USD
80 000
18 558
44 000
43 986
0
0
2 996 905
3 183 449
Subtotal 7
CHF
940 809
410 492
657 537
465 417
1 266 270
633 135
7 540 067
11 913 726
Total 7
CHF
10 871 900
1 835 767
6 243 180
7 933 658
18 018 212
8 055 949
17 390 723
70 349 389
      
      
      
      
      
      
      
      
      
      
      
 Based on assumption of 100% payout at target. Actual payout (0-200% of target) will be known at  the end of the three-year cycle in January 2019.
      
      
      
      
      
  1  Includes mandatory employer contributions of CHF 4 336 for the CEO and CHF 70 880 for the other Executive Committee members paid by Novartis to governmental social security systems. This amount is out of total employer contributions of CHF 3 263 989 paid in 2016 for all Executive Committee members, and provides a right to the maximum future insured government pension benefit for the Executive Committee member.
  2  The portion of the Annual Incentive delivered in equity is rounded up to the nearest share, based on the closing share price on the grant date (January 17, 2017) of CHF 71.35 per Novartis share and USD 71.99 per ADR.
  3  The amounts represent the underlying share value of the target number of PSUs granted to Executive Committee members for the performance cycle 2016-2018, based on the closing share price on the grant date (January 20, 2016) of CHF 79.70 per Novartis share and USD 80.49 per ADR. For F. Michael Ball, the target PSUs were granted on February 1, 2016, at the closing share price of the same date (USD 77.27 per ADR).
  4  Includes any other perquisites, benefits in kind, international assignment benefits as per the global mobility policy (e.g., housing, international health insurance, children's school fees, tax equalization), compensation granted for forfeited entitlements at previous employers and, for F. Michael Ball, a one-off performance award with target value at grant date of USD 3.9 million. In addition, for Executive Committee members who stepped down during 2016, it includes, inter alia, their pro-rata compensation from the date they stepped down from the Executive Committee to December 31, 2016 (see also note 8 below).
  5  All amounts are before deduction of the social security contribution and income tax due by the Executive Committee member.
  6  For those members who joined the Executive Committee in 2016, the information under the columns "annual base salary", "pension benefits" and "Annual Incentive" includes their pro-rata compensation from the date they joined the Executive Committee to December 31, 2016. The information under "LTPP" and "LTRPP" columns reflects their pro-rata compensation at target for the period to December 31, 2018.
  7  Amounts in USD for Mr. Ball, James Bradner, David Epstein, Mark C. Fishman and Jeff George were converted at a rate of CHF 1.00 = USD 1.015, which is the same average exchange rate used in the Group's 2016 consolidated financial statements.
  8  For those members who stepped down from the Executive Committee in 2016, the information under the columns "annual base salary", "pension benefits", "Annual Incentive", "LTPP" and "LTRPP" reflects the pro-rata value during 2016 for the period they were an Executive Committee member. The information under the column "Other 2016 compensation" includes, inter alia, the aggregated pro-rata value from the date they stepped down from the Executive Committee to December 31, 2016.
136
Interim update on the Alcon CEO’s 2016 one-off performance award (performance cycle 2016-2018)
As disclosed in last year’s Compensation Report, the Alcon CEO received a one-off award of 50 000 performance share units in February 2016, subject to the achievement of targets linked to the turnaround of Alcon during the 2016-2018 performance cycle. The targets of this one-off performance award are separate from the Annual Incentive or the LTPP and LTRPP targets.
The performance metrics are based on financial and non-financial targets of Alcon, including sales growth ahead of peers, core operating income growth ahead of sales growth, core operating income margin at the average of peers, and successful launches of new products. Should the Alcon CEO achieve these ambitious targets, Alcon will be performing at a very competitive level in the market.
After 2016, performance was tracking significantly below target. Toward the end of 2017 (the second year of the three-year performance cycle), Alcon began to close that gap versus target. Sales growth is accelerating and core operating income is growing ahead of sales. Innovation targets are being met and products in development are beginning to emerge.
We will disclose the targets and final payout of this Long-Term Incentive award after the full three-year performance cycle concludes and once we are able to assess Alcon’s performance relative to peers.
137
2017 CEO and Executive Committee member total target compensation increases
During 2017, the CEO did not receive an increase in his total target compensation. Most other members of the ­Executive Committee were awarded increases of between 0% and 3%. Exceptions are outlined below. For context, the average of all Novartis employee annual base salary increases was 1% in Switzerland and 3% in the US.
Consistent with our Executive Committee appointments compensation policy (see page 124), four members were appointed to the Executive Committee in recent years with total target compensation below the market median level of compensation against comparable roles at external peer companies. In making its decisions, the Compensation Committee took into account the annual benchmarking analysis, for each of these roles, provided by Willis Towers Watson. The total target compensation for these members has been assessed over the last two to three years, and increases in line with proven performance have been made, as described below.
Vasant Narasimhan
Vasant Narasimhan was promoted to Global Head of Drug Development and Chief Medical Officer, and joined the Executive Committee in early 2016. The Board assessed his performance since appointment as outstanding. He strengthened the pipeline by receiving 11 development approvals and completing 13 major submissions. He also strengthened the interface between the Novartis Institutes for BioMedical Research and Global Drug Development. Therefore, for 2017, his annual base salary was increased by 6.3%, and his target aggregate incentive opportunity was increased from 290% of annual base salary to 320%. Overall, his 2017 total target compensation* increased by 14% compared to 2016. The 2018 compensation details for Dr. Narasimhan following his appointment as CEO, effective February 2018, are disclosed on page 143.
Steven Baert
Steven Baert was promoted to Head of Human Resources (HR) in 2014. During 2016, he played a leading role in the design and transformation of the Novartis operating model, the execution of the portfolio transformation, and various other key HR functions. In this context, Mr. Baert received an annual base salary increase of 4% at the onset of 2017, and his target aggregate incentive opportunity was increased from 290% of annual base salary to 310% for 2017. Overall, his 2017 total target compensation* increased by 9% compared to 2016.
André Wyss
André Wyss was promoted to President of Novartis Operations in 2016. He led Novartis Business Services (NBS) to perform notably ahead of target for the second consecutive year on all customer and financial performance metrics during 2016. He has strengthened the Novartis Business Services organization by improving the governance and optimizing processes. He has ensured great quality of service, as reflected by customer satisfaction scores. At the onset of 2017, his annual base salary was increased by 4% and his target aggregate incentive opportunity was increased from 310% of annual base salary to 320% for 2017. Overall, his 2017 total target compensation* increased by 6% compared to 2016.
Richard Francis
Richard Francis was appointed Sandoz CEO in 2014. He led his team during difficult circumstances to deliver each quarter in 2016 at a high level against ambitious targets in sales and profitability, and without jeopardizing sustainability. Biosimilars sales were significantly ahead of target following the filings for rituximab and etanercept in Europe, and they will continue to be key to the success of Sandoz. Pricing pressures persist on retail generics, especially in the US. Mr. Francis’ annual base salary was increased by 6% at the onset of 2017, reflecting his strong leadership since his appointment and his development in the role during 2016. His target aggregate incentive opportunity remained unchanged at 320% of base salary for 2017. Overall, his 2017 total target compensation* increased by 6% compared to 2016.
* Total target compensation comprises annual base salary plus the value at target of the Annual Incentive and Long-Term Incentive awards.
138
Additional disclosures
This section provides additional disclosures, including information about the shareholdings of the CEO and the other Executive Committee members.
Number of equity instruments granted to the CEO and other Executive Committee members for financial year 20171
Variable compensation
2017 Annual Incentive (performance achieved)
LTPP 2017–2019 cycle
LTRPP 2017–2019 cycle
Equity
(number) 2
PSUs
(target number) 3
PSUs
(target number) 3
Executive Committee members active on December 31, 2017
Joseph Jimenez (CEO)
23 749
58 865
36 791
Steven Baert
7 998
16 399
6 560
F. Michael Ball
10 110
24 893
10 891
James Bradner
10 402
25 268
11 891
Felix R. Ehrat
10 770
22 159
7 821
Richard Francis
5 127
19 061
7 148
Paul Hudson
11 465
21 528
9 419
Harry Kirsch
9 660
24 780
11 661
Vasant Narasimhan
9 741
19 061
7 148
Bruno Strigini (until December 31, 2017) 4
2 715
20 183
7 569
André Wyss
14 862
19 734
7 401
Total
116 599
271 931
124 300
See page 140 for 2016 comparative figures.
 1  The values of the awards are reported in the table "2017 compensation at grant value for the CEO and other Executive Committee members" on page 135.
 2  Vested shares, restricted shares and/or RSUs granted under the Annual Incentive for performance period 2017
 3  Target number of PSUs granted under the LTPP and LTRPP as applicable for the performance cycle 2017-2019
 4  Bruno Strigini stepped down from the Executive Committee at the end of the 2017 business year. The LTPP and LTRPP grants for the 2017-19 performance cycle, included in the table above, will vest at the end of the performance cycle on a pro-rata basis per his contractual agreement and subject to the plan rules
139
Number of equity instruments granted to the CEO and other Executive Committee members for financial year 20161 (comparative information)
Variable compensation
2016 Annual Incentive (performance achieved)
LTPP 2016–2018 cycle
LTRPP 2016–2018 cycle
Other
Equity
(number) 2
PSUs
(target number) 3
PSUs
(target number) 3
Equity/PSUs
(number)
Executive Committee members active on December 31, 2016
Joseph Jimenez (CEO)
19 867
52 698
32 937
0
Steven Baert
7 775
13 175
4 392
0
F. Michael Ball (from February 1, 2016)
7 690
22 548
9 865
50 000
James Bradner (from March 1, 2016)
8 049
20 965
9 867
3 607
Felix R. Ehrat
11 348
19 624
6 926
0
Richard Francis
7 289
16 061
6 023
0
Paul Hudson (from July 1, 2016) 4
4 050
0
0
34 502
Harry Kirsch
10 322
21 970
10 339
0
Vasant Narasimhan (from February 1, 2016)
7 534
13 717
4 573
0
Bruno Strigini (from July 1, 2016)
2 970
13 549
3 388
0
André Wyss
17 870
17 064
5 333
0
Subtotal
104 764
211 371
93 643
88 109
Executive Committee members who stepped down during 2016
David Epstein (until June 30, 2016)
5 951
15 968
7 984
29 902
Mark C. Fishman (until February 29, 2016) 4
0
0
0
0
Jeff George (until January 31, 2016) 4
611
0
0
6 724
Subtotal
6 562
15 968
7 984
36 626
Total
111 326
227 339
101 627
124 735
 1  The values of the awards are reported in the table "2016 compensation at grant value for the CEO and other Executive Committee members" on page 136.
 2  Vested shares, restricted shares and/or RSUs granted under the Annual Incentive for performance period 2016
 3  Target number of PSUs granted under the LTPP and LTRPP as applicable for the performance cycle 2016-2018
 4  Paul Hudson, Mark C. Fishman and Jeff George were not granted LTPP and LTRPP awards for the performance cycle 2016-2018.
140
Share ownership requirements for the CEO and other Executive Committee members
Executive Committee members are required to own at least a minimum multiple of their annual base salary in Novartis shares or restricted share units (RSUs) within five years of hire or promotion, as set out in the table below.
In the event of a substantial rise or drop in the share price, the Board may, at its discretion, amend that time period accordingly.
Function
Ownership level
CEO
5 x base compensation
Other Executive Committee members
3 x base compensation
The determination of equity amounts against the share ownership requirements is defined to include vested and unvested Novartis shares or American depositary receipts (ADRs), as well as RSUs acquired under the company’s compensation plans. However, unvested matching shares granted under former matching programs such as the Leveraged Share Savings Plan (LSSP) and the Employee Share Ownership Plan (ESOP), and any unvested PSUs are excluded. The determination also includes other shares as well as vested options of Novartis shares or ADRs that are owned directly or indirectly by “persons closely linked” to an Executive Committee member. The Compensation Committee reviews compliance with the share ownership guideline on an annual basis.
Shares, ADRs and other equity rights owned by Executive Committee members at December 31, 20171 
The following table shows, in alphabetical order after the CEO, the total number of shares, ADRs and other equity rights owned by the CEO and the other Executive Committee members and “persons closely linked” to them as of December 31, 2017.
As of December 31, 2017, no members of the Executive Committee, either individually or together with “persons closely linked” to them, owned 1% or more of the outstanding shares or ADRs of Novartis. As of the same date, no members of the Executive Committee held any share options to purchase Novartis shares, with the exception of André Wyss, who held 373 000 options, purchased on a private basis.
As of December 31, 2017, all members who have served at least five years on the Executive Committee have met or exceeded their personal Novartis share ownership requirements.

Vested shares
and ADRs

Unvested shares
and other equity rights 2
Equity ownership level
as a multiple of
annual base salary 3

Unvested target PSUs
(e.g., LTPP / LTRPP) 4

Matching shares
under the LSSP 5

Total at
December 31, 2017
Joseph Jimenez (CEO)
287 699
62 693
14x
225 685
0
576 077
Steven Baert
10 955
21 410
3x
33 715
0
66 080
F. Michael Ball
0
7 690
1x
101 532
0
109 222
James Bradner
0
13 234
1x
34 130
0
47 364
Felix R. Ehrat
189 940
23 541
19x
79 764
19 950
313 195
Richard Francis
35 117
17 305
5x
40 453
0
92 875
Paul Hudson
6 616
6 498
1x
29 695
0
42 809
Harry Kirsch
64 769
30 309
8x
58 792
6 277
160 147
Vasant Narasimhan
16 279
58 887
7x
23 413
3 426
102 005
Bruno Strigini
27 871
39 844
6x
38 930
0
106 645
André Wyss
51 183
22 784
7x
40 456
0
114 423
Total
690 429
304 195
706 565
29 653
1 730 842
 1  Includes holdings of "persons closely linked" to Executive Committee members (see definition on page 142)
 2  Includes unvested shares and ADRs as well as other equity rights applicable for the determination of equity amounts for the share ownership requirements, as per the definition above
 3  The multiple is calculated based on the full year annual base salary and the closing share price as at the end of the 2017 Financial Year. The share price on the final trading day of 2017 was CHF 82.40 / USD 83.96 as at December 29, 2017.
 4  Target number of PSUs are disclosed pro-rata to December 31, 2017, unless the award qualified for full vesting under the relevant plan rules.
 5  Matching shares under the Leveraged Share Savings Plan (LSSP) are disclosed pro-rata to December 31, 2017, unless the award qualified for full vesting under the plan rules. LSSP participation for Executive Committee members ceased in 2014 and no new LSSP awards have been made since then. Outstanding awards will vest five years from the grant date, subject to the LSSP plan rules.
141
Fixed and variable compensation
CEO and other Executive Committee members’ annual base salary and variable compensation mix at grant value for financial year 2017.
Annual
base salary 1
Variable
compensation 2
Joseph Jimenez (CEO)
16.3%
83.7%
Steven Baert
20.7%
79.3%
F. Michael Ball
20.6%
79.4%
James Bradner
19.3%
80.7%
Felix R. Ehrat
22.2%
77.8%
Richard Francis
23.6%
76.4%
Paul Hudson
18.9%
81.1%
Harry Kirsch
19.8%
80.2%
Vasant Narasimhan
19.5%
80.5%
Bruno Strigini
27.0%
73.0%
André Wyss
21.6%
78.4%
Total
20.0%
80.0%
 1  Excludes pension and other benefits
 2  See table “2017 compensation at grant value for the CEO and other Executive Committee members" on page 135 with regard to the disclosure principles of variable compensation.
Other payments to Executive Committee members
During 2017, no other payments or waivers of claims other than those set out in the tables (including their foot­notes) contained in this Compensation Report were made to Executive Committee members or to “persons closely linked” to them.
Payments to former Executive Committee members
Two former Executive Committee members stepped down in 2016 and ceased employment in 2017 following a 12-month contractual notice period. During 2017, they received pro-rata payments of salary, pension and other benefits, and an Annual Incentive totaling CHF 2 305 599 per their employment contracts.
Five former Executive Committee members received payments totaling CHF 5 988 375 in line with the company’s Long-Term Incentive plan rules. The payments related to the vesting of LTPP for the 2015-2017 performance cycle, based on actual performance outcomes plus dividend equivalents. No payments were or will be made for the 2015-2017 LTRPP performance cycle.
In addition, in line with the company’s global mobility policy, during 2017 three former members received tax equalization payments totaling CHF 718 151 related to incentive compensation granted during an international assignment.
No other payments (or waivers of claims) were made to former Executive Committee members or to “persons closely linked” to them during 2017.
Loans to Executive Committee members
Our policy does not allow loans to be granted to current or former members of the Executive Committee or to “persons closely linked” to them. Therefore no loans were granted in 2017, and none were outstanding as of December 31, 2017.
Persons closely linked
“Persons closely linked” are (i) their spouse, (ii) their children below age 18, (iii) any legal entities that they own or otherwise control, and (iv) any legal or natural person who is acting as their fiduciary.
Note 26 to the Group’s audited consolidated financial statements
The total expense for the year for compensation awarded to Executive Committee and Board members, using International Financial Reporting Standards (IFRS) measurement rules, is presented in the Financial Report in Note 26 to the Group’s audited consolidated financial statements (see page 240).
Award and delivery of equity to Novartis associates
During 2017, 15.4 million unvested restricted shares (or ADRs), RSUs and target PSUs were granted, and 10.7 million Novartis vested shares (or ADRs) were delivered to Novartis associates under various equity-based participation plans. Current unvested equity instruments (restricted shares, RSUs and target PSUs) – as well as outstanding equity options held by associates – represent 1.98% of issued shares. Novartis delivers treasury shares to associates to fulfill these obligations, and aims to offset the dilutive impact from its equity-based participation plans.
142

2018 Executive Committee compensation

2018 CEO succession – compensation elements
Retiring CEO, Joseph Jimenez
In September 2017, Mr. Jimenez notified the Board that he had decided to retire, following eight years as CEO. He steps down as CEO on January 31, 2018, and will continue to support the Board and new CEO until his retirement date and the end of his 12-month notice period on August 31, 2018.
He will retire in full compliance with the terms of his employment contract and the Novartis incentive plan rules. He will receive his annual base salary and pro-rated Annual Incentive until August 31, 2018. There will be no increase to his target compensation in 2018. No new Long-Term Incentive awards will be made in January 2018.
In line with the incentive plan rules, there will be no accelerated vesting of his unvested equity. The deferred equity under the Annual Incentive for the performance years 2015 and 2016 will respectively vest in January 2019 and 2020 per the rules of the Deferred Share Bonus Plan. His Long-Term Incentives for the 2016-2018 and 2017-2019 performance cycles will vest on the normal vesting dates (January 2019 and January 2020, respectively), to the extent that the company performance conditions are met. As Mr. Jimenez meets the retirement conditions under the Long-Term Incentive plan rules, these two outstanding Long-Term Incentives will not be pro-rated in line with the plan rules. Clawback and malus, and non-compete restrictions as defined by the plan rules will apply.
No severance or non-compete payments will be made to Mr. Jimenez.
Appointed CEO, Vasant Narasimhan
Dr. Narasimhan will become CEO effective February 1, 2018. The Board determined Dr. Narasimhan’s compensation by taking into account his experience and skills, CEO compensation levels at our 15 global healthcare peer companies, advice from the Compensation Committee’s independent advisor, and the fact that this is his first Group CEO role.
As of February 1, 2018, Dr. Narasimhan’s annual base salary will be CHF 1.55 million. Short- and Long-Term Incentive opportunities at target are a percentage of annual base salary as follows: Annual Incentive at 150% (CHF 2.32 million); LTPP at 200% (CHF 3.10 million); and LTRPP at 125% (CHF 1.94 million). Dr. Narasimhan’s total target compensation is CHF 8.91 million. He will also receive pension and other benefits in line with all other Swiss-based employees.
The Board decided to keep Dr. Narasimhan’s compensation strongly performance-based (83% is subject to performance conditions), with an emphasis on equity, to align his interests strongly with those of shareholders. His equity ownership requirement will be five times his annual base salary.
Dr. Narasimhan’s initial compensation is 26% lower than that of his predecessor. It is the Board’s intention to keep Dr. Narasimhan’s annual base salary under review in the coming three to four years, with a view to increasing it subject to strong performance and proven ability in the role.
Dr. Narasimhan’s employment contract and compensation are in line with the requirements of the Ordinance against Excessive Compensation in Listed Companies.
Other Executive Committee member appointments and departures
Retiring CEO Oncology, Bruno Strigini
Mr. Strigini stepped down from the Executive Committee on December 31, 2017. During his contractual notice period, which ends on December 31, 2018, he will receive his annual base salary and Annual Incentive in accordance with plan rules. No new grants of Long-Term Incentives will be made in 2018.
Mr. Strigini’s outstanding Long-Term Incentives will be pro-rated for time employed during the performance period. There will be no accelerated vesting, as awards will remain subject to performance over the full cycle. Clawback and malus, and non-compete restrictions as defined by the plan rules will apply. No severance or non-compete payments will be made.
Appointed CEO Oncology, Elizabeth Barrett
Novartis announced the appointment of Elizabeth Barrett as the new CEO of Oncology, starting on February 1, 2018. Her annual base salary will be CHF 850 000, her target Annual Incentive of 100%, and her target Long-Term Incentives totaling 260%.
Elizabeth will receive compensation for loss of entitlements with her previous employer on a like-for-like basis, subject to evidence and in line with our Executive Committee members appointment compensation policy regarding buy-outs. The value of the replacement cash and equity awards will be determined on the date of her entry into the company. Therefore, details of this buy-out will be communicated in the 2018 Compensation Report.
143
Changes to the 2018 Executive Committee compensation system
In 2017, the Compensation Committee conducted a review of the Executive Committee compensation system, taking into account developments in market practice, and alignment with the strategic objectives and talent agenda at Novartis.
The Compensation Committee believes the compensation system supports the company’s strategy and ensures a strong link between pay and performance.
In view of market changes since the current system was implemented in 2014, the Board and Compensation Committee have decided to make evolutionary changes to provide greater simplicity and further enhance the link between pay and performance. Changes are also based on constructive feedback from shareholders as part of our ongoing dialogue and consideration of their views. They will take effect from January 2018.
2018 Annual Incentive
A simplified Annual Incentive balanced scorecard will be introduced that places additional weighting on financial performance (60% weighting) and that also focuses on key strategic objectives in the areas of innovation, access to healthcare, people and culture, data and digital (40% weighting). Values and Behaviors remain a key component of the Annual Incentive and are embedded in our culture. As such, members of the Executive Committee are expected to demonstrate these to the highest standard.
From 2018, the CEO balanced scorecard metrics will be as follows:
CEO Balanced Scorecard - Key Metrics
Group financial targets (60% weighting)
• Group net sales
• Group operating income
• Group FCF as % of sales
• Share of peers
Strategic objectives (40% weighting)
• Innovation
• Access to healthcare
• People and culture
• Data and digital
The payout schedule for the Annual Incentive will be amended to reflect the simplified structure as follows:
Performance
Payout
Outstanding
170–200%
Exceeds expectations
130–160%
Meets expectations
80–120%
Partially meets expectations
40–70%
Below expectations
0–30%
LTRPP payout for cycles starting in 2018 onward
The performance condition for the LTRPP has been made more stringent from the 2018-2020 performance cycle onward. Going forward, Executive Committee members will receive no payout if relative TSR is below the median of the companies in our global healthcare peer group. The Board retains the right to apply its judgment in determining the final payout, considering factors such as absolute TSR, currency fluctuations and overall economic conditions.
The payout matrix for the 2018-2020 performance cycle onward will be as follows:
Novartis position
in the peer group
Payout range
(% of target)
Positions 1–2
170–200%
Positions 3–5
130–160%
Positions 6–8
80–120%
Positions 9–16
0%
Change in Executive Committee retirement rules for the LTPP and LTRPP from 2019
In line with evolving governance practices, we have revised our Long-Term Incentive plan rules for retiring Executive Committee members, applicable to grants made from 2019 onward. Going forward, members who fulfill the retirement conditions under the plan rules will receive pro-rata vesting, rather than full vesting, of outstanding Long-Term Incentives. These incentives will continue to have performance conditions applied, and will vest at the end of the cycle on the normal vesting date. The timing of this change respects the one-year notice period required in the Executive Committee member employment contracts.
Two members of the Executive Committee (the CEO of Alcon and the General Counsel), who have already met the retirement conditions under the plan rules for LTPP and LTRPP, will be grandfathered under the current rules (with the exception of the one-off performance award granted to the CEO of Alcon in 2016, which vests ­pro-rata on retirement, as per his contract).
144
2018 Executive Committee total target compensation increases
To aid transparency and as part of our commitment to good governance, the Compensation Committee has decided to voluntarily disclose the 2018 Executive Committee total target compensation increases at the start of the year.
Details of the 2018 compensation for Mr. Jimenez as the retiring CEO and Dr. Narasimhan as the appointed CEO are provided on page 143.
The other members of the Executive Committee will not be awarded any increases for 2018 with the exception of two members for reasons set out below. For context, average associate merit increases were 1% in Switzerland and 3% in the US.
James Bradner
James Bradner was hired externally as the President of Novartis Institute of Biomedical Research (NIBR) in 2015. Since he joined the organization he has delivered strong performance and has played a key role in increasing cooperation between NIBR and Global Drug Development. His compensation was adjusted to recognize his performance and also catch up towards US peers (NIBR, as well as most of its competitors are based and headquartered in the US). In this context, Mr. Bradner will receive an annual base salary increase in line with other US associates of 3% as from March 1, 2018. He will not receive increases to target incentives. Overall, his 2018 total target compensation will be increased by 2.8% compared to 2017.
Paul Hudson
Paul Hudson was hired externally as the CEO of the Pharmaceuticals division in June 2016. He led the division to overachieve its targets for 2017, contributing substantially to Novartis’ overall performance for the year. His leadership focused the division on new product performance, securing future revenue for Novartis. He has also enhanced the division’s culture and engagement. His compensation was adjusted to recognize these factors, as well as to gradually bring his compensation in line with his global peers. In this context, Mr. Hudson will receive an annual base salary increase of 3.1% as from March 1, 2018, and his target Long Term incentive will be increased from 230% of annual base salary to 250% as from 2018. No changes will be made to his Annual Incentive. Overall, his 2018 total target compensation will be increased by 7.8% compared to 2017.
2018 Executive Committee compensation system review
The current Executive Committee compensation system has been in place since January 2014. Each year, the Board and Compensation Committee review it to ensure it is in line with business needs and evolving best practice. In 2018, the review will focus particularly on the performance measures for the Long Term Incentive, to ensure they are appropriately aligned to the company’s strategy and goals of the new CEO. The Compensation Committee will engage in dialogue with Novartis’ major shareholders and will consult its independent advisor on this topic.
145

2017 Board compensation

Board compensation philosophy and benchmarking
In line with market practice in Switzerland, the Board sets compensation for its members at a level that allows for the attraction of high-caliber individuals with global experience, including a mix of Swiss and international members. Board members do not receive variable compensation, underscoring their focus on corporate strategy, supervision and governance. Each year at the AGM, shareholders are requested to approve, in a binding vote, the total compensation of the Board until the following AGM.
The Board sets the level of compensa­tion for its Chairman and the other members to be in line with relevant benchmark companies, which include other large Switzerland-based multinational companies: ABB, Credit Suisse, LafargeHolcim, Nestlé, Roche and UBS. This peer group has been chosen for Board compensation due to the comparability of Swiss legal requirements, including broad personal and indi­vidual liabilities under Swiss law (and new criminal liabil­ity under Swiss rules regarding Board and Executive Committee compensation related to the Ordinance against Excessive Compensation in Listed Companies), and under US law (due to the company’s secondary listing on the New York Stock Exchange).
The Board reviews the compensation of its members, including the Chairman, each year based on a proposal by the Compensation Committee and on advice from its independent advisor, including relevant benchmarking information.
Compensation of the Chairman of the Board
As Chairman, Joerg Reinhardt receives total annual compensation valued at CHF 3.8 million. The total com­pensation is comprised equally of cash and shares, as follows:
• Cash compensation: CHF 1.9 million per year.
• Share compensation: annual value equal to CHF 1.9 million of unrestricted Novartis shares.
For 2017, the Chairman voluntarily waived the increase in compensation to which he is contractually entitled, which is an amount not lower than the average annual compensation increase awarded to associates based in Switzerland (1% for 2017).
Compensation of the other Board members
The annual fee rates for Board membership and additional functions are included in the table below. These were approved by the Board with effect from the 2014 AGM, and align our aggregate Board compensation with the current levels of other large Swiss companies.
2017 Board member annual fee rates

CHF
AGM 2017-2018
annual fee
Chairman of the Board
3 800 000
Board membership
300 000
Vice Chairman
50 000
Chair of the Audit and Compliance Committee
120 000
Chair of the following committees:
• Compensation Committee
• Governance, Nomination and
Corporate Responsibilities Committee
• Research & Development Committee
• Risk Committee





60 000
Membership of the Audit and Compliance Committee
60 000
Membership of the following committees:
• Compensation Committee
• Governance, Nomination and
Corporate Responsibilities Committee
• Research & Development Committee
• Risk Committee





30 000
In addition, the following policies apply regarding Board compensation:
• 50% of compensation is delivered in cash, paid on a quarterly basis in arrears. Board members may choose to receive more of their compensation in shares instead of cash.
• At least 50% of compensation is delivered in shares in two installments: one six months after the AGM and one 12 months after the AGM.
• Board members bear the full cost of their employee social security contributions, if any, and do not receive share options or pension benefits.
146
Board member total compensation earned for financial year 2017
The following tables disclose the 2017 Board member total compensation and prior-year comparative information. Board compensation is reported as the amount earned in the financial year.
Board membership
Vice Chairman
Audit and Compliance Committee
Compensation Committee
Governance, Nomination and Corporate Responsibilities Committee
Research & Development Committee
Risk Committee
Shares (number) 1
Cash (CHF) (A)
Shares (CHF) (B)
Other (CHF) (C) 2
Total (CHF) (A)+(B)+(C) 3
Board members active on December 31, 2017
Joerg Reinhardt 4
Chair
Chair
24 407
1 900 000
1 900 000
4 336
3 804 336
Enrico Vanni
•
•
•
Chair
•
3 210
250 000
250 000
3 475
503 475
Nancy Andrews
•
•
•
2 311
180 000
180 000
– 
360 000
Dimitri Azar
•
•
•
2 504
195 000
195 000
– 
390 000
Ton Buechner
•
• 5
4 039
– 
325 000
– 
325 000
Srikant Datar
•
• 7
•
Chair 5
2 989
227 500
227 500
– 
455 000
Elizabeth Doherty
•
Chair 5
• 5
2 591
217 500
217 500
– 
435 000
Ann Fudge
•
•
•
•
2 504
195 000
195 000
– 
390 000
Frans van Houten (from February 28, 2017)
•
1 305
75 000
175 000
– 
250 000
Pierre Landolt 6
•
•
4 238
– 
330 000
3 475
333 475
Andreas von Planta
•
•
Chair
• 8
2 989
227 500
227 500
4 336
459 336
Charles L. Sawyers
•
•
•
2 311
180 000
180 000
– 
360 000
William T. Winters
•
•
4 238
– 
330 000
– 
330 000
Total
59 636
3 647 500
4 732 500
15 622
8 395 622
See next page for 2016 comparative figures.
  1  The shown amounts represent the gross number of shares delivered to each Board member in 2017 for the respective Board member’s service period. The number of shares reported in this column represent: (i) the second and final equity installment delivered in February 2017 for the services from the 2016 AGM to the 2017 AGM, and (ii) the first of two equity installments delivered in August 2017 for the services from the 2017 AGM to the 2018 AGM. The second and final equity installment for the services from the 2017 AGM to the 2018 AGM will take place in February 2018.
  2  Includes an amount of CHF 15 622 for mandatory employer contributions for all Board members paid by Novartis to Swiss governmental social security systems. This amount is out of total employer contributions of CHF 298 206, and provides a right to the maximum future insured government pension benefit for the Board member.
  3  All amounts are before deduction of the social security contribution and income tax due by the Board member.
  4  No additional committee fees for chairing the Research & Development Committee were delivered to Dr. Reinhardt.
  5  From February 28, 2017
  6  According to Pierre Landolt, the Sandoz Family Foundation is the economic beneficiary of the compensation.
  7  Until February 27, 2017, Chair of the Audit and Compliance Committee
  8  Until February 27, 2017, Chair of the Risk Committee
147
Board member total compensation earned for financial year 2016 (comparative information)
Board membership
Vice Chairman
Audit and Compliance Committee
Compensation Committee
Governance, Nomination and Corporate Responsibilities Committee
Research & Development Committee
Risk Committee
Shares (number) 1
Cash (CHF) (A)
Shares (CHF) (B)
Other (CHF) (C) 2
Total (CHF) (A)+(B)+(C) 3
Board members active on December 31, 2016
Joerg Reinhardt 4
Chair
Chair
25 020
1 900 000
1 900 000
4 336
3 804 336
Enrico Vanni
•
•
•
Chair
• 5
• 6
3 291
250 000
250 000
4 336
504 336
Nancy Andrews
•
•
• 5
2 265
177 500
177 500
– 
355 000
Dimitri Azar
•
•
•
2 567
195 000
195 000
– 
390 000
Ton Buechner (from February 24, 2016)
•
1 864
– 
250 000
– 
250 000
Srikant Datar
•
Chair
•
•
3 159
240 000
240 000
– 
480 000
Elizabeth Doherty (from February 24, 2016)
•
•
1 118
150 000
150 000
– 
300 000
Ann Fudge
•
•
•
•
2 567
195 000
195 000
– 
390 000
Pierre Landolt 7
•
• 8
4 553
– 
335 000
3 475
338 475
Andreas von Planta
•
•
Chair 5
Chair
3 055
237 500
237 500
4 336
479 336
Charles L. Sawyers
•
•
•
2 369
180 000
180 000
– 
360 000
William T. Winters
•
•
4 344
– 
330 000
– 
330 000
Subtotal
56 172
3 525 000
4 440 000
16 483
7 981 483
Board members who stepped down at the 2016 AGM
Verena A. Briner (until February 23, 2016)
•
•
1 147
27 500
27 500
579
55 579
Subtotal
1 147
27 500
27 500
579
55 579
Total
57 319
3 552 500
4 467 500
17 062
8 037 062
  1  The shown amounts represent the gross number of shares delivered to each Board member in 2016 for the respective Board member’s service period. The number of shares reported in this column represent: (i) the second and final equity installment delivered in February 2016 for the services from the 2015 AGM to the 2016 AGM, and (ii) the first of two equity installments delivered in August 2016 for the services from the 2016 AGM to the 2017 AGM. The second and final equity installment for the services from the 2016 AGM to the 2017 AGM will take place in February 2017.
  2  Includes an amount of CHF 17 062 for mandatory employer contributions for all Board members paid by Novartis to Swiss governmental social security systems. This amount is out of total employer contributions of CHF 387 308, and provides a right to the maximum future insured government pension benefit for the Board member.
  3  All amounts are before deduction of the social security contribution and income tax due by the Board member.
  4  Does not include EUR 1 045 800 paid to Joerg Reinhardt on January 31, 2016, for lost entitlements at his former employer. This amount is the third and final of three installments totaling EUR 2 665 051, which compensates him for lost entitlements at his former employer. The lost entitlements of EUR 2 665 051 were included in full on page 124 of the 2014 Compensation Report. No additional committee fees for chairing the Research & Development Committee were delivered to Dr. Reinhardt.
  5  From February 24, 2016.
  6  Until February 23, 2016.
  7  According to Pierre Landolt, the Sandoz Family Foundation is the economic beneficiary of the compensation.
  8  Until February 23, 2016, Chair of the Governance, Nomination and Corporate Responsibilities Committee.
148
Reconciliation between the reported Board compensation and the amount approved by shareholders at the AGM
CHF
Compensation earned for the respective financial year (A) 1
Compensation earned for the period from January 1 to the AGM (2 months) of the financial year (B)
Compensation to be earned for the period from January 1 to the AGM (2 months) in the year following the financial year (C)
Total compensation earned from AGM to AGM (A)-(B)+(C)
Amount approved by shareholders at the respective AGM
Amount within the amount approved by shareholders at the respective AGM
2017
January 1, 2017 to 2017 AGM
January 1, 2018 to 2018 AGM 2
2017 AGM to 2018 AGM
2017 AGM
2017 AGM
Joerg Reinhardt
3 804 336
633 334
633 334
3 804 336
3 805 000
Yes
Other Board members
4 591 286
713 334
773 334
4 651 286
4 720 000
Yes
Total
8 395 622
1 346 668
1 406 668
8 455 622
8 525 000
Yes
2016
January 1, 2016 to 2016 AGM
January 1, 2017 to 2017 AGM
2016 AGM to 2017 AGM
2016 AGM
2016 AGM
Joerg Reinhardt
3 804 336
633 334
633 334
3 804 336
3 805 000
Yes
Other Board members
4 232 726
653 334
713 334
4 292 726
4 355 000
Yes
Total
8 037 062
1 286 668
1 346 668
8 097 062
8 160 000
Yes
  1  See page 147 for 2017 Board member compensation.
  2  To be confirmed and reported in the 2018 Compensation Report
149
Additional disclosures
Share ownership requirements for Board members
The Chairman is required to own a minimum of 30 000 Novartis shares, and other members of the Board are required to own at least 4 000 Novartis shares within three years after joining the Board, to ensure their interests are aligned with those of shareholders. Board members are prohibited from hedging or pledging their ownership positions in Novartis shares that are part of their guideline share ownership requirement, and are required to hold these shares for 12 months after retiring from the Board. As of December 31, 2017, all current and former members of the Board who were required to meet the minimum share ownership requirements did so. From the 2018 AGM, the requirement will be increased (see details on page 151).
Shares, ADRs and share options owned by Board members
The total number of vested Novartis shares and ADRs owned by members of the Board and “persons closely linked” to them as of December 31, 2017, is shown in the table below.
As of December 31, 2017, no members of the Board, either individually or together with “persons closely linked” to them, owned 1% or more of the outstanding shares (or ADRs) of Novartis.” As of the same date, no members of the Board held any share options to purchase Novartis shares.
Number of shares
At December 31, 2017 1,2
Joerg Reinhardt
518 310
Enrico Vanni
20 101
Nancy Andrews
4 042
Dimitri Azar
13 094
Ton Buechner
4 428
Srikant Datar
37 239
Elizabeth Doherty
2 761
Ann Fudge
15 457
Frans van Houten
978
Pierre Landolt 3
61 029
Andreas von Planta
130 634
Charles L. Sawyers
7 763
William T. Winters
12 397
Total
828 233
 1  Includes holdings of "persons closely linked" to Board members (see definition on page 142)
 2  Each share provides entitlement to one vote.
 3  According to Pierre Landolt, the Sandoz Family Foundation is the economic beneficiary of the shares
Loans to Board members
Our policy does not allow loans to be granted to current or former members of the Board or to “persons closely linked” to them. Therefore no loans were granted in 2017, and none were outstanding as of December 31, 2017.
Other payments to Board members
During 2017, no payments (or waivers of claims) other than those set out in the Board member compensation table (including its footnotes) on page 147 were made to current members of the Board or to “persons closely linked” to them.
Payments to former Board members
During 2017, no payments (or waivers of claims) were made to former Board members or to “persons closely linked” to them, except for the payments reported in Note 26 to the Group’s audited consolidated financial statements (page 240).
150

2018 Board compensation

Board and committee membership fees
For the year 2018, the Chairman has voluntarily waived his contractual compensation increase entitlement, which is an amount not lower than the average annual compensation increase awarded to associates based in Switzerland.
Board and committee membership fees have remained unchanged since the reduction that took place at the 2014 AGM. The Board has decided to rebalance its fee structure from the 2018 AGM to better recognize the responsibilities and time commitment of the committees, both of which have increased as a result of the evolving governance and regulatory environment. In particular, developments in compensation governance requirements have, over the last few years, resulted in a greater number of interactions between the Compensation Committee and shareholders and other external stakeholders.
The Board membership fee will decrease, and the committee membership fees will increase. The Board took into consideration external benchmarking information in the Swiss market and independent advice. The change is cost-neutral for the company, as the new fee structure results in the same average fee per Board member, excluding the Chairman. The total aggregated Board fees will decrease in 2018 due to the reduction in the number of Board members, following the departure of Mr. Pierre Landolt, who will reach the age limit for Board membership specified in the Articles of Incorporation.

CHF
AGM 2018-2019
annual fee
Chairman of the Board
3 800 000
Board membership
280 000
Vice Chairman
50 000
Chair of the Audit and Compliance Committee
130 000
Chair of the Compensation Committee
90 000
Chair of the following committees:
• Governance, Nomination and
Corporate Responsibilities Committee
• Research & Development Committee
• Risk Committee




70 000
Membership of the Audit and Compliance Committee
70 000
Membership of the following committees:
• Compensation Committee
• Governance, Nomination and
Corporate Responsibilities Committee
• Research & Development Committee
• Risk Committee





40 000
Share ownership requirements
The Chairman’s share ownership requirement of 30 000 shares will remain unchanged for 2018.
For the other Board members, and following a review of market practices at our peer group companies, the Board has decided to increase the share ownership requirement from 4 000 to 5 000 shares, effective from the 2018 AGM. The increase will also strengthen the alignment of interests with those of our shareholders.
To allow sufficient time for Board members to achieve the increased requirement, they will have four years from appointment to acquire the minimum 5 000 shares under the new policy. In addition, Board members will continue to be required to hold these shares for 12 months after retiring from the Board.
151

Compensation governance

Legal framework
The Swiss Code of Obligations and the Corporate Gov­ernance Guidelines of the SIX Swiss Exchange require listed companies to disclose certain information about the compensation of Board and Executive Committee members, their equity participation in the Group, and loans made to them. This Annual Report fulfills that requirement. In addition, the Annual Report is in line with the principles of the Swiss Code of Best Practice for Corporate Governance of the Swiss Business Federation (economiesuisse).
Risk management principles
The Compensation Committee, with support from its independent advisor, reviews market trends in compensation and changes in corporate governance rules and best practices. Together with the Risk Committee, it also reviews the Novartis compensation systems to ensure that they do not encourage inappropriate or excessive risk taking, and instead encourage behaviors that support sustainable value creation.
A summary of the risk management principles is outlined below.
RISK MANAGEMENT PRINCIPLES•Rigorous performance management process, with approval of targets and evaluation of performance for the CEO by the Board •Balanced mix of short-term and long-term variable compensation elements•Performance evaluation under the Annual Incentive includes an individual balanced scorecard and assessed Values and Behaviors•Clawback and malus principles apply to all elements of variable compensation•Performance-vesting Long-Term Incentives only, with three-year overlapping cycles•All variable compensation is capped at 200% of target•Contractual notice period of 12 months•Post-contractual non-compete limited to a maximum of 12 months from the end of employment (annual base salary and Annual Incentive of the prior year only) as per contract, if applicable •Good and bad leaver ­provisions apply to variable compensation of leavers•No severance payments or change-of-control clauses•Share ownership ­requirements; no hedging or pledging of Novartis share ­ownership ­position by Board and ­Executive Committee members
Executive Committee employment contracts provide for a notice period of up to 12 months and contain no change-of-control clauses or severance provisions (e.g., agree­ments concerning special notice periods, longer-term contracts, “golden parachutes,” waiver of lock-up periods for equities and bonds, shorter vesting periods, and additional contributions to occupational pension schemes).
For share ownership requirements, please refer to page 141 – share ownership requirements for the CEO and other Executive Committee members.
Compensation decision-making authorities
Authority for decisions related to compensation is governed by the Articles of Incorporation, Board Regulations and the Compensation Committee Charter, which are all published on the company website: www.novartis.com/investors/company-overview/corporate-governance.
The Compensation Committee serves as the supervisory and governing body for compensation policies and plans within Novartis, and has overall responsibility for determining, reviewing and proposing compensation policies and plans for approval by the Board in line with the Compensation Committee Charter. A summary of discussions and conclusions of each committee meeting is delivered to the full Board. A summary of the compensation decision-making authorities is set out below.
Compensation authorization levels within the parameters set by the shareholders’ meeting
Decision on
Decision-making authority
Compensation of Chairman and other Board members
Board of Directors
Compensation of CEO
Board of Directors
Compensation of other Executive Committee members
Compensation Committee
Committee member independence
The Compensation Committee is composed exclusively of members of the Board who meet the independence criteria set forth in the Board Regulations. From the 2016 AGM, the Compensation Committee had the following four members: Ann Fudge, Srikant Datar, Enrico Vanni and William Winters. Mr. Vanni has served as a member since 2011 and as Chair since 2012.
Role of the Compensation Committee’s independent advisor
The Compensation Committee retained Frederic W. Cook & Co. Inc., appointed in 2011, as its independent external compensation advisor until June 2017. During the year, as part of its normal governance practices, the Compensation Committee conducted a market review of compensation advisors, with a focus on companies with extensive experience in European markets. Following a tendering process and an analysis to ensure that there were no conflicts-of-interest, the Compensation Committee appointed Mercer Limited as its independent compensation advisor with effect from July 2017.
Compensation Committee meetings held in 2017
In 2017, the Compensation Committee held six formal meetings, and one additional joint meeting with the Research & Development Committee to review and endorse for approval by the Board the innovation targets and achievements of the LTPP and Annual Incentive. The Compensation Committee annual performance evaluation was undertaken by an external specialist firm (Egon Zehnder) as part of a wider review of the Board and each of its committees in 2017. In addition, the Compensation Committee reviewed its charter, as it does every year, and recommended updates to the Board to reflect the ongoing evolution of compensation governance practices.
152

Novartis Group consolidated financial statements

Consolidated income statements
(For the years ended December 31, 2017, 2016 and 2015)
(USD millions unless indicated otherwise)
Note
2017
2016
2015
Net sales to third parties from continuing operations
3
49 109
48 518
49 414
Sales to discontinued segments
26
Net sales from continuing operations
3
49 109
48 518
49 440
Other revenues
1 026
918
947
Cost of goods sold
– 17 175
– 17 520
– 17 404
Gross profit from continuing operations
32 960
31 916
32 983
Marketing & Sales
– 12 861
– 11 998
– 11 772
Research & Development
– 8 972
– 9 039
– 8 935
General & Administration
– 2 136
– 2 194
– 2 475
Other income
1 969
1 927
2 049
Other expense
– 2 331
– 2 344
– 2 873
Operating income from continuing operations
3
8 629
8 268
8 977
Income from associated companies
4
1 108
703
266
Interest expense
5
– 777
– 707
– 655
Other financial income and expense
5
39
– 447
– 454
Income before taxes from continuing operations
8 999
7 817
8 134
Taxes
6
– 1 296
– 1 119
– 1 106
Net income from continuing operations
7 703
6 698
7 028
Net income from discontinued operations
29
10 766
Net income
7 703
6 698
17 794
Attributable to:
Shareholders of Novartis AG
7 703
6 712
17 783
Non-controlling interests
0
– 14
11
Basic earnings per share (USD) from continuing operations
3.28
2.82
2.92
Basic earnings per share (USD) from discontinued operations
4.48
Total basic earnings per share (USD)
7
3.28
2.82
7.40
Diluted earnings per share (USD) from continuing operations
3.25
2.80
2.88
Diluted earnings per share (USD) from discontinued operations
4.41
Total diluted earnings per share (USD)
7
3.25
2.80
7.29
The accompanying Notes form an integral part of the consolidated financial statements.
186
Consolidated statements of comprehensive income
(For the years ended December 31, 2017, 2016 and 2015)
(USD millions)
Note
2017
2016
2015
Net income
7 703
6 698
17 794
Other comprehensive income to be eventually recycled into the consolidated income statement:
Fair value adjustments on marketable securities, net of taxes
8.1
38
– 113
28
Fair value adjustments on deferred cash flow hedges, net of taxes
8.1
12
15
20
Total fair value adjustments on financial instruments, net of taxes
8.1
50
– 98
48
Novartis share of other comprehensive income recognized by associated companies, net of taxes
– 37
671
– 48
Net investment hedge
– 237
Currency translation effects
8.2
2 210
– 2 391
– 1 662
Total of items to eventually recycle
1 986
– 1 818
– 1 662
Other comprehensive income never to be recycled into the consolidated income statement:
Actuarial gains/(losses) from defined benefit plans, net of taxes
8.3
851
– 515
– 147
Total comprehensive income
10 540
4 365
15 985
Attributable to:
Shareholders of Novartis AG
10 538
4 382
15 977
Continuing operations
10 538
4 382
5 238
Discontinued operations
10 739
Non-controlling interests
2
– 17
8
The accompanying Notes form an integral part of the consolidated financial statements.
187
Consolidated balance sheets
(At December 31, 2017 and 2016)
(USD millions)
Note
2017
2016
Assets
Non-current assets
Property, plant & equipment
9
16 464
15 641
Goodwill
10
31 750
30 980
Intangible assets other than goodwill
10
29 997
31 340
Investments in associated companies
4
15 370
14 304
Deferred tax assets
11
8 229
10 034
Financial assets
12
2 243
2 196
Other non-current assets
12
818
698
Total non-current assets
104 871
105 193
Current assets
Inventories
13
6 867
6 255
Trade receivables
14
8 600
8 202
Income tax receivables
202
156
Marketable securities, commodities, time deposits and derivative financial instruments
15
625
770
Cash and cash equivalents
15
8 860
7 007
Other current assets
16
3 054
2 541
Total current assets
28 208
24 931
Total assets
133 079
130 124
Equity and liabilities
Equity
Share capital
17
969
972
Treasury shares
17
– 100
– 76
Reserves
73 299
73 936
Issued share capital and reserves attributable to Novartis AG shareholders
74 168
74 832
Non-controlling interests
59
59
Total equity
74 227
74 891
Liabilities
Non-current liabilities
Financial debts
18
23 224
17 897
Deferred tax liabilities
11
5 168
6 657
Provisions and other non-current liabilities
19
7 057
8 470
Total non-current liabilities
35 449
33 024
Current liabilities
Trade payables
5 169
4 873
Financial debts and derivative financial instruments
20
5 308
5 905
Current income tax liabilities
1 723
1 603
Provisions and other current liabilities
21
11 203
9 828
Total current liabilities
23 403
22 209
Total liabilities
58 852
55 233
Total equity and liabilities
133 079
130 124
The accompanying Notes form an integral part of the consolidated financial statements.
188
Consolidated statements of changes in equity
(For the years ended December 31, 2017, 2016 and 2015)

(USD millions)





Note




Share
capital




Treasury
shares




Retained
earnings




Total value
adjustments
Issued share
capital and
reserves
attributable
to Novartis
shareholders



Non-
controlling
interests




Total
equity
Total equity at January 1, 2015
1 001
– 103
72 433
– 2 565
70 766
78
70 844
Net income
17 783
17 783
11
17 794
Other comprehensive income
8
– 48
– 1 758
– 1 806
– 3
– 1 809
Total comprehensive income
17 735
– 1 758
15 977
8
15 985
Dividends
17.1
– 6 643
– 6 643
– 6 643
Purchase of treasury shares
17.2
– 33
– 6 086
– 6 119
– 6 119
Reduction of share capital
– 10
15
– 5
Exercise of options and employee transactions
17.2
14
1 578
1 592
1 592
Equity-based compensation
17.2
6
809
815
815
Decrease of treasury share repurchase obligation under a share buyback trading plan
17.4
658
658
658
Changes in non-controlling interests
17.3
– 10
– 10
Fair value adjustments related to divestments
8
– 100
100
Total of other equity movements
– 10
2
– 9 789
100
– 9 697
– 10
– 9 707
Total equity at December 31, 2015
991
– 101
80 379
– 4 223
77 046
76
77 122
Net income
6 712
6 712
– 14
6 698
Other comprehensive income
8
671
– 3 001
– 2 330
– 3
– 2 333
Total comprehensive income
7 383
– 3 001
4 382
– 17
4 365
Dividends
17.1
– 6 475
– 6 475
– 6 475
Purchase of treasury shares
17.2
– 7
– 985
– 992
– 992
Reduction of share capital
– 19
25
– 6
Exercise of options and employee transactions
17.2
2
212
214
214
Equity-based compensation
17.2
5
659
664
664
Impact of change in ownership of consolidated entities
17.5
– 7
– 7
– 7
Fair value adjustments related to divestments
8
– 12
12
Total of other equity movements
– 19
25
– 6 614
12
– 6 596
– 6 596
Total equity at December 31, 2016
972
– 76
81 148
– 7 212
74 832
59
74 891
Net income
7 703
7 703
7 703
Other comprehensive income
8
– 37
2 872
2 835
2
2 837
Total comprehensive income
7 666
2 872
10 538
2
10 540
Dividends
17.1
– 6 495
– 6 495
– 6 495
Purchase of treasury shares
17.2
– 36
– 5 538
– 5 574
– 5 574
Reduction of share capital
– 3
5
– 2
Exercise of options and employee transactions
17.2
2
253
255
255
Equity-based compensation
17.2
5
607
612
612
Changes in non-controlling interests
17.3
– 2
– 2
Total of other equity movements
– 3
– 24
– 11 175
– 11 202
– 2
– 11 204
Total equity at December 31, 2017
969
– 100
77 639
– 4 340
74 168
59
74 227
The accompanying Notes form an integral part of the consolidated financial statements.
189
Consolidated cash flow statements
(For the years ended December 31, 2017, 2016 and 2015)
(USD millions)
Note
2017
2016
2015
Net income from continuing operations
7 703
6 698
7 028
Reversal of non-cash items
22.1
7 058
8 437
9 070
Dividends received from associated companies and others
987
899
432
Interest received
97
43
34
Interest paid
– 708
– 723
– 646
Other financial receipts
714
Other financial payments
– 272
– 155
– 23
Taxes paid 1
– 1 611
– 2 111
– 2 454
Cash flows before working capital and provision changes from continuing operations
13 254
13 088
14 155
Payments out of provisions and other net cash movements in non-current liabilities
– 877
– 1 536
– 1 207
Change in net current assets and other operating cash flow items
22.2
244
– 77
– 863
Cash flows from operating activities from continuing operations
12 621
11 475
12 085
Cash flows used in operating activities from discontinued operations 1
– 188
Total cash flows from operating activities
12 621
11 475
11 897
Purchase of property, plant & equipment
– 1 696
– 1 862
– 2 367
Proceeds from sales of property, plant & equipment
92
161
237
Purchase of intangible assets
– 1 050
– 1 017
– 1 138
Proceeds from sales of intangible assets
640
847
621
Purchase of financial assets
– 468
– 247
– 264
Proceeds from sales of financial assets
330
247
166
Purchase of other non-current assets
– 42
– 149
– 82
Proceeds from sales of other non-current assets
1
1
Divestments of interests in associated companies
29
Acquisitions and divestments of businesses, net
22.3
– 784
– 765
– 16 507
Purchase of marketable securities and commodities
– 580
– 530
– 595
Proceeds from sales of marketable securities and commodities
549
622
262
Cash flows used in investing activities from continuing operations
– 2 979
– 2 693
– 19 666
Cash flows used in/from investing activities from discontinued operations 1
22.4
– 140
– 748
8 882
Total cash flows used in investing activities
– 3 119
– 3 441
– 10 784
Dividends paid to shareholders of Novartis AG
– 6 495
– 6 475
– 6 643
Acquisition of treasury shares
– 5 490
– 1 109
– 6 071
Proceeds from exercise options and other treasury share transactions
252
214
1 581
Increase in non-current financial debts
22.5
4 933
1 935
4 596
Repayment of non-current financial debts
22.5
– 188
– 1 696
– 3 086
Change in current financial debts
22.5
– 755
1 816
451
Impact of change in ownership of consolidated entities
0
– 6
0
Dividends paid to non-controlling interests and other financing cash flows
10
7
– 4
Cash flows used in financing activities
– 7 733
– 5 314
– 9 176
Effect of exchange rate changes on cash and cash equivalents
84
– 387
– 286
Net change in cash and cash equivalents
1 853
2 333
– 8 349
Cash and cash equivalents at January 1
7 007
4 674
13 023
Cash and cash equivalents at December 31
8 860
7 007
4 674
The accompanying Notes form an integral part of the consolidated financial statements.
 
 1  In 2016, the total net tax payment amounted to USD 2 299 million, of which USD 188 million was included in the cash flows used in investing activities from discontinued operations.
  In 2015, the total net tax payment amounted to USD 3 325 million, of which a refund of USD 94 million was included in the cash flows used in operating activities from discontinued operations, and a USD 965 million payment in the cash flows from investing activities of discontinued operations.
190

Notes to the Novartis Group consolidated financial statements

1. Significant accounting policies
The Novartis Group (Novartis or Group) is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of healthcare products led by innovative pharmaceuticals and also including eye care products and cost-saving generic pharmaceuticals. It is headquartered in Basel, Switzerland.
The consolidated financial statements of the Group are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). They are prepared in accordance with the historical cost convention except for items that are required to be accounted for at fair value.
The Group’s financial year-end is December 31, which is also the annual closing date of the individual entities’ financial statements incorporated into the Group’s consolidated financial statements.
The preparation of financial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the year that affect the reported amounts of assets and liabilities, including any contingent amounts, as well as of revenues and expenses. Actual outcomes and results could differ from those estimates and assumptions.
Listed below are accounting policies of significance to Novartis or, in cases where IFRS provides alternatives, the option adopted by Novartis.
Scope of consolidation
The consolidated financial statements include all entities, including structured entities, over which Novartis AG, Basel, Switzerland, directly or indirectly has control (generally as a result of owning more than 50% of the entity’s voting interest). Consolidated entities are also referred to as “subsidiaries”.
In cases where Novartis does not fully own a subsidiary, it has elected to value any remaining outstanding non-controlling interest at the time of acquiring control of the subsidiary at its proportionate share of the fair value of the net identified assets.
The contribution of a business to an associate or joint venture is accounted for by applying the option under IFRS that permits the accounting for the retained interest of the business contributed at its net book value at the time of the contribution.
Investments in associated companies (generally defined as investments in entities in which Novartis holds between 20% and 50% of voting shares or over which it otherwise has significant influence) and joint ventures are accounted for using the equity method, except for selected venture fund investments for which the Group has elected to apply the method of fair value through the consolidated income statement.
Foreign currencies
The consolidated financial statements of Novartis are presented in US dollars (USD). The functional currency of subsidiaries is generally the local currency of the respective entity. The functional currency used for the reporting of certain Swiss and foreign finance entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in these currencies.
For subsidiaries not operating in hyperinflationary economies, the subsidiary’s results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates:
• Income, expense and cash flows using for each month the average exchange rate with the US dollar values for each month being aggregated during the year.
• Balance sheets using year-end exchange rates.
• Resulting exchange rate differences are recognized in other comprehensive income.
The only hyperinflationary economy applicable to Novartis is Venezuela. The financial statements of the major subsidiaries in this country are first adjusted for the effect of inflation, with any gain or loss on the net monetary position recorded in the related functional lines in the consolidated income statement and then translated into USD.
Acquisition of assets
Acquired assets are initially recognized on the balance sheet at cost if they meet the criteria for capitalization. If acquired as part of a business combination, the fair value of identified assets represents the cost for these assets. If separately acquired, the cost of the asset includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment when it is no longer used are included in their cost.
Property, plant and equipment
Property, plant and equipment are depreciated on a straight-line basis in the consolidated income statement over their estimated useful lives. Leasehold land is depreciated over the period of its lease, whereas freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset.
191
Property, plant and equipment are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life.
The following table shows the respective useful lives for property, plant and equipment:
Useful life
Buildings
20 to 40 years
Machinery and other equipment
Machinery and equipment
7 to 20 years
Furniture and vehicles
5 to 10 years
Computer hardware
3 to 7 years
Government grants obtained for construction activities, including any related equipment, are deducted from the gross acquisition cost to arrive at the balance sheet carrying value of the related assets.
Goodwill and intangible assets
Goodwill
Goodwill arises in a business combination and is the excess of the consideration transferred to acquire a business over the underlying fair value of the net identified assets acquired. It is allocated to groups of cash-generating units (CGUs) which are usually represented by the reported segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under “Other Expense” in the consolidated income statement.
Intangible assets available-for-use
Novartis has the following classes of available-for-use intangible assets: Currently marketed products; Marketing know-how; Technologies; Other intangible assets (including computer software) and the Alcon brand name.
Currently marketed products represent the composite value of acquired intellectual property, patents, and distribution rights and product trade names.
Marketing know-how represents the value attributable to the expertise acquired for marketing and distributing Alcon surgical products.
Technologies represent identified and separable acquired know-how used in the research, development and production processes.
Significant investments in internally developed and acquired computer software are capitalized and included in the “Other” category and amortized once available for use.
The Alcon brand name is shown separately, as it is the only Novartis intangible asset that is available for use with an indefinite useful life. Novartis considers that it is appropriate that the Alcon brand name has an indefinite life since Alcon-branded products have a history of strong revenue and cash flow performance, and Novartis has the intent and ability to support the brand with spending to maintain its value for the foreseeable future.
Except for the Alcon brand name, intangible assets available for use are amortized over their estimated useful lives on a straight-line basis and evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable. The Alcon brand name is not amortized, but evaluated for potential impairment annually.
The following table shows the respective useful lives for available-for-use intangible assets and the location in the consolidated income statement in which the respective amortization and any potential impairment charge is recognized:


Useful life
Income statement location
for amortization and
impairment charges
Currently marketed products
5 to 20 years
"Cost of goods sold"
Marketing know-how
25 years
"Cost of goods sold"
Technologies
10 to 20 years
"Cost of goods sold" or "Research and Development"
Other (including computer software)
3 to 7 years
In the respective functional expense
Alcon brand name
Not amortized, indefinite useful life
Not applicable
Intangible assets not yet available-for-use
Acquired research and development intangible assets, which are still under development and have accordingly not yet obtained marketing approval, are recognized as In-Process Research & Development (IPR&D).
IPR&D is not amortized, but evaluated for potential impairment on an annual basis or when facts and circumstances warrant. Any impairment charge is recorded in the consolidated income statement under “Research & Development”. Once a project included in IPR&D has been successfully developed, it is transferred to the “Currently marketed products” category.
Impairment of goodwill and intangible assets
An asset is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value in use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates.
Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGUs, and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset.
The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group’s activities with regard to:
192
• Amount and timing of projected future cash flows
• Long-term sales forecasts for periods of up to 25 years
• Actions of competitors (launch of competing products, marketing initiatives, etc.)
• Sales erosion rates after the end of patent or other intellectual property rights protection and timing of the entry of generic competition
• Outcome of R&D activities (compound efficacy, results of clinical trials, etc.)
• Amount and timing of projected costs to develop IPR&D into commercially viable products
• Probability of obtaining regulatory approval
• Future tax rate
• Appropriate royalty rate for the Alcon Brand name
• Appropriate terminal growth rate
• Appropriate discount rate
Generally, for intangible assets with a definite useful life Novartis uses cash flow projections for the whole useful life of these assets. For goodwill and the Alcon brand name, Novartis generally utilizes cash flow projections for a five-year period based on management forecasts, with a terminal value based on cash flow projections usually in line with inflation rates for later periods. Probability-weighted scenarios are typically used.
Discount rates used consider the Group’s estimated weighted average cost of capital, adjusted for specific country and currency risks associated with cash flow projections to approximate the weighted average cost of capital of a comparable market participant.
Due to the above factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques.
Impairment of associated companies accounted for at equity
Novartis considers investments in associated companies for impairment evaluation whenever objective evidence indicates the net investment may be impaired, including when a quoted share price indicates a fair value less than the per-share balance sheet carrying value for the investment.
If the recoverable amount of the investment is estimated to be lower than the balance sheet carrying amount an impairment charge is recognized for the difference in the consolidated income statement under “Income from associated companies”.
Cash and cash equivalents, marketable securities, commodities and non-current financial assets
Cash and cash equivalents include highly liquid investments with original maturities of three months or less, which are readily convertible to known amounts of cash. Bank overdrafts are usually presented within current financial debts on the consolidated balance sheet, except in cases where a right of offset has been agreed with a bank, which then allows for presentation on a net basis.
Marketable securities are financial assets consisting principally of equity and debt securities as well as fund investments. Marketable securities held for short-term purposes are principally traded in liquid markets and are classified as marketable securities on the consolidated balance sheet. Marketable securities held for long-term strategic purposes are classified as non-current financial assets on the consolidated balance sheet.
Marketable securities are initially recorded at fair value on their trade date, which is different from the settlement date when the transaction is ultimately effected. Quoted securities are re-measured at each reporting date to fair value based on current market prices. If the market for a financial asset is not active or no market is available, fair values are established using valuation techniques. The majority of non-quoted investments are valued initially at fair value through the established purchase price between a willing buyer and seller. Non-quoted investments are subsequently adjusted based on values derived from using discounted cash flow analysis or other pricing models. These investment values are what is known as “Level 3” in the fair value hierarchy.
The Group has classified all its equity and quoted debt securities as well as fund investments as available-for-sale, as they are not acquired to generate profit from short-term fluctuations in price. Unrealized gains, except exchange gains related to quoted debt instruments, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are recognized in the consolidated income statement when the financial asset is sold, at which time the gain is transferred either to “Other financial income and expense”, for the marketable securities held for short-term non-strategic purposes, or to “Other income”, for all other equity securities and fund investments. Exchange gains related to quoted debt instruments are immediately recognized in the consolidated income statement under “Other financial income and expense”.
A security is assessed for impairment when its market value at the balance sheet date is less than initial cost reduced by any previously recognized impairment. Impairments on equity securities, quoted debt securities and fund investments, and exchange rate losses on quoted debt securities in a foreign currency that are held for short-term non-strategic purposes are recorded in “Other financial income and expense”. Impairments are recorded for all other equity securities and other fund investments in “Other expense” in the consolidated income statement.
Commodities include gold bullion or coins which are valued at the lower of cost or fair value using current market prices. The changes in fair value below cost are immediately recorded in “Other financial income and expense”.
Other non-current financial assets, including loans held for long-term strategic purposes, are carried at amortized cost, which reflects the time value of money less any allowances for uncollectable amounts. For these financial assets, impairments and exchange rate losses are included in “Other expense” in the consolidated income statement and exchange rate gains and interest income using the effective interest rate method are included in “Other income” in the consolidated income statement.
193
Derivative financial instruments
Derivative financial instruments are initially recognized in the balance sheet at fair value and are re-measured to their current fair value at the end of each subsequent reporting period. The valuation of a forward exchange rate contract is based on the discounted cash flow model, using interest curves and spot rates at the reporting date as observable inputs.
Options are valued based on a modified Black-Scholes model using volatility and exercise prices as major observable inputs.
The Group utilizes derivative financial instruments for the purpose of hedging to reduce the volatility in the Group’s performance due to the exposure of various types of business risks. To mitigate these risks, the Group enters into certain derivative financial instruments. The risk reduction is obtained because the derivative’s value or cash flows are expected, wholly or partly, to offset changes in the value or cash flows of the recognized assets or liabilities. The overall strategy is aiming to mitigate the currency and interest exposure risk of positions that are contractually agreed and to partially mitigate the exposure risk of selected anticipated transactions.
Certain derivative financial instruments meet the criteria for hedge accounting treatment. A prerequisite for obtaining this accounting-hedge relationship is extensive documentation on inception and proving on a regular basis that the economic hedge is effective for accounting purposes. Other derivative financial instruments do not meet the criteria to qualify for hedge accounting. Changes in the fair value of those derivative instruments are recognized immediately in “Other financial income and expense” in the consolidated income statement.
In addition, the Group has designated certain long-term debt components as hedges of the translation risk arising on certain net investments in foreign operations. On consolidation, foreign currency differences arising on long-term debt designated as net investment hedges of a foreign operation are recognized in other comprehensive income and accumulated in currency translation effects, to the extent that the hedge is effective. The foreign currency differences arising from hedge ineffectiveness are recognized in the income statement in “Other financial income and expense”.
When a hedged net investment is disposed of, the proportionate portion of the cumulative amount recognized in equity in relation to the hedged net investment is transferred to the income statement as an adjustment to the profit or loss on disposal.
Inventories
Inventory is valued at acquisition or production cost determined on a first-in first-out basis. This value is used for the “Cost of goods sold” in the consolidated income statement. Unsalable inventory is fully written off in the consolidated income statement under “Cost of goods sold”.
Trade receivables
Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as rebates, chargebacks and cash discounts.
Provisions for doubtful trade receivables are established once there is an indication that it is likely that a loss will be incurred. These provisions represent the difference between the trade receivable’s carrying amount in the consolidated balance sheet and the estimated net collectible amount. Significant financial difficulties of a customer, such as probability of bankruptcy, financial reorganization, default or delinquency in payments are considered indicators that recovery of the trade receivable is doubtful. Charges for doubtful trade receivables are recognized in the consolidated income statement within “Marketing & Sales” expenses.
Legal and environmental liabilities
Novartis and its subsidiaries are subject to contingencies arising in the ordinary course of business such as patent litigation, environmental remediation liabilities and other product-related litigation, commercial litigation, and governmental investigations and proceedings. Provisions are recorded where a reliable estimate can be made of the probable outcome of legal or other disputes against the subsidiary.
Contingent consideration
In a business combination or divestment of a business, it is necessary to recognize contingent future payments to previous owners, representing contractually defined potential amounts as a liability or asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at their fair value, which is then re-measured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance and are adjusted for the probability of their likelihood of payment, and if material, are appropriately discounted to reflect the impact of time.
Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in “Cost of goods sold” for currently marketed products and in “Research & Development” for IPR&D. Changes in contingent consideration assets are recognized in “Other income” or “Other expense”, depending on its nature.
The effect of unwinding the discount over time is recognized for contingent liabilities in “Interest expense” and for contingent assets in “other financial income and expense” in the consolidated income statement.
194
Defined benefit pension plans and other post-employment benefits
The liability in respect of defined benefit pension plans and other post-employment benefits is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions where the associates are employed, while the net interest on the net defined benefit liability or asset is recognized as “Other expense” or “Other income”.
Treasury shares
Treasury shares are initially recorded at fair value on their trade date which is different from the settlement date, when the transaction is ultimately effected. Treasury shares are deducted from consolidated equity at their nominal value of CHF 0.50 per share. Differences between the nominal amount and the transaction price on purchases or sales of treasury shares with third parties, or the value of services received for the shares allocated to associates as part of share-based compensation arrangements, are recorded in “Retained earnings” in the consolidated statement of changes in equity.
Revenue recognition
Revenue
Revenue is recognized on the sale of Novartis Group products and services and recorded as “Net sales” in the consolidated income statement when there is persuasive evidence that a sales arrangement exists; title, risks and rewards for the products are transferred to the customer; the price is determinable; and collectability is reasonably assured. When contracts contain customer acceptance provisions, sales are recognized upon the satisfaction of acceptance criteria. If products are stockpiled at the request of the customer, revenue is only recognized once the products have been inspected and accepted by the customer, and there is no right of return or replenishment on product expiry.
Surgical equipment may be sold together with other products and services under a single contract. The total consideration is allocated to the separate elements based on their relative fair values. Revenue is recognized once the recognition criteria have been met for each element of the contract.
For surgical equipment, in addition to cash and installment sales, revenue is recognized under finance and operating lease arrangements. Arrangements in which Novartis transfers substantially all the risks and rewards incidental to ownership to the customer are treated as finance lease arrangements. Revenue from finance lease arrangements is recognized at amounts equal to the fair values of the equipment, which approximate the present values of the minimum lease payments under the arrangements. As interest rates embedded in lease arrangements are approximately market rates, revenue under finance lease arrangements is comparable to revenue for outright sales. Finance income for arrangements in excess of twelve months is deferred and subsequently recognized based on a pattern that approximates the use of the effective interest method and recorded in “Other income”. Operating lease revenue for equipment rentals is recognized on a straight-line basis over the lease term.
Provisions for rebates and discounts granted to government agencies, wholesalers, retail pharmacies, managed healthcare organizations and other customers are recorded as a deduction from revenue at the time the related revenues are recorded or when the incentives are offered. They are calculated on the basis of historical experience and the specific terms in the individual agreements.
Provisions for refunds granted to healthcare providers under innovative pay-for-performance agreements are recorded as a revenue deduction at the time the related sales are recorded. They are calculated on the basis of historical experience and clinical data available for the product, as well as the specific terms in the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until such history is available.
Cash discounts are offered to customers to encourage prompt payment and are recorded as revenue deductions.
Following a decrease in the price of a product, we generally grant customers a “shelf stock adjustment” for their existing inventory for the involved product. Provisions for shelf stock adjustments, which are primarily relevant within the Sandoz Division, are determined at the time of the price decline or at the point of sale, if the impact of a price decline on the products sold can be reasonably estimated based on the customer’s inventory levels of the relevant product.
When there is historical experience of Novartis agreeing to customer returns and Novartis can reasonably estimate expected future returns, a provision is recorded for estimated sales returns. In doing so, the estimated rate of return is applied, determined based on historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a re-sale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired.
Provisions for revenue deductions are adjusted to actual amounts as rebates, discounts and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these sales deductions.
195
Other revenue
“Other revenue” includes royalty and profit sharing income and revenue from activities such as manufacturing services or other services rendered, to the extent such revenue is not recorded under net sales.
Research & Development
Internal Research & Development (R&D) costs are fully charged to “Research & Development” in the consolidated income statement in the period in which they are incurred. The Group considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland or Japan.
Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&D, that is deemed to not transfer intellectual property to Novartis are expensed as internal R&D expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been achieved from a regulatory authority in a major market.
Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are capitalized, as are payments for other assets, such as technologies to be used in R&D activities. If additional payments are made to the originator company to continue to perform R&D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&D services not resulting in an additional transfer of intellectual property rights to Novartis. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Novartis of additional intellectual property developed at the risk of the originator company. Subsequent internal R&D costs in relation to IPR&D and other assets are expensed, since the technical feasibility of the internal R&D activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market.
Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval are capitalized and recognized as currently marketed products.
Inventory produced ahead of regulatory approval is fully provisioned and the charge is included in “Other expense” in the consolidated income statement, as its ultimate use cannot be assured. If this inventory can be subsequently sold, the provision is released to “Other income” in the consolidated income statement either on approval by the appropriate regulatory authority or, exceptionally in Europe, on recommendation by the Committee for Medicinal Products for Human Use (CHMP), if approval is virtually certain.
Share-based compensation
Vested Novartis shares and American Depositary Receipts (ADRs) that are granted as compensation are valued at their market value on the grant date and are immediately expensed in the consolidated income statement.
The fair values of unvested restricted shares, restricted share units (RSUs) and performance share units (PSUs) in Novartis shares and ADRs granted to associates as compensation are recognized as an expense over the related vesting period. The expense recorded in the consolidated income statement is included in the personnel expenses of the various functions where the associates are employed.
Unvested restricted shares, restricted ADRs and RSUs are only conditional on the provision of services by the plan participant during the vesting period. They are valued using their fair value on the grant date. As RSUs do not entitle the holder to dividends the fair value is based on the Novartis share price at the grant date adjusted for the net present value of the dividends expected to be paid during the holding period. The fair value of these grants, after making adjustments for assumptions related to their forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period.
PSUs are subject to certain performance criteria being achieved during the vesting period and require plan participants to provide services during the vesting period. PSUs granted under plans defined as “Long-Term Performance Plans” are subject to performance criteria based on Novartis internal performance metrics. The expense is determined taking into account assumptions concerning performance during the period against targets and expected forfeitures due to plan participants not meeting their service conditions. These assumptions are periodically adjusted. Any change in estimates for past services is recorded immediately as an expense or income in the consolidated income statement and amounts for future periods are expensed over the remaining vesting period. As a result, at the end of the vesting period, the total charge during the whole vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date.
PSUs granted under the Long-Term Relative Performance Plan (LTRPP) are conditional on the provision of services by the plan participant during the vesting period as well as on the Total Shareholder Return (TSR) performance of Novartis relative to a specific peer group of companies over the vesting period. These performance conditions are based on variables that can be observed in the market. IFRS requires that these observations are taken into account in determining the fair value of these PSUs at the date of grant. Novartis has determined the fair value of these PSUs at the date of grant using a “Monte Carlo” simulation model. The total fair value of this grant is expensed on a straight-line basis over the vesting period. Adjustments to the number of equity instruments granted are only made if a plan participant does not fulfill the service conditions.
If a plan participant leaves Novartis for reasons other than retirement, disability or death, then unvested restricted shares, restricted ADRs, RSUs and PSUs are
196
forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Novartis Board of Directors, for example, in connection with a reorganization or divestment.
Measuring the fair values of PSUs granted under the LTRPP, requires estimates. The Monte Carlo simulation used for determining the fair value of the PSUs related to the LTRPP requires as input parameters the probability of factors related to uncertain future events; the term of the award; the grant price of underlying shares or ADRs; expected volatilities; the expected correlation matrix of the underlying equity instruments with those of the peer group of companies and the risk-free interest rate.
Government grants
Grants from governments or similar organizations are recognized at their fair value when there is a reasonable assurance that the grant will be received and the Group will comply with all attached conditions.
Government grants related to income are deferred and recognized in the consolidated income statement over the period necessary to match them with the related costs that they are intended to compensate.
The accounting policy for property, plant and equipment describes the treatment of any related grants.
Restructuring charges
Restructuring provisions are recognized for the direct expenditures arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made.
Charges to increase restructuring provisions are included in “Other expense” in the consolidated income statements. Corresponding releases are recorded in “Other income” in the consolidated income statement.
Taxes
Taxes on income are provided in the same periods as the revenues and expenses to which they relate and include any interest and penalties incurred during the period. Deferred taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax base of an asset or liability and its carrying value in the balance sheet prepared for consolidation purposes, except for those temporary differences related to investments in subsidiaries and associated companies, where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary’s retained earnings are only taken into account when a dividend has been planned.
The estimated amounts for current and deferred tax assets or liabilities, including any amounts related to any uncertain tax positions, are based on currently known facts and circumstances. Tax returns are based on an interpretation of tax laws and regulations, and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made requiring payments of additional tax, interest or penalties. Inherent uncertainties exist in the estimates of the tax positions.
Non-current assets held for sale
Non-current assets are classified as assets held for sale when their carrying amount is to be recovered principally through a sale transaction and a sale is considered highly probable. They are stated at the lower of carrying amount and fair value less costs of disposal. Assets held for sale, included within a disposal group or discontinued operations are not depreciated or amortized.
Status of adoption of significant new or amended IFRS standards or interpretations
The adoption of new or amended standards and interpretations that are effective for the financial year beginning on January 1, 2017, did not have a material impact on the Group’s consolidated financial statements.
The following new IFRS standards will, based on a Novartis analysis, be of significance to the Group, but have not yet been early adopted:
IFRS 9 FINANCIAL INSTRUMENTS
IFRS 9 Financial Instruments will substantially change the classification and measurement of financial instruments. The new standard requires impairments to be based on a forward-looking model, changes the approach to hedging financial exposures and related documentation, changes the recognition of certain fair value changes and amends disclosures requirements.
The impairment of financial assets, including trade and lease receivables, will be assessed using an expected credit loss model rather than the current incurred loss model. Given the nature of Novartis’ financial assets, the Group does not expect a significant impact to our provisions for doubtful accounts or impairments from this change.
The new hedge accounting model introduced by the standard requires hedge accounting relationships to be based upon the Group’s own risk management strategy and objectives, and to be discontinued only when the relationships no longer qualify for hedge accounting. Based on the impact of adoption assessment performed, Novartis expects that the existing hedge relationship will continue to be designated as such under the new hedge accounting requirements.
The Group will implement the new standard on January 1, 2018 and will apply the modified retrospective method, which requires the recognition of the cumulative effect of initially applying IFRS 9, as at January 1, 2018, to retained earnings and not restate prior years.
The most significant impact to the Group, upon adoption of IFRS 9, will be the treatment of the unrealized gains and losses from changes in fair value on certain of
197
the Group’s financial instruments, which are classified as available-for-sale marketable securities and financial investments. The unrealized gains and losses (to the extent of previous recognized unrealized gains), which the Group currently recognizes in the consolidated statement of other comprehensive income, will in the future be recognized in the consolidated income statement. This approach will be applied to equity securities where the fair value through other comprehensive income irrevocable option will not be applied. If this accounting had been applied prior to January 1, 2018, the adoption date, the cumulative effect to be recorded as an increase to retained earnings, as at January 1, 2018, is estimated at USD 0.2 billion.
IFRS 15 REVENUE FROM CONTRACTS WITH CUSTOMERS
IFRS 15 Revenue from contracts with customers amends revenue recognition requirements and establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The standard replaces IAS 18 Revenue and IAS 11 Construction contracts and related interpretations.
Results of our impact assessment:
• The Group’s “Net sales” are derived from the sale of drug substances, vision care products, surgical equipment, other products and services, where control transfers to our customers and our performance obligations are satisfied at the time of shipment to or receipt of the products by the customer or when the services are performed. We do not expect IFRS 15 to significantly change the timing or amount of revenue recognized under these arrangements.
• The Group’s “Other revenue” consists of royalty income from the out-licensing of intellectual property (IP), which is recognized as earned and from manufacturing services and other services, where revenue is recognized when control transfers to the third party and our performance obligations are satisfied. We do not expect IFRS 15 to significantly change the timing or amount of revenue recognized from these manufacturing and other services arrangements, nor from these royalty arrangements, as the standard’s royalty exception will apply for IP licenses.
“Other revenue” also includes revenue from profit sharing arrangements with our collaboration partners. Furthermore, the Group receives milestone payments related to sale or out-licensing of IP. Novartis does not expect IFRS 15 to significantly change the timing or amount of revenue recognized under these arrangements.
The Group will implement the new standard on January 1, 2018 and will apply the modified retrospective method, which requires the recognition of the cumulative effect of initially applying IFRS 15, as at January 1, 2018, to retained earnings and not restate prior years. However, since the results of the Group’s impact assessment indicates that IFRS 15 is not expected to significantly change the amount or timing of revenue recognition in 2017 or prior periods, an insignificant cumulative adjustment to increase retained earnings will be made.
IFRS 16 LEASES
IFRS 16 Leases substantially changes the financial statements as the majority of leases for which the company is the lessee will become on-balance sheet liabilities with corresponding right of use assets on the balance sheet. The standard replaces IAS 17 Leases and is effective on January 1, 2019. The current undiscounted operating lease commitments of USD 3.2 billion as of December 31, 2017, and disclosed in Note 27 provide, subject to the provision of the standard, an indicator of the impact of the implementation of IFRS 16 on the Group’s consolidated balance sheet.
Upon adoption of the new standard, a portion of the annual operating lease costs, which is currently fully recognized as a functional expense, will be recorded as interest expense. In addition, the portion of the annual lease payments recognized in the cash flow statement as a reduction of the lease liability will be recognized as an outflow from financing activities, which currently are fully recognized as an outflow from operating activities. Given the leases involved and assuming the current low interest rate environment continues, the Group does not currently expect these effects to be significant.
There are no other IFRS standards or interpretations not yet effective that would be expected to have a material impact on the Group.
2. Significant transactions
Significant transactions in 2017
Innovative Medicines – Acquisition of Ziarco Group Limited
On January 20, 2017, Novartis acquired Ziarco Group Limited (Ziarco), a privately held company in the United Kingdom, focused on the development of novel treatments in dermatology. This acquisition adds a once-daily oral H4 receptor antagonist in development for atopic dermatitis, commonly known as eczema, to complement the Novartis dermatology portfolio and pipeline. The fair value of the total purchase consideration was USD 420 million. The amount consisted of an initial cash payment of USD 325 million and the net present value of the contingent consideration of USD 95 million, due to Ziarco shareholders, which they are eligible to receive upon the achievement of specified development milestones. The purchase price allocation resulted in net identifiable
198
assets of USD 395 million and goodwill of USD 25 million. Results of operations since the date of acquisition were not material.
Innovative Medicines – Acquisition of Encore Vision, Inc.
On January 20, 2017, Novartis acquired Encore Vision, Inc. (Encore), a privately-held company in Fort Worth, Texas, in the United States, focused on the development of a novel treatment in presbyopia. The fair value of the total purchase consideration was USD 456 million. The amount consisted of an initial cash payment of USD 366 million and the net present value of the contingent consideration of USD 90 million, due to Encore shareholders, which they are eligible to receive upon the achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 389 million and goodwill of USD 67 million. Results of operations since the date of acquisition were not material.
Significant transaction entered into in 2017 and closed in January 2018
Innovative Medicines – Acquisition of ADVANCED ACCELERATOR APPLICATIONS, S.A.
On October 30, 2017, Novartis entered into a binding memorandum of understanding with Advanced Accelerator Applications S.A., (AAA), a NASDAQ-listed company headquartered in Saint-Genis-Pouilly, France, under which Novartis agreed to commence a tender offer for 100% of the share capital of AAA subject to certain conditions. Novartis commenced the tender offer on December 7, 2017, to purchase all of the outstanding ordinary shares for a price of USD 41 per share and USD 82 per American Depositary Share (ADS), each representing two ordinary shares of AAA, which expired on January 19, 2018. The offer values AAAs equity at USD 3.9 billion, on a fully diluted basis. The transaction to acquire AAA is being funded mainly through external short- and long-term debt.
As of the expiration of the tender offer, approximately 97% of the then outstanding fully diluted ordinary shares, including ordinary shares represented by ADSs, were validly tendered. On January 22, 2018, Novartis accepted and paid USD 3.9 billion for the ordinary shares, including ordinary shares represented by ADSs, tendered in the offer.
On January 22, 2018 Novartis also commenced a subsequent offering period that will expire on January 31, 2018, unless extended.
AAA is a radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicines, including Lutathera® (lutetium (177Lu) oxodotreotide), a first-in-class RLT product for neuroendocrine tumors (NETs) and a portfolio of diagnostic products. Radiopharmaceuticals, such as Lutathera®, are unique medicinal formulations containing radioisotopes, which are used clinically for both diagnosis and therapy.
Significant transactions in 2016
Alcon – Acquisition of Transcend Medical, Inc.
On February 17, 2016, Alcon entered into an agreement to acquire Transcend Medical, Inc. (Transcend), a privately-held, US-based company focused on developing minimally-invasive surgical devices to treat glaucoma. The transaction closed on March 23, 2016, and the fair value of the total purchase consideration was USD 332 million. The amount consisted of an initial cash payment of USD 240 million and the net present value of contingent consideration of USD 92 million due to the Transcend shareholders, which they are eligible to receive upon the achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 294 million and goodwill of USD 38 million. The 2016 results of operations since the date of acquisition were not material.
INNOVATIVE MEDICINES – ACQUISITION OF Reprixys PHARMACEUTICALs CORPORATION
On November 18, 2016, Novartis acquired Reprixys Pharmaceuticals Corporation (Reprixys), a privately held, US-based company specializing in the development of therapeutics in certain hematologic and inflammatory disorders, following receipt of results of the SUSTAIN study. The previously held interest of 19% is adjusted to its fair value of USD 64 million through the consolidated income statement at acquisition date. This re-measurement resulted in a gain of USD 53 million.
The fair value of the total purchase consideration for acquiring the 81% stake Novartis did not already own amounted to USD 268 million. The amount consisted of an initial cash payment of USD 194 million and the net present value of the contingent consideration of USD 74 million due to Reprixys shareholders, which they are eligible to receive upon the achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 332 million. No goodwill was recognized. The 2016 results of operations since the date of acquisition were not material.
Significant transactions in 2015
Portfolio transformation transactions
Transaction with Eli Lilly and Company
On January 1, 2015, Novartis closed its transaction with Eli Lilly and Company, USA (Lilly) announced in April 2014 to divest its Animal Health business for USD 5.4 billion in cash. This resulted in a pre-tax gain of USD 4.6 billion, which is recorded in operating income from discontinued operations.
Transactions with GlaxoSmithKline plc
On March 2, 2015, Novartis closed its transactions with GlaxoSmithKline plc, Great Britain (GSK) announced in April 2014, with the following consequences:
Innovative Medicines – Acquisition of GSK oncology products
Novartis acquired GSK’s oncology products and certain related assets for an aggregate cash consideration of USD 16.0 billion. Up to USD 1.5 billion of this cash consideration at the acquisition date is contingent on certain development milestones. The fair value of this potentially refundable consideration as at the acquisition date is USD 0.1 billion. In addition, under the terms of the agreement, Novartis is granted a right of first negotiation
199
over the co-development or commercialization of GSK’s current and future oncology R&D pipeline, excluding oncology vaccines. The right of first negotiation is for a period of 12.5 years from the acquisition closing date. The purchase price allocation of the fair value of the consideration of USD 15.9 billion resulted in net identified assets of USD 13.5 billion and goodwill of USD 2.4 billion. In 2015, from the date of the acquisition the business generated net sales of USD 1.8 billion. Management estimates net sales for the entire year 2015 would have amounted to USD 2.1 billion had the oncology products been acquired at the beginning of the 2015 reporting period. The 2015 net results from operations on a reported basis since the acquisition date were not material.
Vaccines – Divestment
Novartis divested its Vaccines business (excluding its Vaccines influenza business) to GSK for up to USD 7.1 billion plus royalties. The USD 7.1 billion consists of USD 5.25 billion paid at closing and up to USD 1.8 billion in future milestone payments. The fair value of the contingent future milestones and royalties as at the acquisition date is USD 1.0 billion, resulting in a fair value of consideration received of USD 6.25 billion. Included in this amount is a USD 450 million milestone payment received in late March 2015. The sale of this business resulted in a pre-tax gain of USD 2.8 billion, which is recorded in operating income from discontinued operations.
Novartis’s Vaccines influenza business was excluded from the GSK Vaccines business acquisition. However, GSK entered into a future option arrangement with Novartis in relation to the Vaccines influenza business, pursuant to which Novartis could have unilaterally required GSK to acquire the entire or certain parts of its Vaccines influenza business for consideration of up to USD 250 million (the Influenza Put Option) if the divestment to CSL Limited, Australia (CSL), discussed below, had not been completed. The option period was 18 months from the closing date of the GSK transaction, but terminated with the sale of the Vaccines influenza business to CSL on July 31, 2015. Novartis paid GSK a fee of USD 5 million in consideration for the grant of the Influenza Put Option.
Consumer Health – Combination of Novartis OTC with GSK Consumer Healthcare
Novartis and GSK agreed to create a combined consumer healthcare business through the combination between Novartis OTC and GSK Consumer Healthcare businesses. On March 2, 2015, a new entity, GlaxoSmithKline Consumer Healthcare Holdings Ltd. (GSK Consumer Healthcare) was formed via contribution of businesses from both Novartis and GSK. Novartis has a 36.5% interest in the newly created entity. Novartis has valued the contribution of 63.5% of its OTC Division in exchange for 36.5% of the GSK Consumer Healthcare business at fair value. Based on the estimates of fair values exchanged, an investment in an associated company of USD 7.6 billion was recorded. The resulting pre-tax gain, net of transaction related costs, of USD 5.9 billion is recorded in operating income from discontinued operations.
Novartis has four of eleven seats on the GSK Consumer Healthcare Board of Directors. Furthermore, Novartis has customary minority rights and also exit rights at a pre-defined, market based pricing mechanism.
The investment is accounted for using the equity method of accounting using estimated results for the last quarter of the year. Any differences between this estimate and actual results, when available, will be adjusted in the Group’s consolidated financial statements in the following year.
Additional GSK related costs
The GSK transaction resulted in USD 0.6 billion of additional transaction-related costs that were expensed, thereof USD 0.3 billion paid in 2015.
Transaction with CSL
On October 26, 2014, Novartis entered into an agreement with CSL to sell its Vaccines influenza business to CSL for USD 275 million. Entering into the separate divestment agreement with CSL resulted in the Vaccines influenza business being classified as a separate disposal group consisting of a group of cash generating units within the Vaccines Division, requiring the performance of a separate valuation of the Vaccines influenza business net assets. This triggered the recognition of an exceptional impairment charge in 2014 of USD 1.1 billion as the estimated net book value of the Vaccines influenza business net assets was above the USD 275 million consideration. The transaction with CSL was completed on July 31, 2015, resulting in a partial reversal of the impairment recorded in 2014 in the amount of USD 0.1 billion, which is included in operating income from discontinued operations.
Other significant transactions in 2015
Innovative Medicines – Acquisition of Spinifex Pharmaceuticals, Inc.
On June 29, 2015, Novartis entered into an agreement to acquire Spinifex Pharmaceuticals, Inc. (Spinifex), a United States and Australia based, privately held development stage company, focused on developing a peripheral approach to treat neuropathic pain. The transaction closed on July 24, 2015, and the fair value of the total purchase consideration was USD 312 million. The amount consisted of an initial cash payment of USD 196 million and the net present value of the contingent consideration of USD 116 million due to previous Spinifex shareholders, which they are eligible to receive upon achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 263 million and goodwill of USD 49 million. The 2015 results of operations since the date of acquisition were not material.
Innovative Medicines – Acquisition of Admune Therapeutics LLC
On October 16, 2015, Novartis entered into an agreement to acquire Admune Therapeutics LLC (Admune), a US-based, privately held company, broadening Novartis’
200
pipeline of cancer immunotherapies. The fair value of the total purchase consideration amounted to USD 258 million. This amount consists of an initial cash payment of USD 140 million and the net present value of the contingent consideration of USD 118 million due to Admune’s previous owners, which they are eligible to receive upon the achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 258 million. No goodwill was recognized. The 2015 results of operations since the date of acquisition were not material.
3. Segmentation of key figures 2017, 2016 and 2015
The businesses of Novartis are divided operationally on a worldwide basis into three identified reporting segments, Innovative Medicines, Sandoz and Alcon. In addition, we separately report Corporate activities.
Reporting segments are presented in a manner consistent with the internal reporting to the chief operating decision maker, which is the Executive Committee of Novartis. The reporting segments are managed separately because they each research, develop, manufacture, distribute, and sell distinct products that require differing marketing strategies.
The Executive Committee of Novartis is responsible for allocating resources and assessing the performance of the reporting segments.
Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines. The Innovative Medicines Division is organized into two global business units: Novartis Oncology business unit, which consists of the global business franchises Oncology and Novartis Pharmaceuticals business unit, which consists of the global business franchises Ophthalmology, Neuroscience, Immunology and Dermatology, Respiratory, Cardio-Metabolic and Established Medicines.
Sandoz develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. Sandoz is organized globally in three franchises: Retail Generics, Anti Infectives, and Biopharmaceuticals. In Retail Generics, Sandoz develops, manufactures and markets active ingredients and finished dosage forms of pharmaceuticals to third parties. Retail Generics includes the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmics, pain, and respiratory, as well as finished dosage form anti infectives sold to third parties. In Anti Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by Retail Generics and for sale to third party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein or other biotechnology based products, including biosimilars, and provides biotechnology manufacturing services to other companies.
Alcon researches, discovers, develops, manufactures, distributes and sells eye care products. The Alcon Division is the global leader in eye care, with product offerings in eye care devices and vision care. The Alcon Division is organized globally in two global business franchises as follows: In Surgical, Alcon develops, manufactures, distributes and sells ophthalmic surgical equipment, instruments, disposable products and intraocular lenses. In Vision Care, Alcon develops, manufactures, distributes and sells contact lenses and lens care products.
Income and expenses relating to Corporate include the costs of the Group headquarters and those of corporate coordination functions in major countries. In addition, Corporate includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights, certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships. Usually, no allocation of Corporate items is made to the segments. As a result, Corporate assets and liabilities principally consist of net liquidity (cash and cash equivalents, marketable securities less financial debts), investments in associated companies and current and deferred taxes and non-segment specific environmental remediation and post-employment benefit liabilities. Corporate also includes the Alcon brand name intangible asset as it is used to market products of the Alcon Division and products within the Ophthalmology business franchise of the Innovative Medicines Division.
201
Our divisions are supported by the Novartis Institutes for BioMedical Research, Global Drug Development, Novartis Technical Operations and Novartis Business Services organizations.
• The Novartis Institutes for BioMedical Research (NIBR) conducts research activities of the Innovative Medicines Division and also collaborates with Sandoz.
• Global Drug Development organization was established in July 2016 and oversees all drug development activities for our Innovative Medicines Division and the biosimilars portfolio of our Sandoz Division.
• Novartis Technical Operations organization was established in July 2016, to centralize management of our manufacturing operations across our Innovative Medicines and Sandoz Divisions.
• Novartis Business Services (NBS) was established in January 2015 as a shared services organization and delivers business support services across the Group, such as information technology, real estate and facility services, procurement, product lifecycle services, human resources and financial reporting and accounting operations.
Following the portfolio transformation transactions in 2015, described in Note 2, Novartis has separated the Group’s reported financial data into “continuing” operations and “discontinued” operations:
Continuing operations comprise:
• Innovative Medicines: innovative patent-protected prescription medicines
• Sandoz: generic and biosimilar pharmaceuticals
• Alcon: eye care devices and vision care
• Corporate activities
Discontinued operations comprise:
• Vaccines: preventive human vaccines. Excluded are certain intellectual property rights and related other revenues of the Vaccines Division, which are now reported under Corporate activities.
• Consumer Health: OTC (over-the-counter medicines) and Animal Health. These two divisions were managed separately. However, neither was material enough to the Group to be disclosed separately as a reporting segment.
• Corporate: certain transactional and other expenses related to the portfolio transformation.
The accounting policies mentioned in Note 1 are used in the reporting of segment results. Inter-segmental sales are made at amounts that are considered to approximate arm’s length transactions. The Executive Committee of Novartis evaluates segmental performance and allocates resources among the segments based on a number of measures including net sales, operating income and net operating assets. Segment net operating assets consist primarily of property, plant and equipment, intangible assets, goodwill, inventories and trade and other operating receivables less operating liabilities.
202
Segmentation – Consolidated income statements
Innovative Medicines
Sandoz
Alcon
Corporate (including eliminations)
Group
(USD millions)
2017
2016
2017
2016
2017
2016
2017
2016
2017
2016
Net sales to third parties
33 025
32 562
10 060
10 144
6 024
5 812
49 109
48 518
Sales to other segments
668
624
118
104
3
– 789
– 728
Net sales
33 693
33 186
10 178
10 248
6 027
5 812
– 789
– 728
49 109
48 518
Other revenues
898
815
37
37
3
4
88
62
1 026
918
Cost of goods sold
– 9 007
– 9 331
– 5 800
– 5 971
– 3 231
– 3 092
863
874
– 17 175
– 17 520
Gross profit
25 584
24 670
4 415
4 314
2 799
2 724
162
208
32 960
31 916
Marketing & Sales
– 9 089
– 8 435
– 1 811
– 1 681
– 1 961
– 1 882
– 12 861
– 11 998
Research & Development
– 7 630
– 7 709
– 774
– 814
– 568
– 516
– 8 972
– 9 039
General & Administration
– 986
– 978
– 315
– 300
– 383
– 410
– 452
– 506
– 2 136
– 2 194
Other income
1 027
1 091
204
185
47
48
691
603
1 969
1 927
Other expense
– 1 124
– 1 213
– 351
– 259
– 124
– 96
– 732
– 776
– 2 331
– 2 344
Operating income
7 782
7 426
1 368
1 445
– 190
– 132
– 331
– 471
8 629
8 268
Income from associated companies
– 1
23
6
1 086
697
1 108
703
Interest expense
– 777
– 707
Other financial income and expense
39
– 447
Income before taxes
8 999
7 817
Taxes
– 1 296
– 1 119
Net income
7 703
6 698
Attributable to:
Shareholders of Novartis AG
7 703
6 712
Non-controlling interests
0
– 14
Included in net income are:
Interest income
110
43
Depreciation of property, plant & equipment
– 916
– 883
– 270
– 260
– 217
– 229
– 117
– 117
– 1 520
– 1 489
Amortization of intangible assets
– 2 291
– 2 470
– 447
– 450
– 942
– 929
– 10
– 12
– 3 690
– 3 861
Impairment charges on property, plant & equipment, net
– 84
– 93
– 73
– 2
– 5
– 2
– 157
– 102
Impairment charges on intangible assets, net
– 591
– 522
– 61
– 65
– 57
– 4
– 709
– 591
Impairment charges and fair value gains on financial assets, net
– 42
– 55
– 29
– 185
– 77
– 256
– 132
Additions to restructuring provisions
– 122
– 236
– 61
– 46
– 8
– 36
– 3
– 25
– 194
– 343
Equity-based compensation of Novartis equity plans
– 593
– 582
– 52
– 47
– 71
– 53
– 208
– 164
– 924
– 846
 
 
203
Innovative Medicines
Sandoz
Alcon
Corporate (including eliminations)
Group
(USD millions)
2016
2015
2016
2015
2016
2015
2016
2015
2016
2015
Net sales to third parties from continuing operations
32 562
33 345
10 144
10 070
5 812
5 999
48 518
49 414
Sales to other segments
624
518
104
128
– 728
– 620
26
Net sales from continuing operations
33 186
33 863
10 248
10 198
5 812
5 999
– 728
– 620
48 518
49 440
Other revenues
815
792
37
25
4
23
62
107
918
947
Cost of goods sold
– 9 331
– 9 204
– 5 971
– 5 844
– 3 092
– 3 145
874
789
– 17 520
– 17 404
Gross profit from continuing operations
24 670
25 451
4 314
4 379
2 724
2 877
208
276
31 916
32 983
Marketing & Sales
– 8 435
– 8 430
– 1 681
– 1 679
– 1 882
– 1 663
– 11 998
– 11 772
Research & Development
– 7 709
– 7 685
– 814
– 782
– 516
– 468
– 9 039
– 8 935
General & Administration
– 978
– 1 031
– 300
– 346
– 410
– 450
– 506
– 648
– 2 194
– 2 475
Other income
1 091
1 149
185
109
48
54
603
737
1 927
2 049
Other expense
– 1 213
– 1 639
– 259
– 381
– 96
– 69
– 776
– 784
– 2 344
– 2 873
Operating income from continuing operations
7 426
7 815
1 445
1 300
– 132
281
– 471
– 419
8 268
8 977
Income from associated companies
6
2
697
264
703
266
Interest expense
– 707
– 655
Other financial income and expense
– 447
– 454
Income before taxes from continuing operations
7 817
8 134
Taxes
– 1 119
– 1 106
Net income from continuing operations
6 698
7 028
Net income from discontinued operations
10 766
Net income
6 698
17 794
Attributable to:
Shareholders of Novartis AG
6 712
17 783
Non-controlling interests
– 14
11
Included in net income from continuing operations are:
Interest income
43
33
Depreciation of property, plant & equipment
– 883
– 839
– 260
– 277
– 229
– 237
– 117
– 117
– 1 489
– 1 470
Amortization of intangible assets
– 2 470
– 2 384
– 450
– 450
– 929
– 912
– 12
– 9
– 3 861
– 3 755
Impairment charges on property, plant & equipment, net
– 93
39
– 2
– 97
– 5
– 1
– 2
– 21
– 102
– 80
Impairment charges on intangible assets, net
– 522
– 138
– 65
– 27
– 4
– 1
– 591
– 166
Impairment charges and fair value gains on financial assets, net
– 55
– 32
– 77
– 72
– 132
– 104
Additions to restructuring provisions
– 236
– 232
– 46
– 93
– 36
– 25
– 25
– 49
– 343
– 399
Equity-based compensation of Novartis equity plans
– 582
– 620
– 47
– 53
– 53
– 66
– 164
– 164
– 846
– 903
204
Segmentation – Consolidated balance sheets
Innovative Medicines
Sandoz
Alcon
Corporate (including eliminations)
Group
(USD millions)
2017
2016
2017
2016
2017
2016
2017
2016
2017
2016
Total assets
54 075
51 911
18 231
17 611
22 014
22 970
38 759
37 632
133 079
130 124
Total liabilities
– 11 457
– 10 007
– 3 459
– 3 168
– 1 893
– 2 520
– 42 043
– 39 538
– 58 852
– 55 233
Total equity
74 227
74 891
Net debt
19 047
16 025
Net operating assets
42 618
41 904
14 772
14 443
20 121
20 450
93 274
90 916
Included in assets and liabilities are:
Total property, plant & equipment
10 857
10 410
2 525
2 374
2 403
2 163
679
694
16 464
15 641
Additions to property, plant & equipment 1
877
996
326
316
431
396
94
127
1 728
1 835
Total goodwill and intangible assets
31 571
31 630
10 993
10 774
16 176
16 914
3 007
3 002
61 747
62 320
Additions to goodwill and intangible assets 1
984
865
64
45
82
63
16
5
1 146
978
Total investment in associated companies
41
16
7
18
15 322
14 270
15 370
14 304
Additions to investment in associated companies
6
4
40
37
46
41
Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments
9 485
7 777
9 485
7 777
Financial debts and derivative financial instruments
28 532
23 802
28 532
23 802
Current income tax and deferred tax liabilities
6 891
8 260
6 891
8 260
 1  Excluding impact of business combinations
 
The following table shows countries that accounted for more than 5% of at least one of the respective Group totals, as well as regional information for net sales for the years ended December 31, 2017, 2016 and 2015, and for selected non-current assets for the years ended December 31, 2017 and 2016:
Net sales1
Total of selected non-current assets2
(USD millions)
2017
%
2016
%
2015
%
2017
%
2016
%
Country
Switzerland
836
2
830
2
774
2
43 920
47
44 413
48
United States
16 935
34
17 117
35
18 079
37
28 476
30
28 484
31
United Kingdom
1 160
2
1 182
2
1 277
3
7 957
9
6 892
7
Germany
3 690
8
3 634
7
3 262
7
3 128
3
2 733
3
France
2 490
5
2 390
5
2 269
5
284
199
Japan
3 177
6
3 267
7
3 163
6
148
145
Other
20 821
43
20 098
42
20 590
40
9 668
11
9 399
11
Group
49 109
100
48 518
100
49 414
100
93 581
100
92 265
100
Region
Europe
17 492
36
17 079
35
16 472
33
61 699
66
59 879
65
Americas
20 899
42
20 998
43
22 414
45
29 113
31
29 831
32
Asia/Africa/Australasia
10 718
22
10 441
22
10 528
22
2 769
3
2 555
3
Group
49 109
100
48 518
100
49 414
100
93 581
100
92 265
100
 
 1  Net sales from operations by location of third-party customer
 2  Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies
The Group’s largest, second-largest and third-largest customers account for approximately 17%, 12% and 7% of net sales, respectively (2016: 16%, 12% and 6% respectively; 2015: 14%, 11% and 5% respectively). All segments had sales to these customers in 2017, 2016 and 2015. No other customer accounted for 5% or more of net sales in any year.
The highest amounts of trade receivables outstanding were for these same three customers and amounted to 14%, 9% and 5%, respectively, of the trade receivables at December 31, 2017 (2016: 14%, 9% and 6% respectively).
205
Innovative Medicines net sales by business franchise

2017
USD
millions

2016
USD
millions
Change
(2016
to 2017)
USD %

2015
USD
millions
Change
(2015
to 2016)
USD %
Oncology
Gleevec/Glivec
1 943
3 323
– 42
4 658
– 29
Tasigna
1 841
1 739
6
1 632
7
Sandostatin
1 612
1 646
– 2
1 630
1
Afinitor/Votubia
1 525
1 516
1
1 607
– 6
Exjade/Jadenu
1 059
956
11
917
4
Tafinlar + Mekinist
873
672
30
453
nm
Promacta/Revolade
867
635
37
402
nm
Votrient
808
729
11
565
nm
Jakavi
777
581
34
410
42
Kisqali
76
0
nm
0
nm
Other
893
993
– 10
1 030
– 4
Total Oncology business unit
12 274
12 790
– 4
13 304
– 4
Ophthalmology
Lucentis
1 888
1 835
3
2 060
– 11
Travoprost Group
589
619
– 5
631
– 2
Systane Group
400
377
6
380
– 1
Topical Olopatadine Group
284
335
– 15
457
– 27
Other
2 207
2 297
– 4
2 395
– 4
Total Ophthalmology
5 368
5 463
– 2
5 923
– 8
Immunology and Dermatology
Cosentyx
2 071
1 128
84
261
nm
Neoral/Sandimmun(e)
488
515
– 5
570
– 10
Zortress/Certican
414
398
4
335
19
Ilaris
402
283
42
236
20
Myfortic
378
383
– 1
441
– 13
Other
288
308
– 6
294
5
Total Immunology and Dermatology
4 041
3 015
34
2 137
41
Neuroscience
Gilenya
3 185
3 109
2
2 776
12
Other
102
124
– 18
141
– 12
Total Neuroscience
3 287
3 233
2
2 917
11

2017
USD
millions

2016
USD
millions
Change
(2016
to 2017)
USD %

2015
USD
millions
Change
(2015
to 2016)
USD %
Respiratory
Ultibro Breezhaler
411
363
13
260
40
Seebri Breezhaler
151
149
1
150
– 1
Onbrez Breezhaler
112
143
– 22
166
– 14
Subtotal COPD1 portfolio
674
655
3
576
14
Xolair 2
920
835
10
755
11
Other
23
31
– 26
37
– 16
Total Respiratory
1 617
1 521
6
1 368
11
Cardio-Metabolic
Entresto
507
170
198
21
nm
Other
17
14
21
0
nm
Total Cardio-Metabolic
524
184
185
21
nm
Established Medicines
Galvus
1 233
1 193
3
1 140
5
Exforge
960
926
4
1 047
– 12
Diovan/Co-Diovan
957
1 073
– 11
1 284
– 16
Voltaren/Cataflam
465
525
– 11
558
– 6
Exelon/Exelon Patch
381
444
– 14
728
– 39
Ritalin/Focalin
236
282
– 16
365
– 23
Other
1 682
1 913
– 12
2 553
– 25
Total Established Medicines
5 914
6 356
– 7
7 675
– 17
Total Pharmaceutical business unit
20 751
19 772
5
20 041
– 1
Total division net sales
33 025
32 562
1
33 345
– 2
 1  Chronic obstructive pulmonary disease
 2  Net sales reflect Xolair sales for all indications (e.g., including Xolair SAA and Xolair CSU, which is managed by the Immunology and Dermatology franchise)
 
nm = not meaningful
The product portfolio of other segments is widely spread in 2017, 2016 and 2015.
206
4. Associated companies
Net income statement effect
Other comprehensive income effect
Total comprehensive income effect
(USD millions)
2017
2016
2015
2017
2016
2015
2017
2016
2015
Roche Holding AG, Switzerland
456
464
343
108
– 39
– 149
564
425
194
GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK
629
234
– 79
– 145
710
– 4
484
944
– 83
Others
23
5
2
23
5
2
Associated companies related to continuing operations
1 108
703
266
– 37
671
– 153
1 071
1 374
113
Novartis has significant investments in Roche Holding AG, Basel (Roche) and in GlaxoSmithKline Consumer Healthcare Holdings Ltd, Brentford, Middlesex, UK as well as certain other smaller investments that are accounted for as associated companies.
Balance sheet value

(USD millions)
December 31,
2017
December 31,
2016
Roche Holding AG, Switzerland
8 121
7 644
GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK
7 020
6 448
Others
229
212
Total
15 370
14 304
Roche Holding AG
The Group’s holding in Roche voting shares was 33.3% at December 31, 2017, 2016 and 2015. This investment represents approximately 6.3% of Roche’s total outstanding voting and non-voting equity instruments at December 31, 2017, 2016 and 2015.
Since full-year 2017 financial data for Roche is not available when Novartis produces its consolidated financial results, a survey of analyst estimates is used to estimate the Group’s share of Roche’s net income. Any differences between these estimates and actual results will be adjusted in the Group’s 2018 consolidated financial statements when available.
The following tables show summarized financial information for Roche, including current values of fair value adjustments made at the time of the acquisition of the shares, for the year ended December 31, 2016 and for the six months ended June 30, 2017 (since full-year 2017 data is not yet available):

(CHF billions)

Current assets
Non-current
assets
Current
liabilities
Non-current
liabilities
December 31, 2016
28.7
61.4
22.6
27.8
June 30, 2017
26.7
56.9
20.6
26.0

(CHF billions)


Revenue


Net income
Other
comprehen-
sive income
Total
comprehen-
sive income
December 31, 2016
50.6
7.5
0.7
8.2
June 30, 2017
26.3
4.4
0.2
4.6
A purchase price allocation was performed on the basis of publicly available information at the time of acquisition of the investment. The December 31, 2017 balance sheet value allocation is as follows:

(USD millions)
December 31,
2017
Novartis share of Roche’s estimated net assets
2 412
Novartis share of re-appraised intangible assets
673
Implicit Novartis goodwill
2 915
Current value of share in net identifiable assets and goodwill
6 000
Accumulated equity accounting adjustments and translation effects less dividends received
2 121
Balance sheet value
8 121
The identified intangible assets principally relate to the value of currently marketed products and are amortized on a straight-line basis over their estimated average useful life of 20 years.
In 2017, dividends received from Roche in relation to the distribution of its 2016 net income amounted to USD 438 million (2016: USD 433 million in relation to the distribution of its 2015 net income).
The consolidated income statement effects from applying Novartis accounting principles for this investment in 2017, 2016 and 2015 are as follows:
(USD millions)
2017
2016
2015
Novartis share of Roche's estimated current-year consolidated net income
669
678
650
Prior-year adjustment
– 67
– 68
– 157
Amortization of fair value adjustments relating to intangible assets, net of taxes of USD 42 million (2016: USD 42 million; 2015: USD 41 million)
– 146
– 146
– 150
Net income effect
456
464
343
The publicly quoted market value of the Novartis interest in Roche (SIX symbol: RO) at December 31, 2017, was USD 13.4 billion (2016: USD 12.4 billion).
207
GlaxoSmithKline Consumer Healthcare Holdings Ltd.
On March 2, 2015, Novartis closed its transactions with GlaxoSmithKline plc, Great Britain (GSK) announced in April 2014. As part of these transactions, Novartis and GSK agreed to create a combined consumer healthcare business through a combination between Novartis OTC and GSK Consumer Healthcare. On March 2, 2015, a new entity GlaxoSmithKline Consumer Healthcare Holdings Ltd (GSK Consumer Healthcare) was formed via the contribution of businesses from both Novartis and GSK.
At December 31, 2017, 2016 and 2015, Novartis has a 36.5% interest in GSK Consumer Healthcare and four of eleven seats on the GSK Consumer Healthcare board of directors. Furthermore, Novartis has customary minority rights and also exit rights at a pre-defined, market-based pricing mechanism.
The December 31, 2017 balance sheet value allocation is as follows:

(USD millions)
December 31,
2017
Novartis share of GSK Consumer Healthcare’s estimated net assets
1 505
Novartis share of re-appraised intangible assets
3 852
Implicit Novartis goodwill
1 763
Current value of share in net identifiable assets and goodwill
7 120
Accumulated equity accounting adjustments and translation effects less dividends received
– 100
Balance sheet value
7 020
The identified intangible assets principally relate to the value of the indefinite life GSK Consumer Healthcare intangible assets. The identified intangible assets with a definite life are amortized on a straight-line basis over their estimated average useful life of 20 years.
At acquisition date, Novartis has valued the contribution of 63.5% of its OTC Division in exchange for 36.5% of the GSK Consumer Healthcare business at fair value. The retained interest in the OTC Division business contributed was accounted for at net book value at the time of contribution.
The following tables show summarized financial information for GSK Consumer Healthcare, including current values of fair value adjustments made at the time of acquisition, for the year ended December 31, 2016, and for the nine months ended September 30, 2017 (interim unaudited), since full-year 2017 data is not yet available:

(GBP billions)

Current assets
Non-current
assets
Current
liabilities
Non-current
liabilities
December 31, 2016
4.0
21.1
3.1
2.1
September 30, 2017
3.3
20.6
2.6
2.0

(GBP billions)


Revenue


Net income
Other
comprehen-
sive income
Total
comprehen-
sive income
December 31, 2016
6.5
0.6
1.6
2.2
September 30, 2017
5.3
0.6
– 0.4
0.2
Since full-year 2017 financial data for GSK Consumer Healthcare is not available when Novartis produces its consolidated financial results, a projection of the latest internal management reporting is used to estimate the Group’s share of GSK Consumer Healthcare’s net result for the year. Any differences between this estimate and actual results will be adjusted in the Group’s 2018 consolidated financial statements when available.
In 2017, dividends received from GSK Consumer Healthcare amounted to USD 544 million (2016: USD 463 million).
The consolidated income statement effects from applying Novartis accounting principles for this investment in 2017, 2016 and 2015 are as follows:
(USD millions)
2017
2016
2015
Novartis share of GSK Consumer Healthcare's estimated current-year consolidated net income
589
268
– 17
Prior-year adjustment
47
– 22
Amortization of fair value adjustments relating to intangible assets and inventory, net of taxes of USD 1 million (2016: USD 2 million; 2015: USD 18 million)
– 7
– 12
– 62
Net income effect
629
234
– 79
208
5. Interest expense and other financial income and expense
Interest expense
(USD millions)
2017
2016
2015
Interest expense
– 758
– 709
– 669
(Expense)/ income arising from discounting long-term liabilities
– 19
2
14
Total interest expense
– 777
– 707
– 655
Other financial income and expense
(USD millions)
2017
2016
2015
Interest income
110
43
33
Dividend income
1
1
1
Net capital losses on available-for-sale securities
– 1
– 1
– 8
Income on forward contracts and options
1
Impairment of commodities and available-for-sale securities, net
12
7
– 132
Other financial expense
– 25
– 20
– 23
Monetary loss from hyperinflation accounting
– 72
Currency result, net
– 58
– 477
– 254
Total other financial income and expense
39
– 447
– 454
6. Taxes
Income before taxes
(USD millions)
2017
2016
2015
Switzerland
5 289
3 110
5 765
Foreign
3 710
4 707
2 369
Income before taxes from continuing operations
8 999
7 817
8 134
Income before taxes from discontinued operations
12 479
Total income before taxes
8 999
7 817
20 613
Current and deferred income tax expense
(USD millions)
2017
2016
2015
Switzerland
– 462
– 709
– 317
Foreign
– 1 594
– 1 418
– 1 333
Current income tax expense from continuing operations
– 2 056
– 2 127
– 1 650
Switzerland
– 298
765
– 68
Foreign
1 058
243
612
Deferred tax income from continuing operations
760
1 008
544
Income tax expense from continuing operations
– 1 296
– 1 119
– 1 106
Income tax expense from discontinued operations
– 1 713
Total income tax expense
– 1 296
– 1 119
– 2 819
Analysis of tax rate
The main elements contributing to the difference between the Group’s overall applicable tax rate (which can change each year since it is calculated as the weighted average tax rate based on pre-tax income of each subsidiary) and the effective tax rate are:
(As a percentage)
2017
2016
2015
Applicable tax rate
14.5
13.2
12.4
Effect of disallowed expenditures
3.4
3.5
3.5
Effect of utilization of tax losses brought forward from prior periods
– 0.1
– 0.2
– 0.2
Effect of income taxed at reduced rates
– 0.2
– 0.2
– 0.3
Effect of tax credits and allowances
– 2.2
– 2.8
– 2.7
Effect of release of contingent consideration liability
– 1.2
0.0
0.0
Effect of tax rate change on current and deferred tax assets and liabilities 1
0.7
0.2
– 0.5
Effect of write-off of deferred tax assets
0.0
0.5
0.0
Effect of write down and reversal of write-down of investments in subsidiaries
– 1.1
– 1.0
– 0.9
Effect of tax benefits expiring in 2017
– 0.8
– 0.5
– 0.4
Effect of non-deductible losses in Venezuela
0.0
1.3
1.2
Effect of prior year items
1.2
0.2
1.0
Effect of other items 2
0.2
0.1
0.5
Effective tax rate for continuing operations
14.4
14.3
13.6
Effective tax rate for discontinued operations
13.7
Effective tax rate
14.4
14.3
13.7
 1  Included in 2017 is a 0.7% impact related to the revaluation of the deferred tax assets and liabities and a portion of current tax payables. This revaluation resulted from the US tax reform legislation enacted on December 22, 2017, refer to Note 11 for additional disclosures.
 2  Other items in 2016 (+0.1%) include one-time impacts for the deferred tax effects on the net assets of certain subsidiaries resulting from the change in their tax status (-6.2%), the changes in uncertain tax positions (+5.1%) and other items (+1.2%).
209
Novartis has a substantial business presence in many countries and is therefore subject to different income and expense items that are non-taxable (permanent differences) or taxed at different rates in those tax jurisdictions. This results in a difference between our applicable tax rate and effective tax rate, as shown in the table above.
The utilization of tax-loss carry-forwards lowered the tax charge by USD 7 million in 2017, and by USD 18 million and USD 15 million in 2016 and 2015, respectively.
7. Earnings per share
2017
2016
2015
Net income attributable to shareholders of Novartis AG (USD millions)
– Continuing operations
7 703
6 712
7 025
– Discontinued operations
10 758
– Total
7 703
6 712
17 783
Number of shares (in millions)
Weighted average number of shares outstanding used in basic earnings per share
2 346
2 378
2 403
Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options
25
22
35
Weighted average number of shares in diluted earnings per share
2 371
2 400
2 438
Basic earnings per share (USD)
– Continuing operations
3.28
2.82
2.92
– Discontinued operations
4.48
– Total
3.28
2.82
7.40
Diluted earnings per share (USD)
– Continuing operations
3.25
2.80
2.88
– Discontinued operations
4.41
– Total
3.25
2.80
7.29
Basic earnings per share (EPS) is calculated by dividing net income attributable to shareholders of Novartis AG by the weighted average number of shares outstanding in a reporting period. This calculation excludes the average number of issued shares purchased by the Group and held as treasury shares.
For diluted EPS, the weighted average number of shares outstanding is adjusted to assume the vesting of all restricted shares, restricted share units, and the conversion of all potentially dilutive shares arising from options on Novartis shares that have been issued.
No options were excluded from the calculation of diluted EPS in 2017, 2016, or 2015, as all options were dilutive in all years.
210
8. Changes in consolidated statements of comprehensive income
The consolidated statements of comprehensive income include the Group’s net income for the year as well as all other valuation adjustments recorded in the Group’s consolidated balance sheet but which under IFRS are not recorded in the consolidated income statement. These include fair value adjustments to financial instruments, actuarial gains or losses on defined benefit pension and other post-employment plans and currency translation effects, net of tax.
The following table summarizes these value adjustments and currency translation effects attributable to Novartis shareholders:

(USD millions)
Fair value
adjustments
on marketable
securities
Fair value
adjustments on
deferred cash
flow hedges
Actuarial
gains/(losses)
from defined
benefit plans

Net
investment
hedge
Cumulative
currency
translation
effects


Total value
adjustments
Value adjustments at January 1, 2015
433
– 38
– 5 366
2 406
– 2 565
Fair value adjustments on financial instruments
28
20
48
Net actuarial losses from defined benefit plans 1
– 147
– 147
Currency translation effects 2
– 1 659
– 1 659
Total value adjustments in 2015
28
20
– 147
– 1 659
– 1 758
Fair value adjustments related to divestments
100
100
Value adjustments at December 31, 2015
461
– 18
– 5 413
747
– 4 223
Fair value adjustments on financial instruments
– 113
15
– 98
Net actuarial losses from defined benefit plans
– 514
– 514
Currency translation effects
– 2 389
– 2 389
Total value adjustments in 2016
– 113
15
– 514
– 2 389
– 3 001
Fair value adjustments related to divestments
12
12
Value adjustments at December 31, 2016
348
– 3
– 5 915
– 1 642
– 7 212
Fair value adjustments on financial instruments
38
12
50
Net investment hedge
– 237
– 237
Net actuarial gains from defined benefit plans
851
851
Currency translation effects
2 208
2 208
Total value adjustments in 2017
38
12
851
– 237
2 208
2 872
Value adjustments at December 31, 2017
386
9
– 5 064
– 237
566
– 4 340
 1  Net actuarial gains of USD 10 million in 2015 were attributable to discontinued operations up to the respective divestment dates
 2  Currency translation losses of USD 29 million in 2015 were attributable to discontinued operations up to the respective divestment dates
8.1) The 2017, 2016 and 2015 changes in the fair value of financial instruments were as follows:

(USD millions)
Fair value
adjustments
on marketable
securities
Fair value
adjustments on
deferred cash
flow hedges



Total
Fair value adjustments at January 1, 2017
348
– 3
345
Changes in fair value:
– Available-for-sale marketable securities
11
11
– Available-for-sale financial investments
47
47
Realized net gains transferred to the consolidated income statement:
– Other financial assets sold
– 109
– 109
Amortized net losses on cash flow hedges transferred to the consolidated income statement
13
13
Impaired financial assets transferred to the consolidated income statement
102
102
Deferred tax on above items 1
– 13
– 1
– 14
Fair value adjustments during the year
38
12
50
Fair value adjustments at December 31, 2017
386
9
395
 1  Included in 2017 is a USD 18 million impact related to the revaluation of deferred tax liabilities on available-for-sale financial investments held in the US that were previously recognized through other comprehensive income. This revaluation resulted from the US tax reform legislation enacted on December 22, 2017, refer to Note 11 for additional disclosures.
211

(USD millions)
Fair value
adjustments
on marketable
securities
Fair value
adjustments on
deferred cash
flow hedges



Total
Fair value adjustments at January 1, 2016
461
– 18
443
Changes in fair value:
– Available-for-sale marketable securities
1
1
– Available-for-sale financial investments
– 87
– 87
Realized net gains transferred to the consolidated income statement:
– Marketable securities sold
– 1
– 1
– Other financial assets sold
– 154
– 154
Amortized net losses on cash flow hedges transferred to the consolidated income statement
16
16
Impaired financial assets transferred to the consolidated income statement
131
131
Deferred tax on above items
– 3
– 1
– 4
Fair value adjustments during the year
– 113
15
– 98
Fair value adjustments at December 31, 2016
348
– 3
345

(USD millions)
Fair value
adjustments
on marketable
securities
Fair value
adjustments on
deferred cash
flow hedges



Total
Fair value adjustments at January 1, 2015
433
– 38
395
Changes in fair value:
– Available-for-sale marketable securities
– 130
– 130
– Available-for-sale financial investments
80
80
– Associated companies’ movements in comprehensive income
– 8
– 8
Realized net gains transferred to the consolidated income statement:
– Marketable securities sold
– 1
– 1
– Other financial assets sold
– 103
– 103
Amortized net losses on cash flow hedges transferred to the consolidated income statement
21
21
Impaired financial assets transferred to the consolidated income statement
194
194
Deferred tax on above items
– 4
– 1
– 5
Fair value adjustments during the year
28
20
48
Fair value adjustments at December 31, 2015
461
– 18
443
8.2) In 2015, cumulative currency translation losses of USD 10 million were recycled through the income statement as a result of the divestments of subsidiaries. No currency translation losses or gains were recycled through the income statement in 2017 and 2016.
8.3) Remeasurements from defined benefit plans arise as follows:
(USD millions)
2017
2016
2015
Defined benefit pension plans before tax
1 367
– 667
– 252
Other post-employment benefit plans before tax
76
12
168
Taxation on above items 1
– 592
140
– 63
Total after tax
851
– 515
– 147
Attributable to:
Shareholders of Novartis AG
851
– 514
– 147
Non-controlling interests
– 1
 
 1  Included in 2017 is a USD -272 million impact related to the revaluation of deferred tax assets on US post-employment benefits that were previously recognized through other comprehensive income. This revaluation resulted from the US tax reform legislation enacted on December 22, 2017, refer to Note 11 for additional disclosures.
212
9. Property, plant & equipment
The following table summarizes the movements of property, plant and equipment during 2017:

(USD millions)


Land


Buildings

Construction
in progress
Machinery
& other
equipment


Total
Cost
January 1, 2017
687
13 113
2 680
14 816
31 296
Reclassifications 1
5
508
– 1 617
1 104
Additions
13
104
1 186
425
1 728
Disposals and derecognitions 2
– 23
– 324
– 71
– 593
– 1 011
Currency translation effects
38
663
190
1 106
1 997
December 31, 2017
720
14 064
2 368
16 858
34 010
Accumulated depreciation
January 1, 2017
– 40
– 5 436
– 15
– 10 164
– 15 655
Depreciation charge
– 3
– 510
– 1 007
– 1 520
Accumulated depreciation on disposals and derecognitions 2
6
275
34
534
849
Impairment charge
– 25
– 58
– 106
– 189
Reversal of impairment charge
2
30
32
Currency translation effects
– 3
– 287
– 1
– 772
– 1 063
December 31, 2017
– 40
– 5 983
– 38
– 11 485
– 17 546
Net book value at December 31, 2017
680
8 081
2 330
5 373
16 464
Net book value of property, plant & equipment under finance lease contracts
78
Commitments for purchases of property, plant & equipment
318
Capitalized borrowing costs
9
 1  Reclassifications between various asset categories due to completion of plant and other equipment under construction.
 2  Derecognition of assets that are no longer used and are not considered to have a significant disposal value or other alternative use.
The following table summarizes the movements of property, plant and equipment during 2016:

(USD millions)


Land


Buildings

Construction
in progress
Machinery
& other
equipment


Total
Cost
January 1, 2016
688
12 857
2 810
15 093
31 448
Reclassifications 1
4
630
– 1 226
592
Additions
24
176
1 226
409
1 835
Disposals and derecognitions 2
– 8
– 178
– 19
– 656
– 861
Currency translation effects
– 21
– 372
– 111
– 622
– 1 126
December 31, 2016
687
13 113
2 680
14 816
31 296
Accumulated depreciation
January 1, 2016
– 40
– 5 188
– 7
– 10 231
– 15 466
Depreciation charge
– 3
– 530
– 956
– 1 489
Accumulated depreciation on disposals and derecognitions 2
5
157
1
630
793
Impairment charge
– 3
– 47
– 11
– 61
– 122
Reversal of impairment charge
6
1
13
20
Currency translation effects
1
166
1
441
609
December 31, 2016
– 40
– 5 436
– 15
– 10 164
– 15 655
Net book value at December 31, 2016
647
7 677
2 665
4 652
15 641
Net book value of property, plant & equipment under finance lease contracts
81
Commitments for purchases of property, plant & equipment
223
Capitalized borrowing costs
9
 1  Reclassifications between various asset categories due to completion of plant and other equipment under construction.
 2  Derecognition of assets that are no longer used and are not considered to have a significant disposal value or other alternative use.
213
10. Goodwill and intangible assets
The following table summarizes the movements of goodwill and intangible assets in 2017:
Goodwill
Intangible Assets other than Goodwill

(USD millions)


Total
Acquired
research &
development

Alcon
brand name


Technologies
Currently
marketed
products

Marketing
know-how
Other
intangible
assets


Total
Cost
January 1, 2017
31 381
5 150
2 980
6 548
33 007
5 960
1 492
55 137
Impact of business combinations
94
1 223
1 223
Reclassifications 1
– 389
175
214
Additions
697
5
282
162
1 146
Disposals and derecognitions 2
– 353
– 1
– 328
– 64
– 746
Currency translation effects
704
134
86
969
48
1 237
December 31, 2017
32 179
6 462
2 980
6 638
34 105
5 960
1 852
57 997
Accumulated amortization
January 1, 2017
– 401
– 886
– 3 637
– 16 863
– 1 430
– 981
– 23 797
Reclassifications 1
6
– 6
Amortization charge
– 577
– 2 571
– 238
– 304
– 3 690
Accumulated impairments on disposals and derecognitions2
352
317
61
730
Impairment charge
– 615
– 92
– 2
– 709
Currency translation effects
– 28
– 27
– 54
– 416
– 37
– 534
December 31, 2017
– 429
– 1 170
– 4 268
– 19 631
– 1 668
– 1 263
– 28 000
Net book value at December 31, 2017
31 750
5 292
2 980
2 370
14 474
4 292
589
29 997
 1  Reclassifications between various asset categories as a result of product launches of acquired In-Process Research & Development and completion of software development.
 2  Derecognitions of assets that are no longer used or being developed and are not considered to have a significant disposal value or other alternative use.
The following table summarizes the movements of goodwill and intangible assets in 2016:
Goodwill
Intangible Assets other than Goodwill

(USD millions)


Total
Acquired
research &
development

Alcon
brand name


Technologies
Currently
marketed
products

Marketing
know-how
Other
intangible
assets


Total
Cost
January 1, 2016
31 585
4 119
2 980
6 563
33 385
5 960
1 341
54 348
Impact of business combinations
56
690
451
1 141
Reclassifications 1
– 158
6
152
Additions
599
223
156
978
Disposals and derecognitions 2
– 23
– 464
– 130
– 617
Currency translation effects
– 260
– 77
– 15
– 594
– 27
– 713
December 31, 2016
31 381
5 150
2 980
6 548
33 007
5 960
1 492
55 137
Accumulated amortization
January 1, 2016
– 411
– 650
– 3 070
– 14 221
– 1 192
– 998
– 20 131
Reclassifications 1
225
– 225
Amortization charge
– 576
– 2 926
– 238
– 121
– 3 861
Accumulated impairments on disposals and derecognitions2
22
390
123
535
Impairment charge
– 490
– 96
– 5
– 591
Currency translation effects
10
7
9
215
20
251
December 31, 2016
– 401
– 886
– 3 637
– 16 863
– 1 430
– 981
– 23 797
Net book value at December 31, 2016
30 980
4 264
2 980
2 911
16 144
4 530
511
31 340
 1  Reclassifications between various asset categories as a result of product launches of acquired In-Process Research & Development and completion of software development.
 2  Derecognitions of assets that are no longer used or being developed and are not considered to have a significant disposal value or other alternative use.
214
The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2017:
Goodwill
Intangible Assets other than Goodwill

(USD millions)


Total
Acquired
research &
development

Alcon
brand name


Technologies
Currently
marketed
products

Marketing
know-how
Other
intangible
assets


Total
Innovative Medicines
15 237
4 368
9
11 604
353
16 334
Sandoz
8 210
625
539
1 589
30
2 783
Alcon
8 295
291
1 822
1 281
4 292
195
7 881
Corporate
8
8
2 980
11
2 999
Net book value at December 31, 2017
31 750
5 292
2 980
2 370
14 474
4 292
589
29 997
The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2016:
Goodwill
Intangible Assets other than Goodwill

(USD millions)


Total
Acquired
research &
development

Alcon
brand name


Technologies
Currently
marketed
products

Marketing
know-how
Other
intangible
assets


Total
Innovative Medicines
15 010
3 512
11
12 821
276
16 620
Sandoz
7 669
613
563
1 904
25
3 105
Alcon
8 293
139
2 337
1 419
4 530
196
8 621
Corporate
8
2 980
14
2 994
Net book value at December 31, 2016
30 980
4 264
2 980
2 911
16 144
4 530
511
31 340
The Innovative Medicines, Sandoz and Alcon Divisions’ cash generating units, to which goodwill are allocated, each comprise a group of smaller cash generating units. The valuation method of the recoverable amount of the cash generating units, to which goodwill is allocated, is based on the fair value less costs of disposal.
The Alcon brand name is a Corporate asset with an indefinite life. The intangible asset is allocated to Corporate as it is used to market the Alcon-branded products of both the Alcon Division and the Ophthalmology business franchise of the Innovative Medicines Division. Net sales of these products together are the grouping of cash generating units, which is used to determine the recoverable amount. The valuation method is based on the fair value less costs of disposal.
The following assumptions are used in the calculations:

(As a percentage)
Innovative
Medicines

Sandoz

Alcon

Corporate
Terminal growth rate
1.5
2.0
3.0
2.6
Discount rate (post-tax)
7.0
7.0
7.0
7.0
The Alcon terminal growth rate assumption of 3% is higher than the expected inflation rate of the medical device industry, and more specifically the ophthalmic sub-segment of the industry. The growth rates are expected to exceed this long-term inflation rate, due to the impact of the demographic trend of the aging population to which Alcon’s products are prescribed is growing faster than the general population.
The discount rates for all divisions consider the Group’s weighted average cost of capital, adjusted to approximate the weighted average cost of capital of a comparable market participant.
The fair value less costs of disposal, for all groupings of cash generating units containing goodwill or indefinite life intangible assets, is reviewed for the impact of reasonably possible changes in key assumptions. In particular, we considered an increase in the discount rate, a decrease in the terminal growth rate and certain negative impacts on the forecasted cash flows. These reasonably possible changes in key assumptions did not indicate an impairment.
Note 1, Significant accounting policies – Impairment of goodwill and intangible assets, provides additional disclosures on how the Group performs goodwill and intangible asset impairment testing.
The following table shows the intangible asset impairment charges for 2017 and 2016:
(USD millions)
2017
2016
Innovative Medicines
– 591
– 522
Sandoz
– 61
– 65
Alcon
– 57
– 4
Total
– 709
– 591
215
11. Deferred tax assets and liabilities

(USD millions)

Property,
plant &
equipment


Intangible
assets
Pensions and
other benefit
obligations
of associates



Inventories

Tax loss
carry-
forwards

Other assets,
provisions
and accruals



Total
Gross deferred tax assets at January 1, 2017
224
1 331
1 839
4 160
146
2 597
10 297
Gross deferred tax liabilities at January 1, 2017
– 629
– 4 019
– 358
– 511
– 1 403
– 6 920
Net deferred tax balance at January 1, 2017
– 405
– 2 688
1 481
3 649
146
1 194
3 377
At January 1, 2017
– 405
– 2 688
1 481
3 649
146
1 194
3 377
Credited/(charged) to income
– 30
1 279
– 90
– 304
– 49
– 46
760
Charged to equity
– 101
– 101
Charged to other comprehensive income
– 592
– 69
– 661
Impact of business combinations
– 322
5
– 317
Other movements
– 41
33
37
– 14
– 14
2
3
Net deferred tax balance at December 31, 2017
– 476
– 1 698
836
3 331
88
980
3 061
Gross deferred tax assets at December 31, 2017
137
1 287
1 090
3 786
97
1 983
8 380
Gross deferred tax liabilities at December 31, 2017
– 613
– 2 985
– 254
– 455
– 9
– 1 003
– 5 319
Net deferred tax balance at December 31, 2017
– 476
– 1 698
836
3 331
88
980
3 061
After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction the balance amounts to:
151
Deferred tax assets at December 31, 2017
8 229
Deferred tax liabilities at December 31, 2017
– 5 168
Net deferred tax balance at December 31, 2017
3 061
Gross deferred tax assets at January 1, 2016
216
611
1 730
3 821
62
2 866
9 306
Gross deferred tax liabilities at January 1, 2016
– 639
– 3 962
– 401
– 565
– 5
– 1 132
– 6 704
Net deferred tax balance at January 1, 2016
– 423
– 3 351
1 329
3 256
57
1 734
2 602
At January 1, 2016
– 423
– 3 351
1 329
3 256
57
1 734
2 602
Credited/(charged) to income
– 13
1 057
53
373
55
– 517
1 008
Charged to equity
– 44
– 44
Credited/(charged) to other comprehensive income
140
– 2
138
Impact of business combinations
4
– 400
23
37
– 336
Other movements
27
6
– 41
20
11
– 14
9
Net deferred tax balance at December 31, 2016
– 405
– 2 688
1 481
3 649
146
1 194
3 377
Gross deferred tax assets at December 31, 2016
224
1 331
1 839
4 160
146
2 597
10 297
Gross deferred tax liabilities at December 31, 2016
– 629
– 4 019
– 358
– 511
– 1 403
– 6 920
Net deferred tax balance at December 31, 2016
– 405
– 2 688
1 481
3 649
146
1 194
3 377
After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction the balance amounts to:
263
Deferred tax assets at December 31, 2016
10 034
Deferred tax liabilities at December 31, 2016
– 6 657
Net deferred tax balance at December 31, 2016
3 377
The following table presents deferred tax assets and deferred tax liabilities, which are expected to have an impact on current taxes payable after more than twelve months:
(USD billions)
2017
2016
Expected to have an impact on current tax payable after more than 12 months
– Deferred tax assets
3.5
4.8
– Deferred tax liabilities
4.4
5.9
216
For unremitted earnings retained by consolidated entities for reinvestment, no provision is made for income taxes that would be payable upon the distribution of these earnings. If these earnings were remitted, an income tax charge could result based on the tax statutes currently in effect.
(USD billions)
2017
2016
Unremitted earnings that have been retained by consolidated entities for reinvestment
66
63
Temporary differences on which no deferred tax has been provided as they are permanent in nature related to:
(USD billions)
2017
2016
Investments in subsidiaries
3
2
Goodwill from acquisitions
– 29
– 28
The gross value of tax-loss carry-forwards that have, or have not, been capitalized as deferred tax assets, with their expiry dates is as follows:
(USD millions)
Not capitalized
Capitalized
2017 total
One year
37
3
40
Two years
64
4
68
Three years
87
5
92
Four years
26
25
51
Five years
67
16
83
More than five years
654
1 671
2 325
Total
935
1 724
2 659
(USD millions)
Not capitalized
Capitalized
2016 total
One year
21
12
33
Two years
30
5
35
Three years
50
5
55
Four years
75
3
78
Five years
73
25
98
More than five years
405
1 913
2 318
Total
654
1 963
2 617
(USD millions)
2017
2016
2015
Tax losses carried forward that expired
1
19
13
Deferred tax assets related to taxable losses of relevant Group entities are recognized to the extent it is considered probable that future taxable profits will be available against which such losses can be utilized in the foreseeable future.
On December 22, 2017, the US enacted tax reform legislation (Tax Cuts and Jobs Act), which among other provisions, reduced the US corporate tax rate from 35% to 21%, effective January 1, 2018. This required a revaluation of the deferred tax assets and liabilities and a portion of current tax payables to the newly enacted tax rates at the date of enactment.
The following table shows the impact on the revaluation of deferred assets and liabilities and current income tax liabilities:

(USD millions)
Income
statement

Equity

Total
Deferred tax asset and liability revaluation
Items previously recognized in consolidated income statement
– 24
– 24
Items previously recognized in other comprehensive income 1
– 254
– 254
Items previously recognized in retained earnings 2
– 71
– 71
Total revaluation of deferred tax assets and liabilities
– 24
– 325
– 349
Total revaluation of current tax payables
– 37
– 37
Total revaluation of deferred tax assets and liabilities and current income tax liabilities
– 61
– 325
– 386
 1  Related to post-employment benefits and available for sale financial investments.
 2  Related to equity based compensation plans.
The enacted US tax reform legislation includes a provision that requires the US parent company’s foreign subsidiaries’ unremitted earnings to be subject to an immediate toll tax on the qualifying amount of unremitted earnings (the deemed repatriated earnings). Previously, these earnings were taxable upon distribution to the US parent company. The toll tax amount owed is payable, without interest, in installments over an eight year period through 2024. Certain of the Group’s US subsidiaries are the parent company of non-US domiciled companies, and as a result, USD 70 million of deferred tax liabilities related to these entities’ unremitted earnings, the majority of which were recognized in the prior year, were reclassified to current income tax liabilities.
217
12. Financial and other non-current assets
Financial assets
(USD millions)
2017
2016
Available-for-sale long-term financial investments
1 275
1 096
Long-term receivables from customers
197
231
Minimum lease payments from finance lease agreements
122
147
Contingent consideration receivables 1
394
586
Long-term loans, advances and security deposits
255
136
Total financial assets
2 243
2 196
 1  Note 28 provides additional disclosures related to contingent considerations.
Other non-current assets
(USD millions)
2017
2016
Deferred compensation plans
484
451
Prepaid post-employment benefit plans
133
47
Other non-current assets
201
200
Total other non-current assets
818
698
Minimum finance lease payments
The following table shows the receivables of the gross investments in finance leases and the net present value of the minimum lease payments, as well as unearned finance income, related to surgical equipment lease arrangements. The finance income is recorded in “Other income”.
2017
2016

(USD millions)
Total
future
payments
Unearned
finance
income

Present
value


Provision
Net
book
value
Total
future
payments
Unearned
finance
income

Present
value


Provision
Net
book
value
Not later than one year 1
83
– 7
76
– 3
73
91
– 5
86
– 2
84
Between one and five years
180
– 14
166
– 59
107
182
– 16
166
– 37
129
Later than five years
31
– 2
29
– 14
15
63
– 4
59
– 41
18
Total
294
– 23
271
– 76
195
336
– 25
311
– 80
231
 1  The current portion of the minimum lease payments is recorded in trade receivables or other current assets (to the extent not yet invoiced).
13. Inventories
(USD millions)
2017
2016
Raw material, consumables
841
705
Work in progress
2 957
2 700
Finished products
3 069
2 850
Total inventories
6 867
6 255
The following table shows the amount of inventory recognized as an expense in “Cost of goods sold” in the consolidated income statements:
(USD billions)
2017
2016
2015
Cost of goods sold
– 10.3
– 10.3
– 10.5
The following table shows the recognized amount of inventory provisions and reversals of inventory provisions:
(USD millions)
2017
2016
2015
Inventory provisions
– 470
– 283
– 356
Reversals of inventory provisions
189
67
148
The reversals mainly result from the release of products initially requiring additional quality control inspections and from the reassessment of inventory values manufactured prior to regulatory approval but for which approval was subsequently received.
218
14. Trade receivables
(USD millions)
2017
2016
Total gross trade receivables
8 790
8 364
Provisions for doubtful trade receivables
– 190
– 162
Total trade receivables, net
8 600
8 202
The following table summarizes the movement in the provision for doubtful trade receivables:
(USD millions)
2017
2016
2015
January 1
– 162
– 142
– 156
Impact of divestments
12
Provisions for doubtful trade receivables charged to the consolidated income statement
– 119
– 76
– 68
Utilization provisions for doubtful trade receivables
12
17
39
Reversal of provisions for doubtful trade receivables
76
37
32
Currency translation effects
– 9
2
11
December 31
– 190
– 162
– 142
The following sets forth the trade receivables that are not overdue as specified in the payment terms and conditions established with Novartis customers as well as an analysis of overdue amounts and related provisions for doubtful trade receivables:
(USD millions)
2017
2016
Not overdue
7 758
7 386
Past due for not more than one month
279
262
Past due for more than one month but less than three months
230
223
Past due for more than three months but less than six months
137
185
Past due for more than six months but less than one year
137
145
Past due for more than one year
249
163
Provisions for doubtful trade receivables
– 190
– 162
Total trade receivables, net
8 600
8 202
Trade receivable balances include sales to drug wholesalers, retailers, private health systems, government agencies, managed care providers, pharmacy benefit managers and government-supported healthcare systems. Novartis continues to monitor sovereign debt issues and economic conditions, particularly in Greece, Italy, Portugal, Spain, Brazil, Russia, Saudi Arabia and Turkey, and evaluates trade receivables in these countries for potential collection risks. The majority of the outstanding trade receivables from these closely monitored countries are due directly from local governments or from government-funded entities except for Russia, Brazil and Turkey, which are due from private entities. Deteriorating credit and economic conditions as well as other factors in these closely monitored countries have resulted in, and may continue to result in an increase in the average length of time that it takes to collect these trade receivables and may require Novartis to re-evaluate the collectability of these trade receivables in future periods.
The following table shows the gross trade receivables balance from these closely monitored countries at December 31, 2017 and 2016, the amounts that are past due for more than one year and the related provisions that have been recorded:
(USD millions)
2017
2016
Total balance of gross trade receivables from closely monitored countries
1 733
1 717
Past due for more than one year
124
82
Provisions
95
63
At December 31, 2017 amounts past due for more than one year are not significant in any of these countries on a standalone basis.
Total trade receivables include amounts denominated in the following major currencies:
(USD millions)
2017
2016
US dollar (USD)
3 451
3 432
Euro (EUR)
1 533
1 366
Japanese yen (JPY)
600
567
Chinese yuan (CNY)
312
264
Russian ruble (RUB)
268
347
Brazilian real (BRL)
237
222
British pound (GBP)
208
160
Australian dollar (AUD)
165
147
Swiss franc (CHF)
127
135
Canadian dollar (CAD)
73
97
Other currencies
1 626
1 465
Total trade receivables, net
8 600
8 202
219
15. Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents
Marketable securities, commodities, time deposits and derivative financial instruments
(USD millions)
2017
2016
Debt securities
328
306
Fund investments
34
31
Total available-for-sale marketable securities
362
337
Commodities
106
94
Time deposits with original maturity more than 90 days
125
108
Derivative financial instruments
31
230
Accrued interest on debt securities and time deposits
1
1
Total marketable securities, commodities, time deposits and derivative financial instruments
625
770
The following table provides a breakdown of debt securities by currency:
(USD millions)
2017
2016
US dollar (USD)
303
284
Euro (EUR)
14
12
Japanese yen (JPY)
11
10
Total debt securities
328
306
Cash and cash equivalents
(USD millions)
2017
2016
Current accounts
2 970
1 912
Time deposits and short-term investments with original maturity less than 90 days
5 890
5 095
Total cash and cash equivalents
8 860
7 007
16. Other current assets
(USD millions)
2017
2016
VAT receivable
717
521
Withholding tax recoverable
93
282
Prepaid expenses
– Third parties
753
692
– Associated companies
3
5
Receivables from associated companies
8
7
Contingent consideration receivable 1
450
Other receivables and current assets
1 030
1 034
Total other current assets
3 054
2 541
 1  Note 28 provides additional disclosures related to contingent consideration.
220
17. Equity
The following table shows the movement in the share capital:

(USD millions)

Jan 1, 2015
Movement
in year

Dec 31, 2015
Movement
in year

Dec 31, 2016
Movement
in year

Dec 31, 2017
Share capital
1 001
– 10
991
– 19
972
– 3
969
Treasury shares
– 103
2
– 101
25
– 76
– 24
– 100
Outstanding share capital
898
– 8
890
6
896
– 27
869
The following table shows the movement in the shares:
2017
2016
2015

Number of outstanding shares
(in millions)


Note
Total
Novartis
shares
Total
treasury
shares
Total
outstanding
shares
Total
Novartis
shares
Total
treasury
shares
Total
outstanding
shares
Total
Novartis
shares
Total
treasury
shares
Total
outstanding
shares
Balance at beginning of year
2 627.1
– 253.0
2 374.1
2 677.0
– 303.1
2 373.9
2 706.2
– 307.6
2 398.6
Shares canceled for capital reduction 1
– 10.3
10.3
– 49.9
49.9
– 29.2
29.2
Shares acquired to be held in Group Treasury 2
– 9.6
– 9.6
Shares acquired to be canceled 3
– 66.2
– 66.2
– 10.3
– 10.3
– 49.9
– 49.9
Other share purchases 4
– 3.8
– 3.8
– 2.6
– 2.6
– 4.1
– 4.1
Exercise of options and employee transactions 5
17.6
4.6
4.6
4.1
4.1
27.0
27.0
Equity-based compensation 5
8.8
8.8
9.0
9.0
11.9
11.9
Total movements
– 10.3
– 46.3
– 56.6
– 49.9
50.1
0.2
– 29.2
4.5
– 24.7
Balance at end of year
2 616.8
– 299.3
2 317.5
2 627.1
– 253.0
2 374.1
2 677.0
– 303.1
2 373.9
 1  Novartis reduced its share capital by cancelling shares which were repurchased on the SIX Swiss Exchange second trading line during previous years.
 2  Shares repurchased on the SIX Swiss Exchange first trading line
 3  For 2017 and 2016, shares repurchased on the SIX Swiss Exchange second trading line under the CHF 10 billion share buyback authority approved at the 2016 Annual General Meeting (AGM). For 2015, shares repurchased on the SIX Swiss Exchange second trading line under the CHF 10 billion share buyback authority approved at the 2008 Annual General Meeting (AGM).
 4  Shares acquired from employees, which were previously granted to them under the respective programs
 5  Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans
17.1) The amount available for distribution as a dividend to shareholders is based on the available distributable retained earnings of Novartis AG determined in accordance with the legal provisions of the Swiss Code of Obligations.
2017
2016
2015
Dividend per share (in CHF)
2.75
2.70
2.60
Total dividend payment (in USD billion)
6.5
6.5
6.6
221
17.2) The following table summarizes the treasury shares movements:
2017
2016
2015



Note
Number of
outstanding
shares
(in millions)


Equity impact
USDm
Number of
outstanding
shares
(in millions)


Equity impact
USDm
Number of
outstanding
shares
(in millions)


Equity impact
USDm
Shares acquired to be held in Group Treasury 1
– 9.6
– 897
Shares acquired to be canceled 2
– 66.2
– 5 270
– 10.3
– 784
– 49.9
– 4 805
Other share purchases 3
– 3.8
– 304
– 2.6
– 208
– 4.1
– 417
Purchase of treasury shares
– 70.0
– 5 574
– 12.9
– 992
– 63.6
– 6 119
Exercise of options and employee transactions 4
17.6
4.6
255
4.1
214
27.0
1 592
Equity-based compensation 5, 6
8.8
612
9.0
664
11.9
815
Total
– 56.6
– 4 707
0.2
– 114
– 24.7
– 3 712
 1  Shares repurchased on the SIX Swiss Exchange first trading line
 2  For 2017 and 2016, shares repurchased on the SIX Swiss Exchange second trading line under the CHF 10 billion share buyback authority approved at the 2016 Annual General Meeting (AGM). For 2015, shares repurchased on the SIX Swiss Exchange second trading line under the CHF 10 billion share buyback authority approved at the 2008 Annual General Meeting (AGM).
 3  Shares acquired from employees, which were previously granted to them under the respective programs
 4  Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price reflecting the strike price of the options exercised.
 5  Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax deductible amounts exceeding the expense recognized in the income statement are credited to equity.
 6  Included in 2017 is a USD 71 million impact related to the revaluation of deferred tax assets on equity based compensation that were previously recognized through retained earnings. This revaluation resulted from the US tax reform legislation enacted on December 22, 2017, refer to Note 11 for additional disclosures.
17.3) Changes in non-controlling interests represent the impact on the non-controlling interest of transactions with minority shareholders such as change in ownership percentage, dividend payments, and other equity transactions.
17.4) In 2017, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD 5 billion share buyback, as well as to mitigate dilution from equity-based participation plans. The commitment under this arrangement is the expected purchases by the bank under such trading plan over a rolling 90-day period. As of December 31, 2017, this trading plan commitment was fully executed and expired, and as a consequence, there is no contingent liability related to this plan recognized.
In 2014, Novartis entered into a similar irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares. The commitment under this arrangement reflected the expected purchases by the bank under such trading plan over a rolling 90-day period. In 2015, this trading plan was fully executed and expired, resulting in a decrease of USD 658 million in the repurchase obligation. As a consequence, there is no contingent liability related to this plan as of December 31, 2015 and December 31, 2016.
17.5) The impact of change in ownership of consolidated entities represents the excess of the amount paid to non-controlling interest over their carrying value and equity allocation to non-controlling interest due to change in ownership percentage.
17.6) At December 31, 2017, the market maker held 12 million written call options, originally issued as part of the share-based compensation for associates that have not yet been exercised. The weighted average exercise price of these options is USD 62.17 and they have contractual lives of 10 years, with remaining lives up to six years.
222
18. Non-current financial debt
(USD millions)
2017
2016
Straight bonds
22 957
17 285
Liabilities to banks and other financial institutions 1
539
708
Finance lease obligations
87
82
Total, including current portion of non-current financial debt
23 583
18 075
Less current portion of non-current financial debt
– 359
– 178
Total non-current financial debts
23 224
17 897
 1  Average interest rate 0.3% (2016: 0.4%)
Financial debts, including current financial debts, contain only general default covenants. The Group is in compliance with these covenants.
The percentage of fixed-rate financial debt to total financial debt was 82% at December 31, 2017, and 76% at December 31, 2016.
The average interest rate on total financial debt in 2017 was 2.6% (2016: 2.8%).
The following table provides a breakdown of straight bonds:

Coupon


Currency

Nominal
amount

Issuance
year

Maturity
year


Issuer


Issue price
2017
(USD
millions)
2016
(USD
millions)
5.125%
USD
3 000
2009
2019
Novartis Securities Investment Ltd., Hamilton, Bermuda
99.822%
2 997
2 995
4.400%
USD
1 000
2010
2020
Novartis Capital Corporation, New York, United States
99.237%
997
996
2.400%
USD
1 500
2012
2022
Novartis Capital Corporation, New York, United States
99.225%
1 491
1 490
3.700%
USD
500
2012
2042
Novartis Capital Corporation, New York, United States
98.325%
489
489
3.400%
USD
2 150
2014
2024
Novartis Capital Corporation, New York, United States
99.287%
2 134
2 132
4.400%
USD
1 850
2014
2044
Novartis Capital Corporation, New York, United States
99.196%
1 824
1 823
0.750%
EUR
600
2014
2021
Novartis Finance S.A., Luxembourg, Luxembourg
99.134%
713
625
1.625%
EUR
600
2014
2026
Novartis Finance S.A., Luxembourg, Luxembourg
99.697%
714
627
0.250%
CHF
500
2015
2025
Novartis AG, Basel, Switzerland
100.640%
513
491
0.625%
CHF
550
2015
2029
Novartis AG, Basel, Switzerland
100.502%
564
539
1.050%
CHF
325
2015
2035
Novartis AG, Basel, Switzerland
100.479%
333
318
3.000%
USD
1 750
2015
2025
Novartis Capital Corporation, New York, United States
99.010%
1 730
1 728
4.000%
USD
1 250
2015
2045
Novartis Capital Corporation, New York, United States
98.029%
1 218
1 217
0.125%
EUR
1 250
2016
2023
Novartis Finance S.A., Luxembourg, Luxembourg
99.127%
1 480
1 299
0.625%
EUR
500
2016
2028
Novartis Finance S.A., Luxembourg, Luxembourg
98.480%
588
516
1.800%
USD
1 000
2017
2020
Novartis Capital Corporation, New York, United States
99.609%
996
2.400%
USD
1 000
2017
2022
Novartis Capital Corporation, New York, United States
99.449%
993
3.100%
USD
1 000
2017
2027
Novartis Capital Corporation, New York, United States
99.109%
988
0.000%
EUR
1 250
2017
2021
Novartis Finance S.A., Luxembourg, Luxembourg
99.133%
1 480
1.125%
EUR
600
2017
2027
Novartis Finance S.A., Luxembourg, Luxembourg
99.874%
715
Total straight bonds
22 957
17 285
The following tables provide a breakdown of total non-current financial debt, including current portion by maturity and currency:
Breakdown by maturity:
(USD millions)
2017
2016
2017
178
2018
359
345
2019
3 173
3 168
2020
1 997
1 000
2021
2 194
628
2022
2 485
2 442
After 2022
13 375
10 314
Total
23 583
18 075
Breakdown by currency:
(USD millions)
2017
2016
US dollar (USD)
15 945
12 952
Euro (EUR)
5 695
3 092
Japanese yen (JPY)
533
683
Swiss franc (CHF)
1 410
1 348
Total
23 583
18 075
223
The following table shows the comparison of balance sheet and fair value of total non-current financial debt, including current portion:

(USD millions)
2017
Balance sheet
2017
Fair values
2016
Balance sheet
2016
Fair values
Straight bonds
22 957
23 835
17 285
17 943
Others
626
626
790
790
Total
23 583
24 461
18 075
18 733
The fair values of straight bonds are determined by quoted market prices. Other financial debts are recorded at notional amounts which are a reasonable approximation of the fair values.
The following table shows the pledged assets:
(USD millions)
2017
2016
Total net book value of property, plant & equipment pledged as collateral for non-current financial debts
84
94
19. Provisions and other non-current liabilities
(USD millions)
2017
2016
Accrued liability for employee benefits:
Defined benefit pension plans 1
3 157
4 490
Other long-term employee benefits and deferred compensation
625
545
Other post-employment benefits 1
953
1 005
Environmental remediation provisions
706
708
Provisions for product liabilities, governmental investigations and other legal matters
230
264
Contingent consideration 2
809
840
Other non-current liabilities
577
618
Total provisions and other non-current liabilities
7 057
8 470
 
 1  Note 24 provides additional disclosures related to post-employment benefits.
 2  Note 28 provides additional disclosures related to contingent consideration.
Novartis believes that its total provisions are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities in this area, Novartis may incur additional costs beyond the amounts provided. Management believes that such additional amounts, if any, would not be material to the Group’s financial condition but could be material to the results of operations or cash flows in a given period.
Environmental remediation provisions
The following table shows the movements in the environmental liability provisions:
(USD millions)
2017
2016
2015
January 1
773
871
923
Cash payments
– 46
– 75
– 52
Releases
– 153
– 5
Additions
154
1
6
Currency translation effects
33
– 24
– 1
December 31
761
773
871
Less current provision
– 55
– 65
– 80
Non-current environmental remediation provisions at December 31
706
708
791
224
The material components of the environmental remediation provisions consist of costs to sufficiently clean and refurbish contaminated sites to the extent necessary, and to treat, and where necessary, continue surveillance at sites where the environmental remediation exposure is less significant.
A substantial portion of the environmental remediation provisions relate to the remediation of Basel regional landfills in the adjacent border areas in Switzerland, Germany and France. The provisions are re-assessed on a yearly basis and are adjusted as necessary.
In the United States, Novartis has been named under federal legislation (the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended) as a potentially responsible party (PRP) in respect of certain sites. Novartis actively participates in, or monitors, the clean-up activities at the sites in which it is a PRP. The provision takes into consideration the number of other PRPs at each site as well as the identity and financial position of such parties in light of the joint and several nature of the liability.
The expected timing of the related cash outflows as of December 31, 2017, is currently projected as follows:

(USD millions)
Expected
cash outflows
Due within two years
164
Due later than two years, but within five years
241
Due later than five years, but within ten years
315
Due after ten years
41
Total environmental remediation liability provisions
761
Provisions for product liabilities, governmental investigations and other legal matters
Novartis has established provisions for certain product liabilities, governmental investigations and other legal matters where a potential cash outflow is probable and Novartis can make a reliable estimate of the amount of the outflow. These provisions represent the Group’s current best estimate of the total financial effect for the matters described below and for other less significant matters. Potential cash outflows reflected in a provision might be fully or partially off-set by insurance in certain circumstances.
Novartis has not established provisions for potential damage awards for certain additional legal claims against its subsidiaries if Novartis currently believes that a payment is either not probable or cannot be reliably estimated. In total, these not-provisioned-for matters include more than 1 000 individual product liability cases and certain other legal matters. Plaintiffs’ alleged claims in these matters, which Novartis does not believe to be entirely remote but which do not fulfill the conditions for the establishment of provisions, currently aggregate to, according to Novartis’ current best belief, approximately USD 1.5 billion. In addition, in some of these matters there are claims for punitive or multiple (treble) damages, civil penalties and disgorgement of profits that in Novartis’ view are either wholly or partially unspecified or wholly or partially unquantifiable at present; the Group believes that information about these amounts claimed by plaintiffs generally is not meaningful for purposes of determining a reliable estimate of a loss that is probable or more than remote.
A number of other legal matters are in such early stages or the issues presented are such that the Group has not made any provisions since it cannot currently estimate either a potential outcome or the amount of any potential losses. For these reasons, among others, the Group generally is unable to make a reliable estimate of possible loss with respect to such cases. It is therefore not practicable to provide information about the potential financial impact of those cases.
There might also be cases for which the Group was able to make a reliable estimate of the possible loss or the range of possible loss, but the Group believes that publication of such information on a case-by-case basis would seriously prejudice the Group’s position in ongoing legal proceedings or in any related settlement discussions. Accordingly, in such cases, information has been disclosed with respect to the nature of the contingency, but no disclosure is provided as to an estimate of the possible loss or range of possible loss.
Note 27 contains additional information on contingencies.
Summary of significant legal proceedings
The following is a summary of significant legal proceedings to which Novartis or its subsidiaries are a party or were a party and that concluded in 2017.
Investigations and related litigations
Southern District of New York (S.D.N.Y.) marketing practices investigation and litigation
In 2013, the US government filed a civil complaint in intervention to an individual qui tam  action against Novartis Pharmaceuticals Corporation (NPC) in the United States District Court (USDC) for the S.D.N.Y. The complaint, as subsequently amended, asserts federal False Claims Act (FCA) and common law claims with respect to speaker programs and other promotional activities for certain NPC cardiovascular medications (Lotrel, Starlix andValturna) allegedly serving as mechanisms to provide kickbacks to healthcare professionals (HCPs). It seeks damages, which according to the complaint are “substantial”, including treble damages and maximum civil penalties per claim, as well as disgorgement of Novartis profits from the alleged unlawful conduct. Also in 2013, New York State filed a civil complaint in intervention asserting similar claims. Neither government complaint in intervention adopted the individual relator’s claims with respect to off-label promotion of Valturna, which were subsequently dismissed with prejudice by the court. The individual relator continues to litigate the kickback claims on behalf of other states and municipalities. NPC vigor-
225
ously contests the S.D.N.Y., New York State and individual claims, both as to alleged liability and amount of damages and penalties.
S.D.N.Y. / Western District of New York healthcare fraud investigation
In 2011, Alcon Laboratories, Inc. (ALI) received a subpoena from the United States Department of Health & Human Services relating to an investigation into allegations of healthcare fraud. The subpoena requests the production of documents relating to marketing practices, including the remuneration of healthcare providers, in connection with certain ALI products (Vigamox, Nevanac, Omnipred, Econopred; surgical equipment). ALI is cooperating with this investigation.
S.D.N.Y. gilenya marketing practices investigation
In 2013, NPC received a civil investigative demand from the United States Attorney’s Office (USAO) for the S.D.N.Y. requesting the production of documents and information relating to marketing practices for Gilenya, including the remuneration of healthcare providers in connection therewith. In 2017, S.D.N.Y. and New York State declined to intervene in claims raised by an individual relator, which continue to be vigorously contested.
GOVERNMENT GENERIC PRICING ANTITRUST INVESTIGATIONS, ANTITRUST CLASS ACTIONS
In 2016 and 2017, Sandoz Inc. received subpoenas and interrogatories from the Antitrust Division of the US Department of Justice (DoJ) and from the Attorney General of the State of Connecticut requesting documents related to the marketing and pricing of generic pharmaceutical products sold by Sandoz Inc. and its subsidiaries, including Fougera Pharmaceuticals, Inc. (Fougera), and related communications with competitors. Sandoz Inc. is cooperating with these investigations, which it believes to be part of a broader inquiry into industry practice.
Since the third quarter of 2016, Sandoz Inc. and Fougera have been sued alongside other generic pharmaceutical companies in more than 20 consolidated complaints by proposed classes of direct and indirect purchasers, and Attorneys General for 45 states, the District of Columbia and Puerto Rico have sought leave to file a complaint, alleging that defendants, including Sandoz, engaged in anti-competitive conduct with regard to the sales of various generic drugs and asserting violations of federal and state antitrust laws as well as consumer protection laws. Lek Pharmaceuticals d.d., Novartis AG and Novartis International AG were dismissed from the proceedings. The cases have been consolidated for pretrial purposes in the USDC for the Eastern District of Pennsylvania (E.D. Pa.) and the claims are being vigorously contested.
District of Massachusetts (D. Mass.) charitable foundation investigation
In 2016 and 2017, NPC received subpoenas from the USAO for the D. Mass. requesting documents related to NPC’s support of 501(c)(3) organizations that provide co-payment assistance to Medicare patients who are prescribed Novartis medicines, including the respective accounting and tax treatment, as well as related to pricing strategies for Gleevec, Tasigna, Zometa, and Gilenya. The requests are focused on potential violations of federal health care offenses, including the Anti-Kickback Statute, and FCA. NPC is cooperating with this investigation, which it believes to be part of a broader inquiry into industry practices.
Asia/Russia investigation
In 2017, Novartis Group companies, as well as present and former senior executives of Alcon, received document requests and subpoenas from the DoJ and the US Securities and Exchange Commission (SEC) requesting information concerning Alcon’s business practices in Asia and Russia and related accounting treatment, both before and after Alcon became part of the Novartis Group. Novartis is cooperating with this investigation.
Lucentis/Avastin® matters
In connection with an investigation into whether Novartis Farma S.p.A., Novartis AG, F. Hoffmann-La Roche AG, Genentech Inc. and Roche S.p.A. colluded to artificially preserve the market positions of Avastin® and Lucentis, in 2014 the Italian Competition Authority imposed a fine equivalent to USD 125 million on Novartis AG and Novartis Farma S.p.A. Novartis paid the fine, subject to the right to later claim recoupment, and is appealing before the Consiglio di Stato. In 2014 and 2015, the Italian Ministry of Health and the Lombardia region sent letters with payment requests for a total equivalent of approximately USD 1.5 billion in damages from Novartis and Roche entities based on the above allegations. In 2014, the French Competition Authority opened an investigation against Novartis Groupe France with respect to the French market for anti-vascular endothelial growth factor (VEGF) products indicated for the treatment of wet age-related macular degeneration (AMD). Novartis continues to vigorously contest all claims in Italy and France. Also, Novartis is challenging policies and regulations allowing off-label/unlicensed use and reimbursement for economic reasons in various countries, including in Italy and the UK.
Japan investigation
In 2015, a trial started against a former Novartis Pharma K.K. (NPKK) employee, and also NPKK under the dual liability concept in Japanese law, over allegations brought by the Tokyo District Public Prosecutor Office in two counts for alleged manipulation of data in sub-analysis publications of the Kyoto Heart Study regarding valsartan. The charges against NPKK are subject to a maximum total fine of JPY 4 million. In 2017, the Tokyo District Court issued a not-guilty ruling for both the former NPKK employee and NPKK. An appeal by the Tokyo District Public Prosecutor Office remains pending.
south korea investigation
In 2016, the Seoul Western District Prosecutor initiated a criminal investigation into, among other things, allegations that Novartis Korea utilized medical journals to provide inappropriate economic benefits to HCPs. A criminal trial is ongoing concerning allegations that Novartis Korea utilized medical journals to provide inappropriate economic benefits to HCPs. In addition, other authorities in South Korea, including the Korea Fair Trade Commis-
226
sion, the Ministry of Food and Drug Safety and the Ministry of Health and Welfare conducted investigations into Novartis Korea. Those investigations have led to total fines of approximately USD 53 million as well as sales and reimbursement suspensions on Novartis Korea products in 2017.
greece investigation
Novartis is investigating allegations of potentially inappropriate economic benefits in Greece to HCPs and others. Novartis Group companies in Greece are providing information to the Greek authorities related to these allegations. Novartis is also responding to a subpoena and document requests from the SEC and DoJ that it received in 2016 and 2017 in connection with such allegations and is cooperating with their investigation.
Antitrust class actions
contact lenses
Since the first quarter of 2015, more than 50 putative class action complaints have been filed in several courts across the US naming contact-lens manufacturers, including ALI, and alleging violations of federal antitrust law as well as state antitrust, consumer protection and unfair competition laws of various states in connection with the sale of contact lenses. The cases have been consolidated in the Middle District of Florida by the Judicial Panel on Multidistrict Litigation and the claims are being vigorously contested.
gleevec
In 2015 and 2016, Novartis Group companies were sued in putative antitrust class actions in D. Mass. alleging delayed generic entry of Gleevec and seeking damages on behalf of direct and indirect purchasers of Gleevec. The motion to dismiss those actions was granted and plaintiffs have appealed. A similar class action was filed in 2018 in E.D. Pa. on behalf of direct purchasers of Gleevec. The claims are being vigorously contested.
Enoxaparin
In 2015, Sandoz and Momenta Pharmaceuticals were sued in a putative antitrust class action in federal court in Tennessee alleging that Momenta and Sandoz engaged in anticompetitive and unfair business conduct with regard to sales of enoxaparin, and the same allegations were made by Amphastar in a lawsuit filed in federal court in California and subsequently moved to federal court in Mass. (Sandoz, Momenta Pharmaceuticals and Amphastar are currently engaged in patent litigation concerning enoxaparin). The claims are being vigorously contested.
Other matters
Average Wholesale Price (AWP) litigation
Lawsuits have been brought, the latest in February 2016, by various US state governmental entities and private parties against various pharmaceutical companies, including certain Sandoz entities and NPC, alleging that they fraudulently overstated the AWP that is or has been used by payors, including state Medicaid agencies, to calculate reimbursements to healthcare providers. NPC remains a defendant in an action brought by the state of Illinois and in a putative class action brought by private payors in New Jersey, and Sandoz remains a defendant in an individual action in Pennsylvania. The putative class action in Pennsylvania was dismissed in 2017. The claims are being vigorously contested.
Reclast/Aclasta product liability litigation
NPC is a defendant in more than 20 US product liability actions involving Reclast and alleging atypical femur fracture injuries, most of which are in New Jersey state or federal court and in California state court coordinated with claims against other bisphosphonate manufacturers. The Canadian putative class action brought against numerous bisphosphonate manufacturers, including NPC, Novartis Pharmaceuticals Canada Inc. and Novartis International AG, in Quebec was discontinued in 2017. The claims are being vigorously contested.
Taxotere® (docetaxel) product liability litigation
Sandoz is a defendant in more than 1 000 US product liability actions involving Taxotere® (docetaxel), an oncology product, many of which have been transferred to Multidistrict Litigation in the Eastern District of Louisiana. The complaints allege that Sanofi, as innovator, and several 505(b)(2) NDA holders (including Sandoz) failed to warn of the risk of permanent alopecia/hair loss. The claims are being vigorously contested.
Amiodarone product liability litigation
Sandoz entities are named in more than 10 individual and multi-plaintiff US product liability cases involving amiodarone, a cardiac drug indicated to treat life-threatening arrhythmias that have not responded to other treatment. The complaints allege failure to warn, off-label promotion and failure to include medication guides to pharmacies. All claims are being vigorously contested.
Oriel litigation
In 2013, Shareholder Representative Services LLC filed a complaint in New York State Court against Sandoz Inc., two affiliates and two former officers of Sandoz AG asserting various common law and statutory contract, fraud and negligent misrepresentation claims arising out of Sandoz Inc.’s purchase of Oriel Therapeutics, Inc. In March 2015, the court dismissed all parties and claims but for a breach of contract claim against Sandoz Inc. Sandoz Inc. continues to vigorously contest the claim.
Eye drop products consumer class actions
Two putative consumer fraud class actions remain ongoing against Alcon and Sandoz in New Jersey and at the US Court of Appeals for the First Circuit after having been initially dismissed at the trial court level. They claim that Alcon’s and Sandoz’s eye drop products for glaucoma were unfairly designed so that the drop dosage is more than necessary and exceeds the capacity of the eye, leading to wastage and higher costs to patient consumers. The claims are being vigorously contested.
227
IP Matters
MIVS@ platform patent infringement litigation
Johns Hopkins University filed a patent infringement lawsuit against Alcon alleging that the use of certain Alcon surgical products, principally by third parties, infringes a patent directed to certain methods of ocular surgery, and a trial is scheduled for February 2018. The claims are being vigorously contested.
Concluded legal matters
New York State pricing policy investigation
In 2014, ALI received a civil subpoena from the New York State attorney general relating to an investigation into a unilateral pricing policy program. Novartis considers this matter concluded.
Lucentis/Avastin® matter in France
Novartis’ appeals against a temporary recommendation of use and reimbursement of off-label Avastin® for neovascular AMD by hospital ophthalmologists, in force since September 2015, as well as against the decree on which the recommendation is based, were rejected by the Supreme Court in 2016 and 2017.
Solodyn® antitrust class actions
Since the third quarter of 2013, seventeen putative class action complaints and three other complaints had been filed against manufacturers of the brand drug Solodyn® and its generic equivalent, including Sandoz Inc. The cases had been consolidated and transferred for pretrial purposes to the federal district court in Mass. The plaintiffs purported to represent direct and indirect purchasers of Solodyn® branded products and asserted violations of federal and state antitrust laws, including allegations in connection with separate settlements by Medicis with each of the other defendants, including Sandoz Inc., of patent litigation relating to Solodyn®. In 2017, all cases were resolved through settlement, the payment of which was not material to Novartis.
Summary of product liability, governmental investigations and other legal matters provision movements
(USD millions)
2017
2016
2015
January 1
395
1 194
849
Cash payments
– 69
– 811
– 256
Releases of provisions
– 70
– 239
– 223
Additions to provisions
93
243
832
Currency translation effects
2
8
– 8
December 31
351
395
1 194
Less current portion
– 121
– 131
– 743
Non-current product liabilities, governmental investigations and other legal matters provisions at December 31
230
264
451
Novartis believes that its total provisions for investigations, product liability, arbitration and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, there can be no assurance that additional liabilities and costs will not be incurred beyond the amounts provided.
20. Current financial debt and derivative financial instruments
(USD millions)
2017
2016
Interest-bearing accounts of associates payable on demand 1
1 822
1 601
Bank and other financial debt 2
692
836
Commercial paper
2 328
3 174
Current portion of non-current financial debt
359
178
Fair value of derivative financial instruments
107
116
Total current financial debt and derivative financial instruments
5 308
5 905
 1  Weighted average interest rate 0.5% (2016: 0.5%)
 2  Weighted average interest rate 7.0% (2016: 6.7%)
The consolidated balance sheet amounts of current financial debt, other than the current portion of non-current financial debt, approximate the estimated fair value due to the short-term nature of these instruments.
Details on commercial papers are provided in Note 28 – Liquidity risk.
228
21. Provisions and other current liabilities
(USD millions)
2017
2016
Taxes other than income taxes
660
547
Restructuring provisions
153
222
Accrued expenses for goods and services received but not invoiced
977
880
Accruals for royalties
586
550
Provisions for deductions from revenue
4 672
4 183
Accruals for compensation and benefits including social security
2 327
1 993
Environmental remediation liabilities
55
65
Deferred income
305
287
Provisions for product liabilities, governmental investigations and other legal matters 1
121
131
Accrued share-based payments
261
199
Contingent considerations 2
44
49
Other payables
1 042
722
Total provisions and other current liabilities
11 203
9 828
 
 1  Note 19 provides additional disclosures related to legal provisions.
 2  Note 28 provides additional disclosures related to contingent considerations.
Provisions are based upon management’s best estimate and adjusted for actual experience. Such adjustments to the historic estimates have not been material.
Provisions for deductions from revenue
The following table shows the movement of the provisions for deductions from revenue:
(USD millions)
2017
2016
2015
January 1
4 183
3 790
3 533
Impact of business combinations
3
Additions
17 997
16 622
15 603
Payments/utilizations
– 17 452
– 16 189
– 15 218
Changes in offset against gross trade receivables
– 252
10
50
Currency translation effects
196
– 50
– 181
December 31
4 672
4 183
3 790
Restructuring provisions movements
(USD millions)
2017
2016
2015
January 1
222
260
333
Additions
194
343
399
Cash payments
– 200
– 260
– 435
Releases
– 64
– 66
– 36
Transfers
– 7
– 76
Currency translation effects
8
21
– 1
December 31
153
222
260
In 2017, additions to provisions of USD 194 million were mainly related to the following reorganizations:
• The Innovative Medicines Division’s Pharmaceuticals business unit adjusted a regional promotional model which led to a restructuring of the sales force. It also streamlined the above country operating model to facilitate an even higher external competition oriented focus. Furthermore, the development organization streamlined its activities to create efficiencies.
• The Alcon Division continued initiatives to realign its operations to focus on the Surgical and Vision Care business after the Ophthalmic Pharmaceutical business transfer to the Innovative Medicines Division.
• The Sandoz Division launched initiatives to focus resources to gain efficiencies.
• Group-wide initiatives to streamline Novartis Technical Operations in the Innovative Medicines and Sandoz Divisions were launched.
In 2016, additions to provisions of USD 343 million were mainly related to the following reorganizations:
• The Innovative Medicines Division’s Pharmaceuticals business unit realigned its operations to improve its operating agility, to focus resources on key growth drivers. Furthermore, research realigned and focused its operations resulting in redundancies from the consolidation of certain research teams and the outsourcing of certain activities to qualified third party vendors.
• The Alcon Division launched several initiatives to improve its efficiencies resulting in redundancies, as it realigned its operations to focus on its Surgical and Vision Care business franchises after the transfer of its Ophthalmic Pharmaceuticals business to Innovative Medicines division.
• The Sandoz Division launched an initiative to reallocate resources to priority, high growth and higher profitability countries.
• Various group-wide initiatives to simplify organizational structure, including the consolidation of manufacturing sites and support services.
In 2015, additions to provisions of USD 399 million were mainly related to the following reorganizations:
229
• The Innovative Medicines Division implemented a restructuring program targeted at efficiency gains in the business franchises, other than in Oncology. It also initiated initiatives related to the integration of the oncology business acquired from GSK.
• The Alcon Division extended its initiative started in the prior year to realize productivity opportunities.
• Various group-wide initiatives to simplify the organizational structure, mainly related to the manufacturing footprint and support services.
22. Details to the consolidated cash flow statements
22.1) Adjustments for non-cash items from continuing operations
(USD millions)
2017
2016
2015
Taxes
1 296
1 119
1 106
Depreciation, amortization and impairments on:
Property, plant & equipment
1 677
1 591
1 550
Intangible assets
4 399
4 452
3 921
Financial assets 1
256
132
104
Income from associated companies
– 1 108
– 703
– 266
Gains on disposal and other adjustments on property, plant & equipment, intangible, financial and other non-current assets, net
– 1 043
– 935
– 869
Equity-settled compensation expense
683
671
773
Change in provisions and other non-current liabilities
160
956
1 642
Net financial expense
738
1 154
1 109
Total
7 058
8 437
9 070
 1  Including unrealized fair value gains
In 2015, the Group acquired property, plant and equipment of USD 85 million through finance lease contracts.
22.2) Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations
(USD millions)
2017
2016
2015
(Increase) in inventories
– 247
– 235
– 482
(Increase) in trade receivables
– 204
– 229
– 513
Increase/(Decrease) in trade payables
58
– 587
378
Change in other net current assets and other operating cash flow items
637
974
– 246
Total
244
– 77
– 863
230
22.3) Cash flows arising from acquisitions and divestments of businesses
The following is a summary of the cash flow impact of acquisitions and divestments. The most significant transactions are described in Note 2.

(USD millions)
2017
Acquisitions
2017
Divestments
2016
Acquisitions
2016
Divestments
2015
Acquisitions
2015
Divestments
Property, plant & equipment
25
1 000
Currently marketed products
1
– 451
– 12 970
646
(Acquired)/divested research & development
– 1 223
– 690
– 730
13
Technologies
113
Other intangible assets
3
– 15
86
Financial and other assets including deferred tax assets
– 8
– 39
– 555
40
Inventories
– 4
893
Trade receivables and other current assets
34
– 1
– 3
529
Cash and cash equivalents
– 20
– 1
– 25
311
Current and non-current financial debts
– 601
Trade payables and other liabilities including deferred tax liabilities
326
– 15
372
212
– 841
Net identifiable assets (acquired) or divested
– 925
48
– 814
– 14 086
2 189
Currency translation effects
98
Acquired/(divested) liquidity
20
1
25
– 479
Fair value of previously held equity interests
64
Subtotal
– 905
48
– 749
– 14 061
1 808
Refinancing of intercompany financial debt, net
578
Goodwill
– 94
– 56
– 2 438
1 042
Divestment gain
7 401
Taxes paid and other portfolio transformation related cash flows
– 140
– 748
– 1 337
Receivables and payables contingent consideration, net 1
206
84
– 8
– 519
Other payments and deferred consideration, net
– 36
– 3
– 44
Deferred portion of sales price 2
– 49
Net cash flows
– 829
– 95
– 765
– 748
– 16 507
8 924
Of which:
Net cash flows used in/from discontinued operations
– 140
– 748
8 924
Net cash flows used in/from continuing operations
– 829
45
– 765
– 16 507
 1  The contingent consideration of the 2016 Transcend Medical, Inc. acquisition amounted to USD 92 million. Of this amount, USD 60 million has been paid in 2016.
 2  Divestments include USD 49 million proceeds for the divestment of the Animal Health business received in 2014.
Notes 2 and 23 provide further information regarding acquisitions and divestments of businesses. All acquisitions were for cash.
22.4) Cash flows from discontinued operations
(USD millions)
2017
2016
2015
Cash flows used in operating activities
– 188
Purchase of property, plant & equipment
– 41
Proceeds from sales of property, plant & equipment
1
Purchase of financial and other non-current assets, net
– 2
Divestments of businesses 1
– 140
– 748
8 924
Cash flows used in/from investing activities
– 140
– 748
8 882
Total net cash flows used in/from discontinued operations
– 140
– 748
8 694
 1  2017 includes payments related to the 2015 portfolio transformation transaction. 2016 includes mainly payments for capital gains taxes and other payments related to the 2015 portfolio transformation transaction. 2015 includes proceeds of USD 10 925 million reduced by USD 2 001 million, for payments of capital gains taxes, transaction-related costs and purchase price adjustments, related to the 2015 portfolio transformation transaction. See Note 2 for a description of the 2015 porfolio transformation transaction.
231
22.5) Reconciliation of liabilities arising from financing activities

(USD millions)



Non-current
financial
debts





Current
financial
debts and
derivative
financial
instruments










Total
January 1, 2017
17 897
5 905
23 802
Increase in non-current financial debts
4 933
4 933
Repayment of non-current financial debts
– 1
– 187
– 188
Change in current financial debts
– 755
– 755
Changes in fair values and other changes
– 6
– 140
– 146
Amortization of bonds discount
16
16
Currency translation effects
744
126
870
Current portion of non-current financial debt
– 359
359
December 31, 2017
23 224
5 308
28 532
 
23. Acquisitions of businesses
Fair value of assets and liabilities arising from acquisitions
(USD millions)
2017
2016
2015
Currently marketed products
451
12 970
Acquired research & development
1 223
690
730
Other intangible assets
15
Deferred tax assets
8
39
555
Inventories
4
Trade receivables and other current assets
1
3
Cash and cash equivalents
20
1
25
Payables and other liabilities including deferred tax liabilities
– 326
– 372
– 212
Net identifiable assets acquired
925
814
14 086
Acquired liquidity
– 20
– 1
– 25
Goodwill
94
56
2 438
Net assets recognized as a result of business combinations
999
869
16 499
Note 2 details significant acquisition of businesses, which were Ziarco and Encore in 2017, were Transcend and Reprixys in 2016, and were the GSK Oncology products, Spinifex and Admune in 2015. The goodwill arising out of these acquisitions is attributable to buyer-specific synergies, the assembled workforce and the accounting for deferred tax liabilities on the acquired assets. No goodwill from 2017 is tax-deductible. Goodwill of USD 18 million from 2016 and of USD 2.4 billion from 2015 is tax deductible.
232
24. Post-employment benefits for associates
Defined benefit plans
In addition to the legally required social security schemes, the Group has numerous independent pension and other post-employment benefit plans. In most cases, these plans are externally funded in entities that are legally separate from the Group. For certain Group companies, however, no independent plan assets exist for the pension and other post-employment benefit obligations of associates. In these cases the related unfunded liability is included in the balance sheet. The defined benefit obligations (DBOs) of all major pension and other post-employment benefit plans are reappraised annually by independent actuaries. Plan assets are recognized at fair value. The major plans are based in Switzerland, the United States, the United Kingdom, Germany and Japan, which represent 94% of the Group’s total DBO for pension plans. Details of the plans in the two most significant countries of Switzerland and the United States are provided below.
Swiss-based pension plans represent the most significant portion of the Group’s total DBO and plan assets. For the active insured members born on or after January 1, 1956, or having joined the plans after December 31, 2010, the benefits are partially linked to the contributions paid into the plan. Certain features of Swiss pension plans required by law preclude the plans being categorized as defined contribution plans. These factors include a minimum interest guarantee on retirement savings accounts, a pre-determined factor for converting the accumulated savings account balance into a pension and embedded death and disability benefits.
All benefits granted under Swiss-based pension plans are vested, and Swiss legislation prescribes that the employer has to contribute a fixed percentage of an associate’s pay to an external pension fund. Additional employer contributions may be required whenever the plan’s statutory funding ratio falls below a certain level. The associate also contributes to the plan. The pension plans are run by separate legal entities, each governed by a Board of Trustees, that, for the principal plans, consists of representatives nominated by Novartis and the active insured associates. The Boards of Trustees are responsible for the plan design and asset investment strategy.
In September 2017, the pension regulations in Switzerland were amended, which resulted in a change in accounting from defined benefit to defined contribution for a component of the Swiss pension plans. This change resulted in a reduction to the defined benefit pension plans liability and in a corresponding net pre-tax gain of USD 225 million (CHF 216 million).
The United States pension plans represent the second largest component of the Group’s total DBO and plan assets. The principal plans (Qualified Plans) are funded, whereas plans providing additional benefits for executives (Restoration Plans) are unfunded. Employer contributions are required for Qualified Plans whenever the statutory funding ratio falls below a certain level. Furthermore, associates in the United States are covered under other post-employment benefit plans and post-retirement medical plans.
233
The following tables are a summary of the funded and unfunded defined benefit obligation for pension and other post-employment benefit plans of associates at December 31, 2017 and 2016:
Pension plans
Other post-employment benefit plans
(USD millions)
2017
2016
2017
2016
Benefit obligation at January 1
23 614
23 402
1 158
1 132
Current service cost
422
437
34
35
Interest cost
330
390
44
48
Past service costs and settlements
– 1 226
– 73
– 10
Administrative expenses
27
29
Remeasurement losses arising from changes in financial assumptions
11
1 299
32
46
Remeasurement (gains) arising from changes in demographic assumptions
– 26
– 7
– 9
– 26
Experience-related remeasurement losses/(gains)
47
117
– 87
– 33
Currency translation effects
1 138
– 896
5
7
Benefit payments
– 1 300
– 1 250
– 51
– 51
Contributions of associates
207
207
Effect of acquisitions, divestments or transfers
– 34
– 41
– 1
Benefit obligation at December 31
23 210
23 614
1 115
1 158
Fair value of plan assets at January 1
19 225
19 536
153
172
Interest income
236
293
5
6
Return on plan assets excluding interest income
1 429
742
12
– 1
Currency translation effects
909
– 757
Novartis Group contributions
579
542
43
27
Contributions of associates
207
207
Settlements
– 995
– 77
Benefit payments
– 1 300
– 1 250
– 51
– 51
Effect of acquisitions, divestments or transfers
– 15
– 11
Fair value of plan assets at December 31
20 275
19 225
162
153
Funded status
– 2 935
– 4 389
– 953
– 1 005
Limitation on recognition of fund surplus at January 1
– 54
– 50
Change in limitation on recognition of fund surplus (incl. exchange rate differences)
– 30
Interest income on limitation of fund surplus
– 5
– 4
Limitation on recognition of fund surplus at December 31
– 89
– 54
Net liability in the balance sheet at December 31
– 3 024
– 4 443
– 953
– 1 005
The reconciliation of the net liability from January 1 to December 31 is as follows:
Pension plans
Other post-employment benefit plans
(USD millions)
2017
2016
2017
2016
Net liability at January 1
– 4 443
– 3 916
– 1 005
– 960
Current service cost
– 422
– 437
– 34
– 35
Net interest expense
– 99
– 101
– 39
– 42
Administrative expenses
– 27
– 29
Past service costs and settlements
231
– 4
10
Remeasurements
1 397
– 667
76
12
Currency translation effects
– 229
139
– 5
– 7
Novartis Group contributions
579
542
43
27
Effect of acquisitions, divestments or transfers
19
30
1
Change in limitation on recognition of fund surplus
– 30
Net liability at December 31
– 3 024
– 4 443
– 953
– 1 005
Amounts recognized in the consolidated balance sheet
Prepaid benefit cost
133
47
Accrued benefit liability
– 3 157
– 4 490
– 953
– 1 005
234
The following table shows a breakdown of the DBO for pension plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held:
2017
2016

(USD millions)

Switzerland

United States
Rest of
the world

Total

Switzerland

United States
Rest of
the world

Total
Benefit obligation at December 31
14 606
3 788
4 816
23 210
15 436
3 783
4 395
23 614
Thereof unfunded
728
499
1 227
739
497
1 236
By type of member
Active
5 627
796
1 646
8 069
6 426
891
1 460
8 777
Deferred pensioners
1 258
1 646
2 904
831
1 515
2 346
Pensioners
8 979
1 734
1 524
12 237
9 010
2 061
1 420
12 491
Fair value of plan assets at December 31
14 445
2 400
3 430
20 275
13 958
2 282
2 985
19 225
Funded status
– 161
– 1 388
– 1 386
– 2 935
– 1 478
– 1 501
– 1 410
– 4 389
The following table shows the principal weighted average actuarial assumptions used for calculating defined benefit plans and other post-employment benefits of associates:
Pension plans
Other post-employment benefit plans
2017
2016
2015
2017
2016
2015
Weighted average assumptions used to determine benefit obligations at December 31
Discount rate
1.5%
1.4%
1.8%
3.7%
4.2%
4.4%
Expected rate of pension increase
0.5%
0.4%
0.4%
Expected rate of salary increase
2.8%
2.2%
2.9%
Interest on savings account
0.6%
0.5%
0.8%
Current average life expectancy for a 65-year-old male in years
22
22
21
21
21
21
Current average life expectancy for a 65-year-old female in years
24
24
24
23
23
23
Changes in the aforementioned actuarial assumptions can result in significant volatility in the accounting for the Group’s pension plans in the consolidated financial statements. This can result in substantial changes in the Group’s other comprehensive income, long-term liabilities and prepaid pension assets.
The DBO is significantly impacted by assumptions regarding the rate that is used to discount the actuarially determined post-employment benefit liability. This rate is based on yields of high-quality corporate bonds in the country of the plan. Decreasing corporate bond yields decrease the discount rate, so that the DBO increases and the funded status decreases.
In Switzerland, an increase in the DBO due to lower discount rates is slightly offset by lower future benefits expected to be paid on the associate’s savings account where the assumption on interest accrued changes in line with the discount rate.
The impact of decreasing interest rates on a plan’s assets is more difficult to predict. A significant part of the plan assets is invested in bonds. Bond values usually rise when interest rates decrease and may therefore partially compensate for the decrease in the funded status. Furthermore, pension assets also include significant holdings of equity instruments. Share prices tend to rise when interest rates decrease and therefore often counteract the negative impact of the rising defined benefit obligation on the funded status (although the correlation of interest rates with equities is not as strong as with bonds, especially in the short term).
The expected rate for pension increases significantly affects the DBO of most plans in Switzerland, Germany and the United Kingdom. Such pension increases also decrease the funded status, although there is no strong correlation between the value of the plan assets and pension/inflation increases.
Assumptions regarding life expectancy significantly impact the DBO. An increase in longevity increases the DBO. There is no offsetting impact from the plan assets, as no longevity bonds or swaps are held by the pension funds. Generational mortality tables are used where this data is available.
The following table shows the sensitivity of the defined benefit pension obligation to the principal actuarial assumptions for the major plans in Switzerland, the United States, the United Kingdom, Germany and Japan on an aggregated basis:
235

(USD millions)
Change in 2017 year-end
defined benefit pension obligation
25 basis point increase in discount rate
– 753
25 basis point decrease in discount rate
803
1 year increase in life expectancy
840
25 basis point increase in rate of pension increase
533
25 basis point decrease in rate of pension increase
– 138
25 basis point increase of interest on savings account
56
25 basis point decrease of interest on savings account
– 54
25 basis point increase in rate of salary increase
49
25 basis point decrease in rate of salary increase
– 50
The healthcare cost trend rate assumptions used for other post-employment benefits are as follows:
2017
2016
2015
Healthcare cost trend rate assumed for next year
6.5%
7.0%
7.5%
Rate to which the cost trend rate is assumed to decline
4.5%
5.0%
5.0%
Year that the rate reaches the ultimate trend rate
2025
2022
2022
The following table shows the weighted average plan asset allocation of funded defined benefit pension plans at December 31, 2017 and 2016:
Pension plans

(as a percentage)
Long-term
target
minimum
Long-term
target
maximum


2017


2016
Equity securities
15
40
31
31
Debt securities
20
60
35
35
Real estate
5
20
15
15
Alternative investments
0
20
15
15
Cash and other investments
0
15
4
4
Total
100
100
Cash and most of the equity and debt securities have a quoted market price in an active market. Real estate and alternative investments, which include hedge fund and private equity investments, usually do not have a quoted market price.
The strategic allocation of assets of the different pension plans is determined with the objective of achieving an investment return that, together with the contributions paid by the Group and its associates, is sufficient to maintain reasonable control over the various funding risks of the plans. Based upon the market and economic environments, actual asset allocations may temporarily be permitted to deviate from policy targets. The asset allocation currently includes investments in shares of Novartis AG as per the below table:
December 31,
2017
December 31,
2016
Investment in shares of Novartis AG
Number of shares (in millions)
11.0
11.0
Market Value (in USD billions)
0.9
0.8
The weighted average duration of the defined benefit obligation is 14.6 years (2016: 14.5 years).
The Group’s ordinary contribution to the various pension plans is based on the rules of each plan. Additional contributions are made whenever this is required by statute or law (i.e., usually when statutory funding levels fall below pre-determined thresholds). The only significant plans that are foreseen to require additional funding are those in the United Kingdom.
The expected future cash flows in respect of pension and other post-employment benefit plans at December 31, 2017, were as follows:

(USD millions)


Pension plans
Other post-
employment
benefit plans
Novartis Group contributions
2018 (estimated)
395
62
Expected future benefit payments
2018
1 226
63
2019
1 166
65
2020
1 163
67
2021
1 147
68
2022
1 133
69
2023–2027
5 534
344
Defined contribution plans
In many subsidiaries, associates are covered by defined contribution plans. Contributions charged to the 2017 consolidated income statement for the defined contribution plans were:
(USD millions)
2017
2016
2015
Contributions for defined contribution plans continuing operations
406
338
359
Contributions for defined contribution plans discontinued operations
1
236
25. Equity-based participation plans for associates
The expense related to all equity-based participation plans and the liabilities arising from equity-based payment transactions were as follows:
(USD millions)
2017
2016
2015
Expense related to equity-based participation plans
924
846
968
of which continuing operations
924
846
903
of which discontinued operations
65
Liabilities arising from equity-based payment transactions
261
199
209
Equity-based participation plans can be separated into the following plans:
Annual Incentive
The Annual Incentive of the Novartis Group CEO and the other Executive Committee members is paid 50% in cash in February or March of the year following the performance period, and 50% in Novartis Restricted Shares (RSs) or Restricted Share Units (RSUs) that are granted in January of the year following the performance period, deferred and restricted for three years. In 2016, this was extended to Novartis Top Leaders (NTLs). The Annual Incentive payout for the NTLs is 70% in cash and 30% in Novartis RSs or RSUs. Each RS is entitled to voting rights and payment of dividends during the vesting period. Each RSU is equivalent to one Novartis share and is converted into one share at the vesting date. RSUs do not carry any dividend, dividend equivalent or voting rights. The executives in certain countries may elect to also receive their cash incentive partially or fully in shares or share units that will not be subject to vesting conditions.
Share savings plans
A number of associates in certain countries as well as certain key executives worldwide are encouraged to invest their Annual Incentive, and in the United Kingdom also their salary, in a share savings plan. Under the share savings plan, participants may elect to receive their Annual Incentive fully or partially in Novartis shares in lieu of cash. As a reward for their participation in the share savings plan, at no additional cost to the participant, Novartis matches their investments in shares after a holding period of three or five years.
Novartis operates three share savings plans, and associates may only participate in one of the share savings plans in any given year:
• In Switzerland, Employee Share Ownership Plan (ESOP) participants may choose to receive their Annual Incentive (i) 100% in shares, (ii) 50% in shares and 50% in cash or (iii) 100% in cash. After expiration of a three-year holding period for Novartis shares invested under the ESOP, participants will receive one matching share for every two invested shares. Associates eligible for the equity plan “Select” are not eligible to receive ESOP matching shares starting with the 2017 performance period onwards.
• In the United Kingdom, associates can invest up to 10% of their monthly salary in shares (up to a maximum of GBP 150) and may also be invited to invest their net Annual Incentive in shares. Two invested shares are matched with one share with a holding period of three years. Starting with the 2017 performance period onwards, United Kingdom associates can only invest a maximum of 50% of their Annual Incentive in shares and this option is no longer offered to associates who are eligible for the equity plan “Select”.
• The Leveraged Share Savings Plan (LSSP) was available to key executives for performance periods prior to 2016. At the participant’s election, the Annual Incentive was awarded partly or entirely in shares. The elected number of shares is subject to a holding period of five years. At the end of the holding period, Novartis will match the invested shares at a ratio of 1-to-1 (i.e. one share awarded for each invested share). In the United States both the LSSP award and the corresponding match are cash settled.
Following the introduction of the new compensation programs in 2014, the Novartis Group CEO and the other Executive Committee members are no longer eligible to participate in the share savings plans. From the 2016 performance period onwards, the NTLs are also no longer eligible to participate in the share savings plans.
Novartis equity plan “Select”
The equity plan “Select” is a global equity incentive plan under which eligible associates may annually be awarded a grant subject to a three year vesting period. No awards are granted for performance ratings below a certain threshold. Executive Committee members are not eligible for participation in the equity plan “Select” effective from the performance period 2014, and the NTLs are not eligible to participate effective from the performance period 2016.
The equity plan “Select” currently allows participants in Switzerland to choose the form of their equity compensation in RSs or RSUs. In all other jurisdictions, RSUs are typically granted. Until 2013, participants could also choose to receive part or the entire grant in the form of tradable share options.
Tradable share options expire on their tenth anniversary from the grant date. Each tradable share option entitles the holder to purchase after vesting (and before the tenth anniversary from the grant date) one Novartis share at a stated exercise price that equals the closing market price of the underlying share at the grant date.
237
Options under Novartis equity plan “Select” outside North America
The following table shows the activity associated with the share options during the period. The weighted average prices in the table below are translated from Swiss francs into USD at historical rates.
2017
2016


Options
(millions)
Weighted
average
exercise
price (USD)


Options
(millions)
Weighted
average
exercise
price (USD)
Options outstanding at January 1
9.5
59.4
11.7
59.9
Sold or exercised
– 2.1
59.2
– 2.2
61.8
Forfeited or expired
Outstanding at December 31
7.4
59.5
9.5
59.4
Exercisable at December 31
7.4
59.5
9.5
59.4
All share options were granted at an exercise price that was equal to the closing market price of the Group’s shares at the grant date. The weighted average share price at the dates of sale or exercise was USD 80.1.
The following table summarizes information about share options outstanding at December 31, 2017:
Options outstanding

Range of exercise prices (USD)

Number
outstanding
(millions)
Average
remaining
contractual
life (years)
Weighted
average
exercise
price (USD)
45–49
0.7
1.0
46.7
50–54
1.1
2.0
54.6
55–59
2.7
3.3
57.6
65–70
2.9
5.0
66.1
Total
7.4
3.6
59.5
Options under Novartis equity plan “Select” for North America
The following table shows the activity associated with the American Depositary Receipts (ADR) options during the period:
2017
2016

ADR
options
(millions)
Weighted
average
exercise
price (USD)

ADR
options
(millions)
Weighted
average
exercise
price (USD)
Options outstanding at January 1
25.9
59.9
31.9
60.2
Sold or exercised
– 5.6
59.9
– 6.0
61.7
Forfeited or expired
Outstanding at December 31
20.3
59.9
25.9
59.9
Exercisable at December 31
20.3
59.9
25.9
59.9
All ADR options were granted at an exercise price that was equal to the closing market price of the ADRs at the grant date. The weighted average ADR price at the dates of sale or exercise was USD 79.9.
The following table summarizes information about ADR options outstanding at December 31, 2017:
ADR options outstanding

Range of exercise prices (USD)

Number
outstanding
(millions)
Average
remaining
contractual
life (years)
Weighted
average
exercise
price (USD)
45–49
1.8
1.0
46.4
50–54
2.1
2.0
53.7
55–59
8.0
3.5
58.0
65–69
8.4
5.0
66.1
Total
20.3
3.7
59.9
Long-Term Performance Plan
The Long-Term Performance Plan (LTPP) is an equity plan for the Novartis Group CEO, the other Executive Committee members and the NTLs. For the 2017 grant, the target incentive is 200% of base compensation for the Novartis Group CEO and ranges from 150% to 170% for other Executive Committee members. For the NTLs, the target incentive range is from 20% to 160% of base compensation.
The awards of the LTPP are based on three-year performance objectives focused on financial and innovation measures. The financial measure is Novartis Cash Value Added (NCVA). The weighting of this measure is 75%. The NCVA target is approved by the Board of Directors.
The innovation measure is based on a holistic approach under which divisional innovation targets are set at the beginning of the cycle, comprised of up to ten target milestones that represent the most important research and development project milestones for each division. The weighting of this measure is 25%. At the end of the performance period, the Research & Development Committee assists the Board of Directors and the Compensation Committee in evaluating performance against the innovation targets at the end of the cycle.
Under the LTPP, participants are granted a target number of Performance Share Units (PSUs) at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. Payout is between 0% and 200% of target. PSUs granted under the LTPP do not carry voting rights, but do carry dividend equivalents that are paid in shares at the end of the performance period.
Long-Term Relative Performance Plan
The Long-Term Relative Performance Plan (LTRPP) is an equity plan for the Novartis Group CEO, other ECN members and NTLs. For the 2017 grant, the target incentive is 125% of base compensation for the Novartis Group CEO and ranges from 60% to 80% for other Executive Committee members. For the NTLs, the target incentive range is from 10% to 40% of base compensation. The LTRPP is based on the ranking of Novartis’ Total Shareholder Return (TSR) relative to a global healthcare peer group of 12 companies until 2016, and 15 companies from 2017, over rolling three-year performance periods. TSR in USD is calculated as price change of the Novartis share plus the dividend plus the re-investment return of the dividend amount, all translated to USD at the respective exchange rate, over the three-year performance period. The calcu-
238
lation is based on Bloomberg standard published TSR data, which is publicly available. The position in the peer group determines the payout range based on a payout matrix. Under the LTRPP, participants are also granted a target number of PSUs at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. Payout is between 0% and 200% of target. PSUs under the LTRPP do not carry voting rights, but do carry dividend equivalents that are paid in shares at the end of the performance period.
Other share awards
Selected associates, excluding the Executive Committee members, may exceptionally receive Special Share Awards of RSs or RSUs. These Special Share Awards provide an opportunity to reward outstanding achievements or exceptional performance, and aim to retain key contributors. They are based on a formal internal selection process, through which the individual performance of each candidate is thoroughly assessed at several management levels. Special Share Awards have a minimum three-year vesting period. In exceptional circumstances, Special Share Awards may be awarded to attract special expertise and new talents into the organization. These grants are consistent with market practice and Novartis’ philosophy to attract, retain and motivate best-in-class talents around the world.
Worldwide, associates at different levels in the organization were awarded RSs and RSUs in 2017.
In addition, in 2017, Board members received unrestricted shares as part of their regular compensation.
Summary of non-vested share movements
The table below provides a summary of non-vested share movements (RSs, RSUs and PSUs) for all plans:
2017
2016

Number
of shares
in millions
Weighted
average fair
value at grant
date in USD

Fair value at
grant date in
USD millions

Number
of shares
in millions
Weighted
average fair
value at grant
date in USD

Fair value at
grant date in
USD millions
Non-vested shares at January 1
21.0
89.5
1 880
20.1
87.1
1 751
Granted
– Annual incentive
1.3
69.3
90
0.1
73.8
7
– Share savings plans
4.5
69.4
312
4.4
78.1
344
– Select North America
4.5
64.1
288
4.8
72.4
348
– Select outside North America
2.0
65.3
131
1.6
74.4
119
– Long-Term Performance Plan
1.4
71.5
100
1.2
79.2
95
– Long-Term Relative Performance Plan
0.4
47.7
19
0.3
58.5
18
– Other share awards
1.3
67.8
88
0.7
65.8
46
Vested
– 10.7
78.2
– 837
– 10.4
68.8
– 716
Forfeited
– 1.8
80.7
– 145
– 1.8
73.1
– 132
Non-vested shares at December 31
23.9
80.6
1 926
21.0
89.5
1 880
Alcon, Inc., equity plans granted to associates prior to the merger
At the completion of the merger of Alcon, Inc. into Novartis on April 8, 2011, all awards outstanding under the Alcon equity plans were converted into awards based upon Novartis shares with a conversion factor of 3.0727 as defined in the Merger Agreement. The plans are fully vested.
Share options entitle the recipient to purchase Novartis shares at the closing market price of the former Alcon, Inc., share on the day of grant divided by the conversion factor.
Share-settled appreciation rights (SSAR) entitle the participant to receive, in the form of Novartis shares, the difference between the values of the former Alcon, Inc., share at the date of grant, converted into Novartis shares using the conversion factor, and the Novartis share price at the date of exercise.
Both options and SSAR expire on their tenth anniversary. The last grant was made in 2009.
The following table shows the activity associated with the converted Novartis share options and SSARs during 2017 and 2016:

Number
of options
(millions)
Weighted
average
exercise
price (USD)

Number of
SSARs
(millions)
Weighted
average
exercise
price (USD)
Outstanding at January 1, 2016
0.2
36.8
1.8
36.6
Exercised
– 0.1
37.6
– 0.4
38.9
Outstanding at December 31, 2016
0.1
36.0
1.4
35.9
Exercisable at December 31, 2016
0.1
36.0
1.4
35.9
Outstanding at January 1, 2017
0.1
36.0
1.4
35.9
Exercised
– 0.6
39.8
Outstanding at December 31, 2017
0.1
33.7
0.8
33.0
Exercisable at December 31, 2017
0.1
33.7
0.8
33.0
239
26. Transactions with related parties
Genentech/Roche
Novartis has two agreements with Genentech, Inc., United States, a subsidiary of Roche Holding AG which is indirectly included in the consolidated financial statements using equity accounting since Novartis holds 33.3% of the outstanding voting shares of Roche.
LUCENTIS
Novartis has licensed the exclusive rights to develop and market Lucentis outside the United States for indications related to diseases of the eye. As part of this agreement, Novartis paid Genentech/Roche an initial milestone and shared the cost for the subsequent development by making additional milestone payments upon the achievement of certain clinical development points and product approval. Novartis also pays royalties on the net sales of Lucentis products outside the United States. In 2017, Lucentis sales of USD 1.9 billion (2016: USD 1.8 billion, 2015: USD 2.1 billion) were recognized by Novartis.
XOLAIR
In February 2004, Novartis Pharma AG, Genentech, Inc., and Tanox, Inc., finalized a three-party collaboration to govern the development and commercialization of certain anti-IgE antibodies including Xolair and TNX-901. Under this agreement, all three parties co-developed Xolair. On August 2, 2007, Genentech, Inc. completed the acquisition of Tanox, Inc. and has taken over its rights and obligations. Novartis and Genentech/Roche are co-promoting Xolair in the United States where Genentech/Roche records all sales. Novartis records sales outside of the United States.
Novartis markets Xolair and records all sales and related costs outside the United States as well as co-promotion costs in the US. Genentech/Roche and Novartis share the resulting profits from sales in the United States, Europe and other countries, according to agreed profit-sharing percentages. In 2017, Novartis recognized total sales of Xolair of USD 920 million (2016: USD 835 million, 2015: USD 755 million) including sales to them for the United States market.
The net expense for royalties, cost sharing and profit sharing arising out of the Lucentis and Xolair agreements with Genentech/Roche totaled USD 33 million in 2017 (2016: USD 217 million, 2015: USD 309 million).
Furthermore, Novartis has several patent license, supply and distribution agreements with Roche.
Executive Officers and Non-Executive Directors Compensation
During 2017, there were 11 Executive Committee members (“Executive Officers”), including those who stepped down during the year (14 members in 2016 and 11 members in 2015 also including those who stepped down).
The total compensation for members of the Executive Committee and the 13 Non-Executive Directors (13 in 2016, 12 in 2015 including those who stepped down during the year) using the Group’s accounting policies for equity-based compensation and pension benefits was as follows:
Executive Officers
Non-Executive Directors
Total
(USD millions)
2017
2016
2015
2017
2016
2015
2017
2016
2015
Cash and other compensation
18.4
20.8
17.1
4.0
4.0
4.7
22.4
24.8
21.8
Post-employment benefits
2.0
2.2
1.9
2.0
2.2
1.9
Equity-based compensation
49.9
46.2
52.9
4.8
4.6
4.4
54.7
50.8
57.3
Total
70.3
69.2
71.9
8.8
8.6
9.1
79.1
77.8
81.0
During 2017, there was an increase in the IFRS compensation expense for Executive Officers, mainly due to the pro-rata accelerated vesting of equity-based compensation, required by IFRS, for an ECN member who stepped down on December 31, 2017. This was partially offset by the reduction in the number of Executive Officers compared to 2016. The increase in the IFRS compensation expense for Non-Executive Directors was due to one additional Non-Executive Director appointed at the 2017 Annual General Meeting.
During 2016, there was a decrease in the IFRS compensation expense for Executive Officers compared to 2015. This was mainly due to lower equity-based compensation expense attributable to lower performance factors, which was partially offset by higher benefits other than equity-based compensation resulting from the increase in the number of Executive Officers.
The Annual Incentive award, which is fully included in equity-based compensation even when paid out in cash, is granted in January in the year following the reporting period.
The disclosures on Board and Executive compensation required by the Swiss Code of Obligations and in accordance with the Swiss Ordinance against Excessive Compensation in Stock Exchange Listed Companies are shown in the Compensation Report.
240
Transactions with former members of the Board of Directors
During 2017, 2016 and 2015, the following payments (or waivers of claims) were made to former Board members or to “persons closely” linked to them:
Currency
2017
2016
2015
Prof. Dr. Brody
CHF
0
25 000
100 000
Prof. Dr. Zinkernagel
CHF
0
50 000
200 000
Dr. Krauer
CHF
60 000
60 000
60 000
Dr. Vasella
CHF
26 279
0
0
USD
0
250 000
250 000
Prof. Dr. William R. Brody and Prof. Dr. Rolf M. Zinkernagel, who stepped down from the Board of Directors at the 2014 AGM, received in 2016 and 2015, delegated Board membership fees for their work on the Boards of the Novartis Institute for Tropical Diseases (Prof. Dr. Zinkernagel) and the Genomics Institute of the Novartis Research Foundation (Prof. Dr. Brody and Prof. Dr. Zinkernagel). No payments were made in 2017, as their respective mandates ended in 2016.
Dr. Alex Krauer, Honorary Chairman, is entitled to an amount of CHF 60 000 for annual periods from one AGM to the next. This amount was fixed in 1998 upon his departure from the Board in 1999, and has not been revised since that date.
In 2017, Dr. Daniel Vasella, Honorary Chairman, was paid CHF 26 279 for reimbursable costs under his agreement with the company. In 2016, Dr. Daniel Vasella received the contractual minimum compensation under an agreement which became effective on November 1, 2013 and ended in 2016. Under this agreement, Dr. Vasella was compensated at a rate of USD 25 000 per day, with an annual guaranteed minimum fee of USD 250 000. This amount was in line with compensation practices at other large companies when retired Chairmen or CEOs were retained in consulting agreements after leaving the board of directors.
In 2014, Dr. Vasella exercised an option to acquire, at a future date, real estate in Risch, Zug, Switzerland. The real estate transaction closed in 2015 and Dr. Vasella acquired the Group assets from a consolidated entity for an arm’s length transaction price determined on the basis of two independent external assessments.
Transactions with an Executive Officer prior to the start of employment
As announced on September 24, 2015, Dr. James E. Bradner succeeded Dr. Mark Fishman as President of the Novartis Institutes for BioMedical Research (NIBR) and member of the Executive Committee of Novartis with effect from March 1, 2016. In 2015, a Novartis subsidiary acquired Dr. Bradner’s 10 million shares (7% interest) in a non-material entity for USD 10 million. The arm’s length transaction price was determined based on the most recent round of financing of this entity.
The above disclosures related to Dr. Vasella and Dr. Bradner are made on a voluntary basis.
27. Commitments and contingencies
Leasing commitments
The Group has entered into various fixed-term operational leases, mainly for cars and real estate. As of December 31, 2017, the Group’s commitments with respect to these leases, including estimated payment dates, were as follows:
(USD millions)
2017
2018
309
2019
224
2020
161
2021
131
2022
123
Thereafter
2 221
Total
3 169
Expense of current year
337
Research & Development and other intangible asset purchase commitments
The Group has entered into long-term research and development agreements with various institutions which provide for potential milestone payments by Novartis that may be capitalized. As of December 31, 2017 the Group’s commitments to make payments under those agreements and other agreements to purchase intangible assets, and their estimated timing, were as follows:

(USD millions)

Research &
Development
commitments
Other
intangible asset
purchase
commitments



Total
2018
780
130
910
2019
671
671
2020
864
864
2021
801
801
2022
353
353
Thereafter
837
837
Total
4 306
130
4 436
241
Other commitments
The Group has entered into various purchase commitments for services and materials as well as for equipment in the ordinary course of business. These commitments are generally entered into at current market prices and reflect normal business operations.
Contingencies
Group companies have to observe the laws, government orders and regulations of the country in which they operate.
A number of Novartis companies are, and will likely continue to be, subject to various legal proceedings and investigations that arise from time to time, including proceedings regarding product liability, sales and marketing practices, commercial disputes, employment, and wrongful discharge, antitrust, securities, health and safety, environmental, tax, international trade, privacy, and intellectual property matters. As a result, the Group may become subject to substantial liabilities that may not be covered by insurance and that could affect our business, financial position and reputation. While Novartis does not believe that any of these legal proceedings will have a material adverse effect on its financial position, litigation is inherently unpredictable and large judgments sometimes occur. As a consequence, Novartis may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on its results of operations or cash flow.
Governments and regulatory authorities around the world have been stepping up their compliance and law enforcement activities in recent years in key areas, including marketing practices, pricing, corruption, trade restrictions, embargo legislation, insider trading, antitrust, cyber security and data privacy. Further, when one government or regulatory authority undertakes an investigation, it is not uncommon for other governments or regulators to undertake investigations regarding the same or similar matters. Responding to such investigations is costly and requires an increasing amount of management’s time and attention. In addition, such investigations may affect our reputation, create a risk of potential exclusion from government reimbursement programs in the United States and other countries, and may lead to (or arise from) litigation. These factors have contributed to decisions by Novartis and other companies in the healthcare industry, when deemed in their interest, to enter into settlement agreements with governmental authorities around the world prior to any formal decision by the authorities or a court. Those government settlements have involved and may continue to involve, in current government investigations and proceedings, large cash payments, sometimes in the hundreds of millions of dollars or more, including the potential repayment of amounts allegedly obtained improperly and other penalties, including treble damages. In addition, settlements of government healthcare fraud cases often require companies to enter into corporate integrity agreements, which are intended to regulate company behavior for a period of years. Our affiliate Novartis Pharmaceuticals Corporation is a party to such an agreement, which will expire in 2020. Also, matters underlying governmental investigations and settlements may be the subject of separate private litigation.
While provisions have been made for probable losses, which management deems to be reasonable or appropriate, there are uncertainties connected with these estimates.
Note 19 contains additional information on these matters.
A number of Group companies are involved in legal proceedings concerning intellectual property rights. The inherent unpredictability of such proceedings means that there can be no assurances as to their ultimate outcome. A negative result in any such proceeding could potentially adversely affect the ability of certain Novartis companies to sell their products, or require the payment of substantial damages or royalties.
In the opinion of management, however, the outcome of these actions will not materially affect the Group’s financial position but could be material to the results of operations or cash flow in a given period.
The Group’s potential environmental remediation liability is assessed based on a risk assessment and investigation of the various sites identified by the Group as at risk for environmental remediation exposure. The Group’s future remediation expenses are affected by a number of uncertainties. These uncertainties include, but are not limited to, the method and extent of remediation, the percentage of material attributable to the Group at the remediation sites relative to that attributable to other parties, and the financial capabilities of the other potentially responsible parties.
Note 19 contains additional information on environmental liabilities.
242
28. Financial instruments – additional disclosures
(USD millions)
Note
2017 1
2016 1
Cash and cash equivalents
15
8 860
7 007
Financial assets - measured at fair value through other comprehensive income
Available-for-sale marketable securities
Debt securities
15
328
306
Fund investments
15
34
31
Total available-for-sale marketable securities
362
337
Available-for-sale long-term financial investments
Equity securities
12
1 109
989
Fund investments
12
166
107
Total available-for-sale long-term financial investments
1 275
1 096
Total financial assets - measured at fair value through other comprehensive income
1 637
1 433
Financial assets - measured at amortized costs
Trade receivables, income tax receivables, and other current assets (excluding contingent consideration receivables and pre-payments)
14/16
10 650
10 202
Accrued interest on debt securities and time deposits
15
1
1
Time deposits with original maturity more than 90 days
15
125
108
Long-term loans and receivables from customers and finance lease, advances, security deposits
12
574
514
Total financial assets - measured at amortized costs
11 350
10 825
Financial assets - measured at fair value through the consolidated income statement
Associated companies at fair value through profit and loss
216
188
Derivative financial instruments
15
31
230
Contingent consideration receivables
12/16
844
586
Total financial assets - measured at fair value through the consolidated income statement
1 091
1 004
Total financial assets
22 938
20 269
Financial liabilities - measured at amortized costs
Current financial debt
Interest-bearing accounts of associates payable on demand
20
1 822
1 601
Bank and other financial debt
20
692
836
Commercial paper
20
2 328
3 174
Current portion of non-current debt
20
359
178
Total current financial debt
5 201
5 789
Non-current financial debt
Straight bonds
18
22 957
17 285
Liabilities to banks and other financial institutions
18
539
708
Finance lease obligations
18
87
82
Current portion of non-current debt
18
– 359
– 178
Total non-current financial debt
23 224
17 897
Trade payables
5 169
4 873
Total financial liabilities - measured at amortized costs
33 594
28 559
Financial liabilities - measured at fair value through the consolidated income statement
Contingent consideration (see Note 19/21) and other financial liabilities
924
1 018
Derivative financial instruments
20
107
116
Total financial liabilities - measured at fair value through the consolidated income statement
1 031
1 134
Total financial liabilities
34 625
29 693
 
 1  Except for straight bonds (see Note 18), the carrying amount is a reasonable approximation of fair value.
243
Derivative financial instruments
The following tables show the contract or underlying principal amounts and fair values of derivative financial instruments analyzed by type of contract at December 31, 2017 and 2016. Contract or underlying principal amounts indicate the gross volume of business outstanding at the consolidated balance sheet date and do not represent amounts at risk. The fair values are determined by reference to market prices or standard pricing models that use observable market inputs at December 31, 2017 and 2016.
Contract or underlying principal amount
Positive fair values
Negative fair values
(USD millions)
2017
2016
2017
2016
2017
2016
Currency-related instruments
Forward foreign exchange rate contracts
8 410
8 220
31
230
– 107
– 116
Total derivative financial instruments included in marketable securities and in current financial debts
8 410
8 220
31
230
– 107
– 116
The following table shows by currency contract or underlying principal amount the derivative financial instruments at December 31, 2017 and 2016:
2017
(USD millions)
EUR
USD
Other
Total
Currency-related instruments
Forward foreign exchange rate contracts
2 768
4 361
1 281
8 410
Total derivative financial instruments
2 768
4 361
1 281
8 410
2016
(USD millions)
EUR
USD
JPY
Other
Total
Currency-related instruments
Forward foreign exchange rate contracts
3 623
3 427
43
1 127
8 220
Total derivative financial instruments
3 623
3 427
43
1 127
8 220
Derivative financial instruments effective for hedge accounting purposes
At the end of 2017 and 2016, there were no open hedging instruments for anticipated transactions.
Fair value by hierarchy
As required by IFRS, financial assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. There are three hierarchical levels, based on an increasing amount of subjectivity associated with the inputs to derive fair valuation for these assets and liabilities, which are as follows:
The assets carried at Level 1 fair value are equity and debt securities listed in active markets.
The assets generally included in Level 2 fair value hierarchy are foreign exchange and interest rate derivatives and certain debt securities. Foreign exchange and interest rate derivatives are valued using corroborated market data. The liabilities generally included in this fair value hierarchy consist of foreign exchange and interest rate derivatives.
Level 3 inputs are unobservable for the asset or liability. The assets generally included in Level 3 fair value hierarchy are various investments in hedge funds and unquoted equity security investments. Contingent consideration carried at fair value is included in this category.
244
2017

(USD millions)

Level 1

Level 2

Level 3
Valued at
amortized cost

Total
Financial assets
Debt securities
303
25
328
Fund investments
34
34
Total available-for-sale marketable securities
337
25
362
Time deposits with original maturity more than 90 days
125
125
Derivative financial instruments
31
31
Accrued interest on debt securities
1
1
Total marketable securities, time deposits and derivative financial instruments
337
56
126
519
Available-for-sale financial investments
672
437
1 109
Fund investments
166
166
Contingent consideration receivables
394
394
Long-term loans and receivables from customers and finance lease, advances, security deposits
574
574
Financial investments and long-term loans
672
997
574
2 243
Associated companies at fair value through profit and loss
28
188
216
Contingent consideration receivables short-term
450
450
Financial liabilities
Contingent consideration payables
– 852
– 852
Other financial liabilities
– 72
– 72
Derivative financial instruments
– 107
– 107
Total financial liabilities at fair value
– 107
– 924
– 1 031
2016

(USD millions)

Level 1

Level 2

Level 3
Valued at
amortized cost

Total
Financial assets
Debt securities
284
22
306
Fund investments
31
31
Total available-for-sale marketable securities
315
22
337
Time deposits with original maturity more than 90 days
108
108
Derivative financial instruments
230
230
Accrued interest on debt securities
1
1
Total marketable securities, time deposits and derivative financial instruments
315
252
109
676
Available-for-sale financial investments
513
476
989
Fund investments
107
107
Contingent consideration receivables
586
586
Long-term loans and receivables from customers and finance lease, advances, security deposits
514
514
Financial investments and long-term loans
513
1 169
514
2 196
Associated companies at fair value through profit and loss
188
188
Financial liabilities
Contingent consideration payables
– 889
– 889
Other financial liabilities
– 129
– 129
Derivative financial instruments
– 116
– 116
Total financial liabilities at fair value
– 116
– 1 018
– 1 134
The analysis above includes all financial instruments including those measured at amortized cost or at cost.
245
The change in carrying values associated with Level 3 financial instruments using significant unobservable inputs during the year ended December 31 are set forth below:
2017

(USD millions)
Associated
companies at
fair value through
profit and loss


Fund
investments
Available-
for-sale
financial
investments

Contingent
consideration
receivables

Contingent
consideration
payables

Other
financial
liabilities
January 1
188
107
476
586
– 889
– 129
Fair value gains and other adjustments, including from divestments recognized in the consolidated income statement
45
32
278
362
Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement
– 34
– 45
– 193
– 37
Fair value adjustments recognized in the consolidated statement of comprehensive income
45
– 40
Purchases
37
28
113
– 238
Cash receipts and payments
– 20
106
94
Disposals
– 19
– 18
– 52
Reclassification
– 29
4
– 47
December 31
188
166
437
844
– 852
– 72
Total of fair value gains and losses recognized in the consolidated income statement for assets and liabilities held at December 31, 2017
11
0
– 13
278
169
– 37
2016

(USD millions)
Associated
companies at
fair value through
profit and loss


Fund
investments
Available-
for-sale
financial
investments

Contingent
consideration
receivables

Contingent
consideration
payables

Other
financial
liabilities
January 1
181
94
473
550
– 790
– 315
Fair value gains and other adjustments, including from divestments recognized in the consolidated income statement
26
1
51
3
Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement
– 28
– 1
– 24
– 156
Fair value adjustments recognized in the consolidated statement of comprehensive income
14
– 8
Purchases
41
5
122
– 172
Cash receipts and payments
– 15
229
183
Disposals
– 3
– 5
– 18
Reclassification
– 29
– 70
December 31
188
107
476
586
– 889
– 129
Total of fair value gains and losses recognized in the consolidated income statement for assets and liabilities held at December 31, 2016
– 2
– 1
– 23
51
– 156
3
During 2017, there were several individually non-significant transfers of available-for-sale financial investments from Level 3 to Level 1 for USD 73 million (2016: USD 75 million) mainly due to Initial Public Offerings of the invested companies.
Realized gains and losses associated with Level 3 available-for-sale marketable securities are recorded in the consolidated income statement under “Other financial income and expense” and realized gains and losses associated with Level 3 available-for-sale financial investments are recorded in the consolidated income statement under “Other income” or “Other expense”, respectively.
If the pricing parameters for the Level 3 input were to change for associated companies at fair value through profit and loss, equity securities, fund investments and available-for-sale financial investments by 10% positively or negatively, this would change the amounts recorded in the 2017 consolidated statement of comprehensive income by USD 79 million.
246
For the determination of the fair value of a contingent consideration various unobservable inputs are used. A change in these inputs might result in a significantly higher or lower fair value measurement. The inputs used are, among others, the probability of success, sales forecast and assumptions regarding the discount rate, timing and different scenarios of triggering events. The inputs are interrelated. The significance and usage of these inputs to each contingent consideration may vary due to differences in the timing and triggering events for payments or in the nature of the asset related to the contingent consideration.
If the most significant parameters for the Level 3 input were to change by 10% positively or negatively, or where the probability of success (POS) is the most significant input parameter 10% were added or deducted from the applied probability of success, for contingent consideration payables, other financial liabilities and contingent consideration receivables, this would change the amounts recorded in the 2017 consolidated income statement by USD 333 million and USD 322 million, respectively.
Nature and extent of risks arising from financial instruments
Market risk
Novartis is exposed to market risk, primarily related to foreign currency exchange rates, interest rates and the market value of the investments of liquid funds. The Group actively monitors and seeks to reduce, where it deems it appropriate to do so, fluctuations in these exposures. It is the Group’s policy and practice to enter into a variety of derivative financial instruments to manage the volatility of these exposures and to enhance the yield on the investment of liquid funds. It does not enter into any financial transactions containing a risk that cannot be quantified at the time the transaction is concluded. In addition, it does not sell short assets it does not have, or does not know it will have, in the future. The Group only sells existing assets or enters into transactions and future transactions (in the case of anticipatory hedges) that it confidently expects it will have in the future, based on past experience. In the case of liquid funds, the Group writes call options on assets it has, or writes put options on positions it wants to acquire and has the liquidity to acquire. The Group expects that any loss in value for these instruments generally would be offset by increases in the value of the underlying transactions.
Foreign currency exchange rate risk
The Group uses the US dollar as its reporting currency. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Japanese and emerging market currencies. Fluctuations in the exchange rates between the US dollar and other currencies can have a significant effect on both the Group’s results of operations, including reported sales and earnings, as well as on the reported value of our assets, liabilities and cash flows. This, in turn, may significantly affect the comparability of period-to-period results of operations.
Because our expenditures in Swiss francs are significantly higher than our revenues in Swiss francs, volatility in the value of the Swiss franc can have a significant impact on the reported value of our earnings, assets and liabilities, and the timing and extent of such volatility can be difficult to predict. In addition, there is a risk that certain countries could take other steps that could significantly impact the value of their currencies.
The Group is exposed to a potential adverse devaluation risk on its intercompany funding and total investment in certain subsidiaries operating in countries with exchange controls. The most significant foreign exchange losses (USD 0.3 billion) occurred in Venezuela in 2016. The net outstanding intercompany payable balance of Venezuela subsidiaries was not significant at December 31, 2017 and at December 31, 2016, due to reserves against the intercompany balances.
The Group manages its global currency exposure by engaging in hedging transactions where management deems appropriate. Novartis may enter into various contracts that reflect the changes in the value of foreign currency exchange rates to preserve the value of assets, commitments and anticipated transactions. Novartis also uses forward contracts and foreign currency option contracts to hedge.
Net investments in subsidiaries in foreign countries are long-term investments. Their fair value changes through movements of foreign currency exchange rates. The Group has designated a certain portion of its long-term euro-denominated straight bonds as hedges of the translation risk arising on certain of these net investments in foreign operations with euro functional currency. As of December 31, 2017, long-term financial debt with a carrying amount of EUR 1.8 billion (USD 2.2 billion) has been designated as a hedge instrument. During 2017, USD 237 million of unrealized loss was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge. The hedge remained effective since inception, and no amount was recognized in the consolidated income statement in 2017. During 2016 and 2015, the Group did not apply net investment hedge accounting.
Commodity price risk
The Group has only a very limited exposure to price risk related to anticipated purchases of certain commodities used as raw materials by the Group’s businesses. A change in those prices may alter the gross margin of a specific business, but generally by not more than 10% of the margin and thus below the Group’s risk management tolerance levels. Accordingly, the Group does not enter into significant commodity futures, forward and option contracts to manage fluctuations in prices of anticipated purchases.
247
Interest rate risk
The Group addresses its net exposure to interest rate risk mainly through the ratio of its fixed-rate financial debt to variable rate financial debt contained in its total financial debt portfolio. To manage this mix, Novartis may enter into interest rate swap agreements, in which it exchanges periodic payments based on a notional amount and agreed-upon fixed and variable interest rates.
Equity risk
The Group may purchase equities as investments of its liquid funds. As a policy, it limits its holdings in an unrelated company to less than 5% of its liquid funds. Potential investments are thoroughly analyzed. Call options are written on equities that the Group owns, and put options are written on equities that the Group wants to buy and for which cash is available.
Credit risk
Credit risks arise from the possibility that customers may not be able to settle their obligations as agreed. To manage this risk, the Group periodically assesses country and customer credit risk, assigns individual credit limits, and takes actions to mitigate credit risk where appropriate.
The Group’s largest customer accounted for approximately 17% of net sales, and the second-largest and third-largest customers accounted for 12% and 7% of net sales, respectively (2016: 16%, 12% and 6%, respectively; 2015: 14%, 11% and 5%, respectively). No other customer accounted for 5% or more of net sales in either year.
The highest amounts of trade receivables outstanding were for these same three customers and amounted to 14%, 9% and 5%, respectively, of the Group’s trade receivables at December 31, 2017 (2016: 14%, 9% and 6%, respectively). There is no other significant concentration of customer credit risk.
Counterparty risk
Counterparty risk encompasses issuer risk on marketable securities and money market instruments, credit risk on cash, time deposits and derivatives, as well as settlement risk for different instruments. Issuer risk is reduced by only buying securities that are at least A- rated. Counterparty credit risk and settlement risk are reduced by a policy of entering into transactions with counterparties (banks or financial institutions) that feature a strong credit rating. Exposure to these risks is closely monitored and kept within predetermined parameters. The limits are regularly assessed and determined based upon credit analysis, including financial statement and capital adequacy ratio reviews. In addition, reverse repurchasing agreements are contracted and Novartis has entered into credit support agreements with various banks for derivative transactions.
The Group’s cash and cash equivalents are held with major regulated financial institutions, the three largest ones hold approximately 20.2%, 15.0% and 12.7%, respectively (2016: 16.5%, 6.9% and 6.7%, respectively).
The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk.
Liquidity risk
Liquidity risk is defined as the risk that the Group could not be able to settle or meet its obligations on time or at a reasonable price. Group Treasury is responsible for liquidity, funding and settlement management. In addition, liquidity and funding risks, and related processes and policies, are overseen by management. Novartis manages its liquidity risk on a consolidated basis according to business needs, tax, capital or regulatory considerations, if applicable, through numerous sources of financing in order to maintain flexibility. Management monitors the Group’s net debt or liquidity position through rolling forecasts on the basis of expected cash flows.
Novartis has two United States commercial paper programs under which it can issue up to USD 9.0 billion in the aggregate of unsecured commercial paper notes. Novartis also has a Japanese commercial paper program under which it can issue up to JPY 150 billion (approximately USD 1.3 billion) of unsecured commercial paper notes. Commercial paper notes totaling USD 2.3 billion under these three programs were outstanding as per December 31, 2017 (2016: USD 3.2 billion). Novartis further has a committed credit facility of USD 6.0 billion, entered into on September 23, 2015. This credit facility is provided by a syndicate of banks and is intended to be used as a backstop for the United States commercial paper programs. It matures in September 2020 and was undrawn as per December 31, 2017 and December 31, 2016.
248
The following table sets forth how management monitors net debt or liquidity based on details of the remaining contractual maturities of current financial assets and liabilities excluding trade receivables and payables as well as contingent considerations at December 31, 2017 and December 31, 2016:
2017

(USD millions)


Due within
one month
Due later than
one month
but less than
three months
Due later than
three months
but less than
one year
Due later than
one year
but less than
five years


Due after
five years



Total
Current assets
Marketable securities and time deposits
71
72
105
181
58
487
Commodities
106
106
Derivative financial instruments and accrued interest
7
19
6
32
Cash and cash equivalents
4 260
4 600
8 860
Total current financial assets
4 338
4 691
111
181
164
9 485
Non-current liabilities
Financial debt
– 9 849
– 13 375
– 23 224
Financial debt - undiscounted
– 9 893
– 13 519
– 23 412
Total non-current financial debt
– 9 849
– 13 375
– 23 224
Current liabilities
Financial debt
– 4 576
– 169
– 456
– 5 201
Financial debt - undiscounted
– 4 576
– 169
– 456
– 5 201
Derivative financial instruments
– 31
– 48
– 28
– 107
Total current financial debt
– 4 607
– 217
– 484
– 5 308
Net debt
– 269
4 474
– 373
– 9 668
– 13 211
– 19 047
2016

(USD millions)


Due within
one month
Due later than
one month
but less than
three months
Due later than
three months
but less than
one year
Due later than
one year
but less than
five years


Due after
five years



Total
Current assets
Marketable securities and time deposits
32
126
110
124
53
445
Commodities
94
94
Derivative financial instruments and accrued interest
38
102
91
231
Cash and cash equivalents
5 907
1 100
7 007
Total current financial assets
5 977
1 328
201
124
147
7 777
Non-current liabilities
Financial debt
– 5 141
– 12 756
– 17 897
Financial debt - undiscounted
– 5 155
– 12 901
– 18 056
Total non-current financial debt
– 5 141
– 12 756
– 17 897
Current liabilities
Financial debt
– 5 099
– 250
– 440
– 5 789
Financial debt - undiscounted
– 5 099
– 250
– 440
– 5 789
Derivative financial instruments
– 15
– 72
– 29
– 116
Total current financial debt
– 5 114
– 322
– 469
– 5 905
Net debt
863
1 006
– 268
– 5 017
– 12 609
– 16 025
The consolidated balance sheet amounts of financial liabilities included in the above analysis are not materially different to the contractual amounts due on maturity. The positive and negative fair values on derivative financial instruments represent the net contractual amounts to be exchanged at maturity.
249
The Group’s contractual undiscounted potential cash flows from derivative financial instruments to be settled on a gross basis are as follows:
2017

(USD millions)


Due within
one month
Due later than
one month
but less than
three months
Due later than
three months
but less than
one year






Total
Derivative financial instruments and accrued interest on derivative financial instruments
Potential outflows in various currencies - from financial derivative liabilities
– 953
– 972
– 2 824
– 4 749
Potential inflows in various currencies - from financial derivative assets
928
948
2 778
4 654
2016

(USD millions)


Due within
one month
Due later than
one month
but less than
three months
Due later than
three months
but less than
one year






Total
Derivative financial instruments and accrued interest on derivative financial instruments
Potential outflows in various currencies - from financial derivative liabilities
– 1 087
– 1 246
– 2 027
– 4 360
Potential inflows in various currencies - from financial derivative assets
1 109
1 287
2 051
4 447
Other contractual liabilities that are not part of management’s monitoring of the net debt or liquidity consist of the following items:
2017

(USD millions)
Due later than
one month
but less than
three months
Due later than
three months
but less than
one year
Due later than
one year
but less than
five years


Due after
five years



Total
Contractual interest on non-current liabilities
– 113
– 507
– 1 765
– 3 859
– 6 244
Trade payables
– 5 169
– 5 169
2016

(USD millions)
Due later than
one month
but less than
three months
Due later than
three months
but less than
one year
Due later than
one year
but less than
five years


Due after
five years



Total
Contractual interest on non-current liabilities
– 104
– 433
– 1 694
– 4 015
– 6 246
Trade payables
– 4 873
– 4 873
Capital risk management
Novartis strives to maintain a strong credit rating. In managing its capital, Novartis focuses on maintaining a strong balance sheet. Moody’s rated the Group as Aa3 for long-term maturities and as P-1 for short-term maturities and Standard & Poor’s had a rating of AA- for long-term maturities and A-1+ for short-term maturities. Fitch had a long-term rating of AA and a short-term rating of F1+.
The debt/equity ratio increased to 0.38:1 at December 31, 2017, compared to 0.32:1 at the beginning of the year.
Value at risk
The Group uses a value at risk (VAR) computation to estimate the potential ten-day loss in the fair value of its financial instruments.
A ten-day period is used because of an assumption that not all positions could be undone in one day given the size of the positions. The VAR computation includes all financial assets and financial liabilities as set forth in the table on page 243, except trade receivables, income tax receivables and other current assets, contingent considerations, finance lease obligations, long-term loans and receivables from customers and finance lease, advances and security deposits and trade payables. 
250
The VAR estimates are made assuming normal market conditions, using a 95% confidence interval. The Group uses a “Delta Normal” model to determine the observed interrelationships between movements in interest rates, stock markets and various currencies. These inter-relationships are determined by observing interest rate, stock market movements and forward foreign currency rate movements over a sixty-day period for the calculation of VAR amounts.
The estimated potential ten-day loss in the fair value of the Group’s foreign currency positions (including foreign exchange translation risk), the estimated potential ten-day loss of its equity holdings, and the estimated potential ten-day loss in fair value of its interest rate sensitive instruments (primarily financial debt and investments of liquid funds under normal market conditions) as calculated in the VAR model are the following:
(USD millions)
2017
2016
All financial instruments
498
541
Analyzed by components:
Instruments sensitive to foreign currency exchange rates
184
222
Instruments sensitive to equity market movements
27
26
Instruments sensitive to interest rates
242
328
The average, high, and low VAR amounts are as follows:
2017
(USD millions)
Average
High
Low
All financial instruments
521
560
466
Analyzed by components:
Instruments sensitive to foreign currency exchange rates
277
352
184
Instruments sensitive to equity market movements
28
35
21
Instruments sensitive to interest rates
282
338
219
2016
(USD millions)
Average
High
Low
All financial instruments
402
541
316
Analyzed by components:
Instruments sensitive to foreign currency exchange rates
203
245
147
Instruments sensitive to equity market movements
50
99
26
Instruments sensitive to interest rates
308
407
234
The VAR computation is a risk analysis tool designed to statistically estimate the potential ten-day loss from adverse movements in foreign currency exchange rates, equity prices and interest rates under normal market conditions. The computation does not purport to represent actual losses in fair value on earnings to be incurred by the Group, nor does it consider the effect of favorable changes in market rates. The Group cannot predict actual future movements in such market rates and it does not claim that these VAR results are indicative of future movements in such market rates or are representative of any actual impact that future changes in market rates may have on the Group’s future results of operations or financial position.
In addition to these VAR analyses, the Group uses stress testing techniques that aim to reflect a worst case scenario on the marketable securities that are monitored by Group Treasury. For these calculations, the Group uses the six-month period with the worst performance observed over the past twenty years in each category. For 2017 and 2016, the worst case loss scenario was calculated as follows:
(USD millions)
2017
2016
All financial instruments
7
6
Analyzed by components:
Instruments sensitive to foreign currency exchange rates
Instruments sensitive to equity market movements
Instruments sensitive to interest rates
7
6
In the Group’s risk analysis, Novartis considered this worst case scenario acceptable as it could reduce income, but would not endanger the solvency or investment grade credit rating of the Group.
251
29. Discontinued operations
Discontinued operations consolidated income statement segmentation
2015

(USD millions)


Vaccines

Consumer
Health1
Corporate
(including
eliminations)
Total
discontinued
operations
Net sales to third parties of discontinued operations
145
456
601
Sales to continuing segments
18
1
19
Net sales of discontinued operations
163
457
620
Other revenues
18
5
23
Cost of goods sold
– 192
– 184
– 376
Gross profit of discontinued operations
– 11
278
267
Marketing & Sales
– 57
– 187
– 244
Research & Development
– 151
– 30
– 181
General & Administration
– 26
– 32
– 58
Other income
2 870
10 558
– 8
13 420
Other expense
– 57
– 14
– 656
– 727
Operating income of discontinued operations
2 568
10 573
– 664
12 477
Income from associated companies
2
2
Income before taxes of discontinued operations
12 479
Taxes
– 1 713
Net income of discontinued operations
10 766
 1  Consumer Health is the aggregation of the former OTC and Animal Health divisions.
The following are included in net income from discontinued operations:
(USD millions)
2015
Impairment charges on property, plant & equipment, net
83
Additions to restructuring provisions
– 1
Equity-based compensation of Novartis equity plans
– 65
30. Events subsequent to the December 31, 2017 consolidated balance sheet date
Significant transaction closed in January 2018
For significant transaction entered into in 2017 and closed in 2018, see Note 2.
Dividend proposal for 2017 and approval of the Group’s 2017 consolidated financial statements
On January 23, 2018, the Novartis AG Board of Directors proposed the acceptance of the 2017 consolidated financial statements of the Novartis Group for approval by the Annual General Meeting on March 2, 2018. Furthermore, also on January 23, 2018, the Board proposed a dividend of CHF 2.80 per share to be approved at the Annual General Meeting on March 2, 2018. If approved, total dividend payments would amount to approximately USD 6.7 billion (2016: USD 6.5 billion) using the CHF/USD December 31, 2017 exchange rate.
252
31. Principal Group subsidiaries and associated companies
The following table lists the principal subsidiaries controlled by Novartis and associated companies in which Novartis is deemed to have significant influence. It includes all subsidiaries and associated companies with Total assets or Net sales to third parties in excess of USD 25 million. The equity interest percentage shown in the table also represents the share in voting rights in those entities, except where explicitly noted.

As at December 31, 2017
Share
capital 1
Equity
interest
Algeria
Société par actions SANDOZ
Algiers
DZD
650.0
m
100%
Argentina
Novartis Argentina S.A.
Buenos Aires
ARS
906.1
m
100%
Alcon Laboratorios S.A.
Buenos Aires
ARS
83.9
m
100%
Australia
Novartis Australia Pty Ltd
North Ryde, NSW
AUD
2
100%
Novartis Pharmaceuticals Australia Pty Ltd
North Ryde, NSW
AUD
3.8
m
100%
Sandoz Pty Ltd
North Ryde, NSW
AUD
11.6
m
100%
Alcon Laboratories (Australia) Pty Ltd
Frenchs Forest, NSW
AUD
2.6
m
100%
Austria
Novartis Austria GmbH
Vienna
EUR
1.0
m
100%
Novartis Pharma GmbH
Vienna
EUR
1.1
m
100%
Sandoz GmbH
Kundl
EUR
32.7
m
100%
EBEWE Pharma Ges.m.b.H Nfg. KG
Unterach am Attersee
EUR
1.0
m
100%
Bangladesh
Novartis (Bangladesh) Limited
Gazipur
BDT
162.5
m
60%
Belgium
N.V. Novartis Pharma S.A.
Vilvoorde
EUR
7.1
m
100%
N.V. Sandoz S.A.
Vilvoorde
EUR
19.2
m
100%
S.A. Alcon-Couvreur N.V.
Puurs
EUR
110.6
m
100%
N.V. Alcon S.A.
Vilvoorde
EUR
141 856
100%
Bermuda
Novartis Investment Ltd.
Hamilton
USD
12 000
100%
Novartis Securities Investment Ltd.
Hamilton
CHF
30 000
100%
Novartis Finance Services Ltd.
Hamilton
CHF
20 000
100%
Novartis B2 Ltd.
Hamilton
USD
12 000
100%
Novartis B3 Ltd.
Hamilton
USD
106 400
100%
Triangle International Reinsurance Limited
Hamilton
CHF
1.0
m
100%
Trinity River Insurance Co Ltd.
Hamilton
USD
370 000
100%
Brazil
Novartis Biociências S.A.
São Paulo
BRL
265.0
m
100%
Sandoz do Brasil Indústria Farmacêutica Ltda.
Cambé, PR
BRL
190.0
m
100%
Canada
Novartis Pharmaceuticals Canada Inc.
Dorval, Quebec
CAD
13.0
m
100%
Sandoz Canada Inc.
Boucherville, Quebec
CAD
80.8
m
100%
Alcon Canada Inc.
Mississauga, Ontario
CAD
2 500
100%
CIBA Vision Canada Inc.
Mississauga, Ontario
CAD
82 886
100%
Chile
Novartis Chile S.A.
Santiago de Chile
CLP
2.0
bn
100%
Alcon Laboratorios Chile Ltd.
Santiago de Chile
CLP
2.0
bn
100%
China
Beijing Novartis Pharma Co., Ltd.
Beijing
USD
30.0
m
100%
Novartis Pharmaceuticals (HK) Limited
Hong Kong
HKD
200
100%
China Novartis Institutes for BioMedical Research Co., Ltd.
Shanghai
USD
320.0
m
100%
Suzhou Novartis Pharma Technology Co., Ltd.
Changshu
USD
103.4
m
100%
Shanghai Novartis Trading Ltd.
Shanghai
USD
3.2
m
100%
Sandoz (China) Pharmaceutical Co., Ltd.
Zhongshan
USD
36.5
m
100%
Alcon Hong Kong Limited
Hong Kong
HKD
77 000
100%
Alcon (China) Ophthalmic Product Co., Ltd.
Beijing
USD
60.0
m
100%
Colombia
Novartis de Colombia S.A.
Santafé de Bogotá
COP
7.9
bn
100%
Laboratorios Alcon de Colombia S.A.
Santafé de Bogotá
COP
20.9
m
100%
Croatia
Sandoz d.o.o. farmaceutska industrija
Zagreb
HRK
25.6
m
100%
Czech Republic
Novartis s.r.o.
Prague
CZK
51.5
m
100%
Sandoz s.r.o.
Prague
CZK
44.7
m
100%
Alcon Pharmaceuticals (Czech Republic) s.r.o.
Prague
CZK
31.0
m
100%
Denmark
Novartis Healthcare A/S
Copenhagen
DKK
14.0
m
100%
Sandoz A/S
Copenhagen
DKK
12.0
m
100%
Alcon Nordic A/S
Copenhagen
DKK
0.5
m
100%
Ecuador
Novartis Ecuador S.A.
Quito
USD
4.0
m
100%
Egypt
Novartis Pharma S.A.E.
Cairo
EGP
193.8
m
99.77%
Sandoz Egypt Pharma S.A.E.
New Cairo City
EGP
250 000
100%
Finland
Novartis Finland Oy
Espoo
EUR
459 000
100%

As at December 31, 2017
Share
capital 1
Equity
interest
France
Novartis Groupe France S.A.
Rueil-Malmaison
EUR
103.0
m
100%
Novartis Pharma S.A.S.
Rueil-Malmaison
EUR
43.4
m
100%
Sandoz S.A.S.
Levallois-Perret
EUR
5.4
m
100%
Laboratoires Alcon S.A.S.
Rueil-Malmaison
EUR
12.9
m
100%
Germany
Novartis Deutschland GmbH
Wehr
EUR
155.5
m
100%
Novartis Business Services GmbH
Wehr
EUR
25 000
100%
Novartis Pharma GmbH
Nuremberg
EUR
25.6
m
100%
Novartis Pharma Produktions GmbH
Wehr
EUR
2.0
m
100%
Sandoz International GmbH
Holzkirchen
EUR
100 000
100%
1 A Pharma GmbH
Oberhaching
EUR
26 000
100%
HEXAL AG
Holzkirchen
EUR
93.7
m
100%
Salutas Pharma GmbH
Barleben
EUR
42.1
m
100%
Aeropharm GmbH
Rudolstadt
EUR
26 000
100%
Alcon Pharma GmbH
Freiburg im Breisgau
EUR
512 000
100%
CIBA Vision GmbH
Grosswallstadt
EUR
15.4
m
100%
WaveLight GmbH
Erlangen
EUR
6.6
m
100%
Gibraltar
Novista Insurance Limited
Gibraltar City
CHF
130.0
m
100%
Greece
Novartis (Hellas) S.A.C.I.
Metamorphosis/Athens
EUR
23.4
m
100%
Alcon Laboratories Hellas- Commercial and Industrial S.A.
Maroussi, Athens
EUR
5.7
m
100%
Hungary
Novartis Hungary Healthcare Limited Liability Company
Budapest
HUF
545.6
m
100%
Sandoz Hungary Limited Liability Company
Budapest
HUF
883.0
m
100%
India
Novartis India Limited
Mumbai
INR
140.7
m
73.4%
Novartis Healthcare Private Limited
Mumbai
INR
60.0
m
100%
Sandoz Private Limited
Mumbai
INR
32.0
m
100%
Alcon Laboratories (India) Private Limited
Bangalore
INR
1.1
bn
100%
Indonesia
PT. Novartis Indonesia
Jakarta
IDR
7.7
bn
100%
PT. CIBA Vision Batam
Batam
IDR
11.9
bn
100%
Ireland
Novartis Ireland Limited
Dublin
EUR
25 000
100%
Novartis Ringaskiddy Limited
Ringaskiddy, County Cork
EUR
2.0
m
100%
Alcon Laboratories Ireland Limited
Cork City
EUR
541 251
100%
Israel
Novartis Israel Ltd.
Petach Tikva
ILS
1 000
100%
Optonol Ltd.
Neve-Ilan
ILS
752 545
100%
Italy
Novartis Farma S.p.A.
Origgio
EUR
18.2
m
100%
Sandoz S.p.A.
Origgio
EUR
1.7
m
100%
Sandoz Industrial Products S.p.A.
Rovereto
EUR
2.6
m
100%
Alcon Italia S.p.A.
Milan
EUR
3.7
m
100%
Japan
Novartis Holding Japan K.K.
Tokyo
JPY
10.0
m
100%
Novartis Pharma K.K.
Tokyo
JPY
6.0
bn
100%
Ciba-Geigy Japan Limited
Tokyo
JPY
8.5
m
100%
Sandoz K.K.
Tokyo
JPY
100.0
m
100%
Alcon Japan Ltd.
Tokyo
JPY
500.0
m
100%
Luxembourg
Novartis Investments S.à r.l.
Luxembourg-Ville
USD
100.0
m
100%
Novartis Finance S.A.
Luxembourg-Ville
USD
100 000
100%
Malaysia
Novartis Corporation (Malaysia) Sdn. Bhd.
Kuala Lumpur
MYR
3.3
m
100%
Alcon Laboratories (Malaysia) Sdn. Bhd.
Petaling Jaya
MYR
1.0
m
100%
CIBA Vision Johor Sdn. Bhd.
Kuala Lumpur
MYR
10.0
m
100%
Mexico
Novartis Farmacéutica, S.A. de C.V.
Mexico City
MXN
205.0
m
100%
Sandoz, S.A. de C.V.
Mexico City
MXN
468.2
m
100%
Alcon Laboratorios, S.A. de C.V.
Mexico City
MXN
5.9
m
100%
Morocco
Novartis Pharma Maroc SA
Casablanca
MAD
80.0
m
100%
Netherlands
Novartis Netherlands B.V.
Arnhem
EUR
1.4
m
100%
Novartis Pharma B.V.
Arnhem
EUR
4.5
m
100%
Sandoz B.V.
Almere
EUR
907 560
100%
Alcon Nederland B.V.
Arnhem
EUR
18 151
100%
New Zealand
Novartis New Zealand Ltd
Auckland
NZD
820 000
100%
253

As at December 31, 2017
Share
capital 1
Equity
interest
Norway
Novartis Norge AS
Oslo
NOK
1.5
m
100%
Pakistan
Novartis Pharma (Pakistan) Limited
Karachi
PKR
3.9
bn
99.99%
Panama
Novartis Pharma (Logistics), Inc.
Panama City
USD
10 000
100%
Alcon Centroamerica S.A.
Panama City
PAB
1 000
100%
Philippines
Novartis Healthcare Philippines, Inc.
Manila
PHP
298.8
m
100%
Sandoz Philippines Corporation
Manila
PHP
30.0
m
100%
Poland
Novartis Poland Sp. z o.o.
Warszawa
PLN
44.2
m
100%
Sandoz Polska Sp. z o.o.
Warszawa
PLN
25.6
m
100%
Lek S.A.
Strykow
PLN
11.4
m
100%
Alcon Polska Sp. z o.o.
Warszawa
PLN
750 000
100%
Portugal
Novartis Portugal SGPS Lda.
Porto Salvo
EUR
500 000
100%
Novartis Farma - Produtos Farmacêuticos S.A.
Porto Salvo
EUR
2.4
m
100%
Sandoz Farmacêutica Lda.
Porto Salvo
EUR
499 900
100%
Alcon Portugal-Produtos e Equipamentos Oftalmológicos Lda.
Porto Salvo
EUR
4.5
m
100%
Romania
Novartis Pharma Services Romania S.R.L.
Bucharest
RON
3.0
m
100%
Sandoz S.R.L.
Targu-Mures
RON
105.2
m
100%
Alcon Romania S.R.L.
Bucharest
RON
10.8
m
100%
Russian Federation
Novartis Pharma LLC
Moscow
RUB
20.0
m
100%
Novartis Neva LLC
St. Petersburg
RUB
1.3
bn
100%
ZAO Sandoz
Moscow
RUB
57.4
m
100%
Alcon Farmacevtika LLC
Moscow
RUB
44.1
m
100%
Saudi Arabia
Saudi Pharmaceutical Distribution Co. Ltd.
Riyadh
SAR
26.8
m
75%
Singapore
Novartis (Singapore) Pte Ltd.
Singapore
SGD
100 000
100%
Novartis Singapore Pharmaceutical Manufacturing Pte Ltd
Singapore
SGD
45.0
m
100%
Novartis Asia Pacific Pharmaceuticals Pte Ltd
Singapore
SGD
39.0
m
100%
Novartis Institute for Tropical Diseases Pte Ltd
Singapore
SGD
2 004
100%
Alcon Pte Ltd
Singapore
SGD
164 000
100%
Alcon Singapore Manufacturing Pte Ltd
Singapore
SGD
101 000
100%
CIBA Vision Asian Manufacturing and Logistics Pte Ltd.
Singapore
SGD
1.0
m
100%
Slovakia
Novartis Slovakia s.r.o.
Bratislava
EUR
2.0
m
100%
Slovenia
Lek Pharmaceuticals d.d.
Ljubjana
EUR
48.4
m
100%
Sandoz Pharmaceuticals d.d.
Ljubjana
EUR
1.5
m
100%
South Africa
Novartis South Africa (Pty) Ltd
Midrand
ZAR
86.3
m
100%
Sandoz South Africa (Pty) Ltd
Kempton Park
ZAR
3.0
m
100%
Alcon Laboratories (South Africa) (Pty) Ltd.
Midrand
ZAR
201 820
100%
South Korea
Novartis Korea Ltd.
Seoul
KRW
24.5
bn
98.55%
Sandoz Korea Ltd.
Seoul
KRW
17.8
bn
100%
Alcon Korea Ltd.
Seoul
KRW
33.8
bn
100%
Spain
Novartis Farmacéutica S.A.
Barcelona
EUR
63.0
m
100%
Sandoz Farmacéutica S.A.
Madrid
EUR
270 450
100%
Sandoz Industrial Products S.A.
Les Franqueses del Vallés / Barcelona
EUR
9.3
m
100%
Alcon Cusi S.A.
Barcelona
EUR
11.6
m
100%
Abadia Retuerta S.A.
Sardón de Duero/Valladolid
EUR
6.0
m
100%
Sweden
Novartis Sverige AB
Täby / Stockholm
SEK
5.0
m
100%
Switzerland
Novartis International AG
Basel
CHF
10.0
m
100%
Novartis Holding AG
Basel
CHF
100.2
m
100%
Novartis International Pharmaceutical Investment AG
Basel
CHF
100 000
100%
Novartis Bioventures AG
Basel
CHF
100 000
100%
Novartis Forschungsstiftung
Basel
--
--
100%
Novartis Stiftung für Kaderausbildung
Basel
--
--
100%
Novartis Mitarbeiterbeteiligungsstiftung
Basel
--
--
100%
Novartis Stiftung für Mensch und Umwelt
Basel
--
--
100%
Stiftung der Novartis AG für Erziehung, Ausbildung und Bildung
Basel
--
--
100%
Novartis Pharma AG
Basel
CHF
350.0
m
100%
Novartis International Pharmaceutical AG
Basel
CHF
100 000
100%
Novartis Pharma Services AG
Basel
CHF
20.0
m
100%
Novartis Pharma Schweizerhalle AG
Muttenz
CHF
18.9
m
100%
Novartis Pharma Stein AG
Stein
CHF
251 000
100%
Novartis Pharma Schweiz AG
Risch
CHF
5.0
m
100%
Sandoz AG
Basel
CHF
5.0
m
100%
Sandoz Pharmaceuticals AG
Risch
CHF
100 000
100%
Alcon Switzerland SA
Risch
CHF
100 000
100%
Alcon Pharmaceuticals Ltd.
Fribourg
CHF
200 000
100%
Roche Holding AG
Basel
CHF
160.0
m
33/6 2

As at December 31, 2017
Share
capital 1
Equity
interest
Taiwan
Novartis (Taiwan) Co., Ltd.
Taipei
TWD
170.0
m
100%
Thailand
Novartis (Thailand) Limited
Bangkok
THB
302.0
m
100%
Alcon Laboratories (Thailand) Limited
Bangkok
THB
228.1
m
100%
Turkey
Novartis Saglik, Gida ve Tarim Ürünleri Sanayi ve Ticaret A.S.
Istanbul
TRY
98.0
m
100%
Farmanova Saglik Hizmetleri Ltd. Sti.
Istanbul
TRY
6.7
m
100%
Sandoz Ilaç Sanayi ve Ticaret A.S.
Istanbul
TRY
165.2
m
99.99%
Sandoz Syntek Ilaç Hammaddeleri Sanayi ve Ticaret A.S.
Istanbul
TRY
46.0
m
100%
Sandoz Grup Saglik Ürünleri Ilaçlari Sanayi ve Ticaret A.S.
Gebze - Kocaeli
TRY
50.0
m
100%
Alcon Laboratuvarlari Ticaret A.S.
Istanbul
TRY
25.2
m
100%
United Arab Emirates
Novartis Middle East FZE
Dubai
AED
7.0
m
100%
United Kingdom
Novartis UK Limited
Frimley/Camberley
GBP
25.5
m
100%
Novartis Pharmaceuticals UK Limited
Frimley/Camberley
GBP
5.4
m
100%
Novartis Grimsby Limited
Frimley/Camberley
GBP
250.0
m
100%
Ziarco Group Limited
Frimley/Camberley
GBP
3 904
100%
Sandoz Limited
Frimley/Camberley
GBP
2.0
m
100%
Alcon Eye Care UK Limited
Frimley/Camberley
GBP
550 000
100%
Glaxosmithkline Consumer Healthcare Holdings Limited
Brentford, Middlesex
GBP
100 000
36.5%
United States of America
Novartis Corporation
East Hanover, NJ
USD
72.2
m
100%
Novartis Finance Corporation
New York, NY
USD
1 000
100%
Novartis Capital Corporation
New York, NY
USD
1
100%
Novartis Services, Inc.
East Hanover, NJ
USD
1
100%
Novartis US Foundation
New York, NY
--
--
100%
Novartis Pharmaceuticals Corporation
East Hanover, NJ
USD
5.2
m
100%
Novartis Institutes for BioMedical Research, Inc.
Cambridge, MA
USD
1
100%
Corthera, Inc.
San Mateo, CA
USD
1
100%
CoStim Pharmaceuticals Inc.
Cambridge, MA
USD
1
100%
Encore Vision, Inc.
New York, NY
USD
1
100%
Navigate BioPharma Services, Inc.
Wilmington, NC
USD
100
100%
Reprixys Pharmaceuticals Corporation
Oklahoma City, OK
USD
1
100%
Spinifex Pharmaceuticals, Inc.
Wilmington, NC
USD
1
100%
Novartis Institute for Functional Genomics, Inc.
San Diego, CA
USD
1 000
100%
Sandoz Inc.
Princeton, NJ
USD
25 000
100%
Fougera Pharmaceuticals Inc.
Melville, NY
USD
1
100%
Eon Labs, Inc.
Princeton, NJ
USD
1
100%
Alcon Laboratories, Inc.
Fort Worth, TX
USD
1 000
100%
Alcon Refractivehorizons, LLC
Fort Worth, TX
USD
10
100%
Alcon Research, Ltd.
Fort Worth, TX
USD
12.5
100%
Alcon Lensx, Inc.
Aliso Viejo, CA
USD
1
100%
Alcon Laboratories Holding Corporation
Fort Worth, TX
USD
10
100%
Novartis Vaccines and Diagnostics, Inc.
Cambridge, MA
USD
3
100%
ClarVista Medical, Inc.
Aliso Viejo, CA
USD
1
100%
Transcend Medical, Inc.
Menlo Park, CA
USD
1
100%
Venezuela
Novartis de Venezuela, S.A.
Caracas
VEF
1.4
m
100%
Alcon Pharmaceutical, C.A.
Caracas
VEF
5.5
m
100%
In addition, the Group is represented by subsidiaries and associated companies in the following countries: Bosnia/Herzegovina, Bulgaria, Dominican Republic, Guatemala, Kenya, Latvia, the Former Yugoslav Republic of Macedonia, Nigeria, Peru, Puerto Rico, Ukraine and Uruguay
 1  Share capital may not reflect the taxable share capital and does not include any paid-in surplus
 2  Approximately 33% of voting shares; approximately 6% of total net income and equity attributable to Novartis
m = million; bn = billion
254
EX-101.CAL 3 nvs-20171231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 4 nvs-20171231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.INS 5 nvs-20171231.xml XBRL INSTANCE DOCUMENT 0001114448 2017-12-31 0001114448 ifrs-full:CountryOfDomicileMember 2017-01-01 2017-12-31 0001114448 ifrs-full:CountryOfDomicileMember 2016-01-01 2016-12-31 0001114448 ifrs-full:CountryOfDomicileMember 2015-01-01 2015-12-31 0001114448 ifrs-full:ForeignCountriesMember 2017-01-01 2017-12-31 0001114448 ifrs-full:ForeignCountriesMember 2016-01-01 2016-12-31 0001114448 ifrs-full:ForeignCountriesMember 2015-01-01 2015-12-31 0001114448 2015-01-01 2015-12-31 0001114448 2017-01-01 2017-12-31 0001114448 2016-01-01 2016-12-31 0001114448 ifrs-full:PropertyPlantAndEquipmentMember 2017-01-01 2017-12-31 0001114448 ifrs-full:IntangibleAssetsAndGoodwillMember 2017-01-01 2017-12-31 0001114448 nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember 2017-01-01 2017-12-31 0001114448 nvs:InventoriesMember 2017-01-01 2017-12-31 0001114448 nvs:TaxLossCarryforwardsMember 2017-01-01 2017-12-31 0001114448 nvs:OtherAssetsProvisionsAccrualsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:PropertyPlantAndEquipmentMember 2017-12-31 0001114448 ifrs-full:IntangibleAssetsAndGoodwillMember 2017-12-31 0001114448 nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember 2017-12-31 0001114448 nvs:InventoriesMember 2017-12-31 0001114448 nvs:TaxLossCarryforwardsMember 2017-12-31 0001114448 nvs:OtherAssetsProvisionsAccrualsMember 2017-12-31 0001114448 ifrs-full:PropertyPlantAndEquipmentMember 2015-12-31 0001114448 ifrs-full:IntangibleAssetsAndGoodwillMember 2015-12-31 0001114448 nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember 2015-12-31 0001114448 nvs:InventoriesMember 2015-12-31 0001114448 nvs:TaxLossCarryforwardsMember 2015-12-31 0001114448 nvs:OtherAssetsProvisionsAccrualsMember 2015-12-31 0001114448 2015-12-31 0001114448 ifrs-full:PropertyPlantAndEquipmentMember 2016-01-01 2016-12-31 0001114448 ifrs-full:IntangibleAssetsAndGoodwillMember 2016-01-01 2016-12-31 0001114448 nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember 2016-01-01 2016-12-31 0001114448 nvs:InventoriesMember 2016-01-01 2016-12-31 0001114448 nvs:TaxLossCarryforwardsMember 2016-01-01 2016-12-31 0001114448 nvs:OtherAssetsProvisionsAccrualsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:PropertyPlantAndEquipmentMember 2016-12-31 0001114448 ifrs-full:IntangibleAssetsAndGoodwillMember 2016-12-31 0001114448 nvs:PensionsAndOtherBenefitObligationsOfAssociatesMember 2016-12-31 0001114448 nvs:InventoriesMember 2016-12-31 0001114448 nvs:TaxLossCarryforwardsMember 2016-12-31 0001114448 nvs:OtherAssetsProvisionsAccrualsMember 2016-12-31 0001114448 2016-12-31 0001114448 nvs:InvestmentsInSubsidiariesMember 2017-12-31 0001114448 nvs:InvestmentsInSubsidiariesMember 2016-12-31 0001114448 nvs:GoodwillFromAcquisitionsMember 2017-12-31 0001114448 nvs:GoodwillFromAcquisitionsMember 2016-12-31 0001114448 nvs:NotCapitalizedMember nvs:OneYearMember 2017-01-01 2017-12-31 0001114448 nvs:CapitalizedMember nvs:OneYearMember 2017-01-01 2017-12-31 0001114448 nvs:OneYearMember 2017-01-01 2017-12-31 0001114448 nvs:NotCapitalizedMember nvs:TwoYearsMember 2017-01-01 2017-12-31 0001114448 nvs:CapitalizedMember nvs:TwoYearsMember 2017-01-01 2017-12-31 0001114448 nvs:TwoYearsMember 2017-01-01 2017-12-31 0001114448 nvs:NotCapitalizedMember nvs:ThreeYearsMember 2017-01-01 2017-12-31 0001114448 nvs:CapitalizedMember nvs:ThreeYearsMember 2017-01-01 2017-12-31 0001114448 nvs:ThreeYearsMember 2017-01-01 2017-12-31 0001114448 nvs:NotCapitalizedMember nvs:FourYearsMember 2017-01-01 2017-12-31 0001114448 nvs:CapitalizedMember nvs:FourYearsMember 2017-01-01 2017-12-31 0001114448 nvs:FourYearsMember 2017-01-01 2017-12-31 0001114448 nvs:NotCapitalizedMember nvs:FiveYearsMember 2017-01-01 2017-12-31 0001114448 nvs:CapitalizedMember nvs:FiveYearsMember 2017-01-01 2017-12-31 0001114448 nvs:FiveYearsMember 2017-01-01 2017-12-31 0001114448 nvs:NotCapitalizedMember nvs:MoreThanFiveYearsMember 2017-01-01 2017-12-31 0001114448 nvs:CapitalizedMember nvs:MoreThanFiveYearsMember 2017-01-01 2017-12-31 0001114448 nvs:MoreThanFiveYearsMember 2017-01-01 2017-12-31 0001114448 nvs:NotCapitalizedMember 2017-01-01 2017-12-31 0001114448 nvs:CapitalizedMember 2017-01-01 2017-12-31 0001114448 nvs:NotCapitalizedMember nvs:OneYearMember 2016-01-01 2016-12-31 0001114448 nvs:CapitalizedMember nvs:OneYearMember 2016-01-01 2016-12-31 0001114448 nvs:OneYearMember 2016-01-01 2016-12-31 0001114448 nvs:NotCapitalizedMember nvs:TwoYearsMember 2016-01-01 2016-12-31 0001114448 nvs:CapitalizedMember nvs:TwoYearsMember 2016-01-01 2016-12-31 0001114448 nvs:TwoYearsMember 2016-01-01 2016-12-31 0001114448 nvs:NotCapitalizedMember nvs:ThreeYearsMember 2016-01-01 2016-12-31 0001114448 nvs:CapitalizedMember nvs:ThreeYearsMember 2016-01-01 2016-12-31 0001114448 nvs:ThreeYearsMember 2016-01-01 2016-12-31 0001114448 nvs:NotCapitalizedMember nvs:FourYearsMember 2016-01-01 2016-12-31 0001114448 nvs:CapitalizedMember nvs:FourYearsMember 2016-01-01 2016-12-31 0001114448 nvs:FourYearsMember 2016-01-01 2016-12-31 0001114448 nvs:NotCapitalizedMember nvs:FiveYearsMember 2016-01-01 2016-12-31 0001114448 nvs:CapitalizedMember nvs:FiveYearsMember 2016-01-01 2016-12-31 0001114448 nvs:FiveYearsMember 2016-01-01 2016-12-31 0001114448 nvs:NotCapitalizedMember nvs:MoreThanFiveYearsMember 2016-01-01 2016-12-31 0001114448 nvs:CapitalizedMember nvs:MoreThanFiveYearsMember 2016-01-01 2016-12-31 0001114448 nvs:MoreThanFiveYearsMember 2016-01-01 2016-12-31 0001114448 nvs:NotCapitalizedMember 2016-01-01 2016-12-31 0001114448 nvs:CapitalizedMember 2016-01-01 2016-12-31 0001114448 nvs:IncomeStatementMember 2017-01-01 2017-12-31 0001114448 ifrs-full:EquityMember 2017-01-01 2017-12-31 0001114448 ifrs-full:EquityMember 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:GleevecGlivecMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:GleevecGlivecMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:GleevecGlivecMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:TasignaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:TasignaMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:TasignaMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:SandostatinMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:SandostatinMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:SandostatinMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:AfinitorVotubiaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:AfinitorVotubiaMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:AfinitorVotubiaMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:ExjadeJadenuMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:ExjadeJadenuMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:ExjadeJadenuMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:TafinlarMekinistMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:TafinlarMekinistMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:TafinlarMekinistMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:PromactaRevoladeMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:PromactaRevoladeMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:PromactaRevoladeMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:VotrientMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:VotrientMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:VotrientMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:JakaviMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:JakaviMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:JakaviMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:KisqaliMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:KisqaliMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:KisqaliMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:OtherProductsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:OtherProductsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember nvs:OtherProductsMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:OncologyMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:OphthalmologyMember nvs:LucentisMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:OphthalmologyMember nvs:LucentisMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:OphthalmologyMember nvs:LucentisMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:OphthalmologyMember nvs:TravoprostGroupMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:OphthalmologyMember nvs:TravoprostGroupMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:OphthalmologyMember nvs:TravoprostGroupMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:OphthalmologyMember nvs:SystaneGroupMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:OphthalmologyMember nvs:SystaneGroupMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:OphthalmologyMember nvs:SystaneGroupMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:OphthalmologyMember nvs:TopicalOlopatadineGroupMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:OphthalmologyMember nvs:TopicalOlopatadineGroupMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:OphthalmologyMember nvs:TopicalOlopatadineGroupMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:OphthalmologyMember nvs:OtherProductsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:OphthalmologyMember nvs:OtherProductsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:OphthalmologyMember nvs:OtherProductsMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:OphthalmologyMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:OphthalmologyMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:OphthalmologyMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:ImmunologyAndDermatologyMember nvs:CosentyxMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:ImmunologyAndDermatologyMember nvs:CosentyxMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:ImmunologyAndDermatologyMember nvs:CosentyxMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:ImmunologyAndDermatologyMember nvs:NeoralSandimmunEMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:ImmunologyAndDermatologyMember nvs:NeoralSandimmunEMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:ImmunologyAndDermatologyMember nvs:NeoralSandimmunEMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:ImmunologyAndDermatologyMember nvs:ZortressCerticanMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:ImmunologyAndDermatologyMember nvs:ZortressCerticanMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:ImmunologyAndDermatologyMember nvs:ZortressCerticanMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:ImmunologyAndDermatologyMember nvs:IlarisMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:ImmunologyAndDermatologyMember nvs:IlarisMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:ImmunologyAndDermatologyMember nvs:IlarisMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:ImmunologyAndDermatologyMember nvs:MyforticMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:ImmunologyAndDermatologyMember nvs:MyforticMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:ImmunologyAndDermatologyMember nvs:MyforticMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:ImmunologyAndDermatologyMember nvs:OtherProductsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:ImmunologyAndDermatologyMember nvs:OtherProductsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:ImmunologyAndDermatologyMember nvs:OtherProductsMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:ImmunologyAndDermatologyMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:ImmunologyAndDermatologyMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:ImmunologyAndDermatologyMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:NeuroscienceMember nvs:GilenyaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:NeuroscienceMember nvs:GilenyaMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:NeuroscienceMember nvs:GilenyaMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:NeuroscienceMember nvs:OtherProductsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:NeuroscienceMember nvs:OtherProductsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:NeuroscienceMember nvs:OtherProductsMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:NeuroscienceMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:NeuroscienceMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:NeuroscienceMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:RespiratoryMember nvs:COPDMember nvs:UltibroBreezhalerMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:RespiratoryMember nvs:COPDMember nvs:UltibroBreezhalerMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:RespiratoryMember nvs:COPDMember nvs:UltibroBreezhalerMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:RespiratoryMember nvs:COPDMember nvs:SeebriBreezhalerMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:RespiratoryMember nvs:COPDMember nvs:SeebriBreezhalerMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:RespiratoryMember nvs:COPDMember nvs:SeebriBreezhalerMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:RespiratoryMember nvs:COPDMember nvs:OnbrezBreezhalerMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:RespiratoryMember nvs:COPDMember nvs:OnbrezBreezhalerMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:RespiratoryMember nvs:COPDMember nvs:OnbrezBreezhalerMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:RespiratoryMember nvs:COPDMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:RespiratoryMember nvs:COPDMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:RespiratoryMember nvs:COPDMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:RespiratoryMember nvs:XolairMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:RespiratoryMember nvs:XolairMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:RespiratoryMember nvs:XolairMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:RespiratoryMember nvs:OtherProductsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:RespiratoryMember nvs:OtherProductsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:RespiratoryMember nvs:OtherProductsMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:RespiratoryMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:RespiratoryMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:RespiratoryMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:CardioMetabolicMember nvs:EntrestoMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:CardioMetabolicMember nvs:EntrestoMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:CardioMetabolicMember nvs:EntrestoMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:CardioMetabolicMember nvs:OtherProductsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:CardioMetabolicMember nvs:OtherProductsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:CardioMetabolicMember nvs:OtherProductsMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:CardioMetabolicMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:CardioMetabolicMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:CardioMetabolicMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember nvs:GalvusMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember nvs:GalvusMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember nvs:GalvusMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember nvs:ExforgeMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember nvs:ExforgeMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember nvs:ExforgeMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember nvs:DiovanCoDiovanMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember nvs:DiovanCoDiovanMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember nvs:DiovanCoDiovanMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember nvs:VoltarenCataflamMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember nvs:VoltarenCataflamMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember nvs:VoltarenCataflamMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember nvs:ExelonExelonPatchMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember nvs:ExelonExelonPatchMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember nvs:ExelonExelonPatchMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember nvs:RitalinFocalinMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember nvs:RitalinFocalinMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember nvs:RitalinFocalinMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember nvs:OtherProductsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember nvs:OtherProductsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember nvs:OtherProductsMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember nvs:EstablishedMedicinesMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember nvs:PharmaceuticalMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2015-01-01 2015-12-31 0001114448 ifrs-full:IssuedCapitalMember 2014-12-31 0001114448 ifrs-full:TreasurySharesMember 2014-12-31 0001114448 ifrs-full:RetainedEarningsMember 2014-12-31 0001114448 nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember 2014-12-31 0001114448 ifrs-full:EquityAttributableToOwnersOfParentMember 2014-12-31 0001114448 ifrs-full:NoncontrollingInterestsMember 2014-12-31 0001114448 2014-12-31 0001114448 ifrs-full:RetainedEarningsMember 2015-01-01 2015-12-31 0001114448 ifrs-full:EquityAttributableToOwnersOfParentMember 2015-01-01 2015-12-31 0001114448 ifrs-full:NoncontrollingInterestsMember 2015-01-01 2015-12-31 0001114448 nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember 2015-01-01 2015-12-31 0001114448 ifrs-full:TreasurySharesMember 2015-01-01 2015-12-31 0001114448 ifrs-full:IssuedCapitalMember 2015-01-01 2015-12-31 0001114448 ifrs-full:IssuedCapitalMember 2015-12-31 0001114448 ifrs-full:TreasurySharesMember 2015-12-31 0001114448 ifrs-full:RetainedEarningsMember 2015-12-31 0001114448 nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember 2015-12-31 0001114448 ifrs-full:EquityAttributableToOwnersOfParentMember 2015-12-31 0001114448 ifrs-full:NoncontrollingInterestsMember 2015-12-31 0001114448 ifrs-full:RetainedEarningsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:EquityAttributableToOwnersOfParentMember 2016-01-01 2016-12-31 0001114448 ifrs-full:NoncontrollingInterestsMember 2016-01-01 2016-12-31 0001114448 nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember 2016-01-01 2016-12-31 0001114448 ifrs-full:TreasurySharesMember 2016-01-01 2016-12-31 0001114448 ifrs-full:IssuedCapitalMember 2016-01-01 2016-12-31 0001114448 ifrs-full:IssuedCapitalMember 2016-12-31 0001114448 ifrs-full:TreasurySharesMember 2016-12-31 0001114448 ifrs-full:RetainedEarningsMember 2016-12-31 0001114448 nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember 2016-12-31 0001114448 ifrs-full:EquityAttributableToOwnersOfParentMember 2016-12-31 0001114448 ifrs-full:NoncontrollingInterestsMember 2016-12-31 0001114448 ifrs-full:RetainedEarningsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:EquityAttributableToOwnersOfParentMember 2017-01-01 2017-12-31 0001114448 nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember 2017-01-01 2017-12-31 0001114448 ifrs-full:NoncontrollingInterestsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:TreasurySharesMember 2017-01-01 2017-12-31 0001114448 ifrs-full:IssuedCapitalMember 2017-01-01 2017-12-31 0001114448 ifrs-full:IssuedCapitalMember 2017-12-31 0001114448 ifrs-full:TreasurySharesMember 2017-12-31 0001114448 ifrs-full:RetainedEarningsMember 2017-12-31 0001114448 nvs:TotalValueAdjustmentsAttributableToNovartisShareholdersMember 2017-12-31 0001114448 ifrs-full:EquityAttributableToOwnersOfParentMember 2017-12-31 0001114448 ifrs-full:NoncontrollingInterestsMember 2017-12-31 0001114448 ifrs-full:ContinuingOperationsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:ContinuingOperationsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:ContinuingOperationsMember 2015-01-01 2015-12-31 0001114448 ifrs-full:DiscontinuedOperationsMember 2015-01-01 2015-12-31 0001114448 nvs:FairValueAdjustmentsOnMarketableSecuritiesMember 2014-12-31 0001114448 nvs:FairValueAdjustmentsOnDeferredCashFlowHedgesMember 2014-12-31 0001114448 nvs:ActuarialLossesFromDefinedBenefitPlansMember 2014-12-31 0001114448 nvs:CumulativeCurrencyTranslationEffectsMember 2014-12-31 0001114448 nvs:FairValueAdjustmentsOnMarketableSecuritiesMember 2015-01-01 2015-12-31 0001114448 nvs:FairValueAdjustmentsOnDeferredCashFlowHedgesMember 2015-01-01 2015-12-31 0001114448 nvs:ActuarialLossesFromDefinedBenefitPlansMember 2015-01-01 2015-12-31 0001114448 nvs:CumulativeCurrencyTranslationEffectsMember 2015-01-01 2015-12-31 0001114448 nvs:FairValueAdjustmentsOnMarketableSecuritiesMember 2015-12-31 0001114448 nvs:FairValueAdjustmentsOnDeferredCashFlowHedgesMember 2015-12-31 0001114448 nvs:ActuarialLossesFromDefinedBenefitPlansMember 2015-12-31 0001114448 nvs:CumulativeCurrencyTranslationEffectsMember 2015-12-31 0001114448 nvs:FairValueAdjustmentsOnMarketableSecuritiesMember 2016-01-01 2016-12-31 0001114448 nvs:FairValueAdjustmentsOnDeferredCashFlowHedgesMember 2016-01-01 2016-12-31 0001114448 nvs:ActuarialLossesFromDefinedBenefitPlansMember 2016-01-01 2016-12-31 0001114448 nvs:CumulativeCurrencyTranslationEffectsMember 2016-01-01 2016-12-31 0001114448 nvs:FairValueAdjustmentsOnMarketableSecuritiesMember 2016-12-31 0001114448 nvs:FairValueAdjustmentsOnDeferredCashFlowHedgesMember 2016-12-31 0001114448 nvs:ActuarialLossesFromDefinedBenefitPlansMember 2016-12-31 0001114448 nvs:CumulativeCurrencyTranslationEffectsMember 2016-12-31 0001114448 nvs:FairValueAdjustmentsOnMarketableSecuritiesMember 2017-01-01 2017-12-31 0001114448 nvs:FairValueAdjustmentsOnDeferredCashFlowHedgesMember 2017-01-01 2017-12-31 0001114448 nvs:NetInvestmentHedgeMember 2017-01-01 2017-12-31 0001114448 nvs:ActuarialLossesFromDefinedBenefitPlansMember 2017-01-01 2017-12-31 0001114448 nvs:CumulativeCurrencyTranslationEffectsMember 2017-01-01 2017-12-31 0001114448 nvs:FairValueAdjustmentsOnMarketableSecuritiesMember 2017-12-31 0001114448 nvs:FairValueAdjustmentsOnDeferredCashFlowHedgesMember 2017-12-31 0001114448 nvs:ActuarialLossesFromDefinedBenefitPlansMember 2017-12-31 0001114448 nvs:NetInvestmentHedgeMember 2017-12-31 0001114448 nvs:CumulativeCurrencyTranslationEffectsMember 2017-12-31 0001114448 ifrs-full:OrdinarySharesMember 2014-12-31 0001114448 ifrs-full:TreasurySharesMember 2014-12-31 0001114448 ifrs-full:OrdinarySharesMember 2017-01-01 2017-12-31 0001114448 ifrs-full:TreasurySharesMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OrdinarySharesMember 2016-01-01 2016-12-31 0001114448 ifrs-full:TreasurySharesMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OrdinarySharesMember 2015-01-01 2015-12-31 0001114448 ifrs-full:TreasurySharesMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OrdinarySharesMember 2017-12-31 0001114448 ifrs-full:TreasurySharesMember 2017-12-31 0001114448 ifrs-full:OrdinarySharesMember 2016-12-31 0001114448 ifrs-full:TreasurySharesMember 2016-12-31 0001114448 ifrs-full:OrdinarySharesMember 2015-12-31 0001114448 ifrs-full:TreasurySharesMember 2015-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:LandMember 2017-01-01 2017-12-31 0001114448 ifrs-full:BuildingsMember ifrs-full:GrossCarryingAmountMember 2017-01-01 2017-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:ConstructionInProgressMember 2017-01-01 2017-12-31 0001114448 ifrs-full:MachineryMember ifrs-full:GrossCarryingAmountMember 2017-01-01 2017-12-31 0001114448 ifrs-full:GrossCarryingAmountMember 2017-01-01 2017-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:LandMember 2017-12-31 0001114448 ifrs-full:BuildingsMember ifrs-full:GrossCarryingAmountMember 2017-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:ConstructionInProgressMember 2017-12-31 0001114448 ifrs-full:MachineryMember ifrs-full:GrossCarryingAmountMember 2017-12-31 0001114448 ifrs-full:GrossCarryingAmountMember 2017-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:LandMember 2017-01-01 2017-12-31 0001114448 ifrs-full:BuildingsMember ifrs-full:AccumulatedImpairmentMember 2017-01-01 2017-12-31 0001114448 ifrs-full:MachineryMember ifrs-full:AccumulatedImpairmentMember 2017-01-01 2017-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember 2017-01-01 2017-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:ConstructionInProgressMember 2017-01-01 2017-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:LandMember 2017-12-31 0001114448 ifrs-full:BuildingsMember ifrs-full:AccumulatedImpairmentMember 2017-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:ConstructionInProgressMember 2017-12-31 0001114448 ifrs-full:MachineryMember ifrs-full:AccumulatedImpairmentMember 2017-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember 2017-12-31 0001114448 ifrs-full:LandMember 2017-12-31 0001114448 ifrs-full:BuildingsMember 2017-12-31 0001114448 ifrs-full:ConstructionInProgressMember 2017-12-31 0001114448 ifrs-full:MachineryMember 2017-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:LandMember 2015-12-31 0001114448 ifrs-full:BuildingsMember ifrs-full:GrossCarryingAmountMember 2015-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:ConstructionInProgressMember 2015-12-31 0001114448 ifrs-full:MachineryMember ifrs-full:GrossCarryingAmountMember 2015-12-31 0001114448 ifrs-full:GrossCarryingAmountMember 2015-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:LandMember 2016-01-01 2016-12-31 0001114448 ifrs-full:BuildingsMember ifrs-full:GrossCarryingAmountMember 2016-01-01 2016-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:ConstructionInProgressMember 2016-01-01 2016-12-31 0001114448 ifrs-full:MachineryMember ifrs-full:GrossCarryingAmountMember 2016-01-01 2016-12-31 0001114448 ifrs-full:GrossCarryingAmountMember 2016-01-01 2016-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:LandMember 2016-12-31 0001114448 ifrs-full:BuildingsMember ifrs-full:GrossCarryingAmountMember 2016-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:ConstructionInProgressMember 2016-12-31 0001114448 ifrs-full:MachineryMember ifrs-full:GrossCarryingAmountMember 2016-12-31 0001114448 ifrs-full:GrossCarryingAmountMember 2016-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:LandMember 2015-12-31 0001114448 ifrs-full:BuildingsMember ifrs-full:AccumulatedImpairmentMember 2015-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:ConstructionInProgressMember 2015-12-31 0001114448 ifrs-full:MachineryMember ifrs-full:AccumulatedImpairmentMember 2015-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember 2015-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:LandMember 2016-01-01 2016-12-31 0001114448 ifrs-full:BuildingsMember ifrs-full:AccumulatedImpairmentMember 2016-01-01 2016-12-31 0001114448 ifrs-full:MachineryMember ifrs-full:AccumulatedImpairmentMember 2016-01-01 2016-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember 2016-01-01 2016-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:ConstructionInProgressMember 2016-01-01 2016-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:LandMember 2016-12-31 0001114448 ifrs-full:BuildingsMember ifrs-full:AccumulatedImpairmentMember 2016-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:ConstructionInProgressMember 2016-12-31 0001114448 ifrs-full:MachineryMember ifrs-full:AccumulatedImpairmentMember 2016-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember 2016-12-31 0001114448 ifrs-full:LandMember 2016-12-31 0001114448 ifrs-full:BuildingsMember 2016-12-31 0001114448 ifrs-full:ConstructionInProgressMember 2016-12-31 0001114448 ifrs-full:MachineryMember 2016-12-31 0001114448 nvs:InventoryRawMaterialsGrossMember 2017-12-31 0001114448 nvs:InventoryRawMaterialsGrossMember 2016-12-31 0001114448 nvs:InventoryWorkInProgressGrossMember 2017-12-31 0001114448 nvs:InventoryWorkInProgressGrossMember 2016-12-31 0001114448 nvs:InventoryFinishedGoodsGrossMember 2017-12-31 0001114448 nvs:InventoryFinishedGoodsGrossMember 2016-12-31 0001114448 ifrs-full:TradeReceivablesMember ifrs-full:GrossCarryingAmountMember 2017-12-31 0001114448 ifrs-full:TradeReceivablesMember ifrs-full:GrossCarryingAmountMember 2016-12-31 0001114448 ifrs-full:TradeReceivablesMember nvs:ProvisionForDoubtfulReceivableMember 2017-12-31 0001114448 ifrs-full:TradeReceivablesMember nvs:ProvisionForDoubtfulReceivableMember 2016-12-31 0001114448 ifrs-full:TradeReceivablesMember nvs:ProvisionForDoubtfulReceivableMember 2014-12-31 0001114448 ifrs-full:TradeReceivablesMember nvs:ProvisionForDoubtfulReceivableMember 2017-01-01 2017-12-31 0001114448 ifrs-full:TradeReceivablesMember nvs:ProvisionForDoubtfulReceivableMember 2016-01-01 2016-12-31 0001114448 ifrs-full:TradeReceivablesMember nvs:ProvisionForDoubtfulReceivableMember 2015-01-01 2015-12-31 0001114448 ifrs-full:TradeReceivablesMember nvs:ProvisionForDoubtfulReceivableMember 2015-12-31 0001114448 ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember 2017-12-31 0001114448 ifrs-full:TradeReceivablesMember ifrs-full:CurrentMember 2016-12-31 0001114448 ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanOneMonthMember 2017-12-31 0001114448 ifrs-full:TradeReceivablesMember ifrs-full:NotLaterThanOneMonthMember 2016-12-31 0001114448 ifrs-full:TradeReceivablesMember ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember 2017-12-31 0001114448 ifrs-full:TradeReceivablesMember ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember 2016-12-31 0001114448 ifrs-full:TradeReceivablesMember ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember 2017-12-31 0001114448 ifrs-full:TradeReceivablesMember ifrs-full:LaterThanThreeMonthsAndNotLaterThanSixMonthsMember 2016-12-31 0001114448 ifrs-full:TradeReceivablesMember ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember 2017-12-31 0001114448 ifrs-full:TradeReceivablesMember ifrs-full:LaterThanSixMonthsAndNotLaterThanOneYearMember 2016-12-31 0001114448 ifrs-full:TradeReceivablesMember ifrs-full:LaterThanOneYearMember 2017-12-31 0001114448 ifrs-full:TradeReceivablesMember ifrs-full:LaterThanOneYearMember 2016-12-31 0001114448 currency:USD ifrs-full:TradeReceivablesMember 2017-12-31 0001114448 currency:USD ifrs-full:TradeReceivablesMember 2016-12-31 0001114448 currency:EUR ifrs-full:TradeReceivablesMember 2017-12-31 0001114448 currency:EUR ifrs-full:TradeReceivablesMember 2016-12-31 0001114448 currency:JPY ifrs-full:TradeReceivablesMember 2017-12-31 0001114448 currency:JPY ifrs-full:TradeReceivablesMember 2016-12-31 0001114448 ifrs-full:TradeReceivablesMember currency:CNY 2017-12-31 0001114448 ifrs-full:TradeReceivablesMember currency:CNY 2016-12-31 0001114448 ifrs-full:TradeReceivablesMember currency:RUB 2017-12-31 0001114448 ifrs-full:TradeReceivablesMember currency:RUB 2016-12-31 0001114448 ifrs-full:TradeReceivablesMember currency:BRL 2017-12-31 0001114448 ifrs-full:TradeReceivablesMember currency:BRL 2016-12-31 0001114448 ifrs-full:TradeReceivablesMember currency:GBP 2017-12-31 0001114448 ifrs-full:TradeReceivablesMember currency:GBP 2016-12-31 0001114448 ifrs-full:TradeReceivablesMember currency:AUD 2017-12-31 0001114448 ifrs-full:TradeReceivablesMember currency:AUD 2016-12-31 0001114448 currency:CHF ifrs-full:TradeReceivablesMember 2017-12-31 0001114448 currency:CHF ifrs-full:TradeReceivablesMember 2016-12-31 0001114448 ifrs-full:TradeReceivablesMember currency:CAD 2017-12-31 0001114448 ifrs-full:TradeReceivablesMember currency:CAD 2016-12-31 0001114448 nvs:CurrencyOthersMember ifrs-full:TradeReceivablesMember 2017-12-31 0001114448 nvs:CurrencyOthersMember ifrs-full:TradeReceivablesMember 2016-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:ZiarcoGroupLimitedMember 2017-01-20 0001114448 ifrs-full:SubsidiariesMember nvs:ZiarcoGroupLimitedMember 2017-01-20 2017-01-20 0001114448 ifrs-full:SubsidiariesMember nvs:EncoreVisionIncMember 2017-01-20 0001114448 ifrs-full:SubsidiariesMember nvs:EncoreVisionIncMember 2017-01-20 2017-01-20 0001114448 ifrs-full:SubsidiariesMember nvs:AdvancedAcceleratorApplicationsAAAMember 2018-01-22 0001114448 ifrs-full:SubsidiariesMember nvs:TranscendMedicalIncMember 2016-03-23 0001114448 ifrs-full:SubsidiariesMember nvs:TranscendMedicalIncMember 2016-03-23 2016-03-23 0001114448 ifrs-full:SubsidiariesMember nvs:ReprixysPharmaceuticalsCorporationMember 2016-11-18 0001114448 ifrs-full:SubsidiariesMember nvs:ReprixysPharmaceuticalsCorporationMember 2016-11-18 2016-11-18 0001114448 ifrs-full:SubsidiariesMember nvs:EliLillyAndCompanyMember 2015-01-01 2015-01-01 0001114448 ifrs-full:SubsidiariesMember nvs:EliLillyAndCompanyMember 2015-01-01 0001114448 nvs:GSKOncologyProductsMember 2015-03-02 2015-03-02 0001114448 nvs:GSKOncologyProductsMember 2015-03-02 0001114448 ifrs-full:SubsidiariesMember nvs:GSKVaccinesMember 2015-03-02 2015-03-02 0001114448 ifrs-full:SubsidiariesMember nvs:GSKVaccinesMember 2015-03-02 0001114448 nvs:GSKConsumerHealthcareMember 2015-03-02 0001114448 ifrs-full:DiscontinuedOperationsMember nvs:OperatingIncomeMember nvs:GSKConsumerHealthcareMember 2015-03-02 2015-03-02 0001114448 ifrs-full:DiscontinuedOperationsMember nvs:OperatingIncomeMember nvs:GSKTotalTransactionMember 2015-03-02 2015-03-02 0001114448 ifrs-full:DiscontinuedOperationsMember nvs:GSKTotalTransactionMember 2015-03-02 2015-03-02 0001114448 ifrs-full:DiscontinuedOperationsMember ifrs-full:SubsidiariesMember nvs:OperatingIncomeMember nvs:CSLMember 2014-10-26 2014-10-26 0001114448 ifrs-full:SubsidiariesMember nvs:SpinifexMember 2015-07-24 0001114448 ifrs-full:SubsidiariesMember nvs:SpinifexMember 2015-07-24 2015-07-24 0001114448 ifrs-full:SubsidiariesMember nvs:AdmuneTheraputicsMember 2015-10-16 0001114448 ifrs-full:SubsidiariesMember nvs:AdmuneTheraputicsMember 2015-10-16 2015-10-16 0001114448 ifrs-full:RestructuringProvisionMember 2014-12-31 0001114448 ifrs-full:RestructuringProvisionMember 2017-01-01 2017-12-31 0001114448 ifrs-full:RestructuringProvisionMember 2016-01-01 2016-12-31 0001114448 ifrs-full:RestructuringProvisionMember 2015-01-01 2015-12-31 0001114448 ifrs-full:RestructuringProvisionMember 2017-12-31 0001114448 ifrs-full:RestructuringProvisionMember 2016-12-31 0001114448 ifrs-full:RestructuringProvisionMember 2015-12-31 0001114448 nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember 2015-12-31 0001114448 nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember 2017-01-01 2017-12-31 0001114448 nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember 2016-01-01 2016-12-31 0001114448 nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember 2017-12-31 0001114448 nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember 2016-12-31 0001114448 nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember nvs:RangeOfExercisePrices4549Member 2017-12-31 0001114448 nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember nvs:RangeOfExercisePrices5054Member 2017-12-31 0001114448 nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember nvs:RangeOfExercisePrices5559Member 2017-12-31 0001114448 nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember nvs:RangeOfExercisePrices6570Member 2017-12-31 0001114448 nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember 2015-12-31 0001114448 nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember 2017-01-01 2017-12-31 0001114448 nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember 2016-01-01 2016-12-31 0001114448 nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember 2017-12-31 0001114448 nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember 2016-12-31 0001114448 nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember nvs:RangeOfExercisePrices4549Member 2017-12-31 0001114448 nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember nvs:RangeOfExercisePrices5054Member 2017-12-31 0001114448 nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember nvs:RangeOfExercisePrices5559Member 2017-12-31 0001114448 nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember nvs:RangeOfExercisePrices6569Member 2017-12-31 0001114448 nvs:NonvestedSharesGrantedMember 2015-12-31 0001114448 nvs:NonvestedSharesGrantedMember nvs:EquityBasedParticipationAnnualIncentivePlanMember 2017-01-01 2017-12-31 0001114448 nvs:NonvestedSharesGrantedMember nvs:EquityBasedParticipationAnnualIncentivePlanMember 2016-01-01 2016-12-31 0001114448 nvs:NonvestedSharesGrantedMember nvs:EquityBasedParticipationShareSavingsPlanMember 2017-01-01 2017-12-31 0001114448 nvs:NonvestedSharesGrantedMember nvs:EquityBasedParticipationShareSavingsPlanMember 2016-01-01 2016-12-31 0001114448 nvs:NonvestedSharesGrantedMember nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember 2017-01-01 2017-12-31 0001114448 nvs:NonvestedSharesGrantedMember nvs:EquityBasedParticipationNovartisEquityPlanSelectNorthAmericaMember 2016-01-01 2016-12-31 0001114448 nvs:NonvestedSharesGrantedMember nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember 2017-01-01 2017-12-31 0001114448 nvs:NonvestedSharesGrantedMember nvs:EquityBasedParticipationNovartisEquityPlanSelectOutsideNorthAmericaMember 2016-01-01 2016-12-31 0001114448 nvs:NonvestedSharesGrantedMember nvs:EquityBasedParticipationLongTermPerformancePlanMember 2017-01-01 2017-12-31 0001114448 nvs:NonvestedSharesGrantedMember nvs:EquityBasedParticipationLongTermPerformancePlanMember 2016-01-01 2016-12-31 0001114448 nvs:NonvestedSharesGrantedMember nvs:EquityBasedParticipationLongTermRelativePerformancePlanMember 2017-01-01 2017-12-31 0001114448 nvs:NonvestedSharesGrantedMember nvs:EquityBasedParticipationLongTermRelativePerformancePlanMember 2016-01-01 2016-12-31 0001114448 nvs:NonvestedSharesGrantedMember nvs:EquityBasedParticipationOtherShareAwardsMember 2017-01-01 2017-12-31 0001114448 nvs:NonvestedSharesGrantedMember nvs:EquityBasedParticipationOtherShareAwardsMember 2016-01-01 2016-12-31 0001114448 nvs:NonvestedSharesGrantedMember 2017-01-01 2017-12-31 0001114448 nvs:NonvestedSharesGrantedMember 2016-01-01 2016-12-31 0001114448 nvs:NonvestedSharesGrantedMember 2017-12-31 0001114448 nvs:NonvestedSharesGrantedMember 2016-12-31 0001114448 nvs:AlconInc.EquityPlanConvertedNovartisShareOptionsMember 2015-12-31 0001114448 nvs:AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember 2015-12-31 0001114448 nvs:AlconInc.EquityPlanConvertedNovartisShareOptionsMember 2016-01-01 2016-12-31 0001114448 nvs:AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember 2016-01-01 2016-12-31 0001114448 nvs:AlconInc.EquityPlanConvertedNovartisShareOptionsMember 2016-12-31 0001114448 nvs:AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember 2016-12-31 0001114448 nvs:AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember 2017-01-01 2017-12-31 0001114448 nvs:AlconInc.EquityPlanConvertedNovartisShareOptionsMember 2017-12-31 0001114448 nvs:AlconInc.EquityPlanConvertedSharesettledAppreciationRightsSSARMember 2017-12-31 0001114448 ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2017-01-01 2017-12-31 0001114448 ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2016-01-01 2016-12-31 0001114448 ifrs-full:KeyManagementPersonnelOfEntityOrParentMember 2015-01-01 2015-12-31 0001114448 nvs:NonExecutiveDirectorMember 2017-01-01 2017-12-31 0001114448 nvs:NonExecutiveDirectorMember 2016-01-01 2016-12-31 0001114448 nvs:NonExecutiveDirectorMember 2015-01-01 2015-12-31 0001114448 nvs:ProfDrBrodyMember 2017-01-01 2017-12-31 0001114448 nvs:ProfDrBrodyMember 2016-01-01 2016-12-31 0001114448 nvs:ProfDrBrodyMember 2015-01-01 2015-12-31 0001114448 nvs:ProfDrZinkernagelMember 2017-01-01 2017-12-31 0001114448 nvs:ProfDrZinkernagelMember 2016-01-01 2016-12-31 0001114448 nvs:ProfDrZinkernagelMember 2015-01-01 2015-12-31 0001114448 nvs:DrAlexKrauerMember 2017-01-01 2017-12-31 0001114448 nvs:DrAlexKrauerMember 2016-01-01 2016-12-31 0001114448 nvs:DrAlexKrauerMember 2015-01-01 2015-12-31 0001114448 nvs:DrDanielVasellaMember 2017-01-01 2017-12-31 0001114448 nvs:DrDanielVasellaMember 2016-01-01 2016-12-31 0001114448 nvs:DrDanielVasellaMember 2015-01-01 2015-12-31 0001114448 nvs:RocheHoldingAGMember 2017-12-31 0001114448 nvs:RocheHoldingAGMember 2016-12-31 0001114448 nvs:GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember 2017-12-31 0001114448 nvs:GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember 2016-12-31 0001114448 nvs:OthersAssociatesMember 2017-12-31 0001114448 nvs:OthersAssociatesMember 2016-12-31 0001114448 nvs:RocheHoldingAGMember 2017-01-01 2017-12-31 0001114448 nvs:RocheHoldingAGMember 2016-01-01 2016-12-31 0001114448 nvs:RocheHoldingAGMember 2015-01-01 2015-12-31 0001114448 nvs:GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember 2017-01-01 2017-12-31 0001114448 nvs:GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember 2016-01-01 2016-12-31 0001114448 nvs:GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember 2015-01-01 2015-12-31 0001114448 nvs:OthersAssociatesMember 2017-01-01 2017-12-31 0001114448 nvs:OthersAssociatesMember 2016-01-01 2016-12-31 0001114448 nvs:OthersAssociatesMember 2015-01-01 2015-12-31 0001114448 nvs:GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember 2015-12-31 0001114448 nvs:TotalFairValueAdjustmentsMember 2017-01-01 2017-12-31 0001114448 nvs:TotalFairValueAdjustmentsMember 2017-12-31 0001114448 nvs:TotalFairValueAdjustmentsMember 2016-01-01 2016-12-31 0001114448 nvs:TotalFairValueAdjustmentsMember 2016-12-31 0001114448 nvs:TotalFairValueAdjustmentsMember 2014-12-31 0001114448 nvs:TotalFairValueAdjustmentsMember 2015-01-01 2015-12-31 0001114448 nvs:TotalFairValueAdjustmentsMember 2015-12-31 0001114448 currency:USD 2017-12-31 0001114448 currency:USD 2016-12-31 0001114448 currency:EUR 2017-12-31 0001114448 currency:EUR 2016-12-31 0001114448 currency:JPY 2017-12-31 0001114448 currency:JPY 2016-12-31 0001114448 nvs:A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member 2017-12-31 0001114448 nvs:A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member 2017-01-01 2017-12-31 0001114448 nvs:A5.125USD3000MillionBond20092019OfNovaritisSecuritiesInvestmentLtd.HamiltonBermudaIssuedAt99.822Member 2016-12-31 0001114448 nvs:A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member 2017-12-31 0001114448 nvs:A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member 2017-01-01 2017-12-31 0001114448 nvs:A4.4USD1000MillionBond20102020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.237Member 2016-12-31 0001114448 nvs:A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member 2017-12-31 0001114448 nvs:A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member 2017-01-01 2017-12-31 0001114448 nvs:A2.4USD1500MillionBond20122022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.225Member 2016-12-31 0001114448 nvs:A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member 2017-12-31 0001114448 nvs:A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member 2017-01-01 2017-12-31 0001114448 nvs:A3.7USD500MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.325Member 2016-12-31 0001114448 nvs:A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member 2017-12-31 0001114448 nvs:A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member 2017-01-01 2017-12-31 0001114448 nvs:A3.4USD2150MillionBond20122042OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.287Member 2016-12-31 0001114448 nvs:A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member 2017-12-31 0001114448 nvs:A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member 2017-01-01 2017-12-31 0001114448 nvs:A4.4USD1850MillionBond20142044OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.196Member 2016-12-31 0001114448 nvs:A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member 2017-12-31 0001114448 nvs:A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member 2017-01-01 2017-12-31 0001114448 nvs:A0.75EUR600MillionBond20142021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.134Member 2016-12-31 0001114448 nvs:A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member 2017-12-31 0001114448 nvs:A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member 2017-01-01 2017-12-31 0001114448 nvs:A1.625EUR600MillionBond20142026OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.697Member 2016-12-31 0001114448 nvs:A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member 2017-12-31 0001114448 nvs:A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member 2017-01-01 2017-12-31 0001114448 nvs:A0.25CHF500MillionBond20152025OfNovartisAGBaselSwitzerlandIssuedAt100.64Member 2016-12-31 0001114448 nvs:A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member 2017-12-31 0001114448 nvs:A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member 2017-01-01 2017-12-31 0001114448 nvs:A0.625CHF550MillionBond20152029OfNovartisAGBaselSwitzerlandIssuedAt100.502Member 2016-12-31 0001114448 nvs:A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member 2017-12-31 0001114448 nvs:A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member 2017-01-01 2017-12-31 0001114448 nvs:A1.050CHF325MillionBond20152035OfNovartisAGBaselSwitzerlandIssuedAt100.479Member 2016-12-31 0001114448 nvs:A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member 2017-12-31 0001114448 nvs:A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member 2017-01-01 2017-12-31 0001114448 nvs:A3.0USD1750MillionBond20152025OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.010Member 2016-12-31 0001114448 nvs:A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member 2017-12-31 0001114448 nvs:A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member 2017-01-01 2017-12-31 0001114448 nvs:A4.0USD1250MillionBond20152045OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt98.029Member 2016-12-31 0001114448 nvs:A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member 2017-12-31 0001114448 nvs:A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member 2017-01-01 2017-12-31 0001114448 nvs:A0.125EUR1250MillionBond20162023OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.127Member 2016-12-31 0001114448 nvs:A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member 2017-12-31 0001114448 nvs:A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member 2017-01-01 2017-12-31 0001114448 nvs:A0.625EUR500MillionBond20162028OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt98.48Member 2016-12-31 0001114448 nvs:A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member 2017-12-31 0001114448 nvs:A1.800USD1000Million20172020OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.609Member 2017-01-01 2017-12-31 0001114448 nvs:A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member 2017-12-31 0001114448 nvs:A2.400USD1000Million20172022OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.449Member 2017-01-01 2017-12-31 0001114448 nvs:A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member 2017-12-31 0001114448 nvs:A3.100USD1000Million20172027OfNovartisCapitalCorporationNewYorkUnitedStatesIssuedAt99.109Member 2017-01-01 2017-12-31 0001114448 nvs:A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member 2017-12-31 0001114448 nvs:A0.000EUR1250Million20172021OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.133Member 2017-01-01 2017-12-31 0001114448 nvs:A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member 2017-12-31 0001114448 nvs:A1.125EUR600Million20172027OfNovartisFinanceS.A.LuxembourgLuxembourgIssuedAt99.874Member 2017-01-01 2017-12-31 0001114448 ifrs-full:NotLaterThanOneYearMember 2016-12-31 0001114448 ifrs-full:NotLaterThanOneYearMember 2017-12-31 0001114448 ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2016-12-31 0001114448 ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember 2017-12-31 0001114448 ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2016-12-31 0001114448 ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember 2017-12-31 0001114448 ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember 2016-12-31 0001114448 ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember 2017-12-31 0001114448 ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2016-12-31 0001114448 ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember 2017-12-31 0001114448 nvs:LaterThanFiveYearsAndNotLaterThanSixYearsMember 2016-12-31 0001114448 ifrs-full:LaterThanFiveYearsMember 2017-12-31 0001114448 nvs:LaterThanSixYearsMember 2016-12-31 0001114448 currency:CHF 2017-12-31 0001114448 currency:CHF 2016-12-31 0001114448 nvs:CarryingReportedAmountFairValueDisclosureMember 2017-12-31 0001114448 nvs:FairValueDisclosureItemAmountsMember 2017-12-31 0001114448 nvs:CarryingReportedAmountFairValueDisclosureMember 2016-12-31 0001114448 nvs:FairValueDisclosureItemAmountsMember 2016-12-31 0001114448 nvs:GenentechRocheMember 2017-01-01 2017-12-31 0001114448 nvs:LucentisMember nvs:GenentechRocheMember 2017-01-01 2017-12-31 0001114448 nvs:LucentisMember nvs:GenentechRocheMember 2016-01-01 2016-12-31 0001114448 nvs:LucentisMember nvs:GenentechRocheMember 2015-01-01 2015-12-31 0001114448 nvs:XolairMember nvs:GenentechRocheMember 2017-01-01 2017-12-31 0001114448 nvs:XolairMember nvs:GenentechRocheMember 2016-01-01 2016-12-31 0001114448 nvs:XolairMember nvs:GenentechRocheMember 2015-01-01 2015-12-31 0001114448 nvs:GenentechRocheMember 2016-01-01 2016-12-31 0001114448 nvs:GenentechRocheMember 2015-01-01 2015-12-31 0001114448 nvs:DrJamesBradnerMember 2015-01-01 2015-12-31 0001114448 nvs:CashAndCashEquivalentsMember 2017-12-31 0001114448 nvs:CashAndCashEquivalentsMember 2016-12-31 0001114448 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember nvs:AvailableForSaleMarketableSecuritiesMember ifrs-full:DebtSecuritiesMember 2017-12-31 0001114448 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember nvs:AvailableForSaleMarketableSecuritiesMember ifrs-full:DebtSecuritiesMember 2016-12-31 0001114448 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember nvs:AvailableForSaleMarketableSecuritiesMember nvs:FundInvestmentsMember 2017-12-31 0001114448 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember nvs:AvailableForSaleMarketableSecuritiesMember nvs:FundInvestmentsMember 2016-12-31 0001114448 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember nvs:AvailableForSaleMarketableSecuritiesMember 2017-12-31 0001114448 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember nvs:AvailableForSaleMarketableSecuritiesMember 2016-12-31 0001114448 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember nvs:AvailableforsaleLongtermFinancialInvestmentsMember nvs:EquitySecuritiesMember 2017-12-31 0001114448 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember nvs:AvailableforsaleLongtermFinancialInvestmentsMember nvs:EquitySecuritiesMember 2016-12-31 0001114448 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember nvs:AvailableforsaleLongtermFinancialInvestmentsMember nvs:FundInvestmentsMember 2017-12-31 0001114448 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember nvs:AvailableforsaleLongtermFinancialInvestmentsMember nvs:FundInvestmentsMember 2016-12-31 0001114448 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember nvs:AvailableforsaleLongtermFinancialInvestmentsMember 2017-12-31 0001114448 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember nvs:AvailableforsaleLongtermFinancialInvestmentsMember 2016-12-31 0001114448 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2017-12-31 0001114448 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FinancialAssetsAtFairValueThroughOtherComprehensiveIncomeCategoryMember 2016-12-31 0001114448 ifrs-full:FinancialAssetsAtAmortisedCostMember ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember nvs:TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember 2017-12-31 0001114448 ifrs-full:FinancialAssetsAtAmortisedCostMember ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember nvs:TradeReceivablesAndOtherCurrentAssetsExcludingPrepaymentsMember 2016-12-31 0001114448 ifrs-full:FinancialAssetsAtAmortisedCostMember ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember nvs:AccruedInterestOnDebtSecuritiesAndTimeDepositsMember 2017-12-31 0001114448 ifrs-full:FinancialAssetsAtAmortisedCostMember ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember nvs:AccruedInterestOnDebtSecuritiesAndTimeDepositsMember 2016-12-31 0001114448 ifrs-full:FinancialAssetsAtAmortisedCostMember ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember nvs:TimeDepositsWithOriginalMaturityMoreThan90DaysMember 2017-12-31 0001114448 ifrs-full:FinancialAssetsAtAmortisedCostMember ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember nvs:TimeDepositsWithOriginalMaturityMoreThan90DaysMember 2016-12-31 0001114448 ifrs-full:FinancialAssetsAtAmortisedCostMember ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember nvs:LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember 2017-12-31 0001114448 ifrs-full:FinancialAssetsAtAmortisedCostMember ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember nvs:LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember 2016-12-31 0001114448 ifrs-full:FinancialAssetsAtAmortisedCostMember ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember 2017-12-31 0001114448 ifrs-full:FinancialAssetsAtAmortisedCostMember ifrs-full:FinancialAssetsAtAmortisedCostCategoryMember 2016-12-31 0001114448 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember 2017-12-31 0001114448 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember 2016-12-31 0001114448 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember nvs:DerivativeFinancialInstrumentsMember 2017-12-31 0001114448 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember nvs:DerivativeFinancialInstrumentsMember 2016-12-31 0001114448 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember nvs:ContingentConsiderationReceivablesMember 2017-12-31 0001114448 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember nvs:ContingentConsiderationReceivablesMember 2016-12-31 0001114448 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember 2017-12-31 0001114448 ifrs-full:FinancialAssetsAtFairValueMember ifrs-full:FinancialAssetsAtFairValueThroughProfitOrLossCategoryMember 2016-12-31 0001114448 nvs:CurrentFinancialDebtMember ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember nvs:InterestBearningAccountsOfAssociatesPayableOnDemandMember 2017-12-31 0001114448 nvs:CurrentFinancialDebtMember ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember nvs:InterestBearningAccountsOfAssociatesPayableOnDemandMember 2016-12-31 0001114448 nvs:CurrentFinancialDebtMember ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember nvs:BankAndOtherFinancialDebtMember 2017-12-31 0001114448 nvs:CurrentFinancialDebtMember ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember nvs:BankAndOtherFinancialDebtMember 2016-12-31 0001114448 nvs:CurrentFinancialDebtMember ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember nvs:CommercialPaperMember 2017-12-31 0001114448 nvs:CurrentFinancialDebtMember ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember nvs:CommercialPaperMember 2016-12-31 0001114448 nvs:CurrentFinancialDebtMember ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember nvs:CurrentPortionOfNoncurrentDebtMember 2017-12-31 0001114448 nvs:CurrentFinancialDebtMember ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember nvs:CurrentPortionOfNoncurrentDebtMember 2016-12-31 0001114448 nvs:CurrentFinancialDebtMember ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2017-12-31 0001114448 nvs:CurrentFinancialDebtMember ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2016-12-31 0001114448 ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember nvs:NoncurrentFinancialDebtMember nvs:StraightBondsMember 2017-12-31 0001114448 ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember nvs:NoncurrentFinancialDebtMember nvs:StraightBondsMember 2016-12-31 0001114448 ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember nvs:NoncurrentFinancialDebtMember nvs:LiabilitiesToBanksAndOtherFinancialInstitutionsMember 2017-12-31 0001114448 ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember nvs:NoncurrentFinancialDebtMember nvs:LiabilitiesToBanksAndOtherFinancialInstitutionsMember 2016-12-31 0001114448 ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember nvs:NoncurrentFinancialDebtMember nvs:FinanceLeaseObligationsMember 2017-12-31 0001114448 ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember nvs:NoncurrentFinancialDebtMember nvs:FinanceLeaseObligationsMember 2016-12-31 0001114448 ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember nvs:NoncurrentFinancialDebtMember nvs:CurrentPortionOfNoncurrentDebtMember 2017-12-31 0001114448 ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember nvs:NoncurrentFinancialDebtMember nvs:CurrentPortionOfNoncurrentDebtMember 2016-12-31 0001114448 ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember nvs:NoncurrentFinancialDebtMember 2017-12-31 0001114448 ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember nvs:NoncurrentFinancialDebtMember 2016-12-31 0001114448 ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember nvs:TradePayablesMember 2017-12-31 0001114448 ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember nvs:TradePayablesMember 2016-12-31 0001114448 ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2017-12-31 0001114448 ifrs-full:FinancialLiabilitiesAtAmortisedCostMember ifrs-full:FinancialLiabilitiesAtAmortisedCostCategoryMember 2016-12-31 0001114448 ifrs-full:FinancialLiabilitiesAtFairValueMember ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember nvs:ContingentConsiderationAndOtherFinancialLiabilitiesMember 2017-12-31 0001114448 ifrs-full:FinancialLiabilitiesAtFairValueMember ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember nvs:ContingentConsiderationAndOtherFinancialLiabilitiesMember 2016-12-31 0001114448 nvs:DerivativeFinancialInstrumentsMember ifrs-full:FinancialLiabilitiesAtFairValueMember ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2017-12-31 0001114448 nvs:DerivativeFinancialInstrumentsMember ifrs-full:FinancialLiabilitiesAtFairValueMember ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2016-12-31 0001114448 ifrs-full:FinancialLiabilitiesAtFairValueMember ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2017-12-31 0001114448 ifrs-full:FinancialLiabilitiesAtFairValueMember ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember 2016-12-31 0001114448 nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember nvs:ContractOrUnderlyingPrincipalAmoutMember 2017-12-31 0001114448 nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember nvs:ContractOrUnderlyingPrincipalAmoutMember 2016-12-31 0001114448 nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember nvs:PositiveFairValuesMember 2017-12-31 0001114448 nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember nvs:PositiveFairValuesMember 2016-12-31 0001114448 nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember nvs:NegativeFairValuesMember 2017-12-31 0001114448 nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember nvs:NegativeFairValuesMember 2016-12-31 0001114448 nvs:ContractOrUnderlyingPrincipalAmoutMember 2017-12-31 0001114448 nvs:ContractOrUnderlyingPrincipalAmoutMember 2016-12-31 0001114448 nvs:PositiveFairValuesMember 2017-12-31 0001114448 nvs:PositiveFairValuesMember 2016-12-31 0001114448 nvs:NegativeFairValuesMember 2017-12-31 0001114448 nvs:NegativeFairValuesMember 2016-12-31 0001114448 currency:EUR nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember nvs:ContractOrUnderlyingPrincipalAmoutMember 2017-12-31 0001114448 currency:USD nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember nvs:ContractOrUnderlyingPrincipalAmoutMember 2017-12-31 0001114448 nvs:CurrencyOthersMember nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember nvs:ContractOrUnderlyingPrincipalAmoutMember 2017-12-31 0001114448 currency:EUR nvs:ContractOrUnderlyingPrincipalAmoutMember 2017-12-31 0001114448 currency:USD nvs:ContractOrUnderlyingPrincipalAmoutMember 2017-12-31 0001114448 nvs:CurrencyOthersMember nvs:ContractOrUnderlyingPrincipalAmoutMember 2017-12-31 0001114448 currency:EUR nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember nvs:ContractOrUnderlyingPrincipalAmoutMember 2016-12-31 0001114448 currency:USD nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember nvs:ContractOrUnderlyingPrincipalAmoutMember 2016-12-31 0001114448 currency:JPY nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember nvs:ContractOrUnderlyingPrincipalAmoutMember 2016-12-31 0001114448 nvs:CurrencyOthersMember nvs:DerivativeFinancialInstrumentsAtFairValueCurrencyRelatedMember nvs:ContractOrUnderlyingPrincipalAmoutMember 2016-12-31 0001114448 currency:EUR nvs:ContractOrUnderlyingPrincipalAmoutMember 2016-12-31 0001114448 currency:USD nvs:ContractOrUnderlyingPrincipalAmoutMember 2016-12-31 0001114448 currency:JPY nvs:ContractOrUnderlyingPrincipalAmoutMember 2016-12-31 0001114448 nvs:CurrencyOthersMember nvs:ContractOrUnderlyingPrincipalAmoutMember 2016-12-31 0001114448 ifrs-full:DebtSecuritiesMember ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level1OfFairValueHierarchyMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember 2017-12-31 0001114448 ifrs-full:DebtSecuritiesMember ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level2OfFairValueHierarchyMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember 2017-12-31 0001114448 ifrs-full:DebtSecuritiesMember ifrs-full:RecurringFairValueMeasurementMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level1OfFairValueHierarchyMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember nvs:FundInvestmentsMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember nvs:FundInvestmentsMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level1OfFairValueHierarchyMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember nvs:TotalAvailableforsaleMarketableSecuritiesMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level2OfFairValueHierarchyMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember nvs:TotalAvailableforsaleMarketableSecuritiesMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember nvs:TotalAvailableforsaleMarketableSecuritiesMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:ValuedAtAmortizedCostMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember nvs:TimeDepositsWithOriginalMaturityMoreThan90DaysMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember nvs:TimeDepositsWithOriginalMaturityMoreThan90DaysMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level2OfFairValueHierarchyMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember nvs:DerivativeFinancialInstrumentsMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember nvs:DerivativeFinancialInstrumentsMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:ValuedAtAmortizedCostMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember nvs:AccruedInterestOnDebtSecuritiesAndTimeDepositsMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember nvs:AccruedInterestOnDebtSecuritiesAndTimeDepositsMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level1OfFairValueHierarchyMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level2OfFairValueHierarchyMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:ValuedAtAmortizedCostMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level1OfFairValueHierarchyMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember nvs:AvailableforsaleFinancialInvestmentsMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level3OfFairValueHierarchyMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember nvs:AvailableforsaleFinancialInvestmentsMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember nvs:AvailableforsaleFinancialInvestmentsMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level3OfFairValueHierarchyMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember nvs:FundInvestmentsMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember nvs:FundInvestmentsMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level3OfFairValueHierarchyMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember nvs:ContingentConsiderationReceivablesMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember nvs:ContingentConsiderationReceivablesMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:ValuedAtAmortizedCostMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember nvs:LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember nvs:LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level1OfFairValueHierarchyMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level3OfFairValueHierarchyMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:ValuedAtAmortizedCostMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level1OfFairValueHierarchyMember nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level3OfFairValueHierarchyMember nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level3OfFairValueHierarchyMember nvs:ContingentConsiderationReceivablesShorttermMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:ContingentConsiderationReceivablesShorttermMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level3OfFairValueHierarchyMember nvs:ContingentConsiderationPayablesMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:ContingentConsiderationPayablesMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level3OfFairValueHierarchyMember nvs:OtherFinancialLiabilitiesMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:OtherFinancialLiabilitiesMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level2OfFairValueHierarchyMember nvs:DerivativeFinancialInstrumentsMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:DerivativeFinancialInstrumentsMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level2OfFairValueHierarchyMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level3OfFairValueHierarchyMember 2017-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember 2017-12-31 0001114448 ifrs-full:DebtSecuritiesMember ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level1OfFairValueHierarchyMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember 2016-12-31 0001114448 ifrs-full:DebtSecuritiesMember ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level2OfFairValueHierarchyMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember 2016-12-31 0001114448 ifrs-full:DebtSecuritiesMember ifrs-full:RecurringFairValueMeasurementMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level1OfFairValueHierarchyMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember nvs:FundInvestmentsMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember nvs:FundInvestmentsMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level1OfFairValueHierarchyMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember nvs:TotalAvailableforsaleMarketableSecuritiesMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level2OfFairValueHierarchyMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember nvs:TotalAvailableforsaleMarketableSecuritiesMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember nvs:TotalAvailableforsaleMarketableSecuritiesMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:ValuedAtAmortizedCostMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember nvs:TimeDepositsWithOriginalMaturityMoreThan90DaysMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember nvs:TimeDepositsWithOriginalMaturityMoreThan90DaysMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level2OfFairValueHierarchyMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember nvs:DerivativeFinancialInstrumentsMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember nvs:DerivativeFinancialInstrumentsMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:ValuedAtAmortizedCostMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember nvs:AccruedInterestOnDebtSecuritiesAndTimeDepositsMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember nvs:AccruedInterestOnDebtSecuritiesAndTimeDepositsMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level1OfFairValueHierarchyMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level2OfFairValueHierarchyMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:ValuedAtAmortizedCostMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:TotalMarketableSecuritiesTimeDepositsAndDerivativeFinancialInstrumentsGroupMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level1OfFairValueHierarchyMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember nvs:AvailableforsaleFinancialInvestmentsMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level3OfFairValueHierarchyMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember nvs:AvailableforsaleFinancialInvestmentsMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember nvs:AvailableforsaleFinancialInvestmentsMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level3OfFairValueHierarchyMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember nvs:FundInvestmentsMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember nvs:FundInvestmentsMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level3OfFairValueHierarchyMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember nvs:ContingentConsiderationReceivablesMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember nvs:ContingentConsiderationReceivablesMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:ValuedAtAmortizedCostMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember nvs:LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember nvs:LongtermLoansAndReceivablesFromCustomersAndFinanceLeaseAdvancesSecurityDepositsMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level1OfFairValueHierarchyMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level3OfFairValueHierarchyMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:ValuedAtAmortizedCostMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:FinancialInvestmentsAndLongtermLoansGroupMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level3OfFairValueHierarchyMember nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level3OfFairValueHierarchyMember nvs:ContingentConsiderationPayablesMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:ContingentConsiderationPayablesMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level3OfFairValueHierarchyMember nvs:OtherFinancialLiabilitiesMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:OtherFinancialLiabilitiesMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level2OfFairValueHierarchyMember nvs:DerivativeFinancialInstrumentsMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember nvs:DerivativeFinancialInstrumentsMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level2OfFairValueHierarchyMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember ifrs-full:Level3OfFairValueHierarchyMember 2016-12-31 0001114448 ifrs-full:RecurringFairValueMeasurementMember 2016-12-31 0001114448 nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember 2017-01-01 2017-12-31 0001114448 nvs:AvailableforsaleFinancialInvestmentsMember 2017-01-01 2017-12-31 0001114448 nvs:ContingentConsiderationReceivablesMember 2017-01-01 2017-12-31 0001114448 nvs:ContingentConsiderationPayablesMember 2017-01-01 2017-12-31 0001114448 nvs:OtherFinancialLiabilitiesMember 2017-01-01 2017-12-31 0001114448 nvs:FundInvestmentsMember 2017-01-01 2017-12-31 0001114448 nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember 2017-12-31 0001114448 nvs:FundInvestmentsMember 2017-12-31 0001114448 nvs:AvailableforsaleFinancialInvestmentsMember 2017-12-31 0001114448 nvs:ContingentConsiderationReceivablesMember 2017-12-31 0001114448 nvs:ContingentConsiderationPayablesMember 2017-12-31 0001114448 nvs:OtherFinancialLiabilitiesMember 2017-12-31 0001114448 nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember 2015-12-31 0001114448 nvs:FundInvestmentsMember 2015-12-31 0001114448 nvs:AvailableforsaleFinancialInvestmentsMember 2015-12-31 0001114448 nvs:ContingentConsiderationReceivablesMember 2015-12-31 0001114448 nvs:ContingentConsiderationPayablesMember 2015-12-31 0001114448 nvs:OtherFinancialLiabilitiesMember 2015-12-31 0001114448 nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember 2016-01-01 2016-12-31 0001114448 nvs:AvailableforsaleFinancialInvestmentsMember 2016-01-01 2016-12-31 0001114448 nvs:ContingentConsiderationReceivablesMember 2016-01-01 2016-12-31 0001114448 nvs:OtherFinancialLiabilitiesMember 2016-01-01 2016-12-31 0001114448 nvs:FundInvestmentsMember 2016-01-01 2016-12-31 0001114448 nvs:ContingentConsiderationPayablesMember 2016-01-01 2016-12-31 0001114448 nvs:AssociatedCompaniesAtFairValueThroughProfitAndLossMember 2016-12-31 0001114448 nvs:FundInvestmentsMember 2016-12-31 0001114448 nvs:AvailableforsaleFinancialInvestmentsMember 2016-12-31 0001114448 nvs:ContingentConsiderationReceivablesMember 2016-12-31 0001114448 nvs:ContingentConsiderationPayablesMember 2016-12-31 0001114448 nvs:OtherFinancialLiabilitiesMember 2016-12-31 0001114448 nvs:LargestFinancialInstitutionMember 2017-01-01 2017-12-31 0001114448 nvs:LargestFinancialInstitutionMember 2016-01-01 2016-12-31 0001114448 nvs:SecondLargestFinancialInstitutionMember 2017-01-01 2017-12-31 0001114448 nvs:SecondLargestFinancialInstitutionMember 2016-01-01 2016-12-31 0001114448 nvs:ThirdLargestFinancialInstitutionMember 2017-01-01 2017-12-31 0001114448 nvs:ThirdLargestFinancialInstitutionMember 2016-01-01 2016-12-31 0001114448 nvs:USCommercialPaperProgramsMember 2017-12-31 0001114448 nvs:JPCommercialPaperProgramsMember 2017-12-31 0001114448 ifrs-full:NotLaterThanOneMonthMember nvs:MarketableSecuritiesAndTimeDepositsMember 2017-12-31 0001114448 ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember nvs:MarketableSecuritiesAndTimeDepositsMember 2017-12-31 0001114448 nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember nvs:MarketableSecuritiesAndTimeDepositsMember 2017-12-31 0001114448 ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember nvs:MarketableSecuritiesAndTimeDepositsMember 2017-12-31 0001114448 ifrs-full:LaterThanFiveYearsMember nvs:MarketableSecuritiesAndTimeDepositsMember 2017-12-31 0001114448 nvs:MarketableSecuritiesAndTimeDepositsMember 2017-12-31 0001114448 ifrs-full:LaterThanFiveYearsMember nvs:CommoditiesMember 2017-12-31 0001114448 nvs:CommoditiesMember 2017-12-31 0001114448 ifrs-full:NotLaterThanOneMonthMember nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember 2017-12-31 0001114448 ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember 2017-12-31 0001114448 nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember 2017-12-31 0001114448 nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember 2017-12-31 0001114448 ifrs-full:NotLaterThanOneMonthMember nvs:CashAndCashEquivalentsMember 2017-12-31 0001114448 ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember nvs:CashAndCashEquivalentsMember 2017-12-31 0001114448 nvs:CashAndCashEquivalentsMember 2017-12-31 0001114448 ifrs-full:NotLaterThanOneMonthMember 2017-12-31 0001114448 ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember 2017-12-31 0001114448 nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember 2017-12-31 0001114448 ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember 2017-12-31 0001114448 ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember nvs:FinancialDebtMember 2017-12-31 0001114448 ifrs-full:LaterThanFiveYearsMember nvs:FinancialDebtMember 2017-12-31 0001114448 nvs:FinancialDebtMember 2017-12-31 0001114448 ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember nvs:FinancialDebtUndiscountedMember 2017-12-31 0001114448 ifrs-full:LaterThanFiveYearsMember nvs:FinancialDebtUndiscountedMember 2017-12-31 0001114448 nvs:FinancialDebtUndiscountedMember 2017-12-31 0001114448 ifrs-full:NotLaterThanOneMonthMember nvs:FinancialDebtMember 2017-12-31 0001114448 ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember nvs:FinancialDebtMember 2017-12-31 0001114448 nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember nvs:FinancialDebtMember 2017-12-31 0001114448 ifrs-full:NotLaterThanOneMonthMember nvs:FinancialDebtUndiscountedMember 2017-12-31 0001114448 ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember nvs:FinancialDebtUndiscountedMember 2017-12-31 0001114448 nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember nvs:FinancialDebtUndiscountedMember 2017-12-31 0001114448 ifrs-full:NotLaterThanOneMonthMember nvs:DerivativeFinancialInstrumentsMember 2017-12-31 0001114448 ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember nvs:DerivativeFinancialInstrumentsMember 2017-12-31 0001114448 nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember nvs:DerivativeFinancialInstrumentsMember 2017-12-31 0001114448 nvs:DerivativeFinancialInstrumentsMember 2017-12-31 0001114448 ifrs-full:NotLaterThanOneMonthMember nvs:MarketableSecuritiesAndTimeDepositsMember 2016-12-31 0001114448 ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember nvs:MarketableSecuritiesAndTimeDepositsMember 2016-12-31 0001114448 nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember nvs:MarketableSecuritiesAndTimeDepositsMember 2016-12-31 0001114448 ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember nvs:MarketableSecuritiesAndTimeDepositsMember 2016-12-31 0001114448 ifrs-full:LaterThanFiveYearsMember nvs:MarketableSecuritiesAndTimeDepositsMember 2016-12-31 0001114448 nvs:MarketableSecuritiesAndTimeDepositsMember 2016-12-31 0001114448 ifrs-full:LaterThanFiveYearsMember nvs:CommoditiesMember 2016-12-31 0001114448 nvs:CommoditiesMember 2016-12-31 0001114448 ifrs-full:NotLaterThanOneMonthMember nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember 2016-12-31 0001114448 ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember 2016-12-31 0001114448 nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember 2016-12-31 0001114448 nvs:DeriviativeFinancialInstrumentsAndAccruedInterestMember 2016-12-31 0001114448 ifrs-full:NotLaterThanOneMonthMember nvs:CashAndCashEquivalentsMember 2016-12-31 0001114448 ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember nvs:CashAndCashEquivalentsMember 2016-12-31 0001114448 nvs:CashAndCashEquivalentsMember 2016-12-31 0001114448 ifrs-full:NotLaterThanOneMonthMember 2016-12-31 0001114448 ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember 2016-12-31 0001114448 nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember 2016-12-31 0001114448 ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember 2016-12-31 0001114448 ifrs-full:LaterThanFiveYearsMember 2016-12-31 0001114448 ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember nvs:FinancialDebtMember 2016-12-31 0001114448 ifrs-full:LaterThanFiveYearsMember nvs:FinancialDebtMember 2016-12-31 0001114448 nvs:FinancialDebtMember 2016-12-31 0001114448 ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember nvs:FinancialDebtUndiscountedMember 2016-12-31 0001114448 ifrs-full:LaterThanFiveYearsMember nvs:FinancialDebtUndiscountedMember 2016-12-31 0001114448 nvs:FinancialDebtUndiscountedMember 2016-12-31 0001114448 ifrs-full:NotLaterThanOneMonthMember nvs:FinancialDebtMember 2016-12-31 0001114448 ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember nvs:FinancialDebtMember 2016-12-31 0001114448 nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember nvs:FinancialDebtMember 2016-12-31 0001114448 ifrs-full:NotLaterThanOneMonthMember nvs:FinancialDebtUndiscountedMember 2016-12-31 0001114448 ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember nvs:FinancialDebtUndiscountedMember 2016-12-31 0001114448 nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember nvs:FinancialDebtUndiscountedMember 2016-12-31 0001114448 ifrs-full:NotLaterThanOneMonthMember nvs:DerivativeFinancialInstrumentsMember 2016-12-31 0001114448 ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember nvs:DerivativeFinancialInstrumentsMember 2016-12-31 0001114448 nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember nvs:DerivativeFinancialInstrumentsMember 2016-12-31 0001114448 nvs:DerivativeFinancialInstrumentsMember 2016-12-31 0001114448 ifrs-full:NotLaterThanOneMonthMember 2017-01-01 2017-12-31 0001114448 ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember 2017-01-01 2017-12-31 0001114448 nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:NotLaterThanOneMonthMember 2016-01-01 2016-12-31 0001114448 ifrs-full:LaterThanOneMonthAndNotLaterThanThreeMonthsMember 2016-01-01 2016-12-31 0001114448 nvs:LaterThanThreeMonthAndNotLaterThanTwelveMonthsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:WeightedAverageMember 2017-12-31 0001114448 ifrs-full:TopOfRangeMember 2017-12-31 0001114448 ifrs-full:BottomOfRangeMember 2017-12-31 0001114448 ifrs-full:WeightedAverageMember 2016-12-31 0001114448 ifrs-full:TopOfRangeMember 2016-12-31 0001114448 ifrs-full:BottomOfRangeMember 2016-12-31 0001114448 nvs:WorstCaseLossScenarioMember 2017-12-31 0001114448 nvs:WorstCaseLossScenarioMember 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:SandozMember 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:AlconMember 2017-12-31 0001114448 nvs:CorporateMember ifrs-full:OperatingSegmentsMember 2017-12-31 0001114448 country:US nvs:SandozMember 2017-12-31 0001114448 nvs:LucentisMember country:IT nvs:NAGAndNovartisPharmaSpAMember 2014-12-31 0001114448 nvs:LucentisMember country:IT 2014-12-31 0001114448 country:JP nvs:NovartisPharmaKKMember 2017-12-31 0001114448 country:KR 2017-12-31 0001114448 country:US nvs:AlconMember nvs:ContactLensesMember 2016-12-31 0001114448 country:US nvs:NPCAndOthersMember nvs:ReclastAclastaMember 2017-12-31 0001114448 country:US nvs:SandozMember nvs:TaxotereMember 2017-12-31 0001114448 country:US nvs:SandozMember nvs:AmiodaroneMember 2017-12-31 0001114448 nvs:OthersAssociatesMember country:US 2017-12-31 0001114448 nvs:SolodynMember 2017-12-31 0001114448 nvs:PensionPlanMember 2016-12-31 0001114448 nvs:PensionPlanMember 2015-12-31 0001114448 nvs:OtherPostemploymentBenefitPlansMember 2016-12-31 0001114448 nvs:OtherPostemploymentBenefitPlansMember 2015-12-31 0001114448 nvs:PensionPlanMember 2017-01-01 2017-12-31 0001114448 nvs:PensionPlanMember 2016-01-01 2016-12-31 0001114448 nvs:OtherPostemploymentBenefitPlansMember 2017-01-01 2017-12-31 0001114448 nvs:OtherPostemploymentBenefitPlansMember 2016-01-01 2016-12-31 0001114448 nvs:PensionPlanMember 2017-12-31 0001114448 nvs:OtherPostemploymentBenefitPlansMember 2017-12-31 0001114448 ifrs-full:CountryOfDomicileMember 2017-12-31 0001114448 country:US 2017-12-31 0001114448 ifrs-full:ForeignCountriesMember 2017-12-31 0001114448 ifrs-full:CountryOfDomicileMember 2016-12-31 0001114448 country:US 2016-12-31 0001114448 ifrs-full:ForeignCountriesMember 2016-12-31 0001114448 country:US nvs:UnfundedMember 2017-12-31 0001114448 ifrs-full:ForeignCountriesMember nvs:UnfundedMember 2017-12-31 0001114448 nvs:UnfundedMember 2017-12-31 0001114448 country:US nvs:UnfundedMember 2016-12-31 0001114448 ifrs-full:ForeignCountriesMember nvs:UnfundedMember 2016-12-31 0001114448 nvs:UnfundedMember 2016-12-31 0001114448 ifrs-full:CountryOfDomicileMember nvs:ActiveMember 2017-12-31 0001114448 country:US nvs:ActiveMember 2017-12-31 0001114448 ifrs-full:ForeignCountriesMember nvs:ActiveMember 2017-12-31 0001114448 nvs:ActiveMember 2017-12-31 0001114448 ifrs-full:CountryOfDomicileMember nvs:ActiveMember 2016-12-31 0001114448 country:US nvs:ActiveMember 2016-12-31 0001114448 ifrs-full:ForeignCountriesMember nvs:ActiveMember 2016-12-31 0001114448 nvs:ActiveMember 2016-12-31 0001114448 country:US nvs:DeferredPensionersMember 2017-12-31 0001114448 ifrs-full:ForeignCountriesMember nvs:DeferredPensionersMember 2017-12-31 0001114448 nvs:DeferredPensionersMember 2017-12-31 0001114448 country:US nvs:DeferredPensionersMember 2016-12-31 0001114448 ifrs-full:ForeignCountriesMember nvs:DeferredPensionersMember 2016-12-31 0001114448 nvs:DeferredPensionersMember 2016-12-31 0001114448 ifrs-full:CountryOfDomicileMember nvs:PensionersMember 2017-12-31 0001114448 country:US nvs:PensionersMember 2017-12-31 0001114448 ifrs-full:ForeignCountriesMember nvs:PensionersMember 2017-12-31 0001114448 nvs:PensionersMember 2017-12-31 0001114448 ifrs-full:CountryOfDomicileMember nvs:PensionersMember 2016-12-31 0001114448 country:US nvs:PensionersMember 2016-12-31 0001114448 ifrs-full:ForeignCountriesMember nvs:PensionersMember 2016-12-31 0001114448 nvs:PensionersMember 2016-12-31 0001114448 nvs:PensionPlanMember 2015-01-01 2015-12-31 0001114448 nvs:OtherPostemploymentBenefitPlansMember 2015-01-01 2015-12-31 0001114448 ifrs-full:ActuarialAssumptionOfDiscountRatesMember nvs:Change25BasisPointMember 2017-12-31 0001114448 nvs:LifeExpectancyMember nvs:Increase1YearMember 2017-12-31 0001114448 ifrs-full:ActuarialAssumptionOfExpectedRatesOfPensionIncreasesMember nvs:Change25BasisPointMember 2017-12-31 0001114448 nvs:ActuarialAssumptionOfExpectedRatesOfInterestOnSavingsAccountMember nvs:Change25BasisPointMember 2017-12-31 0001114448 ifrs-full:ActuarialAssumptionOfExpectedRatesOfSalaryIncreasesMember nvs:Change25BasisPointMember 2017-12-31 0001114448 nvs:PensionPlanMember ifrs-full:EquityInvestmentsMember 2017-01-01 2017-12-31 0001114448 nvs:PensionPlanMember ifrs-full:EquityInvestmentsMember 2017-12-31 0001114448 nvs:PensionPlanMember ifrs-full:EquityInvestmentsMember 2016-12-31 0001114448 nvs:PensionPlanMember ifrs-full:DebtSecuritiesMember 2017-01-01 2017-12-31 0001114448 nvs:PensionPlanMember ifrs-full:DebtSecuritiesMember 2017-12-31 0001114448 nvs:PensionPlanMember ifrs-full:DebtSecuritiesMember 2016-12-31 0001114448 nvs:PensionPlanMember nvs:RealEstateMember 2017-01-01 2017-12-31 0001114448 nvs:PensionPlanMember nvs:RealEstateMember 2017-12-31 0001114448 nvs:PensionPlanMember nvs:RealEstateMember 2016-12-31 0001114448 nvs:PensionPlanMember nvs:AlternativeInvestmentsMember 2017-01-01 2017-12-31 0001114448 nvs:PensionPlanMember nvs:AlternativeInvestmentsMember 2017-12-31 0001114448 nvs:PensionPlanMember nvs:AlternativeInvestmentsMember 2016-12-31 0001114448 nvs:PensionPlanMember nvs:CashAndOtherInvestmentsMember 2017-01-01 2017-12-31 0001114448 nvs:PensionPlanMember nvs:CashAndOtherInvestmentsMember 2017-12-31 0001114448 nvs:PensionPlanMember nvs:CashAndOtherInvestmentsMember 2016-12-31 0001114448 ifrs-full:NotLaterThanOneYearMember nvs:PensionPlanMember 2017-12-31 0001114448 ifrs-full:NotLaterThanOneYearMember nvs:OtherPostemploymentBenefitPlansMember 2017-12-31 0001114448 ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember nvs:PensionPlanMember 2017-12-31 0001114448 ifrs-full:LaterThanOneYearAndNotLaterThanTwoYearsMember nvs:OtherPostemploymentBenefitPlansMember 2017-12-31 0001114448 ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember nvs:PensionPlanMember 2017-12-31 0001114448 ifrs-full:LaterThanTwoYearsAndNotLaterThanThreeYearsMember nvs:OtherPostemploymentBenefitPlansMember 2017-12-31 0001114448 ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember nvs:PensionPlanMember 2017-12-31 0001114448 ifrs-full:LaterThanThreeYearsAndNotLaterThanFourYearsMember nvs:OtherPostemploymentBenefitPlansMember 2017-12-31 0001114448 ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember nvs:PensionPlanMember 2017-12-31 0001114448 ifrs-full:LaterThanFourYearsAndNotLaterThanFiveYearsMember nvs:OtherPostemploymentBenefitPlansMember 2017-12-31 0001114448 nvs:PensionPlanMember ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember 2017-12-31 0001114448 nvs:OtherPostemploymentBenefitPlansMember ifrs-full:LaterThanFiveYearsAndNotLaterThanTenYearsMember 2017-12-31 0001114448 ifrs-full:PropertyPlantAndEquipmentMember 2017-01-01 2017-12-31 0001114448 ifrs-full:PropertyPlantAndEquipmentMember 2016-01-01 2016-12-31 0001114448 ifrs-full:PropertyPlantAndEquipmentMember 2015-01-01 2015-12-31 0001114448 ifrs-full:IntangibleAssetsAndGoodwillMember 2017-01-01 2017-12-31 0001114448 ifrs-full:IntangibleAssetsAndGoodwillMember 2016-01-01 2016-12-31 0001114448 ifrs-full:IntangibleAssetsAndGoodwillMember 2015-01-01 2015-12-31 0001114448 ifrs-full:FinancialAssetsImpairedMember 2017-01-01 2017-12-31 0001114448 ifrs-full:FinancialAssetsImpairedMember 2016-01-01 2016-12-31 0001114448 ifrs-full:FinancialAssetsImpairedMember 2015-01-01 2015-12-31 0001114448 nvs:DivestmentsMember 2017-01-01 2017-12-31 0001114448 nvs:DivestmentsMember 2015-01-01 2015-12-31 0001114448 nvs:AcquisitionsMember 2016-01-01 2016-12-31 0001114448 nvs:AcquisitionsMember 2015-01-01 2015-12-31 0001114448 nvs:AcquisitionsMember 2017-01-01 2017-12-31 0001114448 nvs:DivestmentsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:DiscontinuedOperationsMember nvs:DivestmentsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:DiscontinuedOperationsMember nvs:DivestmentsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:DiscontinuedOperationsMember nvs:DivestmentsMember 2015-01-01 2015-12-31 0001114448 ifrs-full:ContinuingOperationsMember nvs:AcquisitionsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:ContinuingOperationsMember nvs:DivestmentsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:ContinuingOperationsMember nvs:AcquisitionsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:ContinuingOperationsMember nvs:AcquisitionsMember 2015-01-01 2015-12-31 0001114448 nvs:TranscendMedicalIncMember 2016-12-31 0001114448 nvs:TranscendMedicalIncMember 2016-01-01 2016-12-31 0001114448 nvs:AnimalHealthMember 2015-01-01 2015-12-31 0001114448 ifrs-full:DiscontinuedOperationsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:DiscontinuedOperationsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:DiscontinuedOperationsMember 2015-12-31 0001114448 nvs:NonCurrentFinancialDebtsMember 2016-12-31 0001114448 nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember 2016-12-31 0001114448 nvs:NonCurrentFinancialDebtsMember 2017-01-01 2017-12-31 0001114448 nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember 2017-01-01 2017-12-31 0001114448 nvs:NonCurrentFinancialDebtsMember 2017-12-31 0001114448 nvs:CurrentFinancialDebtsAndDerivativeFinancialInstrumentsMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SocieteParActionsSANDOZAlgiersMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SocieteParActionsSANDOZAlgiersMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisArgentinaS.A.BuenosAiresMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisArgentinaS.A.BuenosAiresMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriosS.A.BuenosAiresMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriosS.A.BuenosAiresMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisAustraliaPtyLtdNorthRydeNSWMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisAustraliaPtyLtdNorthRydeNSWMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaceuticalsAustraliaPtyLtdNorthRydeNSWMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaceuticalsAustraliaPtyLtdNorthRydeNSWMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozPtyLtdNorthRydeNSWMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozPtyLtdNorthRydeNSWMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriesAustraliaPtyLtdFrenchsForestNSWMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriesAustraliaPtyLtdFrenchsForestNSWMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisAustriaGmbHViennaMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisAustriaGmbHViennaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaGmbHViennaMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaGmbHViennaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozGmbHViennaMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozGmbHViennaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:EBEWEPharmaGes.m.b.HNfg.KGViennaMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:EBEWEPharmaGes.m.b.HNfg.KGViennaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisBangladeshLimitedGazipurMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisBangladeshLimitedGazipurMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:N.V.NovartisPharmaS.A.VilvoordeMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:N.V.NovartisPharmaS.A.VilvoordeMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:N.V.SandozS.A.VilvoordeMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:N.V.SandozS.A.VilvoordeMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:S.A.AlconCouvreurN.V.PuursMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:S.A.AlconCouvreurN.V.PuursMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:N.V.AlconS.A.VilvoordeMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:N.V.AlconS.A.VilvoordeMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisInvestmentLtd.HamiltonMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisInvestmentLtd.HamiltonMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisSecuritiesInvestmentLtd.HamiltonMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisSecuritiesInvestmentLtd.HamiltonMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisFinanceServicesLtd.HamiltonMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisFinanceServicesLtd.HamiltonMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisB2Ltd.HamiltonMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisB2Ltd.HamiltonMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisB3Ltd.HamiltonMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisB3Ltd.HamiltonMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:TriangleInternationalReinsuranceLimitedHamiltonMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:TriangleInternationalReinsuranceLimitedHamiltonMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:TrinityRiverInsuranceCoLtd.HamiltonMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:TrinityRiverInsuranceCoLtd.HamiltonMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisBiocienciasS.A.SaoPauloMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisBiocienciasS.A.SaoPauloMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozDoBrasilIndustriaFarmaceuticaLtda.CambeMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaceuticalsCanadaInc.DorvalQuebecMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozCanadaInc.BouchervilleQuebecMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozCanadaInc.BouchervilleQuebecMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconCanadaInc.MississaugaOntarioMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconCanadaInc.MississaugaOntarioMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:CIBAVisionCanadaInc.MississaugaOntarioMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:CIBAVisionCanadaInc.MississaugaOntarioMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisChileS.A.SantiagoDeChileMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisChileS.A.SantiagoDeChileMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriosChileLtd.SantiagoDeChileMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriosChileLtd.SantiagoDeChileMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:BeijingNovartisPharmaCo.Ltd.BeijingMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:BeijingNovartisPharmaCo.Ltd.BeijingMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaceuticalsHKLimitedHongKongMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaceuticalsHKLimitedHongKongMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:ChinaNovartisInstitutesForBioMedicalResearchCo.Ltd.ShanghaiMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SuzhouNovartisPharmaTechnologyCo.Ltd.ChangshuMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:ShanghaiNovartisTradingLtd.ShanghaiMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:ShanghaiNovartisTradingLtd.ShanghaiMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozChinaPharmaceuticalCo.Ltd.ZhongshanMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconHongKongLimitedHongKongMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconHongKongLimitedHongKongMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconChinaOphthalmicProductCo.Ltd.BeijingMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconChinaOphthalmicProductCo.Ltd.BeijingMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisDeColombiaS.A.SantafeDeBobotaMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisDeColombiaS.A.SantafeDeBobotaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:LaboratoriosAlconDeColombiaS.A.SantafeDeBobotaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozD.o.o.FarmaceutskaIndustrijaZagrebMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozD.o.o.FarmaceutskaIndustrijaZagrebMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisS.r.o.PragueMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisS.r.o.PragueMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozS.r.o.PragueMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozS.r.o.PragueMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconPharmaceuticalsCzechRepublicS.r.o.PragueMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisHealthcareASCopenhagenMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisHealthcareASCopenhagenMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozASCopenhagenMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozASCopenhagenMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconNordicASCopenhagenMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconNordicASCopenhagenMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisEcuadorS.A.QuitoMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisEcuadorS.A.QuitoMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaS.A.E.CairoMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaS.A.E.CairoMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozEgyptPharmaS.A.E.NewCairoCityMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozEgyptPharmaS.A.E.NewCairoCityMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisFinlandOyEspooMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisFinlandOyEspooMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisGroupeFranceS.A.RueilMalmaisonMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisGroupeFranceS.A.RueilMalmaisonMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaS.A.S.RueilMalmaisonMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaS.A.S.RueilMalmaisonMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozS.A.S.LevalloisPerretMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozS.A.S.LevalloisPerretMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:LaboratoiresAlconS.A.S.RueilMalmaisonMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:LaboratoiresAlconS.A.S.RueilMalmaisonMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisDeutschlandGmbHWehrMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisDeutschlandGmbHWehrMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisBusinessServicesGmbHWehrMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisBusinessServicesGmbHWehrMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaGmbHNurembergMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaGmbHNurembergMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaProduktionsGmbHWehrMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaProduktionsGmbHWehrMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozInternationalGmbHHolzkirchenMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozInternationalGmbHHolzkirchenMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:A1APharmaGmbHOberhachingMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:A1APharmaGmbHOberhachingMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:HEXALAGHolzkirchenMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:HEXALAGHolzkirchenMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SalutasPharmaGmbHBarlebenMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SalutasPharmaGmbHBarlebenMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AeropharmGmbHRudolstadtMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AeropharmGmbHRudolstadtMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconPharmaGmbHFreiburgImBreisgauMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconPharmaGmbHFreiburgImBreisgauMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:CIBAVisionGmbHGrosswallstadtMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:CIBAVisionGmbHGrosswallstadtMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:WaveLightGmbHErlangenMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:WaveLightGmbHErlangenMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovistaInsuranceLimitedGibraltarCityMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovistaInsuranceLimitedGibraltarCityMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisHellasS.A.C.I.MetamorphosisAthensMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriesHellasCommercialAndIndustrialS.A.MaroussiAthensMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisHungaryHealthcareLimitedLiabilityCompanyBudapestMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozHungaryLimitedLiabilityCompanyBudapestMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozHungaryLimitedLiabilityCompanyBudapestMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisIndiaLimitedMumbaiMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisIndiaLimitedMumbaiMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisHealthcarePrivateLimitedMumbaiMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisHealthcarePrivateLimitedMumbaiMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozPrivateLimitedMumbaiMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozPrivateLimitedMumbaiMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriesIndiaPrivateLimitedBangaloreMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriesIndiaPrivateLimitedBangaloreMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:PT.NovartisIndonesiaJakartaMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:PT.NovartisIndonesiaJakartaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:PT.CIBAVisionBatamBatamMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:PT.CIBAVisionBatamBatamMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisIrelandLimitedDublinMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisIrelandLimitedDublinMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisRingaskiddyLimitedRingaskiddyCountyCorkMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriesIrelandLimitedCorkCityMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriesIrelandLimitedCorkCityMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisIsraelLtd.PetachTikvaMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisIsraelLtd.PetachTikvaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:OptonolLtd.NeveIlanMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:OptonolLtd.NeveIlanMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisFarmaS.p.A.OriggioMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisFarmaS.p.A.OriggioMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozS.p.A.OriggioMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozS.p.A.OriggioMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozIndustrialProductsS.p.A.RoveretoMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozIndustrialProductsS.p.A.RoveretoMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconItaliaS.p.A.MilanMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconItaliaS.p.A.MilanMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisHoldingJapanK.K.TokyoMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisHoldingJapanK.K.TokyoMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaK.K.TokyoMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaK.K.TokyoMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:CibaGeigyJapanLimitedTokyoMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:CibaGeigyJapanLimitedTokyoMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozK.K.TokyoMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozK.K.TokyoMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconJapanLtd.TokyoMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconJapanLtd.TokyoMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisInvestmentsS.aR.l.LuxembourgVilleMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisInvestmentsS.aR.l.LuxembourgVilleMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisFinanceS.A.LuxembourgVilleMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisFinanceS.A.LuxembourgVilleMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisCorporationMalaysiaSdn.Bhd.KualaLumpurMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriesMalaysiaSdn.Bhd.PetalingJayaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:CIBAVisionJohorSdn.Bhd.KualaLumpurMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:CIBAVisionJohorSdn.Bhd.KualaLumpurMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisFarmaceuticaS.A.DeC.V.MexicoCityMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozS.A.DeC.V.MexicoCityMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozS.A.DeC.V.MexicoCityMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriosS.A.DeC.V.MexicoCityMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriosS.A.DeC.V.MexicoCityMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaMarocSACasablancaMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaMarocSACasablancaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisNetherlandsB.V.ArnhemMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisNetherlandsB.V.ArnhemMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaB.V.ArnhemMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaB.V.ArnhemMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozB.V.AlmereMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozB.V.AlmereMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconNederlandB.V.ArnhemMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconNederlandB.V.ArnhemMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisNewZealandLtdAucklandMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisNewZealandLtdAucklandMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisNorgeASOsloMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisNorgeASOsloMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaPakistanLimitedKarachiMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaPakistanLimitedKarachiMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaLogisticsInc.PanamaCityMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaLogisticsInc.PanamaCityMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconCentroamericaS.A.PanamaCityMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconCentroamericaS.A.PanamaCityMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisHealthcarePhilippinesInc.ManilaMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisHealthcarePhilippinesInc.ManilaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozPhilippinesCorporationManilaMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozPhilippinesCorporationManilaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPolandSp.ZO.o.WarszawaMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPolandSp.ZO.o.WarszawaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozPolskaSp.ZO.o.WarszawaMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozPolskaSp.ZO.o.WarszawaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:LekS.A.StrykowMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:LekS.A.StrykowMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconPolskaSp.ZO.o.WarszawaMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconPolskaSp.ZO.o.WarszawaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPortugalSGPSLda.PortoSalvoMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPortugalSGPSLda.PortoSalvoMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisFarmaProdutosFarmaceuticosS.A.PortoSalvoMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozFarmaceuticaLda.PortoSalvoMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozFarmaceuticaLda.PortoSalvoMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconPortugalProdutosEEquipamentosOftalmologicosLda.PortoSalvoMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaServicesRomaniaS.R.L.BucharestMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaServicesRomaniaS.R.L.BucharestMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozS.R.L.TarguMuresMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozS.R.L.TarguMuresMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconRomaniaS.R.L.BucharestMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconRomaniaS.R.L.BucharestMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaLLCMoscowMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaLLCMoscowMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisNevaLLCSt.PetersburgMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisNevaLLCSt.PetersburgMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:ZAOSandozMoscowMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:ZAOSandozMoscowMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconFarmacevtikaLLCMoscowMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconFarmacevtikaLLCMoscowMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SaudiPharmaceuticalDistributionCo.Ltd.RiyadhMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisSingaporePteLtd.SingaporeMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisSingaporePteLtd.SingaporeMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisSingaporePharmaceuticalManufacturingPteLtdSingaporeMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisAsiaPacificPharmaceuticalsPteLtdSingaporeMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisInstituteForTropicalDiseasesPteLtdSingaporeMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconPteLtdSingaporeMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconPteLtdSingaporeMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconSingaporeManufacturingPteLtdSingaporeMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconSingaporeManufacturingPteLtdSingaporeMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:CIBAVisionAsianManufacturingAndLogisticsPteLtd.SingaporeMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisSlovakiaS.r.o.BratislavaMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisSlovakiaS.r.o.BratislavaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:LekPharmaceuticalsD.d.LjubjanaMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:LekPharmaceuticalsD.d.LjubjanaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozPharmaceuticalsD.d.LjubjanaMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozPharmaceuticalsD.d.LjubjanaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisSouthAfricaPtyLtdMidrandMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisSouthAfricaPtyLtdMidrandMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozSouthAfricaPtyLtdKemptonParkMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozSouthAfricaPtyLtdKemptonParkMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriesSouthAfricaPtyLtd.MidrandMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisKoreaLtd.SeoulMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisKoreaLtd.SeoulMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozKoreaLtd.SeoulMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozKoreaLtd.SeoulMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconKoreaLtd.SeoulMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconKoreaLtd.SeoulMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisFarmaceuticaS.A.BarcelonaMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisFarmaceuticaS.A.BarcelonaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozFarmaceuticaS.A.MadridMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozFarmaceuticaS.A.MadridMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozIndustrialProductsS.A.BarcelonaMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozIndustrialProductsS.A.BarcelonaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconCusiS.A.BarcelonaMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconCusiS.A.BarcelonaMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AbadiaRetuertaS.A.SardonDeDueroValladolidMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AbadiaRetuertaS.A.SardonDeDueroValladolidMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisSverigeABStockholmMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisSverigeABStockholmMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisInternationalAGBaselMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisInternationalAGBaselMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisHoldingAGBaselMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisHoldingAGBaselMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisInternationalPharmaceuticalInvestmentAGBaselMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisInternationalPharmaceuticalInvestmentAGBaselMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisBioventuresAGBaselMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisBioventuresAGBaselMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisForschungsstiftungBaselMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisStiftungFuerKaderausbildungBaselMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisMitarbeiterbeteiligungsstiftungBaselMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisStiftungFuerMenschUndUmweltBaselMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:StiftungDerNovartisAGFuerErziehungAusbildungUndBildungBaselMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaAGBaselMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaAGBaselMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisInternationalPharmaceuticalAGBaselMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisInternationalPharmaceuticalAGBaselMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaServicesAGBaselMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaServicesAGBaselMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaSchweizerhalleAGMuttenzMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaSchweizerhalleAGMuttenzMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaSteinAGSteinMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaSteinAGSteinMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaSchweizAGRischMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaSchweizAGRischMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozAGBaselMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozAGBaselMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozPharmaceuticalsAGRischMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozPharmaceuticalsAGRischMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconSwitzerlandSARischMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconSwitzerlandSARischMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconPharmaceuticalsLtd.FribourgMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconPharmaceuticalsLtd.FribourgMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:RocheHoldingAGBaselMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:RocheHoldingAGBaselMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisTaiwanCo.Ltd.TaipeiMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisTaiwanCo.Ltd.TaipeiMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisThailandLimitedBangkokMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisThailandLimitedBangkokMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriesThailandLimitedBangkokMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriesThailandLimitedBangkokMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisSaglikGidaVeTarimUrunleriSanayiVeTicaretA.S.IstanbulMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:FarmanovaSaglikHizmetleriLtd.Sti.IstanbulMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozIlacSanayiVeTicaretA.S.IstanbulMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozIlacSanayiVeTicaretA.S.IstanbulMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozSyntekIlacHammaddeleriSanayiVeTicaretA.S.TuzlaIstanbulMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozGrupSaglikUrunleriIlaclariSanayiVeTicaretA.S.GebzeKocaeliMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratuvarlariTicaretA.S.IstanbulMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratuvarlariTicaretA.S.IstanbulMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisMiddleEastFZEDubaiMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisMiddleEastFZEDubaiMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisUKLimitedFrimleyCamberleyMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisUKLimitedFrimleyCamberleyMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaceuticalsUKLimitedFrimleyCamberleyMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisGrimsbyLimitedFrimleyCamberleyMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisGrimsbyLimitedFrimleyCamberleyMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:ZiarcoGroupLimitedFrimleyCamberleySurreyMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:ZiarcoGroupLimitedFrimleyCamberleySurreyMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozLimitedFrimleyCamberleyMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozLimitedFrimleyCamberleyMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconEyeCareUKLimitedFrimleyCamberleyMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconEyeCareUKLimitedFrimleyCamberleyMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:GlaxosmithklineConsumerHealthcareHoldingsLimitedBrentfordMiddlesexMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisCorporationEastHanoverNYMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisCorporationEastHanoverNYMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisFinanceCorporationNewYorkNYMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisFinanceCorporationNewYorkNYMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisCapitalCorporationNewYorkNYMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisCapitalCorporationNewYorkNYMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisServicesInc.EastHanoverNYMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisServicesInc.EastHanoverNYMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisUSFoundationNewYorkNYMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaceuticalsCorporationEastHanoverNYMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisPharmaceuticalsCorporationEastHanoverNYMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisInstitutesForBioMedicalResearchInc.CambridgeMAMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:CortheraInc.SanMateoCAMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:CortheraInc.SanMateoCAMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:CoStimPharmaceuticalsInc.CambridgeMAMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:CoStimPharmaceuticalsInc.CambridgeMAMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:EncoreVisionInc.NewYorkNYMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:EncoreVisionInc.NewYorkNYMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NavigateBioPharmaServicesInc.WilmingtonNCMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NavigateBioPharmaServicesInc.WilmingtonNCMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:ReprixysPharmaceuticalsCorporationOklahomaCityOKMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:ReprixysPharmaceuticalsCorporationOklahomaCityOKMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SpinifexPharmaceuticalsInc.WilmingtonNCMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SpinifexPharmaceuticalsInc.WilmingtonNCMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisInstituteForFunctionalGenomicsInc.SanDiegoCAMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozInc.PrincetonNJMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:SandozInc.PrincetonNJMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:FougeraPharmaceuticalsInc.MelvilleNYMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:FougeraPharmaceuticalsInc.MelvilleNYMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:EonLabsInc.PrincetonNJMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:EonLabsInc.PrincetonNJMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriesInc.FortWorthTXMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriesInc.FortWorthTXMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconRefractivehorizonsLLCFortWorthTXMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconRefractivehorizonsLLCFortWorthTXMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconResearchLtd.FortWorthTXMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconResearchLtd.FortWorthTXMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLensxInc.AlisoViejoCAMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLensxInc.AlisoViejoCAMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriesHoldingCorporationFortWorthTXMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconLaboratoriesHoldingCorporationFortWorthTXMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisVaccinesAndDiagnosticsInc.CambridgeMAMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:ClarVistaMedicalInc.AlisoViejoCAMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:ClarVistaMedicalInc.AlisoViejoCAMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:TranscendMedicalInc.MenloParkCAMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:TranscendMedicalInc.MenloParkCAMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisDeVenezuelaS.A.CaracasMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:NovartisDeVenezuelaS.A.CaracasMember 2017-01-01 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconPharmaceuticalC.A.CaracasMember 2017-12-31 0001114448 ifrs-full:SubsidiariesMember nvs:AlconPharmaceuticalC.A.CaracasMember 2017-01-01 2017-12-31 0001114448 ifrs-full:RefundsProvisionMember 2014-12-31 0001114448 ifrs-full:RefundsProvisionMember 2015-01-01 2015-12-31 0001114448 ifrs-full:RefundsProvisionMember 2017-01-01 2017-12-31 0001114448 ifrs-full:RefundsProvisionMember 2016-01-01 2016-12-31 0001114448 ifrs-full:RefundsProvisionMember 2017-12-31 0001114448 ifrs-full:RefundsProvisionMember 2016-12-31 0001114448 ifrs-full:RefundsProvisionMember 2015-12-31 0001114448 nvs:InnovativeMedicinesMember 2017-01-01 2017-12-31 0001114448 nvs:SandozMember 2017-01-01 2017-12-31 0001114448 nvs:AlconMember 2017-01-01 2017-12-31 0001114448 nvs:ConsumerHealthMember 2017-01-01 2017-12-31 0001114448 ifrs-full:DiscontinuedOperationsMember ifrs-full:PropertyPlantAndEquipmentMember 2015-01-01 2015-12-31 0001114448 ifrs-full:DiscontinuedOperationsMember ifrs-full:RestructuringProvisionMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:SandozMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:SandozMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:AlconMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:AlconMember 2016-01-01 2016-12-31 0001114448 nvs:CorporateMember ifrs-full:OperatingSegmentsMember 2017-01-01 2017-12-31 0001114448 nvs:CorporateMember ifrs-full:OperatingSegmentsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:PropertyPlantAndEquipmentMember ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2017-01-01 2017-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:PropertyPlantAndEquipmentMember ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2016-01-01 2016-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:PropertyPlantAndEquipmentMember ifrs-full:OperatingSegmentsMember nvs:SandozMember 2017-01-01 2017-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:PropertyPlantAndEquipmentMember ifrs-full:OperatingSegmentsMember nvs:SandozMember 2016-01-01 2016-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:PropertyPlantAndEquipmentMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2017-01-01 2017-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:PropertyPlantAndEquipmentMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2016-01-01 2016-12-31 0001114448 ifrs-full:ContinuingOperationsMember nvs:CorporateMember ifrs-full:PropertyPlantAndEquipmentMember ifrs-full:OperatingSegmentsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:ContinuingOperationsMember nvs:CorporateMember ifrs-full:PropertyPlantAndEquipmentMember ifrs-full:OperatingSegmentsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:IntangibleAssetsAndGoodwillMember ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2017-01-01 2017-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:IntangibleAssetsAndGoodwillMember ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2016-01-01 2016-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:IntangibleAssetsAndGoodwillMember ifrs-full:OperatingSegmentsMember nvs:SandozMember 2017-01-01 2017-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:IntangibleAssetsAndGoodwillMember ifrs-full:OperatingSegmentsMember nvs:SandozMember 2016-01-01 2016-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:IntangibleAssetsAndGoodwillMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2017-01-01 2017-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:IntangibleAssetsAndGoodwillMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2016-01-01 2016-12-31 0001114448 ifrs-full:ContinuingOperationsMember nvs:CorporateMember ifrs-full:IntangibleAssetsAndGoodwillMember ifrs-full:OperatingSegmentsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:ContinuingOperationsMember nvs:CorporateMember ifrs-full:IntangibleAssetsAndGoodwillMember ifrs-full:OperatingSegmentsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2017-01-01 2017-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2016-01-01 2016-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2017-01-01 2017-12-31 0001114448 ifrs-full:ContinuingOperationsMember nvs:CorporateMember ifrs-full:OperatingSegmentsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:ContinuingOperationsMember nvs:CorporateMember ifrs-full:OperatingSegmentsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:OperatingSegmentsMember nvs:SandozMember 2017-01-01 2017-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:OperatingSegmentsMember nvs:SandozMember 2016-01-01 2016-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2016-01-01 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:SandozMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:AlconMember 2015-01-01 2015-12-31 0001114448 nvs:CorporateMember ifrs-full:OperatingSegmentsMember 2015-01-01 2015-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:PropertyPlantAndEquipmentMember ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2015-01-01 2015-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:PropertyPlantAndEquipmentMember ifrs-full:OperatingSegmentsMember nvs:SandozMember 2015-01-01 2015-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:PropertyPlantAndEquipmentMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2015-01-01 2015-12-31 0001114448 ifrs-full:ContinuingOperationsMember nvs:CorporateMember ifrs-full:PropertyPlantAndEquipmentMember ifrs-full:OperatingSegmentsMember 2015-01-01 2015-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:IntangibleAssetsAndGoodwillMember ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2015-01-01 2015-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:IntangibleAssetsAndGoodwillMember ifrs-full:OperatingSegmentsMember nvs:SandozMember 2015-01-01 2015-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:IntangibleAssetsAndGoodwillMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2015-01-01 2015-12-31 0001114448 ifrs-full:ContinuingOperationsMember nvs:CorporateMember ifrs-full:IntangibleAssetsAndGoodwillMember ifrs-full:OperatingSegmentsMember 2015-01-01 2015-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2015-01-01 2015-12-31 0001114448 ifrs-full:ContinuingOperationsMember nvs:CorporateMember ifrs-full:OperatingSegmentsMember 2015-01-01 2015-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:OperatingSegmentsMember nvs:SandozMember 2015-01-01 2015-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2015-01-01 2015-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:SandozMember 2016-12-31 0001114448 ifrs-full:OperatingSegmentsMember nvs:AlconMember 2016-12-31 0001114448 nvs:CorporateMember ifrs-full:OperatingSegmentsMember 2016-12-31 0001114448 country:US 2017-01-01 2017-12-31 0001114448 country:US 2016-01-01 2016-12-31 0001114448 country:US 2015-01-01 2015-12-31 0001114448 country:GB 2017-01-01 2017-12-31 0001114448 country:GB 2016-01-01 2016-12-31 0001114448 country:GB 2015-01-01 2015-12-31 0001114448 country:GB 2017-12-31 0001114448 country:GB 2016-12-31 0001114448 country:DE 2017-01-01 2017-12-31 0001114448 country:DE 2016-01-01 2016-12-31 0001114448 country:DE 2015-01-01 2015-12-31 0001114448 country:DE 2017-12-31 0001114448 country:DE 2016-12-31 0001114448 country:FR 2017-01-01 2017-12-31 0001114448 country:FR 2016-01-01 2016-12-31 0001114448 country:FR 2015-01-01 2015-12-31 0001114448 country:FR 2017-12-31 0001114448 country:FR 2016-12-31 0001114448 country:JP 2017-01-01 2017-12-31 0001114448 country:JP 2016-01-01 2016-12-31 0001114448 country:JP 2015-01-01 2015-12-31 0001114448 country:JP 2017-12-31 0001114448 country:JP 2016-12-31 0001114448 nvs:OtherCountriesMember 2017-01-01 2017-12-31 0001114448 nvs:OtherCountriesMember 2016-01-01 2016-12-31 0001114448 nvs:OtherCountriesMember 2015-01-01 2015-12-31 0001114448 nvs:OtherCountriesMember 2017-12-31 0001114448 nvs:OtherCountriesMember 2016-12-31 0001114448 nvs:EuropeMember 2017-01-01 2017-12-31 0001114448 nvs:EuropeMember 2016-01-01 2016-12-31 0001114448 nvs:EuropeMember 2015-01-01 2015-12-31 0001114448 nvs:EuropeMember 2017-12-31 0001114448 nvs:EuropeMember 2016-12-31 0001114448 nvs:AmericasMember 2017-01-01 2017-12-31 0001114448 nvs:AmericasMember 2016-01-01 2016-12-31 0001114448 nvs:AmericasMember 2015-01-01 2015-12-31 0001114448 nvs:AmericasMember 2017-12-31 0001114448 nvs:AmericasMember 2016-12-31 0001114448 nvs:AsiaAfricaAustralasiaMember 2017-01-01 2017-12-31 0001114448 nvs:AsiaAfricaAustralasiaMember 2016-01-01 2016-12-31 0001114448 nvs:AsiaAfricaAustralasiaMember 2015-01-01 2015-12-31 0001114448 nvs:AsiaAfricaAustralasiaMember 2017-12-31 0001114448 nvs:AsiaAfricaAustralasiaMember 2016-12-31 0001114448 nvs:LargestCustomerMember 2017-01-01 2017-12-31 0001114448 nvs:LargestCustomerMember 2016-01-01 2016-12-31 0001114448 nvs:SecondLargestCustomerMember 2017-01-01 2017-12-31 0001114448 nvs:SecondLargestCustomerMember 2016-01-01 2016-12-31 0001114448 nvs:ThirdLargestCustomerMember 2017-01-01 2017-12-31 0001114448 nvs:ThirdLargestCustomerMember 2016-01-01 2016-12-31 0001114448 nvs:LargestCustomerMember 2015-01-01 2015-12-31 0001114448 nvs:SecondLargestCustomerMember 2015-01-01 2015-12-31 0001114448 nvs:ThirdLargestCustomerMember 2015-01-01 2015-12-31 0001114448 ifrs-full:DiscontinuedOperationsMember nvs:VaccinesMember 2015-01-01 2015-12-31 0001114448 ifrs-full:DiscontinuedOperationsMember nvs:ConsumerHealthMember 2015-01-01 2015-12-31 0001114448 ifrs-full:DiscontinuedOperationsMember nvs:CorporateMember 2015-01-01 2015-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:GoodwillMember 2017-01-01 2017-12-31 0001114448 ifrs-full:GrossCarryingAmountMember nvs:AcquiredResearchAndDevelopmentMember 2017-01-01 2017-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:IntangibleAssetsOtherThanGoodwillMember 2017-01-01 2017-12-31 0001114448 ifrs-full:GrossCarryingAmountMember nvs:CurrentlyMarketedProductsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:OtherIntangibleAssetsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:TechnologybasedIntangibleAssetsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:GoodwillMember 2017-12-31 0001114448 ifrs-full:GrossCarryingAmountMember nvs:AcquiredResearchAndDevelopmentMember 2017-12-31 0001114448 ifrs-full:GrossCarryingAmountMember nvs:AlconBrandNameMember 2017-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:TechnologybasedIntangibleAssetsMember 2017-12-31 0001114448 ifrs-full:GrossCarryingAmountMember nvs:CurrentlyMarketedProductsMember 2017-12-31 0001114448 ifrs-full:GrossCarryingAmountMember nvs:MarketingRelatedIntangibleAssetsMember 2017-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:OtherIntangibleAssetsMember 2017-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:IntangibleAssetsOtherThanGoodwillMember 2017-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember nvs:AcquiredResearchAndDevelopmentMember 2017-01-01 2017-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember nvs:CurrentlyMarketedProductsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:TechnologybasedIntangibleAssetsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember nvs:MarketingRelatedIntangibleAssetsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:OtherIntangibleAssetsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:GoodwillMember 2017-01-01 2017-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:IntangibleAssetsOtherThanGoodwillMember 2017-01-01 2017-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:GoodwillMember 2017-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember nvs:AcquiredResearchAndDevelopmentMember 2017-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:TechnologybasedIntangibleAssetsMember 2017-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember nvs:CurrentlyMarketedProductsMember 2017-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember nvs:MarketingRelatedIntangibleAssetsMember 2017-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:OtherIntangibleAssetsMember 2017-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:IntangibleAssetsOtherThanGoodwillMember 2017-12-31 0001114448 ifrs-full:GoodwillMember 2017-12-31 0001114448 nvs:AcquiredResearchAndDevelopmentMember 2017-12-31 0001114448 nvs:AlconBrandNameMember 2017-12-31 0001114448 ifrs-full:TechnologybasedIntangibleAssetsMember 2017-12-31 0001114448 nvs:CurrentlyMarketedProductsMember 2017-12-31 0001114448 nvs:MarketingRelatedIntangibleAssetsMember 2017-12-31 0001114448 ifrs-full:OtherIntangibleAssetsMember 2017-12-31 0001114448 ifrs-full:IntangibleAssetsOtherThanGoodwillMember 2017-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:GoodwillMember 2015-12-31 0001114448 ifrs-full:GrossCarryingAmountMember nvs:AcquiredResearchAndDevelopmentMember 2015-12-31 0001114448 ifrs-full:GrossCarryingAmountMember nvs:AlconBrandNameMember 2015-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:TechnologybasedIntangibleAssetsMember 2015-12-31 0001114448 ifrs-full:GrossCarryingAmountMember nvs:CurrentlyMarketedProductsMember 2015-12-31 0001114448 ifrs-full:GrossCarryingAmountMember nvs:MarketingRelatedIntangibleAssetsMember 2015-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:OtherIntangibleAssetsMember 2015-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:IntangibleAssetsOtherThanGoodwillMember 2015-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:GoodwillMember 2016-01-01 2016-12-31 0001114448 ifrs-full:GrossCarryingAmountMember nvs:AcquiredResearchAndDevelopmentMember 2016-01-01 2016-12-31 0001114448 ifrs-full:GrossCarryingAmountMember nvs:CurrentlyMarketedProductsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:IntangibleAssetsOtherThanGoodwillMember 2016-01-01 2016-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:OtherIntangibleAssetsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:TechnologybasedIntangibleAssetsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:GoodwillMember 2016-12-31 0001114448 ifrs-full:GrossCarryingAmountMember nvs:AcquiredResearchAndDevelopmentMember 2016-12-31 0001114448 ifrs-full:GrossCarryingAmountMember nvs:AlconBrandNameMember 2016-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:TechnologybasedIntangibleAssetsMember 2016-12-31 0001114448 ifrs-full:GrossCarryingAmountMember nvs:CurrentlyMarketedProductsMember 2016-12-31 0001114448 ifrs-full:GrossCarryingAmountMember nvs:MarketingRelatedIntangibleAssetsMember 2016-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:OtherIntangibleAssetsMember 2016-12-31 0001114448 ifrs-full:GrossCarryingAmountMember ifrs-full:IntangibleAssetsOtherThanGoodwillMember 2016-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:GoodwillMember 2015-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember nvs:AcquiredResearchAndDevelopmentMember 2015-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:TechnologybasedIntangibleAssetsMember 2015-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember nvs:CurrentlyMarketedProductsMember 2015-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember nvs:MarketingRelatedIntangibleAssetsMember 2015-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:OtherIntangibleAssetsMember 2015-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:IntangibleAssetsOtherThanGoodwillMember 2015-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember nvs:AcquiredResearchAndDevelopmentMember 2016-01-01 2016-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember nvs:CurrentlyMarketedProductsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:TechnologybasedIntangibleAssetsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember nvs:MarketingRelatedIntangibleAssetsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:OtherIntangibleAssetsMember 2016-01-01 2016-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:GoodwillMember 2016-01-01 2016-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:IntangibleAssetsOtherThanGoodwillMember 2016-01-01 2016-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:GoodwillMember 2016-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember nvs:AcquiredResearchAndDevelopmentMember 2016-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:TechnologybasedIntangibleAssetsMember 2016-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember nvs:CurrentlyMarketedProductsMember 2016-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember nvs:MarketingRelatedIntangibleAssetsMember 2016-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:OtherIntangibleAssetsMember 2016-12-31 0001114448 ifrs-full:AccumulatedImpairmentMember ifrs-full:IntangibleAssetsOtherThanGoodwillMember 2016-12-31 0001114448 ifrs-full:GoodwillMember 2016-12-31 0001114448 nvs:AcquiredResearchAndDevelopmentMember 2016-12-31 0001114448 nvs:AlconBrandNameMember 2016-12-31 0001114448 ifrs-full:TechnologybasedIntangibleAssetsMember 2016-12-31 0001114448 nvs:CurrentlyMarketedProductsMember 2016-12-31 0001114448 nvs:MarketingRelatedIntangibleAssetsMember 2016-12-31 0001114448 ifrs-full:OtherIntangibleAssetsMember 2016-12-31 0001114448 ifrs-full:IntangibleAssetsOtherThanGoodwillMember 2016-12-31 0001114448 ifrs-full:GoodwillMember ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2017-12-31 0001114448 nvs:AcquiredResearchAndDevelopmentMember ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2017-12-31 0001114448 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2017-12-31 0001114448 nvs:CurrentlyMarketedProductsMember ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2017-12-31 0001114448 ifrs-full:OtherIntangibleAssetsMember ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2017-12-31 0001114448 ifrs-full:IntangibleAssetsOtherThanGoodwillMember ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2017-12-31 0001114448 ifrs-full:GoodwillMember ifrs-full:OperatingSegmentsMember nvs:SandozMember 2017-12-31 0001114448 nvs:AcquiredResearchAndDevelopmentMember ifrs-full:OperatingSegmentsMember nvs:SandozMember 2017-12-31 0001114448 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:OperatingSegmentsMember nvs:SandozMember 2017-12-31 0001114448 nvs:CurrentlyMarketedProductsMember ifrs-full:OperatingSegmentsMember nvs:SandozMember 2017-12-31 0001114448 ifrs-full:OtherIntangibleAssetsMember ifrs-full:OperatingSegmentsMember nvs:SandozMember 2017-12-31 0001114448 ifrs-full:IntangibleAssetsOtherThanGoodwillMember ifrs-full:OperatingSegmentsMember nvs:SandozMember 2017-12-31 0001114448 ifrs-full:GoodwillMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2017-12-31 0001114448 nvs:AcquiredResearchAndDevelopmentMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2017-12-31 0001114448 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2017-12-31 0001114448 nvs:CurrentlyMarketedProductsMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2017-12-31 0001114448 nvs:MarketingRelatedIntangibleAssetsMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2017-12-31 0001114448 ifrs-full:OtherIntangibleAssetsMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2017-12-31 0001114448 ifrs-full:IntangibleAssetsOtherThanGoodwillMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2017-12-31 0001114448 nvs:CorporateMember ifrs-full:GoodwillMember ifrs-full:OperatingSegmentsMember 2017-12-31 0001114448 nvs:CorporateMember nvs:AcquiredResearchAndDevelopmentMember ifrs-full:OperatingSegmentsMember 2017-12-31 0001114448 nvs:CorporateMember nvs:AlconBrandNameMember ifrs-full:OperatingSegmentsMember 2017-12-31 0001114448 nvs:CorporateMember ifrs-full:OtherIntangibleAssetsMember ifrs-full:OperatingSegmentsMember 2017-12-31 0001114448 nvs:CorporateMember ifrs-full:IntangibleAssetsOtherThanGoodwillMember ifrs-full:OperatingSegmentsMember 2017-12-31 0001114448 ifrs-full:GoodwillMember ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2016-12-31 0001114448 nvs:AcquiredResearchAndDevelopmentMember ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2016-12-31 0001114448 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2016-12-31 0001114448 nvs:CurrentlyMarketedProductsMember ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2016-12-31 0001114448 ifrs-full:OtherIntangibleAssetsMember ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2016-12-31 0001114448 ifrs-full:IntangibleAssetsOtherThanGoodwillMember ifrs-full:OperatingSegmentsMember nvs:InnovativeMedicinesMember 2016-12-31 0001114448 ifrs-full:GoodwillMember ifrs-full:OperatingSegmentsMember nvs:SandozMember 2016-12-31 0001114448 nvs:AcquiredResearchAndDevelopmentMember ifrs-full:OperatingSegmentsMember nvs:SandozMember 2016-12-31 0001114448 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:OperatingSegmentsMember nvs:SandozMember 2016-12-31 0001114448 nvs:CurrentlyMarketedProductsMember ifrs-full:OperatingSegmentsMember nvs:SandozMember 2016-12-31 0001114448 ifrs-full:OtherIntangibleAssetsMember ifrs-full:OperatingSegmentsMember nvs:SandozMember 2016-12-31 0001114448 ifrs-full:IntangibleAssetsOtherThanGoodwillMember ifrs-full:OperatingSegmentsMember nvs:SandozMember 2016-12-31 0001114448 ifrs-full:GoodwillMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2016-12-31 0001114448 nvs:AcquiredResearchAndDevelopmentMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2016-12-31 0001114448 ifrs-full:TechnologybasedIntangibleAssetsMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2016-12-31 0001114448 nvs:CurrentlyMarketedProductsMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2016-12-31 0001114448 nvs:MarketingRelatedIntangibleAssetsMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2016-12-31 0001114448 ifrs-full:OtherIntangibleAssetsMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2016-12-31 0001114448 ifrs-full:IntangibleAssetsOtherThanGoodwillMember ifrs-full:OperatingSegmentsMember nvs:AlconMember 2016-12-31 0001114448 nvs:CorporateMember ifrs-full:GoodwillMember ifrs-full:OperatingSegmentsMember 2016-12-31 0001114448 nvs:CorporateMember nvs:AlconBrandNameMember ifrs-full:OperatingSegmentsMember 2016-12-31 0001114448 nvs:CorporateMember ifrs-full:OtherIntangibleAssetsMember ifrs-full:OperatingSegmentsMember 2016-12-31 0001114448 nvs:CorporateMember ifrs-full:IntangibleAssetsOtherThanGoodwillMember ifrs-full:OperatingSegmentsMember 2016-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:OperatingSegmentsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:ContinuingOperationsMember ifrs-full:OperatingSegmentsMember 2016-01-01 2016-12-31 0001114448 nvs:SubsequentEventMember 2017-01-01 2017-12-31 0001114448 nvs:RocheHoldingAGMember 2017-06-30 0001114448 nvs:RocheHoldingAGMember 2017-01-01 2017-06-30 0001114448 nvs:GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember 2017-09-30 0001114448 ifrs-full:TradeReceivablesMember 2017-12-31 0001114448 ifrs-full:TradeReceivablesMember 2016-12-31 0001114448 nvs:GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember 2017-01-01 2017-09-30 0001114448 ifrs-full:SubsidiariesMember nvs:CSLMember 2015-07-31 2015-07-31 0001114448 ifrs-full:DiscontinuedOperationsMember ifrs-full:SubsidiariesMember nvs:OperatingIncomeMember nvs:CSLMember 2015-07-31 2015-07-31 0001114448 nvs:EquityBasedParticipationAnnualIncentivePlanMember 2017-01-01 2017-12-31 0001114448 nvs:EquityBasedParticipationShareSavingsPlanMember 2017-01-01 2017-12-31 0001114448 nvs:EquityBasedParticipationEmployeeShareOwnershipPlanMember 2017-01-01 2017-12-31 0001114448 nvs:EquityBasedParticipationUKShareSavingsPlanMember 2017-01-01 2017-12-31 0001114448 nvs:EquityBasedParticipationLeveragedShareSavingsPlanMember 2017-01-01 2017-12-31 0001114448 nvs:EquityBasedParticipationNovartisEquityPlanSelectMember 2017-01-01 2017-12-31 0001114448 nvs:EquityBasedParticipationLongTermPerformancePlanMember 2017-01-01 2017-12-31 0001114448 nvs:EquityBasedParticipationLongTermRelativePerformancePlanMember 2017-01-01 2017-12-31 0001114448 nvs:EquityBasedParticipationSpecialShareAwardsMember 2017-01-01 2017-12-31 0001114448 nvs:AlconInc.EquityPlansGrantedToAssociatesPriorMergerMember 2017-01-01 2017-12-31 0001114448 ifrs-full:BuildingsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:MachineryMember 2017-01-01 2017-12-31 0001114448 nvs:FurnitureAndVehiclesMember 2017-01-01 2017-12-31 0001114448 ifrs-full:ComputerEquipmentMember 2017-01-01 2017-12-31 0001114448 nvs:CurrentlyMarketedProductsMember nvs:CostOfSalesMember 2017-01-01 2017-12-31 0001114448 nvs:MarketingRelatedIntangibleAssetsMember nvs:CostOfSalesMember 2017-01-01 2017-12-31 0001114448 ifrs-full:TechnologybasedIntangibleAssetsMember nvs:CostOfSalesOrResearchAndDevelopmentMember 2017-01-01 2017-12-31 0001114448 ifrs-full:OtherIntangibleAssetsMember 2017-01-01 2017-12-31 0001114448 ifrs-full:BrandNamesMember 2017-01-01 2017-12-31 0001114448 nvs:GSKConsumerHealthcareMember nvs:GlaxoSmithKlineConsumerHealthcareHoldingsLtdMember 2015-03-02 2015-03-02 xbrli:shares iso4217:USD xbrli:pure iso4217:CHF iso4217:USD xbrli:shares ns0:year iso4217:CHF xbrli:shares iso4217:EUR iso4217:JPY iso4217:DZD iso4217:ARS iso4217:AUD iso4217:BDT iso4217:BRL iso4217:CAD iso4217:CLP iso4217:HKD iso4217:COP iso4217:HRK iso4217:CZK iso4217:DKK iso4217:EGP iso4217:HUF iso4217:INR iso4217:IDR iso4217:ILS iso4217:MYR iso4217:MXN iso4217:MAD iso4217:NZD iso4217:NOK iso4217:PKR iso4217:PAB iso4217:PHP iso4217:PLN iso4217:RON iso4217:RUB iso4217:SAR iso4217:SGD iso4217:ZAR iso4217:KRW iso4217:SEK iso4217:TWD iso4217:THB iso4217:TRY iso4217:AED iso4217:GBP iso4217:VEF 2317456499 5289000000 3110000000 5765000000 3710000000 4707000000 2369000000 12479000000 8999000000 7817000000 20613000000 -462000000 -709000000 -317000000 -1594000000 -1418000000 -1333000000 -2056000000 -2127000000 -1650000000 -298000000 765000000 -68000000 1058000000 243000000 612000000 760000000 1008000000 544000000 -1713000000 -1296000000 -1119000000 -2819000000 0.145 0.132 0.124 0.034 0.035 0.035 -0.001 -0.002 -0.002 -0.002 -0.002 -0.003 -0.022 -0.028 -0.027 -0.012 0.000 0.000 0.007 0.002 -0.005 0.000 0.005 0.000 -0.011 -0.010 -0.009 -0.008 -0.005 -0.004 0.000 0.013 0.012 0.012 0.002 0.010 0.002 0.001 0.005 0.144 0.143 0.136 0.137 0.144 0.143 0.137 0.007 0.051 -0.062 0.012 7000000 18000000 15000000 -30000000 1279000000 -90000000 -304000000 -49000000 -46000000 760000000 -101000000 -101000000 -592000000 -69000000 -661000000 -322000000 5000000 -317000000 -41000000 33000000 37000000 -14000000 -14000000 2000000 3000000 137000000 1287000000 1090000000 3786000000 97000000 1983000000 8380000000 613000000 2985000000 254000000 455000000 9000000 1003000000 5319000000 476000000 1698000000 -836000000 -3331000000 -88000000 -980000000 -3061000000 151000000 216000000 611000000 1730000000 3821000000 62000000 2866000000 9306000000 639000000 3962000000 401000000 565000000 5000000 1132000000 6704000000 423000000 3351000000 -1329000000 -3256000000 -57000000 -1734000000 -2602000000 -13000000 1057000000 53000000 373000000 55000000 -517000000 1008000000 -44000000 -44000000 140000000 -2000000 138000000 4000000 -400000000 23000000 37000000 -336000000 27000000 6000000 -41000000 20000000 11000000 -14000000 9000000 224000000 1331000000 1839000000 4160000000 146000000 2597000000 10297000000 629000000 4019000000 358000000 511000000 1403000000 6920000000 405000000 2688000000 -1481000000 -3649000000 -146000000 -1194000000 -3377000000 263000000 3000000000 2000000000 -29000000000 -28000000000 37000000 3000000 40000000 64000000 4000000 68000000 87000000 5000000 92000000 26000000 25000000 51000000 67000000 16000000 83000000 654000000 1671000000 2325000000 935000000 1724000000 2659000000 21000000 12000000 33000000 30000000 5000000 35000000 50000000 5000000 55000000 75000000 3000000 78000000 73000000 25000000 98000000 405000000 1913000000 2318000000 654000000 1963000000 2617000000 1000000 19000000 13000000 3500000000 4800000000 4400000000 5900000000 66000000000 63000000000 0 0 24000000 24000000 254000000 254000000 71000000 71000000 24000000 325000000 349000000 37000000 37000000 61000000 325000000 386000000 0.21 P8Y0M0D 70000000 8999000000 7817000000 8134000000 1296000000 1119000000 1106000000 8229000000 5168000000 10034000000 6657000000 1943000000 3323000000 -0.42 4658000000 -0.29 1841000000 1739000000 0.06 1632000000 0.07 1612000000 1646000000 -0.02 1630000000 0.01 1525000000 1516000000 0.01 1607000000 -0.06 1059000000 956000000 0.11 917000000 0.04 873000000 672000000 0.30 453000000 867000000 635000000 0.37 402000000 808000000 729000000 0.11 565000000 777000000 581000000 0.34 410000000 0.42 76000000 0 0 893000000 993000000 -0.10 1030000000 -0.04 12274000000 12790000000 -0.04 13304000000 -0.04 1888000000 1835000000 0.03 2060000000 -0.11 589000000 619000000 -0.05 631000000 -0.02 400000000 377000000 0.06 380000000 -0.01 284000000 335000000 -0.15 457000000 -0.27 2207000000 2297000000 -0.04 2395000000 -0.04 5368000000 5463000000 -0.02 5923000000 -0.08 2071000000 1128000000 0.84 261000000 488000000 515000000 -0.05 570000000 -0.10 414000000 398000000 0.04 335000000 0.19 402000000 283000000 0.42 236000000 0.20 378000000 383000000 -0.01 441000000 -0.13 288000000 308000000 -0.06 294000000 0.05 4041000000 3015000000 0.34 2137000000 0.41 3185000000 3109000000 0.02 2776000000 0.12 102000000 124000000 -0.18 141000000 -0.12 3287000000 3233000000 0.02 2917000000 0.11 411000000 363000000 0.13 260000000 0.40 151000000 149000000 0.01 150000000 -0.01 112000000 143000000 -0.22 166000000 -0.14 674000000 655000000 0.03 576000000 0.14 920000000 835000000 0.10 755000000 0.11 23000000 31000000 -0.26 37000000 -0.16 1617000000 1521000000 0.06 1368000000 0.11 507000000 170000000 1.98 21000000 17000000 14000000 0.21 0 524000000 184000000 1.85 21000000 1233000000 1193000000 0.03 1140000000 0.05 960000000 926000000 0.04 1047000000 -0.12 957000000 1073000000 -0.11 1284000000 -0.16 465000000 525000000 -0.11 558000000 -0.06 381000000 444000000 -0.14 728000000 -0.39 236000000 282000000 -0.16 365000000 -0.23 1682000000 1913000000 -0.12 2553000000 -0.25 5914000000 6356000000 -0.07 7675000000 -0.17 20751000000 19772000000 0.05 20041000000 -0.01 0.01 -0.02 33025000000 32562000000 33345000000 1001000000 -103000000 72433000000 -2565000000 70766000000 78000000 70844000000 17783000000 17783000000 11000000 -48000000 -1758000000 -1806000000 -3000000 -1809000000 17735000000 -1758000000 15977000000 8000000 6643000000 6643000000 6643000000 33000000 6086000000 6119000000 6119000000 10000000 -15000000 5000000 14000000 1578000000 1592000000 1592000000 6000000 809000000 815000000 815000000 658000000 658000000 658000000 -10000000 -10000000 -100000000 100000000 -10000000 2000000 -9789000000 100000000 -9697000000 -10000000 -9707000000 991000000 -101000000 80379000000 -4223000000 77046000000 76000000 77122000000 6712000000 6712000000 -14000000 671000000 -3001000000 -2330000000 -3000000 -2333000000 7383000000 -3001000000 4382000000 -17000000 6475000000 6475000000 6475000000 7000000 985000000 992000000 992000000 19000000 -25000000 6000000 2000000 212000000 214000000 214000000 5000000 659000000 664000000 664000000 7000000 7000000 7000000 -12000000 12000000 -19000000 25000000 -6614000000 12000000 -6596000000 -6596000000 972000000 -76000000 81148000000 -7212000000 74832000000 59000000 7703000000 7703000000 -37000000 2872000000 2835000000 2000000 2837000000 7666000000 2872000000 10538000000 2000000 6495000000 6495000000 6495000000 36000000 5538000000 5574000000 5574000000 3000000 -5000000 2000000 2000000 253000000 255000000 255000000 5000000 607000000 612000000 612000000 -2000000 -2000000 -3000000 -24000000 -11175000000 -11202000000 -2000000 -11204000000 969000000 -100000000 77639000000 -4340000000 74168000000 59000000 38000000 -113000000 28000000 12000000 15000000 20000000 50000000 -98000000 48000000 -37000000 671000000 -48000000 -237000000 2210000000 -2391000000 -1662000000 1986000000 -1818000000 -1662000000 851000000 -515000000 -147000000 10540000000 4365000000 15985000000 10538000000 4382000000 15977000000 10538000000 4382000000 5238000000 10739000000 2000000 -17000000 8000000 433000000 -38000000 -5366000000 2406000000 -2565000000 28000000 20000000 48000000 -147000000 -147000000 -1659000000 -1659000000 28000000 20000000 -147000000 -1659000000 -1758000000 100000000 461000000 -18000000 -5413000000 747000000 -4223000000 -113000000 15000000 -98000000 -514000000 -514000000 -2389000000 -2389000000 -113000000 15000000 -514000000 -2389000000 -3001000000 12000000 348000000 -3000000 -5915000000 -1642000000 -7212000000 38000000 12000000 50000000 -237000000 -237000000 851000000 851000000 2208000000 2208000000 38000000 12000000 851000000 -237000000 2208000000 2872000000 386000000 9000000 -5064000000 -237000000 566000000 -4340000000 10000000 29000000 10000000 1001000000 -10000000 991000000 -19000000 -3000000 103000000 2000000 101000000 25000000 -24000000 898000000 -8000000 890000000 6000000 896000000 -27000000 869000000 2706200000 -307600000 2398600000 -10300000 10300000 -49900000 49900000 -29200000 29200000 -9600000 -9600000 -66200000 -66200000 -10300000 -10300000 -49900000 -49900000 -3800000 -3800000 -2600000 -2600000 -4100000 -4100000 4600000 4600000 4100000 4100000 27000000 27000000 8800000 8800000 9000000 9000000 11900000 11900000 -10300000 -46300000 -56600000 -49900000 50100000 200000 -29200000 4500000 -24700000 2616800000 -299300000 2317500000 2627100000 -253000000 2374100000 2677000000 -303100000 2373900000 10000000000 10000000000 10000000000 12000000 62.17 10 6 5000000000 2.75 2.70 2.60 -897000000 -5270000000 -784000000 -4805000000 -304000000 -208000000 -417000000 -70000000 -12900000 -63600000 -56600000 -4707000000 200000 -114000000 -24700000 -3712000000 71000000 17794000000 6698000000 74891000000 7703000000 74227000000 972000000 969000000 76000000 100000000 5000000 508000000 -1617000000 1104000000 13000000 104000000 1186000000 425000000 23000000 324000000 71000000 593000000 1011000000 38000000 663000000 190000000 1106000000 1997000000 720000000 14064000000 2368000000 16858000000 34010000000 -3000000 -510000000 -1007000000 -1520000000 6000000 275000000 34000000 534000000 849000000 -25000000 -58000000 -106000000 -189000000 2000000 30000000 32000000 -3000000 -287000000 -1000000 -772000000 -1063000000 -40000000 -5983000000 -38000000 -11485000000 -17546000000 680000000 8081000000 2330000000 5373000000 78000000 318000000 9000000 688000000 12857000000 2810000000 15093000000 31448000000 4000000 630000000 -1226000000 592000000 24000000 176000000 1226000000 409000000 8000000 178000000 19000000 656000000 861000000 -21000000 -372000000 -111000000 -622000000 -1126000000 687000000 13113000000 2680000000 14816000000 31296000000 -40000000 -5188000000 -7000000 -10231000000 -15466000000 -3000000 -530000000 -956000000 -1489000000 5000000 157000000 1000000 630000000 793000000 -3000000 -47000000 -11000000 -61000000 -122000000 6000000 1000000 13000000 20000000 1000000 166000000 1000000 441000000 609000000 -40000000 -5436000000 -15000000 -10164000000 -15655000000 647000000 7677000000 2665000000 4652000000 81000000 223000000 9000000 841000000 705000000 2957000000 2700000000 3069000000 2850000000 6867000000 6255000000 10300000000 10300000000 10500000000 470000000 283000000 356000000 189000000 67000000 148000000 8790000000 8364000000 -190000000 -162000000 -156000000 12000000 119000000 76000000 68000000 12000000 17000000 39000000 76000000 37000000 32000000 9000000 -2000000 -11000000 -142000000 1733000000 1717000000 124000000 82000000 95000000 63000000 7758000000 7386000000 279000000 262000000 230000000 223000000 137000000 185000000 137000000 145000000 249000000 163000000 3451000000 3432000000 1533000000 1366000000 600000000 567000000 312000000 264000000 268000000 347000000 237000000 222000000 208000000 160000000 165000000 147000000 127000000 135000000 73000000 97000000 1626000000 1465000000 717000000 521000000 93000000 282000000 753000000 692000000 3000000 5000000 8000000 7000000 450000000 1030000000 1034000000 16464000000 15641000000 3054000000 2541000000 420000000 325000000 95000000 395000000 25000000 456000000 366000000 90000000 389000000 67000000 1.00 41 82 2 3900000000 332000000 240000000 92000000 294000000 38000000 0.81 268000000 194000000 74000000 0.19 64000000 53000000 332000000 0 -5400000000 4600000000 16000000000 1500000000 15900000000 12.5 13500000000 2400000000 1800000000 2100000000 7100000000 6250000000 -5250000000 2800000000 5000000 0.365 7600000000 5900000000 600000000 300000000 1100000000 312000000 196000000 116000000 263000000 49000000 258000000 140000000 118000000 258000000 0 7703000000 6712000000 7025000000 10758000000 2346000000 2378000000 2403000000 25000000 22000000 35000000 2371000000 2400000000 2438000000 0 0 0 333000000 194000000 343000000 399000000 200000000 260000000 435000000 64000000 66000000 36000000 7000000 76000000 8000000 21000000 -1000000 153000000 222000000 260000000 924000000 846000000 968000000 261000000 199000000 209000000 11700000 59.9 2100000 59.2 2200000 61.8 7400000 59.5 9500000 59.4 7400000 59.5 9500000 59.4 80.1 700000 1.0 46.7 1100000 2.0 54.6 2700000 3.3 57.6 2900000 5.0 66.1 3.6 31900000 60.2 5600000 59.9 6000000 61.7 20300000 59.9 25900000 59.9 20300000 59.9 25900000 59.9 79.9 1800000 1.0 46.4 2100000 2.0 53.7 8000000 3.5 58.0 8400000 5.0 66.1 3.7 20100000 87.1 1751000000 1300000 69.3 90000000 100000 73.8 7000000 4500000 69.4 312000000 4400000 78.1 344000000 4500000 64.1 288000000 4800000 72.4 348000000 2000000 65.3 131000000 1600000 74.4 119000000 1400000 71.5 100000000 1200000 79.2 95000000 400000 47.7 19000000 300000 58.5 18000000 1300000 67.8 88000000 700000 65.8 46000000 10700000 78.2 837000000 10400000 68.8 716000000 1800000 80.7 145000000 1800000 73.1 132000000 23900000 80.6 1926000000 21000000 89.5 1880000000 200000 36.8 1800000 36.6 100000 37.6 400000 38.9 100000 36.0 1400000 35.9 100000 36.0 1400000 35.9 600000 39.8 100000 33.7 800000 33.0 100000 33.7 800000 33.0 18400000 20800000 17100000 4000000 4000000 4700000 22400000 24800000 21800000 2000000 2200000 1900000 2000000 2200000 1900000 49900000 46200000 52900000 4800000 4600000 4400000 54700000 50800000 57300000 70300000 69200000 71900000 8800000 8600000 9100000 79100000 77800000 81000000 0 25000 100000 0 50000 200000 60000 60000 60000 26279 0 0 0 250000 250000 7703000000 6712000000 17783000000 3.28 2.82 2.92 4.48 3.28 2.82 7.40 3.25 2.80 2.88 4.41 3.25 2.80 7.29 924000000 846000000 903000000 65000000 8121000000 7644000000 7020000000 6448000000 229000000 212000000 456000000 464000000 343000000 108000000 -39000000 -149000000 564000000 425000000 194000000 629000000 234000000 -79000000 -145000000 710000000 -4000000 484000000 944000000 -83000000 23000000 5000000 2000000 23000000 5000000 2000000 -37000000 671000000 -153000000 1071000000 1374000000 113000000 28700000000 61400000000 22600000000 27800000000 50600000000 7500000000 700000000 8200000000 4000000000 21100000000 3100000000 2100000000 6500000000 600000000 1600000000 2200000000 2412000000 673000000 2915000000 6000000000 2121000000 669000000 678000000 650000000 -67000000 -68000000 -157000000 -146000000 -146000000 -150000000 1505000000 3852000000 1763000000 7120000000 -100000000 589000000 268000000 -17000000 47000000 -22000000 -7000000 -12000000 -62000000 0.333 0.333 0.333 0.063 0.063 0.063 0.365 0.365 0.365 438000000 433000000 544000000 463000000 13400000000 12400000000 0.635 758000000 709000000 669000000 19000000 -2000000 -14000000 1000000 1000000 1000000 -1000000 -1000000 -8000000 1000000 -12000000 -7000000 132000000 25000000 20000000 23000000 -72000000 -58000000 -477000000 -254000000 11000000 11000000 47000000 47000000 -109000000 -109000000 13000000 13000000 102000000 102000000 -13000000 -1000000 -14000000 50000000 395000000 18000000 1000000 1000000 -87000000 -87000000 -1000000 -1000000 -154000000 -154000000 16000000 16000000 131000000 131000000 -3000000 -1000000 -4000000 -98000000 345000000 395000000 -130000000 -130000000 80000000 80000000 -8000000 -8000000 -1000000 -1000000 -103000000 -103000000 21000000 21000000 194000000 194000000 -4000000 -1000000 -5000000 48000000 443000000 1275000000 1096000000 197000000 231000000 122000000 147000000 394000000 586000000 255000000 136000000 484000000 451000000 133000000 47000000 201000000 200000000 328000000 306000000 34000000 31000000 362000000 337000000 106000000 94000000 125000000 108000000 31000000 230000000 1000000 1000000 2970000000 1912000000 5890000000 5095000000 303000000 284000000 14000000 12000000 11000000 10000000 22957000000 17285000000 539000000 708000000 87000000 82000000 23583000000 18075000000 359000000 178000000 0.003 0.004 0.82 0.76 0.026 0.028 0.05125 3000000000 0.99822 2997000000 2995000000 0.04400 1000000000 0.99237 997000000 996000000 0.02400 1500000000 0.99225 1491000000 1490000000 0.03700 500000000 0.98325 489000000 489000000 0.03400 2150000000 0.99287 2134000000 2132000000 0.04400 1850000000 0.99196 1824000000 1823000000 0.00750 600000000 0.99134 713000000 625000000 0.01625 600000000 0.99697 714000000 627000000 0.00250 500000000 1.00640 513000000 491000000 0.00625 550000000 1.00502 564000000 539000000 0.01050 325000000 1.00479 333000000 318000000 0.03000 1750000000 0.99010 1730000000 1728000000 0.04000 1250000000 0.98029 1218000000 1217000000 0.00125 1250000000 0.99127 1480000000 1299000000 0.00625 500000000 0.98480 588000000 516000000 0.01800 1000000000 0.99609 996000000 0.02400 1000000000 0.99449 993000000 0.03100 1000000000 0.99109 988000000 0.00000 1250000000 0.99133 1480000000 0.01125 600000000 0.99874 715000000 178000000 359000000 345000000 3173000000 3168000000 1997000000 1000000000 2194000000 628000000 2485000000 2442000000 13375000000 10314000000 15945000000 12952000000 5695000000 3092000000 533000000 683000000 1410000000 1348000000 22957000000 23835000000 17285000000 17943000000 626000000 626000000 790000000 790000000 23583000000 24461000000 18075000000 18733000000 84000000 94000000 849000000 69000000 811000000 256000000 70000000 239000000 223000000 93000000 243000000 832000000 2000000 8000000 -8000000 351000000 395000000 1194000000 121000000 131000000 743000000 451000000 1822000000 1601000000 692000000 836000000 2328000000 3174000000 107000000 116000000 0.005 0.005 0.070 0.067 2 1900000000 1800000000 2100000000 920000000 835000000 755000000 33000000 217000000 309000000 25000 250000 10000000 0.07 10000000 11 14 11 13 13 12 8860000000 7007000000 328000000 306000000 34000000 31000000 362000000 337000000 1109000000 989000000 166000000 107000000 1275000000 1096000000 1637000000 1433000000 10650000000 10202000000 1000000 1000000 125000000 108000000 574000000 514000000 11350000000 10825000000 216000000 188000000 31000000 230000000 844000000 586000000 1091000000 1004000000 22938000000 20269000000 1822000000 1601000000 692000000 836000000 2328000000 3174000000 359000000 178000000 5201000000 5789000000 22957000000 17285000000 539000000 708000000 87000000 82000000 359000000 178000000 23224000000 17897000000 5169000000 4873000000 33594000000 28559000000 924000000 1018000000 107000000 116000000 1031000000 1134000000 34625000000 29693000000 8410000000 8220000000 31000000 230000000 -107000000 -116000000 8410000000 8220000000 31000000 230000000 -107000000 -116000000 2768000000 4361000000 1281000000 2768000000 4361000000 1281000000 3623000000 3427000000 43000000 1127000000 3623000000 3427000000 43000000 1127000000 303000000 25000000 328000000 34000000 34000000 337000000 25000000 362000000 125000000 125000000 31000000 31000000 1000000 1000000 337000000 56000000 126000000 519000000 672000000 437000000 1109000000 166000000 166000000 394000000 394000000 574000000 574000000 672000000 997000000 574000000 2243000000 28000000 188000000 216000000 450000000 450000000 852000000 852000000 72000000 72000000 107000000 107000000 107000000 924000000 1031000000 284000000 22000000 306000000 31000000 31000000 315000000 22000000 337000000 108000000 108000000 230000000 230000000 1000000 1000000 315000000 252000000 109000000 676000000 513000000 476000000 989000000 107000000 107000000 586000000 586000000 514000000 514000000 513000000 1169000000 514000000 2196000000 188000000 188000000 889000000 889000000 129000000 129000000 116000000 116000000 116000000 1018000000 1134000000 45000000 32000000 278000000 362000000 -34000000 -45000000 -193000000 -37000000 45000000 -40000000 37000000 28000000 113000000 -238000000 -20000000 106000000 94000000 -19000000 -18000000 -52000000 -29000000 4000000 -47000000 188000000 166000000 437000000 844000000 -852000000 -72000000 11000000 0 -13000000 278000000 169000000 -37000000 181000000 94000000 473000000 550000000 -790000000 -315000000 26000000 1000000 51000000 3000000 -28000000 -1000000 -24000000 -156000000 14000000 -8000000 41000000 5000000 122000000 -172000000 -15000000 229000000 183000000 -3000000 -5000000 -18000000 -29000000 -70000000 188000000 107000000 476000000 586000000 -889000000 -129000000 -2000000 -1000000 -23000000 51000000 -156000000 3000000 73000000 75000000 79000000 333000000 322000000 300000000 1800000000 2200000000 237000000 0 0.202 0.165 0.150 0.069 0.127 0.067 2 1 3 9000000000 150000000000 1300000000 2300000000 3200000000 6000000000 6000000000 6000000000 0.95 71000000 72000000 105000000 181000000 58000000 487000000 106000000 106000000 7000000 19000000 6000000 32000000 4260000000 4600000000 8860000000 4338000000 4691000000 111000000 181000000 164000000 9849000000 13375000000 23224000000 9893000000 13519000000 23412000000 9849000000 13375000000 4576000000 169000000 456000000 5201000000 4576000000 169000000 456000000 5201000000 31000000 48000000 28000000 107000000 4607000000 217000000 484000000 269000000 -4474000000 373000000 9668000000 13211000000 32000000 126000000 110000000 124000000 53000000 445000000 94000000 94000000 38000000 102000000 91000000 231000000 5907000000 1100000000 7007000000 5977000000 1328000000 201000000 124000000 147000000 5141000000 12756000000 17897000000 5155000000 12901000000 18056000000 5141000000 12756000000 5099000000 250000000 440000000 5789000000 5099000000 250000000 440000000 5789000000 15000000 72000000 29000000 116000000 5114000000 322000000 469000000 -863000000 -1006000000 268000000 5017000000 12609000000 953000000 972000000 2824000000 4749000000 928000000 948000000 2778000000 4654000000 1087000000 1246000000 2027000000 4360000000 1109000000 1287000000 2051000000 4447000000 113000000 507000000 1765000000 3859000000 6244000000 5169000000 104000000 433000000 1694000000 4015000000 6246000000 4873000000 498000000 541000000 184000000 222000000 27000000 26000000 242000000 328000000 521000000 560000000 466000000 277000000 352000000 184000000 28000000 35000000 21000000 282000000 338000000 219000000 402000000 541000000 316000000 203000000 245000000 147000000 50000000 99000000 26000000 308000000 407000000 234000000 7000000 6000000 7000000 6000000 15370000000 14304000000 1108000000 703000000 266000000 777000000 707000000 655000000 110000000 43000000 33000000 39000000 -447000000 -454000000 2243000000 2196000000 818000000 698000000 625000000 770000000 8860000000 7007000000 23224000000 17897000000 230000000 264000000 5308000000 5905000000 9485000000 19047000000 7777000000 16025000000 5169000000 4873000000 1367000000 -667000000 -252000000 76000000 12000000 168000000 -592000000 140000000 -63000000 -1000000 272000000 0.015 0.020 0.030 0.026 0.070 0.070 0.070 0.070 3157000000 4490000000 625000000 545000000 953000000 1005000000 706000000 708000000 809000000 840000000 577000000 618000000 923000000 46000000 75000000 52000000 153000000 5000000 154000000 1000000 6000000 33000000 -24000000 -1000000 761000000 773000000 871000000 55000000 65000000 80000000 791000000 164000000 241000000 315000000 41000000 1000 1500000000 20 45 125000000 1500000000 4000000 53000000 50 1 20 1000 10 2 17 3 225000000 216000000 23614000000 23402000000 1158000000 1132000000 422000000 437000000 34000000 35000000 330000000 390000000 44000000 48000000 -1226000000 -73000000 -10000000 27000000 29000000 -11000000 -1299000000 -32000000 -46000000 26000000 7000000 9000000 26000000 -47000000 -117000000 87000000 33000000 1138000000 -896000000 5000000 7000000 1300000000 1250000000 51000000 51000000 207000000 207000000 -34000000 -41000000 -1000000 23210000000 1115000000 19225000000 19536000000 153000000 172000000 236000000 293000000 5000000 6000000 1429000000 742000000 12000000 -1000000 909000000 -757000000 579000000 542000000 43000000 27000000 -995000000 -77000000 -15000000 -11000000 20275000000 162000000 -2935000000 -4389000000 -953000000 -1005000000 -54000000 -50000000 -30000000 -5000000 -4000000 -89000000 3024000000 4443000000 953000000 1005000000 3916000000 960000000 99000000 101000000 39000000 42000000 231000000 -4000000 10000000 1397000000 -667000000 76000000 12000000 -229000000 139000000 -5000000 -7000000 19000000 30000000 1000000 133000000 47000000 -3157000000 -4490000000 -953000000 -1005000000 14606000000 3788000000 4816000000 23210000000 15436000000 3783000000 4395000000 23614000000 728000000 499000000 1227000000 739000000 497000000 1236000000 5627000000 796000000 1646000000 8069000000 6426000000 891000000 1460000000 8777000000 1258000000 1646000000 2904000000 831000000 1515000000 2346000000 8979000000 1734000000 1524000000 12237000000 9010000000 2061000000 1420000000 12491000000 14445000000 2400000000 3430000000 20275000000 13958000000 2282000000 2985000000 19225000000 -161000000 -1388000000 -1386000000 -2935000000 -1478000000 -1501000000 -1410000000 -4389000000 0.015 0.014 0.018 0.037 0.042 0.044 0.005 0.004 0.004 0.028 0.022 0.029 0.006 0.005 0.008 P22Y0M0D P22Y0M0D P21Y0M0D P21Y0M0D P21Y0M0D P21Y0M0D P24Y0M0D P24Y0M0D P24Y0M0D P23Y0M0D P23Y0M0D P23Y0M0D -753000000 803000000 840000000 533000000 -138000000 56000000 -54000000 49000000 -50000000 0.15 0.40 0.31 0.31 0.20 0.60 0.35 0.35 0.05 0.20 0.15 0.15 0.00 0.20 0.15 0.15 0.00 0.15 0.04 0.04 1.00 1.00 11000000 11000000 900000000 800000000 P14Y7M7D P14Y6M1D 395000000 62000000 1226000000 63000000 1166000000 65000000 1163000000 67000000 1147000000 68000000 1133000000 69000000 5534000000 344000000 0.065 0.070 0.075 0.045 0.050 0.050 406000000 338000000 359000000 1000000 309000000 224000000 161000000 131000000 123000000 2221000000 3169000000 337000000 780000000 130000000 910000000 671000000 671000000 864000000 864000000 801000000 801000000 353000000 353000000 837000000 837000000 4306000000 130000000 4436000000 7057000000 8470000000 1677000000 1591000000 1550000000 4399000000 4452000000 3921000000 256000000 132000000 104000000 -1043000000 -935000000 -869000000 683000000 671000000 773000000 160000000 956000000 1642000000 738000000 1154000000 1109000000 85000000 -247000000 -235000000 -482000000 -204000000 -229000000 -513000000 58000000 -587000000 378000000 637000000 974000000 -246000000 25000000 1000000000 1000000 -451000000 -12970000000 646000000 -1223000000 -690000000 -730000000 13000000 113000000 3000000 -15000000 86000000 -8000000 -39000000 -555000000 40000000 -4000000 893000000 34000000 -1000000 -3000000 529000000 -20000000 -1000000 -25000000 311000000 601000000 -326000000 15000000 -372000000 -212000000 841000000 -925000000 48000000 -814000000 -14086000000 2189000000 98000000 20000000 1000000 25000000 -479000000 64000000 -905000000 48000000 -749000000 -14061000000 1808000000 578000000 -94000000 -56000000 -2438000000 1042000000 7401000000 140000000 748000000 1337000000 206000000 84000000 -8000000 -519000000 36000000 3000000 44000000 49000000 -829000000 -95000000 -765000000 -748000000 -16507000000 8924000000 -140000000 -748000000 8924000000 -829000000 45000000 -765000000 -16507000000 92000000 60000000 49000000 -188000000 41000000 1000000 2000000 -140000000 -748000000 8924000000 -140000000 -748000000 8882000000 -140000000 -748000000 8694000000 10925000000 2001000000 17897000000 5905000000 4933000000 1000000 187000000 -755000000 6000000 140000000 146000000 16000000 16000000 744000000 126000000 870000000 -359000000 359000000 23224000000 5308000000 451000000 12970000000 1223000000 690000000 730000000 15000000 8000000 39000000 555000000 4000000 1000000 3000000 20000000 1000000 25000000 326000000 372000000 212000000 925000000 814000000 14086000000 94000000 56000000 2438000000 999000000 869000000 16499000000 0 18000000 2400000000 7058000000 8437000000 9070000000 244000000 -77000000 -863000000 23802000000 4933000000 188000000 -755000000 28532000000 25000000 650000000 1.00 1.00 906100000 1.00 1.00 83900000 1.00 1.00 2 1.00 1.00 3800000 1.00 1.00 11600000 1.00 1.00 2600000 1.00 1.00 1000000 1.00 1.00 1100000 1.00 1.00 32700000 1.00 1.00 1000000 1.00 1.00 162500000 0.60 0.60 7100000 1.00 1.00 19200000 1.00 1.00 110600000 1.00 1.00 141856 1.00 1.00 12000 1.00 1.00 30000 1.00 1.00 20000 1.00 1.00 12000 1.00 1.00 106400 1.00 1.00 1000000 1.00 1.00 370000 1.00 1.00 265000000 1.00 1.00 190000000 1.00 1.00 13000000 1.00 1.00 80800000 1.00 1.00 2500 1.00 1.00 82886 1.00 1.00 2000000000 1.00 1.00 2000000000 1.00 1.00 30000000 1.00 1.00 200 1.00 1.00 320000000 1.00 1.00 103400000 1.00 1.00 3200000 1.00 1.00 36500000 1.00 1.00 77000 1.00 1.00 60000000 1.00 1.00 7900000000 1.00 1.00 20900000 1.00 1.00 25600000 1.00 1.00 51500000 1.00 1.00 44700000 1.00 1.00 31000000 1.00 1.00 14000000 1.00 1.00 12000000 1.00 1.00 500000 1.00 1.00 4000000 1.00 1.00 193800000 0.9977 1.00 250000 1.00 1.00 459000 1.00 1.00 103000000 1.00 1.00 43400000 1.00 1.00 5400000 1.00 1.00 12900000 1.00 1.00 155500000 1.00 1.00 25000 1.00 1.00 25600000 1.00 1.00 2000000 1.00 1.00 100000 1.00 1.00 26000 1.00 1.00 93700000 1.00 1.00 42100000 1.00 1.00 26000 1.00 1.00 512000 1.00 1.00 15400000 1.00 1.00 6600000 1.00 1.00 130000000 1.00 1.00 23400000 1.00 1.00 5700000 1.00 1.00 545600000 1.00 1.00 883000000 1.00 1.00 140700000 0.734 0.73 60000000 1.00 1.00 32000000 1.00 1.00 1100000000 1.00 1.00 7700000000 1.00 1.00 11900000000 1.00 1.00 25000 1.00 1.00 2000000 1.00 1.00 541251 1.00 1.00 1000 1.00 1.00 752545 1.00 1.00 18200000 1.00 1.00 1700000 1.00 1.00 2600000 1.00 1.00 3700000 1.00 1.00 10000000 1.00 1.00 6000000000 1.00 1.00 8500000 1.00 1.00 100000000 1.00 1.00 500000000 1.00 1.00 100000000 1.00 1.00 100000 1.00 1.00 3300000 1.00 1.00 1000000 1.00 1.00 10000000 1.00 1.00 205000000 1.00 1.00 468200000 1.00 1.00 5900000 1.00 1.00 80000000 1.00 1.00 1400000 1.00 1.00 4500000 1.00 1.00 907560 1.00 1.00 18151 1.00 1.00 820000 1.00 1.00 1500000 1.00 1.00 3900000000 0.9999 1.00 10000 1.00 1.00 1000 1.00 1.00 298800000 1.00 1.00 30000000 1.00 1.00 44200000 1.00 1.00 25600000 1.00 1.00 11400000 1.00 1.00 750000 1.00 1.00 500000 1.00 1.00 2400000 1.00 1.00 499900 1.00 1.00 4500000 1.00 1.00 3000000 1.00 1.00 105200000 1.00 1.00 10800000 1.00 1.00 20000000 1.00 1.00 1300000000 1.00 1.00 57400000 1.00 1.00 44100000 1.00 1.00 26800000 0.75 0.75 100000 1.00 1.00 45000000 1.00 1.00 39000000 1.00 1.00 2004 1.00 1.00 164000 1.00 1.00 101000 1.00 1.00 1000000 1.00 1.00 2000000 1.00 1.00 48400000 1.00 1.00 1500000 1.00 1.00 86300000 1.00 1.00 3000000 1.00 1.00 201820 1.00 1.00 24500000000 0.9855 0.99 17800000000 1.00 1.00 33800000000 1.00 1.00 63000000 1.00 1.00 270450 1.00 1.00 9300000 1.00 1.00 11600000 1.00 1.00 6000000 1.00 1.00 5000000 1.00 1.00 10000000 1.00 1.00 100200000 1.00 1.00 100000 1.00 1.00 100000 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 350000000 1.00 1.00 100000 1.00 1.00 20000000 1.00 1.00 18900000 1.00 1.00 251000 1.00 1.00 5000000 1.00 1.00 5000000 1.00 1.00 100000 1.00 1.00 100000 1.00 1.00 200000 1.00 1.00 160000000 0.3333 0.055 170000000 1.00 1.00 302000000 1.00 1.00 228100000 1.00 1.00 98000000 1.00 1.00 6700000 1.00 1.00 165200000 0.9999 1.00 46000000 1.00 1.00 50000000 1.00 1.00 25200000 1.00 1.00 7000000 1.00 1.00 25500000 1.00 1.00 5400000 1.00 1.00 250000000 1.00 1.00 3904 1.00 1.00 2000000 1.00 1.00 550000 1.00 1.00 100000 0.365 0.37 72200000 1.00 1.00 1000 1.00 1.00 1 1.00 1.00 1 1.00 1.00 1.00 1.00 5200000 1.00 1.00 1 1.00 1.00 1 1.00 1.00 1 1.00 1.00 1 1.00 1.00 100 1.00 1.00 1 1.00 1.00 1 1.00 1.00 1000 1.00 1.00 25000 1.00 1.00 1 1.00 1.00 1 1.00 1.00 1000 1.00 1.00 10 1.00 1.00 12.5 1.00 1.00 1 1.00 1.00 10 1.00 1.00 3 1.00 1.00 1 1.00 1.00 1 1.00 1.00 1400000 1.00 1.00 5500000 1.00 1.00 83000000 7000000 76000000 3000000 73000000 91000000 5000000 86000000 2000000 84000000 180000000 14000000 166000000 59000000 107000000 182000000 16000000 166000000 37000000 129000000 31000000 2000000 29000000 14000000 15000000 63000000 4000000 59000000 41000000 18000000 294000000 23000000 271000000 76000000 195000000 336000000 25000000 311000000 80000000 231000000 660000000 547000000 153000000 222000000 977000000 880000000 586000000 550000000 4672000000 4183000000 2327000000 1993000000 305000000 287000000 44000000 49000000 1042000000 722000000 3533000000 3000000 17997000000 16622000000 15603000000 17452000000 16189000000 15218000000 252000000 -10000000 -50000000 196000000 -50000000 -181000000 4672000000 4183000000 3790000000 11203000000 9828000000 49109000000 48518000000 49414000000 26000000 49109000000 48518000000 49440000000 1026000000 918000000 947000000 17175000000 17520000000 17404000000 32960000000 31916000000 32983000000 12861000000 11998000000 11772000000 8972000000 9039000000 8935000000 2136000000 2194000000 2475000000 1969000000 1927000000 2049000000 2331000000 2344000000 2873000000 8629000000 8268000000 8977000000 7703000000 6698000000 7028000000 10766000000 0 -14000000 11000000 0.50 200000000 3200000000 3 2 3 2 2 31750000000 30980000000 29997000000 31340000000 104871000000 105193000000 202000000 156000000 28208000000 24931000000 133079000000 130124000000 73299000000 73936000000 74168000000 74832000000 59000000 59000000 35449000000 33024000000 1723000000 1603000000 23403000000 22209000000 58852000000 55233000000 133079000000 130124000000 987000000 899000000 432000000 97000000 43000000 34000000 708000000 723000000 646000000 714000000 272000000 155000000 23000000 1611000000 2111000000 2454000000 13254000000 13088000000 14155000000 877000000 1536000000 1207000000 12621000000 11475000000 12085000000 -188000000 12621000000 11475000000 11897000000 1696000000 1862000000 2367000000 92000000 161000000 237000000 1050000000 1017000000 1138000000 640000000 847000000 621000000 468000000 247000000 264000000 330000000 247000000 166000000 42000000 149000000 82000000 1000000 1000000 29000000 -784000000 -765000000 -16507000000 580000000 530000000 595000000 549000000 622000000 262000000 -2979000000 -2693000000 -19666000000 -140000000 -748000000 8882000000 -3119000000 -3441000000 -10784000000 6495000000 6475000000 6643000000 5490000000 1109000000 6071000000 252000000 214000000 1581000000 1935000000 4596000000 1696000000 3086000000 1816000000 451000000 0 6000000 0 10000000 7000000 -4000000 -7733000000 -5314000000 -9176000000 84000000 -387000000 -286000000 1853000000 2333000000 -8349000000 13023000000 4674000000 2299000000 3325000000 188000000 965000000 -94000000 -83000000 -1000000 10060000000 10144000000 6024000000 5812000000 668000000 624000000 118000000 104000000 3000000 -789000000 -728000000 33693000000 33186000000 10178000000 10248000000 6027000000 5812000000 -789000000 -728000000 898000000 815000000 37000000 37000000 3000000 4000000 88000000 62000000 9007000000 9331000000 5800000000 5971000000 3231000000 3092000000 -863000000 -874000000 25584000000 24670000000 4415000000 4314000000 2799000000 2724000000 162000000 208000000 9089000000 8435000000 1811000000 1681000000 1961000000 1882000000 7630000000 7709000000 774000000 814000000 568000000 516000000 986000000 978000000 315000000 300000000 383000000 410000000 452000000 506000000 1027000000 1091000000 204000000 185000000 47000000 48000000 691000000 603000000 1124000000 1213000000 351000000 259000000 124000000 96000000 732000000 776000000 7782000000 7426000000 1368000000 1445000000 -190000000 -132000000 -331000000 -471000000 -1000000 23000000 6000000 1086000000 697000000 916000000 883000000 270000000 260000000 217000000 229000000 117000000 117000000 1520000000 1489000000 2291000000 2470000000 447000000 450000000 942000000 929000000 10000000 12000000 3690000000 3861000000 84000000 93000000 73000000 2000000 5000000 2000000 157000000 102000000 591000000 522000000 61000000 65000000 57000000 4000000 709000000 591000000 42000000 55000000 29000000 185000000 77000000 256000000 132000000 122000000 236000000 61000000 46000000 8000000 36000000 3000000 25000000 194000000 343000000 593000000 582000000 52000000 47000000 71000000 53000000 208000000 164000000 10070000000 5999000000 518000000 128000000 -620000000 26000000 33863000000 10198000000 5999000000 -620000000 792000000 25000000 23000000 107000000 9204000000 5844000000 3145000000 -789000000 25451000000 4379000000 2877000000 276000000 8430000000 1679000000 1663000000 7685000000 782000000 468000000 1031000000 346000000 450000000 648000000 1149000000 109000000 54000000 737000000 1639000000 381000000 69000000 784000000 7815000000 1300000000 281000000 -419000000 2000000 264000000 839000000 277000000 237000000 117000000 1470000000 2384000000 450000000 912000000 9000000 3755000000 -39000000 97000000 1000000 21000000 80000000 138000000 27000000 1000000 166000000 32000000 72000000 104000000 232000000 93000000 25000000 49000000 399000000 620000000 53000000 66000000 164000000 54075000000 51911000000 18231000000 17611000000 22014000000 22970000000 38759000000 37632000000 11457000000 10007000000 3459000000 3168000000 1893000000 2520000000 42043000000 39538000000 42618000000 41904000000 14772000000 14443000000 20121000000 20450000000 93274000000 90916000000 10857000000 10410000000 2525000000 2374000000 2403000000 2163000000 679000000 694000000 877000000 996000000 326000000 316000000 431000000 396000000 94000000 127000000 31571000000 31630000000 10993000000 10774000000 16176000000 16914000000 3007000000 3002000000 61747000000 62320000000 984000000 865000000 64000000 45000000 82000000 63000000 16000000 5000000 1146000000 978000000 41000000 16000000 7000000 18000000 15322000000 14270000000 6000000 4000000 40000000 37000000 46000000 41000000 9485000000 7777000000 28532000000 23802000000 6891000000 8260000000 6891000000 8260000000 836000000 0.02 830000000 0.02 774000000 0.02 43920000000 0.47 44413000000 0.48 16935000000 0.34 17117000000 0.35 18079000000 0.37 28476000000 0.30 28484000000 0.31 1160000000 0.02 1182000000 0.02 1277000000 0.03 7957000000 0.09 6892000000 0.07 3690000000 0.08 3634000000 0.07 3262000000 0.07 3128000000 0.03 2733000000 0.03 2490000000 0.05 2390000000 0.05 2269000000 0.05 284000000 199000000 3177000000 0.06 3267000000 0.07 3163000000 0.06 148000000 145000000 20821000000 0.43 20098000000 0.42 20590000000 0.40 9668000000 0.11 9399000000 0.11 1.00 1.00 1.00 93581000000 1.00 92265000000 1.00 17492000000 0.36 17079000000 0.35 16472000000 0.33 61699000000 0.66 59879000000 0.65 20899000000 0.42 20998000000 0.43 22414000000 0.45 29113000000 0.31 29831000000 0.32 10718000000 0.22 10441000000 0.22 10528000000 0.22 2769000000 0.03 2555000000 0.03 0.17 0.16 0.14 0.14 0.12 0.12 0.09 0.09 0.07 0.06 0.05 0.06 0.14 0.11 0.05 145000000 456000000 601000000 18000000 1000000 19000000 163000000 457000000 620000000 18000000 5000000 23000000 192000000 184000000 376000000 -11000000 278000000 267000000 57000000 187000000 244000000 151000000 30000000 181000000 26000000 32000000 58000000 2870000000 10558000000 -8000000 13420000000 57000000 14000000 656000000 727000000 2568000000 10573000000 -664000000 12477000000 2000000 2000000 12479000000 1713000000 10766000000 94000000 1223000000 1223000000 -389000000 175000000 214000000 697000000 5000000 282000000 162000000 1146000000 353000000 1000000 328000000 64000000 746000000 704000000 134000000 86000000 969000000 48000000 1237000000 32179000000 6462000000 2980000000 6638000000 34105000000 5960000000 1852000000 57997000000 6000000 -6000000 -577000000 -2571000000 -238000000 -304000000 -3690000000 352000000 317000000 61000000 730000000 -615000000 -92000000 -2000000 -709000000 -28000000 -27000000 -54000000 -416000000 -37000000 -534000000 -429000000 -1170000000 -4268000000 -19631000000 -1668000000 -1263000000 -28000000000 31750000000 5292000000 2980000000 2370000000 14474000000 4292000000 589000000 29997000000 31585000000 4119000000 2980000000 6563000000 33385000000 5960000000 1341000000 54348000000 56000000 690000000 451000000 1141000000 -158000000 6000000 152000000 599000000 223000000 156000000 978000000 23000000 464000000 130000000 617000000 -260000000 -77000000 -15000000 -594000000 -27000000 -713000000 31381000000 5150000000 2980000000 6548000000 33007000000 5960000000 1492000000 55137000000 -411000000 -650000000 -3070000000 -14221000000 -1192000000 -998000000 -20131000000 225000000 -225000000 -576000000 -2926000000 -238000000 -121000000 -3861000000 22000000 390000000 123000000 535000000 -490000000 -96000000 -5000000 -591000000 10000000 7000000 9000000 215000000 20000000 251000000 -401000000 -886000000 -3637000000 -16863000000 -1430000000 -981000000 -23797000000 30980000000 4264000000 2980000000 2911000000 16144000000 4530000000 511000000 31340000000 15237000000 4368000000 9000000 11604000000 353000000 16334000000 8210000000 625000000 539000000 1589000000 30000000 2783000000 8295000000 291000000 1822000000 1281000000 4292000000 195000000 7881000000 8000000 8000000 2980000000 11000000 2999000000 15010000000 3512000000 11000000 12821000000 276000000 16620000000 7669000000 613000000 563000000 1904000000 25000000 3105000000 8293000000 139000000 2337000000 1419000000 4530000000 196000000 8621000000 8000000 2980000000 14000000 2994000000 -591000000 -522000000 -61000000 -65000000 -57000000 -4000000 -709000000 -591000000 6700000000 6500000000 2.80 0.97 0 0 100000000 1000000000 8600000000 8202000000 26700000000 56900000000 20600000000 26000000000 26300000000 4400000000 200000000 4600000000 3300000000 20600000000 2600000000 2000000000 1728000000 1835000000 1728000000 1835000000 8600000000 8202000000 5300000000 600000000 -400000000 200000000 1000000 2000000 18000000 42000000 42000000 41000000 0.10 0.05 275000000 100000000 1800000000 NOVARTIS AG 0001114448 NVS 6-K 2017-12-31 false --12-31 Yes No Yes Large Accelerated Filer 2017 FY Novartis’s Vaccines influenza business was excluded from the GSK Vaccines business acquisition. However, GSK entered into a future option arrangement with Novartis in relation to the Vaccines influenza business, pursuant to which Novartis could have unilaterally required GSK to acquire the entire or certain parts of its Vaccines influenza business for consideration of up to USD 250 million (the Influenza Put Option) if the divestment to CSL Limited, Australia (CSL), discussed below, had not been completed. The option period was 18 months from the closing date of the GSK transaction, but terminated with the sale of the Vaccines influenza business to CSL on July 31, 2015. Novartis paid GSK a fee of USD 5 million in consideration for the grant of the Influenza Put Option. The Annual Incentive of the Novartis Group CEO and the other Executive Committee members is paid 50% in cash in February or March of the year following the performance period, and 50% in Novartis Restricted Shares (RSs) or Restricted Share Units (RSUs) that are granted in January of the year following the performance period, deferred and restricted for three years. In 2016, this was extended to Novartis Top Leaders (NTLs). The Annual Incentive payout for the NTLs is 70% in cash and 30% in Novartis RSs or RSUs. Each RS is entitled to voting rights and payment of dividends during the vesting period. Each RSU is equivalent to one Novartis share and is converted into one share at the vesting date. RSUs do not carry any dividend, dividend equivalent or voting rights. The executives in certain countries may elect to also receive their cash incentive partially or fully in shares or share units that will not be subject to vesting conditions. A number of associates in certain countries as well as certain key executives worldwide are encouraged to invest their Annual Incentive, and in the United Kingdom also their salary, in a share savings plan. Under the share savings plan, participants may elect to receive their Annual Incentive fully or partially in Novartis shares in lieu of cash. As a reward for their participation in the share savings plan, at no additional cost to the participant, Novartis matches their investments in shares after a holding period of three or five years. In Switzerland, Employee Share Ownership Plan (ESOP) participants may choose to receive their Annual Incentive (i) 100% in shares, (ii) 50% in shares and 50% in cash or (iii) 100% in cash. After expiration of a three-year holding period for Novartis shares invested under the ESOP, participants will receive one matching share for every two invested shares. Associates eligible for the equity plan “Select” are not eligible to receive ESOP matching shares starting with the 2017 performance period onwards. In the United Kingdom, associates can invest up to 10% of their monthly salary in shares (up to a maximum of GBP 150) and may also be invited to invest their net Annual Incentive in shares. Two invested shares are matched with one share with a holding period of three years. Starting with the 2017 performance period onwards, United Kingdom associates can only invest a maximum of 50% of their Annual Incentive in shares and this option is no longer offered to associates who are eligible for the equity plan “Select”. The Leveraged Share Savings Plan (LSSP) was available to key executives for performance periods prior to 2016. At the participant’s election, the Annual Incentive was awarded partly or entirely in shares. The elected number of shares is subject to a holding period of five years. At the end of the holding period, Novartis will match the invested shares at a ratio of 1-to-1 (i.e. one share awarded for each invested share). In the United States both the LSSP award and the corresponding match are cash settled. The equity plan “Select” is a global equity incentive plan under which eligible associates may annually be awarded a grant subject to a three year vesting period. No awards are granted for performance ratings below a certain threshold. Executive Committee members are not eligible for participation in the equity plan “Select” effective from the performance period 2014, and the NTLs are not eligible to participate effective from the performance period 2016. The equity plan “Select” currently allows participants in Switzerland to choose the form of their equity compensation in RSs or RSUs. In all other jurisdictions, RSUs are typically granted. Until 2013, participants could also choose to receive part or the entire grant in the form of tradable share options. Tradable share options expire on their tenth anniversary from the grant date. Each tradable share option entitles the holder to purchase after vesting (and before the tenth anniversary from the grant date) one Novartis share at a stated exercise price that equals the closing market price of the underlying share at the grant date. The Long-Term Performance Plan (LTPP) is an equity plan for the Novartis Group CEO, the other Executive Committee members and the NTLs. For the 2017 grant, the target incentive is 200% of base compensation for the Novartis Group CEO and ranges from 150% to 170% for other Executive Committee members. For the NTLs, the target incentive range is from 20% to 160% of base compensation. The awards of the LTPP are based on three-year performance objectives focused on financial and innovation measures. The financial measure is Novartis Cash Value Added (NCVA). The weighting of this measure is 75%. The NCVA target is approved by the Board of Directors. The innovation measure is based on a holistic approach under which divisional innovation targets are set at the beginning of the cycle, comprised of up to ten target milestones that represent the most important research and development project milestones for each division. The weighting of this measure is 25%. At the end of the performance period, the Research & Development Committee assists the Board of Directors and the Compensation Committee in evaluating performance against the innovation targets at the end of the cycle. Under the LTPP, participants are granted a target number of Performance Share Units (PSUs) at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. Payout is between 0% and 200% of target. PSUs granted under the LTPP do not carry voting rights, but do carry dividend equivalents that are paid in shares at the end of the performance period. The Long-Term Relative Performance Plan (LTRPP) is an equity plan for the Novartis Group CEO, other ECN members and NTLs. For the 2017 grant, the target incentive is 125% of base compensation for the Novartis Group CEO and ranges from 60% to 80% for other Executive Committee members. For the NTLs, the target incentive range is from 10% to 40% of base compensation. The LTRPP is based on the ranking of Novartis’ Total Shareholder Return (TSR) relative to a global healthcare peer group of 12 companies until 2016, and 15 companies from 2017, over rolling three-year performance periods. TSR in USD is calculated as price change of the Novartis share plus the dividend plus the re-investment return of the dividend amount, all translated to USD at the respective exchange rate, over the three-year performance period. The calculation is based on Bloomberg standard published TSR data, which is publicly available. The position in the peer group determines the payout range based on a payout matrix. Under the LTRPP, participants are also granted a target number of PSUs at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. Payout is between 0% and 200% of target. PSUs under the LTRPP do not carry voting rights, but do carry dividend equivalents that are paid in shares at the end of the performance period. Selected associates, excluding the Executive Committee members, may exceptionally receive Special Share Awards of RSs or RSUs. These Special Share Awards provide an opportunity to reward outstanding achievements or exceptional performance, and aim to retain key contributors. They are based on a formal internal selection process, through which the individual performance of each candidate is thoroughly assessed at several management levels. Special Share Awards have a minimum three-year vesting period. In exceptional circumstances, Special Share Awards may be awarded to attract special expertise and new talents into the organization. These grants are consistent with market practice and Novartis’ philosophy to attract, retain and motivate best-in-class talents around the world. Worldwide, associates at different levels in the organization were awarded RSs and RSUs in 2017. In addition, in 2017, Board members received unrestricted shares as part of their regular compensation. At the completion of the merger of Alcon, Inc. into Novartis on April 8, 2011, all awards outstanding under the Alcon equity plans were converted into awards based upon Novartis shares with a conversion factor of 3.0727 as defined in the Merger Agreement. The plans are fully vested. Share options entitle the recipient to purchase Novartis shares at the closing market price of the former Alcon, Inc., share on the day of grant divided by the conversion factor. Share-settled appreciation rights (SSAR) entitle the participant to receive, in the form of Novartis shares, the difference between the values of the former Alcon, Inc., share at the date of grant, converted into Novartis shares using the conversion factor, and the Novartis share price at the date of exercise. Both options and SSAR expire on their tenth anniversary. The last grant was made in 2009. 20 to 40 years 7 to 20 years 5 to 10 years 3 to 7 years 5 to 20 years 25 years 10 to 20 years 3 to 7 years Not amortized, indefinite useful life 20 20 USD 2009 2019 Novartis Securities Investment Ltd., Hamilton, Bermuda USD 2010 2020 Novartis Capital Corporation, New York, United States USD 2012 2022 Novartis Capital Corporation, New York, United States USD 2012 2042 Novartis Capital Corporation, New York, United States USD 2014 2024 Novartis Capital Corporation, New York, United States USD 2014 2044 Novartis Capital Corporation, New York, United States EUR 2014 2021 Novartis Finance S.A., Luxembourg, Luxembourg EUR 2014 2026 Novartis Finance S.A., Luxembourg, Luxembourg CHF 2015 2025 Novartis AG, Basel, Switzerland CHF 2015 2029 Novartis AG, Basel, Switzerland CHF 2015 2035 Novartis AG, Basel, Switzerland USD 2015 2025 Novartis Capital Corporation, New York, United States USD 2015 2045 Novartis Capital Corporation, New York, United States EUR 2016 2023 Novartis Finance S.A., Luxembourg, Luxembourg EUR 2016 2028 Novartis Finance S.A., Luxembourg, Luxembourg USD 2017 2020 Novartis Capital Corporation, New York, United States USD 2017 2022 Novartis Capital Corporation, New York, United States USD 2017 2027 Novartis Capital Corporation, New York, United States EUR 2017 2021 Novartis Finance S.A., Luxembourg, Luxembourg EUR 2017 2027 Novartis Finance S.A., Luxembourg, Luxembourg No other customer accounted for 5% or more of net sales in either year. 0.38:1 0.32:1 The discount rates for all Divisions consider the Group’s weighted average cost of capital, adjusted to approximate the weighted average cost of capital of a comparable market participant. The major plans are based in Switzerland, the United States, the United Kingdom, Germany and Japan, which represent 94% of the Group’s total DBO for pension plans. In September 2017, the pension regulations in Switzerland were amended, which resulted in a change in accounting from defined benefit to defined contribution for a component of the Swiss pension plans. This change resulted in a reduction to the defined benefit pension plans liability and in a corresponding net pre-tax gain of USD 225 million (CHF 216 million). 2025 2022 2022 Société par actions SANDOZ Algiers Algeria Novartis Argentina S.A. Buenos Aires Argentina Alcon Laboratorios S.A. Buenos Aires Argentina Novartis Australia Pty Ltd North Ryde, NSW Australia Novartis Pharmaceuticals Australia Pty Ltd North Ryde, NSW Australia Sandoz Pty Ltd North Ryde, NSW Australia Alcon Laboratories (Australia) Pty Ltd Frenchs Forest, NSW Australia Novartis Austria GmbH Vienna Austria Novartis Pharma GmbH Vienna Austria Sandoz GmbH Kundl Austria EBEWE Pharma Ges.m.b.H Nfg. KG Unterach am Attersee Austria Novartis (Bangladesh) Limited Gazipur Bangladesh N.V. Novartis Pharma S.A. Vilvoorde Belgium N.V. Sandoz S.A. Vilvoorde Belgium S.A. Alcon-Couvreur N.V. Puurs Belgium N.V. Alcon S.A. Vilvoorde Belgium Novartis Investment Ltd. Hamilton Bermuda Novartis Securities Investment Ltd. Hamilton Bermuda Novartis Finance Services Ltd. Hamilton Bermuda Novartis B2 Ltd. Hamilton Bermuda Novartis B3 Ltd. Hamilton Bermuda Triangle International Reinsurance Limited Hamilton Bermuda Trinity River Insurance Co Ltd. Hamilton Bermuda Novartis Biociências S.A. São Paulo Brazil Sandoz do Brasil Indústria Farmacêutica Ltda. Cambé, PR Brazil Novartis Pharmaceuticals Canada Inc. Dorval, Quebec Canada Sandoz Canada Inc. Boucherville, Quebec Canada Alcon Canada Inc. Mississauga, Ontario Canada CIBA Vision Canada Inc. Mississauga, Ontario Canada Novartis Chile S.A. Santiago de Chile Chile Alcon Laboratorios Chile Ltd. Santiago de Chile Chile Beijing Novartis Pharma Co., Ltd. Beijing China Novartis Pharmaceuticals (HK) Limited Hong Kong China Shanghai China China Novartis Institutes for BioMedical Research Co., Ltd. Suzhou Novartis Pharma Technology Co., Ltd. Changshu China Shanghai Novartis Trading Ltd. Shanghai China Sandoz (China) Pharmaceutical Co., Ltd. Zhongshan China Alcon Hong Kong Limited Hong Kong China Alcon (China) Ophthalmic Product Co., Ltd. Beijing China Novartis de Colombia S.A. Santafé de Bogotá Colombia Laboratorios Alcon de Colombia S.A. Santafé de Bogotá Colombia Sandoz d.o.o. farmaceutska industrija Zagreb Croatia Novartis s.r.o. Prague Czech Republic Sandoz s.r.o. Prague Czech Republic Alcon Pharmaceuticals (Czech Republic) s.r.o. Prague Czech Republic Novartis Healthcare A/S Copenhagen Denmark Sandoz A/S Copenhagen Denmark Alcon Nordic A/S Copenhagen Denmark Novartis Ecuador S.A. Quito Ecuador Novartis Pharma S.A.E. Cairo Egypt Sandoz Egypt Pharma S.A.E. New Cairo City Egypt Novartis Finland Oy Espoo Finland Novartis Groupe France S.A. Rueil-Malmaison France Novartis Pharma S.A.S. Rueil-Malmaison France Sandoz S.A.S. Levallois-Perret France Laboratoires Alcon S.A.S. Rueil-Malmaison France Novartis Deutschland GmbH Wehr Germany Novartis Business Services GmbH Wehr Germany Novartis Pharma GmbH Nuremberg Germany Novartis Pharma Produktions GmbH Wehr Germany Sandoz International GmbH Holzkirchen Germany 1 A Pharma GmbH Oberhaching Germany HEXAL AG Holzkirchen Germany Salutas Pharma GmbH Barleben Germany Aeropharm GmbH Rudolstadt Germany Alcon Pharma GmbH Freiburg im Breisgau Germany CIBA Vision GmbH Grosswallstadt Germany WaveLight GmbH Erlangen Germany Novista Insurance Limited Gibraltar City Gibraltar Novartis (Hellas) S.A.C.I. Metamorphosis/Athens Greece Maroussi, Athens Greece Alcon Laboratories Hellas- Commercial and Industrial S.A. Budapest Hungary Novartis Hungary Healthcare Limited Liability Company Sandoz Hungary Limited Liability Company Budapest Hungary Novartis India Limited Mumbai India Novartis Healthcare Private Limited Mumbai India Sandoz Private Limited Mumbai India Alcon Laboratories (India) Private Limited Bangalore India PT. Novartis Indonesia Jakarta Indonesia PT. CIBA Vision Batam Batam Indonesia Novartis Ireland Limited Dublin Ireland Novartis Ringaskiddy Limited Ringaskiddy, County Cork Ireland Alcon Laboratories Ireland Limited Cork City Ireland Novartis Israel Ltd. Petach Tikva Israel Optonol Ltd. Neve-Ilan Israel Novartis Farma S.p.A. Origgio Italy Sandoz S.p.A. Origgio Italy Sandoz Industrial Products S.p.A. Rovereto Italy Alcon Italia S.p.A. Milan Italy Novartis Holding Japan K.K. Tokyo Japan Novartis Pharma K.K. Tokyo Japan Ciba-Geigy Japan Limited Tokyo Japan Sandoz K.K. Tokyo Japan Alcon Japan Ltd. Tokyo Japan Novartis Investments S.à r.l. Luxembourg-Ville Luxembourg Novartis Finance S.A. Luxembourg-Ville Luxembourg Novartis Corporation (Malaysia) Sdn. Bhd. Kuala Lumpur Malaysia Alcon Laboratories (Malaysia) Sdn. Bhd. Petaling Jaya Malaysia CIBA Vision Johor Sdn. Bhd. Kuala Lumpur Malaysia Novartis Farmacéutica, S.A. de C.V. Mexico City Mexico Sandoz, S.A. de C.V. Mexico City Mexico Alcon Laboratorios, S.A. de C.V. Mexico City Mexico Novartis Pharma Maroc SA Casablanca Morocco Novartis Netherlands B.V. Arnhem Netherlands Novartis Pharma B.V. Arnhem Netherlands Sandoz B.V. Almere Netherlands Alcon Nederland B.V. Arnhem Netherlands Novartis New Zealand Ltd Auckland New Zealand Novartis Norge AS Oslo Norway Novartis Pharma (Pakistan) Limited Karachi Pakistan Novartis Pharma (Logistics), Inc. Panama City Panama Alcon Centroamerica S.A. Panama City Panama Novartis Healthcare Philippines, Inc. Manila Philippines Sandoz Philippines Corporation Manila Philippines Novartis Poland Sp. z o.o. Warszawa Poland Sandoz Polska Sp. z o.o. Warszawa Poland Lek S.A. Strykow Poland Alcon Polska Sp. z o.o. Warszawa Poland Novartis Portugal SGPS Lda. Porto Salvo Portugal Novartis Farma - Produtos Farmacêuticos S.A. Porto Salvo Portugal Sandoz Farmacêutica Lda. Porto Salvo Portugal Porto Salvo Portugal Alcon Portugal-Produtos e Equipamentos Oftalmológicos Lda. Novartis Pharma Services Romania S.R.L. Bucharest Romania Sandoz S.R.L. Targu-Mures Romania Alcon Romania S.R.L. Bucharest Romania Novartis Pharma LLC Moscow Russian Federation Novartis Neva LLC St. Petersburg Russian Federation ZAO Sandoz Moscow Russian Federation Alcon Farmacevtika LLC Moscow Russian Federation Saudi Pharmaceutical Distribution Co. Ltd. Riyadh Saudi Arabia Novartis (Singapore) Pte Ltd. Singapore Singapore Singapore Singapore Novartis Singapore Pharmaceutical Manufacturing Pte Ltd Novartis Asia Pacific Pharmaceuticals Pte Ltd Singapore Singapore Novartis Institute for Tropical Diseases Pte Ltd Singapore Singapore Alcon Pte Ltd Singapore Singapore Alcon Singapore Manufacturing Pte Ltd Singapore Singapore Singapore Singapore CIBA Vision Asian Manufacturing and Logistics Pte Ltd. Novartis Slovakia s.r.o. Bratislava Slovakia Lek Pharmaceuticals d.d. Ljubjana Slovenia Sandoz Pharmaceuticals d.d. Ljubjana Slovenia Novartis South Africa (Pty) Ltd Midrand South Africa Sandoz South Africa (Pty) Ltd Kempton Park South Africa Alcon Laboratories (South Africa) (Pty) Ltd. Midrand South Africa Novartis Korea Ltd. Seoul South Korea Sandoz Korea Ltd. Seoul South Korea Alcon Korea Ltd. Seoul South Korea Novartis Farmacéutica S.A. Barcelona Spain Sandoz Farmacéutica S.A. Madrid Spain Les Franqueses del Vallés / Barcelona Spain Sandoz Industrial Products S.A. Alcon Cusi S.A. Barcelona Spain Abadia Retuerta S.A. Sardón de Duero/Valladolid Spain Novartis Sverige AB Täby / Stockholm Sweden Novartis International AG Basel Switzerland Novartis Holding AG Basel Switzerland Novartis International Pharmaceutical Investment AG Basel Switzerland Novartis Bioventures AG Basel Switzerland Novartis Forschungsstiftung Basel Switzerland Novartis Stiftung für Kaderausbildung Basel Switzerland Novartis Mitarbeiterbeteiligungsstiftung Basel Switzerland Novartis Stiftung für Mensch und Umwelt Basel Switzerland Basel Switzerland Stiftung der Novartis AG für Erziehung, Ausbildung und Bildung Novartis Pharma AG Basel Switzerland Novartis International Pharmaceutical AG Basel Switzerland Novartis Pharma Services AG Basel Switzerland Novartis Pharma Schweizerhalle AG Muttenz Switzerland Novartis Pharma Stein AG Stein Switzerland Novartis Pharma Schweiz AG Risch Switzerland Sandoz AG Basel Switzerland Sandoz Pharmaceuticals AG Risch Switzerland Alcon Switzerland SA Risch Switzerland Alcon Pharmaceuticals Ltd. Fribourg Switzerland Roche Holding AG Basel Switzerland Novartis (Taiwan) Co., Ltd. Taipei Taiwan Novartis (Thailand) Limited Bangkok Thailand Alcon Laboratories (Thailand) Limited Bangkok Thailand Istanbul Turkey Novartis Saglik, Gida ve Tarim Ürünleri Sanayi ve Ticaret A.S. Farmanova Saglik Hizmetleri Ltd. Sti. Istanbul Turkey Sandoz Ilaç Sanayi ve Ticaret A.S. Istanbul Turkey Istanbul Turkey Sandoz Syntek Ilaç Hammaddeleri Sanayi ve Ticaret A.S. Gebze - Kocaeli Turkey Sandoz Grup Saglik Ürünleri Ilaçlari Sanayi ve Ticaret A.S. Alcon Laboratuvarlari Ticaret A.S. Istanbul Turkey Novartis Middle East FZE Dubai United Arab Emirates Novartis UK Limited Frimley/Camberley United Kingdom Novartis Pharmaceuticals UK Limited Frimley/Camberley United Kingdom Novartis Grimsby Limited Frimley/Camberley United Kingdom Ziarco Group Limited Frimley/Camberley United Kingdom Sandoz Limited Frimley/Camberley United Kingdom Alcon Eye Care UK Limited Frimley/Camberley United Kingdom Brentford, Middlesex United Kingdom Glaxosmithkline Consumer Healthcare Holdings Limited Novartis Corporation East Hanover, NJ USA Novartis Finance Corporation New York, NY USA Novartis Capital Corporation New York, NY USA Novartis Services, Inc. East Hanover, NJ USA Novartis US Foundation New York, NY USA Novartis Pharmaceuticals Corporation East Hanover, NJ USA Cambridge, MA USA Novartis Institutes for BioMedical Research, Inc. Corthera, Inc. San Mateo, CA USA CoStim Pharmaceuticals Inc. Cambridge, MA USA Encore Vision, Inc. New York, NY USA Navigate BioPharma Services, Inc. Wilmington, NC USA Reprixys Pharmaceuticals Corporation Oklahoma City, OK USA Spinifex Pharmaceuticals, Inc. Wilmington, NC USA Novartis Institute for Functional Genomics, Inc. San Diego, CA USA Sandoz Inc. Princeton, NJ USA Fougera Pharmaceuticals Inc. Melville, NY USA Eon Labs, Inc. Princeton, NJ USA Alcon Laboratories, Inc. Fort Worth, TX USA Alcon Refractivehorizons, LLC Fort Worth, TX USA Alcon Research, Ltd. Fort Worth, TX USA Alcon Lensx, Inc. Aliso Viejo, CA USA Alcon Laboratories Holding Corporation Fort Worth, TX USA Novartis Vaccines and Diagnostics, Inc. Cambridge, MA USA ClarVista Medical, Inc. Aliso Viejo, CA USA Transcend Medical, Inc. Menlo Park, CA USA Novartis de Venezuela, S.A. Caracas Venezuela Alcon Pharmaceutical, C.A. Caracas Venezuela <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">1. Significant accounting policies</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Novartis Group (Novartis or Group) is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of healthcare products led by innovative pharmaceuticals and also including eye care products and cost-saving generic pharmaceuticals. It is headquartered in Basel, Switzerland. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consolidated financial statements of the Group are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). They are prepared in accordance with the historical cost convention except for items that are required to be accounted for at fair value. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s financial year-end is December 31, which is also the annual closing date of the individual entities&#x2019; financial statements incorporated into the Group&#x2019;s consolidated financial statements. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The preparation of financial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the year that affect the reported amounts of assets and liabilities, including any contingent amounts, as well as of revenues and expenses. Actual outcomes and results could differ from those estimates and assumptions. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Listed below are accounting policies of significance to Novartis or, in cases where IFRS provides alternatives, the option adopted by Novartis. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Scope of consolidation </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated financial statements include all entities, including structured entities, over which Novartis AG, Basel, Switzerland, directly or indirectly has control (generally as a result of owning more than 50% of the entity&#x2019;s voting interest). Consolidated entities are also referred to as &#x201c;subsidiaries&#x201d;. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In cases where Novartis does not fully own a subsidiary, it has elected to value any remaining outstanding non-controlling interest at the time of acquiring control of the subsidiary at its proportionate share of the fair value of the net identified assets. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The contribution of a business to an associate or joint venture is accounted for by applying the option under IFRS that permits the accounting for the retained interest of the business contributed at its net book value at the time of the contribution. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Investments in associated companies (generally defined as investments in entities in which Novartis holds between 20% and 50% of voting shares or over which it otherwise has significant influence) and joint ventures are accounted for using the equity method, except for selected venture fund investments for which the Group has elected to apply the method of fair value through the consolidated income statement. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Foreign currencies</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated financial statements of Novartis are presented in US dollars (USD). The functional currency of subsidiaries is generally the local currency of the respective entity. The functional currency used for the reporting of certain Swiss and foreign finance entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in these currencies. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For subsidiaries not operating in hyperinflationary economies, the subsidiary&#x2019;s results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates: </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Income, expense and cash flows using for each month the average exchange rate with the US dollar values for each month being aggregated during the year. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Balance sheets using year-end exchange rates.</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Resulting exchange rate differences are recognized in other comprehensive income.</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The only hyperinflationary economy applicable to Novartis is Venezuela. The financial statements of the major subsidiaries in this country are first adjusted for the effect of inflation, with any gain or loss on the net monetary position recorded in the related functional lines in the consolidated income statement and then translated into USD. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Acquisition of assets </font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Acquired assets are initially recognized on the balance sheet at cost if they meet the criteria for capitalization. If acquired as part of a business combination, the fair value of identified assets represents the cost for these assets. If separately acquired, the cost of the asset includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment when it is no longer used are included in their cost. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Property, plant and equipment</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Property, plant and equipment are depreciated on a straight-line basis in the consolidated income statement over their estimated useful lives. Leasehold land is depreciated over the period of its lease, whereas freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Property, plant and equipment are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the respective useful lives for property, plant and equipment:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Useful life</div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20 to 40 years</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and other equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7 to 20 years</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Furniture and vehicles</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 10 years</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Computer hardware</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Government grants obtained for construction activities, including any related equipment, are deducted from the gross acquisition cost to arrive at the balance sheet carrying value of the related assets. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Goodwill and intangible assets</font> </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Goodwill</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Goodwill arises in a business combination and is the excess of the consideration transferred to acquire a business over the underlying fair value of the net identified assets acquired. It is allocated to groups of cash-generating units (CGUs) which are usually represented by the reported segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under &#x201c;Other Expense&#x201d; in the consolidated income statement. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Intangible assets available-for-use</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has the following classes of available-for-use intangible assets: Currently marketed products; Marketing know-how; Technologies; Other intangible assets (including computer software) and the Alcon brand name. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Currently marketed products represent the composite value of acquired intellectual property, patents, and distribution rights and product trade names. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketing know-how represents the value attributable to the expertise acquired for marketing and distributing Alcon surgical products.</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Technologies represent identified and separable acquired know-how used in the research, development and production processes. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Significant investments in internally developed and acquired computer software are capitalized and included in the &#x201c;Other&#x201d; category and amortized once available for use. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Alcon brand name is shown separately, as it is the only Novartis intangible asset that is available for use with an indefinite useful life. Novartis considers that it is appropriate that the Alcon brand name has an indefinite life since Alcon-branded products have a history of strong revenue and cash flow performance, and Novartis has the intent and ability to support the brand with spending to maintain its value for the foreseeable future. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Except for the Alcon brand name, intangible assets available for use are amortized over their estimated useful lives on a straight-line basis and evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable. The Alcon brand name is not amortized, but evaluated for potential impairment annually. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the respective useful lives for available-for-use intangible assets and the location in the consolidated income statement in which the respective amortization and any potential impairment charge is recognized: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Useful life </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement location <br></br> for amortization and <br></br> impairment charges </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 20 years</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketing know-how</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25 years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Technologies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10 to 20 years <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold" <br></br> or "Research <br></br> and Development" </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other (including <br></br>computer software) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> In the respective <br></br> functional expense </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon brand name</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Not amortized, <br></br> indefinite useful life </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Not applicable <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Intangible assets not yet available-for-use</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Acquired research and development intangible assets, which are still under development and have accordingly not yet obtained marketing approval, are recognized as In-Process Research &amp; Development (IPR&amp;D). </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">IPR&amp;D is not amortized, but evaluated for potential impairment on an annual basis or when facts and circumstances warrant. Any impairment charge is recorded in the consolidated income statement under &#x201c;Research &amp; Development&#x201d;. Once a project included in IPR&amp;D has been successfully developed, it is transferred to the &#x201c;Currently marketed products&#x201d; category. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Impairment of goodwill and intangible assets</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">An asset is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value in use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGUs, and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group&#x2019;s activities with regard to: </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Amount and timing of projected future cash flows</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Long-term sales forecasts for periods of up to 25&nbsp;years</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Actions of competitors (launch of competing products, marketing initiatives, etc.)</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Sales erosion rates after the end of patent or other intellectual property rights protection and timing of the entry of generic competition </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Outcome of R&amp;D activities (compound efficacy, results of clinical trials, etc.)</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Amount and timing of projected costs to develop IPR&amp;D into commercially viable products</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Probability of obtaining regulatory approval</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Future tax rate</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Appropriate royalty rate for the Alcon Brand name</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Appropriate terminal growth rate</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Appropriate discount rate</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Generally, for intangible assets with a definite useful life Novartis uses cash flow projections for the whole useful life of these assets. For goodwill and the Alcon brand name, Novartis generally utilizes cash flow projections for a five-year period based on management forecasts, with a terminal value based on cash flow projections usually in line with inflation rates for later periods. Probability-weighted scenarios are typically used. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Discount rates used consider the Group&#x2019;s estimated weighted average cost of capital, adjusted for specific country and currency risks associated with cash flow projections to approximate the weighted average cost of capital of a comparable market participant. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Due to the above factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Impairment of associated companies accounted for at equity</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis considers investments in associated companies for impairment evaluation whenever objective evidence indicates the net investment may be impaired, including when a quoted share price indicates a fair value less than the per-share balance sheet carrying value for the investment. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If the recoverable amount of the investment is estimated to be lower than the balance sheet carrying amount an impairment charge is recognized for the difference in the consolidated income statement under &#x201c;Income from associated companies&#x201d;. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Cash and cash equivalents, marketable securities, commodities and non-current financial assets </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash and cash equivalents include highly liquid investments with original maturities of three months or less, which are readily convertible to known amounts of cash. Bank overdrafts are usually presented within current financial debts on the consolidated balance sheet, except in cases where a right of offset has been agreed with a bank, which then allows for presentation on a net basis. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities are financial assets consisting principally of equity and debt securities as well as fund investments. Marketable securities held for short-term purposes are principally traded in liquid markets and are classified as marketable securities on the consolidated balance sheet. Marketable securities held for long-term strategic purposes are classified as non-current financial assets on the consolidated balance sheet. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities are initially recorded at fair value on their trade date, which is different from the settlement date when the transaction is ultimately effected. Quoted securities are re-measured at each reporting date to fair value based on current market prices. If the market for a financial asset is not active or no market is available, fair values are established using valuation techniques. The majority of non-quoted investments are valued initially at fair value through the established purchase price between a willing buyer and seller. Non-quoted investments are subsequently adjusted based on values derived from using discounted cash flow analysis or other pricing models. These investment values are what is known as &#x201c;Level 3&#x201d; in the fair value hierarchy. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group has classified all its equity and quoted debt securities as well as fund investments as available-for-sale, as they are not acquired to generate profit from short-term fluctuations in price. Unrealized gains, except exchange gains related to quoted debt instruments, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are recognized in the consolidated income statement when the financial asset is sold, at which time the gain is transferred either to &#x201c;Other financial income and expense&#x201d;, for the marketable securities held for short-term non-strategic purposes, or to &#x201c;Other income&#x201d;, for all other equity securities and fund investments. Exchange gains related to quoted debt instruments are immediately recognized in the consolidated income statement under &#x201c;Other financial income and expense&#x201d;. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A security is assessed for impairment when its market value at the balance sheet date is less than initial cost reduced by any previously recognized impairment. Impairments on equity securities, quoted debt securities and fund investments, and exchange rate losses on quoted debt securities in a foreign currency that are held for short-term non-strategic purposes are recorded in &#x201c;Other financial income and expense&#x201d;. Impairments are recorded for all other equity securities and other fund investments in &#x201c;Other expense&#x201d; in the consolidated income statement. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Commodities include gold bullion or coins which are valued at the lower of cost or fair value using current market prices. The changes in fair value below cost are immediately recorded in &#x201c;Other financial income and expense&#x201d;. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Other non-current financial assets, including loans held for long-term strategic purposes, are carried at amortized cost, which reflects the time value of money less any allowances for uncollectable amounts. For these financial assets, impairments and exchange rate losses are included in &#x201c;Other expense&#x201d; in the consolidated income statement and exchange rate gains and interest income using the effective interest rate method are included in &#x201c;Other income&#x201d; in the consolidated income statement. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Derivative financial instruments</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Derivative financial instruments are initially recognized in the balance sheet at fair value and are re-measured to their current fair value at the end of each subsequent reporting period. The valuation of a forward exchange rate contract is based on the discounted cash flow model, using interest curves and spot rates at the reporting date as observable inputs. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Options are valued based on a modified Black-Scholes model using volatility and exercise prices as major observable inputs. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group utilizes derivative financial instruments for the purpose of hedging to reduce the volatility in the Group&#x2019;s performance due to the exposure of various types of business risks. To mitigate these risks, the Group enters into certain derivative financial instruments. The risk reduction is obtained because the derivative&#x2019;s value or cash flows are expected, wholly or partly, to offset changes in the value or cash flows of the recognized assets or liabilities. The overall strategy is aiming to mitigate the currency and interest exposure risk of positions that are contractually agreed and to partially mitigate the exposure risk of selected anticipated transactions. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain derivative financial instruments meet the criteria for hedge accounting treatment. A prerequisite for obtaining this accounting-hedge relationship is extensive documentation on inception and proving on a regular basis that the economic hedge is effective for accounting purposes. Other derivative financial instruments do not meet the criteria to qualify for hedge accounting. Changes in the fair value of those derivative instruments are recognized immediately in &#x201c;Other financial income and expense&#x201d; in the consolidated income statement. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, the Group has designated certain long-term debt components as hedges of the translation risk arising on certain net investments in foreign operations. On consolidation, foreign currency differences arising on long-term debt designated as net investment hedges of a foreign operation are recognized in other comprehensive income and accumulated in currency translation effects, to the extent that the hedge is effective. The foreign currency differences arising from hedge ineffectiveness are recognized in the income statement in &#x201c;Other financial income and expense&#x201d;. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">When a hedged net investment is disposed of, the proportionate portion of the cumulative amount recognized in equity in relation to the hedged net investment is transferred to the income statement as an adjustment to the profit or loss on disposal. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Inventories</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inventory is valued at acquisition or production cost determined on a first-in first-out basis. This value is used for the &#x201c;Cost of goods sold&#x201d; in the consolidated income statement. Unsalable inventory is fully written off in the consolidated income statement under &#x201c;Cost of goods sold&#x201d;. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Trade receivables</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as rebates, chargebacks and cash discounts. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions for doubtful trade receivables are established once there is an indication that it is likely that a loss will be incurred. These provisions represent the difference between the trade receivable&#x2019;s carrying amount in the consolidated balance sheet and the estimated net collectible amount. Significant financial difficulties of a customer, such as probability of bankruptcy, financial reorganization, default or delinquency in payments are considered indicators that recovery of the trade receivable is doubtful. Charges for doubtful trade receivables are recognized in the consolidated income statement within &#x201c;Marketing &amp; Sales&#x201d; expenses. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Legal and environmental liabilities</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis and its subsidiaries are subject to contingencies arising in the ordinary course of business such as patent litigation, environmental remediation liabilities and other product-related litigation, commercial litigation, and governmental investigations and proceedings. Provisions are recorded where a reliable estimate can be made of the probable outcome of legal or other disputes against the subsidiary. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Contingent consideration</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In a business combination or divestment of a business, it is necessary to recognize contingent future payments to previous owners, representing contractually defined potential amounts as a liability or asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at their fair value, which is then re-measured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance and are adjusted for the probability of their likelihood of payment, and if material, are appropriately discounted to reflect the impact of time. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in &#x201c;Cost of goods sold&#x201d; for currently marketed products and in &#x201c;Research &amp; Development&#x201d; for IPR&amp;D. Changes in contingent consideration assets are recognized in &#x201c;Other income&#x201d; or &#x201c;Other expense&#x201d;, depending on its nature. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The effect of unwinding the discount over time is recognized for contingent liabilities in &#x201c;Interest expense&#x201d; and for contingent assets in &#x201c;other financial income and expense&#x201d; in the consolidated income statement. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Defined benefit pension plans and&nbsp;other&nbsp;post-employment benefits</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The liability in respect of defined benefit pension plans and other post-employment benefits is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions where the associates are employed, while the net interest on the net defined benefit liability or asset is recognized as &#x201c;Other expense&#x201d; or &#x201c;Other income&#x201d;. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Treasury shares</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Treasury shares are initially recorded at fair value on their trade date which is different from the settlement date, when the transaction is ultimately effected. Treasury shares are deducted from consolidated equity at their nominal value of CHF&nbsp;0.50 per share. Differences between the nominal amount and the transaction price on purchases or sales of treasury shares with third parties, or the value of services received for the shares allocated to associates as part of share-based compensation arrangements, are recorded in &#x201c;Retained earnings&#x201d; in the consolidated statement of changes in equity. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Revenue recognition</font> </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Revenue</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Revenue is recognized on the sale of Novartis Group products and services and recorded as &#x201c;Net sales&#x201d; in the consolidated income statement when there is persuasive evidence that a sales arrangement exists; title, risks and rewards for the products are transferred to the customer; the price is determinable; and collectability is reasonably assured. When contracts contain customer acceptance provisions, sales are recognized upon the satisfaction of acceptance criteria. If products are stockpiled at the request of the customer, revenue is only recognized once the products have been inspected and accepted by the customer, and there is no right of return or replenishment on product expiry. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Surgical equipment may be sold together with other products and services under a single contract. The total consideration is allocated to the separate elements based on their relative fair values. Revenue is recognized once the recognition criteria have been met for each element of the contract. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For surgical equipment, in addition to cash and installment sales, revenue is recognized under finance and operating lease arrangements. Arrangements in which Novartis transfers substantially all the risks and rewards incidental to ownership to the customer are treated as finance lease arrangements. Revenue from finance lease arrangements is recognized at amounts equal to the fair values of the equipment, which approximate the present values of the minimum lease payments under the arrangements. As interest rates embedded in lease arrangements are approximately market rates, revenue under finance lease arrangements is comparable to revenue for outright sales. Finance income for arrangements in excess of twelve months is deferred and subsequently recognized based on a pattern that approximates the use of the effective interest method and recorded in &#x201c;Other income&#x201d;. Operating lease revenue for equipment rentals is recognized on a straight-line basis over the lease term. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions for rebates and discounts granted to government agencies, wholesalers, retail pharmacies, managed healthcare organizations and other customers are recorded as a deduction from revenue at the time the related revenues are recorded or when the incentives are offered. They are calculated on the basis of historical experience and the specific terms in the individual agreements. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions for refunds granted to healthcare providers under innovative pay-for-performance agreements are recorded as a revenue deduction at the time the related sales are recorded. They are calculated on the basis of historical experience and clinical data available for the product, as well as the specific terms in the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until such history is available. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Cash discounts are offered to customers to encourage prompt payment and are recorded as revenue deductions. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Following a decrease in the price of a product, we generally grant customers a &#x201c;shelf stock adjustment&#x201d; for their existing inventory for the involved product. Provisions for shelf stock adjustments, which are primarily relevant within the Sandoz Division, are determined at the time of the price decline or at the point of sale, if the impact of a price decline on the products sold can be reasonably estimated based on the customer&#x2019;s inventory levels of the relevant product. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">When there is historical experience of Novartis agreeing to customer returns and Novartis can reasonably estimate expected future returns, a provision is recorded for estimated sales returns. In doing so, the estimated rate of return is applied, determined based on historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a re-sale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions for revenue deductions are adjusted to actual amounts as rebates, discounts and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these sales deductions. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Other revenue</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">&#x201c;Other revenue&#x201d; includes royalty and profit sharing income and revenue from activities such as manufacturing services or other services rendered, to the extent such revenue is not recorded under net sales. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Research &amp; Development</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Internal Research &amp; Development (R&amp;D) costs are fully charged to &#x201c;Research &amp; Development&#x201d; in the consolidated income statement in the period in which they are incurred. The Group considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland or Japan. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&amp;D, that is deemed to not transfer intellectual property to Novartis are expensed as internal R&amp;D expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been achieved from a regulatory authority in a major market. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are capitalized, as are payments for other assets, such as technologies to be used in R&amp;D activities. If additional payments are made to the originator company to continue to perform R&amp;D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&amp;D services not resulting in an additional transfer of intellectual property rights to Novartis. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Novartis of additional intellectual property developed at the risk of the originator company. Subsequent internal R&amp;D costs in relation to IPR&amp;D and other assets are expensed, since the technical feasibility of the internal R&amp;D activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval are capitalized and recognized as currently marketed products. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Inventory produced ahead of regulatory approval is fully provisioned and the charge is included in &#x201c;Other expense&#x201d; in the consolidated income statement, as its ultimate use cannot be assured. If this inventory can be subsequently sold, the provision is released to &#x201c;Other income&#x201d; in the consolidated income statement either on approval by the appropriate regulatory authority or, exceptionally in Europe, on recommendation by the Committee for Medicinal Products for Human Use (CHMP), if approval is virtually certain. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Share-based compensation</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Vested Novartis shares and American Depositary Receipts (ADRs) that are granted as compensation are valued at their market value on the grant date and are immediately expensed in the consolidated income statement. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair values of unvested restricted shares, restricted share units (RSUs) and performance share units (PSUs) in Novartis shares and ADRs granted to associates as compensation are recognized as an expense over the related vesting period. The expense recorded in the consolidated income statement is included in the personnel expenses of the various functions where the associates are employed. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Unvested restricted shares, restricted ADRs and RSUs are only conditional on the provision of services by the plan participant during the vesting period. They are valued using their fair value on the grant date. As RSUs do not entitle the holder to dividends the fair value is based on the Novartis share price at the grant date adjusted for the net present value of the dividends expected to be paid during the holding period. The fair value of these grants, after making adjustments for assumptions related to their forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">PSUs are subject to certain performance criteria being achieved during the vesting period and require plan participants to provide services during the vesting period. PSUs granted under plans defined as &#x201c;Long-Term Performance Plans&#x201d; are subject to performance criteria based on Novartis internal performance metrics. The expense is determined taking into account assumptions concerning performance during the period against targets and expected forfeitures due to plan participants not meeting their service conditions. These assumptions are periodically adjusted. Any change in estimates for past services is recorded immediately as an expense or income in the consolidated income statement and amounts for future periods are expensed over the remaining vesting period. As a result, at the end of the vesting period, the total charge during the whole vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">PSUs granted under the Long-Term Relative Performance Plan (LTRPP) are conditional on the provision of services by the plan participant during the vesting period as well as on the Total Shareholder Return (TSR) performance of Novartis relative to a specific peer group of companies over the vesting period. These performance conditions are based on variables that can be observed in the market. IFRS requires that these observations are taken into account in determining the fair value of these PSUs at the date of grant. Novartis has determined the fair value of these PSUs at the date of grant using a &#x201c;Monte Carlo&#x201d; simulation model. The total fair value of this grant is expensed on a straight-line basis over the vesting period. Adjustments to the number of equity instruments granted are only made if a plan participant does not fulfill the service conditions. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If a plan participant leaves Novartis for reasons other than retirement, disability or death, then unvested restricted shares, restricted ADRs, RSUs and PSUs are forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Novartis Board of Directors, for example, in connection with a reorganization or divestment. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Measuring the fair values of PSUs granted under the LTRPP, requires estimates. The Monte Carlo simulation used for determining the fair value of the PSUs related to the LTRPP requires as input parameters the probability of factors related to uncertain future events; the term of the award; the grant price of underlying shares or ADRs; expected volatilities; the expected correlation matrix of the underlying equity instruments with those of the peer group of companies and the risk-free interest rate. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Government grants</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Grants from governments or similar organizations are recognized at their fair value when there is a reasonable assurance that the grant will be received and the Group will comply with all attached conditions. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Government grants related to income are deferred and recognized in the consolidated income statement over the period necessary to match them with the related costs that they are intended to compensate. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The accounting policy for property, plant and equipment describes the treatment of any related grants. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Restructuring charges</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Restructuring provisions are recognized for the direct expenditures arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Charges to increase restructuring provisions are included in &#x201c;Other expense&#x201d; in the consolidated income statements. Corresponding releases are recorded in &#x201c;Other income&#x201d; in the consolidated income statement. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Taxes</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Taxes on income are provided in the same periods as the revenues and expenses to which they relate and include any interest and penalties incurred during the period. Deferred taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax base of an asset or liability and its carrying value in the balance sheet prepared for consolidation purposes, except for those temporary differences related to investments in subsidiaries and associated companies, where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary&#x2019;s retained earnings are only taken into account when a dividend has been planned. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimated amounts for current and deferred tax assets or liabilities, including any amounts related to any uncertain tax positions, are based on currently known facts and circumstances. Tax returns are based on an interpretation of tax laws and regulations, and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made requiring payments of additional tax, interest or penalties. Inherent uncertainties exist in the estimates of the tax positions. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Non-current assets held for sale</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Non-current assets are classified as assets held for sale when their carrying amount is to be recovered principally through a sale transaction and a sale is considered highly probable. They are stated at the lower of carrying amount and fair value less costs of disposal. Assets held for sale, included within a disposal group or discontinued operations are not depreciated or amortized. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Status of adoption of significant new or amended IFRS standards or interpretations</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The adoption of new or amended standards and interpretations that are effective for the financial year beginning on January 1, 2017, did not have a material impact on the Group&#x2019;s consolidated financial statements. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following new IFRS standards will, based on a Novartis analysis, be of significance to the Group, but have not yet been early adopted: </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">IFRS 9 FINANCIAL INSTRUMENTS</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">IFRS 9 Financial Instruments will substantially change the classi&#xfb01;cation and measurement of &#xfb01;nancial instruments. The new standard requires impairments to be based on a forward-looking model, changes the approach to hedging &#xfb01;nancial exposures and related documentation, changes the recognition of certain fair value changes and amends disclosures requirements. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The impairment of financial assets, including trade and lease receivables, will be assessed using an expected credit loss model rather than the current incurred loss model. Given the nature of Novartis&#x2019; financial assets, the Group does not expect a significant impact to our provisions for doubtful accounts or impairments from this change. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The new hedge accounting model introduced by the standard requires hedge accounting relationships to be based upon the Group&#x2019;s own risk management strategy and objectives, and to be discontinued only when the relationships no longer qualify for hedge accounting. Based on the impact of adoption assessment performed, Novartis expects that the existing hedge relationship will continue to be designated as such under the new hedge accounting requirements. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group will implement the new standard on January 1, 2018 and will apply the modified retrospective method, which requires the recognition of the cumulative effect of initially applying IFRS 9, as at January 1, 2018, to retained earnings and not restate prior years. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The most significant impact to the Group, upon adoption of IFRS 9, will be the treatment of the unrealized gains and losses from changes in fair value on certain of the Group&#x2019;s financial instruments, which are classified as available-for-sale marketable securities and financial investments. The unrealized gains and losses (to the extent of previous recognized unrealized gains), which the Group currently recognizes in the consolidated statement of other comprehensive income, will in the future be recognized in the consolidated income statement. This approach will be applied to equity securities where the fair value through other comprehensive income irrevocable option will not be applied. If this accounting had been applied prior to January 1, 2018, the adoption date, the cumulative effect to be recorded as an increase to retained earnings, as at January 1, 2018, is estimated at USD&nbsp;0.2 billion. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">IFRS 15 REVENUE FROM CONTRACTS WITH CUSTOMERS</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">IFRS 15 Revenue from contracts with customers amends revenue recognition requirements and establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash &#xfb02;ows arising from contracts with customers. The standard replaces IAS 18 Revenue and IAS 11 Construction contracts and related interpretations. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Results of our impact assessment: </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Group&#x2019;s &#x201c;Net sales&#x201d; are derived from the sale of drug substances, vision care products, surgical equipment, other products and services, where control transfers to our customers and our performance obligations are satisfied at the time of shipment to or receipt of the products by the customer or when the services are performed. We do not expect IFRS 15 to significantly change the timing or amount of revenue recognized under these arrangements. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Group&#x2019;s &#x201c;Other revenue&#x201d; consists of royalty income from the out-licensing of intellectual property (IP), which is recognized as earned and from manufacturing services and other services, where revenue is recognized when control transfers to the third party and our performance obligations are satisfied. We do not expect IFRS 15 to significantly change the timing or amount of revenue recognized from these manufacturing and other services arrangements, nor from these royalty arrangements, as the standard&#x2019;s royalty exception will apply for IP licenses. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x201c;Other revenue&#x201d; also includes revenue from profit sharing arrangements with our collaboration partners. Furthermore, the Group receives milestone payments related to sale or out-licensing of IP. Novartis does not expect IFRS 15 to significantly change the timing or amount of revenue recognized under these arrangements. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group will implement the new standard on January 1, 2018 and will apply the modified retrospective method, which requires the recognition of the cumulative effect of initially applying IFRS 15, as at January 1, 2018, to retained earnings and not restate prior years. However, since the results of the Group&#x2019;s impact assessment indicates that IFRS 15 is not expected to significantly change the amount or timing of revenue recognition in 2017 or prior periods, an insignificant cumulative adjustment to increase retained earnings will be made. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">IFRS 16 LEASES</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">IFRS 16 Leases substantially changes the &#xfb01;nancial statements as the majority of leases for which the company is the lessee will become on-balance sheet liabilities with corresponding right of use assets on the balance sheet. The standard replaces IAS 17 Leases and is effective on January 1, 2019. The current undiscounted operating lease commitments of USD&nbsp;3.2 billion as of December 31, 2017, and disclosed in Note 27 provide, subject to the provision of the standard, an indicator of the impact of the implementation of IFRS 16 on the Group&#x2019;s consolidated balance sheet. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Upon adoption of the new standard, a portion of the annual operating lease costs, which is currently fully recognized as a functional expense, will be recorded as interest expense. In addition, the portion of the annual lease payments recognized in the cash flow statement as a reduction of the lease liability will be recognized as an outflow from financing activities, which currently are fully recognized as an outflow from operating activities. Given the leases involved and assuming the current low interest rate environment continues, the Group does not currently expect these effects to be significant. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">There are no other IFRS standards or interpretations not yet effective that would be expected to have a material impact on the Group. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Scope of consolidation </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated financial statements include all entities, including structured entities, over which Novartis AG, Basel, Switzerland, directly or indirectly has control (generally as a result of owning more than 50% of the entity&#x2019;s voting interest). Consolidated entities are also referred to as &#x201c;subsidiaries&#x201d;. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In cases where Novartis does not fully own a subsidiary, it has elected to value any remaining outstanding non-controlling interest at the time of acquiring control of the subsidiary at its proportionate share of the fair value of the net identified assets. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The contribution of a business to an associate or joint venture is accounted for by applying the option under IFRS that permits the accounting for the retained interest of the business contributed at its net book value at the time of the contribution. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Investments in associated companies (generally defined as investments in entities in which Novartis holds between 20% and 50% of voting shares or over which it otherwise has significant influence) and joint ventures are accounted for using the equity method, except for selected venture fund investments for which the Group has elected to apply the method of fair value through the consolidated income statement. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Foreign currencies</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated financial statements of Novartis are presented in US dollars (USD). The functional currency of subsidiaries is generally the local currency of the respective entity. The functional currency used for the reporting of certain Swiss and foreign finance entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in these currencies. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For subsidiaries not operating in hyperinflationary economies, the subsidiary&#x2019;s results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates: </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Income, expense and cash flows using for each month the average exchange rate with the US dollar values for each month being aggregated during the year. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Balance sheets using year-end exchange rates.</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Resulting exchange rate differences are recognized in other comprehensive income.</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The only hyperinflationary economy applicable to Novartis is Venezuela. The financial statements of the major subsidiaries in this country are first adjusted for the effect of inflation, with any gain or loss on the net monetary position recorded in the related functional lines in the consolidated income statement and then translated into USD. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Acquisition of assets </font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Acquired assets are initially recognized on the balance sheet at cost if they meet the criteria for capitalization. If acquired as part of a business combination, the fair value of identified assets represents the cost for these assets. If separately acquired, the cost of the asset includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment when it is no longer used are included in their cost. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Property, plant and equipment</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Property, plant and equipment are depreciated on a straight-line basis in the consolidated income statement over their estimated useful lives. Leasehold land is depreciated over the period of its lease, whereas freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Property, plant and equipment are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the respective useful lives for property, plant and equipment:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Useful life</div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20 to 40 years</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and other equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7 to 20 years</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Furniture and vehicles</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 10 years</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Computer hardware</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Government grants obtained for construction activities, including any related equipment, are deducted from the gross acquisition cost to arrive at the balance sheet carrying value of the related assets. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Useful life</div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buildings</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20 to 40 years</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and other equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Machinery and equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7 to 20 years</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Furniture and vehicles</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 10 years</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Computer hardware</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Goodwill</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Goodwill arises in a business combination and is the excess of the consideration transferred to acquire a business over the underlying fair value of the net identified assets acquired. It is allocated to groups of cash-generating units (CGUs) which are usually represented by the reported segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under &#x201c;Other Expense&#x201d; in the consolidated income statement. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Intangible assets available-for-use</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has the following classes of available-for-use intangible assets: Currently marketed products; Marketing know-how; Technologies; Other intangible assets (including computer software) and the Alcon brand name. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Currently marketed products represent the composite value of acquired intellectual property, patents, and distribution rights and product trade names. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketing know-how represents the value attributable to the expertise acquired for marketing and distributing Alcon surgical products.</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Technologies represent identified and separable acquired know-how used in the research, development and production processes. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Significant investments in internally developed and acquired computer software are capitalized and included in the &#x201c;Other&#x201d; category and amortized once available for use. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Alcon brand name is shown separately, as it is the only Novartis intangible asset that is available for use with an indefinite useful life. Novartis considers that it is appropriate that the Alcon brand name has an indefinite life since Alcon-branded products have a history of strong revenue and cash flow performance, and Novartis has the intent and ability to support the brand with spending to maintain its value for the foreseeable future. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Except for the Alcon brand name, intangible assets available for use are amortized over their estimated useful lives on a straight-line basis and evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable. The Alcon brand name is not amortized, but evaluated for potential impairment annually. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the respective useful lives for available-for-use intangible assets and the location in the consolidated income statement in which the respective amortization and any potential impairment charge is recognized: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Useful life </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement location <br></br> for amortization and <br></br> impairment charges </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 20 years</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketing know-how</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25 years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Technologies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10 to 20 years <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold" <br></br> or "Research <br></br> and Development" </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other (including <br></br>computer software) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> In the respective <br></br> functional expense </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon brand name</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Not amortized, <br></br> indefinite useful life </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Not applicable <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Useful life </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income statement location <br></br> for amortization and <br></br> impairment charges </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5 to 20 years</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketing know-how</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25 years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold"</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Technologies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10 to 20 years <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> "Cost of goods sold" <br></br> or "Research <br></br> and Development" </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other (including <br></br>computer software) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3 to 7 years <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> In the respective <br></br> functional expense </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon brand name</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Not amortized, <br></br> indefinite useful life </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Not applicable <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Intangible assets not yet available-for-use</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Acquired research and development intangible assets, which are still under development and have accordingly not yet obtained marketing approval, are recognized as In-Process Research &amp; Development (IPR&amp;D). </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">IPR&amp;D is not amortized, but evaluated for potential impairment on an annual basis or when facts and circumstances warrant. Any impairment charge is recorded in the consolidated income statement under &#x201c;Research &amp; Development&#x201d;. Once a project included in IPR&amp;D has been successfully developed, it is transferred to the &#x201c;Currently marketed products&#x201d; category. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Impairment of goodwill and intangible assets</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">An asset is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value in use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGUs, and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group&#x2019;s activities with regard to: </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Amount and timing of projected future cash flows</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Long-term sales forecasts for periods of up to 25&nbsp;years</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Actions of competitors (launch of competing products, marketing initiatives, etc.)</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Sales erosion rates after the end of patent or other intellectual property rights protection and timing of the entry of generic competition </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Outcome of R&amp;D activities (compound efficacy, results of clinical trials, etc.)</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Amount and timing of projected costs to develop IPR&amp;D into commercially viable products</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Probability of obtaining regulatory approval</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Future tax rate</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Appropriate royalty rate for the Alcon Brand name</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Appropriate terminal growth rate</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Appropriate discount rate</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Generally, for intangible assets with a definite useful life Novartis uses cash flow projections for the whole useful life of these assets. For goodwill and the Alcon brand name, Novartis generally utilizes cash flow projections for a five-year period based on management forecasts, with a terminal value based on cash flow projections usually in line with inflation rates for later periods. Probability-weighted scenarios are typically used. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Discount rates used consider the Group&#x2019;s estimated weighted average cost of capital, adjusted for specific country and currency risks associated with cash flow projections to approximate the weighted average cost of capital of a comparable market participant. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Due to the above factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Impairment of associated companies accounted for at equity</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis considers investments in associated companies for impairment evaluation whenever objective evidence indicates the net investment may be impaired, including when a quoted share price indicates a fair value less than the per-share balance sheet carrying value for the investment. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If the recoverable amount of the investment is estimated to be lower than the balance sheet carrying amount an impairment charge is recognized for the difference in the consolidated income statement under &#x201c;Income from associated companies&#x201d;. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Cash and cash equivalents, marketable securities, commodities and non-current financial assets </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash and cash equivalents include highly liquid investments with original maturities of three months or less, which are readily convertible to known amounts of cash. Bank overdrafts are usually presented within current financial debts on the consolidated balance sheet, except in cases where a right of offset has been agreed with a bank, which then allows for presentation on a net basis. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities are financial assets consisting principally of equity and debt securities as well as fund investments. Marketable securities held for short-term purposes are principally traded in liquid markets and are classified as marketable securities on the consolidated balance sheet. Marketable securities held for long-term strategic purposes are classified as non-current financial assets on the consolidated balance sheet. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Marketable securities are initially recorded at fair value on their trade date, which is different from the settlement date when the transaction is ultimately effected. Quoted securities are re-measured at each reporting date to fair value based on current market prices. If the market for a financial asset is not active or no market is available, fair values are established using valuation techniques. The majority of non-quoted investments are valued initially at fair value through the established purchase price between a willing buyer and seller. Non-quoted investments are subsequently adjusted based on values derived from using discounted cash flow analysis or other pricing models. These investment values are what is known as &#x201c;Level 3&#x201d; in the fair value hierarchy. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group has classified all its equity and quoted debt securities as well as fund investments as available-for-sale, as they are not acquired to generate profit from short-term fluctuations in price. Unrealized gains, except exchange gains related to quoted debt instruments, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are recognized in the consolidated income statement when the financial asset is sold, at which time the gain is transferred either to &#x201c;Other financial income and expense&#x201d;, for the marketable securities held for short-term non-strategic purposes, or to &#x201c;Other income&#x201d;, for all other equity securities and fund investments. Exchange gains related to quoted debt instruments are immediately recognized in the consolidated income statement under &#x201c;Other financial income and expense&#x201d;. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A security is assessed for impairment when its market value at the balance sheet date is less than initial cost reduced by any previously recognized impairment. Impairments on equity securities, quoted debt securities and fund investments, and exchange rate losses on quoted debt securities in a foreign currency that are held for short-term non-strategic purposes are recorded in &#x201c;Other financial income and expense&#x201d;. Impairments are recorded for all other equity securities and other fund investments in &#x201c;Other expense&#x201d; in the consolidated income statement. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Commodities include gold bullion or coins which are valued at the lower of cost or fair value using current market prices. The changes in fair value below cost are immediately recorded in &#x201c;Other financial income and expense&#x201d;. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Other non-current financial assets, including loans held for long-term strategic purposes, are carried at amortized cost, which reflects the time value of money less any allowances for uncollectable amounts. For these financial assets, impairments and exchange rate losses are included in &#x201c;Other expense&#x201d; in the consolidated income statement and exchange rate gains and interest income using the effective interest rate method are included in &#x201c;Other income&#x201d; in the consolidated income statement. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Derivative financial instruments</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Derivative financial instruments are initially recognized in the balance sheet at fair value and are re-measured to their current fair value at the end of each subsequent reporting period. The valuation of a forward exchange rate contract is based on the discounted cash flow model, using interest curves and spot rates at the reporting date as observable inputs. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Options are valued based on a modified Black-Scholes model using volatility and exercise prices as major observable inputs. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group utilizes derivative financial instruments for the purpose of hedging to reduce the volatility in the Group&#x2019;s performance due to the exposure of various types of business risks. To mitigate these risks, the Group enters into certain derivative financial instruments. The risk reduction is obtained because the derivative&#x2019;s value or cash flows are expected, wholly or partly, to offset changes in the value or cash flows of the recognized assets or liabilities. The overall strategy is aiming to mitigate the currency and interest exposure risk of positions that are contractually agreed and to partially mitigate the exposure risk of selected anticipated transactions. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Certain derivative financial instruments meet the criteria for hedge accounting treatment. A prerequisite for obtaining this accounting-hedge relationship is extensive documentation on inception and proving on a regular basis that the economic hedge is effective for accounting purposes. Other derivative financial instruments do not meet the criteria to qualify for hedge accounting. Changes in the fair value of those derivative instruments are recognized immediately in &#x201c;Other financial income and expense&#x201d; in the consolidated income statement. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, the Group has designated certain long-term debt components as hedges of the translation risk arising on certain net investments in foreign operations. On consolidation, foreign currency differences arising on long-term debt designated as net investment hedges of a foreign operation are recognized in other comprehensive income and accumulated in currency translation effects, to the extent that the hedge is effective. The foreign currency differences arising from hedge ineffectiveness are recognized in the income statement in &#x201c;Other financial income and expense&#x201d;. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">When a hedged net investment is disposed of, the proportionate portion of the cumulative amount recognized in equity in relation to the hedged net investment is transferred to the income statement as an adjustment to the profit or loss on disposal. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Inventories</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Inventory is valued at acquisition or production cost determined on a first-in first-out basis. This value is used for the &#x201c;Cost of goods sold&#x201d; in the consolidated income statement. Unsalable inventory is fully written off in the consolidated income statement under &#x201c;Cost of goods sold&#x201d;. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Trade receivables</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as rebates, chargebacks and cash discounts. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions for doubtful trade receivables are established once there is an indication that it is likely that a loss will be incurred. These provisions represent the difference between the trade receivable&#x2019;s carrying amount in the consolidated balance sheet and the estimated net collectible amount. Significant financial difficulties of a customer, such as probability of bankruptcy, financial reorganization, default or delinquency in payments are considered indicators that recovery of the trade receivable is doubtful. Charges for doubtful trade receivables are recognized in the consolidated income statement within &#x201c;Marketing &amp; Sales&#x201d; expenses. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Legal and environmental liabilities</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis and its subsidiaries are subject to contingencies arising in the ordinary course of business such as patent litigation, environmental remediation liabilities and other product-related litigation, commercial litigation, and governmental investigations and proceedings. Provisions are recorded where a reliable estimate can be made of the probable outcome of legal or other disputes against the subsidiary. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Contingent consideration</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In a business combination or divestment of a business, it is necessary to recognize contingent future payments to previous owners, representing contractually defined potential amounts as a liability or asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at their fair value, which is then re-measured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance and are adjusted for the probability of their likelihood of payment, and if material, are appropriately discounted to reflect the impact of time. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in &#x201c;Cost of goods sold&#x201d; for currently marketed products and in &#x201c;Research &amp; Development&#x201d; for IPR&amp;D. Changes in contingent consideration assets are recognized in &#x201c;Other income&#x201d; or &#x201c;Other expense&#x201d;, depending on its nature. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The effect of unwinding the discount over time is recognized for contingent liabilities in &#x201c;Interest expense&#x201d; and for contingent assets in &#x201c;other financial income and expense&#x201d; in the consolidated income statement. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Defined benefit pension plans and&nbsp;other&nbsp;post-employment benefits</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The liability in respect of defined benefit pension plans and other post-employment benefits is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions where the associates are employed, while the net interest on the net defined benefit liability or asset is recognized as &#x201c;Other expense&#x201d; or &#x201c;Other income&#x201d;. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Treasury shares</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Treasury shares are initially recorded at fair value on their trade date which is different from the settlement date, when the transaction is ultimately effected. Treasury shares are deducted from consolidated equity at their nominal value of CHF&nbsp;0.50 per share. Differences between the nominal amount and the transaction price on purchases or sales of treasury shares with third parties, or the value of services received for the shares allocated to associates as part of share-based compensation arrangements, are recorded in &#x201c;Retained earnings&#x201d; in the consolidated statement of changes in equity. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Revenue recognition</font> </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Revenue</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Revenue is recognized on the sale of Novartis Group products and services and recorded as &#x201c;Net sales&#x201d; in the consolidated income statement when there is persuasive evidence that a sales arrangement exists; title, risks and rewards for the products are transferred to the customer; the price is determinable; and collectability is reasonably assured. When contracts contain customer acceptance provisions, sales are recognized upon the satisfaction of acceptance criteria. If products are stockpiled at the request of the customer, revenue is only recognized once the products have been inspected and accepted by the customer, and there is no right of return or replenishment on product expiry. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Surgical equipment may be sold together with other products and services under a single contract. The total consideration is allocated to the separate elements based on their relative fair values. Revenue is recognized once the recognition criteria have been met for each element of the contract. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For surgical equipment, in addition to cash and installment sales, revenue is recognized under finance and operating lease arrangements. Arrangements in which Novartis transfers substantially all the risks and rewards incidental to ownership to the customer are treated as finance lease arrangements. Revenue from finance lease arrangements is recognized at amounts equal to the fair values of the equipment, which approximate the present values of the minimum lease payments under the arrangements. As interest rates embedded in lease arrangements are approximately market rates, revenue under finance lease arrangements is comparable to revenue for outright sales. Finance income for arrangements in excess of twelve months is deferred and subsequently recognized based on a pattern that approximates the use of the effective interest method and recorded in &#x201c;Other income&#x201d;. Operating lease revenue for equipment rentals is recognized on a straight-line basis over the lease term. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions for rebates and discounts granted to government agencies, wholesalers, retail pharmacies, managed healthcare organizations and other customers are recorded as a deduction from revenue at the time the related revenues are recorded or when the incentives are offered. They are calculated on the basis of historical experience and the specific terms in the individual agreements. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions for refunds granted to healthcare providers under innovative pay-for-performance agreements are recorded as a revenue deduction at the time the related sales are recorded. They are calculated on the basis of historical experience and clinical data available for the product, as well as the specific terms in the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until such history is available. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Cash discounts are offered to customers to encourage prompt payment and are recorded as revenue deductions. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Following a decrease in the price of a product, we generally grant customers a &#x201c;shelf stock adjustment&#x201d; for their existing inventory for the involved product. Provisions for shelf stock adjustments, which are primarily relevant within the Sandoz Division, are determined at the time of the price decline or at the point of sale, if the impact of a price decline on the products sold can be reasonably estimated based on the customer&#x2019;s inventory levels of the relevant product. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">When there is historical experience of Novartis agreeing to customer returns and Novartis can reasonably estimate expected future returns, a provision is recorded for estimated sales returns. In doing so, the estimated rate of return is applied, determined based on historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a re-sale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Provisions for revenue deductions are adjusted to actual amounts as rebates, discounts and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these sales deductions. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Other revenue</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">&#x201c;Other revenue&#x201d; includes royalty and profit sharing income and revenue from activities such as manufacturing services or other services rendered, to the extent such revenue is not recorded under net sales. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Research &amp; Development</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Internal Research &amp; Development (R&amp;D) costs are fully charged to &#x201c;Research &amp; Development&#x201d; in the consolidated income statement in the period in which they are incurred. The Group considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland or Japan. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&amp;D, that is deemed to not transfer intellectual property to Novartis are expensed as internal R&amp;D expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been achieved from a regulatory authority in a major market. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are capitalized, as are payments for other assets, such as technologies to be used in R&amp;D activities. If additional payments are made to the originator company to continue to perform R&amp;D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&amp;D services not resulting in an additional transfer of intellectual property rights to Novartis. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Novartis of additional intellectual property developed at the risk of the originator company. Subsequent internal R&amp;D costs in relation to IPR&amp;D and other assets are expensed, since the technical feasibility of the internal R&amp;D activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval are capitalized and recognized as currently marketed products. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Inventory produced ahead of regulatory approval is fully provisioned and the charge is included in &#x201c;Other expense&#x201d; in the consolidated income statement, as its ultimate use cannot be assured. If this inventory can be subsequently sold, the provision is released to &#x201c;Other income&#x201d; in the consolidated income statement either on approval by the appropriate regulatory authority or, exceptionally in Europe, on recommendation by the Committee for Medicinal Products for Human Use (CHMP), if approval is virtually certain. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Share-based compensation</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Vested Novartis shares and American Depositary Receipts (ADRs) that are granted as compensation are valued at their market value on the grant date and are immediately expensed in the consolidated income statement. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair values of unvested restricted shares, restricted share units (RSUs) and performance share units (PSUs) in Novartis shares and ADRs granted to associates as compensation are recognized as an expense over the related vesting period. The expense recorded in the consolidated income statement is included in the personnel expenses of the various functions where the associates are employed. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Unvested restricted shares, restricted ADRs and RSUs are only conditional on the provision of services by the plan participant during the vesting period. They are valued using their fair value on the grant date. As RSUs do not entitle the holder to dividends the fair value is based on the Novartis share price at the grant date adjusted for the net present value of the dividends expected to be paid during the holding period. The fair value of these grants, after making adjustments for assumptions related to their forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">PSUs are subject to certain performance criteria being achieved during the vesting period and require plan participants to provide services during the vesting period. PSUs granted under plans defined as &#x201c;Long-Term Performance Plans&#x201d; are subject to performance criteria based on Novartis internal performance metrics. The expense is determined taking into account assumptions concerning performance during the period against targets and expected forfeitures due to plan participants not meeting their service conditions. These assumptions are periodically adjusted. Any change in estimates for past services is recorded immediately as an expense or income in the consolidated income statement and amounts for future periods are expensed over the remaining vesting period. As a result, at the end of the vesting period, the total charge during the whole vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">PSUs granted under the Long-Term Relative Performance Plan (LTRPP) are conditional on the provision of services by the plan participant during the vesting period as well as on the Total Shareholder Return (TSR) performance of Novartis relative to a specific peer group of companies over the vesting period. These performance conditions are based on variables that can be observed in the market. IFRS requires that these observations are taken into account in determining the fair value of these PSUs at the date of grant. Novartis has determined the fair value of these PSUs at the date of grant using a &#x201c;Monte Carlo&#x201d; simulation model. The total fair value of this grant is expensed on a straight-line basis over the vesting period. Adjustments to the number of equity instruments granted are only made if a plan participant does not fulfill the service conditions. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If a plan participant leaves Novartis for reasons other than retirement, disability or death, then unvested restricted shares, restricted ADRs, RSUs and PSUs are forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Novartis Board of Directors, for example, in connection with a reorganization or divestment. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Measuring the fair values of PSUs granted under the LTRPP, requires estimates. The Monte Carlo simulation used for determining the fair value of the PSUs related to the LTRPP requires as input parameters the probability of factors related to uncertain future events; the term of the award; the grant price of underlying shares or ADRs; expected volatilities; the expected correlation matrix of the underlying equity instruments with those of the peer group of companies and the risk-free interest rate. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Government grants</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Grants from governments or similar organizations are recognized at their fair value when there is a reasonable assurance that the grant will be received and the Group will comply with all attached conditions. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Government grants related to income are deferred and recognized in the consolidated income statement over the period necessary to match them with the related costs that they are intended to compensate. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The accounting policy for property, plant and equipment describes the treatment of any related grants. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Restructuring charges</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Restructuring provisions are recognized for the direct expenditures arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Charges to increase restructuring provisions are included in &#x201c;Other expense&#x201d; in the consolidated income statements. Corresponding releases are recorded in &#x201c;Other income&#x201d; in the consolidated income statement. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Taxes</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Taxes on income are provided in the same periods as the revenues and expenses to which they relate and include any interest and penalties incurred during the period. Deferred taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax base of an asset or liability and its carrying value in the balance sheet prepared for consolidation purposes, except for those temporary differences related to investments in subsidiaries and associated companies, where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary&#x2019;s retained earnings are only taken into account when a dividend has been planned. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimated amounts for current and deferred tax assets or liabilities, including any amounts related to any uncertain tax positions, are based on currently known facts and circumstances. Tax returns are based on an interpretation of tax laws and regulations, and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made requiring payments of additional tax, interest or penalties. Inherent uncertainties exist in the estimates of the tax positions. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Non-current assets held for sale</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Non-current assets are classified as assets held for sale when their carrying amount is to be recovered principally through a sale transaction and a sale is considered highly probable. They are stated at the lower of carrying amount and fair value less costs of disposal. Assets held for sale, included within a disposal group or discontinued operations are not depreciated or amortized. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Status of adoption of significant new or amended IFRS standards or interpretations</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The adoption of new or amended standards and interpretations that are effective for the financial year beginning on January 1, 2017, did not have a material impact on the Group&#x2019;s consolidated financial statements. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following new IFRS standards will, based on a Novartis analysis, be of significance to the Group, but have not yet been early adopted: </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">IFRS 9 FINANCIAL INSTRUMENTS</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">IFRS 9 Financial Instruments will substantially change the classi&#xfb01;cation and measurement of &#xfb01;nancial instruments. The new standard requires impairments to be based on a forward-looking model, changes the approach to hedging &#xfb01;nancial exposures and related documentation, changes the recognition of certain fair value changes and amends disclosures requirements. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The impairment of financial assets, including trade and lease receivables, will be assessed using an expected credit loss model rather than the current incurred loss model. Given the nature of Novartis&#x2019; financial assets, the Group does not expect a significant impact to our provisions for doubtful accounts or impairments from this change. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The new hedge accounting model introduced by the standard requires hedge accounting relationships to be based upon the Group&#x2019;s own risk management strategy and objectives, and to be discontinued only when the relationships no longer qualify for hedge accounting. Based on the impact of adoption assessment performed, Novartis expects that the existing hedge relationship will continue to be designated as such under the new hedge accounting requirements. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group will implement the new standard on January 1, 2018 and will apply the modified retrospective method, which requires the recognition of the cumulative effect of initially applying IFRS 9, as at January 1, 2018, to retained earnings and not restate prior years. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The most significant impact to the Group, upon adoption of IFRS 9, will be the treatment of the unrealized gains and losses from changes in fair value on certain of the Group&#x2019;s financial instruments, which are classified as available-for-sale marketable securities and financial investments. The unrealized gains and losses (to the extent of previous recognized unrealized gains), which the Group currently recognizes in the consolidated statement of other comprehensive income, will in the future be recognized in the consolidated income statement. This approach will be applied to equity securities where the fair value through other comprehensive income irrevocable option will not be applied. If this accounting had been applied prior to January 1, 2018, the adoption date, the cumulative effect to be recorded as an increase to retained earnings, as at January 1, 2018, is estimated at USD&nbsp;0.2 billion. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">IFRS 15 REVENUE FROM CONTRACTS WITH CUSTOMERS</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">IFRS 15 Revenue from contracts with customers amends revenue recognition requirements and establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash &#xfb02;ows arising from contracts with customers. The standard replaces IAS 18 Revenue and IAS 11 Construction contracts and related interpretations. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Results of our impact assessment: </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Group&#x2019;s &#x201c;Net sales&#x201d; are derived from the sale of drug substances, vision care products, surgical equipment, other products and services, where control transfers to our customers and our performance obligations are satisfied at the time of shipment to or receipt of the products by the customer or when the services are performed. We do not expect IFRS 15 to significantly change the timing or amount of revenue recognized under these arrangements. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Group&#x2019;s &#x201c;Other revenue&#x201d; consists of royalty income from the out-licensing of intellectual property (IP), which is recognized as earned and from manufacturing services and other services, where revenue is recognized when control transfers to the third party and our performance obligations are satisfied. We do not expect IFRS 15 to significantly change the timing or amount of revenue recognized from these manufacturing and other services arrangements, nor from these royalty arrangements, as the standard&#x2019;s royalty exception will apply for IP licenses. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x201c;Other revenue&#x201d; also includes revenue from profit sharing arrangements with our collaboration partners. Furthermore, the Group receives milestone payments related to sale or out-licensing of IP. Novartis does not expect IFRS 15 to significantly change the timing or amount of revenue recognized under these arrangements. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group will implement the new standard on January 1, 2018 and will apply the modified retrospective method, which requires the recognition of the cumulative effect of initially applying IFRS 15, as at January 1, 2018, to retained earnings and not restate prior years. However, since the results of the Group&#x2019;s impact assessment indicates that IFRS 15 is not expected to significantly change the amount or timing of revenue recognition in 2017 or prior periods, an insignificant cumulative adjustment to increase retained earnings will be made. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">IFRS 16 LEASES</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">IFRS 16 Leases substantially changes the &#xfb01;nancial statements as the majority of leases for which the company is the lessee will become on-balance sheet liabilities with corresponding right of use assets on the balance sheet. The standard replaces IAS 17 Leases and is effective on January 1, 2019. The current undiscounted operating lease commitments of USD&nbsp;3.2 billion as of December 31, 2017, and disclosed in Note 27 provide, subject to the provision of the standard, an indicator of the impact of the implementation of IFRS 16 on the Group&#x2019;s consolidated balance sheet. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Upon adoption of the new standard, a portion of the annual operating lease costs, which is currently fully recognized as a functional expense, will be recorded as interest expense. In addition, the portion of the annual lease payments recognized in the cash flow statement as a reduction of the lease liability will be recognized as an outflow from financing activities, which currently are fully recognized as an outflow from operating activities. Given the leases involved and assuming the current low interest rate environment continues, the Group does not currently expect these effects to be significant. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">There are no other IFRS standards or interpretations not yet effective that would be expected to have a material impact on the Group. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">2. Significant transactions</div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Significant transactions in 2017</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">Innovative Medicines &ndash; Acquisition of Ziarco Group Limited</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On January 20, 2017, Novartis acquired Ziarco Group Limited (Ziarco), a privately held company in the United Kingdom, focused on the development of novel treatments in dermatology. This acquisition adds a once-daily oral H4 receptor antagonist in development for atopic dermatitis, commonly known as eczema, to complement the Novartis dermatology portfolio and pipeline. The fair value of the total purchase consideration was USD 420 million. The amount consisted of an initial cash payment of USD&nbsp;325 million and the net present value of the contingent consideration of USD 95 million, due to Ziarco shareholders, which they are eligible to receive upon the achievement of specified development milestones. The purchase price allocation resulted in net identifiable assets of USD&nbsp;395 million and goodwill of USD 25 million. Results of operations since the date of acquisition were not material. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">Innovative Medicines &ndash; Acquisition of Encore Vision, Inc.</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On January 20, 2017, Novartis acquired Encore Vision, Inc. (Encore), a privately-held company in Fort Worth, Texas, in the United States, focused on the development of a novel treatment in presbyopia. The fair value of the total purchase consideration was USD 456 million. The amount consisted of an initial cash payment of USD 366 million and the net present value of the contingent consideration of USD 90 million, due to Encore shareholders, which they are eligible to receive upon the achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 389 million and goodwill of USD 67 million. Results of operations since the date of acquisition were not material. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Significant transaction entered into in 2017</font> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;"> and closed in January 2018</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">Innovative Medicines &ndash; Acquisition of ADVANCED ACCELERATOR APPLICATIONS, S.A.</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On October 30, 2017, Novartis entered into a binding memorandum of understanding with Advanced Accelerator Applications S.A., (AAA), a NASDAQ-listed company headquartered in Saint-Genis-Pouilly, France, under which Novartis agreed to commence a tender offer for 100% of the share capital of AAA subject to certain conditions. Novartis commenced the tender offer on December 7, 2017, to purchase all of the outstanding ordinary shares for a price of USD&nbsp;41 per share and USD&nbsp;82 per American Depositary Share (ADS), each representing two ordinary shares of AAA, which expired on January 19, 2018. The offer values AAAs equity at USD&nbsp;3.9 billion, on a fully diluted basis. The transaction to acquire AAA is being funded mainly through external short- and long-term debt. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">As of the expiration of the tender offer, approximately 97% of the then outstanding fully diluted ordinary shares, including ordinary shares represented by ADSs, were validly tendered. On January 22, 2018, Novartis accepted and paid USD 3.9 billion for the ordinary shares, including ordinary shares represented by ADSs, tendered in the offer. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">On January 22, 2018 Novartis also commenced a subsequent offering period that will expire on January 31, 2018, unless extended. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">AAA is a radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicines, including Lutathera&#xae; (lutetium (177Lu) oxodotreotide), a first-in-class RLT product for neuroendocrine tumors (NETs) and a portfolio of diagnostic products. Radiopharmaceuticals, such as Lutathera&#xae;, are unique medicinal formulations containing radioisotopes, which are used clinically for both diagnosis and therapy. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Significant transactions in 2016</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">Alcon &ndash; Acquisition of Transcend Medical, Inc.</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On February 17, 2016, Alcon entered into an agreement to acquire Transcend Medical, Inc. (Transcend), a privately-held, US-based company focused on developing minimally-invasive surgical devices to treat glaucoma. The transaction closed on March 23, 2016, and the fair value of the total purchase consideration was USD&nbsp;332 million. The amount consisted of an initial cash payment of USD&nbsp;240 million and the net present value of contingent consideration of USD&nbsp;92 million due to the Transcend shareholders, which they are eligible to receive upon the achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD&nbsp;294 million and goodwill of USD&nbsp;38 million. The 2016 results of operations since the date of acquisition were not material. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">INNOVATIVE MEDICINES &ndash; ACQUISITION OF Reprixys PHARMACEUTICALs CORPORATION</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On November 18, 2016, Novartis acquired Reprixys Pharmaceuticals Corporation (Reprixys), a privately held, US-based company specializing in the development of therapeutics in certain hematologic and inflammatory disorders, following receipt of results of the SUSTAIN study. The previously held interest of 19% is adjusted to its fair value of USD&nbsp;64 million through the consolidated income statement at acquisition date. This re-measurement resulted in a gain of USD&nbsp;53 million. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value of the total purchase consideration for acquiring the 81% stake Novartis did not already own amounted to USD&nbsp;268 million. The amount consisted of an initial cash payment of USD&nbsp;194 million and the net present value of the contingent consideration of USD&nbsp;74 million due to Reprixys shareholders, which they are eligible to receive upon the achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD&nbsp;332 million. No goodwill was recognized. The 2016 results of operations since the date of acquisition were not material. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Significant transactions in 2015</font> </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Portfolio transformation transactions</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">Transaction with Eli Lilly and Company</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On January 1, 2015, Novartis closed its transaction with Eli Lilly and Company, USA (Lilly) announced in April 2014 to divest its Animal Health business for USD&nbsp;5.4 billion in cash. This resulted in a pre-tax gain of USD&nbsp;4.6 billion, which is recorded in operating income from discontinued operations. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">Transactions with GlaxoSmithKline plc</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On March 2, 2015, Novartis closed its transactions with GlaxoSmithKline plc, Great Britain (GSK) announced in April 2014, with the following consequences: </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase; font-style:italic;">Innovative Medicines &ndash; Acquisition of GSK oncology products</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis acquired GSK&#x2019;s oncology products and certain related assets for an aggregate cash consideration of USD&nbsp;16.0 billion. Up to USD&nbsp;1.5 billion of this cash consideration at the acquisition date is contingent on certain development milestones. The fair value of this potentially refundable consideration as at the acquisition date is USD&nbsp;0.1 billion. In addition, under the terms of the agreement, Novartis is granted a right of first negotiation over the co-development or commercialization of GSK&#x2019;s current and future oncology R&amp;D pipeline, excluding oncology vaccines. The right of first negotiation is for a period of 12.5 years from the acquisition closing date. The purchase price allocation of the fair value of the consideration of USD&nbsp;15.9 billion resulted in net identified assets of USD&nbsp;13.5 billion and goodwill of USD&nbsp;2.4 billion. In 2015, from the date of the acquisition the business generated net sales of USD&nbsp;1.8 billion. Management estimates net sales for the entire year 2015 would have amounted to USD&nbsp;2.1 billion had the oncology products been acquired at the beginning of the 2015 reporting period. The 2015 net results from operations on a reported basis since the acquisition date were not material. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase; font-style:italic;">Vaccines &ndash; Divestment</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis divested its Vaccines business (excluding its Vaccines influenza business) to GSK for up to USD&nbsp;7.1 billion plus royalties. The USD&nbsp;7.1 billion consists of USD&nbsp;5.25 billion paid at closing and up to USD&nbsp;1.8 billion in future milestone payments. The fair value of the contingent future milestones and royalties as at the acquisition date is USD&nbsp;1.0 billion, resulting in a fair value of consideration received of USD&nbsp;6.25 billion. Included in this amount is a USD&nbsp;450 million milestone payment received in late March 2015. The sale of this business resulted in a pre-tax gain of USD&nbsp;2.8 billion, which is recorded in operating income from discontinued operations. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis&#x2019;s Vaccines influenza business was excluded from the GSK Vaccines business acquisition. However, GSK entered into a future option arrangement with Novartis in relation to the Vaccines influenza business, pursuant to which Novartis could have unilaterally required GSK to acquire the entire or certain parts of its Vaccines influenza business for consideration of up to USD&nbsp;250 million (the Influenza Put Option) if the divestment to CSL Limited, Australia (CSL), discussed below, had not been completed. The option period was 18 months from the closing date of the GSK transaction, but terminated with the sale of the Vaccines influenza business to CSL on July 31, 2015. Novartis paid GSK a fee of USD&nbsp;5 million in consideration for the grant of the Influenza Put Option. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase; font-style:italic;">Consumer Health &ndash; Combination of Novartis OTC with GSK Consumer Healthcare</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis and GSK agreed to create a combined consumer healthcare business through the combination between Novartis OTC and GSK Consumer Healthcare businesses. On March 2, 2015, a new entity, GlaxoSmithKline Consumer Healthcare Holdings Ltd. (GSK Consumer Healthcare) was formed via contribution of businesses from both Novartis and GSK. Novartis has a 36.5% interest in the newly created entity. Novartis has valued the contribution of 63.5% of its OTC Division in exchange for 36.5% of the GSK Consumer Healthcare business at fair value. Based on the estimates of fair values exchanged, an investment in an associated company of USD&nbsp;7.6 billion was recorded. The resulting pre-tax gain, net of transaction related costs, of USD&nbsp;5.9 billion is recorded in operating income from discontinued operations. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis has four of eleven seats on the GSK Consumer Healthcare Board of Directors. Furthermore, Novartis has customary minority rights and also exit rights at a pre-defined, market based pricing mechanism. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The investment is accounted for using the equity method of accounting using estimated results for the last quarter of the year. Any differences between this estimate and actual results, when available, will be adjusted in the Group&#x2019;s consolidated financial statements in the following year. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase; font-style:italic;">Additional GSK related costs</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The GSK transaction resulted in USD&nbsp;0.6 billion of additional transaction-related costs that were expensed, thereof USD&nbsp;0.3 billion paid in 2015.</div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">Transaction with CSL</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On October 26, 2014, Novartis entered into an agreement with CSL to sell its Vaccines influenza business to CSL for USD&nbsp;275 million. Entering into the separate divestment agreement with CSL resulted in the Vaccines influenza business being classified as a separate disposal group consisting of a group of cash generating units within the Vaccines Division, requiring the performance of a separate valuation of the Vaccines influenza business net assets. This triggered the recognition of an exceptional impairment charge in 2014 of USD&nbsp;1.1 billion as the estimated net book value of the Vaccines influenza business net assets was above the USD&nbsp;275 million consideration. The transaction with CSL was completed on July 31, 2015, resulting in a partial reversal of the impairment recorded in 2014 in the amount of USD&nbsp;0.1 billion, which is included in operating income from discontinued operations. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Other significant transactions in 2015</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">Innovative Medicines &ndash; Acquisition of Spinifex Pharmaceuticals, Inc.</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On June 29, 2015, Novartis entered into an agreement to acquire Spinifex Pharmaceuticals, Inc. (Spinifex), a United States and Australia based, privately held development stage company, focused on developing a peripheral approach to treat neuropathic pain. The transaction closed on July 24, 2015, and the fair value of the total purchase consideration was USD&nbsp;312 million. The amount consisted of an initial cash payment of USD&nbsp;196 million and the net present value of the contingent consideration of USD&nbsp;116 million due to previous Spinifex shareholders, which they are eligible to receive upon achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD&nbsp;263 million and goodwill of USD&nbsp;49 million. The 2015 results of operations since the date of acquisition were not material. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">Innovative Medicines &ndash; Acquisition of Admune Therapeutics&nbsp;LLC</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On October 16, 2015, Novartis entered into an agreement to acquire Admune Therapeutics LLC (Admune), a US-based, privately held company, broadening Novartis&#x2019; pipeline of cancer immunotherapies. The fair value of the total purchase consideration amounted to USD&nbsp;258 million. This amount consists of an initial cash payment of USD&nbsp;140 million and the net present value of the contingent consideration of USD&nbsp;118 million due to Admune&#x2019;s previous owners, which they are eligible to receive upon the achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD&nbsp;258 million. No goodwill was recognized. The 2015 results of operations since the date of acquisition were not material. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">3. Segmentation of key figures 2017, 2016 and 2015</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The businesses of Novartis are divided operationally on a worldwide basis into three identified reporting segments, Innovative Medicines, Sandoz and Alcon. In addition, we separately report Corporate activities. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Reporting segments are presented in a manner consistent with the internal reporting to the chief operating decision maker, which is the Executive Committee of Novartis. The reporting segments are managed separately because they each research, develop, manufacture, distribute, and sell distinct products that require differing marketing strategies. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Executive Committee of Novartis is responsible for allocating resources and assessing the performance of the reporting segments. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines. The Innovative Medicines Division is organized into two global business units: Novartis Oncology business unit, which consists of the global business franchises Oncology and Novartis Pharmaceuticals business unit, which consists of the global business franchises Ophthalmology, Neuroscience, Immunology and Dermatology, Respiratory, Cardio-Metabolic and Established Medicines. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Sandoz develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. Sandoz is organized globally in three franchises: Retail Generics, Anti Infectives, and Biopharmaceuticals. In Retail Generics, Sandoz develops, manufactures and markets active ingredients and finished dosage forms of pharmaceuticals to third parties. Retail Generics includes the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmics, pain, and respiratory, as well as finished dosage form anti infectives sold to third parties. In Anti Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by Retail Generics and for sale to third party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein or other biotechnology based products, including biosimilars, and provides biotechnology manufacturing services to other companies. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Alcon researches, discovers, develops, manufactures, distributes and sells eye care products. The Alcon Division is the global leader in eye care, with product offerings in eye care devices and vision care. The Alcon Division is organized globally in two global business franchises as follows: In Surgical, Alcon develops, manufactures, distributes and sells ophthalmic surgical equipment, instruments, disposable products and intraocular lenses. In Vision Care, Alcon develops, manufactures, distributes and sells contact lenses and lens care products. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Income and expenses relating to Corporate include the costs of the Group headquarters and those of corporate coordination functions in major countries. In addition, Corporate includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights, certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships. Usually, no allocation of Corporate items is made to the segments. As a result, Corporate assets and liabilities principally consist of net liquidity (cash and cash equivalents, marketable securities less financial debts), investments in associated companies and current and deferred taxes and non-segment specific environmental remediation and post-employment benefit liabilities. Corporate also includes the Alcon brand name intangible asset as it is used to market products of the Alcon Division and products within the Ophthalmology business franchise of the Innovative Medicines Division. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Our divisions are supported by the Novartis Institutes for BioMedical Research, Global Drug Development, Novartis Technical Operations and Novartis Business Services organizations. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Novartis Institutes for BioMedical Research (NIBR) conducts research activities of the Innovative Medicines Division and also collaborates with Sandoz. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Global Drug Development organization was established in July 2016 and oversees all drug development activities for our Innovative Medicines Division and the biosimilars portfolio of our Sandoz Division. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Novartis Technical Operations organization was established in July 2016, to centralize management of our manufacturing operations across our Innovative Medicines and Sandoz Divisions. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Novartis Business Services (NBS) was established in January 2015 as a shared services organization and delivers business support services across the Group, such as information technology, real estate and facility services, procurement, product lifecycle services, human resources and financial reporting and accounting operations. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Following the portfolio transformation transactions in 2015, described in Note 2, Novartis has separated the Group&#x2019;s reported financial data into &#x201c;continuing&#x201d; operations and &#x201c;discontinued&#x201d; operations: </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Continuing operations comprise:</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Innovative Medicines: innovative patent-protected prescription medicines</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Sandoz: generic and biosimilar pharmaceuticals </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Alcon: eye care devices and vision care </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Corporate activities</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Discontinued operations comprise:</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Vaccines: preventive human vaccines. Excluded are certain intellectual property rights and related other revenues of the Vaccines Division, which are now reported under Corporate activities. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Consumer Health: OTC (over-the-counter medicines) and Animal Health. These two divisions were managed separately. However, neither was material enough to the Group to be disclosed separately as a reporting segment. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Corporate: certain transactional and other expenses related to the portfolio transformation.</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The accounting policies mentioned in Note 1 are used in the reporting of segment results. Inter-segmental sales are made at amounts that are considered to approximate arm&#x2019;s length transactions. The Executive Committee of Novartis evaluates segmental performance and allocates resources among the segments based on a number of measures including net sales, operating income and net operating assets. Segment net operating assets consist primarily of property, plant and equipment, intangible assets, goodwill, inventories and trade and other operating receivables less operating liabilities. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Segmentation &ndash; Consolidated income statements</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Alcon </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate (including eliminations)</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33&nbsp;025</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 32&nbsp;562</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;060</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;144</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;024</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;812</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 49&nbsp;109</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 48&nbsp;518</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to other segments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 668</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 624</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 118</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;789</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;728</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33&nbsp;693</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 33&nbsp;186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;178</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;248</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;027</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;812</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;789</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;728</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 49&nbsp;109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 48&nbsp;518</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 898</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 815</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 88</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 62</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;026</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 918</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;9&nbsp;007</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;9&nbsp;331</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5&nbsp;800</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;5&nbsp;971</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3&nbsp;231</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3&nbsp;092</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 863</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 874</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;17&nbsp;175</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;17&nbsp;520</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 25&nbsp;584</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24&nbsp;670</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;415</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;314</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;799</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;724</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 162</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 208</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 32&nbsp;960</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31&nbsp;916</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketing &amp; Sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;9&nbsp;089</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;8&nbsp;435</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;811</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;681</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;961</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;882</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;12&nbsp;861</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;11&nbsp;998</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research &amp; Development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;7&nbsp;630</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;7&nbsp;709</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;774</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;814</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;568</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;516</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;8&nbsp;972</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;9&nbsp;039</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">General &amp; Administration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;986</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;978</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;315</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;300</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;383</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;410</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;452</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;506</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;2&nbsp;136</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;194</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;027</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;091</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 204</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 185</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 47</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 48</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 691</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 603</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;969</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;927</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;213</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;351</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;259</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;96</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;732</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;776</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;2&nbsp;331</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;344</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;782</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;426</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;368</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;445</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;190</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;132</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;331</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;471</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;629</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;268</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;086</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 697</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;108</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 703</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;777</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;707</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;447</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;999</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;817</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;296</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;119</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;703</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;698</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Shareholders of Novartis AG</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 7&nbsp;703</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 6&nbsp;712</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Non-controlling interests</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net income are:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of property, <br></br>plant &amp; equipment </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;916 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;883 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;270 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;260 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;217 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;229 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;117 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;117 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;1&nbsp;520 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;1&nbsp;489 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;2&nbsp;291</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;470</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;447</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;450</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;942</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;929</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3&nbsp;690</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3&nbsp;861</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on property, <br></br>plant &amp; equipment, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;84 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;93 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;73 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;5 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;157 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;102 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on intangible <br></br>assets, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;591 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;522 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;61 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;65 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;57 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;709 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;591 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges and fair value <br></br>gains on financial assets, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;42 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;55 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;29 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;185 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;77 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;256 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;132 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to restructuring provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;122</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;236</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;61</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;46</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;343</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation of <br></br>Novartis equity plans </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;593 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;582 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;52 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;47 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;71 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;53 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;208 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;164 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;924 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;846 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Alcon </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate (including eliminations)</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from <br></br>continuing operations </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 32&nbsp;562 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 33&nbsp;345 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 10&nbsp;144 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 10&nbsp;070 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 5&nbsp;812 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 5&nbsp;999 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 48&nbsp;518 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 49&nbsp;414 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to other segments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 624</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 518</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 128</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;728</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;620</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 33&nbsp;186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 33&nbsp;863</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;248</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;198</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;812</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;999</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;728</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;620</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 48&nbsp;518</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 49&nbsp;440</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 815</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 792</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 62</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 107</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 918</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 947</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;9&nbsp;331</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;9&nbsp;204</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;5&nbsp;971</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;5&nbsp;844</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3&nbsp;092</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3&nbsp;145</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 874</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 789</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;17&nbsp;520</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;17&nbsp;404</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24&nbsp;670</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25&nbsp;451</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;314</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;379</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;724</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;877</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 208</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 276</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31&nbsp;916</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 32&nbsp;983</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketing &amp; Sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;8&nbsp;435</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;8&nbsp;430</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;681</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;679</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;882</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;663</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;11&nbsp;998</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;11&nbsp;772</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research &amp; Development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;7&nbsp;709</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;7&nbsp;685</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;814</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;782</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;516</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;468</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;9&nbsp;039</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;8&nbsp;935</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">General &amp; Administration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;978</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;031</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;300</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;346</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;410</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;450</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;506</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;648</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;475</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;091</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;149</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 185</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 48</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 603</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 737</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;927</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;049</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;213</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;639</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;259</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;381</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;96</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;69</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;776</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;784</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;344</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;873</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from <br></br>continuing operations </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 7&nbsp;426 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 7&nbsp;815 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 1&nbsp;445 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 1&nbsp;300 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> &ndash;&nbsp;132 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 281 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> &ndash;&nbsp;471 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> &ndash;&nbsp;419 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 8&nbsp;268 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 8&nbsp;977 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 697</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 264</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 703</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 266</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;707</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;655</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;447</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;454</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from <br></br>continuing operations </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 7&nbsp;817 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 8&nbsp;134 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;119</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;106</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;698</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;028</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;766</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;698</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&nbsp;794</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Shareholders of Novartis AG</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 6&nbsp;712</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 17&nbsp;783</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Non-controlling interests</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net income from continuing operations are:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of property, <br></br>plant &amp; equipment </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;883 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;839 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;260 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;277 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;229 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;237 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;117 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;117 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;1&nbsp;489 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;1&nbsp;470 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;470</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;384</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;450</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;450</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;929</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;912</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3&nbsp;861</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3&nbsp;755</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on property, <br></br>plant &amp; equipment, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;93 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 39 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;97 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;5 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;21 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;102 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;80 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on intangible <br></br>assets, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;522 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;138 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;65 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;27 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;591 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;166 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges and fair value <br></br>gains on financial assets, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;55 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;32 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;77 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;72 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;132 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;104 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to restructuring provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;236</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;232</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;46</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;93</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;49</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;343</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;399</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation of <br></br>Novartis equity plans </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;582 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;620 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;47 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;53 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;53 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;66 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;164 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;164 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;846 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;903 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> </table> </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Segmentation &ndash; Consolidated balance sheets</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Alcon </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate (including eliminations)</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 54&nbsp;075</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 51&nbsp;911</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&nbsp;231</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&nbsp;611</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22&nbsp;014</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;970</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 38&nbsp;759</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&nbsp;632</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 133&nbsp;079</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 130&nbsp;124</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;11&nbsp;457</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;10&nbsp;007</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;3&nbsp;459</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;3&nbsp;168</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;893</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;2&nbsp;520</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;42&nbsp;043</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;39&nbsp;538</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;58&nbsp;852</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;55&nbsp;233</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 74&nbsp;227</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 74&nbsp;891</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 19&nbsp;047</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&nbsp;025</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net operating assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 42&nbsp;618</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 41&nbsp;904</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;772</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;443</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20&nbsp;121</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&nbsp;450</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 93&nbsp;274</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 90&nbsp;916</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in assets and liabilities are:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total property, plant &amp; equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;857</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;410</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;525</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;374</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;403</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 679</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 694</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&nbsp;464</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&nbsp;641</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to property, <br></br>plant &amp; equipment <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 877 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 996 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 326 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 316 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 431 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 396 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 94 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 127 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;728 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;835 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total goodwill and intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31&nbsp;571</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31&nbsp;630</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;993</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;774</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&nbsp;176</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16&nbsp;914</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;007</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;002</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 61&nbsp;747</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 62&nbsp;320</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to goodwill and <br></br>intangible assets <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 984 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 865 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 64 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 45 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 82 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 63 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 16 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 5 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;146 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 978 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total investment in associated <br></br>companies </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 41 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 16 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 7 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 18 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 15&nbsp;322 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 14&nbsp;270 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 15&nbsp;370 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 14&nbsp;304 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to investment in associated <br></br>companies </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 40 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 37 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 46 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 41 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents, <br></br>marketable securities, commodities, <br></br>time deposits and derivative <br></br>financial instruments </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 9&nbsp;485 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> <br></br> 7&nbsp;777 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 9&nbsp;485 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> <br></br> 7&nbsp;777 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debts and derivative <br></br>financial instruments </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 28&nbsp;532 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 23&nbsp;802 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 28&nbsp;532 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 23&nbsp;802 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current income tax and deferred <br></br>tax liabilities </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 6&nbsp;891 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 8&nbsp;260 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 6&nbsp;891 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 8&nbsp;260 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Excluding impact of business combinations </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows countries that accounted for more than 5% of at least one of the respective Group totals, as well as regional information for net sales for the years ended December 31, 2017, 2016 and 2015, and for selected non-current assets for the years ended December 31, 2017 and 2016: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="11" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net sales<sup>1</sup></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total of selected non-current assets<sup>2</sup></div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="11" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div> </td> <td></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Country</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 836</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 830</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 774</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43&nbsp;920</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 47</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44&nbsp;413</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 48</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&nbsp;935</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;117</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&nbsp;079</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&nbsp;476</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28&nbsp;484</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United Kingdom</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;160</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;182</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;277</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;957</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;892</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Germany</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;690</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;634</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;262</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;128</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;733</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">France</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;490</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;390</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;269</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 284</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 199</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japan</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;177</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;267</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 148</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 145</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20&nbsp;821</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20&nbsp;098</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 42</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20&nbsp;590</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 40</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;668</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;399</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 49&nbsp;109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 48&nbsp;518</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 49&nbsp;414</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 93&nbsp;581</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 92&nbsp;265</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Region</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17&nbsp;492</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;079</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16&nbsp;472</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 61&nbsp;699</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 66</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 59&nbsp;879</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 65</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Americas</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20&nbsp;899</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 42</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20&nbsp;998</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22&nbsp;414</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29&nbsp;113</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 29&nbsp;831</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;718</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;441</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;528</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;769</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;555</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 49&nbsp;109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 48&nbsp;518</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 49&nbsp;414</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 93&nbsp;581</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 92&nbsp;265</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Net sales from operations by location of third-party customer </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s largest, second-largest and third-largest customers account for approximately 17%, 12% and 7% of net sales, respectively (2016: 16%, 12% and 6% respectively; 2015: 14%, 11% and 5% respectively). All segments had sales to these customers in 2017, 2016 and 2015. No other customer accounted for 5% or more of net sales in any year. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The highest amounts of trade receivables outstanding were for these same three customers and amounted to 14%, 9% and 5%, respectively, of the trade receivables at December 31, 2017 (2016: 14%, 9% and 6% respectively). </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Innovative Medicines net sales by business franchise</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> 2017 <br></br> USD <br></br> millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> 2016 <br></br> USD <br></br> millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change <br></br> (2016 <br></br> to 2017) <br></br> USD % </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> 2015 <br></br> USD <br></br> millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change <br></br> (2015 <br></br> to 2016) <br></br> USD % </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Oncology</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;943</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;323</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;42</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;658</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;29</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;841</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;739</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;632</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;612</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;646</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;630</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;525</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;516</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;607</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;059</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 956</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 917</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tafinlar + Mekinist</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 873</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 672</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 453</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 867</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 635</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 402</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 808</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 729</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 565</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 777</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 581</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 410</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 42</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 893</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 993</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;030</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Oncology business unit</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12&nbsp;274</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;790</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;304</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ophthalmology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;888</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;835</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;060</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Travoprost Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 589</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 619</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 631</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Systane</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 400</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 377</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 380</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Topical Olopatadine Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 284</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 335</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 457</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;27</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;207</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;297</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;395</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Ophthalmology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;368</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;463</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;923</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Immunology and Dermatology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;071</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;128</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 84</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 261</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Neoral/Sandimmun(e)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 488</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 515</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 570</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;10</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 414</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 398</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 335</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 402</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 283</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 42</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 236</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Myfortic</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 378</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 383</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 441</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 288</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 308</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 294</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Immunology and Dermatology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;041</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;137</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 41</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Neuroscience</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;185</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;776</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 102</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Neuroscience</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;287</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;917</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> 2017 <br></br> USD <br></br> millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> 2016 <br></br> USD <br></br> millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change <br></br> (2016 <br></br> to 2017) <br></br> USD % </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> 2015 <br></br> USD <br></br> millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change <br></br> (2015 <br></br> to 2016) <br></br> USD % </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Respiratory</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ultibro Breezhaler</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 411</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 363</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 260</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 40</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Seebri Breezhaler</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 151</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 149</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 150</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Onbrez Breezhaler</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 112</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 143</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal COPD<sup>1</sup> portfolio</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 674</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 655</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 576</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 920</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 835</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 755</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;16</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Respiratory</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;617</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;521</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;368</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cardio-Metabolic</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 507</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 170</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 198</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Cardio-Metabolic</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 524</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 184</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 185</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Established Medicines</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Galvus</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;193</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;140</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exforge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 960</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 926</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;047</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Diovan/Co-Diovan</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 957</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;073</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;284</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;16</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Voltaren/Cataflam</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 465</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 525</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 558</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exelon/Exelon</i> Patch</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 381</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 444</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 728</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;39</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ritalin/Focalin</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 236</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 282</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 365</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;682</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;913</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;553</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Established Medicines</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;914</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;356</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;675</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;17</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Pharmaceutical business unit</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20&nbsp;751</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 19&nbsp;772</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&nbsp;041</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33&nbsp;025</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 32&nbsp;562</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 33&nbsp;345</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Chronic obstructive pulmonary disease </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Net sales reflect <i>Xolair</i> sales for all indications (e.g., including <i>Xolair</i> SAA and <i>Xolair</i> CSU, which is managed by the Immunology and Dermatology franchise) </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The product portfolio of other segments is widely spread in 2017, 2016 and 2015.</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Alcon </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate (including eliminations)</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33&nbsp;025</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 32&nbsp;562</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;060</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;144</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;024</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;812</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 49&nbsp;109</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 48&nbsp;518</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to other segments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 668</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 624</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 118</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;789</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;728</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33&nbsp;693</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 33&nbsp;186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;178</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;248</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;027</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;812</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;789</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;728</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 49&nbsp;109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 48&nbsp;518</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 898</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 815</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 88</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 62</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;026</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 918</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;9&nbsp;007</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;9&nbsp;331</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5&nbsp;800</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;5&nbsp;971</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3&nbsp;231</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3&nbsp;092</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 863</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 874</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;17&nbsp;175</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;17&nbsp;520</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 25&nbsp;584</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24&nbsp;670</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;415</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;314</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;799</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;724</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 162</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 208</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 32&nbsp;960</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31&nbsp;916</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketing &amp; Sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;9&nbsp;089</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;8&nbsp;435</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;811</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;681</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;961</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;882</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;12&nbsp;861</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;11&nbsp;998</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research &amp; Development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;7&nbsp;630</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;7&nbsp;709</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;774</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;814</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;568</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;516</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;8&nbsp;972</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;9&nbsp;039</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">General &amp; Administration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;986</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;978</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;315</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;300</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;383</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;410</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;452</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;506</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;2&nbsp;136</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;194</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;027</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;091</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 204</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 185</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 47</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 48</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 691</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 603</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;969</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;927</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;213</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;351</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;259</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;96</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;732</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;776</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;2&nbsp;331</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;344</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;782</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;426</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;368</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;445</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;190</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;132</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;331</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;471</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;629</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;268</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;086</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 697</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;108</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 703</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;777</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;707</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;447</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;999</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;817</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;296</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;119</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;703</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;698</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Shareholders of Novartis AG</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 7&nbsp;703</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 6&nbsp;712</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Non-controlling interests</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net income are:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 110</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of property, <br></br>plant &amp; equipment </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;916 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;883 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;270 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;260 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;217 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;229 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;117 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;117 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;1&nbsp;520 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;1&nbsp;489 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;2&nbsp;291</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;470</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;447</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;450</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;942</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;929</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3&nbsp;690</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3&nbsp;861</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on property, <br></br>plant &amp; equipment, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;84 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;93 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;73 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;5 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;157 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;102 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on intangible <br></br>assets, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;591 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;522 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;61 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;65 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;57 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;709 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;591 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges and fair value <br></br>gains on financial assets, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;42 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;55 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;29 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;185 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;77 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;256 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;132 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to restructuring provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;122</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;236</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;61</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;46</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;343</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation of <br></br>Novartis equity plans </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;593 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;582 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;52 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;47 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;71 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;53 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;208 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;164 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;924 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;846 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Alcon </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate (including eliminations)</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties from <br></br>continuing operations </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 32&nbsp;562 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 33&nbsp;345 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 10&nbsp;144 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 10&nbsp;070 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 5&nbsp;812 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 5&nbsp;999 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 48&nbsp;518 </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 49&nbsp;414 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to other segments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 624</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 518</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 128</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;728</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;620</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 33&nbsp;186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 33&nbsp;863</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;248</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;198</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;812</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;999</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;728</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;620</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 48&nbsp;518</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 49&nbsp;440</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 815</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 792</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 62</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 107</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 918</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 947</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;9&nbsp;331</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;9&nbsp;204</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;5&nbsp;971</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;5&nbsp;844</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3&nbsp;092</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3&nbsp;145</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 874</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 789</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;17&nbsp;520</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;17&nbsp;404</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 24&nbsp;670</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25&nbsp;451</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;314</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;379</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;724</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;877</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 208</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 276</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31&nbsp;916</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 32&nbsp;983</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketing &amp; Sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;8&nbsp;435</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;8&nbsp;430</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;681</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;679</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;882</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;663</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;11&nbsp;998</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;11&nbsp;772</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research &amp; Development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;7&nbsp;709</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;7&nbsp;685</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;814</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;782</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;516</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;468</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;9&nbsp;039</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;8&nbsp;935</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">General &amp; Administration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;978</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;031</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;300</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;346</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;410</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;450</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;506</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;648</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;475</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;091</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;149</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 185</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 48</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 603</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 737</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;927</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;049</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;213</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;639</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;259</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;381</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;96</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;69</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;776</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;784</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;344</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;873</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income from <br></br>continuing operations </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 7&nbsp;426 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 7&nbsp;815 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 1&nbsp;445 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 1&nbsp;300 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> &ndash;&nbsp;132 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 281 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> &ndash;&nbsp;471 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> &ndash;&nbsp;419 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 8&nbsp;268 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 8&nbsp;977 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 697</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 264</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 703</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 266</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;707</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;655</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial income and expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;447</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;454</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes from <br></br>continuing operations </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 7&nbsp;817 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 8&nbsp;134 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;119</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;106</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;698</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;028</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net income from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;766</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;698</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&nbsp;794</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Shareholders of Novartis AG</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 6&nbsp;712</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 17&nbsp;783</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Non-controlling interests</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in net income from continuing operations are:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation of property, <br></br>plant &amp; equipment </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;883 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;839 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;260 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;277 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;229 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;237 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;117 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;117 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;1&nbsp;489 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;1&nbsp;470 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;470</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;384</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;450</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;450</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;929</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;912</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3&nbsp;861</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3&nbsp;755</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on property, <br></br>plant &amp; equipment, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;93 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 39 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;97 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;5 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;21 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;102 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;80 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on intangible <br></br>assets, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;522 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;138 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;65 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;27 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;591 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;166 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges and fair value <br></br>gains on financial assets, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;55 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;32 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;77 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;72 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;132 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;104 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to restructuring provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;236</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;232</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;46</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;93</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;49</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;343</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;399</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation of <br></br>Novartis equity plans </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;582 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;620 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;47 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;53 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;53 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;66 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;164 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;164 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;846 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;903 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative Medicines </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Sandoz </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Alcon </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Corporate (including eliminations)</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Group </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 54&nbsp;075</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 51&nbsp;911</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 18&nbsp;231</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&nbsp;611</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22&nbsp;014</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22&nbsp;970</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 38&nbsp;759</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 37&nbsp;632</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 133&nbsp;079</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 130&nbsp;124</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;11&nbsp;457</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;10&nbsp;007</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;3&nbsp;459</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;3&nbsp;168</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;893</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;2&nbsp;520</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;42&nbsp;043</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;39&nbsp;538</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;58&nbsp;852</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;55&nbsp;233</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total equity</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 74&nbsp;227</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 74&nbsp;891</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 19&nbsp;047</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&nbsp;025</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net operating assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 42&nbsp;618</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 41&nbsp;904</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;772</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;443</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20&nbsp;121</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&nbsp;450</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 93&nbsp;274</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 90&nbsp;916</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Included in assets and liabilities are:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total property, plant &amp; equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;857</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;410</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;525</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;374</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;403</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 679</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 694</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&nbsp;464</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&nbsp;641</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to property, <br></br>plant &amp; equipment <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 877 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 996 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 326 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 316 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 431 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 396 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 94 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 127 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;728 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;835 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total goodwill and intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31&nbsp;571</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31&nbsp;630</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;993</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;774</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&nbsp;176</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16&nbsp;914</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;007</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;002</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 61&nbsp;747</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 62&nbsp;320</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to goodwill and <br></br>intangible assets <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 984 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 865 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 64 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 45 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 82 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 63 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 16 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 5 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;146 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 978 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total investment in associated <br></br>companies </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 41 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 16 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 7 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 18 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 15&nbsp;322 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 14&nbsp;270 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 15&nbsp;370 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 14&nbsp;304 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to investment in associated <br></br>companies </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 40 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 37 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 46 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 41 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents, <br></br>marketable securities, commodities, <br></br>time deposits and derivative <br></br>financial instruments </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 9&nbsp;485 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> <br></br> 7&nbsp;777 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 9&nbsp;485 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> <br></br> 7&nbsp;777 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debts and derivative <br></br>financial instruments </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 28&nbsp;532 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 23&nbsp;802 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 28&nbsp;532 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 23&nbsp;802 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current income tax and deferred <br></br>tax liabilities </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 6&nbsp;891 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 8&nbsp;260 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 6&nbsp;891 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 8&nbsp;260 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Excluding impact of business combinations </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;</sup> </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="11" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net sales<sup>1</sup></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total of selected non-current assets<sup>2</sup></div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="11" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> %</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> %</div> </td> <td></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Country</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 836</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 830</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 774</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43&nbsp;920</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 47</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 44&nbsp;413</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 48</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&nbsp;935</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;117</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18&nbsp;079</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28&nbsp;476</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28&nbsp;484</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">United Kingdom</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;160</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;182</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;277</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;957</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;892</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Germany</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;690</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;634</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;262</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;128</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;733</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">France</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;490</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;390</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;269</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 284</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 199</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japan</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;177</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;267</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 148</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 145</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20&nbsp;821</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20&nbsp;098</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 42</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20&nbsp;590</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 40</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9&nbsp;668</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;399</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 49&nbsp;109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 48&nbsp;518</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 49&nbsp;414</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 93&nbsp;581</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 92&nbsp;265</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Region</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Europe</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17&nbsp;492</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;079</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16&nbsp;472</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 61&nbsp;699</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 66</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 59&nbsp;879</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 65</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Americas</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20&nbsp;899</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 42</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20&nbsp;998</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22&nbsp;414</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 45</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29&nbsp;113</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 29&nbsp;831</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Asia/Africa/Australasia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;718</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;441</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;528</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;769</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;555</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 49&nbsp;109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 48&nbsp;518</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 49&nbsp;414</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 93&nbsp;581</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 92&nbsp;265</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Net sales from operations by location of third-party customer </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> 2017 <br></br> USD <br></br> millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> 2016 <br></br> USD <br></br> millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change <br></br> (2016 <br></br> to 2017) <br></br> USD % </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> 2015 <br></br> USD <br></br> millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change <br></br> (2015 <br></br> to 2016) <br></br> USD % </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Oncology</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gleevec/Glivec</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;943</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;323</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;42</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;658</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;29</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tasigna</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;841</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;739</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;632</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Sandostatin</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;612</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;646</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;630</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Afinitor/Votubia</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;525</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;516</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;607</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exjade/Jadenu</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;059</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 956</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 917</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Tafinlar + Mekinist</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 873</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 672</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 453</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Promacta/Revolade</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 867</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 635</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 402</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Votrient</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 808</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 729</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 565</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Jakavi</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 777</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 581</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 410</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 42</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Kisqali</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> nm</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 893</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 993</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;030</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Oncology business unit</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12&nbsp;274</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;790</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;304</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ophthalmology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Lucentis</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;888</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;835</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;060</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Travoprost Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 589</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 619</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 631</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Systane</i> Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 400</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 377</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 380</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Topical Olopatadine Group</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 284</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 335</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 457</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;27</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;207</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;297</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;395</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Ophthalmology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;368</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;463</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;923</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Immunology and Dermatology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cosentyx</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;071</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;128</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 84</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 261</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Neoral/Sandimmun(e)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 488</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 515</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 570</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;10</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Zortress/Certican</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 414</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 398</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 335</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ilaris</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 402</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 283</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 42</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 236</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Myfortic</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 378</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 383</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 441</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 288</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 308</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 294</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Immunology and Dermatology</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;041</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;137</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 41</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Neuroscience</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Gilenya</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;185</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;776</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 102</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Neuroscience</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;287</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;917</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> 2017 <br></br> USD <br></br> millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> 2016 <br></br> USD <br></br> millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change <br></br> (2016 <br></br> to 2017) <br></br> USD % </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> 2015 <br></br> USD <br></br> millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Change <br></br> (2015 <br></br> to 2016) <br></br> USD % </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Respiratory</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ultibro Breezhaler</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 411</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 363</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 260</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 40</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Seebri Breezhaler</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 151</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 149</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 150</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Onbrez Breezhaler</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 112</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 143</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal COPD<sup>1</sup> portfolio</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 674</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 655</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 576</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Xolair <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 920</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 835</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 755</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;16</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Respiratory</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;617</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;521</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;368</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cardio-Metabolic</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Entresto</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 507</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 170</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 198</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Cardio-Metabolic</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 524</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 184</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 185</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> nm</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Established Medicines</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Galvus</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;233</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;193</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;140</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Exforge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 960</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 926</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;047</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Diovan/Co-Diovan</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 957</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;073</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;284</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;16</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Voltaren/Cataflam</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 465</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 525</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 558</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"><i>Exelon/Exelon</i> Patch</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 381</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 444</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 728</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;39</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Ritalin/Focalin</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 236</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 282</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 365</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;682</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;913</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;553</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Established Medicines</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;914</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;356</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;675</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;17</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total Pharmaceutical business unit</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20&nbsp;751</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 19&nbsp;772</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&nbsp;041</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total division net sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33&nbsp;025</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 32&nbsp;562</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 33&nbsp;345</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Chronic obstructive pulmonary disease </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Net sales reflect <i>Xolair</i> sales for all indications (e.g., including <i>Xolair</i> SAA and <i>Xolair</i> CSU, which is managed by the Immunology and Dermatology franchise) </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">nm = not meaningful</div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">4. Associated companies</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net income statement effect</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other comprehensive income effect</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total comprehensive income effect</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Roche Holding AG, Switzerland</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 456</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 464</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 343</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 108</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;39</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;149</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 564</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 425</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 194</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">GlaxoSmithKline Consumer <br></br>Healthcare Holdings Ltd., UK </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 629 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 234 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;79 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;145 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 710 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 484 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 944 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;83 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies related to continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;108</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 703</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 266</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 671</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;153</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;071</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;374</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 113</div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has significant investments in Roche Holding AG, Basel (Roche) and in GlaxoSmithKline Consumer Healthcare Holdings Ltd, Brentford, Middlesex, UK as well as certain other smaller investments that are accounted for as associated companies. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Balance sheet value</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31, <br></br> 2017 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31, <br></br> 2016 </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Roche Holding AG, Switzerland</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;121</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;644</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">GlaxoSmithKline Consumer <br></br>Healthcare Holdings Ltd., UK </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 7&nbsp;020 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 6&nbsp;448 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 229</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 212</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&nbsp;370</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;304</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Roche Holding AG </font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s holding in Roche voting shares was 33.3% at December 31, 2017, 2016 and 2015. This investment represents approximately 6.3% of Roche&#x2019;s total outstanding voting and non-voting equity instruments at December 31, 2017, 2016 and 2015. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Since full-year 2017 financial data for Roche is not available when Novartis produces its consolidated financial results, a survey of analyst estimates is used to estimate the Group&#x2019;s share of Roche&#x2019;s net income. Any differences between these estimates and actual results will be adjusted in the Group&#x2019;s 2018 consolidated financial statements when available. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following tables show summarized financial information for Roche, including current values of fair value adjustments made at the time of the acquisition of the shares, for the year ended December 31, 2016 and for the six months ended June 30, 2017 (since full-year 2017 data is not yet available): </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(CHF billions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Current assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-current <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Current <br></br> liabilities </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-current <br></br> liabilities </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">December 31, 2016</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28.7</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61.4</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22.6</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27.8</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">June 30, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 56.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(CHF billions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Revenue </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Net income </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other <br></br> comprehen- <br></br> sive income </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br></br> comprehen- <br></br> sive income </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">December 31, 2016</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 50.6</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7.5</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.7</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8.2</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">June 30, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">A purchase price allocation was performed on the basis of publicly available information at the time of acquisition of the investment. The December 31, 2017 balance sheet value allocation is as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31, <br></br> 2017 </div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of Roche&#x2019;s estimated net assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;412</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of re-appraised intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 673</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Implicit Novartis goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;915</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current value of share in net identifiable assets <br></br>and goodwill </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 6&nbsp;000 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated equity accounting adjustments and translation effects less dividends received</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;121</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance sheet value</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;121</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The identified intangible assets principally relate to the value of currently marketed products and are amortized on a straight-line basis over their estimated average useful life of 20 years. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2017, dividends received from Roche in relation to the distribution of its 2016 net income amounted to USD&nbsp;438 million (2016: USD 433 million in relation to the distribution of its 2015 net income). </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consolidated income statement effects from applying Novartis accounting principles for this investment in 2017, 2016 and 2015 are as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of Roche's <br></br>estimated current-year <br></br>consolidated net income </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 669 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 678 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 650 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prior-year adjustment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;67</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;68</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;157</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of fair value adjustments relating to intangible assets, net of taxes of USD 42 million (2016: USD 42 million; 2015: USD 41 million)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;146</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;146</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;150</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income effect</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 456</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 464</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 343</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The publicly quoted market value of the Novartis interest in Roche (SIX symbol: RO) at December&nbsp;31, 2017, was USD&nbsp;13.4 billion (2016: USD&nbsp;12.4 billion). </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">GlaxoSmithKline Consumer Healthcare Holdings&nbsp;Ltd.</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On March 2, 2015, Novartis closed its transactions with GlaxoSmithKline plc, Great Britain (GSK) announced in April 2014. As part of these transactions, Novartis and GSK agreed to create a combined consumer healthcare business through a combination between Novartis OTC and GSK Consumer Healthcare. On March 2, 2015, a new entity GlaxoSmithKline Consumer Healthcare Holdings Ltd (GSK Consumer Healthcare) was formed via the contribution of businesses from both Novartis and GSK. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">At December 31, 2017, 2016 and 2015, Novartis has a 36.5% interest in GSK Consumer Healthcare and four of eleven seats on the GSK Consumer Healthcare board of directors. Furthermore, Novartis has customary minority rights and also exit rights at a pre-defined, market-based pricing mechanism. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The December 31, 2017 balance sheet value allocation is as follows:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31, <br></br> 2017 </div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of GSK Consumer Healthcare&#x2019;s <br></br>estimated net assets </div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;505 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of re-appraised intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;852</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Implicit Novartis goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;763</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current value of share in net identifiable assets <br></br>and goodwill </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 7&nbsp;120 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated equity accounting adjustments and translation effects less dividends received</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance sheet value</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;020</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The identified intangible assets principally relate to the value of the indefinite life GSK Consumer Healthcare intangible assets. The identified intangible assets with a definite life are amortized on a straight-line basis over their estimated average useful life of 20 years. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">At acquisition date, Novartis has valued the contribution of 63.5% of its OTC Division in exchange for 36.5% of the GSK Consumer Healthcare business at fair value. The retained interest in the OTC Division business contributed was accounted for at net book value at the time of contribution. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following tables show summarized financial information for GSK Consumer Healthcare, including current values of fair value adjustments made at the time of acquisition, for the year ended December&nbsp;31, 2016, and for the nine months ended September 30, 2017 (interim unaudited), since full-year 2017 data is not yet available: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(GBP billions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Current assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-current <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Current <br></br> liabilities </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-current <br></br> liabilities </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">December 31, 2016</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.1</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">September 30, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(GBP billions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Revenue </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Net income </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other <br></br> comprehen- <br></br> sive income </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br></br> comprehen- <br></br> sive income </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">December 31, 2016</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6.5</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.6</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.6</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.2</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">September 30, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;0.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since full-year 2017 financial data for GSK Consumer Healthcare is not available when Novartis produces its consolidated financial results, a projection of the latest internal management reporting is used to estimate the Group&#x2019;s share of GSK Consumer Healthcare&#x2019;s net result for the year. Any differences between this estimate and actual results will be adjusted in the Group&#x2019;s 2018 consolidated financial statements when available. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2017, dividends received from GSK Consumer Healthcare amounted to USD&nbsp;544 million (2016: USD&nbsp;463 million).</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The consolidated income statement effects from applying Novartis accounting principles for this investment in 2017, 2016 and 2015 are as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of <br></br>GSK Consumer Healthcare's <br></br>estimated current-year <br></br>consolidated net income </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 589 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> <br></br> 268 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> <br></br> &ndash;&nbsp;17 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prior-year adjustment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 47</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of fair value adjustments relating to intangible assets and inventory, net of taxes of USD 1 million (2016: USD 2 million; 2015: USD 18 million)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;62</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income effect</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 629</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 234</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;79</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net income statement effect</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other comprehensive income effect</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total comprehensive income effect</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Roche Holding AG, Switzerland</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 456</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 464</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 343</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 108</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;39</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;149</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 564</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 425</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 194</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">GlaxoSmithKline Consumer <br></br>Healthcare Holdings Ltd., UK </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 629 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 234 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;79 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;145 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 710 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 484 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 944 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;83 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies related to continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;108</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 703</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 266</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 671</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;153</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;071</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;374</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 113</div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Balance sheet value</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31, <br></br> 2017 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31, <br></br> 2016 </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Roche Holding AG, Switzerland</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;121</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;644</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">GlaxoSmithKline Consumer <br></br>Healthcare Holdings Ltd., UK </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 7&nbsp;020 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 6&nbsp;448 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 229</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 212</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 15&nbsp;370</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;304</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31, <br></br> 2017 </div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of Roche&#x2019;s estimated net assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;412</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of re-appraised intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 673</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Implicit Novartis goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;915</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current value of share in net identifiable assets <br></br>and goodwill </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 6&nbsp;000 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated equity accounting adjustments and translation effects less dividends received</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;121</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance sheet value</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;121</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of Roche's <br></br>estimated current-year <br></br>consolidated net income </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 669 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 678 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 650 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prior-year adjustment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;67</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;68</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;157</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of fair value adjustments relating to intangible assets, net of taxes of USD 42 million (2016: USD 42 million; 2015: USD 41 million)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;146</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;146</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;150</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income effect</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 456</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 464</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 343</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31, <br></br> 2017 </div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of GSK Consumer Healthcare&#x2019;s <br></br>estimated net assets </div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;505 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of re-appraised intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;852</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Implicit Novartis goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;763</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current value of share in net identifiable assets <br></br>and goodwill </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 7&nbsp;120 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated equity accounting adjustments and translation effects less dividends received</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance sheet value</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;020</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(GBP billions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Current assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-current <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Current <br></br> liabilities </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-current <br></br> liabilities </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">December 31, 2016</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.1</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">September 30, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(GBP billions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Revenue </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Net income </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other <br></br> comprehen- <br></br> sive income </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br></br> comprehen- <br></br> sive income </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">December 31, 2016</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6.5</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.6</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.6</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.2</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">September 30, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;0.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis share of <br></br>GSK Consumer Healthcare's <br></br>estimated current-year <br></br>consolidated net income </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> <br></br> 589 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> <br></br> 268 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> <br></br> &ndash;&nbsp;17 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prior-year adjustment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 47</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of fair value adjustments relating to intangible assets and inventory, net of taxes of USD 1 million (2016: USD 2 million; 2015: USD 18 million)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;62</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income effect</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 629</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 234</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;79</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">5. Interest expense and&nbsp;other&nbsp;financial&nbsp;income&nbsp;and&nbsp;expense</div> <div style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Interest expense</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;758</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;709</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;669</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Expense)/ income arising from discounting long-term liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total interest expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;777</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;707</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;655</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Other financial income and expense</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 110</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net capital losses on <br></br>available-for-sale securities </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;8 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income on forward contracts <br></br>and options </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment of commodities <br></br>and available-for-sale securities, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 12 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 7 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;132 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Monetary loss from hyperinflation <br></br>accounting </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;72 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency result, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;58</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;477</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;254</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other financial income and expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;447</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;454</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest expense</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;758</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;709</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;669</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Expense)/ income arising from discounting long-term liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total interest expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;777</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;707</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;655</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 110</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net capital losses on <br></br>available-for-sale securities </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;8 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income on forward contracts <br></br>and options </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment of commodities <br></br>and available-for-sale securities, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 12 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 7 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;132 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Monetary loss from hyperinflation <br></br>accounting </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;72 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency result, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;58</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;477</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;254</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other financial income and expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;447</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;454</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">6. Taxes</div> <div style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Income before taxes</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;289</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;110</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;765</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;710</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;707</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;369</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes <br></br>from continuing operations </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 8&nbsp;999 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 7&nbsp;817 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 8&nbsp;134 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income before taxes from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;479</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total income before taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;999</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;817</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&nbsp;613</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Current and deferred income tax expense</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;462</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;709</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;317</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;594</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;418</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;333</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current income tax expense from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;2&nbsp;056</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;2&nbsp;127</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;650</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;298</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 765</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;68</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;058</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 243</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 612</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Deferred tax income from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 760</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;008</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 544</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income tax expense <br></br>from continuing operations </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> &ndash;&nbsp;1&nbsp;296 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> &ndash;&nbsp;1&nbsp;119 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> &ndash;&nbsp;1&nbsp;106 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income tax expense from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;713</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total income tax expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;296</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;119</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;2&nbsp;819</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Analysis of tax rate</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The main elements contributing to the difference between the Group&#x2019;s overall applicable tax rate (which can change each year since it is calculated as the weighted average tax rate based on pre-tax income of each subsidiary) and the effective tax rate are: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(As a percentage)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Applicable tax rate</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14.5</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13.2</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12.4</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of disallowed expenditures</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of utilization of tax losses <br></br>brought forward from prior periods </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;0.1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;0.2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;0.2 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of income taxed at reduced rates</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;0.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;0.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;0.3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax credits and allowances</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;2.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2.7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of release of <br></br>contingent consideration liability </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;1.2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 0.0 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 0.0 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax rate change <br></br>on current and deferred <br></br>tax assets and liabilities <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 0.7 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 0.2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &ndash;&nbsp;0.5 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of write-off of deferred tax assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of write down and reversal of <br></br>write-down of investments in subsidiaries </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;1.1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;1.0 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;0.9 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax benefits expiring in 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;0.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;0.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;0.4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of non-deductible losses in Venezuela</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of prior year items</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of other items <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Effective tax rate for continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13.6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effective tax rate for discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13.7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Effective tax rate</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13.7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <b> </b> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Included in 2017 is a 0.7% impact related to the revaluation of the deferred tax assets and liabities and a portion of current tax payables. This revaluation resulted from the US tax reform legislation enacted on December 22, 2017, refer to Note 11 for additional disclosures. <b> </b> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Other items in 2016 (+0.1%) include one-time impacts for the deferred tax effects on the net assets of certain subsidiaries resulting from the change in their tax status (-6.2%), the changes in uncertain tax positions (+5.1%) and other items (+1.2%). </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has a substantial business presence in many countries and is therefore subject to different income and expense items that are non-taxable (permanent differences) or taxed at different rates in those tax jurisdictions. This results in a difference between our applicable tax rate and effective tax rate, as shown in the table above. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The utilization of tax-loss carry-forwards lowered the tax charge by USD&nbsp;7 million in 2017, and by USD&nbsp;18 million and USD&nbsp;15 million in 2016 and 2015, respectively.</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;289</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;110</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;765</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;710</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;707</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;369</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes <br></br>from continuing operations </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 8&nbsp;999 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 7&nbsp;817 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 8&nbsp;134 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income before taxes from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;479</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total income before taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;999</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;817</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&nbsp;613</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;462</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;709</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;317</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;594</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;418</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;333</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current income tax expense from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;2&nbsp;056</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;2&nbsp;127</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;650</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Switzerland</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;298</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 765</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;68</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Foreign</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;058</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 243</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 612</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Deferred tax income from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 760</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;008</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 544</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income tax expense <br></br>from continuing operations </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> &ndash;&nbsp;1&nbsp;296 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> &ndash;&nbsp;1&nbsp;119 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> &ndash;&nbsp;1&nbsp;106 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income tax expense from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;713</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total income tax expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;296</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;119</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;2&nbsp;819</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(As a percentage)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Applicable tax rate</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14.5</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13.2</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12.4</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of disallowed expenditures</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3.5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of utilization of tax losses <br></br>brought forward from prior periods </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;0.1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;0.2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;0.2 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of income taxed at reduced rates</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;0.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;0.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;0.3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax credits and allowances</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;2.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2.7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of release of <br></br>contingent consideration liability </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;1.2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 0.0 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 0.0 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax rate change <br></br>on current and deferred <br></br>tax assets and liabilities <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 0.7 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 0.2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &ndash;&nbsp;0.5 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of write-off of deferred tax assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of write down and reversal of <br></br>write-down of investments in subsidiaries </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;1.1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;1.0 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;0.9 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of tax benefits expiring in 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;0.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;0.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;0.4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of non-deductible losses in Venezuela</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of prior year items</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of other items <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Effective tax rate for continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13.6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effective tax rate for discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13.7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Effective tax rate</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13.7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <b> </b> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Included in 2017 is a 0.7% impact related to the revaluation of the deferred tax assets and liabities and a portion of current tax payables. This revaluation resulted from the US tax reform legislation enacted on December 22, 2017, refer to Note 11 for additional disclosures. <b> </b> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Other items in 2016 (+0.1%) include one-time impacts for the deferred tax effects on the net assets of certain subsidiaries resulting from the change in their tax status (-6.2%), the changes in uncertain tax positions (+5.1%) and other items (+1.2%). </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">7. Earnings per share</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income attributable to shareholders of Novartis AG (USD millions)</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Continuing operations</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;703</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;712</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;025</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;758</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#x2013; Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;703</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;712</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&nbsp;783</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Number of shares (in millions)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Weighted average number of shares outstanding used in basic earnings per share</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;346</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;378</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;403</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Weighted average number of shares in diluted earnings per share</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;371</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;400</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;438</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share (USD)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.82</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.92</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.48</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#x2013; Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2.82</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7.40</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Diluted earnings per share (USD)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.80</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.88</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.41</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#x2013; Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2.80</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7.29</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Basic earnings per share (EPS) is calculated by dividing net income attributable to shareholders of Novartis AG by the weighted average number of shares outstanding in a reporting period. This calculation excludes the average number of issued shares purchased by the Group and held as treasury shares. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For diluted EPS, the weighted average number of shares outstanding is adjusted to assume the vesting of all restricted shares, restricted share units, and the conversion of all potentially dilutive shares arising from options on Novartis shares that have been issued. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">No options were excluded from the calculation of diluted EPS in 2017, 2016, or 2015, as all options were dilutive in all years. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income attributable to shareholders of Novartis AG (USD millions)</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Continuing operations</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;703</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;712</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;025</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;758</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#x2013; Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;703</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;712</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&nbsp;783</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Number of shares (in millions)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Weighted average number of shares outstanding used in basic earnings per share</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;346</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;378</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;403</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Weighted average number of shares in diluted earnings per share</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;371</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;400</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;438</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Basic earnings per share (USD)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.82</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.92</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.48</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#x2013; Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2.82</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7.40</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Diluted earnings per share (USD)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.80</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.88</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.41</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">&#x2013; Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2.80</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7.29</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">8. Changes in consolidated statements of&nbsp;comprehensive income</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated statements of comprehensive income include the Group&#x2019;s net income for the year as well as all other valuation adjustments recorded in the Group&#x2019;s consolidated balance sheet but which under IFRS are not recorded in the consolidated income statement. These include fair value adjustments to financial instruments, actuarial gains or losses on defined benefit pension and other post-employment plans and currency translation effects, net of tax. </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes these value adjustments and currency translation effects attributable to Novartis shareholders: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Fair value <br></br> adjustments <br></br> on marketable <br></br> securities </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Fair value <br></br> adjustments on <br></br> deferred cash <br></br> flow hedges </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Actuarial <br></br> gains/(losses) <br></br> from defined <br></br> benefit plans </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Net <br></br> investment <br></br> hedge </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Cumulative <br></br> currency <br></br> translation <br></br> effects </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total value <br></br> adjustments </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at January 1, 2015</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 433</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;38</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;5&nbsp;366</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;406</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;2&nbsp;565</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 48</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net actuarial losses from defined benefit plans <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;147</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;147</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;659</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;659</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;147</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;659</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;758</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments related to divestments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 461</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;5&nbsp;413</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 747</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;4&nbsp;223</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;113</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;98</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net actuarial losses from defined benefit plans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;514</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;514</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;389</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;389</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;113</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;514</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;2&nbsp;389</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;3&nbsp;001</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments related to divestments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 348</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;5&nbsp;915</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;642</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;7&nbsp;212</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;237</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;237</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net actuarial gains from defined benefit plans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 851</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 851</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;208</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;208</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 851</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;237</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;208</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;872</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 386</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;5&nbsp;064</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;237</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 566</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;4&nbsp;340</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Net actuarial gains of USD 10 million in 2015 were attributable to discontinued operations up to the respective divestment dates </div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Currency translation losses of USD 29 million in 2015 were attributable to discontinued operations up to the respective divestment dates </div> </td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">8.1) The 2017, 2016 and 2015 changes in the fair value of financial instruments were as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Fair value <br></br> adjustments <br></br> on marketable <br></br> securities </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Fair value <br></br> adjustments on <br></br> deferred cash <br></br> flow hedges </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value adjustments at January 1, 2017</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 348</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;3</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 345</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair value:</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Available-for-sale marketable securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Available-for-sale financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 47</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 47</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Realized net gains transferred to the consolidated income statement:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Other financial assets sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;109</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortized net losses on cash flow hedges transferred to the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impaired financial assets transferred to the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 102</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 102</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax on above items <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value adjustments during the year</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 50</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value adjustments at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 386</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 395</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Included in 2017 is a USD 18 million impact related to the revaluation of deferred tax liabilities on available-for-sale financial investments held in the US that were previously recognized through other comprehensive income. This revaluation resulted from the US tax reform legislation enacted on December 22, 2017, refer to Note 11 for additional disclosures. </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Fair value <br></br> adjustments <br></br> on marketable <br></br> securities </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Fair value <br></br> adjustments on <br></br> deferred cash <br></br> flow hedges </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value adjustments at January 1, 2016</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 461</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;18</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 443</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair value:</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Available-for-sale marketable securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Available-for-sale financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;87</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;87</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Realized net gains transferred to the consolidated income statement:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Marketable securities sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Other financial assets sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;154</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;154</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortized net losses on cash flow hedges transferred to the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impaired financial assets transferred to the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 131</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 131</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax on above items</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value adjustments during the year</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;113</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;98</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value adjustments at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 348</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 345</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Fair value <br></br> adjustments <br></br> on marketable <br></br> securities </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Fair value <br></br> adjustments on <br></br> deferred cash <br></br> flow hedges </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value adjustments at January 1, 2015</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 433</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;38</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 395</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair value:</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Available-for-sale marketable securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;130</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;130</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Available-for-sale financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 80</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 80</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Associated companies&#x2019; movements in comprehensive income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Realized net gains transferred to the consolidated income statement:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Marketable securities sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Other financial assets sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;103</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;103</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortized net losses on cash flow hedges transferred to the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impaired financial assets transferred to the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 194</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax on above items</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value adjustments during the year</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 48</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value adjustments at December 31, 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 461</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 443</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">8.2) In 2015, cumulative currency translation losses of USD&nbsp;10 million were recycled through the income statement as a result of the divestments of subsidiaries. No currency translation losses or gains were recycled through the income statement in 2017 and 2016. </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">8.3) Remeasurements from defined benefit plans arise as follows:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit pension plans before tax</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;367</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;667</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;252</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other post-employment benefit plans before tax</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 168</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxation on above items <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;592</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 140</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;63</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total after tax</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 851</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;515</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;147</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Shareholders of Novartis AG</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 851</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;514</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;147</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Non-controlling interests</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Included in 2017 is a USD -272 million impact related to the revaluation of deferred tax assets on US post-employment benefits that were previously recognized through other comprehensive income. This revaluation resulted from the US tax reform legislation enacted on December 22, 2017, refer to Note 11 for additional disclosures. </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Fair value <br></br> adjustments <br></br> on marketable <br></br> securities </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Fair value <br></br> adjustments on <br></br> deferred cash <br></br> flow hedges </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Actuarial <br></br> gains/(losses) <br></br> from defined <br></br> benefit plans </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Net <br></br> investment <br></br> hedge </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Cumulative <br></br> currency <br></br> translation <br></br> effects </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total value <br></br> adjustments </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at January 1, 2015</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 433</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;38</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;5&nbsp;366</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;406</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;2&nbsp;565</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 48</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net actuarial losses from defined benefit plans <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;147</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;147</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;659</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;659</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;147</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;659</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;758</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments related to divestments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 461</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;5&nbsp;413</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 747</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;4&nbsp;223</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;113</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;98</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net actuarial losses from defined benefit plans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;514</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;514</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;389</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;389</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;113</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;514</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;2&nbsp;389</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;3&nbsp;001</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments related to divestments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 348</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;5&nbsp;915</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;642</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;7&nbsp;212</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments on financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net investment hedge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;237</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;237</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net actuarial gains from defined benefit plans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 851</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 851</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;208</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;208</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total value adjustments in 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 851</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;237</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;208</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;872</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Value adjustments at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 386</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;5&nbsp;064</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;237</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 566</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;4&nbsp;340</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Net actuarial gains of USD 10 million in 2015 were attributable to discontinued operations up to the respective divestment dates </div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Currency translation losses of USD 29 million in 2015 were attributable to discontinued operations up to the respective divestment dates </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Fair value <br></br> adjustments <br></br> on marketable <br></br> securities </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Fair value <br></br> adjustments on <br></br> deferred cash <br></br> flow hedges </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value adjustments at January 1, 2017</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 348</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;3</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 345</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair value:</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Available-for-sale marketable securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Available-for-sale financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 47</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 47</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Realized net gains transferred to the consolidated income statement:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Other financial assets sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;109</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortized net losses on cash flow hedges transferred to the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impaired financial assets transferred to the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 102</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 102</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax on above items <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;14</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value adjustments during the year</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 50</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value adjustments at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 386</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 395</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Included in 2017 is a USD 18 million impact related to the revaluation of deferred tax liabilities on available-for-sale financial investments held in the US that were previously recognized through other comprehensive income. This revaluation resulted from the US tax reform legislation enacted on December 22, 2017, refer to Note 11 for additional disclosures. </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Fair value <br></br> adjustments <br></br> on marketable <br></br> securities </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Fair value <br></br> adjustments on <br></br> deferred cash <br></br> flow hedges </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value adjustments at January 1, 2016</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 461</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;18</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 443</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair value:</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Available-for-sale marketable securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Available-for-sale financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;87</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;87</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Realized net gains transferred to the consolidated income statement:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Marketable securities sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Other financial assets sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;154</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;154</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortized net losses on cash flow hedges transferred to the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impaired financial assets transferred to the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 131</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 131</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax on above items</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value adjustments during the year</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;113</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;98</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value adjustments at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 348</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 345</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Fair value <br></br> adjustments <br></br> on marketable <br></br> securities </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Fair value <br></br> adjustments on <br></br> deferred cash <br></br> flow hedges </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value adjustments at January 1, 2015</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 433</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;38</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 395</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair value:</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Available-for-sale marketable securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;130</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;130</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Available-for-sale financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 80</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 80</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Associated companies&#x2019; movements in comprehensive income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Realized net gains transferred to the consolidated income statement:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Marketable securities sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Other financial assets sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;103</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;103</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortized net losses on cash flow hedges transferred to the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impaired financial assets transferred to the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 194</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax on above items</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value adjustments during the year</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 48</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value adjustments at December 31, 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 461</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 443</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit pension plans before tax</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;367</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;667</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;252</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other post-employment benefit plans before tax</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 168</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxation on above items <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;592</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 140</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;63</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total after tax</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 851</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;515</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;147</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Attributable to:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Shareholders of Novartis AG</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 851</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;514</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;147</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Non-controlling interests</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Included in 2017 is a USD -272 million impact related to the revaluation of deferred tax assets on US post-employment benefits that were previously recognized through other comprehensive income. This revaluation resulted from the US tax reform legislation enacted on December 22, 2017, refer to Note 11 for additional disclosures. </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">9. Property, plant &amp; equipment</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of property, plant and equipment during 2017: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Land </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Buildings </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Construction <br></br> in progress </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Machinery <br></br> &amp; other <br></br> equipment </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cost</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2017</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 687</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;113</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;680</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;816</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 31&nbsp;296</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 508</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;617</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;104</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 104</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 425</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;728</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;324</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;71</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;593</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;011</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 663</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 190</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;106</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;997</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 720</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;064</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;368</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&nbsp;858</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 34&nbsp;010</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Accumulated depreciation</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;40</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;5&nbsp;436</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;10&nbsp;164</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;15&nbsp;655</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;510</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;007</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;520</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation on disposals and derecognitions <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 275</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 534</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 849</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;58</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;106</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;189</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;287</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;772</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;063</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;40</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;5&nbsp;983</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;11&nbsp;485</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;17&nbsp;546</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 680</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;081</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;330</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;373</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&nbsp;464</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value of property, plant &amp; equipment under finance lease contracts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 78</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for purchases of property, plant &amp; equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 318</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Capitalized borrowing costs</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Reclassifications between various asset categories due to completion of plant and other equipment under construction. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Derecognition of assets that are no longer used and are not considered to have a significant disposal value or other alternative use. </div> </td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of property, plant and equipment during 2016: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Land </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Buildings </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Construction <br></br> in progress </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Machinery <br></br> &amp; other <br></br> equipment </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cost</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2016</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 688</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;857</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;810</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&nbsp;093</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31&nbsp;448</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 630</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;226</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 592</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 176</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;226</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 409</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;835</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;178</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;656</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;861</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;372</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;111</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;622</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;126</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 687</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;113</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;680</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;816</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31&nbsp;296</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Accumulated depreciation</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;40</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;5&nbsp;188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;10&nbsp;231</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;15&nbsp;466</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;530</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;956</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;489</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation on disposals and derecognitions <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 157</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 630</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 793</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;47</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;61</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;122</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 441</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 609</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;40</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;5&nbsp;436</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;10&nbsp;164</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;15&nbsp;655</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 647</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;677</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;665</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;652</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&nbsp;641</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value of property, plant &amp; equipment under finance lease contracts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 81</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for purchases of property, plant &amp; equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 223</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Capitalized borrowing costs</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Reclassifications between various asset categories due to completion of plant and other equipment under construction. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Derecognition of assets that are no longer used and are not considered to have a significant disposal value or other alternative use. </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Land </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Buildings </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Construction <br></br> in progress </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Machinery <br></br> &amp; other <br></br> equipment </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cost</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2017</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 687</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 13&nbsp;113</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;680</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;816</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 31&nbsp;296</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 508</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;617</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;104</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 104</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;186</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 425</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;728</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;324</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;71</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;593</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;011</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 663</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 190</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;106</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;997</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 720</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;064</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;368</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&nbsp;858</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 34&nbsp;010</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Accumulated depreciation</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;40</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;5&nbsp;436</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;10&nbsp;164</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;15&nbsp;655</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;510</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;007</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;520</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation on disposals and derecognitions <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 275</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 534</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 849</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;58</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;106</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;189</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;287</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;772</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;063</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;40</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;5&nbsp;983</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;11&nbsp;485</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;17&nbsp;546</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 680</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;081</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;330</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;373</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 16&nbsp;464</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value of property, plant &amp; equipment under finance lease contracts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 78</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for purchases of property, plant &amp; equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 318</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Capitalized borrowing costs</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Reclassifications between various asset categories due to completion of plant and other equipment under construction. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Derecognition of assets that are no longer used and are not considered to have a significant disposal value or other alternative use. </div> </td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of property, plant and equipment during 2016: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Land </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Buildings </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Construction <br></br> in progress </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Machinery <br></br> &amp; other <br></br> equipment </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Cost</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2016</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 688</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;857</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;810</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&nbsp;093</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31&nbsp;448</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 630</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;226</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 592</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 176</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;226</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 409</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;835</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;178</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;656</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;861</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;372</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;111</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;622</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;126</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 687</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;113</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;680</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;816</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31&nbsp;296</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Accumulated depreciation</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;40</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;5&nbsp;188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;10&nbsp;231</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;15&nbsp;466</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;530</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;956</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;489</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated depreciation on disposals and derecognitions <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 157</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 630</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 793</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;47</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;61</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;122</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of impairment charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 441</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 609</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;40</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;5&nbsp;436</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;10&nbsp;164</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;15&nbsp;655</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 647</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;677</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;665</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;652</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&nbsp;641</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value of property, plant &amp; equipment under finance lease contracts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 81</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Commitments for purchases of property, plant &amp; equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 223</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Capitalized borrowing costs</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Reclassifications between various asset categories due to completion of plant and other equipment under construction. </div> </td> </tr> <tr valign="bottom"> <td colspan="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Derecognition of assets that are no longer used and are not considered to have a significant disposal value or other alternative use. </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">10. Goodwill and intangible assets</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of goodwill and intangible assets in 2017: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="1" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill</div> </td> <td></td> <td align="center" colspan="13" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible Assets other than Goodwill</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="1" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="13" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Acquired <br></br> research &amp; <br></br> development </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Alcon <br></br> brand name </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Technologies </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently <br></br> marketed <br></br> products </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Marketing <br></br> know-how </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other <br></br> intangible <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cost</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2017</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 31&nbsp;381</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;150</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;980</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;548</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33&nbsp;007</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;960</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;492</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 55&nbsp;137</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of business combinations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 94</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;223</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;223</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;389</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 175</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 214</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 697</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 282</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 162</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;146</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;353</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;328</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;64</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;746</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 704</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 134</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 86</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 969</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 48</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;237</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 32&nbsp;179</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;462</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;638</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 34&nbsp;105</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;960</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;852</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 57&nbsp;997</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Accumulated amortization</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;401</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;886</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;3&nbsp;637</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;16&nbsp;863</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;430</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;981</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;23&nbsp;797</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;577</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;2&nbsp;571</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;238</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;304</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3&nbsp;690</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated impairments on disposals <br></br>and derecognitions<sup>2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 352 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 317 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 61 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 730 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;615</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;92</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;709</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;416</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;534</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;429</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;170</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;4&nbsp;268</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;19&nbsp;631</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;668</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;263</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;28&nbsp;000</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 31&nbsp;750</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;292</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;370</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;474</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;292</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 589</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;997</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Reclassifications between various asset categories as a result of product launches of acquired In-Process Research &amp; Development and completion of software development. </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Derecognitions of assets that are no longer used or being developed and are not considered to have a significant disposal value or other alternative use. </div> </td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of goodwill and intangible assets in 2016: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="1" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill</div> </td> <td></td> <td align="center" colspan="13" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible Assets other than Goodwill</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="1" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="13" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Acquired <br></br> research &amp; <br></br> development </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Alcon <br></br> brand name </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Technologies </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently <br></br> marketed <br></br> products </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Marketing <br></br> know-how </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other <br></br> intangible <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cost</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2016</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31&nbsp;585</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;119</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;980</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;563</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 33&nbsp;385</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;960</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;341</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 54&nbsp;348</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of business combinations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 56</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 690</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 451</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;141</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;158</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 152</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 599</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 223</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 156</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 978</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;464</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;130</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;617</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;260</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;77</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;594</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;713</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31&nbsp;381</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;150</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;548</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 33&nbsp;007</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;960</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;492</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;137</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Accumulated amortization</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;411</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;650</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;3&nbsp;070</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;14&nbsp;221</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;192</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;998</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;20&nbsp;131</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 225</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;225</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;576</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;926</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;238</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;121</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3&nbsp;861</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated impairments on disposals <br></br>and derecognitions<sup>2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 22 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 390 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 123 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 535 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;490</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;96</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;591</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 215</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 251</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;401</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;886</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;3&nbsp;637</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;16&nbsp;863</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;430</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;981</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;23&nbsp;797</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 30&nbsp;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;264</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;911</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&nbsp;144</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;530</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 511</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31&nbsp;340</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Reclassifications between various asset categories as a result of product launches of acquired In-Process Research &amp; Development and completion of software development. </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Derecognitions of assets that are no longer used or being developed and are not considered to have a significant disposal value or other alternative use. </div> </td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2017: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="1" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill</div> </td> <td></td> <td align="center" colspan="13" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible Assets other than Goodwill</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="1" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="13" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Acquired <br></br> research &amp; <br></br> development </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Alcon <br></br> brand name </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Technologies </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently <br></br> marketed <br></br> products </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Marketing <br></br> know-how </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other <br></br> intangible <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&nbsp;237</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;368</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&nbsp;604</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 353</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&nbsp;334</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;210</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 625</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 539</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;589</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;783</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;295</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 291</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;822</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;281</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;292</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 195</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;881</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;999</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 31&nbsp;750</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;292</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;370</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;474</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;292</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 589</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;997</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2016: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="1" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill</div> </td> <td></td> <td align="center" colspan="13" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible Assets other than Goodwill</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="1" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="13" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Acquired <br></br> research &amp; <br></br> development </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Alcon <br></br> brand name </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Technologies </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently <br></br> marketed <br></br> products </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Marketing <br></br> know-how </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other <br></br> intangible <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&nbsp;010</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;512</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;821</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 276</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16&nbsp;620</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;669</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 613</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 563</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;904</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;105</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;293</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 139</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;337</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;419</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;530</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 196</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;621</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;994</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 30&nbsp;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;264</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;911</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&nbsp;144</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;530</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 511</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31&nbsp;340</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Innovative Medicines, Sandoz and Alcon Divisions&#x2019; cash generating units, to which goodwill are allocated, each comprise a group of smaller cash generating units. The valuation method of the recoverable amount of the cash generating units, to which goodwill is allocated, is based on the fair value less costs of disposal. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Alcon brand name is a Corporate asset with an indefinite life. The intangible asset is allocated to Corporate as it is used to market the Alcon-branded products of both the Alcon Division and the Ophthalmology business franchise of the Innovative Medicines Division. Net sales of these products together are the grouping of cash generating units, which is used to determine the recoverable amount. The valuation method is based on the fair value less costs of disposal. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following assumptions are used in the calculations:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(As a percentage) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative <br></br> Medicines </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Sandoz </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Alcon </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Corporate </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Terminal growth rate</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.6</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discount rate (post-tax)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Alcon terminal growth rate assumption of 3% is higher than the expected inflation rate of the medical device industry, and more specifically the ophthalmic sub-segment of the industry. The growth rates are expected to exceed this long-term inflation rate, due to the impact of the demographic trend of the aging population to which Alcon&#x2019;s products are prescribed is growing faster than the general population. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The discount rates for all divisions consider the Group&#x2019;s weighted average cost of capital, adjusted to approximate the weighted average cost of capital of a comparable market participant. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The fair value less costs of disposal, for all groupings of cash generating units containing goodwill or indefinite life intangible assets, is reviewed for the impact of reasonably possible changes in key assumptions. In particular, we considered an increase in the discount rate, a decrease in the terminal growth rate and certain negative impacts on the forecasted cash flows. These reasonably possible changes in key assumptions did not indicate an impairment. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 1, Significant accounting policies &ndash; Impairment of goodwill and intangible assets, provides additional disclosures on how the Group performs goodwill and intangible asset impairment testing. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the intangible asset impairment charges for 2017 and 2016: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;591</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;522</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;61</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;65</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;57</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;709</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;591</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="1" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill</div> </td> <td></td> <td align="center" colspan="13" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible Assets other than Goodwill</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="1" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="13" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Acquired <br></br> research &amp; <br></br> development </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Alcon <br></br> brand name </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Technologies </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently <br></br> marketed <br></br> products </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Marketing <br></br> know-how </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other <br></br> intangible <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cost</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2017</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 31&nbsp;381</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;150</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;980</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;548</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33&nbsp;007</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;960</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;492</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 55&nbsp;137</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of business combinations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 94</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;223</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;223</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;389</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 175</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 214</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 697</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 282</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 162</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;146</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;353</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;328</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;64</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;746</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 704</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 134</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 86</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 969</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 48</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;237</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 32&nbsp;179</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;462</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;638</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 34&nbsp;105</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;960</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;852</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 57&nbsp;997</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Accumulated amortization</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;401</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;886</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;3&nbsp;637</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;16&nbsp;863</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;430</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;981</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;23&nbsp;797</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;577</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;2&nbsp;571</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;238</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;304</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3&nbsp;690</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated impairments on disposals <br></br>and derecognitions<sup>2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 352 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 317 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 61 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 730 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;615</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;92</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;709</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;416</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;534</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;429</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;170</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;4&nbsp;268</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;19&nbsp;631</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;668</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;263</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;28&nbsp;000</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 31&nbsp;750</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;292</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;370</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;474</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;292</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 589</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;997</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Reclassifications between various asset categories as a result of product launches of acquired In-Process Research &amp; Development and completion of software development. </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Derecognitions of assets that are no longer used or being developed and are not considered to have a significant disposal value or other alternative use. </div> </td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movements of goodwill and intangible assets in 2016: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="1" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill</div> </td> <td></td> <td align="center" colspan="13" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible Assets other than Goodwill</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="1" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="13" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Acquired <br></br> research &amp; <br></br> development </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Alcon <br></br> brand name </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Technologies </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently <br></br> marketed <br></br> products </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Marketing <br></br> know-how </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other <br></br> intangible <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cost</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2016</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31&nbsp;585</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;119</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;980</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;563</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 33&nbsp;385</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;960</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;341</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 54&nbsp;348</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of business combinations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 56</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 690</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 451</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;141</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;158</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 152</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 599</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 223</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 156</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 978</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals and derecognitions <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;464</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;130</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;617</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;260</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;77</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;594</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;713</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31&nbsp;381</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;150</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;548</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 33&nbsp;007</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;960</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;492</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 55&nbsp;137</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Accumulated amortization</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;411</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;650</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;3&nbsp;070</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;14&nbsp;221</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;192</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;998</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;20&nbsp;131</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassifications <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 225</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;225</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;576</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;926</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;238</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;121</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3&nbsp;861</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accumulated impairments on disposals <br></br>and derecognitions<sup>2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 22 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 390 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 123 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 535 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charge</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;490</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;96</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;591</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 215</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 251</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;401</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;886</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;3&nbsp;637</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;16&nbsp;863</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;430</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;981</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;23&nbsp;797</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 30&nbsp;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;264</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;911</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&nbsp;144</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;530</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 511</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31&nbsp;340</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Reclassifications between various asset categories as a result of product launches of acquired In-Process Research &amp; Development and completion of software development. </div> </td> </tr> <tr valign="bottom"> <td colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Derecognitions of assets that are no longer used or being developed and are not considered to have a significant disposal value or other alternative use. </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="1" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill</div> </td> <td></td> <td align="center" colspan="13" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible Assets other than Goodwill</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="1" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="13" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Acquired <br></br> research &amp; <br></br> development </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Alcon <br></br> brand name </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Technologies </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently <br></br> marketed <br></br> products </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Marketing <br></br> know-how </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other <br></br> intangible <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&nbsp;237</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;368</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11&nbsp;604</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 353</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16&nbsp;334</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;210</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 625</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 539</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;589</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;783</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;295</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 291</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;822</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;281</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;292</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 195</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;881</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;999</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 31&nbsp;750</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;292</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;370</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;474</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;292</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 589</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 29&nbsp;997</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2016: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="1" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Goodwill</div> </td> <td></td> <td align="center" colspan="13" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Intangible Assets other than Goodwill</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="1" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="13" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="1" height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Acquired <br></br> research &amp; <br></br> development </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Alcon <br></br> brand name </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Technologies </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currently <br></br> marketed <br></br> products </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Marketing <br></br> know-how </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other <br></br> intangible <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&nbsp;010</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;512</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;821</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 276</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16&nbsp;620</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;669</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 613</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 563</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;904</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;105</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;293</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 139</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;337</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;419</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;530</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 196</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;621</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corporate</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;994</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net book value at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 30&nbsp;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;264</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;911</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&nbsp;144</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;530</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 511</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 31&nbsp;340</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="18"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(As a percentage) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Innovative <br></br> Medicines </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Sandoz </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Alcon </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Corporate </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Terminal growth rate</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.6</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discount rate (post-tax)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">11. Deferred tax assets and liabilities</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Property, <br></br> plant &amp; <br></br> equipment </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Intangible <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pensions and <br></br> other benefit <br></br> obligations <br></br> of associates </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Inventories </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Tax loss <br></br> carry- <br></br> forwards </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Other assets, <br></br> provisions <br></br> and accruals </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax assets at January 1, 2017</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 224</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;331</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;839</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;160</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 146</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;597</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;297</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax liabilities at January 1, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;629</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;4&nbsp;019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;358</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;511</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;403</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;6&nbsp;920</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at January 1, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;405</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;2&nbsp;688</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;481</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;649</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 146</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;377</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;405</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;2&nbsp;688</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;481</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;649</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 146</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;377</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;279</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;90</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;304</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;49</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;46</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 760</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to equity</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;101</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;101</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to other comprehensive income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;592</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;69</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;661</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of business combinations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;322</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;317</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;41</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;476</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;698</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 836</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;331</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 88</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;061</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax assets at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 137</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;287</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;090</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;786</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 97</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;983</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;380</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax liabilities at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;613</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;2&nbsp;985</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;254</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;455</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;003</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5&nbsp;319</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;476</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;698</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 836</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;331</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 88</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;061</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction the balance amounts to: </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 151</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;229</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5&nbsp;168</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;061</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax assets at January 1, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 216</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 611</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;730</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;821</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 62</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;866</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;306</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax liabilities at January 1, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;639</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;3&nbsp;962</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;401</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;565</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;132</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;6&nbsp;704</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at January 1, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;423</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;3&nbsp;351</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;329</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;256</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 57</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;734</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;602</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">At January 1, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;423</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;3&nbsp;351</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;329</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;256</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 57</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;734</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;602</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;057</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 373</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 55</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;517</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;008</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to equity</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;44</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;44</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to other comprehensive income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 140</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 138</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of business combinations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;400</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;336</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;41</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;405</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;2&nbsp;688</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;481</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;649</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 146</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;377</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax assets at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 224</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;331</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;839</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;160</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 146</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;597</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;297</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax liabilities at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;629</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4&nbsp;019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;358</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;511</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;403</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;6&nbsp;920</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;405</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;2&nbsp;688</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;481</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;649</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 146</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;377</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction the balance amounts to: </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 263</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;034</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;6&nbsp;657</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;377</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table presents deferred tax assets and deferred tax liabilities, which are expected to have an impact on current taxes payable after more than twelve months: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected to have an impact on current tax payable after more than 12 months</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Deferred tax assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.5</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.8</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Deferred tax liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For unremitted earnings retained by consolidated entities for reinvestment, no provision is made for income taxes that would be payable upon the distribution of these earnings. If these earnings were remitted, an income tax charge could result based on the tax statutes currently in effect. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Unremitted earnings that have been retained <br></br>by consolidated entities for reinvestment </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 66 </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 63 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Temporary differences on which no deferred tax has been provided as they are permanent in nature related to: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investments in subsidiaries</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill from acquisitions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;28</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The gross value of tax-loss carry-forwards that have, or have not, been capitalized as deferred tax assets, with their expiry dates is as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Not capitalized</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Capitalized</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017 total</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One year</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Two years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 68</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Three years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 87</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 92</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Four years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 51</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 83</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">More than five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 654</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;671</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;325</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 935</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;724</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;659</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Not capitalized</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Capitalized</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016 total</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One year</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Two years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Three years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 50</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 55</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Four years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 75</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 78</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 73</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 98</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">More than five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 405</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;913</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;318</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 654</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;963</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;617</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tax losses carried forward <br></br>that expired </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 19 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 13 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Deferred tax assets related to taxable losses of relevant Group entities are recognized to the extent it is considered probable that future taxable profits will be available against which such losses can be utilized in the foreseeable future. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">On December 22, 2017, the US enacted tax reform legislation (Tax Cuts and Jobs Act), which among other provisions, reduced the US corporate tax rate from 35% to 21%, effective January 1, 2018. This required a revaluation of the deferred tax assets and liabilities and a portion of current tax payables to the newly enacted tax rates at the date of enactment. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the impact on the revaluation of deferred assets and liabilities and current income tax liabilities: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income <br></br> statement </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Equity </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax asset <br></br>and liability revaluation </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Items previously recognized <br></br>in consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;24 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Items previously recognized <br></br>in other comprehensive income <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;254 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;254 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Items previously recognized in retained earnings <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;71</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;71</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total revaluation of deferred <br></br>tax assets and liabilities </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;325 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;349 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total revaluation of current tax payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;37</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total revaluation of deferred tax assets and liabilities and current income tax liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;61</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;325</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;386</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Related to post-employment benefits and available for sale financial investments. </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Related to equity based compensation plans. </div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The enacted US tax reform legislation includes a provision that requires the US parent company&#x2019;s foreign subsidiaries&#x2019; unremitted earnings to be subject to an immediate toll tax on the qualifying amount of unremitted earnings (the deemed repatriated earnings). Previously, these earnings were taxable upon distribution to the US parent company. The toll tax amount owed is payable, without interest, in installments over an eight year period through 2024. Certain of the Group&#x2019;s US subsidiaries are the parent company of non-US domiciled companies, and as a result, USD 70 million of deferred tax liabilities related to these entities&#x2019; unremitted earnings, the majority of which were recognized in the prior year, were reclassified to current income tax liabilities. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Property, <br></br> plant &amp; <br></br> equipment </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Intangible <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pensions and <br></br> other benefit <br></br> obligations <br></br> of associates </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Inventories </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Tax loss <br></br> carry- <br></br> forwards </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Other assets, <br></br> provisions <br></br> and accruals </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax assets at January 1, 2017</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 224</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;331</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;839</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;160</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 146</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;597</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 10&nbsp;297</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax liabilities at January 1, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;629</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;4&nbsp;019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;358</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;511</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;403</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;6&nbsp;920</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at January 1, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;405</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;2&nbsp;688</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;481</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;649</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 146</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;377</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">At January 1, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;405</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;2&nbsp;688</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;481</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;649</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 146</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;377</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;279</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;90</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;304</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;49</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;46</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 760</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to equity</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;101</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;101</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to other comprehensive income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;592</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;69</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;661</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of business combinations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;322</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;317</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;41</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;476</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;698</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 836</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;331</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 88</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;061</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax assets at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 137</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;287</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;090</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;786</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 97</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;983</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;380</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax liabilities at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;613</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;2&nbsp;985</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;254</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;455</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;003</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5&nbsp;319</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;476</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;698</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 836</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;331</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 88</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 980</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;061</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction the balance amounts to: </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 151</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;229</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5&nbsp;168</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;061</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> </div> </td> <td></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax assets at January 1, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 216</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 611</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;730</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;821</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 62</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;866</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;306</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross deferred tax liabilities at January 1, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;639</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;3&nbsp;962</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;401</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;565</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;132</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;6&nbsp;704</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at January 1, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;423</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;3&nbsp;351</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;329</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;256</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 57</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;734</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;602</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">At January 1, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;423</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;3&nbsp;351</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;329</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;256</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 57</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;734</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;602</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;13</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;057</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 373</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 55</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;517</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;008</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Charged to equity</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;44</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;44</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Credited/(charged) to other comprehensive income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 140</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 138</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of business combinations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;400</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;336</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other movements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;41</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;405</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;2&nbsp;688</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;481</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;649</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 146</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;377</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax assets at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 224</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;331</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;839</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;160</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 146</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;597</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;297</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gross deferred tax liabilities at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;629</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4&nbsp;019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;358</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;511</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;403</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;6&nbsp;920</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;405</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;2&nbsp;688</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;481</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;649</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 146</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;377</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction the balance amounts to: </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 263</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;034</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax liabilities at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;6&nbsp;657</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net deferred tax balance at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;377</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected to have an impact on current tax payable after more than 12 months</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Deferred tax assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.5</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.8</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Deferred tax liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Unremitted earnings that have been retained <br></br>by consolidated entities for reinvestment </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 66 </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 63 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Temporary differences on which no deferred tax has been provided as they are permanent in nature related to: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investments in subsidiaries</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill from acquisitions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;28</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Not capitalized</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Capitalized</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017 total</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One year</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Two years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 68</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Three years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 87</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 92</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Four years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 51</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 83</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">More than five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 654</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;671</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;325</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 935</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;724</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;659</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Not capitalized</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Capitalized</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016 total</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">One year</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 33</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Two years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Three years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 50</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 55</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Four years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 75</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 78</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 73</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 98</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">More than five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 405</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;913</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;318</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 654</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;963</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;617</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tax losses carried forward <br></br>that expired </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 19 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 13 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Income <br></br> statement </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Equity </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax asset <br></br>and liability revaluation </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Items previously recognized <br></br>in consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;24 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Items previously recognized <br></br>in other comprehensive income <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;254 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;254 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Items previously recognized in retained earnings <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;71</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;71</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total revaluation of deferred <br></br>tax assets and liabilities </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;325 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;349 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total revaluation of current tax payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;37</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total revaluation of deferred tax assets and liabilities and current income tax liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;61</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;325</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;386</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Related to post-employment benefits and available for sale financial investments. </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Related to equity based compensation plans. </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">12. Financial and other non-current assets</div> <div style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Financial assets</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Available-for-sale long-term <br></br>financial investments </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;275 </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;096 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term receivables from customers</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 197</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 231</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Minimum lease payments <br></br>from finance lease agreements </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 122 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 147 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 394</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 586</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances and security deposits</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 255</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 136</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;243</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;196</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Note 28 provides additional disclosures related to contingent considerations. </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Other non-current assets</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred compensation plans</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 484</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 451</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid post-employment benefit plans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 133</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 47</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 201</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 200</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other non-current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 818</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 698</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Minimum finance lease payments</font> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the receivables of the gross investments in finance leases and the net present value of the minimum lease payments, as well as unearned finance income, related to surgical equipment lease arrangements. The finance income is recorded in &#x201c;Other income&#x201d;. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br></br> future <br></br> payments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Unearned <br></br> finance <br></br> income </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Present <br></br> value </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Provision </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net <br></br> book <br></br> value </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br></br> future <br></br> payments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Unearned <br></br> finance <br></br> income </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Present <br></br> value </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Provision </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net <br></br> book <br></br> value </div> </td> <td></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not later than one year <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 83</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;7</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 73</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 91</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;5</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 86</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 84</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between one and five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 180</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;59</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 107</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 182</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 129</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Later than five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 63</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 59</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;41</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 294</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 271</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 195</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 336</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 311</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;80</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 231</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> The current portion of the minimum lease payments is recorded in trade receivables or other current assets (to the extent not yet invoiced). </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Available-for-sale long-term <br></br>financial investments </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;275 </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;096 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term receivables from customers</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 197</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 231</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Minimum lease payments <br></br>from finance lease agreements </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 122 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 147 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 394</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 586</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans, advances and security deposits</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 255</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 136</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;243</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;196</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Note 28 provides additional disclosures related to contingent considerations. </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred compensation plans</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 484</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 451</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid post-employment benefit plans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 133</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 47</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 201</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 200</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other non-current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 818</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 698</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br></br> future <br></br> payments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Unearned <br></br> finance <br></br> income </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Present <br></br> value </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Provision </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net <br></br> book <br></br> value </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br></br> future <br></br> payments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Unearned <br></br> finance <br></br> income </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Present <br></br> value </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Provision </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Net <br></br> book <br></br> value </div> </td> <td></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not later than one year <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 83</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;7</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 73</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 91</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;5</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 86</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 84</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Between one and five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 180</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;59</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 107</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 182</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 129</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Later than five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 63</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 59</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;41</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 294</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;23</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 271</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 195</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 336</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 311</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;80</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 231</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> The current portion of the minimum lease payments is recorded in trade receivables or other current assets (to the extent not yet invoiced). </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">13. Inventories</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Raw material, consumables</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 841</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 705</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Work in progress</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;957</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;700</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Finished products</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;069</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;850</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total inventories</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;867</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;255</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the amount of inventory recognized as an expense in &#x201c;Cost of goods sold&#x201d; in the consolidated income statements: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;10.3</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;10.3</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;10.5</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the recognized amount of inventory provisions and reversals of inventory provisions:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventory provisions</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;470</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;283</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;356</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversals of inventory provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 189</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 67</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 148</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The reversals mainly result from the release of products initially requiring additional quality control inspections and from the reassessment of inventory values manufactured prior to regulatory approval but for which approval was subsequently received. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Raw material, consumables</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 841</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 705</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Work in progress</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;957</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;700</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Finished products</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;069</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;850</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total inventories</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 6&nbsp;867</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6&nbsp;255</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD billions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;10.3</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;10.3</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;10.5</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventory provisions</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;470</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;283</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;356</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversals of inventory provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 189</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 67</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 148</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">14. Trade receivables</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total gross trade receivables</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;790</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;364</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;190</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;162</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;202</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table summarizes the movement in the provision for doubtful trade receivables:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;162</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;142</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;156</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of divestments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables charged to the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;119</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;68</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Utilization provisions for doubtful trade receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of provisions for doubtful trade receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;190</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;162</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;142</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following sets forth the trade receivables that are not overdue as specified in the payment terms and conditions established with Novartis customers as well as an analysis of overdue amounts and related provisions for doubtful trade receivables: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not overdue</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;758</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;386</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for not more than one month</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 279</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 262</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one month <br></br>but less than three months </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 230 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 223 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than three months <br></br>but less than six months </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 137 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 185 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than six months <br></br>but less than one year </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 137 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 145 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one year</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 249</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 163</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;190</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;162</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;202</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Trade receivable balances include sales to drug wholesalers, retailers, private health systems, government agencies, managed care providers, pharmacy benefit managers and government-supported healthcare systems. Novartis continues to monitor sovereign debt issues and economic conditions, particularly in Greece, Italy, Portugal, Spain, Brazil, Russia, Saudi Arabia and Turkey, and evaluates trade receivables in these countries for potential collection risks. The majority of the outstanding trade receivables from these closely monitored countries are due directly from local governments or from government-funded entities except for Russia, Brazil and Turkey, which are due from private entities. Deteriorating credit and economic conditions as well as other factors in these closely monitored countries have resulted in, and may continue to result in an increase in the average length of time that it takes to collect these trade receivables and may require Novartis to re-evaluate the collectability of these trade receivables in future periods. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the gross trade receivables balance from these closely monitored countries at December 31, 2017 and 2016, the amounts that are past due for more than one year and the related provisions that have been recorded: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total balance of gross trade <br></br>receivables from closely <br></br>monitored countries </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 1&nbsp;733 </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 1&nbsp;717 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one year</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 82</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 95</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 63</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At December 31, 2017 amounts past due for more than one year are not significant in any of these countries on a standalone basis. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Total trade receivables include amounts denominated in the following major currencies:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;451</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;432</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;533</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;366</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 567</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chinese yuan (CNY)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 312</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 264</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Russian ruble (RUB)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 268</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 347</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Brazilian real (BRL)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 237</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 222</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">British pound (GBP)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 208</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 160</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Australian dollar (AUD)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 165</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 147</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 127</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 135</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canadian dollar (CAD)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 73</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 97</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other currencies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;626</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;465</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;202</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total gross trade receivables</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;790</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;364</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;190</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;162</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;202</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;162</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;142</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;156</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of divestments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables charged to the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;119</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;68</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Utilization provisions for doubtful trade receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reversal of provisions for doubtful trade receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;190</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;162</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;142</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Not overdue</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7&nbsp;758</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;386</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for not more than one month</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 279</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 262</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one month <br></br>but less than three months </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 230 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 223 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than three months <br></br>but less than six months </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 137 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 185 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than six months <br></br>but less than one year </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 137 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 145 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one year</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 249</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 163</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for doubtful trade receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;190</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;162</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;202</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;451</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;432</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;533</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;366</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 567</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Chinese yuan (CNY)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 312</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 264</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Russian ruble (RUB)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 268</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 347</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Brazilian real (BRL)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 237</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 222</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">British pound (GBP)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 208</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 160</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Australian dollar (AUD)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 165</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 147</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 127</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 135</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Canadian dollar (CAD)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 73</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 97</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other currencies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;626</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;465</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total trade receivables, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;202</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">15. Marketable securities, commodities, time&nbsp;deposits, derivative financial instruments and&nbsp;cash and cash equivalents</div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Marketable securities, commodities, time&nbsp;deposits and derivative financial instruments</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 328</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 306</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total available-for-sale marketable securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 362</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 337</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 106</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 94</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits with original maturity more than 90 days</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 125</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 108</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 230</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued interest on debt securities and time deposits</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities, commodities, time deposits and derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 625</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 770</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides a breakdown of debt securities by currency:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 303</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 284</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total debt securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 328</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 306</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Cash and cash equivalents</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current accounts</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;970</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;912</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity less than 90 days</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;890</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;095</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;860</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;007</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 328</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 306</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total available-for-sale marketable securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 362</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 337</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 106</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 94</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits with original maturity more than 90 days</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 125</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 108</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 230</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued interest on debt securities and time deposits</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities, commodities, time deposits and derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 625</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 770</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 303</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 284</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total debt securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 328</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 306</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current accounts</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;970</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;912</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits and short-term investments with original maturity less than 90 days</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;890</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;095</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;860</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;007</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">16. Other current assets</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">VAT receivable</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 717</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 521</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Withholding tax recoverable</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 93</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 282</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid expenses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Third parties</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 753</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 692</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Receivables from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivable <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 450</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;030</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;034</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;054</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;541</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Note 28 provides additional disclosures related to contingent consideration. </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">VAT receivable</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 717</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 521</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Withholding tax recoverable</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 93</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 282</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid expenses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Third parties</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 753</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 692</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Receivables from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivable <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 450</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other receivables and current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;030</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;034</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;054</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;541</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Note 28 provides additional disclosures related to contingent consideration. </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">17. Equity</div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movement in the share capital:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Jan 1, 2015 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Movement <br></br> in year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Dec 31, 2015 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Movement <br></br> in year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Dec 31, 2016 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Movement <br></br> in year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> Dec 31, 2017 </div> </td> <td></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Share capital</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;001</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;10</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 991</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;19</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 972</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 969</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Treasury shares</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;103</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;101</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding share capital</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 898</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 890</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 896</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 869</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movement in the shares:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>Number of outstanding shares <br></br>(in millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Note </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br></br> Novartis <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br></br> treasury <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br></br> outstanding <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> Novartis <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> treasury <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> outstanding <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> Novartis <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> treasury <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> outstanding <br></br> shares </div> </td> <td></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at beginning of year</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;627.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;253.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;374.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;677.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;303.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;373.9</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;706.2</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;307.6</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;398.6</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares canceled for capital <br></br>reduction <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;10.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 10.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;49.9 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 49.9 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;29.2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 29.2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be held in <br></br>Group Treasury <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;9.6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;9.6 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be <br></br>canceled <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;66.2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;66.2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;10.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;10.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;49.9 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;49.9 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4.1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options <br></br>and employee transactions <sup style="white-space: nowrap">&nbsp;5</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 17.6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 4.6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 4.6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 4.1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 4.1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 27.0 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 27.0 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation <sup style="white-space: nowrap">&nbsp;5</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total movements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;10.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;46.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;56.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;49.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 50.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;29.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;24.7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at end of year</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;616.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;299.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;317.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;627.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;253.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;374.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;677.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;303.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;373.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Novartis reduced its share capital by cancelling shares which were repurchased on the SIX Swiss Exchange second trading line during previous years. </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Shares repurchased on the SIX Swiss Exchange first trading line </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;3&nbsp;</sup> For 2017 and 2016, shares repurchased on the SIX Swiss Exchange second trading line under the CHF 10 billion share buyback authority approved at the 2016 Annual General Meeting (AGM). For 2015, shares repurchased on the SIX Swiss Exchange second trading line under the CHF 10 billion share buyback authority approved at the 2008 Annual General Meeting (AGM). </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;4&nbsp;</sup> Shares acquired from employees, which were previously granted to them under the respective programs </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;5&nbsp;</sup> Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">17.1) The amount available for distribution as a dividend to shareholders is based on the available distributable retained earnings of Novartis AG determined in accordance with the legal provisions of the Swiss Code of Obligations. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend per share (in CHF)</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.75</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.70</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.60</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total dividend payment <br></br>(in USD billion) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 6.5 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 6.5 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 6.6 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">17.2) The following table summarizes the treasury shares movements:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Note </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Number of <br></br> outstanding <br></br> shares <br></br> (in millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Equity impact <br></br> USDm </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Number of <br></br> outstanding <br></br> shares <br></br> (in millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Equity impact <br></br> USDm </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Number of <br></br> outstanding <br></br> shares <br></br> (in millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Equity impact <br></br> USDm </div> </td> <td></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be held in Group Treasury <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;9.6</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;897</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be canceled <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;66.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5&nbsp;270</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;10.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;784</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;49.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4&nbsp;805</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;304</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;208</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;417</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;70.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5&nbsp;574</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;12.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;992</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;63.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;6&nbsp;119</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 255</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 214</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;592</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation <sup style="white-space: nowrap">&nbsp;5, 6</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 612</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 664</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 815</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;56.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;4&nbsp;707</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;114</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;24.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;3&nbsp;712</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Shares repurchased on the SIX Swiss Exchange first trading line </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> For 2017 and 2016, shares repurchased on the SIX Swiss Exchange second trading line under the CHF 10 billion share buyback authority approved at the 2016 Annual General Meeting (AGM). For 2015, shares repurchased on the SIX Swiss Exchange second trading line under the CHF 10 billion share buyback authority approved at the 2008 Annual General Meeting (AGM). </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;3&nbsp;</sup> Shares acquired from employees, which were previously granted to them under the respective programs </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;4&nbsp;</sup> Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price reflecting the strike price of the options exercised. </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;5&nbsp;</sup> Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax deductible amounts exceeding the expense recognized in the income statement are credited to equity. </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;6&nbsp;</sup> Included in 2017 is a USD 71 million impact related to the revaluation of deferred tax assets on equity based compensation that were previously recognized through retained earnings. This revaluation resulted from the US tax reform legislation enacted on December 22, 2017, refer to Note 11 for additional disclosures. </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">17.3) Changes in non-controlling interests represent the impact on the non-controlling interest of transactions with minority shareholders such as change in ownership percentage, dividend payments, and other equity transactions. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">17.4) In 2017, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD&nbsp;5 billion share buyback, as well as to mitigate dilution from equity-based participation plans. The commitment under this arrangement is the expected purchases by the bank under such trading plan over a rolling 90-day period. As of December 31, 2017, this trading plan commitment was fully executed and expired, and as a consequence, there is no contingent liability related to this plan recognized. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2014, Novartis entered into a similar irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares. The commitment under this arrangement reflected the expected purchases by the bank under such trading plan over a rolling 90-day period. In 2015, this trading plan was fully executed and expired, resulting in a decrease of USD 658 million in the repurchase obligation. As a consequence, there is no contingent liability related to this plan as of December 31, 2015 and December 31, 2016. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">17.5) The impact of change in ownership of consolidated entities represents the excess of the amount paid to non-controlling interest over their carrying value and equity allocation to non-controlling interest due to change in ownership percentage. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">17.6) At December 31, 2017, the market maker held 12 million written call options, originally issued as part of the share-based compensation for associates that have not yet been exercised. The weighted average exercise price of these options is USD 62.17 and they have contractual lives of 10 years, with remaining lives up to six years. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Jan 1, 2015 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Movement <br></br> in year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Dec 31, 2015 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Movement <br></br> in year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Dec 31, 2016 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Movement <br></br> in year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> Dec 31, 2017 </div> </td> <td></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Share capital</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;001</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;10</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 991</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;19</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 972</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 969</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Treasury shares</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;103</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;101</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding share capital</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 898</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 890</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 896</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 869</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>Number of outstanding shares <br></br>(in millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Note </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br></br> Novartis <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br></br> treasury <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br></br> outstanding <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> Novartis <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> treasury <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> outstanding <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> Novartis <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> treasury <br></br> shares </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> outstanding <br></br> shares </div> </td> <td></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at beginning of year</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;627.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;253.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;374.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;677.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;303.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;373.9</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;706.2</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;307.6</div> </td> <td align="right" width="1%"></td> <td align="right" width="4%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;398.6</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares canceled for capital <br></br>reduction <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;10.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 10.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;49.9 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 49.9 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;29.2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 29.2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be held in <br></br>Group Treasury <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;9.6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;9.6 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be <br></br>canceled <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;66.2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;66.2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;10.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;10.3 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;49.9 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;49.9 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4.1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options <br></br>and employee transactions <sup style="white-space: nowrap">&nbsp;5</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 17.6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 4.6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 4.6 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 4.1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 4.1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 27.0 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 27.0 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation <sup style="white-space: nowrap">&nbsp;5</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total movements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;10.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;46.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;56.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;49.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 50.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;29.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;24.7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Balance at end of year</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;616.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;299.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;317.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;627.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;253.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;374.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;677.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;303.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;373.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="22" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Novartis reduced its share capital by cancelling shares which were repurchased on the SIX Swiss Exchange second trading line during previous years. </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Shares repurchased on the SIX Swiss Exchange first trading line </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;3&nbsp;</sup> For 2017 and 2016, shares repurchased on the SIX Swiss Exchange second trading line under the CHF 10 billion share buyback authority approved at the 2016 Annual General Meeting (AGM). For 2015, shares repurchased on the SIX Swiss Exchange second trading line under the CHF 10 billion share buyback authority approved at the 2008 Annual General Meeting (AGM). </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;4&nbsp;</sup> Shares acquired from employees, which were previously granted to them under the respective programs </div> </td> </tr> <tr valign="bottom"> <td colspan="22"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;5&nbsp;</sup> Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dividend per share (in CHF)</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.75</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.70</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.60</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total dividend payment <br></br>(in USD billion) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 6.5 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 6.5 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 6.6 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td height="1"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Note </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Number of <br></br> outstanding <br></br> shares <br></br> (in millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Equity impact <br></br> USDm </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Number of <br></br> outstanding <br></br> shares <br></br> (in millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Equity impact <br></br> USDm </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Number of <br></br> outstanding <br></br> shares <br></br> (in millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Equity impact <br></br> USDm </div> </td> <td></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be held in Group Treasury <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;9.6</div> </td> <td align="right" width="1%"></td> <td align="right" width="6%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;897</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shares acquired to be canceled <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;66.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5&nbsp;270</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;10.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;784</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;49.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4&nbsp;805</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other share purchases <sup style="white-space: nowrap">&nbsp;3</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;304</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;208</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;417</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of treasury shares</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;70.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5&nbsp;574</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;12.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;992</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;63.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;6&nbsp;119</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercise of options and employee transactions <sup style="white-space: nowrap">&nbsp;4</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 255</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 214</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;592</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation <sup style="white-space: nowrap">&nbsp;5, 6</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 612</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 664</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 815</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;56.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;4&nbsp;707</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;114</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;24.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;3&nbsp;712</div> </td> <td align="right"></td> </tr> <tr> <td colspan="16" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Shares repurchased on the SIX Swiss Exchange first trading line </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> For 2017 and 2016, shares repurchased on the SIX Swiss Exchange second trading line under the CHF 10 billion share buyback authority approved at the 2016 Annual General Meeting (AGM). For 2015, shares repurchased on the SIX Swiss Exchange second trading line under the CHF 10 billion share buyback authority approved at the 2008 Annual General Meeting (AGM). </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;3&nbsp;</sup> Shares acquired from employees, which were previously granted to them under the respective programs </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;4&nbsp;</sup> Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price reflecting the strike price of the options exercised. </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;5&nbsp;</sup> Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax deductible amounts exceeding the expense recognized in the income statement are credited to equity. </div> </td> </tr> <tr valign="bottom"> <td colspan="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;6&nbsp;</sup> Included in 2017 is a USD 71 million impact related to the revaluation of deferred tax assets on equity based compensation that were previously recognized through retained earnings. This revaluation resulted from the US tax reform legislation enacted on December 22, 2017, refer to Note 11 for additional disclosures. </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">18. Non-current financial debt</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22&nbsp;957</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;285</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities to banks and other financial institutions <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 539</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 708</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Finance lease obligations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 87</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 82</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total, including current portion of non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;583</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;075</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion of non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;359</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;178</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;224</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&nbsp;897</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Average interest rate 0.3% (2016: 0.4%) </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Financial debts, including current financial debts, contain only general default covenants. The Group is in compliance with these covenants. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The percentage of fixed-rate financial debt to total financial debt was 82% at December 31, 2017, and 76% at December 31, 2016.</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The average interest rate on total financial debt in 2017 was 2.6% (2016: 2.8%).</div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table provides a breakdown of straight bonds:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>Coupon </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Currency </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Nominal <br></br> amount </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Issuance <br></br> year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Maturity <br></br> year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Issuer </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Issue price </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017 <br></br> (USD <br></br> millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016 <br></br> (USD <br></br> millions) </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5.125%</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;000</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2009</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Securities Investment Ltd., Hamilton, Bermuda</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.822%</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;997</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;995</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4.400%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2010</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.237%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 997</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 996</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.400%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2012</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.225%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;491</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;490</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3.700%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2012</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2042</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.325%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 489</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 489</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3.400%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;150</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2014</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.287%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;134</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;132</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4.400%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;850</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2014</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2044</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.196%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;824</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;823</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.750%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2014</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.134%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 713</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 625</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.625%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2014</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2026</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.697%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 714</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 627</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.250%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis AG, Basel, Switzerland</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.640%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 513</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 491</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.625%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 550</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2029</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis AG, Basel, Switzerland</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.502%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 564</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 539</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.050%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 325</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2035</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis AG, Basel, Switzerland</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.479%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 333</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 318</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3.000%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;750</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.010%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;730</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;728</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4.000%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2045</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.029%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;218</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;217</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.125%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.127%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;480</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;299</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.625%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2028</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.480%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 588</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 516</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.800%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.609%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 996</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.400%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.449%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 993</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3.100%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2027</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.109%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 988</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.000%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.133%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;480</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.125%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2027</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.874%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 715</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total straight bonds</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22&nbsp;957</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&nbsp;285</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables provide a breakdown of total non-current financial debt, including current portion by maturity and currency: </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Breakdown by maturity:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2017</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 178</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 359</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 345</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;173</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;168</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;997</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;000</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 628</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;485</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;442</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After 2022</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&nbsp;375</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;314</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;583</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;075</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Breakdown by currency:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&nbsp;945</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;952</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;695</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;092</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 533</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 683</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;410</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;348</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;583</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;075</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the comparison of balance sheet and fair value of total non-current financial debt, including current portion: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017 <br></br> Balance sheet </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017 <br></br> Fair values </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016 <br></br> Balance sheet </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016 <br></br> Fair values </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22&nbsp;957</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23&nbsp;835</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;285</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;943</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 626</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 626</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 790</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 790</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;583</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 24&nbsp;461</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;075</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;733</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The fair values of straight bonds are determined by quoted market prices. Other financial debts are recorded at notional amounts which are a reasonable approximation of the fair values. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the pledged assets:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total net book value of property, <br></br>plant &amp; equipment pledged as <br></br>collateral for non-current financial debts </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 84 </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 94 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22&nbsp;957</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;285</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities to banks and other financial institutions <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 539</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 708</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Finance lease obligations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 87</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 82</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total, including current portion of non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;583</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;075</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion of non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;359</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;178</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;224</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&nbsp;897</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Average interest rate 0.3% (2016: 0.4%) </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>Coupon </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Currency </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Nominal <br></br> amount </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Issuance <br></br> year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Maturity <br></br> year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Issuer </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Issue price </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017 <br></br> (USD <br></br> millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016 <br></br> (USD <br></br> millions) </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">5.125%</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;000</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2009</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2019</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Securities Investment Ltd., Hamilton, Bermuda</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.822%</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;997</div> </td> <td align="right" width="1%"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;995</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4.400%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2010</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.237%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 997</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 996</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.400%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2012</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.225%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;491</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;490</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3.700%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2012</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2042</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.325%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 489</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 489</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3.400%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;150</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2014</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2024</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.287%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;134</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;132</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4.400%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;850</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2014</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2044</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.196%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;824</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;823</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.750%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2014</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.134%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 713</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 625</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.625%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2014</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2026</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.697%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 714</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 627</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.250%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis AG, Basel, Switzerland</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.640%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 513</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 491</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.625%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 550</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2029</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis AG, Basel, Switzerland</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.502%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 564</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 539</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.050%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 325</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2035</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis AG, Basel, Switzerland</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.479%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 333</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 318</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3.000%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;750</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2025</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.010%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;730</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;728</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">4.000%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2015</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2045</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.029%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;218</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;217</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.125%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2023</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.127%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;480</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;299</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.625%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2028</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.480%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 588</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 516</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.800%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2020</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.609%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 996</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2.400%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2022</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.449%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 993</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">3.100%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2027</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Capital Corporation, New York, United States</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.109%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 988</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">0.000%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2021</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.133%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;480</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1.125%</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2027</div> </td> <td align="right"></td> <td align="right"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Novartis Finance S.A., Luxembourg, Luxembourg</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.874%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 715</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total straight bonds</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22&nbsp;957</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&nbsp;285</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2017</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 178</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 359</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 345</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;173</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;168</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;997</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;000</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 628</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;485</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;442</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">After 2022</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13&nbsp;375</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;314</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;583</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;075</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">US dollar (USD)</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15&nbsp;945</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;952</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Euro (EUR)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;695</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;092</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Japanese yen (JPY)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 533</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 683</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Swiss franc (CHF)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;410</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;348</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;583</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;075</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017 <br></br> Balance sheet </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017 <br></br> Fair values </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016 <br></br> Balance sheet </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016 <br></br> Fair values </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22&nbsp;957</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23&nbsp;835</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;285</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;943</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Others</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 626</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 626</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 790</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 790</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;583</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 24&nbsp;461</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;075</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 18&nbsp;733</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total net book value of property, <br></br>plant &amp; equipment pledged as <br></br>collateral for non-current financial debts </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 84 </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 94 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">19. Provisions and other non-current liabilities</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued liability for employee benefits:</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit pension plans <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;157</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;490</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other long-term employee benefits and deferred compensation</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 625</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 545</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other post-employment benefits <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 953</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;005</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Environmental remediation provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 706</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 708</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for product liabilities, governmental investigations and other legal matters</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 230</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 264</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 809</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 840</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 577</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 618</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total provisions and other non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;057</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;470</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Note 24 provides additional disclosures related to post-employment benefits. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Note 28 provides additional disclosures related to contingent consideration. </div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis believes that its total provisions are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities in this area, Novartis may incur additional costs beyond the amounts provided. Management believes that such additional amounts, if any, would not be material to the Group&#x2019;s financial condition but could be material to the results of operations or cash flows in a given period. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Environmental remediation provisions</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movements in the environmental liability provisions:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 773</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 871</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 923</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;46</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;75</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;52</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;153</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 154</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 761</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 773</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 871</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current provision</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;55</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;65</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;80</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current environmental remediation provisions at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 706</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 708</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 791</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The material components of the environmental remediation provisions consist of costs to sufficiently clean and refurbish contaminated sites to the extent necessary, and to treat, and where necessary, continue surveillance at sites where the environmental remediation exposure is less significant. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A substantial portion of the environmental remediation provisions relate to the remediation of Basel regional landfills in the adjacent border areas in Switzerland, Germany and France. The provisions are re-assessed on a yearly basis and are adjusted as necessary. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the United States, Novartis has been named under federal legislation (the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended) as a potentially responsible party (PRP) in respect of certain sites. Novartis actively participates in, or monitors, the clean-up activities at the sites in which it is a PRP. The provision takes into consideration the number of other PRPs at each site as well as the identity and financial position of such parties in light of the joint and several nature of the liability. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The expected timing of the related cash outflows as of December 31, 2017, is currently projected as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Expected <br></br> cash outflows </div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due within two years</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 164</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due later than two years, but within five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 241</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due later than five years, but within ten years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 315</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due after ten years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 41</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total environmental remediation liability provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 761</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Provisions for product liabilities, governmental investigations and other legal matters</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has established provisions for certain product liabilities, governmental investigations and other legal matters where a potential cash outflow is probable and Novartis can make a reliable estimate of the amount of the outflow. These provisions represent the Group&#x2019;s current best estimate of the total financial effect for the matters described below and for other less significant matters. Potential cash outflows reflected in a provision might be fully or partially off-set by insurance in certain circumstances. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis has not established provisions for potential damage awards for certain additional legal claims against its subsidiaries if Novartis currently believes that a payment is either not probable or cannot be reliably estimated. In total, these not-provisioned-for matters include more than 1&#xa0;000 individual product liability cases and certain other legal matters. Plaintiffs&#x2019; alleged claims in these matters, which Novartis does not believe to be entirely remote but which do not fulfill the conditions for the establishment of provisions, currently aggregate to, according to Novartis&#x2019; current best belief, approximately USD 1.5 billion. In addition, in some of these matters there are claims for punitive or multiple (treble) damages, civil penalties and disgorgement of profits that in Novartis&#x2019; view are either wholly or partially unspecified or wholly or partially unquantifiable at present; the Group believes that information about these amounts claimed by plaintiffs generally is not meaningful for purposes of determining a reliable estimate of a loss that is probable or more than remote. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A number of other legal matters are in such early stages or the issues presented are such that the Group has not made any provisions since it cannot currently estimate either a potential outcome or the amount of any potential losses. For these reasons, among others, the Group generally is unable to make a reliable estimate of possible loss with respect to such cases. It is therefore not practicable to provide information about the potential financial impact of those cases. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">There might also be cases for which the Group was able to make a reliable estimate of the possible loss or the range of possible loss, but the Group believes that publication of such information on a case-by-case basis would seriously prejudice the Group&#x2019;s position in ongoing legal proceedings or in any related settlement discussions. Accordingly, in such cases, information has been disclosed with respect to the nature of the contingency, but no disclosure is provided as to an estimate of the possible loss or range of possible loss. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 27 contains additional information on contingencies.</div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Summary of significant legal proceedings</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following is a summary of significant legal proceedings to which Novartis or its subsidiaries are a party or were a party and that concluded in 2017. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Investigations and related litigations</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">Southern District of New York (S.D.N.Y.) marketing practices investigation and litigation</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2013, the US government filed a civil complaint in intervention to an individual <i>qui tam </i>action against Novartis Pharmaceuticals Corporation (NPC) in the United States District Court (USDC) for the S.D.N.Y. The complaint, as subsequently amended, asserts federal False Claims Act (FCA) and common law claims with respect to speaker programs and other promotional activities for certain NPC cardiovascular medications ( <i>Lotrel, Starlix </i>and <i>Valturna</i>) allegedly serving as mechanisms to provide kickbacks to healthcare professionals (HCPs). It seeks damages, which according to the complaint are &#x201c;substantial&#x201d;, including treble damages and maximum civil penalties per claim, as well as disgorgement of Novartis profits from the alleged unlawful conduct. Also in 2013, New York State filed a civil complaint in intervention asserting similar claims. Neither government complaint in intervention adopted the individual relator&#x2019;s claims with respect to off-label promotion of <i>Valturna</i>, which were subsequently dismissed with prejudice by the court. The individual relator continues to litigate the kickback claims on behalf of other states and municipalities. NPC vigorously contests the S.D.N.Y., New York State and individual claims, both as to alleged liability and amount of damages and penalties. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">S.D.N.Y. / Western District of New York healthcare fraud investigation</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2011, Alcon Laboratories, Inc. (ALI) received a subpoena from the United States Department of Health &amp; Human Services relating to an investigation into allegations of healthcare fraud. The subpoena requests the production of documents relating to marketing practices, including the remuneration of healthcare providers, in connection with certain ALI products ( <i>Vigamox</i>, <i>Nevanac</i>, <i>Omnipred</i>, <i>Econopred</i>; surgical equipment). ALI is cooperating with this investigation. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">S.D.N.Y. <i>gilenya</i> marketing practices investigation </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2013, NPC received a civil investigative demand from the United States Attorney&#x2019;s Office (USAO) for the S.D.N.Y. requesting the production of documents and information relating to marketing practices for <i>Gilenya</i>, including the remuneration of healthcare providers in connection therewith. In 2017, S.D.N.Y. and New York State declined to intervene in claims raised by an individual relator, which continue to be vigorously contested. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">GOVERNMENT GENERIC PRICING ANTITRUST INVESTIGATIONS, ANTITRUST CLASS ACTIONS</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2016 and 2017, Sandoz Inc. received subpoenas and interrogatories from the Antitrust Division of the US Department of Justice (DoJ) and from the Attorney General of the State of Connecticut requesting documents related to the marketing and pricing of generic pharmaceutical products sold by Sandoz Inc. and its subsidiaries, including Fougera Pharmaceuticals, Inc. (Fougera), and related communications with competitors. Sandoz Inc. is cooperating with these investigations, which it believes to be part of a broader inquiry into industry practice. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Since the third quarter of 2016, Sandoz Inc. and Fougera have been sued alongside other generic pharmaceutical companies in more than 20 consolidated complaints by proposed classes of direct and indirect purchasers, and Attorneys General for 45 states, the District of Columbia and Puerto Rico have sought leave to file a complaint, alleging that defendants, including Sandoz, engaged in anti-competitive conduct with regard to the sales of various generic drugs and asserting violations of federal and state antitrust laws as well as consumer protection laws. Lek Pharmaceuticals d.d., Novartis AG and Novartis International AG were dismissed from the proceedings. The cases have been consolidated for pretrial purposes in the USDC for the Eastern District of Pennsylvania (E.D. Pa.) and the claims are being vigorously contested. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">District of Massachusetts (D. Mass.) charitable foundation investigation</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2016 and 2017, NPC received subpoenas from the USAO for the D. Mass. requesting documents related to NPC&#x2019;s support of 501(c)(3) organizations that provide co-payment assistance to Medicare patients who are prescribed Novartis medicines, including the respective accounting and tax treatment, as well as related to pricing strategies for <i>Gleevec</i>, <i>Tasigna</i>, <i>Zometa</i>, and <i>Gilenya</i>. The requests are focused on potential violations of federal health care offenses, including the Anti-Kickback Statute, and FCA. NPC is cooperating with this investigation, which it believes to be part of a broader inquiry into industry practices. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">Asia/Russia investigation</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2017, Novartis Group companies, as well as present and former senior executives of Alcon, received document requests and subpoenas from the DoJ and the US Securities and Exchange Commission (SEC) requesting information concerning Alcon&#x2019;s business practices in Asia and Russia and related accounting treatment, both before and after Alcon became part of the Novartis Group. Novartis is cooperating with this investigation. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;"> <i>Lucentis</i>/Avastin <sup>&#xae;</sup> matters </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In connection with an investigation into whether Novartis Farma S.p.A., Novartis AG, F. Hoffmann-La Roche AG, Genentech Inc. and Roche S.p.A. colluded to artificially preserve the market positions of Avastin <sup>&#xae;</sup> and <i>Lucentis</i>, in 2014 the Italian Competition Authority imposed a fine equivalent to USD&nbsp;125 million on Novartis AG and Novartis Farma S.p.A. Novartis paid the fine, subject to the right to later claim recoupment, and is appealing before the Consiglio di Stato. In 2014 and 2015, the Italian Ministry of Health and the Lombardia region sent letters with payment requests for a total equivalent of approximately USD&nbsp;1.5 billion in damages from Novartis and Roche entities based on the above allegations. In 2014, the French Competition Authority opened an investigation against Novartis Groupe France with respect to the French market for anti-vascular endothelial growth factor (VEGF) products indicated for the treatment of wet age-related macular degeneration (AMD). Novartis continues to vigorously contest all claims in Italy and France. Also, Novartis is challenging policies and regulations allowing off-label/unlicensed use and reimbursement for economic reasons in various countries, including in Italy and the UK. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">Japan investigation</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2015, a trial started against a former Novartis Pharma K.K. (NPKK) employee, and also NPKK under the dual liability concept in Japanese law, over allegations brought by the Tokyo District Public Prosecutor Office in two counts for alleged manipulation of data in sub-analysis publications of the Kyoto Heart Study regarding valsartan. The charges against NPKK are subject to a maximum total fine of JPY 4 million. In 2017, the Tokyo District Court issued a not-guilty ruling for both the former NPKK employee and NPKK. An appeal by the Tokyo District Public Prosecutor Office remains pending. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">south korea investigation</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2016, the Seoul Western District Prosecutor initiated a criminal investigation into, among other things, allegations that Novartis Korea utilized medical journals to provide inappropriate economic benefits to HCPs. A criminal trial is ongoing concerning allegations that Novartis Korea utilized medical journals to provide inappropriate economic benefits to HCPs. In addition, other authorities in South Korea, including the Korea Fair Trade Commission, the Ministry of Food and Drug Safety and the Ministry of Health and Welfare conducted investigations into Novartis Korea. Those investigations have led to total fines of approximately USD 53 million as well as sales and reimbursement suspensions on Novartis Korea products in 2017. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">greece investigation</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis is investigating allegations of potentially inappropriate economic benefits in Greece to HCPs and others. Novartis Group companies in Greece are providing information to the Greek authorities related to these allegations. Novartis is also responding to a subpoena and document requests from the SEC and DoJ that it received in 2016 and 2017 in connection with such allegations and is cooperating with their investigation. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Antitrust class actions</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">contact lenses</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since the first quarter of 2015, more than 50 putative class action complaints have been filed in several courts across the US naming contact-lens manufacturers, including ALI, and alleging violations of federal antitrust law as well as state antitrust, consumer protection and unfair competition laws of various states in connection with the sale of contact lenses. The cases have been consolidated in the Middle District of Florida by the Judicial Panel on Multidistrict Litigation and the claims are being vigorously contested. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;"> <i>gleevec</i> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2015 and 2016, Novartis Group companies were sued in putative antitrust class actions in D. Mass. alleging delayed generic entry of <i>Gleevec</i> and seeking damages on behalf of direct and indirect purchasers of <i>Gleevec</i>. The motion to dismiss those actions was granted and plaintiffs have appealed. A similar class action was filed in 2018 in E.D. Pa. on behalf of direct purchasers of <i>Gleevec</i>. The claims are being vigorously contested. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">Enoxaparin</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2015, Sandoz and Momenta Pharmaceuticals were sued in a putative antitrust class action in federal court in Tennessee alleging that Momenta and Sandoz engaged in anticompetitive and unfair business conduct with regard to sales of enoxaparin, and the same allegations were made by Amphastar in a lawsuit filed in federal court in California and subsequently moved to federal court in Mass. (Sandoz, Momenta Pharmaceuticals and Amphastar are currently engaged in patent litigation concerning enoxaparin). The claims are being vigorously contested. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Other matters</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">Average Wholesale Price (AWP) litigation</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Lawsuits have been brought, the latest in February 2016, by various US state governmental entities and private parties against various pharmaceutical companies, including certain Sandoz entities and NPC, alleging that they fraudulently overstated the AWP that is or has been used by payors, including state Medicaid agencies, to calculate reimbursements to healthcare providers. NPC remains a defendant in an action brought by the state of Illinois and in a putative class action brought by private payors in New Jersey, and Sandoz remains a defendant in an individual action in Pennsylvania. The putative class action in Pennsylvania was dismissed in 2017. The claims are being vigorously contested. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;"> <i>Reclast</i>/ <i>Aclasta</i> product liability litigation </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">NPC is a defendant in more than 20 US product liability actions involving <i>Reclast</i> and alleging atypical femur fracture injuries, most of which are in New Jersey state or federal court and in California state court coordinated with claims against other bisphosphonate manufacturers. The Canadian putative class action brought against numerous bisphosphonate manufacturers, including NPC, Novartis Pharmaceuticals Canada Inc. and Novartis International AG, in Quebec was discontinued in 2017. The claims are being vigorously contested. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">Taxotere&#xae; (docetaxel) product liability litigation</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sandoz is a defendant in more than 1&#xa0;000 US product liability actions involving Taxotere&#xae; (docetaxel), an oncology product, many of which have been transferred to Multidistrict Litigation in the Eastern District of Louisiana. The complaints allege that Sanofi, as innovator, and several 505(b)(2) NDA holders (including Sandoz) failed to warn of the risk of permanent alopecia/hair loss. The claims are being vigorously contested. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">Amiodarone product liability litigation</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Sandoz entities are named in more than 10 individual and multi-plaintiff US product liability cases involving amiodarone, a cardiac drug indicated to treat life-threatening arrhythmias that have not responded to other treatment. The complaints allege failure to warn, off-label promotion and failure to include medication guides to pharmacies. All claims are being vigorously contested. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">Oriel litigation</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2013, Shareholder Representative Services LLC filed a complaint in New York State Court against Sandoz Inc., two affiliates and two former officers of Sandoz AG asserting various common law and statutory contract, fraud and negligent misrepresentation claims arising out of Sandoz Inc.&#x2019;s purchase of Oriel Therapeutics, Inc. In March 2015, the court dismissed all parties and claims but for a breach of contract claim against Sandoz Inc. Sandoz Inc. continues to vigorously contest the claim. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">Eye drop products consumer class actions</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Two putative consumer fraud class actions remain ongoing against Alcon and Sandoz in New Jersey and at the US Court of Appeals for the First Circuit after having been initially dismissed at the trial court level. They claim that Alcon&#x2019;s and Sandoz&#x2019;s eye drop products for glaucoma were unfairly designed so that the drop dosage is more than necessary and exceeds the capacity of the eye, leading to wastage and higher costs to patient consumers. The claims are being vigorously contested. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">IP Matters</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">MIVS <sup>@</sup> platform patent infringement litigation </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Johns Hopkins University filed a patent infringement lawsuit against Alcon alleging that the use of certain Alcon surgical products, principally by third parties, infringes a patent directed to certain methods of ocular surgery, and a trial is scheduled for February 2018. The claims are being vigorously contested. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Concluded legal matters</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">New York State pricing policy investigation</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2014, ALI received a civil subpoena from the New York State attorney general relating to an investigation into a unilateral pricing policy program. Novartis considers this matter concluded. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;"> <i>Lucentis</i>/Avastin <sup>&#xae;</sup> matter in France </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis&#x2019; appeals against a temporary recommendation of use and reimbursement of off-label Avastin <sup>&#xae;</sup> for neovascular AMD by hospital ophthalmologists, in force since September 2015, as well as against the decree on which the recommendation is based, were rejected by the Supreme Court in 2016 and 2017. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:8pt;color:#000000; font-weight:bold;text-transform:uppercase;">Solodyn <sup>&#xae;</sup> antitrust class actions </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Since the third quarter of 2013, seventeen putative class action complaints and three other complaints had been filed against manufacturers of the brand drug Solodyn <sup>&#xae;</sup> and its generic equivalent, including Sandoz Inc. The cases had been consolidated and transferred for pretrial purposes to the federal district court in Mass. The plaintiffs purported to represent direct and indirect purchasers of Solodyn <sup>&#xae;</sup> branded products and asserted violations of federal and state antitrust laws, including allegations in connection with separate settlements by Medicis with each of the other defendants, including Sandoz Inc., of patent litigation relating to Solodyn <sup>&#xae;</sup>. In 2017, all cases were resolved through settlement, the payment of which was not material to Novartis. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Summary of product liability, governmental investigations and other legal matters provision movements </font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 395</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;194</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 849</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;69</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;811</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;256</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases of provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;70</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;239</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;223</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 93</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 243</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 832</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 351</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 395</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;194</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;121</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;131</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;743</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current product liabilities, governmental investigations and other legal matters provisions at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 230</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 264</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 451</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis believes that its total provisions for investigations, product liability, arbitration and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, there can be no assurance that additional liabilities and costs will not be incurred beyond the amounts provided. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued liability for employee benefits:</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Defined benefit pension plans <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;157</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;490</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other long-term employee benefits and deferred compensation</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 625</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 545</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other post-employment benefits <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 953</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;005</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Environmental remediation provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 706</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 708</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for product liabilities, governmental investigations and other legal matters</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 230</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 264</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 809</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 840</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 577</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 618</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total provisions and other non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;057</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;470</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Note 24 provides additional disclosures related to post-employment benefits. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Note 28 provides additional disclosures related to contingent consideration. </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 773</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 871</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 923</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;46</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;75</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;52</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;153</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 154</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;24</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 761</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 773</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 871</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current provision</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;55</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;65</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;80</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current environmental remediation provisions at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 706</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 708</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 791</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Expected <br></br> cash outflows </div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due within two years</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 164</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due later than two years, but within five years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 241</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due later than five years, but within ten years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 315</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Due after ten years</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 41</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total environmental remediation liability provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 761</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 395</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;194</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 849</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;69</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;811</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;256</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases of provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;70</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;239</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;223</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 93</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 243</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 832</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 351</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 395</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;194</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Less current portion</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;121</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;131</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;743</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current product liabilities, governmental investigations and other legal matters provisions at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 230</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 264</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 451</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">20. Current financial debt and&nbsp;derivative&nbsp;financial&nbsp;instruments</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of associates <br></br>payable on demand <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;822 </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;601 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other financial debt <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 692</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 836</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;328</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;174</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current portion of non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 359</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 178</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value of derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 107</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 116</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt and derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;308</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;905</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Weighted average interest rate 0.5% (2016: 0.5%) </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Weighted average interest rate 7.0% (2016: 6.7%) </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated balance sheet amounts of current financial debt, other than the current portion of non-current financial debt, approximate the estimated fair value due to the short-term nature of these instruments. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Details on commercial papers are provided in Note&nbsp;28 &ndash; Liquidity risk.</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of associates <br></br>payable on demand <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 1&nbsp;822 </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 1&nbsp;601 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other financial debt <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 692</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 836</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;328</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;174</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current portion of non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 359</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 178</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value of derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 107</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 116</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt and derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;308</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;905</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Weighted average interest rate 0.5% (2016: 0.5%) </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Weighted average interest rate 7.0% (2016: 6.7%) </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">21. Provisions and other current liabilities</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes other than income taxes</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 660</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 547</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Restructuring provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 153</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 222</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued expenses for goods and services received but not invoiced</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 977</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 880</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accruals for royalties</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 586</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 550</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for deductions from revenue</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;672</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;183</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accruals for compensation and benefits including social security</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;327</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;993</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Environmental remediation liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 55</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 65</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 305</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 287</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for product liabilities, governmental investigations and other legal matters <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 121</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 131</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued share-based payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 261</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 199</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent considerations <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 49</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;042</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 722</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total provisions and other current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;203</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;828</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Note 19 provides additional disclosures related to legal provisions. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Note 28 provides additional disclosures related to contingent considerations. </div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Provisions are based upon management&#x2019;s best estimate and adjusted for actual experience. Such adjustments to the historic estimates have not been material. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Provisions for deductions from revenue</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the movement of the provisions for deductions from revenue:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;183</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;790</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;533</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of business combinations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17&nbsp;997</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16&nbsp;622</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&nbsp;603</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments/utilizations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;17&nbsp;452</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;16&nbsp;189</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;15&nbsp;218</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in offset against <br></br>gross trade receivables </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;252 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 10 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 50 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 196</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;50</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;181</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;672</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;183</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;790</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Restructuring provisions movements</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 222</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 260</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 333</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 343</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;200</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;260</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;435</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;64</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;66</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;36</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transfers</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 153</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 222</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 260</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2017, additions to provisions of USD&nbsp;194 million were mainly related to the following reorganizations:</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Innovative Medicines Division&#x2019;s Pharmaceuticals business unit adjusted a regional promotional model which led to a restructuring of the sales force. It also streamlined the above country operating model to facilitate an even higher external competition oriented focus. Furthermore, the development organization streamlined its activities to create efficiencies. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Alcon Division continued initiatives to realign its operations to focus on the Surgical and Vision Care business after the Ophthalmic Pharmaceutical business transfer to the Innovative Medicines Division. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Sandoz Division launched initiatives to focus resources to gain efficiencies.</div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Group-wide initiatives to streamline Novartis Technical Operations in the Innovative Medicines and Sandoz Divisions were launched. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2016, additions to provisions of USD&nbsp;343 million were mainly related to the following reorganizations:</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Innovative Medicines Division&#x2019;s Pharmaceuticals business unit realigned its operations to improve its operating agility, to focus resources on key growth drivers. Furthermore, research realigned and focused its operations resulting in redundancies from the consolidation of certain research teams and the outsourcing of certain activities to qualified third party vendors. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Alcon Division launched several initiatives to improve its efficiencies resulting in redundancies, as it realigned its operations to focus on its Surgical and Vision Care business franchises after the transfer of its Ophthalmic Pharmaceuticals business to Innovative Medicines division. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Sandoz Division launched an initiative to reallocate resources to priority, high growth and higher profitability countries. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Various group-wide initiatives to simplify organizational structure, including the consolidation of manufacturing sites and support services. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2015, additions to provisions of USD&nbsp;399 million were mainly related to the following reorganizations:</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Innovative Medicines Division implemented a restructuring program targeted at efficiency gains in the business franchises, other than in Oncology. It also initiated initiatives related to the integration of the oncology business acquired from GSK. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Alcon Division extended its initiative started in the prior year to realize productivity opportunities. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; Various group-wide initiatives to simplify the organizational structure, mainly related to the manufacturing footprint and support services. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes other than income taxes</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 660</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 547</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Restructuring provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 153</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 222</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued expenses for goods and services received but not invoiced</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 977</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 880</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accruals for royalties</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 586</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 550</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for deductions from revenue</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;672</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;183</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accruals for compensation and benefits including social security</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;327</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;993</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Environmental remediation liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 55</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 65</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 305</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 287</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions for product liabilities, governmental investigations and other legal matters <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 121</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 131</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued share-based payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 261</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 199</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent considerations <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 49</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;042</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 722</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total provisions and other current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;203</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;828</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Note 19 provides additional disclosures related to legal provisions. </div> </td> </tr> <tr valign="bottom"> <td colspan="6"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Note 28 provides additional disclosures related to contingent considerations. </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;183</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;790</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;533</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impact of business combinations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17&nbsp;997</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 16&nbsp;622</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15&nbsp;603</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payments/utilizations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;17&nbsp;452</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;16&nbsp;189</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;15&nbsp;218</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in offset against <br></br>gross trade receivables </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;252 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 10 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 50 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 196</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;50</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;181</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;672</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;183</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;790</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 222</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 260</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 333</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 194</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 343</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 399</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;200</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;260</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;435</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Releases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;64</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;66</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;36</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transfers</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 153</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 222</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 260</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">22. Details to the consolidated cash flow statements</div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">22.1) Adjustments for non-cash items from continuing operations</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;296</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;119</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;106</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments on:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant &amp; equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;677</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;591</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;550</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;399</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;452</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;921</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial assets <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 256</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 132</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;108</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;703</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;266</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gains on disposal and other adjustments on property, plant &amp; equipment, intangible, financial and other <br></br>non-current assets, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;1&nbsp;043 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;935 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;869 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-settled compensation expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 683</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 671</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 773</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 160</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 956</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;642</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net financial expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 738</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;154</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;109</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;058</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;437</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;070</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Including unrealized fair value gains </div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In 2015, the Group acquired property, plant and equipment of USD&nbsp;85 million through finance lease contracts.</div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">22.2) Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations </font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Increase) in inventories</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;247</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;235</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;482</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Increase) in trade receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;204</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;229</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;513</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase/(Decrease) in trade payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 58</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;587</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 378</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other net current assets and other operating cash flow items</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 637</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 974</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;246</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 244</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;77</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;863</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">22.3) Cash flows arising from acquisitions and divestments of businesses</font> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following is a summary of the cash flow impact of acquisitions and divestments. The most significant transactions are described in Note 2. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017 <br></br> Acquisitions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017 <br></br> Divestments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016 <br></br> Acquisitions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016 <br></br> Divestments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015 <br></br> Acquisitions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015 <br></br> Divestments </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant &amp; equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;000</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;451</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;12&nbsp;970</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 646</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Acquired)/divested research &amp; development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;223</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;690</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;730</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Technologies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 113</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 86</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial and other assets including deferred tax assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;555</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 40</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 893</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables and other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 529</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 311</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;601</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables and other liabilities including deferred tax liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 326</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 372</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 212</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;841</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net identifiable assets (acquired) or divested</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;925</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;814</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;14&nbsp;086</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;189</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 98</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired/(divested) liquidity</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;479</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value of previously held equity interests</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 64</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;905</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;749</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;14&nbsp;061</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;808</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Refinancing of intercompany financial debt, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 578</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;94</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;56</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;438</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;042</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Divestment gain</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;401</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes paid and other portfolio transformation related cash flows</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;140</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;748</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;337</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Receivables and payables contingent consideration, net <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 206</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 84</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;519</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other payments and deferred consideration, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;44</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred portion of sales price <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;49</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;829</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;95</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;765</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;748</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;16&nbsp;507</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;924</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Of which:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows used in/from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;140</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;748</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;924</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows used in/from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;829</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 45</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;765</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;16&nbsp;507</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> The contingent consideration of the 2016 Transcend Medical, Inc. acquisition amounted to USD 92 million. Of this amount, USD 60 million has been paid in 2016. </div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Divestments include USD 49 million proceeds for the divestment of the Animal Health business received in 2014. </div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Notes 2 and 23 provide further information regarding acquisitions and divestments of businesses. All acquisitions were for cash. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">22.4) Cash flows from discontinued operations</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used in operating activities</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;188</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of property, plant &amp; equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;41</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sales of property, plant &amp; equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of financial and other non-current assets, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Divestments of businesses <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;140</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;748</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;924</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used in/from investing activities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;140</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;748</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;882</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total net cash flows used in/from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;140</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;748</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;694</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <b> </b> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> 2017 includes payments related to the 2015 portfolio transformation transaction. 2016 includes mainly payments for capital gains taxes and other payments related to the 2015 portfolio transformation transaction. 2015 includes proceeds of USD 10 925 million reduced by USD 2 001 million, for payments of capital gains taxes, transaction-related costs and purchase price adjustments, related to the 2015 portfolio transformation transaction. See Note 2 for a description of the 2015 porfolio transformation transaction. <b> </b> </div> </td> </tr> </table> </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">22.5) Reconciliation of liabilities arising from financing activities</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Non-current <br></br> financial <br></br> debts </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> <br></br> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Current <br></br> financial <br></br> debts and <br></br> derivative <br></br> financial <br></br> instruments </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> <br></br> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2017</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 17&nbsp;897</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;905</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;802</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;933</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;933</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayment of non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;187</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;188</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;755</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;755</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values and other changes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;140</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;146</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 744</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 126</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 870</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current portion of non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;359</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 359</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;224</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;308</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&nbsp;532</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <b> </b> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;</sup> <b> </b> </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;296</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;119</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;106</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Depreciation, amortization and impairments on:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant &amp; equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;677</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;591</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;550</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;399</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;452</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;921</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial assets <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 256</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 132</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 104</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;108</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;703</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;266</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gains on disposal and other adjustments on property, plant &amp; equipment, intangible, financial and other <br></br>non-current assets, net </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;1&nbsp;043 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;935 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;869 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-settled compensation expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 683</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 671</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 773</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in provisions and other non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 160</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 956</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;642</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net financial expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 738</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;154</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;109</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7&nbsp;058</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;437</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9&nbsp;070</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Including unrealized fair value gains </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Increase) in inventories</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;247</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;235</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;482</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Increase) in trade receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;204</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;229</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;513</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase/(Decrease) in trade payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 58</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;587</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 378</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in other net current assets and other operating cash flow items</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 637</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 974</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;246</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 244</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;77</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;863</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017 <br></br> Acquisitions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017 <br></br> Divestments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016 <br></br> Acquisitions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016 <br></br> Divestments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015 <br></br> Acquisitions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015 <br></br> Divestments </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Property, plant &amp; equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;000</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;451</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;12&nbsp;970</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 646</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">(Acquired)/divested research &amp; development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;223</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;690</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;730</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Technologies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 113</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 86</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial and other assets including deferred tax assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;555</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 40</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 893</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables and other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 529</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 311</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current and non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;601</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables and other liabilities including deferred tax liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 326</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 372</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 212</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;841</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net identifiable assets (acquired) or divested</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;925</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;814</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;14&nbsp;086</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;189</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 98</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired/(divested) liquidity</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;479</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value of previously held equity interests</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 64</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Subtotal</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;905</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 48</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;749</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;14&nbsp;061</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;808</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Refinancing of intercompany financial debt, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 578</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;94</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;56</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;438</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;042</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Divestment gain</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;401</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes paid and other portfolio transformation related cash flows</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;140</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;748</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;337</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Receivables and payables contingent consideration, net <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 206</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 84</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;519</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other payments and deferred consideration, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;36</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;44</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred portion of sales price <sup style="white-space: nowrap">&nbsp;2</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;49</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net cash flows</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;829</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;95</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;765</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;748</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;16&nbsp;507</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;924</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Of which:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows used in/from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;140</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;748</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;924</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net cash flows used in/from continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;829</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 45</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;765</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;16&nbsp;507</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> </div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> The contingent consideration of the 2016 Transcend Medical, Inc. acquisition amounted to USD 92 million. Of this amount, USD 60 million has been paid in 2016. </div> </td> </tr> <tr valign="bottom"> <td colspan="14"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Divestments include USD 49 million proceeds for the divestment of the Animal Health business received in 2014. </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used in operating activities</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;188</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of property, plant &amp; equipment</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;41</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Proceeds from sales of property, plant &amp; equipment</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchase of financial and other non-current assets, net</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Divestments of businesses <sup style="white-space: nowrap">&nbsp;1</sup> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;140</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;748</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;924</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash flows used in/from investing activities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;140</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;748</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;882</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total net cash flows used in/from discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;140</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;748</div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;694</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <b> </b> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> 2017 includes payments related to the 2015 portfolio transformation transaction. 2016 includes mainly payments for capital gains taxes and other payments related to the 2015 portfolio transformation transaction. 2015 includes proceeds of USD 10 925 million reduced by USD 2 001 million, for payments of capital gains taxes, transaction-related costs and purchase price adjustments, related to the 2015 portfolio transformation transaction. See Note 2 for a description of the 2015 porfolio transformation transaction. <b> </b> </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Non-current <br></br> financial <br></br> debts </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> <br></br> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Current <br></br> financial <br></br> debts and <br></br> derivative <br></br> financial <br></br> instruments </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> <br></br> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1, 2017</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 17&nbsp;897</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;905</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;802</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Increase in non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;933</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;933</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Repayment of non-current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;187</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;188</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;755</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;755</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changes in fair values and other changes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;140</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;146</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Amortization of bonds discount</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 16</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 744</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 126</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 870</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current portion of non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;359</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 359</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;224</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;308</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28&nbsp;532</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <b> </b> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;</sup> <b> </b> </div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">23. Acquisitions of businesses</div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Fair value of assets and liabilities arising from acquisitions</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 451</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;970</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired research &amp; development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;223</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 690</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 730</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 555</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables and other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payables and other liabilities including deferred tax liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;326</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;372</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;212</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net identifiable assets acquired</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 925</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 814</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;086</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired liquidity</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 94</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 56</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;438</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of business combinations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 999</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 869</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&nbsp;499</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Note 2 details significant acquisition of businesses, which were Ziarco and Encore in 2017, were Transcend and Reprixys in 2016, and were the GSK Oncology products, Spinifex and Admune in 2015. The goodwill arising out of these acquisitions is attributable to buyer-specific synergies, the assembled workforce and the accounting for deferred tax liabilities on the acquired assets. No goodwill from 2017 is tax-deductible. Goodwill of USD&nbsp;18 million from 2016 and of USD 2.4 billion from 2015 is tax deductible. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currently marketed products</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 451</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;970</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired research &amp; development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;223</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 690</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 730</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other intangible assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred tax assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 555</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Inventories</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables and other current assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Payables and other liabilities including deferred tax liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;326</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;372</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;212</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net identifiable assets acquired</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 925</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 814</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 14&nbsp;086</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Acquired liquidity</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;25</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Goodwill</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 94</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 56</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;438</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net assets recognized as a result of business combinations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 999</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 869</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 16&nbsp;499</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">24. Post-employment benefits for associates</div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Defined benefit plans</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In addition to the legally required social security schemes, the Group has numerous independent pension and other post-employment benefit plans. In most cases, these plans are externally funded in entities that are legally separate from the Group. For certain Group companies, however, no independent plan assets exist for the pension and other post-employment benefit obligations of associates. In these cases the related unfunded liability is included in the balance sheet. The defined benefit obligations (DBOs) of all major pension and other post-employment benefit plans are reappraised annually by independent actuaries. Plan assets are recognized at fair value. The major plans are based in Switzerland, the United States, the United Kingdom, Germany and Japan, which represent 94% of the Group&#x2019;s total DBO for pension plans. Details of the plans in the two most significant countries of Switzerland and the United States are provided below. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Swiss-based pension plans represent the most significant portion of the Group&#x2019;s total DBO and plan assets. For the active insured members born on or after January 1, 1956, or having joined the plans after December 31, 2010, the benefits are partially linked to the contributions paid into the plan. Certain features of Swiss pension plans required by law preclude the plans being categorized as defined contribution plans. These factors include a minimum interest guarantee on retirement savings accounts, a pre-determined factor for converting the accumulated savings account balance into a pension and embedded death and disability benefits. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">All benefits granted under Swiss-based pension plans are vested, and Swiss legislation prescribes that the employer has to contribute a fixed percentage of an associate&#x2019;s pay to an external pension fund. Additional employer contributions may be required whenever the plan&#x2019;s statutory funding ratio falls below a certain level. The associate also contributes to the plan. The pension plans are run by separate legal entities, each governed by a Board of Trustees, that, for the principal plans, consists of representatives nominated by Novartis and the active insured associates. The Boards of Trustees are responsible for the plan design and asset investment strategy. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In September 2017, the pension regulations in Switzerland were amended, which resulted in a change in accounting from defined benefit to defined contribution for a component of the Swiss pension plans. This change resulted in a reduction to the defined benefit pension plans liability and in a corresponding net pre-tax gain of USD 225 million (CHF 216 million). </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The United States pension plans represent the second largest component of the Group&#x2019;s total DBO and plan assets. The principal plans (Qualified Plans) are funded, whereas plans providing additional benefits for executives (Restoration Plans) are unfunded. Employer contributions are required for Qualified Plans whenever the statutory funding ratio falls below a certain level. Furthermore, associates in the United States are covered under other post-employment benefit plans and post-retirement medical plans. </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables are a summary of the funded and unfunded defined benefit obligation for pension and other post-employment benefit plans of associates at December 31, 2017 and 2016: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment benefit plans</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;614</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;402</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;158</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;132</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current service cost</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 422</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 437</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest cost</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 330</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 390</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 48</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past service costs and settlements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;226</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;73</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Administrative expenses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurement losses arising from changes in financial assumptions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;299</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 46</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurement (gains) arising from changes in demographic assumptions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Experience-related remeasurement losses/(gains)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 47</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 117</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;87</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;33</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;138</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;896</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;300</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;51</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;51</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions of associates</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 207</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 207</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;41</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;210</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;614</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;115</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;158</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at January 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 19&nbsp;225</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 19&nbsp;536</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 153</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 172</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 236</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 293</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Return on plan assets excluding interest income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;429</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 742</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 909</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;757</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Group contributions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 579</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 542</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions of associates</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 207</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 207</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Settlements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;995</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;77</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;300</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;51</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;51</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20&nbsp;275</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 19&nbsp;225</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 162</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 153</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;2&nbsp;935</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;4&nbsp;389</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;953</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;005</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Limitation on recognition of fund surplus at January 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;50</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in limitation on recognition of fund surplus (incl. exchange rate differences)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income on limitation of fund surplus</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Limitation on recognition of fund surplus at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;89</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability in the balance sheet at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;3&nbsp;024</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;4&nbsp;443</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;953</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;005</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The reconciliation of the net liability from January 1 to December 31 is as follows:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment benefit plans</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability at January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;4&nbsp;443</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;3&nbsp;916</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;005</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;960</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current service cost</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;422</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;437</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;35</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net interest expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;99</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;101</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;42</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Administrative expenses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past service costs and settlements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 231</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;397</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;667</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;229</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 139</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Group contributions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 579</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 542</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in limitation on recognition of fund surplus</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;3&nbsp;024</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;4&nbsp;443</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;953</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;005</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Amounts recognized in the consolidated balance sheet</div> </td> <td align="right"></td> <td align="right"></td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"></td> <td align="right"></td> <td align="right"></td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid benefit cost</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 133</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 47</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued benefit liability</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3&nbsp;157</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4&nbsp;490</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;953</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;005</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows a breakdown of the DBO for pension plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Switzerland </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> United States </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of <br></br> the world </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Switzerland </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> United States </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of <br></br> the world </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;606</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;788</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;816</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;210</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&nbsp;436</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;783</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;395</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;614</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof unfunded</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 728</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 499</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 1&nbsp;227</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 739</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 497</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 1&nbsp;236</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">By type of member</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Active</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;627</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 796</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;646</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;069</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;426</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 891</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;460</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;777</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred pensioners</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;258</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;646</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;904</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 831</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;515</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;346</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Pensioners</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;979</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;734</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;524</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;237</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;010</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;061</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;420</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;491</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;445</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;400</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;430</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20&nbsp;275</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;958</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;282</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;985</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 19&nbsp;225</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;161</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;388</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;386</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;2&nbsp;935</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;478</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;501</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;410</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;4&nbsp;389</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the principal weighted average actuarial assumptions used for calculating defined benefit plans and other post-employment benefits of associates: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans </div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment benefit plans</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average assumptions used to determine benefit obligations at December 31</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discount rate</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.4%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.8%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.7%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.2%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.4%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected rate of pension increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.5%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.4%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.4%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected rate of salary increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.8%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.2%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.9%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest on savings account</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.6%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.5%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.8%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current average life expectancy <br></br>for a 65-year-old male in years </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 22 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 22 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 21 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 21 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 21 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 21 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current average life expectancy <br></br>for a 65-year-old female in years </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 23 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 23 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 23 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Changes in the aforementioned actuarial assumptions can result in significant volatility in the accounting for the Group&#x2019;s pension plans in the consolidated financial statements. This can result in substantial changes in the Group&#x2019;s other comprehensive income, long-term liabilities and prepaid pension assets. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The DBO is significantly impacted by assumptions regarding the rate that is used to discount the actuarially determined post-employment benefit liability. This rate is based on yields of high-quality corporate bonds in the country of the plan. Decreasing corporate bond yields decrease the discount rate, so that the DBO increases and the funded status decreases. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In Switzerland, an increase in the DBO due to lower discount rates is slightly offset by lower future benefits expected to be paid on the associate&#x2019;s savings account where the assumption on interest accrued changes in line with the discount rate. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The impact of decreasing interest rates on a plan&#x2019;s assets is more difficult to predict. A significant part of the plan assets is invested in bonds. Bond values usually rise when interest rates decrease and may therefore partially compensate for the decrease in the funded status. Furthermore, pension assets also include significant holdings of equity instruments. Share prices tend to rise when interest rates decrease and therefore often counteract the negative impact of the rising defined benefit obligation on the funded status (although the correlation of interest rates with equities is not as strong as with bonds, especially in the short term). </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The expected rate for pension increases significantly affects the DBO of most plans in Switzerland, Germany and the United Kingdom. Such pension increases also decrease the funded status, although there is no strong correlation between the value of the plan assets and pension/inflation increases. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Assumptions regarding life expectancy significantly impact the DBO. An increase in longevity increases the DBO. There is no offsetting impact from the plan assets, as no longevity bonds or swaps are held by the pension funds. Generational mortality tables are used where this data is available. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the sensitivity of the defined benefit pension obligation to the principal actuarial assumptions for the major plans in Switzerland, the United States, the United Kingdom, Germany and Japan on an aggregated basis: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in 2017 year-end <br></br> defined benefit pension obligation </div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in discount rate</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;753</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in discount rate</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 803</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 year increase in life expectancy</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 840</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in rate of pension increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 533</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in rate of pension increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;138</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase of interest on savings account</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 56</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease of interest on savings account</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;54</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in rate of salary increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in rate of salary increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;50</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The healthcare cost trend rate assumptions used for other post-employment benefits are as follows:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Healthcare cost trend rate <br></br>assumed for next year </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 6.5% </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 7.0% </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 7.5% </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rate to which the cost trend <br></br>rate is assumed to decline </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 4.5% </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 5.0% </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 5.0% </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Year that the rate reaches <br></br>the ultimate trend rate </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 2025 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 2022 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 2022 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the weighted average plan asset allocation of funded defined benefit pension plans at December 31, 2017 and&nbsp;2016: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(as a percentage) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-term <br></br> target <br></br> minimum </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-term <br></br> target <br></br> maximum </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> 2017 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> 2016 </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Real estate</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alternative investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and other investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Cash and most of the equity and debt securities have a quoted market price in an active market. Real estate and alternative investments, which include hedge fund and private equity investments, usually do not have a quoted market price. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The strategic allocation of assets of the different pension plans is determined with the objective of achieving an investment return that, together with the contributions paid by the Group and its associates, is sufficient to maintain reasonable control over the various funding risks of the plans. Based upon the market and economic environments, actual asset allocations may temporarily be permitted to deviate from policy targets. The asset allocation currently includes investments in shares of Novartis AG as per the below table: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31, <br></br> 2017 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31, <br></br> 2016 </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investment in shares of Novartis AG</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Number of shares (in millions)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Market Value (in USD billions)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The weighted average duration of the defined benefit obligation is 14.6 years (2016: 14.5 years).</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s ordinary contribution to the various pension plans is based on the rules of each plan. Additional contributions are made whenever this is required by statute or law (i.e., usually when statutory funding levels fall below pre-determined thresholds). The only significant plans that are foreseen to require additional funding are those in the United Kingdom. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The expected future cash flows in respect of pension and other post-employment benefit plans at December 31, 2017, were as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Pension plans </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post- <br></br> employment <br></br> benefit plans </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis Group contributions</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2018 (estimated)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 395</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 62</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Expected future benefit payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;226</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 63</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 65</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;147</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 68</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;133</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 69</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023&#x2013;2027</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;534</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 344</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Defined contribution plans</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In many subsidiaries, associates are covered by defined contribution plans. Contributions charged to the 2017 consolidated income statement for the defined contribution plans were: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions for defined contribution plans <br></br>continuing operations </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 406 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 338 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 359 </div> </td> <td align="right" width="11%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions for defined contribution plans discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment benefit plans</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;614</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;402</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;158</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;132</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current service cost</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 422</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 437</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest cost</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 330</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 390</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 48</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past service costs and settlements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;226</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;73</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Administrative expenses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurement losses arising from changes in financial assumptions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;299</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 46</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurement (gains) arising from changes in demographic assumptions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;26</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Experience-related remeasurement losses/(gains)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 47</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 117</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;87</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;33</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;138</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;896</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;300</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;51</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;51</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions of associates</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 207</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 207</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;41</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;210</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;614</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;115</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;158</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at January 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 19&nbsp;225</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 19&nbsp;536</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 153</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 172</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 236</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 293</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Return on plan assets excluding interest income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;429</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 742</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 909</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;757</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Group contributions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 579</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 542</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions of associates</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 207</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 207</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Settlements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;995</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;77</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Benefit payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;300</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;51</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;51</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20&nbsp;275</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 19&nbsp;225</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 162</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 153</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;2&nbsp;935</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;4&nbsp;389</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;953</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;005</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Limitation on recognition of fund surplus at January 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;50</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in limitation on recognition of fund surplus (incl. exchange rate differences)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest income on limitation of fund surplus</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Limitation on recognition of fund surplus at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;89</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability in the balance sheet at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;3&nbsp;024</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;4&nbsp;443</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;953</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;005</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment benefit plans</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability at January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;4&nbsp;443</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;3&nbsp;916</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;005</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;960</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current service cost</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;422</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;437</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;35</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Net interest expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;99</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;101</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;39</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;42</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Administrative expenses</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;27</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past service costs and settlements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 231</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Remeasurements</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;397</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;667</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 76</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Currency translation effects</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;229</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 139</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Group contributions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 579</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 542</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Effect of acquisitions, divestments or transfers</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Change in limitation on recognition of fund surplus</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net liability at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;3&nbsp;024</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;4&nbsp;443</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;953</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;005</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Amounts recognized in the consolidated balance sheet</div> </td> <td align="right"></td> <td align="right"></td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"></td> <td align="right"></td> <td align="right"></td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prepaid benefit cost</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 133</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 47</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued benefit liability</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3&nbsp;157</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4&nbsp;490</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;953</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;005</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Switzerland </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> United States </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of <br></br> the world </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Total </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Switzerland </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> United States </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Rest of <br></br> the world </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Benefit obligation at December 31</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;606</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;788</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;816</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;210</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 15&nbsp;436</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;783</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;395</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 23&nbsp;614</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Thereof unfunded</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 728</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 499</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> 1&nbsp;227</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 739</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 497</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> 1&nbsp;236</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">By type of member</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Active</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;627</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 796</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;646</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;069</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6&nbsp;426</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 891</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;460</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;777</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Deferred pensioners</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;258</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;646</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;904</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 831</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;515</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;346</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Pensioners</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;979</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;734</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;524</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;237</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 9&nbsp;010</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;061</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;420</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 12&nbsp;491</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Fair value of plan assets at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 14&nbsp;445</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;400</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;430</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20&nbsp;275</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 13&nbsp;958</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;282</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;985</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 19&nbsp;225</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Funded status</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;161</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;388</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;386</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;2&nbsp;935</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;478</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;501</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;410</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;4&nbsp;389</div> </td> <td align="right"></td> </tr> <tr> <td colspan="18" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans </div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post-employment benefit plans</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Weighted average assumptions used to determine benefit obligations at December 31</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Discount rate</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.4%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.8%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.7%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.2%</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.4%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected rate of pension increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.5%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.4%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.4%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expected rate of salary increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.8%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.2%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.9%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest on savings account</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.6%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.5%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.8%</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current average life expectancy <br></br>for a 65-year-old male in years </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 22 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 22 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 21 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 21 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 21 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 21 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current average life expectancy <br></br>for a 65-year-old female in years </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 23 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 23 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 23 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Change in 2017 year-end <br></br> defined benefit pension obligation </div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in discount rate</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;753</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in discount rate</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 803</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 year increase in life expectancy</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 840</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in rate of pension increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 533</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in rate of pension increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;138</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase of interest on savings account</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 56</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease of interest on savings account</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;54</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point increase in rate of salary increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">25 basis point decrease in rate of salary increase</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;50</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Healthcare cost trend rate <br></br>assumed for next year </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 6.5% </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 7.0% </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 7.5% </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rate to which the cost trend <br></br>rate is assumed to decline </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 4.5% </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 5.0% </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 5.0% </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Year that the rate reaches <br></br>the ultimate trend rate </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 2025 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 2022 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 2022 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Pension plans</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(as a percentage) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-term <br></br> target <br></br> minimum </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Long-term <br></br> target <br></br> maximum </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br> <br></br> 2017 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> 2016 </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 40</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 35</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 35</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Real estate</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alternative investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 15</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and other investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 100</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> December 31, <br></br> 2017 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> December 31, <br></br> 2016 </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Investment in shares of Novartis AG</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Number of shares (in millions)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 11.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Market Value (in USD billions)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Pension plans </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other post- <br></br> employment <br></br> benefit plans </div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Novartis Group contributions</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2018 (estimated)</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 395</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 62</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Expected future benefit payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;226</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 63</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 65</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;147</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 68</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;133</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 69</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2023&#x2013;2027</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5&nbsp;534</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 344</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions for defined contribution plans <br></br>continuing operations </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 406 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 338 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 359 </div> </td> <td align="right" width="11%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contributions for defined contribution plans discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">25. Equity-based participation plans for associates</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The expense related to all equity-based participation plans and the liabilities arising from equity-based payment transactions were as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense related to equity-based <br></br>participation plans </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 924 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 846 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 968 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">of which continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 924</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 846</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 903</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">of which discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 65</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities arising from equity-based payment transactions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 261</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 199</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 209</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Equity-based participation plans can be separated into the following plans:</div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Annual Incentive</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Annual Incentive of the Novartis Group CEO and the other Executive Committee members is paid 50% in cash in February or March of the year following the performance period, and 50% in Novartis Restricted Shares (RSs) or Restricted Share Units (RSUs) that are granted in January of the year following the performance period, deferred and restricted for three years. In 2016, this was extended to Novartis Top Leaders (NTLs). The Annual Incentive payout for the NTLs is 70% in cash and 30% in Novartis RSs or RSUs. Each RS is entitled to voting rights and payment of dividends during the vesting period. Each RSU is equivalent to one Novartis share and is converted into one share at the vesting date. RSUs do not carry any dividend, dividend equivalent or voting rights. The executives in certain countries may elect to also receive their cash incentive partially or fully in shares or share units that will not be subject to vesting conditions. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Share savings plans</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">A number of associates in certain countries as well as certain key executives worldwide are encouraged to invest their Annual Incentive, and in the United Kingdom also their salary, in a share savings plan. Under the share savings plan, participants may elect to receive their Annual Incentive fully or partially in Novartis shares in lieu of cash. As a reward for their participation in the share savings plan, at no additional cost to the participant, Novartis matches their investments in shares after a holding period of three or five years. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify;margin-top:15px;">Novartis operates three share savings plans, and associates may only participate in one of the share savings plans in any given year: </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; In Switzerland, Employee Share Ownership Plan (ESOP) participants may choose to receive their Annual Incentive (i) 100% in shares, (ii) 50% in shares and 50% in cash or (iii) 100% in cash. After expiration of a three-year holding period for Novartis shares invested under the ESOP, participants will receive one matching share for every two invested shares. Associates eligible for the equity plan &#x201c;Select&#x201d; are not eligible to receive ESOP matching shares starting with the 2017 performance period onwards. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; In the United Kingdom, associates can invest up to 10% of their monthly salary in shares (up to a maximum of GBP 150) and may also be invited to invest their net Annual Incentive in shares. Two invested shares are matched with one share with a holding period of three years. Starting with the 2017 performance period onwards, United Kingdom associates can only invest a maximum of 50% of their Annual Incentive in shares and this option is no longer offered to associates who are eligible for the equity plan &#x201c;Select&#x201d;. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt;color:#000000;margin-bottom:0mm;margin-left:9px;margin-right:0mm;margin-top:0mm;text-indent:-9px;">&#x2022; The Leveraged Share Savings Plan (LSSP) was available to key executives for performance periods prior to 2016. At the participant&#x2019;s election, the Annual Incentive was awarded partly or entirely in shares. The elected number of shares is subject to a holding period of five years. At the end of the holding period, Novartis will match the invested shares at a ratio of 1-to-1 (i.e. one share awarded for each invested share). In the United States both the LSSP award and the corresponding match are cash settled. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Following the introduction of the new compensation programs in 2014, the Novartis Group CEO and the other Executive Committee members are no longer eligible to participate in the share savings plans. From the 2016 performance period onwards, the NTLs are also no longer eligible to participate in the share savings plans. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Novartis equity plan &#x201c;Select&#x201d;</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The equity plan &#x201c;Select&#x201d; is a global equity incentive plan under which eligible associates may annually be awarded a grant subject to a three year vesting period. No awards are granted for performance ratings below a certain threshold. Executive Committee members are not eligible for participation in the equity plan &#x201c;Select&#x201d; effective from the performance period 2014, and the NTLs are not eligible to participate effective from the performance period 2016. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The equity plan &#x201c;Select&#x201d; currently allows participants in Switzerland to choose the form of their equity compensation in RSs or RSUs. In all other jurisdictions, RSUs are typically granted. Until 2013, participants could also choose to receive part or the entire grant in the form of tradable share options. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Tradable share options expire on their tenth anniversary from the grant date. Each tradable share option entitles the holder to purchase after vesting (and before the tenth anniversary from the grant date) one Novartis share at a stated exercise price that equals the closing market price of the underlying share at the grant date. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Options under Novartis equity plan &#x201c;Select&#x201d; outside North America</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the activity associated with the share options during the period. The weighted average prices in the table below are translated from Swiss francs into USD at historical rates. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Options <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average <br></br> exercise <br></br> price (USD) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Options <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average <br></br> exercise <br></br> price (USD) </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Options outstanding <br></br>at January 1 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 9.5 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 59.4 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 11.7 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 59.9 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sold or exercised</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;2.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 59.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61.8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forfeited or expired</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 59.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 59.4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 59.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 59.4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All share options were granted at an exercise price that was equal to the closing market price of the Group&#x2019;s shares at the grant date. The weighted average share price at the dates of sale or exercise was USD&nbsp;80.1. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table summarizes information about share options outstanding at December 31, 2017: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Options outstanding</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>Range of exercise prices (USD) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Number <br></br> outstanding <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Average <br></br> remaining <br></br> contractual <br></br> life (years) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average <br></br> exercise <br></br> price (USD) </div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">45&#x2013;49</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.7</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 46.7</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">50&#x2013;54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 54.6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">55&#x2013;59</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57.6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">65&#x2013;70</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 66.1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 59.5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Options under Novartis equity plan &#x201c;Select&#x201d; for North America</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows the activity associated with the American Depositary Receipts (ADR) options during the period: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> ADR <br></br> options <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average <br></br> exercise <br></br> price (USD) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> ADR <br></br> options <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average <br></br> exercise <br></br> price (USD) </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Options outstanding <br></br>at January 1 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 25.9 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 59.9 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 31.9 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 60.2 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sold or exercised</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 59.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;6.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61.7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forfeited or expired</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 59.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 59.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 59.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 59.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">All ADR options were granted at an exercise price that was equal to the closing market price of the ADRs at the grant date. The weighted average ADR price at the dates of sale or exercise was USD&nbsp;79.9. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table summarizes information about ADR options outstanding at December 31, 2017: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> ADR options outstanding</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>Range of exercise prices (USD) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Number <br></br> outstanding <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Average <br></br> remaining <br></br> contractual <br></br> life (years) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average <br></br> exercise <br></br> price (USD) </div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">45&#x2013;49</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.8</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 46.4</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">50&#x2013;54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 53.7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">55&#x2013;59</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 58.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">65&#x2013;69</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 66.1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 59.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Long-Term Performance Plan</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Long-Term Performance Plan (LTPP) is an equity plan for the Novartis Group CEO, the other Executive Committee members and the NTLs. For the 2017 grant, the target incentive is 200% of base compensation for the Novartis Group CEO and ranges from 150% to 170% for other Executive Committee members. For the NTLs, the target incentive range is from 20% to 160% of base compensation. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The awards of the LTPP are based on three-year performance objectives focused on financial and innovation measures. The financial measure is Novartis Cash Value Added (NCVA). The weighting of this measure is 75%. The NCVA target is approved by the Board of Directors. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The innovation measure is based on a holistic approach under which divisional innovation targets are set at the beginning of the cycle, comprised of up to ten target milestones that represent the most important research and development project milestones for each division. The weighting of this measure is 25%. At the end of the performance period, the Research &amp; Development Committee assists the Board of Directors and the Compensation Committee in evaluating performance against the innovation targets at the end of the cycle. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Under the LTPP, participants are granted a target number of Performance Share Units (PSUs) at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. Payout is between 0% and 200% of target. PSUs granted under the LTPP do not carry voting rights, but do carry dividend equivalents that are paid in shares at the end of the performance period. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Long-Term Relative Performance Plan</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Long-Term Relative Performance Plan (LTRPP) is an equity plan for the Novartis Group CEO, other ECN members and NTLs. For the 2017 grant, the target incentive is 125% of base compensation for the Novartis Group CEO and ranges from 60% to 80% for other Executive Committee members. For the NTLs, the target incentive range is from 10% to 40% of base compensation. The LTRPP is based on the ranking of Novartis&#x2019; Total Shareholder Return (TSR) relative to a global healthcare peer group of 12 companies until 2016, and 15 companies from 2017, over rolling three-year performance periods. TSR in USD is calculated as price change of the Novartis share plus the dividend plus the re-investment return of the dividend amount, all translated to USD at the respective exchange rate, over the three-year performance period. The calculation is based on Bloomberg standard published TSR data, which is publicly available. The position in the peer group determines the payout range based on a payout matrix. Under the LTRPP, participants are also granted a target number of PSUs at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. Payout is between 0% and 200% of target. PSUs under the LTRPP do not carry voting rights, but do carry dividend equivalents that are paid in shares at the end of the performance period. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Other share awards</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Selected associates, excluding the Executive Committee members, may exceptionally receive Special Share Awards of RSs or RSUs. These Special Share Awards provide an opportunity to reward outstanding achievements or exceptional performance, and aim to retain key contributors. They are based on a formal internal selection process, through which the individual performance of each candidate is thoroughly assessed at several management levels. Special Share Awards have a minimum three-year vesting period. In exceptional circumstances, Special Share Awards may be awarded to attract special expertise and new talents into the organization. These grants are consistent with market practice and Novartis&#x2019; philosophy to attract, retain and motivate best-in-class talents around the world. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Worldwide, associates at different levels in the organization were awarded RSs and RSUs in 2017. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition, in 2017, Board members received unrestricted shares as part of their regular compensation.</div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Summary of non-vested share movements</font> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The table below provides a summary of non-vested share movements (RSs, RSUs and PSUs) for all plans: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Number <br></br> of shares <br></br> in millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average fair <br></br> value at grant <br></br> date in USD </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Fair value at <br></br> grant date in <br></br> USD millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Number <br></br> of shares <br></br> in millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted <br></br> average fair <br></br> value at grant <br></br> date in USD </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Fair value at <br></br> grant date in <br></br> USD millions </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-vested shares at January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 21.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 89.5</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;880</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 87.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;751</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Granted</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Annual incentive</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 69.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 90</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 73.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Share savings plans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 69.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 312</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 78.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 344</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Select North America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 288</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 72.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 348</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Select outside North America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 65.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 131</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 119</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Long-Term Performance Plan</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 71.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 79.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 95</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Long-Term Relative Performance Plan</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 47.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 58.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Other share awards</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 88</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 65.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 46</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vested</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;10.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 78.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;837</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;10.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 68.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;716</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forfeited</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;145</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 73.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;132</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-vested shares at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 80.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;926</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 21.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 89.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;880</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Alcon, Inc., equity plans granted to associates prior to the merger</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At the completion of the merger of Alcon, Inc. into Novartis on April 8, 2011, all awards outstanding under the Alcon equity plans were converted into awards based upon Novartis shares with a conversion factor of 3.0727 as defined in the Merger Agreement. The plans are fully vested. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Share options entitle the recipient to purchase Novartis shares at the closing market price of the former Alcon, Inc., share on the day of grant divided by the conversion factor. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Share-settled appreciation rights (SSAR) entitle the participant to receive, in the form of Novartis shares, the difference between the values of the former Alcon, Inc., share at the date of grant, converted into Novartis shares using the conversion factor, and the Novartis share price at the date of exercise. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Both options and SSAR expire on their tenth anniversary. The last grant was made in 2009. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The following table shows the activity associated with the converted Novartis share options and SSARs during 2017 and 2016:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Number <br></br> of options <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average <br></br> exercise <br></br> price (USD) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Number of <br></br> SSARs <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average <br></br> exercise <br></br> price (USD) </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at <br></br>January 1, 2016 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 0.2 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 36.8 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 1.8 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 36.6 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercised</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;0.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;0.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 38.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 36.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 35.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 36.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 35.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at <br></br>January 1, 2017 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 0.1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 36.0 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 1.4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 35.9 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercised</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;0.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39.8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Expense related to equity-based <br></br>participation plans </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 924 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 846 </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 968 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">of which continuing operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 924</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 846</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 903</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">of which discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 65</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="margin-left: 10px;font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities arising from equity-based payment transactions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 261</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 199</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 209</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Options <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average <br></br> exercise <br></br> price (USD) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Options <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average <br></br> exercise <br></br> price (USD) </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Options outstanding <br></br>at January 1 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 9.5 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 59.4 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 11.7 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 59.9 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sold or exercised</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;2.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 59.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61.8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forfeited or expired</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 59.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 59.4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 59.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 59.4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Options outstanding</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>Range of exercise prices (USD) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Number <br></br> outstanding <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Average <br></br> remaining <br></br> contractual <br></br> life (years) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average <br></br> exercise <br></br> price (USD) </div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">45&#x2013;49</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.7</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 46.7</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">50&#x2013;54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 54.6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">55&#x2013;59</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57.6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">65&#x2013;70</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 66.1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 7.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 59.5</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> ADR <br></br> options <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average <br></br> exercise <br></br> price (USD) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> ADR <br></br> options <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average <br></br> exercise <br></br> price (USD) </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Options outstanding <br></br>at January 1 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 25.9 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 59.9 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 31.9 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 60.2 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sold or exercised</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 59.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;6.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61.7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forfeited or expired</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 59.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 59.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 59.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 25.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 59.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> ADR options outstanding</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>Range of exercise prices (USD) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Number <br></br> outstanding <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Average <br></br> remaining <br></br> contractual <br></br> life (years) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average <br></br> exercise <br></br> price (USD) </div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">45&#x2013;49</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.8</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 46.4</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">50&#x2013;54</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 53.7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">55&#x2013;59</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 58.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">65&#x2013;69</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 66.1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 20.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 59.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Number <br></br> of options <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average <br></br> exercise <br></br> price (USD) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Number of <br></br> SSARs <br></br> (millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average <br></br> exercise <br></br> price (USD) </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at <br></br>January 1, 2016 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 0.2 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 36.8 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 1.8 </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> <br></br> 36.6 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercised</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;0.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 37.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;0.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 38.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 36.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 35.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31, 2016</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 0.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 36.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 35.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at <br></br>January 1, 2017 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 0.1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 36.0 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 1.4 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> <br></br> 35.9 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Exercised</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;0.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39.8</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Outstanding at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Exercisable at December 31, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 0.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">26. Transactions with related parties</div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Genentech/Roche</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has two agreements with Genentech, Inc., United States, a subsidiary of Roche Holding AG which is indirectly included in the consolidated financial statements using equity accounting since Novartis holds 33.3% of the outstanding voting shares of Roche. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;font-style:italic;">LUCENTIS</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis has licensed the exclusive rights to develop and market <i>Lucentis</i> outside the United States for indications related to diseases of the eye. As part of this agreement, Novartis paid Genentech/Roche an initial milestone and shared the cost for the subsequent development by making additional milestone payments upon the achievement of certain clinical development points and product approval. Novartis also pays royalties on the net sales of <i>Lucentis</i> products outside the United States. In 2017, <i>Lucentis</i> sales of USD&nbsp;1.9 billion (2016: USD&nbsp;1.8 billion, 2015: USD&nbsp;2.1 billion) were recognized by Novartis. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;font-style:italic;">XOLAIR</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In February 2004, Novartis Pharma AG, Genentech, Inc., and Tanox, Inc., finalized a three-party collaboration to govern the development and commercialization of certain anti-IgE antibodies including <i>Xolair</i> and TNX-901. Under this agreement, all three parties co-developed <i>Xolair</i>. On August 2, 2007, Genentech, Inc. completed the acquisition of Tanox, Inc. and has taken over its rights and obligations. Novartis and Genentech/Roche are co-promoting <i>Xolair</i> in the United States where Genentech/Roche records all sales. Novartis records sales outside of the United States. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis markets <i>Xolair</i> and records all sales and related costs outside the United States as well as co-promotion costs in the US. Genentech/Roche and Novartis share the resulting profits from sales in the United States, Europe and other countries, according to agreed profit-sharing percentages. In 2017, Novartis recognized total sales of <i>Xolair</i> of USD&nbsp;920 million (2016: USD&nbsp;835 million, 2015: USD&nbsp;755 million) including sales to them for the United States market. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The net expense for royalties, cost sharing and profit sharing arising out of the <i>Lucentis</i> and <i>Xolair</i> agreements with Genentech/Roche totaled USD&nbsp;33 million in 2017 (2016: USD&nbsp;217 million, 2015: USD&nbsp;309 million). </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Furthermore, Novartis has several patent license, supply and distribution agreements with Roche. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Executive Officers and Non-Executive Directors Compensation</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2017, there were 11 Executive Committee members (&#x201c;Executive Officers&#x201d;), including those who stepped down during the year (14 members in 2016 and 11 members in 2015 also including those who stepped down). </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The total compensation for members of the Executive Committee and the 13 Non-Executive Directors (13 in 2016, 12 in 2015 including those who stepped down during the year) using the Group&#x2019;s accounting policies for equity-based compensation and pension benefits was as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Executive Officers</div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-Executive Directors</div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and other compensation</div> </td> <td align="right" width="5%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.4</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20.8</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.7</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22.4</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24.8</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21.8</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Post-employment benefits</div> </td> <td align="right"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div> </td> <td align="right"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 46.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 52.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 54.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 50.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 57.3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 70.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 69.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 79.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 77.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 81.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2017, there was an increase in the IFRS compensation expense for Executive Officers, mainly due to the pro-rata accelerated vesting of equity-based compensation, required by IFRS, for an ECN member who stepped down on December 31, 2017. This was partially offset by the reduction in the number of Executive Officers compared to 2016. The increase in the IFRS compensation expense for Non-Executive Directors was due to one additional Non-Executive Director appointed at the 2017 Annual General Meeting. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">During 2016, there was a decrease in the IFRS compensation expense for Executive Officers compared to 2015. This was mainly due to lower equity-based compensation expense attributable to lower performance factors, which was partially offset by higher benefits other than equity-based compensation resulting from the increase in the number of Executive Officers. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Annual Incentive award, which is fully included in equity-based compensation even when paid out in cash, is granted in January in the year following the reporting period. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The disclosures on Board and Executive compensation required by the Swiss Code of Obligations and in accordance with the Swiss Ordinance against Excessive Compensation in Stock Exchange Listed Companies are shown in the Compensation Report. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Transactions with former members of the Board of Directors</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2017, 2016 and 2015, the following payments (or waivers of claims) were made to former Board members or to &#x201c;persons closely&#x201d; linked to them: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currency</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prof. Dr. Brody</div> </td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25&nbsp;000</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 100&nbsp;000</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prof. Dr. Zinkernagel</div> </td> <td align="right"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 50&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 200&nbsp;000</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dr. Krauer</div> </td> <td align="right"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 60&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 60&nbsp;000</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dr. Vasella</div> </td> <td align="right"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;279</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 250&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 250&nbsp;000</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Prof. Dr. William R. Brody and Prof. Dr. Rolf M. Zinkernagel, who stepped down from the Board of Directors at the 2014 AGM, received in 2016 and 2015, delegated Board membership fees for their work on the Boards of the Novartis Institute for Tropical Diseases (Prof. Dr. Zinkernagel) and the Genomics Institute of the Novartis Research Foundation (Prof. Dr. Brody and Prof. Dr. Zinkernagel). No payments were made in 2017, as their respective mandates ended in 2016. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Dr. Alex Krauer, Honorary Chairman, is entitled to an amount of CHF 60&#xa0;000 for annual periods from one AGM to the next. This amount was fixed in 1998 upon his departure from the Board in 1999, and has not been revised since that date. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2017, Dr. Daniel Vasella, Honorary Chairman, was paid CHF 26&#xa0;279 for reimbursable costs under his agreement with the company. In 2016, Dr. Daniel Vasella received the contractual minimum compensation under an agreement which became effective on November 1, 2013 and ended in 2016. Under this agreement, Dr. Vasella was compensated at a rate of USD&nbsp;25&#xa0;000 per day, with an annual guaranteed minimum fee of USD&nbsp;250&#xa0;000. This amount was in line with compensation practices at other large companies when retired Chairmen or CEOs were retained in consulting agreements after leaving the board of directors. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In 2014, Dr. Vasella exercised an option to acquire, at a future date, real estate in Risch, Zug, Switzerland. The real estate transaction closed in 2015 and Dr. Vasella acquired the Group assets from a consolidated entity for an arm&#x2019;s length transaction price determined on the basis of two independent external assessments. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Transactions with an Executive Officer prior to the start of employment</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As announced on September 24, 2015, Dr. James E. Bradner succeeded Dr. Mark Fishman as President of the Novartis Institutes for BioMedical Research (NIBR) and member of the Executive Committee of Novartis with effect from March 1, 2016. In 2015, a Novartis subsidiary acquired Dr. Bradner&#x2019;s&nbsp;10 million shares (7% interest) in a non-material entity for USD&nbsp;10 million. The arm&#x2019;s length transaction price was determined based on the most recent round of financing of this entity. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The above disclosures related to Dr.&nbsp;Vasella and Dr.&nbsp;Bradner are made on a voluntary basis.</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Executive Officers</div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-Executive Directors</div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and other compensation</div> </td> <td align="right" width="5%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.4</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 20.8</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.7</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22.4</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 24.8</div> </td> <td align="right" width="1%"></td> <td align="right" width="5%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 21.8</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Post-employment benefits</div> </td> <td align="right"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.9</div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation</div> </td> <td align="right"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 49.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 46.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 52.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 54.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 50.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 57.3</div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 70.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 69.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 71.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 9.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 79.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 77.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 81.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="20" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> <td> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Currency</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prof. Dr. Brody</div> </td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 25&nbsp;000</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 100&nbsp;000</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prof. Dr. Zinkernagel</div> </td> <td align="right"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 50&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 200&nbsp;000</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dr. Krauer</div> </td> <td align="right"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 60&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 60&nbsp;000</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dr. Vasella</div> </td> <td align="right"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;279</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0</div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 250&nbsp;000</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 250&nbsp;000</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">27. Commitments and contingencies</div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Leasing commitments</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has entered into various fixed-term operational leases, mainly for cars and real estate. As of December 31, 2017, the Group&#x2019;s commitments with respect to these leases, including estimated payment dates, were as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2018</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 309</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 224</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 161</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 131</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 123</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Thereafter</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;221</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;169</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Expense of current year</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 337</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Research &amp; Development and other intangible asset purchase commitments</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has entered into long-term research and development agreements with various institutions which provide for potential milestone payments by Novartis that may be capitalized. As of December 31, 2017 the Group&#x2019;s commitments to make payments under those agreements and other agreements to purchase intangible assets, and their estimated timing, were as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Research &amp; <br></br> Development <br></br> commitments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other <br></br> intangible asset <br></br> purchase <br></br> commitments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2018</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 780</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 130</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 910</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 671</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 671</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 864</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 864</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 801</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 801</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 353</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 353</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Thereafter</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 837</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 837</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;306</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 130</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;436</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Other commitments</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has entered into various purchase commitments for services and materials as well as for equipment in the ordinary course of business. These commitments are generally entered into at current market prices and reflect normal business operations. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Contingencies</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Group companies have to observe the laws, government orders and regulations of the country in which they operate. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A number of Novartis companies are, and will likely continue to be, subject to various legal proceedings and investigations that arise from time to time, including proceedings regarding product liability, sales and marketing practices, commercial disputes, employment, and wrongful discharge, antitrust, securities, health and safety, environmental, tax, international trade, privacy, and intellectual property matters. As a result, the Group may become subject to substantial liabilities that may not be covered by insurance and that could affect our business, financial position and reputation. While Novartis does not believe that any of these legal proceedings will have a material adverse effect on its financial position, litigation is inherently unpredictable and large judgments sometimes occur. As a consequence, Novartis may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on its results of operations or cash flow. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Governments and regulatory authorities around the world have been stepping up their compliance and law enforcement activities in recent years in key areas, including marketing practices, pricing, corruption, trade restrictions, embargo legislation, insider trading, antitrust, cyber security and data privacy. Further, when one government or regulatory authority undertakes an investigation, it is not uncommon for other governments or regulators to undertake investigations regarding the same or similar matters. Responding to such investigations is costly and requires an increasing amount of management&#x2019;s time and attention. In addition, such investigations may affect our reputation, create a risk of potential exclusion from government reimbursement programs in the United States and other countries, and may lead to (or arise from) litigation. These factors have contributed to decisions by Novartis and other companies in the healthcare industry, when deemed in their interest, to enter into settlement agreements with governmental authorities around the world prior to any formal decision by the authorities or a court. Those government settlements have involved and may continue to involve, in current government investigations and proceedings, large cash payments, sometimes in the hundreds of millions of dollars or more, including the potential repayment of amounts allegedly obtained improperly and other penalties, including treble damages. In addition, settlements of government healthcare fraud cases often require companies to enter into corporate integrity agreements, which are intended to regulate company behavior for a period of years. Our affiliate Novartis Pharmaceuticals Corporation is a party to such an agreement, which will expire in 2020. Also, matters underlying governmental investigations and settlements may be the subject of separate private litigation. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">While provisions have been made for probable losses, which management deems to be reasonable or appropriate, there are uncertainties connected with these estimates. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 19 contains additional information on these matters.</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A number of Group companies are involved in legal proceedings concerning intellectual property rights. The inherent unpredictability of such proceedings means that there can be no assurances as to their ultimate outcome. A negative result in any such proceeding could potentially adversely affect the ability of certain Novartis companies to sell their products, or require the payment of substantial damages or royalties. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In the opinion of management, however, the outcome of these actions will not materially affect the Group&#x2019;s financial position but could be material to the results of operations or cash flow in a given period. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s potential environmental remediation liability is assessed based on a risk assessment and investigation of the various sites identified by the Group as at risk for environmental remediation exposure. The Group&#x2019;s future remediation expenses are affected by a number of uncertainties. These uncertainties include, but are not limited to, the method and extent of remediation, the percentage of material attributable to the Group at the remediation sites relative to that attributable to other parties, and the financial capabilities of the other potentially responsible parties. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Note 19 contains additional information on environmental liabilities.</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2018</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 309</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 224</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 161</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 131</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 123</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Thereafter</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;221</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 3&nbsp;169</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Expense of current year</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 337</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Research &amp; <br></br> Development <br></br> commitments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other <br></br> intangible asset <br></br> purchase <br></br> commitments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2018</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 780</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 130</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 910</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2019</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 671</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 671</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2020</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 864</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 864</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2021</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 801</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 801</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">2022</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 353</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 353</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Thereafter</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 837</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 837</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;306</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 130</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;436</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">28. Financial instruments &ndash; additional disclosures</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017 <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016 <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash and cash equivalents</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;860</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;007</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets - measured at fair value through other comprehensive income</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Available-for-sale marketable securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 328</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 306</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total available-for-sale marketable securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 362</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 337</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Available-for-sale long-term financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 989</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 107</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total available-for-sale long-term financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;275</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;096</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets - measured at fair value through other comprehensive income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;637</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;433</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets - measured at amortized costs</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables, income tax receivables, and other current assets <br></br>(excluding contingent consideration receivables and pre-payments) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 14/16 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 10&nbsp;650 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 10&nbsp;202 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued interest on debt securities and time deposits</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits with original maturity more than 90 days</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 125</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 108</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans and receivables from customers and finance lease, advances, security deposits </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 574</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 514</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets - measured at amortized costs</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;350</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;825</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets - measured at fair value through the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Associated companies at fair value through profit and loss</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 216</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 188</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 230</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12/16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 844</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 586</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets - measured at fair value through the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;091</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;004</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22&nbsp;938</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&nbsp;269</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"></td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities - measured at amortized costs</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of associates payable on demand</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;822</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;601</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 692</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 836</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;328</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;174</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current portion of non-current debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 359</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 178</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;201</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;789</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22&nbsp;957</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;285</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities to banks and other financial institutions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 539</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 708</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Finance lease obligations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 87</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 82</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current portion of non-current debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;359</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;178</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;224</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&nbsp;897</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Trade payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;169</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;873</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities - measured at amortized costs</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33&nbsp;594</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28&nbsp;559</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"></td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities - measured at fair value through the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration (see Note 19/21) and other financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 924</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;018</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 107</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 116</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities - measured at fair value through the consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;031</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;134</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 34&nbsp;625</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 29&nbsp;693</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Except for straight bonds (see Note 18), the carrying amount is a reasonable approximation of fair value. </div> </td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Derivative financial instruments</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following tables show the contract or underlying principal amounts and fair values of derivative financial instruments analyzed by type of contract at December&nbsp;31, 2017 and 2016. Contract or underlying principal amounts indicate the gross volume of business outstanding at the consolidated balance sheet date and do not represent amounts at risk. The fair values are determined by reference to market prices or standard pricing models that use observable market inputs at December 31,&nbsp;2017 and 2016. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Contract or underlying principal amount</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Positive fair values </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Negative fair values </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Currency-related instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;410</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;220</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 230</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;107</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;116</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments included in marketable securities and in current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;410</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;220</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 230</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;107</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;116</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table shows by currency contract or underlying principal amount the derivative financial instruments at December&nbsp;31,&nbsp;2017 and 2016: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div> </td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td colspan="9" height="3"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td colspan="9" height="3"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> EUR</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Currency-related instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;768</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;361</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;281</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;410</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;768</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;361</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;281</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;410</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> EUR</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> JPY</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Currency-related instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;623</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;427</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;127</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;220</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;623</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;427</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;127</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;220</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Derivative financial instruments effective for hedge accounting purposes</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">At the end of 2017 and 2016, there were no open hedging instruments for anticipated transactions. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Fair value by hierarchy</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">As required by IFRS, financial assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. There are three hierarchical levels, based on an increasing amount of subjectivity associated with the inputs to derive fair valuation for these assets and liabilities, which are as follows: </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The assets carried at Level 1 fair value are equity and debt securities listed in active markets. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The assets generally included in Level 2 fair value hierarchy are foreign exchange and interest rate derivatives and certain debt securities. Foreign exchange and interest rate derivatives are valued using corroborated market data. The liabilities generally included in this fair value hierarchy consist of foreign exchange and interest rate derivatives. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Level 3 inputs are unobservable for the asset or liability. The assets generally included in Level 3 fair value hierarchy are various investments in hedge funds and unquoted equity security investments. Contingent consideration carried at fair value is included in this category. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Level 1 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Level 2 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Level 3 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Valued at <br></br> amortized cost </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 303</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 328</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total available-for-sale marketable securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 337</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 362</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits with original maturity more than 90 days</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 125</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 125</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued interest on debt securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities, time deposits and derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 337</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 56</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 126</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 519</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Available-for-sale financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 672</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 437</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;109</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 166</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 394</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 394</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans and receivables from customers and finance lease, advances, security deposits</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 574</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 574</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial investments and long-term loans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 672</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 997</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 574</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;243</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit and loss</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 216</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Contingent consideration receivables short-term</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 450</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 450</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;852</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;852</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;72</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;72</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;107</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;107</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities at fair value</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;107</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;924</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;031</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Level 1 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Level 2 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Level 3 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Valued at <br></br> amortized cost </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 284</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 306</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total available-for-sale marketable securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 315</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 337</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits with original maturity more than 90 days</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 108</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 108</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 230</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 230</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued interest on debt securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities, time deposits and derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 315</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 252</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 676</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Available-for-sale financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 513</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 476</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 989</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 107</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 107</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 586</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 586</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans and receivables from customers and finance lease, advances, security deposits</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 514</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 514</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial investments and long-term loans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 513</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;169</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 514</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;196</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit and loss</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 188</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;889</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;889</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;129</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;129</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;116</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;116</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities at fair value</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;116</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;134</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The analysis above includes all financial instruments including those measured at amortized cost or at cost. </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The change in carrying values associated with Level 3 financial instruments using significant unobservable inputs during the year ended December 31 are set forth below: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="13" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="13" style="border-bottom: solid #000000 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Associated <br></br> companies at <br></br> fair value through <br></br> profit and loss </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Fund <br></br> investments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Available- <br></br> for-sale <br></br> financial <br></br> investments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Contingent <br></br> consideration <br></br> receivables </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Contingent <br></br> consideration <br></br> payables </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Other <br></br> financial <br></br> liabilities </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 188</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 107</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 476</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 586</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;889</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;129</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value gains and other adjustments, <br></br>including from divestments recognized <br></br>in the consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 45 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 32 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 278 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 362 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value losses (including impairments and <br></br>amortizations) and other adjustments recognized <br></br>in the consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &ndash;&nbsp;34 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &ndash;&nbsp;45 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &ndash;&nbsp;193 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &ndash;&nbsp;37 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments recognized in the consolidated statement <br></br>of comprehensive income </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 45 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;40 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 113</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;238</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash receipts and payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 106</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 94</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;52</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;47</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 437</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 844</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;852</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;72</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of fair value gains and losses recognized <br></br>in the consolidated income statement for assets <br></br>and liabilities held at December 31, 2017 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 11 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 0 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &ndash;&nbsp;13 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 278 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 169 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &ndash;&nbsp;37 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="13" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="13" style="border-bottom: solid #000000 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Associated <br></br> companies at <br></br> fair value through <br></br> profit and loss </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Fund <br></br> investments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Available- <br></br> for-sale <br></br> financial <br></br> investments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Contingent <br></br> consideration <br></br> receivables </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Contingent <br></br> consideration <br></br> payables </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Other <br></br> financial <br></br> liabilities </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 181</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 94</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 473</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 550</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;790</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;315</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value gains and other adjustments, <br></br>including from divestments recognized <br></br>in the consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 26 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 51 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 3 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value losses (including impairments and <br></br>amortizations) and other adjustments recognized <br></br>in the consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &ndash;&nbsp;28 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &ndash;&nbsp;1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &ndash;&nbsp;24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &ndash;&nbsp;156 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments recognized in the consolidated statement <br></br>of comprehensive income </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 14 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;8 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 41</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 122</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;172</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash receipts and payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 229</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 183</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;70</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 107</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 476</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 586</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;889</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;129</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of fair value gains and losses recognized <br></br>in the consolidated income statement for assets <br></br>and liabilities held at December 31, 2016 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &ndash;&nbsp;2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &ndash;&nbsp;1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &ndash;&nbsp;23 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 51 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &ndash;&nbsp;156 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 3 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">During 2017, there were several individually non-significant transfers of available-for-sale financial investments from Level 3 to Level 1 for USD&nbsp;73 million (2016: USD&nbsp;75 million) mainly due to Initial Public Offerings of the invested companies. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Realized gains and losses associated with Level 3 available-for-sale marketable securities are recorded in the consolidated income statement under &#x201c;Other financial income and expense&#x201d; and realized gains and losses associated with Level 3 available-for-sale financial investments are recorded in the consolidated income statement under &#x201c;Other income&#x201d; or &#x201c;Other expense&#x201d;, respectively. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If the pricing parameters for the Level 3 input were to change for associated companies at fair value through profit and loss, equity securities, fund investments and available-for-sale financial investments by 10% positively or negatively, this would change the amounts recorded in the 2017 consolidated statement of comprehensive income by USD&nbsp;79 million. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">For the determination of the fair value of a contingent consideration various unobservable inputs are used. A change in these inputs might result in a significantly higher or lower fair value measurement. The inputs used are, among others, the probability of success, sales forecast and assumptions regarding the discount rate, timing and different scenarios of triggering events. The inputs are interrelated. The significance and usage of these inputs to each contingent consideration may vary due to differences in the timing and triggering events for payments or in the nature of the asset related to the contingent consideration. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">If the most significant parameters for the Level&nbsp;3 input were to change by 10% positively or negatively, or where the probability of success (POS) is the most significant input parameter 10% were added or deducted from the applied probability of success, for contingent consideration payables, other financial liabilities and contingent consideration receivables, this would change the amounts recorded in the 2017 consolidated income statement by USD&nbsp;333 million and USD&nbsp;322 million, respectively. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Nature and extent of risks arising from financial instruments</font> </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Market risk</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis is exposed to market risk, primarily related to foreign currency exchange rates, interest rates and the market value of the investments of liquid funds. The Group actively monitors and seeks to reduce, where it deems it appropriate to do so, fluctuations in these exposures. It is the Group&#x2019;s policy and practice to enter into a variety of derivative financial instruments to manage the volatility of these exposures and to enhance the yield on the investment of liquid funds. It does not enter into any financial transactions containing a risk that cannot be quantified at the time the transaction is concluded. In addition, it does not sell short assets it does not have, or does not know it will have, in the future. The Group only sells existing assets or enters into transactions and future transactions (in the case of anticipatory hedges) that it confidently expects it will have in the future, based on past experience. In the case of liquid funds, the Group writes call options on assets it has, or writes put options on positions it wants to acquire and has the liquidity to acquire. The Group expects that any loss in value for these instruments generally would be offset by increases in the value of the underlying transactions. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Foreign currency exchange rate risk</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group uses the US dollar as its reporting currency. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Japanese and emerging market currencies. Fluctuations in the exchange rates between the US dollar and other currencies can have a significant effect on both the Group&#x2019;s results of operations, including reported sales and earnings, as well as on the reported value of our assets, liabilities and cash flows. This, in turn, may significantly affect the comparability of period-to-period results of operations. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Because our expenditures in Swiss francs are significantly higher than our revenues in Swiss francs, volatility in the value of the Swiss franc can have a significant impact on the reported value of our earnings, assets and liabilities, and the timing and extent of such volatility can be difficult to predict. In addition, there is a risk that certain countries could take other steps that could significantly impact the value of their currencies. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group is exposed to a potential adverse devaluation risk on its intercompany funding and total investment in certain subsidiaries operating in countries with exchange controls. The most significant foreign exchange losses (USD&nbsp;0.3 billion) occurred in Venezuela in 2016. The net outstanding intercompany payable balance of Venezuela subsidiaries was not significant at December 31, 2017 and at December 31, 2016, due to reserves against the intercompany balances. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group manages its global currency exposure by engaging in hedging transactions where management deems appropriate. Novartis may enter into various contracts that reflect the changes in the value of foreign currency exchange rates to preserve the value of assets, commitments and anticipated transactions. Novartis also uses forward contracts and foreign currency option contracts to hedge. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Net investments in subsidiaries in foreign countries are long-term investments. Their fair value changes through movements of foreign currency exchange rates. The Group has designated a certain portion of its long-term euro-denominated straight bonds as hedges of the translation risk arising on certain of these net investments in foreign operations with euro functional currency. As of December 31, 2017, long-term financial debt with a carrying amount of EUR&nbsp;1.8 billion (USD&nbsp;2.2 billion) has been designated as a hedge instrument. During 2017, USD&nbsp;237 million of unrealized loss was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge. The hedge remained effective since inception, and no amount was recognized in the consolidated income statement in 2017. During 2016 and 2015, the Group did not apply net investment hedge accounting. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Commodity price risk</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group has only a very limited exposure to price risk related to anticipated purchases of certain commodities used as raw materials by the Group&#x2019;s businesses. A change in those prices may alter the gross margin of a specific business, but generally by not more than 10% of the margin and thus below the Group&#x2019;s risk management tolerance levels. Accordingly, the Group does not enter into significant commodity futures, forward and option contracts to manage fluctuations in prices of anticipated purchases. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Interest rate risk</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group addresses its net exposure to interest rate risk mainly through the ratio of its fixed-rate financial debt to variable rate financial debt contained in its total financial debt portfolio. To manage this mix, Novartis may enter into interest rate swap agreements, in which it exchanges periodic payments based on a notional amount and agreed-upon fixed and variable interest rates. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Equity risk</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group may purchase equities as investments of its liquid funds. As a policy, it limits its holdings in an unrelated company to less than 5% of its liquid funds. Potential investments are thoroughly analyzed. Call options are written on equities that the Group owns, and put options are written on equities that the Group wants to buy and for which cash is available. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Credit risk</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Credit risks arise from the possibility that customers may not be able to settle their obligations as agreed. To manage this risk, the Group periodically assesses country and customer credit risk, assigns individual credit limits, and takes actions to mitigate credit risk where appropriate. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s largest customer accounted for approximately 17% of net sales, and the second-largest and third-largest customers accounted for 12% and 7% of net sales, respectively (2016: 16%, 12% and 6%, respectively; 2015: 14%, 11% and 5%, respectively). No other customer accounted for 5% or more of net sales in either year. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The highest amounts of trade receivables outstanding were for these same three customers and amounted to 14%, 9% and 5%, respectively, of the Group&#x2019;s trade receivables at December 31, 2017 (2016: 14%, 9% and 6%, respectively). There is no other significant concentration of customer credit risk. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Counterparty risk</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Counterparty risk encompasses issuer risk on marketable securities and money market instruments, credit risk on cash, time deposits and derivatives, as well as settlement risk for different instruments. Issuer risk is reduced by only buying securities that are at least A- rated. Counterparty credit risk and settlement risk are reduced by a policy of entering into transactions with counterparties (banks or financial institutions) that feature a strong credit rating. Exposure to these risks is closely monitored and kept within predetermined parameters. The limits are regularly assessed and determined based upon credit analysis, including financial statement and capital adequacy ratio reviews. In addition, reverse repurchasing agreements are contracted and Novartis has entered into credit support agreements with various banks for derivative transactions. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group&#x2019;s cash and cash equivalents are held with major regulated financial institutions, the three largest ones hold approximately 20.2%, 15.0% and 12.7%, respectively (2016: 16.5%, 6.9% and 6.7%, respectively). </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk. </div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Liquidity risk</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Liquidity risk is defined as the risk that the Group could not be able to settle or meet its obligations on time or at a reasonable price. Group Treasury is responsible for liquidity, funding and settlement management. In addition, liquidity and funding risks, and related processes and policies, are overseen by management. Novartis manages its liquidity risk on a consolidated basis according to business needs, tax, capital or regulatory considerations, if applicable, through numerous sources of financing in order to maintain flexibility. Management monitors the Group&#x2019;s net debt or liquidity position through rolling forecasts on the basis of expected cash flows. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">Novartis has two United States commercial paper programs under which it can issue up to USD&nbsp;9.0 billion in the aggregate of unsecured commercial paper notes. Novartis also has a Japanese commercial paper program under which it can issue up to JPY&nbsp;150 billion (approximately USD&nbsp;1.3 billion) of unsecured commercial paper notes. Commercial paper notes totaling USD&nbsp;2.3 billion under these three programs were outstanding as per December 31, 2017 (2016: USD&nbsp;3.2 billion). Novartis further has a committed credit facility of USD&nbsp;6.0 billion, entered into on September 23, 2015. This credit facility is provided by a syndicate of banks and is intended to be used as a backstop for the United States commercial paper programs. It matures in September 2020 and was undrawn as per December 31, 2017 and December 31, 2016. </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table sets forth how management monitors net debt or liquidity based on details of the remaining contractual maturities of current financial assets and liabilities excluding trade receivables and payables as well as contingent considerations at December 31, 2017 and December 31, 2016: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="11" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="11" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due within <br></br> one month </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one month <br></br> but less than <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one year <br></br> but less than <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due after <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities and time deposits</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 71</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 72</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 105</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 181</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 58</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 487</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 106</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 106</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments and accrued interest</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;260</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;860</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;338</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;691</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 111</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 181</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 164</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;485</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;9&nbsp;849</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;13&nbsp;375</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;23&nbsp;224</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &ndash;&nbsp;9&nbsp;893</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &ndash;&nbsp;13&nbsp;519</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &ndash;&nbsp;23&nbsp;412</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;9&nbsp;849</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;13&nbsp;375</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;23&nbsp;224</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;4&nbsp;576</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;169</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;456</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5&nbsp;201</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &ndash;&nbsp;4&nbsp;576</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &ndash;&nbsp;169</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &ndash;&nbsp;456</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &ndash;&nbsp;5&nbsp;201</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;48</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;107</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;4&nbsp;607</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;217</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;484</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;5&nbsp;308</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;269</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;474</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;373</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;9&nbsp;668</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;13&nbsp;211</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;19&nbsp;047</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="11" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="11" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due within <br></br> one month </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one month <br></br> but less than <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one year <br></br> but less than <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due after <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities and time deposits</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 126</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 110</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 124</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 445</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 94</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 94</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments and accrued interest</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 91</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 231</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;907</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;007</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;977</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;328</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 201</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 147</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;777</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;5&nbsp;141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;12&nbsp;756</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;17&nbsp;897</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;5&nbsp;155</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;12&nbsp;901</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;18&nbsp;056</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;5&nbsp;141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;12&nbsp;756</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;17&nbsp;897</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;5&nbsp;099</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;440</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;5&nbsp;789</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;5&nbsp;099</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;440</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;5&nbsp;789</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;72</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;116</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;5&nbsp;114</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;322</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;469</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;5&nbsp;905</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 863</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;006</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;268</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;5&nbsp;017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;12&nbsp;609</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;16&nbsp;025</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The consolidated balance sheet amounts of financial liabilities included in the above analysis are not materially different to the contractual amounts due on maturity. The positive and negative fair values on derivative financial instruments represent the net contractual amounts to be exchanged at maturity. </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group&#x2019;s contractual undiscounted potential cash flows from derivative financial instruments to be settled on a gross basis are as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due within <br></br> one month </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one month <br></br> but less than <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Derivative financial instruments and accrued interest on derivative financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="1%"></td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential outflows in various currencies - from financial derivative liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;953</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;972</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;2&nbsp;824</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;4&nbsp;749</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential inflows in various currencies - from financial derivative assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 928</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 948</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;778</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;654</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due within <br></br> one month </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one month <br></br> but less than <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Derivative financial instruments and accrued interest on derivative financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential outflows in various currencies - from financial derivative liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;087</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;246</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;027</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4&nbsp;360</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential inflows in various currencies - from financial derivative assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;287</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;051</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;447</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Other contractual liabilities that are not part of management&#x2019;s monitoring of the net debt or liquidity consist of the following items: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one month <br></br> but less than <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one year <br></br> but less than <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due after <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contractual interest on non-current liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;113</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;507</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;765</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3&nbsp;859</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;6&nbsp;244</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5&nbsp;169</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5&nbsp;169</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one month <br></br> but less than <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one year <br></br> but less than <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due after <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contractual interest on non-current liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;104</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;433</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;694</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4&nbsp;015</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;6&nbsp;246</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4&nbsp;873</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4&nbsp;873</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Capital risk management</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">Novartis strives to maintain a strong credit rating. In managing its capital, Novartis focuses on maintaining a strong balance sheet. Moody&#x2019;s rated the Group as Aa3 for long-term maturities and as P-1 for short-term maturities and Standard &amp; Poor&#x2019;s had a rating of AA- for long-term maturities and A-1+ for short-term maturities. Fitch had a long-term rating of AA and a short-term rating of F1+. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The debt/equity ratio increased to 0.38:1 at December 31, 2017, compared to 0.32:1 at the beginning of the year. </div> <div style=" padding-bottom: 10px;"> <font style="font-family:arial,helvetica,sans-serif; font-size:12pt; color:#000000; font-weight:bold;">Value at risk</font> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The Group uses a value at risk (VAR) computation to estimate the potential ten-day loss in the fair value of its financial instruments. </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">A ten-day period is used because of an assumption that not all positions could be undone in one day given the size of the positions. The VAR computation includes all financial assets and financial liabilities as set forth in the table on page 243, except trade receivables, income tax receivables and other current assets, contingent considerations, finance lease obligations, long-term loans and receivables from customers and finance lease, advances and security deposits and trade payables.&nbsp; </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The VAR estimates are made assuming normal market conditions, using a 95% confidence interval. The Group uses a &#x201c;Delta Normal&#x201d; model to determine the observed interrelationships between movements in interest rates, stock markets and various currencies. These inter-relationships are determined by observing interest rate, stock market movements and forward foreign currency rate movements over a sixty-day period for the calculation of VAR amounts. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">The estimated potential ten-day loss in the fair value of the Group&#x2019;s foreign currency positions (including foreign exchange translation risk), the estimated potential ten-day loss of its equity holdings, and the estimated potential ten-day loss in fair value of its interest rate sensitive instruments (primarily financial debt and investments of liquid funds under normal market conditions) as calculated in the VAR model are the following: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">All financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 498</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 541</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Analyzed by components:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to foreign <br></br>currency exchange rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 184 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 222 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to equity <br></br>market movements </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 27 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 26 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to interest rates</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 242</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 328</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The average, high, and low VAR amounts are as follows:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Average</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> High</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Low</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">All financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 521</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 560</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 466</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Analyzed by components:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to foreign <br></br>currency exchange rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 277 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 352 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 184 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to equity <br></br>market movements </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 28 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 35 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 21 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to <br></br>interest rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 282 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 338 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 219 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Average</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> High</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Low</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">All financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 402</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 541</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 316</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Analyzed by components:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to foreign <br></br>currency exchange rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 203 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 245 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 147 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to equity <br></br>market movements </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 50 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 99 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 26 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to <br></br>interest rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 308 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 407 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 234 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The VAR computation is a risk analysis tool designed to statistically estimate the potential ten-day loss from adverse movements in foreign currency exchange rates, equity prices and interest rates under normal market conditions. The computation does not purport to represent actual losses in fair value on earnings to be incurred by the Group, nor does it consider the effect of favorable changes in market rates. The Group cannot predict actual future movements in such market rates and it does not claim that these VAR results are indicative of future movements in such market rates or are representative of any actual impact that future changes in market rates may have on the Group&#x2019;s future results of operations or financial position. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; text-indent:20.0pt;">In addition to these VAR analyses, the Group uses stress testing techniques that aim to reflect a worst case scenario on the marketable securities that are monitored by Group Treasury. For these calculations, the Group uses the six-month period with the worst performance observed over the past twenty years in each category. For 2017 and 2016, the worst case loss scenario was calculated as follows: </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">All financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Analyzed by components:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to foreign <br></br>currency exchange rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to equity <br></br>market movements </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to <br></br>interest rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 7 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 6 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">In the Group&#x2019;s risk analysis, Novartis considered this worst case scenario acceptable as it could reduce income, but would not endanger the solvency or investment grade credit rating of the Group. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Note</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017 <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016 <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Cash and cash equivalents</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;860</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;007</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets - measured at fair value through other comprehensive income</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Available-for-sale marketable securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 328</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 306</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total available-for-sale marketable securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 362</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 337</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Available-for-sale long-term financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 989</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 107</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total available-for-sale long-term financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;275</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;096</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets - measured at fair value through other comprehensive income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;637</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;433</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets - measured at amortized costs</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade receivables, income tax receivables, and other current assets <br></br>(excluding contingent consideration receivables and pre-payments) </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 14/16 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 10&nbsp;650 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 10&nbsp;202 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued interest on debt securities and time deposits</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits with original maturity more than 90 days</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 125</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 108</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans and receivables from customers and finance lease, advances, security deposits </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 574</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 514</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets - measured at amortized costs</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 11&nbsp;350</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;825</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets - measured at fair value through the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Associated companies at fair value through profit and loss</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 216</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 188</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 230</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12/16</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 844</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 586</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets - measured at fair value through the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;091</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;004</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 22&nbsp;938</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20&nbsp;269</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"></td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities - measured at amortized costs</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Interest-bearing accounts of associates payable on demand</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;822</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;601</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bank and other financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 692</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 836</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commercial paper</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;328</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;174</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current portion of non-current debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 359</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 178</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;201</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;789</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Straight bonds</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 22&nbsp;957</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 17&nbsp;285</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Liabilities to banks and other financial institutions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 539</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 708</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Finance lease obligations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 87</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 82</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Current portion of non-current debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;359</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;178</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23&nbsp;224</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 17&nbsp;897</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Trade payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 5&nbsp;169</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 4&nbsp;873</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities - measured at amortized costs</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 33&nbsp;594</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 28&nbsp;559</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"></td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities - measured at fair value through the consolidated income statement</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration (see Note 19/21) and other financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 924</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;018</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 107</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 116</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities - measured at fair value through the consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;031</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;134</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 34&nbsp;625</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 29&nbsp;693</div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;</sup> </div> </td> </tr> <tr valign="bottom"> <td colspan="8"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Except for straight bonds (see Note 18), the carrying amount is a reasonable approximation of fair value. </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Contract or underlying principal amount</div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Positive fair values </div> </td> <td></td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Negative fair values </div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> <td colspan="3" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Currency-related instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;410</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;220</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 230</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;107</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;116</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments included in marketable securities and in current financial debts</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;410</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;220</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 230</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;107</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;116</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div> </td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td colspan="9" height="3"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td colspan="9" height="3"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> EUR</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Currency-related instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;768</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;361</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;281</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;410</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;768</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;361</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;281</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 8&nbsp;410</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> EUR</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> USD</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> JPY</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total</div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Currency-related instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forward foreign exchange rate contracts</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;623</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 3&nbsp;427</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 43</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;127</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8&nbsp;220</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;623</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 3&nbsp;427</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 43</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;127</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 8&nbsp;220</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Level 1 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Level 2 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Level 3 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Valued at <br></br> amortized cost </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 303</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 328</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 34</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total available-for-sale marketable securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 337</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 25</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 362</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits with original maturity more than 90 days</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 125</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 125</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued interest on debt securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities, time deposits and derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 337</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 56</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 126</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 519</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Available-for-sale financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 672</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 437</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;109</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 166</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 394</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 394</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans and receivables from customers and finance lease, advances, security deposits</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 574</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 574</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial investments and long-term loans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 672</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 997</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 574</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 2&nbsp;243</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit and loss</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 216</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Contingent consideration receivables short-term</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 450</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 450</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;852</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;852</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;72</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;72</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;107</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;107</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities at fair value</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;107</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;924</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;1&nbsp;031</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Level 1 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Level 2 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Level 3 </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Valued at <br></br> amortized cost </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Debt securities</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 284</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 306</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 31</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total available-for-sale marketable securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 315</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 22</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 337</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Time deposits with original maturity more than 90 days</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 108</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 108</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 230</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 230</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Accrued interest on debt securities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total marketable securities, time deposits and derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 315</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 252</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 676</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Available-for-sale financial investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 513</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 476</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 989</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fund investments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 107</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 107</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration receivables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 586</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 586</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Long-term loans and receivables from customers and finance lease, advances, security deposits</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 514</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 514</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial investments and long-term loans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 513</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;169</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 514</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;196</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Associated companies at fair value through profit and loss</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 188</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contingent consideration payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;889</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;889</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other financial liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;129</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;129</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;116</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;116</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total financial liabilities at fair value</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;116</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;018</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;1&nbsp;134</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="13" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="13" style="border-bottom: solid #000000 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Associated <br></br> companies at <br></br> fair value through <br></br> profit and loss </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Fund <br></br> investments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Available- <br></br> for-sale <br></br> financial <br></br> investments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Contingent <br></br> consideration <br></br> receivables </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Contingent <br></br> consideration <br></br> payables </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Other <br></br> financial <br></br> liabilities </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 188</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 107</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 476</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 586</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;889</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;129</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value gains and other adjustments, <br></br>including from divestments recognized <br></br>in the consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 45 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 32 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 278 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 362 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value losses (including impairments and <br></br>amortizations) and other adjustments recognized <br></br>in the consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &ndash;&nbsp;34 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &ndash;&nbsp;45 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &ndash;&nbsp;193 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &ndash;&nbsp;37 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments recognized in the consolidated statement <br></br>of comprehensive income </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 45 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> &ndash;&nbsp;40 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 37</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 113</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;238</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash receipts and payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;20</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 106</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 94</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;52</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;47</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 166</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 437</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 844</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;852</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;72</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of fair value gains and losses recognized <br></br>in the consolidated income statement for assets <br></br>and liabilities held at December 31, 2017 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 11 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 0 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &ndash;&nbsp;13 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 278 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 169 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> &ndash;&nbsp;37 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="13" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="13" style="border-bottom: solid #000000 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="13" height="3"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Associated <br></br> companies at <br></br> fair value through <br></br> profit and loss </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Fund <br></br> investments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Available- <br></br> for-sale <br></br> financial <br></br> investments </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Contingent <br></br> consideration <br></br> receivables </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Contingent <br></br> consideration <br></br> payables </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Other <br></br> financial <br></br> liabilities </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 181</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 94</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 473</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 550</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;790</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;315</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value gains and other adjustments, <br></br>including from divestments recognized <br></br>in the consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 26 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 51 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 3 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value losses (including impairments and <br></br>amortizations) and other adjustments recognized <br></br>in the consolidated income statement </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &ndash;&nbsp;28 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &ndash;&nbsp;1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &ndash;&nbsp;24 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &ndash;&nbsp;156 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fair value adjustments recognized in the consolidated statement <br></br>of comprehensive income </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 14 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> &ndash;&nbsp;8 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Purchases</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 41</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 122</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;172</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash receipts and payments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 229</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 183</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Disposals</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reclassification</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;70</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 188</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 107</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 476</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 586</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;889</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;129</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total of fair value gains and losses recognized <br></br>in the consolidated income statement for assets <br></br>and liabilities held at December 31, 2016 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &ndash;&nbsp;2 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &ndash;&nbsp;1 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &ndash;&nbsp;23 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 51 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> &ndash;&nbsp;156 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 3 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="11" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="11" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due within <br></br> one month </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one month <br></br> but less than <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one year <br></br> but less than <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due after <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities and time deposits</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 71</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 72</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 105</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 181</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 58</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 487</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 106</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 106</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments and accrued interest</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;260</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;600</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8&nbsp;860</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;338</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;691</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 111</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 181</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 164</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 9&nbsp;485</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;9&nbsp;849</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;13&nbsp;375</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;23&nbsp;224</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &ndash;&nbsp;9&nbsp;893</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &ndash;&nbsp;13&nbsp;519</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &ndash;&nbsp;23&nbsp;412</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;9&nbsp;849</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;13&nbsp;375</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;23&nbsp;224</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;4&nbsp;576</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;169</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;456</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5&nbsp;201</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &ndash;&nbsp;4&nbsp;576</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &ndash;&nbsp;169</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &ndash;&nbsp;456</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> &ndash;&nbsp;5&nbsp;201</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;48</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;28</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;107</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;4&nbsp;607</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;217</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;484</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;5&nbsp;308</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;269</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 4&nbsp;474</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;373</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;9&nbsp;668</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;13&nbsp;211</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;19&nbsp;047</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="11" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="11" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="11" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due within <br></br> one month </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one month <br></br> but less than <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one year <br></br> but less than <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due after <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current assets</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketable securities and time deposits</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 32</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 126</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 110</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 124</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 53</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 445</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Commodities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 94</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 94</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments and accrued interest</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 38</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 102</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 91</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 231</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cash and cash equivalents</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5&nbsp;907</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7&nbsp;007</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 5&nbsp;977</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;328</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 201</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 147</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 7&nbsp;777</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;5&nbsp;141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;12&nbsp;756</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;17&nbsp;897</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;5&nbsp;155</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;12&nbsp;901</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;18&nbsp;056</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total non-current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;5&nbsp;141</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;12&nbsp;756</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;17&nbsp;897</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Current liabilities</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;5&nbsp;099</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;440</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;5&nbsp;789</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Financial debt - undiscounted</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;5&nbsp;099</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;250</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;440</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> &ndash;&nbsp;5&nbsp;789</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Derivative financial instruments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;15</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;72</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;29</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;116</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total current financial debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;5&nbsp;114</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;322</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;469</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;5&nbsp;905</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net debt</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 863</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;006</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;268</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;5&nbsp;017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;12&nbsp;609</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;16&nbsp;025</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due within <br></br> one month </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one month <br></br> but less than <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Derivative financial instruments and accrued interest on derivative financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="1%"></td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential outflows in various currencies - from financial derivative liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;953</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;972</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;2&nbsp;824</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;4&nbsp;749</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential inflows in various currencies - from financial derivative assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 928</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 948</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;778</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4&nbsp;654</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due within <br></br> one month </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one month <br></br> but less than <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> </div> </td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Derivative financial instruments and accrued interest on derivative financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> </div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential outflows in various currencies - from financial derivative liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;087</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;246</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;2&nbsp;027</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4&nbsp;360</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Potential inflows in various currencies - from financial derivative assets</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;109</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1&nbsp;287</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;051</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4&nbsp;447</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one month <br></br> but less than <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one year <br></br> but less than <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due after <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contractual interest on non-current liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;113</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;507</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1&nbsp;765</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;3&nbsp;859</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;6&nbsp;244</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5&nbsp;169</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;5&nbsp;169</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="9" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="9" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="9" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one month <br></br> but less than <br></br> three months </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> three months <br></br> but less than <br></br> one year </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Due later than <br></br> one year <br></br> but less than <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Due after <br></br> five years </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> <br></br> Total </div> </td> <td></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Contractual interest on non-current liabilities</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;104</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;433</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;694</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4&nbsp;015</div> </td> <td align="right" width="1%"></td> <td align="right" width="8%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;6&nbsp;246</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trade payables</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4&nbsp;873</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4&nbsp;873</div> </td> <td align="right"></td> </tr> <tr> <td colspan="12" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">All financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 498</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 541</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Analyzed by components:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to foreign <br></br>currency exchange rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 184 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 222 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to equity <br></br>market movements </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 27 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 26 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to interest rates</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 242</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 328</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Average</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> High</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Low</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">All financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 521</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 560</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 466</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Analyzed by components:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to foreign <br></br>currency exchange rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 277 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 352 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 184 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to equity <br></br>market movements </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 28 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 35 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 21 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to <br></br>interest rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 282 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 338 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 219 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1" width="3" style="border-bottom: solid #FFFFFF 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Average</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> High</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Low</div> </td> <td></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">All financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 402</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 541</div> </td> <td align="right" width="1%"></td> <td align="right" width="11%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 316</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Analyzed by components:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to foreign <br></br>currency exchange rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 203 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 245 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 147 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to equity <br></br>market movements </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 50 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 99 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 26 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to <br></br>interest rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 308 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 407 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 234 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="8" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">All financial instruments</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 6</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;">Analyzed by components:</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-style:italic; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to foreign <br></br>currency exchange rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to equity <br></br>market movements </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Instruments sensitive to <br></br>interest rates </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> 7 </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> 6 </div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">29. Discontinued operations</div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Discontinued operations consolidated income statement segmentation</font> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td colspan="3" height="3"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td colspan="3" height="3"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Vaccines </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Consumer <br></br> Health<sup>1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Corporate <br></br> (including <br></br> eliminations) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> discontinued <br></br> operations </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties of discontinued operations</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 145</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 456</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 601</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to continuing segments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales of discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 457</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 620</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;192</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;184</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;376</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit of discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 278</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 267</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketing &amp; Sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;57</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;187</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;244</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research &amp; Development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;151</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;181</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">General &amp; Administration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;58</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;870</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;558</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13&nbsp;420</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;57</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;656</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;727</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income of discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;568</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;573</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;664</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;477</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes of discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;479</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;713</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income of discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;766</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Consumer Health is the aggregation of the former OTC and Animal Health divisions. </div> </td> </tr> </table> </div> <div style="padding-top:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following are included in net income from discontinued operations:</div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on property, plant &amp; equipment, net</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 83</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to restructuring provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation of Novartis equity plans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;65</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="7" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td align="center" colspan="3" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td colspan="3" height="3"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="7" style="border-bottom: solid #000000 1px;"></td> <td colspan="3" style="border-bottom: solid #000000 1px;"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="7" height="3"></td> <td colspan="3" height="3"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(USD millions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> <br></br> Vaccines </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Consumer <br></br> Health<sup>1</sup> </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Corporate <br></br> (including <br></br> eliminations) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Total <br></br> discontinued <br></br> operations </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales to third parties of discontinued operations</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 145</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 456</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 601</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sales to continuing segments</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 19</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net sales of discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 163</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 457</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 620</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other revenues</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 23</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cost of goods sold</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;192</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;184</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;376</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gross profit of discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;11</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 278</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 267</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Marketing &amp; Sales</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;57</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;187</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;244</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Research &amp; Development</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;151</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;30</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;181</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">General &amp; Administration</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;26</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;32</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;58</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other income</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2&nbsp;870</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 10&nbsp;558</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 13&nbsp;420</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Other expense</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;57</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;14</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;656</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;727</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Operating income of discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 2&nbsp;568</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;573</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;664</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;477</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Income from associated companies</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 2</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Income before taxes of discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 12&nbsp;479</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taxes</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1&nbsp;713</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Net income of discontinued operations</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 10&nbsp;766</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 3px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Consumer Health is the aggregation of the former OTC and Animal Health divisions. </div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2015</div> </td> <td></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Impairment charges on property, plant &amp; equipment, net</div> </td> <td align="right" width="1%"></td> <td align="right" width="20%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 83</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Additions to restructuring provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Equity-based compensation of Novartis equity plans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;65</div> </td> <td align="right"></td> </tr> <tr> <td colspan="4" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">30. Events subsequent to the December 31, 2017 consolidated balance sheet date</div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Significant transaction closed in January 2018 </font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">For significant transaction entered into in 2017 and closed in 2018, see Note&nbsp;2.</div> <div> <font style="font-family:arial,helvetica,sans-serif; font-size:11pt; color:#000000; font-weight:bold;">Dividend proposal for 2017 and approval of&nbsp;the Group&#x2019;s 2017 consolidated financial statements</font> </div> <div style="padding-bottom:15px;font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">On January 23, 2018, the Novartis AG Board of Directors proposed the acceptance of the 2017 consolidated financial statements of the Novartis Group for approval by the Annual General Meeting on March 2, 2018. Furthermore, also on January 23, 2018, the Board proposed a dividend of CHF&nbsp;2.80 per share to be approved at the Annual General Meeting on March 2, 2018. If approved, total dividend payments would amount to approximately USD&nbsp;6.7 billion (2016: USD&nbsp;6.5billion) using the CHF/USD December 31, 2017 exchange rate. </div> <div style="font-family:arial,helvetica,sans-serif; font-size:16pt; color:#000000; font-weight: bold; margin-bottom:20px;margin-top:30px;">31. Principal Group subsidiaries and&nbsp;associated&nbsp;companies</div> <div style="font-family:arial,helvetica,sans-serif; font-size:10pt; color:#000000;text-align:justify; ">The following table lists the principal subsidiaries controlled by Novartis and associated companies in which Novartis is deemed to have significant influence. It includes all subsidiaries and associated companies with Total assets or Net sales to third parties in excess of USD&nbsp;25&nbsp;million. The equity interest percentage shown in the table also represents the share in voting rights in those entities, except where explicitly noted. </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>As at December 31, 2017 </div> </td> <td></td> <td></td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share <br></br> capital <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br></br> interest </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Algeria</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Soci&#xe9;t&#xe9; par actions SANDOZ</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Algiers</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DZD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 650.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Argentina</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Argentina S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buenos Aires</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ARS</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 906.1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratorios S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buenos Aires</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ARS</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 83.9</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Australia</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Australia Pty Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">North Ryde, NSW</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals Australia Pty Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">North Ryde, NSW</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.8</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Pty Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">North Ryde, NSW</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.6</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratories (Australia) Pty Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frenchs Forest, NSW</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.6</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Austria</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Austria GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vienna</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vienna</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kundl</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32.7</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">EBEWE Pharma Ges.m.b.H Nfg. KG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Unterach am Attersee</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Bangladesh</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Bangladesh) Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gazipur</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BDT</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 162.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Belgium</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">N.V. Novartis Pharma S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vilvoorde</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">N.V. Sandoz S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vilvoorde</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19.2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">S.A. Alcon-Couvreur N.V.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Puurs</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 110.6</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">N.V. Alcon S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vilvoorde</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 141&nbsp;856</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Bermuda</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Investment Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Securities Investment Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finance Services Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis B2 Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis B3 Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 106&nbsp;400</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Triangle International Reinsurance Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trinity River Insurance Co Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 370&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Brazil</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Bioci&#xea;ncias S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">S&#xe3;o Paulo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRL</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 265.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz do Brasil Ind&#xfa;stria Farmac&#xea;utica Ltda.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Camb&#xe9;, PR</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRL</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 190.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Canada</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals Canada Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dorval, Quebec</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Canada Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Boucherville, Quebec</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80.8</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Canada Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mississauga, Ontario</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;500</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CIBA Vision Canada Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mississauga, Ontario</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 82&nbsp;886</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Chile</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Chile S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Santiago de Chile</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CLP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratorios Chile Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Santiago de Chile</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CLP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">China</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Beijing Novartis Pharma Co., Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Beijing</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals (HK) Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hong Kong</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HKD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 200</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">China Novartis Institutes for BioMedical Research Co., Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Shanghai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 320.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Suzhou Novartis Pharma Technology Co., Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changshu</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 103.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shanghai Novartis Trading Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shanghai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz (China) Pharmaceutical Co., Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Zhongshan</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Hong Kong Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hong Kong</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HKD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 77&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon (China) Ophthalmic Product Co., Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Beijing</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Colombia</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis de Colombia S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Santaf&#xe9; de Bogot&#xe1;</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> COP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.9</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Laboratorios Alcon de Colombia S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Santaf&#xe9; de Bogot&#xe1;</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> COP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.9</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Croatia</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz d.o.o. farmaceutska industrija</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Zagreb</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HRK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.6</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Czech Republic</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis s.r.o.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prague</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 51.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz s.r.o.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prague</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44.7</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Pharmaceuticals (Czech Republic) s.r.o.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prague</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Denmark</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Healthcare A/S</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Copenhagen</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz A/S</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Copenhagen</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Nordic A/S</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Copenhagen</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ecuador</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Ecuador S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Quito</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Egypt</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma S.A.E.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cairo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EGP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 193.8</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.77%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Egypt Pharma S.A.E.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New Cairo City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EGP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 250&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Finland</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finland Oy</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Espoo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 459&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>As at December 31, 2017 </div> </td> <td></td> <td></td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share <br></br> capital <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br></br> interest </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">France</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Groupe France S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rueil-Malmaison</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 103.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma S.A.S.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rueil-Malmaison</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz S.A.S.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Levallois-Perret</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Laboratoires Alcon S.A.S.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rueil-Malmaison</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12.9</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Germany</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Deutschland GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Wehr</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 155.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Business Services GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Wehr</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nuremberg</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.6</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Produktions GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Wehr</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz International GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Holzkirchen</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 A Pharma GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oberhaching</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">HEXAL AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Holzkirchen</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 93.7</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Salutas Pharma GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Barleben</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 42.1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aeropharm GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rudolstadt</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Pharma GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Freiburg im Breisgau</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 512&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CIBA Vision GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Grosswallstadt</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">WaveLight GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Erlangen</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.6</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gibraltar</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novista Insurance Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gibraltar City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 130.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Greece</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Hellas) S.A.C.I.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Metamorphosis/Athens</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratories Hellas- Commercial and Industrial S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Maroussi, Athens</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.7</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Hungary</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Hungary Healthcare Limited Liability Company</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Budapest</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HUF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 545.6</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Hungary Limited Liability Company</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Budapest</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HUF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 883.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">India</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis India Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mumbai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 140.7</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 73.4%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Healthcare Private Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mumbai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Private Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mumbai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratories (India) Private Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bangalore</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Indonesia</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">PT. Novartis Indonesia</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Jakarta</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IDR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.7</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">PT. CIBA Vision Batam</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Batam</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IDR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.9</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ireland</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Ireland Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dublin</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Ringaskiddy Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ringaskiddy, County Cork</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratories Ireland Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cork City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 541&nbsp;251</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Israel</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Israel Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Petach Tikva</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ILS</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Optonol Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Neve-Ilan</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ILS</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 752&nbsp;545</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Italy</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Farma S.p.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Origgio</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz S.p.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Origgio</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.7</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Industrial Products S.p.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rovereto</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.6</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Italia S.p.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Milan</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.7</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Japan</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Holding Japan K.K.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tokyo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma K.K.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tokyo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ciba-Geigy Japan Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tokyo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz K.K.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tokyo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Japan Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tokyo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Luxembourg</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Investments S.&#xe0; r.l.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Luxembourg-Ville</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finance S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Luxembourg-Ville</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Malaysia</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Corporation (Malaysia) Sdn. Bhd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kuala Lumpur</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MYR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.3</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratories (Malaysia) Sdn. Bhd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Petaling Jaya</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MYR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CIBA Vision Johor Sdn. Bhd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kuala Lumpur</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MYR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Mexico</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Farmac&#xe9;utica, S.A. de C.V.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mexico City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 205.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz, S.A. de C.V.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mexico City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 468.2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratorios, S.A. de C.V.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mexico City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.9</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Morocco</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Maroc SA</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Casablanca</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MAD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Netherlands</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Netherlands B.V.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Arnhem</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma B.V.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Arnhem</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz B.V.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Almere</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 907&nbsp;560</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Nederland B.V.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Arnhem</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18&nbsp;151</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">New Zealand</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis New Zealand Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Auckland</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NZD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 820&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>As at December 31, 2017 </div> </td> <td></td> <td></td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share <br></br> capital <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br></br> interest </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Norway</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Norge AS</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oslo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NOK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Pakistan</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma (Pakistan) Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Karachi</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PKR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.9</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.99%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Panama</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma (Logistics), Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Panama City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Centroamerica S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Panama City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PAB</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Philippines</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Healthcare Philippines, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Manila</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PHP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 298.8</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Philippines Corporation</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Manila</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PHP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Poland</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Poland Sp. z o.o.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Warszawa</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44.2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Polska Sp. z o.o.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Warszawa</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.6</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lek S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Strykow</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Polska Sp. z o.o.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Warszawa</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 750&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Portugal</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Portugal SGPS Lda.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Porto Salvo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Farma - Produtos Farmac&#xea;uticos S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Porto Salvo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Farmac&#xea;utica Lda.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Porto Salvo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 499&nbsp;900</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Portugal-Produtos e Equipamentos Oftalmol&#xf3;gicos Lda.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Porto Salvo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Romania</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Services Romania S.R.L.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bucharest</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz S.R.L.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Targu-Mures</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 105.2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Romania S.R.L.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bucharest</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10.8</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Russian Federation</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma LLC</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Moscow</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Neva LLC</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">St. Petersburg</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.3</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">ZAO Sandoz</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Moscow</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Farmacevtika LLC</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Moscow</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44.1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Saudi Arabia</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Saudi Pharmaceutical Distribution Co. Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Riyadh</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SAR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26.8</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 75%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Singapore</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Singapore) Pte Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Singapore</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Singapore Pharmaceutical Manufacturing Pte Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Singapore</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 45.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Asia Pacific Pharmaceuticals Pte Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Singapore</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Institute for Tropical Diseases Pte Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Singapore</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;004</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Pte Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Singapore</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 164&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Singapore Manufacturing Pte Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Singapore</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 101&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CIBA Vision Asian Manufacturing and Logistics Pte Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Singapore</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Slovakia</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Slovakia s.r.o.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bratislava</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Slovenia</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lek Pharmaceuticals d.d.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ljubjana</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 48.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Pharmaceuticals d.d.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ljubjana</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">South Africa</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis South Africa (Pty) Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Midrand</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 86.3</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz South Africa (Pty) Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kempton Park</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratories (South Africa) (Pty) Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Midrand</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 201&nbsp;820</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">South Korea</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Korea Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Seoul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> KRW</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.55%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Korea Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Seoul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> KRW</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17.8</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Korea Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Seoul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> KRW</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33.8</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Spain</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Farmac&#xe9;utica S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Barcelona</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 63.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Farmac&#xe9;utica S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Madrid</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 270&nbsp;450</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Industrial Products S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Les Franqueses del Vall&#xe9;s / Barcelona</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9.3</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Cusi S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Barcelona</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.6</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Abadia Retuerta S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sard&#xf3;n de Duero/Valladolid</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sweden</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Sverige AB</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">T&#xe4;by / Stockholm</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SEK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Switzerland</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis International AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Holding AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis International Pharmaceutical Investment AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Bioventures AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Forschungsstiftung</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Stiftung f&#xfc;r Kaderausbildung</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Mitarbeiterbeteiligungsstiftung</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Stiftung f&#xfc;r Mensch und Umwelt</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Stiftung der Novartis AG f&#xfc;r Erziehung, Ausbildung und Bildung</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 350.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis International Pharmaceutical AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Services AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Schweizerhalle AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Muttenz</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.9</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Stein AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Stein</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 251&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Schweiz AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Risch</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Pharmaceuticals AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Risch</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Switzerland SA</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Risch</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Pharmaceuticals Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fribourg</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 200&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Roche Holding AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 160.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33/6 <sup style="white-space: nowrap"> 2</sup> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>As at December 31, 2017 </div> </td> <td></td> <td></td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share <br></br> capital <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br></br> interest </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Taiwan</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Taiwan) Co., Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taipei</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TWD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 170.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Thailand</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Thailand) Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bangkok</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> THB</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 302.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratories (Thailand) Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bangkok</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> THB</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 228.1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Turkey</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Saglik, Gida ve Tarim &#xdc;r&#xfc;nleri Sanayi ve Ticaret A.S.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Istanbul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Farmanova Saglik Hizmetleri Ltd. Sti.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Istanbul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.7</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Ila&#xe7; Sanayi ve Ticaret A.S.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Istanbul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 165.2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.99%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Syntek Ila&#xe7; Hammaddeleri Sanayi ve Ticaret A.S.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Istanbul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 46.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Grup Saglik &#xdc;r&#xfc;nleri Ila&#xe7;lari Sanayi ve Ticaret A.S.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Gebze - Kocaeli</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratuvarlari Ticaret A.S.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Istanbul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United Arab Emirates</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Middle East FZE</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dubai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AED</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United Kingdom</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis UK Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frimley/Camberley</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals UK Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frimley/Camberley</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Grimsby Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frimley/Camberley</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 250.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ziarco Group Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frimley/Camberley</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;904</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frimley/Camberley</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Eye Care UK Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frimley/Camberley</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 550&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Glaxosmithkline Consumer Healthcare Holdings Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Brentford, Middlesex</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36.5%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United States of America</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Corporation</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 72.2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finance Corporation</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New York, NY</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Capital Corporation</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New York, NY</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Services, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis US Foundation</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New York, NY</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals Corporation</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Institutes for BioMedical Research, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cambridge, MA</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corthera, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">San Mateo, CA</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CoStim Pharmaceuticals Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cambridge, MA</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Encore Vision, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New York, NY</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Navigate BioPharma Services, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Wilmington, NC</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reprixys Pharmaceuticals Corporation</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oklahoma City, OK</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Spinifex Pharmaceuticals, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Wilmington, NC</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Institute for Functional Genomics, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">San Diego, CA</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Princeton, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fougera Pharmaceuticals Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Melville, NY</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Eon Labs, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Princeton, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratories, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fort Worth, TX</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Refractivehorizons, LLC</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fort Worth, TX</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Research, Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fort Worth, TX</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Lensx, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aliso Viejo, CA</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratories Holding Corporation</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fort Worth, TX</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Vaccines and Diagnostics, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cambridge, MA</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">ClarVista Medical, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aliso Viejo, CA</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transcend Medical, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Menlo Park, CA</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Venezuela</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis de Venezuela, S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Caracas</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VEF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Pharmaceutical, C.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Caracas</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VEF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">In addition, the Group is represented by subsidiaries and associated companies in the following countries: Bosnia/Herzegovina, Bulgaria, Dominican Republic, Guatemala, Kenya, Latvia, the Former Yugoslav Republic of Macedonia, Nigeria, Peru, Puerto Rico, Ukraine and Uruguay </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Share capital may not reflect the taxable share capital and does not include any paid-in surplus </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Approximately 33% of voting shares; approximately 6% of total net income and equity attributable to Novartis </div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">m = million; bn = billion</div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>As at December 31, 2017 </div> </td> <td></td> <td></td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share <br></br> capital <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br></br> interest </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Algeria</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Soci&#xe9;t&#xe9; par actions SANDOZ</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Algiers</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DZD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 650.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Argentina</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Argentina S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buenos Aires</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ARS</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 906.1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratorios S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Buenos Aires</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ARS</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 83.9</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Australia</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Australia Pty Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">North Ryde, NSW</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals Australia Pty Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">North Ryde, NSW</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.8</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Pty Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">North Ryde, NSW</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.6</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratories (Australia) Pty Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frenchs Forest, NSW</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AUD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.6</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Austria</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Austria GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vienna</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vienna</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kundl</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32.7</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">EBEWE Pharma Ges.m.b.H Nfg. KG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Unterach am Attersee</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Bangladesh</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Bangladesh) Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gazipur</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BDT</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 162.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Belgium</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">N.V. Novartis Pharma S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vilvoorde</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">N.V. Sandoz S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vilvoorde</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19.2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">S.A. Alcon-Couvreur N.V.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Puurs</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 110.6</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">N.V. Alcon S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vilvoorde</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 141&nbsp;856</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Bermuda</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Investment Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Securities Investment Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finance Services Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis B2 Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis B3 Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 106&nbsp;400</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Triangle International Reinsurance Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Trinity River Insurance Co Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hamilton</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 370&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Brazil</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Bioci&#xea;ncias S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">S&#xe3;o Paulo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRL</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 265.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz do Brasil Ind&#xfa;stria Farmac&#xea;utica Ltda.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Camb&#xe9;, PR</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> BRL</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 190.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Canada</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals Canada Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dorval, Quebec</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 13.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Canada Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Boucherville, Quebec</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80.8</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Canada Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mississauga, Ontario</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;500</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CIBA Vision Canada Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mississauga, Ontario</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CAD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 82&nbsp;886</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Chile</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Chile S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Santiago de Chile</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CLP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratorios Chile Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Santiago de Chile</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CLP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">China</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Beijing Novartis Pharma Co., Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Beijing</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals (HK) Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hong Kong</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HKD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 200</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">China Novartis Institutes for BioMedical Research Co., Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Shanghai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 320.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Suzhou Novartis Pharma Technology Co., Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Changshu</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 103.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shanghai Novartis Trading Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Shanghai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz (China) Pharmaceutical Co., Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Zhongshan</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Hong Kong Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Hong Kong</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HKD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 77&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon (China) Ophthalmic Product Co., Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Beijing</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Colombia</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis de Colombia S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Santaf&#xe9; de Bogot&#xe1;</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> COP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.9</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Laboratorios Alcon de Colombia S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Santaf&#xe9; de Bogot&#xe1;</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> COP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.9</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Croatia</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz d.o.o. farmaceutska industrija</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Zagreb</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HRK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.6</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Czech Republic</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis s.r.o.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prague</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 51.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz s.r.o.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prague</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44.7</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Pharmaceuticals (Czech Republic) s.r.o.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Prague</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CZK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 31.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Denmark</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Healthcare A/S</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Copenhagen</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 14.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz A/S</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Copenhagen</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Nordic A/S</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Copenhagen</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> DKK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ecuador</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Ecuador S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Quito</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Egypt</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma S.A.E.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cairo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EGP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 193.8</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.77%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Egypt Pharma S.A.E.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New Cairo City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EGP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 250&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Finland</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finland Oy</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Espoo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 459&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>As at December 31, 2017 </div> </td> <td></td> <td></td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share <br></br> capital <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br></br> interest </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">France</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Groupe France S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rueil-Malmaison</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 103.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma S.A.S.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rueil-Malmaison</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 43.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz S.A.S.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Levallois-Perret</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Laboratoires Alcon S.A.S.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rueil-Malmaison</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12.9</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Germany</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Deutschland GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Wehr</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 155.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Business Services GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Wehr</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Nuremberg</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.6</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Produktions GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Wehr</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz International GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Holzkirchen</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">1 A Pharma GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oberhaching</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">HEXAL AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Holzkirchen</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 93.7</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Salutas Pharma GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Barleben</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 42.1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aeropharm GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rudolstadt</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Pharma GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Freiburg im Breisgau</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 512&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CIBA Vision GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Grosswallstadt</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 15.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">WaveLight GmbH</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Erlangen</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.6</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Gibraltar</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novista Insurance Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Gibraltar City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 130.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Greece</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Hellas) S.A.C.I.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Metamorphosis/Athens</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 23.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratories Hellas- Commercial and Industrial S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Maroussi, Athens</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.7</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Hungary</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Hungary Healthcare Limited Liability Company</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Budapest</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HUF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 545.6</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Hungary Limited Liability Company</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Budapest</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> HUF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 883.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">India</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis India Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mumbai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 140.7</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 73.4%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Healthcare Private Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mumbai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 60.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Private Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mumbai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 32.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratories (India) Private Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bangalore</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> INR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Indonesia</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">PT. Novartis Indonesia</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Jakarta</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IDR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.7</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">PT. CIBA Vision Batam</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Batam</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> IDR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.9</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Ireland</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Ireland Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dublin</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Ringaskiddy Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ringaskiddy, County Cork</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratories Ireland Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cork City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 541&nbsp;251</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Israel</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Israel Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Petach Tikva</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ILS</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Optonol Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Neve-Ilan</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ILS</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 752&nbsp;545</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Italy</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Farma S.p.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Origgio</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz S.p.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Origgio</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.7</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Industrial Products S.p.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Rovereto</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.6</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Italia S.p.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Milan</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.7</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Japan</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Holding Japan K.K.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tokyo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma K.K.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tokyo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ciba-Geigy Japan Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tokyo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 8.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz K.K.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tokyo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Japan Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Tokyo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> JPY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Luxembourg</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Investments S.&#xe0; r.l.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Luxembourg-Ville</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finance S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Luxembourg-Ville</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Malaysia</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Corporation (Malaysia) Sdn. Bhd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kuala Lumpur</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MYR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.3</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratories (Malaysia) Sdn. Bhd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Petaling Jaya</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MYR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CIBA Vision Johor Sdn. Bhd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kuala Lumpur</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MYR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Mexico</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Farmac&#xe9;utica, S.A. de C.V.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mexico City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 205.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz, S.A. de C.V.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mexico City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 468.2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratorios, S.A. de C.V.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Mexico City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MXN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.9</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Morocco</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Maroc SA</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Casablanca</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> MAD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Netherlands</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Netherlands B.V.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Arnhem</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma B.V.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Arnhem</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz B.V.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Almere</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 907&nbsp;560</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Nederland B.V.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Arnhem</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18&nbsp;151</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">New Zealand</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis New Zealand Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Auckland</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NZD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 820&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>As at December 31, 2017 </div> </td> <td></td> <td></td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share <br></br> capital <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br></br> interest </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Norway</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Norge AS</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oslo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> NOK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Pakistan</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma (Pakistan) Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Karachi</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PKR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.9</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.99%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Panama</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma (Logistics), Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Panama City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Centroamerica S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Panama City</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PAB</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Philippines</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Healthcare Philippines, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Manila</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PHP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 298.8</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Philippines Corporation</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Manila</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PHP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 30.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Poland</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Poland Sp. z o.o.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Warszawa</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44.2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Polska Sp. z o.o.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Warszawa</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.6</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lek S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Strykow</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Polska Sp. z o.o.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Warszawa</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> PLN</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 750&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Portugal</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Portugal SGPS Lda.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Porto Salvo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 500&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Farma - Produtos Farmac&#xea;uticos S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Porto Salvo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Farmac&#xea;utica Lda.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Porto Salvo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 499&nbsp;900</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Portugal-Produtos e Equipamentos Oftalmol&#xf3;gicos Lda.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Porto Salvo</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Romania</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Services Romania S.R.L.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bucharest</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz S.R.L.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Targu-Mures</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 105.2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Romania S.R.L.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bucharest</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RON</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10.8</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Russian Federation</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma LLC</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Moscow</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Neva LLC</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">St. Petersburg</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.3</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">ZAO Sandoz</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Moscow</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 57.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Farmacevtika LLC</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Moscow</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> RUB</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 44.1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Saudi Arabia</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Saudi Pharmaceutical Distribution Co. Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Riyadh</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SAR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26.8</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 75%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Singapore</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Singapore) Pte Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Singapore</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Singapore Pharmaceutical Manufacturing Pte Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Singapore</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 45.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Asia Pacific Pharmaceuticals Pte Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Singapore</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 39.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Institute for Tropical Diseases Pte Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Singapore</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2&nbsp;004</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Pte Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Singapore</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 164&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Singapore Manufacturing Pte Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Singapore</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 101&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CIBA Vision Asian Manufacturing and Logistics Pte Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Singapore</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SGD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Slovakia</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Slovakia s.r.o.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bratislava</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Slovenia</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Lek Pharmaceuticals d.d.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ljubjana</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 48.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Pharmaceuticals d.d.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ljubjana</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">South Africa</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis South Africa (Pty) Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Midrand</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 86.3</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz South Africa (Pty) Ltd</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Kempton Park</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratories (South Africa) (Pty) Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Midrand</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> ZAR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 201&nbsp;820</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">South Korea</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Korea Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Seoul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> KRW</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 24.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.55%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Korea Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Seoul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> KRW</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 17.8</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Korea Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Seoul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> KRW</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33.8</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> bn</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Spain</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Farmac&#xe9;utica S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Barcelona</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 63.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Farmac&#xe9;utica S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Madrid</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 270&nbsp;450</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Industrial Products S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Les Franqueses del Vall&#xe9;s / Barcelona</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 9.3</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Cusi S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Barcelona</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 11.6</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Abadia Retuerta S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sard&#xf3;n de Duero/Valladolid</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> EUR</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Sweden</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Sverige AB</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">T&#xe4;by / Stockholm</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> SEK</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Switzerland</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis International AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Holding AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100.2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis International Pharmaceutical Investment AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Bioventures AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Forschungsstiftung</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Stiftung f&#xfc;r Kaderausbildung</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Mitarbeiterbeteiligungsstiftung</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Stiftung f&#xfc;r Mensch und Umwelt</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Stiftung der Novartis AG f&#xfc;r Erziehung, Ausbildung und Bildung</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 350.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis International Pharmaceutical AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Services AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Schweizerhalle AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Muttenz</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 18.9</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Stein AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Stein</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 251&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharma Schweiz AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Risch</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Pharmaceuticals AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Risch</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Switzerland SA</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Risch</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Pharmaceuticals Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fribourg</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 200&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Roche Holding AG</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Basel</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> CHF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 160.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 33/6 <sup style="white-space: nowrap"> 2</sup> </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> <br></br>As at December 31, 2017 </div> </td> <td></td> <td></td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Share <br></br> capital <sup style="white-space: nowrap"> 1</sup> </div> </td> <td></td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Equity <br></br> interest </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Taiwan</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Taiwan) Co., Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Taipei</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TWD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 170.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Thailand</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis (Thailand) Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bangkok</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> THB</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 302.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratories (Thailand) Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Bangkok</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> THB</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 228.1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Turkey</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Saglik, Gida ve Tarim &#xdc;r&#xfc;nleri Sanayi ve Ticaret A.S.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Istanbul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 98.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Farmanova Saglik Hizmetleri Ltd. Sti.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Istanbul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 6.7</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Ila&#xe7; Sanayi ve Ticaret A.S.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Istanbul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 165.2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 99.99%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Syntek Ila&#xe7; Hammaddeleri Sanayi ve Ticaret A.S.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Istanbul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 46.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Grup Saglik &#xdc;r&#xfc;nleri Ila&#xe7;lari Sanayi ve Ticaret A.S.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Gebze - Kocaeli</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 50.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratuvarlari Ticaret A.S.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Istanbul</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> TRY</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United Arab Emirates</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Middle East FZE</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Dubai</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> AED</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 7.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United Kingdom</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis UK Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frimley/Camberley</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals UK Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frimley/Camberley</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Grimsby Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frimley/Camberley</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 250.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Ziarco Group Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frimley/Camberley</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3&nbsp;904</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frimley/Camberley</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Eye Care UK Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Frimley/Camberley</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 550&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Glaxosmithkline Consumer Healthcare Holdings Limited</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Brentford, Middlesex</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> GBP</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 36.5%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">United States of America</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Corporation</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 72.2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Finance Corporation</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New York, NY</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Capital Corporation</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New York, NY</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Services, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis US Foundation</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New York, NY</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> --</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Pharmaceuticals Corporation</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">East Hanover, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.2</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Institutes for BioMedical Research, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> Cambridge, MA</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Corthera, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">San Mateo, CA</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">CoStim Pharmaceuticals Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cambridge, MA</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Encore Vision, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">New York, NY</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Navigate BioPharma Services, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Wilmington, NC</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Reprixys Pharmaceuticals Corporation</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Oklahoma City, OK</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Spinifex Pharmaceuticals, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Wilmington, NC</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Institute for Functional Genomics, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">San Diego, CA</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Princeton, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 25&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fougera Pharmaceuticals Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Melville, NY</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Eon Labs, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Princeton, NJ</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratories, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fort Worth, TX</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1&nbsp;000</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Refractivehorizons, LLC</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fort Worth, TX</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Research, Ltd.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fort Worth, TX</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 12.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Lensx, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aliso Viejo, CA</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Laboratories Holding Corporation</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Fort Worth, TX</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 10</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis Vaccines and Diagnostics, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Cambridge, MA</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 3</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">ClarVista Medical, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Aliso Viejo, CA</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Transcend Medical, Inc.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Menlo Park, CA</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> USD</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Venezuela</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"></div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Novartis de Venezuela, S.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Caracas</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VEF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.4</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon Pharmaceutical, C.A.</div> </td> <td align="right" width="9%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Caracas</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> VEF</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 5.5</div> </td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> m</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100%</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"></div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">In addition, the Group is represented by subsidiaries and associated companies in the following countries: Bosnia/Herzegovina, Bulgaria, Dominican Republic, Guatemala, Kenya, Latvia, the Former Yugoslav Republic of Macedonia, Nigeria, Peru, Puerto Rico, Ukraine and Uruguay </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;1&nbsp;</sup> Share capital may not reflect the taxable share capital and does not include any paid-in surplus </div> </td> </tr> <tr valign="bottom"> <td colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;margin-left:12pt; text-indent:-12pt;"> <sup>&nbsp;2&nbsp;</sup> Approximately 33% of voting shares; approximately 6% of total net income and equity attributable to Novartis </div> </td> </tr> <tr valign="bottom"> <td height="10px" colspan="10"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">m = million; bn = billion</div> </td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Innovative Medicines</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;591</div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;522</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Sandoz</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;61</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;65</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Alcon</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;57</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;4</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Total</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> &ndash;&nbsp;709</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> &ndash;&nbsp;591</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;">(USD millions)</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Total balance of gross trade <br></br>receivables from closely <br></br>monitored countries </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> <br></br> <br></br> 1&nbsp;733 </div> </td> <td align="right" width="1%"></td> <td align="right" width="14%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> <br></br> <br></br> 1&nbsp;717 </div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Past due for more than one year</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 124</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 82</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Provisions</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 95</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 63</div> </td> <td align="right"></td> </tr> <tr> <td colspan="6" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(CHF billions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Current assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-current <br></br> assets </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Current <br></br> liabilities </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Non-current <br></br> liabilities </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">December 31, 2016</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 28.7</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 61.4</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 22.6</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 27.8</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">June 30, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 56.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 20.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26.0</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br>(CHF billions) </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Revenue </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> <br></br> Net income </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Other <br></br> comprehen- <br></br> sive income </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Total <br></br> comprehen- <br></br> sive income </div> </td> <td></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;">December 31, 2016</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 50.6</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7.5</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.7</div> </td> <td align="right" width="1%"></td> <td align="right" width="9%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 8.2</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">June 30, 2017</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 26.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.6</div> </td> <td align="right"></td> </tr> <tr> <td colspan="10" style="border-bottom: solid #000000 1px;"></td> </tr> </table> </div> <div style="padding-top:10px; padding-bottom:30px;"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse" width="100%"> <tr valign="bottom"> <td height="10px"> <div style="font-family: arial, helvetica,sans-serif; font-size:10pt;color:#00ff00;"></div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"> 2017</div> </td> <td></td> <td align="center" colspan="5" height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> 2016</div> </td> <td></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr> <td height="1"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> <td colspan="5" style="border-bottom: solid #000000 1px;"></td> <td height="1"></td> </tr> <tr bgcolor="white"> <td height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> <td colspan="5" height="3"></td> <td height="1"></td> </tr> <tr valign="bottom"> <td height="12"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; font-weight:bold; color:#000000;"></div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Number <br></br> of shares <br></br> in millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> Weighted <br></br> average fair <br></br> value at grant <br></br> date in USD </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#000000;"> <br></br> Fair value at <br></br> grant date in <br></br> USD millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Number <br></br> of shares <br></br> in millions </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> Weighted <br></br> average fair <br></br> value at grant <br></br> date in USD </div> </td> <td></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:8pt; color:#666666;"> <br></br> Fair value at <br></br> grant date in <br></br> USD millions </div> </td> <td></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-vested shares at January 1</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 21.0</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 89.5</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;880</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 20.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 87.1</div> </td> <td align="right" width="1%"></td> <td align="right" width="7%"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;751</div> </td> <td align="right" width="1%"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Granted</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> </div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Annual incentive</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 69.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 90</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 73.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 7</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Share savings plans</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 69.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 312</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 78.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 344</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Select North America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 4.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 64.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 288</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 4.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 72.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 348</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Select outside North America</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 2.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 65.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 131</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 74.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 119</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Long-Term Performance Plan</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 71.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 100</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 1.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 79.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 95</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Long-Term Relative Performance Plan</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 0.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 47.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 19</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 58.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 18</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">&#x2013; Other share awards</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 1.3</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 67.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 88</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 0.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 65.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 46</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Vested</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;10.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 78.2</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;837</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;10.4</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 68.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;716</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 1px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;">Forfeited</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;1.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> 80.7</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#000000;"> &ndash;&nbsp;145</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;1.8</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> 73.1</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; color:#666666;"> &ndash;&nbsp;132</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 2px;"></td> </tr> <tr valign="bottom" bgcolor="#ffffff"> <td height="16"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;">Non-vested shares at December 31</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 23.9</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 80.6</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#000000;"> 1&nbsp;926</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 21.0</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 89.5</div> </td> <td align="right"></td> <td align="right"> <div style="font-family:arial,helvetica,sans-serif;font-size:10pt; font-weight:bold; color:#666666;"> 1&nbsp;880</div> </td> <td align="right"></td> </tr> <tr> <td colspan="14" style="border-bottom: solid #000000 3px;"></td> </tr> </table> </div> Included in this amount is a USD 450 million milestone payment received in late March 2015. Novartis has valued the contribution of 63.5% of its OTC Division in exchange for 36.5% of the GSK Consumer Healthcare business at fair value. In 2016, the total net tax payment amounted to USD 2,299 million, of which USD 188 million was included in the cash flows used in investing activities from discontinued operations. In 2015, the total net tax payment amounted to USD 3,325 million, of which a refund of USD 94 million was included in the cash flows used in operating activities from discontinued operations, and a USD 965 million payment in the cash flows from investing activities of discontinued operations. EX-101.LAB 6 nvs-20171231_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Switzerland, Francs Switzerland Document Type Non-current assets Total non-current assets Current assets Total current assets Assets Total assets Treasury shares Equity attributable to owners of parent Issued share capital and reserves attributable to Novartis AG shareholders Equity Total equity Non-current provisions Total non-current provisions Total non-current liabilities Non-current liabilities Current liabilities Total current liabilities Liabilities Total liabilities Equity and liabilities Total equity and liabilities Property, plant and equipment Goodwill Intangible assets other than goodwill Deferred tax assets Other non-current non-financial assets Current inventories Other current financial assets Cash and cash equivalents Issued capital Other reserves Non-controlling interests Trade and other non-current payables Deferred tax liabilities Other non-current financial liabilities Other non-current non-financial liabilities Other current financial liabilities Current tax liabilities, current Other current non-financial liabilities Inventories Share capital Reserves Other non-current assets Provisions and other non-current liabilities Financial debts Financial debts and derivative financial instruments Current income tax liabilities Provisions and other Non-current liabilities Provisions and other non-current liabilities Document and Entity Information Investments accounted for using equity method Investments in associated companies Non-current assets [abstract] Current assets [abstract] Treasury shares Equity and liabilities [abstract] Equity [abstract] Liabilities [abstract] Non-current liabilities [abstract] Current liabilities [abstract] Disclosure of detailed information about property, plant and equipment [abstract] Disclosure of detailed information about property, plant and equipment [table] Classes of property, plant and equipment [axis] Property, plant and equipment [member] Land [member] Land Buildings [member] Buildings Construction in progress [member] Construction in progress Machinery [member] Machinery and other equipment Disclosure of detailed information about property, plant and equipment [line items] Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis] Carrying amount [member] Gross carrying amount [member] Accumulated depreciation [member] Property, plant and equipment at beginning of period Property, plant and equipment at end of period Increase (decrease) through transfers from construction in progress, property, plant and equipment Reclassifications Additions other than through business combinations, property, plant and equipment Additions Disposals and retirements, property, plant and equipment Disposals and derecognitions Currency translation effects Increase (decrease) through net exchange differences, property, plant and equipment Depreciation, property, plant and equipment Depreciation charge Impairment charge Impairment loss recognised in profit or loss, property, plant and equipment Reversal of impairment loss recognised in profit or loss, property, plant and equipment Reversal of impairment charge Net book value of Property, plant and equipment under finance lease contracts Contractual commitments for acquisition of property, plant and equipment Commitments for purchases of property, plant and equipment Borrowing costs capitalised Capitalisation rate of borrowing costs eligible for capitalisation Borrowings, interest rate Interest rate on borrowings for new additions Capitalized borrowing costs Capitalization rate used to determine the amount of borrowing costs eligible for capitalization Statement [table] Statement [line items] Disclosure of property, plant and equipment [text block] Property, plant and equipment Property, plant and equipment [table text block] Movements of property, plant and equipment Inventories Disclosure [abstract] Disclosure of inventories [text block] Inventories Schedule of Inventory, Current [table text block] Inventories by class Inventory, Current [table] Inventory [Axis] Inventory [member] Inventory, Raw Materials, Gross [member] Raw material, consumables Inventory, Work in progress, Gross [member] Work in progress Finished products Inventory, Finished goods, Gross [member] Inventory [line items] Inventory Cost of inventories recognised as expense during period Amount of inventory recognized as expense Inventory write-down Inventory provisions Reversed inventory Provisions Reversal of inventory write-down Earnings per share [abstract] Earnings per share [text block] Earnings per share Schedule of Earnings Per Share, Basic and Diluted [table text block] Earnings per share Earnings per share [table] Earnings per share [line items] Continuing and discontinued operations [axis] Aggregate continuing and discontinued operations [member] Continuing operations [member] Discontinued operations [member] Profit/loss attributable to shareholders of Novartis AG Profit (loss), attributable to owners of parent Weighted average number of ordinary shares outstanding Weighted average number of shares outstanding used in the basic earnings per share Dilutive effect of share options on number of ordinary shares Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options Adjusted weighted average number of ordinary shares outstanding Weighted average number of shares in diluted earnings per share Basic earnings (loss) per share from continuing operation Basic earnings per share, Continuing operations Basic earnings (loss) per share from discontinued operations Basic earnings per share, Discontinued operations Basic earnings (loss) per share Total basic earnings per share Diluted earnings (loss) per share from continuing operations Diluted earnings (loss) per share from discontinued operations Diluted earnings (loss) per share Total diluted earnings per share Diluted earnings per share, Continuing operations Diluted earnings per share, Discontinued operations Assets [abstract] Statement of financial position [abstract] Disclosure of detailed information about intangible assets [abstract] Goodwill and intangible assets Goodwill and intangible assets Disclosure of intangible assets and goodwill [text block] Disclosure of Movements of goodwill and intangible assets [text block] Movements of goodwill and intangible assets Allocation of net book values of goodwill and intangible assets by reporting segment Assumptions used in the calculation of valuation [text block] Assumptions used in the calculation of valuation Allocation of net book values of goodwill and intangible assets by reporting segment [text block] Disclosure of IncomeTax [abstract] Disclosure of income tax [text block] Taxes Income Before Taxes [table text block] Income before taxes Current and deferred Income Tax Expense [table text block] Current and deferred income tax expense Analysis of Tax Rate [table text block] Analysis of tax rate Disclosure of Interest Expense and Other Financial Income and Expense [abstract] Disclosure of interest expense [text block] Interest expense and other financial income and expense Interest Expense [table text block] Interest expense Other Financial Income and Expense [table text block] Other financial income and expense Disclosure of Deferred Tax Assets and Liabilities [abstract] Disclosure of deferred taxes [text block] Deferred tax assets and liablities Schedule of Deferred Tax Assets and Liabilities [table text block] Schedule of Deferred Tax Assets and Liabilities Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets. Temporary Differences On Which No Deferred Tax Assets Have Been Provided [table text block] Temporary differences on which no deferred tax assets have been provided Disclosure of temporary difference, unused tax losses and unused tax credits [text block] Gross value of tax-loss carry-forwards Significant Accounting Policies [abstract] Disclosure of significant accounting policies [text block] Significant accounting policies Respective Useful Lives of property, plant and equipment [table text block] Respective Useful Lives of property, plant and equipment Respective Useful Lives of Available-for-Use Intangible Assets [table text block] Respective Useful Lives of Available-for-Use Intangible Assets Description of accounting policy for subsidiaries [text block] Scope of consolidation Description of accounting policy for foreign currency translation [text block] Foreign currencies Description of accounting policy for business combinations [text block] Acquisition of assets Description of accounting policy for property, plant and equipment [text block] Property plant and equipment Description of accounting policy for goodwill [text block] Goodwill Description of accounting policy for Intangible assets available-for-use [text block] Intangible assets available-for-use Description of accounting policy for Intangible assets not yet available-for-use [text block] Intangible assets not yet available-for-use Description of accounting policy for Impairment of goodwill and intangible assets [text block] Impairment of goodwill and intangible assets Description of accounting policy for Impairment of associated companies accounted for at equity [text block] Impairment of associated companies accounted for at equity Description of accounting policy for financial assets [text block] Cash and cash equivalents, marketable securities, commodities, derivative financial instruments and non-current financial assets Description of accounting policy for measuring inventories [text block] Inventories Description of accounting policy for trade and other receivables [text block] Trade receivables Description of accounting policy for provisions [text block] Legal and environmental liabilities Description of accounting policy for contingent liabilities and contingent assets [text block] Contingent consideration Description of accounting policy for employee benefits [text block] Defined benefit pension plans and other post retirement benefits Description of accounting policy for treasury shares [text block] Treasury Shares Description of accounting policy for recognition of revenue [text block] Revenue Description of accounting policy for research and development expense [text block] Research and development Description of accounting policy for share-based payment transactions [text block] Share based compensation Description of accounting policy for government grants [text block] Government grants Description of accounting policy for decommissioning, restoration and rehabilitation provisions [text block] Restructuring charges Description of accounting policy for income tax [text block] Taxes Description of accounting policy for non-current assets or disposal groups classified as held for sale [text block] Non-current assets held for sale Disclosure of expected impact of initial application of new standards or interpretations [text block] Status of adoption of significant new or amended IFRS standards or interpretations Property, plant and equipment [abstract] Useful lives or depreciation rates, property, plant and equipment Property, plant and equipment useful lives Range [axis] Ranges [member] Bottom of range [member] Top of range [member] Computer equipment [member] Furniture and vehicles [member] Furniture and vehicles Useful lives or amortisation rates, intangible assets other than goodwill Available for use intangible asset useful lives Classes of intangible assets other than goodwill [axis] Intangible assets other than goodwill [member] Brand names [member] Other intangible assets [member] Technology-based intangible assets [member] Marketing related intangible assets [member] Currently marketed products [member] Income statement location [axis] Income statement location [member] Cost of sales [member] Cost of sales or Research and Development [member] Interest expense [abstract] Expense due to unwinding of discount on provisions Interest expense Income/expense arising from discounting long-term liabilities Interest expense Total Interest Expense Other financial income and expense [abstract] Income on forward contracts and options Gains (losses) on net monetary position Monetary loss from hyperinflation Foreign exchange gain (loss) Currency result, net Major components of tax expense (income) [abstract] Geographical areas [axis] Geographical areas [member] Country of domicile [member] Foreign countries [member] Switzerland Foreign Profit (loss) before tax Profit (loss) before tax, discontinued operations Accounting profit Income before taxes from continuing operations Income loss before taxes from discontinued operations Total Income before taxes Tax expense (income), continuing operations Income tax expense from continuing operations Income tax expense Total Income Tax Expense Current tax expense (income) continuing operations Current income tax expense from continuing operations Deferred tax expense (income) continuing operations Deferred income tax expense from continuing operations Reconciliation of average effective tax rate and applicable tax rate [abstract] Applicable tax rate Applicable tax rate Tax rate, effect of credits and allowances Effect of tax credits and allowances Tax rate, effect of write off of deferred tax assets Effect of write off of deferred tax assets Tax rate, effect from write down and reversal of write down of invest subsidiaries Effect of write down and reversal of write down of investments in subsidiaries Effect of tax benefits expiring in 2017 Tax rate, effect from benefits expiring Effect of non-deductible losses in Venezuela Tax rate effect of adjustments for current tax of prior periods Effect of prior year items Effect of other items Other tax rate effects for reconciliation between accounting profit and tax expense (income) Average effective tax rate continuing operations Effective tax rate for continuing operations Effective tax rate for discontinued operations Average effective tax rate discontinued operations Effective tax rate Average effective tax rate Deferred tax assets and liabilities [abstract] Assets and liabilities [axis] Assets and liabilities [member] Pensions and other benefit obligations of associates [member] Inventories [member] Tax loss carryforwards [member] Other assets, provisions and accruals [member] Deferred tax assets Deferred tax liabilities Deferred tax liability (asset) Net deferred tax balance Credited/(charged) to income Deferred tax expense (income) recognised in profit or loss Deferred tax relating to items credited (charged) directly to equity Charged to equity Income tax relating to components of other comprehensive income Credited/(charged) to other comprehensive income Increase (decrease) through business combinations, deferred tax liability (asset) Impact of business combinations Increase (decrease) through other movements deferred tax liability (asset) Other movements Offsetting of deferred tax assets and liabilities within the same tax jurisdiction Temporary differences on which no deferred tax assets have been provided [abstract] Investments in subsidiaries [member] Goodwill from acquisitions [member] Deductible temporary differences for which no deferred tax asset is recognised Temporary differences on which no deferred tax has been provided as they are permanent in nature Disclosure of temporary difference, unused tax losses and unused tax credits [abstract] Disclosure of temporary difference, unused tax losses and unused tax credits [table] Balance sheet treatment [axis] Balance sheet treatment [member] Capitalized [member] Not capitalized [member] Year of expiry [axis] Year of expiry [member] One year [member] Two years [member] Three years [member] Four years [member] Five years [member] More than five years [member] Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets Value of tax loss carryforwards expired Tax loss carryforwards expired Deferred tax asset expected to have an impact on current taxes payable after more than 12 months Deferred tax liabilities expected to have an impact on current taxes payable after more than 12 months Unremitted earnings retained by consolidated entities for reinvestment Provision for income taxes on unremitted earnings Net capital losses on available-for-sale securities Gains (losses) on available-for-sale financial assets Disclosure of financial and other non-current assets [abstract] Disclosure of financial and other non-current assets [text block] Financial and other non-current assets Disclosure of financial assets [table text block] Financial assets Disclosure of other non-current assets [table text block] Other non-current assets Disclosure of minimum finance lease payments [table text block] Minimum finance lease payments Disclosure of finance lease and operating lease by lessor [abstract] Disclosure of finance lease and operating lease by lessor [table] Other current assets [abstract] Disclosure of other current assets [text block] Other current assets Other current assets [table text block] Other current assets Current value added tax receivables VAT Receivable Withholding tax recoverable Current income tax receivable Income tax receivable Prepaid expenses - third party Current prepaid expenses associated companies Prepaid expenses - associated companies Receivables associated companies Other receivables and current assets Total other current assets Other current non-financial assets Disclosure of marketable securities commodities deposits derivative instruments and cash [abstract] Disclosure of marketable securities commodities deposits derivative instruments and cash [text block] Disclosure of marketable securities commodities deposits derivative instruments and cash Marketable securities, commodities, timedeposits, and derivative financial instruments [table text block] Marketable securities, commodities, timedeposits, and derivative financial instruments Cash and cash equivalents [table text block] Cash and cash equivalents Debt instruments held Debt securities Equity instruments held Equity securities Fund instruments held Fund investments Commodities Short-term deposits, not classified as cash equivalents Time deposits with original maturity more than 90 days Derivative financial instruments Derivative financial assets Interest receivable Accrued interest on debt securities and time deposits Available for sale marketable securities Total available for sale marketable securities Current accounts Cash Cash and cash equivalents [abstract] Total cash and cash equivalents Time deposits and short term investments with original maturity less than 90 days Cash equivalents Debt securities denominations [abstract] Debt securities denominated in other currencies Currency [axis] Computer equipment Movement in deferred tax balance [roll forward] Net deferred tax balance at beginning of period Net deferred tax balance at end of period Net deferred tax assets Net deferred tax liabilities Gross deferred tax assets Gross deferred tax liabilities Disclosure of financial assets [abstract] Contingent Consideration Receivable Contingent consideration receivables Financial assets Non-current financial assets Total financial assets Non-current loans and receivables Minimum finance lease payments receivable, at present value Non-current trade receivables Non-current financial assets available-for-sale Available-for-sale long-term financial investments Long-term receivables from customers Minimum lease payments from finance lease agreements, at present value Long-term loans, advances and security deposits Disclosure of other non-current assets [abstract] Other non-current assets Total other non-current assets Deferred compensation plans assets Prepaid post-employment benefit plans assets Disclosure of finance lease and operating lease by lessor [line items] Maturity [axis] Aggregated time bands [member] Not later than one year [member] Later than one year and not later than five years [member] Later than five years [member] Not later than one year Between one and five years Later than five years Gross investment in finance lease Total future payments Unearned finance income on finance lease Unearned interest income Finance lease provision Provision Non-current finance lease receivables Profit or loss [abstract] Consolidated income statements [abstract] Revenue from sale of goods Net sales from continuing operations Other revenue Other revenues Cost of sales Cost of goods sold Gross profit Gross profit from continuing operations Sales and marketing expense Marketing and Sales Research and development expense Research and Development Other income Profit (loss) from operating activities Operating income from continuing operations Share of profit (loss) of associates and joint ventures accounted for using equity method Income from associated companies Profit (loss) from continuing operations Net income from continuing operations Taxes Profit (loss) from discontinued operations Net income/loss from discontinued operations Profit (loss) Net income Profit (loss), attributable to [abstract] Profit (loss), attributable to non-controlling interests Non-controlling interests Basic earnings per share [abstract] Continuing operations Discontinued operations Diluted earnings per share [abstract] Continuing operations Discontinued operations -Total Income before taxes from continuing operations Disclosure of classes of share capital [abstract] Movement in the share capital [table text block] Schedule disclosing information related to movement in the share capital Movement in the shares [table text block] Schedule disclosing information related to movement in the shares Disclosure of classes of share capital [table] Disclosure of classes of share capital [line items] Classes of share capital [axis] Share capital [member] Increase (decrease) in equity Movement in the year Treasury shares [member] Ordinary shares [member] Number of shares issued and fully paid Number of shares outstanding Increase (decrease) in number of shares outstanding Number of shares outstanding at beginning of period Number of shares outstanding at end of period Number of shares issued and fully paid at beginning of period Number of shares issued and fully paid at end of period Share capital at beginning of period Share capital at end of period Treasury shares at end of period Treasury shares at beginning of period Equity at end of period Equity at beginning of period Purchase of treasury shares Sale or issue of treasury shares Disclosure of non-adjusting events after reporting period [abstract] Disclosure of events after reporting period [text block] Events subsequent to the December 31 consolidated balance sheet date Subsequent Event Typ [axis] Subsequent Event Type [member] Subsequent Event [member] Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners Commitments and contingencies [abstract] Disclosure of commitments and contingencies [text block] Commitments and contingencies Disclosure of significant transactions [abstract] Disclosure of Significant transactions [text block] Significant transactions Disclosure of financial liabilities [abstract] Disclosure of financial liabilities [text block] Non-current financial debt Disclosure of current financial debt and derivative instruments [abstract] Disclosure of current financial debt and derivative instruments [text block] Current financial debt and derivative financial instruments Disclosure of non-current portion of non-current borrowings by type [table text block] Disclosure of non-current portion of non-current borrowings by type Disclosure of detailed information about borrowings Disclosure of detailed information about borrowings [table text block] Disclosure of non-current financial debt including current portion by maturity [table text block] Non-current financial debt including current portion by maturity Disclosure of non-current financial debt including current portion by currency [table text block] Non-current financial debt including current portion by currency Disclosure of comparison of balance sheet and fair value of total non-current financial debt including current portion [table text block] Comparison of balance sheet and fair value of total non-current financial debt including current portion Disclosure of collaerallized non-current financial debt and pledged assets [table text block] Collaerallized non-current financial debt and pledged assets Disclosure of current financial debt and derivative instruments [table text block] Current financial debt and derivative instruments Disclosure of Leasing commitments [table text block] Leasing commitments Disclosure of research and development commitments [table text block] Research and Development and other intangible purchase commitments Leasing commitments [abstract] Schedule for commitments under fixed term operating leases [table] Schedule for commitments under fixed term operating leases [line items] Later than one year and not later than two years [member] Later than two years and not later than three years [member] Later than three years and not later than four years [member] Later than four years and not later than five years [member] Lease and sublease payments recognised as expense Expense of current year Research and development and other intangible asset purchase commitments [abstract] Schedule for commitments under research and development and other intangible asset purchase [table] Schedule for commitments under research and development and other intangible asset purchase [line items] Commitments under long-term research and development agreements Current financial debt and derivative financial instruments [table] Current financial debt and derivative financial instruments [line items] Interest bearning accounts of associates payable on demand Current borrowings Bank and other financial debt Commercial papers issued Commercial Papers Current portion of non-current borrowings Current portion of non-current financial debt Credit derivative, fair value Derivative financial liabilities Fair value of derivative financial instruments Weighted average interest rate, associates Total current financial debt and derivative financial instruments Interest expense Disclosure of components of non-current financial debts [abstract] Disclosure of components of non-current financial debts [table] Disclosure of components of non-current financial debts [line items] Straight bonds Bonds issued Total including current portion of non-current financial debt Borrowings Less current portion of non-current financial debt Total non-current financial debts The amount of outstanding funds that the entity is obligated to repay Later than five years and not later than six years [member] Later than six years [member] Later than six years Others Disclosure of the collateralized non-current financial debt and pledged assets [abstract] Disclosure of the collateralized non-current financial debt and pledged assets [table] Disclosure of the collateralized non-current financial debt and pledged assets [line items] Property, plant and equipment, pledged as security Non-current financial debts covered by collateral Total amount of collateralized non-current financial debts Total net book value of property, plant and equipment pledged as collateral for non-current financial debts Disclosure of detailed information about borrowings [abstract] Disclosure of detailed information about borrowings [table] Disclosure of detailed information about borrowings [line items] Borrowings by name [axis] Borrowings by name [member] 4.25% EUR 1 500 million bond 2009/2016 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.757% [member] 4.4% USD 1 000 million bond 2010/2020 of Novartis Capital Corporation, New York United States, issued at 99.237% [member] 2.4% USD 1 500 million bond 2012/2022 of Novartis Capital Corporation, New York United States, issued at 99.225% [member] 3.7% USD 500 million bond 2012/2042 of Novartis Capital Corporation, New York United States, issued at 98.325% [member] 3.4% USD 2 150 million bond 2014/2024 of Novartis Capital Corporation, New York United States, issued at 99.287% [member] 4.4% USD 1 850 million bond 2014/2044 of Novartis Capital Corporation, New York United States, issued at 99.196% [member] 0.75% EUR 600 million bond 2014/2021 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.134% [member] 1.625% EUR 600 million bond 2014/2026 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.697% [member] 0.25% CHF 500 million bond 2015/2025 of Novartis AG Basel Switzerland, issued at 100.64% [member] 0.625% CHF 550 million bond 2015/2029 of Novartis AG Basel Switzerland, issued at 100.502% [member] 1.050% CHF 325 million bond 2015/2035 of Novartis AG Basel Switzerland, issued at 100.479% [member] 3.0% USD 1 750 million bond 2015/2025 of Novartis Capital Corporation, New York United States, issued at 99.010% [member] 4.0% USD 1 250 million bond 2015/2045 of Novartis Capital Corporation, New York United States, issued at 98.029% [member] 0.125% EUR 1 250 million bond 2016/2023 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.127% [member] 0.625% EUR 500 million bond 2016/2028 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 98.48% [member] Notional amount Borrowings, original currency Borrowings, maturity Borrowings, lender Borrowings, premium discount Disclosure of fair value measurement of liabilities [abstract] Disclosure of fair value measurement of liabilities [table] Disclosure of fair value measurement of liabilities [line items] Levels of fair value hierarchy [axis] All levels of fair value hierarchy [member] Level 1 of fair value hierarchy [member] Level 2 of fair value hierarchy [member] Level 3 of fair value hierarchy [member] Other non-current financial debt Others Total Fair value by measurement basis [axis] Fair value by measurement basis [member] Carrying reported amount fair value disclosure [member] Fair value disclosure item amounts [member] Fair values Balance sheet Statement of comprehensive income [abstract] Net income Components of other comprehensive income that will not be reclassified to profit or loss, net of tax [abstract] Other comprehensive income never to be recycled into the consolidated income statement Other comprehensive income, net of tax, available-for-sale financial assets Fair value adjustments on marketable securities, net of taxes Fair value adjustments on deferred cash flow hedges, net of taxes Other comprehensive income, net of tax, financial instruments Total fair value adjustments on financial instruments, net of taxes Other comprehensive income, net of tax, exchange differences on translation Currency translation effects Other comprehensive income that will be reclassified to profit or loss, net of tax Total of items to eventually recycle Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract] Other comprehensive income to be eventually recycled into the consolidated income statement Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans Actuarial gains/losses from defined benefit plans, net of taxes Comprehensive income Total comprehensive income Comprehensive income attributable to [abstract] Attributable to Comprehensive income, attributable to owners of parent Shareholders of Novartis AG Comprehensive income, attributable to non-controlling interests Non-controlling interests Continuing operations Discontinued operations Other financial income and expense Total other financial income and expense Other financial income and expense Other financial income and expense Revenue from sale of goods, sales to discontinued segments Sales to discontinued segments Attributable to Statement of cash flows [abstract] Statement of changes in equity [abstract] Statement of changes in equity [table] Components of equity [axis] Equity [member] Equity attributable to owners of parent [member] Non-controlling interests [member] Issued capital [member] Retained earnings [member] Statement of changes in equity [line items] Other comprehensive income Dividends recognised as distributions to owners Dividends Exercise of options and employee transactions Equity-based compensation Increase/decrease of treasury share repurchase obligation under a share buyback trading plan Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity Impact of change in ownership of consolidated entities Total of other equity movements Reduction of share capital Fair value adjustments related to divestments Share capital Treasury shares Retained earnings Other comprehensive income, net of tax, fair value adjustments on deferred cash flow hedges Interest received, classified as operating activities Interest received Interest paid, classified as operating activities Interest paid Income taxes paid (refund), classified as operating activities Taxes paid Cash flows before working capital and provision changes from continuing operations Payments out of provisions and other net cash movements in non-current liabilities Change in net current assets and other operating cash flow items Cash flows from (used in) operating activities, continuing operations Cash flows from operating activities from continuing operations Cash flows from (used in) operating activities, discontinued operations Cash flows used in operating activities from discontinued operations Cash flows from (used in) operating activities Total cash flows from operating activities Purchase of property, plant and equipment, classified as investing activities Purchase of property, plant and equipment Proceeds from sales of property, plant and equipment Purchase of intangible assets, classified as investing activities Purchase of intangible assets Proceeds from sales of intangible assets, classified as investing activities Proceeds from sales of intangible assets Purchase of financial assets, classified as investing activities Purchase of financial assets Proceeds from sales of financial assets, classified as investing activities Proceeds from sales of financial assets Purchase of other long-term assets, classified as investing activities Purchase of other non-current assets Proceeds from sales of other long-term assets, classified as investing activities Proceeds from sales of other non-current assets Other cash payments to acquire equity or debt instruments of other entities, classified as investing activities Purchase of marketable securities and commodities Other cash receipts from sales of equity or debt instruments of other entities, classified as investing activities Proceeds from sales of marketable securities and commodities Cash flows from (used in) investing activities, continuing operations Cash flows used in investing activities from continuing operations Cash flows from (used in) investing activities, discontinued operations Cash flows used in/from investing activities from discontinued operations Cash flows from (used in) investing activities Total cash flows used in/from investing activities Payments to acquire or redeem entity's shares Acquisition of treasury shares Proceeds from exercise options and other treasury share transactions Cash flows from (used in) financing activities Cash flows used in financing activities Effect of exchange rate changes on cash and cash equivalents Increase (decrease) in cash and cash equivalents Net change in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash flows before working capital and provision changes 5.125% USD 3 000 million bond 2009/2019 of Novaritis Securities Investment Ltd., Hamilton, Bermuda issued at 99.822% [member] Borrowings, issuance date Currency, others [member] Equity-based compensation, equity impact Less current portion of non-current financial debt Disclosure of detailed information about business combination [abstract] Disclosure of detailed information about business combination [table] Disclosure of detailed information about business combination [line items] Subsidiaries [axis] Entity's total for subsidiaries [member] Subsidiaries [member] Operating income [member] Transcend Medical Inc [member] Transcend Medical Inc. Selexys Pharmaceuticals Corporation [member] Selexys Pharmaceuticals Corporation Ziarco Group Limited [member] Ziarco Group Limited Encore Vision, Inc [member] Encore Vision, Inc. Eli Lilly and Company [member] Eli Lilly and Company GSK Oncology Products [member] GSK Oncology Products GSK Vaccines [member] GSK Vaccines GSK Consumer Healthcare [member] GSK Consumer Healthcare GSK Total Transaction [member] GSK Total Transaction CSL [member] CSL Spinifex [member] Spinifex Admune Theraputics [member] Admune Theraputics Consideration transferred, acquisition-date fair value Portion of consideration paid (received) consisting of cash and cash equivalents Contingent liabilities recognised as of acquisition date Identifiable assets acquired (liabilities assumed) Additional recognition, goodwill Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage Acquisition-date fair value of equity interest in acquiree held by acquirer immediately before acquisition date Gain (loss) recognised as result of remeasuring to fair value equity interest in acquiree held by acquirer before business combination Percentage of voting equity interests acquired Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations Description of arrangement for contingent consideration arrangements and indemnification assets Disclosure of provisions and other current liabilities [abstract] Disclosure of provisions and other current liabilities explanatory [text block] Provisions and other current liabilities Disclosure of acquisition of businesses [abstract] Disclosure of business combinations [text block] Acquisition of businesses Disclosure of defined benefit plans [abstract] Disclosure of employee benefits [text block] Schedule of provisions and other current liabilities [table text block] Provisions and other current liabilities Provisions for reduction of revenue [table text block] Provisions for reduction of revenue Restructuring provisions movements [table text block] Restructuring provisions movements Fair value of assets and liabilities arising from acquisitions [table text block] Fair value of assets and liabilities arising from acquisitions Disclosure of defined benefit plans [table text block] Summary of the funded and unfunded defined benefit obligation for pension and other post retirement benefit plans table Disclosure of net defined benefit liability (asset) [table text block] Reconciliation of the net liability table Breakdown of defined benefit obligation for pension plans [table text block] Breakdown of the DBO for pension plans by geography and type of member and the breakdown of plan assets Schedule of assumptions used [table text block] Principal weighted average actuarial assumptions Schedule of sensitivity analysis for actuarial assumptions [table text block] The sensitivity of the defined benefit pension obligation to the principal actuarial assumptions Schedule of health care cost trend rates [table text block] The healthcare cost trend rate assumptions used for other post-employment benefits Schedule of allocation of plan assets [table text block] The weighted average plan asset allocation of funded defined benefit pension plans Schedule of expected benefit payments [table text block] The expected future cash flows in respect of pension and other post- employment benefit plans Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [abstract] Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [table] Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items] Currently marketed products intangible assets recognised as of acquisition date Currently marketed products Acquired research and development intangible assets recognised as of acquisition date Acquired research and development Other intangible assets recognised as of acquisition date Other intangible assets Deferred tax assets recognised as of acquisition date Deferred tax assets Inventory recognised as of acquisition date Inventories Trade receivables and other current assets recognised as of acquisition date Trade receivables and other current assets Cash and cash equivalents recognised as of acquisition date Cash and cash equivalents Net assets recognized as a result of business combinations Goodwill as of acquisition date Goodwill Goodwill expected to be deductible for tax purposes Provisions and other current liabilities [table] Potentially refundable consideration from acquisition Fair value of potentially refundable contingent consideration Contract right of first negotiation term Revenue of acquiree since acquisition date Revenue of acquiree full year Sale of business assets arising from contingencies amount recognized Sale of business assets arising from contingencies amount recognized other than at fair value Sale of business, contingent consideration arrangements, range of outcomes, value, high Sale of business, contingent option arrangements, range of outcomes, value, high Sale of business, contingent option arrangements, fee paid Investments in subsidiaries, joint ventures and associates Percentage of voting equity interests contributed Transaction related costs Transaction related costs paid Impairment loss Reversal of impairment loss Provisions and other current liabilities [line items] Accrual for taxes other than income taxes, current Current restructuring provision Restructuring provisions Accrued royalties payable classified as current Accruals for royalties Taxes other than income taxes Refunds provision Provisions for deductions from revenue Short-term employee benefits accruals Accurals for compensation and benefits including social security Deferred income classified as current Deferred income Current legal proceedings provision Provisions for product liabilities, governmental investigations and other legal matters Other current payables Other payables Provisions for deductions from revenue [roll forward] Classes of other provisions [axis] Other provisions [member] Refunds provision [member] Deductions from revenue Other provisions Provision at end of period Provision at beginning of period Decrease through loss of control of subsidiary, other provisions Provisions related to discontinued operations Acquisitions through business combinations, other provisions Impact of business combinations Additional provisions, other provisions Additions Provision used, other provisions Payments/utilizations Changes in offset against gross trade receivables Increase (decrease) through net exchange differences, other provisions Currency translation effects Unused provision reversed, other provisions Cash payments Releases Restructuring provision [member] Restructuring provision Restructuring provisions movements [roll forward] Disclosure of trade receivables [abstract] Disclosure of trade receivables explanatory [text block] Trade receivables Provisions for trade receivables [table text block] Provisions for trade receivables Trade receivables provision movements [table text block] Trade receivables provision movements Overdue amounts and related provisions [table text block] Overdue amounts and related provision Trade receivables denominated in other currencies [table text block] Trade receivables denominated in other currencies Disclosure of provision matrix [abstract] Disclosure of provision matrix [table] Disclosure of provision matrix [line items] Classes of financial instruments [axis] Financial instruments, class [member] Trade receivables [member] Current trade receivables Total trade receivables, net Provisions for doubtful trade receivables related to discontinued operations Provisions for doubtful trade receivables charged to the consolidated income statement Utilization of reversal of provisions for doubtful trade receivables Analysis of overdue amounts [table] Past due status [axis] Past due status [member] Current [member] Analysis of overdue amounts [line items] Disclosure of receivables denominated in various currencies [table] Current trade receivables from closely monitored countries Current trade receivables from closely monitored countries past due more than one year Current trade receivables from closely monitored countries past due more than one year, provisions recorded Disclosure of subsidiaries [abstract] Disclosure of subsidiaries [text block] Principal Group subsidiaries and associated companies Principal Group subsidiaries and associated companies [table text block] Principal Group subsidiaries and associated companies Disclosure of subsidiaries [table] Disclosure of subsidiaries [line items] Name of subsidiary Principal place of business of subsidiary Country of incorporation of subsidiary Proportion of ownership interest in subsidiary Proportion of voting rights held in subsidiary Share/paid-in capital Societe par actions SANDOZ, Algiers [member] Novartis Argentina S.A., Buenos Aires [member] Alcon Laboratorios S.A., Buenos Aires [member] Roche Holding AG, Basel [member] Disclosure of defined benefit plans [table] Disclosure of defined benefit plans [line items] Disclosure of net defined benefit liability (asset) [line items] Rest of the world Defined benefit plans [member] Domestic defined benefit plans [member] Foreign defined benefit plans [member] Concentration of major plans, geographic Description of the major plans and the concentration of the Group's DBO by geography. Description of plan amendments, curtailments and settlements Defined benefit plan, recognized net gain (loss) due to curtailments Net Pre-tax curtailment gain (loss) Defined benefit plans [axis] Retirement plan type [axis] Retirement plan type [member] Pension plan [member] Other post-employment benefit plans [member] Pension plans Other post-employment benefit plans Defined benefit obligation, at present value Benefit obligation at beginning of period Benefit obligation at end of period Current service cost, net defined benefit liability (asset) Current service cost Defined benefit plan, interest cost Interest cost The increase in a defined benefit pension plan's projected benefit obligation or a defined benefit postretirement plan's accumulated postretirement benefit obligation due to the passage of time. Administrative expenses Actuarial gains (losses) arising from changes in financial assumptions, net defined benefit liability (asset) Remeasurement losses/(gains) arising from changes in financial assumptions Actuarial gains (losses) arising from changes in demographic assumptions, net defined benefit liability (asset) Remeasurement (gains) arising from changes in demographic assumptions Experience-related remeasurement losses/(gains) Currency translation effects Payments from plan, net defined benefit liability (asset) Benefit payments Contributions to plan by plan participants, net defined benefit liability (asset) Contributions of associates Increase (decrease) through acquisitions, divestments or transfers, benefit obligation Effect of acquisitions, divestments or transfers Plan assets, at fair value Fair value of plan assets at beginning of period Fair value of plan assets at end of period Interest expense (income), defined benefit liability (asset) Interest income Return on plan assets excluding interest income, net defined benefit liability (asset) Return on plan assets excluding interest income Currency translation effects Contributions to plan by employer, net defined benefit liability (asset) Novartis Group contributions Defined Benefit Plan, Settlements, Plan Assets Settlements Increase (decrease) through acquisitions, divestments or transfers, defined benefit liability (asset) Effect of acquisitions, divestments or transfers Defined benefit plan, change in benefit obligation [roll forward] Defined benefit plan, change in fair value of plan assets [roll forward] Surplus (deficit) in plan Funded status Defined benefit plan, change in limitation on recognition of fund surplus [roll forward] Net defined benefit liability (asset) Net liability in the balance sheet at end of period Limitation on recognition of fund surplus Limitation on recognition of fund surplus at beginning of period Limitation on recognition of fund surplus at end of period Change in limitation on recognition of fund surplus Change in limitation on recognition of fund surplus (incl. exchange rate differences) Interest income on limitation of fund surplus Interest income on limitation of fund surplus Disclosure of net defined benefit liability (asset) [table] Defined benefit plan, change in net liability [roll forward] Net liability at end of period Net liability at beginning of period Interest expense (income), net defined benefit liability (asset) Net interest expense Gain (loss) on remeasurement, net defined benefit liability (asset) Remeasurements Increase (decrease) through changes in foreign exchange rates, net defined benefit liability (asset) Currency translation effects Increase (decrease) through acquisitions, divestments or transfers, net defined benefit liability (asset) Effect of acquisitions, divestments or transfers Amounts recognized in the consolidated balance sheet [abstract] Accrued benefit liability Defined benefit pension plan, accrued benefit liability Breakdown of defined benefit obligation for pension plans [table] Obligation by type [axis] Obligation by type [member] Unfunded [member] Obligation by type Unfunded Active [member] Active Deferred pensioners [member] Deferred pensioners Pensioners [member] Pensioners Schedule of defined benefit plans disclosures [table] Actuarial assumption of discount rates Discount rate Actuarial assumption of expected rates of pension increases Expected rate of pension increase Actuarial assumption of expected rates of salary increases Expected rate of salary increase Actuarial assumption of expected rates of interest on savings account Interest on savings account Defined benefit assumption life expectancy, male Current life expectancy for a 65-year-old male Defined benefit assumption life expectancy, female Current life expectancy for a 65-year-old female Disclosure of sensitivity analysis for actuarial assumptions [table] Disclosure of sensitivity analysis for actuarial assumptions [line items] Actuarial assumptions [axis] Actuarial assumptions [member] Actuarial assumption of discount rates [member] Discount rate Life expectancy [member] Life expectancy Actuarial assumption of expected rates of pension increases [member] Rate of pension increase Actuarial assumption of expected rates of interest on savings account [member] Interest on savings account Actuarial assumption of expected rates of salary increases [member] Salary increase Change in actuarial assumption [axis] Change in actuarial assumption [member] Decrease, 25 basis point [member] 25 basis point decrease Increase, 25 basis point [member] 25 basis point increase Increase, 1 year [member] 1 year increase Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption Schedule of health care cost trend rates [table] Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year Healthcare cost trend rate assumed for next year Defined Benefit Plan, Health Care Cost Trend Rate Assumed to Decline Rate to which the cost trend rate is assumed to decline Defined Benefit Plan, Year that Rate Reaches Ultimate Trend Rate Year that the rate reaches the ultimate trend rate Schedule of allocation of plan assets [table] Classes of assets [axis] Assets [member] Equity investments [member] Equity securities Debt securities [member] Debt securities Real estate [member] Real estate Alternative investments [member] Alternative investments Cash and other investments [member] Cash and other investments Defined benefit plan, target plan asset allocations range minimum Defined benefit plan, target plan asset allocations range maximum Defined benefit plan, plan asset allocations Shares held by defined benefit plan Value of shares held by defined benefit plan Weighted average duration of defined benefit obligation years Defined contribution pension and other post-retirement plans disclosure [abstract] Defined contribution pension and other post-retirement plans disclosure [table] Defined contribution pension and other post-retirement plans disclosure [line items] Post-employment benefit expense, defined contribution plans Schedule of expected benefit payments [table ] Defined benefit plan, expected future benefit payment [abstract] Defined benefit plan, expected future employer contributions [abstract] Novartis Group contributions Expected future benefit payments Contributions, next fiscal year (estimated) Expected future benefit payment Past service cost and settlements Past service cost and gains losses arising from settlements, defined benefit liability (asset) Defined benefit plan, expected future employer contributions, next fiscal year Analysis of income and expense [abstract] Disclosure of discontinued operations [text block] Discontinued operations Disclosure of details to the consolidated cash flow statements [abstract] Details to the consolidated cash flow statements Disclosure of cash flow statement [text block] Adjustments for non-cash items from continuing operations [table text block] Adjustments for non-cash items from continuing operations Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations [table text block] Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations Cash flows arising from acquisitions and divestments of businesses [table text block] Cash flows arising from acquisitions and divestments of businesses Cash flows from discontinued operations [table text block] Cash flows from discontinued operations Consolidated income statement segmentation [table text block] Consolidated income statement segmentation Expenses included in net income [table text block] Expenses included in net income Revenue from sale of goods, sales to continuing segments Sales to continuing segments Segments [axis] Segments [member] Vaccines [member] Consumer Health [member] Corporate [member] Vaccines Consumer Health Corporate Operating income/loss of discontinued operations Operating income/loss of discontinued operations Income tax expense of discontinued operations Income tax expense of discontinued operations Net income from discontinued operations Net sales to third parties of discontinued operations Net sales of discontinued operations Gross profit of discontinued operations Depreciation expense Amortisation expense Impairment loss (reversal of impairment loss) recognised in profit or loss Expense from share-based payment transactions with employees Equity-based compensation of Novartis equity plans Intangible assets and goodwill [member] Intangible assets Property, plant and equipment Financial assets impaired [member] Financial assets Depreciation, amortisation and impairment loss (reversal of impairment loss) recognised in profit or loss [abstract] Depreciation, amortization and impairments on: Adjustments for losses (gains) on disposal of non-current assets Gains on disposal of property, plant and equipment, intangible, financial and other non-current assets, net Adjustment for share based payments Equity-based and settled compensation expense Adjustment for change in provisions and other non-current liabilities Change in provisions and other non-current liabilities Adjustments for finance income (cost) Net financial expense Adjustments for decrease (increase) in inventories (Increase) in inventories Adjustments for decrease (increase) in trade accounts receivable (Increase) in trade receivables Adjustments for decrease (increase) in trade accounts payable (Decrease)/Increase in trade payables Other inflows (outflows) of cash Change in other net current assets and other operating cash flow items Total Purchase of financial and other non-current assets, net, classified as investing activities Purchase of financial and other non-current assets, net Increase (decrease) in cash and cash equivalents, discontinued operations Total net cash flows used in/from discontinued operations Acquisitions and divestments [axis] Acquisitions and divestments [member] Acquisitions [member] Acquisitions Divestments [member] Divestments Financial and other assets including deferred tax assets Other assets [member] Other intangible assets Technologies Brand names Inventories Net identifiable assets (acquired) or divested Cash inflow (outflow) from Net identifiable assets (acquired) or divested Cash inflow (outflow), currency translation effects Currency translation effects Currency translation effects Cash inflow (outflow), acquired/(divested) liquity Acquired/(divested) liquity Cash inflow (outflow), fair value of previously held equity interests Fair value of previously held equity interests Cash inflow (outflow) from net identifiable assets, currency translation effects, Liquidity and fair value of equity interests Subtotal Cash inflow (outflow) from Net identifiable assets (acquired) or divested, currency translation effects, Acquired/(divested) liquidity and fair value of previously held equity interests. Cash provided by refinancing of intercompany financial debt, net Refinancing of intercompany financial debt, net Cash provided by refinancing of intercompany financial debt, net. Cash inflow (outflow), Goodwill Goodwill Divestment gain Cash inflow (outflow), Divestment gain (loss) Taxes paid and other portfolio transformation related cash flows Receivables and payables contingent consideration, net Other payments and deferred consideration, net (Deferred)/prepaid portion of sales price (Deferred)/prepaid portion of sales price to cash flows (used in) provided by acquisitions/divestments of businesses. Net cash flows Contingent consideration arrangements and indemnification assets recognised as of acquisition date Contingent consideration paid Business combinations [axis] Entity's total for business combinations [member] Change, 25 basis point [member] 25 basis point change Dividends payable, amount per share Treasury shares acquired to be held Treasury shares acquired to be cancelled Other share purchases Share-purchase of treasury shares Exercise of options and employee transactions shares Equity based compensation shares Treasury shares acquired to be held, equity impact Treasury shares acquired for cancellation, equity impact Other share purchases, equity impact Comprehensive income [abstract] Changes in consolidated statements of comprehensive income [text block] Changes in consolidated statements of comprehensive income Schedule of comprehensive income [table text block] Comprehensive income Schedule of share value adjustments currency translation effects [table text block] Schedule of share value adjustments currency translation effects Fair value adjustments financial instruments reconciliation [table text block] Fair value adjustments financial instruments reconciliation Schedule of defined benefit plan amounts recognized in other comprehensive income [table text block] Schedule of defined benefit plan amounts recognized in other comprehensive income Disclosure of terms and conditions of share-based payment arrangement [abstract] Disclosure of share-based payment arrangements [text block] Equity-based participation plans for associates Disclosure of transactions between related parties [abstract] Disclosure of related party [text block] Transactions with related parties Post-employment benefits for associates Officer and director compensation [table text block] Executive Officers and Non-Executive Directors Compensation Disclosure of number and weighted average remaining contractual life of outstanding share options [text block] Disclosure of range of exercise prices of outstanding share options [text block] Schedule of unvested restricted stock units roll forward [table text block] Schedule of share-based compensation, activity [table text block] Schedule of share-based compensation, activity Schedule of unvested restricted stock units roll forward Disclosure of range of exercise prices of outstanding share options Disclosure of number and weighted average remaining contractual life of outstanding share options Disclosure of transactions between related parties [table] Disclosure of transactions between related parties [line items] Categories of related parties [axis] Entity's total for related parties [member] Key management personnel of entity or parent [member] Non-Executive Director [member] Associates [axis] Entity's total for associates [member] Roche Holding AG [member] Products and services [axis] Products and services [member] Lucentis [member] Xolair [member] Proportion of voting rights held in associate Net expense, royalties cost sharing and profit sharing Key management personnel compensation, post-employment benefits Key management personnel compensation, share-based payment Key management personnel compensation Post-employment benefits Equity-based compensation Total Genentech, Inc., USA [member] Prof. Dr. Brody [member] Prof. Dr. Zinkernagel [member] Dr. Alex Krauer [member] Dr. Daniel Vasella [member] Dr. James Bradner [member] Key management personnel compensation, daily rate Key management personnel compensation, annual guaranteed minimum Key management personnel compensation, shares acquired Key management personnel compensation, ownership interest acquired Changes in consolidated statements of comprehensive income [table] Fair value adjustments on marketable securities [member] Fair value adjustments on marketable securities Fair value adjustments on deferred cash flow hedges [member] Fair value adjustments on deferred cash flow hedges Actuarial gains/losses from defined benefit plans [member] Actuarial gains/losses from defined benefit plans Cumulative currency translation effects [member] Cumulative currency translation effects Changes in consolidated statements of comprehensive income [line items] Value adjustments on comprehensive income at end of period Net actuarial gains/losses from defined benefit plans Total value adjustments Fair value adjustments on financial instruments Available-for-sale financial investments Available-for-sale marketable securities Gain (loss) on sale of marketable investments Marketable securities sold Gain (loss) on sale of other financial assets Other financial assets sold Fair value adjustments during the year Remeasurements from defined benefit plans [line items] Disclosure of reconciliation of changes in intangible assets and goodwill [table] Classes of intangible assets and goodwill [axis] Goodwill [member] Intangible Assets other than Goodwill Goodwill Currently marketed products Marketing know-how Disclosure of detailed information about intangible assets [line items] Intangible assets and goodwill Intangible assets and goodwill at beginning of period Intangible assets and goodwill at end of period Acquisitions through business combinations, intangible assets and goodwill Impact of business combinations Increase (decrease) through transfers, intangible assets and goodwill Reclassifications Additions other than through business combinations, intangible assets other than goodwill Additions Disposals and retirements, intangible assets and goodwill Disposals and derecognitions Increase (decrease) through net exchange differences, intangible assets and goodwill Currency translation effects Amortisation, intangible assets other than goodwill Amortization charge Impairment loss recognised in profit or loss, intangible assets and goodwill Impairment charge Reversal of impairment loss recognised in profit or loss, intangible assets other than goodwill Reversal of impairment charge Net book value Segment consolidation items [axis] Entity's total for segment consolidation items [member] Operating segments [member] Innovative Medicines [member] Innovative Medicines Sandoz [member] Sandoz Alcon [member] Alcon Unallocated amounts [member] Growth rate used to extrapolate cash flow projections Terminal Growth Rate Discount rate used in current measurement of fair value less costs of disposal Discount Rate (post-tax) Impairment loss recognised in profit or loss, intangible assets other than goodwill Intangible asset impairment charges Description of justification for using growth rate that exceeds long-term average growth rate Description of growth rate Disclosure of terms and conditions of share-based payment arrangement [table] Disclosure of terms and conditions of share-based payment arrangement [line items] Types of share-based payment arrangements [axis] Share-based payment arrangements [member] Equity-Based Participation Annual Incentive Plan [member] Equity-Based Participation Share Savings Plan [member] Equity-Based Participation Leveraged Share Savings Plan [member] Equity-Based Participation Employee Share Ownership Plan [member] Equity-Based Participation UK Share Savings Plan [member] Equity-Based Participation Novartis Equity Plan "Select" [member] Equity-Based Participation Long-Term Performance Plan [member] Equity-Based Participation Long-Term Relative Performance Plan [member] Equity-Based Participation Special Share Awards [member] Description of share-based payment arrangement Description of method of settlement for share-based payment arrangement Description of vesting requirements for share-based payment arrangement Liabilities from share-based payment transactions Disclosure of number and weighted average remaining contractual life of outstanding share options [table] Disclosure of number and weighted average remaining contractual life of outstanding share options [line items] Number of share options outstanding in share-based payment arrangement Number of share options outstanding at beginning of period Number of share options outstanding at end of period Disclosure of number and weighted average exercise prices of share options [roll forward] Weighted average exercise price of share options outstanding in share-based payment arrangement Weighted average exercise price of share options outstanding at beginning of period Weighted average exercise price of share options outstanding at end of period Number of share options exercised in share-based payment arrangement Number of share options forfeited in share-based payment arrangement Weighted average exercise price of share options exercised in share-based payment arrangement Weighted average exercise price of share options forfeited in share-based payment arrangement Number of share options exercisable in share-based payment arrangement Weighted average exercise price of share options exercisable in share-based payment arrangement Number of share options exercised or sold Weighted average exercise price of share options exercised or sold Number of share options forfeited or expired Weighted average exercise price of share options forfeited or expired Number of share options exercisable Weighted average exercise price of share options exercisable Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract] Exercise price of outstanding share options Ranges of exercise prices for outstanding share options [axis] Ranges of exercise prices for outstanding share options [member] Range of exercise prices, 45-49 [member] 45-49 Range of exercise prices, 50-54 [member] 50-54 Range of exercise prices, 55-59 [member] 55-59 65-70 Weighted average remaining contractual life of outstanding share options Weighted average share price Range of exercise prices, 65-70 [member] Range of exercise prices, 65-69 [member] 65-69 Equity-Based Participation Restricted Shares [member] Remeasurements from defined benefit plans, total after tax Other comprehensive income, before taxes, gains (losses) on remeasurements of defined benefit plans Defined benefit pension plans before tax Other comprehensive income, before taxes, gains (losses) on remeasurements of other post-employment benefit plans Other post-employment benefit plans before tax Other comprehensive income, gains (losses) on remeasurements of defined and other post-employment benefit plans, taxation Taxation on above items Key management personnel compensation, shares acquired, price Value adjustment on comprehensive income Value adjustments on comprehensive income at beginning of period Gains (losses) on value adjustment on comprehensive income Total value adjustments attributable to Novartis shareholders [member] Total value adjustments Alcon, Inc., equity plan, converted, Novartis share options [member] Alcon, Inc., equity plan, converted, Share-settled appreciation rights (SSAR) [member] Number of share options exercised Weighted average exercise price of share options exercised Schedule of unvested restricted stock units roll forward [table] Non-vesting [axis] Non-vesting [member] Non-vested shares granted [member] Annual incentive Share savings plans Select Long-Term Performance Plan Long-Term Relative Performance Plan Special share awards Fair value at grante date at end of period Vested, fair value at grante date Forfeited, fair value at grante date Granted, fair value at grante date Disclosure of operating segments [abstract] Disclosure of operating segments [table] Disclosure of operating segments [line items] Material reconciling items [member] Revenue from sale of goods, sales to other segments Sales to other segments Interest income Depreciation and amortisation expense Impairment charges and fair value gains on financial assets, net Total liabilities Net debt Net debt Net operating assets Net operating assets Purchase of interests in associates Additions to investment in associated companies Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments Financial debts and derivative instruments Current income tax and deferred tax liabilities Net sales (in % of total net sales) Total of selected non-current assets Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies. As percent of total selected non-current assets. Other Other countries [member] Geographical regions [axis] Geographical regions [member] Europe [member] Americas [member] Asia/Africa/Australasia [member] Percentage of entity's revenue Highest amount of trade receivables Disclosure of major customers [abstract] Disclosure of major customers [table] Disclosure of major customers [line items] Major customers [axis] Customers [member] Largest customer [member] Second largest customer [member] Third largest customer [member] Disclosure of entity's operating segments [text block] Segmentation of key figures Disclosure of operating segments [text block] Segmentation - Consolidated income statements Disclosure of operating segments, balance sheet [table text block] Segmentation - Consolidated balance sheets Disclosure of operating segments, by countries and regions [table text block] Net sales and total of selected non-current assets, by countries and regions Disclosure of operating segments, net sales by business franchise [table text block] Net sales by business franchise Disclosure of associates [abstract] Disclosure of investments accounted for using equity method [text block] Associated companies Disclosure of associates [text block] Schedule disclosing information related to associates Disclosure of associates balance sheet [table text block] Schedule disclosing information related to associates, balance sheet value Associates summarized financial information [table text block] Purchase price allocation associates [table text block] Disclosure of associates [table] Disclosure of associates [line items] Roche Holding AG, Switzerland GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK GlaxoSmithKline Consumer Healthcare Holdings Ltd. [member] Others associates [member] Others Share of total comprehensive income of associates and joint ventures accounted for using equity method Total comprehensive income effect Balance sheet value Proportion of ownership interest in associate Dividends received Associates summarized financial information [table] Purchase price allocation associates [table] Revaluation increase (decrease), intangible assets other than goodwil Novartis share of re-appraised intangible assets Implicit Novartis goodwill Share of estimated net assets Novartis share of estimated net assets Current value of share in net identifiable assets and goodwill Accumulated equity accounting adjustments and translation effects less dividends received Consolidated income statement effects [table] Novartis share of current year consolidated net income Prior year adjustment Amortization of fair value adjustments relating to intangible assets Taxes on Amortization of fair value adjustments relating to intangible assets Disclosure of detailed information about provisions and non-current liabilities [abstract] Disclosure of other provisions, contingent liabilities and contingent assets [text block] Provisions and other non-current liabilities Disclosure of other provisions [text block] Accrual for environmental loss contingencies [table text block] Accrual for environmental loss contingencies, fiscal year maturity [table text block] Accrual for product liabilities government investigations other legal matters loss contingencies [table text block] Disclosure of other provisions [table] Disclosure of other provisions [line items] Non-current net defined benefit liability Defined benefit pension plans Other long-term employee benefits and deferred compensation Other post-employment benefits Environmental remediation provisions, non-current Contingent consideration Total provisions and other non-current liabilities Environmental provision [roll forward] Cash payments Releases Additions Currency translation effects Less current provision Environmental provision, fiscal year maturity [abstract] Total environmental remediation liability provisions Due within two years Due later than two years, but within five years Due later than five years, but within ten years Due after ten years Product liability, government investigations, other legal matters provisions [roll forward] Provisions related to discontinued operations Cash payments Releases Additions Currency translation effects Product liabilities government investigations other legal matters provisions at end of period Less current provision Non-current product liabilities, governmental investigations and other legal matters provisions at end of period Legal proceedings provision [member] Solodyn [member] Contact Lenses [member] Gleevec [member] Reclast/Aclasta [member] Tekturna/Rasilez/Valturna [member] NAG and Novartis Pharma SpA [member] F Hoffman La Roche AG and Roche SpA [member] Novartis Pharma K.K. [member] NAG [member] NPC and others [member] Novartis NC [member] Product liability contingency, loss exposure not accrued, number of cases Product liability contingency, loss exposure not accrued, best estimate Estimated financial effect of contingent liabilities Description of nature of obligation contingent liabilities, number of legal questions referred to court Estimated financial effect of contingent liabilities, maximum fine Description of nature of obligation contingent liabilities, number of putative cases referred to court Description of nature of obligation contingent liabilities, number of other cases referred to court Description of nature of obligation contingent liabilities, number of states with alleged violations Description of nature of obligation contingent liabilities, number of cases still pending Revenue 1.800% USD 1'000 million 2017/2020 of Novartis Capital Corporation, New York, United States, issued at 99.609% [member] 2.400% USD 1'000 million 2017/2022 of Novartis Capital Corporation, New York, United States, issued at 99.449% [member] 3.100% USD 1'000 million 2017/2027 of Novartis Capital Corporation, New York, United States, issued at 99.109% [member] 0.000% EUR 1'250 million 2017/2021 of Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.133% [member] 1.125% EUR 600 million 2017/2027 of Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.874% [member] Transactions with former members of the Board of Directors [table text block] Transactions with former members of the Board of Directors Leasing commitments Minimum lease payments payable under non-cancellable operating lease Total fair value adjustments [member] Total fair value adjustments Provisions at beginning of period Provisions at end of period Current prepaid expenses, third party Disclosure of maturity analysis for non-derivative financial liabilities [abstract] Disclosure of maturity analysis for non-derivative financial liabilities [line items] Disclosure of maturity analysis for non-derivative financial liabilities [table] Later than one month and not later than three months [member] Later than one year [member] Later than six months and not later than one year [member] Later than three months and not later than six months [member] Not later than one month [member] Other non-current liabilities Past service cost and gains losses arising from settlements, net defined benefit liability (asset) Past service cost and settlements Tax rate, effect from change in tax rate Effect of tax rate change on current and deferred tax assets and liabilities Tax rate, effect of expense not deductible in determining taxable profit tax loss Effect of disallowed expenditures Tax rate, effect of tax losses Effect of utilization of tax losses brought forward from prior periods Other expense Other expense, by function Par value per share Other current assets Marketable securities, commodities, time deposits and derivative financial instruments Total marketable securities, commodities, time deposits and derivative financial instruments Taxotere [member] Amiodarone [member] Disclosure of equity [abstract] Disclosure of equity [text block] Equity Dividend [table text block] Schedule disclosing information related to Dividend Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Trading Symbol Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Well-known Seasoned Issuer Entity Current Reporting Status Entity Voluntary Filers Entity Filer Category Entity Common Stock, Shares Outstanding Entity Public Float UNITED STATES UNITED KINGDOM GERMANY FRANCE JAPAN US UK Germany France Japan ITALY Italy CANADA Canada United States of America, Dollars USD Euro Member Countries, Euro EUR Japan, Yen JPY China, Yuan Renminbi CNY United Kingdom, Pounds GBP CHF Document Information [Table] Document Information [Line Items] Legal Entity [Axis] Entity [Domain] All Currencies [Domain] Need new ITEM here General and Administration Increase (decrease) in non-controling interests Changes in non-controlling interests Dividends received from associated companies Dividends received, classified as operating activities Finance income received, classified as operating activities Other financial receipts Finance costs paid, classified as operating activities Other financial payments Proceeds from sales of interests in associates Divestments of interests in associated companies Acquisitions and divestments of businesses, net Dividends paid to shareholders of Novartis AG Dividends paid to equity holders of parent, classified as financing activities Proceeds from non-current financial debts Repayments of non-current borrowings Repayment of non-current financial debts Proceeds from non-current borrowings Cash flows from (used in) increase (decrease) in current borrowings Change in current financial debts Impact of change in ownership of consolidated entities Impact of change in ownership of consolidated entities Dividends paid to non-controlling interests and other financing cash flows Other inflows (outflows) of cash, classified as financing activities Income taxes paid (refund) Income taxes paid (refund), classified as investing activities Number of Reportable Segments Number of Business Units Number of Franchises Additions to restructuring provisions Additions to property, plant and equipment Additions to intangible assets and goodwill Revenue from sale of goods, third parties and other segments Net sales to third parties from continuing operations Revenue from sale of goods, third parties and other segments, as percent of total net sales Selected non-current assets, as percent Selected non-current assets (in % of total selected non-current assets) Fair value of investments in associates for which there are quoted market prices Investments in subsidiaries, joint ventures and associates Interest expense, gross Dividend income Impairment loss on commodities and available-for-sale securities, net Impairment of commodities and available-for-sale securities, net Other finance cost Other financial expense Tax expense (income), discontinuing operations Income tax expense from discontinued operations Tax rate, effect from non-deductible losses Effective income tax rate reconciliation change in uncertain tax positions Effective income tax rate reconciliation other adjustments Effective income tax rate reconciliation change in enacted tax rate Other comprehensive income net of tax gains/losses on remeasurements of defined benefit plans related to discontinued operations dup_1_Total value adjustments Other comprehensive income net of tax exchange differences on translation related to discontinued operations dup_2_Total value adjustments Business unit [axis] Business unit [member] Oncology [member] Pharmaceutical [member] Franchise [axis] Franchise [member] Ophthalmology [member] Immunology and Dermatology [member] Neuroscience [member] Respiratory [member] Cardio-Metabolic [member] Established Medicines [member] Product portfolio [axis] Product portfolio [member] COPD [member] Gleevec/Glivec [member] Tasigna [member] Sandostatin [member] Afinitor/Votubia [member] Exjade/Jadenu [member] Tafinlar + Mekinist [member] Promacta/Revolade [member] Votrient [member] Jakavi [member] Kisqali [member] Other [member] Travoprost Group [member] Systane Group [member] Topical Olopatadine Group [member] Cosentyx [member] Neoral/Sandimmun(e) [member] Zortress/Certican [member] Ilaris [member] Myfortic [member] Gilenya [member] Ultibro Breezhaler [member] Seebri Breezhaler [member] Onbrez Breezhaler [member] Entresto [member] Galvus [member] Exforge [member] Diovan/Co-Diovan [member] Voltaren/Cataflam [member] Exelon/Exelon Patch [member] Ritalin/Focalin [member] Accumulated depreciation on disposals, property plant and equipment Accumulated depreciation on disposals and derecognitions Accumulated impairments on disposals and derecognitions dup_1_Accumulated impairments on disposals and derecognitions Acquired research and development [member] Acquired research and development Alcon brand name [member] Alcon brand name Gross value of tax loss carry forwards expiring in future years Net sales, change in % Shareholders of Novartis AG Cumulative currency translation losses recycled throught income statement Impaired loss on financial assets transferred to the income statement Reclassification adjustments on financial assets measured at fair value through other comprehensive income, net of tax Other comprehensive income, available-for-sale financial investments Other comprehensive income, maketable securities Available-for-sale marketable securities Net book value Finance lease receivables Minimum lease payments from finance lease agreements Provision for doubtful receivable [member] Outstanding share capital Total outstanding share capital at beginning of period Total outstanding share capital at end of period Treasury shares movement of period Issued capital, movement Share capital movement of period Outstanding share capital, movement Total shares outstanding movement of period Shares cancelled for capital reduction Treasury shares, movement Total number of outstanding treasury shares Purchase of treasury shares Purchase of treasury shares, equity impact Exercise of options and employee transactions, equity impact Equity impact of treasury share movements Total equity impact of treasury share movements Average interest rate on loans received dup_1_Financial debts dup_1_Total non-current financial debts Ratio fixed rate financial debt to total financial debt dup_2_Financial debts dup_2_Total non-current financial debts Average interest rate on borrowings dup_3_Financial debts dup_3_Total non-current financial debts Borrowings, coupon Borrowings, issuance year Borrowings, maturity year Borrowings, issuer Borrowings, issue price Environmental remediation provisions Accrual for environmental loss contingencies Environmental liabilities provision at beginning of period Environmental liabilities provision at end of period Accrual for environmental loss contingencies, payments Accrual for environmental loss contingencies, releases Accrual for environmental loss contingencies, additions Accrual for environmental loss contingencies, foreign currency translation gain (loss) Accrual for environmental loss contingencies, Current Non-current environmental remediation provisions at end of period Environmental provision, expected cash outflow, next two years Environmental provision, expected cash outflow, later than two years, but within five years Environmental provision, expected cash outflow, later than five years, but within ten years Environmental provision, expected cash outflow, after ten years Product liability, government investigations, other legal matters provisions Product liabilities government investigations other legal matters provisions at beginning of period Product liability, government investigations, other legal matters provisions, discontinued operations Product liability, government investigations, other legal matters provisions, payments Product liability, government investigations, other legal matters provisions, releases Product liability, government investigations, other legal matters provisions, additions Product liability, government investigations, other legal matters provisions, foreign currency translation gain (loss) Product liability, government investigations, other legal matters provisions, current Product liability, government investigations, other legal matters provisions, non-current Product liability, government investigations, other legal matters provisions Weighted average interest rate on interest bearning accounts of associates payable on demand. Weighted average interest rate on Bank and other financial debt Weighted average interest rate on Bank and other financial debt Environmental remediation liabilities Accrued expenses for goods and services received but not invoiced Accruals classified as current Contingent consideration, current portion Contingent considerations Provision for deduction from revenue [table] Restructuring provisions movements [table] Restructuring provision transfers Transfers Reclassification adjustments on cash flow hedges, net of tax Amortized net losses on cash flow hedges transferred to the consolidated income statement Trade and other payables and deferred tax liabilities recognised as of acquisition date Payables and other liabilities including deferred tax liabilities Identifiable assets acquired Net identifiable assets acquired Property plant and equipment recognised as of acquisition divestment date Property, plant and equipment Currently marketed products intangible assets recognised as of acquisition divestment date Currently marketed products Acquired divested research and development intangible assets recognised as of acquisition divestment date (Acquired)/divested research and development Technologies recognised as of acquisition divestment date Technologies Other intangible assets recognised as of acquisition divestment date Other intangible assets Financial and other assets including deferred tax assets recognised as of acquisition divestment date Financial and other assets including deferred tax assets Inventory recognised as of acquisition divestment date Inventories Trade receivables and other current assets recognised as of acquisition divestment date Trade receivables and other current assets Cash and cash equivalents recognised as of acquisition divestment date Cash and cash equivalents Current and non-current financial debts recognised as of acquisition divestment date Current and non-current financial debts Trade and other payables recognised as of acquisition divestment date Trade payables and other liabilities including deferred tax liabilities Animal health [member] dup_1_Transcend Medical Inc. Proceeds from sale of business Cash flows (used in) acquisitions and divestments of businesses discontinued operations classified as investing activities Divestments of businesses Cash flows used in/from investing activities from discontinued operations Financial debts and derivative instruments at beginning of period Financial debts and derivative instruments at end of period Changes in fair values and other changes Amortization of bonds discount dup_1_Changes in fair values and other changes Currency translation effects Non-current financial debts [member] Current financial debts and derivative financial instruments [member] Current portion of non-current financial debt Genentech / Roche [member] Number of contracts with related parties Related parties, number of executive commitee members Executive Commitee members Related parties, number of non-executive directors Non-executive directors Defined benefit plan, expected future benefit payment Administrative expense net defined benefit liability asset Administrative expenses Actuarial gains (losses) arising from changes in expreience related assumptions, net defined benefit liability (asset) Defined benefit plan, foreign currency exchange rate gain (loss) Increase (decrease) through changes in foreign exchange rates, defined benefit liability (asset) Later than five years and not later than ten years [member] Disclosure of financial assets [table] Disclosure of financial assets [line items] Financial assets Classes of financial assets [axis] Financial assets, class [member] Financial assets at amortised cost, class [member] Cash and cash equivalents [member] Categories of financial assets [axis] Financial assets, category [member] Available-for-sale marketable securities [member] Available-for-sale long-term financial investments [member] Balance sheet item [axis] Balance sheet item [member] Equity securities [member] Fund investments [member] Trade receivables and other current assets excluding pre-payments [member] Contingent consideration receivables [member] Accrued interest on debt securities and time deposits [member] Time deposits with original maturity more than 90 days [member] Long-term loans and receivables from customers and finance lease, advances, security deposits [member] Associated companies at fair value through profit and loss [member] Derivative financial instruments [member] Disclosure of financial liabilities [table] Classes of financial liabilities [axis] Financial liabilities, class [member] Financial liabilities at amortised cost, class [member] Financial liabilities at fair value, class [member] Groups of financial assets/liabilities [axis] Groups of financial assets/liabilities [member] Financial assets at fair value, class [member] Financial assets at fair value through profit or loss, category [member] Financial assets at fair value through other comprehensive income, category [member] Financial liabilities, category [member] Categories of financial liabilities [axis] Financial liabilities at fair value through profit or loss, category [member] Financial liabilities at amortised cost, category [member] Financial assets at amortised cost, category [member] Current financial debt [member] Non-current financial debt [member] Trade payables [member] Interest bearning accounts of associates payable on demand [member] Bank and other financial debt [member] Commercial paper [member] Current portion of non-current debt [member] Straight bonds [member] Liabilities to banks and other financial institutions [member] Finance lease obligations [member] Contingent consideration and other financial liabilities [member] Disclosure of derivative financial instruments, by type of contract [table] Derivative financial instrument, nature of instrument [axis] Derivative financial instrument, nature of instrument [member] Derivative financial instruments, at fair value currency related [member] Financial instruments, principal amounts [axis] Financial instruments, principal amounts [member] Contract or underlying principal amout [member] Positive fair values [member] Negative fair values [member] Disclosure of derivative financial instruments [line items] Disclosure of financial liabilities [line items] Financial liabilities Derivative financial instruments Derivative financial instruments, forward foreign exchange rate contracts Derivative financial instruments, over-the-counter currency options Disclosure of derivative financial instruments, by currency contract [table] Disclosure of fair value measurement of assets [table] Measurement [axis] Aggregated measurement [member] Recurring fair value measurement [member] Marketable securities, time deposits and derivative financial instruments [member] Financial investments and long-term loans [member] Total available-for-sale marketable securities [member] Available-for-sale financial investments [member] Disclosure of fair value measurement of assets [line items] Valued at amortized cost [member] Classes of liabilities [axis] Liabilities [member] Contingent consideration payables [member] Other financial liabilities [member] China Novartis Institutes for BioMedical Research Co., Ltd., Shanghai [member] Dividends proposed, cash per share Dividends proposed or declared before financial statements authorised for issue but not recognised as distribution to owners per share Dividends proposed Increase/decrease through net exchange differences other provisions Increase/decrease in fair value measurement liabilities Financial assets, at fair value Financial liabilities, at fair value Other comprehensive income, net of tax, hedges of net investments in foreign operations Net investment hedge Novartis Australia Pty Ltd, North Ryde, NSW [member] Novartis Pharmaceuticals Australia Pty Ltd, North Ryde, NSW [member] Alcon Laboratories (Australia) Pty Ltd, Frenchs Forest, NSW [member] Sandoz Pty Ltd, North Ryde, NSW [member] Novartis Austria GmbH, Vienna [member] Novartis Pharma GmbH, Vienna [member] Alcon Ophthalmika GmbH, Vienna [member] Sandoz GmbH, Kundl [member] EBEWE Pharma Ges.m.b.H Nfg. KG, Unterach am Attersee [member] Novartis (Bangladesh) Limited, Gazipur [member] N.V. Novartis Pharma S.A., Vilvoorde [member] S.A. Alcon-Couvreur N.V., Puurs [member] N.V. Alcon S.A., Vilvoorde [member] N.V. Sandoz S.A., Vilvoorde [member] Novartis Securities Investment Ltd., Hamilton [member] Novartis Biociencias S.A., Sao Paulo [member] Sandoz do Brasil Industria Farmaceutica Ltda., Cambe, PR [member] Novartis Pharmaceuticals Canada Inc., Dorval, Quebec [member] Alcon Canada Inc., Mississauga, Ontario [member] CIBA Vision Canada Inc., Mississauga, Ontario [member] Sandoz Canada Inc., Boucherville, Quebec [member] Novartis Chile S.A., Santiago de Chile [member] Alcon Laboratorios Chile Ltd., Santiago de Chile [member] Beijing Novartis Pharma Co., Ltd., Beijing [member] Novartis Pharmaceuticals (HK) Limited, Hong Kong [member] Suzhou Novartis Pharma Technology Co., Ltd., Changshu [member] Shanghai Novartis Trading Ltd., Shanghai [member] Alcon Hong Kong Limited, Hong Kong [member] Alcon (China) Ophthalmic Product Co., Ltd., Beijing [member] Sandoz (China) Pharmaceutical Co., Ltd., Zhongshan [member] Novartis de Colombia S.A., Santafe de Bogota [member] Laboratorios Alcon de Colombia S.A., Santafe de Bogota [member] Sandoz d.o.o. farmaceutska industrija, Zagreb [member] Novartis s.r.o., Prague [member] Alcon Pharmaceuticals (Czech Republic) s.r.o., Prague [member] Sandoz s.r.o., Prague [member] Novartis Healthcare A/S, Copenhagen [member] Alcon Nordic A/S, Copenhagen [member] Sandoz A/S, Copenhagen [member] Novartis Ecuador S.A., Quito [member] Novartis Pharma S.A.E., Cairo [member] Sandoz Egypt Pharma S.A.E., New Cairo City [member] Novartis Finland Oy, Espoo [member] Novartis Groupe France S.A., Rueil-Malmaison [member] Novartis Pharma S.A.S., Rueil-Malmaison [member] Laboratoires Alcon S.A.S., Rueil-Malmaison [member] Sandoz S.A.S., Levallois-Perret [member] Novartis Deutschland GmbH, Wehr [member] Novartis Pharma GmbH, Nuremberg [member] Novartis Pharma Produktions GmbH, Wehr [member] Novartis Business Services GmbH, Wehr [member] Alcon Pharma GmbH, Freiburg im Breisgau [member] WaveLight GmbH, Erlangen [member] CIBA Vision GmbH, Grosswallstadt [member] Sandoz International GmbH, Holzkirchen [member] HEXAL AG, Holzkirchen [member] Salutas Pharma GmbH, Barleben [member] 1 A Pharma GmbH, Oberhaching [member] Aeropharm GmbH, Rudolstadt [member] Novista Insurance Limited, Gibraltar City [member] Novartis (Hellas) S.A.C.I., Metamorphosis/Athens [member] Alcon Laboratories Hellas Commercial and Industrial S.A., Maroussi, Athens [member] Novartis Hungary Healthcare Limited Liability Company, Budapest [member] Sandoz Hungary Limited Liability Company, Budapest [member] Novartis India Limited, Mumbai [member] Novartis Healthcare Private Limited, Mumbai [member] Alcon Laboratories (India) Private Limited, Bangalore [member] Sandoz Private Limited, Mumbai [member] PT. Novartis Indonesia, Jakarta [member] PT. CIBA Vision Batam, Batam [member] Novartis Ireland Limited, Dublin [member] Novartis Ringaskiddy Limited, Ringaskiddy, County Cork [member] Alcon Laboratories Ireland Limited, Cork City [member] Novartis Israel Ltd., Petach Tikva [member] Optonol Ltd., Neve-Ilan [member] Novartis Farma S.p.A., Origgio [member] Alcon Italia S.p.A., Milan [member] Sandoz S.p.A., Origgio [member] Sandoz Industrial Products S.p.A., Rovereto [member] Novartis Holding Japan K.K., Tokyo [member] Novartis Pharma K.K., Tokyo [member] Alcon Japan Ltd., Tokyo [member] Sandoz K.K., Tokyo [member] Novartis Investments S.a r.l., Luxembourg-Ville [member] Novartis Finance S.A., Luxembourg-Ville [member] Novartis Corporation (Malaysia) Sdn. Bhd., Kuala Lumpur [member] Alcon Laboratories (Malaysia) Sdn. Bhd., Petaling Jaya [member] CIBA Vision Johor Sdn. Bhd., Kuala Lumpur [member] Novartis Farmaceutica, S.A. de C.V., Mexico City [member] Alcon Laboratorios, S.A. de C.V., Mexico City [member] Sandoz, S.A. de C.V., Mexico City [member] Novartis Pharma Maroc SA, Casablanca [member] Novartis Netherlands B.V., Arnhem [member] Novartis Pharma B.V., Arnhem [member] Alcon Nederland B.V., Arnhem [member] Sandoz B.V., Almere [member] Novartis New Zealand Ltd, Auckland [member] Novartis Norge AS, Oslo [member] Novartis Pharma (Pakistan) Limited, Karachi [member] Novartis Pharma (Logistics), Inc., Panama City [member] Alcon Centroamerica S.A., Panama City [member] Novartis Healthcare Philippines, Inc., Manila [member] Sandoz Philippines Corporation, Manila [member] Novartis Poland Sp. z o.o., Warszawa [member] Alcon Polska Sp. z o.o., Warszawa [member] Sandoz Polska Sp. z o.o., Warszawa [member] Lek S.A., Strykow [member] Novartis Portugal SGPS Lda., Porto Salvo [member] Novartis Farma - Produtos Farmaceuticos S.A., Porto Salvo [member] Alcon Portugal-Produtos e Equipamentos Oftalmologicos Lda., Porto Salvo [member] Sandoz Farmaceutica Lda., Porto Salvo [member] Novartis Pharma Services Romania S.R.L., Bucharest [member] Alcon Romania S.R.L., Bucharest [member] Sandoz S.R.L., Targu-Mures [member] Novartis Pharma LLC, Moscow [member] Alcon Farmacevtika LLC, Moscow [member] ZAO Sandoz, Moscow [member] Novartis Neva LLC, St. Petersburg [member] Saudi Pharmaceutical Distribution Co. Ltd., Riyadh [member] Novartis (Singapore) Pte Ltd., Singapore [member] Novartis Singapore Pharmaceutical Manufacturing Pte Ltd, Singapore [member] Novartis Asia Pacific Pharmaceuticals Pte Ltd, Singapore [member] Novartis Institute for Tropical Diseases Pte Ltd, Singapore [member] Alcon Singapore Manufacturing Pte Ltd, Singapore [member] CIBA Vision Asian Manufacturing and Logistics Pte Ltd., Singapore [member] Alcon Pte Ltd, Singapore [member] Novartis Slovakia s.r.o., Bratislava [member] Lek Pharmaceuticals d.d., Ljubjana [member] Sandoz Pharmaceuticals d.d., Ljubjana [member] Novartis South Africa (Pty) Ltd, Midrand [member] Alcon Laboratories (South Africa) (Pty) Ltd., Midrand [member] Sandoz South Africa (Pty) Ltd, Kempton Park [member] Novartis Korea Ltd., Seoul [member] Alcon Korea Ltd., Seoul [member] Sandoz Korea Ltd., Seoul [member] Novartis Farmaceutica S.A., Barcelona [member] Alcon Cusi S.A., Barcelona [member] Sandoz Farmaceutica S.A., Madrid [member] Sandoz Industrial Products S.A., Barcelona [member] Abadia Retuerta S.A., Sardon de Duero/Valladolid [member] Novartis Sverige AB, Stockholm [member] Novartis International AG, Basel [member] Novartis Holding AG, Basel [member] Novartis International Pharmaceutical AG, Basel [member] Novartis Pharma AG, Basel [member] Novartis Pharma Services AG, Basel [member] Novartis Pharma Schweizerhalle AG, Muttenz [member] Novartis Pharma Stein AG, Stein [member] Novartis Pharma Schweiz AG, Risch [member] Alcon Switzerland SA, Risch [member] Alcon Pharmaceuticals Ltd., Fribourg [member] Sandoz AG, Basel [member] Sandoz Pharmaceuticals AG, Risch [member] Novartis (Taiwan) Co., Ltd., Taipei [member] Novartis (Thailand) Limited, Bangkok [member] Alcon Laboratories (Thailand) Limited, Bangkok [member] Novartis Saglik, Gida ve Tarim Urunleri Sanayi ve Ticaret A.S., Istanbul [member] Alcon Laboratuvarlari Ticaret A.S., Istanbul [member] Sandoz Ilac Sanayi ve Ticaret A.S., Istanbul [member] Sandoz Grup Saglik Urunleri Ilaclari Sanayi ve Ticaret A.S., Gebze - Kocaeli [member] Novartis Middle East FZE, Dubai [member] Novartis UK Limited, Frimley/Camberley [member] Novartis Pharmaceuticals UK Limited, Frimley/Camberley [member] Novartis Grimsby Limited, Frimley/Camberley [member] Alcon Eye Care UK Limited, Frimley/Camberley [member] Sandoz Limited, Frimley/Camberley [member] Glaxosmithkline Consumer Healthcare Holdings Limited, Brentford, Middlesex [member] Novartis Corporation, East Hanover, NJ [member] Novartis Finance Corporation, New York, NY [member] Novartis Capital Corporation, New York, NY [member] Novartis Pharmaceuticals Corporation, East Hanover, NJ [member] Novartis Institutes for BioMedical Research, Inc., Cambridge, MA [member] Novartis Institute for Functional Genomics, Inc., San Diego, CA [member] Novartis Vaccines and Diagnostics, Inc., Cambridge, MA [member] Novartis Services, Inc., East Hanover, NJ [member] Alcon Laboratories Holding Corporation, Fort Worth, TX [member] Alcon Laboratories, Inc., Fort Worth, TX [member] Alcon Refractivehorizons, LLC, Fort Worth, TX [member] Alcon Research, Ltd., Fort Worth, TX [member] Alcon Lensx, Inc., Aliso Viejo, CA [member] Sandoz Inc., Princeton, NJ [member] Eon Labs, Inc., Princeton, NJ [member] Fougera Pharmaceuticals Inc., Melville, NY [member] Novartis de Venezuela, S.A., Caracas [member] Alcon Pharmaceutical, C.A., Caracas [member] Financial Instruments - additional disclosure [abstract] Reconciliation of changes in fair value measurement [table] Fair value measurement, carrying value, level 3 Fair value measurement, carrying value, level 3, at beginning of period Fair value measurement, carrying value, level 3, at end of period Fair value gains and other adjustments including from divestments recognized in the consolidated income statement Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement Fair value adjustments recognized in the consolidated statement of comprehensive income Purchases fair value measurement assets Disposals fair value measurement assets Reclassification fair value measurement assets Fair value gains and losses recognized in the consolidated income statement for assets and liabilities held Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end Monitoring of net debt or liquidity based on contractual maturities [table] Maturity of net debt [line items] Non-current financial debts Current financial debt Current financial assets Marketable securities and time deposits [member] Commodities [member] Deriviative financial instruments and accrued interest [member] Financial debt [member] Financial debt - undiscounted [member] Net debt Later than three month and not later than twelve months [member] Derivative financial instruments and accrued interest on derivative financial instruments [line items] Potential outflows in various currencies - from financial derivative liabilities Potential inflows in various currencies - from financial derivative assets Derivative financial instruments and accrued interest on derivative financial instruments [table] Contractual interest on non-current liabilities Contractual interest on non-current liabilities Ten day loss fair value VAR model [table] Ten day loss fair value VAR model [line items] Financial instruments, value at risk computation Financial instruments, value at risk computation, sensitive to foreign currency exchange rates Financial instruments, value at risk computation, sensitive to equity market movements Financial instruments, value at risk computation, sensitive to interest rates All financial instruments Instruments sensitive to foreign currency exchange rates Instruments sensitive to equity market movements Instruments sensitive to interest rates Weighted average [member] Average High Low Worst case loss scenario [member] Worst case loss scenario Cash receipts and payments fair value measurement assets Potential outflows in various currencies - from financial derivative liabilities Deferred tax liabilities Gross deferred tax liabilities Total liabilities Net deferred tax balance Reversal of provisions for doubtful trade receivables Publicly quoted market value of the Novartis interest Current service cost Net interest expense Administrative expenses Equity-Based Participation Novartis Equity Plan "Select", outside North America [member] Select outside North America Equity-Based Participation Novartis Equity Plan "Select", North America [member] Select North America Alcon, Inc., equity plans, granted to associates prior merger [member] Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value Forfeited, weighted average fair value at grante date Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares Forfeited, number of shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Weighted Average Grant Date Fair Value Vested, weighted average fair value at grante date Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Outstanding, Number Vested, number of shares Granted, weighted average fair value at grante date Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Granted, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Granted, Number of Shares Granted, number of shares Weighted average fair value at grante date at end of period Weighted average fair value at grante date at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value Number of shares at end of period Number of shares at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares Weighted average share price at dates of exercise Schedule of unvested restricted stock units [roll forward] Income from associated companies Equity-Based Participation Other Share Awards [member] Other share awards Alcon equity plans granted to associates prior merger Restricted Shares Leveraged Share Savings Plan (LSSP) Employee Share Ownership Plan (ESOP) UK Share Savings Plan Provisions for product liabilities, governmental investigations and other legal matters Share movements in period Total movements Net expense, royalties cost sharing and profit sharing Net investment hedge [member] dup_1_Actuarial losses from defined benefit plans Written call options held by market maker Written call options, contractual live Written call options, contractual live, remaining Written call options, weighted average exercise price Interest expense Change in current financial debts Dividends paid to non-controlling interests and other financing cash flows Payables and other liabilities including deferred tax liabilities Taxes paid Taxes paid and other portfolio transformation related cash flows Other payments and deferred consideration, net Deferred portion of sales price Stock repurchase program, authorized amount Shares repurchased on the SIX Swiss Exchange second trading line under the share buyback authority approved Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement Disposals fair value measurement assets Reversal of non-cash items Total reversal of non-cash items Adjustments to reconcile profit (loss) Income taxes (paid)/refund Income taxes (paid)/refund, classified as investing activities Income taxes refund/(paid), classified as operating activities Depreciation and amortisation expense Impairment loss (reversal of impairment loss) recognised in profit or loss Impairment charges and fair value gains on financial assets, net Additions to restructuring provisions Equity-based compensation of Novartis equity plans Net income statement effect Tax rate, effect of income taxed at reduced rates Effect of income taxed at reduced rates Movements of property, plant and equipment [roll forward] Disposals and derecognitions Intangible assets [member] Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss Share-based Compensation Arrangement by Share-based Payment Award, Options, NonVested in Period, Fair Value Fair value at grante date at beginning of period Share-based Compensation Arrangement by Share-based Payment Award, Options, Granted in Period, Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited in Period, Fair Value Spinifex Pharmaceuticals, Inc., Wilmington, NC [member] Encore Vision, Inc., New York, NY [member] Novartis Investment Ltd., Hamilton [member] Novartis Finance Services Ltd., Hamilton [member] Novartis B2 Ltd., Hamilton [member] Novartis B3 Ltd., Hamilton [member] Ciba-Geigy Japan Limited, Tokyo [member] Novartis International Pharmaceutical Investment AG, Basel [member] Novartis Bioventures AG, Basel [member] Novartis Forschungsstiftung, Basel [member] Novartis Stiftung fuer Kaderausbildung, Basel [member] Novartis Mitarbeiterbeteiligungsstiftung, Basel [member] Novartis Stiftung fuer Mensch und Umwelt, Basel [member] Stiftung der Novartis AG fuer Erziehung, Ausbildung und Bildung, Basel [member] Farmanova Saglik Hizmetleri Ltd. Sti., Istanbul [member] Ziarco Group Limited, Frimley/Camberley [member] Vivacta Limited, Frimley/Camberley, Surrey [member] Novartis US Foundation, New York, NY [member] Corthera, Inc., San Mateo, CA [member] CoStim Pharmaceuticals Inc., Cambridge, MA [member] Navigate BioPharma Services, Inc., Wilmington, NC [member] Reprixys Pharmaceuticals Corporation, Oklahoma City, OK [member] ClarVista Medical, Inc., Aliso Viejo, CA [member] Transcend Medical, Inc., Menlo Park, CA [member] Triangle International Reinsurance Limited, Hamilton [member] Trinity River Insurance Co Ltd., Hamilton [member] Sandoz Syntek Ilac Hammaddeleri Sanayi ve Ticaret A.S., Istanbul [member] Russia, Rubles RUB BRL Brazil, Brazil Real Australia, Dollars AUD CAD Canada, Dollars Disclosure of detailed information about financial instruments [text block] Disclosure of associates, net income effect [table text block] Schedule disclosing information related to associates, net income effect Associates summarized financial information Purchase price allocation associates Deferred tax assets/liabilities, expected to have impact on current taxes payable Disclosure of deferred tax assets and liabilities, expected to have impact on current taxes payable [table text block] Disclosure of unremitted earnings retained by consolidated entities for reinvestment [table text block] Unremitted earnings retained by consolidated entities for reinvestment Disclosure of amount of inventory recognized as an expense in cost of goods sold [table text block] Amount of inventory recognized as an expense in cost of goods sold Disclosure of recognized amount of inventory provisions and reversals of inventory provision [table text block] Recognized amount of inventory provisions and reversals of inventory provision Gross trade receivable from closely monitored countries [table text block] Gross trade receivable from closely monitored countries Debt securities, breakdown by currency [table text block] Debt securities, breakdown by currency Summary of treasury shares movements [table text block] Schedule disclosing information related treasury shares movements US Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities [text block] US Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities Reconciliation of liabilities arising from financing activities [table text block] Reconciliation of liabilities arising from financing activities Schedule of asset allocation, investments in shares of Novartis AG [table text block] Asset allocation, investments in shares of Novartis AG Schedule of defined contribution plans [table text block] Defined contribution plans Schedule of expense related to all equity-based participation and liabilities arising from equity-based payment transactions [table text block] Expense related to all equity-based participation and liabilities arising from equity-based payment transactions Disclosure of financial assets and financial liabilities [table text block] Disclosure of financial assets and financial liabilities Disclosure of derivative financial instruments [text block] Derivative financial instruments Contract or underlying principal amount the derivative financial instruments, by currency Disclosure of derivative financial instruments, contract or underlying principal amount the derivative financial instruments, by currency [table text block] Disclosure of fair value measurement [text block] Fair value by hierarchy Disclosure of reconciliation of changes in fair value measurement [table text block] Reconciliation of changes in fair value measurement Disclosure of monitoring of net debt or liquidity based on contractual maturities [table text block] Monitoring of net debt or liquidity based on contractual maturities Disclosure of derivative financial instruments and accrued interest on derivative financial instruments [table text block] Derivative financial instruments and accrued interest on derivative financial instruments Disclosure of other contractual liabilities of the net debt or liquidity [table text block] Other contractual liabilities of the net debt or liquidity Disclosure of ten day loss fair value VAR model [table text block] Ten day loss fair value VAR model Disclosure of ten day loss fair value VAR model, average, high, and low VAR amounts [table text block] Ten day loss fair value VAR model, average, high, and low VAR amounts Disclosure of ten day loss fair value VAR model, worst case loss scenario [table text block] Ten day loss fair value VAR model, worst case loss scenario KOREA, REPUBLIC OF South Korea Purchase of treasury shares Reduction of share capital Impact of change in ownership of consolidated entities Purchase of treasury shares, equity impact Payments out of provisions and other net cash movements in non-current liabilities Portion of consideration paid (received) consisting of cash and cash equivalents Reprixys Pharmaceuticals Corporation [member] Reprixys Pharmaceuticals Corporation Tax rate, effect of release of contingent consideration liability Effect of release of contingent consideration liability Income tax expense from continuing operations Impact of business combinations Provisions for doubtful trade receivables charged to the consolidated income statement Currency translation effects Deferred tax asset and liability valuation [abstract] Impact of new tax law deferred tax expense income recognised in profit or loss Impact of new tax law deferred tax relating to components of other comprehensive income Impact of new tax law deferred tax relating to items charged or credited directly to equity Impact of new tax law increase decrease in deferred tax liability asset Impact of new tax law increase decrease in current income tax liability Impact of new tax law change in deferred tax assets and liabilities and current tax liabilities Items previously recognized in consolidated income statement Items previously recognized in other comprehensive income Items previously recognized in retained earnings Total revaluation of deferred tax assets and liabilities Total revaluation of current income tax liabilities Total revaluation of deferred tax assets and liabilities and current income tax liabilities Impact location [axis] Impact location [member] Income statement [member] Increase to retained earnings arising from first application of IFRS 9 Undiscounted operating lease commitments Contribution of business to joint venture Percentage impact of new tax law change in deferred tax assets and liabilities and current tax liabilities Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense Impact of new tax law income tax relating to available-for-sale financia investments previously recognized through OCI Impact of new tax law income tax relating to deferred tax assets on US post retirement previously recognized through OCI Impact of new tax law effective tax rate after implemetation of new law changes Impact of new tax law tax on unremitted earnings period allowed for payment Impact of new tax law income tax relating to deferred tax assets on unremitted earnings Impact of new tax law income tax relating to revaluation of deferred tax assets on equity based compensation that were previously recognized through retained earnings Acquisitions through finance lease contracts property plant and equipment dup_1_Reversal of non-cash items dup_1_Total reversal of non-cash items Principal group companies materiality of assets or sales to third parties Other intangible asset purchase commitments Research and Development and other intangible asset purchase commitments Total Disclosure of financial instruments - narrative [table] Open hedges for anticipated transactions Transfers out of Level 3 of fair value hierarchy, assets Amount of change in OCI when pricing parameters for level 3 change more than 10% Most significant foreign exchange losses Long-term financial debt with a carrying amount Unrealized loss was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge Net investment hedge recognized in the income statement Upper limit on holdings on unrelated company Borrowings commercial paper maximum borrowing amount Debt/equity ratio VAR estimate confidence interval Borrowings commercial paper maximum amount outstanding Borrowings credit facility committed Counterparty risk [abstract] Percentage of entity's cash and cash equivalents held with financial institution Vendor [axis] Vendor [member] Largest financial institution [member] Second largest financial institution [member] Third largest financial institution [member] Pre tax profit (loss) from divestment of business Consideration transferred, divestment-date fair value Potential receivable from divestment Fair value of contingent consideration received Milestone payment already received Future put option to sell business Payment put option Interest exchanged Changes in offset against gross trade receivables Benefit payments Number of share options exercised Number of share options exercised or sold Financial liabilities, at fair value Total outstanding shares Total Novartis shares Total treasury shares Liabilities to banks and other institutions Liabilities to banks and other financial institutions Contingent consideration receivable, current Contingent consideration receivable Impact of divestments, other provisions Impact of divestments Accumulated depreciation Gross carrying amount Customers with net sales over five percent Net cash flows used in acquisitions and divestments of businesses, classified as investing activities Share of other comprehensive income of associated companies and joint ventures accounted for using equity method, net of tax Associated companies' movements in comprehensive income Impairment (loss) reversal of impairment loss recognised in profit or loss Acquired liquidity Prepaid benefit cost Accrued share-based payments Inventory Trade receivables Other comprehensive income effect Contingent consideration receivables short-term [member] Decrease of treasury share repurchase obligation under a share buyback trading plan Options excluded from the calculation dup_1_Total diluted earnings per share dup_1_-Total US commercial paper programs [member] JP commercial paper programs [member] Borrowings commercial paper, number of programs Amount of change in OCI when most significant parameters for level 3 change more than 10% Amount of change in OCI when POS for level 3 change more than 10% Advanced Accelerator Applications (AAA) [member] Advanced Accelerator Applications (AAA) Percentage of Share capital in tender offer Cash offer per ordinary share Cash offer per ADS Number of ordinary share per ADS Value of equity Maximal amount of share buyback programm dup_1_Decrease of treasury share repurchase obligation under a share buyback trading plan Description of Annual Incentive Trade payables Trade payables and commitment for repurchase of own shares Provisions and other current liabilities Total provisions and other current liabilities Revenue from sale of goods, third parties, change in percent Impact of new tax law income tax relating to deferred tax assets on US post retirement previously recognized through OCI Deferred tax on above items Benefits other than equity-based compensation Key management personnel compensation, short-term employee benefits Finance lease liabilities Finance lease obligations Share of other comprehensive income of associates and joint ventures accounted for using equity method that may be reclassified to profit or loss, net of tax Novartis share of other comprehensive income recognized by associated companies, net of taxes Intangible asset impairment charges [text block] Intangible asset impairment charges Percentage of share capital tendered at the expiration of the tender offer Transaction related costs paid Transaction related costs Amortization of fair value adjustments relating to intangible assets tax dup_1_Income from associated companies dup_1_Income from associated companies dup_1_Net income statement effect Maximum margin percentage impact of commodity price change Maximum holding in unrelated company EX-101.PRE 7 nvs-20171231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 8 nvs-20171231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Document and Entity Information link:calculationLink link:definitionLink link:presentationLink 1001000 - Statement - Consolidated income statements link:calculationLink link:definitionLink link:presentationLink 1002000 - Statement - Consolidated statements of comprehensive income link:calculationLink link:definitionLink link:presentationLink 1004000 - Statement - Consolidated statements of changes in equity link:calculationLink link:definitionLink link:presentationLink 1003000 - Statement - Consolidated balance sheets link:calculationLink link:definitionLink link:presentationLink 1005000 - Statement - Consolidated cash flow statements link:calculationLink link:definitionLink link:presentationLink 2400900 - Disclosure - Property, plant and equipment (Details) link:calculationLink link:definitionLink link:presentationLink 2400901 - Disclosure - Property, plant and equipment (Details 2) link:calculationLink link:definitionLink link:presentationLink 2100900 - Disclosure - Property, plant and equipment link:calculationLink link:definitionLink link:presentationLink 2300900 - Disclosure - Property, plant and equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 2101300 - Disclosure - Inventories link:calculationLink link:definitionLink link:presentationLink 2301300 - Disclosure - Inventories (Tables) link:calculationLink link:definitionLink link:presentationLink 2401300 - Disclosure - Inventories (Details) link:calculationLink link:definitionLink link:presentationLink 2100700 - Disclosure - Earnings per share link:calculationLink link:definitionLink link:presentationLink 2300700 - Disclosure - Earnings per share (Tables) link:calculationLink link:definitionLink link:presentationLink 2400700 - Disclosure - Earnings per share (Details) link:calculationLink link:definitionLink link:presentationLink 2100100 - Disclosure - Significant accounting policies link:calculationLink link:definitionLink link:presentationLink 2100500 - Disclosure - Interest expense and other financial income and expense link:calculationLink link:definitionLink link:presentationLink 2100600 - Disclosure - Taxes link:calculationLink link:definitionLink link:presentationLink 2101000 - Disclosure - Goodwill and intangible assets link:calculationLink link:definitionLink link:presentationLink 2101100 - Disclosure - Deferred tax assets and liabilities link:calculationLink link:definitionLink link:presentationLink 2200100 - Disclosure - Significant accounting policies (Policies) link:calculationLink link:definitionLink link:presentationLink 2300100 - Disclosure - Significant accounting policies (Tables) link:calculationLink link:definitionLink link:presentationLink 2300500 - Disclosure - Interest expense and other financial income and expense (Tables) link:calculationLink link:definitionLink link:presentationLink 2301000 - Disclosure - Goodwill and intangible assets (Tables) link:calculationLink link:definitionLink link:presentationLink 2301100 - Disclosure - Deferred tax assets and liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 2400100 - Disclosure - Significant accounting policies (Details) link:calculationLink link:definitionLink link:presentationLink 2400500 - Disclosure - Interest expense and other financial income and expense (Details) link:calculationLink link:definitionLink link:presentationLink 2400501 - Disclosure - Interest expense and other financial income and expense (Details 2) link:calculationLink link:definitionLink link:presentationLink 2300600 - Disclosure - Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 2400600 - Disclosure - Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 2400601 - Disclosure - Taxes (Details 2) link:calculationLink link:definitionLink link:presentationLink 2400602 - Disclosure - Taxes (Details 3) link:calculationLink link:definitionLink link:presentationLink 2401000 - Disclosure - Goodwill and intangible assets (Details) link:calculationLink link:definitionLink link:presentationLink 2401001 - Disclosure - Goodwill and intangible assets (Details 2) link:calculationLink link:definitionLink link:presentationLink 2401100 - Disclosure - Deferred tax assets and liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 2401101 - Disclosure - Deferred tax assets and liabilities (Details 2) link:calculationLink link:definitionLink link:presentationLink 2401102 - Disclosure - Deferred tax assets and liabilities (Details 3) link:calculationLink link:definitionLink link:presentationLink 2401103 - Disclosure - Deferred tax assets and liabilities (Details 4) link:calculationLink link:definitionLink link:presentationLink 2400101 - Disclosure - Significant accounting policies (Details 2) link:calculationLink link:definitionLink link:presentationLink 2101200 - Disclosure - Financial and other non-current assets link:calculationLink link:definitionLink link:presentationLink 2301200 - Disclosure - Financial and other non-current assets (Tables) link:calculationLink link:definitionLink link:presentationLink 2401200 - Disclosure - Financial and other non-current assets (Details) link:calculationLink link:definitionLink link:presentationLink 2401201 - Disclosure - Financial and other non-current assets (Details 2) link:calculationLink link:definitionLink link:presentationLink 2401202 - Disclosure - Financial and other non-current assets (Details 3) link:calculationLink link:definitionLink link:presentationLink 2101600 - Disclosure - Other current assets link:calculationLink link:definitionLink link:presentationLink 2301600 - Disclosure - Other current assets (Tables) link:calculationLink link:definitionLink link:presentationLink 2401600 - Disclosure - Other current assets (Details) link:calculationLink link:definitionLink link:presentationLink 2101500 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents link:calculationLink link:definitionLink link:presentationLink 2301500 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Tables) link:calculationLink link:definitionLink link:presentationLink 2401500 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details) link:calculationLink link:definitionLink link:presentationLink 2401501 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 2) link:calculationLink link:definitionLink link:presentationLink 2401502 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 3) link:calculationLink link:definitionLink link:presentationLink 2101800 - Disclosure - Non-current financial debt link:calculationLink link:definitionLink link:presentationLink 2100200 - Disclosure - Significant transactions link:calculationLink link:definitionLink link:presentationLink 2102000 - Disclosure - Current financial debt and derivative financial instruments link:calculationLink link:definitionLink link:presentationLink 2102700 - Disclosure - Commitments and contingencies link:calculationLink link:definitionLink link:presentationLink 2403000 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date (Details) link:calculationLink link:definitionLink link:presentationLink 2301800 - Disclosure - Non-current financial debt (Tables) link:calculationLink link:definitionLink link:presentationLink 2302000 - Disclosure - Current financial debt and derivative financial instruments (Tables) link:calculationLink link:definitionLink link:presentationLink 2302700 - Disclosure - Commitments and contingencies (Tables) link:calculationLink link:definitionLink link:presentationLink 2400200 - Disclosure - Significant transactions link:calculationLink link:definitionLink link:presentationLink 2401800 - Disclosure - Non-current financial debt (Details) link:calculationLink link:definitionLink link:presentationLink 2401801 - Disclosure - Non-current financial debt (Details 2) link:calculationLink link:definitionLink link:presentationLink 2401802 - Disclosure - Non-current financial debt (Details 3) link:calculationLink link:definitionLink link:presentationLink 2401803 - Disclosure - Non-current financial debt (Details 4) link:calculationLink link:definitionLink link:presentationLink 2401804 - Disclosure - Non-current financial debt (Details 5) link:calculationLink link:definitionLink link:presentationLink 2401805 - Disclosure - Non-current financial debt (Details 6) link:calculationLink link:definitionLink link:presentationLink 2402000 - Disclosure - Current financial debt and derivative financial instruments (Details) link:calculationLink link:definitionLink link:presentationLink 2402700 - Disclosure - Commitments and contingencies (Details) link:calculationLink link:definitionLink link:presentationLink 2402701 - Disclosure - Commitments and contingencies (Details 2) link:calculationLink link:definitionLink link:presentationLink 2103000 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date (Details) link:calculationLink link:definitionLink link:presentationLink 2102100 - Disclosure - Provisions and other current liabilities link:calculationLink link:definitionLink link:presentationLink 2102300 - Disclosure - Acquisitions of businesses link:calculationLink link:definitionLink link:presentationLink 2102400 - Disclosure - Post-employment benefits for associates link:calculationLink link:definitionLink link:presentationLink 2302100 - Disclosure - Provisions and other current liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 2302300 - Disclosure - Acquisitions of businesses (Tables) link:calculationLink link:definitionLink link:presentationLink 2302400 - Disclosure - Post-employment benefits for associates (Tables) link:calculationLink link:definitionLink link:presentationLink 2402100 - Disclosure - Provisions and other current liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 2402101 - Disclosure - Provisions and other current liabilities (Details 2) link:calculationLink link:definitionLink link:presentationLink 2402102 - Disclosure - Provisions and other current liabilities (Details 3) link:calculationLink link:definitionLink link:presentationLink 2402300 - Disclosure - Acquisitions of businesses (Details) link:calculationLink link:definitionLink link:presentationLink 2402400 - Disclosure - Post-employment benefits for associates (Details) link:calculationLink link:definitionLink link:presentationLink 2402401 - Disclosure - Post-employment benefits for associates (Details 2) link:calculationLink link:definitionLink link:presentationLink 2402402 - Disclosure - Post-employment benefits for associates (Details 3) link:calculationLink link:definitionLink link:presentationLink 2402403 - Disclosure - Post-employment benefits for associates (Details 4) link:calculationLink link:definitionLink link:presentationLink 2402404 - Disclosure - Post-employment benefits for associates (Details 5) link:calculationLink link:definitionLink link:presentationLink 2402405 - Disclosure - Post-employment benefits for associates (Details 6) link:calculationLink link:definitionLink link:presentationLink 2402406 - Disclosure - Post-employment benefits for associates (Details 7) link:calculationLink link:definitionLink link:presentationLink 2402407 - Disclosure - Post-employment benefits for associates (Details 8) link:calculationLink link:definitionLink link:presentationLink 2402408 - Disclosure - Post-employment benefits for associates (Details 9) link:calculationLink link:definitionLink link:presentationLink 2402409 - Disclosure - Post-employment benefits for associates (Details 10) link:calculationLink link:definitionLink link:presentationLink 2401402 - Disclosure - Trade receivables (Details 3) link:calculationLink link:definitionLink link:presentationLink 2401401 - Disclosure - Trade receivables (Details 2) link:calculationLink link:definitionLink link:presentationLink 2401400 - Disclosure - Trade receivables (Details) link:calculationLink link:definitionLink link:presentationLink 2301400 - Disclosure - Trade receivables (Tables) link:calculationLink link:definitionLink link:presentationLink 2101400 - Disclosure - Trade receivables link:calculationLink link:definitionLink link:presentationLink 2401403 - Disclosure - Trade receivables (Details 4) link:calculationLink link:definitionLink link:presentationLink 2401404 - Disclosure - Trade receivables (Details 5) link:calculationLink link:definitionLink link:presentationLink 2103100 - Disclosure - Principal Group subsidiaries and associated companies link:calculationLink link:definitionLink link:presentationLink 2303100 - Disclosure - Principal Group subsidiaries and associated companies (Tables) link:calculationLink link:definitionLink link:presentationLink 2403100 - Disclosure - Principal Group subsidiaries and associated companies (Details) link:calculationLink link:definitionLink link:presentationLink 2402901 - Disclosure - Discontinued operations (Details 2) link:calculationLink link:definitionLink link:presentationLink 2402900 - Disclosure - Discontinued operations (Details) link:calculationLink link:definitionLink link:presentationLink 2302900 - Disclosure - Discontinued operations (Tables) link:calculationLink link:definitionLink link:presentationLink 2102900 - Disclosure - Discontinued operations link:calculationLink link:definitionLink link:presentationLink 2402203 - Disclosure - Details to the consolidated cash flow statements (Details 4) link:calculationLink link:definitionLink link:presentationLink 2402202 - Disclosure - Details to the consolidated cash flow statements (Details 3) link:calculationLink link:definitionLink link:presentationLink 2402201 - Disclosure - Details to the consolidated cash flow statements (Details 2) link:calculationLink link:definitionLink link:presentationLink 2402200 - Disclosure - Details to the consolidated cash flow statements (Details) link:calculationLink link:definitionLink link:presentationLink 2302200 - Disclosure - Details to the consolidated cash flow statements (Tables) link:calculationLink link:definitionLink link:presentationLink 2102200 - Disclosure - Details to the consolidated cash flow statements link:calculationLink link:definitionLink link:presentationLink 2402202 - Disclosure - Details to the consolidated cash flow statements (Details 3, Parenthetical) link:calculationLink link:definitionLink link:presentationLink 2100300 - Disclosure - Segmentation of key figures link:calculationLink link:definitionLink link:presentationLink 2100400 - Disclosure - Associated companies link:calculationLink link:definitionLink link:presentationLink 2100800 - Disclosure - Changes in consolidated statements of comprehensive income link:calculationLink link:definitionLink link:presentationLink 2101900 - Disclosure - Provisions and other non-current liabilities link:calculationLink link:definitionLink link:presentationLink 2102500 - Disclosure - Equity-based participation plans for associates link:calculationLink link:definitionLink link:presentationLink 2102600 - Disclosure - Transactions with related parties link:calculationLink link:definitionLink link:presentationLink 2102800 - Disclosure - Financial instruments - additional disclosures link:calculationLink link:definitionLink link:presentationLink 2300300 - Disclosure - Segmentation of key figures (Tables) link:calculationLink link:definitionLink link:presentationLink 2300400 - Disclosure - Associated companies (Tables) link:calculationLink link:definitionLink link:presentationLink 2300800 - Disclosure - Changes in consolidated statements of comprehensive income (Tables) link:calculationLink link:definitionLink link:presentationLink 2301900 - Disclosure - Provisions and other non-current liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 2302500 - Disclosure - Equity-based participation plans for associates (Tables) link:calculationLink link:definitionLink link:presentationLink 2302600 - Disclosure - Transactions with related parties (Tables) link:calculationLink link:definitionLink link:presentationLink 2302800 - Disclosure - Financial instruments - additional disclosures (Tables) link:calculationLink link:definitionLink link:presentationLink 2400300 - Disclosure - Segmentation of key figures (Details) link:calculationLink link:definitionLink link:presentationLink 2400400 - Disclosure - Associated companies (Details) link:calculationLink link:definitionLink link:presentationLink 2400800 - Disclosure - Changes in consolidated statements of comprehensive income (Details) link:calculationLink link:definitionLink link:presentationLink 2400801 - Disclosure - Changes in consolidated statements of comprehensive income (Details 2) link:calculationLink link:definitionLink link:presentationLink 2400802 - Disclosure - Changes in consolidated statements of comprehensive income (Details 3) link:calculationLink link:definitionLink link:presentationLink 2400803 - Disclosure - Changes in consolidated statements of comprehensive income (Details 4) link:calculationLink link:definitionLink link:presentationLink 2401900 - Disclosure - Provisions and other non-current liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 2402500 - Disclosure - Equity-based participation plans for associates (Details) link:calculationLink link:definitionLink link:presentationLink 2402501 - Disclosure - Equity-based participation plans for associates (Details 2) link:calculationLink link:definitionLink link:presentationLink 2402502 - Disclosure - Equity-based participation plans for associates (Details 3) link:calculationLink link:definitionLink link:presentationLink 2402503 - Disclosure - Equity-based participation plans for associates (Details 4) link:calculationLink link:definitionLink link:presentationLink 2402504 - Disclosure - Equity-based participation plans for associates (Details 5) link:calculationLink link:definitionLink link:presentationLink 2402505 - Disclosure - Equity-based participation plans for associates (Details 6) link:calculationLink link:definitionLink link:presentationLink 2402506 - Disclosure - Equity-based participation plans for associates (Details 7) link:calculationLink link:definitionLink link:presentationLink 2402507 - Disclosure - Equity-based participation plans for associates (Details 8) link:calculationLink link:definitionLink link:presentationLink 2402508 - Disclosure - Equity-based participation plans for associates (Details 9) link:calculationLink link:definitionLink link:presentationLink 2402600 - Disclosure - Transactions with related parties (Details) link:calculationLink link:definitionLink link:presentationLink 2402601 - Disclosure - Transactions with related parties (Details 2) link:calculationLink link:definitionLink link:presentationLink 2402602 - Disclosure - Transactions with related parties (Details 3) link:calculationLink link:definitionLink link:presentationLink 2402800 - Disclosure - Financial instruments - additional disclosures (Details) link:calculationLink link:definitionLink link:presentationLink 2401002 - Disclosure - Goodwill and intangible assets (Details 3) link:calculationLink link:definitionLink link:presentationLink 2401003 - Disclosure - Goodwill and intangible assets (Details 4) link:calculationLink link:definitionLink link:presentationLink 2400302 - Disclosure - Segmentation of key figures (Details 2) link:calculationLink link:definitionLink link:presentationLink 2400303 - Disclosure - Segmentation of key figures (Details 3) link:calculationLink link:definitionLink link:presentationLink 2400304 - Disclosure - Segmentation of key figures (Details 4) link:calculationLink link:definitionLink link:presentationLink 2400305 - Disclosure - Segmentation of key figures (Details 5) link:calculationLink link:definitionLink link:presentationLink 2400306 - Disclosure - Segmentation of key figures (Details 6) link:calculationLink link:definitionLink link:presentationLink 2400307 - Disclosure - Segmentation of key figures (Details 7) link:calculationLink link:definitionLink link:presentationLink 2400401 - Disclosure - Associated companies (Details 2) link:calculationLink link:definitionLink link:presentationLink 2400402 - Disclosure - Associated companies (Details 3) link:calculationLink link:definitionLink link:presentationLink 2400403 - Disclosure - Associated companies (Details 4) link:calculationLink link:definitionLink link:presentationLink 2400404 - Disclosure - Associated companies (Details 5) link:calculationLink link:definitionLink link:presentationLink 2400405 - Disclosure - Associated companies (Details 6) link:calculationLink link:definitionLink link:presentationLink 2401901 - Disclosure - Provisions and other non-current liabilities (Details 2) link:calculationLink link:definitionLink link:presentationLink 2401902 - Disclosure - Provisions and other non-current liabilities (Details 3) link:calculationLink link:definitionLink link:presentationLink 2401903 - Disclosure - Provisions and other non-current liabilities (Details 4) link:calculationLink link:definitionLink link:presentationLink 2401904 - Disclosure - Provisions and other non-current liabilities (Details 5) link:calculationLink link:definitionLink link:presentationLink 2401905 - Disclosure - Provisions and other non-current liabilities (Details 6) link:calculationLink link:definitionLink link:presentationLink 2101700 - Disclosure - Equity link:calculationLink link:definitionLink link:presentationLink 2301700 - Disclosure - Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 2401700 - Disclosure - Equity (Details) link:calculationLink link:definitionLink link:presentationLink 2401701 - Disclosure - Equity (Details 2) link:calculationLink link:definitionLink link:presentationLink 2401702 - Disclosure - Equity (Details 3) link:calculationLink link:definitionLink link:presentationLink 2401703 - Disclosure - Equity (Details 4) link:calculationLink link:definitionLink link:presentationLink 1005010 - Statement - Consolidated cash flow statements (Parenthetical) link:calculationLink link:definitionLink link:presentationLink 2400301 - Disclosure - Segmentation of key figures (Details 1) link:calculationLink link:definitionLink link:presentationLink 2401704 - Disclosure - Equity (Details 5) link:calculationLink link:definitionLink link:presentationLink 2402204 - Disclosure - Details to the consolidated cash flow statements (Details 5) link:calculationLink link:definitionLink link:presentationLink 2402801 - Disclosure - Financial instruments - additional disclosures (Details 2) link:calculationLink link:definitionLink link:presentationLink 2402802 - Disclosure - Financial instruments - additional disclosures (Details 3) link:calculationLink link:definitionLink link:presentationLink 2402803 - Disclosure - Financial instruments - additional disclosures (Details 4) link:calculationLink link:labelLink link:presentationLink link:definitionLink 2402804 - Disclosure - Financial instruments - additional disclosures (Details 5) link:calculationLink link:definitionLink link:presentationLink 2402805 - Disclosure - Financial instruments - additional disclosures (Details 6) link:calculationLink link:definitionLink link:presentationLink 2402806 - Disclosure - Financial instruments - additional disclosures (Details 7) link:calculationLink link:definitionLink link:presentationLink 2402807 - Disclosure - Financial instruments - additional disclosures (Details 8) link:calculationLink link:definitionLink link:presentationLink 2402808 - Disclosure - Financial instruments - additional disclosures (Details 9) link:calculationLink link:definitionLink link:presentationLink 2402809 - Disclosure - Financial instruments - additional disclosures (Details 10) link:calculationLink link:definitionLink link:presentationLink 2402810 - Disclosure - Financial instruments - additional disclosures (Details 11) link:calculationLink link:definitionLink link:presentationLink 2402811 - Disclosure - Financial instruments - additional disclosures (Details 12) link:calculationLink link:definitionLink link:presentationLink 2402812 - Disclosure - Financial instruments - additional disclosures (Details 13) link:calculationLink link:definitionLink link:presentationLink 2401104 - Disclosure - Deferred tax assets and liabilities (Details 5) link:calculationLink link:definitionLink link:presentationLink 2400102 - Disclosure - Significant accounting policies (Details 3) link:calculationLink link:definitionLink link:presentationLink GRAPHIC 9 x_arcoverfront.jpg IMAGE begin 644 x_arcoverfront.jpg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

  •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cogo_0001.gif IMAGE begin 644 cogo_0001.gif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end GRAPHIC 11 cogo_0002.gif IMAGE begin 644 cogo_0002.gif M1TE&.#EA_@)Z ?< 0! 0D$!0X)"@P'"!$-#A,/$!41$AD5%AL7&!X:&QL0 M#2$='B 5$R,?("4B(RDE)BTI*BLG*#(N+C,O,#8R,S@U-CTY.CHW.$$]/D,_ M0$5!0DE%1DY+2TM'2%!-3E)/4%524UQ966!=7F)?8&5B8VMI:7!M;7)O<'5R M(%^?@!%G@A6BQ-DFP!,H@!4I@!7J !=J@U?K !CK@IEKQ)CKAII MK !GL IGL !KL@MMLP!NN1%GL!)MLQIMLP9PM0QQM0!PNQ-SMAITMQ9VN!MW MN!=XN1MYN2-TMR)WN"-\NRI^O"EWMS)\NSA_O2-SJX)_@": O2R"OC*#OSJ$ MOT"$OR^%P#2&P#J'P#>(P3R*PD.&P$*.Q$N.Q$61QDN3QTV5R$^8R5*2QU*6 MR%F6R%29RER>S5N3QV*>S&B=S%Z@SF.BSFJCSW&CSV:DT&NFT6ZHTG*FT72K MTWJNU7VQUG^TV'>PUHV+C(:$A)".CY22DYB6EYV;FYN8F)&/D*6CI*BFIZNJ MJK2SL[R[N[BWM["OKZ"?G\"_OX.NU8BOUH&RUX2UV(JVV8>XVHR[VXNRUY&V MV9.]W9F_W<&_P);!WIK!WZ#"WY?#X)S$X)_(XJ+&X:3)XZO,Y*C'XK'/YK/1 MY[;3Z+S5Z;[8Z[C1YZ_0YL3#Q,S+S,C'Q]#/S]/2T]S;V]C7U]#/T.#?W\'6 MZL3;[,K>[LW@[]#A[\[B\-3D\=GG\M?H\]SJ]./CX^SL[.CGY^/M]NCO]^;P M]^CP]^?Q^.SS^?3T]/+V^O7Y_/____#O[P M M M M "'Y! (?\+26UA9V5-86=I8VL-9V%M;6$] M,"XT-30U-0 L /X">@$ "/X BPD<*) 8P8,($RINW;MX\\)D!<' 0D8%B0@H$BFD((**@WLN8,VO>S+FSYXX>$J,P1NP4A $&? H4IHK556&P!UJ]:JQU MV=G%=.DB:U/8J54'U OZYO?OW\./+GP]QP0(,7 NE6 %<6!X(!!QPP2'% M& *!!(0()((#E?4Q 0$&4 "(0"LT( (@":A B ,8 '(! @ND(- J("PP@("% M%"-(!!@<Z-08?6BFJ>::;+89T@,% MK$#6G):=$$ "(7!@P " &-/ "CL9.(A@@1P @@+"E(,24,$ $" )A@2 . M'&#?GRE6 , $47! @ /""#) I0W8-\ @C([IP040GE(,"?X!+$ "!I_J9!-8 M$12 P8L#4'4(A!R$D$ 6KK2@ $/E+C 9%9$$!D?9R(Z)*&%#/! ",8"H+G&#*+"!@GPB,H@!1S0]VE[@+6 MWK'M(54'&W@0P0 7L&Q F6O0( $@3A0 -3%J-*Q'TM?<-4'D$DV FJ6!KW MW &JXJP!"W2P G9:]^[[[\ 'GY!]&MBDRRH<$]!''SZW(A @TYDB3 0&K)!! M (*H8D #%F!@00=YYJ+"Y^6UO)C? SQ,00"0J6 XX@@L/L >S"_@O$$&Z4$ MB]XC*L)58WL+0'$F#N*B"PDNO<=@ '7,![X"N3+E1@ M@00,8 /X)WP1DC"$IIP/AF T0H,(@P1#,8/J+#1A(JA @,X #@D* $&N" M7>B">OY4*<8N5.$J?T&@?'XY'^,.$0 (Z,04@SE >.$4 J""7?1A,-4YTR+G2<]ZVM,CB/Z@P)X",( 3F MYFH* 0 /\SSRY"@#0R$(" Q!T !W (0 A-,: *@<11 # M %HV4 Q-J448.@4 2):C#TP( O/>D]ITK5JEJU(<(HA![TD")7%,(5JRD$ M'O: BL:D A&4X(Y 3N$'/!#B*JP@A"FRL@M"(.(XPC %(8!S,#](3Z^YT(5= M=Y/70K!'&(,8J]Y60P@\^&&Q JFK]!"!AT-0S3IM'01<3(&'/NB"%85PWBD( MX;RUMO6M V'%(1P+V:NZ]K6PC?XM8V1+V]K:]K:?$49C=DNG@\C3,F[Q;7#G M=*;BNF4K"?GMD5:3W.5VI;>[Q5]PE8O;ZEKWNMC-KG:WR]WN>O>[X VO>,=+ MWO*:][SH3:]ZU^O=WU*7NAF1)WP[XE[A$M?C=2W\,TU[_//4E_!?Q? MF,B7P %.R8'9R^ &._C!$(:(*"9,X5=0>,(6%L4H+EQA4G#8PZ+(L(<(AM_.(>O.M6P1O6K1QWK6I]ZUIW&M:TO78,8,(+1'=&!L'<@;!T0V]C" M!D*QE3WL8CO[V,4F-K.3[>QJ'UO9S)YVM9NM@VE#V]K4YK:XH2UM9RO[V^!^ M=K++O6UN9SO<[;YVM-N-[&[/^][UEO>RQ:WN>6N;W.FN-[^WK6^!I]O;_^_SG0 ^ZT(=.]*(;_>A(3[K2 ME\[TICO]Z5"/NM2G3O5AW]RY.;](U;?.]:Y[_>M@#[O8QT[VLIM]ZSNX>M8S MUKU_K<<6#WOOO][X /O. ';_2T-R+O&"&\XI/. M]\4[_O&0CSS@\8YXBDC^\IC/O.8CW_C-A_WJ^ZW\03Q/^M*;_O2H-WOGGPX$ MRHL^(G9??>JI3H/9VU[U09<]U'7O=MX+W?=*3SO.7S^1L@-_][??^?&3S_SF MZV#YRZ=Z]*?N>N([A.?3Q_[3H_Z?_=]WO?O.#__MP>]L\@_=_'8W/-:MWQ"D MH]_X4^=^T5=__/<''.PA-WO'\U]Z^^?^\O['=-E' X[ ?K#7=/5';]D7@.Y7 M?@+H@&?G:*U&>[57;(]F@8X6=#30>!FX=)_6>:TF@<+6@49G:C]7@IF M?CLX?_[CAW:@9X/MIWP*Z'>'^'.Z%XG4=WC#$ O!4 R54($T\&DC6'N>6&RD M]HDZP(F>2 .;4 Q34'LX$ L"004T0 4"$0NBN($6&(HTP N\4'NU, NE"(HH MV(F_6&V=* /")@.B4 R=L 3#5@O% NC<"1%, 7%P FC>(RA6 ,;:(JU1P-R M4 QI$ .V^(G=F ;%P ;=& -A4 QTT(T="&DC&(J0&(,OJ'UM)WR,>'U?EX.4 MZ'PTH 7%P M(( -&$ L"V8=GP A?4'M; 9$, =OD(1$$ =U (L[$ 9;L 1F M@ ,^T :,0 9IEPG%( 5PV(J_4 R+ -S4 R_0 NFQ@1U,/X'1L!W-/ %C, & M:=<%P? +9K #9$ &.H"12U '9,!W.[ &/U69_ECEX-9B/!.%T#-B"?9>93K<#,D '["@#0" #GK@#L% ,M@"6 M,9",N" 0H4 #4Q ,PS";9T #P\ +OW +2^ +Q.",F2 #GC"2W5@+N& +LB # ML& +N% +,G & 8F;L"@)Q7 +Q?X@"SAPG*ZY!+_ "SLPE2=9#'- \DX#">Y M"7UH;-$XFZ- ][Y"UC =TLP#,40"DFIF@#)"UFQ!460B;10#,69C+)0#$OP M:]H9"TI8#+,9D$.@ ZVY:+! ]1Y!CO0"\4P#,[8CJZHG980F\4PH%,@"L,0 M"L5 BX[W?I.X>"O8>L/'F3?X?^+GF4OG@C2 ">!HF[4 "[&@!6U0#&00 ]BY M!"(Y!SOPFCO0"<5@!#10"[] !+/I"$B !9C0!#)P"\1 R(I!Y& S01@-D\* C&@2RB M#$*1W@ 23L 19.@PTP G% M I+T 7%( DP$*=G0)V=@ .IJ 5^^08Q8*AGL(YA8*ASFHIO8(Y#BIU@^*E, M0(V@L -: 9&6*/-1P.')Z,SVG.BZ8A>]YF5>7Y#UWJ_1@>B:4J [(@#R8@#.VML.$ +4:J+N$ $OP +2% ,HK $5- %4T"='HL%74 %.L + MN&",P5"POV"G.Y"P6_"PACJHK6<)Q; %+Y %FKBHQV:AQ> (,? "7D"@'[L) M,O"G,XCH "Z%@L&FGHV>P!ANJJLA9BK2PI:FX M"3@PG#( "N89!\2P"#KP"[U@!I) #&'PI 2*!'AJL -;"UPJ$!K*GE#YI[1P M!LZ(!:);;$N0B;"P"2<)!E_I"3)PN750@/V[H2FKBC0P!+W@"Q+X BOL -S$ M-2&R6 HX M :U 8T J#&@26, S#D E%P(;)V MT\'QT* M(T F>L .?P(6R; DZ8 1A M8+C%@ F<" 8#2@N*N0.;\ G.%HN=$ S#F08T( 6R0 .6@M?( -F4 M;D,>N2 MA( .<# 8RL C!T N5S 8Q0 9[ M+(B-8,FE2 9:R@MOH,5BO*+[N'<^IW[(FA"7Z<;$>L;D:X\\5WNM]X[N.(PC M2(K:*-$ZD)<7:(+%IM'&*-'MJ8+/UX<:/8$9"-&!2\3)2/X&P0B'$'V9M0>5 MG,B!-/F+$6V!(2W1ID:3M5?1I3C1OTB3+%W3%]V>_AQ[Q-J/BUC0G4FUIX>] MA#AS^1>'7GA_ YUPQ:R'OU +:1!]_ =TA&C50??5=)> "?UY!:C4HR=Y7ES6 M\2=U.*""&LW6=:+W47*S0]UT7=W75KM]@/UTQKI^2GW0?)W7 M;Q>):SW8CBV)C^US.PA\9+W1Q'BL=RT08>=[C4UZGCL2W;=#>. M3%V*EJG%P@C22D>"Q4R#[^?<1?Y=@M.]T9\FCW7'BEH;MF4!@E4,0!T% B9 9H<46!I- !&_U=W3O'!JO8W62PF\\7!/0]44@F5]0XDE7J2>^T5_@R3L7X?2&WT_GAV;\B'X- MVZB]T#Q.;S10F)Y0@3IMV8Y6!+UPR6PX#'>PI"4N@I\(@DV>SYT@;-K8C;%P!AUMTQ9=S)U0 MP6E'X/ZKAXK%L.$ZD,)(0(8O#8,ZP-QD^-:?\ 8PX B,(-)USH-@0 R=, #/)^66?=ZD^,7&/8$SR-UMGG:R@)&?P($Q, G%N>?&5IHAB[=0WHFQL 8O M+0.;4 M2,,.<&.OGG=,;;8M( M$,()Y*0.2P)Y;?HRAT 8=W8$[, L'?N>' MWNG4_HE ,0PG(0$#L=>G=1WS>FS376M!PJ-( M,P'='D -4$ 90J0-$L -? M8( #&IGE(&\&_5[O.P &9 GG+>Z6R&:;$U^*<]Z>CTD$ M]1F5[(X#32AL0T#O(X@%9D $-% $^"WU._#T(Y@)M@ +^OX+_8X#70 &^L[O M-& $)K^827\%.R +CN"'[5[V[3YLOR 'XA@#;] +.E $-< $@'R179"7MUQL M1M#W.[#N]5W,5*#SW8@$9@"+.I#R9C"3-$ $&$GXL>CX-'#T5GGY&-H(FJ"" M6U#YM6<)%U^*5$\$&"WQ$JK,PT8+=^#OQ.8#1# &_GWY)H_R.W#S--GX*Y^$ M/0\&04"DEM#1?-?B05 #01 +C?YP\!=I]K89P<36\&D7!$1 !&1@]0K?C3X M\'FY T/P_0<^":,P!#@P!&-@AW.7QISYS^%.V$80#$80"HO@:*$ "J "[RP M!$$P"P#A*92M43(6D8JU2<.&F!P28*U*0:CFZ^"4:'1J1;4AU.1P")&BLBH+W-J;?**A4:H M49)L8=F!L5.O332&F 2%:TF76C(8U>H9)X:L,S2 &";E$4?,F3Y$O:%! Q:9 M4&QB8/[RB(O*G$\RA@Q+$\.,K)$CY]+Y-"G&DF!(=ICLA$N)G8TR'DG:PNM1 MUJVB9%E*0XQ7F4699( "M1<+CATRS/2:BD-&C!HT/GGJQ6;)K4^P8.E 4I0& M%EPX/GT*%>O6DJDZ:%1:V:M-C#:X-LVR9"M9X IF"B/>&D66'6B0Y"U>]I,E MC"QJH:&+7J*KI1(92'EE$ENFP**77R9A\"U;OI"!#EX^VS&!$ M$BIXN2248>"0@0Q>L-**JTM@"48+&2JYJ9(X6&2YLC5%%V6T44*5,UZ X14SSH@%AACNF((Z&8H]-J1B>*6!%S,:R>2%%Q;I MJQA'7K(D"1;&F 6&14*)H8A?@H#%DHEXZ>(+7G!0;1B1[&-D#!9^Z$6'PVB( MH1-&PL"E!OZ*00('(&C((F(99/F"#EL8[J21(3:1@85)*J&A&#-@8"(8'20! M)888'&EDBUIT:/?=6F*(90T9'OYK9)AA,RGW!48FH38&)G#1(98PP-CYA2Y@ MN;%"6R2)89-&9!AXKCN(&(:*(H@! N9C84EV!QQJR6(.@Q'>P0YBEM!!AE?F M> $33.SUX84SP+#8H%AHT&$+2R:Q Z98[*M%L1A*D22(7HI8KQ<::-TNRI=H M, .7'6( 0Q0D@L$BAAWXI>,6AC]AQ(QJKRTB#%X^I^*7(9S>XF-;WC#=ET>* M<(X%2"#?U&8PH89 MV?-S,& 9 I@APJCCA1AFV0+=GVN8 A@?6&"##!A@P?L,.MR/!1EDP(LJ$,L2 MYF*$)?ZH0+'W=0(&6/#%#ACC/E&888%+@,$;:@&#XKT@#K"P%K:DMRH2EI!1 M-'"$J52X0A:VT(4OA"&F3#A#&E[,/&U((15X-H;,0&T(1;%/(RI1!T_$0 >U M /AB, +(L0"#(6BC24JX8A:9"(O*]G"")&H1-'8@@A!](0H0O&;4-3"![Q0 M @YP,(0[/$(6R9L3#8C0"WPUYG)?L$-?=$"$612A-3A8@R0Z$8P=..(2F9'$ M(QZA(1T,X2$Z6%#Y[MB=4#B"@[<,AA%DP<,]^J*)3ZR%&L\@2($Y0BL7&P4=8# )3^-E(.@$,4*B3!G<3:",F00PR=%(NM1CC(T#A1%G1 MH'JS0>H1-F>!\86%H%,G0!+(TH[A(L(8?SC) &H%C$ M1&31(/XDT((,A/-!+W9 !]AB+1:D>.(MTDNRZHP";Y-P#@ZP, =?+%5MT%." M.V%P V(P011LD,$21DJ#,LCBJ?X,U.5N3 ,O$/0QFU@J$'8P!#9,"0C$:@1J M;57A'7RA$<7H@B0"])A:A($4&KXE/J#LZK^;X" H8)")3U"AQ$9XP^ > M PN,PC6BJQ,_X$XW*AL%4G+)$R M7NW %V @(B)=8IB%3B$6L3!2+'@5@TIL(8$P>$$G-$IA6##,$;"H03'BP#5> MA&%>,=@>'3HI!1F 1@RD!\ MX O%T$%Q9>#02OCK7<@QN5J)8-.8/5B8?"D:FK!VB_$@ C! MR(+\'/J(.Z@TX770PB^(T'%"QD+#%*I%O7]AS*4WO5PL58WG8$ %BWSE><6X ML4@T\[_]5N%CFZ:%; ^/(58> 4=^$%1.!3<@J29,(XE.!VH&(N7 (59$(5: MF *50/X"&@@"(_2$1<"%,: "8K"$9!J"=,H,43@#I0$%4DB#%IP*_5J)AUL$ M.I@W&@"F&' *I*@%W+*[6;"TMIC#1G@$)+@%4-@$1["%+& >IZJ%BKG!41@M MR4L36/ $KB.#3F@,H'FO'0"%6IA"N9@Y1L@,:9D97/@$7, I6P@]+""&*4"" M89"+B_&$NGL,1B &J;C!'&0"-1*%5U"C!@D96(A#3-B<8#$#.A#&& P,,J@/ MZA@D6NB%.=B$++!$PED"6C".3UB01NB%[Y %'!"%45BK6VH-.JP%AQ"@,L"% M4+@%1Y@9E*&(1R "@GB%6F "P["%4B2#&'B%+]B"*8&[4?ZX049(#T)TA";9 M F(@F8)T",^8 UZ0B5JXLD@OJH 2KX AQPR2!HC1V@ B;P"\HI C^*N1T8&*:8@CH M.:(;QRG0@I>PC8'!3/O @KL;F/[6B#D=R*?2A"0@J($=V (C>*Z\E#G7.,T% MV8%\4K)Z=$'7A*347(\N6)"1R*?;M(\E (,A<,G@?$FMRA:22$W6= TJZ(+N M& DU3F_X(P2**J)HL(&@J1:G/O\H,$FS.(K"%*!NL+&V4S$@4UWB4+-2(7^%2 MZ:FL+J4A=Q++,K6V.4T5.-TV2#F"+JA3.F65<:0LP.I3UW ,P,*LOR)3S5B# M7O%2S'H4#+6V076-P7)31B%30"VW$0HL-4*WIBHL,LV.0W44:Z/45<%3+?TC M0H720#75._.V)H756!6W5472*S&"*SE3) C+,T45H:-5^Y""!I741UV4Z412 M8VT49-7.#&3,1>'58OU517E6$B*"%E459(56[XQ61<%6$<35;9565)E61^E/ M)#W2).5 6577=64L5*6LLW 4_XM(1FXU[H)3'U% ME4ME%7FUE3L=UG&,5'"M(3,M6!&T%8%=% OC5S0-S(3=5XS-RHJU#_DZ+#G] M(XUU5#LU5]>0)W9%V91=(88E5T;9@38(@F4,@TD8@C6(3G035T?!@2E@@_H\ M@YMME"(X4U[ET.P<(1W5@2EX@VUK@]YR MC3/@A%*8 Z6UCWY)6!P @R2*6FMEV3L]VSK5T9WM61JBRRF8A"T8K''E5I*( M R P@ZGE5IAMC1KX@B\061,"*K3%V5_]V3KE$AR0VK\*@C@842QMW!(" L % M5XI0V+@=,V;%/["(-/ MD%V7O)Q="UG"H8Y9F-JFDJ\JD)7Z.-5$I=1*M0](,JJ7*LT.-L %/U+/+-[BS%I<'= \ M1\-2'R!;5<3-/*A,R09+\%K$)VSXX& GBF@B% VNF2"B"XDB/( 65KPR)0YQV@ MG$*FU!T8 W.VY3MNY"DP@QIX!=T5+)^6 B]P,_10S2+0OAT@@R7P@K9: IMU MIT@N ]/%@<$E"M,EP;#DME>-XK)667.KUTV["N+@"@()3;'H!%#H!5W%@;,8 MAE @ E@ @SFX"5$(!@$\C$=HG U9$Z7 3/, A8?H EE9A%D0;,6@8\? 2D8 M$)#P 4L@AEBH G_!"DLH E@8!OY0*((IP B-L*Z;($5+$(5A\(PVN(67TK^V M7NTI: /E8(,ON 6[&.G6$*Y/8 @=> /E4.;J."8ZF!("(9%" -:X+=*\ 5B[II:*(,X<(GZFH.-BH'F)5X+"07, MJP1BF85+L(4D$JY."$**< ZQ>(^Y3I,UD05=#850\ 1@B$OT>(N98,J5" 6A MV(I8.(I@ ,)LH2X+!X7().@(5*0(G383^?"051F 31 M" )<6/Y)3HR!DN*/-ZD%4*Y.6^ $C2 33 "%85",.=C&O:@T(A@\'X\PIP$% M97:K.?AO-]>(0Z%>6["$67 \(1F%K_".67@/7[#2L#RL!=E*L^9T=LW*-_6> M&TB8PP 8A[$*AFF#8CB"-H2[[IB%5U.=AB&13' 7>.&9 F7+9B3[: 9FZ&! MG(&PC=%=&J@\:ZF#J HN@W@;9:F"B*&!"8*!42 #CZ&!'BB&-WB!.A %'P"& M)'B!'@CC1?@8.SP@_GD!4'"$@TD?Y M!26HA=J+Q?ASGU=?H# &$90-#*@$%SP A;(@A87+/:@@23H!:$;!K250TD M@_1P+L&JA?W8@5]PA"\H#*FAD'9/[U$ T6H!*N8'J#3@9A"N 0R F#H@1=( M@]:U#S-H'QBPKP72(28@AB*H@V#P ?ZPA1T@AG51@E_0H1WHA2Z8 X'A#UYH M)0TVK4H8 DN8 >$YH.)I8.3CE>=PA O:'@H1K-$IG1V@R7!Q O?T'K@)F>TA M!230%Y-!F6!@/S,X@KH_F911C'"Q.$O8 6!0@F__$/FBA6>)]C4H KY'F6)@ MA#G&=0):A'GC+:6Q'8'KE5J@@_[5L!8ZF +\I>))(>M.EWXG#>M/WZ:7*RJ2,2U%2C-'JIB+\9>ZL:_*SPR=(P(>8Z7( M3CE8X"$B%C8BF -)2'^?41LD4 I/R*(@ :PP $V$"2\!X@MOG0@"5:IDB-; MCNILDC$$%Q49:TB!">8(DZ-A8!C2H"%I4PQ8Q!DF1T8P,S1V+&HT2Y2..2]U2.E%1$<,28\6*:QDZ1<8 M6W=M3G+T**@.'[R,Q KUZ!$H6SHZ]0JE5N7*+X\L$7LZ2RJ-6&,668J1F-<6 M7$MDM(DE-49A.I9D).YE9%0:&C(^QICB2!(O2S :61TCRXC=E6-@??E,PTLM M'"O7N)XZ*1.-7EAP>-6!XXRD3L%VD(D5(U2F=+&!6"<0M1 M9NS02UR>U ",$;*$T1$8L) 1C( 9@4%:1Y$\(@E2.A#!RQ%?D-$B9F&*.2:9 M9=+P2#%IJKDFFVVZ^2:<<@<+14O8$D0C MF^@VR6.SG8:$=#2DMD-H7]3AR:*5N#<)%6#((D,L:W0DBQFPE%'3$$5X6@0P MG(;Q::@MXH #&(\0HU8O5-1 *!B&'J$%+C@4-,8786BQPR,-#<&+%C&\(0H8 MJ(7Q!14Z-(+I;IO 0!,.09S!23 I"?M+$)'3([B<480H8FQ12_Y-5($20TPK+=&:+)CA4 LH!XUBGBB>F$8# M"Y.,(@-M"@/STF[UB4(%&5TL,85^*B&APR.&(:98DHML0<863*RDQ1R]3 ): M(_X"#,86GTX52QAU..H#+E7<(H5$GPXUH-&T#6%7?!UAJ<4P\ E'T" 85-C!,/;7 M!6($00N^"(*%Y@"#O&R!$9X0"K,D HL=_((*,.A!)W8 0!EX1%NQN,,%S_"" M&.!">922!2/*!XO:Q6(.,O *NUY1DQW$HAA/(5<,OA", &HA.,(42+L8@!I70PB+JN;-P50B#15E$ZG[!.E8-P1&R MJ((9\&FT%):B$;3)X1R#T85NOHJ.5(B!%HJA%AQ: A1,+$4R8\&&4\:"%#J8 M&A JX5(:@$(6^3.B#SH!A&MUI/X2C_B"+T0)AV(,80I2")3]HJH#2CEB?E:] M*E:SJE4Y2;6K*Y%$+3KA"$W*IB-'D8$G;D&*3LQB"9'JPBQ6PIPY)(X&C=@9 M+&#A";Z,H1.E$X5:>@J+6A2A"[#005X]P0A<]%540,#!%&8QBE'(PI>?<.$C M;B'6+>IM%D$P%"QBL4$!.:06$3G#*V)@!EY\PA:3B,%1S%H:.A0C#='J:2<> MR01:O"(6GZ 4*-ZP+CF$8BTTZ%\88N"(6H0"%U^B 1V&000:L $7G9C$)NQV MV)7L1!)\DT'/6KL(5V;B>T!8R2L<@3!@V*(6L&B#)8HP#"V )C6C^ 0L&J%< M7#27#?XRV*TH9!$*\*+0$[8012=JP;H B\*T.@@%+4#!6-"L@1>>J 0G*&)= M4@ #BHZ8!2A&P8LN[ !O%1H#?VV11;=\0A2\^((,7J$6NSX"";@ Q24:P0LD M;($8WG7-%&018%"\"!85\D(LI+,#')#A%J"X!2-H$(1:3"%0.)A$6!L!B]?V MSPLRH((M0+&)A%1!%D0(11B0$&;:V:(*L.@$*30+V]*L-A2N#1,3W!N+4>A@ M"C>^Q"/:' M(T0"P'6$.'2J! Q*UKJTQF(,LZ' )1Q0!%Z^ A2Q2LI+J=J(2 MGM"NCV)Q$UY4K!9?\@X18M&84%!3%&=P2# \6@2\#4$6J_YV5QE2C,+8VA4I ME\#%6CU;"5*8SZN"VMWZMJKL93.[V7,RMJ"@ZB(I8&$M>?,*=\Y+ RQL8:IB M>@G^IAH$E0!AR3C @B^+,(0=G%<'05@R#::P!4JY>U94F (-AC"$(#QV;CC8 MPA>6K++=38$*UN[6Z'2P!8.OI=USZ@.Q5?"1*&(.4OR$U,"V]1 MN<.T@W%CAN0L 8,/6K0#'[C("/,6UL@?200CW%1A8& "F-8M\I>L90M;J-!C M.V%P'>QN"%] 0@[&S9(O:'PE.]A"M:>J[2O\W.32QWSR8*AXN[TC=GR_A/3@KGE-MH!O MI1M=H$ X+W>43H6?:WP,E:C!F*0-56G/[7QG*@8QG*W][7/_JM"6:H5<9";H M1U],U%^)5/I$)AR0'ZH=43_U!SG]N:7?RH\L-IG >/[QDVF0QL9_F*P+^@"@ MG[R?=QA=L24@^6W>F!C@(RV@^)G?Y=6 IW0$#DQ%(\P& :X$T8$7.T&@PS"@ M_8F)__Y57P'NG\/(BIB<%PB*"0U(A_N=7X7LGP/JGOH!B@G"8 ">@2UT@H!U M1PTR( &&'YD$H0FZX (^E@.>GP'^&Z1\W_GL3B-T'Q56H17>"0[>#Q1N(1>2 M"?)U89CD'AAV(;MYFZ!TQQAB1L@YS/$1'12*(;F!7Q @01L*7KG4C[ZE(?J@ MX1::GAZ*8;OQ810^4N3A&PK:CR".(1QZH<,<(AA>WQ5&HB1*HE(B:. MH1%V%0XPT?UQ3,=\WP9:G_F (L>,HE=MXI_HA@6&8/W0("J*8A=6""C&HJ"H M(K2]8)B4X/\QD:R@(BYV52)FHAIZQ"0>(S)NW_H1XY\LXOXBJJ%4/2,S"N.X M34$;;.$45$*WJ<1&, (CU '.>97IO8'?8<8PCLD93(&+3,$B>",C/((96"(T M^@FX@8'RV(^D; (H+ +7Q6&92*/#V&.^.1P7X@ 3G('(I8_?"2)DW8$W.L(6 MF ] KE\:J.,6(A\0M$$Y^LE$/M(:=$(GM &E+ $;,*)WM$&5155'3F,#3F$R MOB1,8A5+WD\3HE\(ZF*?A%^%J*"_N0B8[&3_F<\2ZH#_U>0,GI<2@HDK*:50 MCI$,T('%D$%N^>1-\M]*U$) $1T-> (P5$(FD (Q1*022ELK"J$,$$$O:)Y- MJ&!'+" -U$#S@$998%U.AHP86Z M$H)>YG^J!!$ P13T@AF1PO= EAFP3H'N !/T M" [@2TT0 8#*@( N6;F147M($!D479"N"Y;VH_EU 1GX@ S$Q*PPJ)"N!!8D M:$U8 BP0*(-V@?O%P2S$0 V<$L&LQ8>N8SK6A()N3KR900TL:<>L&Q.,P0[4 M@)ZNA!*WE0!C@&Q_Q6!>L"Q68P70! 1+4 !5H'/Z6JJ6+T$$OP*4, MU, OY&JXO5L15,O=C4$12,H71$H1E(%^_N<2E,$3\QBM7O>(C,D(M)$0$(OX!LIB,(DB*P6]$(P M+()QT$ 5A!7#=H&*?,(P")>+M $N;$(M@ YG% 5H@ )V> 5!6>TFS,+./)@H M5$(M8 ');D*N9,(ME$(HB(Z+B/X!+D@"+#0$(\S")KQ",&C!4_;")W0",)A! MV]2 ITI%&;8$OLV"&720+&2"+8#!*>&"@2&%+%A1+73!%,8".X9'(M& DY ! M+EA"+=S!Y#;))0L+K2!P U-( F'G"FZT$EK%M MC2)M(^Q6)DR,Z;&+V>S.)+B4%M0"?HV"QMFK(]P"&ZSM+S!!' N9:@%9,[" M)=C")UB"* R#?+!!QLY"'<0 (]#NC0W;,""D=94"-&PXL@=$%!R@00[[F;:"EAX:TRP9O07#$@BPX BGTPFR$ M 2Y4 BQ< @+S[RBX$'5>8@VXJ[P6L1&K"10&\9AD0A*P@''$@(!QD"=! C&;),J*/$I.E2QZQ9<")&3!J*(-#5!&*9Q!A?B&?:!0P5Y%+&P) MSY%!"#D'=. (=;3-;F!'+]"738 "*"Q!%N3+(Y2'E&5+;S3"(]Q'/X4R)^3S MH[1(#9S!(WC",.Q !EJ-)+R*>)<0CB 3$RS<%BA=*/P"6)#N15@"+S#"!FD; M)%F/#O[@0K>5-VQDPI#L %WMA"-D H$8R%2$@J,(G@YL0NWLC@/-QD-$Q!H8 M65K^=G";%H=L2P@'[3 I2$(T0D((2"4,@Q2LP=#A0(0]!BC$ AC0@A$$PR0L MR)6\5K\9C P@08IXPJ36 !SX@KQ-P2/$ A.D# W$1+[1@22(5A"D90RP@?'$ MAWA/ HQ#A$38C44,B$8L @\' 2\8W(SOP.(8%5\XPD$0DVITQ!T$@RC<02+V M H:K1+F P6?0RF<4 6?+<$5OR ^5N7.(PEDL 2]HW!J$1S ,55U%PB7HD'L MCC;J/L(6' XCD#?3W+?4O YFU$VOV,)0*0I_/$(%3@4L>'1,EX]QAL@KV$(: MP$!VD4P7&$%KZ/,2 ,$L>,%;KG.?YP5(R%@G=$&T;,'V# :[:+5TR$ B1$R] M9/JE. 2SM+F1K8[!O. M()0GZ#@0,<$PE3O0[$#JFOP4N$WZZ4 M,,+,;($1 ME,!.]W[(!1: &YG#/(W "T9\4&Q@9+NS'@-"PR3,!$KQ.I"R,#,_*(_VL M:> %+-1!%=C"B<4"JT00@<]3 $$JZ'I12PS!*)#"%TS!H1#5;FB"=+)K6+PZ M[L-D9I]-+\@ #%00%!=7#$3,+#4+%0A#16%*:"P"$VW1*?U@#NT0QH?"15>1 M*\D"\YO.&=3!!BF7WH=R5;Q@FP'RY(:&#N7%2(TJ=^LZ#;#2/M;3)KS -%V% M3& 1$SU1%D@&9[9($?Q",/4_0("AT8L*#1T[:(#RI,-($5&B=@3[$H-(,"QU M2+V0 ?YK$HU?4F2;D11=B.AQMDB%CDJ4=PZC$T%*,# T@ M-.;4(K($B124L.8P"48$#*\:,*A8JM@EQI)?2Y#&Z%(LBXY?6V),\@2C32Q1 M.HC\PO)BAZ-%)D@R2900C*6 ,K(A48.SKM<'2)1A!?5=3#HE%LCOZ,',#"$"T'J*3J M[CM;EGBAB5^0P"(N'6C8Z0T=<&#CI"YFP8&&,6#I ACL%K$EAEF^6,03&F@( MHQ8-7^E/"ERL[-'''X$,$LB?'BG&R".13%+))9EL MTLDGH8Q2RBFIK-+**Y$4DD(MN>1RAU=@V8017,KH!)908)EE!]$Z(847.F!H MI!(:<%A"%E%D 87"BABI 0@FEDUIZ M@O ,8G@I>!A+TM"O-U)B: 274'!I0UM<8(WNC%]$L<06S3H99HDZ+)&!B&$: MH:&&W;B5I,?O9 &FEF$#0*%%% 1[I0%04T6).L2:R9"ABV$P M6:*645ZI90EW!ZZ6%UL$^A7/3W9X#A9/%JE%CG(AG(,74?[M"8C>0AXBLI!> MB:$,7OZXU;>1D(.HI6=2=HC%$U+BA=!A4'@Y S*4:! 7UCN0P,F@G\ !A=; M@CE#AE0U! ,6'4R]A!%;QOCD"SKFI %W&D*1> E;=GADEDX%.4<@I@I M#.I2^^TA+!++[\$/7_SQR2\_R1YYY%Y](+%@0H8B=(AE#".^(&D,67"0]?4@ MXH*KBX+@@H.M]6\'6R@(A(;P!2K@('TTR($!HS6%+2!$!_Q35!#@4H3/3 (' M88C:H@IXP H^*#4TF (8B)"2+:00"4&@ 1&.,$*M;0$+V;-@WU:60'/I(#4] M"L(0BD"$(41+AX\YR!:,( ,D[,""$,+"! ?HKBE@H08[6/XB$.*"P^_4#X=9 M',(7B5"$(!1A@#@P H26\(4B&(0&.F1CKKIHQ8,,,(IMU)^/-"3!(V1OBU%3 M%!9YF$7^I4: TS-#K!( R3TD%(SU (?T[C&F;4A>TZT*L(Q*X&$4@6+")_+.C=W PR[@0FT*,:Z$ +EXQ+$X=H%^P5@8R*BB(M#0FA*13$BDR,"Q 6 MAZZLDA!REY 0VJ6*UM.B#TJDCY89 MT(VZBX\8Y6@GMW10'V74HI4<*46%I%#T$11]79KH14E*T4[6;Z4O96E'^_>@ MGP;U1RP=:EQ0&=,?::B<#-U2)].WJ*.BR"#T&RE+[0G0B*84CPN5*E$3>H0O MW)2>'/T10KPG3[6NE:UMA9+ZR%I6'Q4!D-^$GUSQRCTQAU1?%D&[/KXAU[(-DR=7#+O:Q9=UJ98/TDT:XE;.=]2P\T8G9KHZV ML#*505RW=UF\9L^(ZV/M80&:/9F*5J6&?>E*'WO;I5(60E2E*6UQJS[="A>U M&&5@2?Y%6UR]&K:X-"@2.S\;7>E.-TK M:Y-B;")V8%""5'U*S@5%5[ ]HBP MXB5L><6[A!HBH1/M:BQD5TJ$3-BB%I_8X1Q]]-[Q1C$37Z!!%X98A EJ";WC M%:]'?517+-:@$5WP28*#M#7TIJ@20OH)%2I!5D2N3[-?"&ECZSJ$+?C($J,P M<2>\0]B^Z==+41P@>H=@B2*<4\$]$G"/6/S-@#["OQ#6D@O;T 8MF.;&70)G M@:^;6L/^1!+4=?*3H8Q8Y5HVKXX+A0$[T8N[TH"?%$+18[AL$ ;BH,LZJ$&7 M-71F/G)YL6$&0@P2 0H8'&$1)9R)4'5PYQX1P197QD(G"%"R$4 M0#T3E(T)3>>@-31KBEP%LKU6%$+/; 5(7WO99F8CJ]LL@V5NQFJ )#.*/HI3 M% $'"7>@P:\!*K/6FHS0ITWRO0.Z6>A"F=_]9JOVXCKERC;7$K"(P9=%P0;C MP&$2 =O"$N:P"!QTP1)A4&05IB )..2S"H^X0]200(6HM &-C&B$9N+"ADF\ MP8R@J 48=H"%GV"A$8Q(<1>6P/X(1LRXH04_.)E?\8:JV.$1*']XQ'&PA8HK M,@M;F,06U"#JE")+>! MZC,^32/JL$8D5&$+:F?[(C0("S.<81('W,$<)M'C%:[!OV< ^W=KT(9:G&8) M<9 $M$PH"3:,H180JD(C[L#"*E!!$G%PUQ8\+G<#6H+D#&R#):;PBGW^71+^ M!0+.:TX$'33B%VUH8B_&(!V/A&$*1F!#%V30<3N@A S>V4$8C !S"%$!"SRJ MP1F$.&H$7IF '?B$4YD!09*L*M:9' MIH 7'F$.?"$-7I 6Z 6:F$3:)"&BJ$2NA 4%@$6#(X6V. -BF$3NB 3AN$1 M=D 28N$,0*$31H47%@$Y- ,AO& (&\$70F$/#6X-(D829OY!!UP"#RF'$?A0 M!N+&$1IA�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�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

    "5E2%9@8"#!H!<>VB%A1(C8.8#MZX@XUBC@D+;[/6EVWQ M:Q>!#?[N"%+^*J_B(!Y% 0G:*E^%JYYPX0PSX0Q"&0=*BQ;NZ$*$*Z5MI[3@ MUGGBH)>(8*=ARPA*BPGRZF,&AEN&P9: 9=3+]B;.+**PN"@0@6 MSA:(X!:HP!<4#,8:H6#,(IQDX 7:X-R,0P9H00Y>P >"@1B#H3YB(<) =E%J MX2Y\2@I,\)\I^T[N(J&]FG(M0IA=+ETPN#;QN.6L M&A=KXVO!,QB: FTQ P&AQ:(8),PX0U&TA> H0=BP(JH@/X6@J$'8""OP"!+ MJH!MBB&TB $3VL (9*"TBL#)J &X,J*BB!+>+HEQ:<(GX*O3H\1BJ'FU*H. MAK6C93LHZ5B/\=2U]!0/6_LHMD"L@J 6X&4(:L$(+.459.%K)F'^ M:L':9@%#%*(4#'P6H*P. JI=$2*CGW679;.VHS6^N6X.O[8N1 <4- _EK$X2 M'J\3@LL7<,F!RJ08N@ 7=!"\J?[[ 8O!!Y@@S=_W$X=ZU6)@#(HA#JS(",8[ MYI#@S7QELAYADH(\%#8!C.: 7QS0R^4TE[?<#NETOO$EF(4#CMVG"$:RJEJI M+:TO(:90_;JC(H0O*HP@_8Q/8;[ 6(//_*("_30"/;X@+76 ^0#S1G "9F/ M1DC]($P]^)"/U*L*,U)I*8%/+*AU!P@#"(# V,04?+.\16.[RR>]-HP-!_@8 M7AK[=(-!%@:C#<* "4 !#%[@XL@@S'2@78B@>QPL% 8PYB@9CKJ $\ !C1K M"[K'"+K' 9WL"[JG"(3:R0Q=N'1 '<-G'8V #JA@#BJA!GQ@4GZ$V^^8;S&] MRNW[VOZM:R"URR"M'3#6Q3B5!3,'42/&MS$@HBQ/?N6_XC.VU$KI\.6HFK;K M^+ITN=CX^#]B!U>%L1C8 ?:)1:(P1:0H!?FBBDD0080=G'8.P;FG9+G; F^ M-A9B10<8"VV+87F]OHO8V0B4<@KFP#!]X':E4@=.LD-*,GC(H!'88 CL\@M(L@N(( XVUO0A!"5/ MLB>^0PN X".;D@[88'KP:A'(3\LU_NVUDS>R6EXAQ^[-5_XD D,X*=,XDS\A MXN(Z<1Z1KMRZT$7N-S[C6;27@3*1WN(N2 ('8%,L8','H!$WXZ)*2?/YQV(L MGA])X)0027,TBU/D?[_C,]U9?1_CUX4@A?DAR>#FHAD@X@310;"@P8,[#A(< M @3'ES T""94N(-.%AP$I7ZM"I3&HV)HTZ)U!%*LVQTT-A7+$G%),"0$:;3-J@.'7I=]97R2 M Z,1(QIP]^8%4ZQ31!Q(<,6:P_Z(F"7%(L/.U!QRB-N2G#^OM.HUM&B:ID^/ MGJE7!D@:J5/^52TZ-NW;N',#GKK9)-Q&:M$2*]8(L6Z9<6W!V@'9%UX=7<+X MH(%DX@XD-(B8V8(#QY =1+#LD.4HZ<2'< W2^-0H%A,=-$25BD$CQA1B6# ? M5Q@694O.MNU74( "AD2@@07V5=L.94C2B!G6+<425 ."L4A"1IGG6V\UA79@ M@B"&&*)9Q0P7W"/ZB1B2#*#0T9A&E=Q!(?L'W23%+&#$,BC1(,LP2B,&E M%6RXL;F:;EPYJIJD*BI$@R/!I86B4I4B)$,H=!!!#!5%#!.$)*#$$,,2LS1A0QF#(-6*#I040PHO#0F"5J,X/ ++;$4 M4\L<:(U"@R?#8&$+6IW0D188.HR"5B]:R( %+FC!\G79+'DL]G_\W28ZQ@FB M6Z):PZ%(NH L,B)##;%(4@L2LI0!\R\[U"')')+$$(LH7S!QRPZ-;"(#7+\2 M[20-6LS12R6(X] M'?RB%E@HAB=>@+@RO 6@ )&+V+@A&),X@6)4)A#:TPLS59PV+NX.2Z3!(HA1!!UT M0A9&:OX"?$0!"QS4P':=< 0L%D$'3"S/B\4P QTF$1]:A (7R=)!+=)@'"(D M, 9U"$8M>)$).FRMC>A+I2G;6* #D9*<),'!+(K1!55IL@Z:K",P:I$%/:ZJ M&&*( 2"1 Q>T""/CXC!(A19#"0LH1B6H$\#DT #7@1C#G=X0QH8,QDZI.$, MG)HA.L?YK8J1342_"=D'VX*5<[XD"#BI 1'R@H6%260BULO/=7: $^J@-"$T MN,(7BM 6-.Y@(#080A%;G1+-6%62K-"<88$8IH, MQAWH$ R%$<%P2XB#_@[Z,\3E$Y!+$.0_/RA0@@;*<%^@@?XD&:Ò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�@1T:V%K$O+0.L;@(+-ZP"$PPH1AST$$;@E$F3?B5#CCH@BV0$!T: M[!))3-:!7&4S3+,@I VX6,(.1!$S'"%A"#1# C]Q$# 9Q )U39.L)[QYMBVD M,PALJ/.=-^%1=/9B"*)PA R^4(PS^-1:X)1"#!P!BMK8(@NA2'$7,MT%?](@ M#+ HF*$/PX9@J&P8BQBS#LP\!%B@KJBQ\<1IWJF#)T9YL/XT^,4;Y$R#: 9! MI&^(02Q0&A<:!&PCG2@&@MN\"%OT#12^*$,,9&'I+Q#C#%:0,!!D4(=9#"$, ML@B",.+[!='5&([SUHO?\B@X%==[WV_BMT$&Z>^ VXT1T$X,:ID@BEC(P@SR M$? X=S +1\#"%G% 2!@4+@HFT& 2U*$!+6FP"5G4PA,T>$,$$?$HA-D^$1^.C&*)6P"-7-8>=)WT DDX& (G0C"%& ABD6\H1-=R 10 M@HN$KS%BN9N@@A1BD78VL-T25O[)L=2IW@G44:$\N(K!%!(.WZ>#008V1P@= MXA"#"^.=OE#?.'4@9I[$90+H*"U3?$%BAC2%-!9;:'@L2+$$CYSA%7VC BQ& M80<\KL4 MDQC_WB\OGN-R9QP26&8_"#6@01%X883O@43[>?!@+W7?@XX! FX@-YS)[Q!?_$7$1,&7M>G?M8B&8CQ M$M@W8?X". 00.'WU9E660P..<&+Y5GQ[L28^>"B60U75!WUM0H0Z 7 UJ(1[ M(V<,$PJH@3E.T8,X,86)(Q0@%R)5V'Q)106DL$V)P'M-6(3<$29+Z!-'N&) MN"A&<6)ULX5F^(,<2'V @GQ0L51H"(=YJ(=)!8'ZMH=_Z%6 "'SWYE1' 3BB M)XB)B#@S&(1=U8AXHQ-^J(B3F!=:2(F(@X>/R'LF=F)[=(DVV&+@=8;/9X0A M1H>DN"69*&.0^(FM&(=_(55"J(EAHHH[<6]MR!!S.!1$6(N7""=).(9_U(NC MV(K#B"C&Z(JS&(QB-WX@7 M>%@F.XB(_(:,X"@3TH>.R7B.J0B*B9*)?MB.KHB'\UB)A)@4A\@44;B.@*B. M_9B(]@B(PTB0K!B% MEB"'F*D1B-9S*-S%B#QP>1K]B,VFB1D0.,"FF.!@F0 M';F,=YB'Y_@E&OF1%IEF#9D4*?:&'BD30L%\?80#UWB,+%E52TB2-(F3NCAO MD1-\^$9\O^>2RY>3@N)B?.2+Q2AP!;F0I3B40XF/#BF)9AB+J B+Q%@7URB+ MSL@349F-$ZF(-UEC8,F/$4E'+ 8F6FF+B9*#Y+B/2QF)39DH_PB76=ZF(?[QE(;(@X,)B#*)F(O)F(W)EWD)E8Z9AT50 M$!YA$NW'@IAYF7-B$I?IF97)F331F9K9F3%8FIZYF94YFI])$Z#)@BQ8F0^( MF>U'FA%8FK3)?I;YFKAYFYRYFM8"FJXYFY>9?7NA)O^7FIJ)F\$IFL,9@[+Y MF[7IFZBY@ALXFZ&IFJ@)@+E)G-?)G+\IG+\9F]K)F^YYG]\IFMJYF@@1GJ>YG?_)GM;BG $X M@/:)GGUE)FTX1/'I?O,9@=/IH)F)G\UYG@;JG0EZGK:Y)Z:9G"3*G]-YFA]J MHKLIGO[8J:(H"I^KA00S2J,U:J,WBJ,YJJ,U:@1&L*,_"J1!*J1#2J1%:J1' MBJ1)JJ1+RJ1-ZJ1/"J51*J5.VJ-3:J4XN@.8L(.5(*-7ZJ5?"J9A:J-', 7$ M8*9F.@QGBJ9J2@QIRJ9LZJ9P&J=O"J=KVJ9U2J=G.J=ZNJ=Y>J=JNJ=]BJ># M:J=ZZJ>%"JB"2J=I.@QN&JB'^J=R"JF&^J>/>JB.BJB1^J:6NJB$ZJE]BJF MZJ><2JFD^JF0VJB3NJ:IJJFMNJF+JJBO*JJS.JJPJJJ5FJFQFJEHJJN%&JJK MFJ?#L(-'T:N^BJB,BJJV&JRY6JNT6JJ>ZJRN^JN[2JG5^G.LT>JL<9JFP\JM MW>JMWPJNX2JNXTJNY6JNYXJNZ:JNZ\JN[>JN[PJO\2JO\TJO]6JO]XJO^:JO M^\JO_>JO_PJP 2NP TNP!6NP!XNP":NP"\NP#>NP#PNQ$2NQ$TNQ%6NQ%XNQ 1&:NQ&\NQ'>NQ'PNRY1H0 #L! end GRAPHIC 12 cogo_0035.gif IMAGE begin 644 cogo_0035.gif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end GRAPHIC 13 cogo_0003.gif IMAGE begin 644 cogo_0003.gif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�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ɼ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cogo_0005.gif IMAGE begin 644 cogo_0005.gif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end GRAPHIC 15 cogo_0006.gif IMAGE begin 644 cogo_0006.gif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�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�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end GRAPHIC 16 cogo_0007.gif IMAGE begin 644 cogo_0007.gif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�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end GRAPHIC 18 cogo_0033.gif IMAGE begin 644 cogo_0033.gif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cogo_0009.jpg IMAGE begin 644 cogo_0009.jpg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end GRAPHIC 20 cogo_0011.jpg IMAGE begin 644 cogo_0011.jpg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end GRAPHIC 21 cogo_0010.jpg IMAGE begin 644 cogo_0010.jpg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end GRAPHIC 22 cogo_0012.jpg IMAGE begin 644 cogo_0012.jpg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end GRAPHIC 23 cogo_0014.jpg IMAGE begin 644 cogo_0014.jpg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�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end GRAPHIC 24 cogo_0013.jpg IMAGE begin 644 cogo_0013.jpg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end GRAPHIC 25 cogo_0015.jpg IMAGE begin 644 cogo_0015.jpg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end GRAPHIC 26 cogo_0017.jpg IMAGE begin 644 cogo_0017.jpg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end GRAPHIC 27 cogo_0034.jpg IMAGE begin 644 cogo_0034.jpg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cogo_0016.jpg IMAGE begin 644 cogo_0016.jpg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end GRAPHIC 29 cogo_0018.jpg IMAGE begin 644 cogo_0018.jpg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cogo_0020.jpg IMAGE begin 644 cogo_0020.jpg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cogo_0019.jpg IMAGE begin 644 cogo_0019.jpg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end GRAPHIC 32 cogo_0021.gif IMAGE begin 644 cogo_0021.gif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end GRAPHIC 33 cogo_0022.jpg IMAGE begin 644 cogo_0022.jpg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end GRAPHIC 34 cogo_0024.jpg IMAGE begin 644 cogo_0024.jpg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end GRAPHIC 35 cogo_0023.jpg IMAGE begin 644 cogo_0023.jpg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�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end GRAPHIC 36 cogo_0025.jpg IMAGE begin 644 cogo_0025.jpg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end GRAPHIC 40 cogo_0030.jpg IMAGE begin 644 cogo_0030.jpg M_]C_X 02D9)1@ ! 0( )0 E #_VP!# ," @(" @," @(# P,#! 8$! 0$ M! @&!@4&"0@*"@D("0D*# \,"@L."PD)#1$-#@\0$!$0"@P2$Q(0$P\0$!#_ MVP!# 0,# P0#! @$! @0"PD+$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0 M$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!#_P 1" "R +$# 1$ A$! Q$!_\0 M'@ 00# 0$! !P0%!@@" PD! K_Q !/$ ! P,# 00&! D( M" 4% ! @,$ 41!A(A!Q,Q05$(%")A<8$5,I&Q"18C,T)28J&R)#5#4U5R MD\$71E168W:2HF:CT>'P&'."L\+_Q ; 0 !!0$! " $# M! 4&!__$ #41 (! P,"! 4# P,% ! @,1(002,05!$R)1@084,F&Q M0G&1(Z'!%3/P%B0T4M'_V@ , P$ A$#$0 _ #*6FD<-I/UAR31P,ID ](5L M*TKHM([SK"V#_P \5._I!A]9;-;84M1;Y&:J%U&!24D@TW8;N)IP(C/*/<6E M_=0(4SGQU.6U^.5W:6G*C)R"333RT9DOJ9";M<2]*"6'%;4M@*!XR110II1& M1AH@N3(\HNJ D*.,T-L,)DM4MQE?:$;OVL]U,T^P.'R)KH^A4-PETK*D@?. ME8E2]".3Y+K4)U&Y&Q31X([N*;;?D2DH_2+M'7#?IB$RM@$)225@^^B4?0%N M3>1\#R%E*4-* 5XFA2:>01@U.P(D=]>Y.IE$D1^88?6AM23N"P M,'-#P,-^J@MNT22EOM6TI&[W\T+E@*/([6%V(_#0AN*E!)1RKN[JAFPF3/1& MGV[S,1WC0KZ[.CW&Z0'&(MQ4IMH1 MF2I*E#@$?/PI.G>/!->ZP)ID&3:GY[+CRF9806W6UIVJ'CC!]U%&VVP,;WLP M?ZG0;HU%86ZHM!\!:TGNS[J*DL,LPCM>#6O34AZ3'998<94E"GFRYQEH?I#S MS4U.*L-.]V-?8)\U?94NP'S%Q0V5X5CC4_NRHIR? #BI$\6&N:]"E+D2 M8X O/K"AP/"@]4%+!,(QE+>;C,1B^ZXK:AL#))II6BKL>,)RDHP5VR0M:0B/ M@M3^T2>@UIBQ!"TJXN$_'!#<>2OT4G!Q^U3RB[ I6));V=T1O!^JD?= M02!;$VHRE&FYC2 HI (H-K>1T\B6,\M4:.WMVJ*1@#X4MN+A7"%H5 [%,E_ M:^E+B4J1@Y3N[S]E4ZDXPED4H[@KQ.HMU>+5BMW\D4P^3&PV%J"0/K#R/ IE MJ:BCM[!QBEDCMYMEQ6JX7V[O(D7$+)4EWDO;APK-!XFZ6&31]0+WZ2B5/89: M8$]8N/^T_N%2V1#N+Q(CE:@$)/*Q5J-T17N0CTA8#[6F^G[JV5)2YK6 MV)SC_C58SMR-"VXM(0%.*5C ).*J%R)K=1DYH!"*X-[H3PSC\FK[J90JAKJ MKC9(ZWH6B4X[VLA4TQ80Z^VZM"5**N2.,'RKGZT[L]&TE+:DD@N6VSH92ALH M4-V,*'A44;,ON\7D73+5$[0H4ZD+/U.CGZR#_=Y4*V.FZCS;7P<;\2]*C.CXD5DJGJ> VFW$R7%8"T8 M&._VNZMNJ_0\SVNF[,D:'FXS26V\@[1D>Z@M$$N1 MVLT%Z4U#7%0A;HVA*%'E1Q44W9!I%A+7H\/0[9%O45-G<$12Y?JV,+P"0H^^ MLBG.,JDO$8][<">QZ;2CU:_-3W$1@@M%PX"^20.?&CG4@_+$-&B\WJT6]URW M0VDRDN_DGWG\J6%=PV_/QHJ--I7?)(FGCN0C4V@KM8W)DR=8Y4=#:6MRWT;" MH.YP4_K#COK1I7<C]"@XTU()>G)\9BYUFU62([*O=PC165DA2UJ^P ^= M&X>(K >/*EYEP(M#ZFL-UU!]'1&Y :7N0"^TI*7001E.>_QJQIJ3I5$9VNJK M4T9I%,^M=O&F=0W:VN\)9GE+2,8]DKRDX\!@UTK6Y'D&IA*%>2:Q<^2 \D;@ M <#)%->Q6&_4L$?0$Q4=X*P!P1GC-1RD'&-F$;1>G].3=,7^?-4M%SM\6.Y$ M2VK ((]KCSJI6JN%HI36=6I M[JEAF\V$6L[^S'MENMEON#K':I2X6E '9DY'(JU2H*#N$C?8X-Q>/WU))I3P'GE&CK1J?6LF9:M/775L:XPG(,?86&_926^0@ MGOR,\U;IS-4Y%Z4;L'MXM4BV/J: M<2=O>#[JC7!')68U3F4>IO\ !_-*^ZG7(#^@Y\]2X#KVK;G( )0F2L$T,WY[ M&1>TF0Z%9V7;F$O*)24E1.>>[FIFK0N%? _Z LR;E9KA<9"Q'@1''.Q)XW;3 MR,=_=5# M4R4K27!Z+H83HWI/L/SJ5PR;=;=#HU%,#9<2)$@LQ6UGN;<4D[BHCR[JJQE& M]V[&RJ\5/4U$4TXJQ0I:&I"G)5'< M#WIBV"/;[HQ=?54DW62'NW Y4%;3MS[CNK>TM24UGT1YW\0Z54&IKO)H@[:" M&TH XP/C4[.77)A=(K8L8SX5%/@D613#NUPCMNL075,B0PE"B MM.,I]QH=JE&[0+NC:P]=&7UQXCKCVUDE:0<(V@ ARVEM#N]Q15+"3DJ/EY4M145*GN2%"^XM%TNZ=6&W(U YJ$-P8EX;# M3<1EQ2$):/U+!H\$]^K;9_&: MDYO[%CC;[_@+R .?B:JLT&(+S:8]SCJ0M [0#@T%@)13R#2^6V3!:D-NI.WL MUX/RI-69%;RLHAK-+C^HKPPA&4"2LD$5#5=I7[F')VF_W(%&C..W1M++>,[@ ML>:?$5/4;V-(.4&R/KI"@=HK"K]V;/P[4=/J] M":ME_P 88LZ*W^=?]/R+U)8$=Y,M; 9V%)80@^R#GDG!/-5*J:BH]CTMJ*U# M?J&>U6U4\)9B\$K&]><#)\_,U1M9W-RA*.S:,G4>9"MS3%DC-R VVD.29*6" M\N0[NP&FP/+O-34X;W<&L]B^Q*;!=[CR6ULR$%B6T4A82OV5H/\ 2)^(H%!<,DJU7) 8],W#^D+$ MI824HG(0S@8(2 01^\&MS12;?V2//OBI0^5CCS;W_%@-NE4="%E&!@8K02N< M"F(-8/RDZ>F-L)]M24X'GS0V6;DB-]ICR)9:BW!2@[V;:02KN&*"<]BL*UR; MZ>L4V,S,??MWKD,)4V%@X"21C<#XXJE*NMRBP_L3*Q]*[DQ]%WO3[:I4U: T MD)5M#BE'C(]PJN]:IOPF$Z3W>0NII_IM(;L<)S4$Q4^XM-I<;[4^RRK RCV> M\?'-7Z,'C:7U3V0R 3TXFF9=PT8R\VZS-';!"P/84D!)4/MQ5F[:R')9N6)Z M-S(E^Z<:;E,L*2PW!:3[?!+B!M41[L]U2;FT,HJV2:4&O65@D?.JU7DYZ?U MO]R'L.")=7)+8RAI*MIQW\U/45X-!3RD23IO-M=QMLQIN:I/K*G6E!Q( 5NR M#S\_W5C^%)^60\:WR6HA7@KM&W3$>[6>_7"ROK;?AMQ$=G(2H9<*3@$^:L8S M565.<891ZA2ZMH];LV3\]N OZ>3/;MK[-O3NENLY8&>63HH5 ME&GY>0?/:JL,#6+NF+E)?1,C[5MH?"T-+'ZW:;3N5GO [JMPCB\2+Q'>U2[] M C7:]PHUH)B 4MPX3#ZU.$)RG#A R>-QX%387,D$KSXHR7NA9H6) M=9D=N;J5IJ',882OU1#O:;0YQLW'ZQ!R?C5.33F[!N].*BP.>EY->F_1%K96 M"U$_*8\"I3@'W"M?0?[3E['G_P 45?\ N%2^U_R#2:M[LF^T' 4.*UH1P7;G<;G!AE^&F<6G7L<(42>*AE'SF!.G>3D1.PVN?>]0&U1(JUNJ0I*4 M)22I1QW >=2S3<0G#GT=1X\4_4W-/6>?=#<>U2MI["MQ1E2"><$56;E%V- MK3U83=PA6UY*((6U#5V13P0C''G5CQ6X6#JP2GN3$+]S$,!X(PM2L@?#NQ34 MH-K//OKHJ-/PJ22/*>J:B6KULJ MD^4V.6JM,R[;:(*WV-BG7!QY9[JMP2V&9%-/)IU1:KK#TI*CMVQ\NJ2A6%(. M2,CN%5MC::'23DA)H"X76Q:P9E1%J8<4MM+C:DXSGO%-J*$*L-LBPKMMKL%[ M7]W-RM=P>MMK4VD24DNISE.",CWBLNAIU3K;'P*$O&@'_HO:8@FV2\@,MO/) M 4E!'/'!]]9NGE):Q4UP7*6+(LD #CNKK$[R+$N"M'IM-,/673;;G"_6WB@ M^7L"GGP1RY#!TAE=MTUL*0,%JW-)^.$BA3RAU]+)CV@_6'VU("0R$C:$G'Z0 MJ2!G/@C_ %@_FS1/_-UN^]52/A^Q8CS#W_ 6A^E\ZK,O,^'U12CW&?837+^; MI9_X#G\)IUR#+Z65+M'3:XW_ *<7:Y-!E1EZE&$K.!M2Z$_OS3V3=TS/E3;@ MVEZD6Z$:55;?2:DVN4RT7X#DO>D#*04XQCY5)C;= :>#=7;(L?U/T&O4FL-+ M7&&EIM<=UY+N\ MA&?GS4=G+N7*]..Y8(]ZA4MR:N!\NHR*E=6+:SI?J1?;)!E(VQI!4PZRK*-B@%;?EFL#412J-';Z._ MR\6NR(K#N5ZC++L52=RB#L4,C[:A<4V6Z=25+*"79-9:SG,LHV-1>S;+2MA* M@L'W4ZC%(O?,U9X)+:[9/=(F7!:WI)*0RVD9Y\./.E)K"B/&GO3G,!OI.6BW M=-.MB-*72=V-OO4&W:C8*QQ#<+A1);)_4*TA0/ADCNKI:--NDD_0\XU].$]1 M.<.+LFW4J=%G6Z!,:"5,E]I2'$$*0H#'((X-262C@R'+-F3K7TRX3M,ID6JV MLNOQX33ZG7",;PZ?<=C3XTE'J;BWVE(RH< Y-FSAJ%5E+(,:L=UD6=1@I.TYK M?O>5RX\HJSZ<[JQ"TLR%[4+> I1[B[H37,A-LF$_U#G\)I=P9?2P-:00872,*(PDWP.' MYOHHH)-LK/RTK@IZ42$2O2LOUQCJPAE'<@ 'LD94![SBBA'_P!BY4DFUM]2BWI+?A-9 M>N;/(TIT(MEQLD>8VY'?OTPA,I;*AREAL?FR?UCR/"G4%'@:<]]@B].NG*^O M70W0_4O2KX7J%ZQQHT^,\X )KC +2B%'ZKH*3G/UN#WUGZS1^)YX\FSTSJ?R M\O"J\"2)H*X6^:J-/BN,R([G9.MNC"DJ'>"*PIJ46U(ZZG&+M4IY3"!:=/R8 M,IEB4A*PL!324ISO)[@/$T%.6]V19G3\);I818/I_P!+DV9:-17YK,_&&&!@ MIC@^)_;^ZMS1:/9F?)R?5>KNLW"CPX&;;U-UUI"-$8M.HYK<5E6&XRU[V1XXV'BG;]" MNZ2GR'K3'IVWM^V*L^N=+0Y+;D543UN"HM.)'@I2%9"OAQ44H;LCJFH*R'O0 MNM=.:OU3%ICZO?4SY-7LBJWIS&,8^E$OME1*Y6T^ X30L"IP% MGH:J6.C%G9?"0ENV^P4^((.*9<,2X'KM%^= %8T0.5(/D:LTS+? R=7?YNT. M/_%UN_\ [J1\/V+"YA[_ ("UX*^=5F7C J( ]DX\Z2?(O01720A=NF(''\G< M^/*3X4ZBY- U+1BRGO4?TJNE/2WIQ.TC>[\AV^-NI>:A0E)=YKFW6XR)[ M_*GX8/:QTX_!@7B0_P!'IMI4[[-LO3I;RKE >2%$ >603Q[Z"]I+T)HIRCM? M),?2)],GT?-+R7+%!,O5.J(BE,O/6,-EN*M)P4.O+(2ORVC)%4=;IJ>HXY.B MZ1J-3I7SY>X/>@OIH],U:O8E:]TSJEB=/=1#MJHS"),6,HG"0A""75.*SRO' M'=5;2:.%&6Z7)H=5KZG54KPQ#N6QZ_\ 7.Q]/N@NKNH]ANT>4Y!@KC1"TYW3 M'/R;:"!RE0*LX/ZM:T5YOV.2J6BL'#]]^3/7V\QY3TAQ9<=<65R,U\7'5&,?<#(W!2$#DCWGRI@)?8;68V1[6<^%,)?:9NR%%8$GTS%_XGV5'<(<8 * M.?T@*M4S*? Q]7?YOT/_ ,X6\?QU(^&6%S#W_ 6O _.JS+PCF2&XS:GWW AM MIHNE2CM2D)&22?*DE<2=LG&WTD/3LZN]1M7:BL^F]63;3I(REL0XD/:RMQE! MV[G'$C\ MT_([/50'%K0^EY;*F_J*2<'[/&G0QG)WJ *W"<<9IAF[%XO0G@:CN'0K7$33 MNH7(#URE)BAR.HI=:4A(*B%#NW(.WX9II0;CA7'5VB9>FM?S+4VZ MPLJ29*$#.$+*CE"AX=Q(/OJC5DH.QT72:4M1YO3/\%W_ ,'_ -!(#UGC>D%> M[C%FW%]3T6SP@WE-LV+VNNDG^E(X!XP%5/0I)\D74=;*=XK]R#_A(M?P1>+3 MTXL#+4;UUL3[KZN @/(0K\GV@'>2K)R>>*GBE?!AU\891V4X6DGLTG=YBCD5 M%A#6AML;]J>2X< M>-/80JM[0BJ,HDCLW-H*>#QWX^!^ZB:30E=,Z[?@YNH-YU=T7F6.]/JD+TW< MO5(SI5G,9;:5H'P!*O\ X*JU?*[$\,Y$7IRRWUW#3#+05L;8D.*P._VDYJON MN%45@T=%;--1T@L,?ME.QY'VTA+BY*?Q%@_UY^RFV"NQKAD]L MC^]5JF94F,W5\8MNACYZPMY_CH^4_8M+]'O^ L@Y"OG51O-BZ!STN=4?B?Z. M.O;RB88[RK0Y$94#@E;V&\#WX4:DBL@SE:-C@]*:0U(VI3[."G[*F2*KEM21 MZW'2&%.*! '=1#7-*T)4@I4."D@TPUSYK=ZLA"E94@;3GW=W[J0Z9XX#L42D M'%(:Y>K\'8[,E],.H$",\$=C<&7U$]Z$EA63^ZI%F#B6Z$]L&RMU^O:KOU3U M%>4/=JTN8ZVVI7.4).U/[A6+6]3N>E1VPVEV?0&ZFIC=/]9].),HI5:)S=TB M(.!AEX;5\]^-Z4_;5_3N\;]S"ZK3\&NTN&4MZZ]0%]4>KVI-5ETNQ6WS!A*/ M]2T=N1[BK)^=6$KY.>G)MV!G)D$+5@ \GPHFP+]A(4A2NS0.?K*\ *%C,V1V M%.R E*:2$LDD3"3'8)/)(J1(=HTQ 4,//G'Y,%0^([J0R/<&-"8B;5%;8RM1 M\5'D_?3V"N7Y_!==585IO6INC=P6$RYZ6[W:UJ/#S+:2EQI/O&<_#-5=3%I; MER2TY92#3Z9ZU?3VGPXLEMJ"_N&._X"N.-P^-5.Y>*7_A3-:MV+H5:])H=2)&HKPVD(W>T6V4%:CCRR M14\2"H\'(N8XE"F K^D<*?CD5)PBN\NPM4C^2#/<#BB$(4@*W>6:81B$['=O M@L?O%(1FM'LG/-(5RUOH/ZY8TEH;K:U)?2TEO32;HV3X%!4CC_K'VT[>V++> MECO;CZE?[$'$[)3@.Y\;U<]Y/)K'J/!W^CALLPHZ*Z@O],6=3W^*L^L7&Q+M M[",X!>6L!/V=_P JLZ-WNC,^)::A&,UW8'0%1XB6E'*L94<=ZO$UH\'%CDH]8-*6.T*T\AWL(S;2UAW@I QQQ3J&;@3U"BK"K_ .K" M'_8+/^-_[5+9%?YD*4)2B^GG]*I8%=NZ&OJWDVW0I)_URM_W.4[PW[?DN1RH M>_X"HXX4*X!/!R!X_#WU6LK7+SY.1OX3GJHWK?KNSHJWOAV!H>#ZLXH'OEO8 M6X/D-@^VIEA%:J[LI3>3A4 (.3ZVC./#@T8'W'R0-D/N\CVJ0C-Q0V!8Y!YIQKV)/HS6#NE[%K2$R2$ZBL3EI4 /%;K:A_#02=H MNY>T>:T4A=$:#;#2$$8PG[*R9.]ST:A'A(0ZCEKFWB-;@<,1&0XO!X*U=P/R M%7-###DSG/BBONJ0HI\9$$GR@\>>?$TR$+[=;2Y M(0V?=3I DNCL(C@-)YQ4B#2$5U="$;/$G I,3&UQMMN?:673RE3KRQ[\;1]] M,"C=<8Z&"K:G'=FG'&:2RAQ*FW%%+;R2VHCPSW'[:3X$6DT5=+C>]#6>X.O) M2\J TEW=R=[8V$G[*S*B:E@F5MI-G+C=Y-MBIC3PUE(0"">>*&2GV92J58+# M1Y]"WW^TVOMH-M3U(?'I^AT-@_G$_P!ZM" V=6/YKT/_P X6_[G*4N7[?DO M4^(^_P" C7JX1+1:)MVGOI:C6]AV6ZI7Q% M.!3O@9B6&A6SD"F0R-BTD;B0*0A.!A"FO=N'PI#I7-L ;^V:5R"D'[#F@J?2 MR]T[_P F'[DNA24.1E.N#&U/[JRY+-CT*C/R;O09H2EW&1(N*OZ=>!\!P/NK M6T\-M,X'J==ZC52F_P!CZ>"T.Q0O"W#@>X>)J5F?:QY&:V$MD9*@#GQ%,A#_ M &^$6V^V#Q1GC=@?YT=@K"E#+JMVVY%SYI'W4@DA.^&W-B'#N7O R3GQIP6, MT^6$:H<."KL&PVD'N!/)-,P4.YQ/"O\J<<:%I[5/9+6$%9VY/C!KB?;GNRFSH:;8PL'D&0L-G_M*A4$47:C\M MCB)(05%*&R$LM -(\B$\9J9%1#/J$-,Q&)2"#V4ALGGS.*<5APG+2Z!'' /G MX4]VL I)WN$@="M=1.D37661&CIL+KJ6TH[8>LE!44I>V8^H3[_$&H%J8.KX M2Y-%]+K1TBUNI3DX'=4Y0$SNW ="?J\'X>-(2Y,[84F8$JY"PI)]_%, MU=$VGGLJJ7HQS5.+%K6VG@N)*0?CQ6J^IKK M9]1R)+*DP>SMZV'-G9R59VK7YI!\*S]=JGI7'T;-[H?2H]4E4OS%8_DA5XL< MO3J2!'9V$/50A-MT5G/&K8!.!GC"Z>2;O8N0:6V_W_!7G\*QJX6/H=8K$ M9B66[Q>TEQ)("E)9;4L8^9J*FTRQ7=D\_D8R1PH\;AX8J;]B!<#- MJ[L6+;OCUTQ_TEW1N_7Z*[^*]O]J0Z%8]8 M<2 0RGS'(W'RXJAKM8J$=J?F-7I'39:ZHIR7E3_N&'TB>J4E"AAF,A?L)2D=V2!\A53I=%U9.O+DZ+XEUJTU".@IK#S_!5Z0L)4JMK M@X:S-,9:''-BB"#P:=*XES831%JCW+U?G++@22?(\Y^S[J)*SR,[\H<76TE^ M-&*O92LJ5\*J4H?U&V=%KM0OE8Q3Y,WV+YJJ^0-#:5MDJXW&:L),:(V5N+ Y MV #O\SY 5;G)1C=F#&$IRV05QZNU@U#H^<-/:GLDRT3T)W&-+:+:]OF,\$>\ M<4U.I&HKIX#J4JFGELJQLR8=&]83M$Z^M-V@RDM-/2&VI!7RG83WG[:J:^BJ MU%^JX-?H.LEHM7%WM%X99KTL^DCNJM.L]9-*6\R93+:4W41B%)7'"?SI2.2I M![_':?=6;TS5['X51X['1?$/356I_-4EYNZ^Q5!E:$,-E1[FQ70G#7[LCE\N MVQ!;2H=QI7L12R#^T:B=M6H5,3,AYDYW#WBBM<9'C3TV&.QFI[>.?9"QY?Y4UK!+U%6FY;EMNRV4*)3(2I3! MS];CD?&FFL#+')*DRKU)+?9VA:@"#E0JOM7)7DU0,X'MYH\Y2)U^F_W_!R?_"!]9%]8?2) MND9B:I=@TDI5EM<4.[FG5H_/R,9Q[2\@8\$B@C':33EOE8K2_/D1AEBW+DI/ M<&R"<>\>52)#+EHCESTS=]0OMR[4),]Z20 QMPIOG&,>&#Q32:2)*#! MZUT==2E&K%VL4@ZQ:#D]*=>7?0=QNL2>]:G4I]:9P$NI6D*20,\<'NKI*53? M'<>?:S3?+U71D[M$0@**GL%0XYQXU(K(J1*3Y#MY3R#.]NYW-Y9([8M1T^>,=WSH(JS9/5J^)%1?:X=?0MTA+U-K6]ZDL M5R5%U;94-.VEYUPI8"G H+"L'*FB>0I/'@1672E5TSOW!/JWT'4VZ6S+T;KEN7;W9 )A7!(;D(:[\)<3[*E#W@9J\ MNKK8U)&2_AB7B*4)77?[?\^Y:&/$;L^C7=.+<4\MR IEY9&$*4IK83@=^<\U MAPJ6GN^YULZ6^/A/T:_LZ]![@W?5Z3V2A;KE@[5#);4?=3W:0 M^#?:M8"RZBMMQN]L^F;$XW.D$CJ%TSEQ&) MT?1$!Z/*;2\RYZLC8I*AD8(\.\?*J\ZD4^"BXN]KC'^.G3O_ '!MO^'4?B1% ML^Y?N"P>T;]H?6J:.!+."MOX3G6EZT-Z+Z)M@NC]OER+W&9]9CK*'4(PK=L4 M.02.,CP)HT\,M*&$<=X3I$F^ MQ;!;@II3BPEUQ.>T//M'/AQ]E)M@Q5LA1TC&AO:LL=@CA+3PVLM<';N![ M_$X2:AJOR-DM!?U8?O\ Y+BF_2+(Z^F%$#DEYS&2L!&PGA7/.:Y>HE,].TLU M36>&A]U#H?674/2<2):-92]%3)*NM MW.?B_,:XL9YUB.A]0'8("CCQ41DGXTDQFDY7+$>B5?V+$J_/V^,?I9EYJ0X MK!K0E*QU'PS54'*W/I]BX4R?TBZ\V"%/U"747FU!0M]VA/ MABXV]>/JI7WX[\I4"D^594*[HK;+N=E\I#4_U%AKCLT/FE]%]0;?#2T]KRUZ MD@QP"TZ_&+$M2? .[[_<=[]J);T5;3[(B. MQVE(7D_7.#[(]]1V1)47='-?5NGDMZRU)$=3M5])O.@XQGM,+^]5==H'NT\3 MRWK%-T];43_?^Y#)>FWV9"%QE^KNM*W 8]ASX^56]IE"R1'/:;)*!M>2%IQR M ?$9I[",K9:+G ?]9MDI"6<96PLG!^'E3;1'U\TW&G*^D;;*]1N6PE+B3@*/ MD1W&B><"MW&B--^F+5,M%YMJ$SH(WO-*&4R!^NGR^5,LJP5TLH/_ *.6GM4: MRZ>+%LF/N6^TS5Q6"O.].4A8;SW$)W?OJ&5)R()2C>]@H_B#KS^S$?::C^78 M'B1]#IY"X=;'DJI"*')6+\)WH:Z:U]'>V>HR6D1K=?H[\QM9Y<;5[(V^\*Q] MM*V&R\G9(Y$R8TB'>!;GT_REQ_+V!W>UPFD"Q-$0J!?;K> $E:"6F?/<3S^[ M-/V$NZ)?I*SW/M%)9CW*&YN\4I+@!.?@34+1)1^M/T+%V#58/%<_J:$J$G)+#.YZ=J8:F"C) MV:)C;>J$F,Y&M6I=0,LQ(NTIT9*MRO:6?(4<*,YX1).O3I>>>$NYSV])'K#;^ MK_4/Z9L3TQ5FM\=,6 97#CHSEQTCPWJQ@> KIM%0\"G9GFW7>HKJ.HWP>$! MZ3*!EQ XA+J0\DEM1P%@')'NSW9JRS*IKU)_U7U]H/51@)2DD$)&1O/*N\T]PY1RFN1-T@ZCQNG^O&+U.+G8267(;JDD;YIJ_-+O6N]&3)#JG?5TS;0'&RV ME0X<2ZV< CR4D@@GFN9G%P;C^3T&-1ZA1G^ K0;PC1<,7K0?4!F7;'5I2Y#N MKF7D'PQQG(J..Y=L_8ON<8KFZ^XSWO74F4B1=[BXRZG&X*0\,%9YR$]_=S24 M>P#J_J?!4R]SUWR^S=0K4%)NKRY"">\MY*4GY[<_,5UG3X[*"1YQUJJJVKE- M#7(64MJ'!([N*O&0-:(/KKS:'G,,J':)*?T5#O'PIK"%S3R&$J) 2D]P%(0A MN#:'EI4A(PH$C:-*^CI93JR(N+/O*B3FG3%ML/^D6HJDP'9204;V]X(SD!6/N- M,^;"I8D61USTVTAJ*/;]1ZNN-RLU\L3*([5]MRAVCT0KAW . >"!QS0 MU:#:-*$U3:E%Y UU4ZYS]%34V.S6:'-"HB7EOSV@F04JX;*T()2"H#=C.?.L M^/2HMW;9J2^(*L4HI+^ %:AZEZPUV4LWR[O*B(.6X3)*6$?_ (YP?GFM"CIJ M='Z496LZA7U7^X__ ()%9*O91@D>56#,OV2$SC#O:LA6[D#N%,QT[N[&]Y;ZE=ZB!2)%9!'Z6>D+U&Z1K2W99B)<%*]_JDHE24']D M]XSY=U4M1HJ=?+636T/5]3H7Y'CT85X?I=-ZNOK:[[9X=L5*6$O/=EN99!." MM6.<#.2>_%4/]-<5:+-?_J%3=ZD>0UZAT%U1AWS3=AD:6%RLNL$I*=0VZ4'H M3,(H*W'TN)X&&P>3C!X[Z/\ TZ4'=L4NMJ=-J,0%7^Y6E^]S5V&/ZO;&W2Q! M:SG9&;]AKO\ V4@_.MNA%PII,Y2O/Q*CD-*Y;15M4KOJ6Y%9&=N6$PU%0 4T MI0'OS23&LA$XX5*&3QX4UQ,32'W&GD[1N1@[AW<4S>;CIO@L-Z*'HO=1.L6M M=/:O@Z8<1IFV7)B1,N4U/9LK:0L**$!7YT\8XX]]13FB2,+9.SS+#?8H2E 0 MD ;4I& /+ ]U5914\DL;I&W9^T:;8A[D)B?G4_&K$3'CR,O53^;M*#_Q+!^] M52?I99ES'W_!!O3,L=EN'1N^7*?9X4F7&: 9D/1T+<:':#ZJB,I^50+Z2Y^H MY)Z]C1E0W5F.V5<\E SW4D0ON1?2P'T5&..0ZO%&_J!@6+U=.G/7724!Z8^Y M%=<07&%.$MK.WO*>XU8GPB:)3'K*\Z[U$U6MUU:U?3;RB78[+J#KG9;=?K/"N45:CN8EQT/-GXI4"*B[A MK@[36^%#MMOB0K=$9BQV6FT--,MA"$)QW)2. /<*KRY)5P/"/J)^ IAS*D(_ "_]D! end GRAPHIC 41 cogo_0029.jpg IMAGE begin 644 cogo_0029.jpg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end GRAPHIC 42 cogo_0031.jpg IMAGE begin 644 cogo_0031.jpg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cogo_0032.jpg IMAGE begin 644 cogo_0032.jpg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end GRAPHIC 44 comp_0001.gif IMAGE begin 644 comp_0001.gif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comp_0003.gif IMAGE begin 644 comp_0003.gif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comp_0002.gif IMAGE begin 644 comp_0002.gif M1TE&.#EA_P+6 ?< ,! 0H$ PX)"@T(!Q(-#!()!!<0#A,/$!81$AH5%1X: M&AP7&"$='B,?("8B(RDE)BHG*"TJ*R7DQ49%A;951><6)?8%]A:EUI?UAC>&5B8VAF M9FIG:&UJ:V%D;7!N;F=J=7)O<&YQ?75RWEW>(!^?P!5I@!:J0)8 MJ =3I@!AK05JLA=UMQ%MLR1\NVITB&5SBW9ZAGQ^AGA]B7-WA&IZE6%NA5YK M@8%_@"V"OGN#E'F!D7:)J'V2M#F)PE>;RT>2QFZ?T6&?S7>LU&^ITE^ASH6" M@XF'AXR*BXF'B)".CX"%DXB.G86+FI&/D):4E)B6EYR;FYF7F(F0GZ">GXR3 MHX^7J)2;K9"8IX*8O)>?L:&?H)NDMIBAK:2BHJBFIZRKJZFGJ+"OKZ.LOZRM MM+&OL+2SL[BWM[RZN[FWN*NPN<"_OX:=PHNDRHZKV)&KU9.OV8:VV9:RW9JU MWI.^W:2NP:ZYS:JTR+&\T;&\SIJVX9RZY)Z\ZI6SX:"^[,"_P)C!W[O&W;?# MV9S$X*#&X:K*Y;#/YK[*XK'0Y[;2Z+S6ZJ7%]L3#P\C'Q\O*R\C'R-#/S]33 MT]C7U]O;V]C7V,[/T>#?W\'-Y<+/Z,?4[B40) '384A)C!7&%\(5>I"Z!*FQ8&/F$5\5/'9 MJ$?+!$*3!.:+R6<[)SYB*;'GJ##03"F5N$S72I0(GT++-374S:\NCRY[)+)E M&#"/FB&52#-,+H&GW"(D)C',(T]!F4U]%"JB)VC0F'D",^9@0Y<3CW)5*ND9 M8HFC*@Z=RM+Q6: ()X;Q5,PLYI%V=29S;NW[]_ @PL?3KRX\>/(DX;F&\]\PM1'C17W?.+?'6%0EF:(1'3!#!WTC<-3<=,<1P-V$15Q"X!& ( M+N$<>Z4]8F1W[+5XI!+//&($$@XB"9B$W1DATB,T%K&$2272V%UC4A9AG1?= M549,$D:($:412[!4S'X"DNTQ4*PH2 M2WIB!'3,+,&$0*@ B\2PN2#AA:4MC@$-J=(]4HRR6(ZB+U)>Y)F9$6/H@@H3 M11#C2;P7=R8E5,1HZ)422HQ:[E: 0C.*B#K!3,PRI(B8)< R+G,MLS\S,6*? M#LI(C,.WQJP7$5M4AU&!4C!(T2 M!ZO]3!=)G/S(C%* M*,]9ODQ%6AY^(A$'7:L60KFO-D81OL(L5!)8/M)X$E$YG*Q 5UPA)6I9(IGZ M,D7(F+NQ _%5%Y! "DN!QVL(3* "%\C !CJP-LS0T+N0-9-G2"([ @D%!BNB MKK<8JD1<(%"2#+>$*_AB8^;Q1 F+L3&_&:9%AP,A@=H&PZ_ 27%<:!$JI+,, M4X"L7OZ9HTZ*C! U$&+G%-(95C%6=:?&1(@)T+C"$M0".PFMJS16"8,62<,] M-RF!7!NK&TLJ^.(8^[:KU, ,,.K:$A.LTZ?^ M/4(,#EJ&))BCHC&-!XY)J%TSEK4$))AQ8:4IXS.HXX4N,&$)J"%3WE AAC=" MVI)E8M!PJY*1LB%P #)GO/ACWH^*8(PB_ 6[!P.B&(D$!<*QH4!$@,5 MM%.;3DJT!$^$PA.HD2'G!JC$7QHN0T@811*()Z4NG!,OI?X)!7.$Y)'OH4(4 M=4K"*:D9)0Q*R1-7P)+SGF.[U(U$1%=@@L,P)Q"_E85 1WN&+QX!IR*@AGM< M$80D'&5>] M2A2U?U%G6*!K8D+D5Q8MK:8A@(EL3[@75\:EU3P&.A 2W@*Z)*!*.LVAJV.0 M "4Q$ & YSL*,]3G"2\ HT\#B_[2O>[WIW3JL10 M$$X!;+E>$L@%YP8-"EID:54$OYY1'>XAO4OB+.2!!>(\"XX5;(@A0.OGO?,YSYO;:=";$Y01B&>\8VW718Q%)@(A\2] %),X4G25$^0A'&8.E^]1( 1\D%$?@8Q80NP099^D(MWW;$FC%/5.3-:.U M><01RJ)I*/&B;MR1&$)*'4*?)!HA?CL%,98 I5MLNC^8#@\4LR0>@.79@M>((QE+V0=@&Q&(@BSE=P!PTC(:YU1Y,A;HHF(S$L 20+*&?4F0& MH@U#<"BU;$*X%'9HF>;GBEO\XA@?#F!H&UFU7>PFM:TM9/ZMC!2=!.:#DB&Y MR#DUK\#\!QK1V+C)2>[RS!FJYJGYN#A/#AB;B[,AM%5;O:#AC)&/L^>WZ;A MG%$O=0S5W2H"_WF'R05R9&"=,@V@^'BN](S;_>YXSWL#R:[WOOO][X /O. '3_C"&_[PB$^\XA?/ M^,8[_O&0C[SD)T_YREO^\EZ[N=N$ L3.6\3SM-&\4(3^^=)#UO2]4/_BNC_TWK5;_[V0R>[YCL?^]6#_O:UASWN?_]ZV@L?]ZCO^NM%3WSC MSQ[KKC>^]&>/?-@W__JN?S[I;?Y?_-_KOOK![W[TB:_]U'-_^ME/_O#'SW[N MES_\Z#\_]8]/>^7''_CWK__ZY=_^XF/^_P 8@ (X@,=Q"J9P@ =("@BX@*2@ M@*;0@ MX@ :8@ Z(@*1P"A#X@!$8@15X"A-H@1O(@1C8@",8@A((@1EX@1+X M@198@0G(@"I(@2^X@2ZH@29H@S=X@0VH@"GX@#S(@R\(A#0X@1D(@BU8@@]H M@#^(A"&X@T[8@DZ(@E'H@U'X@U7XA%(DIPAV@ BI(8 1;LHF@&(J9 MN(FC"(JE&(JH&(K;D2*C>(JB2(JB6(JEN!VA2 2DZ(JFF(J<:"2ZV(NYV(J^ M"(RJN(O>X8O&F(O#B(R[^(J@0HO'6 3.N(G.&(VI2(W/V(O6F(S7N(W0B(K3 M:(S9R(V@&([2*([;:(WHJ(OD:([KV(WF^(SIV(S@>(WMZ([8^([PZ(WEZ(OU MV(R>R(_SB(\!.8[[Z(NB$ F9@)"A$ FA( F9@ F9D D+*0H1&0J90)&1( D. M&9$(R9"10)$2^9&1 )$-:9$*&0DB*0H0Z9 .*9(*F9 ?N?Z0'UF1(KF1$AF2 M"9F0$^F1%[F0%:F1"7F0"'F3(8ED$5F1/GF4#!F4.!F2,GF04!F2!RF3-XF2 MHB"3%BF5*)F5%)F7>KF7?-F7?&D*?AF8@!F8!DB8AGF8ACF8B(F7BKF8COF8B0F9 M=MF8DEF9EEF8E4F9E[F9BZF9GF:I9F:N^ +J>F:N4F:O"";NSF;ODF;N#F;NVF:P]F:O)";OUF8'?N'G M>2BZ>;VW??27HKY'+RJ:?U(G?B[ZKS'HS;J?3%Z>N\W64/JI$7:HSNJ?E+J?B^J>E!*I,XWI2U:>D>:?#YZ>[C0 MH/5)IB *H&::H+O@H&EZIO;9IF[*H/AI"VO*IG$*I[=0IV4:I_F)IV^*GWJ: MH V*"_ZVL'7R>:B(^G]PBJ$9"J)^BJ9\&JF2.JGZ^:B4:J>72J&%FBCNF:AZ MUZF2LJ*>VD -:IZ_T O"T N56I^_L*;F*:FX\ N_8)Z]X*>6:I_F&:CVN0O" M<*O^":"O>@N]H*N9*J?%.JA_NI^^JJP/:JBC^JS0FGCT29^\( 4GP (G -U MP L&6I^[8 DGD ;"P (PL N,.J?=>JZE( 4>@ =KT &?0*CZ>:X.*J&]$ 7P MNJ:,Z@MK8 *6P*V:>@L2:J[GN@L\ ,"&PB40*$%2J8->ZP/:J8/NZ^ MZJS 0UP, (9@ *$@']*BG]#*A#(H K&('M3Z@I_+]=\(OM].Y ##6$,01 "B9!_.'NS)/H,9+ "R.!\R3 $(- *JB " MKF![1^M_[LEWA/ #K$"RAC ;]8(,3MNU0"H0. $.^NU"($,.["T.AM] M$* M)\NB4?JUJ_!=TVH+OD " P !$8 !> #JGH+OR ,PG +O& ) 0 #PM !'K + ML\JJOE"?A!NXO#"KO1"YMC ,60 (% )/L EB"KNC"X%CNXK6JXPK +O)"Z M]CFYPOJY_WH+A/L+MB ,.A E0"PO< +NQ"X@UNXWCJ[K/H+]=D+PVH!#K + MI4 ,# ,MA"KPO +#CNIQ"JHUO[;I\6*O=B+"AB+I*%G P P 27 #@!J'Z M#*P &W &V0 *K J0J @VQ"@FPO@\$ 0\P>C\ "NPM9!" @2PM#<1! " M K( !P!0"-+7*'_ #F@ %N+ SU@&Q4Q! "0 JVPP++7 !<@',;0 *L&YTZ M GV@P2+\#*U0 7;[G[UP @B0NY5@ 02@![NK!U(0![;P"Y:0 #H@#'10![5 M!Y/ K7BPK;= !U* ![OPK7-0"GB0N]]* @N0!9\P"6EP"Y8P!Y]@!UD0N[Q0 M!U*P!J5PN', "G70Q;Q[Q$^PK;Q@Q;; "[:P!E)@![7+ R\,L'6@!Z P!X9K MPVKPO/Z[ II( 5Z0,1*?,0TW $5< MJP AH =KN@8^P,< BY_3&Z?5:ZR6 MO*J3ZJ>!.K&;JG'/0 @%O+2PD $C\ RO0 C1X 4 &@( 06]W5SE !(B 0R> &9J#.HTP&*OW+0S $,4L+' + M95 &(3P(/_ &%4$( MP*+*L*08 &T= 0JH !.)#!SY '0, ' L$*L9 (HHT, M96 %L* *!-T&/[#/SA $%E#5W#6F ML+)7 N3L,:1 /C ,/$ &9 'H + MEH ,/ +#5 !MN $= +EE +?[ "R20 !E #,P#%$0 !X0 &D@JVF@ [ M ',P P$ "FH0 !C 40 9] W0% @I@ ;[0V^L] .Y]"R- !,0 "8PK@% M"WJ# 7T #P #U; -_7@""/@+B/0(] M0P,#@ $)@ '(@ P($ $5$ 1D ()$ @ M W(D $*8.9FT! XP+D/\ #(8 @ @ &,3NK/0, /< %.CA!6T.0.8 B4?@$# M(-<#D $-, 'U[ 8"@ $., $G6Q'( .@3 ^VP>*G@$(8 C0D $1L (#D.?C M>P$( [4!IET.0,H KFWK5'/MP6@-H T K( <\ Q" !32W1F+@()L-=] M0 LD $",+05\0< 8 & [LW/( ,> T,T P'%\\! O"Q$U#PKM $& !!U#7/X +N #A"WSV (#S#,%I , MR !*7 &-X !F9T#(^ &+E "SR ";( 4$\ *?G !# /$ )OCT,>.#=I6#@OT !%O +4C ED 'N*L& % 'P^ # 7#YPJT'M2"P MMDL DS ,,' GS '!8"PMUL'N. #>- ,/!#@=C +' +.! >C ' ) &PP % M\*H#"& )EL #EK"X"L +P4T)=?[: 0G@ U5< #PP#'K@W7H %)P"WH R1J0 M ;Q0"@W L*0 100R G0O)9 "50"Y. !QIZO3:>I_0/H+K K#C^JQ-[X\FZ MJYR!$,C0 ^/P-O"H!!H,K$FB6F..5,00KGKT:( 0: =NO!/2H.00 MH6=!1#CS8^;9K % : '8@4R5H6"86 0B,P(-G1F! I P<>L""6&(Q1*2$6@'J MF0L2@8:!L9[QH(]8("@H T(,,5$5$)Z9("JIE$OHF1/\>,:900CJ@X-GA##Q M&39&(.B5![0\@2!8OGP%/HC.1#---==DDTU<;H'S%Q,.J/Z$EV'6 .").0C MP (,$H#A$P-T^"6""GZ99( T8&" %Q@2R,""#0J8HPX U!@&3EN$T8& 28:! M@8!/Y@!@CF;6"* .8?!H08,)#)C$C@!,56, /7@XP!)>A&D&5 ,HX64-$C!X MX(%;>" 6#@MD&"7.Q'H4X,$6,"%! (*T*".7BK0@)=2&CA!& TBV 440'G9 MQ0<$!H#@B3?AA//=6]Z4%UY[;]GE7GWWO;=>?O^%MUY_[1T87WWKW46@-@TY M@ +N#O3A@"H,R0%"P!XI8P Z(L% 1L(2HN5,P: !1H72AIB@.]@&>"'FH08 M8*P@!)"E! 8X.' B5P!@PZ RUOY]P(J$_#B!@P@60*8-C'_FX (,!#@C&0P" M($ $^@XZI"C$!CF#@ R<)L"*N,(LR*XVG$D@A6>06: 'MHPJ*(@ 6H$&KQ&0 M46 NMK+ZX:<4;K[ @@.(2V@5&YH>@!!6 %#.KCX65^X9#B8P2(773E1 I$.@ MO2"#!5 PA/,,%!"AH!$<$*F@8(1X#P$";2A@@ JRLCF:9TIX &(7$/C.*U:\ M4B7*":Q$\(85.#B#@2$,(@2%#"+@O14) EA@!0R? @$#!&0P*)K@2_ C@Q^" M<( [F:ASQH(+ZC/@NX2@R8$ V6E*9HCL$W#A&0B.FR""2"-00#+DD( . ( M$'/&$/Y2@(,(J (9#T/(#ZS@AQ)$Z1D_<%D$G!&$J#G !BN0 0@.4Y 29.49 MG7"!###RC!V0AX5!@ 8THK&^'6# !3?T #)6@8$FM;%&K./S"%G'B M :Q 10!0S"$ :QA&&@J@ATD :VR$( *F&' < 157J00@ "T8Q)Z 4G0)% M% "0!5^@0 &XX$$"Z@2GP&VJ#@/PP1,#08DGQLH""P"%!BHPC$\LH 7"R % M=F&)!_(( "*(,,!I;M@ )Y"LA,QP"0 2$1Y D">A/@D>$+(S H4 ML(I8N,(0W@N &PKBC%>TXA V&(X? $ &9.Q ,IH0P!@L14^Q.(5JHB%,5K! M"CDP@'+)T$Q= J <0@1@$,TLZ"M (0ME-$!M90M &W(4)F,L8 >P"$"$H!$$ M0KQA.,](1@)6X RY/.,0 :!)#E1F@P0@E!6)2)UO2A ,?1+B%0 XC.-B$0"7 M.0,"%^BA"A80C!,Y(!G08$5?8@$+5;PBJSDPJ'@*L@($:,800H@%!AK BF @ M ?1F 4K"$&" +QB!0Q(QNVV4_X3&2R@=US1)Y3P5CH@Y 40.;@ ^B3D#X M @]$< K@M&*5IA! +9!2&);4=*/'82"?XE%,@C@GV9VQAD*.)(->!LPA _8%Q!3G #V*C"&1.PW3-D@ 95L(8@ M+EB>"MZ0 ED@XP&T< 8TCI$Z@I2@,ZI@@"JP>B0,$J0-V'2% RY((&1 @Q8G MM%(0Y3M?^CY#7L(@P0 ,E8 !S* 7I9C ^; @P;H 10!@,$O&A"!6PA#"@5 M@!Z(,8D#D, .)8B +?"T!F%H2A@P$.0P6!" 3Z@! &MH!A8 H <] $ '@K@ M &(% /XLI!@ 7W18&B P@%* &!0^>&,<%)" 6^A C[R $P0>8 M#74;S6$4ANT0@4",,8)")!7$"@ 8B@(P'?84.[%. .*OA*11B"#)=> M &);.0,@*I#R&PB $ NI4)0B$ %# ,&9-2$(,B80/ : M<$$93C !:'@I$@ M( $C63 #6_""$B2XXRUXH0<0/" #JMK#!_;P9CCQ(@T@H(0PHD""4NBA W48 M1AU H(=>\" "), ""63Y 57A@01Z$ ;Q'P""20CC"20 Q2=: $82,$$&B:! MKN $ Q@T'Q2TKX HP(5=2(,G\P#T"P00B( H@ $?Z 7^$[XUR 6Z 7K

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�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cogo_0027.jpg IMAGE begin 644 cogo_0027.jpg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cogo_0026.jpg IMAGE begin 644 cogo_0026.jpg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end GRAPHIC 39 cogo_0028.jpg IMAGE begin 644 cogo_0028.jpg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

    (CJ 6SC#2H 5WHH!QZ@!%ZA$)('2W9@ M!42 2D3 24<@ YR!B];K3^_2]A JZ_0N\R"3GT:&$UFQ]Z8NVVQ05'7-H%S1 M,3MQ+P5J%B7- VX(2]<+ N1+#A,$Q(+,J@,!A@,_B*+,S@HV(A+OA@U:0#0()5+% (/F" 2HE,CCC00R! M \R@7\G' 3@@ R8@1&Z3+#+ +0@!=] '#W%@E)X!C69C4I\!#0"28)DC+2V M%8R! _X(5CWTD$KXDWSNPP*>* 5ZYAG88)16(#K^QQ@<8"2YAQ8(P55NXV*) M@Q M0$8B@!7*-5!X1!8 1D@8!>3AS)<0U12[4O08#/.-BTJ@$#ZH$XF(#U7H#0P M(#H -!;&=KPP%2_Y*51+U5-?L5-+L?=$D7!OL-K>[B\9=_=:IF:@[O4V+5:A M80%DA \(D7R$Y14N@"W/ $YB; =0 &O;H# @0$5>84A4(*YN+!8R(#\513?% M@EDY8SC@H$Q$]AGZ8%12H"XFX!5(%@-(8 $MC=1Q&(( B M;FP$R, 8 M8J$$3:3>+J N9, "U# !@ .+9$!&RO4&>K%1.F8UVF,'8'8'&L49V(!1*R :]-!L_J $:&%"3"-Y2E8L*@1# M(P"*!;?V+J\&535Q54_K@%!F OZS,4'15/,8<5GU,;7M%%\1SQ:3GR[7TM1X M J#1& QD45+ +6+! AZ,J;26#(HV>53W&2" MECA=3V-WU;!#!0 HN#D0$I# M@\6"3*1744Q8+$Z@+D164%KA#!A %01%%O(@ MI BD_@OY*3#T;%#5) 4)+! M#TI@5/C" H+ DI_A#:X78\N$>,5"#IS99Y(!$$H 0-87&51 >]_"2<:"#*C9 M&!(@%@0T",B@#/B5+&3 D^GU&2Q8+/3V2&)A,VR@! S!&4K ;(4TT]S2 C[* M!IHVH)_!1<2B M0C%M!V!5"P! "!%;*D$&F!3L0BB(184-*KL=0B< M 6W+8%6BJE-T,0>^! -VH#\X(!IP:#/\X 1T9S+\H$Y6&DS2(A;ZP$U%T(T+ M3XX!T_>L OE6KW$],8]U<*QCAJS_4B__&*RC3G$SD2FVK-D<9MJD[E47+4?< M1@5"A90%!05*R76I9+22(0$$I0UX$.45NP(%_MP*HA U2]T14UT2I MQ!#"U4_2X@VRY@WFQPW$0P48!!DXX'KW:@^?(1&&I (>1/X%].0!N,0PW&+Q MK, #8D$6"B$"&,0- E$L:(&<8:T"/NH' &0%FK9ZTJ*PGN$!+.05$J _XH)[ M'L08EM"'8-8%>H9A\428FT@&& -.7D$!W.N$!@$(S >J*9H04;BX+2!,K,B! M;:.%E)$0^R!<&^046;+6G5FAH+Z*"T%;.X&Q# %-M.E MHLI1;Z,T=@ $7* -1B /_N!ZD?ZA447 !M("![XY3CR@!-J<4D^ W)@!>X# M!7H@.+'P&4; -@!A-VW O4! %F2! _KP"2#A, M+C*@!#" 1' 7!%: #4K #0B!E/L 3HQA!$1@!6S@B92$U.WG&41 %CKA:YZA M$$# $5? Q,0"#B RZ@8.,9N@5E! ST0&S !4@ !#9C!SQ-4$IS!#A@E2\@ M!:S 5#:=2I((;&[@NX/@67^@E$9 468DB$9 !0HL ^JF!!QIK@S! U[A$$Z% MT! 42 1IL8-(CY,ACSS#I^(XG-W*9G/@\T07E3O>HO,K5 MFH^7GJVEW,E];\KFFMR^?-).C1:JD.+L#8NL,5".X5@5A.R-Q:;-8O$$97Y# MCN)N+*3)@A; D"R00>\!CN_M$J2PZGW[[16HA-7^/N'P$ _9;_$9CRR<0>^5 M1^_K2RQ>*&O-<>3&8NP#9"R0X0<8QP'$3_T:]-]@(0[-8B2= 1I8^17H\A J MP.$VV.[KT1C ,)9A]@\",=\H+AG<*AG+7A9>R^.,01Z/OO[R0@_KSCKK]1A4 MHSSJ]=@5L2(O PKYVWKX#G)9$AJPGRF2QC"I=RK2ITHT>HTJ=2K6JU:M8LVJ] M"%)J2*=@PXH=2[:LV;-H@:9=R[:L0%QPX^["M6ON7(-UY\:EJ_=N75UYZ_+% M!1ANX+IX#PO>*YG5YQARY,^+3&>_2 M39P:(\;6KQF_U8N1\NO4G??B5LR;E^UF;8,+'TZ\N/'CR),'MU6K%O-2MJ"7 MDA[=5O52M:A+IQY]>_3FV)MG!Q]>_/3QZ,LW[VY=N_?IU\E+!P_^^_OT],O# MQZZ=/7;VV=G7G7@$%FC@@0@FB&!XZBE8X'0,Y@,8X8^&%&&:HX8891M,A MAR ZXV&());XH8D8CHBBA2JNZ&*++XHHHXDPNFCCC#=>6*.-.X+8HXXE_ICC MD#X2:>212":)819/-.GDDU!&*>4344P999556JGEE%ENV6277GX9II-18"DF ME666.?ZFE&":B:848%)))9QJ9AD%G6=B62>97DHA9YI/^OF$%' &^H05922J MZ**,-NKHHY!&*NFDE%9JZ:61DH'IIIQVZNFGH(8JZJBDEFKJJ:A.ZHLON_C" MRZNO[@*KK+3R(BLOKMJJJZVUQ@HKKK'>^BHNLP;[ZZ['UBKLLK^Z6E>RON[J M[*W/'OMKK\_2FA>RO>8J[+#/.LLKKMK"Z@NQQ&I;+;6^TF4KJ^NR:^VWZGYK M+2^]P"J2PTU%G];%'/.0N-%=8*;:0U00F! MM"_39)=M]MEH#_>U1@UQQ'70#K\-]T1MU^WVTPSM#)MK5:U]$51R7SQVVH07 M;OCAB*L$ET6Z@)TUWE,%CE#@DE,M,]65&S3YY@\/GOCGH(<_[WW7/3 MG;KD6#\D]=43?C]^[[[\"C]="P6[5FM>40O>W++US9 M&I5#SO_"/$:^5;4W55 =CSK;FNN_ MSY!U;SUT<$$'WZ]Q0A:+/) >>O[@7\-^@0<-U(%](*N8=6[A"SU@H Z_ * M M>A&%#EBB*_P#F0 /EI$%VJUT7#&=W;SG.(@4S2A^R$ 01A(+$)"A)#_Q"4J@ M$<-GQ/ GL2!$,I[1"@?XP89 3$D-94B2(1;1)$:TH1&C00BA!-$D-GC%$Z<( MQ!I&\1F$H,4S:.$"GM3P)T9,XA%5(D:?A/$D7TSB#9$X0RK"D(IB/&,9X##& M(O[D!JQPR4^"T 8>MF(D-_AC&<_(1C?2$(U$?",,:\B*52A2D4,\)$PD^8P5 M&"*1C\2D#-G !B F8P1%T61;#L*+#A"@$KWX!:Z$P8M;"(.5M^@%*X7QBXS@ M@I6I'/[(+X8Q/>GI4A@#$<8P@*F07[RR%P@QIC P^$IA%&07QTSF*UN)D68F M1!@:@, R;\&+:2)$&&L 0!J:H4II;K.:PW0E'0" A698X &RA$$ *L%+G'63 MEN;LI2I_80MH\E)UI@-AUZZB/8M832"\LPD: D 0CSC%0! @5+. IKN(! M?4@.,A[0D@CD4281<.0%+ND*")3/)BY881E'4H%+KK0DAE#%,X* @Y%8X)(! M^PD9;.#&L?A!BSW900Z Z P^.-$X<;$%+TBP $O8(@N5J(,/*F$+0GVB%WA8 M@R7\] E>? (+E=@#'7QABS7H( W]C(,:E*J'*!P,"SI0P_[YN(D''?A@$JWD M11UX$(52V,H6:>"!&NKRBZWR0 _(Q,4<8""%]>V"$CZ8P1Q.4X<(0 +I1#& M)'S@@T!04QAJ&, :Z,"#2N25#CKHJZP^$04=8%88=1A '/00@0A$81X/46<<"#)6Y[BS3$=34\@QP)MQ$8B9-'E9R@CR6[X22=8T88;),,5-VC#3XP1A!UD MU"1^R($5=NB*+!/"%= @Q"MZ\ ,*/\,99\A!&WB2"%;(P05I'DD>9#"('0QA M)(3 P1 ^'.(;K ($."4),OKP$U8< M2Q>(4L8B$"$8P9!'XH QY-$@LAY"#+ MD+Z!(73HC"P&08N#R,&H25)G/3\C%H8XA PZ@0PA .'#R+ "#@ !:E?H^H^O M*($(,O[JBA[T(!$E*7:Y@>#H5P!A!Y=\Q8(+\> _A/++5L#P2%2Q0V>8P0:& M*$0RC&&(1-C #$)YQ8E3_(P^N, /0OA!$2])"T,8XN!'9 3X\P $0L#@ S! - M!V1@!P58 1"1T8 $K" !)7@V!!:0 0#<8/D1J O$R& 90 @]@#-$ 1CP M P.0 L^0 @SP P\ :$48A P!+10"!/P!F\0 0LV$AF GD !!"@#,^ CM0 M""Y04WD0 870!Q=0%!;0"H00 3;0"K3 #L@!R40?X40 1;H YU 4"@"BCP M:7"@ "M !M"0 CE @D-%$C+@ /YG\ 80T$DV $KT ?&8 %DX <>L$*Q$ %D MP *G4 0R '%R!QJE !?. '%M )ST &%I '5L 5N!)"N ,AF"1B"5/$ ,>A 3U *40 *O) !#( +=3"5P_[0 10 36BW!KY M @A0"C! )0@##P [8P!VHP#+'U!#R) $^ "VD0 '1 #%$ %K9/=0E$;D7 M0JI3G J14"=!" ,@>2"(2&X '[ @I@" E C1,0 3]1 @3@##F - ! B0 M#(50BX80 $+P#") &5 8680 'E$" # !Q"E7ZWP8E_F!J\ #2?0G3\ G\]0 M!BN #!CP #1D V00# -04ZT0 $, 43\0"ZOP"M&0 !SP"J_0"DX4#1:08]PF M7_E($A. 4Q,0"X=P 2#6 +'@"CN$#"WX#!;@2" @4Z_P #Q!"Q, #;XX$H7P M0ZAH!MWHCZ"&HH_F %)T1_>G9OXF=0/J9XE)J@P-H P[-1*L, '/D /*]VBH MB ;=: ,2YPP.D!1M@( 8]6BRH&H1D!3JR8F%( (GX%"#J*8@X&4XU0;2=P,2 M-X9&J(O/X %F T/ LC(0)OT H=^F@-@(HRE -E\ PN@ (2FH]"%I)YF@%9 ME@$N]64/Y@)G NM:%.LX P,\$<#^&(CH)]6.A)A:@A$*@*<2 LF508(^ RL MX #0X %9MF(!.E2NT !Y= R.]F400&'. '04 )N,!*K8*4>H JTD +J9P8U MY1,3L&30(*BH%@LF95.NH J'6@@9\ PEP(G/8*> JJ8E\(@CD0P3X R)<*B& M$*["0?Y*J&D)ET .J"6 X 'PV ""6 +,+ GR ,@1 4? )! #O 0#8]<+ MEK +. +#M "6# EC #"7 !$V !"H %PJ!4@< "%J !!) &=L";^=(,S< " M"!!UPM ,NV !A;FQ#' )>O X * *NL "!# $+ &"+0+&3":E8"ON.(# M!(!7>#>5S: &66D'!* !-,L"N_ $&9!-#F +>S"5V!0!M;!TK#D,&&L)&% ! M M$,P\ +DR"R&( .VD!$' +P\"P&$"S4?"QU25"PED1.U-[?*LYRFD2JH M Y !&2=#T4E? I "#B #R( XO4,9@ K) (TID!TN<*,OYP 1F !+' 0X@ M%&40 *J0: "0K#AP 'P 'T$8F[@ 1DP 0I "R(0 4Z4#-=9$GZ & !K10 4 D M8<;0 #+@ BXP;FX@43PA IE*$OZ D *L 1HD =EL(8K! 0Y\!,<@%-37$1G M< (Y@ %N4 C=R!,CL K06Q2N4,+\*P=]4,(JX (A+(XV- (9]0H$G $NT+TH M@ R?.!*Z&@0W\!,J: $J$*S&4 '((,#.FP&K\!/'H)U60 9]T 8_L HID('/ MX H> ,(RE0&J8 @@\&CBV@JJL,G/ B;S $EX,,H\ -P[ P_8042]Q/L"@V: M#&J@'!STN@"@< D', /#D 8#4 ?#, )R.0-+VPQ@F0:@@*^IQ ,%$ C-, D# MD*\Z$ $DD '#P ,$L >V8 F! IU 0HVYW(!@ 63 !/T R6 -XD)/,'+*4 M0 (.X/Y4E! (GS )D[!< < #MA"9@?"YW&P012L,I; )# ,P\"R%_0+<5!W M:IF5!2L%N *VRP% #";U.F9 Y &PR"8I(D ],2PH& "#% *NPP#EJ &' + ME% .ZD!%1"V/M#+MV )]6Q+ #4SR/D1>\LW Z73)C2X)D$(0J"F*0$' 5"+ M/T "B #T- 'C 2.3 L0 -#J" L8 %F ,X)6>'H"[(U$& X!CA! ;I , MJA +JC " :"F;9"Z5TH R+ "X]EP-M"%\CH$9, * 0 $R& ,$TK6L+ *(S MK- *K. *0#"?0.2.(S$!J.BM)6'(-A4+?S#+P:"C9? 3(OZ 8Q?@2$#V4.K[ M#+!@ =!P :BX"H1@" ^0%(0@46\@4<\@![-<(4QXD@]E4C;0J,]@ RLT$L-J MIR,Q"$OZ0EB4VEHF43-\A136!BX0#5*D#/E+9A'PG,BP0WP C2?9A4*1 F[ M"@QPIH80?S<@W#=P!M%@HR/!J<[P *%$%'XPRQ: ;B:!#*?>;J4$ D5A!6:0# W $Z)*C!-0%,;P !^6#,A "/*Z1= "-(GKK4( M"U9Z8F36IPNFJT/0 \^V0\D@OIXDR,\0R,Z :R,!"R;%"BF [#0!SM0QZHF M11O&442<# Y0%&#Z"K'\#(,PROY_)L#)$ &AE -Y^@S'T*X_3@@AH#8(L9D6 M2PD P +-D 4 8 ?# (# + (< $ZX *\ E4#@.U= D*$ %00 $)4 D$2[Q> M5PD*H %8 (2 IP 0KT-P_N09Z PH 4 D + !, G#H (!\ E=2P(\8'6EH 7 M, P,SDG=!,_P08 ( ?> M& $ $/Y_96!_01 37H# , @VS5?+ " #!4%I 0K'6,6H(J0M1D4QR'[;6 M9. &#A 9!T '" $ V"EE6L#. -54""' &/X ?N *$44((, K^ $3 ( M/0 F6H,#O &SM &&. *KG !?11##Q!?,P^]:)"]&. ,%X &QO &&O\,#W#) MC1;RZ]L S^ &.E92?V ($6 ,KS "%Q -RC@2RF !-NP&.0]$.^ 6P8".Q"" MGT:K#T!?,B#$(* "0 #UE;3;?@ !M. *)6 !T8#V6Q2FE%O'"N 'QN &$9[; M*Q +B1 !K1"GT= U)8 $>H'"I ,J.WT<8\,+I">E21Q(_YP ['@!P3P0BZ@ M F8=4L7J!K%0NN ;!&NT PN@118@ C_A A+W>W\T 0LV ?/X#$(P L:@"ML+ M#3]0@$WH"LA [X $J;A_NAA 8GG0KGY I!S@92%_K0\ D$ @4>]H4S]$!M9+ M" JP"LF0 ]3HR@RP0\; -#@!Q,PH2"@4AZ <^&^"61# SP!LG !QUZ 3\4 M!!EI R!_AR/AD2],OK$P @ QY)D*%[$&&0CR#-HS9 J<$;+P[)F?B!(M7L28 M4>-&CL]PW0*YZPF+3Z!8I!&VI\4D82-OP6#P! ,)/<(LG>QEBU>E%A1.3.H% M4@<,2[MVGJ!@0@\OD+SH=.@0!_[&&F&@9ECP@(?7SA856E#JQ7V" M4>%"E%N_GDXH42GH+5Z36)@ Q2M+!@U2;NVBJZ=%3<&!A'W28:'#&EZEKO)( MPZ(6SYIV3=1:T\+2KS4L0 FK0Z*"CE*_ZGCPH&;J+QXZFE+JJI0IR%L?:=^V M;?OV;MZ]>^O>#=AW[=VX;#'K>'%A\D,K5$DDM**-1#@<+I!Q)G'5"C,2"XW@ MP">'FV=#<<$"#N3 B(T3:'FFC1)&(.\B(&*1" A8GHEEA1%6 M()&5%/Y6Z../')X1XI5GOE,%F1\6,F;'9]SXD#QHSD#AAU5N:&65,BR*Q845 M;;3HAA]^ "&([-SPPR)#4!CAAV@4>F80/V")"$N+T"AR%1Q6X:,/AGY YL8S M_.,R!2@E"89&T"PPHPL M\]RSSV=800$$-X)X!1D(2+0HD1\D*@/09]X M+TE095H"%485,E!]SA@@LE.%2QSB#(+9\IBE985G M^1AAA!OBE$C'.,U]AH\/NZ..W1U: 5,[+E& -PAXGW'E#?YDUGLEH4VMD C< M$99D:($6C3AI.#..*-@.M%&%QP$88I7C*FZQ=A6@C@LZW^$L87 MVGCY!>79;JG8MHUW$68ND,(JF6.84?ZEJ913!NF77RH&[&:4/_I9Y=MP_BAC M7WX1CBYA@A9&E]HR]OFOE(7!FF2-A6'Z9:?OTC MUHNC>[B/7@>)=]I\'P[XW'6G;?[WX'O/7?C;@+_]%MZ;'Q[WZ(>+>WK<4-%[ M\N4DVGZC[BW:OOOPN0=?.?(%_UYUC-(_WWN-V'W&;HP)&[[#=W>=KN@M7!N MO"(4X1"(6T8A'1&(2E;A$)HINA*W#30MKF$+S(XQ.;9# MH0JO"/Z]+=(FC5XL7A2_&$9%,A**)(0D&-NVPK6!,8NM6Z,?-;E)3G;2DY\$ M92@Q[H41839+?Q(SAALX=)%B0@,:Q1Q(!WUL("KJ3 M@5U*C TN6.(Q3D"N&V#@$ )D8%5W+$CSN! "F2!D?X1D&@5%@B!!SA M*L)-@)UQ? 8:GM41/CB #3#ER 0@M1 J;6H"-RB#"$#P)388P($]Q!E@!1D7F&$:*G#.0B39E/1S8TH=,C:!?Q*3VV M[9.O()&:7RMIU[IE4GNO ">8$NC.9-PIG)$=WW)>@1XX@" ["T'@ 2T2JHO( M@J@:H84Q:$%78]QI!6@0;??08UJ+9">T"SS6:9%AV8O$@K=,BNP!7_$E\B$# M&K$8E4(P<-3*6L0&2TK@PHB+D>9*)!83T-\;/) $I'A/,@P1OHV2UT\C= N-'?ZT#BQN*T^&*K,2)@HX5$@U3X M11%1_TCNPK<0R*U\,>V89/7FB66:=DQI[R(Q(-'"R4Q8&$O&$'SR@! MH-R0T8L$@0,C ,&)6"&"$G 8,[H::1$ T_I& '9'G%*RPP 1<,49'& !0%D!U""8U:'17%-FU[E1%B&#!TJ M;6BDX-KP6@@@X%"!G=J@#X8XZD(&H8(>D.6M?I !#D 'PZ4( .-VK4(=F ! M5AA#!-EIQ0E057 .P((0$)C J=@ A5P %[9&<0$,GXCBI>5%BE8\)TP<*GR M -@*%1!KG- @NU!H!!@6H4" "PCI(F? P0TX8 $;T6($G7I6,E! AK""R0PNP$$%K'#V"4B( M%A\"@7UEL ,75$#N#YB '!)A 2I-X*5$O)W4 EI*-#*TRX=%O9,1VN0I#C#I#!M#04+/2;@$9+^0-&?C2$%3P# N4%1D5 MZ!,$;&0,"$!##@SHSPU0^H819 <"*B!1\)>KD O$HA,3D,@/Y DF-V @.SAX M0+I"()$V."X%L!T5LQ4R@5C\ @240'RB( 4(!$/>08($ AC8(!8,(8&L!%# M.( 368A50*EG2('I6(A8( #B_X%!G"%9' 9G$%!T@M BB#_HB%"N 09_ M/X"&/K" .)&#B'BN9YB 5@!!$7P $IL("SB&=(D(6N"_C+ $HD K>, $9@N M/R" YQB$!N S O #9*"%!X"75W !G2 66'"5XB%"%B(S7L&0)B 6&#$8"& M']@!!&J G>(#=CF@'\ !9ZC"YWB%!X %9$" (0BO_>JF( "P:+B!![@ %V G M-$@PBP"!.;D(%8BT_5*![*@2 E,5#F"%3H"PX"J$3DLO$;"1(&"S' "8N&*( M"7"&8RB\'] P8R" Z?@Y&@E%@;B '+BF!U %9Q"!1RR?(&@ #K$"#GB&$3 P M C,$:/Y(@!_HPX4 @N(!F- @.D Q& $&&@PNO2R*&=X@$2 AA%XJD/PP ,; M.-"K,M.C,B@SQX#**TG2(BP:(REKQX3:HGO",MJ#Q^$QCF6X'$*( !O0EZ1" M*SD8@)?:'F$\+U6@*S1 J0G8*6.8 &B [1Z Q1(ET3D.XE@@QN(!0> S9X M P@P@VBX@!(H@P^3B!)XQ%>H@%%SQ#88 @5X!A> +9B#!NQ2!1&PP2!H _NQ MR0G0%CA( >:#DO+K P"3" \0JTB1 S.8 R2B J(A1QX%N*3@ZE\R26)*;!\A@I@!?YGJ(#@@H9C*,(7 M9"L.4,MTD3B)L !7&(1P= .)6X@5P!*B?(8+8(75R@Y#P("79,1(4;5"YLQ*8,R)*%"(*]9(A"^ $$,+ S",>BA*WM08%(6PX.J ] M$ $0;(,V@(,+&().\(",2 1@3*^;FRE4Z7(4), ..K,YG>(#/H:J$< 8, M()$_* %100]" $8/^#P0R)(2,+"_E A#V$UQG"4OVBR0L6RQ[/#V^LOX=W2.<6# #%'B 9'"#Y4NJ!X!#B1 !0%F@ M1,@ T6J#GU3(4G24G_23GP07A6 XB[2!.^P#.9"#0M@I:-B/!N@FBQB!LD*1 MB$"!&Y"#-_@#"8')MJPI&!F"[H@ ,WB#-QB$6;F >X$#B;2 FF*^6""$U*S( MA2"$"0B"0\@!.'R%%5V(&T"#-U@^MT,#9#!%B=!*$_ M^Q&M&[BS9S@!IK2 5H!+&I.(:*A+/$FJGUP(.5B^A:"I04A$-/C)[+"!-CA+ MT?* 5E#,9UB%QDR!I[*MR+0(0@"""< !\@F"&6$#B7P_[)@ 9<"("^B3[" # M /L!'OYS Z!!F58K@J@UD& !53\P8OX@1YX5QN1RJM$CT)840_0%(E%U$@;A/\D MA/\[*]H0/<%RT)+5*]>K4-*S4'8LJ-KK)]X ,\#9 *W;CB_*@:9#A82$]) M@P"UZY!P7(4'<(9DJ("#I94*, 9CR$)\G9/L^ / 11$&<(8_2$17>%QL9(4[ MS Y80(#!=8"%:(,R^<]# $8UG!"T@@4&V)Y9Q9?5C5P[?:8-PA,+ !@00*OW M2C $DPA#XX#Q65:+P$V)N(&,2COZ>X5"2$V+V$1\?8^7;!A#^ -G0(#LN,-K MB@ 2V8'_0P9X33 7\!=5 )1\+F<'' !#H@&-E"!JWP.0X &G,&%$"!')B FZ.('!@! M$0V"JW(!".@0B?03B5L%!K"!Y=26X#L=' @79X %0LL!"^@$9T@TBTB&G*)B M#=OA$?#ALDJ![KA!A8@ M(J%0I0!GK3!>S' [&6^FI*%$O - [,"'#*8EA MMKKB%! XM"*#ZLR A'B%.ST@#ABJ]'HK:&@U')B +/$6&WR.0MX!#'@8A=B@ M'*B +*$^1WT&97A11+.!@DN@/X" @%.V54FPA3@##,@T?]F!#(!A!WB.%." M'$ !8/Z$!B>19$CA P:P FCHE![@ (%8#B!X-3/(#P[XOR]\)F/8NQ*8CS@Q M!A#@ +:K2#9( S +@0Y6= ?) #SB#X?+S#UA%@0Q !D#8S>YQW!2 !OL] ME@Q(@1OHXA0H@2FYCF>0CQXY%3L]D3>P26K.YP@XE P(WPSH$R!H $ PA@?H M#T^K@!O( 0C($D.X*ETV!E'!K/\:9$EX=@SV0*=GI'M6)5%/7M"H7E$H5UH8<&A!3[P@R]!AF1 M!AE[ACS$"$/@@\A:ZF1M%D)P!A(YAFFB0AQCEEA #_#"4_X^."IG (0\(!4; M."J%\ .N)BI#R .V6AP400]:B"S3\0/T(.MR0<'9<@9D,!9H@ >>P99\ ,. M^95PXH!DN+>+<(4\T);CN@ADN$6\UI*YQ=,X^6M\D8.C+!7.5@A@ZZWED 6T MQ@@Y6 %CR(,(0H;3<@4^**E$X ,J)"Y",(2N'FT> ,>@^RW4HA8^!YC M "=9<&^V0H8^"%_-1A%=?08"*8(9_@M#Q*B/MH(].HC..J?$")SC" MP/$?)J(%#EGS*^^D$;8>H.[@(6_R M)J_P5OK@/7_'$,>A5-KI=!1Q#)Z;*/_Q16?T1G?T1X?TC(@>Y3GR2E>W_D=X$$%X,'T3>]PW[$%X["%4S]UY.$=54<.]BJ?6+^@.Q(?"[)U M#])R6?[/]5BO=5FWJ0':=6NZ==P"(5ZO()7^'['=X2W M]X,7>%^ >(BO=X-?>(?'>(<7^+ (^%[P>(,'>8G7]W^W^)+G^(0_>90'>9"G M^);WF98'^9\!^3F/])O'^9S7^9T'G31X BB @B@0^BR(@BP(^BS(@B<@>J%G M^J:/ J!?>J-W^JFG^J)_^JD/^BAX JVO^J+/>J??>J$/^_ZP[_JJ?P*R+WNO M/_JK3_NV;_NSY_JSWWJT-_NREWJP;WJZAP*Z=WHKF(*^9_HT.(,S,(/"-P/" M)WS#3_S$/WS#/_PS0(/!=WPS*(/")_PRJ/S&/_PR6/S&1WS%U_S0MWS1I_S. MKWS&/WW/G_S.I_S4MWS&A_W5)WW5+_W++X/(1_S.7WS,'WW6YWW)E_W,!_W' M1WW7CWW4#W[6E_S/'WW%AWS@'W[F)_W+U_S$Y_SF]WS=-WSA'WW>I_WLG_S3 M?W[K9_SN7_W8=W[<+WSO9W[NWWS9+__2[_[,EW[J)_[U%W_0/_[)K_[99_W0 M!X@R9LX,-&.0($&#!1K+YV\>V[BU=?7K=X ?9K^##BQ(H+*V[L^+%AQI G4Z8LF>_EP)DW(\X< MN'/DT)UQ,7MF^C3JU*I7LV[M^C7LV+)GTZYM^S;NW+IW\^[M^S?PX,*'[\9U MZSCR6[:2,V_NO+GQY]*G0Y\>7?IUZMJ/9]_N_3OX\.+%9\=EJS3Q].K7LV_O M_CW\^/[RY]/GW5W[?>;YL2??-3[Y?MKYMUV MW0W(( )E@@VB]R.666JY M)9===GC?Z.:.:WP7()IH?&GBC;]"@IJ=I>OJY M)VQ\]KFGH*?]N5NAAJKV9Z*'YI:HEY'*!ZFDE1:GWR_"_/(++V+*:2 OUS$) MWH!\O1DCGMLM?Q_7":7*9=BI,'0+8(/RHDNY#8K*G)2I!K@\>:CD^FC" "S@RC.O & #(=8?<$ " >3PC! ! M+$ ! 0CDBYHS#VQOF@L L(RW P\@, #-< S@@ <(!&!RVEC#"@#<0&UD" " M(G ?1!:0!(0 (&$ 43,T&#[S? ,C0F@>P#&W/: ,(GD&&]?4&A!B*@,, M!0<./.,,#?Q-+!J@#/E,H!"!$N$.GD&+'( --6S(PS,ZP4*@5_L(0=\% +-J*.$G'0PRU\08D*1& 2M["$%K'(BU+@H0ZE$ PEM*@' M/1B'%Y^H0R4^@<6_5**+FY.D+2@!"EV@SA)U8*1_>E')20"F%H$@BB&%LE.T].-&Q*P@!%D M[P V<(8QDA$"!;#"&,XP1 ! @+!6-* !"&/?!1J @$,\ P<":,4S*E"!J;5B M "5X!@@04#166" (J6F%']#Y#&.X AJK,(2@#*&*5Q#@!_Y/4\4 ,J U53C@ M L_P0P &]@H5 $"#.1B 'XYQ"0L,((6G*80@ P0=,(TJFC#Q_CP3I8F ZHQG>HW:6%5F;E!GP#C M@Q]B<8$9GL88;UB?30DAAQZN-!G)< -.5VH,9-CP:(#%JE9)X##L/<,9LC"- M,_H0THO)( 6O@ ;!7@$V6K T&M! PP56@8R8/O4TB9C 'XZQ4CDTM;%%(X13 MD;$T921UJ7R86C)L@ +L+34/JOYEXG!.5 H(/* 6A"&D)2AQ@!,PX 3#@ $" M'(" */RB%!D@@ *C4 D%." !/A &# X@7>K:PG%K. $&% !2W3J%VE00 <6 M$ %;0+=^I8!!!:@!>;Q@ $B@ ?/'? !39Q!"!PG IHX)?-,;*"8)0\)!531<=DS24\ZK,V M' % R!$,@:P@M. ( %NPT$ !O&T( B.R+P 4L8(%GY$ % MR*V+QA@2X MX1DGT/XR'[3&OA$,8 ((R"$0"% "_[D 8"X8@ )$\.>G 0$ )-33'P!0!J,F MP*$_"$ *^P" '/+)!A[800H@@$XAB& ('&A#S=Z) IMEP#1N4&D)7!"$"R3B M&3<0 0C*X(Q8S[K6JXC #7* @4+S"1 6 $(*1A"-9WA !1D X#-D@0$<[* " ML2!$JY7VSA+TZP(.PP$) "%!A( M"CL ( [#X,'@Z8#=-.R2%Y8X@-[4H( Z["&*Q(@" -0 B@1$H!(Z<* (#.)4Q* R',("/!8K\)QI[.(K(&,L M)$ U38#+.90*V-,'^9L5Y! M1, SP,$[M8(I&I0J>(!I[ XUEN?6(!J$4)A M98 J.(,"O) +^.$S# $SJ4 @GL&6)1'(.(">J$)@P=UO#(CQ-8 %)$=45,*% M#0-X)0 )D$ &!$ 69!X,D,#=X((=!, :R%A#=D"&"0,J[,(G1$$+7)<4(,XO M2$'Z7 4#$8&5, ME%X!5$(S5 ("')@P\ !6((.Y&0SP/Z [F6 !?#",)01 M*.@ 0XI !D1?'618,YB',*C! ,S!YPC#&RT #("" )1'__%E=8A( MD01FC$#)+0 @; #" S "['& 1("-OV SC@)R; -ZW $#96S0 '2K5!%P M-'! !=P :#3!$" *K "(3 !_!)*[1!"214#ZU"#YP !"P ,I0!")*/ "3# M&00 .M'" /3 T]@ ICT#(90F *!F!FX@!$ A *30*@3 ENF)%R [Q"'S#3"DS:"K2!,_ZLFP!F,(P=D "NX M015.#0>\ A]$ (-ZIROXP2;ZFPV< 30@J V07(-J(PX$8AM,P [,W .P@@NP M@6G8)UUUH9[X00BQHVEPP,T\ U ]#0>H0B&$@&FT@4I-30Z807YB9@BH0M:Y M7*M5 ,4(RA#@P#/$ C1F'30,@4'A@#T1PA"Y A;^@+^QC04\%I#> YP4#1$ MP+(] P8 %#0DPL=A@ K@0 Z<0 A9P0WHR0],@ C0*$ "1W+P H'5P3 ,@QH4 M@ ^ OX!Z$#PR "K,$>%!(HI$$ J)\),( NT,$ V$%/5BH>E"HEA$HI!!GS MF9$P'$U$$=@ *HKD$O+,0.0)AD0F#9M $/]@D(# #%.!5D3<":M0+U+0#+ M3 %G(8'*( K<-MI."''^L'VM (.$$ TD,$ J (T",%N]OZFP[#" !B4GKP! M 9T&"A +'1/(+I! *C (@9 K3G##0! G4T-&BBM:5A +,@!"-#"*\0"+4## M&X3AI/G!"LB!#3P#"@1!++P"+<",>YI&"@A!VAJ#-=VG:'* UG(M-/ ! M,]F !A&""O1!H4F,XA8-#BRANWF UJZM,[C >])"!<1I+&BC:;P!,\UICSK, MU#2I:6 *Q1""+D;"3R-"[0!(+CB,["C?>H)*V# ,UA 8"$#RPP!-E: :IT M(*0 .H'I,Q2".)K&"!1O4KE+??X^@PV40#NB@"',XF^50"ZZ@7_R@2R\@C' M#!F,#S "0@9P6J'V1G+TPB1 D [HP A> B7(ZR_T@AX,P Q<@@]X0"U<7R!, M0@,P@$4&@ A4 EK.JQ1X 'L97P&@ /=%$>+<@@9T0"W@05KFGA3L @P,P!CQ M@@D00!S0P0&$ 'BY<( 10"GH@3(%&0-4PAP P!JT*M^4P@-( MP%KV'B44 D$ @L$@!Z P@"4ZQI$WS"4@ "4 @\,P C@ 0CHEP]8,25 0 +< M0@OK*P%<@C#0P0BF >>-A_W9"7Z BS#]Y8(8)J)\$ )FCP(( -4^ P<0 ,Q M@S-P /X C&<( "6_@ #2. &(N@B#@ "L P$*( +W, (! ).,,( *F $. M#(!*Z0D92.$K6( > T X%2C&4,K $ (Y $( ( 2/4,T/"0*E $$'L LN*P% MH '# #4,P-9!,*6 > #'9D\#_ L?# L[!S%N,((0 ,)M,L?,S@.XSR,"9LAQ. MP<((.(,?5(!327(/]=M*60 064 *L?1I#$("L,P@\.,?_/YN,D .;%" \1" M,C0 .B%F*R@# [B"TVDC/4Y-">30#Z0 ,M "!!!,'U2 #.@)V!GG!!A#CDY MR9V&,CQ )S0A$$EB^CX QQJ" \@!'Q3S/,HSR3Q#$)0 ,OC!!4BM\>[O;B"( MX^B!!S! G2 'B!8!/@ Y_6"&DC C@ %/A")6 Y@ #&# 4S 7#YCK)C= M%+B*%#! !/# !=#?+@1"!3 [3 )_R"&E !)2"%$0 >X&D@"E "8#"35+ M@_F !8 "+U1"%.B!#QP )3RE&CO $PB#'3@ '=3Q8$Q"!BQ ZPP+\1!!&AV M&@B#)6SV,-@!!.!!X%$ ]RF @/XQP'!70@8,& Q8@"VL]F_[P.@) RY$0 /@ MY9C02IL@F<'VGW.42<)N36OPP0,P31M @,_&VP4843+< ,@ 3H&I 2 -/T M7 GHB30%W3.,P 5,0 1\7=?D@'0Q@ OP5#" @ *, Y80#*T002@DQE$@-:0 M@7_]P 68;HW*@#B) "%8 "S<' 9,P+3%E!540(5SP!!$\^Q>P C\P E0#"%@ MP A@0+OT0=G^0-*($+R9QAEDP B( ,7\0"XFC)5C^<64 CD:0Z=1BR4 ,4% M8M1IH#/@ B$@ R #3"?AAE8.0AD^6:BAAQ<@ C\0 FP3"%8.0?\G!]8)Q#0 MX1F /Z?H &=HQ,0T*B>& ('+/G/02$&E,!2QZD.F3D':)#9!E8*\.(S_ $' ML#D&F P@6*=I)$*DP!CV?6E)(ZM[OQN 3D!,XN3$2^ MOXZ!((@;4<3FZ.6*G*0#J($>. %H,Z[V[O]$491L'?K-+SLK(C0%<+5+Q]X[%X%&R;Z'&=((LC^K]#^E@Q"(6^($#Q =)&F8_ "##U#?6];]QQM9C+\9<(&QT2Y2=_ MB8A\>/!%N7^*XI<^B[2\=[Q*]O[?PI,1O_=__VW ?88X@_C;AE^!OWL$D_,; M27FX2NI7/Y-1O\LC_Y*\?Y1/N&Z%%+EKUTB1)U&>Y%4R9LG6+ M94J0,6_=M!E39TZ>(D'BZHFSIZ-(KR*%&@3T,V=7JR)M*0MI9YU+J5 M:U>O":%]%3N6;%FS9\T&C;H+5"FI*7<)XQ6R[=20O#Y]8AK2E["J=JU&!4QT MZ6#!AD^J3?Q6:6"35.W>["GU;TMF'F.],L8QV69GL=!VC16VJS-CSB(F0];1 ME;*'R?Y(0W2&&BVT9*%QY]9=42VN4B8(L/@UDS H'7.$55HP0]C473X21" N MTA8O.CH^E9P^'?'>PTF])V8J>>CD[X7#IU??O29ZJSHK?]][>>,K$00&)/A! M.O; _OT/0N&!9X( H)5G $3PJP01@B,(VOP+RY ?0#,$@#(4/(C!!#=\A@\! M^B"(08'"47D>3Z9.TQ4PI2S+/,?Z7 NV.,<8( R^I MILJ#JKNI$ 7*%OHR2B:" X3@8P0 @-!H! >@406'VY \: 0$$C+#P!1OR+&K M/@ ($A'4LD M7BJY@ $-HA!FDA8N.*$282QI(0X>?!C3EA,8B, '2@Z @0<->'A)"@LZ6&,N M7&PQ08$*=+!%!QYX*:6%-.IXX($,*@G$!#V(4<.$3_0P 0\6Z!B&C@PJ\,&6 M^!X];+*C)%O/4?'D3&"$T/7THM"DM5#)]!!H4;GG$FB Q"X$,@ M((*0 P,*;<,!"$H +0\0+K@! MF54F<("#1&*1H1!6K4ZD9AG:* .#'5P;B \0+,!AL[D'*0$$KSW,8(4S O!Y M(#E R,",G&UXW1@6^H#& 120$8&!"MJ(!06O+TG!E6=<<*,-'%)TP>I7!G+F MA@=.B,4-0 0B8Q5E@O #A%=V> %5THHPP4,VDY1A1%< ,V-/G((0L$W_'AF MB#=0&*&5(3#H-)D@^B#! [P3@08VH(@6*Q@!"EZ1C!R4"'.T.%_Z!/('#Z" M#1EP5OZT,)A!CMR$%Y8P00)", =0+, "69A D!1"0(T@ %2Z$5(>* #*RA M$@IP@ DT$( T#$,&!H@"#PJ@AN'<(H86D((M'%"!7GPB.-5B M H08 T*$9 M/ " )=0P

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�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end GRAPHIC 47 comp_0024.gif IMAGE begin 644 comp_0024.gif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comp_0004.gif IMAGE begin 644 comp_0004.gif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�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end GRAPHIC 49 comp_0006.gif IMAGE begin 644 comp_0006.gif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end GRAPHIC 50 comp_0005.gif IMAGE begin 644 comp_0005.gif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end GRAPHIC 51 comp_0007.gif IMAGE begin 644 comp_0007.gif M1TE&.#EA_P)W O< ,! 0D%!@L'" X*"Q$-#A,/$!82$QD5%AL7&!X:&R$= M'B,?("8B(RDE)BLG*"TJ*S$M+C,O,#4R,SDU-CLW.#TZ.T$]/D(_0$5"0TE% M1DI'2$U*2U%-3E)/4%524UE65EI76%U:6V%>7F)?8&5B8VEF9FIG:&UJ:W!N M;W)O<'5R'UZ>X!^?P!-H@!4I@!7J !9J0%CK@%GL -JL@IMLPEG ML!)MLPUQM1-SMAUZNAAVN"-]NR9[NX)_@"R"OB: O3&$OS.&P#R+PS>)P4.- MQ$61QDN3QTV6R%6:REN=S%*4QU^ASF*BSVFCSVJFT6JGT72LU'FOU7RQUH6" M@XB&AXF'B(N)BI".CY&/D)63DYB6EYF7F)V;FZ">GZ&?H*2BHZBFIZFGJ*RK MJ["OK[&OL+2RL[BWM[FWN+V[O,"_OX.UV(R[VX:UV)*^W9B_WK^_P,&_P); MWIG!WYS$X*'&XJS,Y:7)X[+.YK+0Y[_1Y[72Z+S5Z;[8ZZ_0YL/"PLC'Q\C' MR,S+S-#/S]#/T-33T]C7U]C7V-S;V^#?W\'6ZL3;[,G>[N#?X,S@[\[B\-/D M\=SJ]-CF\N3CX^CGY^CGZ.SL[/#O[^/N]N_O\/#O\.;P]^WT^>CP]_3T]/CW M]_+V^OCW^/7Y_/___P M M M M M M "'Y! (?\+26UA9V5-86=I8VL-9V%M;6$] M,"XT-30U-0 L /\"=P( "/X 1S5B]*@@HU"A_$PBQ9"40$8#!X8BQ8B1 MI(:,_%R41! BHX61_(QBF,F/)X&/*CYJM+ AJ5!][C1R61&2P8DN,]W)T[)A MI#MZ/#4LR6@DJ4P$1ZI\% FCQT:-.E%DU'"2'YR2\MQIZE*2GTP,.:JL&"K3 M(K D\^3A2JH3([907S+BQ MX\>0(TN>3+FRYS+FSY\^@0T?.E&/&#!DS8O!A!*-)3ALU4*>^,\K& M#"(,_9B&0DJ*[-,]2!&1\82A&QAX),FN<1J(RSL\9$A'PNFH[=.G_;BD8D/Z M##<,0_XI.2T#1QV&4TSK88A$1@U)H7(P1TW$4Z<<-$RGQD,JAXSSI+3W""EM M=(=:<0T1$8,2#"41PPPU,!?#(F_ =#;!@X X)]S&##3*'HP -.BW6B@WZW M54>*&QHZH90,2= $(T-Z].!=$@+-X,-$C,A0A%&B!2GDD$06:>212":IY)), M5I:)#3RT\48;;G#B1PQ..,00)S7HT,8<;[@A22#FB0TZX$DE6"/5(4,/=]RQPPMV MD+($#$GX 9T,?/0&89:<628U!"&7'C*X-E3!Y)P8O. HT1R46\U4"$#LT?C9EP,S/8PP\C2$[S5/$2/# JL^.*,-^[X MXY #3%J7/.# (,)9&C5Y#CK8P"#!1^R@A-1+U+"F#)SK@ -50.A 10QXP '# M>1,I(4,?HP"IYT(CO?Y&;388<001&&="P\U:,G2'#.'F3J;15,RPQ R21)%# M$C00W6H?C$BQX"CRZ= Y@YW40$3(D]@.3 -\-F4 %4GB"?I*801*F-R"@ M*<%&,OC8(F0PA0 %D"&30)J6]E<'"$IP) *"1 RDT <83 $(.7 ;8KA%GEV5 M3X(,88(,*A@C+2%.@S/H(]-V((-5:3*%L(RE+&=)RUK.A6 &8H @DK"L M(7-KPAUJ<(0@\&U5WGM?@F8 $QD$808?&XGM\-5$&6 ,@"*)(&)&T0,:<"42 M2&B#,00B)"#.D1!!FS, 5#Z()5#+ +8F*L$H(0N,+6=*TYK:]*;Y(@T/Z%"'.L#!*[>Q M0QWH\(A/]G2H8ZK! TLSA4RTLC<5[2D=X$0#L-@*FEI20@RT Z1TZ> .D-": M<\ATS[FT(09#X%X17L"L]C0!$GZP$7^T-@DW>*@33<@>^(SF$D^PC0X\G4.L MZ.>0;M9@$HQX@0XTX@8"DH('.5A""VL0G(1>:R1T:@.!T.H'2&@U2X/,$B1H M$$$2;4L'<9/+&V( !#\\0JOATO[-$*0*E1DUPD-V> 048"!0:=X.I\ -KG"' M2US'$$PZTJ'4(AX4 QF\ JCH %RG3N'4>A,."^P" RR!(7IPL &I ""##9B M Y--$ 9/U-8;;H!<("RD9CIX)2G>B5P$96(XWD&H%&# *]8:DFBD[020N#3= M%X#'9LI##54^Z$8?Z.2Y"8)!'D@1"1DXIW&$G%#R\(5V]B,"(% M1DA%#1E%%#J1$48L MP@^+L,\BEKSDB_C!#T8VLE ZFU"1Z&4AD]A#18P\$\,8)1)[0 N%]R"56^+! M#;AK"/Z4%Q.)GLHT-VVH0T\D0692[ $D>\B=D>?"B#XLF1%[J,X>1D:1JR"R M#FZ@34+W(!0N[N$BH1AT0P9S-0J#2::=N'-XN/>8(RDH(MZV!KDMB^ MWK6RE\WL9CO[V=".MK2G3>UJ6_O:V,[VM8'4P63[FMOV^W6RM45N<8?[W%H" MM[#+?>YC?]O;[ YWO-]X%7W?#)^[MA1N\WP''.,+=EF]N4]SB"K<8^O_.45;WF*/XYREG=\YC"O^ M\J#TIC-=#T!I^M*E_G2E5SWI5Y^ZTZ6.]:1'O>M;YSK8K2[VL8?]#US/NMJI MSO:PM_WM9D_[J^72B*IG/>YNC_O:M[[VO9,][W#7NMCO+OBT!][O>B_[X ,/ M>,+CO?"'CSS@&R_YQ4_^[XS'?.(ICWC(;][RFH=\YRE/^M#;O?*/_[SA5P]Z MU8L^\X1_NNQ9__;43/?VN,^][G?/^][[_O? #[[PAT_\X,> T')) @R*S_SF M.__YT(^^]*=/_>I;__K8S[[VM_[/_>Y['[E]\"@?QC]^\9/__.@W/_K7S_[R MJY_\[V^__)$^__2S/_[MQW_]TX]__>\?_NEG6BX!"7FP?OYG?_\G?P>8@/G' M@/W'@!#8@ 8(@ LX@0GX@/]7@?7W?DH7@??G@!^X?TGG@0AH@218?B<(@!DX M?R/(@AKH@2](?R:X@2FH@B58@_]G=#JX@SS8@\R6<2:W<^QV;]LT%T"H;P)' MA B'A$:X<4MH<_)6A/OFA.G6A%48:(ARV(>,*(4/-XA-B&]?R&\^N(F^(E")PH, M(8J@6(J1(8FFJ"^:F(JLV(JN^(H_)@@=T 6(08JC>(NW:!2 L & (N.L8L? M$ (A\ $9, AH@ 6D8(L-H8PN88O,.(K,Z(P-D0@G0 IE@(Q^B(O+F#PGD AR M(8K1.!?/J(U8< :D\ G?V(S;> 97L([MV! ID BB$(Z)08K1&(Y84 ;)N(VV M: C>6(_I&)#[J([-:(N5( BB^ -A0 J&8 BD< @C@([;J(TNT9#\^(U?8 &" ML(_A*(I5L) HD B6( *?( J ()')V(\..9$N\0DG20I;(/X& \F2XDB3'$F0 MXE8"&VF1-TF1,\F2B6 (SZB,@X !7#"3]D@*@- "%<<"&QF.([&4-6F3/PF- MM<@0@Z (I* &*""00_F25LD0+="+*3F5I' )9#D99P )G 9HC@& +"0X^B+ M#4$)8G &&X !9A &EH %'K D@- I& %?SF7CB$*#3 (H"&*&X"-D9$%&S"3 M6!"9I)B80N(!5J 8HG@"+/"3AJD9HH@&%L 08J &I( "*D *E) %GZF.*I": MAHF8:H"2BS$&IOD @( )R!@*#4";M\@"L*D8G^ ET *(; "2L(%AT *+5"- MEP$*I% %;:F9I. !+5":X&&2PG4.R 0LI"%X@&0] "8E! M 63P&(,0 96!!@.0FLU(!EA@FI] !HJYE:8I"O9IFJ1 !@$P!G3Y&"HPG8-Y M FN@ M_)D"UP!94P%V&P @3Z"6E BH#@C8;@ E@0H:(PFUS@D$MI!>HI"!, MDR+@$H!0"5G@ H[0$&3 ET@D9> !2S0BZ) 8I)"&C $(+0 B3*$)_ !2U@ M"(!0G'W9 ONYC%_0 @1JG%PP!BJPD0RA!BV0!9APE@!:":;)!2#@HRI !EZZ MC!8 "$2JGE7* EQ FT&I!BJ0")]0!5L@D8/@ E6@GFC9EY] LAX"6. CHE0 M!4%J"/X;\ $ ZA*)8*?_2 ICL (+>9: < @KT*->T +J&92#X*@-\0E9T (; M:0DJ0 $$F@B5D @;X %J( J#\*$2F:%;V0)S6I$=@*KGN 4K<*C)Z 40X 41 M6J=5L*B-^JB)H)X5T(N"\ E? %9H)Z5@ 5C^9 =T &I2@IB$*9RH:M8< DG M4 5GD )I"0@L$*O32 B)L 4,T:A/6JLLD 8,<:1A, B60):(L)&#\ F*X $; MH :8D*$MT)YAT +_^ E;<*-8F0AGH *FF0CX>J$N$:->((J , $JL)(,4:-5 M< AK$* 9P!"44 4N0 @,D0%H$ 8L0+%6F@66H+$SV;$_X/Z-B0"@@["?9+ " M,BFD7#"I59JR6_D)@E !)5"OAO )/9JS :JI+C$&$/"K9YD%+ "@&:"/UFBT ME" (F7J><2H!8>";CG$& A"F+FSD"YPB3#5 %6* "WD&$L %55 !$3J*'P "7; !;0D!YF@)#4 ) M:O"W5B"XHO &\ !AB &#S &6& !JBH!I( %:RN*GP !&F %*N WE@"&V & M)$ "JDD!*[ %#T"+$$ )@] /1H&F;NYZ+@!() %(F E% )%? #7C !0RN* M*! "8X !KDL"$X %5: BAFY7/Z A3@D@_ $&3@N5OPEV3@ %CP P]0 @-9 M 1M@!2OP -Z(!1<0!BC@ >!("EV0 %7 A 0 E9@ >8K!@X@!EI0 9]@" S@ M 2 @"B.P!:(P 55@DG^+!1/PLA2 >>IHA!@!5; +T8 A[0!1ZPMH:0 "90 M!1+@ 550 I[[!0B E9 =5H"1; EY 6= "1Z0M-59!8) 180!HBP *)0 M 0OY">S[!17P!2K >@(L15P 5T PR? !17PCN?X PY@ HF !@T0!E*([!A, "(!0 19PE"7P 6'@ ?1Y MCE5PQ?Z4T (1(+T*D+%2[ 4KL %+3*T,\ '5> (>L,==>0D88 )<( %50 H5 M@ $;( AA@ $,404?0 H.H :#4 $5X 64D D8 43T $_< (0\ F?D $JX 46 M<)XGT !8< 4)0,<64 %'V1 GL %=$ )*C+D D5< )8P $+0 IG ,J# M@,E9 'ZF $78 55P "!$)T30 8M,,9E ,H-80C1>\F#0 D:? D-L)%)' 8@ MT):?H $EP 43T)D/@)\/0 AE0+EJ< 83\ G@3 J)T)OE' 8A8+ZCB 4-\+.6 MD+3AV9X8T)XJ0)XAX+IH< K@ 40X *70 (/T (Z&QEH$/X ]"F*7 /=H" M ) (6! E "7E^O2S!G3:!"W!@N"Y:N"-HA !AE )";"? M(E %'C#,%_"D+9"B*I#)GW )M$P*/@H!_\H 80@",=-"B?P"=O:G8)P"1 @BN:-T Z DS9 LCYN WA X) MCO== M,9W8CYCV"\CV7 ,6YVPQAV7[)$(F G!60R9K]EY_KNA5@CE60FI30 M -[H L\MU]^+E=NK LMM JG9X2X1"-O+$+>] >9(BELPQJ10"-M[SJ30 =CH MWQ6 C2ZPMF4 J \@"FB S@S! 5G $%L0F6BP 2%PE('0WJCK!<]-":EI ?A9 M 8KI 01*!J!,U:8+QTL=S@TQ 1%*">QZFEVIY8G@ $MMI,>-!B=J".(Y&2G= MQV)] /X6, $3, !BH @ T 4EP "B0 ('4 $30 $#8)L\/;=T>0*N*XI6,.E7 MX+H/$ (B, (:$)RO*0KH^ %>,-%D/ :3J^FY8K\.J'D B>NYD/( %7?0D2((PCL 'F>]2B ,$28*[L M"^H,X0(D /%\:@GF+0HIT *@+@%VN;;H6*PF8 $C((P8(/X*9E#RT)W)5,W5 MHE )]6T"7I (\+[1%V"NI/CIQGRW%="?I% )$8"G+0 ")0#B8XJ2T1W5@C#1 MHF#Q_^C!)B !R*@")R *LOO8([#S#>'SWGCTI% "5^#.5H\!R"B*8D"97%"^ M&ZVC"7RW#%&L#''=0YVB%="C*V "HN#OER *+="5"VP(*% !)" "(L"Y*@#8 M)X"<+% "\UOBZ*@"79D!CRJ*)N "\^C,U@C*$H"CEO ]PP(\SCN"%T"(D " M$B *U;R,%> !@O_!HN@!#, 07^ CPV]@!#?*(GUGT !&YG@9' !2KF=&2 ( M9M L[_A^X@)ZHW;'E "%<"46OY^!@PP^Q2@!H PFJ0@FDI) 9 ^%_()FZ*H M @. !H=@I.HY 1P =4(_F?0II5P!@/:TXV! I.>X4/MNO%,RYC@H9\[W*2 M 3*Y 0 Q9L,E41 $??JTJ9(H"89(D:+@HA*I"Y0,22"E1<1#4J(B('J(A<0E M!60^4;) RL.6AY?&D'IP: Q&4A5:6"*%@=(:FI867 IA1=2E3Q,?BJ)$JI(7 M!9]$L"0%X@NE!QRKG# TX2&:E%M"P'1(:@N(C@\;AB11J0%1498^<>3BX2$& M-*0 4.& M,)8D;/XBI8+%8PF4!'*$D,A$"U$(DY+13(J$%<8M2%U\ZT',!DN)&KB%?(EC MZ-$A'#^$0*ALI=*D,IR8J,%0&0P.5:P@]05# M:U&5WCZT- %GB1\/2UCYQ, ]9)P/=_NW@#U*1%GMH4_$H$B-A^(*:82:%&1! M!5+\PLF%$QZ:()$53AA*%,-0L(V4$T9K04+ 2!DCI< ^^Q#$G)XBPM)+1@#4#^POX$336J(X4KN_ < MKD\_.2(C 8DF$"!+!(98(,Q0)# L"H"( 04@8A0%$0'KB$# "P//%/3S\% M-5111R6U5%-/1?53P$KX"K J/GBH"KE4Z* 22C+ \B%%'B#C$BXB$*X+!4)< M@0-;<26%@4(Z:L D,0H0Q) 9K9#KQ =$L(B!-"A)0)%+5E# $C4<&,22#S9J M0+D,T'- R3$,4- ##K (@8%+U'C D$M4**&L3Q[HXA-"&/C$ RP>FM>Y%2P! MA(%!*DD D$0XT H+#43TP))"&H"5HP8\4"21=DG90(5+!J& 2\"RB&T",^RJ M"H(P/B'# (D;>,\#VK"80)0J=/ZJ9 ,M2#'! \.&^UD12B38XA,'PK@D# VM$B3,CY(S"#CC$BLP6H/<2UKXJHP'N 3!MA,X2,00!]X:8X$+53+9$ HJ M*TN%#1(!I % ]HWM(;62DD#(,PPXXQ,(O+@$# 9$$<&V!P*QA.!+&!A#%!0^ M^,20!RY408-$NO/BDS,JZ(^4RY4D83121$#/ Q,ZKT!2P,)0\1()&#^#@D\& M\=L2%&R$ $B3PC-MP# +P"B+%$PL( $+#B" 4BLN*$B$$@Y2(&6"Z)?N BDB=@DM&* 2 M91K._?X2 90J7,(!@ 'GW4E!J<)B%K6X12YV$51;N$)9QG"<,7:$!1G( MP'$X$H@-9, #8;'$!O FBC.FL2,E.%H:-. !+V1!!8GH5QD-9 %960 J6\B M",YP I:$ 8TE&!()#),(#UP"$!OX@!>VT"\H82$1%7!(&#"0@1*DCA2"X, & M,("@%NB0%%5XB25(@$97>J$"\4,/&1SS"1-@@ 15H,U15/ZP!0]8X&"DD"4: M0E"'Z=(!+@'S+%@(H"A)80B LP, &PC(&-(Y@(I80P5>P@"5R8D&6;_G$!JYX MB1)H( -?X A@#($!QY !C6D9CB5*:9<->( +7?B*(3R0@0UP::#@TQ<)WO*S M!8; RTXPP8JD0@,V,80'""II(9SA0M4@@M>" E$+V$"- :0(VKXWFU&N@&= MGL&A(<#)"53VR@HTYF GJ(PATN@4X?3Q(29PB$4S +#9 &H8@F@(380(LM\ M(*UC(@ 98 /X8%HP% ^(DA1C&.H866&$05AH.7CDHBBX< MIPPF(,4A1JJ!*ZH!C2%(BB$(! MAF%NGY3[ITXEH@.&"8,%R^>IZ?ZINY_Z;D2EBZKH+K>\QP5N>/O$!0Z00A-^ M4F^IXKO=4"%WOGXZ[WV].ZKNZA>+_AWOIP3Q >&@D[KP1=5\^]NG\W+WM^ U M;H.-.V$*5]C"6)1P@R7;A:1"^+@AAC#HV)F M4L7+8/[R5MC%J;IQBDN5XPN+ @LE]K".+WQ<+?)XR$=&YR%X&QF0RCW=Z*:J9?S;-Q$&$7,O9ESH 4]:$(7VM!_TIU#J@!10- O5*_B,)5+ M4)DJ;.3*0N9 %B+]X!J3 @OS/!5@L$"635_ZT*=&=:I5O>HL#BDJC@%$D1;R MIZ1PX2N"XRU'!M0G/_?)$KPE(A%[K91"V=5)GJ(M97"Z_>TAMG%+@JKU;UN=OZW.]6 EF$\,Z'0+&-BC(DCQ Q:00&95J$#T2%$>$E @ M8X\YP08T8!LQ/$ "];E3&[E$AJM1W"&EK0!+R&"BK&<@1%[ 0 ?VYFZZU]WN M=R?S(*J2" 9(:-3)JO,'6G"R R0N"WCA2 A4*K)^7>TA&]!A!(0,$!O2SJ%B 80,H MG0>L%(+GWOLK*)@;![[@%),E(@+D4T-*O(" .I/ >A80"M\3\04;J6!NNB&% M ARE:;SWW___!\ A Z4QJ!Y1X #GB0"'B!^[**&L*)\'<"$KL)X&R (Q( ,G MX3LR"(,S: Q"(-;.XRP^)C^0"C&@3P@ L*$%Y 0N.J!U/ M(PL5F( JL)T7+$$0")S' (0PX("-R();ZP))?Z+(B0]J% >\X%!,@B!ZC@!V]B""3B#,*B91!"#COD"$= 1:/L$+X 5 M"+B"$OQ"DA&:L C /-3#/>3#!V,!+%@!04"!,1D2"' ($8 UQ .$$D(F")@U M+B !YZH"+, "+Q@$?.$"+,B"+TB$+<@MB-"I[IC$2M2I$F O/F S/&0%I* M4?0"0& (/+0 !<&"CBF#$X $;@$"'!%G:(\# B!QOJ*+" U+)@TK; :EGB+ M%D XCM 3ID,0#J81)" B;""C?@ Y:-&2I@ %Z!$+U"0U(.Z+; "$KP$+Y + ML2"!NA*%$^&".&R!;[RB(V0 FNO#>\3'?,0[0-" K_ "#OXB#8< @8.)M8<0 M!$;$(5?Z .OYK(=0 S6PA+6H.[A KPF8Z1 M$P M'H^LD@>HC"V @!8HN#=L@!)H@1<H J^($0< !$X(+8D)]7D@!F M3 "A>R:*J@ )N80,"($6> LX8 P.H3?6#JY*('+9($&J(O41 $5< !)P8($ M8(D3L( 6N("O@!'4LI$OB( 6 ('UV(*+&00(Z+P'T)X*\("?08\-.*:VI,_Z MM$\U,X2D$(6#,,BW$ 4TJ#.\N;/A, 0L4(-*"(M*D*=<&P08# FLP )?A+:/ MP@E".!I24 -1" %P]*0)[0+>&H0TN80SB(RP4 ,LN [!H= ^280N4) #M80$ M-5$L,(3\Z1,UR *Y743O743P754!7542754C754T75 M5%7556755G755X756)756:756K756\757-757>757O757P768!7682768C76 M8T769%7696769G769PTS2876::76:JU3^Y16:]764QL*HL@V;WLRU1&$+F4S M2B@7,]L\A'K3<&6R9$,U2U,XQ"YTJ$$D=!,;2C ^P64_A MD;KC[S M% I0D!R3 FE@+J@5RJK !WZQ_XL,@2<6 & #;<':# 3& U"L-=/L00C1;,& M&+8E8T*E>(#1T]846,J5/#H5> ]T_(#3H@0$N-!]>0LU $.$ H,]0(LP( S M (0.(*L\"0,N> [>8EZ/JCDR6 $,B$)T] !NL@05 $V3#B_K(0QD)1/J (. M" ';R8(S$($,P!%F.DN.$(3C"(,C)D'/D"[.,UC$@/"PH!C.H00\!(+ M\$4NAQB$$%BKMPA",?@*2SB!#D !4^H""% H,N N-NH3S#,$*@,2\B" M"^P .N4"2@@$"JB R?VD,O@ #PC%M8$.$;&-G+5C#SB!R)CBCJ@"G+""#B#D MARB#(XI"RP JX?& $L!#%!&#GZF"MQ >#C !HR $)6:!][A _".%7/X %A". M-_Z %1C>T\222XC0-]J"9<'05&X!!RCE,YADJ. (0Q"!8N:M,04!G0*<$7 ( M,=A@0 MGT0XR,H C)GX$X\$+=GQ-,1! P48 4 0@?;* @+H D& 8P8,!$K2- [H7#5( M $%(3P2% "WA &'V@HOY@@=0$ODD/1$@X*W,OQ (A"Y@ )P #!5HE3[9@KN9 MDP#R@ =8@RTX !=8Q(-A@/DE@04( T!( $!5 +MH14>P+D*>$XDQ&+'(@#FM M #DHBRK0#$ 8@)<('P%"P_8:R.'X ),)@R)Y1U$X197 B$I8 *= @4L0@Y1X MJ8?X7)NSA#.0 )I^0L?XF"!4@$H0A-RH 7 MK0H5P!8UD \=D9X)F+S;P0@22 %EGJ&\48 E;0 L26\%O1@=^8)Z:R\R *5# MP =D@ QL(000(\)@/ 0L!(Q:"'SJ[,#6 GL6,J$ 0PT>(!%-ALU("?'0)+. M$ $K68$0< 0YP!_G4 %#R *"\9Z'>$]2L( (L )#Z!U S0#=HSP28*J(3 %! ML(*J6/Z:,Z"$$T L944!?/:TF_P*7LD?$KAI6_H3#^"_2\"9=\1K!5E$L2AN MK;P$[Z$$-#S+:GJ(;#0$!@@#2D (RON$%GUKFO" ,/A;N+H00]R2LB@!3CHN MRG!(K3#A2OA(D2"%"!@[/.D ,5@:P"BZAU !QQ"!$TAS,B"8"0B#_*',LJ!& M-BF!T4B9:!1"TIQ/.D\$+X@ 4O""]BH!B<7R1#!!.E>$+Z"?%KP-C.@""2!1 MY5I 0N\?2<$ !2&!$I@I,T@ V0@F*D2#"^"(V#Z1##!VCLT70$>/V]@12]"$ M2O!("\6(0Y 20#\.$\ /@@D)LE@^"%C&D&R4".$(".3KA_X@@VJ4'@60T UP M'C# $S.P$3DW#7:O!'97'0C@78JHBRH -\I33I5X1>G+G^!C@=&H $%HM#3G ME@)%/2Q@:XFIA#2J'"](A#FG=QO)NC7 !.4Z#TJO KW#^*7FR*-X"0S( J6Y M@B+YN1!]BYR?<[>PA,+.4 8@+8'7+HYH(1WG)ATI-PQ 9WW\C7HLPUP 4-H M=7JGDA 1@8.Q@"A,;TI0A#81L4U"I@? B7_Q,6/AFP0(W&'E/)CU- <1!2N( M(@*:]DKL3J/LJ8(YCOWNC>@AJ-P% ((':-HM$ MX-JR/I$NP #%+))7AY(00(,JV((O4($ X@++;P$+V/D&_1Z;>X 0&#W R/K) MT*D)('8=\@ -\/TP9/; \ );,[=)YP@,>(D-Z )S4[FR (@17$2)H@3ADZ , M(:Q4D$/* B L*DA1)%6B"D4261))($5P3(:*'"^14C'QDX1$(;:(^D2J@J S M&RAN@7"BA D5@RJ*TA"&5)B90#60^H*AA L*GPR23!2!),4*:4BQ."%*9 6" MHE!8(?[SX*:)$XE4L" U0="8KR5.G#AD2&D%1XD:G# 1=@PI01XFG/5(B@P& MBE4P-&!Q]>J)%HBQE'%P\P0*0R6PM*Q8 83=$UA(72)AH<'/2R4J./A":M"& M#U4JJ/GTP%+%#6K"D/#+68(A4A( $;P$@5)%3*,;B*'$X+&),T$]7B65^*J( MS1C.$+3PP<3:S7ZQA!!E*0)P2P\^J:CP>$6EBNK7LV_O_CW\^/+GTZ]O_S[^ M_.^OIBBQO38I6-0&P4ZD5)(;1:)(@!%%81P@R@@M4&2<*%N(X)$%:Y"B1@6D M9"'4)0Q\0@*#I !"R@==4/1!&( @*,()E1P &R4=)C+!BOY?A.B212OH5HA' M$R!(BB,'J%%1"8%)<"0I8W2X$BF)4 ;%OY)L%,8'%#$P1B43'!5!0668 4I M)$A(D2!FG$!*"%GXE4@"X>'HQ9V7>$""&H:(P($E ME" 07H>D;%'"![F-P>,$*EY%PF83K%E!( ^=F%-%)V)*T0A><)C@ VE6A,&1 M*,!)RB<-).(7"1/E!8%N7E!T09II1Q $.R< &!I&(!V3N* 6;6L%^H!L5^&\ :;O*!D(X M0BR@ 0.VHH@*&-"_")!I R50@Q44@)%+2. #/"$%",J"(A^UH )GR((#AI2( M!9#D)A[AG24@4 4T9 !.76B4*#@0 C2D@ )0V5(&#"&&1GGA J[Y' H>6 D% M-(4!9WP X*[@@)61@A(&",$9JO :4G0 D"H@&PE20 H\DOZ" R! PR%)P@4 MK*P*$S@#%Q9@B$$@H MJX("/<(8C#FP #5Y(VJ5>10(X>> #9SCD)RPA@1_4 ML#9J:( 7O#*0!JA #2O8@'AZV8+ B&!G61!B[-)SE4]40"@5^00$2D )0#P@ MEQ*P%"DP\0!A!B8+$B"#%QIP(A!\ ))D\YL8MF /4G : [H0ADDH)VK<($! M8XA=>!1 "92PX RM;$[< BK0@1*TH/-1 ^!>EE! )+1U)EB3>BC1@C>EC12& M2 $)C)90+P#'?@$J@1A 0)FK& (%(Z 8&0I$AC2IH00BV)H@$I.(]9&B#"KX MQ!E4Y041J$ 1'O$";$@!U",.0OX%(6B!O39$@A*L::6<49V) ->%]!AB96,P MQ">"9@@5I,D2+<#+(5! M-0I*4_9 \79D4)JU&D"Y>HZE\J>AJ9CH$,<#T- M6<6PID&@H 6)Z!M%*,!'VI #>HI@_7LQ5&+JN!$8RD511!+D3.0ZS L2H@P=8J8H(J;"$$%+.$"U B$$PR *Z BAE)[NF,8P@!;.JR"6Z MK)[@D)5X1)>..X&] 10 M$ZE@5C%%\'HLL6 5((L,J^Q=A43 @J""(:.Q#4-NKO)AEZD'O+IU*ZQP+&(1 M:,&@/OXQD(,LY+A5 7)#/C*2@1P(%4S@N$F6SU4^@,+W"&(%$G#RD[.LY2W# MQQ M>, 9N2SF,9.YS&K;L&W69 M/F]N#D #K1Z"#'K.@F[/G]G<9[^<@01M\HN;%YUF0B,Z<(;>LWK(@,%#7Z5U MCX8/I=US:5'K.7"D+K6B[XSF4"=ZT*[FLYIYDF=)FSK61_X4=*0G;2(1 ,_6 M@*[TJVTM:U#3NL^S-C.RDZWL93.[VUI4[O:UI[/L:'YUL[O=[GXWO(%=GS4P3]Z!8RA/N!#44HNB$KH" M!(T'K>\C>@%9\K9$:..M\(4SO.$.?WBRN=V%$LVGR'[Y1 AN^YZC"?5,-?Z MQJ^X7RHW@-P0/SG*4Z[RE;<;.(-(#TYY%J4Q7.(2+J'$88!3F?0HXEP;,D.W M5):(+ESHF1ZQ!$Y[3=FW>.03GS XS@VH4&9B%5DUI\@F-'V5032*Y5[_.MC# M+G9F?\(")8@ (!)1@1*0TR5[^_X "20 . BH-0*."ED(0% !+'RBE26P0&X" M%@(25, $D$Y)QTX0@@9LYA(9Z ).- A 55B:%S_Q 2 = (+C" $#ZA$%@!D M$E*L00($/IN^3#[VU;.^]:Y_O:@;<"9\482^U-I))1( N ?XU!&XRL+9/) ! MDDB+(F"XDP6XL"O_)(CN?)J5&IS6 B-*SVG ?PA>6#"1!R2"FKLMP"6P, ** MI& B7# L*>A^"++!OOWN?S_\PXZ2667Q!"I8P05*P'6_@ O=(_2[X4,!Y#5 M!GC "GR6!!@$SI$"%X3,82">MIP&CF# RAA"1VB!$16?!:0)!%1"%?C'521@ MZ.&0K?Z0@0J80 ,H@@7&'PNVH N^H+JA1&Y< AX!@HM8 B!H2Y3YGX/A2FDU MDO+=2Q78H"$H@GC8RP\FB 2HX)?D14>4#')U1!:$C"%@ ""$A()4@H!4A 1H MH>$ERT1\@ >@@25@P-*P'PRFH1JN(1N6&30AR ><"0M,2@,<22(< . P@(9X M00($B!%M0!!F 5$T25ELP-0PT[)X!/=U#)K@"A8,$ I4CMEDA 58C6LP3?20 M 0%8@@#=AH0HP(D8 @(D B,R31N>(BJFHBJ^C2A@@,]5@@9L@ 9X &R<@01L M E, %YLP0-XP D$!A?XAVE5Q E<@ ? A$4UDPAXP V)@OX%4$(54L0@!,8G M? &P-U,= 'SC<$"Z!S@D<(/4$ 'F( %),(E8 &G$ '8,064$ (N$!^&<(% MD((+2- JWB,^YJ,^.IDAM,DEG B+4$0EG%?3P!$,U"AIH^?B1(AB0^]A^JB:1)GB1*IB29.9U*MJ1+ MOB1,QJ1,SB1-UJ1-WB1.YJ1.[B1/]J3[V1FA 1I0#B6>$:50%B52'N6AZ5JM M+26N)66"&&540B5S4&503J52[IE3JIJ?01I6?F559F58@N55CJ59EB5:2N59 MGJ5:IB6>L:55MB5DE6>*E70)F4VJE81:F M8 8F8=:E8@ZF8Y+E7#8F9#)F9*XE95ZFG?FD9FXF9[H?%V"!%F2!:(ZF:((F M:9YF%I@F:HZF:JYF:H:F:[[F:&X!%IPF%M"F:.+F;=9F%N@F;O9F;;;F:@HG M:A*G;<*F:QHG:;;F;_HF;SKG:>[;>J#!;@XG8HG>B:G>7:G>+9G:<*G=K+G>\[F>)9F@XH<.:F?O9G:NYG=18H@,[G>C[H=PHH?1+H<$(H>2:GA2[G?V:H>R8G M)7RH(OY\J(B.*(F*:(B::(F6J".0Z(F":(J^*"6$Z(J.Z(R2:(W"J(OB:(JV M:(SJZ(Z.*(_ZJ)"F*)8138X.:8\BZ8^BJ)(FZ9$^J9,R*8OZ:(@&J90"Z91> M:91"Z9-:*95B:9,&J9AJ:9>6Z(E::97::(HZPHVJ*)=^*9FVJ)?RJ):)N^*9_FZ9*2J8[.*9X.:8AV)J,VJJ.RGNJE&GY$:GV0 M&Z4*FW[DV:AAZJ3:QZQ=:DD>&:B6V:C6VL.5ZMIHJKUA&JM*:J>R#:H25*RN M*BL^JJW>*JZFW*QVYJ^EJIGMJD$!:ZX.*[&J7)&6V[$6J_ZRRM\)A!!7WEJP MN5ESL(5(5 V=>:2IEF2B784E=,#H9"90-AP@>,\'B"$&#$+N5.6PN=H98$ % M4(!VM&JO_F6AT1JV M0GM$9)N$QFKNMZ:$$%5( %!!RJS:NI49HA=(>)(,L@ M#,F?;2NK@ANV\ANL4<5]U1H@&%R33$2_!DY76,('2%W@C '';H><'29%8(') MJ.M\H !\L9JJ"MO$9NO,ND<_+F6L;6JHI4#7S.S#BMJJ 2VGANI4<@8)G!$7 MJ(B3]6NNK:I6X-")="S1XB#&1*VP6<(:!*T:$$ E&S<0(#3(!< $B0)4( MC%_858*F;0 &I '-6<'=S C/T"8;&4#4>DP !J$)'[V':GQ"$*X'6JP'"$P9F[UC?CP XR+;550% MT>J'!!B6L&99)43/583%D%4 P58J*1""QU# Z[+'('@,>Y3 VQ _ (8B4" M%M 80U7"%G@!)I@(&;@$0C$+%E2!AKP$CB 7 316%0 /(%0!%B#"A&"!"_", M)6Q!]:['(/Q %73-]7),'QW %YYO;FC"&"2"(!2*&,"&)8C!I[7;"5;$UZB! M"?#1(*Q %2059R@ SQA"!KB$!_82R4U,JLL M8C1ED,*RH021352B'7+XNL14H3"B?BR$P MB8MXA"(C5P=L0$*) 0H,Q'HDL,SEJR5<07H @@I4 ;)8 /Z3A($*@ %[)((+ ML$"!"((AD,$)4'*"=($*>,'61?,TJYDUZU9>:#/ZK; 5YP9.7<4EH-\@A')N MJ,O-E$05J,$)?'(AM,!S*4TH6Z\*6(%T;@@ VXLE2 3Z94#6B((7$(^,)<)L M('1%H('5M8 $7!B7<,$)( A!JX#R?8)#>T&8P4H"D$ 7 (!A48L"1$ !!,!F M?, 4, ! ( 1?4 I$<%]*$: $ $9( _ 1?-(@<*9Q! MV!X11[B %TQ CV%! F!!"T" "&2!>01( JQ %DS 1*@=%H0!!0".!T %U1! M IPA&=13;I! *1V8*+" ZP8!Y")"U1 05> )8C" W! ,%Z97TR/KJ'!"//B MD7S ",?="60! _R$ U0-!EQ "V"! I!BS(3! X2 ( @"!61 &-1(%:P17JB! M!'S!%E3 K)"4 6B&!' %IC EXA"!: &FR %PB" [@$-64D*:! !D"2$75! M J@ P/K'Y:A =QN>EZS ]6!$_BP2()X F#GWSO@%%U@ *8B XBCWB; !11. M A1< OXXHZ[$"B6$@8.S0 58<0(H'P.D28B$* -L@1E(19E@! 94 1E @)ZX M!&X; E#C#>180-6HP'A<0@5<$@"4$C!=P@9#X MA2(< EP00R9R#5U04H,0LDMDG\(PGB\S'&K2.1]P:%T"R4\@/E0@.E&"0,4 M$L)5B@M$P*Q4@&']RAB$P!>BB9IS 03@!0HP@&@2L&W@HAI\@(\$>FT2NE\8 M.J+/MZ!G00(8%@5<0.'842*(",ML2/N$ ;3XQKZYP .T0$ULAAK84Q@DX"5, M@!>$ 0, SO6(015< %;$$+,,"L=("PWY0)/$ 5[#,9@/0G#$!M? (%* A) ("!$8) M1/4Y'L G.%!Z9(#3J,%FR,B=4$#T6I0!5,!2*("#>X%IG $ F(I:8VV:A, ! M ,<&%!!%G$ J($EK'!1_(2_DS !&!Z__S4 <$'NV5-L/T!@8(# O!MB)"(6 M",7!E&["H\!"7D][E("MS$6%",4WD5Y'=/>$*, GH("MV"**, @'B($@'$N4 MI$"Y%0$",680)O)GK-L@\@H"$X!/>7,@%_87';$"7 ML!^OX!!&4.N&V!VP)TLB)HY+S/Y7Y"3")Z ?%B ?X(R6;:"?(."*&.S+)=#1 M&.B] F "/ JDB$R&;J#?;ES-FER%%V@)@U%$"/ =T)N%ON'*XO]U2'A!R$;^ MWIG%3A#1AZZ)G#RX[;PZK$A11P2%A&0 \TA O>'&P7"&K%2$()R7! C")[R. MMVQ-%5!?139 >E2" X@">WO-G4R ""TYWL )H37RAN"N!:QL'ZV)F?C%')U( MK""(LJA)XE2$ _3.O02A&N"*"C"?_5T<^GEX29!_*,%*0H7!/'Z6QDQ$!5 , M:US"4YR&MC2L1["&*-B,7ZP 0'0@14H0A$^##I$254%-)06&2%%*].G!H($? MJB@DU?YE@B52ACY=4C/P1 I2%LJ0.C-P3 52+3 ,).5A"ZDJ)C1^=$D*@Y>! M&,BH9.G2T$Z9 T,8\(+F@0*/#W8^B$FB "52) Q\.F&@$JD-#D19:F&AP@$/ MI"A,$#70D(",I#@D^&2H1(4* ["(\C! @(2@$AI4D A@<6/$P(0V&!QD(D* M% A@^52@Q$?'%/!:&D!"9HL#:A*TR'F4=&G3IU&G5KV:-8H1&K%P%H6EA*@' M(4*,V,!"(QH(.469^014H2@(E+B(4&@!D"@U$TAA.4'J$ZD)@T)@$!$"A, / M711ZX&)3@@05U06%V&Z!5"()73V$$42A.)>S$"!^NJZQQ?[9M6'1N.0X440Q MY#<0QC-D@DM(L8*S""P*0R!1.!"CD@C6J@"-@4QH090.," AA \\H$0"$-3C MP*2U%*SNA"I$^40"B,CP@(0,E,,B!.L2.0J[[:#K@@0"2:E@$#&4JXXY$+P@ M<@)#3K""% D$4:B"0$Y*:2U2O." E!"P4$@$+A"1@#I23M#BD@=(L00"44S( M8J,0##&S.A2DE, B2R3H,0L/3)@@3!$R0F,""3J 2"8+!E&A#!(2J8#!"II# MJY 0N(BQR)$&ND0%$$YX0)!*#**. @]$$*&#R@9R[Q-1W+/$ E1%L)$4%+8( M8XL3#/& TX%8J V+#Z@31045-/X2Q;X2*)!R($4B>'40"?X[(Z8*!!FC 1%) MN.!7*@FLA$T5/+Q5-)G0L)$#+T\0S5C>9%+C Q+6-54?P8 -2\#V3C)@N .0H0"BH#H,SULK@Y'E5)H7FZHZBI $%$#" @0+$ M( 4"EXS+@)02#$B(!+E,,,"C"M[

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�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end GRAPHIC 52 comp_0008.gif IMAGE begin 644 comp_0008.gif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�CWD2);D["1"([0]!XP_V\N^\LN^2WY"T2W*,-Q#2\9D M[2N^0H!%^VI#4Q:V(M2^2UYEH/"#*G@_@UN_3ZZO53;"2>;E7O;E7P;F8!;F M829F16Q#(/3D,05E#>2]#BSF9X;F:);F::;F:B; ,:B"*@ "+TB4QX/6,$T. M,EA(N".#Y .%+KA"M+L$K?XR^^FCG^*- THAGM@L$=_Y&BF^>O=AJ!!7P M T,@RG<6B9?\**VY9W#N/.+K-: @ S@#YX=NDC%0@6XN48@( PB59QZ$DG7^ M*"\@:$RV! SFPZ#P#S((D^3P1AH\08^6$D) 6]_+:$R>YU#3.(B.:6H,16L> M9 K @!9@@0IXK+0#"D2H@-B[A%=;Y-0K!0U@/$I #_23$M#PD)R:$AZV:2@! M"JL>(2PX#>F#"?WB@)#:@KV8/0W(:8C0 '7) N!\NTN@@%V;MPP$"BP- QI4 M@Z/($W6QOYS[(07X9B?)(TR DJH4DSHC#4K0M<->@+]>/S&8&?\#"@E0POPJ M@2W2:?ZM '=V@#( A4L A>XBA/XW81+/_FR(.(0QZ*XS@(! 0&,R.&M_"8,0 M* %I"H4C-H/N6F=*&(-'HX3#00P$,<=(!R=!2]-@XRD+10>!V? MN(LUT.M#@+=+.,%0J+[>+H5**.?D<$%"((.:[@JW.(,1.NWN.D')".\P6(IP MQ(*" PI#"._DV 1,"(7NLH3N+H5&F Q4&$T&H7G]HE+:&B(0 0*Z()+( 6( MH 0*L&,O$(%+$&V(R.^^K#'><.@?JAJ16.>*A( U8)[YL @>?4*B:,S@*%MIQ89N;%)<3"?#LVL*$R-!M.".#H^"B MR+"$1-%N!'5H D=Q+"$#,P^%'.(5^KB+0"B#W.DS!A\#.C\:[(8(%1\A2Q@# M2@""XKALS'Z_!U #,!#6 !"M@6#[B[2FB ]*@ _S*MKJP M!8,+0[@ $@B!EQL%"_ O!Q*3!K@ -8!P2H P28$"0@%-*" $\!(TMB"DO@S M%9" " ,C$1 !#< !ND""FB!#""8DA $";A,"T .H""$]_Y #F4K@0J(, _! M \HB32X]@P8C2HHC]^ B=(38@Y@$&LG@0RXLBI@@ KS"8>O@#1PTQ, 09H M#W\_@0T0&1NG !( @5^'"'N'5!<# 0\(G0:0FA-8#7^/]=,Z! @H 1'PLL-^ M,1&H@$,P!.6*@8!@0P@ 0^0K#"(W:S %*YB 0[PTC$@:T=YTN(XA @@< H8_$FU M@$G2@&XNA8T_ 0I8@X>[ !1 ]OX4 ($&Z)JP%@$.H #2L8!M0:\2B'R,J+,6 M4 %;\2\,N LT@(#+I "B./3]W?=LY@ )&(4M4 #-4 ,(T!I*R/7D 'X,:8'% MF/8O@AB"&*."*))9IX(HHF8N!!%2UL(=,5 7;D'T,>> %*!_X<@'#="&*!LL4* M'D!'"%T'C<&""0X A=,6#&RQ10.;47!0(!)<)^,6*FT@$5@@5:%"!0$B)58E M;4'$4WB4Q"A63P^70=2I50 @A# C4P@,H,;FC& YL)%-5 M%!AR4W4];:$""%9VL>,#!I;RQ4.CX%1:*56(L% I=H':Q0<'^=$ "RFT $%& M%9C14*D0E*""?2 0R>9!%^1E$0;Z;;'C*%^$< @#+, I048X$3(E3B5@\<6. M#)&PQ1DNX42)!!^-L$5(8H7A ;8,'2*!;S=! )1N9SBVDKH'5?"'NX&(\< + MJBY0%DY^3%!*"E=04JRJ$A2FIOX**\Z6[$H9B &2!.+2%:8**GBP;BF(5#8& M!S>-X5($@>#4K@F%D7!%>)984ED(@EXB4A@97_=I*%ZP(()(9% \VQ=GO$ " M)21X<9/,-(-"B05APFM1"1@8>X("HZS0PDP5&!B&2Q6\5@H:%2#D1QGWE1)Q M*1 E.2<"-+2OMZE!C93^D\6Q% 2ABBG6J[+5JC> M4YGK@>!DOC$$!,H5MJ^DBV(?6U<%HE(*"A!"#!8(Q!H"00@-EN(":L@ )=+" MN]Y1@A .N$(@SI"Q$@ !0QK0C^/6-(HJQTD:T'Q0[MP@H+1H/X "RW0P@BW@,08 M0H AMAG-W3*IR4URLI.>/!$%O)!&G%Q!):4 C('^T E&L:4@9A.0RIC" >L M)0%_20#X3LF "RD@$(; 7RD (1(LA X+#]D U AQ@$ \YR AV%$'*H(3 O'D M ;*#@"$,P8!%G2H4(A#."R2"''/91 +ZR<(726 !]/DD+R1 $ZQ&&#P%*!$" MPJE %RAQ@(-\@0$CR9@'5K 0#(1N4Q4 16QXTB>>,*0++@L%!?3&1SLU)&,D M0,%!JB!*"7RA346A@!C2Z*Z%;<$Z7L@82 ]2@N"-13^58$ @_J50!E"":F*A MA))*$8*,A+(G(+5@*3"HP1/T[?X$*B'#!2SR,0KXA@(*@<@?7K4D4E:OB:C+$@3),VQ&6D< Z";<$ Q)2@, M*#C0*[<^D0);F0X91!(*#)@@% :0R1D >[-+8" #H[B?"9:(@+4DMC["81&H MRO X/P3H33/!YJ4<8P$9=6 T%$@#*!CP&D2B"AXQ+(%_RR$!!H860:V$(H-4. 26ZA "';V MMU*\H 0WP0D)6'"("W@..EO 4H#\$ $-H !YY &!":[@%13\;)KB00B:+L 3 M+U3@N/ZDL\0&-+ !. 8EOSQI@6K%T".6* SG.. !50@& Z1P(?L #4P%,> M$)2'(2? P,@PX 4RJ,00%MC ,XD;5 D\1 S]3:E%O/ IS_77 @/12_]48@D/ M9& #&_A(("P@I "X'.FK!XR8$U/> M)%*68 %*!"'D"XSF$ <%B05\@Q-0@$# '%@+&OYGD4-0@ .CT,#5,O :,;"X M I%9"2@.D!="]!?$H;A$!SQ0@BM,X(ZUV1L#R%!$F5#BH&S.0%V56.G=?)$, M#Z%$CT$0 I6LH#95J.02+2"3$@B9!!FX!"BR3 (0I* C%_X8P1NOH 8YJQ1F M$"!=1S!@%P^TX! 6R-&/5U*%.E,@+"S@R"4NL"@QE&H#(&CS!F2R@;"9!2*$&! KSSQ P4V0((-9$0$ OTMO.,M[WG/;6V+"84E#V*)0+!0J?D. MJH$.K>^#U/ @E; (*,@Z"M_D6S"6'(4E$?K=@Q!B+9=8&UG+I4$-7N(/F%@) MGQ!N$7O/1%,-7TP@6'D32V+B#RJ70"$,$1>+&,) H[@$Q"T24U"M)!2IZ7B_ M<[Z2E(\<)T*'3>6HQ,J++\82.'EXOHF^DD)(X+&L!(4?K'KT@9/\E(T0N64P M%'+P_/L@/E](54@.BC\4T")J>/ZQC[WJRGHCV(3KAW6PO>T-4H.PHTKTG5<" MA0%?]L8/T;8]A!,RN.GXSG\^]*,O_>EG".?4KUOCKY\A2F!&^]Z72_$7 PJY M?[_\YC\_^M.O_O6SO_WN?S_\XR__^=.__O:_/_[SK__]\[___O\_ :@ X@ M 1:@ 1X@ B:@ BX@ S:@ SX@!$:@!$X@!5:@!5X@!F:@!FX@!W:@!WX@"(:@ M"(Z@B?Z$'PF>( JFH JN( NVH N^8 1N@0;45W+A2E7HWH6$0N\LD0<(RF+0 M'O I'(8(H>U=R W"(!(FH1+^'R@\0 # 78J 0@&HQ"$$@/C4WA)FH19N(0/B M1!D<@ @8P%,% AE4@A=T G'$("9 L:!$"M/4!G M7$(#*$8&$ 0'$)5L( @ "_24#GK(=CA$'K^ $ 8$$@ $ +4((?_(%G]$8I M9( !@$(5", 57(('% #YO:-.[B1/_EY.!( *H$$(!,#"H, \(0*# E&-8* M7 $!=!\%5-(HK$$ ;,$H' 5&D" 4 (!K( E)$ $"&,#0 !C[=)*L$ V$0N MAB4%'&,H',()5 %& +C$(($/Z /Q:)6CE35R!,U9! / $"Q! 3O:D81XF M8F:(!QB AC F#EUQ" 3:B 2P*"41 !;B,1BB 3(@! (@!0HY%CQR" :Q M*"3 CQU"^[205(K%8-J$)2B !AR":F8= V!3(0A "UP"(+B%!63C1!Y$"@ M)W;! K0 *"1 LY$ M2IYD"?A!!AQ *%0! #1E #S$<+Y&?28=22!'68)=2*9F6J9F>*9JF:9H:897FGIJ^*9S&J9S.*9TZX,[) M!>IQB!]TG]SPFT5<0I[*C>_4*:$6ZOU50 38FQJ(A-M@B"$4@(QLB EB2"A8 MDUB0@6QHR*2.*26 @&_82*-NJJ&.*JD>WPNP$*U&7MDM)<4]P%ITW6)< B*4JOZR+NOS98 7/,!K MI,$!V #.H0 '>( (K$T$ M5,X9B 0A@$ +8 $_.)^6( &>$"R$@*F88!$S.L+V.L9A$('-( &4 (+G $9 M8-1N>%<58 "*<2FS5JS%PEL%R(M(K"IL-(!-I,$#\*D::$V[E$(6%(A=1I:/ MP=H#_&(#+,KKA,(:A(X&+,RY7*J\$L 9C )670H%.)T*A, H5$!8S 4E&,( M[&S/5HDAC ('>(%MR80'A$')0LC%7BW6ZM8%E$4%8,$@B 00;->6))<)> B M]=)^8 DT<8ERA(V!C,M:4 (9;/X!!'34S7Z,2' .Q5G)T[H.8(B!%XQ! ^03 MK][*N/@&"%1$:(1'*( "8C!%^#1.F8MY59NBNA*QW:!UJP C93"F*R9!&R M!X# T!-*;724[1.*73 SXC-$C7,&42 "IQ!"+3.W99"&>1MU9V2E63 &(B4 M&CR %SS)&!@"D7B.E<"MYU;$%03E,4U+%GQ!&DRNY5:O]7[(51Q$DY#/&?"J M1,8%0X@!JY9!91@.ZH)J*7S S[RLJLK&!J"$5"S,NXI%]Y[2 7U."Y@2&8 M37!H/ATO[ZX83HR)(: 8Z60.P?W,]2XP WM(LXD%!DS0A[% !:2J52!,7P3" M%I3*?OX\1'1I1$68@ 0$;6!@50NP0("=#-\MGVP$P@-XS@N#0@80Q@/HQ[,& M29JY, S/A 1H )O]&0@$QDP0E H(;P,?,1*#')=:0N6HP1;DJ9\>'B58 O@< M;5!AAB%@QAF,P240@N>$P:),+R'D&Z NQ,Q)W$V00182G?_U5/MU M10,V7_^U4JV75]V5H,V:4MV2>!9K=V:N>V M8W.V;GNV;_.7/SE][S+ .A)_/SE7IW=G]W=ROW+1-/S(4MWJ+)W>C>WW3U>>7,W M>=;/S@8\I+*_S@&.W?2MX@?-W@DNX?HMR M+3\XA?[3]R$#.'H+^'RO]X=[N'6KLA%FPE M,KS1^'+:N-S@^ +J./WQ."VW.) '^0!Z017PJ83_^)6B015852A@@0)+*HC< M(*SUQ,(BN8@4WZ1>RPOL8<9]7'=KDA<$3Q?4Y7T/89G?G:H"6PT^XI=GR(58 MPK^Q87Z7" Y:>8;D$WG;^9&OQ"4<=G+AN8CT>0E:!)X'X9\>=HQ_2**/ 55H MJIG+A4Q40A8@>*/FN0E.4Q;(Z*/O^2%[@:ORLZ![TMG-^8]0;X>,@M,=:Q:@ M]$)D(A"& E_<=R$H<'-O^IY?:2 0 \6MPTBS,2G &\\/[<6,("C,8_]HV> MQTT# $*E MY_C7( R&M%:4=X2ZFX@#7,V/L\!8N3AW!:2-LTUA%$*[ZM8AA "KOPT$5'N& M,,27G#N,*\_-: @E-)CRN3D%&#DEB("KGQ)T=$AL&GERE0$P>1(+,(!<5L4A M.!U:$)R!!,)76/$26C;&.SL M37R$']BJ!'C!Q95+*)!!7C2>W5/"T?^I&/#]$HT"&O"]XWC!P3%)WQ3^_O@! M&,]$]QT"0P3"YA\$(HB!O*]$&HR!E_].(+P**"S^$JEJ&1A=G)0*4NE$/H)0PDAI5"$Q#!$.!%B((2C M&/H!-?Z1TB@U:DI1BHCP4L,Q:2:6(A3&XL0S9#:&?+AP8B QH#* -(0P5,&$ M(R^9 +$S92E0$B\Q[!AG3*A2AT8AK,1PU$NG"->(*1C*"P5!3E<22GGF#"4* M!QMB;!F6(DN$@2# M!2*DL62/[=ZD3 (;!A!*=...&J4JZHH(H,HIMHBPI(",$!+TI)0P(61 !AE%$L($$"/ZY@ M ,_M@B0$!Y!J, 202 H90L*2O 12"%;&,%(^4(PH0(/1JG"R3-*<2H+*2LX M000.-@JA@Q6$"U <,S'KBO%+U>X$ % 2_P 1*(/"I LQ* MR4#)LBIH5H.#3@!AA0;&6"TZ%BCHL8%"+'F@!!(@N-=/%DK8()0S(+CO$ A MH7"#$R00HQ04+% !! ?$FBB+."V([9"(*2 J8 ],D. $$G2E9,]0!#G4@PS< MI.#1\RC!((02O"IE4)<;$ MBB?_@URD_E,5.@Q/B4B-D![,MC@.$L AAYQ,R ML"#@0DO!((U+,""A! P84L$#%AR(2(,'1@#%BPI4L "+-CW0@(0/)*@DL@$ AFP3L(-++"$@P!0("&X!XKY0SH\0 M @D#>T1D1U+](<0H:A !-1%/C](( &:"(0!0F )0@C !*6@0)98$( !"H 0 MVC+1BBY2 0.(H0L$\! ) ."'47P@"P\"P"'($( G\<\/9]#>(48 @"JL\'!5 MZ-\E*O J& @ 82@1 .RI (!5, +H, =1_>>38Z@%&MP&P0P MLX%918 0AD"7&I35(X1P8%;41$@5E/( X2$@9B*(#CI3XK.HA*"%I6!!;!0@ M%HC(!@N48$!)*)$ 0UQ" 18A1/X#1D$&,R"$ B!IP7GF.*\+O 6B*/ 0CPP MJZ@\]""A\! H# "&HE#@<&@X0$DRT 50-(!&XIN7)0K1 ,==(@.@(,&]M/3+ M$WP4E%>@A )*0@A2[BF,?_*"V[KYT2N@X'$I^<+92I$%M55@B@\@Q%5+(8@_ ME2!'53A!*1I:"D,4BFMJ?4"*(& )S"$D# DH251:$%>W7F57(%!C*8)7"@DP MA 6DVU-$N^B'CP9"68= )D(@4 DQ=$T,"3A(5#S02/0I?3'J)4"0 MFJ7(TSHCD@!D 4Q%)QB '_CE *>4!B$/^&4)"L 0$A@ %"=8WRA4%XI1F$$% M&CB ^/Y44#^$6.)^ @* RL*00A80P">1H4 #0@ ""+Q0B04I@0$N<0D#5) 0 M!=#=%000" MDP((-J)4$ M 20U"@ O6% "(1,@$$4H( ]_(" -ATB#9.@ "! ML&&AQ " .!"P%($(0'0$+ ()&(!-%Y G?W7G0D.T8$0(.80 KM"% .BLBB"\ MXA8^FB*#7$%O%HA*5*YPUJB$2D J* $@2Q$!G?V+1J)T %7>\BZ& !/(,0?!>5+(KB%("/I&E&2F!!5$Z)01;&,4#0/X1AH]J%2$8N(X? MB/.!#:@@!6V6#31',8)9F2 VCZL"-Z-2 4(8*RIGP(!W2D!E#6 U*F(N!2?; MA)UBJN1/*LB"(1 8E2^(KUSF1):R1-!""D7G!"N(BA-=]B=!/P[1ZA(I12W" M9!)0F0/BN\(#Q.D4$70A,:G. "$L(0&G:&@C8TC!"1KP'A6<-:,@@+0%":$" MD9X 6VX*D%-.4(71S0@A@BS%&=A+(2V8E"X8J( (WH/BJIK1(AB19PJ*>8(L MC.%L47E2)4@V&>*$8%8S:D$%54Q7FZ;-M-% @!HSVPT2]N MH I.0>X*"7*+)**ATQ4I!UE0G MA *C$(/,>\T -:A C:, Q6")+8'3[03?D4'#1D?A!4L^P!*@T.LA&O#M09W5 M! _H )! 2/0#(. "2@ FWP5&0C\T 8Q$ &,F "!07P^TLI88"SEE=W2E6! J )HS"$0?-H M.80'&@6"#:!J%!/XDR$(X.LM " -AS# J4)CX.LYUP]52.]DI.A["Y0A-""Q MP)]"?TE_!H 2T^U@5#B 4^5N,17[ )1I1*!%P1B$+^(FB-JV+U."7 M(& ,$M 0)"(J5" VKN#=$ 2.$"(G-@ 1,@HAOD^P!.%%$B*=IH@$HL/HI(," MRN<0E"4,;"HR,$ --J"Z3"L.VD0"6,(/G- I*&$,7.71[ ^RL T"2B*C.@8- M+J$#4&(%[B6C@C J=$P%R$;IG*(+Q,4,+3$/ZBS\SN$J("$*X@ M ?R #-C+,$!A LKHB%8F$K> ##[)!F%+VQKL3\CP<2S"K#IC7HB*!4T+#0J- M33;@#$#@/23 "Q+0B*+"$L@@Y4HA#I1%#"B $/[@"WTJ1XA.YU3@/#I+TQ3P M$.XJ#5: 3I">:0&J"IF%,SP+29#6<9@&A.P$ "/;*ZN,")##5B 2Q!#:#J M##8* TJ ,B[ $BY!!4/" >*@"1U"K<* J@JXU(B# +@!,@""P+ /_$,]R& M! 9 +$* $)A!0#@!:K "0 %"* 3\Y ,3G! 0@.!+ J0 D?[+#P(! $+ M#^KC$+ ,;@$%! =TJ @["C /[@QR3/8((R# ,.@ $*PH>T @5, "+C(R75 MBGQ*00M22 T 8 LL 03ZQX: )+H^ @! P)< O\H"LKX0-XKQ0LX "Z8!1 M0 #.0 T.0%E.(+X>9PSH[MRX;T4H $BV *L0X@\4@)!N*2JV8 $*X@M.,JT" MX0!VPJORCPQ&80H1Y*SB!GODR0L2H"#"(#)'8S+%PC)-2BPB #//+T!.#B%4 MX P&IQ.SB 0J )H"P0$*HA",1 2FB%!2[:FB0@RHR@,.!]9(4&T<(#:T!9J\ M"A$80"P"@0%V M$\8",*L]YP4)Z^H *B@@RH"C000CQ)0$92I)4*@@P$X! 0 M00$ZXOX$B*,$*NA!X"XJ3* $'J(!+**5B"(JNB!B(N,VI<,.">ZH&F$44N!/ M0B!'%K1T2" 4# $!G"(,$M,+;"HJO "J"J?RNAGWLD+*$$"^H0!',:T4 - M6. #J$2^&2O'H!-#"$!0$(%1@!"'>#>R$Y LH0$L 4[AC DPDTEHI-%,6&E M-K%K^ D42'0=-R"3-C 0$@ 46J #$")AL",2JX"YQ"(-". /&$HL6D">X,5Q MNN!/6" $A$L-9F0,3"04,."2*(!-3(M-PF!3HN),$>(*MH#H&((0$E,-(B I MIL<@/@ 40&8C1O&NU 6H]F0TOI(29@\A@M0!Q VH*J$!0OYA#7ZL%,#@3ZQI M$V@)$ CU$D"F2+, = B8%2F%*JFV.X- T)!17<' 2YAIB1"G! B(+T)(9YJ MX(J"!*)S(BR ,#+@DY#DHU( EE;& 3;A1<+' ]90 1) !##@HUK *7&.O<@ M 1JFLE!B"QC !A 94)!!0[ 0AI&!9),!1S <50 3P [2H--#.L7,^585(B M12 R W[I$!C 04 S#4*A Q" DP@4]0@ 52&#!( )4R@[DS 1:I P[ 8!F M3>IH 2C!$CS@7#.@$/PIR5+D 4(S,*EH U3F"T1)7TV'!+) \YM"^IF RJ* M$01>( 4^2@T8X 4LX0(VHEK8MI2F2-U2H@PJ@ . M,V[3UOZ00"(-B.H$FJ@"(+1T-< #'.<,SA=Y?2H#$N4@6&"*6" ZMF "3N9) M2N$%(,!1%.4*UO96-/5>"/37JF0@[F5PUPDD*@9(1B$41D#[XI!&** #!C,D M,."3TD!L*Z"?*(4#3" #GJ4%5NV$^_9PSH "/, "-O0$A.@*R 9Z&6)FT/<] MFN;3U "%X6@%*J #3$ #"N.$;[B"T@"KHOC4+(#B0L#7+$ B*(%_ZR84TJ=T M!U!%0('>-OA(KD*X(N,J-I@G?.(JDB*-(R/CO)@G+N)(=%<>4\(2=&:-X5AW MG0*-+Z(H+$$.J6B.V^3%5.P0-@*-T=B.&Z*D4D21#YDG-OXC0[)%Q2:/ &K0 M9$$(D*GR$*A"DTYM*@-A1@:9))9N(CSAQ2A"9YQBSD:AE"?BE*5CX&8D$QU9 M)4!V(@QA(\8XD"<"% 0A;!O1D)!EB/#L7S"D55L M1H[YDNM8=], 6A R\1!VMC- $)BKRI)K&9V/NB&D MF9.A.JJE>JJINJJM>A>QX #<[ZJE>@O2#ZFKVJNYNHJH,C[,.JK;EJRUQ''' M&C[*NJWA.C#5M0RN>A1:P ) 8(3CFHK>6JI5K*_A>A0&::\)N[#5VK 1.[$5 M>[''&K#CNJSG>:\CF[&MVK%U-S"/@K(UV[ M(56O^A(*:+.YVK)%N[1-^[11 M.[55^[1)>[5=^[7/&K9E&[%;>[9M^[9Q.[<+N[9-EK<=6K>!.S!]^[6'.[B- M^[@9N[AM6[F3^[!=>Q3F(NZ8FRK)'>_Z[ ].\OQN]'[NV+T$UX,<2* &[+?!90#&8US[G$WC@^>!N[ M\S43?_F^"]O *5N]?16Y&7RLG0+!BT+ N3H4)-RMT<, +.J" $#!@!(T#GC M6+FJ[+@%%* _(>"#_EHZJD!.?QNL7;RJ+N$*RH"5H\(0 H#(TMD+_*S%4R0$ M&D# 4\3?4AJ8]97(5:2L/0!]HAK$=U%+<+S%TSE%_""P6+D$!XX(2IDG&L@44TIJO8SN. M,:;@S!I9&@"HRB8( Z&??CLJ"L$")-H_#T L2JV%+F"PB_[\R&M:RPM-F_ \ MS\% >K1$U"$RQ25]P3%]P<7\K%.$$*8(U3')TE]\UF$] MTW\-GH3GEX8QD,^@4"RA H#,S&-[U>'09-?RU=RX.9!."&,R2 1*N(.LC[(B3@E@@[]%9MKSE.JK_@%/.8V2J?EY4 WTY2]&8 $D %M MH0JJ%1@G0NS\@"#F1?M0A1!$H(HCQ>S5J 6RH Q.@!)60&4N0>USDD8:8'4. MP@OD7G=; />Q*Y<@@,N(.H%JP+ ( /Z'B'$P%->@#^PX Q$"11>X **$2'0 M /(O/Y"#'OZX3^J=1RS.H L8^ 3LN5I88 6X/#/5@ /> PLXX /D5.PS"S

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end GRAPHIC 53 comp_0009.gif IMAGE begin 644 comp_0009.gif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end GRAPHIC 54 comp_0010.gif IMAGE begin 644 comp_0010.gif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end GRAPHIC 55 comp_0012.gif IMAGE begin 644 comp_0012.gif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

    (E2D 0>9X)1MZDB $-B(*]X(4YQE&HJ("J-$T?G $I1 V M.L,;2-T$2((SV-G0[1X$F @.!,TR1)CP?=XJA%6_I,H.G",AC((#[$ .Y( 8 MA.365%\.!,TS2$ JQ( 'F&,/-)+9#1_V.8/)#9HN.4,?C$ J-(!,XH 8A$* MR5Y'=O[6KN$$!=S?V[P +^T &K$!X+F6&TB &.! #I3!^MS$! C+'_2*"L34 M+A*>6/;*-YZ7X>T Y%&%,WP .J%"^KA!EBD4!MC$7YZ '."!YDS "\AD%/1! M62@@CMB #F0C,GC%93Z# SR##(2A?+7!,+A-03K;H008,:#"!/@:*@!# ^B M3XK!LF3?!C3 LMB$M#7*,VB (<" *," 'QC0) \3F*8J"']@+CKP0LN1$;G@&(;).514<'SZ5((:'<1 B2R BL^P$!GC- M>;W< 9B()&1ZMP@+DPB%D MC V(Z$T@I0Q GBD4V!N80-S P-E1@$T,C3/XWDT,PP&^)BZJ0,[4J#/H6-_I MZ 4.0U7@(Z6LXWIV$OS0P%DE*08.#ANP0;IX!1YX'NA%'JR8@@C( *S@P'(& MJ$T@0@'DVDTX 0IVDW 0-!00$@& @?Q4KV"@H67U5L #H1 MJ2@LPP.T%RA83[A(@&WXY)X"@YO=A##,50Q,BK>XI!L8T";QS:XY@%M*0BYX MBT,M0QGPQ3(PP,\Y PE.#"D00OZ!I5.OH(('5.4!#9$S$,+C;$#)8$_;X0J M&H*K]H'4Z24-&-Y\A=6Q=,"EP("(?N/GW(0&5,4?G( *5$6@;4U( LH#=(D& M7,H"*%<'N,$S%-@9&-!&5877W80?!(T'7(JWT 4)Y$!@?:%R@<(J4-Y-K$'N MW00$!.@.C "VJ)O6@$#_H,*Q;( AD (#\,4;#)XA6**M6J(;G@4$_%PHH +? M;=0#!&@>ZF&^-!- 2;1%7'*H=XPL[KU,E*2,P$2( *G '*!HQ M/ 9],$++$ HC (#R%2\D-<)O%\#O5^N@< )V!D:LAH;E$$#'$M8_H$-) #- M$8("G/Z!'TS I8" "8P:&A+" [1!&3P E7Q _ZP"!.! 'T# I'QMV#9 <:UM MSBJ *$0=EF #/3!"0P *J19#U' @7K%">3,Y^5 'TB -$F=3H@! Q0"C.(( M*128M]" X7813I !!:BKGE$+ Q""XV)*Y$K Y%H MHP KE3)(0Q \(R !V@. M#*!A*B@ *1!#Z!IN"#Z E3( E4@ #+B!!G2,, 15,YP S8RC HQ(,$R #/3! M!&"7N=15%$0 "'A%GO5!#G IASD#UMY$6@E#L\6 JCP# ZR"'X".RIT CXP MHXR"S;4! R@2!,B!#MQB/S6;BSI* XS"HL0 UMI VPTN _[PV"(Y@P5, -.> MZO' KPZTVH+]R G,GS,]C@1,TMA"33UU5@.=@ $TR0ML ""1 QT@+1&8C <@ C@@0VD':,)PS-<$B#<;2Z2 M 1/WBPIT6JV-2!\ @.F\0:,M;BK85P_8&:[8!'K=!"BDL3.0&U]L6!2\@0- MBP48U!E, #MU#"%8 "=% )'"VE,^@!LL;@.M[A_ P !L;$_\B[^U;"8SC+\5 M!\L6HGH@V(0T MX\ !XL0AX "I8@D\+T. NG(]3W. 2@(P(TX?O$%"N\$?+(,?_,CS.4,PE($- M3(M1D56:YD(/M(''W80H %G+W<0H;.PPE,$Q\P0I^"*ZX80AX 9@$B(.4,N M8!XBG,(ST/,E_EQMR71(GP%? ,,:--"UZ(!R'5!5KLM=>84H."4A\(4P3'2 M@@+1$OX"CJ3"L1A"*I1!X[E758[(7?F,']" &+@D3A!"C<"T*/3 &S3T\)B" MZ9P%6*>C3H0"# *$#A):;U,OS!*,!=1Q-M'_1+64?T&330(.C M("##&XQ((4#+(=0(1&\-XZ$J3@""#<3U,A3"*>B &(S(,#Q 4Y\!#;@U*O1 M#OS<,*P!3>&(,#@T3H "5V-S0^X.3A2IH_R!;:#"QJ*".3IE(0"#,*#",\#( M SS#E Y?@!I"&^ (*.0D+CY#&\@ *!@"+C+5)8^GQ]:)P8CR<4P5=^]A*(^W M>&!R5=T)@.2*>K.WXEA%=8!->V^'3> !G<:W=BS#":RA;/Z0054L"N3NS0CB,R7DO^''0CDK 2<*D;'HC15DHQ>6\]]X4C:C$ M#;*@Q8>K)TYPI'_PC*C Q7ZLN+YL^'N#N-QHYVPX#8S;>+FTS*,)![^%L,>=6D^"G,E8WON.7$>#,H18^;N.* C%<\PQ^\BXA'>8P' M^84YQ5BL AGH@$K/N,^4>5 ,1%,-'"@WC'FL1V70SH3'!TU@N'S;^9WC>9[K M^9[S^5= %I][NG3HRI:3QH3+^?YWR@Z% ]QBS(2!6U5XRDZ:F_I363I6+$-6 M?OJMXWJNZ_JNVSFL7]6_*'AO'(A)2$9XHZS*(OIX P;8#,,;M$&6$T(9H.HP MG$%OF0)5CX#>$,61.\,9',LS**(4A M:,T.,&(_$>^%$8*@W?B^G_G?Y.#FX 0;W)N(U[B7KW?F35\J/(H0!P./ ,,.A IT"$.4Q0J+.T,9 +.^H *. M],%<<7O'%_S%)\F($(/)SWR7VTS,=SF8V\8RB(%MB/I.Y)$8L0'3Y$I8_'FI MKWJ!S/Z.9AR$F4 (=P?[FZ_Y>D@,A,& ##3 \#0#"7! #SP K 09&7# L83" MBJH /[F%38C!M/S! Q07#M3[3LA!XO[$S"2Q:I!!1?_$C"$:=N-V#KSX!HU& MPG:ZY9IS:TC1\*D+3XA5*)4!&]B-3^BP'QA"#!R 0:\%(N0ND.> DF5?Y?L$ M%C[.59!24*B<];R #$]'#^P:LZT+?GC H9!-EO\$*2Q #!R"!*UH7T!XFS?, M?,!Y5)7ZJ1_[TR/[>\R'Q(# NG=D([7!&L)N,( "G;:!YIS VS"6\1#.L[27 M*0@#(,C!XY#"&OC] :V!4W)),T B*KA362#"&O361NW !OZ,@MJMP4U#S@B\ MV2@ A 9@;@8Y,[C,3YMQ,&)XW;(6=.'&J&5MGS0:Q(54Q&"C,-E%50$7TF<%F@=A$ MWNCFS4>#A]H,VV!(:MZN<@M!Z/[CS,884V60ODR5-SAJ.:LI,CY-$=B;-RJE M+C.$5-CXFA2)O1"!"A@%5'@ =:7-)C.*:KL-IC7TFNV48-QXRA WE'N&$ #M M,L7 KE(CCR)4-LAAF&$F0*4//RQ433F*-"CL)6 D0,H49"2Y#9D^W) -/]RD M$J://J8SZ)4>7?D1R"!?"9+((H4T$LDA75$222.'[/&55IHT4I8I@6322B*? MS'+**K/T4LA77K*+3/HF,$4.,1::BPUGHNI CJ"<*6,'4&*P"1@&_#)H!!G* M8. 09R08 0<2)E#I#0K.$$$&@V38@(P)"NO 00P@T$&8!VY[--(=9I-J@TN= MZ4,",?Y( &$Z0B"8H ]3'(BA!PAP< :9#EX08X*3Z +&@1,Z8.LE21[ 008) M[FP %1D* .H!%738@(3%(#"(D FB[8!:&YP9@0Q!1>@!! R"PX&#,S H@RD* MVB!! V<0J>#A<3\MHUYG=+AS A!Z\ "#NQX8A@8&3B#0)@[(6&858*("1((H M3N @*@Q(J* 0-YTAH;#P/GT44HTQ(&.#1M<0P: >-(JA AEP:*"@X%;QP $: MA)'@I$R'(80!'')@X VI*'#Z@5-$D< "-U!I8*(11L"U+OX:+-B8@5'0>^"% M'29X]QD23B"#@I]">:",>6N2 8,=3JC;E G64*$"GX7#@8$15HE"4AD8$,69 M?,E0H5YD-MBAA[J=$6.#,S80XR9G1GF C!TVJ(F#$2H@1!@*<- ! [)> F4" M"@.7P(#F8IB B\912Q'T $:P$ % ML33!:B0@.6% (#)NT @$;B.!5/S!F.N5& 0J (.=K.$%I(AE5-I@3 F(@ PP.#(JXRGSI#AJ518-(@!335)%L7-N!@ 5#);ZD'[9R95EGJ,P@@WB# M#!YP6()B3&<\PP,0 $%' M73N,%9\S"HX2 UUE@%@*> H'#DA8MH:%V =TU"!R>/%P)_F39E#@!#&( 0C( M^I(>O"L7U=S(/VE0@?>^ )K&I7]G04.O#U"V M@2NBI(@J,+0.') ZN8B@DA)0"?& L8$1R'H$ GTH6X;1!CPT@&$;D.P$"CF, MM>9@62=H$P3F$X7D482%JRV2:9L4\--J2192&F$("6YP#I:0M1%?(<2Y)*;7 MDJD9$/Z ZRCTQ3V*5$"'P0D&")K1@9-0 !C":$ =28,28"@7BLZ*@Q\D(Y@A-8.#! MF#!L7'CD"DM\C0NY:(?6"U"<%4&A0@X;.$HN7!:54\A! 8&Z"^0#%1R]&H3' MSK" 8NXL9%T;L"YC,@4$NG(&8S;9)H ['QOTY?1U86ON;_ #/&\-4X*F@M_X MM%B*[RL,-1ND#]B2@!*!D943L#!C0X"C MN*(*1H 4#XSB#^KV:"%!Q #)VD08'SJGI\XI!F0H&A7X$494@J'1*.2KZHP7 MC#-: (+;3+K5#(("\& 83@$84NIT[D1%/F*::" &L@\8PN,9GF$90.$%*L"C M H,4&V$_?)$@VX,PF,@BT5$C@)JZT M*@Y("*Y)L%"#)$Z%M+"#F,3B+LXN[(Q9RB"LC#,&30@8(;ADV;J*6R"ZU0@&)!A$#$PIAB"U4"AK?[@GY!A M OI(!B#@(VA &,DL9 2E+N0@ 1#"8O!@7'2 GCI@5@K%KICB =B"#6()!APK M;_K, ?ZH#UH.@2&=P0^2!P)J001&@1 H("K&0 2:@=5.H0/&3%#"QA0,X" 10>0"7^@)G^2E/*Z@%RH:)ARW4DB*> M$2G\P "6@1 D("K.0-U>H@,RC5?80GN6X0P.,9CT+#C^P #T AAPH!@]2K+( M ->0@:,*5PH0P'JX@!8YXV>AT>XD+2FD L_R#6ID.(RZS4WJ+-$40QG YTX MH 0-@EHV8 ,XB3(2:Q0\ 1J20;83S,JP'9.8M! 0 5?POX4. !DYB@0,*!@ M'",&KN,/^@@ID>(/L!,#S@,5,$ C3L$#0&:<*.(0'& -&L44TA,#P*P9NF\V()0BR@ # MC%,D^H"H*.(41D CTZ;M). $S/I>L /)\(-*L #[%-CQOYI!]83&$!@(H#! R:"#2J /SD'Q$Q #*)@ MC/Y@ CAR!$2A7#I@ U2@&5!!3VP"!["+#.:H!QAF%42@ Q)G-G!@ _@3*1!! M/)&4*6Q&#,1@C$Y B9H!!S" TQ E=8K!Y!A%1W) S[B3L4%K@SB3D<@AY1) M _1M@9;A5YV!#1R+!$[B3OG3\ R"#R++8!!*.Q"&%*!G2#@%)!!8G,A M+@["9?YR\QE084"QA: M5AB(@;M286?+9!EH-DD1D/'(9!A2-H9D-H92+C>'06+EXF1WI&D_1058AV)? M:QFLB6G15121H8!J5A_+UDW8XQE>XFCE8FG=! 9V%FI!0I6& 15\YE*==AG8 MPVD=J6K/QVB[5BZ6@6,I0AB4HV\'5W#1#W$-8C1P4W+L@FIC*!>*UB8F5RS& M)%."X7#M DH$5DN(Q L/5DD*EC85]DM.US5'-TD&5G4=UFQCURY0P4DQ3D]E M%W=S5W=WEW=[UW=_-W?G%GAM(@? ;'B/ETPBUVR#(4"0U_XNA-=YHU=Z8U=F M=?!O+VL+83-A$99['\Y*O!!+6-=[4PMUK01ZI_?BE!=]UY=]V]=]WQ=YF^%\ MX9=^Z]=^[Q=]Y[8UN[>#O(1AMW>S_C=[OQ> A61^\1>!$QCC%)B!$_B &QB" M(UB")QA@^;=U(XYAQ3=U+5B#6^B!*1B$G?>#0YB$2WAX1]B$4UB%R>1S"TYA ME22#;9,U W@V:;A[8QA(4-B1D,(A@!>YR.1K(W@92*%E#;>(Q5 I,P,95@'G MXB^9@($00"%QQP(_<&XA(O!AD2%Q,QYAWJZ)F M+1WB&<2X=Z\7ME*A97(A_E"# MC=D7C<70 \50D(\7"L'02@38@@FXDFOXD@>X85%XIS1BPLYW;N676<+&1I4I M+RG"$.;(R7)W!Y;B@)]A!,Z$(H(!4XIJ/<4P%S9 D"@ 5H@.,A 32@ BPE M;):!!AY 7'#1+F! C"@ 2B@8YX! X;UXDC 05]K D[!% S392/H)5Z"\%:Y M3#ZJ3()##N")PMB@R\8$:H5!!SYBHI[W8?N@R]Y8*DC/LIHA.&* =6#(#]3E MXE!A HY8265#&& .#N*%-Q&,=Y ,? MAOQ@C.B-*;I&,O 4; $7)#XO-Z%V M <59+OYT *5!:3S&:%Z)H:"0=Q:>GA]Q#4I>>!J&(8Y MBWQELX-SFG0U6:B/! QA5PR#HPWHJ2%>JX_+I&1;YR4N;P+71?SD<8'EPK4@ M(,?Z&(9P#V=/H0%J@@3:1!355P*(:AF,Q1EP0"/F[X=I( <-PC)KUTUB@P&R MPL[ *Y3DN=@09@VOXFFKIFS[>1G?_I'N-N%)YE[<=I)1I@4*D "K 44:-D-@)- @M$# MHF\'WH $+."2O"+=3H LSJ"JN$\$.*<,F"XH(@ ')C '1L #U,44HJ /-*!# M3D #=F 'GF(8YFD$LB(*&L"UH\4X5=D@ J$^:< A3J !2"" D.$$'F $)AP' M<.#3')?"%>,E &8*((4*DM$^?H " 0TA5%C&Z 4A*-!3Z " -H42, #5.#: M#*(-?B*^#26*),$#.*!02<&=C3DR=, 4^L!\@$$%AF8$VD 8B-.QSAD$ CY%MA2$ D$(%AD/Z!!HQ3B4S!5T@ *5Z@ >X##PS!$ A*% KC M%'P%R=VD@CR@O@UB%!J@&22!_7; ?$A&BVF@ T"@QG0@*C;C!&X0'T%5VC9Z@ .00F;^"@*.8@!D #HX M( <(4P#,QP,8!A0HP&[5ARGN11C&D\+:4 01AV( 'B#Z+>AC(@2E$G"P<08@#\ *P_+)9 0=D;5W&A01DBA0F( (AH V687J6 1%P\6^8ZG!F90)V'?XC-=QU*N C@H-4 MI"(PEL$!DN0(TMV]O[JE:O+F#-KWLRYL^?.EC^+!KTY].C3G"V; M1EV:=>:-DR6[(>ALQ)]4$C:&FJ 262I$$YY"D+L,0K V(C@V,^2,Q!MGPH2- M&L.[C$EG&^707B;,%" 'JTXY0.;,U$V.MH$Q 4J%00VSBHP']6@S*BB/T>4 MX2C, 3!@$A"CG#.)#=/VW4@R.01:%!&+HD,,.4$GP&"$0P/;8 M, TLQI$$H(R82A\5G )** >(HI(S*IPQ5XG.2( *'AYPM,P#IN1B%B%2E4'5 M"6T$\P!^'KBQBH;.%*)!;ZA(@H&,$H3RH@H]Z.A ,'Y41-0#P/A! HB2M$9+X1U MQC(,&"(**A6(45PS=7+T!D$O8.@,#!CB((,S?>@Y2EPX[$76D3^1TL$RS^CD MC!BT.7.(AJBH<,(I+X 2PP@FD!?#=1Q-0 A';7#05"%YC>6,(15 %8$IH)#2 MHB$4/ :,?QR=4$9_SYPR 7[.!%(M5%)MI&TS#O!$0BJC#'* ,)$U,]1*.-C M$0UB@,(C**8H8,@P1R96%+UC">-J'QTX@TQW;CP@## /(#8!>1OEL)<&=CJC M@2&@\+8F3V/)I]($N?3@DS.I-/!,#R"@(DHA!L 9V\R2K?ZVVF4WNR*+9Z'M MC)K/KJ666-FFH>TOS3;!QY0*6+S=@HY(L5]-CA,F^2 M,$AS;IC7S$HOM($*!"L9(E4J') P&Y56;I2DV3J)^6+Y)Y@">N$[F/(V47$# M"+R*P'42!#('! B [LK0%ZP4$4 M0%&Y96" .<[P Z;FM*DLY>!3^>L!#0P7#.%Q)!<3(&!\3O &,4! !L# 0T6* M @A#68H,?R!(UV TEHVTRD5025@%D*4#93'+&6Z 0.\,-XQ!),Q# &*5,VBP MEPX08@W*VL@?& #'(!P1_:<#)ZP=%@.T&8,]B 1JTH0)P$L$?W' RCI2J*<]K"BC^8"S) M.7(O%/#+!% A TVY:1DXV( (=:!&J9GR)Z$Q#=&2E"DSWB> #X3 ML!)66$<@!LC$8\%@ #'Z,(*_ $^:PC $D[Y2$PEH[@5D* \(:!!50GC,(L^0 M@X@VX"!I-H \H@#!"83A!Q-0!6"IX @%*^<,'/"R-@2! ?X'8Q"%MN[%JC\9 MED(Y8@@'@ L09R #&2! \HIX*@GV,M&D)$C-OB$!F/06%HTEA)G1"%A&$ 6 M&ODJ%40PR2)!?!%'@BH79W1@#: Z 0EHM!)*JA5['(G(CIQ!!JH0Y2#Q@@!S M-H(#'7#$!O[K$%\-] <2F(!&',G!'QT"JJ(:8"< (JYQ65KW2%:N0; MM/P"+;]/NZ5[.<(&8]&I#^I;4P,8@P%"D$$")_"GV 33!4,@@,FL4HS'E & M0+1 :-80W)@0X@#[ <$+R"$#OX6P(;/_604%.@ #"H@$1U,X \X>(#F-K ! M5(BD#8"@0$HV J = $("^S$% R['$1#!H#91#694=S !0.189AP9A )40 8/ M/ !X.4# "41 @Z@-C$;^.X"]D*,"93V)\,P@.T:$#XZ.P,$MAD!%S5H0%]> .)@"*!4%.@(J@0 .?*(($^]* !_UG ,II! @V<8 1# M\JT^X?Y(A@5(Y 0>"$2QG9$+!T0!#QQ8 'D>(V&.N/ -,)# &O,BHU%4 $@/ M@0"6G3&(!KQA#1!(& 2&90.>$B("'%%!!_Z@@F;Y09D_ <8!1M ''$B /,^@ M -V $N2?O"#=*C!64(6Q# K$("J.D>MCFJ& 83U(63'X5 LX\(?%%:49&.#B M06/@$V%0^ U/JH"J::" YP ]80.2P9,ED+$;;XH#@5"!5&CP9!I, \R& I MBJ.#/H!@),\8]*H7.N"9 7B6<(]E*N?+2J7Q3#2M"$W>9=&*N*NRO33;BD91 M@8R,#2,0V)%##O[5!F$,XG)_@-"072,JR+"34>2 !NS,N!AH@-ME_"%N/P$%&98A MB9TLR_B#H"I @3)[&32>(Z1P@_3=L 9$Z.@-**51,_JP;QW]8=_?YT@@#+0, M[+\!^,>'RAK'#YTQT$ 4Y/2]#_N0"XX@HK1R@ $A)"$75.R #:: +!F4 ^3$ M!L) ",NW3&2 >QQA"I)@")A6%&\P

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

    MP=. M4 BX !22!#8YG^'6!-(!FX5]3<913Q_@R_*T7;ZYVU5TG^(:%I%(@MT@#"V MX ATX/Y&=$ )C$!H5/ (/<$*:( &K# 4)+:*LC #!M!KM7 'WR(V"O !#>8$ MFR V3L '@<$(@N (5G"*KF 'WR(+L% ,!4$+CG '#.,(E3 +K- LF5()=] V MLB (>0 G Z&%=B(+E- (X?B,E*!,C5 )P KW @7@=0\ E0YP PQ@('M$$&IR'JX""\F6 M MJD$=JT$'KE7-3D"H)T0<,%-G/))G4$(6KU&MJ4-AQ$A6Q3"^AD-8C#"T[0 M2@E5$;2P4$I5E]N4)GG9$XC31GK5,W\Y/-H436)7DZ&)$HU(B4:!$6F7DJE) M?T766AXEFD&V-7D@ %;0AAEP#'-P NP!\>P @K "I1P?%8P 'L@:V@@G)=R M ^PH%K:P!ZH&3+WP #6@#&E0? PP \HP!ZY7 P;@"JW&""' #A5"1&T$W99 M4;"1F1O$3NDI"RR7'0IA=VZD-?[HR38;44=L@QU]]))M=!T.,9*O>8C.4TG> MTV1G-R^KJ9IJI!$T": _U"><\Q@U\ 2(E9N/X)42H!AD4P,*L (N, -W, ,/ MH";P%&&B50,54 ,24 *\$)W328(+= QV* @U &\L A4T0HK$ $'<(1*,8FM M92]% 8$"@98744,C=%'O22X;9$?A1F0'\9\-"G\">E&^\:/$<7\;14E ZF1; M^J3E)AP,*J4M! N 50!,H()TH$4?@" WYQES@&>RN0>/X (""0"U)P!Y@)5S M4 D!P .N $PL:F'9:0D(L@DL@ "OT)N\,!][(*$*<@&\4*0)BCU.:CSPE!=X MU*3 8_XN^TDOH#FF)=D[5UJI[D:I"!J3GII_&2&FH5H]-U$+=' !#6 !CT ' M#U )B\ >E ##< Z_3$+750I6?,$#6"=[1,BF]!%!^<"BWD 5F!?E% )%= M$I 'O7 #&]"'$< (=; L&7 'OE [6D*J>=,:A(E'Q^$::G-'%%6EI>H0Q>"J M-6FE22J3ZAI;3.80.M1NXF:J$=*J\VHX:_-6?>DT=YD"#4 +#Z<3:<,*!)@V M8R$0$.(SL#!:!H80/C$+"ZM62I.6>IDMM)!4Y;HW)6L7=_$US:2OF@J?]DFR M&Y$N DN29J>(0?HJ+VL0J;JJ)DMN9A1E,BM*0Z&>X0$H;OY4"W/ !(M11TM! MM-9Q5'ASKS*Y01$DB3?$I"X9)< Q"YFJ6G810B&DDB0;I4 [92?YKU9;H-IS MI3B;L_"ZKWG#;@%+MG)3"^32-]I1,S\VE_>9H!$T?SR;?PIQ).'QI4G6,EDR M//9J2:IIB',[I9-HFJ>JJN2SLY)KJ0@AMXX+,'=!'AQ1GY7+I3MA*+"%DG0Q MI!F;)9$[32J;KE8F'K)3LQ'Q/55+6IK[N$<3NH"+?S8$LYGT*L6C4:5[))EK MN^U2MV8K'$.AGRGI"7A5?SO[06"+/<OD;['D505)<'D8:7=)@N3 M"J\_2K)(TL#IAKR*FZ\*C)(I@Z"Y6Q>TVS<9Q, C7#AU&V[F$D*+5,)N%Q*_ MD\!M"[4: 3W7D9>;5!>PX$'">[E)K,1(;#0"+,.XM3;DNK*J";[@X\,FC*4Z MC$'L^\1+LJF\P;3L6L'S"Q&TL[S@@Y[F4;V:>,8(X9X2\L%,_+M%UKA=#,7R MBW]QC,+ZZ[82L<)JQ\5V'!U/VQOY>\4':L $<7CIN[9>PD&U$XE!'+Y9W+O; M$QN"#/Z;)9S#=R/'WWO"BXR2'1'(F.P<8;8];6RIC3P+'OS'WU:OH'M1 M6RN[VE&^BSC&^^K$INQ0HTK&!JJ^MXR[?K#LHB:L7C:S-<\+-Y^R@>(S%O^P;XYR[U S'[ RU1V+._%PF /C/ M:*O-Y DF BU!23%)$!Q;;0>[^ZS0+12Y[FI_Y&S,2WS,K(F]"]Q1/[O1VX:O M6OQVA9)&E+I:6>+.[VG#X7S)*2U)FWPWCGBV#;VXD>B[/OXMN0F-TTS2PVJD M9*T\Q%8L355LS!V$-U_[B"@LPD4-1#HMRY,,REO]S4A]N;E,U%8M'0QM%Q1< MTD4S'./3$8_,GRW-28!$N"/]DDSZQJK%M,,LQ4DJ.Y*HT6)=.']KP!ZMH-JK MOE2,Q&'MU\_QEY4LQ.]L+SEDGTX*T;WA&A>TJ48JN*AK/)I4%[\CNU+2/"J# MLE RVL1\UF#3UXD]-SPMTM)W/3TQI+JM?4G^+->%G<^6S$.0 MB]CPC1NW ."W4 NU$. #3N $+N '3N B6^ B.^ !GN &;N 1#N$3/N"V@. & M[@O-H. (#N 8#N >+N*W@ NW8 L%CN(1?N"WX. &CN$/7@L,KN(A?@O-D. MWN("3N,J+N&':>(J?N(GON 9[N,Z[N,BWN,/+N#'N9?#N9D3N9<8.9DG@5CSN5;H 5=@.9I_N9R M_N5K3N=MO@5LSN9<'N9[WN9?S@5A,.=B?N=:X.:$3N9C[N>%?NARC@6?@.7Q M7:[@//['4PS/C@VW!@HH]&?;D6X22> #0A $03 $I#X$I4[JHSX$0H#J/G#J MI^[JI8[JIV[J0^#JHS[JL4[KLV[JN([K1.#KNF[KM.[KLM[KOI[JJ2[KJ([L MJH[KQL[LO@[LSV[JNB[LRS[LO][LT<[LT7[LK>[LX?[LJ"X$/A )GEXX]HQ! M]1+"EV[:^4WEE4C2 WWEZ#X323 $1*#O^Z[O1<#O^Y[O_TX$_M[O C_P!V_P M!(_P ^_O!._P J_P!?_O#5_P11#Q_&[Q$D_Q%U_Q%1_P&+_O'-_Q!Y_Q(2_Q M)+_P"-_P);_P'%\$0W )]DXW@(W?V ,<$NW'/BW83-V2^_Y2[S(/$_AN\$-/ M]$5O]$>/]$FO]$O/]$WO]$]O]##O#)T.]+6Q\SM$Z>&VUS#=R2"\9#]?]2V! M[R(/]65O]F>/]FFO]F9?!$$0\V&_N9->S4$M[_-^T?1]T/%.]>@N]&OO]W\/ M^(&O]!_O](0O\&X/]YN[POV:]5Y]JN9&FBJS]Y[>]U'?](8O^)G?[YBO^9V/ M]&W_]HG?+OSZR2!=N3C/\RW)V5 V^9&>!$_/^4H?!/_.^:?N^?\^^[A_]+;/ M]+%_^TB/^*(_^OL=N%,P[T:0!$@@ M\-C_^_J._=JO[T=0_4=P!+%?!/[DW_O9O_:^__2(W_K/C]M)&LMXS_SW;=,C MKR7E) ;CS23M=&BRX1#L#A+Y /C39@YQ;$YF362QP,5',&&Q M79LS9?XBKD'W)5[\9]"\R94O9]YO6N<*-798M=^M>JVLV6 M!=M]N]97<9VO9]_>/=&]QN7W[$C3A\+D"N67^RKE0M-# HJ"=@T MN8(F(HQYQHM!MY!5KDE$2X2+9!()HB(JZ:0O*+G>M/9:;)%*4TVWO!PK33+! M"_?,[,@=+[SSK*LV6W;;K2M.*:,U+HA!ITA&ER.OD&*+9G;QP;%"!\MSSV** MF0*+58W ] LMCIAH"BFF&,F($<, (B@IQT)I,@(DXB*"ZF(%4+9["PV0O1P$#1&4Z*8*:95CWJA(LK,I+6."N1 M<_=IJ+.LQ5QTM]N6.C.I/O>LJ_ZU?FO=J,,66Z@D,EL:)GDEJF_$FK!0N1-F MBFF,T!%;S?4*9I+Y91=//#%"BD&=836A(SQAQI.1CF!T"Q_J=NR(T$:#:)=G MD/#!AY&N2.;>76+A9(IF8@F"4DZ"F.297PHJ]9E,4B-B)B\4U2(());1!;9? M3/5B5&VSBBX..KOQ9>X.=+HIE1 M"1O4"!^,D1O@$;DH M4C="DF,2VV."*1+7[PJ-0@&-4"B%PI=H;Q$9.8Q!DM M#,QC1-A%,ZYP!"PDHQE'^,4QBN #+' !-J*CE":DT+LEA(%4/[@$,XBA"1_T MZ0N_2O[$#W[%H]@D9 N)0$(0=,$,I9WM=YY1F].L=T,<$@4ZT&->]*S2G:N! MZSO309Z8QM6U<1TQ/&O*81.WA#TY96]*!8'%8O[7-V>T;%!%F(G@1G6$/BEC M),ZJE29J-86!B$87G1B5_ABG"(/8K!G,. :I4H(JH=2D3_>B"1),,CJ@&8%[ MG$ 5&"!(D@#BK":.T<4<>?7'((AF%[G*Q-)FZ).F.5&3-^3A$+5&E6V!LH<^ MK%I7QN4=K*6K:]3;9"N7 T4I%N<*8+A"2(J &BQ$D(MA6(@6DC4%,%A)"HF8 M1(8@$@9-* (E$M'")<(@!3#\#0S^F:41@G"%27@A"6!(@OY$N! &<"(-(3'[ MT>R*$(8M'#-#4TA$(K:)QD])D A' ,,4GL4%3'S!/^=,YT"2D A-!#.6Q,FD M*PT:-:Z "7I<%",W@66 _6+#S(3!(]Z!CB_&6EE MGB69D:(T.)S9#$F%TXI2O+XD*K22VI9!@O5 M,)')JGUE+-F^FE?(1E:RDZ4L1/ZNU%C,.L=;A56+18M(RL-^EI1<":W5OK38 MS/95JY6=$VM=*]G'3K:@J:4M7A1*6%.*5GG+F^HG=RL=I79K/-:Y:&T;6S:) MQ/:URV5N55N]^D !:Q$@WE?O4K5:V5=JD*!2]^6SE>\[8V MBI7M#$\_*E,(FZW! UE(32UR4\V,M C)D(US@3=; X>X*!%-Z+=T2\3]/A6J MWD5L@47<1 1[N#AV0F=$C/!-_T $"\],R1&XL(67VF8+8;!G0J80!BQ,*FE7 MR-"-B_X<,Z2%Q A7^!L7J-D,74@!KS(FZ&5?_&62;#9,MVT>:?'(.ZHA&I8LB'&%SJ +)H$:"B$%?O8MD&(SP#$]0R!G:)/8W MC7 O(DS!"T48$2:D,"HNB 9(-/F!HE"6Q23 ,9@F00)EJ33?>=EWUN$E\XFK M6R8!_W<[:'8U$85H%EFO.X>UODC:_)T]K_[S$\;X]?:2$(S/S/+1'X)=M*QG"ESPD,DO[XPI%",61/ (%\*..6:0/>'.\$02$B0%$E9Z MV4%(QK \/?2WQOSPM54JBT?9\_[ NX+>P'<>54W][C+G>_?$$SKN-Y*:8DS" M&&$8 B=(4@PC)4(NR_A"S!C^"?]H7]+=9Q9),!$$+RP#"S[@Q"_F:8Q)A*8T MSE#$-9OA!0@FHU1>8 :>G<\TW5N^S)J:P?L]IWHUU,^ 0P; MH9.SQ:.3T;$2A%@,(]@+QG"Z%NJ-(["FGR@"*?A Q."5N0N)(["2P#"KLZG MOD"W (Q QO*][4H3I!(3[^HO[)JW4_,*PZ-!:VF^R(+!G>")B##"_^.R&11" MK&HWXO,Y=_M!K3@E\V"QP5) _PY)R2>@UA", Q##P.Q+N0K+?RMX%) WX,W M%5M M/X(PC+D$B*T#3&L0SN4CR:,0XSB03%SBRLLLS$+/M]JB\.ZMZJ 0SW, MDO&B,R7TBSOTL$8LCDQ"Q$0L'K9HJC9TGC74P4RLPM[B+0#+BK^:PNFI1*B9 MPUB*Q$=<1;HS1:-*C^?Q&C4\0#<4OEKDEB6B1%=IK*^BP/[(:L>APD-6A"Z* MQ*%-O$$CPL>OJ#E0W$)DU+M8F\B/U(LA0"L7) (C,*NTP@V:#"N-B$FU9"N83$JDA @A4,J@=$J>C$JHG$J(>,FE?,JKE,JL MI$J?M,:6)!X"[,$!4TB4;)Y[7,@?/,MO<<:O;(Z"V06XC$NYC,MBF$N[5)"Y MK,NZE$N]O,N]O$O ]$O!Q,O +$S#/$S$-,R_3$S&3$Q,:\L;,D91K#= E,*< M"Z)66#.(I,?J8$G(_$S0A$PRN4IM%/^0. M ^50J'K/R;S-WPNE_#Q1&[U1HX+/Y!DB[T2L!ES.;JE1'!U2(G4B&$T7X4S2 M#-71%(/-(GU2*#VH'N5.-OO.6PRB4!32*-U2+LT6"_U/)@W3,"71+BU3,TT. M+53 0OX4TP&5SB8]Q#.-4SF]%G-!T*IH!1<5+3MUA3WE4[;HT^8!5"5%B^#D M.4$55*HATSE=5$8]BEJ0A5F8!5F0A5J@A4B%5$FE!4C%5%G0U$C]5%"5U$N] M5$P%U5(=U5#]5$OEU%!EU5%U55&=!4M%U5.-U5+=5%5U55J8U53]U%K]55KU MU6"-U5I0U$8]UF-]!&5=5F9M5F:E!&=MUDJ(UFF-5FN]5F>M5FS=5FW=5FE5 MUFKMUFB%UFN%A&P55V]E5JL*AE5 A5S(!6! A7A=!7I]5WJ]5WS%5W?-A7W- MUWK%5WX-6%3X5WN5UX'UUWQ]UUSX5X0%6'@UV'I]V'F-V/Z&C=B O5B$7=A5 M6%A^G=AWC==YA5A_M=>*)=F,E5AWW5B%Y==V!0:+-=F*O=>55=B6;5B8C5E_ ME5>!5J$U=F===JD75BHC=J$ M[5FB35IW/=B%!=F!%5FK#=I[W5>N?=>M!=BSI=B2M5>D!=B(]=JWA5BP=5AZ M10,G<((HN-N\M8*[O5LKX%N\[5O!=0+ Q=O"[=LH.%R_#5R^/=R_%5S%U=O! M7=R[M=N^M5S!S5O)S5S(W5S/G5S%U5S,G5S$)=W&]5LJ(%S(I0(JF+2B^(,S M:(,V8 ,VF%W:M5WX"U>X.U=V97=-=C=V[7= MVAW>W"W>YYU>X!5>ZXW>W&W>W_5=ZGW>X/5>Z]5=XKU>Z"5?[ZW>[#U>]&W> MY5U>Y67>W6U?W6U?[#7?\9U?YN7>^WU?[>5>ZLW?_;U>]V5?WGW?ZM7?[L5? M]RW@VQW@^DW@ /[?_OW>XEW>\H5@!R;@"09@ :;@ I;>[!5?^$5>#I9@XUU@ M\$U>^T5@#3Y?\DW?!!9?%@9>6Z %6[AA'*YA&\[A&]YA'>9A(.;A71UB'\[A M(:[A'O[A(-;A(UYB)][5'CYB&VYB(F9B(JYB*W;B)X[B'9X%(RYB'#969!UC M.2430_[M#D.]4S[-"@0%43P]T)T[T#VU4T/5.36FXSN%XP,]T *MCCIV8_F\ MTSY%4/.88ZQ(8ZV@8T 63SSEN3C&TS6.9#7N8SLESN%9%TPN";!Y!I+(Y$XF M"4[^9*'@Y$O6Y)((Y;HS95!>95&N%K!QY:'PY%0695:6Y5)69>J!95JV955V MAE#69:*XY75!Y5GF95HNYEXV9E_N962F9516YE?>Y606BF$^9F!69F(&YF:> M96Z&9FJ69E;NYFD>YV5N97+.Y6!.9W$.9VQ6YUC^9G#FYEE^9ERVYF,V9VF. MXQ_:"C4SS=\D#SDV++C8T^[RI.ALT(,DBTOD.=(BT"C44OXRCFB))HE)#0]( M;N0SR<&$S$P#U<;M/&1$A4\[K@YY\\2R$.-3-BYBOJ&5GFB)M@XPG@4$Y.>J MD84;ICF=Z^@,38^_2H\;YCM6.Y/6Y&.'@FB7KHN6=FF4[L+R$(0[R(,\V(,[ M> 0M%$^P(&2.WH,\*%2J*$^RP%,2R\Q%N .O!B5$A:ALI.F1[B$%I,1<.(2D M)@IA (7F( :Z3HI0P(.DE@1D<(YED(-1:")0Z&ND6 908*5G2&QB!@93$(IE M, 77E32B 5AJ M0((:AH.R2R(7 3HYE0(2)7 9)2&I2.(4MT6RB, 73?HIF M4&RA0 92B&QG, 5@..7A4>VZ*/[MH3"%QB8)PXYKDC"$52@)8+CKO B%8; 6 MU,R 1@ 4@ & "7LC,/UWH24V/H>;GA,)N.Z;N%!" "& %V\Q,2:5NG*[/ MKI94/\7N\&R%2,T ]@$$@,M3LS3W5Q)J7@! >AL9\B!-RAG9] !-W &4'B MY@@%!S@*N0"%!8@"5 Z$&/#E!^#OY3B!"J#KI5Z.9<" P%XL4W" EI8$"=B M#<" 7" )'*@ $D<%25,!$CB!21.%'.#F9\ 4:"+9L" 4.!F"*!K3G:#$U". M5&@ S*Z+(:]LDA"&$:AM%9AQ+=D 1'AG&1"#IUB&#L" #9 /R")/Y@ #YB M/R ),OX8 0^X\660@>3^9!J@;YO>A$J051"U!3Z=FDVP MA1!0@$F/'ACUZ-4,+.)"Q%S8 #E/91* 6 M=KDX!6EW!E1 AE&8 *) !18G"3< 5-V PZ0M DP!6$8]VGO;:) AFH7BE2H M[4^N[&>8@"@GB8$UY64@;&C0(4[ M=X:&CVRYJ.S(?NQ)"^55$ 93D(!L=H8=P %G$(9QV=X8+'^6$=W>A&(936)?'GGAQEPM4 M4/E5R'FB. 6CYW:IG_9A 8)B.Q5>(#&A@$R"'A,QOET1O**_^1E0 5.!@9[ M?_>?_V2)!V52[GFCCU>B" 4,6(9E (;*/H4%H&M0.(!<$ 8)<(8^$/0S:/:A M2&R26(5Y_V9X%0IA& 77?8:?;VP<<'+?KGE3V&0/:("P=P9 V("2\'A.MGS; MIOC8'N7*/H2MEVR2R(7'UQ)$__X Z"$8^@%7I#4&V !<@ 0>B%-' )W" M.;@!"Z@!!8B .[#]#Y!OGKZ!!CB #%@$5[" !5@ #?AT*,C^!]@#1E@ )^B% M%@CO2G@ *)"%%,A^#6@$6Z@!"V""!3!7"S" %- !9#OABSH=P-VDVY.@' E M<"#!@@8/%GS5S!G#A@V'"7/H<(T)4P^6.9/30$(99\\R-H#09M2$'!X>_&&8 M8\,($A$;DMI@ H,<9Z1 F$3I44:%$3$P.!1VP@.'%\Y&27C0 N/1"0]@"-M M@P2$'0QW;! QXN5"'#A.5. S)E0$!QP.#-%H@>$85$63$@YM"@R9SAZ8" # MS .."OX@^HB T,-9LQ@B2(S 2 ('U1P,_V 046&0,V0JS*)M:&K$#@X2SCS& M0$(#*&=]8,#PX S$*&>!,(S D-(N!1$\F3I4\2=4:884 C%;$SH[>P/#&Z% @&\[TT)$*7\W(4!2UR9 88>39@ HA=3FC@_X*3Y)0QC! &9(8 M"+@U% 49SM! (@@A,A3,"#UX(,%@IF&PGR'.B#$F*1AP $,'@RTT3 ?.G*%" M#!5L,!9#SV#0AP/C]:$!0VW AL$HR!1*5@?"0+;?=F3@($(,43FPU0N'V$6B M!\$PEZJJJ[+*T"L#R?*! 1EH8$$-O3P! !2"/+# *VH0L$ (C:P00 HW''# M#2L X 0OK=C"! W+-+ INDH8 &>[3BRBR"'/ $*Q!$L,D"&LP200""W % M'FD<< $&!QC.",7UD!R=P!@;P<((WB,$/J'@#5YP!@QX HP$8V<'8 M/C(, XRI>MMQCC/\L %GQ M%>@(*A0 LC0QH!D[J)\S. "RCSQ# J@H P6J MR"('C,6"SO" &]9S11+J&& -3!#@&X02]LP8("/*(7#[! +QA!@/X:\.(5LK# UQQ MC#0 P ZN2$"]$J9*1]0!"KV2!0L64 <+6 *-3C )EZQB#G,X ?Z,4*!% ' M93RB "S@!2\^<*V'-P 8_%!05)QO>R3P@H7PV M9!EJ8P@H3H:'IS5$#BI+XWW2B(H3G* /ZUL &IU!@L,Q5!@2$(,;G$:"7$ M-Q4HV0/NXXQ0].P$]23%!#XB ZLL8W_. $8?U@"!.DK@>1)811M&\"1A2)2E M?2#!GSYBBIX&K:42\,,:WF 4_[XH6CM6X4;G+J0$<@!!B!B !#?#2PRLL84H%1]" SP* ;@C1&S%<400X)!+6 M4H&#/H@"!J#@0 ZPUI#Q\M #9%A=FMK"$!F@91F&**MJ:- #8K"0(31 RT*" MT;,<./[&+A3VR&"=$8$W$*("1G3,0M+S!]6<8$@*=@-5[;*SF(4K(F"!5_!B#@"@@QT , =;S.*3CI#% S)@ M"T&H +$ M#,<9+QC30CZR:?Q\#M1SE($?VN '4,#0$ _P@QM / R2+$04D=O QFPB8[(\ M(!<,&47/G"817W/4&4%%!0EBP.I3NY4$$K)NX\H@!S?\(?X5L&Y(!4IC.X9\ MSSU#L@D98S 8B0(C<#L Q0N.EU2/2" 79;@2#(D! 6>[(1"MP7;D/J("-KQ! M-FW P]C>X%2&J/$,.\3("=J@ I2>8@)@\LA"EG@E",S)(Q H&4. ,8)A5& 8 MJ!"Q8$N#BC.,P $-A-X./U)M44! !Z"(P9@8V :L800#!;RL,S+;7X 9"U-4T17-#7-H@!T(\XP_2=<8'JGLR4$0 !Y)P<,TEX>Z(H$*\Y-V. M9DDA!J")2.$-^4BLQ;L6& !K3!7 I[@ M" 44@!KP@@,\0"\\@@$LTR8A);1M/@7$,**3" O@1#C2 6U6 A(@!EW!.@C# S+&'>SA>*%B6#) !*&0& M&WCB,"A Q$U (!B"\#B#&S@*#5"' Y"*9@W&1S3.\-F%ZW&838F! @PAQYE" MIL' SZP'1;H!4'B%92&"/F4A*,B'&W <].ED0TB?!N@9D7D+)?CD A2 $QP# M&@ ^$79 %1? U3 ^04 *K7"+%1"!AC AB LT!"F*V?*]@"'1@ V1 !"Q M)=A""@A 'E#9 039#0S UA3!M@+4\X"+:1! 0C T2 E0"HQ&,!G93-ODE M8&)@0BC$JCC?1&($1HA!Y)3! ?[$($,\IA^4@@_*GK!Q C@@$XT1!],CP>H M!LI]!$XY0S!,P"IV0 5,S%7%P M4@ 2]054U!"@H@ P\@^5(',9D9@ZLFCU5 M S(0!Z>8SHZ3L6XU020BBG\IFNF@C.,0&"!HZ91QS(" R$(!F-L #%(0#=" MP'CH0 7TP 2 C'6] S@)D.8@@.0H0;4S0Y,P Y0P'*DS)- @$'N0 7"8\, ME!#?3<#8$((&"!@&L):JG0!5S-L.Q(>7%B$)-*(#*# ,%Q, .R$!LZ8!Q] $$[*!@/$D2V85\T( -%"$$S!NCI8,#1G0R"#3=&C1(0"*CP##2X##3X#(Z:&\P;60#M2V ;!@Q#'QS" MQ(B"&XQ'@H"LU1[%&V0M,OA!(!!# \&ATZ)G_$7MPIA$D0Y99.VND*Z_* _]E-]LP-W%S8?9R-NVQ M*FDS']MQ-N/P"=.S/=?S,BP<0T-T$P_#T$9T15OT12OP_BH2+7NSPBKL/QLT M0#>L1W>TH>6P./7Q)#_RX$W,*;"H9;5!A@T>0^AH$9Y3[X#,Q"P$@NQ 2F#R M.4W,,]QTJL"03DN$*'" !W0 !YS ZH#"4E< #F#$'RB>FAC*3J_*1YR"U#AR M95S&T5G6)J]T5UN6&)!IWVJ XC7#'^="Q+U Z$I$/,?U/*.R1 AU72=JJJ@ MF=XU*O]TJHQ"V2;J0A3"AC%$8?[/=" #=2!SLE$#M?,9K=61P0N4 5-(PAKT M%>T\21M(0 $I,@A^A"'(!X(@2&#']4+D%19!7EA3\NB4E$.PP;:]LA,^6E#+ MM4,@@LH.,E;;-.H5 N$!\F+']?EN1S-P@$&&<<*"M#\7=$D[MQU_\P8NMW0O M]&Q3,LI(U^B( JD\FC;^L2(2L@;0DK4*1#+ M@'%(^/ZJF*%UTS4B^& /RUXZ850^,6\62$> $)#$,)"@?@"F((IX ]#I,(?BE422:WD2;([T8 8%$(%8$0N[.J< M!(-K_L$S+ ,;P$!-V 0H2,*82#D9&*1"Y@"!W3DBM$!'?$1,C,"<+(,;P ; M8(0P$$*'H(GN4( <^!XAD($,8(RQIX+HK8<,B,%+/$,;Q/Z '$Q,,"!2(6#, M'UC[2Q!#&33>0D@"6-5$*'B%8"\$#,B'N$?!) +#KO+M*'A% J<%:#*Q'UC[ M6,C!"8S"L&/$1>V:5U#T,[R!6F$$,A#"*(Q7%Q-"(L: 8/N[&#AM+N0 #H@" MVI7FWS$Q0PC% P#%IS($,M"5[SE?&R2-A1["3T4L(:S"&40<17DXZ&%;HD.B M623?&L@ L0]5:6S V."[W,5U6I6!\#X\#NB TWY$Z]&T#$1!QN]J2I@"$Z-O M@NPY<.#'*!!"'2W$3*J *#S#(*Q"#TC0RR-1Q56]L.6 !!"[(?C=#BS#(;S M;"@\P8N((2 "#)1!,RS#VQ/[Z/[!+(]GH$D+)@X']#A%=\,09L20,TIS4S@3 M^3$_GT0512X00IV6!S"$C1L0%" @PP@0*S) >T@)ZKAA\L5QLH@"@$@@/ M .-,@!N$>DJXP:J-00/(A[!50!M(@H&XQP08U %@C)N8@@=T! E(P D !PC8 M "B0X<[$ "EX@%$@2"! P#]!P':DC><]B75:[IN6T6?X$4.PP9\LQ"HH ,1J MAQ\H@+ZCYP.40;Y%COBRP2%TS#*< (TN PD A Q0)&@X"0! ]2)@C"7,0#EC%B#4VPX#.6PS%D%'*9(['#V MXL&)/\ D# *TX"E,9Q,X]L$@2@R$9\(JE#&$@:.AB'XFD'+6S)FI#1S^.*/! M@52/E'\4X/C#X80S/!V.&/$S: "3 <0 0F"08R9D8"E+ OV!0 M<>:-$3IZP ^8RGAA(43[*(P"2;ZBSYGT%CH$P!;^*I !4HW1H8YK&C511#4H\."1FF'E<6&!4( MD%&K A5[(*&RX%,E!Q "MG'A@%Y._\[ENM#,$:($S(\()F M/.!1'AF8?SS @1><@ 0J*!O'UO XM1"B@2)@U0A4-((V0 H$,O @27XS*PE\ M4 4<, 4P." !#1WN :SZ"+Q(\$(-.H,0#@!%*$9Q@EL-HW;:,L RWD 9CP"# M 2T[@P0D$ .L_,EU*C*%PDBP@0^>0%* 6! 9(- D%6P@%_YX8)M'U%,@"9 M@2 0 \B"]942:5 &3HO"X["B@C4,(P)'A D@N+66Z$E@AQ+ 2K@^V +"O,$! M;N2 *$YE"B+^X10,^. +./";/H@@!AXP@3-4H!"/N(&+,'B.6B!@K&7@@(NN M4H$&SDB"550@A"IHB69PL!11'/ %(3ME']4SB)18H"1H+ A@SB"IL\% #,N MP'-0(8%9=BPM@?!;$U603(L RQFY4-@+,(!#$:RN9@H+%@T@4!C@6*@B@!D& M!()AB@4D".&J8'P_YH0 M.T (/E*@,(* !!KPBAI^$C 85P&$' MEK$#IRD25LX@RTM,T0 5(/"ESCA##&E:&0H=+1!$PX!'8F 7!KAQ Z A:Z0 MJ"M04"!\&/B-(H%#OS*!B4_P4]-9PX2_+\U/36[BW_[H6E>VOLE.:K+?_P ( MJ/R4# *0XENJTXT'EJ(9$D@.%!'8C*O^\BAY::N1H3'(W-8B6 CT M3ABN_?XG3$:P/K7#K# M03%A0%2!<5LU,@B#SEP+HI8!SURI!5;:Y*8$S@:3P<$D@@LH3# 4MBV8%&(G M,K !@\8%$X]L%28$T4P?TB(,!SQ,&!,(QC M0P5S-$9@\">,TA0A@N6BRSE\@@.O-( CKUD0L1P M1@^<-@H/M %3.'AH,QX58N", \QDU45 M16]SX8Q"!)<07N5J,R @*P"B%:UVI6O_7N'6.?4/K[+6=:YG_28P]E4SBQM6 M#S8 C%1P.!4&\(\8%B0'")!B9 0\I$ %;LS3 M *C!P%3(T@T$VK",-MQ69FIYK*4J@(I5O&P#.%C&'P20.8^@2S<%7\9X M. M\$&LV^)+2^Z 8728F. %Y'[V0O[8L(SJA \P@SA %&""0'(_(!6'(# J/*"P M$WBE/L-MQ@O:]9\=1(:4A"T6*AA@"&+0@&ULF$ J@+&!-1@L!QH 1C!:TU,# M (,0 7@#,GJ@,!HY0^^GX&&)$#Z!,B###?_,!8%#P_FP<2 5IW" 'Y[!J&5$ MP0 5X0 )Q ""D!65$+?D[M.,]H8!7.8-D3X((E!Q L/!Q$(M>P$)AA&*!HSD M4, IPP2 00J&0 J2P?" JWI @6 8@@'! 8)IJ8P"1@"% <813-H@+>!10$9 M?2"P,&(KXI/*X%82'08I(# *X#9C%!(PH0F<5]1 ]#0E9*!=@"KJAH$!5D<& M1F#^ OYK#32@&9R/;4)!2;*B4@PA7[X"82J@!W8. I9!+]PE9$1A CUI&88! M![ZIK'!MUUS!UN*'3_HD3U30KMQ*!EM03&P-?V2PKOKDUX"-07 GLC SR@ MA@+A64Z@98;A!7"@&7"@U)PA$"PK*#Q 103J*?Y@"', *PY+ V2@#70+B8;0 M!%B%#!"%#)9D!T0@!X[)%-A@) "C<$Z 54SA!$"@ Q!%+=B@ XC04O 0)D:A MN98!!BH"%6" S8 !CCF%$B) [())M:@ SJ !K"" HQ%+42'!-Y@![""$(;P M!*>'ND[!!#S@!"J"$"0'Q(1(J8;0O(!!0<1 #(Q%@]P@6_Y4(H?D,)UP@*R6 M009@H F%" =601AH0(-NB0- P!)/@00\@ 0>9E M"QT[( 904"7HHTA(8 1&@/CJHSW442UNJ5P T .BRAET(#/ J!F8[07<0'+> M@!O% #!R@02 ):9D(!1BP!!,P2M8TAGD(!)A0+;2Z04Z@ 0R8QBQ0AALH,8@ M)=)Z*A(K!1EL8 1Z("DJ(A LJ/YFGN4%7N(-F.?70 $CR&^6GF$'AC!;;DD$ M=H -380$7O(I3,%I#");@(&41N I1@'M_/(O=D!2QF!91.$O/6 MR*05VB0'9[!^\.0&5W!_;-!_OJ0'?9 S.],S/Q,T0U,T1S-0=H!C2!,U4U,U M^RH7=B"[5E,M< ,89,V??#[V =00*$#7H(&EJ8V?Q,X@U,XA].O.N T 0@S MW^JN5# Y)U,YZ<0RYZ0Y\VO5+,'7?(SP8BL@&,SS85+N',\03,\ M?? \R_-4GN'#Q!,XCF@[/3,^^RH] :4^<1/87L,9N00^U=.O!.8^\1,\!]1@ M!-1 0_Z3!G0'OIC%($0 E6KG.P'%(P C0#41WO41W\4 M2(-42(>42(O42/O*K.S*11NS3%@T,\_$UFKM1=M*1I^T1<408DT35/4.:M4U_;*2IET1O='!9?4U]143_>4 M3_O43_\44 -54 $%!M6*1>^42N.T2>&T1M_T?O3'1K/3,T>!$"J5$ 9!T'Y3 M& 0+3$D!1([S-T\5./Z7(7I2\QD^!E"" M@5,!2!0T$CB& 3]^3HYE4YX,#0KX(Y P Y'E31WX#<0@:M6LTW%L[(.%#95X%E% MLT25BK-&\P%,8<"H%3:O\4 ]XAENHF5V901>X@2X#C@!(Q4:("I3LPQ<#4] A#FS!E @#[XE3-?B>N.[1N! M#0N!K0$TX%3L0S6;R&5$EE@MY%-7,ZVTM4Z]E5OQ-$Z!-D]!LT=P\^C^HR-. M(5.9XA26%CA. %B>84(!I<$TH_ZP @45#/(HCO89I/89NM8=V]-4LT(;U6)K_1$"OA$5+*T%UB=O_P)N >5RC)SA:IG)Y<&;J49CJZP?@T9ZC984N'HDE8S,(!Y^H!X!E=OX6EI M-5)(R@\XM&]!4Y] )@U0(8B@PX4D%GAD$"A@$8OG$5 M7!49_OX$&(XS>\$H,7&-:*TS4!P!#Z+!/P !"# E60 !$"R/B)L%4 @*O^@ D0 T9BH5Y@ E0F,#H BBW+ M%#Q@!#! "D<8](Y+*7U7,W: 2J@4,3@)CK@!$0$&"C&@ MC)ZB#X#P*M+) YXAU?)8,X!A!$Z ^X2DA#WZ 2Q'%_@;'0@"C@ 80+J!6Q@ M VZ3D WY+D\ .PCA#!: BKE3\I TSC%)J!!!I@ W1G&?Y.0)51 0>.8@+& M+32X6 -J2"W*X"9TR#PXX(TX@I!-8 .\XMARP ,@(-).)0IPH 4P0 /:3(8" MDGLZ^=\@0 R 02P D)&@ ,R0PQ@ 8HP .^T1!*N0(J10P:8%_^@PS4N5(K M( (08B40:DUQ00H05PP $U8Q P0&.>< E/( +:)1A&8 = X %>" =J M2 :R910XH 4TH& 8B7U$ &$J* 8H8 -*2@0\H*D@#P-&P ,>A0Q@8*,UP ,? M )T8!B8^ 1DY05BCXLWP+( PQ BXPQ:( 8PH-@$10/PP $RHP^"ZPUN C:0 M@0,$!AG&>1 VH)G7+0=&P#DVH/X!1D 87H!4<* #R%6VA($$RJ@@AF$"=$ $ M'F!]D.'-0 !3A,$$RN !..DP/,".^T #3F"R8,):GU,ZA59^T@I2>^U:H11; M%55-SO,4( "5#$A*0"$/ #MWHX0_*89**!1F&]A*^(/0F8#:K%8-L,K0 %N M3 !8)"%D7@"=0 0EF$!2JT,?@,P2*$ 2 6DCTL!GD$2\,8#_("U39IMX#!W MX@Q>$@@F(*!2UED8:FDA?B.Y">$9%N!1SN W*F DZ.)AG@',^N"];$0S6L ! M.*D/&JD,'@<&3(@#VF"?!.:KM(5XDJ\,-@H"2FVKCN@,JA:2%D)?6P'#@ M5A9LMD(!$02@#[X),%3 543 LB:@70P0V@H@6PXA-U0 84&@8&(@6U)A:EX3 MH2L6*S9 (3; 5?)#JR; (^3 QB7V:%PE!S"EZ:CM<387&48 MM?L/YP8Q&C, M&3J NCI" E!A0ISAQ0SA 03F#^"FE.)E048@,]27V@X $?Z>HQ H0- HH!"P MZ&QLXS_:8$'H&!5*3WL4(%3:CJ ,0 8$A@SPA@:\X@%(!1#03@8C^% %>UMU M[8'A]()/Q0T !4I'=Q@!#\H ]<[008H-2*!@_: ! 8H _:P/Q> @1J<0.D M6"&4HZM #%@>@ S>X#8D!03P7%E%80+.A>N000)D!Q#8 (X(B$ZAE0\(MC5 MXB5(('-(0 X\22U..K$C/C)$0 /(@).,[PW:X-,5XD\(R@,R1YO\PB,*GLY4 MP _>H =ZI?Z8PAG68 ( H0WPH !. 7BI;5DX !&T&Q#< \0P#M@XA3P8 R" M.SM600+,M.6'R!E:@.O *%+40OX"ZA(/VCDS;A,F-, /ZXR62 $9^&F0(4!@ M6@E SB 8%N -W&"S%7PS7*E 8$(4WH">S.,!8 /GD/.*TS2SR44\VL"TL*3 MFH&Z_T,'"D+.OZ+2(;%:P9U#F31M HYP] R2#@526HR8D?2%5 M&(1@AB#LD*1B3<\.I# 49+D#AMBCSDBP*3BB#RD)@->\2 NXS0BQ@&@L*#.J M 5 W@5*YQ'#(V08Y?R6$37K"KC,1+_JLD0-JF(13!9.2T0!HS9M!SMX\%H7A M% 5G9S#X8?.&4+"69"B0 ;6!H 13JR D/0K!5$%3#YR]*/Y#T\T)P!9 N9FP MO+FS"023:L ]'80;9RPGB%KVUB4P"<"@2G6F@@VJ!F^X(11LA V65%(J>.!& M(1@,XPPJ9(C@P"K 0(",,Z= @)1VW#F3"P3 3!#6@QIB@ A\SNA @S.I0! 8 M=S.)F$,/!<$0Q5]G/#93##EX]D=++'7@AS-]?%"0'QXX(T$/ JV<% 1D$DO/<"!VX84L$S@5")X@@]RM"C M,S*($+#A!R@L'8(#!"\8A-!(%*7D MT+5 @R@-/#., Z@4M 9<$23E MFS,=M.%,, UT=H)4H?SF# XGJ- 44\[\@8@I1O6474%I)07#&,ZXM-29NA54<8^'2,#2,F5<6! #3[E% MBI+02?XP4T$@=$U&DBIPEQ1+>$AM2@-[Q@U!6!.$TI*I>SFS=T&@.+ ,LL<% M:^P+7;? W0,COC&:,V5T4! A(J!RP'&@9->#KIZQ@8R%#]K]5PPB%-1'52@+ M3&4%)R:%PXHM.M.&G*,P@">-SL @U4RC.. @?5]R\H0+7:4# 8* "O_RA 05Y@UYFU1)$5$5:B "%IOYR@T*6D $TSCC! M AV0'V0MHP(VF\ AH)4?[2QP*GX0A@HNE(H#M,]=[E+7N]B517!MT14E 4E' MM+B0+I+1(^E:2!@Y8A'JT<[$0I*(, ZPC3H65X 0[>,#*3"$!&<1@ @'#@4 J8)0U M@* @;@C B'(P3AFX9)!C&*1?JOZ#"LFUY!03B,$WYT8"DKFD#PYH@0XD<"9X M#K);$= @#!KPI=B(0 0[D,"0@+R'.0,0R20!!MH7&Q*( MH <0N D(3!"%;$HJ*@ #&4A@ M;A?\2Q\,P 9@-& F(\!F!$#S@OY5U25BH$ /-&"#@M"&)C)0 "@N93L.SDP% M-'C B0Y'" ZZY!0*"%A2$.D,"CS%&18PQ#(8X*!<] L4#8 !#0 TP!&T% )N M((1>6N(!3;U@AS'05"$D0+%6!H8#.X# F2);$!FXTP\&&,._CH.* ?3/$ ^@ M&$U1]/X'%,J@JWCJZH$.%QL(N%4%'^B!!(!%" \)1@6X)\,^DR3>"R#& TT2*IBEX"BRW/SLQLT\Z#* MH9@FI&@#F$]AY8LB>1D$$@:KD0&KRJE8US01!IJ7,8IEI.)NI1;TF16,!U3D MXGF$",0S5J$5-*$,L$=&&!OZ_MXMK1!>Y\)N0D)/\Y"+9[Q9-OI#^^O?E M,(^YS&=.E0 MC[K4/ZYRE(>DZO8U%\I)0M^4;WTD2H&YSTE^PO/WO-X?B,/Z1Z7FAO M'$W4'G>XRYS10#+[W>U>]I?C?5[ L,XSQL[SNL/\[R[Y>W\1/Z]3,!GQAG=) MY*OT\\D7?NZ2K[S>B6[YF3,^[SL/^^=![U_(M^0@KVA%ZD,2+X6XB^7E@CU' M9#]?VG\=7;8WR2LZ/_7>^_[WP ^^\(=/_.(;__C(3SZ]4)\2B:B^Y*W ;^Y/ M;G(S5OY]^JX7"?;OJWO>AU[YH!\]^/]&^?%OGNU][SGUJ"?^M"??^^#_?>3A M'W^FTU_SB(_70>(EBU9$7XW_=WMIM"ZRMWWGPG4"R$87<7_UUX .2'3/T$P/ MZ'/+(($3>($8F($:^'.IEQ"JMW^OEX J(8*Z5T;X!7(*:%]5)R[CPH P!PP[ M(&6;YW?.8 A#(G<[MPQGL ,ZH -WY68RIW9B40;'$0P2:'G+L 8[L ,Y0 9] M)H29UQ)ED!_KUQ+#8('S\@)O5P8_N QLP(,[\!22M(0ZD ,_0GHXT08$TA,W MX0R'\ (GL -]AH8X,0H8XQ+!< (6.#GHQ&1DQX(DA<,>.=RRR &^U%^,K88F,@&L&&$ M-.>"F4>(&1,W#B(,9=!,+@>%.,$&2J-TJ'@**U-^+H<*55,09W!@@* ")T & M'>8MJ[=Z6K1?^B=&VI> +*A?Y8)ULU=R)+>"JNA?91 H?AS>' 6/P<,"! # MJO0 6+-T&Q4P)O)SPX RN,TV46!+X!F<90^2L<2;W!.:&$ ;E4R!X Y.@ ! M(Y 4.[ 9- #.Z _0-S#? 4(I,D+R0'AA ##W!C-.<&_A<^,=<,+P ,?H!"0B2*+S<,$_[09RJP0T;7!RCD$F2P,K,8;.#D$L(@ 0.G M=VP@ 6!6>JEDD9SF,TMA?"SQ!XA1!@HC!GX!#"I0:YA'!\ >K>6#&1B05M)YI=C?!D)SUA@G"3D6.A.L":*2]P(RP1+J&6'-D L5APR@A"T(YY_"T S#0$C+( Q-- Q% M* RY$&&@( =SN#!]4 AN! HL5A#$$ PING#$X >FT%8ELPS-( ,C S-8&6@ MT&P7I:4F6A 2RFHX(0%/ 9J@ BU9DE#4@@>H&8+YV_QV?XXAW!#8O&1>'6# MIT%G5/<*LL!_([AU822-9_0N!OA%DWI&6?2H)EA?\K)S?C !.> !%G-$+2 ! M=IF=B#$! O23., !(( #,. =F$*%6 #*@ "R_ ,%3"J"S:?R[*J%C,,%$ # M.H ! :,"&V #(X ?E]D E4!_%,!FM$"(U !Q;%8HR [Q]( 2B,!A3@!.]!8!=$#%9 # M$B 5J8 !,F"M,T%/W (#$] M8L &F (HV!,'A!C"\, K+8,F?E I=DS@%$& M*+0#\YD4+R0\&U &2R**@ '[0D\A1 3I0 2F34X(% 9KB!A7T M *S&.\W )2B""AOP #(@#!PP CBP 52"#!L SU 2@6M#% 4H0PD_CJ#(<1 M0J2 /VQ1)1LP C:P 1L@2N8C 3^R4"+P.3B@ 3'A .D##!@0$QQ@D=8D VD5 M#*@0 3-!%1GC4S)0G3"P0(8@ 3HP MT"'!00LSWB*R 08<\P7!Y "L*P 2JP M3W\1N'+A#&L L]_J(0E; :20 PS0 <6VM#&P ?F15WXP1X3P!]@S+,[PJ1S0 M(R^ 37EE:A) R/ 3,D3N_;J,9[% "N#3RVT 4GR/]STKWMR'# 0NQ.P,H0@ MM&7Q'O[*) 8/ $0T8:%* 0(VT $:U1(VP ?8 JI\[L*0Q4Y0 (JP&AI T)L MZS\/4 A$>7H'H7KTVY;VRWU<5*F2ND58M'L[QS C@@$K8Q8X 0,I(P;? 1PS MR0"#T:F>@0<%@3G.T #(0P8MX P^VPPB8 JD8!HCH# CX%X;\!XLP3#6 3B( MX0&[^ (DTP OHQ12T0 E]AFI@_Z=;5 !#S !IE$0 MH= J\DYPW <\,OSH '21*'-3B39%MV'5D0NW44] HA!4$J?R G%P4!V[8! MWU$&%O,<@CL("I ?IJ ST #-"+$!<$!A ,#%!$'G"%$=!G.QDP)W G;9"1/>!.3IP? MT*)7"+"+T\P?-V(U?L$X1_D&K6L"KQL![8/.!>$F+F$!9Z@"B-!:*;1G#-#. M>H%>-:(7--!540!!#_ ,)WD=VXD(IN0,JSS!)T(*ANH2 20M^S$!5HF5UG$( M?$4D>E$!=R4"-CDT6RD6#9 ^R_Y 2P]0 7=8$.$R+JFGC&#$@HU*@%O'EAG1 M>FT)ER2PQM7\ARE5,C\C0 "_0!C"@ ,=AP6+!*#6H :\3 X8"RC]=$&0@ M Z)0%7!D"#A@ ]5[&L!" @I3PO3Z%VZ 5LA6#D U:^!-"=0U8#!!O.9K"3P M(\UP5,Y0 0V&"+/B .\Q G;A.RLB'U:86F5P!AS@%Z# #E@)]K$!M]Q-_1A MUD5+-S,#&%O+T2Q2 15 BF%,R#DQ 6TP!@6@*VC\%W[@(F(@ 6PP!A%U(L_[ MK?E!"C^H)%_"$EY,/<$ " ;@2630V/Q1!CLY$Z;@(M=3@U5!CI1\ADGI5A50 M8LL]%?ZS @'<\0?]R!(FX > ( 8E&==TL\G:L9'-75>DL!V 40&20!],]A

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�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end GRAPHIC 56 comp_0011.gif IMAGE begin 644 comp_0011.gif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end GRAPHIC 57 comp_0014.gif IMAGE begin 644 comp_0014.gif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

    !Q40J*Y0 3K@",$J?1@0 2UP!K00NS; ".TK XV !@NP?3BP "D CCTP M %X N130 WJ@M[B@!P@80!Y/ B:FGCTN+$)(@LXQ LRHY A_P"(P0 M 0_H 0UPC2!0@T.)HM>X 3MX"QL0 XX !P\0ACCC"A,P 1NP 1( AI/X>)*J M BO(JP)A!AAP?PM0A#% I16 N0K: X$J$"I0KJ*'?0EPE A1H +!"I7@"@LP ML:S0 OZXT ,?@!!0\'LR$(72V X6GA\^<*Z"'YST(,R0+ SL)H"<0&U=YD- ML)G>5\8"80(S< L-H'^%QPJND*IC_,*TT I+! -\( 80+ =J0!E1PL*P'<1 M@'=W\'4Z +(X,).WX "4, D(T(.-0 ,J;)F7G(D"$8.X\ !,N<<.X0'EB@LA M@,RXH *2.L4\\0 0^X)$ZH:TQYJLP H+H'\O(*E\VH.YC! -T':6C MXZ1!Z M &IUP!?9P(VB1 J ,@"L0.,@'X($0?V[ @+D,\\T*[5O I_UP/^+ FM[ C_ M]P@=+! I(*DB^'=!MPH+@*.BV:'*7+KW9P!\U[1\-P.RC/X+)V"9$+"94(@+ M-% "".$%VP@#6"'-WD =B 00,C/ MDMH(11T'J[D#02@0+< #0XAVJP"?N-"&S]>!)1.'N% !"2T0#H 'CU#4*QF% M-!#/C#"Q@(Q>Q_"-&0N$ '7X<#(#N^#L$*";"6EW MKE &CHP+-D"PL>P00HP+8.#)N% &%!#($1!T/##(N! &E@R@YHIV"YS(K>P% M(*#"5"H0.. (;F#9/0"R15QW*S-8Y 8@)\D"40N/I\>K0 !B>@ H/ZW9+'AG@71B%@C$$G QC]V2$P"0O@ MWB=PJ86W"O0-!AMP"Q)-MV%D @G]JP)Q"0]0";= ?HDY 7@WH"F@ B>,"R@] ME _0=A= >170 1MI @V0T$&'OBL) 1OZB0*AY+B@I!;] WP\ B50 G1ZE(X@ M REP @]@=73 Y-NY"@FPM?*\@CI@ I)7"0YPD":0 @>@!SH0 [=0=V@PDP=J MSS@==/XF<(%!5P&W6723;'F5@,^.L-F2E[%S& $0T '5V=1AA ADNPHC[!!TD-,.L0$AG=D2W8/E?8.X\ 'M?9 0 ,@0P'>BC0&S2-^29ZUB MT G<.4;, &TP H?\ 6L -:.(JWL .X&T:N\ !4N-SG/0(5D)PF( %JG@?F MC0MQ3;'-CN414+0/P*Z7V>H.P;BT@!+'W:XO:\UA <"O)$>\'\R0*4]" ?B M[<*SSGB5H "T4 8=8'ELZ CJ:WEE>)EA\. 3@,SC6[X10.("$0%[8 .G>9 5 M,,@6 =U/NO;9P(Z,/&1T "WP ,@6W"L#^#L%X#(0^H :RD0^'H+JZX'L= #*]@"R&P"%V ' M=_?":?UU?-@ 83@)T"<#0.P($"N"]E=WF%@3CF &"@ %E* 1QA&;C@"Y5IW MU9N"V/P(<=@(C1 )E4 +)9#0=:?'M& !*2!X[RG/J^WUY;Z/=KJ"=?<%(W ) MA]H(C" )C[\*#E *EA<&OY?#8A=&HSC6FZGI*AG.ESG7N' !(R!X9A"H,P"R MTO@ ES 'FDENAB&0R0-,"X=M^H]0 M":]P!PA0!H]P"QCP?NY9_=FG?S& S#R@YDVI '/@_8\_ X!<=V:0VD%7S[BP M!R?XR0#Q ]= 7!?,X**%BQ(K'29PW5+8P)4C" EQG>A!L%&8!5YPZ4@QT,L# M. LGW'I4<: *';A8/8!$$)<>"+<@HL35X0O$.Q1P470UT-P,_V'#$R!$E M5[A EIH7C^DY6#2G0D$-QRT8$*/ MJS(J"''5 [(/N=(XT50IPKC*E$4+Z0IFX+-BGJHR!&(&@/ A*JJ2"A&:(H3\+K$N( MDE5>HD$/6F;PR ,PA(*@J(%>@2"F@9YR"ZSI^D,Q11579+'%%FEY0#:(Z!A MDDD*(*@"CUIH:0'):'@KI:!,0\T$\EQ!@!(U>A-I,P]0L\N S0:B!01'T+-@ MJX-PP6,!7-RH:: 1C%/!!BHE<&.@55"#(\R"PG"E (LV:/[I!>X*>V$@2@Z( M0R8<5/)/( FV9&6&6Y8K#:(P.ABH JL4.D"^_]2$@!*7(I"/%@DF$,2!/+Z2#US+4K!BULV* V7'MZ:@;P-!,(%CN\HLD@%8%EQ MP%*"7FE CH'@>* P,S\B+"6+-!XH#'=%@NJI@=28J@PF<:E 0 @:H63>@>;8 M,(8M)T' (H@\P.P1!.C"!8R3ROYZ8,@S?!(I.YH2BL-=,T[^@@ZGMM1C@80> MB%8MIP3$)9(#Z*J /%8.<&25!!S&0Z#3"#IPH!_, 6N@H$#W[+K!/K0CHP&6.!BR*P5@;6JA+!_*\ M"->,MR;84@QR2Y6/75=U4&^@!O1HI &US+!.IM6,PKH1 "#(F F&X# ,1 09/\&8H(*[" %$S 60?20@)DH0"WGDPDM M6/B[$"1D!Q$ 28AF4CU<@* E,GC #FC@@.R8P0 IN 4:&O[ S0ZD7@6*8&9 M:'&!""3P.)&T00/L0P<$R$ &'_ )\8:DS>28 ( @J, J;K$ +>)B:0@QP05X MX($-0$8!F_G! W30 D<6+ $QZ($$+O:J [3D"\]K =5DHK4AW2(%G11@:?" M ,$D[J [&,$$+!7!"5;P(1]PP)8&)$$=/$ ,W[) $4.%BS \@ 8RH-]%&I20 M']2100HX" @JZ H#6*H,#\!!#!X %30D#F4?#0$&XN=%1^CA.W59100\,$$$ M8"T&$F@(!.03@>L]1 '9$=4$("I17,C (0L*%P\^,! Q$"8,#NC!21\0!EH< M0$3_HJ('VA@IX &IXEYJ5;N]6S " M#W? QZ:@Q UD,%2U"*)TM7&"[(AB!V\H#>"K"(, M8&!%V/K#""]X86Y8$<,7]#J0.W@!#A:)!,_4) ;KR@0/7D"#16@!AS#(9PZL MT*U,6/%<5CQBMEW5P21Z8 :+N(0,Y46(A0A2B6B1J@P +A>]:"'@X%J$$4'A M5AABP*I,&M$.<0!DI40CZ3N"X5S0!CFW/PKEKV,*15%!@7ROWN0/8L%"^4@5X*"8,7II3*.:#V$84^-)6$ M*Y/NII=4DV:%DRO=7U:0=[NNB,.7Q_N%ZU;@#GKH08@!"08Q-(>X,M$#G,N5 M*E?$J\''^H(8+C&03&N$+.MM+R[H4(E8#$(F2:4$'(X,:_1R%AV9:V/DZ>Y[##V)<+B^<>[4'1WC"%;YPAC>\11!) 7DQ>_SJ[8F7UH\]\ZVG/NLU=T8.FL-U% M:"=[T=W.]*C;/.S-T[O053YXPA?>\(='?.(5OWC&-][QCX=\Y!F.]Y2K!?!P MOSOF);]YSG?>\Y\'O>9#7W'*C_[>]*='?>I5OWK6M][UKW\\+8*,HE6@05E. M-CDM!M%?@K#"#GC(@Q[RD(<[N((5?M:>)%Y[ASN47.&WWOQB8#_Z6PPZE8Z( M.:<DELEXKFM_@ML)^B2CB_\.H?/\9O88>!3W_AA2,+ MS2L! 0Q, @Y,"AR[ZSNXPSDD0A$\<( *B( #B( *6(!'^(RSSJ(\()'$3RN$T$9C,&R MVS*)4RV:DP%5J\$8I 4?N;F9*("\D($^<84#@)QUN3J<"P'V>(0!R+\1[$&X MZ!ERD?XYM:B$!.@P0#J!_O*[%10\23 !FQ$]HS.Z&0B)NABLE^,XM M @E ! MJ*"$ E@[G5,!8V%#T0N\O1.Z52@ W+/!MZ-!F:,!T=*5-^1#UI)"R(LCJ8N@ MJ ">DVL%"-BUF1GR^!<@_7FPX3521_;LO2? 2AX.(22 E MBYNG0XR_AMNIAP!&*GE&PIO&B],,6K0_[JD$@>A&1D@!G'FV#XB $Z"$.7"7 M.]@0A."!YD"#$0@!J!&#.P"!#[ #@H"#$/@ &*P$&1B!%OZ ,C#P@!; PG8 MPOYXA +XLC/P@#L( 0\(,7 , 1WPPL* DH% PHD)@1#P HMPA3 J [JES"0R2F+ S6 M P\(@50A PJX@!WH+TBP+A/P@"V) SC8 Q"PE#L8 5OJ+SRH2XH\EA;8B^9P MA!/PH$ITA!3PH"W4 P^0@!>@"TFX0Q4 P5OX@HT\GH' Q,(@1^PB5<21YD MQ\*L-AB#QTI@!)F\$EIXG!WP /Z'08.-#(-DU$M<^ ): MLX$1, 'DXK6 "@$ZF+M<6(4C"T=?P84X,($1T,MO/,ZZ8(03 ($9"(H]^"A M4@$CH0M*@( D4(M""8$4*!VI M_(&E<@5:H $(^(#OX@%:*(,0XX%*N(,T@8(6D $=H(%8804;B%#THX4?D$D M6;:9V)"H; 2VG$PJ8M$4F)O<+(,7>-'F$(.-W!*UG(00V R(H(4>> 0:^(#; MQ(4A'?X! )D#-=B#$)"$'O@L7['/$, :2?""(Y4M@1N!$;B$!-6/@>A'$S ! MU)K', MAZ&%'6A!0I(F3SP@+%B!.G! PIH 0M! "WB@0G TAU 2XI &<#'5Q( M@12 P ,P-B6]J1XHOP+@TZV=@U:U#S1(@#P00]1XPA,X7 -(DWTU SUH@>4I M PF %#, TRPI!0@HA0%C5C.@A/Y;J( 8D(1KI0L)J( 6.(-;^( 0T ,U:,!- M&@%&F ,'N(/BO-E5:!/1@"5=D:+V"@,%P04*D TT(,*"(E*:( =P ,=6( _ MJ@LTJ!@X #V# .PB5)XT8,-@*P*T(&NJ!3_B( S@-1<@8-)<@16& !7*-X4 M,YP9< @X (,S2($"H 1:J ;:(2;*AV(V($-<(2%LH\%F,SXO8, T%B.Q0Q: ML( 9: 0S> #YV( (4 $S6(4#B!49L ]P(,),),[,( 0F($Z'*,+* ,\N !A M_5:&C0 !X8$$"-E5L(,(D &HH($* .$)0(T\,(#IE(1&" 5N .=,N*PU<3G M,0L((/X+F5KAQGJ(#4B!V3T ^]"!#]:#"<#/Q'.$ *7)B5_OZ(A'(>"D#RQ=44 M9<\*W0? FC^^BX3P BY121QL0.H!.^8$^NP .A9A?NBA6BEB%L(XWXYFSS@ M&3.8"F/4:-2P .2,@55P _6@A'*:A*!!%)F0A,3AEAR!'!'>,M<9"#,@C#SP M*3AXC946">.U"YFH!.2Z!.9 &:S! W+9 4LRB@8!O*2)')^JCEP 0BI2+# 8 MJX&8 9%>QW$9"$==3>:(#URP@3RA@08A%0B0#8%\%;2&N#1T!4NA@-@I@[? MOX&(@XI)#X+8 >-(25)9'RD:DCV9'@- /[D D"/L,9M^M@(9B?ZJ@#%+ 'K9 MX/HJ@ (3A 4("OLAB^5@A5? *O[33)40P(&!8-GDM,*"@2Y:@@2=7;R+C@1= M?H@8^"/$20@U2&/@89A2: 0$(,R=/(!54 /U@(@*R .$X;@12*020,H80.ZX MB("#E+E"E@^(. /BMF?[B( /V,D36(!UA @/VMD$0 -):("B@(C+Q(5+ DO MRHX6@)*A<(7FH84)$+6TP4UC<841< +H(&@F !P85/"PH4=6 #F13^&B+@& MZ!.U< 43Z&\:R OSUK?>:!XZ(!=?KHO.J.AXA@@*.$<:9NX0,*4>.)((2!43 MY;@[^)C5G)P>R)5J:P!Q@@@>D8LDVB,,Z&Z38I<&F "E5)4&H @+S(FJ0 X M$,;!$/[J#> _S&28$%)A6_S@(#LR#%KC#WD 8E+CEU3S5"*C#__C9H-@ M/2+%1]B#+/3 K!_AM#Z@) MH'")$&B B.;%1GBA$G#BX\V.6Z #GPB!C$@(+R /%.P-0ZV+#8 #YVT*F5"! M'V?3"1BK2;F%$(8("8"<58C655XB TO[]:MBB838- :GA M'%V9ZY'$FT:Y@Y2HBS2'"-N!C$DX54E PQ1P@"O9S#O'!1J@(8*8@P7X[7Q' M,<2[Z+L8DA?XHSG0630NCVOWK%5X! 40#49XA$JX!4UO%#R8! > C!HJ#!E( M"K&8'EV&B%*1[BQ3U>J]C>S&A9MM!+]H1,.0"?KE]5S78 0XLEPP >LX&T * M&MS E.M@CU(F"/\#(GD.@Z)?BBOK6@2H[HC8 4:@A0Q&D63[@).@!*.>@Y.) M^S\[F0\0D 9 K8JN!)#O"T:0A-+88^>)%M[1N1"&"W'_@7!9!05((A/H@1^L MA*2K-EH0JIOG#RK" QPP@ )S!?X\L $#0"V(F'LJOPJ11T@TF( 3:&,X /M* M"(ITESDOD*:Q.(FA2 B.7^_U&?I#9_6WYZP-*(,E?H2A8#D*"'BIL8PY9P0R M6 ""@0A6,/2?> ^=8 A.9L4L #6.$RJMWXSP?NK4(PS*)D/>@T*P?:(1;$$I<0/:!L .?BH/>*-Z^EP2R$/5C>58, (A;N :B27 F$JT* ME7!1F#.0S@1<)G;@HH6KAXJ! ^%4P,51XP8XK!:XPB50TBT5*APQ:C2)%2X+ M< ;BD3!0@L-*#R;A*C-"4@6+-%H,5/&A(JX6)Q[M8?12HT9'9B#$P"5A)JXS M&W#1Z?YHP&8CE;*(]S;NW+IWYW84X98DS -CT,!UIS(N-1=PD?&J!P&E M6Q L%#2P%U- C05I(,]1$"21K19,>%00VN M%"\TVJ T4* ),VBDTP^X1%#&0),!*)0J4-(=7 MBD4$ET8@A(&+#190"B0G'NZ3$ (P-Y$1$/ M+0JT096XL() F!M0A(N"KOS@@48Z2-+("!I5@(8C(>B)H&1SQ.6%!1IAT,-A M*E#'"'@?(#H0#3#)=%A:!7K4 "Z7611<2:M @!8$Q>$BB0&L!&<1!AW2$@$C MMSRP* *N2!(KB0O,< Y^DE_^'"R ,"E1&7*VQ:=<= J^[@BB,66"O) MWB@D>. MCH2+RPP(XK+* 24)E$)5N.BQ@/Y%%5!'9!B,#50!A1MU%$>A WG0X01'?HO M+7$XV--,D\X;%P2C50*!?ZMT$$.:-A!U1E :S;&Q&3-)9D*$BMUE@<5&S0OF M0%!T-,>,6>&G%EL//)E LG,H0(L>-N'ER@(Y9GH *U"#%JRQ/9QP6 4SC52S MMK0P$D$N U%FF00EC4P+KP-5<@!/I9T662,(P+1E"[0TD*PDQKIR-V^!"SYX M(PG<\DB_ P&L&,'AV>3I"#.DL("4=S00@PX/Y!A&D"\:]X ,.CB0V"TF6-!# M"!,L=,8".LCP@0*5T&* S% Y H"4 ID1EU6)K5)!"#Q84()M'AZ 0045*%!" M27]A[OZ :95$H (/KUM BPI$600' C;( ,("\DE61@(TS&"!GW<@$,,/%63D MB@6.8@ "+:M$ $(/(UC0[+X2I,###$!@ 9@(9& M@((%6N0*"$R@$;%Q&:: M9J@O#$0'%<# %RH0IC,TP'P-2,P,\O2@,'G! $KH ,^0 ,9)"!"-/#3:::G M PB\"1(04,$.'E"@6'B@ SSP 90 (:&H@C$+ ! M2M#B Q[HP08^4+RL(( &/8@ HH(S$0G$0" M0,"C!L+!'G@/ F"(HD7@ Y.W MM0<"&VC!#AI D3W0*@9HO 72%/. &=#@@Q4) <->H 0/OY !Z*3 U1680 M M.>( MX $K?)3E1E(X :L< C+O$ E,E@ QYPQ:ODP@H05, $/,@.&!R QDTP$:4:$ %'O$<]E%@ ME7*Y@P(4Z0%=F FU( :*T)CEW0!^X0&)B( $=I" "\M$(&!9@ QZX$1?J MF<$,,- !XS@ !"M$UD!D$($=B%-*%1O(FJ2DA@?@8 ;!M)Q[V"*!#6!. 5)3 M0P,PVH"UZ $4.G.1AY@ QHX8/XF>%B 9/ 0%EPT@B2V[-O31L,TR3R")ZQ(UBJTM*\RH,$5C;!- M)<+@!2E51Z[?NMLJ],K7A_P #<5S1&%=,0B+Z(%_&J&%>0;D5T:@I2)H@((= M;O,(/-RALX-5DQB\<+6Y\I,6< #.0P<""2_P<[%XT0,8&L$*N>:U!]0QB1I^ M<%M:H*$'_,0+*\Q0!E;< @Z.#>P/XB"92HC$%[WP7(]X 2LF@4,/AOL? M_.H7+_Z/,.Y YI#J"S8T_CA1\\-\*,X(QQ]I=>J!SZM]^J+'AM,PDO@.&? M'WY:!" !!Q[,=Q)? $-WK;N'RMH2#*AFRW,_[8H]8-C/MOX4@V%=$8=,_7/& MC(!"&?A'"5<_=!+612NRDZWL93.[V0!!" B,;&U)N]O> M_C:XPRWNQT9@!GN PTXI->YULQNMM&( 36 M]KYQ$W"!]SLW^QZXO@VN\!??9N .5S?"&XD\2B$^[OA'F;YYXQYMLT(')U"!?;VUFX"CG.3(7GFT M)>/RDB=<+MHU"= #AW%:] M!U=YR\V:]'M3O>I6OSK6LZ[UK7.]ZU[_.MC# M+O:QD[WL9E=VS\^N]K5W7>AL?_X[W.,N][G3O>YVOSO>\Z[WO?.][W[_.^ # M+_C!$[[PAC\\XA.O^,4SOO&.?SSD(R_YR5->Z96_/.8SK_G-<[[SGO\\Z$,O M>M&'007SI918]#QM2/>,[_YSG\^WW6G !,L8"$"T;4:%@),$ZP"#>^=0[)< 0"@)TW@B?O*?IA'B'XTDT*"K3)G!PWI@!23D;TM]NB'1T/\_ :@ &X= M$,T! *S%J$ C3 -P* TW #3@+2S 1DT"!#Q !!Q (]P.HJ@! ,S!R&#@ M 8P&"/Y(T0 @@ P\P H@'ST0 %40 &8P"TT0@!@P ,(0/65P0% @ ,\V #^ M(! &H1 ^VR0,0($T )U MT-1 ;, M,P7 ( 8W(%$CL $!<"T(DXAH'>7 "]1, C2 ( %$7KI>)1BB MZPF.'I0!@ W$*IR!&>C*]9U!_>B!60C"JM'DYO7 A)@/1OE+TDU=)42''I83 M+N3;+6Q1NCR)7A9/8#Z6SE4$:]Z&:@K@+<0 $ !A0 @P":02 C2 Q0 M#O1$ "1 !T !@+6DU %T(%"%! ;=;;"#A ;)J5#03 03 !/#$41T A0 M5MS"# ! )?0 A #0 '2(/FJFX7G CB 2S WS*LX' QF@F*ZI>LPE$ M)0A @;QG\\4! *1 2=Q! /A4"L#-8U4" DR ?[A"" ! S; %')S!8+4"',!! M96V !?XP2,WH@8U4Q!R<@7RX0AXXW6.8:&0FB![H ATX1/>-UB2@P1Q8!"WL M0254 I^,"@9 @)$%"V/Z'V[H 0"H0' !0 _0@@-$ "6PPFYNV (@@ ),@OE9 MI@= @+S Y^71@FFU(BUD1BFB!=.L0B6$"2W,P1RL@AY4EB2<@1U8!"1@0 0, MZ0!*@JVM0AXT#QGDZ&WD AH

    2GE&:#4J&$%1, "3,(J#( ((, (T,(&! $ M4$ '$D94.L!> MX "0 "4VB8N_ C(8*!( K>,&X1FBBL<($/, "E!$( MU.!"[HH F("%-H(!'$ $*& 2A< !U&H9K(H#-("T]*$'0(>ZF0 "'$ !! #& M/.2N"<0C%$"+T$1?TL("^$D%0 KL,(&&$L''$ <-H"U;&*(# !/4)\7*D N M0,$ N$(/" !/I "L,VM5D*O,OY"'A!D+ Q 5:RK2':E)"BH@(2 U9)&];%" M*.E;:]Q"+FC;(U# $B"') B33#I0.R (B/) 1 P_!KY0F$ 0ZH&5#0L(:! M,2Z &# 7 .PL#P2 <0F @*SDD7Q !'SB#U+" "!* V2$U[+"),R!_SE"[:J) M#HR&#(#L&0S !IP?"#1 E%I 6-1A=-F .CN +P)+9Z ) * #8 2O\;A_J3DHF" (4R@DLH>T8KVW(P!); MA H,@!RX@@2$ )2DB!H,S02@RG)TP 0 Y0,, C8V%M3$0 ,@R 5,( $ 5'TH KF$ #/.-R!@Z2+H\)7(!I9+,-3/(' M2$9Y2@D>H+(O_S(N&&B5L,(!A, CT( ;ND( /&TLK.P#5, !K,4$".FX.$0( M%( -&"GT50(&5\4"Z60=WH%!1OZ70!0A3L!K&>B!!9AG6U,QK&;B%0ZK#."! M"P213%- A]2B*^S R89$!7F %7F !53)+90!\TY DT(%(]B@ZZA +M#"# F5 M1;R "5C$0$E(:&=%!#1 !^@9'EP ('GR 0JR"%8X3X!R&V[E!!X2 $%M CG"V4L8 ;$2!OC''5A M8NSK4D.>71?V&4B !'C!!Y"!+G# H]0/^.%! "1&)>#T2'VB'GB 0@0A#6! MLC3"!F"@#MS"'%S _"'E!/2E"D! "'A!!ZS"'%A F*3F(X#@#"0 3,A!!33 M!:#+KOY4@#798FJ:%2T$7&V"Z5D=,520.&Y\^(B;^.!L=GT<+J\."V*N."0N X8!!H8 CC@B[$,(Z#7I&W^/.A@?MZ (;3(Y(+CBO0 M@'C'0!X^N95?>>$1*)9O.9=WN9=/WI'S*X[O*YF_>)B35VZ4C9FO^&[ 'G?' M')GC19P[.9VW.6ZXN9P'SIJSN4;,N9T'JEF=>9_7.9KSQIX+#IX3>IK?N:*? M>:(/.I\C.IT7N9_KQJ$3>J6?)J1O>J%C>IX;.J-SNJ8C6Z9_^JB+.JH#>J3K M>:.SNJI_.:S'NJPGGBS,@BS(@BW<.J[K.J_WNJ__^JWG>OZP SNQ^SI4R (G M)+NR)_LB,+NR-_NR.[NT0_NS+SNU1_LB9/NU2SNW8[NV1SLG7'NS4_NV^WIL]ZS<^X[^^X(_](FA$*A2^ MY3]^[B\^[CL^YN\^XG]"U \_\1._\!>_\2/_TG<]+LP"(B#"(42_]!_"\T^_ M]5\_]3\_]&?_]&N_]6]_]E<_]TN_]W<_^9>_^$=_^6,_^[>_^U/_^8M_^H?_ M]V,_^&O_]L__^JM__.<_^-,_0!P2> C10$0'"Q),*!#A0(8&&RITV!!APH,3 M+TZ$F/XQ(\..#SUR7*AP),&-%D=&-.AP94B4&$N69,FR8,%.N'#B6H01YLN6 M-$]ZA G4I="?,Y$F53IS846C(8E&=2IQ(\-9.6U5] E5HT!%-%-^-%F4*M2I M'U6")+F5I-2(: ]^TC27;EV[=_'FU;LWKZV'+JQI\WGQ[.[!Q,G[AI_LR M\L@GH8Q2RBFIK-+**S-+DLDM[6K1KA=Q@B,$#TS8@[ @STSSKUM\E,05('N$ M$R<>5L$)S3BQS%///2N[(XR<6*'A34E>"&&$,W!R18<7C3IQ:P2,G6L[P M8@["]*CD+SW*P!,7+R3=@156=L"%CC]S#.Q1/@%#0X>_H)B$33G59'4Q+9G$ ME4N]P+0A C@8">. 2S>TX)'%;OZ!X%A;F6W6V<)T].*#G"8Y@!5:)/CB$3PB M^ &72Q#PP@TR,/B %L$VV G6CQ0(0P/8A!,#P#TP!.,$ KH]X')IGD 5SP M0'359P6C!8,&EL5%@GK7)+@RN5#4-4E=)\2+8KY>9&2!-W$R0P5<7'%3C7,= M^0(.'6]Q1$=:&L&EDE4>\8+AG")QY0XO*,FI$4MQ8J2"+S3-:0XP9G;%## F MZ=&"2'":PXM!=#9Y8(>IKGK&,$R(DQ('6(X@IT=FP&45"%C)J8(_>=21!PP^ M-M6"G!H(.B=*/-A TCC+F($2F7%:YYK8)?N#C7NUJE CQ,RV4@R$,ET'"[OQA,#R8@EH[.$ $;]& " M7L!%"/XT 4I48@*X" .^&E&!'O!@ L=2006\8(,'/,YA)C #^.;W@0_TP%=) M@P,,9X !5_2@;2KXPBHJ\(,?8"!G]J/8ZEIW%RC2Y44J>/X5+LX A/(X!:0 M0,"Q"*BX$)@!%Q.XA,L&9X;!;>X!',.%"7J DP_ X7<=-3S$(# G!@ PC$*Y:/T-$<3$ )"O3H%G- Y08J M+HJ%M=!?[M" V.C! ?,T)"Y\EA,>5$X";V*%+\/ UC*"\HV(PD4)X@ ^5_B- M%6_"0#7M-*@O0. 6/?# L6R * FLP@PA&&U3:?&F5<"A =E;Z6^!&YGUS6T! MMP"#9OYQT0!)Q ("=<*)!W@0ITEL( 4CZ$ $2D"+$ @,?7'$B0Y"8((12* " M9#S75G,2 59<%1<4H(1J1 -H<8+O/>";GQP; MU$YYBQ38X)G$"NZ3H8R822"@#)60! @H*8D%G,$5KO!"!&JZ #@T @\IJ"Q@ MS@6'G8:A I2@A2,'96&+@4C\Y0 $;0(@QO&T&1*?XQ"0@H%5\Z*$&7 M=_A95)D ;A4"'1P"Q*VDA(6$.JGS'4+&21O:LU"IQ0A M1.&^H%D'%K "!K1 UI,HFVV-,$'/-!*4U5@!%[X6!GTZX$/T/"[Q-+!I2@Q M@KH-4ZD5\*T>/ "# Q3$N'MP8%9H8*D0=L#'C!3)4P @@YD.LKE-K>\/( ! M#,B 8XSXP 8Z$()CL2($Z?* #MP(&#U0M4<_Z, ',( H/7P@2#% *H_B0 ,= M=/M8QW[C*L"-BSF\ZA8+O[>.=J!K'NC:66=@\BW.2]49>,$$%\=%MG']39S( M(+IJ$W8,'$D_U9V:2S3/BY%\9_Z8?*\K)UZ(E^8.XXI2LR)(._\+T$%F]',O MO=RTN%.7)W,+I"=&Z81Q1]]]_O?"4/8BBT)[*?1.^ 1GWC%+SZE M$8MBDB:\)#"AK&%XHGRJTI:V5+V.\W2M_.8O'WK,KRE(LRJKYRN/)LUKOO,^ M^#C_O2FI_WM@Y][XMN>^<17 MO>^7[ZG7OT[UU%>^]"U?^MU//_335[[QG7][TXL^]7(B/_:;#_[G#Q_\S3>[ M]>,4^_[5YY[UWX=^^\-_?/OWGOWWM],X[T[LG(3Q"+ #? JT3PE"0 -2'R M6@1%+L05Z /[J "+? ",3 #+Y "-; #/? #0? ..# $2; $3? $43 %57 % M6; %7? %83 &9= "\6 .*@HG'&$.1G &>; '?? '.Y .'(D6=A (C? (63#R M=D4)E20V*&$&=$ ';""M< 'I- &KC +I[ *H] &L+ *OS"M= ,QU ,JY + MO5 +S[ +L3 -M] *LY ,Y= ,Q7 +V5 -N5 +VW -XY .P_ /RQ .W7 /\W 0 MI9 /TW . 7$.#[$0VY 0&U$0'[$1(_$.W1 -$7$2[? -+?X1$CE1#RGQ$PUQ M$S,1#Q?1#P.Q$RL1%$7Q%%V1$EF1"V? R; ("M&P#[$P$!4Q%6/1$?%0$LOP M%>60%0D1&"_1%WIP#371$TMQ$(O1"D<1$Y<1 M&[\Q%+,1')M1'+_1!B"F+NZ. 2OD\!#P'>$Q'N6Q0]A1[/;B15"&\E9O_L:/ M'^/O'\-/(A$2(B=2("_2 M(A^2(QM2(SN2(D,2)#_2($O2'S&R(K-O(452(%%R(U=2)4\/(1M2]";2(_N1 M)4G2)/.1^O@1)W'R(B.R)7/R)/X+,OJ$\B5[QC#.[C$YQ8 D(2\%4Q[O@ P !=\V)P9"H 2835'^2@;08&HZ## D M 0_TX YN4*E\RX!T8%3B:#-!A3)G$G74(+IZCK,@,S('JT(.4T(@$#!VX,3T MX <0X. \8Q4^[#%T1 8\R#,+XX1.CL,^4RZC95IT9!(,H+0ZZ!'N('Q<)ESZ M"P- /[K_B(,=LI.RB4%/H#./@A5UH4'7 $2&HL[P^ VG\Q@$"8G)@"BW&XO M=R4 Q[(N7J01$$!S?*YOQ, ,.$82:$$/6FP2#H?C: $-PJ"B*H$5*(%8X , M#@X-)F .=*L,SB#F7&$25B$,YH!'.LH,SH420B &&I,6,!0.SJ6C7A0G2H$, M++1'6JQ'6N8,%@D.)H".OE,NL69NN,81O&:4PF9L-(<"&NTO5L$$%B!KJ 4$ MXBX%X& /< 8G*N$6)"&-/L9O<"(2PN!D>D1DCM1^XB %?N#C8@ESPL"-.,=S M_DAQ6.%87*$,[M2)^C**4D-[9"=.WH01)N '=* "DJ;D//X@#B2A 6)@X1;) M%39@Y"J@E=AL!&R %CX@!M ^2 %F( F2@$AP!AA;.C1Y! 6: !RK@57S& M"W9@ VQF C: C' 0 E* J1Z!5H5H%3 @#'K@ 7+FDTX.D=!@D9PG!IHH2M$R M?[2F?[#%! 1(I@KH@!@(S7:+@=YJ!,(@!9@M)V( W2@.:$&6BE!J[(F!&!I M?+S@!4*-UWK !#9 ._7$!,I@$L!,CD)@LB0@9W[("V0 VAA!_()%UK@B%1H MB;)5YI)S+P[S15+@B@#C HB%Y-ZH;1PA;G " B*A!]C*$0;-#! )9)@-#-[T M;7 ! U!J!N)(1R0! M[D$4K( _Z(!0MQ80:Z=,H"3&AQP@:\P&5QHA'6U%)/ M3IO0@))<092TU2PGZ:7JY!)H0),\H)H(B+-^B##LH%P_)0+, XHP+MTA'J( MB:_>:Z[*(&NXAQ:@-9!@*0)02@*(S6I809MPP0-0R@*2!Q>DR<0"[)JR">0J MP!7""IPFMGXVMB]?9 :HBD=@.ARHA)H )%L:A)PZI?FWP@.2"FISB!K*J S;^$"$H9J(@Q? 0,8"P"@J:0WHC9 M&N&Q/B@.5(#9D@5W)M8.($ /7 $.XD42WN86(H 15N'!="1_YPEB)V /R0"5<((2B@L,^ TG ME(NYG&MP6ZY' F=-)8Y,@ ?50@MS; @SX@C@\ 2/>@ 5QA#BK@$F@!!Q!LD7!!#.J)%K3H%OREFD * MY$X ?N=I G3$2G$!!U1 EQ$EI+CNCR2 1[8'Y%)@#N 8HN6JB+ %3FBLURRLR ?D$ 7[QHQ[P,S%9A >(@KU3@S 9C#M0%@HIV _S&-%\G!0"' M%E)@FMYKT,0 7T+@FS;@"VSYA7$A @**H.E'$A3 D2:@4RB P%SA CH%!#+M M$BB@E2;!T\K&"T+ Z8P6PDR#8B8L\BY&I#4!3&BA4EU-UVAA!G#-NVB 6!H! M7@&.6-[E U2@;-! ."'7!&8@#OX^H!%N(08V@.ADH-MTP)$F(05X=I%6&M=P MX%STX&RD2[!Z9 :$C08X6MA,H$[NP )"P N4>N(,R 8P0&ZTN2OU8 ,PP +8 MK6<^H .B;=[J#0,\@ :F[G7T(%Z@K4?(>J* K@=ZH 7:Y4VV.N+@X%5TH)7 M[:V'278QUVOZ!9VX.5> <*2)!,T(11" M 13:LI(Q9D>,[NH$([*.>5VJMWJ3CNIL.S"@+B_X4WB #!F #L %,N$33+LNXEN^Z2*^YWN^]>(!$5.\^;N__7M$D@04 M!,$!%, )V( % , %L#NUL7L33@$40 &[-0$40F$N4'O"0V$4(+S"&_0>__O# M03S$/P-%,F$4;B H 53D$4QF ,1H$-1 #&U^ 4'++AY+. MZ;S)XUS/0[+/_WS. ]W/_S'NVAS-\?S0%9W-&7W1 [P#$/Y $$8A$ A$*Y[ M# 0 B+@#4X\!YZ %P %4J@ *Z; Q0 %%P@ "K@!B @ 0!!M;=D $5\UFF] MU@V#L#;A$S@ 0 !%9P@ !H 0(A#0(@U L! 4K@%$X!!0H@$6I@ :[; R( M%&"@ .I %M8@ )S@%+1;ILH #< ]W,5=W,]@W,M]W-$=W<\=W-<]W=T]W=M= MD-_=W>,]WN>=WX-4=X0L^WP^>X1/> MX1?>WR4^W.T=X/^]WPF>XC'>W\V@97@$#\R@WP=^XS,>WTE^Y#<>Y3%>Y47^ MXEL^W!/U0QO>WV=>XVU>D!6>W/YSGN)WGMU['NX!3PNT(R MX4(JX0>^X N\P.W;_NWE_NW;WNWI'N[I7N[Q?N_C_N[UWN[C?N_UW@O^GN_Y M?O !W^_A/O#S7O +__$7'_$)?_$-_^\E'_(5O_$1W_ 9O^X[W_,+__/K/O0Y MO_1)__0I7_15W_13O_(I'_,[?^Y??_8U'^]A__,E'_#;'@QZ *+FX ? P/)M M'_0S/_83?_1I__"/7_2%?_!O7_F=/_EQW_&E'_J'/_.]8!IK'_1;'_7O/O(] MG_6_7_[\P]_[R[_[T7_\41_NDV04VJ *. -/"$-$L !FEX TN 4, $"*. 3 M0"$# *+!)A<%W@2"H $4# )C4#T)D&94IDV:*EJ\B#&C+5P<.WK\"#*DR)$D M2YH\B3*ERI4L6[I\"3.FS)DT:]J\B3.GSIT\>_KT2;&BIU%/#!1 @(!%@4)C M (P9!6J- 0T2#*1!-:; @0@-&H!R@4!"A (8, 7-J.D36HMJ-6W\> M7W+AR M.=Z::UW:]&+CPR,7?[V\M=_>N$E7KRQ]]?7=T(UC;PZ;]UFUH?XX<0((TYI, M@=8$4@L*D),G@$9Y M7FR9\_;$ZY6/"&$U,D LI:!J+UUD\*+LA@@PX^"&&$ M$DY(88467LC@61:!B*5% M"89$&)%>?@EFF&*FE MUAN4U9IIJ.IBBD6P92&)&(HZB5IQ9&KAE1[2LLF:? M?OX)*$^KN!)HH89&Z&:4=ZZU9/Y&BE:DX:,X>D3+#!5<,($8<#EG4I<>>;H8 M+G+PV9$*<.1&':>?JHKFH:Z^*B0:-'14B0>LX#('!B!@$ ,MN+ "0@<>;-#" M)1Y-TH,7RH(125V.Q'!"'!_!H<-A+:B!RPBK5%("+F7,,%VJL)*T P@>G=!( MJ'R-=.:X'MGXR2ATCA(*6F[>Z2%:\19XX):W@!#")*XP@H 7#T[P2%^,5.)N MPPX?&M<7(=0U"0*NK/* 'K2P\H$*N*RRP!R3-"(#!*S0A:RR/1S "$>,/( & M'1.$D5<8)GRT,"X14#))!+A,XLC#+;&R 05X=%1!RT++E");B:S!1B93_,'O MHHXJN?Y))F-0C1$HB:111]63QD4'!!XQ8G E8 -2 .KH H7 QK#C M(6.XZ($'\( &"%1"#!/C'1H:40$\Z,$"ZWM84.X#" 20 !-:HUHB,A&*0"0B M%)X(Q28"$0A0%*@0F_B$($J$S/YD%@(JFM@:*$:!"4$40IJ!4( ++KB6+<&- M(UZ0@ 4V<(M''*]X9N-(#'Z "PKPJ1+6*X.Y<.&*!^S.!&/$Q??L ,\]K1 7 M&&A61U* !EP@C",HG(,'.E(&6O"2(W:X "Y. (9?F;*2,@CH*FAQ"PR<05UM M;*E+0>*]NE!"H!R90PPLT("(7N(!CXL+)C^RB@BH+G>[PT#PXH+&P4& %BW MW00FZ2V/30![=[ +E00TJMJ:G63F$ L4!E17%@ ?&!H 2U,QLX8W"("KW!% M!6X1@C/$ 0$ M7) ! _YP()J!\$ "$L!806C@!J<80U<:<(-1! (!Y]3$O=X2%QVD0"ZKF(0> M:N<(#-3THB@5@U095@D*5-(&@+$ XPP:T3K.@0P4B$$+7G""QVVT(R; '06B M1XL)K.('-+B%!PE)QUMT]:-CG$0%".4%&QA/!BIX00K ]]+TJC=BYI/C UBQ MBJ'"(0&L""@?<1&&B^;%"RW("R$K84C/Q24,U8W+]&(PQ@E0@A(2B*K.LKM= MPW$D!6,LD\,&C 3C "-\/%!AYQESF4P+MWN04=.L [/A5.PT@I$[Q858 4C^MWC-8CR..2 NO/#'CC1 $J4\Y5J)UY$-'#76 M8:W$2)$Z HZM"=6(_FK12<]90Q M-8,-9A \#-S!+@S+7T4D& @#N& 6@"A #7A< 7E)@ .AR 0;G""" DRA$ 48 MMR (D(-$U!L5HBA$)@!Q !>Z?&",#DC8 M+1X@"5I4X N2L(%5S9 T/4@ 6R (Z20>T(I6WDP%)GA$'" 0/5!+O8V$5,$< M8EDM5DQ !GI@A DNN@H$Z" ,4*# ";K$BC-S1 ?;QD,#YK '"^ 3HP- PR-4 MD.L/))%G+@R#N&5 !S(0 J?"$6&0@/@C!F&%*S=8@]Z6-1-D M>J?P!ZD7"A) 6HA 1X0"%@V"V,0 /.V;^7&6170 (!0!_X$@ +T=@-L<&2S MX ($4 >8P #GU#238#X-Z(=_"(B!*(@?01$407JD=0KE5@.C0 &MIPD: M 'LHL!4D@ "W%W"H ' W@ I_H $'@ 44 CAY@*80 $(4 $BD !MD @)<$Z2 M&2 MJ,*3/CF4/UF40)F4.LDE-DF4W"&3)(F3J/*44]F306F4,5F5C:&52"F4L\$E MV&%A7DF5/ZD=6\F23(F645F3:[F5N' O5G,CZRB79 :1=XF7>:F706(C'5F7 M'/F7>E@)/Z LA6F8AXF8B:F8B\F8C>F8CPF9D2F9DTF9E6F9EXF9F:F9F\F9 MG2F9/2!@'!$'/? %GFF:IXF:J>F80^4*JNF:K\F9A0@I]!*8^D*;M)G,FIG,O)G,WIG,\)G=$IG=-)G=5IGP@-G#F]?IG=\)GN%YG.5'"^)IGN=9GJHBQ:HCAJ@I/ !OH D'0*!K4&6!\ ?7I*B_FGCD M.HAGLI#F"JP;(@C<&@J?, 88D $9< #*"A$#5 $9 JP &2%\ (*D 'N] !( MIG":4 ,($ .X 0)E"7YN2<\H?Y&%I*N/S*QZFJQG^9I\)B'\<&MLV!D.3 + M3A @, &$ $5*" :]!7"5 (3T ;Q"@;X )H^4"F&@0@- !"/ >' '., J37F,RKBU M'3$'YZ5K'JBE=A%&3NBT>?$#*Q6,67JQ/B(R'($'Q[5M=N,%,? XQ8,_YJH' M&S L*G!*#;1:HVK$VL5=2!Q <'S.A6+$XRP 8T0>:>6526Q :>"O!S1 M O@TO6VK(ZZ !P>0!R%W0W-0 2NU SJ !_!D4)5CKH241ZXP11RA;>6J$G"0 M:BBQ"DL5)AH2"FS C< "E/ 2[ !C" 8RY0!Z*@"8"P'Z%0 P80"*, ")"% M H @36R IS5!B*P91*P6MD3 UR'-^ #!]"%!FIT"V00 _XHO(-C'+@=0<(Q M("UU\04QM@,9%0*A! 3, -\ @<_ M''5KPP,JH#2B/ -Z<"IS, *T8 9T<0?;>09F_#&1-P,S$+BLL ,M,$:N(%<< MH0:W$@>XC"@601$N0B/RTJ"G\ F?@*"GX 0!5 ,%0 )L^DTKPB\.J@D.RDUW M0B(=O$'#"$(J\ .W0 ,C((0H1 L+@%LN5 8'\ 4614.Z!@81$ :ZD (1T,J2 M4 %QH <><"IP@ $J9@%22PL>0/Z^[0MXCG 'WZ51D5,!3G5>4-!$'3%$-# ) M9W SGC<'M (9O/.U1+1>1$#*2 )$@-L'O (9# !=<,1QG,'L74T<1$' MN18">@":ZL(#KU0&.X,'$S #OX4&,&T&="967B ))XP++X!//5 "C& &G%<) M$R!YK*3(/.(!GJ-H'$$)"G +,7 &M( !JV "UG6Q+? .S 'IZ0'%" #CI!V M(Z #!ZAM2QT]%> !E "-/0 +?,(2Q4&'\ (:( !20M421)0 1T03_/4,QT1 P8C7;C 3]X":295%ZQ@ M50;E.RVP W*!18QV!W%A _T5%VJ@7_A%"P(C:!,P"6<%!T[$)Q,0/Q5@D2!JM5 50E6Q9 "8Z0 C1$ P9#%S:'!PT6!AOP."?5:0SC"B- ,W%1*2.P M XPP Y,0 DWWW".%"SS 01_02V* 8]S,O%D-V!@+C$ !F=%";XR/*70R+3@ M"N77U3FR 4?C!1:P;"JP *X X2 P!V !W/P 6UCL4:, 0H0>B%P-#L5/:6D M.H'T;!QQ 8]@6V)-21:%7ZLU!__$$2!&<4WD"@[0;2, !_YE<,6X8#)> "X[ M$&,0\ B^8@(Q=KTV 2^+LB(KHA9QB9NYF5J"Q J3< >P)5NX0ENW( ;])4G* M34EAP%N$AC\ 32@EX 9E$@(?\ (MH (VL H4H (MT (IP-^XH -!I$:2D (I M@+0)TP@>4 $?)CT)HU'HFU)'4P8>LW%W4=PS< 9B$ @0!Q@A6=1>/ADJSQA%0< $2H /B M$P(RD +F\P)A@#$QH (Q8 (1E2L58 *[T^(8L@'=BPMBX $F( <8(#?PI0*3 MD&GB9ZZL,%1X@ "[3M""5@&^XOX(UG,7,L10V%-H.I YM^ *'L7COS(!M M9Y. -G#PT(U2MP#Q-$#$)JX'E& !M[ !DE"_+W#N)P!K;$+G&XD6GO">=7XG M6^(("-!MN' &:];G;]81,V#)$D H037ENK9Q%&,!:EZ#I0,[MS!1=K,[9Q!H M7^!6Q-,!E> *-A<&'F4!NWX+,NX1'>#J'D,!D[9+E*8")54&-!#FRMT 0?,* MLJ4TJS !THL+,R!MG#Y&P0$',695M&"^RIW1I^8Q'M##AJR;6?0RMZ('N29^ MM/ 'E1?DY#"T/+N.O)*N')*DZ!;QNT(>+!:I7S)_9DX'B$!V_;5ROU='\/4 ME;1:!_[MOI?7YW=@-G-02R(^ HSK"@W@\!+_^B=P!F# 0105-"& !KGVNP U M5&R2$.,)U"P)%7!DGW,$%Y@.N,A4:,:* !A!X"Y>-$93N0)A!*V-&5B%8X?HP1TV*C#YEF) TYR*N"G.B M_L3P2%(%/8P@2'(4HH(K%3MPR2CQ:.@D/0GT4%)AX^51O/YY]>[EV]?O7\"! M!0\F7-CP8<0\(H6GH( MH85',I+D!!7FV+",%\ P0;7CF*E!Z/*H"TC/5(8X0N?<$&C!!/@R*L2&4:8 MP35)7FCACCETP(61$TR0815 M. !%SSY!!,4$#" @C="V00%#2AHXY1 .$CDDU%04 34!1T<&(';1&U!ZC6 MU7ACCOX[]OACD$,6>6222VYD@T=6D2'CC![YKF12)5ZO 110>8, % J9PH$U M3EDA "?:B""!1-HH(!$7,IC%A1M&6624.@1P D$'):9XP0CYRGHO6?7RZ0XN MN_8:T;[$#G0KM',T.S"UR>;+IZ[7OJLSN;F>N^ZV8=9[;[[WVKIOP$7.&^VW MQ\8E#A4>;=$G+X+RRVRQ\2;YO$T\&:4- IQ8.@% V&!C/D$. &&46=((8 PV M&$#%B0P"T0"44T!9SP$10$FOOJLGKL_BP'OW_7?@@Q=^>.*+-]X\!4]Q0@ V M3ND @@H6*& "3&YN&I0_"G !DP9<@, )%\8 Q(E 9,] @_Y,K,Z=8MY#K?MX M^..7?W[ZZY(L7WH6$ M+ASA"E%XPQC2$(8LM&$/;]C"&I90AD DPBU/<(A9YJ,3!G4V*3T1B$)M(Q"J2T892].(94=A&66F1<'*\ M6]KDIL8R&A&.9XO*&*T813/2,8U_A"'N,J$\ K!A:0@X9"@B(() % %IS@% M&P*0@U-\XA2SX, ;2.""63C "?ZGJ( $TDP!)>2. I0E \5W ( 4"C&P %4=&"2#9@"*!(@ JI]\&KMF\0, M=&"#:]I FSC09C:Y:0-N>E.;X,SF-LW9S7/:@ ;<#.@^4TI/ M'<&_1R][R EBSGCH)=+%KW?V:U\"UQ?XM>JN+W?Y"V+42 M=O!]Z9OARUIM%$X8 "!$$8I L.$/H !0Q/[0AD*$ CW[*I]^ +&&1 #0 ?R1 M[#1G^6,@!UG(0R9RD3/2K@>Q8 RCR 0H\,J@43SY=J#PQ'F6;=K*MW:!51EO;V^9VM[TM MY&I?6]S)SC::W??CM;WOV^LNC+K9C6[#O3LOX1YWO==7;GGG6]_[YG>_08/D M!=';WB <]]\R4@HXF.$.#/9,56CA"CD ZI6NN$.QCB()-)Q!#P8O#\7U0 LT M2/PS(!5%# @)0 !8 M %ETP\4. $")/0 @,BP?%=//!H<*P)POKK! ")R%"\4X.=6QU/',0 8@& M!Z#Q"2, H*0Q/P( :H&;DSX3H5N<@#)]H84!(N!TQ/A$#Q10>=EPP0H,@.'5 M&_,))?[ ;NZ8MU(7$@# #%[R@0*8RV_>%KC.+2]"EDQ #Z4PPP V0 O0X[CD$DZZQHD7I'_KRS06) D#A);1X 9D50GB\XG3"\&3^#(!'#WB.[B\8+Z*0 .,6+ZN:_Z%DDN\X[F#!," M"-"%C#"!!J %^!$"\@22H#%!?@ TO[31DZ\@!"9A \HPQFXA4>0@,C0 PEHPQC( M!1+\@:,P@05X ()@A'A4 !D /0N0 14 CC)0 0X@0G8$'AL0RXY@06 'EK( M@PD@1%F,DQ!0 5R8 0RP@0-P #7 "ST@0P<0O$:! 6 @(^,! BP@0TH *7 MA3"(@ A @#-XA(=, ,$[@T=L@ V91!Z821V@A0IP@ ; Q:- @S^, *W @0AP MC10 #AVP "]8@$@8 329@)6@ 1H@&BAA B@ 0\X@ \H$T:P@ 1H 'NL! L@ MCD:H@ 10 ,&[!1N @%K$0AXL'I]0@5\,@#W!A1* @!C8RITJ@P=8 *7$A1' M *,P ?[_$X\V?+T@@\(IE"PI7!!;D!40. !DB9$.Q(,KO(6#O 4'&$LS2#Y6 M0 $:(I)@ R<(4-4 !C"8!+<+V7@(,'T(-5.( 3R 4$* %7. -9' $%6 5& M2(%'F(0 T &5&0!7*$WB! 'B$1XB M"V"$;*P 5J #%7"5DW "\ %%0@ %3@#!0A#F$ "] #*QP) ,A/*#W. GB M,H@!.J2% +B3,!@2*"B '@# "A@2*W0%^KR ,_ &@$/#B %* (O0. %M # M#S 5Y ! X 2#W" C!R "5!.#"B "P@#5E" $"@%"66$W&R ,J ! ,@6!= \ M!,4#5FA16E $*B$'&4$%"T#5] !'[W+XFD%!'@!5A@ C,2%%!@ &= #"R@ M5_!,&G $$P@ 2LC11W"%Y)32%OZH4@&XP(V090B8X @$@H@RM=BP.(T"UTQ8E]">0D#CT(@&AI@(^@A03 2%H8A#-X M@0-P/+ MLP6(@:V%"5=@A #8$(H+@Q 8 #C@47O,D0GXB)B] [L5 ). @ DP M"C0PTO[E*X!MZ5,O@%7LDP /&,(!\("3Y9 (V !<:($#6(H3:(T-O-#EHX49 M.( R8=)!%0#L@X0 ^()Z-KH M1= 8H(2./ $QZ#IB%1[ZU(H/6 H,0$%< WRO(/1A1*4!0-6\%KIHP0X$( 8 M:-RS0[Q8PKD>*]?\8D="(!5N58AM0 <2(!:L -EU0$>"(,Y* 4# M(%$M60 ,$):JY:6 K4.8/ 30(/+_3LP* 'IH0@T4($(Z/Y B;4F+P@#\L"# M&;@ ,!(5K!;!1B 25B]$,$ "J@,DV6$ 4@!'=B!,)"#TTR!6\A-ROB"J9U4 M,1A"!* %E-W;(10 =6D%"B!9, @ VG %!8!9D 1Y!:9-'4" V 0[F$ B!1 MGW"$WM626,6%!@ !IH6*T8V!,T" =6S:6S#C&*!1_<.%4F %N8V5#G" ':#B MO.W1_>O;D_" !]"!,3:)!_!;^O01E T#.!B &-"!'@B#.\C&R#V),G#$ ,!" M6HB #C!3!*B$7% !SVV4\LP( &S/4L %2B@ ,NE==AR ,_2"="Q>V77%") M+["! *@* ) #768$5A#FN]#4,O[A/1E -<( 0C(2 -8OPJP@"\;Y18P90S> MWG6!010"@_HCD^F >RC M! &0E#SF0E8H ^K$B@I8A0\0:@ 7#7&A0W 2GJV 7>%V578 3UP!02 "I^F M#%X"UHQPA0:P %9@B8B0VT3."#P@4#78 \V5@%L P 8!,EM!%:X@ 2P6C#0 M P@H0OX)?8%*@ *!K6.3Q>,PR(6F9=H6P(4$^ BYQ;['1FL5H 7"K00]$#L: M#0/#LT<)E8-2H.0XB8 )>(0Y'#N:_4@'6&560-(6J !CKH3_%8A#D0 )8([7 MQ86D^]F32&$5*%XS78 6<6<36(4F($"0)9L5,"5=E9@ MEI15& #'8U(O<(4F787#/0, QP$ IPSVA@1+#9$7&(#8"VC?H00$\ P^((? M. "52 $!Z(%)" %LI4]@15"."(,V'#L4';M("9$G%#<"UOZY3%BEO0N $AB MR%5 M5T!1+Z"%=*R $2@ -"CM/O<. EV%$3B "C"! 8B,!ECEO\.!%$"#!!B[^UR M < *-&! 7 ;1F :;0 ,=5LX/Y0 =+%!1-( #PY@WN94J, 7@5X5^D> +MX M! &(%14 U4*\!4JH@"@=F@L @0)X!-S59?(8@0!899_0@0) $'5D@8 @'(F M61D XHJ8@-[8P!TO HHA4K@[\JX8SA S0(8@0PA9=\X@ 28'@!$V FH1 @7 M'@G=*5P(RTE( ; =@#NF!4T%T3ZG!!!5\3(P@ 3PO/+[L1:?&(G9>8T../;1 MBUIH!#VH/Z2H!%F95CZ4/NB[N(_3WHR@!#K@TK/.K*I? MZ3N N5O0@SF@.:WG>NTUBE4HDUNHO;/.@QEQ]Z7(!4HP%U:0A*^/63Q@A*R! M>H!V!?X]T.NVCUE*8+!;8!;7L$,]D#]D^5=?[3N_ESW76 U>WA5'T(,HAI)* MV!6WC]FP^$ "+ U@GORAQ8M)<)5<$/T&W'P^R0R0ZT"DP -Q/7V8H(./PXM* M^&56B/J_*SFGG_T[$%-W=PT&;)&JN$%7D 37F-9)N(5) #U*$,)7F+V*D(22 MFX0[J+]5N'I7<07>7^G88P4\6/H,68KACWWRIX0647J\:(23&WG@807JMT-* M> 56,#X]4'$160B\N 21(1K(,&"!@\B3*AP(<.&#G%MVJ1IXD2)%"]B MS*AQ8T6.F2Q2M&CK(.W?LG4>6OF_\>$=1W]=PCNN^^"=1MZ?;OX\^O?S__TDR.(('$$0 &N(2 M!@X8(!)+&%A@@0PZN."#$"[8X/Z#"DIHX8))*'%$$@%ZR&&(281X1(&.+-HY8(HLN#@CCCS"J&*.'-^KH(HT[YMAC MDSBN*".10DKY8I0C+JEDDCY6&>253'IIY(PG'LDCCATJH>.47P)9Y(]/,IDE MERB&.:258M;H9I=Y4LEEFWV"R2>;,0)I9YU=ZHGEEG JB>>:CM[YIIR,S@EF MHI8"*BBD/5X:Y9^#*AFIE#=F^JBAG5*:*JB'THGJI*]NVJFI(U+!1!5,1!&% M%$Q((46NNN;:*["_]NJKL;[^JFNQQBI;++'!"IML%5106^VT5%1Q[;758LMM MM]QN2_YMN-MJ*ZZUY8J++K;J6NMMN-^V&^^WZF9K;KKVKHNOO/K"J^^[]<(+ M\+O]$OPON-[.JRVZTS+LKL,'[YMOP.SR:S#$_!;\<+\ (YSQQ>,.K''%(O]+ M+\4>1SRNNR9C;''*%[_\,;@ACRSSN1W#C+*_\;),L,XZEXROP B[7+.]HB"= M-'I),]UTT^B5QS0HH)C7='E3.YTUTJ#TU[777X,=MMA>1_111JVQAA':4:U] M4=N:M/:V1&C'+N>>?@_[9<(Z3#E5LH:.>NNJKL_XN4V6!ETXZY ?1 M7:'DRAR3&-3('+A0 L=7>^#1TB1SN-+6'8W0@@8K0='BQBH(Z:Y7Z]=C MOSHD>A2D1_*K7S1Z[+''AM(= 0P0DT%Z *!#3P2%$ M- @"2T=_- 3! ?P MI#DN/0# $>]S104 ((,[ ,/T&)'0#@A?<%!A=[<.#[:!$"]_W$@AC,'@<[ MV)M;?" !SQL(!;BGEL6)KW&PR\@*5Q.Y@J@@ @Z@ 01900M)!."! YF>"A+@ MBDF8H1:K*$ *!H*'.!#$%=\;"$]>L412P( !3! "!- "#!9X! @:T( 1W$(%(\"%*U2P 6$ M0"\]J /%K ,O3$"PI00 3@@ LO"$ @N)C$ QZ@ !TP0@-SH(4$9A"" WA M+W.(P#+=IX<(\* "!W@!3R#1@04T8 <2I ;<'$'! B %=_B %+I@0+$H0REI(4.ZJ<'.E*T @_( M10P",(>O;@ 771V!&2*0 %I00J&NV, "GEG%GM B# 6( 23F ( SQ,*87NAJ M*C&0 E8 M5MPA#!\8@!X8T6%[6G:X'L9%)5S!OCBB. P@$, =) $ 9*+D%@\H(B]3O.,[ M. ( X]UO WBB5$F<(;=?D $%'5 "&MO2!&$H(W.[[.65H 0/#K@#'BS @X%@ M0("X@(,)5A$!@L A!+BH "4DD=8+Z( ,96A!2\4FE16JUZA1B " 2$)0WW_O.2PA8#QZ5N4$#E!*[ME P[BPP0!886K2;@ !K@"#[@?"O@?Z]0RT("*-"T # M92/ B$8 !Y<[&&_NN'#"D! 3R@BQO38O72'\ R MOT\/)R#W /;PS (H8 ?2)X,!" !5H1 5# KQ ,@ -.'4)5@ R,@ F,T07L$AD95@Q, $6)S5.@U^5)Q2)H1B[(7 11@E[< M@AXTPBU,PO=0PATH$>_\T!A)@EY4@O7D@A[@P2L,!"M, D\((5&4PAU(T1"Z M MSA40Q"D1-2PO2@X/30 A[H&R7H EPE#RU,@B[\T1V8UA,^3Q5>H2N\UQ/A M0B3P#BWH01ERX?? 00HX BVH0 &L$8TQ7$&HX4 XPOLAX!_&VRIP&5SAPBJT MX#8E41R84! NT2W< 2*.S0B2H&J\D')-@CHA )P&R!R8B>>U.M,XD8$VNDL MQ%R<1&D8H$I( B.\6RIZXBO"(O[?.$[F743$T6+A_,7BN&(LMLXN\B)S4<8F M22(G(967^>(O(F,R]D->T$(EI$5R:<5A M#$0E-%0VDB-?2,XI!N'SK,(/?*-=?(4>;.+>E:,\WDTY/L8Y1E 99%+ET*/D M.((T]B,_\N/E^,0C]N,]FJ-@8 Y!5(*'Z4'E60X^$L8)4:1 GF-7O 4NY,$9 MY&)'&H09+*(\F@5=C*0R(L0(#F-(%!56H(0;O)E2H 0<7-E#K()W&45B4 )R M?09*[( \Y>10/00>F)=I)%Y0,(+A>09*Z$ +R 9*[ $$_ ^1H<5L8$!,S($" MF<07//Z522Y&2AH',U;B'+34&4E"&4320>R!&32<*Z !'/3/6^B!&8Q0+LP! M&I0"+_' !S@"2C@"2#(B$%E1'$P '@"E!)F!FK'"71;B]/ .'JR"%$F"FJ7E M69X1)91!PU&"&2@>&?V1&KAE8-1E%RG$'9R!:+Y%7XHF+WEF__#.'N@%+<@! M&G31*JB "DP"9[H"*U3"81($8.9F06@1+I0"+3@"%Q'$):#![Q $'IA!)N7F M;C[/'"@G%,&!&Q3F0,S!&5C/);A"7P8>4[D""$265M""P@T5$-U![JQ"+$06 MW.$!&FRA.KK"(YA!X%FF([@"%<(!?!I$?K)E2#*G];31)?Z$)"X\PAF84 _T M@"2(P3Y6PAG,@7K63CN9P2 L!&PMXH$6Z _MT @YH23X)2XP0DN!@8!UQ1V8 MP8,-!)05ST$ 48OV!!V< 26=$2NT:%R>I4%0PADH'O#E0 ?L M@$0]CPG,0 ] @![8V02XSP]@@!B,@#R5003HP PT &&J 2H@/4HI0?DZ9G] M %/NGOM80 I$#RJ$ ,A-3O? 4MC, )Y*DSR< &S( ,0$#Q3 (&Z "P/L\&G &>(\% MV, 75, DX,$$5( 8Q-6'00 .S, #9!\<2 -T, #Q"H#JH% S4"?RL #",0= M4( .I( 'P$4**&L%H $NQ $$Z( *8, ,U.M!50*UZL &8",O.2L87$!,Z$ % M[,"]"I .8( -9&I(KL(&V,##=A$:5$ 8#&M%54 *[%((@, .F$ %U$[L#=.< M/D!,T$$$V( -*!0(D1L$4!0#GI,,S "N#D0,F$ /6,#O]$ '7%!!P,$&@,$' M%)$78/ZL##B _<$!!91H$>G!!*0 ",@J!OQ ",@30NC JH8 \FW %X! "@29 M*D4 3XQ $;%"!+ EV8Z ^S""=WV!B3+1"*A &%S 4\T!!GS!XW6%R>Z XKY" M"*C Q?Y.&&! !.Y>"#BJ&AB$&N"J"6#@+5S "<"4!3P/'%Q #YB #!AH1'5 M+"WIWCX3!'P 4\E9"V# #KP X W"KR F1($YEW&<'AE)<:!=X6!0.$"#P N MK-ED)9P +7C P$;EXF&0![CE CP/V*T9@L'ID?Y;&6! I_X=G4T2Q-<&(;7] M[4#H@#Q%@ ZI0!TA5.SAPBO,+1I \!? +01(DPI @K_A0@AH+B[@0"HI@%Z MJUUXP2X9:,W- JC04N% $?JU$%-P-E* OP2JTZ=V21( ,'^FZSB4@2H#ZQ" MK=C*@'Z=P -!@/K$@".@@?E24^V\) :D4B2\V>!V6OKNZ$#0@#S1 +7A0@N MP26,$BY< @+8W_NH %:" 5.:01>Y0@2T( *<90?,6 4XPA[\[PZ@L S(4U'B M @B$@2MX7B. H/$MP/2X0@-0G1/_FQ=,0"/B0@I@D#-YP0<,A V,UQFL(030 MPB,<@$!4PMP.A!TC1!B@1-]VV_Z2!>E =,"YC< NS0$&XNTH2\(C>)<78%H0 M^A,N?(%\3>] K#(KZ&XD7X(7Z-<>O-D9/,#SX$&?N<(C)Q$$9!((Q!$$Q"HN MC$!#1< (5>4J'( )B0%-V61PX0(94)L*+%D(H,$D0&4A/D#@=9L_24!)0< J M0*KQ"5@(S)@8R)G ?E@#H,0'#&P$6(\'&*N9BH\SUF)4I&0+L20NR,$M+]D! MOP\.N$__O+$9[NF;FH SW8()<&1(?8 7\,09X%*U]< ,F,#_A@&FB8%\24(% M/%%*[QTN([ \44 FI0 ,>ZL-R -0$ EN(%^E4$,Q/0T0H(%$% +S -? "U MA4$$>/[ #UQG!VLN2M 9P?7$*E# *J"=PH( M?6$#83!',@93WQ \?@$!HCN"EMR+,V "DS +>"!^?8<'E07(^"Q6J62 MS9T9WL+%%Z22#D3 !^SR^P2V%X7 ''@!M\H M-+"8!V$)%Q O0D$#V#0#XQ7 M7LU ];X"(_RO/1EL#-A ,]$C*_" -PG4M,I4PZ%$#WC!4>K (]@ &CC" ^A M#." !)3?+>?R0*#J#"0L\&" 3*G90-S! A+$!AST!+2"&?Z(JM7Z- U$@ "% MV?_R1!D4406(YAFHP"- @$_;P 3(I@"[@G&O="-%ECGCP@E<\PG 01QZD0?D M:#S/F=[)WB2DP,#Z!"U, M2@LRFV8<)]HE7P@/\MYYR;_B@J>-48D3S,J9Y M@>KZ1 ^H[D T BM,P!VB,D@/A F$6)$]'BZ@ 8E)0!A, B6DU4L/!,I.$[Y% MD!>(JH@^TY+UY)Q)TPEP6QB$P"5(0B5PHQD065%7P@Y_GA#*;.)ADB V$1ZX M$D+T-4%(P"K, +=5 @7DVAS4F2#*'@B*007@@7$]D W(TR3\&QRP,&9'2IY MB<&I#X0'E*D%J,$D3)(-W:XDS!5H"Q11>(#B;8!I_Z\.8% "2]99O@!55QL= M.&M!A#9!V!T4M$ E3!(W]@ -=05/_*,"<-:2?3LN; -0()VN0)S&Q&"3T(E MW)%!5 ($E$&=;;:!AH$#J"B1I\!*Q0'JL@(C3$ EQ'N--4+L'7!!0L 0+"!NL((?/ MX*T9Z-<)<[N\#U4C"/ 7;&_!#\2>40)!5WD; M*6GN1, 7Q+OQXD(KXT(94%L*['(*J$'"!T8$_*Z(D_(M%%@+[/(M[.4$G*4D M?';%?OZ8)>^7&@@S)D4A&BJC5W9$<3S.0\/!FQESIWTY+D "!D,T'%.O&(5 M*GW -8< '.AP\LR!=YT!!G1G PS$%]1<&! 9&" 8.]]F;T* -'! \CJ!= " M*TA *D6 -)G +K-S)#D"+N'\0(@!M6$7&3O (X3R[F$:#B7#L3J!*@/4_,20T%8"_P05,(!U#>Q3F' '(C! J#X M0,SK%QM>#%C5 [G"S39"4,NJ=\&!^=*O*D'E#W@Q#\@U>3&E<[E/#)RM#/0 M+30 1=T!BW6Y%_= &-!" G11',#2'31WIFVE!3""'L0>#?[DU.[1D-7&@1DH M !H 1*,*M'"9\8 +URU<>@[H6?B EJ,(JW#A.8%+QPR$&W%]*(,P@B0O,A#R MT(A $JX["%PQJH#0584[N%:%6%7)84) *UX^#7E(@ ME 1A$JY&)0@BO'7!#,T(1B/HH 4U;04U4T=0FA1!H:0$!,5 ((CV5ID0N$P, MQ75B*(89G3ITZE7M_Y^7;HF[=NY=_?^7=,F\./%C_! #ETI&"&$#+]SC\(-(<*%#35Q: MF.G&6V3HX(,49MN(D@],L,$,++\X$PH[X;#@ QM*^&VC6V8@U(39P-@@!3)B M\(*1NOX02B&G%!QQY"(O[,3J53Q:4$.''4[DL /E$-)#M \L^ \-#$#8P*$O M?M!IHT8XW '7,+H :%G<;DRA3!DV.$1$S9RI(/ZX,0C@KX2HN&#%\X( 0Y) MEL4A/IV\N @7$!;#Y9%N,1C+D1$*$A(A5DPP888S,'AD$@]"Z&"&^"+[H+[ ML.H A!$JP>4,^,04%H.9.)*$X0W@O"5$$S"P(3*#Z\1%$GU+\D %,TX8"XP( M&BGSQ+1PL<'FD1C9 !*.< XJI>%Z_H)#$":F188//HB!H!%:N\,I7&98;)*. M>V@7NZRUWIKKKKV&KCSSPA.;[+*U^\0\6[*^Y32.5CGT.?Y7*,&Z+U?@>NHY M<3-M>R.XHV-;.DKN7FZ5#!&B99*^S+"9(UJKDH278R5VA(*_CA+C*Z\EH?@J$1[15QI_?3G)F^O=KPFNISQ. MT!MO'EGG6%'^D0C,A\YQPLF'[O.O[;\?__SO-YO_[<+NGVQJT]\ "4A 1V"M M>S=K4P'WU $000L["F/@!*FC!P^,P ,Z0.!R]%""3%'0.0JAQ/Q 6,+I*.06 M'PA: 6_A!2IE[&L;-.$,:5A#L/YU!VT U.$.-;$(]-@0B$%DSE9*N(KW"1&) MT"G%$9DCO20^$8A.S!\M3@=%*U[QBCS$H18!*$ L?A&,882.#,581C.>,7T# M1" *J4-&-+[1A/_KCAS'QL7QY%!L7H3C'OG81S_^T8^ND"(@"5G(Z]B1AW@$ MX \3>)0$6JATCARB)#_8'!FN$7.H,Y($*9E&2S:RDJ#L08H;&9\SV F7AU-!AK9"BQ08#FO9!.4D]$#&5;+R*2$XS3D1 M!4N$J/[ *)4PP8XD-A43*,T#,\#>&-,H0U;P( 9AZ LMO! #,9#1#%+*C R" MMHJ<&!*BV*&C'2?:/T5VAY%9PPL8;S$')MHP!5_88R4@X,8(0N"CU5%(067Y M"@]$0&/WLX,%EA."Q6Q0$E=ICBL@$$GG;" .6E-(#UX0'5I @'6X0*K7%**& MS6RMHREU!$0V$H'%>* 'KFC%#L+EB@6XH1%ZB$$$]LFUF.@@.!>A!09B,(<0 MF&HCPIP# *02AA;@ 0,$N6M$^6H=LLFQHH@4VRA I+;X0 \:9Y?X+,F <)#(BS3FL MH@>3H(0>TN0P/=#"%7=H1&;OA@>#AO4I8)A!&?26VT?,0 ?% X,,SH"01S1B M#Z\Z7!AF( :]AN$,*M"8*[PP S-$AA&,.-8MK/7=YL"A%;A@Q>V ZP@;Z$!* M>UJ%%_: "T?0P ;QY8@>;$"#UE!B ^[5 3?-$ ,P$ 0.O962>VV@JX2400(] M. U__8N0.ZSB"PYAQ*@:D0?GZF"R* N!!V[G2#BD W:TIU(8M"(I]CA$3; MP<3TH!P]2(D6UA*H2H2#$#Q80 4>&DES7:&#"H0!+HW 0WN4P'*20+$G;-I M&%2 *=@&"+2/N,-0N(MEK-A@3/Z,PZQFH7(:5H"8$96=RDC< %I'X.%,/JY$ M&:0RB8PXI!(IP$!S[]"VU[H"#Y/8@7%-DE0\X%:WO.5(^\3U*UPT0+]?L%L$ M1 <"B]TBP7'Z#R/J"^49:(RSH_G@E0[7 %>*A"',$PJ9C (1^81#%E MV5=;UPM^<1#YB#L%T<@0_(H!)H.$ 9X "! MCRR $I0H@ [@$ )MP2$"<#C# ]34@ADPP@11B\P!8N B"S1-!WHP>$$6H +/ M($0&,OY@Q FT)8,*H $-"_A-!7K *FB=(0$J\,(M%B56"3'' T,Q0P$H0N)& M4& . @![N4(&)8> ",7#$K]&@A@F !=!C\/0&P&)$9=X M.<3AZ:$PL $X?*$!1D1 #.#P@@O@X@5"*H%(\^D(&6CD#AO8;P50Y0H,[( . M)9 !+71P;5?H 0)XR ,%$C( @6&<2'N!N M,D8/:&HJ3$WG'"D$= N\J(%(/YH1'8B(;Y 7^ *%3"#H]JA71"#;1%!TQ@ M#F@A_CZ@S;!"6RK 83I@7KQ 6S9"$F8C)ASA%1H@DCQ@#A[A$'%A ^[ @E3B M W#! QS&EY9C(' !$BC"%2S (3# ,T+ 8 N3AK@%L# 5+J+%:CQ5,;"?=#@J2KA M ^% .%:A 6BA41RI2A#B#^6# F#$5- %(3R@$2I! 6;C%B8@OB8@+U#( DJ! M$B+ +OY>8B,8;2,LX';R0 8PH ':HQ4@("54Y! 5P@R<@@9,X-"4;16TD#AP M0=T.@WM\+ )$J@/2@B!TP)C>24"F[0SGI.W$0 \^8 8&"08A2M=D4&RZ4A,( M2X]B00=*P ;*@@+F1A*+3(,40LU4Q"OB(V.(B )8H0S"I 4L $(N"I.H"9<*$##DTV;F$5)$!!(,@UW2H&4F S\* ; M<4&83"!R6F#E" ($YL#[",(5;&!19.(C*0?\*J $)F;:A D$@BH,1F &/J ] M>H W%,0"=#,$7"&U$N('P.T@B!2Q R@*# M(&:@0AX&$AK! [S@:'KG!"BA EC!!K!I*SN5B]"&!KUR.PCKAQ0B!9@&\9HQ M+9\"ZL0@:F2/;U!Q(] @S^"D &EA,8?1@S:K7;X04400EJ8&,8.&#**F6,TS M"Y6-7EXB!-HD!DBB-_5@"NU"IX)"#N;@%9V'8E0L4Q1*#Q8@%K93(M& $1Z M(BQB6Q%"(:-3AEI !WZ 24P+,7."BI(34W3Q<'Q*%7\@2Q^!I_H"Q7AE(SH# M%UK&!";& C1&01OG+6#1#8?#(3; PPIVW&AC,R#0+T[#"_AE.3Z 5!@A#Y;* M S3& _[*20) $2AFX%5. T\,"\>X15W9SGL441X@/T XRM2 TH@=>)"M^=200P@MVX"0W8@;&;3S!H$^.BA;$ M *Y. PQL=F!MI@06Z#2R*R,UY@(:H4O](DR?H@*2Z18JX!+*U+GLT'E,;2,< M )D:\@$E>0$!BP 0(P@;.(!:T\ M4\G! ((0H@?@ M"F/=PSA;@ (PP&$P @\< >Z&LU-/5SO 4HM4UVSTZ 1D8!7NH $0]P&T\ $J M8174C1)T8 #:1B%@E!+F8 %:8NPHP02^Y ","?L"AR$HGTB^VAD^0 M*$ ,*H$,(K,,LC532,ZA+$/E$((X0&\5'@$$'LX@8,("PJ 2S& @YJ"Y4$,- M!F F7F *S8#HU.4C5 TASF#G),$#M \#O& 5X. $JP 'FL.S/46+, +*,$, M9&,A$.!%T* "'*%@X@P78@$"K.L#>F"$$2 P)@#4*F &=@ #ZL(-)L"&/18K MN$Y!],L1/G C]L,\_T,FYF\V&!)7=XX.#$ -)('^5 "6N$.*I(C3B %)J$, MX6!W#^(1)A 7S'(5Y@ !K O:=/Z"$19 #U;A$7'A FXG_-S E;!$2Y@!&AA M!_JD%"* 5J' "G<@:B"Y(VR $N( BKA%J M=^> $FQ@ -XF LZ@$KQ \GX M7CC" QX8]- O!31B-!W"^"#!# *@$23A 0[G 0[0 #/E=N^"U01R8#-F.&OQ MGO1 $L1 :(' 7X #<0 SQ 7'2R !PB!=SG2!SJ 7H (>> %<) .+@" >8 M#1:'BB @#"8!!_**%FS@=4Q1)QJA+E:A O!T+![K=&\-+$-55%O7;2+4#,3* M%7A@27: (O2 *MF7W'3 WURL(DH@!!!7)0*C U4@!&( G,Z0HE^ (M8G5!CA M!5C!A_Y]K$WNX".2Z\PVRU:> @T>82?5H@5&8 04"R$@80/,( 1& %,J83=; M@,8N;B,JP31#8";(0&/*8"; H$H<;U7B3*?!(B_F@W!D "[F0+K.)03( '-7 M" WFQ%8W8A)4X 3@@ YH8+[@8$YR0CJ=VB]B@)?48$Y\>D(D9A54 7OX!Z+ MCA;@@!'LX*G,&G!IXG]EH#?WY%44 @^L+[Z\0$KX\"D,XQ9V 3"( R,P@Q, M8+)T \HX7)!"R,?@:)I "X(2@6H*$+/0 ^DF@= 9PY,H*)G@U2DUL5X( 5^ MP!%X&@\>&&4D5 9F0YSE@\@4^@1:@_-F0P]N&@U"6A(HVOZBQ42BA^2A[&!. M^'4JD&LJEO2:)B&R-H*@$V*[46C05J%B.4MU>D!*D\LOO$!*@WLJ;("N&^1[ M9B 68.1,7&$&JJ415" 6&,&A5>!USB!"4^!4M4<23L #8F VF"0O?QR,3,DI_A F+?L &Y,;_4JE]H$@/X'HK%]-Q M/(!P*=S%7QS&8UQK6%<&:?P\0,F<0DG'.VF2V@BJIH('3& $0MERH M?'PC4JK6D#R5F,/#[X>3VH6@_@6'G5PZ7I#'T2F"9@F5GIRILAQ_FHF!+JG) M>5R<@<)&G\,FSKURP_TH MS_F\KPH]B!#=T!>=T?GJS_!'D+KFU;\(M\YHULDM(3Z=G"8\:V*]T1L]T'4H MP^MH5%/7._3(#A1@ S"@ CZ@T^=Y@A0=#:2B#L-IDEI:RQFA ()*(=!6T;LF MP/"X D8@0/_#C39H!EHR].\?9_1)J/B@ (.@Q5&0$WP$[J]3EZ%:YR? ;>2B8S_H2@7(MB:T(8IWC;VM2U0X"$20ZX'@-IH:9%IC//0,C/) R@AES#P M<$@\8QD0$OP1>A;XC M!E/F8$Y>Y;5I8Q+N0 +V#*01@@ZD= <( C@YKC6\]@PY3@5T?2HF0!(J$R%< M)A]!P&$H(3]2/TZ8&00^P,&<;02NIB J!@,8WKZD] PV@/Z7* "W&6$V' % MEUL/P(!(GLD58J!._I<6>(!&I&(56N %:"#(@'8W7V!BS. X;*!T#!H$LK*Q M_0VM=_IQL-4$&@4N?&\/^^)39 "]_4('(F $)N$'9 @?F#000O7+1XA3.3! MY:H'KD=BT(PHB N.F1T6[LSQ8.(20QTF0N#!Y2B,FA"X/LS!Y>;'K5L_0HRX M@PM-! ]H<.F$$Z+$CX(CO,C ($8G'A,E:,3"!>9."C.X&H6TX4JGSC,>5)CY M@FN.FA\R2*;XT((5+1NK<.G9H3.,GCL1,,!QM,&,AQ"2K,*9@ %JGA0F9E2= M@\9+#%R,0H HTX/5PQ,A!--2$?Y!Q2I*)TRTH&15)RT=E:+JT%E&#YH48##$ MJ-K#E:0*M[J.".$EMLXY$#KCH@"U!YP4&.3HI#1616A<94*$**-311A7AJ968D+DD-#B01FW@*&";K&= 0(N,O! F@FX?+'! M))-$ /X'+1.$#2 WI0HL(#M+SF MR&,W%'!)+C0(,,KDESP""4>\-!J)1"LXDH(<. " M EZ.*'!>!)'\Z865;5)2B06,T/+#8;'-$<$CDX!0 2Y>'/[P12.51""D%U)N M< 8N.C3@RBT2.++*!S14XD@":%!" TK#A4 #):Q,T B8HX%Q0':K0! ')3\, MX HK%>!!2QA;[G7J!V?%C UPBV-8%!5?\ '+_SPQ!=_WW^?**C\\@ F MS[R F'#&)#8#A6Y,05 (@L8,K4@QH*9C$(^Z0 ^-I";*2F)::" F M7.R ![1@%LP^P!8):&AFT]/!:&YQL*Y\X(!XBP M&!$XG9A !0UPC"L@< P8/ 5CO8$@7R@@OO\<0JIZK HJ(2N!2<89)6$(F7U E!2A MF0:E78>!'99L\P@([ '.M@!(]PP =+JH >5<$YL M7 $;&7Q !Z45@RMV^1(]O) A%LB+#>I( R],$K@ZX$$>7.%'/!Q2<8)D2 7R M H\,2( M8\8FP[=@A0IH8U&:A>467X ;D/YBX84+0-<+K*#$BW3B!1! X#N=644'&$$# M/?"@##1@RI:LA2L)_&UF(V"J#9Q*$3$H*S:Q&8%#*+"H6SSH"W*=*2W<:I T M_>D,DLC=2]1P@JK=(A=@8DYS&P&UV. A!7, PQG.0(.&85J%%3:%# 5>8P':P6XDLV\(RH6Y8 M8]\Q@7ZAM3I)V #3&K(2@OLYDA<\1UO]&LU#=$ )=^&"$KDK@Z4(Z H%'">A M)J"%64I\1%Q<@#MH.(,> -G/+(X0%V&V30J"C(L70$6%N&@!&CKL&0@,=$[\ M3(D9\/X0 9W$@8=DPH4:4I#'WUWI%A XC@W"\K9PJH79I]+8' 98GB%70@9 M_-TC*L$(?,,DM8[(C6$ :B7^A>&0U)FQ#;YS6WC#4A+? U@>XBC1T= "6Q4Q MP2T2P!DKJX7C'SA5 Q;%95R@*98KB8TCN&,&U8& .Q]@1!A>Z(712!4YZ5:+ M;;P <1M(R0O5PL49((Z+"%RM!2E8DPI&($-<#!87>^ PGIH#%2_$,0S56OBR MTG('!-PB#DS7PRTFD3M:,$>Q"G",;F2@@K:]H 0&#$,NQ6 I[\D83#@VH$Y8 ML0#NJ 4!G+% E8F5AV3^R16?W$E7M9)'NNI/<=":/"*-%)'_P M23!,T4IO_P$2;Q&!/> "+N7Y9!BF>)!7Z6"$E9# #RKH$"^T:0>8 IH$\/ ( M)%6" E[82QFV' 8XR& !C2C#ESQ0@CG#:^' KA=67=@+F; ++"C M KU$)N57$)! :F6" 7-0!A4P$9?F2".# 3( !RU0 #(4&V$ 5Z !BT0 0AT M*&A0 A! "6K054HG)48'!S^P-65B 2X8 :S0" P SHP \*!9H !!S& ;30 M [Y25O-C 3L !T9H+10 !UX ?YY,74^B &WL H1X 4GX2[#90/), 0":Q80860"3>PR($WAV#>4, GF)P&^40$XA@MVT M 8QL "9! %5 M]P R]/Z)SD@FY&8&9@ !"T$;N" 0<- #%9 6CX !'S 4/_("BF1O-&!K$:!1 M%/ %[@=%'0@':# !ZR%['-F1'HD+NI<@B!:2C-89E&!XW?)!!A$'58$&/* ' MKA &&H(P#R%X<^ 8JQ!S+@F31-05,^!<.K$*/4 #C(4&.M (>1 :,7DJW"&4 M1*D3D] #8. *=] L(W$+9>!@:8$'4$,+;I!5MQ ND_!&CR!( W4+9C #;<,0 MW.$** D'D.(*8K!( Z4'B^(*2-<(=R!W.L$(.S #$]27.G &NH &D[ *D4() M;X0&,C 'C%!U>$ #/Y 6DW &95 &;M$99P"8+X$&OZ,'"_[A"E\P X87F3S@ M$5?!F<,16X\P!P6!EZIH%8P F(_P1CKQ",[U"(G%"(FE!\L5&K0@2CFI&XUP M-;2@DI1 $Z7@!5Y '=P'(BB%LO5*L2X'K%A*S/P(YFB$]UI!SRP)F40 M.B4''6"PG3D&/N_25?<2:6(P VY@%:S /XP@> SQ16Y)'2BYE+>C VMB!JLP M"8(W-K20%A.0%K3PGC^C$WKP!725E9-)/=)$'6L2%8(G"1=J0&OBEK%Q"0O& M6%91"4@'!:W2%;^CDF@Y _"5)V;)H)#@G3\I=Z$1&B>PH#/P7[HQ"=Q12J7RX2!S M, >34Z6K4 %A@ AA:BA^3&JJ4RJFG*JJ=JJJ5&A^,$%FVF:JH MRJJVJJJ7&D(]AP:Y&JJ 2JNVNJJGNJB^>JNNBJJW< 83%1J48 /.MQ^!NJIU M.JT=B:^JW@&J[B.J[D6J[F&A\KA:W9JCS<>J[N^J[P M:J[Q=?ZETAJO^M&K]IJOL*>N"L*OZQH@3BH?E+ HCL"7,T2D\5$) S4?>Y!5 M\[%(^AJQ$CNQ%%NQ%GNQZ%I[!.*O_YH@[6IO/[ E^[.I?2D!NL$D!>$%ZO2H M$/"BK^H(N5BO\7$'26<\*I!8&)NS.KNS/-NS[EH@ \*Q':L@[7H+Y_%584%7 MGB&GC-!5E/ [CC !C@&/\QI:A+0*K/!K.B$)KY GCL<*-#FLC+)T2NMRL&05 MX/2TFWJTT&$!=B"S/ANW=JDG1$)( <(U-O,; 2&^8! M,A "C? :.O !$7 'M! "$/ !KD &,L *'E 0MV "54<+&_[ R9P :WS$!S1 M 3E153K1 W?Q 9=0"2!0$#L09+

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�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

    614HT@(NM;/ M$Z $$04YTUZ7%'AC!3[H"9!"1_@(U4EHS\J?">#'YZZ$Z1P!@AJ(6/BRA.@ M$SD#*F($$Q #!\0 E$$(:&3.UI"!5\2%"& %H<9?_:6$#E#[6J<@'QS2 >6B M'.EY8QPHM@FH+J/+Z/INL W]HTWPT$X)>$T('92HA 0@T5=3B%]FA75K4.VJ M62HZ5E>F(@]XXP\X@PI!@U4 @W+!!4EX "M=#3<0]P/PB@KH 5<(@PK"#>/( M\570 ]FUF3E0G%68CWE< (J0@#/8S-;! PAXA'UV ,&J&RZML'6K!,PJ R8N M@[H! PQ0J@:G@SK;M&&3Q : C@85K74F7"='K;E$!T @?ZULP ZX!NBB0#_ MFX'M.(%7[/.3"($9N 0[* ^K@ QX,0*T!I%4H$ -($)B0@+"(.\IP49<$ 3 M&GP5HX5V:P1*L*''-I71O,3V]59:T-FG@ Z6 4=*)PYB#&:5P^6)26"HY\- MD(1)F #EFLU2>(22E1BQBP [.]2L# $3L8"ONH,(QN)L2K/1Q ,$P),+&#/L MO:H(71/ D=P'H PO .N!8(0"@!HO. #+*@-T;NT3BP R* C! M 0A< G&=@$#+5005 J%XH#3IPOX<2@]P?1F!ZY9 "6A8H3G :!($C(X@X-(# M@=$J&3)P33C#2LT!/*X>S+GT0X"DB[@80="SJL4)7)0@N!J(B]4#.+1FJ'#% M4\>M"(P$/HJ@HT>%E6 P3*+D@0PN'!\DT?)2U"C:M&K7LFWK]BWO'KWWOW$]R_@P'MEI74E@Y5 6C96X5+,^-&)#RHJ&3TC!M<0)IB&6'W]]7 +*R?0.5 9'G20 M B0"K:("""HXATL<(81P&(@IA'"AFVWV@"$E)B"(RPA"3A*#;H:QUU@,.3&R M4F,]G* #(RH\4JFBP.DT1Y@ZV#$0&%&"18D-N-QQWFVNP?ZF0R50@8B#0'1H M5V4COJHAFQ[]F;$#)4;A,: .G=(0HT!@A,"**S&< (8>*;#"PZ$-FK&'&FOB M4D:4MN$RR0BV8=!A7?7:>R^^^>KKUB:"^?LOP/_:I*R!>C4\+X6TR6R0"0+BH8%V!IL,L@MVXO1%]6N M@@%W%M_20[0NZ[PSS_L&#)A?/_\;M%Z9$-:S6PFS'#'2.Q>L=%LD+YW6U/6: M#/'2&-'2@PDA0)$PJE2[S'#5 UT=M=6X\##6RDU_C+916$\,MUNNZ%!"".XN M?-&>;OO]=]/]"JT)T7\5/OA>0?X/##CCC3O^..212SXYY95;?CGF^.XE.%Z' M(_XY7T=G/CKI!Y>-^>FEJX[PZB"GWCKL+0/&.>BU\Y7)XF[1HK)\GZYU4"NL M"/]ZX[>(?(MNQK<==RR9JZPO+8VLB.\MOKML_>/(7T0Q]B4_;Y0KWZ/5?>P# MB;][7*X07S[[/ M.N^W^>@ZPZ'N'(9ORN(00D0+E1@&S@@:!(8$)_9_">VN,VM++YCT!Q6 M,XD*%(5!3ZL+&"8@P E),3!#%]?B M 0S)32USJ"$5VR='?=4.?G>Q(U_FYZ_NX);U,!(# MO/ MW(L.'>@90B0I.3U8X"A],U\$?!>!G-"R+5+2W03*-9=5D.1AN(C!#](X%UJ@ M)BTGX)5;*D"BN&!DD\J<(S;OA>=*F&""-B& M%3,800PH@Q$\< <74)B**WIPD!FX!D/@?,]G!L((-%!D#BKH !S-8 )0- P A.LAA4T M*,H$ '9IC#+3" AA1XX#,_B, ( M'/&(#X93(&I8$$'"H ,/A(%!8AC!81M# >=,H@6+8L5^&$,D7*"!#KN)001> M$"TXA)8SM_C"'D8P%>+BX P=*L-2$30'"FR@HD;1@QG","]&@-Q"T MBO#HH0SI_!$N4H"&1IQG:^QYA E H 8,0((50I($?91J@CA(JP)I[0Y-7]#, M;-)8+MW\RS8!-K_Z;8"D.TA 42(P"34T ^2P 4<#$O2A"2EI)@A07]!X<& MA.$+7NBN*Q#@A4GT8 .X:,0$\$"+'S2@#)# P8DX8H1G.$6$&B$*T)0!EJ\ MP%"LJ/Z &$KAA0TPB"<-:D"N1HR+$F@4#J_T@@EH<0<+V#0,.7R "B 1AP8$ ML40K71(N(/V(.5":%O-ZA1A6FI@(?,D$A$0*+4[@A57@]1&56( 7)-&#"_C/ M1JNH1 ? ^((8((5$,FC '2#A =G$X*F#N !E8I""2=PAE7J(P!Q<(8E=T@($ M&RFKJQM BZ'0@1(TR.$<0$V8L8"KYC$!$KAB%KJ8$W]MG<#=H +",Q $F"ZP'N]" !B,%Z8N P@3LXA>ROV(!H M'N"!,[CB"QN0!",>\,>*L,*#>ZC$H@(5PC+$A!$*4!4-0( +;;V"$AR?1 /8 M>P Z2**XN'#1*AP U>!B!"%GD(0.#% )2(1$5Y\T0PA608D-]-5,JG*%!<)0 M"3.PL,:^ATN.^Y(7/ ;_QIK G4!X6 :%R" &>*!$+;_0 NPH9'\K_#RT)H&& MUN-G U[H00]LPP@O5R=)1Q9("/[0B(L-A,$A.S#!+2J0GP8=DZ0Z(!4N**!7 M7,1<#\W'10N@$2O0@B3P7HE4P!RL BT4S#GEG^)9 (E@!"5E$'=4P(K$W!Q8 M0"5(PB0D0 3B@@U\ 9V=QAQ44@M8%L[)) _ G18 D50!E7 OU1*: ME41CH9_ZX0&?T9 D4$(+3%\NJ=1 8 CS,%*S4 ,W$$ET-I K,([A<\1]A@N M2(5 2!-OR88$Q$%7R(!%S(!M,$P9J L&? ;,\6$E/!LE-"$NG(&H*55V8%%_\Z)'\ M:$+]>(4CV, =_ 9<)(?\1"3Z,\<7%^*T, ,Z$!\#(0'T MO_9':Y(H9! 4M MQ-PM>)Q&VH .3,@,1,!]8,"7>, =& \M5(!S8(0-E($7X/[!###"!U!&&'@ M#4!!!^@&'(R !)Q \JS+FD#C+5@ S_'B"5P&5*HB[]G #-A #^2DKJC '7S! M&9R!<670=6S2+>R@;JR0?-QD#,S )@6D%PP :IR1\R ;)!C"HB!]FP (]1C??RCMD" L!@%RA401OCA; C$' CB M(^7/,VE/<^W!*U5 (QB/(]'"!R!6LX@7*[0 ;"7&=D$ =Y2<#("!!0Q@%^K M!F@E#OQ 460'TV$$1I0!#J !&G@!':2 'D* 1F[2'- ":95)!- #; D'.F! MJ6% *S1"+?V -*X"1F@7+DA M/ZX @50A@5,!2.0GBK:P#QAQ C0P2WD@B, M$4QJI ZL1B[Q %3HAG2XP@8T @W@00^8 23((*F$"RA<<,7 =;"H7&]2)PN *&-$L&*M)W?%D%L$(7 M"H0DK((K0( D_8 >2*=NQ(!"@&!XZ(#2D:,7W&HHN<(=2!YFY%! TD(#K-9 MC,"M7L0$7,<<_*,=1D7.>$89!,5%P*H>]$_ZW48$X,+["<0,J!L/V( )L(%GQ, +G $M7&I?O0LA88K2$02+58!>I0 4?H!LF/ZF0+ "AL2 9J!% MA[;I9[3GTB%6;E8"(9V!NO"B"G '+83 $QH%'#06&5*")W%F<'7C;D2"4=! M,M'!.RD9'!FID08&D@H&0B*.Z$A@ .1$"-0H+I@*<:S4O$C"1$@"!(#!'%1 M,FW6 +RE,(8'W#DP "_& !A/"\Q! M#!RE4$ &AP<'*S" TQ%"ZR)#3R @DR M;?S XX8!! 1*VLT!&,"JP_U(&?Y8P!V<@06 "UH[QR4@K;A7@_, 5&R%YO" M02V- C801EP'$=^C,=QEQ=,0&[4QSNA+BZ0Z!R$P0,$D@7PP+.NA!P0$B-$ M@!D$7,,Q5Y0&19G &OA,P S<@0Z@+P:\KPXLP,0I@ )6 [885"T0$RA0<$. M1 C84Y9!X1E, !R8P?/>P@*@A@O?\ /4*Y'! =C>P4C@0M&!2 > 0 QX0#(U M@(,Y,2Y

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

    ASQ**BG1T$R'T! N85+QZ.'#\O ,>@(ER,=!T>*@GQ(<6JW#=^N%!19D?N'J4@?G0"YJ"M&:8 MR&BBDA=&N"ZI^#!B#ZY&.&WBI*7#Q"NN9H+BDJ$15Y@0?&?,Y'%T!U&893;, M*/,%U_[8&!Y,%EP5II$7G#)8%:24PH28.REH31H!E(=&5B\^A.A+1W49'5$? MQ@F3M6]&F'1+Z-"38A(8/'MC/[SSX<-K5W? %&1DXK 7X%! ?!B*:X9#.4YU MQ,(UIS$N.HT?F7!*\,P&KFA"Q,BCPXT>O7>"TO4P(XQRF)521.Y!ISJE@C9L M51 8*>E%PR00T1 "4+CH <6 (#B$RP:TL<35A1AFJ.&&'';HX8<@ABABB)]H M8N*)**:HXHHKELCBBR_:,N*%%LY84(T8'@83CE+9R...&7K1PRVL8&"&C2/^ M"!,K.NB(Y),=5H"6DB#R2"625T()9(<8$%2C#F'<4LD$!/YY^&.66J;)%95H MXJ*C'K3-F&6;9F[(RAP1:*;FGGSVZ2>2FV@2*(R$%FKHH3+^J2B=?M;(R@PC MA."=B(R&Z,I$'5;JYPPU4:IHCY]JN=N-F\40Z9$9HLEFJ&NRBN$JFKKZ(4MN M6%"FK+CFJBN&@Q[JZZ^_)KKKL,06:^RQR":K[++,-NOLLZSVJJ*TFKC(HK7 M!MLJM,_&RNVWX(8K[KCDEFLNG]B:2&VVZV;+HK#%TB)2X+LL+0\0533.7'?M]==@V[A)P3]76W:, M,'D1@0ENP=$9JF?H,<.1IAP@ADQ0B2L6 !="!&!(H@<$ M>CSR ?X%#:*\R@AF< 4-/+ '5D3 $:PP3H]F 7,; (QC1 . X0!*7&( -'&$&"&B&)9+RRP$<4@$].*\2D\" M1B2 3&L @T?P.(&^O*X GC!$8?30QPN:9DO6_#"Q040="E7. (#+QS!?5(0)T:J M=IBD_? 1$7@(#GK $"?=8@*K@,,&5C$)221@$K2XE",V /Z'582R(!YP RL> M( E*K*(":-CE85+0.'TQLB MH,T&;6FA$&R%)7$8P49B$ =75. 6&'!#)2JA M@Q#@H@+4PX4%U+!-'2R-)928 $MX0(."5* 2=Z@ *RNA@,M1P&IZS*<^]\G/ M3XWMCP!%VT.PB9;1F, +'OA*". Q9G< A(>P 4(6C<#&P1%>"RI1 LP( $R MXN)H=S@/+6Y1AA=0P@(1H\ JP% !&\B !CN@1"5*<% /Q*$1*+W%+6*@AD@\ M0 VB,#7$P@ M!D&UP1G$Z8C$50"L0D45+B9!@?[MZ& DM)#G&2;@4AKHP(04N$0_]\K7OOH5 M1+WB8Z'(YS-@P>L6%_A/9 J2 H*,X(6X ,/26 5*=R3/.7S@(6A)@0T*H@(YN ("%J+E;1_R"%=,P@(F MFPDN5H$ 5\A #+3=2@4F48JLX1*R!9%!#,+$.NI9H"^N0 @&.G4![';D<14@ MB@YVX"8+5$(/&'B((VC!BFO^];WPC2\_=68HL@D61H5542 QD()5F%,/98A M#'#1@2.QY"%]!N2N0C]#!)&X1 M!AKL\ MF_OZV)=>]*E[/&)0 MOSK2T:[QAG>=[&M_V-7GCG6UEQWL<4?[V_?.=KSOG>Y2!_S=Q_YWL[?][(.' M.\;[[G:[YWWL6/<[VP5_=,H77O[RD%]3TQFO>,=KO>Z@Q_OA+Q]VQ)N>](_' MQ9X!;JB9!WSGL(^][&?/(=?7=T7D6Y?MA36)&-#@][^O* V$;X/?VT#XP!>^ M\HN??.8#?_C%=_[Q:<#\XSL?^M"//O"GC_S@7S_XU#=^][%/_.8_?_G?GW[U MQX_^[EL__.*'__O-7U'MBS_]0EW_]9?_?/-+/__W=W[%5W_P1WT :(#[-X#V M-W_>1WX)V'_8]W_RQWX*:'\&B'WFUW\'R( ..($/2( 2J'\"F'T%^'XA&(#T M9P,6:(+;MX$42(+_MX(N^($J6((S.(+EAX XJ( CJ($6:'PRT# "Q'_4)X,8 MV( :Z/Z!.ZB$*6B$(MB$-NB$*-B XP=\M@=TK"<"%>( ' M>: '8KAM9@B&7^B%75B&;)@'<'B&8VB&9)B&;.B%A"&=,B'A)B'>SB'8_B'=ZB&ARB&>2B'@>B(@ B&DVB'<+B(E;B'B5B( M:=B&>AB(=&B)B9B)I-B(GAB*AJB*@\B*B-B&H5B(HQB)@CB+>(B*H?B*?HB+ MI;B*>-B)KYB+M4B-S B, M8'B-EPB*J]B+;UB,9B@SM."+V:B-L2B.E^B*TMB*Q_B-V?Y(B;\XC)BHC-98 MC^\(BF<(=%CX,RI'>P(YD 0YAZ7>1(W<5[7,A')>8>W M<4IWD1M'D0[Y<2US=AJ9OL2DB!7D1.9D7WW="@)_B,FA)+EOS MEG+9*.8F6 B97^N6"60YEWS9EWZI;KG'EBQ"-N_V"GI@![J3)J7 "+'$"'K" M-;?@"-\U"8[#(;3 " Y!5!BRA?XXB^)2??JEM"4 ! M]U00)J M+!P7+&E#X&F7[-ZAU(P?::6K:>5I*(# !=*1 C2 [$]$#;U8) M(= $? 5E8 !8/ " P9C#Q _68&AC:"A/4(7$. (8 @=V !$! !6S$)(0 ! M$$ #1*$'%M %^ 6KS #$0 !(? ?>( !$1 !R!4&'A &$7!=,Z OXD+,]4 M$' D5\4#,: );"%N@H!7C)<508!0[(*%. $7!F!:$#*:!9&R &% !&PH' MK=H#"& #MQ "SP%.#5)%KO42<# !$= #"3 #M] !Y%4)%_Y &X[P 0\ 5CQ M" *@%P4!!Q7P &-$;0, *0TP%+20 C@Q%0_@ #(P$;?@!1#P "U "XW@ T[ M!Q\A"6:P7+AP!N\D"1C0 !7@)3UPJA[P$ES*I3$0 5X0 'E0$",0 3R0J'VA M/P\@ 4>28"PA TOS"!O0 !.0H]^#A0@ !S$ ;G>0L]< FX%D3<@"X M 7:V0,0< "^-0 8@ 8@, !-,@ CP H!($(S "ND*)T.P 6(+L#0 .W8 "D M!0 X<3B0\*".0 GWVB-Z G< <84 "KT @& &O 0#*<0#IE;)SH >*2UGG M.:4IX HO< !W!;IZT*BT80$1L H.()\S, "5@ < ,&$C\" EBY^NT J0 D! M4&3L14ZH'3-L? MM* )R">. H D" 'R/O+R'N?>K8N'9PM^:67&!I4POKG@"!,P >:DMSJ?!314P H 2U^ 0@0 M /%1 "EP C.@ _8)!R'@ '03@AM E@%@+ Q4;EO*91 "&0 KA6!JR0 "EP M"\0U8#J<,KB OP*2 @E "XX0 %AA(1] QSKL%C\0 )0! (Y3HX*0 $NQ"B@,0PJ@ CJ0R9N,KR/0S+A I)LDR@5Q 16P2Q$* M 17P @3[ Y,0 9/E)A^USJ!+/30 6%@OV9@P"<@ [ZLFR; FRU]S*VI @5@ M :Q: "\4 E:FS(RL$;0P >E5 ?XF( ,.X!<%8 (0]-?@0Z P,LY Q./< #$ M"@E@ )U$ 0> &JV3,+P4409*=@ #UA( \!\@<-.G?0D\_! 74$EI&P*LH ($ M 0=*VP.-,0D"@ /1ZP9K%3-H, /2*0< +#79^U7!,=,-*4[ H%0)ZT4 :- M(,/1N@H),& I"P0 N5@ 1U0@!P+]&1L>GK1$VM@IW@+RN,+6";*MJ MK-8\A@OT"<0 @ /['0 XX+080 FG[063(,=3JLF$[9>L MH 74/Y\,H /Y0"-Q;< " )UTF\T=M.7J"KLU6<,1X&&]P]GNU'0FLH@30' M#1 P @EL0K= REP093 $( "_ (JP (J2;!0#7%5 ND"?L$G6"M/$ M%? !"F !M' " = !$# !KE#&%F !": 1&0P! W !KK '9-X!!@ &MY " .#G M@+X#1/U-)$8) + 4:% "7P X3T WF35(H0'!^"H+*$&I)T $% 3T3L2#[$! MJ/N@&N&=DI +'P "( !_WH+ _!:KZ/F!4'KM_ ! >"] R!",@ &DZ[<;7K M'@ ;J#I5>4F(=#F ]!5''X!#C "> X#[!@$8 $"#'#/YV U0MF^Q !K* MMVYR 4DZ[&3>YJR$ K@ >J;XWX)NCUL 0- "7EK 080 #' $CTP !%P *LD MR08P )5Y\!!@ "4TH*#MY"A KFB_6*:1);@X1"0H M[*X@XB;_"B+>,)1@]2J/*; I]OY#>@9W$#2Q$ =ET&7ZSI>3\/'H%)N3T%MW MWZ*27R..4%:\-?II6>4 M9>9/R.N\ !T!BTV?JT;Y"W>7*J+Z<<9R8"RI05 MQQ6]OS))"^+Z&=3G4*!$A18= M>E0I4?ZD0)M6<&#":P$;'HRX\&' >?D^=AQY;]VKDRT7 M3,PX\^;%6),8 1U:]&C2I4V?1FWZR&K6K5V_AAU;]FS:M6W?QIU;]V[>O7W_ M!AY<^'#BQ8T?1YY<^7+FS9UCL4*%BA7JTZ-;CUX=NW7IU+-?]\Y]N_;PY*N# MEY[^NOKTW=M/?[_>?7OY\.G'QW]?/_O]\_G_]R_ _@ D4$ #[>D4\Y;;O$( M3USTG)-/@_S4$T\^!3W(SX0,[0A1*Q6MLU%''XW34$8AI12A22O%-%---^64 MS4K"X &,23::1-1B6,X;=R%5M657(78+F0/X@ 4&,(!=B_"< P X= &@!7C_C)=)/!M9 M((Z!#_I @ [0%4B/!@!88( #YL %# 8$(" ""X914,*#X @!@([1>,A?0 M0.5W#RWH$9,7?NCEB28!X(1Q=^:Y9XH:&0" ,HA-P(*!;,86ESL2N';;B/!< M^EM<*FG@ 49H<22" R1Q914\N>*.%;H$D:J356O"$7 M" X O@!<($H<@5B2!4!@14]7(%B CECT2. 6M0( (Q**KF$$EQ. " ,6EB) M(7=6[_X( U7'.'3E4;X9F2 H6,]GEB\AZ\<%ZS;5OMN@B29I)(#;"!(%T9V MS=L1O >ZI!&(:?':%58$JL3\ZXG/NWF!5G'EEL,GD605!&+PN7___T\7+G0 M@0IX@%@1",$M0$>0R=6*%J6 &"O&U[[.T:(, $!#Y2:W/LOA@G&Q<@0MU#>0 M281P3V8 @!E>A8LP!, + SF#T. @@&1Y80"/J$0%$'" $-2/ A\8P0-PX84" M. !,L!%O^(VMX'0(@5%3,#0YO" "2 ZZ@Q0D@,($"G $7D[ ACP ;S] MH $3& #_[O "B#@ JXHQ0).8($ I. ' R@ #Z2G @,@ /X"C,"%#1K0@@(, MP N46 $$* #5M%"!@A8@ *&98&J50!BFF.D0!B1033D;A6EN,34$+"!@50B M 1C0TQT*8 ()#. #ZRN# 1ZP !/<@A&^*\,!&H" $]Q"#P=0 01:*$ $^""%0L0V Z4F3!6,<*/!P # M+4)@@ 8L VX4$$$9B 5N0A ?X%L, $2&E194: $H\XZ0O3&0 Z%&4/ : ! M*P2 UQ<8 *XP, $7"&) C#2 @48P1Q<$8(7Z@ I6"95IF(IT=T(%D8>, M M,! !5SRB!ZM@F0K+4(9;> "KJ#$ 71 "P*T@!9S\ (M-G!72?2 $JM( 3N M,(, A$ /8;P%& ) N0U$0( !B $>*G 5L#!D!S,& 9780(!3&(2HZ.$GKP M #0 0#F0 LJ3D(- D #)0 0V-5^#@ OF 1CN8( )AC6)!QS CA8!2M.&8,8+, !*B6 !%I0"%SP ,\C M&);V7N VZ>*B!0>HQ <>0&@+U-<) 2B;#0HP/ P2I ,1P/YR"G&1@(ZR:KEF M*,HMD"F &E@.,QD( 7(L5!N#?AA6^<#C%P "28 4$ M+. J".Q;@ 5PA 4PD+F"WQ(/-%@ +L;\@AA\P%^LZE<[<>&(+ZC@ 9:5P0V_ M. ]XL(#J PRH2D %:$%>4!$)@S2TV&F/Q#CW8 /YR)V&&&!R H]8P =^%8$&!7HG8%RX:E)[O6JL9GH 4M"<*( MQ@XD!@I8A>;T%2L(/&!\>AA 1Z&FZH22T<1H($, \'#<(I\1#1?4@X2;*>P[ MR$QE':8$& ;0 S.@@<3$O18EQMU$/$ !!+F+X;5HH0=6G& !\ 8 &8X;AI[4 MNPQF@$,<'A&!#PA$$G>30 3.<(8 #*L!(Q!("]M9"80SW/WO/]/I$B#.!1P MD!#H?B QKG&!=!)C"HB!"IBT%D ,, ^."@;/-&<9#&# 6@!/ B!!A Y3'.G M ^BH6/Z @ V@A0J8@%\1/%=(N48: 9-1 \;2P*EI@ 8P(%SH B@A$IX 5B3 M@ KH"3G H"P"@*J3KE<8 -L:*HB3 =@A1 X 5J0,"_0@P? @UQ(@0%PA1%H M@.R)@3-8!0GP@ENXH#LX 1/ &@#H 5?8M:RKM"9TA>6: U;X 232 A MZJ0B"X,6N 4:\)?D^0"9Z8%<\*IA28#\HSS'4@',PC#X\\9OI!(%;$4YD(/5 M8B0)* PN(,&B(!O\A=)L( %6)\96( %L -( & M:*9*",D#B(!&&"*?!,!;P(.?;( .6(554 "ZF8.7%+D&\!IU"B=8XX$%V!4> MP#Q=6*D$(Q9P\B.%884(X#6"H/X%':B8 S@!O#D#=ER !D@ ":@5,A FG%(Y M@<"#!H@!"!" 5^HO!)B R^/$CLR%$B#,R[L#1S@ 2>B)^L&% M6E O6_Y9H(&@!.H!H8VD!;+)FUK)A16BA(GA0U MB/X<'^G!HL894&+!'H/(!729*@9:GP6-%0WJT5KQT5M(T'29!-MIHD< K8], M&Q<="$F !+544H)@!4BH'%=A4%>P4L*9!#Z9!+SQ42>=FK2I4>4TTS-5$C$5 M(2+%$ZXAB%*0!#\ITUAQ4VQQA0?MTEB)4!'-!1-0@4G( P% (H& 4S]A!09% MTYKQBR4A*'YSFD2%U$CMGT:]@PBHS1$H!8)1"*V0$DX%B4:%"$]5$U&5"%"5 MU%-%524Q58M8A59(U5>%U5B5U4WQ5%(%"QP]B%I]U%R]U?Y%[55?Y56'Z E; M%0M<+=:_0(BO^%5DQ55B=59>?=9DE=9HE=9FW=1KI=9C!=9@98AAO=:$(-5P M_=9E)=>M&%=N]8ML-=9M4===38MV3==SA==M!5=M959WO==R559TM=9Z]5=\ M[8MUG=6!)=B"-5@J,86$-85.4-B&55B&;5B(A=B%?=B*M=B+35B)Q5B'[82) MS5B'C5B.%5F0]=B)]5B2'5F315F075F6_5B7/5F-?5F6[=B4O5B5A=F8S=B3 MI=B9I5F;G5F+=JB5=JD#=J6/5J77=JIC=J7%=J?/5JA MO5JH[5FMW=B1M5BO]5FNE5FJK?Y:LQU;G87:K05;J_U:I6U:IT5:MQW;MNW: MF[U9M0U;D"6"(/#;OP77URW>Y77>W37> MYUW>YI5>VJ5>XCU>V,U>[-7=ZKW>Y_W>Y(7>WMW>ZE7>W#5?YHW>]"7?[F5? M]QW?Z2U?][U=^85?Y_U>_%W?\QU?Y)U?[]W?]^7?^&W=@S7@ T;@!/8(714* MJQ!5!L5.BK[X"F^-X*6 "[&@X PVC'>-X+" 8'.%B@;F8 L>87S58 ?F5Q#6 M8,:@UQ.6X!1V80]>5 HV5Q*NX'A5X0WNX!5V"P[.8:?HX!IFBPOFU _FX7PU M8KO0UB1&88'=826>X,:8"R+&X2/NU1B."B8V"A&^X&XSB6XSFFXSJVXSO&XSS6XSWFXS[VXS\&Y$ 6Y$$F 8Y$(VY$-&Y$16Y$5FY$9VY$>&9#H)" [ end GRAPHIC 58 comp_0013.gif IMAGE begin 644 comp_0013.gif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

    S\.DX4 ?&3.J,P.A*8 EV M $2,.OPS=[2',?9_,"T>0$?W0><$ ,83A*=H F < ; ( Q,L )S+A"=0.P^ M#0QRD (V,-=JX * , )O@!:%$ J=S0DRX )1+>$N, .:@-@'\>V<< $A4-&@ M, ,NL ?ZP0>B4 ,V+0@M$ ,Z+1!ZL (U,-

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�(0!-X>MG01M:T8Y6 MJE_EE&FQBMILJC:KL^1$ ?HSDD#8@A,#( $G-J&)6OQ" @Y8W 8.4%?2#I>X MQ37N=&;7O4B-X2L!2L%W2M3P:+1M/%M%76S.X VJ:@7H@A&)P8P@DT40A"U MZ,4#(G"7JXR@ !-;[X,A'&$).Q6ZI<*4?9V;X9KB=):V> #SI6# /A!%-*! M% D"8!R&)6 "P>B%#2<<8QG/F,;H7*F&*]S1U6;5M"!$U3 Y^P FN& $.@0 MHT3P@1!XH!:@> D-S@"! %0E Q<@:(VQG&4M;]F!?M5PJW1\P1R#<\P>%:.H M+$7-/E@ 0D8P2?L,P$,2(#.#P"@)CZ0I0N,QT">Y?*? ?X=Z!E?U8(8UK![ M/5CFC6)3G+^H13 =>(O=VE+0E;;TI8>K0:Y6N,?\-+1AP_CI33$4TZ4V]:DA M[&41@AF;UM3JEU<=:^F"6M8?]"*I49UK7>\:M(J^*$:G"VM?/Q?7O#;VL9&= MTAO#.HS!9K9%[UGL9$^;VM4NJ)>'_6Q52U"#V6:VM*T=;G&/6XN<(L6ESEV* M=&\JW>NV5+O1;6Y0P5O=\7[WO>N=[W73&][NSK>^.T5O>^];WI_B-Z8(CN]2 M7)F5=X1F+FOY3&,N4^(0;VC%&QI-B_/1XR9*# MO)4,ICSDT5\$*J4^=ZJQ8Q=6CK@JI7YWJ6L?ZU\&^"E6L8A:L: 4K9J%UK;<" MZU0/.]9GP76K1WWJ8(\[W>6^=:Y_W>UMU_K]I9L?:VUWWP M@Y\%N2$?>\YW7_.\Z3TO^LRK/O6= M9SWGF3"'UZ.>]*4'_>IK3WK:LV'WK1]]&\ 5*3^\(0YO@,/QD9]\Y2^?^Q?7_O;GW[WO1_^YH-?_-*/ _G'C_[R8U_]ZU_^ M^;G??O[WFW_^]9?_^N]?_OR+?_]PN,4H:F$4),T57*$6#/ $3 !%? )6T! M'? !(9 !(Q !&U !"5 7>$6"' ")[ ".? #%= #$7"6 K 6-M 51B$%1X$ M43 %6= $0R$%0R$ 6U %5_ "7; &57 &"] &<[ &7] 58G 4># ?9 %51 ' M;; (E[ =? 'D_ )B= $C5 &J= ';Q (I9 )=] )L1 )_ (E5 )=_ *U5 +G7 (X9 -C7 .=; *LS *XQ -\1 *P] 'QU /]? ,5U / MZ= %#?$.R7 -3W ( ]$/;U ,W7 1X9 0'S$/_W ))Y$(O8?P#:-0$M.0#[^0 M$4$1#T.A$RGQ$P%Q$B>O%5WQ%6$Q%F5Q%FFQ%FWQ%G$Q%W5Q%WFQ%WWQ%X$Q M&(5Q&(FQ&(WQ&)$Q&95Q&9FQ&9WQ&:$Q&J5Q&JFQ&JWQ&K$Q&[5Q&[FQ&[WQ E&\$Q',5Q',FQ',WQ'-$Q'=5Q'=FQ'=WQ'>$Q'N5Q'K$Q( .P$! end GRAPHIC 59 comp_0016.gif IMAGE begin 644 comp_0016.gif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

    -L&>] RWK"R7P?[@P"@TPBB @ M 3I@!SI7 PH:%'N@M FZ"SS@A[M :,8%&;8![PPEKJ0 1A@!HNH :$0"NTZ M(V;X?BJP +J@ PN@ YM0"@_0![C OV+I"7/0 + 0"AAP ["0!QGP"02L![J M 3H0"CF0 ,O'>&2H"V:@ KN0 #<0"CIPNOTI!YM0 IFH!QD0M!P@I==G!J&G M"SR0 AV, ;$ "P,HA5ZH R 0"G7 *.0!A!P!YL 9\8%&_;!J00 RA NQ*@ MGA]S!A>0!Z, 3', Z9T 2<"@&?6@ RD&M40 6+T 0$<'8*T &90 4%\ *: M\ ()\ GVP9K&!1P<,X(T09^>+9Y M,+F).0?G? '[6;^]0 ,XP))V,+L(T0G;BQ O ML? $TJ[TE?&.J<#-_#4?MF_!)C0"($"7D@*+,D#73P#3X 0+8"Y#;D+V,WW3M(L!-2<+#5#-& !_DQL+ M=G#7\!F*Z <"E=D&%] )N# +TM$&Y1>S#P "($ !/( 0N% '%]L CY>@"ZJT M9CD*NT"H(WS%#JH*NR +)U#6&.";'+!XN' &[2S$]AH*IYL#*X 0O #;LG"8 MH2BENG#0NB "CW?;0'<&)] '@/Z]"Q( I*C;Q:Y) ZU8>*;(VPCQ"1#P>6Q@ M0FE0?K=M)+$ 9Y@C@)G#)WV;<+HJ3,07 M<(<8L'QT,,^%JPL]$ (YT +(NP)GN@)NX 8JT)U!D;'@:>[=OK0<( '%!P>" MON@S'0(TH ,9@+J"CJZHKN<@/MG*:0&S8 ?SG-1$*$##V9/]X-B " M<(T&IIA_09$#2,WXH]X"XEN(HT@!SE=Z>B@+A$>8*IL#&H#G-& #MK@+%P"D M01$#XL=X'M '9V")TT>T>A@4(M 'L "(; "@2Y0J8LP M ;Q:!5+>"!"PY7&@ +V\C[+L /WX ,8).W9$"-0%"I= 4GL$MK&@RPT*7:$6P-+528,N-3%T[=(%A^)' MB2$08M@3Z\)"DB(_8@CU\0(L&D\$XHHI$)0$EASRU#$IL).N%6Q(VNA!5(= M51!VQ3":, /(&C9Y81AU8ZZ\&E7KPBSZBQ7KBO#)ETAS.H9)5"#49";>.HJP1HD MR!8J2(9JH*N'29!N(MY9"*M!J%T/8H*\8:0 B-AZ0@R$D-3I[(02 =E@+IB15NDB"OW 3:9"-99KK- MQ3-:$&@7Z1"Z@"Z2GG#OHPA&,2-)773@ 1?_=-%/3,/FI/ZS3H00.23/0Q8Q M@8 &)$A@@P, 8<& *ASYPX$*9.@@ !G^,,"$3.(PP 5-8"# @2D8&<01)P)@ M(A,J$JB A0(Z<*2) )IXA!$3#(B#$0&"1#A20 MH<\.&-$S66679;999_5&B-"@"R0X'[D (%PUX"(4&DT)Y MX#G*'J@#%PB&V@4"4MYRHQ,0;GA/ 1LZZ8&"A3+((90;FBLA#9)62/(3"#+> M>$/6,G)*EQ:6FN6!4430010T%/Z80Y2:.X%P#@GVX.,!LS+ (90<1A3(!A$^ M84-G."7@,CD*]M"C 3U*B<]H/?:@@ Z;P]7%!@CF\.2"R0( ^RW2!)APL\ MV82"3NAX]PT1*H:C$QL4"&6.=W4!P890>," I8%:V.0& F:9HSF)/ C<(1%* MB&4'"SCAY *S0%+Q,PX2FZQ'"&S8(X\+8JR[A3G.: !S$%0(A7)>-HE-+@Y" MJ8."U"X03)<\(,BC\Z@$HH$#&E+XBP8USQB_C@LH,KXWLT80 2SVH"_WD44' MG=#! /Y*E)$&S&%],\!% V0!IX:1HH&<.($"YB!#DYXATY\Z"-FL E"9,&#%)@A+K%0 S1W M84V.;(L-&.G$#%*0+H1HK XJH &/9*$#*,9E#MP!21T.E# 5O$&9 H'%&@+* MAX^D81:PT"(D^G &62A4%[)@ TCRL((5V"86/.CGG-B0 AK\$ -;T2A'S9)0 MD."!HW@0B CJ0)(9F.$,*##H1]B 3U!-0P>4)"&GV!V(>A<""D$!Q6TX#.[8,-K5:&#\,BANI]9K4#"BY!1W" %:5A(:R=HF#;H *.\ MH&8:X#N*NYQ!=KMH0PYRH ,;;&44.!CN0L8;7ES$H@^[ $'ZRKA@PYPQ68U@ M!(01T8A#,,(1BSAD(QSAB$9( EF.0-8B0(S(#1_RD!8^I"0W?&$5(^L0)>Z4 M(_8TXOY%-,+&-AZ$C?>DX0A3.)>S_+&R;"GD:44KE[QD<)*5O&0F-UG)G(B MDZ4\92F_+G9.-B=)4$"@YE'9RU\&^" ^],PTK@3,MDX1*7A_CS( 0]:$$#&M"!1B2AC3SH:!&ZEH4^]*-K MJ:="0QK1AS9RD*F5Z5S^F=-[^K.F=8GD:\WILJ4V3//68^HZK?K4K&:UJE%M MIU4C1!5GJ'67QEC&7*<:U;+V-4*ZW&M=[R)@*"!FE[KLZ_5 $PX+A#6O=PWL M5@L[VKE>MK6S+>Q7#WO7UOYVL+^];5QLN]C7RC;RH*EL7?Z7>ME[H$$+T)!> M<2^;VN,.-[=_G6]^B_LCW>YWK,$=[7:3)-W_'GB^8]N"'/!(S Z>5J)-_*Q$ M3QK4M9RXM$(M:HZ+FL_,^O3%.YXG4M/9Y"='>M!E.618EIS9!:>RN6F.]):;6^E??OK2I3YUJB\Y MZE7'^LROWF0\A5SHR4KQSV_^=;(WR^LWWWC'C9YUMK?=[6^'>]SE/G>Z+]CF MFCZ[D#&<=HV7?4]^-_O0SX 8VG(%!!$\X->< 7UJ;^NFX MR ]@F]P\.YAYUG"&10\*:Q@]?/Y"%W18;\#KOGK6M][UKS?YW0&_)Q-G6NQY MROOLR]YH67XZ]\U:>T9BD ,*2" 'UO4R+!+P0R\#2&6;0,'6:1V!9+-\!"AX M/$E2I@L(>$+UL =_^,4__O#KGNB8AC3(_:Q[]E-:[YT&.[6"3Y(LI,0^2%9T /FNPV]^(A- MV(3)* IU(:80P0Q96 _'N,!8B$'R(\(B-,(C9#G9 SJQX[F,:[\GA,)I,3P[ M60@;F/X!@2@%$&B!$O (7 B!') 3Z@0&K@ 'K"!$I !H&%N0D%#+"!%8" M=%$%$$B!$@ >74 ##K !#3"+&4 !=]& 7: #"+B -@"%$/@$#5B(3F@.-M!# M/BP8$: !%> %%@("H@)$6@!&@"!N !,+J *V1$'/" -S,,.#@8$% 93N" M&P !4]R!!^!#+TP!%!"!N$@!H[" H6 ##: !## H#A ,.CB/%G"#4M" '/A$ M)&3&9G3&9V0P)22[%(.6GJ.X7/J]*"0[PF.6^1.(&[A"],@I%4B7!\@!D#@! M+O&$ O@,AB,)6' 6,B6F-"?#0DGZPF%"P")3AB+%/ (P/ZXJQ@@$ \"C)E: MDGQ<"%#( -F! (I$)6A@%'HA G1!9SB/H/2CX^Z0E[(LCDY(%WPA(C(@2N, M+#/3D!)(C,QXDES4A8@,!0C B#4\+([9 0KXC,;8 2[!A1[8A3<(1V@$RJ 4 M2O"3QO8[/R#31J$[RH@C,MPK.C(""1O@$AS*@1U( Q!X$DP4"!3 G%#(@+@P M@QIX1S:,#4[0 "0*C\DX PQ( QXP@P48A1;(*10PBA8@D.+1!3.X0@T(!39@ M2[=<@/S;!9@0"#:@" N(B4XX QZ0@!I!3)D@A5"@ !'8 =[X-F3J@108BTZ8 MS!UP./&@"PD0!:%@'*.0 %A0@_XG60BN# 4.P(49. ,CX1W.% $>*(Q-\*:A MU,W=Y,VL*TJC!+0F3$ILU+2E%+F_B[\C6S!PO T)H(/H\015P(4+R D42)@4 S& &IVH.AF*>M3)>:T@6\! 408,6\% %/L!R% MZ!(,R(V1:LE1F ,*< .:2!<*,#WH,+U8J(,;>!/#P 7YV01. (&%P(4#?0#3 M0P@.@(3 R0E/8)PU:,E22$UJJDBC $WT"8:X(%RH28)I=#>9-$6=5&7T\:? M2[ML',X:'3EO3)MP% &5P<.92D.!* &#RL?L%$N0@$=8^(2_:,^_0 &*+ $V M" 4)@/ZO4A!+Z]Q*HUB!"<%+HMA173 /^.JMYX@ -1 (#B#3"( %*'H)S!'0 MCXA(&[@KP-B*%>V$!9B%Y) U:@1P% K\7 (%%B*M'D2N@P<4L@7C,B7F-@! MK2 *##"]&<"< H$#7*B^%[742\74*?M-Y-R]IK11:&$_&N6X^0,)'-@B6*C$ M$@B!N," T=0%%>C*A%W,@5W*_EN%!;W,3% MW&EQ7,GEW,[U7$NEW++EM,O%N/[,-=UN_-S45=W5;='0O:61LUR\#56+S:4S MVES6Q=W "_ES7-5OS1;L^TSW[Q=P! M-N (EN# =6 KE@9I5]12[1!L 6AC+H/KK,05CUOJSQPD[[F@ST2-CBH?-M@ M.^&D.[H29KK(:V&:>^'5C98*!E4++E^\4V"G-+2RQ:5%@&"7DP0C0((C4&(C M4.(C8/[B)6[B)V[B*89B)Z;B**[B*WYB*:;B+;[B+P;C,!9C)%""5CBY7;@" M+<;B+);B-EYC*V;C-W;C.!;C.K;C->9B)28#E*,$)$CB.Q9C+P9D.29D.H;C M0YYC1.[B-UYB,C;CU.U?'M9>*)0XC M;(*8TXQ0T(ROBE0.)1/@!++B"42;E M4C;E4T;E5%;E569E5A;E5A[E5U[E+4""('"%,TX"(]@"6.;E7O;E4Y9E7@[F M7R9E'^ "DP.)2 CE5!YF8FYF8H;F:)YE)!B"1SY@2<9F:K'&[,7DTJ6]/^MD MEHL$'SB%[^M-D""#(+!F.C."+#!G%K4%(CCF&UZR22#GK?X%B3 ( EI0W4@6 M7AWNX?/[82'&V+E+!!\PA1F>X:=S.A:F886&:,AC,&/3!3%09Y1K9X>NX7QK M:(F.Z(U6,HHNHUL8@F,^.4E Z'=.-7J.X<^#Z(.K-A&V-GWF9TCFYFQ.SD^] MZ;&3I7!.N63V@5?HVG2N:3K;A8SFVG@N Y5F,I! Z83F6GU>Y\[-1AI=7("> M1B@,.9Q+/_DSZ!\H9ZX5 Q\P8Y:>:*3>VG@V:9.SY[!FV'S>YW[&Z;F&I:Z6 MN$K>V[E39K=>6'3V@:)F9W:CE#:_Z4.S7-ACFE1KE)^ &HWEJ:5EW+?NSMW>2[ MW>#)OEZ)?5ZW VJ^9E@R(.LS#FV&O05Y1F9=>.K-]F#&CFM(?FU)INQ&V[NP MN]N@\VG1UH6#UFTGBYXY"X71JP//6V@X PG/QFAW3CG49 ,W@(,V2(-*E3(+ M7#FU-NXE*^ZHOFCE-EVLUNF*HVW7_K'I3CGKCN^;L( '\&X83@/@F(PP=#+2 M%@CQ1N;?IK-0:($;P( 'N($5@+8%UP4]:"*4"^ZE-FI=L&?5;M@OJ._/O6J] MQ>\>QKB[YFJ<*SO_1KEQOFXF0XT6>)^X^(1.:#9!,$&$VH/<6 ,N M68\0;/[;YI$%/IB26"ARPP"%3?A;)N/MSP9O"#\Y,TB->MH#EBBW6,",3N#Q MD=UNEG ##OC9DPMNPYXSU*[Q3&5M^UYNL&T_G,/S3<;KBR M$G"#.M"=70B!>/LB74C$&U"!.*S(#RD!LY@##= !,^6(,OD(^5D!#TBS2A]8 M,O6$U@$!L=2%&A"!& B!S[0Z74AG+(>SC&;P!5N('CB!C\ %'G*7\,"!&5@> MF^$ T1J=" D!7R^%4= K#E:.BOL $^R^7YK7?""$_=\#U[QRCP2G M2! @TWH'29$DR<08*H%X@RZ7,MZ^Y9/3]TR%:\#N7&O'=K]S<=K>X.A6OYZ6:9D#ZI)/ M,I!X PB@ \HIE^G\CPL8!5&(C4[XBQ*(4QS!!3J0K+%8 X,?S"))C:27+.3@ MS!$P@U*HR!1 S.P <9V;[6[/\[T;,OY>7PU_N8,6ZBG[ MG1N@E^8@4#7R(F=*I#/WX0'O0TZH($' M* 45N(%-Z"#^F#('-[F%ES.0Z(&1H ,*8 -2&!";0=$;4!.B?U4;D/T#5)^/ M]W#A[GLZ@7;.9L:_K_:=7ODEU.;:TW/M[_;(IM@@UMPRB@5.@ 16E_Y6%_?X M?LGUFH4&X(XVW86(% 4*V,>(* $"&1=.( 4&N%,ZB#+]! A= B.8$0B"#2P% ML731D:!KQAR!&NK $2%P3P^!&C=R[*B+3)!6'D>2)+G+2):2*E=V[%%"8(H; M CF@T;7BC,!.#_*06D%!5YL0 CGQT&6' \ND)6\1*:/TJ<9)/DQ!'2FKCAU8 M5;<*W/XUBBO4,"'!DBUK]FQ)1(?6LFWK]BW"2EL8-"C"T4)&STPT)FS0N.N$"U:A!B!RV9P M'AK<>*(PXX2(A3,\S+C 9RMF,3Y$)MVL]&1*M"O-H,9]H4:.&[=MU,3,J<2* M-QPPT^#0_8XNH>AFGGH+,FF5K'PL8EYG^Q!YE9BC+6B+B@1VE&< M LGRIRZCI.DD)Q'I4L=M H62!YFQ?'6H+DPE2.@D/U UHE)U+!"*0)X(L(=' MB2+W'&8ZS$#E2+@X^2&@'-E:5HF#2TCNH,L9(6RZDOZA\][+D2H@J$##!:P>W-&!3AFL42A[<++) M'NRR%"I59'&0!I6=D**+&FS$@(,N;(B P@S/M6$&;\?M8<$%16%VQAL"P0$R M#BB(4% I$NRRQ[]&%01P""$<39:)#SOM]"&#+#LUU5736-B-/CX[V([. EDM M22H (,![G.B2!P40I+%+#@+,T48 :NB"00 B[)# !4[:R@8 =9"H2[U8/JWB MB!.KA!E(Y*VT0@!O"%!#>88.+F(GC&YDN(J>KL1? PH4( &FS?X(%B\&)E: M)WV HA4."\P12R@:+*1"3390X"@&&M80PY8"S1&Z+AKL40=JNUSP22P.N2$4 MP*BET?Y>"AIRU>N)DUM/Z+!6:]\6LMO76"RT6?<(6&+.2GW8^=1R#Y>U'MFQ M@@0!"&"'+B X%$L#(.R1QP,0[.(!!+S$@P X3&=]^YMH!'>]!9)D7ZY(2BPX M@( 0.(DEDF,@!B&&( C"HH.PR!5)'-0QKL0" NS"Q0DXL(!9U4 F L&%)_+ M@8+4H"BZL($.=,$#&W#) J48!6W>]J73S,%Z/&-?*%;TLOYZ,*8D9#"#:A*H@!24#^' MC&(!&"B!"&B @P@&T0U*RHP?_88YCEA)@5I<(.+X)3H4!/Y CI%+SR$SR!2) MK><"( !!!HZS,=*!!0,Y6U .G$@#RB!I!7.805%&*9 :ZI"'YFD!'-[ 0SMD MX 9V",$>>.$0)0JDB7.S@1EXD(8[#)(D7_!5)).IDC RLYETZ1Y;S+=J=.J75,N6!/?CX+ZEJ^I,?Z;&S&# 2@@ !<8&0X ( "8-$'!#S @"P MD 8<0($' ( &%VH# .1U'L")BE:$P@R'T)I$F6R&5 2J)UGVA<^.8,83 $!- M!@*@,8*E!*X<^00(8&76S%SHNKBGOXL^416=$$*.[R1KV6911_0@AD[ &\3E!T)+S#0"1H4) ].-$O$!KLA M#9=$$F4URR;,< 92X()=G2CP'LZP!UR\+A1O_(0[ZR!3C6Q"8[N8PQE" 0OT MKCA 9\B#*!;KH328H<#@T473FJMD7>1TNM1]\O:DB5WQ<8U[1*7+=\%"@=VF MJ)#!JD-H0=,H'+3 #,]9PW%P8885Y. KJIC#)F8 BS;8=W_ \N^* $J66$2D M$W908@^#!"LRL"T_\N00[V(4L4G"!,^""O'0P&V[\%HH:K . M=K(('HY3 G>6Y4"811%FI#+")3\LR:RV:9.A+.LN\LA\.?XBXXV,E67#\IJP M NG#'M2JGL !BQ,4"$4?(- F"K1A%BK(2!I4\!L:X"(-%@&% E( ,A'4)'@1 M\6M5Y)JO>EZ0*Z%X0!(+\ 9.8* H86R ]@R440*^(0-SP$@P 2!=]V$0>,& K62Q@Q\QSPP@F MQ;SW)@\7I0!Z#F8U-/]II TB:/Y!)UH0BA:(P VEWN#15Z)9D!_LBGP/Z)5/ MWL666^W6/O(:4'/MEL#+9=='1K4N\ LL.G" B=8B!E$T+,8,%&.= C!#&P0 M.E#<9C--/4,.\ZX4!YZUW%OQC"[3&6O! MDYS\*)=RRLOX%S'.R/$9]/*O3BP0%.P #Q3 S!N/MH%ZX'P;%'*? 00- PBB$0!OLP;]M B9U'BXX0!YLV@*,0BA P$:D M0@1<&+"$@0_4E(H43-.AVQLP3U XX 5(T0-,20;HP"@,ARZ\ 08"!0;F00/X M31%Y2+@\ARA @!NQ3$<4FB[T@ W81@5M!<7%("?AX(I\'"0N$!#ZH"7.Q!E5=PC3J)Z@!\Y,I .SD@E7J+5K"/5=*+UP-PX MVE0HF$'>W(NX$/?T$I:78A;%19*56V$(0G-K2C8Y7 MDN5"%21;20FE?CE1C2&&))ABI@A8W8<8/H:82+F8@IFKREF87'F178F2FI.48Z$JJ5& M8!:F88*FKZ%F8!XF95[F9PZFL+$FDM'46_Y*57J/=.7F7-;%3L[%3UJ/E(XG>9:G>9XG>J:G>JXG>[+G)6C!<2H8$F#!);2G?=XG?N:G?I8G)DP"$73! MH4B%=^XG@1:H@>KG>Q(!34XG68P?;[+C@WZ/B^!E5KK%5B83S/V #_R AFXH MAVIHA_Y^:(ARJ(>**(F6Z(B"*(E^:(FBJ(CZ (K"*(O.Z(K6J(FF:(IN*(P^ M4)XE@8R^*([^J(K>J)#F*(T>*8@6J8LJJ8NR:(PN*9#*Z(:B)8J(1HL&J8DR MZ8V>Z(M"Z8QJJ8UFZ9,>J9>N:)$&01#P*(,62(5>Y_9$Z YF)UXPI$\V5RM, M0GA60B7DJ9Y:0I_ZZ9\"*I\"JI[N*:'N::$.JJ N:I\6ZI\Z*J$JZJ,::J-" MZJ%&:IX&9U5@@I_R*:)2:J!.ZJ&":J6"JJ>2*J-.:J)>:J(Z*JE^ZJJV*J52 M G&N""VX:JJ^ZJM&*JZRJJ7*JJ>*IZCV*J3&ZJ[R*JI6POYHKNE&5*>;6F(F M_B8F.AEP,JNU7BNV9BNS.NNS=JO57&A *:9:H=5L7B:Y9N:XFJNZINN"G.:Z MOBN[ENNXRJM'FB9@TNN\HBN\KJN\SB:^VFNZ\NMB]JME'F!CM6M7_"O"*JR_ MHJO" FQELBN\$FQK:FM9<&N,5"6>M. M26L0>JQ=@LU-Y4(KW (MW +-UFS-VBS-[FS.XBS/_BS.^BPMY"S0]BS0'NW0 M\BS1"JW1"BW2(FW0-;#XJH!:4K%(2,$=(1:UJJSF^\$JHA=1D8ILFRPS7\% 9"[@>4E=^YFIJ MIKVZ9L-B\BL64&[%L5)F:8 M)94JV.C,X,&B9!K#L6;NL1[_<6QFYF'Z<17;ZW*YL!'G1LK9F&!!O M1$"6K"=_,D<,RT,R,BF_R"5"DRD'RQ2_\B2&1WR>!=.)[/Y _2/W2;*UCC$M M@W(N/W.-]/*][&7)BALPIX81;($/;Y CKF6Y"N5)SG(S"\3?$F$H#YZQM-PH M.Y,T!\MP5G,"DG')4MPU)_/(VN XDP3*V@B-?.PZ0_/+ZD6+M#.P2-[(/N:A M)">S'C/D-91'H)E!U4 +W("38&3A; 0I8!]GL$1;U17(E"1';T0>B(#9<(@X MCW.3=0_+4JLN,_&< G1=$/2A9*A#96M8$HY"KZEEU;%Z[!U'Y $;L $#Y < MN(%?C0@(4.-9_ Y:J!0<+&*'G'0SE_,_@V]5:Z5,'Z"7U3,D[K \DZPK9Y9S M(@H%E'2CJ &=Z4*)L=A">,(9;/X"*=@7P-'!<\3.#I2"1L!.*)R!3.F8I8#) M)ZB"&B18'JB!5MA!"O"BF*4&';"70,1U)RQV:M0!&@@9VM0!]'4$,^>S1I0S M+L-TQCY95A^*01/Q1^;B-O.T6:0:3&*&2CG,)D0 &Y@!!_!6!*1 ",1"0YA! M#C0 R- !!K"!-3I@!(0 @&!&'31 #IC! \A-"AQ-W>'" [3 #F! "^# "MQ& M'D0 #9P!!K06+K ,&V3 E." !HC +(:W"J@!!LB-#D# "AB@1LPD9WL$$(HR MA7YVRC[S#(\VH52DMA(E3K-RMC:B)H]*JTA G>"&PV1 2C$ :. "!7QC"%@( M!6A,W?[I0@@@%V;]4X9(50DB$E_% MW*$$=H(.V(!7Q,(XX<"_F$<-D)8$F@V0C\20?[*27[I<.AXGJ$$:Y %4;P4N MB,(H@%LDC#58>$(/Y "Q3X]?8)HG),"?0$"(>+<=G,%K:7A&X(((L(H'G(%YS,$= M,O4-H$8GQ(MT+X2L"(3M;4( @ 8=<.$F2,!7R %JP,>%; ($H H;W$;R1+IA M;;L1[_.R7/65!1[A+M[((?W2Z_?)[5H/#$ "+ G,!SQ, (@-LF7( %( ( MI )4R)-9\, #Y(!W4]#?Z !,*?Y%!"Q6DT^Y2L1" KB2!1'X4\0"!LR &X Y MJJ1 1M1S9Z#]P7,S1R,L2_@THHR QNP!"*3 &:!!"\ ""O0.;M# 'B24A^ V M!R@4$;VY'GB5+GR^AY2 !NA "Y!["2S$;,/$*'!""^@ "'" P_R."(@ JIC! MVFO$''" "(R:+O ""MB79H-Z?6_$$K=C=;FLM[]%EJE"MCP'#@0 @&@ C)N) M\._** "*="M '9@! &!42%L)@I?&V32 \%] 0=@*;PG$*#C8"WD()VP&FU$) M+[35<^ ")[0);*!*15>T_%DY0.@B$Z25+H,'$2+2NECB@H7S8*E- M-W%R2GF1*,);0[@455I4D@]32U7*Y)CPQAZ<%O),E<4+*L)9777!6GA0I]*R M11>&(0B6;5NW;^%"172(+MU%=?$N&H27;U^_?P$'%CR8<&'#>0_WO6LXET55 M#"38$5NRA@(($&#%$J% @0J9($*H$/# SE11$LZ$?:"!;20?I^+J0L%C*D>N M;E:H0*&+1P@;'#;ILK%B!@&IV'39(X04.$@-KO7R0O?1* MS,DGH8PR,26EK+*NQBS:H0 $-" #5U(R4 "JU!88)1."LA!%PT$R"$/"1KH MCT%=T " -A\O2N0'V.*Z@ Z#YC!C#3UT>2,!3G2190:9T%!!MA0,TL#%&9Y@ M< X/<*( EC?:R%1""LYT3Y<[6%M!QQ;4V%&@]+H:I0 =H:*(QC8HL""$-DJJ MSB 0OK3!JE HT(6.!'ZUH+]0,/[@:B$:,"AIAXUHD""E4"1@"(.%WMA-@ZQT MX: /$HE("L^$>(#@@@LDV&VIIF;\,1:@C(P7K"_6DM?>>XN<*\F]K.RWWR3S M8I+?0ZCTUV H]\+2(E+22&$! %(%H5I8%M# C!T6> 7#B0HJ4ZK#H*E! !6 M@'>I1%Z+#0,X##)C!@U88P/2A6*!XPP/9I"M4UU22'6&$0V:A0)9]!#!($[2 MT &"3T?Y! .#[@AA%PIX.(.-$D:HS2TQ@A 2*C4$$ 4L67\,Q8T&X/8]75#FLT>V M6V!PC8W26,$@8'GPI WO4?B2YR]I8&ZAA5:80X=>/8!#E! ZT<6",UGS3VH* MVLB#CCW$%A?T% 0J&N#.>V05.J7TX Y3X40#V.8V7:Q@0")( 1XXP0%=P$%= M:@#!'N: PX+^UB)9V0 ![J4(=-N 0NE#N1 J$C@ 4L( 'Y M(\I")N&4TPUQ2 OQ0M>(F,0D(FEUM.L7E?0R,+LXJ4F!:?ZB$Z64I-LAI!, M6, <.)$# %2* PW("@@>\*X=N @$!7@#+#20 !KBX@((L,$F\) MA0+TJ(M0/( [W3,(&C0H'$>5SR",;$'D$(('$9Q@)PVP2BD>\"GM0* D/-!@ M"=;FAM+$A6L$_*$N.C$ %^$0(62#2P\Z9I V5*L%$EP!&V*A )GH07!P^ XJ M*2"36.A )LNJFQI8TP(=':Y0B9P#=RX ,C,@"BXE2LI2/#&'&-H!9$H)XE-8 M^2-9D$(4H=A)R.K A_N8KN+E)0$Q9E!XH@)U+@0^-;$"!%9R E:II4'4QC,1 MY( '*[/#=Q:BA@O8( .07,@-$M0""@1G!LM,'MM"4 ,+\*%&%YA!"%!@LLE5 M[EXQ:I?H6O $' @ CA8R!HH, ,4S%58/IP%!![B3B.I):KS]&R\YG)%?\)N MM*5]'906L<69>&(/3EWI*-;'"4CQ!-Y MD!-X\L")\4:D1">"RE@T.PD9E6XA*"C<+D9AQETT@!0&84.UZM!1@^#B =1D M(1%)]UD5&ZF>@*FB:0'YSI'*9^SQDOJ!B9K6[ VVBFU8 M;%U\\W0M@( (%BN'@\B"#CEHP'=$'=\'?$)H.MC#5P2=XF./&R)*>C%?SNUB M?9X;UK9&3)WIS&LK%2RUY*9>RNP]SR$;NB*.SG=RLWKC4 1_X*)5 MD)87$(5HNMM&!!(]T$$=S+.',YSA(24\@PY0;3IZ=9;Q*OZ[X*<^B'TM0B]5 MS+7J6;^OU=.EU@:C^L$(#V3#E]Y>82 VOWE_KYE'>D@V#_YF^7[\SYX>]02[ M=>RCV/HITE[VK8?]7O85:ZCG7L581[GRB015KR<0_$02.Y3EQ>SN-UIRZW/Y M]#!>_OXEUOZ>4X^S]65?^^A;/_JTOWWS^X+[/NOD"$[^SL,'6@[X#/!'&DS9 MC&\!X4+-()"(D,2*I.CI2JOZ8*__ZB))\&\#01 I001!%#%JF<"547\BFWQ M4+ K NY>) P56O!Z)' &Z4GD4&_UH@]@HL@N-!#ZWNS_M,]@2O"S4 :Q'*61',7Q&Y=Q'<^Q'(, _>)%$H+@%MLQ'=EQ'/'1'IVQ':/1 M'/,Q'[WQ&Q/A"HB ]$QQ2# 0Y*3.%6'QGE:Q_U8O(N]/GVA1B7@L"(3 !X+ M!S22(S?2(SN2(W_@(SLR"#[R)#FR)%-R)%-R(X. )4'2)$$R)%52)$G2)6&R M)%&2)ETR)3ER"(:@ZXH-"7JR)OYW,B==ST_X] P,YR7,^Z;,^[=/T\K(X[V\Z5:\O=Y XJZ@W ; 2[[- #?1 $92( MT),]!4\]7['U(/0'L?,]#T,^$_1",31#+]3-^A/[5&])/!3[0%1$.S1$/]1U M^A-%^:5#1_1$2_1%831&4_1#291&5;1&<71$4=1?#,%$5U1'!1 -PQ 0_= . M^S -R3 )B90/]1 +C?0*V1!*A;1)I71(IQ0-HY )H71)MU1)^= +F]1+Q?1+ MG]1*RY1+J]1)TW1,]S!-F?1*S]1+W10/X91,T?1. _%-XS1)]U1/Y^01&"%0 M!750";50#941&N%0%551$W50&[50&S52%W52*;52#Y7U&/YA$3)U4UE/4SV5 M4T'U42G50C6T5$WU5).S"9: "5BU55WU56$U5F5U5FFU5FWU5G$U5V=U56&5 M5W=55U^U"6K!(NQ #=C@6-> #9(U697U6)&U69W569F569W56)]U6:F5#:PU M6IMU6;M56;.56[EU6[U56I^56\,56K.57*&U6LU57*.57<-57L?57.?57NOU M7//U6^,57_OU7J]U7\O57;$U6@O67K/U8-VU78^57OLU8!^67Q=68AL67]<@ M8<'58#,68>%U8@>V8B&68 668;757Q?66@&68DLV9$%691W68T$V93]V95W6 M9%MV9K=5$/Y@9WFV9WWV9X$V:/YY-A#\0&C_@&B--FF5=FF9MFF=]FF!%A!Z MUM.@2"+U$P"G M5WO5=_Y]V9?-_D[VG(^?<,TA);)*3E05H;<_ Q1@_)+ZJ B+" ],%]#1LK=] M#?B *; #]\(15"]0+Y O^I,1'"$AEW>%F&"2VL1$I4'>U 168]@-#CP MN._$Z#-+$3B%53C8WI<1%.$%)L !-L )&('Z4A1\X\ )%$&!!\9#6[2'/W01 M_, )_*!@;IA&@?B&;9A@.E2(B3B*KL]'&<$/'. %'&&(B]A%SY=U"-0BBN8! M)& &.HQ!\ 07ZH":ID(*J5"-#V(/\@"%R9A/SU BZG"XZ##(TFH!),2-2Z*H MEI"-5SB0!5ET*I#V-H .@ &*L F"!3'0%1'[F',\$%"/[@#QA8@AW!$>CB M$1Y9@S/9$1JA$>[IDP?!$:0@ )P@$_B7DR-94SO9$1XA25ZYAO4"DQDA21ZA M44T9E57YD47X+AZ9DS/U#S8 !C*!"G@Y@VNY$<1W%B^"#@*@ 6R@!00 ES+ M(F!! -1K2,I(L.S% Q; FRW"#3"@P\"Y)&P !0IXD-FYG2-BXP:A$63 & @ MD_]@ A@@$.) !OR "5P@#F[9=>)@ ZHX#JX8!EB "4K9"9C #V3@#Q:A"5S M"9R@"0YABF%@HAWA#TQ@ 4R "IJ$$:S !5R "C)5"I@@#F !OR $0)!!JS M"2:ZAAEA"EZ@I$^ZH9<@#ER ?X^6A"60 JN6 ;B0!"(6J9I>!"8@ H$H:,_ MFJ$#0:1E !":^3"Z>"8H0(]E"0"NPPWJH!-N0"3F) T:@ .DS3]H( >L(A;2 M@+58AA1X8 @ ;28"=P80TVH0YLP [FHPU" M80=Z8"C\&K#[HQ;4@!- : _VV@QP81/20";RX$LV@0U(P0QXH,,X 0W RP(@ MP QBX0[<8"%*H0=H /,X@@YF( ?JAR?<.;=U6R[JK ,4 * #P1%>P "DP D, M8 (F( $Q&JH $J MP ,0H/X)_* "'* "FN"6&Z$)#F #-J F" 33( )L ""F "!B$."F"]'8"^ M,Z$)$'F^ER 32. \-D).F !)H"(#8 %,N&4F> /", !)J !"$ *_"#"_T"] M'< )8" J, 1?#L0JKI"]VP3!,!12@(6'B!Y+N +N ! $!-),)A("!G>@ M5& $ H 39"$ +D 6B#,$@"- &! ;D 5D "TN@,,B8$5&'$0D";%R"8LKD! M* " " U: **#((V G0J 5& !)" 68&$ *$ 8F!O(( #8D&,)*0$ F 7 MQ.@"(("C=$&,0($-%@ "0$ 5-$ !,*P!+F %!( VS$ =OZ@! 8@%#SABW;[ MTC$](4YO QH@BQMA"0S ":2@ %X@$[I;"A8A#OS #X1; 5C=#YH@$ :A R9@ M$5R U ^!BJ\[$"*@ AJA Y:;$7Q[$:0@U!E8+V18@CN 0[A!0H@E9F )S@ M#QB@ Q9!$![ @(AV4U\ 0;!V5] $1JAV%,Y#A2@U$==AQM@ QB!"@H !A0A M 21<"J0]$_S@W ?AW!MABXG0(O(@ *YCQ/8Z%D) C\.,-6 A%$(!%V)A 7*F M1NI %_ @ - @%AK@ :R"#0 @XM\@ .8 %FY<%S8! - N!&)I(=P /2H#P! MM1N@6>CH 72A!P*@4]Y Y>L /Y89N2?(!8> .-+8@0XB3<2H,-6H %VH0<& MX UT031@X0P&X"%$8.A!0'!JH ! 20$(!900--&0<$VP8V(+]/)/I#_CA$^ M( 'B8-\=@9*IP FD71,(W JHP 4G!%>0.T9P:@KH /4^Q!O0%<()/] M?A#4NP+R>P+\@-Z=X)+C( %>(%!AH #\X 44P)*M@ J_-T#E=:M@ %<@/(+ M( Y>0/ EV D*H FN6/(=8?.;X \.P 7L70%@(! .P 0R0?6; % [8(8)@ KV M/ M@A, P/X.]* ,F#,(2![3+XD%B('"N A8*$!5$ 6$B#@8P !<$%+Q"84 N , MS"#J 4(7K 8I9"E(H2NA" FQ=/$H0$I7BP6[>@3PI$O'@%AF+NH2 :$A" FX M0CC 0 %# TZA+@ 0$"+BKH0T:]J\B3.GSIT\>_K\"32HT*%$BQH]BC2ITJ5, MFSKUB>C0H4&,FA@PL, M*E3PXZ!Q)A()!+EH$">KDP)AXRA@81GLG]>.7,.8S2(38OY'C9PPKC!HD=3A MQ(L7%VX\^7'BN7+NTE @3\(= ';HTD !UW4-NC;1F4,JEH(8NF(EX!YJP!E> M"68DI - 1RP: .:$ O"D/$M=(4CJFKD& -)U(D .XHF04 @-[+)# -+E 0 ; M"D';+#"&M?< M33-MPH (+@$0D,2+*B+!!+8A,L#!=@0RP,7S($" #S$ @!"">D@0 (A(,"& M+B,@8$8+!=BA2[;,!"%8P\8H4)5OS)0FJ#3+V( M(C!T4/[%("_PZ00+@W1]ER!Q6)':!A;(.<71LPK'1 =._+I($QULT,0BC[#0 M0-L>4%';:R]8($-P<<_-!%5-L!"G5$8WX8@4'9C0=5DNP.4'"TXHPL*@@P_J MB D%5-'(L**/3NQ.HN00P@AJS)+0$SO,U$-^_\T4Y HZ!%E""'7D, 69P8$(=20DB@TMT)O0*#9DT *)HS#00@\9]-!0#@RL(<((>T0_ M_0HDQE)#&S218L,*]")_AALW['+'#*/H0L<,O-P1P_VBW. ^->1 .YM @09N M4(KC:8 #:1#(## BM A*<((4K* %+Z@3H@VG$8U@1 <5L_Z(1BR"*HX0#@B# MXYA%9*41O''$(%@X0L 4X 536H(+.1@FY+"0$<01TPU-$ "V,&*(<:A5"'78 MP49,+8?#<0Q>AL@9SF0%+R%D1!6EPD&M5" !'1@AZ8:%'-(52V>=&( &S/" M!M"+=D(910!.0).9@"Q%&*RC'>^(QSSJ<8\X081BB#,UJ?Q1D".D6B&G,K5$ M*A*14A'.$CK@ 2<@)Y"!9"0@%7D8%\1IB7Z8'%X&J4@5)G(XB?2B(DO)2% & M)PXF@($?0O?%6 YKC,Y)"!MSALN:T(Z-NV2C)V@@@AN$PEAQ)&:'T >\G-FA M?[,KIBZ-:P'..8088S M3,?AC')&"$]U&H>>P1MG0C"*BGT&Y98>N64V05O.C1_'H3TQ*T)2J=*4L M3:E!OT@5*R+4G&#<)]6^Z$51!DNBA\RH.'T*+(ZV=*A$+:I1CVI'FI(N.%1P M@N#J*4]!)@>4P[+B<$P8T:Q.Y9#JA&@Y)3I1H(I5.1LERB[VT 8W#+,\=4[EJHS80 ," 4]X\E QBADB(+>:4W)B53B-F$(% M$M/(K6Y5IHTLK2GE]%34;A:13U7J6'\K%:'R)!8H"( I ]>VA7 $80 " M,,PY," !0 !M9Z2UZD 0AX,#]=)&&"Y3@ HS]SPPX$ (0W(^X*UC!3/C0 M Y[,! T22&R19M*)"(#T!&C(II$D@!&46G; !"YP4#2HPC\ (K.". 0C $$5 MJA &, X0A E!NP@_.#BFDN*A("9*-4;\X0]6I>0@ G$8 PP*H8+X)%[\@&+A M@)81?H@P(Q3QAT(&1\2*L"IJ9PK=@)XN5G"&7,*"$ZS3A79@$0K::8<4C]U%+Q.B(^B!(@-L7($;=-$)7G9B MK?\)!:7+XXDM(]H30TH(*3H1UPR02"!\CB8O8K&+N^)"P 9NM:M;*LX_?* ! M"]A V3Y@ D=-H39;)(%< E'..$R !1M00 =>684*4,H$@V#!!/S@B!@(,N* )1#\@%FC@@43N4(?;W803'D@! M!^([!PA0(,\T,4,(:. !C-P@!C/00 BT4X(;J( "-]"%&G"0D![$]PX@"Y]P M 2#E=MIA PB1!FK@9Q0 "WL0<@[1":- 0W1"1K 1AI@@ M5RE +VJ $"U :)0'A P3&@@+HXGAF/H3P95!4U0%R2P"/X24 &<$1I^0!MQ MX0# Q@AQ< NP!ER,352(#<'( .,4"E%Y 2!@ #8YP@ND !QX!DB5BF94"J) M,0B'2!:90&-.P 0;< !6\ <) !MV* -3\!:9$ @-X )_T ;( .BYP @I%#U M-'[OM$_"U60 X![1Q'X2%TV<@ >D 9GL /C4P((0"+:P08 T :[8 :/U2%T M( $N=QWJIPLQT .XD( T<0'2P0[8 &PL ;D$2(YX&=\L 8S,(Z@<(,=(H\)X0D# MV0ELP ,/$ JXH $B8 ;#E 88X/X&:< &"N Q,Z$&$D #=!!7I> &:$ !P--W MY6$':A "(K@".#,3->!R'C ^K$:&,TF3%21.,L '] $#_ !C# !%S 5%> ! M?I >"B'=&B'XD9A@6!M+\ $"0 #FN "WJ8 BD"4+L!"+W <:!M+O1[NL$: M+D05++ 6-"8!$2 #+_ Y?W V.>)59 FFG"5IK@!+^"4A5-(.156Y?2*P2)^ MRD%D;; "!U Q?B8!G] AH; "LJ!UGY!F,[$'XS@3:4""Z)@S+9$#?< &(H@"D/F.)R>: M]@@+:OY0BSIP.R*0 G6P!QZ@"RW!1BKP:,<9)N1J3X4<)E R 8CD! @< ;7 MTQ!X$'(V&$TK0(*Z@ 8(9H@@OX %-X E&@<0\'P,( 54%$AY:5-$ MRD\Z(6"[P ,)\%P0(!V;D +(/X E 9 B>W !S24 *9! =A AMG0!%* ! M&" !_/@Q&# #$F!RY1$"*4D!)**: >,09V=W-'$'[#EV,S$#LN-I%V #.6 # M$C *+8";@^JRA!H+%G "TQ-?:0><%B '1KAU[4@#%( 1S@F<(6 #JG !*V # M%P!W/8 !.7 !SC@=%Z #(L AXZD#.>!VL8 !GQ +%T #.8 #$D *,V"K[Y$ M=J:K?>NW2W(<52 %A_ '<>('@" 5DB(G?!$(A;M$\PI[/39"5# %&?8'BB % M%3"',30(LQ=ABQ '5$ 8.58U53 8Y>2X#A8(4A '@^ 'BN"Z.38(<8!C), $ MB_ 5,OY00H+@N4JD4$$:?@1+<$01A-WI9Z0P"J, "ZHP"G$E6(N)<&PT"I9F M:0?7"7- F&=5!YU6'IV6!Y]9$[! !W0D$-Q;'M ;"K&@OO72$*- .\U[ON'1 M$+@090)Q/X0)"W-*!YWF"78UIWZ6!W2P1L=I'S<1"G.P">];!_0":OE[OJ*9 MONO;(6D 1W]KP1=<) ;%0;'E8S(5'"(D)U-1AY;'&9\D)U:4%:6R "L&3QTT M22'L8W(21B'<2"BL0C*\1"JD%@V@ "1@88J10J4T2+^[5$-*L$2V$[>*P4H2 M"RL >2[Q%$LQ4/Q4@*G5<0A"( P&#A%+Q"2E6"!,=!YLFB0\>SI)]X[!2[]$RFG$L3E\M'8DW$],NZ/%FH M_(I$'$ZO[)<_);P'A<;AA,3RU<<5%,V$+,Q3/,W5/$'$#%3B)\< !TBSO%!2 MU$%_6Q,N[K MSD#P< (:((*\ M?,]_C,/'N3!J"1$*/HAH M9K ":1!7H8"WM),'YIO'U_3+L) "FC8'T&,'+6 #$%0>9]#3/ST#:"#41#W( MI "42C2_G7/(DT[LH "A14D[A=2(&W(:1U-$Y<&Z$E2SG3-2*7-/E7&=,S- M5V7%YF3&YZS,-:59=,V74V7.@RTZ1&92,U$' M -: " 4 !]P,AZD,* R"" M'05> & !(, !&+"F2Q$+!$""L7!S0#$3>$ "T!V 8 !9*T4N "MV,& $!' M(: +?[M)#,!(?W%%*'@'[5D+WSK%'/: -"X"QE @__! 3.P!R?P, ZY!RW0 M0'L0AD5!"A"@:G:@ ,.$/$MJ9?\! C&P!RB (+O 7Q WD&"=,]9PY1V4AB M+PTQ$W;P,DHB1PKMMW,MO'L=2W<=6SBUS,A\Q;0<%+A 0LP:L68 [M0 PR0 M IX "PE0 WUP _95!S9P!O02"VS "7L C?JWG#1!5[C "VQ0(;C0!C30!LXK M/VW0$)# !@V1!VZP"VS0 1HXI @"VEPT'4E$&9@ ](11Q? '2D P50(;"0 M!C;0.[HP"FD0"G"@ [!0"CJP.MW1!J-P!F> "Y# .__1!OY[D HCL V@&07 M$ %H@(0YD -0G0YD 8[ MP(5Y$ !I0 G)[(':Z@'CQ"-4UH0K31,\@ $0 MQ^EAN(*9L M,-\GQP>CD&9Y0((ID"(>Y0DV0 /C$YTB .0[C;?:$0INA6?:40>>T ,SX#$] M,A/BFQ![H.PI!PL6 -^Z8 L ).R +2T[LQVY@^#U^X[S,^0W.8Q4E1#8' M-@#< $, &5RHM"A !9@#&2L!(0$+ J O/,^FE)T&9O $ M$9$& * &5\]8N-X""=#<(5 (1 -'@# #!,(E 'K@ $T #I! $A@ " (A M+VZ8DLF2D%8 %>QGLK +H_ #H " D""''L!$A &J !#0 -O QUO4 ,$$! MBK^] + ">_ #V!E;, #Z !LK '!+"R O!F/"#X%/ ]S,3. &> Q " M%K /X@![J !P7 70&@![%0 -JR^R+P *H=) EP 1I@+>.S QD;^;"@^Q90 M U. %P;(;N 3"K"Z3P "V0!V*+=!D_ XS?,EH> @W$!DZJ"QS0.Q?P!O2I M/GB 7R0!QA (A3@[F80$C91 C-[!C&P"6Z: GFF'30 $#QP4="E1D>>'+IP MZ6*X2Q<="9[R7(@%*X&-/2I"Z!H%(4V=$!(6,E1X812N"[ 8YH&@:X49A;IL MY-A%D$T./3=BDM2U1\*<.Q3HP H!(@]/#CI4M<"AJPZ",WHPZ-"% 02>,PYX MD7JP<%/+.Q(X\4DIBT(LDGD:Y."#HH2N.Q X[3&I*T2:4/X<>.@Z$X)3&PYH M'=;1$*H-A%FR'L )Y6&.3*HY0I!BXT%7'@4ITN"2<$?7+@E]>(XF7=KT:=2I M5:]FS1/1(=BQ9<^F7=MV[$6#-.CV;^#!?0@A CJH42 64 '+ MA8$4=$$C $\8.J$K72S( !?../X818#I.AE )X?,".# #!(8)10!KJ, R@E MT "6!W"<0SJ7!H %QA9T":6 %6 1X,1.!! 2@@7J:+&[-V6)Y8$)&>*J%(8X MR*,/''69I0%28DE)ES=0T"4'%.H82!<=9F!HCPATX> Q77:P%(.CJMID-!$> MVV.C331@2(0UJ-,ASC-$2*&3%4*Q(00[> H%44D]B04"E4B1X-+I>H)@)(9P ML2#$%E*0Y9.0="DA#>IXN# -$5#XI 5?0P"0)!#@^-2"4IMRZ+-5 ]S(#@X8 MHF,C#?S418--8+E@(4XRX&@476+!8)-8)! ,+H(4DB 46!K$!0/\*&A#(5AP M@2!$;?YA6NB-24?9)99/&(J!*ANHX@2M3B38!=21TK T#Q!:L_EFG'/.^;7E M>C[D.-AX6R2WH673S>>@@0Y.:>*87FXXVXY&FCCG2HM%@P(N;DB73@IXBR%5 M&L"1CP N'B6!&#@JX(D\"M!@S =HL.A"G@2\&$J2]DA@ 19M4$ #"3!8P TS M5N1)AP(:7&$!7&*14)=4%)BPC@#LR& $74!X((,Q'1!-S@)$("D5.T(!0>&> M & C/38X+8!@"MCE ,,<00>\ MF-1G+N [CBQK!R@ %5V8882Y $.X", M+C:1@A78X *[R,-&'++&/=9*9_ZC)&4I;S:UI^&F-[T9&M1H,QQ7P@9H3D-E M+6UY2]M4K32R8-%H=M&E5/4 %3)0P"\0PH%I.UL/0@% )Z 0DZ, A8*\)1# M'-*&LNF"%WC3%@0>\*T > 86[Q'043:!@E#L0 E"T%7''>A5%BH8!! 00,. M5((%D&(7HH#$+- E@&#I8@8THH&7=+&F.G " #Q$7(,NX,8>",!W'K!= 81$ M)%T4#HLE>!8N'@"";78B%)P( %5BP8D0.>0)$LT<]0IPG0=X $J=Z 0LNG>9 M[]E &\*$D<8@,Z>GC2 #2A4*/JUB0BTI!.IH$X.7QB".=",) 3SUPM;< ,S M[#$&!_YJP5X^0S!4,:0B^XH7OT93 DVU@ 8M* $%4H"+-'QM7X_!X5M0X!D0 M^,XA'(")78S%1HX0A 94X9I(>#*Q!M7AA7*H6:Y(P@%U.604;TF!GT*@P7WI MBQ,$Z8%.J*,'"/1"%WAXBQW89P5EI K$/-/C.M$GA5 M!'O819)TX88!2H!$L) %26Q8L O,@0T<< @/]F*#'NBB 4CB 0^X% !\1P$J&Y@&O B MZ 1$@:.L @B(6 :F &!>@$!04P0PT$ ""'Y&! NKA S@"@ E-^,P*T$$L M]GL9 %QLH*G8 X55P('NZ"(% C"#3NV BRXS1$ ZN ,#1! + ,C*4 3( 2SD M\( 77^ ,L0CAR![P!K2X00!A?H!*.@$!/,@B!A=JPP5"00H.7"PT#)% O$CB M@""PAN/BX6[ Q0+>@ LW MN-$&"=I$K[NE 6EF ]K\ O-ELD&B3D 8KM00)"D0]ZAIQ=I4"_.?5L3BAMPX"Y ;$,).#Z#B\5B M!CR*10]8_!BQ)W(E,[@!#6Q @Q;:@)*P&.QW9H"!%,1+%'?OE4+,H $SM,$& M"\E#"OYR$ L::(T3*Q!ED4N @7B/AA0Z ,%=>,&0_!VJ6R-]@\R0$+%[YZ"V M?P*4:, M4*P /W!07RA:4 <::*!U?L\ " [$>FXQI/87J(%*"$-&B#$&B!!B&%&$@!)#P13TB!$E"!DMF% M7"F!%@3!$A !$M(!%#B#3FB!6)A!7>"#%)B!/6 #-0B%OHH6]P Z/,Q#U1"Z MJ',ZHSN.^FJ:XIBEVDB./C0:J;,-0PPOJ]-#1WQ$2(Q$29Q$2JQ$2[Q$3+09 M4N !R\A$3V0-/@POWQ":I)&:1?R96EJZ0T0.\3(ZW&!%/ZPZG7F7^>FY^;E% M7RJ-7:!%DL#%7D0-7B2-6AQ&8-P:8_1%%$'&8$3&SUC&7^PY8TS&9YS&6FR( M8(1&;!1&GJC&:.Q&9>3&7!PE!NHULQ=@0&I,$ M2E)[,O3&(4U.,'1\(0ALD=U!,O5Z(3-["Y( ")([ 0V MH,P\3$S/7$V?%$59(DM#+,BI=*^U5(Y 9#I6>LNH7*5"Q(VB:TG2&)0"&( M" "42\>H( =N#P!1<[5S%!2:LU47,FC M$4I 9#I7O*6D9"^BBZ^@=$NBH8VFS,WS4AJ@L6%3F!2ZE").JB7 MAIC5K8F%'8V%_@L@8?F_A1"%*?ZMU%ND5@W54 YE2[($RE9"Q7\4276-Q5<" M25:2RJ=K2X $SM%(&-0)!0:H&3-H@ : @#S MKU8HX0P P=8 (JYC 4X"C=H M@%#0 06 E8OSQX !YK'16HC^W1EA*@ 03P(SGA 0(@1( @84P@P50 ! ( MD5"8@_G1@0? @#ZH@QE@JX/B@!3(%UP5@2(J 3A 0J@3X>( 3K5!0^@@U#8 M"#CHO@CC"5Y @0<(@4-= 1$0@?,TTCK!SAF8!5 3-HZ @!?R"44["A!0!1YX MC&KL 0Y 0\X5!2 ! H&85(@:B%A0:,/OXTG13@@.DC";5%@;A]B#T- 0I( M$GCL@?Z8!9 9*($5* &TT '*HXH;D" X ($4N+11R )4,.\ 0$:R+71 MFZ$+:+T1D !UV:.J30&TL %UT846R(-8Z-,2D( #40$(" $6<0@;4($9 $. M:)#O;-QFH8$3< NT$(406*#L@X,+* %-LE( ] #G])T>4"L-(+-GS:U *L \ M,"(.P(/1:@$;$('&H*=94(5P 8&$< DS #,V6 $:H SZ($0L( D@843:-P3 M24\=. $)4,$TD" .2!)2T!40F+]Q7I0]>2A,N"-$FW MK,U#L,M9D("9VP,; <&(4&V P-Z H.L+,"V8,UV8$S3?Z 66"RQW"1:,( M"B>4+"#!=B#44" (M& ,$$# JB9$"@ Y2H @O"/:K, -QHH"/T, M1:E/!,"/3X" !GDU;$T T2B!>@F%5D,7'G&(&; @.A !A-B#3N X89F4%F@6 M\K7%[VB />"$1OE:7*"+J7H6-T !-R@!3F@!7& #+-*^=GL#@2&%*C*424$_ MAM 0#T*7. O3JH=G/>@VH [[N06@0!/]D$3]$%%>"6&9 R9R#3>(+*IN# MC:C/(J$#VR()&SB*1#VH!5 )";@..R (&Z";8-:%$6((8.&%!KN,4/&7]7.( M&Z (3A&=-N@K6_N$4,D1_. /_[9A0*VJ1!YBDRN@PNXO%^6">;*'&[YI 1H M'>%!& H@F/JY# +0E,N05@[@(6YN'0P0 96X 8$9A0(XD!PH$C>@3PS@!%Q0 M #_I RK+@SIR@XW8OA=_48D54,'\*84': ,U M@ /ZI8X34,&:((4YB+! ;I$:H $6N6(4@H,TL >:H%GPI"^VES8%>0UZ($% MN(Q8[L4^8(,: +BO 0'/^ 0RN2+Z6985F#X14"P+6(A1H(!=D(4J0N/Y$P7 M,HP>D MN#@$SD,Q0@ V2(,YH TT$"2T(#'7H$E<@A;TX$"A"[J&(7H9H@9 M. .'AFTW4(!-X /+< @]&&/#.BA\216Y0ZX&@8,3H)\W,(,'X,LZ4H5EH8'H M^E1"4H,T@ /-P]"*OLF+[F@1O8V/]IE3/,6A0\F1/LFVS/Y-@1Q(>P4W"8B M30@%2.V#!L@ -B@!!8B%6% &O(4SB4\ )"#0@.0- #JS#&LP2"? %$ 1#J> M?0$L#=" 6&@ ]CD=7&BG)CJ#,]!'GCBC%J&;'?"4A1#D-7((&GBF6+ @G$( M%/ 8;4EGAD !6$"!HSC.'OH7SLA6ZB:)6,!"$90F%"&!23RCPT=N! M3JB9-C@1AQ"! W$("P % 2+-NRZN% #QBP![X!O4J"#!J>4 MMZ #-5"#!C'NRZ" 'O $&UBB%7 R\"$L4,"1-[P#-["#59$JGDB!$YB#/:B7 M,6((4>::Y.XE98%=%1P!Q3*L'/X:F4<6*!6<[EU( PQ8 T#"#XVS@0:H@XZ8 M SB ]FU0>KP@,?6#.K @$_0 ?I$Z_HF$VCQ'3J M"5C&S'W!CS2@FSX +#3IM[.&"2K:S#K8;C&E#C;8"S;6A0QX\^^H(Q&8/QYP MGM]IW_YWT7'\+E -$*49*&6%<%Q.J!DVD'0C^1H^6):JLNLZZG2&:&Y=B B& M@'CJ2(-8!I7?0NVF7>^CF"%CYA;WQKP',)89( B9H9\ELH-:EI.=[X.6D(/B M/HI.P!$5H,^^4+3HFH4(D%T*N#S[KNX!VIKR98@WJ)<(\!/A%P4\("PT$!T* MB)";U=H@]Z,0+\ QB MW@LQEPE*DA2"2>V?.'A$="BER),F2)!>9)#G(Y$J3*%/"C"ES)LQ%+?Y+#K(Y*&=.FSIU M]N3)TV=0FH=R58P%X4$L@[MT]5'0P ,'!:-TY2F 9>N6"40-$B0IJN& M$ M"-BCZTR!!*0,V@'0QN :!!!$0"BHX0%7#!=T[6H3(DT)"+AXE2C00( .738 M<(J806V:%(!U[="@(P,:79TH/)W10]9#? M9[K PD$+,V@0BBY[0!###1'4H10ONI!" 2Z[@*#!6T_=H $--DB@UA,:])"# M"#' @D$*.6 7AX4V%!""+/H4N0-*T 240MA) #!70LN(-!-/!P&2P2I'!# M""H\E<8%.ABIRQP)&:1'03->$%\)7$UF4 UMRD+!6V^(L%8&.^@PP@IO-D7I M@F6>.2.6*(! GD>?@AJJJ*.2:A%(1J$ZTDVINK0JJX>\].I)KM:TTR)$"?73 M3D,1A6NL,2&"5$6DO"71*'F,4DLHNXS"1@ Y7*8+)W64 E$L>83"2RCTA;*L M0;.$0OY>)WG$ HLHP9T;W%LZY!!++ WPN8LG=9R&2[$0C<)5N1%U,H>,NN!R M&BRR&$0*@!!Q(L>]NO ""\)W'&Q0+)MPA4L=>7@(L"B??!)*)P1W94<>$<=R M<<;YED?'OQ%!,H?#@(T2<5>;[ )+(BT;ER>QNQ3LU , MDJ.TW"BCH" !K('?M%=B2@0 (1/.0ZZ\YC MG[WVGRI.@PX4W.'4]M:/?_W5$7@JD?GCL]^^^^]S=*I1MM/^J_&'W,^[_OL' MSZM0N?JO>#NA2; ^%3%8;$M]%%G?1 *1[4+;XDJA2C4B ;A9\,;9D]^^YM)_F+B MNQV.Y(#.=HQSOB,8\?,>+]T-B3 MDPQQ)2]!B>\&610R A)6O".B'WU2D_GI;HE,3&.OT%A)XNV*B&_4(R<[ZF;&4P8RG+4^)*F,I,I2QU LM-3O!@ )IF-*L9K8CM0IK1NHPV0WA-:YZ0 MFM3D9CB_"1AO8G.;WB0G-L?93G">LYSF7*XSH@:])CHARM"+/E2?^I4I1I4HCZUJ&+M MZ4ZK.M.S&A6J194I-$?IUK?"-:YRG>LGIR"%N^*5"GC=*U_SVM>_ C:P@OVK M705;V, >=J^)_:M>#:O8P4IAL82]JV3Q:E M/BO:TNXAM*I-[=9(R]K5?K:SL8UM:6,K6M.&-K6KA2UM5^M9U^;VM+X5+FNW MUMK7UG:VME5NY M:UK:CE>ZH35O=7V+7>^>%KV@U>YZM^O<\';VNKME+7MO2UW[[K>_H$UO:>&; MW>(2-[@'#NYQ5>O>_=9WNYWU+X&E*V#KMI:\!MXP?>7;8-T2N+R@M2V%]:O> MZ9JVQ!E.[8*-V^+O(CBZH:6"$YRPUQI+P<8YAJP4HA"%'N/UQT(&\H^#?-\Y!W?E,YWK_&8\V#G/>LX#GO?LYS_7N<^ ]K.@!VWH0R,Z MT7=6-*,;+>="(QK2CIZTH25=:?Y*8SK3?[:TIO><5:W25*A/E2FIU3K64Z]5 MJTC]Z5"="M:H$E6J5=UJ55LM:EEO]:JA]FJH=RWKL9KZU$BUJ5)1+52?UI&N MREXVLYOM[&=3Q)FN-.:N>#E :B^3EM6F-BZY?4M!7MN6J^REMI>);5Y:FYC' M_!^[L^WN:E_[* TLJ#K9*4Z0UK/>XELHZ?!]T'U7M)_WMN? V7E"??8;X/O6 M-S<+GO"&$SSB#D\IQ3T*\8OSF]X/WWC% ^YQ@X8PXR)G.,?Y;=)N3ESD'Q]X MRE-.\HXO/-\E;[G$%4YSC"=4X1@_^0Q5KO.$L]SF"Y??JM0XQ)3$BI"17'H? M>^B2(OXJ_>A$.7K3$5F2GZSQC,8;)*Q:HO3BE:2MT!X[VH%(08 M995U+[+$Z3,AXJN2&#Q'PEWL%]>HLI-]1[]+$?!]KR!\)-78$UPE\N@EZ>)("E@1 M-^0@!S= 0W,X,0,4T$!R;LB<)\9R4GI/$/S;1%SXPP\+-:SP8+ 8W/H)-P>4 M+M1M:L#G^!>^!S?LW?[X-ZD*(9*'%:Q,S3S%'*@%"U6$"?X18/EE!"PT".;H M0AH AP(=W,'A0O-H'"Q@4REPA1T4H 0ND K9@>-XX(RHP">@4/N%8/VI("QP M22>\@0J*'TKU'_B93PU-X":LP';$G\9-8 _6GPTFGD4<3"C,Q0R*WU,081#^ M($>\Q" XP@L80 ,P ,4 F\WDSY#B(PPB$PPJV@A$SE1"/0'4\Y4@4D@ FL M"DWY1!?FQ!9RX>LM0D\-T1:R(:EM@ (H MU)WJRP41_>BDJP1.6%A-A=0 E4 MAP@H2"= !MP AHL0&2 0(-PQ1L(1/:$QGJLCR=$ $9H0.881"?J AHTBD9T M0@34D1VLAT:@8JDHA1MXB'@0#/X*- CYE,>'-(@,D0(-Z((*- @$5(\!Z4(= M\(E%P((%-(\L&.,NJ@GBA=\*+&-%X(($K($$=<4%7$4+-,8%A0":P,&?B%(T MI@$UM($)AL?$N('#>(4-O,PF MM,'*X/X" 7)"!D@$++@!V>@"*& &Y!'*&# &N@"&] +#REM3(6RQ-<$BEPP1,+,"!"/[E* 0F1-P?+* ,"NF!&YS&'5 M)WC(E>3!@KP!$5;+U;R!)SI%'D"F+J@"Y8@"5VS"&WB"0;2 ]XU"&WCB"U5, ML>@&BRS(6&! 9#P%*32'+%Q%+)0(?>P":%[%+J2!!GQ"Q(3"&URFIN"!AQ1( M?M" &I!"&P#'*+@!0Z@/:+Z,*L2""P('$+$!3H, ;R,(#+$AG M7 !NZOY"#4 +T:I!+&# NW:*+L3 :CX N8" !-P >;!!69X #ESM Z1L>= MR\("#VA #LP !,C('= L"O@K"J6 "CP!!JB%#61 #L0 !(""+KC!Q,X !0CE M6M"G!T"+#4! "4#E+E!N"'# #=Q ;DB$"%BK8[0)[,HN0WR&&>@ "-3,!;0 !]Q+")2 M#:R HD -Z*X BUR LX8"#SQ "8!"+'# #%!)9 L"* !C7R)!M &!MR +N1K M#PQO4X2 ".A "6 EZ0!!O0 !^@B+(! ZG) !*H!_7) #?[L@@1L!P?DP6JJKK6*P@7,@ V '] A .S00M$KQY,;Z.T M@0:<00BH248T83LF@ ,L@ ),P"*X0 %(P2&0P '\@1,<@ 0T@2"X '(@!4X M@ )0 9K*0". J0L<@!0LP@V+I *@H2#% 0E8029LP ,,0@5L@""888X1@!\X M@0<,0B H ED @L40 =(02!\JA],@0-,P$7NH0^QFQ\-A?+A$MZEBMB!@/OF M > %?D@0A0 7@0%,$Y67DZM7JXE9RQ5/P@ KTAX*P 5.P"!IP!1I$;PED M+0B\((-@Q9^,@D# K$&< 05$1/X"XL(%R(@&_*)!F&ZQ&D0/2#((9(AC/&,H M,( )XD($= (G2,THH/(9G(!!S $JLT%/ID!MZ$((P($L-,!50() M$%/J@ S MBP ,HHD#/1)JT(S(4$)*XN>,!E/H49<' >Z.(% MJ(4.\$ H1 !7P,((+ CZ48#D@ !XQ/,,Z *>J 4%,"8JSP#56BTD_,4JQT(* M[*X.-$8#).ZXZ,(=G$A$L(&,],@NR,(%-,\X.PP-1*\N1(@N4$!J-G-^U(EE M'$1!H+1!H,!Z4 _ ..YE:.)T4 #/)"-$C'2UU$!*QRY+;\C !0BR!'#%LWK&)NY!4^L" 9NU M]UG )L#" SC,+)1 +-3 :*R%0>X!)!1$#*0P M&H@N@%SIF^#")D! 4\Q!0:P 7]]N1+A!9,B"8'-" F2-*(P'P+!R1F1I.QX M"ZS>$@R"!5C (3B"$W!I%!B F3H""S"J(TC !F1"%3PJ$O-I_BP"%;Q !SS RS""Y3I!G2 "[B \"*$[" F'J (_[,8U$@#QA.S5WH*S"A^W@!ND 1UDS&L_ARXD,JXJ""EH ;D8$2@ M /X=![&F0?0BH?1I0 VHM(BCP%RTP&CTP 7D W< -Z6 $[.ZP2Y00W$;2M[ M)BB6N$&H@>A*0 ;G B8N&<4!(7(P>+J (U_[ SL+B@4!!M81HL;1 I,Y04\ M12?\13)_R.ZFP!S<)\ DMHP\A0CLGT)\3'#C"TD3[>ZNP!N0P@/,> Y8P*UB M^ L>C%8KQ"BL09*S1QO4^9U? "8J>2S0 !N< 2C#&\LFT8>G BXSS@-2(## MS$$-V, #<,(L2*M$<$#UL/LHH*[WT"\N4 #(Q,(%O,4%5,^;7"M?UT%'WSB/ M/#4=T#L$J 4'B" '3,N)' P'7+,-<,IEN$&C'(S/'G0/Q,(^1TN05] !1R"TP> $P@"%&\AF**I"_@! M"2R 0B[ !K" $TA !;" I2+ $L3!!'3 &2M '#R"'T Q376 ^2A2_:.Y=T= MX0>2JJ#*JK[?P:@ T<_()J+ ,[J!@G!%)Z1! V3-4WB/07SN XKNC$ A;N! MZ)[ "ZKT7("R/'?G*%1+-AN$)W@E1)3 "GP"+H" ";KR-H&B&J3TD.N"!" + M*,QFTT@-AMM!R+?^5=ANSG^Y95!TEF_Y4WR"!>B',JOEA\C!)LQ^+$C D-0J M^NFT;IXSOF P:R ]\VYOXM"MQR.2HM_T>B"*( N^N"&OY4M;3D.AO MZ& M@B@ 1*E8N@CJ*I%&!ZP9.<[H"D5!UPPTNC!P*JA+!YH<;W11J#,JU"A8N'3% MVH-"A*X[*0OBNL!CU"@.NV1=D'41U@58$;#&^TB=CW;U,1G':5Z(.+PMN"'/80 MM","EH1.HD*5F@4K,\%9%\ABX$-P% 2,.@C>J6L0SF&(-B;O0I%'%P?@P3?E MX5"P$RX.;F!],FP7!/*!(NB4"/X5"\);4;'T1-?PIOES@AQL7-> :\]Q77F\ M#V=_D7PH61QX[?% L Z&YJ1,7_1?$)%##AG$$1@"<(*1009I1(8 9*@B@@8& M<>) 1Q@QH0 _%GE@ T>J,. %1PAL\,$*&A $D -,8&3 1E@HH(HX'G! P0H( M8.*/!11PHI$*)E#$B0(ZR.3%.!A9I (%FH!! 0<"643 **6,J.!3W@9A0*]#B((@SK8 M_.2!-M@[#@T5"$+C/EU02$$7$1S3900V=%GA!ET^@0!.3T[010WU:)#@H@V9SC EY:U4"742303)=2 M( !%EQ0F:K=9-77!)05/V+3C@H%ZN,T&"G(CY0&+]FA@TH;DI=?>-A^0:P4+ M3 U%MA9ZHF 3@JSR1 /0=+%A!H)T@ ,U57390[;\ICIL@9W@:("FM7""P*(6 MGB!(XFP=VR6%BJVJXP*2[.BX!;-TB<&L"]8D98%FK0JJCV ?& 47";XB"#N+ M9M K(AZ"DQ3GIMGT0-(YHIOK.!JT7B]?E6+ B%%=>FBV(/Y<,QXHC]3P:*&C MW$19 !+LT UN!8)"T L$I5?8!)?LJ*9 %+=9LH'1&G+ 3ST1U@P%U PX0AHX M#(;+ #@(@.MD 5S.6%:7,ZHJ28+1O>6Y8X.TWD4"/?I U@S4T5@]E@5,O4,! M],A=#]D<4#]A^)(6^$07/(+?8_A8*.@,EA*F1I.@ =TA(D&$(P2$1@:6."" M*3)QXH$HCGQ! @T[^*"1*AZ00<1#%A&_ 0NL<,0/"5Y(\!",B(,%&M !%E3@ M#XUXP0.,U($-**(13H! UC0 1(4: (:8D05+*" #IB@ D^J4IC(5"8LE7!+ M*>32"+=4PBZ9T(2(.!/V2N G__Z@ 0,AX$ )1*8+,U! Q3( 4DZ 8(2@* & M5BF(*&S SH+G.$!GK!##0CB!EK%8@4A"$$+3A:*$N3@6(^R M P;&:$-2-+$.QW$##9JRIHT-1@2XJLL<.E8#2]JJ)&:807I,59 S[% $<%*% M"/[6@GSIX%&-<4@(1J !H9F2 R,( 9Q44CJ"&&>,991E*&C)@;,AAP)D0<.K M#E,76#:J$_X9 0X(@HL8@" $*AC(&<28 3_UP@,E4*+;0- "-J2@)S.P0.,* M0H/,[/X 6[K( ;9$$0(1< !K!4&#!HYHD1RLP6/-X@0'1$"#%#R*('I HP;D M$HL07$\7-?"*&>"F@V;5\YZTN4@;'F [0ZTG<#Q0&J?XZ0&+X.*,(D#!3=A4 M$!!4RBIJX"<'+'('#:R@!SQ( 2Q"\#<1S" %(%@!26 A A&\5!<\?0LN-+:+ M&X! !"K8R0X:LIZ/SD NHX@.]'#:@Y2DH#/MZLP>C*@!5NW"!@2UWD7Z@$;! M5+,!J4HJ2CPPN3TP"JT$/<'UTL"!%JBA!3OP!#-/,J\4<" %'+M(I_X: QYP M@IFZV(0&D(=0[&5OA%EJ1" L0@6P7!*CQ"$!C-+)19U-OY!+812E5[("$'\ MX4B9K=(@$N0'1AQI0"4\(6C+]*44;DE*I9T2<'D[I1FB:9S^P04I6!JWD5QD M%[[R3Q[@=KJ6%J04),%%CB5\%;SLN7JX7]&@:[O3F4/ M54T#2[@;-_LB-ZE#U(4GSN6?6/ RO>?U#RG^1C5>6N4&'?,N>/\3W0)?MK[I MU84JKA<+!EOLO+'8R2[,^Q\!7X2Y:/IOA%LB"I)P][T2_G!!1M' M,4[(TN#01+,@L1#%.''!E'EA3P-[P$6-63Q>B]%8PF@:,GJA&S=1S +)#29P M0?H@E8N()\K^W?"*RS40[FJ8R?[0G7*2=:&],&WILU#2^;.Z'=.5A%O%PR7Q=[)"Z(+%(@@A*D$L*';K"$ M%2UI2^=8!2H-02DOC;T=@" %9.STJ$4< @WXF-2I5O6J6=UJ5[]Z#@^X9:I+ M$-97W_K(A[;*#A[ *ES_^M!K9K.?K:2@,O59ME3*K99RRT)FF[#/Q XNG:,] M)N(J6TIZQI*A@8T]61BYV^'NM"R(_.H[<7G5E2[(<\7=;G=3^MWNIDFK81SO M>,_BP0A-VZ=H$+Q.W[=UPASM\WP^7^,0I7O$D M1]SB&?[7^*J%+7#>*AR&U[[VGSWN9X3S&86#!JV>95AQC&\[XP$LN;97O.4L_Q[:?_5W<:@M]N-)F.,WGW9*7_R<6)]M%OE-=[T/' MXNDYU_K6N=YUKW-]YSTON;,%_>:#6PGD()^2VH-.[);'O*7))?'B&X=SW MR)U0#T%*P)%Q*O$,G,XU7%@BV>0-7M=)[0%)4,"U1.>: ]'\.^+5G?6O7Q[S MF=>\YI$N=H^S/>1@^GG1B3WRH:/]S* _Q-+MC-0F(,)J4B@.%E#6]05PO'GC'Q_YR5=^>L/N>>>;7NRD/_ZXE]8^[&=3J?/9 M-M-E8\$;%%2L>8_F 4GRH 9N=LP.CX)$0^HP A%P)5EW:$$;]B !#4@*%"DH M05_Z6,XU[#U9*J8'YN"P_,0,($ $["@/'DT'PJL$?LA4-N$"<"606J 4=@$' MOH('K@.H4,!>2.$,ZB"5/F4%8 $.%+ $#BF\\@ %5'!K5H #Y&(N6G!F=*$- MZH &&N(.'LT,K$(45@ %6@# EH\(B] (C_#5FL_Y/J_G%$[U4B_HC&VW2,Z$ M6 ]2MP %]1 ]D*@62"&7GK"#HXC% J !O( %^H&.$H H"# 7M2037A!--H% M6R@@$+40%V)O)T @55;@ =A %3@! ^ D:'0!$U.G;9"0&(O1&(\10)90&=UL MV0"NM* /X+)/2U*.A*1O^]"$$RA B2XC!>(I*':!#0*G5? & RHF,XYB%$CA M#1Z@758G!AHB#4"@%#[!$Q0 %E8@GO1 ]M@D!=:$^,#B DQ% YH&!=XE%B0 MU4 ."1 #CX!(JJ%(#P@#]X##2@I%F8A%-) ]B#F+4@! P9"!1SC G+ $\(+ M%S @!_XX05QVP0(L8AN0$2B#4B@W MK]^6<>S$I+2>\..,+KC0+H5@B$L*;=*, RR4R /D@L.\@@WP)G4"YP;.H ^6 M10120 =LP*(4Y58B8F9X0 -XP 9RP QB001\K1,.[UDZPE1Z@%L MB"!@X:D@P$_^\25#H:A2@ W\,#.=I03*4@?48+OF"P*.:2AKTS9O$^:44."4 M,MLR2^U0Z/.L,0IY[L^@T7Z>43A9CQ0BX"UHX)$T"A1D0_X-8B<-.@824, & M'".PJ 82T))-8F BW. V$'%2A(8.]C$-_3$O,4 @NW,A" )S-",$AD,'+J N MZ"!Y+@ X9H '7B44%F @,,92,$")2"$#!J(?8\&2\K @0F&+=*$.( (#F.(MJ09QV( D8J$!! \W2]1$3S3<>),)C9)%?:Y%H\0**8AS*!MS("90( Y=4$4), ,>,8L0D!22"(')* S!DD/&FV_ D4. M- !4V$0U729QHLD#4@DUS. ., !N".("; @S9*-18D /%B6A F B0D,-\& & M&H 3(&;1'H!63N 0&X ']F %8OXGJ1Y !_2T8U 1+-Y$IO9@#2[@54[@7?!D M!_ [3&B/; #)!%#2@)12\54S.UT[1-15_4Y#P52T0.5*U0%_;(#%AJ%'; M!H:C$\*J50D"$CQS%,K2/3@M%M( .'@A#6B@#92H$VR@!SK!,]?#5.;@+>Q@ M($+!#$PE55?5/^Z +*3%UW"!#:S(N\ #/G?@5.] %'V-("05/:)I%'J !M8@ MO&"!7&%3%^C@6 <"#G @#V0A#<)UW7K !L2T#6H )B2KC#357_\58 FB4^T' M5 OV10=-.(N+5 .681O681_VX0;68"?6"9NPMXKK[=)+[OPCPKA+T28/9"_M M[_9M\OXXMLE>[V3MRV,1#;]8]LA"%O$@5F9GE@@E=F+%Q&9!51I+;F%IUF=_ M%FB#5A=VEF)OUFB7,&,GK2J[RV5E#N,L[]6>5FA-%&JG]@AS]FBS]N,2EF>M MUFN_%FPU%6NU-N#&%@JM3^RL$ YT0 =P("T(PA,,JCP( @YT)E@D)693-F]% M-JFPA0^\-6[.X"N4B VFIKY6=A, -V\KS0VZ\_$(HG#Q3LFNI[YPX2LB=V-; MPL@J[6--UF+2 -6L@@U0;1,X8F^OZU8[-M(\5VGG!:(L%S\Z8V4?5V^5J V& M$/$V806*;Q< T)EMW59EW;OP(XD]S/#ZW"?:R)9%FI[-_YSL8?=U@W*0L'O MTBMZ-\]LR59[0(.9BW) ;=6LTJ\N V"H*#"6(%9N?7+,#66#9JWI9J6",B:*-J(^T] M%8TZ!+@D>C$B8*K55B-:R:P$SJH@2F"+%BG)2B W6GCCLM?LMG!5K,(,>F)/K$(.^- AW*"$+28/Y&!J0.$-'#<6OJT[1V$7(*$7 M5&&IAA 7Z& 3.(%<< $7>.' 2/YAZK9Q#F0A ]A%%SC!#4I)PT8AD-<-#D8A M'*^+%-P _+Z57=$8S))J)[ .%KYBN>:E#@:#3W ,D 49%@B977;A##Q@QR0+ M#HJ/($YIQS2@5>G@9/K@#9@G=3@@%)(K%+BXFJ!&R,H%#KPFQRKYE-=M#NQ@ M*GY2%_K 6&FJ)08":O+ E?UC%.!@#ZR"%#0 %NB #Y0(%H99NW0Y1.V@#HK9 M#I#U/S;!#7 L#30 %,8IG:.)!M2 D*>F$]Q EB^"%^@@G&$#%_1@#E[96$&@ MB_O@D+^58L:I#SQB8]" D(D,%G#Y/_8 #N D%HB,%$B">BE#%VX :TRP>->- M ^*2(/[,&7=Y3RX8@I!1S02G^:'=H,88;!=J.1OS&1?J@)CU>0^,-:DXH /3S>1F*EYRQJ-V K-JB @@ \Z(0'2 (\+ MX@2:A23D0/:,8[Z&<5Y*( 5R@ (@\_Y$0"\ZI8IVP:\"$@,\,>,,J6G)C.$"-6M$J MW&!9Q"@'!&F<)NL,3J N2($"%D*(_I@"SCLE1N$"*+N26;L&>@H70D ';D " M:LPJ:, /&:JX)8#_RB4$)("2=$ #0 #6*4&'J $< P7;,#&2V$'-KP%@$4/,& '4(!/:48$>*!U MLM$J\(1:'Y6]-T9K]D#(4X KK:(-(( #4J4%COP": )11[PA[4 M*AB8 E@%%R*@ELV )-A@4PC8/]+@82!B%!*@C&(!)@FBUTDBU@:B$QX %^Z@ M7S' 7OX"DA.LK!XE[RJ6A0+6!#-$WM4!G1=@843W*P(@U(8PH!-B(0%LJ!M' MNP<@QBKPH/A,!\K@("5L8[K&A@;$L?&87!=DP2OX$6YXH%(NX&8D@"T4YQ,4 MP"63Y38Z(3MJ#&^N6!?@ M %E$00,T8 ;J67VQ,L?.( ?&B%/$$1<<9C/X8!0R8)S\DOX@/@%9UN!5T !O MO+TC8*'Q=V$7,* 7#K4LP9R0Q5&T(Z#&VB!PK (2(" ':D ')& .VD#;*2(6 M1%N>*@4%L 4%W$ L2();&'Q-** 4V"!/:" ''D 4"! @=.EJ@T+7G! "]5#P M@ .60(%S1 C$T$G7+@R>=(7BD8-#"X,2=SV,E>9&"@RZ1%W I8O3@QPT=%@X M8U'7FQ6Z6&K88] �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end GRAPHIC 60 comp_0015.gif IMAGE begin 644 comp_0015.gif M1TE&.#EA_P*J ?< L&!1,-#!()!!@1#AH5%!X:&A@4%!,/$"$='B,?("8B M(RDE)BHG*"TJ*R M7DU49%%:;%1><6)?8%ED>65B8VAF9FIG:&UJ:W!N;W)O<'5R'UZ M>X!^?P!5I@!GX*8O*&?H*2CHZBFIZFGJ*RKJ["OK[&O ML+2SL[BWM[FWN+R[N\"_OX:=PXNCRI.OVI&LU8JWVHN[VX.UV):RW9NVWY.^ MW8^IT9FVXINYYIZ\ZJ"WX*"_[<"_P)?!WYS$X*S-Y:/'Y++1Y[O5Z;K5Z:7% M]K+/Z,3#P\C'Q\C'R,S+R]#/S]#/T-33T]C7U]S;V]C7V.#?W\3;[,G>[L#7 MZM#?[N#?X,SA[\[B\-+D\=SI]-#@[^3CY.CGY^SKZ^CGZ/#O[^/N]NSN\?#O M\.WT^>?P]_3T]//V^_3X^_____CW^._P[P M M M M M "'Y! (?\+26UA9V5-86=I8VL-9V%M;6$] M,"XT-30U-0 L /\"J@$ "/X :7WR-+!4K5H"/WT:I1!6K4^@&)*B==!4 MQ(6?#"+\Q @2Q8.E0"G\Y+ 6+$^>8AV$!K#5([!M)3'2R'1FTI))J;95JM#42J */;6B5?/@3D>20L2(]!>98?US' H$2MJBP;]I'E4QY>O@^I5W&A1 M8UJ,%/X1KW7J$4C8 WG;;-5(D?):K18U4O\HU$W5VRLRDB0;HEY8D- E%V:U M;)584@PQU%@M4Q!QFFJ=Z:;01$3U,0@R2Q& M!MG$A5X$B60.59#GA Y8$H$3@T$&&<0BM3@2I!<'_1$D(PC5XH4.1'ST2 ]# M'#7+$$)05,H46.HPA4%B_I!G#YI- 2=8L BA@Q.U0-*#GUCV()LI0>C@ATV/ M&'KD%"IUD4,C9>:@2"T_ (FDEHDN^F=CIOQ0A(Q6[(#%0?Z"Y"#(07X L0.2 M7!#50Q,V-?$#6*U$^D>:?^C Z ]=U*)(#D$"F8,7IN1P!4QX!BE$5E7YX><. M/9!I4Q4[0+=2M3L(8=XGX5:TJTV-N*HNK[6\V8-Y!UVA@R=5":K1%3M<&$23 MLJ9YD+R0'$0+$5+^8(5L"!_9P\(/F8KD#J6T8NJB78A6"Q$."K(#$6"9T@,5 M Q/1*,F.Y)!%6S\X6(LG0<9(D<<%IYE%ETEJ42 56)8K<\/6UCSP$-SV,"Q1 M)H]I$RQ!"'&0$P[GT(>&D$0:Y-&,#($D$& :YBHM/MRZ: _8'M1%#[<",:NF M1W.1 YB+!+$#MQG7PL4.,=K$A?Z4:%=)Z0Z<^H"DJ0-)N<,0+P_AQ! %>T*$ MB+,UT?,4F#4\Y:<'$?&#;+ @220A]/2!-]-ZPZ5OO&J/K+?N^NNP[]C* M$$/\(<@4S]+R0Q!^^"'('ZT4*81D=T^AI@Y8*/+''XX/&)IJM"HN!+Q9H@-Q*0).JZO%'W; !4@L@@AX:\4?_""$ M'WSA#_X*V<&TO/ L6"AB!S&L1;N(()DB\ !SI=C=Y@[RA2*2T$&?T,&T"K2N ME0PA" Z)5=NR]RJ*V(M>!]%7O72 DW_]01'*6Q 70O6J@_3P"XJ8P@XZ>,<\ M[O$TN[I@[V@A,B'\C@@IM DH=O"%6OCA2%VPA07JX"$>LR64(,5E'A@"H6EQI M$:; ':>XP$L',6D*D)#$(DXAL,P!KFJ :H4/@O (4 @!4+&HPO=>Y8<^"$); M0A!1%9'9""'PP!.S (09E&*'B#J15]ZQ!1X,"PLX,U@=OY+)?W^$#Z*6*$' M*NE=[[Y("S]("A*-X-05'.2$*CEA:J)AF@Z ^ 4="($JOOI"[_XP$U_)AA:" M$(05M C'6OC*"XK(P@ZJ-#HO"$*EQOO"#O 5NYK:]*8XG5$K?E"GB%4!%C^ MUWJ"JBX'>0%P56E7'=4D-2YIY$HLZ0'^2M$YJ(7O15[X@2G%=$U. <%I2K6) M%S3Y"'?): I!",*TN- T!ST">6=MPMXN=+ ?<(HH!NG"#AKX0)X>1'@OTX$I MU=***0@*46ZI"A5^,(2.!:P(/:!I+(8 A!#FH)%5[%J#N,!&6GF*B@&CR.C@ MDD7H:(&1%#$%A=(XKX.,P@JSDOYA#RIZ-+UZ(;5'*2U(B&H3+.C /",U2.>L M0(4A?,1>-&6M;)!;B[1216.UF),5M%D2S<%%CP7K88;TZ E3M% MWNU@JH#@ M$(K,,$:/1%C%]%2+*H)R%EI(%@-KT2JQ+?)C=)'1PM MIVA.L_Z:=;13:I9"KUS0W>[^M;(V"V(15^C!I]8T!2M,865ZY11%RKPR07UA M$5WXP:O$I(4>U+('>PN?;TWAA%\)N M-",+LG*97,.7&)F+Z8@_/S" A6"$( MMB#"%)K@-$5]\5];+D4J(9'(&>[@!U-0!$4TQ5TN;GJH4(04A5 4%AJQZH6R4P8^P7NWB01N2.MXQXFXCORER;J+$6]FKC MG!66DUH$?!&Q$K2OX*+E6O20XK(2V>YZ2"99&\^?*_RO#OX,X@ M2,TC&D?L(%E <%G*0OI UFKF9GV>0J[\<-DTD8*]FO/#(L#P V^II1$] &L. MI+S3-IG$KX'( 1#0W8,8?4(1C6#$4)#NM/G60A(YJ&.9RUB+123R(%G\N&AF M(00A (%DM+AX,_.IXUJ H0=I3:MR+"8NBIB=3,[[WA]](VQ&3.$X76!F;_>: M)G_G2G,Y)[7FE&/>'4Q*M#UH1"D,BJC1-<(4CUS5*'0 AC6;_O2HA\^/CE0N M4P#U!U?(@A6&-;M0H6T*5(E2TWY<"TUY.E%"Y%*H=A $G)39#T3 0A>$4'(T M[=1X#@13RKX0\"_T5TT[Z%I5%/XEA"QD@0K]+/4C]_>%*;0ZZ=ZWPEUG6+#& M?F047!A=#G3&ZS)EGQ8_ AVF*MA]V=\5*5+E<%GP$O]D"JPV0XK )!>5)O92 M,/CS" Q7"WUP3TU#%682*DBR95Q6;I[P7?!1?NCF=$]';;.A \F2<&T!@A\3 M,?CE9P&X-$ P!9)@9O4"*"(C+@5'$0?'7/\2>U9@=#78"K(&'7%G:8[45'(G M0QF'=^D')BF7)B.5%6;D*);5"%J&:TFV0FLW!$W@F0 NMPBF,D 6@$ A5T A \$\IYEN2D":,0$,;DW0])&5<-D55 M 6.]TB6W%B.G M-C,YD"N@U4B"@B](9SQEAFA$(%?^AB:+8%$-H@,HTSZ^M''*$G9BA2D=6'IG M-02E, 0;- I"X%:DIR&C4P2+,R^TP#RN!01!@'UW=52IU .Q)2A-, 6\]&)JN/X9/:0()&4$-3I4 %9')4JF8H9*((@N 9>I01-\E%0F5&BM99M><$4#,$?E%P MK'4A':8#%P)F^+0>/R*5H>(7VG40(W6+2=@JCV *.T R51%>;9&$O3=3EO4I M38.%1W4TX,OP>).E?8#&H$_+Z%2!?,1+D>$9;<#.C.3CF16;0$U M=2-@XI)%?@-8L9!!=&(+I; (GDDM)O@1#G0T/'K,#/;8T 4@1+F=*LS 8G@51F>,)3@ =0I KYG5V>C4KDW=E MP&@3PKB!BO (D@ 7HR,(CN (%7 C+%G8-R9+/EF3->$BB7G M5E+5'9YY/\:%)\8SD/&RH)ZI:X_8!)[X3[DB.(T "V+B("2T)Y7265_%AL;S M)E/ H(N0&$_8"%D@(@6XET$R*3PW!1F!!>%8$5,W18](!-[WGZ\B8K$%!KAI M,!.'=C=9!0HDA*,S$QY3!)[PDSPP*4(P!)ZX04ZCI%[ I(0XA!7!6S;!"(OB M!#.C)]Z')[/R3U_ H$S%!:;0"(SE$)Q4GMYA$^_X9UB IAOS X3@HA]#$9J# M=?;D(/ZD(%5T"@N5U 2>J4=DIT0[,"NQ,BM(]P,D4PKJY!Y$U$%BVC)^9Z9Y M:GE/UT$4(6QHA!!7LJ62<$TX,3X.<8U5$9LRR @KNHN, M7\%G9Z#2WNFXS MQ)95,5)4X CM04A)5PJE0)('(3]UU&D:2416P!"(%#ZI(E2^(00!@DG)XEM> M(*N+((?/PZ!UMSAZ04109%&?0 IZ=(L4X0550@33$@0ZDUI3=YXO- 0.<:0& M^0-^T!V-8(&A95*"J1:5MB#+\G_@>; (JQ@.F1^5A#:W(FULDEHZL"I>\$1J M436W1(N]T,E9L,#2;NTM- ' M/# U+/M_AK*=:GNL2((EH"16:(,EKR()/!"O298#*(M#1_(\MU.\ #C:2#%.,UB()#/[0OH58(XP!,Q"?/1B,AJV,3V3 SZ@$G_ WM@$SAD$,[1L25 ML"2;AH6"!PC0QQ5/Q"1XQ M&X@!'U;8""(B$)Z)&2=<-J!0,$S1%"C,%CF1&O#18Z%@&IM!PW;R30%6(#^, M=E,!QOZPT HT?,3*X<4?X<-H[ B^0R!540H7Y).#S,<&X<.+?!"(;#"0L,W,*V0,HM40I# 0HF5!C1 MU<(HS,+;V,*D_!YI(E-459UMX0@I!@N-X >,D!\Z#!9I_,H.2(*E$,:L<<,9 MIDB@\!&D[!,MO,)_#!^+\ )W7>KW7?-W7?OW7@!W8@CW8L!/4/XUFA@V_ M,^(94CW50GW8/:(Q9FUZD[TCD(W42]W5BTW5BMW9G)W9ENW938W9-@+4GSW: MIPW:J+W9K%W:HMW:5AW9F@W;A;W:1DW6N.W:E*W;:Y;8A/W;P!WZW=FMW:-@(J4P MW=^MWB=W-0=WMNMW>N]W.V-WM0]W_1=W_9]W_B=W_J]W_S=W_[]WP > MX (^X 1>X 9^X B>X J^X S>X [^X! >X1'.2SA3X19^X1B>X1J^X1S>X1[^ MX2">X8,3XAV>)R9^XBB>XBH^M2O>XB[^XBA^*S ^XS1>XS9^XRR.XSH>XSO> MXRY$).Y$5NY$>.Y#8^Y$I>XTP>Y%N@!5(^Y51>Y59^Y5B>Y5J^ MY5S>Y5[^Y6 >YF(NY3LD4&9^YFB>YFJ^YFS>YF7>YG >YW(^YV;^YG1>YW>> MYWJ^Y_Y\;N=\_N> 'NA^X.>"7NB&#N>$?NB*ON@;Q>AT?@B!< B2#NF$,.F6 M;NF5+NF9?NF8SNF>WNF;?NFA_NFD7NJB?@BCSNF;GNJ8SNJE7NFN[NJH'NF' ML-;&?>NXGNNZONLX$@A[ C #@B_#NR_7NS!+NS!O@=[T ?(?NS$/NS#3NR MT ?1KNS2'NW-GNW7/NW)_NS.KNS+WNS&CNS0KNWE'N[8GNWI/NS4+N[;WNWI MKNW 7A*B8=IS9^_-5.\-I^]=*=F>C>^>S-D!S]7Y3O /]7\SM4#[]@'W^\" MK_ /?^]:[=2FG? +3_ 0G_$6G_$:'_$%/_$;_]C_/O$2[_[P!D_R'Y_R!1_R M_C[:#<_R%%_4(:_R%1_Q+>_Q]@[S)X]/'Q$(SO[S0/_M03_T1%_T1B_O1Y_T M11_OP4X(3*_T4'_L-/^,OB[W?-_W?O_W1D_W>3_XA%_X MAM_K/P_N3]_UBR_T@/_XD#_T@2#X:H%D&%\+EO_:A[_Y<9WY;FWKG)^P:P\( MA6 (AH (J-_LHT_L<'_TA( (A3#TA0#WA& (3B_LK1_YN@_XE!_ZOO_[P*_K M6K\'AK $(7 "Q[\$@-#ZUO[K3OX/[KEO[=X."'J 4A0",V/[(,0!7I0"%)@ M 5)@",(N_@(0!Q@TXM6[5HU4*(\&!"A0P-,K2DJI8;,0\39H+1T.'"A!PW?D1(8Y-& MAAY+.K28$F5"695DU2(SL.!*DS5KV1F#TM9"CR934IH (1 M(4*%$!7B@^B)@"61EA!X8FA/H=BZ 16Z;[=O7\''U[\>/+ES9\'-,OJ MA0!T[31 **,!G4QG!E2*HR"AI0(2.TEHX#&&TJA$- ,1DN".6NIP@Z"&-L'L M0 D98@"N"2_\:!,&)!*A(@P=.J.##T%#A0S!'%H#CQ%7'/$@&610B46R:EEC M@UH>4%#&"P^B@P*K#DID@<J23>2P@>1-5EF6$QSB M=2.,71NVQ 8X$+($%3L&8B6-&Q*I11.Z5%&1%31PH(L25,KP^(X;"HRXWYTW MF<,&2FH1!801Z$8HDVCSY62,,9:L6*JV1YH$!S4 <\.#6BI0\:+!$=I$##$$ MM'R,?#/?'/,Q0D>(:2YEN6'+*N685]\;*KA#E=?OD$43P&11X^:R;Q>;;K?5 M8")?W&]>&2%9[N"IEC(DQV&".(:B!6/6WSB1CAO<6,A>,:A*10*)2@SC,53H MWJ3 #092Y8RQ:TG%! \FT3?WO1'"8^0::+!(%31NJ!SWJ2&J0 U&D@HR,$%< M&Y@$)?XN@! "AN$LEA#0)"22.$O@X PZ.U"H@ !N2!$ Y0 0($( C;.=55\1B%E?EI@OJ4.4:$""+NFK%B8H MT^2V-CDZW"%*#.' &CHQ@!B<80)ELL,#R("#!0 ,!2B PT0H-/JK)+(Q#!&5!@@%NX80$CJ$$M6/X C=T( :J0&4M M1K! 53S $C=8P#%C, $QW !73E('!H AS$L4!,&>,$9*@ F.BQ@##9X@ L2 MHHD"P$ ,$B@!#DQ0@5K0@0%O(,,".:& 6Y6DQ 10>QPP*0JE155. ,9U! @0Y2![&* M\Q5E/2L"+"&+"<2U0#$001Q )43 M%Z! RSQ@V:'6X@P/*(,,%*"5@LA" C>8 P4&@D8Y/$ KV7Q !^RPB>]>]RA= MI 0]-='>!DPB#;5*Q0 \E@8/9&("[VK ! T4B-W,"35W H00+<"& +@0"LR! M @". @H2&$/#FC 'O(0@144P@($6($>V !B(39 Q B0 "*6P!SG,"\,G$ M UYBB0F\1 +P>\@(W-")!4@D$5&JP!L0<@8ZU(&>?%L +4S@F5IXP&.4@XDZ M S0Y2W#B2<0B8QS.C(H%O"(#9]@+EI_\DDJ@0A9P. @93' C4=AASPM@Q6;W M0K:BOI'/JG # UA1SS?>J!(F@)@)0/"*.MB(O1(I03"5">B"W $N$L@$GW=E MB0>DM$$?&]8H'> S&"S:M^5KUP,RD0H#[$T5##B@&U91:Q? J*&9+ @*A);, M&)!1%@M(11RD7(M-($ 6,L"M8A9="TXT !43V-L&*$$&,/[5PHU=;9 <%E 0 M#[3A$K6N!2NZ+(.,G'&6P5Q((N@F 4M<0@$2N<222@!H%'@ %9380%4QM@$Y MT*%67GW().@V@4ID @$(SU?&YL=Q37Q\9ZFPQ,%K88E45$("!Y$% Y!\7(1, MX@'=98 H)G%<.YRV I9 @^1JD0G\70#H**T%)6I=W5I$ .CASD0-FDD5#]SZ M(3%U=P;Z4FL2!%,6>%A()7ZKKQBLPA)8[F+,95$"K=0"#FJ@@]#/L.@+V.$5 M1ZF%#&90BS"HDPPBX%H$6/& ^6W ,P=!!=YI@#\&'"45\T/("" V KTL*$H; MN,,DZ$F"RO=H$P^@A<7Q1X(WQ/[ASN6"0Z>OHD%$&,%.V!GQ!Y P O4?@ G MV(,% D "TB!A\+90R0BL8<(-" 0,AZ "O30X.%\ $49C$2(,R( *$(.U0H$7R( R>0!1N*X!A#5-J ./(N7F#M]H84* M6(4U("/%4*>7( $U>(,7F 0;N($ZN &MF*]=63B$, ',. A5D*<7"!#V*HB@ M6C8!6?X#I!NZ*AL3O? N3:"%&S"!%T V]GH)_Y*%EW"!-4@%^$"!3%JRG#@( M:5,%"7@)&? ,[]H8:^NJ2I !#P$!-'"0"8BZ,)C#,\H %T !$]B LH*?." M M$G #-V@ %M2$/D0(%] *&; _XPF#$H!"^&&"!J@ ODJ(-4 !2Z !,8@#,0B# M3E %S !%Z@ N!,1"J@E$&*@OOA-%4C0>,4 C!B";, A!4A0#40PF-9C$ M6)2 2M"\AE#&%PA#": $S>.1X_JY%ZB(PZ@ 2J"!"GB!1*P 5>" '/DY&-"* MPVC#.7R)@S@(,[ 11]NZ5^B$#9" #E"0@T #W-H)XQF#$OZ( 6&4A0=8A0H@ MFW[D*NL:E@L8"#

    XD9\#H)V)APNQ%.L$1_,YX&V(1)&($S*),UZ\TL*;() MK)5:* $WD -FDH5=>8&VP\1:H(%@F@D/> &)X("%.<-,J*R'0 40J($WH(1J M*[0%,#35G(CD4I&" $7D(CW.4-SX8",.(@=784V2P1:4!85C0%:8 4@%0AZ MNLR;./XMA' ##K?FY&H 1J-F5ND.(G[,!^SNT6L"#$<@N ME#@#&[F#*05."5A-)'T#!!"0.*"YYTG$(@4!VOFM#< [3JB$-Q ZS^Q&-Y" MQPB#8,(!=8J!C% 65=B$!M"9&!!1ZX(UOK,!]@%.'(@ CMC,"EBC2?HL/(BO ME%JC35@ ZXH!%Y"%&I GX+2%97D 0,N@US@- 6 "U ;" 0=@#!F@ *&@! M!9 "HM0#"T" /0B! &B!%0" %"@$!W" K-0A/9"A%5@!&'.. (@ -EB"(RH$ M!D" )1#*/4D !B@-!X@ ZYC+>(W7NF2("1B(E1L 'UFR*_[;& *XU[[D , H MIYFP!040LX/H@#8H-X2@!/B@ 1!8J@98@U=8@'@QKEH 5SU $"+ ,PXJ;VP M1X!1.EN@ !C@A#O8!#X;F$"JJ@;1!"Q!"#.@ ,! 2:(@RAA!0[ K07(A/D< MB#B(.(DM&QI-"+]1 Q1 @%?81P9: "Z11%0+L&9"NDU0@'@9 3]FSJ $;D0 \R(0^4AXRLE<$P8.7+9 :6"!; M( %G^LA\A(DG:=Q,6(A+NP"MF$^Z\"Y I -OVX!,F@0"B(-70 !;2(,*2 5; MV '2H!..+=AH<8PD!Q4D !U"H,,:(D*L2[<6), "/H8$.. B8>IL!XPY#6 (+ MT ,^/Z %N #XL@##5" !FB!TFB!!E "X "1."#%% !5@!X@B!$P"4/+" M(\@# O@ #$B $- #W4@!!C@"*8B +LZ#$$B !S@"W2CCT@B!%(!+>27D(*/7 MA( !M8*)<:.%,* H<([@A"!"!D=@SB(,-"+@J@!._"+\U0G6AC?"*8?#O M#R@0&\ [5,YA@K.>HE"GH8L!3> $O" #,"?1"#E#MB;2=#9"[ Z6[B!#=@ M$Y"(& "!51J!.XB!KN#E4M[E#O 7W8(-\ !%T0%.@"XI/, G:6+-8B_CR&J M#[P 50B#6[N!@W6W648#SNH$%#B(35@T67"!"T !'&@[;OYC@9<@ T"4!11X M/ Y8N%Y!!10(BTD8F@5TI"%YFTQG,Z0X8@6G) M:0\@@9&P!):.%U8P 1(XC$L @6V.%TKP%=%,:Q?8FT#:Z8_9FSC( X8@9%P M ;IY@;C>Z)%.BS.; 6C[R#+I9XA%B(<&KK*^ %P-G!'89@6I!*LF@S2H2120 M"#(09C11C F 2;0BKM6K>>D@_X.2-D-P)\Y".D1$)\1V !,!<0F1 '0]H"3 ME:GS88@:N->8XH 9>(FYR(2TQFW#0 @4:!!.Z(!ID848X( -\!4ZP,+5ZXY MP [JF(W2( 3IJ W3 (0H+H0]J(VV' [8N WN-HX<2H%(X(-"T(W:(([CTPWC MB.+IQH[VOHU"[HY!CDO[WJ(1J=4W08DS+ G X&\I<0A5.!%]*5T:7(H#[\V^ M&($LT;8"WXLWV6_0\*P)H04(%Z:!X3/(6Q'>5'"RJ!*= '#1J%4,MXH07ZH) M\>^KL(432?&-.!%;./ 73X@/=X@2/Q!:"'&%L/&2&(H-K8#)&!%E60D"9X@= M-YXJ:?[QE4!RA0AQ5;B+'8?RJUCQI:AR*F]RJR P[RBPW> .+P=S0)&3UP $ M BNP[N#N/," %K B,.]R0&E+.7%S[AYS^K9S'W.3 -=S";_Q-\GS'.X $7B? M/2?T"4D$OVDE&3 M^Q8/],8B>+WS4\^B0Y;T56=U'1GQ5H=U!(_U6:?U6K?U&;GU7-?U7 T_+P\/ M7T?U8+?S.%'U73?V3S_V9%?V96?V9G?V9W\3'A/V::=V>2UV:,?V;-?V;>?V M;O?V;V<2::_V<2?W'KMV<$?W=%?W=6?W=G=W#!'W?X_CT X]W?']WS7 M]WWG]WZ7]'BG]X 7>.^X=W\W^(-'^(17^';?\H%W>(>W]X67^(FG^(JW>&,' M^(?7>'(O^(OW^(\'^9 7^8S?^)(7]HX7^917^95G>88W^?+ [Y9XW^O!#^:%7^J5G>J5O^%>)^:.7>NY( M^J:W^JO'^I O^JGG>B'+^J\'^[ /^:CO^K)O%5 7^[17^[4']ZT/>& W^^^K M>K:G^[JW>XSG>;(W>[<'C[F_^[\'_, O=+Z/^\(/#[\7_,17_,67$,(W_,[_VIO_:O( DG2_ZQ M4/Z?8/[G7W[G=[+I=PKJ;PCK1XKJU_[KW_[LY_[O]_[P=\?N'_\8:?[SA_Y8 M+W_QEW[R;W_P7__X?W_VQW[YK__Y=_[HS__]1W_][W^+ A:M08*%$BPED&$ M"@\F7)BPX<"($B=2K&CQ(L:,&BT& N3Q(\B0(D>2+&ER)*&3*4^R;.GR)4R8 MLS;2K&GS)LZ<.G?R[.GS)]"@0H<2+6KT*-*D2B4>BNGT*=2H4J=2+0DQHJ,_ M?;9RW?[JI\_7KE_# MT*!5IP;[I]'2V!JKTJYM^S9NJQ:SY-#A^_?O'<"##_.O#AT MX]&G-V\^W3GVY]>K7]=AO3MW[GFCBAQAF".*+),;HHHHFQCC*C/XNRFCCB2/JV"&& M.]88HH] -9*Z)9YM !KEA$ 4>>&A$ M#BJZ**-424@1A8\B.BFEE2+JR Z,7*F#'PM9^BFHH085!!6B*I4@2Z@VNBJK MN1%RE4!8] #+0:9NA-Y-N"*JJZTU,9+IIIWV.BRQQ!9$:K%$M;HLLZQ**A&% MM"8[+;658JJI4J5PZFFUW7J+%++?\K12L^6:"Q6Y(CT;4;3B1F2+N_'R=&VP M\MI[+T[(\HHO4^:F>R[ 3T&X[OY [=J[+[_W.J*#I@CWI*VP"4L\<2WA4GQ1 MP!EK[!2ND;HK"QUK7&*4*JOXD!=$34P0@2T7*T1*Q M+0J!G'2@"JUR(*W MX$LC1'A$@[^+>"VO3*2XW4G+8CCDWV)J)5("?:UUV9W+1G;8.*<].DFBW[82 MP;48W"T*+B $;RH%6%*+#&F 4($8 Z%B @@=U%%+)C2@,8$JFHA @>3V$+" M AZD0OY'&+7$4,8($IPQ4!T7<' ##*@H!+WTU$=P?2V3=-"!!Y4@= ,'VPLD M1A@N2! '&16 D#(M-;1/AK@+-^SU#F#FN0%^BF8#)!T"S[6'5U%$(%F8U;AZ@02UJX+I:> .W$H6O3B7D\T1L(R5TE?GSI; VW1DC29)W>JJ-8$. M+JT":JB%"P<2OTW@D Z5:$ :4,$ O-&B$W>PP01JL0D)!/ZN#"C X^QL\0!1 MN,$#2JL )VH!KS-(30*SJ\4#.I&&'PY$$Z^(@/I8&(%:F(!_G'A RLC @EHT MX QVH(0+.M MK@$K6]LR(S 1!3JPM9$JIG,C,D<"Q[95"UXCP"(MX*4*!% " MCYFL!2!P9+22@B54@0/Y]<#" *!3"24@B9 *=2(0$!I**#LAB W?$ MY@8,BM# B<%U%^A@+2J!!\OU,BFF^*5%7_8@VTV(3Z[H W M/,CB%?Z?9$4#DCH0_+(P<"Q\FDQO((>(;$(,9(AI)3(IBSO BQ.I;/ 8>$A6 M;'D-K1551290L8$8I"(3C&MK3L:&TS)G1$P@<6(""B,)AI;8H0R=J40<4H, .I8Q!*ZD;S&': MK,4O_G),8*4Z9FYM(G0('$00IN:!J&(-8J"#EB>RM(),1&M$_E08.XQ<8,(+ M!-&KA1LDP E+$#:L-21#5CM+"4I00+AV5,7V4&Q=%H.YTD[9KH\S[1->R"L(X#I94( $+J R%#E!@@E(P,K5 M77'9#L'K7S/(UZU:VYAE3.QUT^17F#.KA],Z@C]7@'^UX,"I44 &#TRP EZL MA2HZL8I3!^W.%$-CV;Q,[H5_=#=D9C?$-9)G3P<0Q0+9@ T&X@$9O+< _#O# M"BN!@.D:YY>L@H3D-$ M12$#%\QA$C6@A1@R,1 U=) .)"#!!&NAB1>,X 4:QC5O!UOYY">2FYH1X.[MML88U<* &:2AISG_5 M:[ROS.>H]Z_>$0?U\JTVYV MVI?>]A''_<5FCC;=[[YC=S4^XXM;%,T5'_K$?NL E3\5->[^W(+_0>JLK^G9 M&\5E:!=_IM=.Z>[_&MV#1__X&59WR!O\^V,ZQ7@R]5"XQE%*5274"P&6#2?80#?9@!G<7M8E' A6&LY-!"?<&E"@ N?0PGG= MA"W\H$[X8+>@@@YBA"IX3RJ<6$;(@LG8! 2Q:>=8/IUX%!LPJW)PM6%E1M, M@D#( B?PS36%D [B@1W$62U\8 VZ$>9M @'$P$_80?2HP@,HW;Z4P03=P008 M#M9,@DT1F4#X(1KFG5NQT T410D<5$8(Q!G4C0@<%,+00#615NQ%UT2M8$9, M8BTD?OY7AB, ?\X-TH34,48YUA4ZP!W$4HCOY F 4V5K6G!@3 M(H0.XHTM0 3C0 XM'&'B&.-$W )%$$X;N-SA8(0M'&$T343@F DOLL1'@T: MU$VM-6-"2(# M2&[4V[604RZC&12 )FC"&V91K,%!H9UE%"V ''B/&&CD9)D8)73"7K+0!@@$ M!WC1,]4")2Q +,4*5@^4@PT428T M@-2,P&TI@-*M@@+(0C "3X\2Z?6<0:R9@)*J0@.LE .LE!H$P!@NC)4X3#8B MA!AIHG&FE1"4BL-L AY,@J &'T[0P@1HP@U8TANL4!F8HT2@@@*,C QX9&>M M4]U@DTSNXT2(X'AN3"#8E;0(!):]PB1X:2U8S4 T&@NMD >@ 9LM@"JTTCVI M0=W(PJ$.A!M40$&P@B7(@03<$0I$#R4DD@B0CRK :AJ4P/Y L!.W6$)4G0%O MU0)MZE0ME("]3<(J =PDJ,$"; )/U0(:6-)-3<#1Q, ARL(#J((:5$ EU($= M#, FN,&E-B*@65*+FD ">OIP5T@ &( !!, #W)DM3,#L1)8*U0*B600(Y(X$C!4KP0#(*$!2J0$9 MA('<403WJ42G:LPO_HPLI")B(D#TB,$CR4(%C%T=K- &>-'=/,#NW-'1J,$\ M3:W244(!*!V!7H +R*NK!BN!1OX5!TP0+=""V*8!1)(!1!Z$LZX31%Z <.EA M%%T50=E"&U# #"PJ)[P2/@V$)9!K+;P $P!AIRYK*00Z% M%28A*H2OONH$!8S='/QJ5M7!8MW3)F00JG5 Y$I3 VQ U;K:ON3?TV[4I_)? M1,1!5 F$&D05&6Q1!533SL: 1Q9H%+D:O-"JX!PJ+5R W H%-4"" !K[@PK M[63H3?X9Z%*M4]9*1.0^;BT(;BW@P0J10%.N 2DB@'#)0@2@PK=^A 41"JU/.TR786QTHD>& W$"0@;)&[$"80!I,EH"AW#V= 04D ML=14 %C% &\%K(UE@@*HPAFDT@5<3P7(31K4#?.:P!G(0@%4$QT0P)RFK$70 M 0 <0 8 #\&TUH;Q-N0C7:BRP(K:CH"J\$H3=J(>.HPN(5Q0$*1!E(P&]6 M0 ETKUNQZT#(0 -$ZP/08BW00%1-9P:XP"&B&BDRHD/R"DCF;\YL%X!FG$"H MP@!<@AF(8@,(%QU$%2I,@/ \P!UQP/4(!!T40!C(@@*@ OX-#( ,H, (O)<$ MN $3 &8MX$ "U($E&&@J*"X:/("KCNFI_A (3!"\5,*)/NQ /("5V8$2N< # MX$ 9*,""/9T;T, "A($7\^P\W50#' T*U # *4 FD0!KT0W/BNN^L1 !A$$J M/,#;;EPMC, =!2(#G 'U $X)_-F\U<(,V)$,$, OAU4MS7(#H (=*, 9X # M;#'_N$ %<%(!L,(9+$!Y28#250\GJ$%67704/:EG@=;) N3CI )0 _4?5T3M M-:%*7D #5*1 4-=22]T&#$X;:.K2D "A*H1!D$ UW>UT)>.[[$U%C $# US )@_8 M"Z2"!XQ=FHD936 ?3<2!"] #<0 #A@< U23X"0 2F7I]GC MB30+@ +!M MO2G$)@1 57\DX#7MET5M1-#!^-:"'6P"@158+< HFYW!#7P2)6PA':R4'[00&_% MRQJD>49X0"Z"2IPO!0 7P%A1LD;(P@7,0!QX0-^B[.A)( 5JA-K>VAW X9.A M@ QDDBJTP22TCM*I AR(:0/$0";!@0NXP*EMK41P@@R8Y$!L@!O4P B<6BK4 M@ F$0>#0P22-M 3$(^UX((U, L9<("I$PF MT*;DUE@'O;)BLN?544*/=7(J'&N:NX$)6#O N<$=H +\.Y&%&1&V,*=QDLJ MKWG [.^$O'FN!/S=/419<[72U(26"00>:/96$V(E9OR#D#D &5"]0D2 /58 @=\(#E($E;$"&7@ (W$%>IHC>= %Q/Y!'"B <#DI*R"P4UX *K0! [S"*DS &EQF M]+A! ]AZT4@$#FP )?B]^GC6': ! IS7*_SH)EQ 30':,N* U$S 2DGH$\*+ M0)@!.M6*0 0G'BU81#!!!DR"&]"U+! #%""#%BG1JB?J6@UQ.M$P1L\P#3@ M]A(0G6:\3_!Q1=! M$[$ATI9S7Z]AG5 &@14-TI RFQ"\P=M+9"D0DRJ[KC: M!,@=!8R5PUI2#*2]#6P1H671(PE1F$:$"6!1+5! U(V!LI84CX*K4!&A#3P2 M+5 " G@06(U!K+UR<^J1LE8 0,2I5>L"G8$#/:QQ8Z+6!$TQ<-2R5<$@DQ&U M[BR0=?[P8!@/$CD.'(.J5@4TM6C54L6 DT@3MAATJH7JP:J0-P\&H8(29T^? M/X$&%3JT5B! 1Y$F5;J4:5.G3Z%&E3J5:E6K5X_.NID2RP]80U,2%3L69UBR M9]&F5;OVK*V0*1WM8,16:"D=?H*F/',!Y$PSM>IX0$&C@JU-$V2EC'&#U0-; MJAYLJJ6)!(D;$B8UO,-SQ)E:&P=6P!-Z\QD.,4Q<=!%FX.J!HB;4/!"=H87)E"\0#7A=YP./"T]2%PKSH:2 MFPG:X5E+S(L8GF&( ;&9D@$.'BHHD+4)@:CQ9U2]D3#0[?ZJ,Z 'HL -GC)I MX)64Y.! E0AL0B4"58;2B:X)*?3)**PPS%###3GL\"JM<.KJJPI)+-'$$U%, M\::XYE*Q%E/N&FH3 Q+A*0P)5"F@DEHVJ:"63AB L!80T&A,%E4D2*6A,@;B M(+,*,G,KAA@&VH2U"T8K*9,[Y.-.A%I>8*V6-/CB;H%::)!A(%HTX2@,$$(3 MJ)8Q7)A$ 0CG^'(2DFB9P(TPF$.IS0OD/..C@59I0+):PB AO($V$ ^D22[P MH$TX-A!AH^)0L603"DZZ@ ;L MCDE0(,TDL!CF1I@)*#5%'4)5D8G$D"FX22 MT,5=A;H0$$(\#%;888D=UJR#N/[R2JA4Q'B5/[;N:(FL,\0 *9,:B7+K+#K( M./99G[3EE:QC0<,C$V358G%7&/$:"HT"R*##!@,FD46!.#BAP8!+5#'@!4W. MN%,4^5Y10 Q9.*@!E3,(\*R!S=SBA $U-A&LE@8D=;42!3*I!(0&9+/A(!). M&R&V31:@N 2&#IK$L8:@M/,.2Q*XQ!(1'J#ELDLRD8 .55+>Q+A:T'C DCL: M$.X@&CC()(X%,GO H%I\YH@6!B1()C;=@@$SD6J$06!)1$10$E\PIB"G$)[RF0/8I-7/&I@%W<0Q!O M$E$H#_Y .-?;M% 8,-RM<)I /+?&^-*LS<>Z?" \%/C/1-(+'PB5#6QR88T) MU771+KQ,Q^D.$SIP84>,3(C!$C340.4"-T8PP9):5@G#K3=,0"45&%"@XXX: MD)-VH$Q<&,'Y[$5J20T3;N"D!DKHD'.C2BC11(*-+F'!>P AE:.6,NAXP0,X MTC:A!DYP()XRC$ $:AA(_$2 ]"DP0,SB$,:0G*&Y/V&#&U"SKDX!2- $FU%%&%Y1BU>$@7X_ MT57K@-@XQPV1B$5,BJ^L KF02 XH2'*A)B@!&EO(8CXAV?Y$% '$B3L("33P M6]Y 5)&(186$#F5*B1E0U@&.'VF%J(0 MDB6^J$-:=(*-LJ $K@Z2F$P$O60<($$EN>&"\1 K,+*/X)0.""E!34!1-87DHN,0$&N$ 5(JC!PV1Q M0A"( $(R..<#<$ ##S0 @RCQ /4D$$PT;< $[:S%&C@@ Q PX%4I"8LN39"! M4=$"!#$@005(L!%*7( %&6#-&DA@@H_(H0(SV(!G1K #HA"!G_QP'-B.I R M2( $+JB !7]2.Q2E9)9L<4M*5G$#*;X%7>&ZG$]_XA;6U4(.*"B! K]E.E6$ MY5BC^Y9=QR-#;\4R+PDG'#@/Q4BTJ@C01D&(@)T&"+!#AW@REQ YQL\0 7;(0$ MHZH%#())@HMD(@!UD V5M+4 )J4" :I00YG>$(%:J&$!$*(!RY 5 3E58'8+ M,.\%JB6!T=#B IJ0PP%^,X/,7.(!?4S2/JV[ .NN @&;&)ADVM.2O1[$E2U2 MD2EZT"[-KIC%+:X0+3+K8A-Q]K,UMO'C>L)$H% @,QO88*M4<09'O14Y#*'% M1"23"C6(@39#,N #VD2K35BB 2,8 ^!LQ *>N(4,6F9)W/;S@@G$8&IGV*@: M:"&+!]1 #&6@G&PD0.:0M &\$5B>FBU8B0J;P#/N@U"7Q_XS 3;:0@*;(,%) M;!%>44!UAHZZ@0E*P(E+Z-"!A-H0@%DP(&9T0"'C[QU#F) 06P< MI"03, FA RGT=WER@9;Z)"Z22.R)VBIC"N%5U[U&48Q]/:'#W9C8QU\/% 6N6?-*YI3(=Z14TTT8 ;6.(,:03!DPK) MX(A1P=1KJVE1:!(8D!:T>,"BCR/D6LQA#6I@A27TJY>+B'L@X\L$ ](7AWJI MP5$HZ28=)I$!6Z#BPB:PK@1>1?[H3901VB2W;"TD(1<5L35&EPWVT9%>.& G M/2TT-O;3,R3$(9:V%CIF=F9PL$XQ$Q9*G! %J0P3OG90\43@ M$HF '1,X$!DP9 1_T<2#&LZ15MLB IM 0]GC4&&-#^PER$@98=TAH M:\!O;H"*->PQ$P7 $\A$T0!5W]Q9K6[ &9AE@#'Z1!*OW%4I=J!BIO_$Z!,* MRR08.18Z8#E;0&F^TG>R?+HXO4-2A_KW<4S7+%13*%"2B%0KFIDQ:#DDG""! M!^XKBO[IN$ &-8B,"2"H]L](H!-W$.\(/""'W,+F(JL,&&(3+B U%&2?[FD" M(.A&9.">>.0"*N,"[(,$&M" &.\C^L2.1&$#2H!DE(0$F(03&"X,@BDL""[B MV @%.. %%&PX6NX,R"DEM.4.). %-B!0+F $7, #.( 5:L$.Q&L#'"4-6FZ? M/ "&*N O-D "7N$%;NYW)N!5-H%WR"3Z<$*M4F26KD_[4$05.( D:(!)1@PH MJD8HSA!=)F&/]$F9! <,V8+[P*\.BXWJK,XG4L$L*H$.A%"'CFDF-%!B($05 M0HE'7D$5-F(/72$ M$EYE%63B%=A(%7(H%FLA%4YB&1F )("""U$DUX8)%; ()1)#)B2BDI %D,R" M$QR)F!(!<-*L%BP!W50!#W ES6AA45#A#@"'$QI@1TH)VMJ'/Q*C$M M$^JE M-R0%CN#Q(%)A$K#,D-"J%CBA'[EC H1D$Q1RF&!L)[Y0#F^"#NV00[SO(JL" M#Y5%+-80VD8 !&1 OII+2QA=BC21<)" N@116R!=VA@ ECOYTKLUDR$&H$H M#, )E2LE0$D.PQ;H( ,0A9<@"0:;Q4*#4QBR &;Y#_>IA8FX4PR M(5!<(/XB*@!B/L,%G$LX/& PS0 6\23)B MH )@X $&9!,> 1DX7'924PJ,UEI-B3,%&9!=U@0AR.IKG-/A!/NQ'31HM:& M[D5B9)A4(0T<45%H@?I8@0Y^9QOE ,N<9M:J1 X6Y3!4H0Z%M=@I(K2()\F. M:L!1<" #4(%ZR8.,;<$^WH O9JX^: Y"EE 59LZ+5^1")1AWZ#B/6P=!'_AE MM_B/E:)E 4%-Q^\SZ7@,EG $F(,6<( "'B"&:N$&)N !1O[E1N3)!4I@$VA" M25+AU"37)HM83C'T6O6XE(?NBJ4UBP'YQ@196+I8C]7 1=4@C;9()1@ #C+! M)H#F#OKUCG@$,6P!#U*B$A"@>O.8=9%8*&S3E)E9120DF;5/E5?YCU_9BU/B M#2*#$C; 1UQ@ Z;,:&0@ S:!PC9# L) %&[ 1U ! ="@46< %>"@N/0X)8(N M@E'$%)*OF?7Y1%!96:5YFF_,CZ5B=.O7D+U8R' @7U[%(D1@0&0A# AH@T0! M!D02&F=9%58A!D: !(I7CXO/GJV5:/=YI->BG^'T67I>D8K_X(B]I &:B_1:A+693O.*AK.JEQPJ3?-*=U M&G15V'Z5>JKU25V@&2A*(<6H>JM[@JG)U*EA5J!W>J^RH"/-XJFJYR%JXYI[+6FB=L%JEM,J^)6J\7:Z[_VJX3ZZP#NQ9@ND1LL^)R M%JV%6JT;FZU)DZ\9>[#KFK+7Y*TEVZTK]*X'&[,76[/[VK)%>Z\!6ZXW6V5+ M&*R?FG&,C:>YFJJ-FHKM0A!>N[8'@H_O5[57^TSQL >LX J .[B%>[B)N[B- M^[B1.[F%^[>5N[F'F[F=.[JA.[J;>[JI^[JQ^PJR8 J,SW9ZH FR(+O%>[S) MN[S-^_Z\T9NXK3N]A]NW65BW=]M!J:X+?F (?N"^\3N_]7N_^;N__?N_ 3S M!3S @0 (!OS $3S!%7S!&3P(A@"D;U(([)O!*;S"+?S",3S#-7S#^7L(@ + MWAMQ6#N^T93J:&$69J'B5'S%6;S%7?S%83S&97S&:;S&;?S&<3S'=7S':3S% M9P$6KEHH8"'%>;S(C?S(D3S)E7S)EQS(65BL21QT@]RVJ;S*K9RJ6_FILQR0 MI_S*O?S+P3R/X?O[H'R52S?,T3S-U;R4QSS*OR^TUCS.Y7S.4]O-I_G,Z3S/ M]7S/F0ZE2;S,.1//_7JN-YNF4[/+^3S1%;W-[1SJD$W1(?X]TB5=F1B]T9^N M=+41^A!R0&@!#C9"#4:3%M1 !L;@#RW!!FB ,LE"%+:)VNJ()UY!25A'.Q$= M+6BK)[A-^E#A%@)1%?YQTH%=TBO]*@#=TJGBT7'"$J@$.(*IAB?C.BXA4&LA M!OX7HLTQ4K09;H;B0&9"4D!##"!H(^@ >SX#0*8HJ1+IECI8)1P+0,J1(Z8H MD0AK.\(@A3Y#6S*'57J150:"#F2!#'[LE-*HUH.]X)-ZV(W]QDH7#33X(FK M!>XF(FQ@#9CC$MS0(%S ?B;C=U:A$BRA$G %!U0A$T;E#"K!#6B@!EY!$PP( M!H+KY%&@!F" %FC@ CHA$6B !OXL%05N@ 2TQ0ULH 8T00PD(PQ2(0QHH%KH M (8XP09PP+HT@>>_$Q5R/H7L 9>0"#.8$HTP1:8 "U5 01,0$BN_@7N@,(T M%PUBX 4RX15H( P&DPQJX 5B* TLH01*0!;@(.4U81.6W> !7\\1/N%K;.'Q MG0YNX(&88#,^X@4LP0[@2UM&H$V.)1/0P W0 (.88 ZZ0Q5B 'IHH0QJH!)L M8,EJ80;@ .5EPQ(F 0=L@0/ T0-2P7(Y@0.TY0V"C&/=0&31 'M,0 [ O7. ._E>#@,.^9" 5 B7PX5_._9SP8;9TS1(9,F#"=:I"9=(,&FC&6TC2T9,.-"4TN M-M6Z,)2#4X%MV;-E-0$*AJ5 M:IU1,5BC"HU M&VK=X9!IDPBYKL T)K*&>7%0$8M&V3B!@UV5+#)#7R9H4HM MLHR0B24Q9#*"+&_44 D:M8R0"!I,%&2+")=P0A +5=5RR5=JH!&&&+5DD$D, M(Y)020R;G!&&*A70\@8*G*#069%&'HEDDDHNR6233CYIV&>Q34EEE59>B>5K M@'@ @VH%'3'"R[PI5B8M0A72QPOW*#*)GS1@<<- M;EB"1RUPL$7#)9K$, ,EM4SRPOX8:=!2D!LWS#$&6 V-^4*!=R12GPU&Q?&* M1RA88DL-,;PQ6"8TS'")=C+@H HM8L3 E28SK.+0##-4M0:N!=$1PPVOH'*# M47;4<,,,Y;F1RB8TJ!+'#7*<<0F<4%Z+;;;:;LMMM]XV1DB6XHY+;KGF@@;I MMXE90@,<34'I1AAJQ$#?M9"^,)&Z^N[+;[_^_MMO(.>*&^[ !A^,6KJ,I.UP0)Y2422)A$T/*L6(C%_2P M8:N\'',M]+V,V<@@ \QSSS[_##1D B-,=&D%%XVT:EP>9LO.ACDMV2M06QQT MU9&EJ_X*SE9;IC5B76\-=MC\!K)'TF:?;=K11"]=V"5GP#G)3,8Q%Q@**#P7 M1D&:R,@4REF!S(H-?B<6!V\*LR+#)&@,#ADJ=6E&!QV2V2+F8Y">.)@=.*R9 MB,:'<9+W*S&D,F9=CF85APE2%62)"RB\ "1SW=(LYATB?3W8092I,LEAMFNF MB28A^VXDI).@.K78RFNK]I7-HPU]]*6Q31@JJ(P1W1P&H)J&#;5X@"H=(+RR M@2ASYDV&!))[K96,JE"B,2>5T"<+)6N&<8;U@^7'2@G195(5642'%9#2F"R< M4PO>14@-+DA@02+T"E6D0A:H:)7#+-$)F\F"$VS1&UM4900#6L1O.4)$UM#DYXQCUDNZ@T& M%6'H(!QL0 )5O($,WUGF4QI" OZVN& 2,-@8'>#P!CD,!@7PDTHTY7"#G-1" M!FUP02K4, (RC."/,MC )6!7!AK(( V6F(D()A&8@JC! V'0A%!H( L<;" 5 M,J@*#%1! A?(@01B0$&!:!*#,&SSCF< 6]J@88ZR"&>%&I@)7#0G3.,: QD MD-8=(C )&H@%!6( 02<8J@89T,)4-7C!>EQP$X-RP@9H4)1B4) )--#@#*+( MCDDZ@I;U20T-I:R%^4Q@P1RE0CT&>4$80* *$Z#@#I6@:30A0QRJHHR5* 3:=C)I=P !SR H*,=3$\8 MG!J#N'Y(HV) "&93X0(2R.(,8@@#'%2Q@8[2@1(20%4"62 &$E@"!K)(!0U2 MT8$+N< $=,B$#*A:"Q,PX05MK0$.6!"Y\NQ3!L/9B8>&B5XF%1.9[&WOE*96 M!S'0@3YK(,,=8@"',MS79O6Z PQ0H1\ZD$ 4&^B@+>H0ASC0(5T@2 43^&(_ M35 BL;8 P1L"508=RF!]=AB1"S*1G5J0(!,PP,X;W%">6I !B#6H02I,H(9, MU* 6+&@5"E;! 530H@.VV$2(XS!C3KB $B2HA1O:.J""WHPX3RV&+0^U%(FBM@R/[0 @6JX(!3L/J4.(S! M!I-(Q2,K\;A40#*[EA!!!EE0!Q'< 0\A$QV@ M PI$P0H7X $KJ$!01MP9 XS(@/[:Z2UXDM;KWH0K/&&-63(-0*"&E@SF!:1S M 1,:0H,2B($#YZ4%1V!2KQ)H@M*UF"!+[^ "6X@"#B9(A$E04KDZY"T&C"J( M"79$@SA8L8,0J45&[? &3MSA/TC=SU;#F!UC"U2'VI:)H'2H8CJ@^"F42,0- M;*#I-=3A#:*011UD$ 96$.E"N)W3'<)P@SNX@1,RJ(L+=FO&#&8?! )H"+[.+8(,5UL"^12MY P"OWA%9U79"4G I2 ]22&Y)2$-7' M$3XG.1?05F,@!II0 S]T!_9&"QEP"1_V>+6 W30.CX( _YU(0*RX&;T 2ET MH :JP$X%HC4-4!YGT !=!G4QD :R$%QQL %B8@)D-@)< 0)E,@GNY$1M(0-D MP%@C)!'.+ &P,06 MED!(J3 1O<,*9X &$2(+O*$)^=)Y':0Y'Q5TMG &=% )LM [MM []3-)8X J MAU0?*Z()J" *);DF=^ 4M! OK8(*94 &2YD(EG +/)E"3C%TO#%*DV +LN & MGF,)$3()9X R3@-0M=0[E580\5%R/(())!(OD@,'>0,IE, 6RK8HE7 )],A) M!2$'8E 5J9!AI+,&3""3LD >$5("@ ^($EJJ@"65P"7<0DR67DNM3"_[(&X1I![1I5).0 M+G& F(LBG+4T!B/92Y30?JIP$4XQD.=9&05ID.MI3(2@D$ZRD^A9<&.I&&J M ^V"&;2 4!LCG_WIGP6GGNPIH&CSGHV1/)*Q,PVS&!#C&%!SH!](&0RZ, BJ M&2!#"P]*& +T-!9SH%/CH(;1,A^3/#4#,QO3,3"#H24*,SCC,0K*&"NSH.P# MH2KZGS6:& $ZH#E:-"EJHSWJHS\*I$&*&3B*)42JHP/*HT*JI$O*I$WZGPEX MI%%:- 7JI%5JI5>*I5MCI%+*I5A"I5D*IF$JIF,*)0B)-/YFVJ7']*5DRJ9M MZJ9OZAEI*J?)!*=U:J=WBJ<% :5SRJ=6DJ1Y"JB!*JC^N:4+AZ9G(R7F#ZJB/"JEBLZ=]2JFPL::1BJF9JJG_4JB5ZJF@,327NJFC2JJE^B2=^JFI M*JJFRJJMZJJ7@:JIZJFK^JJU:JNW:ACJN:BR*J=;@JN_"JS!:AB$4#:\NAJ[ M.J"T*JS+RJR#>@C%:JS1"JK*VJS5:JUO&JO2*J?4"B6->JW?"J[;DJW:VJ7< M&J[GBJY!.J[D*J4**0N;P F;@ KP*D">LQBV@ HHHPJ>(PM?2$@21!@ *R&9 M=!FR4)K?0@N90$B=00OV:AA$LA0$'' "(."UE>$T)^J/B?$U'GHU1A:0 M*I.VCC$RJ# #4]@!WE-+,I(8&2 FN#,!AL.?EU!*+O ?20JY-N,R=EL8B%L= MI .'B2$&8N(&Q1$R$HH[3M,U6E.VE$&L*FNLR1,=,4 DK% +%46YA0&CJ/ M"F!4./Z0'9A@ &5Q"0&@$ NP/JB@ ,+3:"!@EXU1L9KP #>1MRKSH'\VHX2Q MN XS,AX3 8P[NX@AL?Q),B9@AX4Q.-++MU23"1(P.#@S-8,C"W2P 1-0HG2 M #=T!F@KMC;SH%\3!Q50)*?+GV[@ <-#HQ]CNK1K!QRPAW90'"# '/O$O;50 M 1\EP(7Q1(.!,G8@ 0_DO!/,P?M*,A,*O8-Q 15IMQ.S 0W17)I1NOF+),^J MNKQ*I3+00/1!!B40!A5@ HG$!!ZP'(2Q"1L0!A0 *4R0'2;00.D"!Y(# X=' M')$" I,@ 1YC"WXR A5P7L'H ;]8)SQRC2; ".P"9;5 ?X@(#FR< -T0$5X M@'82D 9WL $;,!&R4 ,CX $C.51G\,:/$P<=P $R$!VJ\ )9W#N#$08+L &2 M<&\"=0$D0 85X#=ET $=8+@"$@,4 $2$D0@C, *5 M]T W0 (>.!AN0@:YG&*%01=F$1TD M00<=0 87( (QA,L>D&+2T@%\L?Y8';#/!4%DPVR>"70#)G ?:2 8-S"5S5@8 M>KJ>!3$I)983!M),#2J !=#Y!RK%4A'[#+ :CB ::,!PB@L!-0'GC #<4 P2! @FP!JQ41+70 69@%TM('R_P M (C$ 4 D I?'OWCP %^9 =@I 0JA!AY(!PO@1R)PWUDA!A?@TD"<71+ ":+ M 'P!*;(P 6*")L-S@K5$!A.I!B =9$2 &WP"CB0P1TE0P^P"C+03;4P 760 M"0OP:S3@@:Q<$#9 )+5<207!"@^0!K:0!@LP)@'\%-DA 14 !SH.NA2@=DAM M"^ SNY!B D!4!@,P$8N;" 9@F0&H(@?W\;DV(P%S M?@>RD !CQ)QFC1_%00L3H.G_$0<9K 82L FJ( *"40,*,);13;EP +\&DL09 M$!TBX"$90-E@>1^;4 &J ?\>^4!_ "3? -RTQDIFZK4#M@/+-CT4>9STD , MX :5,"1%!BFH$ $;9 #70R0/4!:&\0 8V0!.@0HLCA8-M#$1D"\W .=@+NI MU@"LQV4ED\&6\ #I8@-8T0"!LO[>!3'"M9 (_"L+K) )<, \!H!]'$)$2!B M4 ="*XX>FB !!9(NC&^/A<#+0GU;1LI M 3P!RBEC_$OG$$SY-<#L!4%!.;*W!='P;5'',9$Y46X$ 99A.:FB U M/:AUIT(M6;7*E*@5(1/&L1@OW*F%9T(M.!5BI*G B=,$G?Z6)-A<4\L6R#L, M;E2EI/&"G5J9-IA( \*-7HP@U=*IQ4&-W[*<7I3YV#F3!)UG1BR0$;D68XR9 M'M 2<^%&F0MA,[FXP&0EA9M@8HTH$&HR:)H0%V^!L+4T-:KD8@Q%%3Y"O M4'@84Z.F1CL7-%)2BK&!G,YJ2("M50$/'@HNUER85&O#G3 U:GDX0W[")3TFB$33;( M9).O,#)#O[ VJ 2.!\) 28Q-./ZI0)4+G*J K1MS!*&6[$"*@0PX1@Q+AAML M>0 F49+"3 ;Y*J"LE@LHTRD.#H:*@(D9:K"*D@I<4&,#RM:2Y8%5N$1 %(SP MN,#/#< #(8U:Y !P@A9K2:4!6V+$B 8))7,AC3<\J@"%&''H"]#.)G%A@N'H MJ',G_5X1PP,%Q,CP5EQSK240BGKU]5=@@P6$$&$EN@A7D&104"[L MD 4JS.ZB!94%4,&HA#!JD> X,ZZ[H,5$M%, L56(K2LY4A Y!9;C3*?4IBQ#J540T 0S%"J&:X-- M"H#)DK?H *^6&5R8I,A:*).AM%KF6"VC"_JJ98VOGL/(A9YT4F.O6@QL A\XF6%$G-WQ498%-)(CC(PK:2\,$$BZIQ084,-I$ 5O2$ $C&&#P[U6, M[H@@7!)D:4 WU+TRC1KC,RFIL %54J(,X.KM>V!#*,ZE"*A!I&JL"2.A@@<<0Z M,O!I#$X:(.Z"-P95"A4)E *)!AO@K ,C5'6:X]5)0 N>EOX)(/4>3CRL?\5Q MC"10?X/O/5CQOUI&L+66.KBJ0;Y:I$0C="@!"QS%F5IL@BT<>),;VE.+F=QA M=C= @2S( )),(* [NN+@K7A5+!"&4(0C)"$@)),K%XQ')V$X4!CT$X<%G*$, M"FB13O96J,0 P%DW0 -PM LF2D @502B4(H+U:T !IMIB 9<*P *?S9X MPP/J(T4WT* !&L-(&<-0 3F080);$L,$WB"#"+#")A?(A"HD8 ,W2* Y(-A? M1BS1,A!T8 XUB W.%B"&-2P #OYF"L,;7H" .U"B &"JP&5$ ((XC$ HG%A M&-20 080IRL-.,,9&H"8S6%D!$SH#"46L 8U@. !3LD(';BB%UHDAP9N(,$% M= (2.!1 !O_ICPE&,(<;+*![LI# =51! 1K 80(!NV08RK !4VB &'0)0I M((<1;.D2"' G/&O! -2!90%AFP0#R("&!8!G V+$"!T @!@8%. 6M?@3B;Y2 MT#&D092U^"5&,*I1#$6, 6I8PP@88+>,)$)Y>O- 6"C$'XUXH 1P<$$ V((" M#L !!1D(RQD ,#0)W(%?:1 /%#51 /G 8 :U8($'XH!3.2J@4*B0:F=@4+$R M"HPRV/ZD0$9>P(&G?B4&'J #$QI0,0G0018(D 4)$G"#%[C@%3,@JUD5Q((' M9((.>['$ \:@A@:LZ*H^J9AD:"$!"H#$$@RPY0(@-8'/32T!) VJ*A1P@S,\ M8#SEI,,+=M1!T&KD@R4D;6E->UI '"M7E'A@8AZ8B41@I!(UN,'-,B*+.>C2 M#K'%""4&(P>86>Q-F6!)1CH!!\G(8BUBL $SDR8#,A0J$Y6JQ2OD(!DZS&!F M&)E#=Z;;4'^E@C*J. ,.-)$)-ZCB3:H8VBK$,(-I/5<,&VPH3&CQAAO<@;Q* MH8,,YJLW,IPE%6.@P;3P<)R,J-J((,,WN1B&L3!$@^D [HBTP89H($XLX7# ME)/&1_ZU-A.#$:,):!0N.(1%$V_:Q+3:G)H;U* 2]0 VO>,.< M$_QD3OC9@F/@\6W+$ -*V,%?M'"##,Y G!IWAP[^JH2>9?&&PM"A/I6PUGVS M'!99Q$$GH0XN)>8\:? :]WL9<8..0:V&&UA"%,"I RIH(6H[K $-:4"#*FP! MZTK,NA:K*(,E%)Q ',A9MG[F]/Y&[A!03E"E,/PS62TFD9)*7:(&;L@$6UYQ M!NC2-[2@'2UJS7WN@1 +W0U1[;C=C:O@OELCM@BCO.U];WSG6]_[YO>^T4 X M7.'!!!-]*Y28W3V8'F&H9E+/5<]GWK'95YUHPL= MWE"_NKNS'O5YG_V:2Z]YSE%^[Z"7_6M4/WN^ [$'C.==[ZCE>,3]_G? !U[P M@R=\X?X-?WC$)U[Q&9KXWAW_^??&*E_SD*9_XN,O=\@JO>^8W__G%5S[P MC8=\Z4T_$-(71/2@9WWK7?]ZV,=>]K-O_=U/?WO<+Z3O!C\[):H-6IT$.N*7 MN$1P-5%M6^@R5W=0)-KY[7O+5X)LK$A#:Q,O"SNL?M^R^-XFICWN2MA6WY1X M=,D+G1KQ?T06LG@%<3B!8%HHOQ:6:'%H46']R7L^5W20VM]EL8;X"A==(H[D M6S_B$ 7X@YE8P[?4RST'-+W=PX@W$!Q^VP00( Z0H ^QXR QN") "9"/ M. !$#BR&\ _%Y"/E].\DG.#KYBY5_ 1*E!B#N#[M$(.%" (QNZ6GB!MQ&] MD*L!:?D:&B 73N" ,9& #9B TJ ##Q !4C%2HA.:+GIO!N) !@<-X&X1,2$ M/(O E?Y*D( &Z \ZN 8N( VZ!H7\*:N&"07Z #*4(,+0($+$$4/6 /< J0 M$ %(D9V!.[(PX 76*@$V@ .L*?^@(,,6)6WP0A5& T/V 3%J*: T8@PV #: MP+,W># TV!(*D(4@L04@N15.$H$,N)D+D($2>(#2H 46& $3$ &E*!H7J( . M4*0SF 1^"JG4,.!>R OZ0L1D $3X!:-<(,2B $NI(Q-Z ![*@T?P@@YJ(D; MV( 1R !K00.F"0,QP)8&0 $> PD;&(\U,IM:"% 2@$TW8('-U B5-(&4(8'Z M4(/K> $T\@"E& $9& 'YH8TZL< :\( '("9.B("PP($-(/X!-[R5,]B R;0^ M$PB#!U@1"NW-KI#,#*@/3N"*..@/%%B,+JR%''T!]CB-!;B 3< !SL@$#JC" MD*E/$Y 9PD7%_ $F3."U@ $N@.ZQ*#KU@%ML$(2UB Q !37 #D[F 3I % MW3$!/-,)&, )60A3$&"!L$ #'8U'53 *$R@!_9"@%Z *[,%%EB #*B$5,C2 M#6":SDB##)C,:6$6%V"!#: NYF$#7B!#6B.$8BLZE@.#@ !)4PB0 _-9@[T@@R "2]"ID^ B'K4 #S48CJG9"S<(@#K0 M)4V0@)]YBTQH@!XY"U7Y%S/@*)Q(@P$ %[=YA0#H"U1 $M !:YX@U<1#Y)# M'$01#?Z-D( 1@ DW&%S]B '*^(P$XHK&I3%KLPU:( %P2:9:Z(1EJ@44()L) M()<+J(\'Z![+ZK1:L,X5' \Y6,F,.)I:J(2G&;8%6 4X,(!/50!(B0$+V:8; M4(4R,,F>7%VFB8& (8'T%(H7R!M:\( Z\8">R(20P8A5> #J[ GW0""_,('E M);D:N%T$T8YT2B#E0(,IG(!*$ /8L8$M"5UAXHP;^%*,8 */R 03\!*!L/@!1GXB\XO8, L+$$6X 6N906"<,,,0$$DIA(T5T76("> $MHH0,: M>(4VVI3KD#?;.U<1IKA,3(,=H05-0X&O((/K:$S)&($Z0/Z#"E@#,C # ] $ M43!(C0"!-\@$!4 #,E@#@Z*Q-X"-BFD 9J*)D&B ;5JZM+6VO0 ),?A@(BZ# M4B4YG<@$." !LE&%,#@#3H@*#AB##5"D#+Q#63@LNV$B:]F$D'T X/!087*# M-_@;C*" 5$"#":#A,R" ]M )$Z@/"1"C"5#=,S@0@2D,2T"#<+*6N'D%O!P! M$M ;8A$UXDTE0 %:@A=I!!3WM #'8@#?D")Q Q#-( Q3HJE C M9OV0 -ZJ7,!Z@390/EM.!51H@$)S@W8&BS@0#3M.%DZN:)A(A#.(@:20A08H MQ:^8 -1)RM6%V!*86QQ0$)!8H95)!3<0I-Z@%P&L!0>&D<[8D$GH*M-X P#Q M$@GQ@,N &4">V_G;BWIV4P2 B3,(@U2("@\0@PPX"QO0#W)EO!'^ZG-;3%Q1 M R3I !.(@\A\EI&X!+S$B ZP@S)@(#5X@TF0A;O 0)Y^@TMH@#A8 S>P U6( MT1E(!/XR> %:8("1/(,X-$D&H%@%AG"@-+B('F -C!$:8U<*2W>X'YXHJ7Q.TX>,6-$(4) MB $[(-R,H #>FF\UJ&]94%0'BHUI%AV,\("EDJ,)@(']UH]NYABLJ>B7<,Z9'.[9?@8("'Q(Q!F3.0F!'(X8@FA/X!LLF-.% #.0 M$? 754" :OMT66" :;L X-"),7">)'+>CU #.F*!2BT21@/JLB?D$(0V%F# M+8D NWD75/!:.*D/2?X72%& ]/XB@P$(RK96!1S0)1.8VT'^B'#7FER:77I9 M@.])A7H#00]@BUG!"#M0#F).\-+ Z)([@U>)DVHBFW:5 M!0DU48S@ ,Y0;SI1Q571YM1H#E0@$(KBFC"(1"1[((M/C#/8 M! . B7Z?7 3O^(S8FOT8$<#]YH#)*A (&$K!B)3!"!,(F3&HD]G^\"+A (B= M@;^)@>NH P5PORU!@[QY@;G57Y$A;SJ8 ]HA"RJA43@ ^X&1?0F3/0#AI+.'H[T/66@"*_D !'Z8N"^_8]WXL;@)U' M[PY4&)$<[\\,N(Q-&$(.:D!%/WU@R<1'CP%9D*F4@!=\N5C:Z/@5H8$)H $) MZ&)#7#2>K@\WP,XL10X)^ DJ"K0&B*L^2:(NY PKP56J( +4*\'H('9U(BT ME0$:D($'4%UW1($78(#^0X'VX(0-J($+7(I\TO[8VGZ_".7^B1$.K8420" 2 MF%[H-8,*. LK"J5H61MOX^RI @IQ8:$!E_ MU@HC@<8$&[(>V*E%:8$J.P]JT&!1054%/+7@;,@X0@TK!B5D7$!12],#6;5* M;)C1P$VM$3@,UD(UX04-&@T2_9Q@-:.)#0_9D@!AHX:$,ZH6U'(#0I:!#1XN MQ$!5P47=!E8W2% 5XT8M.Q)D>!AA=L*=C%7AHMI@PD6%3+7H7 ":<1+'6IPF MC!!1052M5!DXH& )V&M&#M1<:C!8:9"&#;B7B#QXL$EJI3MXD'UP,6+##[' M/* !8L3+C!XD;*HD(0:(Q3]577 !]8'-6C>Z_4@@,";,&P 6%KU")' M;+*E,0$-%ZA4BP=JR%:+"61D=$D$MK#"P08L,("B0C6PI8H'RJ6B2@.I#!1' MC4\"%0@@4U)9I9578IFEEEMRV:677A+RI9ACDGGE+%!FQ(EKLM Q22V;;"(+ M*AVY858M%-21D25NN%9@)>6APDI&J+CA9D:KR'%)+9FH$I<;E[ RYZ)NE":; M*I681:BA0"&JZ"5,OD>'&Y(FM,E/F[C1J&QXP"%I)R]U8A8G!+JM!1D":D%OL3MKPE=$=2J&AB6RURVG;))99DS+##T/]G"*KL%K_(&N[AN'#/*=%0R M5LV[3H)OFI1:"Q0KE)BUZ\JA)LW)G K%$ 8J:U!,"QYUW-KG!"-E9$L=N>>?6;FIV?T(@X;B/Z%NNNOPQZ[[+-G M;LMX-TP@(.W$G>$3E-92DD$%;>\^*(3%(_^3)@R\#*5"? MSG6,3UH[ATG8IPV^^+*=$;WLA.Q!.I>BJ]^^^^^#;CKJ44.921Q) U4>ZOH[ M7R/__=>(?OZCG0 !B"9:4"(.S9J>[%9AJ@("A6$SD4T!__(/" 6,8M:;!\6WQ>( M(R(OAU4<(QD-6,8SHC&-/4R;M?YL41Y:\+")<8SB')_8Q2WB,8]ZW!(8U2@] M,?HQD((<)"$+J4-#(K)Z=]PC(QNIQ2^>+@T74)4.]<>_2Z)P#9QQ :]>4D&X MN($S'G0!6RI1@1H )6J81*$J F,6A6#R;SRC8 MU2#]K85"$_]/?)++F$N*, M\$F;R).-7/-)XJP2A/FK(RR#23]*4&)1'C"+&QF8D%SN,I@9 0'^FIF_6K!@ M6M:B0P0BXLU:H(!1)'@E,'\BAC1LK)8NP-\A7:<*')B@#&:)@QC*0(8SJ,$6 MLKC!#"0U"44%L#RRZ(ZV4(&VCA20?K'\B1WBE4%KAL^,[;RE,Z'D4-F0H#3G MI&4]V_XYRS-4RZ296^26V.?(E\+T2WW,GP<:0*,ZNC ,)'B-15TXAIUZT ZN M<4CRW%"!1(*0,BMI0/,NZH85/2":2$4A#&+0FSC@5'9RF&#F)'"U#, 3@A*8 MA"H48,-9R@=U$D@*(&U6@1C[O 6/67 W?(Q 7P>X,);D+ #^T-"B: !EEL0 XX<$%!^*8) M&C!)M3B8H"S&P (T\.]9&3%PHU0L*578]@QFL<,EU$"CA*Q!50JLQ1M<0-_9 MQ$ &I;G$!CH K9%HH@YTR&?4[L ",4PB*3]1(!-S5@-Y]K$")B4@3@=50PXXI\E9 "#I&A& M FAH6ZK+4&/GF.H5<>!$#4SE!A.HP0[XDP-UYT2'"9A@4\J=Q!IHVY$TL" , M -X$'=P;AC9OP@:DK$4=#*4*-U@K#2A0]EAV4HM+V$$6,9 &2AYAUK)( ;$ MA D=ZF ".JBB!I&!B0U>@*+4FB .-+C<:P!=,#0%(GV8=2EF"[X^S2IDM;58 MP)HV$(-$B&"NF7A &>CP@#$41\)"F0D#-O "5*CA 7,@@P*LNH&(*& $=+#+ MHA9PACAL( +"=8$M$. :5#B@8 KAP!DD X*586( +I##1A3B 1M8P@0RJ,49 M"H""-/ZDHL,H4LX=PO 56C" "-XC@D:$ >UR$ ."X"G"4@ 6XD'@ 9V&,]5 M'@ '-R0@*308@27"P('RQ(0,=[A &&1A\]?H%00UL 0*K)J& IC ##]AL@[% MP05D0ADT0*-82PTL0/=% (YX!AW\6C150&F,0+#EGXP(B!H$0+QX@.*9!0J0 M01J XTDRU4 &IM0")LP@9P GG4"(:L@1Q$ %N,VX=EQ"N$1$3< Z6 0?T M!@* @ R\PAB55&N(!8 M@ "-'.#&3."^900='!49D-]OU4(9F$"-D$!$7!DP8<("@ II*..A(, KK$%M M)(9/< )3 ",3K ("\(L)",@XFLJ(H)O.'(:DG!]R88,<$8FY.*BZ%ZZ9813Z% &-<-N,0"6-0EYE[4 MM,8D*/YD+5P '8QD@2B L'& DV2"J:@":=0" ZH" S#=!#1*L5A+#+! 1BP6 M!QR/&+CA!%0")6QE!NB,$M: "+"% OZ$"UP:I/^J3B' S ")" M!.@5#5C5N6S <,C"\\2&63AE;V8,*C3 X9Q!- ZC?F[, _ZD@@E89G,)5S32 M1BTXV?18RPA0H^XHA"G%DPF< 1H\P N8 IX0"J@032:Q1H8YS::A1FPP";H ME4),XZ*X95!@!!NR &M\VP0H1'.MP@-DC"U82R*Z@ FP BT 5QT (JXD01$ MF7%FQAEDZ(9Z@"BLP5RI4G&@TB5,@%ED@EZA18]N*/&\@1*F9=+0@@1D0DF8 MQ20X0(^B@).E00-H*(=J@B68WURFP5Q)0"I8P@*@*0B@"$[&0 BB4TKUB@0$ MY!IP@@+D*8VH 05$@ D,Y=+)8S@FI0BDI:&X ?F]1 7@SQN 0";@*9/&@47" MQ01H0AKLE%FX@!FL@:2:A:(!!?X'#(88 MQ($2F@4R6@NHFH5*!@5(; !G,*0JZ)4:&&>_XL =>.D9[-0=5(#^A-A55, # MB,#6O(9G;<6;9$8MC$$39D 8K$(N*L0-V K+ *;"@(X,A*F6<0D6?,9A:: MR.HE3(+MC:KOR *.D,#+:L*C/,!+.*.8#NBT2&4MB "-&*TAKH).):5>D4'K M@$#O-/[5BKI N;R$)0S6@,B!&R1FO/PG<2@&1-K)#- *DC 2Y1 1-Q&HX1! M#,@" 403A2V*!%C+)4RL!.R%]&T"4PW*()K ]VT+ XB"+<3D7*6!<:9)+:C! M7,E&#+P%E5K+E:+3@]$"OUB+IF:$7G9N)JBM60 2TL ,6L I-$ MHDKA:RW,P!A4 D>HJ-:^!KE*@"6<007X+RI5@@>$@4K\VD^0 !K0@9>20<1B M[T]P +QE#"W(@$^,DV>1 (W$A'!5@%F$ 2\>S@L\!T]NB_G4B'C2;!?G$2%H M%B<0@.^>130V !JH @U0P&4RP+DY7"V P ND AQ092TH0)]8!"K8 0*(!<_9 M<4'( L/9P@68@')DA1A +AP80$10@H3*"(Z,0"U6+@'<0"JD 5, !'E,#WZ8\<& "_S7,]W_,<(( EO$+AL>8%B (G)(#C>JD:<&LF M1,!O30905 '9,*=\HJPUG,#< (<##']I:6RF4%9X.89/"T =&%XT43?K8$! M$"-9%4 MU, %H()DL$6R%@ =I ('2)8:$,0-SE]I>&\[RT1B!,!P_)]TQD4$ M!!D3J<%W *ZSP7+' "*P"'1" 2LA !W1")43 NFF.%_MV3&G6).@JNER.)G"H M"T@*&X( $UC+*]" !Y! -J I S4!M! &L"3WMGTUDRW0<@!'BPH'43$FR! MO% T5Y5!GJ2!MSI+3(8&_FC"1[B J8@W<4R"[;Y"#4"WF_[ UD^809Z@ NI% M2$3HY LTLAJHP@TH1"?4H@L&Z,8\]W/)QAVT(0Y$C>RI"B>X@ ><:&>\+%!P M&AK3@$*@@@U8BQVT8?X"A2S IWWPRPW 30V\Q$"%1J5T @ODM:!U\P+,N V$ MAI:1@:Q: @P,#FH!Q2NX@%31^ @0T[&"P R\9=NR@DK<][6,FH$9ZUR]!.NR M ?\F"S@0&B,1)5GQ VX!JQRN$59 @G891@84T:$033%-VW1@63A@";( NK9 M A,XYH = MT )U$$<;&)<;L(4K>X )+! =R&8'E$#&Y/D(A('L94QC_T0J@ 8*()0:),<: M0 @M6,BYA$'2:*JD4Y(E$*YVIP+JT<(-C 3$)XFT,(,%.P9J"9>@@ #P^QO MR_N4S.P0I>(8R8$'8.L(+%U':'CR;L*GHXD 9]54314'<4 "GY%"C,$J2T:E M]^;5&/S$O\Z5T0(N"]N3J,*@STX! ;D"\3?>)1,%.-JU1TUM0>7#49.'2-WW08[F\-K63*,@ "8R MD4/0;8KB17&]LPSW(2D$)R2\&>D/S[^.U<\2[=0[RON]^Q0\R0O^X!-^X1O^ MX5,\%__]XG>.!P6^]>"]V(//:LI]";%\T^_.XT\^&3D^XE<1,Q&0YO^1Z*>1 MXC/^Z8N)RGO^ZK-^Z[O^Z\-^\9@^ZM,^'V4.L3T]ZMS!RZA"QEN/V#05[<0! M>^.,Q-^^Y%R"&\0!'<@!'+S!*VS"I\)!#65$)4C_)%Q2N&6$'!CY[E""=K%^ M>N$461U^>BD1^9].(E"2*-"3ZZ2"[RE: M#".F5J8%;]7:06'QP9VZ@PG3K4B&2=X*KPH;[;A!,,Z6$N@H=3/"HV2,%>%4 M:.R21IJ1)CB0J%"V5I@*)B8DI>6"Q A5M33%R-F1!F6,+^+4LJ5YL*6PGPL' MFG@<>7+ERYD3--Y\X*R6+,M@MOZH*A-?I:M^GO$P<@(G59LN\I65:?;F6JHT M2>9$_J>LV29N6-2.JGW\[!]M94KENQ84PO (!1MJJ:0"6C1)SR)4,M%L@[3F MVBHIEFSXBR409*CE M%&6F .C%1A ), <5#J)T[^NT@52[2CA9;_U.C@HOZT M^DD5&&M9A3P%M9/%DA654A$C3CC9[!(A,4HE$Y9LF>NW]2YYD18&:XG!-DTF MD(7(BQS4S(T+*CI-E2-Q=-(_$:?D#R<=;<1H%4L84TJ^\BZB!.$FEBJ294&,-/E/LHI2T02C_H2L:+:YSK,2.P[MP(@O)B>T+TB+XO@./3CW MT]&B*/[?Q&@2$P1(*@8::U%C@EKD0&"V3!1@Y0X:7R CP,HTF_0B#B0,5J8& MUU3JE3E1.1*G5?:KQ0X)M"..KN>@NQ;;;+7=UB#I6J)$@@986*H"$BZHK!(2 M;HA@14LF: &52Z0X:L::K'D.TTX0*&" 2^:0083+N! *U5(\( #%]Z2 8<* MR*!# 0G&J,6#(V_(0 0.;%IC!!DVF,"FBR[98(0+!G1C@0<2J\@-!AXX(Q,) M:/"@@;2 (AD$*R^PN=1:,D #P!I, '"&L#I4J@*@652 $SI23LRB3$"PH8,( M>*T%C@L$QF,I%U@8(9,*&##!%GU+/E&3$7!X@!4<7$#A ?XR:LA IOLR."% M"Y+2Q(,:0& @*5E0X* #$][*I+0+BKTHC M&V( 3439@I191.+"%CM4NN/0- M%U[@ , X&GA C$TD\+N!I%+#62N6-+F 118X2"&$AZPC9,1F&A %,G-+<,B M.;3>7"F6Z+!NE0U4Z:2T#("O!8T-\IX$J!H\H.$B$ 2KA00\4MF A VNAF$$ M$3R@I8[1<4!%)3I H(&#!Z@W^((24)@!HP)'H("$MS;AX'$3FX,)8I ![G&- M#AK<, $/Q& "D:D%'89VA@WPBQ(8J<0&7""^6L0A S.30&_,DH&264(5 M&?B/*CBPBE1TX'%XN0@EX) !T?[ (61VB!4EZG"=!:@"#D.[P1@N\9>/W"$# MI@$:&2(F$^HH8 ) LQX*.D >%X1! J+!P01& (.(N /H2*-E2 )6?P#!H4P!T7N*!X$DC+ M*R0 !Q-YA 7UN40!N/:&!]0B#77<"2HODH&T2.8"0*O(#6B("M=C$ "HCNEK 8%SE $%JWB 5MR%M0#0@2\5D0'^.%& RM"! 4L!'2Z'PQF5U&("]5%% L03 M@##,9@.],2@*'R"*>%9@6K)@0%GHR*'>V.("&1P!>=3PG1A,\RTLH0&@,O$ M67# E;2X@"4NL0"6W*"'-+#-)A8PP0)8[#OTLDCY4 05BVS@1!GP"2TJ8 D\ MS/,M$92% JC'U4RL0@'4I$, J,>2-ZAD 1E\ UYPX\I-(-(. Z">'11 BSLT M@#MQN"4'DK(&T$7HK)?"B0ED4A$\F* !U*O()F30 )EL8OX"=-C )%B@B3KP M;#T+$ PJ%D ]#Z@N>Z+)A.&N9* ,B+$6CYV-&@H0W 1]$'1WH,"TTJB60.P! MCM&5[G27(\>/I $S-D!E13@0!TX\8"X544,@92$!1LEBHI>00"W2YP(U6&D$ MJJ/$!%3Q #--8KTD %Y%KJA.5,37/I!%P]#,,C26X/1]HP&V,M$ M!-ZBB5M^[<),H-5%YG!2"E"O%A2PQ"H:,)NJ!.J0B 6?HL@0,) LZ> @8$/7D0,.0, = M2L1@$FL8@QI,\ )[L4PE%8D!]CS0!H^ 8 W7<<,94LHA5]:B!K99SWIK(*PS MD,$ JOY 4'/K0@CJ?ASD(3^(=>^$RSIJ=22U ($;M/01-6!&%A&P"7H[$;,] MD0$$$U7*"&SF+E0\ #Z5R"<)1./@ 95W$RL/U$330& R-#FXL7I+=:KIKXO$ M ,(2OM=Z00"#.*0A#I282P82[I%@!HW &-F AUHB36K"X$07L81G6(("-*CA M7#6^E!K"PA(X@ [!H30!*A0ZR22#:]&&0'J$!O;21 0H9^=)NB .:H##)-Y2$6=;Y,^X M#Q+;[L4 -UB>#JI P7DH 8WW$$5J"!#EP]T@;#5 A-H4?[#&N@P1@JX@ YJ MJ&-_S4Z)$4R"JVY0@QKH<"19N"$&"4A*#39T6*R-U TTN@ ).8:1"P#Z4YQ8 MP!K:0'X@/ML2W*".W@(&R .ON,M-N!26$+9@NL&'@!0+@(%;FL2$D0.ZH@E M*F 2) U +J .9&$"0$\6N,KRR*]/*@EHSB ]YBH3XH":*F(#]FLF1$!>LF-+ M+**H4HX&-L0#$@XG0" I)B$":F 2;,!>+B"9:L%M&N269& $X@ -WH!K$&13 M."XGUDCD$@(+LY +D0,X+N+E)LBI:@$5% 5*JKD>JJ\SBL"'&2]8J"'4"HM MWF($>$D,:"0&+:(&P@($BBY COZ.7<3 .NC@ELR P,J,)48D@[9")A@,0#@I MPB9LO<* P"QA<7PFX9ZD*#XL:"2IPI(,@:.-NB,-FZ)#$Y/$ZZ& M 4]J @!MVW;Q+6(.T,Y $S+A&F7AI3Z"!5Y-G0#-##8!#O*I%L;@.QX,12QB M#$B ;&@A KBF%LZ@:>QE($$'Y;[K@[Y#I':" E!A$^JGK/S%!6SC 1R2'ND M=,;DT?[,\!8U00%FHZ-$JQ;> 12@;X 6>,2\FX 50X *T M @2121JH0+:C0;Z#B.24^UDT!2KZ?Z:*L(>28 &+B"@ M;F ":F "-N0,,(-E1DH.8#,L[*PH2F!B#NL_Q&!H/$!=:@ I4.$:[5&?4LP% M)H \Y* !9 $..!%3.!Z'B )UR 4 .+:B#=7@4C?\(-#. ,#JO.KI$$.( & M'J#LHD8!4" I 4T"*B$5&( O"%$&1& R#S1!?0,GXF S"1]8N!Q9"$5)@ & MV(\!,D$&KJE( N!JZN!V7C1&20 ^>\,-"& ,4J&KX."DSNDA4\P&S-(B.F # M8@ %\).]>O38D!39*H,,)L &*D B:: ":, $9 M _JH6KH*8<'220. &X/,, M[F !6" W0)(#X--FY@ ML<:8_[ 7*RD%D9 )MRE!&3@ 09$%?H33$V@(S1! M4H(2^SR+O>25FNUNEYB>>1N#4*&2UJ"$ZAI$_AB$VAA!"VB$]P@ M#N9DK-P@$]8@4F8"#N: +U#!2BR!/#B!+^S #58D^:X#C9.%=S (2W"$M0 MRW+5/N #7+ &G= *-J MX140%F9I(V$.X. $U_=W MI[=ZVZ@A)A@BLE=Y,UB#-YB#.]B#/QB$0UB$1UAY)=B"3UCD"-AV59B$6]B% M8?<+\:1^R7=") ."7Y@P6!B'=SB-=!AYGPN%J_=Z:]6'>=B(CQB)DUB)EYB) MF[A:@AB*]1*#>P9^<>)U2<5^OW6+&*4BWI<.M,(-8*PC7F"MX!= #K@E*N(5 MNC8&?@E%9S@S)@2+;*(B..%X;_Z@C$M.,R;!B-;C<3S -RN (R:4 S; !(ZD M$@BG S*@!FHO+T1@W<(W,PYX4P[8ABM"#OZM43O"#EB65-"XPPH8%5K9B7>9ES/8A*%CB*-8F EB MBF$WM#J,JUC6*![@4L+ .BZ"#F*MN?1O-NZ76I(9(];@I$: 5]:7#A"I5";! M$LH 1+A#L0# =B6$J846A#@#B8!#V3T(E8!E#L8#1:T)1@+GL9HS.Z=7]YF#L: MF 5BBOYI00XTP09B(&12@0E>( @5U@W>P@U< ?^0Q;@(![?@!9LR:1/8FW* M@#LVD :P#//2P)58PLM@(!7.P 7\(@U0XEHC+@DM8A4V%09N8$5DH0Q<@)1W M))IO !7&H%!;!#[@X 76YR;FX!)*&G\;Q 9XPS?"(&YN)!7X1310H S6 5. M3!;(P+U*K@XN^B*BI2A&)&14 0$V81L[XILO@A6.UPU>X :@"2/N30900Q7$ MP 70@#HGP2^R.A/NX Y( ZAA04N[)EO8@W&FCN\.@QZY$^Q!UI" MRH)*Y0$J8P0,)"\0X"%M@P;.P!8Z@+E& JE#6PQC ,LF2/X"7""#5($,7@"X M@RL3W$ T."'.*&$.6 (51CM$5 $&HFBX-5J\QWLP" &Z/!J]L==U%\ #W" , M%& 3;(%T],4-$@&][KARS"! 8$Z,@0&)&S;6GC!B4@ M#M5 )4A XIHS$78"(UOS3Q,N 2K#8/.B*(_B;8<2I1)!%!# 3%!K-DA #>9J M15S 7D;2-R+ )"KB!2J5JUZ!\-*#972I!.*.Y^Y@+E0E\MH@(>;@Y[C_B.& MO=CK'B+ %^DLXCL?,NII)S5>0+YEP0X\XRV>;LS(PW1F@P*VA^3I+-:#[I8 M3#*@;2>,R/!%0"8R1P(\@(L/A/ G"0WT.N7B2Q36JX[!B>"201LTY#Q050N-BUJ;.)0Y6^G!PEHR:-1JT*D6)PFL:E6@%%/3A(4/^-:2 M0Z'6B#028U:85(L,"H-D3!A>8_XK4RU;.%P:M/3 ED$.<=P4-'B!SB8)%#E- M($MB#2H&;VN\J"7!TF4*7B>:$%E+U8)4J2203>Q&A,$29XZ[@<.!8B?/!NN4 ME%DG DQ5#2R_K&4G G29F294?H6VP1N*$NX8O'/'S@)4M=PD3#/:5@-1;YHK MI!OCQDM1M42 !V0C4)0* G:@54$MP0UGT%T1)89#@9Y5L$8M&Y1A4"H*;)(8 M''*MIDH%;[FQ 44>)+212":I9$Y%7>7DDU!&*>645FE%DWTE=#() I>X(5PF%W@P$0T(" 9" M#*K(L?Z )K2%@8H,!I EP0UD393) F2%<<$FF4B 6 ?)R22!#;6,46"AQG&0 M!BH&T$&+&$)F,@ .JJBA@"I4 :0"T*EB M0"6)&41' M_%9(D##'FP"BH2O#C1&1-HHLD"<-C1P"J<=+#@&P&XH0H-[PX@ M;PT+5K* ':J@5$MFJ%"R0($3B8+ )*K44, FJB2@QENU>$"!'6J@P6(J"Y"! M2@WB<8> :1W,9I L'GBX8AP@4"3+!&.H&!!QP MF+#< ])2@^6OQV3'"![(C3:C()4L-'G 0*$5H#(Z&06*,0$,E+EP"AZ\<5%Y+&KYN MX'XM=TR>NT0X; "#&F;H.H(+>/X(@ZG. (/&>0&*!B!"4#@LTR0X"3P098' M-F [BDQB5+5PH G8Y!P7>&"#!@D#M6)RAPZPR% RL,0++GB>Q-!!#GU:"!Y$ MX $9D$46-#A+&#!HM1[Z\(= !"+6ND;$(AKQB$GYFDQLL0#M;.428JM6$'M2 MB09,\8H_U)P4!8?%+LYD$AQ !2UB4 (OFO&,:$QC38:(Q#:Z\8U7H9E,Q@B@ MF,!D(JGH@ SD2!&:08=F?*1)(.>(DT%R8H\U&>1VAJ1(BF1+D)!\)!"/58LZ M\,:%EYR))!4)R$AB\8XW4<,(0&!#F\!$DFI,I2I7*10VPO&5L(RE493(REK: M\I:XS/ZE+G?)RQZZ4I; #"81:=G+8AJ3)XT\IC*7RE)=SI3B][T*!N]Z$]_*M.6CI,6MD@J+9":U*8VE:E*=2I4H?I4J5;5J;:@ MZE2QFE6N1I6J5XVJ5Y&ZU:J"5:M=!2M6U?K5L*9UK58EJ_Y7W1I7M\K5JF;M MJECQRM6[ZK6M?'WK7^$Z5[^B]:QUE45?Z9K7O0K6KH]5*ULC6]? RK6L@:WL M8/WJV,LR=K*&U6QG*4O8Q6+VL:,-;6D'F]4CM* %KC6";(T06]G"%K:VG:UN M;>O:WL*VM[X%[FN#>]LCN+:XQ15N<'V;7-P2][B[U2UQFWL$VMZVN$9H072C M>]O,K#WO>IU;WOANU[YUI>^\7VO?>&[ MW_S>%[_^G2^ ^TM? A/XOP+&[X'UR]\!-]C! XP@A^,Q&)D=9R0)=:$2WS.4N M>_G+-SGR/\/I%#%?Q8WV_G.>,XS&N,\YSX# ML\YZ#K2@!TWH(OV2$(4@Q$:G20@K^YFEBSXBH&V93$)66HZHM*,4CUGI0E>M MD9V>8J:+&>I5EIHF52:$'M@PB$)\DQ"#&(0P'?T40QC"C0M5!7!246I;Z,XG MLO@U0U41:DSUT4%&$K9-B$T38RM[*++("U",;1!;(#L5=[C$1&RQBN_08A4O M4<6H9?XB"TW0C-DC&PXM,G&'5,!MU\_^B2R0+9&%B+LW]>[AJ0UR;Z'T^R:< MH#<:57$\N,6$VK2H1"(W^E0B5Q2F1L%"4:(=$5'OG.7@YSG2UFH M"!I0@0I(0 TX\0P.S@+JF82!360XRTXV80(.>(!NM@C#!C; PT(QQA(H"#L* M!'Z'"9J >JEXP08\()C+ "X._T-!#%Q0QT6:,B:VN(!7QDTJ(56B I[9MR,- M4@E3R:(VFZ[)!6RC:1_. XWF&!")Q";%' @TP M*K3 0]P 1,@ 1<1%/6D!PM "JP!!@ "E0"!A8"+<&"+96"(B041YH%!@( M"!B("![X8R:("(> "/OD@8B ""I%""KX@GQ !; !AAE@H;@:B28@8"0@AGX M@DWB@;:F:#MXA"UXA$=A"(<0@OY =0B&\(+N1 B&,(55: @0D !5N ='N($_ M&(4\"(2)MH,\2(5%J!0+10'CHPIW8 &>!.J@'P]\0 )(@:2P7<*,2>J@ 8( M " QL &B("L7P0ED$ L@C9X$ =O\&N7@ !QH HOH!D78$-N@ #'8PDP$">: ML!QV$ ,D,A2(EQ,D, "!0@D/D'TSX0::L0EX:! 20"W>5@LF8"JL:"2IES) M80(!\"NU< EN40LV\ /%P-O@P),1RJ\(0-R4TB#L2 Q,0$1X1DUD#(R(!D, M4@ 143N]40D)\!$P00O4 9_01Q"PF_P,0$(TP#!5G<_ M,1%D /X ;Q@3NL@F( 'D^ 2G> !\481M(>*#\$BBH0=')03&X!T?204=_ V M-N$987"'_+8 _A:=(H#LA2AM " M "D1 )@*!=A8 $ M*0 %'Z 'A7 $&% !1T""1W "K=8"*4 (1Y "%/@!4L"#@* "L&4!)Z 'C<8& M'V !*: 'B %(0 %0ID""! !*F!1*V !&@ %KH:42["4(; $7;D$%$>4A! ( M2( !%K "?$ (2(D$2LF4A0 %;MD">Q (0&D!&+ $^R1Q,@F5@X (4J !4A ) M2S"31Y ##"3A-"6&( $B<8'78D!3Q"6+; $;SD()_"7@?Y0"'D0 A*PE#^6 M%391 6^(!J@1!X6S!A>! T%B"92 =#OT0')@$)0P.6B P]7"V' !U@"6A0 M F1P$L-A.A[P-+6 !]-1"Q, ![(@([6P!@NB!B[ EB G5P&4M4"W:X(0B@ M"G: &B A [5P R8 ,R/A+3&!0QT HQ! P7G!A,0# C#PFS$A M F&0';5 "1+@&79 0W+!"33@&?,B"Y90 B/P NYF!VBP%IRP 0^0.V/@(00$ M M]#>).C!A5 +<3C 2\ '[/X+ZN0.AAQGR F'@&6D0!S$@$G1 .TP '7I" M S>0$' # R0P-_1#!LH"&;X $/4$H&,0$(60LU4"#^TGFVX0'>""/0XIWE0W@,$!-NT#B^ MP2:>X08CH'HF<#R4D!R+H0JG: D:4IV#TSAND 8V4 $U$$B> 7D0'/L2 T,"J/5 :C-#X10P:1Z)"30#N M@":U0 ,#TW:U *H@(*H&H08-P'49E$#NXP9Y@YYVH'QH$ 8+<:KY20NI( (/ M0*%]% :#7%=<"&! 2U ("U "/ !;'!Q M'Z 6;FN#9"Q * "1R *V (#."P%7@"BAD &+"O&! )*Q /DFRB""8/ML" M!" !AH $ + $0@L ;+ $"J *; '*!D"(0 +8 (Z[H"&B 2V (#1"Q$6 M#8 !"C K)8 %>L #8"&J7DAGM&(Z@ M"AI1"P^0";8P ;D)JC2Q 70";3 )EP"?*X"I>;&+ZQ!G\S .96 1'!12NJ )J !OHQ 79P%^3K M H3B @C@+)8@ 9;AO_]R :*0" SP&#!1 J1#!R7A!@$@!ZI0J]5B0N32BU:4 M"/*H20W (JJ'$2X1 S&0&!.!!N72"> *GA5@"32#O-Z9IG81 1$ VWP%C*: M& ?B1+(PH6< $3.1"F_0NS%!!_ZDJ HW4!ANL"#PB!VU\ ;7*0&:@ H4U'X+ M4 F;T "%(Q.'BV 0)K4#^5(!GD6WD78 NL@'@7, *;< <+ MLPE+*@,EO 870 NL$ &80+QDL"D!T#?V9S3STAQX\ !NL! 3H8J^AG@%$[G@ M9B&-81PU8 !CH F\B(N, (%UQL, M<#P3P4#TDP"3& ?0$0'F&BM6"A1#9 $%P :1@)()JPF#0>2 %"1 !BN;0$*W- K#.8CO, Q %D6 !#1 ) M@V#0D1"94" %*;G2#J#1$I A) ' ^#/'UVS%-T"3VL(B[90%= &B:$)!2 + M8E#"<,$$\EL$5J; &H[$REF,0%9 (C0&DCC$7;S#%+I 0#] )2[P)EV )! M';+0)PR1HIH !P7 $-'C L(-!PI "Q. N6* B_PF"YQP!E9T?8@:$QXP*A)P M!IU0IW7P*33Q F<1+, B$G'0&<\8/)/P-HDC$Q/P(IYA T J"W2 +PK %QX@ M$@ZJ +"2"?F)(ZB;&C)0 0Y!$7"@&;30?W30 3$S":Q0IW' X!60FTQJ13) M*.WG']E""R.@'IV=&AT@)Y;!"2A IFP0C0 B8 ,<'6"1&9(!7P(GI1"6$P M JB@"710 .(6AQ%9"7?@C+31G?Z>0L-&,' MA8%4%-'"-^ 0&T"W,"$!FW &$!2)=5!#P)&\ * M%*"Y+\ !81 #DG$&";$0S%&F?$$)*$ !$V 9GL$$KZL7G) &,>^C_6(J$H#? M=' &Z#E*-1 #-? K+M XM%H# Z\Q78$1%&(09K !-" &"\*GOQKW$3,J J/S M=H$ \.$9MC #EJ'PX.(AHJ %[ !'& W3DRH9C%,#+:9?[*(@LAWS,B;;7P M @R.YG6+ +]Y 8=J'X3AAB G>ZH9;1R$Q $+50 CT?*_+SP]U9 8^_%S2P 65?]U[> M_"7J!@R^$":4&(:]$+07[[*Z 2;PP]M'*JY7 Q3$/;=*.K<:/=4'%]0? S3 MK)0 >$,]%LBR(&&P?V;.\0 !(DPM.;1J'2!H&Z#DB0$HD/4OV+-%9B/Y0'@0A(DD1H((I @R%($38F,? B4A+!#R) M] &!G@@)$!%"\,$KA#V (DA ]($ T106\BC @,B0%"E[-GXH0'2%4K-&#(4P M$,5E \,*)!0"A.$$&P$I(JFT,'EJ <])H2 1 (4I%#T8,P(R:/'@!3>U;-6Z M\*)6#1@'20Q\H.D@&1>U) B7)0%5)@6H:M4IX'QBA4FUR+ 87ES"G8.:,E'D M((:BK 75:X4!4VD"WV^(@ $5;-IBAA(/*X("6540T@:(,UC@H#A?IX&"BVS:X 4X0 M)ER R=O(N! $)@TB@,@-!&H90]!S:YE$R&D;D/:\&,"L/ >3"*0 ,%$! BD(44& C MSJPZ H"=,!! CQ,&" 'GT-C.2($%$&%CI*#)0B* ".@V A&W$T@@@P!" !P! M QA8(+5(=%9@$*@:H!J)2%(0 ,&"% ;[:D$("ON)5PB0(,"%M"#D(SJFN7E M"2J0P84(0$"QC@32.(. @13X3O[C6A#XSI8%+I%1@A%B $PX 9'C!!1:$0V,!-<)8P)*))&AH P_><.&! &FQQ: 8#+#! M!11H>,@+P.2""F@(%0EPSAL84!&#W. "=+#! U"DB@84IQ:=>$ 8?J4E![B/ M R:P0PDB18:$380"I:(%+1[P,%1D4 X5F(\8 &"R.RP@#F[PP -DD89(W>8. M!3B#\C(Q"0.D@0X7X)=!;%&!&-"!!0%PGP= :((+C6 @#JB.*A10JUJT\ 9T MJ, ,:F'%@W@1C!-:0P/B< 8%O.E*#Q@#'6!0 $JL(42U2,,=#U(!-1R$%A4H MP$,X\?Z #IQ!!@6HC4'" ( Y/:"/!IE$ )QCD#LT0 UN4&,MX. BBMP! 2XH MPP@8D*\[*( &;@@# N90BPX\('>W*]!!W*" ,\2!!!?*Q 5HD0D&?%%W^S%( M' ) SJ(($9J0%(#)J&*A[V! K5(1 /2@,G:N*"$UDQ1QBK" 7Y=X@(HFM;R MX(2L6EB" GBX@#910(([A,&4Q@&?<7@D 6)N 6U6&<[%Z 0#J! CB6#$RLJ M0(,Z; !"K%" <";B G:*89\4,0$%+,$)!;@A#B-0P"IHT!M%3N!Y$V"%+"8@ M TC=TQ(%"(.&H"2!.)"! >X;4T72@ :).L"KZB%]\+@!OX9)+06"]A #%S0 M !+$YF4OBUE&#B&%%:1 "H,X A^D< 2H :(044B!4S%#B"6D JG*<0)"@"% M%;0@=J]I@ 6@D((C["$0@>##$4Y@A$$ [@@\ \0@D %C'#U!"M@ U"6L(2, MZ&&OA6##$?(0$B3L@0\M2$$4H$#8P>Z!JX2=2E.7(+M"2"&K4"A$7:R:AQ:< M@+!6]>P2$JN'0ABV!765@@JT"HA /.&OBP7$8/-Z!"D8@@U&6"P?D'""%O!! M=J\!1.U<1@ TQ(FJZYZJBN+5,@"%;)H@'/@HXD;;$(3 M\;SN0281 QJX;R*70$-SR3 &Z?[8X04S*%ZCI&X:'T&(- M_06G0]SPD$PPJR)Q> $.I&.<51H$%3=X09C<$"!9E.$%!'X.%_4[$4O,Z<(O M:$@9TZ A.] #;(X@R8V$<^#M(%?< @0)6CP@CE-1!48GD0<.&P&4#[$#N[; M\$&D.Y$3EZH61V8RAIWL*U!2@L:U(&\84$&'.71BE5B^,AT4BJ8UP ?&+ZB! M>P^R"32@2!9J2+"!I4?B&^U@!C*4H0[PH<@D M=GP&%*4"#;?9! X03!%-V,$.12[1*N& "EO49A,IO@0-8F">.]RYU+4PP2,G M8A Z,/Y/%8^&DRS>D& Y:.@.+[CR*\I0 TIP@DEQ.%,MXB ]583!!8QR2!EH MT.LRT$(6QKX#'>8<*T"'S#:S'H\9:# )7R,:%6%XKJ+[K(9*6"(1L5)%NC>A MPRL9NX\'D<,85/KD&-0@7[6HA,DJ0HD;S$ -*K6$#5X0!NG1(@YE&$,9S'/4 MHR95(XB .&80 0B(([<0B(A$:#-B"(X7XN(Z(XHADLHVC@-%(X$P!,0)8=FW MO 81F%%J)-Y2%XYGA! OIVW++PZ(F[]\YS4G1,UY#G&36Q7B$W^-95..=*-[ MW!"RNWDD-'*(CL_NZ,=->49>SG*L5QRY&5$NP\4N]E0\0/[A)##7V-6^=K:W M?>R30('%U,YJ\"':[7?'>][UOG>^]]WO?W<[&1(,>,(7ONV:<.0D.F EPS=> M-@[7B&'J(EK1)MTPR)V\94^C!XU\O;*=GYWDDX[YRHM^=J3'".4M'_G3LS[T ME7?]:V1G^LA/?O6=AWWL+P]ZWN_^Z[ YJA(M$AN[,WP3>W[Q\(-OU%6SBOEP M>MGS*2)\!@;?^KZ2P;2;+QNC/K_XW5?^]*%O]_R%W_S;C[[XK[_][U??[;3!'O3!'P3"(!3"'70XVIM!W\N]T7L] MTLL])&Q!(^0]S(M"&OP]QZ+"*_R]0 @[B]"_!10[YL,?5AG"'_1 ,MR_+AQ# MM4-#^DO#-G3#-BQ#O&O QBL_]Y.--60XAPL$KX/!X]I#F(/!BTO!NH"X0*B\ MH,N(0/"XGAG!B].XUQ"ZV4'$GEE$0+S"0V Z+-3$+7S#3O3$3P3%4!3%423% M4MR[I H$TFH!U?LZV-L#/1@$0M"#%5B=)D1"V9&")P@LC3"$0?BJ6#0,0O!% MX](#-O[( S9@@]PC!$+(19"0&5^$@D' #,O2 RC8@SS QF/, SYH11>)0^^C/[O[+O5SF7330+%+0/HS*CQH X3$P(E QFX 3'HMX%8,O@0 M!2:9R*/BP QD/_,C@V 3PW+JL9>Y#3AXKBZ4/EM !:/"0Y?Y1P:+H2I*WCDL4$ MT(JWR;BOPSG9&P2<&0 "6(&>@8($"( !6 #)N+D0. I#^(#")(#4, 31$D:< M"0# %$P%&( !4 "UN;D3" ^. $!(( !2( "6 +%T0A!E!E G,:;6SE$ !V0 MV A$6$MRC,$ K!@0Z 2&( 4>P,)J($1\ "!K(6! \(:88*[6P,?*H4@Y %"M"$.X ##0F02G 1,K@G5="02E"#XO$N57"# 6XL0#-5 H5%"%2EB# M %&%$?Z @?\J)S4X5%Y=,UF@A5:] UKXKK*T#5.E1U%X!5^=L$U0U6EI1U6 M@SG0$%J@@U-]&0K*2GQ* UF=)'#"UF:5%$ZX#5F8LU5PCE2P* WAUC@@4(?H M!$[]CDEXU&FA@S60CD.1!5%@A3=@5S6(D3%#!7KL#CB# 2WAA%B-#4O(U(K M@P>@@X= A36P ^F;!#50LS)B!4N UK@5/=JU36+C4L@MX-X 3+8!#5@4(IX MA3B( Q1!A0H8 U585EFX@T9S@WA,5CN ^($UYR=MCL0V#)ZA4W0IH/ @S68 M,U9HV#6(6J:5#EZ%6O4(V/UR@1*(28=-A#6XMU= !5' VOZ)P%8[<$H)2#!4 M8 5-4(-[B/8BRK5D?,XA6C0/+G8V6H0'M&8,,4"\$D(5.$($!L* U\P"[ M5RD!'$Z/.^!9#V 3]N$ \"$!$2@#,$&U#?"1!E"%A9D ?9P(![J!". !.#TB/,TB/3!@H%_ %/$? M)EB *]L_(G&?VWB!#)@!$V" 5>"$!9H$G@6!])B("^@0AT&1$:C;!@B##KX2 M*Y:!!\A<3FB \ID &G"!#4B/OOU.1EV(2S@0%YB!!U"(-" !\KBW"LC)B!"J M!^"7!_Y@'E:(@'P)@PP(@PK@EVEY@3;BA#L SA$0 ;M[ 0\X@PJ(2A&Y !SF MX&0&GPAP'U4(CEH0@PJX@3"JA1FX9A1@@/QB!0^0@1EH@$U(@P5XH/DDH%28 M!'HB 0_ $Q&@@0[( ( !@="5@(= @1' @0DPF1GP $JA"!10$0E@E#AX !>( M@0<0EH+^8AZA@86NE WHKPG0A$JX"_K"XEI@ 169@#Z2 P88$07HHS60@%#2 MC19"D0;*C1=8@%5"A0V @1BX .>0H@F8@UFBYEIP@0[XXFZ1@PDH 1*H#Q9X M 7KBXPVX#1G8@#/( '[Y$%-> &G! PF0 0O%*1< @8.^LOX' N'_F8#5M8Y[ M*X,0H0U6J8!2.3Y!B8T-V$^QJTUFG-%",(L6.-^SH H$ "R;*UZK*=X%D +J M;0%$^ I9)( 3B$RKXK@E* &( 3JA8*;0XVAN1P"\$4!L P"* #$K$2X% G, MUNR>00W/N9S$D JL2(&)VP-$,(O_38&U2 IC] DI ( 5V(/<'H0]K4:?T%X^ MA> 6E.!5FX"\0 F"2\(+>$4>8-*:(#;D!7S0@#IL0-W M.0@1Z",;NI(%R)<&BA$@D0'R<"]N^JF0D155,&6'4 . MJ 7Z[B_HNP-VXX1:P61OL8-4&/Z >.I0@\"!>P*2$#$!W6"E;E$ @1P!6663 M#NB681D(!!".21!D'Q,G^[0@,4Z%!MB-1)&%-:AI.BD.&\#EA4B%.8BGXZ $ M&!ZKP164$%32B#@S !)HF 2UB%(J>$!:B%-:@5$U@5.[ 8\G@2 M\NAE5WN 54B3ARB[ +F-5(B 0X&7@QB![+R-5P@#%+'R_8,!-D$% N .)A 4 M"9"65XB )%^ 0TD%#Z"%L/:-@;B-26" @I$6_>PB Z@-6]#8@RB!2MF7@Z#0 M(&D4*D<#23Z26J"!"9BW,[BC2R 8.XB.$D$ 59CS6E#BW1AH+//(>J.3">D$ M&%\#(?[)A 6PA3I8 )Q2@Q Q VD1!899!0EB%1J8[C>0"!?(SO,HC@I8W8#) MJ>G6! 60!3P8 /=)A01XKB]6CP=X$O\2M@NI 2["I@<($Q? SFXHT=6%/!! M@.?:A!.QB$E @ YY .XX;X^D9581@Q_YP!+4@\C^[#C-@P%(@82WBI7CN3P@ M ,]@ X6/!#8( +,B GX +58@&\LFPA@@^D]"];VB4((!+V 15TT!"@8@ ] MA!" ?X"4!0 0$ >9'?+)\I^4((@;U(3)_G SZ S0&@7[A$A#RX^",(@$%( MX,4B!$Q4@0#0 Q68T0\(FL9.PN1.Q.4^B#6(%(JP! G@X?X8^'K;F(":I=2% M$&$U(0,3E@,RT(V'$ $WV 1.H@1.2I4^BH#O2([\XH!JM@,D>8AR,0Z^EP!. MV-D*8 'WRG$LHT!I'Z,1)P%^.7!6D;23!($QMH,6BHT2X&(1"&@98 &),(%C M+H%,->^#.(-$F6@9H $.:.(%N.YY^]3V@9/29W(T*+M:$(4+J 4B-I*^"87 M, ,QH(00Z;08P&GW,8$'&($IP[)8GX%*$2GFN0,:H($&X!<)<&5VRP2)6(,D M=I$7$(]$5Q-#%@]NOA*X58,&P# :4 !^[R()N@2), @A*EUPT6M3@UJH:!8M,*D.REKQ4DIZXP,$P]DJ7H@ M$JB,KK56/=BTP82,&2(VU+I YRH(-;5,="UZ 0^>#!%314A5*PR,B$T_XJ#1 MP4,M&C4BPE35X%5$O!=PQEBP*6*M#'5L/;",Z@$JV$1?/#A<2\*=BR"&UCI3 M\.$#2KJ7,]<="!#T0GD(A(AT8D">2'D&J-##O= >Z(2FIXC$AD!Y-@%:#"* M8J@PP!%/Q,<&(= IN22333KY)'2S- >;!V=!VB02UD&%"+1[$<0:;$'$ QR8EU5()!:G5,H)B$61" MU 1_0N1!&A&ILLDD:8Y9I@27/"3!G[14,@8""%40W!T+K*'*&F6.8&505K[0 ME2U B5$";);LN49$&]A1)U"UE J"#B@4@DGKYE@1D0DK/[!R0.P96)+&FPV M( G':1:2PP6U3(J;!!M\H8$,7$0QT<+U:))R!&I =JE$5&0R9H173*6"S&D M0@DG8L804ZRUL*"SP'2D!%$%6;V "M:OR1!3+6L\$(K":$!-0 D>?:>"VV5@ MJ41)*@N4@8I:H=% V@VR++!*1)RP(H,+M^8*%$0;T$%;;IM;)M,$5L'6 :] M2> ;01'-4<&4R0AP@B%*!C)=!%"P<;UY :B " 8) M2,%&!D> EZ, $:200@AL%!(! 4BT, &@>Q1R <#[-$" #[P! T((#^%,$0A M(K$" 31 !2GX )(@0( C' %_A-B#(3Y0(D0L 0 K0(22"B$% 60@#Q@ 0(R0 M@(#Z(0(* 2@A!@20AQ4$@ W?2\$@CH !/3 /2C[\(9.Z)BUJ1>0. HF 8L"D MF)\HP/XJMI# 1A;0B:G50@P%Z< :4*$ 3=0"#PJ0Q<,B0HD(Z 8$A6) M1[@ M**"HH0)%L8%2(L JT\RA%@VH5@,V@0+B5& C$8"#FBX0D1(X! 2@&L%04" # MW6B"B'500%!.9PD"3&(3$(O(",H0D35< "AN6&0F,:E)"2AF%0K(Q!I PX*Z MA>8-EA0)'8*5"#'I1A4*4!5$A())-*"" 61A66$4 YLQ+, C)I %Q=0QTL8 M(%Z@J84-"@*43#P -3$XG2P:8*ZZ@6DH#[ $*I*F"5\N+2)IB, ,EO. C6S" M )ILP$;<0 !5H&(!?^($"40"D7K^Z0*:E,4$6 64-2@*!OXVNX@++'(;F"EE MG;6 P%08M:A#F5XPFIV5B187 M.!T-V-2)G=QAI+5XPUCB(,B'%A"1&M D,!&1P2(Y8!':T.%A(KE# MF6!C&%HL('<,L Q$0( "6FQ"$[F)PP(L M')""0A ""0LH@ *0@ @V*."#2_XBA H0\($\]':W"\B0'NZ# O([[4?:$ $ M', !$#A1/HC0"A&P B7M(3S/A< "I@L%[5SW WJX8"%2 MT 3J7 )B.!#")&0 0D8 D% D0"$I '$>FW /U%1 L2D$(%( !+0 BA",L MI2EQ@G <44PE,M"!"2SU2R.@P0@N4#=;8$P3*4'#(EG0AEJTH0(C<.M(/ "4 M2QPT(B[8R :X: L.L BU%8/.&"I!@ H>QQ 0X0 ,.3 (5?:L%#(3IE0J( M( .J>OZ!,&-0J$ML0 05Z,H:P***$FR@ _F<&X5!%@I;"91 0^X0 0IA<,#0% #(;-E B]FE6Y8\(!.B&(# M(+A 3HE" F*CP3!7H<%05H&QMH$E#A'P0 T85HOCC6 "&Z&!)FM1@Z$ 118L M*/(%5&6&!,B!%1E #;PZ<&W?@8"BM2CX1V(0 SFXL8ITO@"XYLT<68O@ LJ) M0P5!O2<\T"(#EK&ZH2I0 0E,8 %AE\ & M'GV10$<$!: 2Q2E9ZQPFT0<0AN!#'OBPHOH47DF$X$-XRKNDUQI"#]\%#R N M&)XD)2GSL-4#;J4KV2(3M/P2[?XV(1)9<"LU$9.%I@U5?=C(8A,_&;\06Y:) M[,/F^YE@'?1]Q/,9BB6P0@#J!O;UW_T]A,8TQ_8',P8<2\ 6B$GVY M86IHGP;6 @?.8 ZJPO[9(/2E@D#8 FK$"D1L32U+A)[PL0@C8F*31.+FZ0_Q86+H(=B#Y($E L+I35[FB>(H MOJ*2&!\BSB(MCB MWJ(0XJ(N;I\N]J(O_B(P!B,BRH "' 8OXJ(M"J,R(B R M3HDLH("A35T.SB)0H(PO'F-S8",BWL!B+:,W?J,PJH*JT&(DPB(0;2)];*(Y MKJ,YIB+J 4(YLJ,/R2(XUB,B:J,]YJ,^[B,_TF+A)$\R]J- "F,J<$) 4B,? M#J3@L9]"-J1#+D<\RJ-$3B1%5J1% M%!/J1&;B1'=J1'?B1(9J,^XF-(EJ1) MSF)$7J1*KB1+JF1* D)&GJ1,\F-,;B1)SJ1 UB1.[J0RZOXD3\KD2[:D4 XE M44HD/3HC'[H@3B:DH3P$4](?#](BZ0S@3])?4J8"5F+E38*D*HQ@EM ?"\KD M4\ZD^#DC5J["*G1EZC*D#$6 +D6R(B)X2E52ZC*Q:E7_XE M8!+?42X'4)# 1G1@1'B 0$U)3.)C_AWC" (%'N3)-#I59R%/\IR!Y\2D++B MLT6 "Y@A83)'9"['&.2&3T+F:-:"&L0);*! UR W$V F.3?)'39-.:F;HS! M\QUD:4[)!KP+;+S" [S 5;@!JO@A8^JB*H1!6ZZF#6:"QQP@,^K&)1 '&+*6 M$-UDK,3!1@S.<^J&3ES !5# K/[E)IO) @7X0HF[(0GT^5-\(*"W20 , &X&^Q@U4SG[>HNP%)H56 MJ(5&"2)Z@)Q%A R*Y?FYY[1E AF)9!E$B^#]!42*)W6J5 &PF#*A$V<@0>XP2J(01QX@"RH02;009=- D70@0B,"U"@ MP2=5 /YV1D0FF (R,#ZT0 (D$!P&"H90-GN*.IPP :?]FDMB$*8N<$(B$# MV$($=!9-V<#SN<%AUD(9H :9( +'$H-Q$H8X-) C&A$3$)*$2@(B( =* T( MF!&'OL (Q$[+A$$:>$ )J$(JE(#HI$+J1,0-:,(EZ(4-4!10J$(,D )J,HF MB($;> (J HMB,%JV ";Q(K!M"49J $*L%G;/ "/R<$:O "KJ,$()$:PD@ ( MT( LH(*U=D4JQ (F,"9PD8<$*Q>C $$0M9,((Q)4TPD9'N !Q=$E$ MP!2Z%47<7)EO4"P*9,!&P,8:Q,%]?H3&O8!EQ #E, FJ/Z!;Y !);Q"&(B- M*L"!&MA !<1$#FIG%=#(C$[8X 0D!$#30 "'!"&$Q$!:CM M95R9V@E>4-HI]W:OA"7/:JS"&?X< !UP0@"\ -%P@!M40@, Q;6@B0;J$@@$ M2B50V46HP@0H6A@4!+S6@AS0Q!D$0!N82TK05:MH$@:2 NHPB.I B6,0(B-P&N,$M#$ )>(3-5H(F%*,J% !;! G MV$$!H,(F%"/9BA5LW,$#L H.-, D@$RAY 0MH-GYB92C?(I*5$ E7 (#%(K< M58(E-(!'VX$M( ]-0 WA(_N#"N]P02@@OD5@"7(0@3DA@G0"ARDJ4# 64:-@2P$"QRLA1O8 MS 5TG!J8*!U(QAML52V( *] A)S"2YK$P68K\1&K 24@#PVX0!J B4C<0-V( ME&TIQ*1XSB;0 M5*,A4RT85FC$!)5QPBIXP(H21>%D @A8A38K#6&L,I<7AAUDDU=XCBP<1I9T M@AN,U!-QT1QT%0,\7QK8S 9 W080#438@.?\!D4Q.?TY=0UDAKR=3C)S0BJ, M0-W49/Y?3K6B+_HGYBDC%P4)P($FT 10*&L,B $>@,:5T0 , ,R>=-D(% I$ MX "'P4!/O :1,D!!C %8(+++%1$39?O&F$7[$'Q!MLI &J=$XMI&O&*KE" M1T6^*, M)73&9"AY1+P"I#3Y4L5 &*S" B#6-=61H93 "J]B" M(O.,4N;[!< &5" (%.,''C *P4]XRL:Y-<14."4V==Y+?C)E8")JLCX8+%< MX"L<#70<(FXOH]]^G>;I)5132\S!I!]QH> !"<2 E9@ ,*D"19$ J*&S!@5CK 1Q9%!2"0+.03D>++4V\6.B"3*T)E!8:I%-A MH2H&E5Q6:H!*E2PW#6JUT4G#Q<)+,E0MX+101HQ:% ;6$EBKY0LQ3+DNG$1+ ME814M4A4K74ASJT'(6O!"#.5C"RT<#PL=)/9!8N%)DBXK$6GHIT(%B^X<0E' M JU::/X4U)*XT(X$BQO41"XQV04)U;5NR*BU28)"41)86;0X8@Q!UZH:#+6! M0N^D5P]JA2G1E<'<$2;DB#(AXM++&XOK++Q Z4Z#D&L40*Y5>.Z,\S7/+]#D M=A/?ER,6HN&\"M)8J(S,"#0PLPSLL,R6,0"LI9,84D' DEI008X6"?:C@X-: M&K@PN] V**D6#DIJB8P(+2MO@OTLDF4"B&J@82$;:@!11$WF4LY''PD!1,@A MB2S2R".13%+))9ELTLDGH8Q22B%G^=$B$D2XHP8 Y,C$ 8LXH*F6#1902!,& MQFCJO# 7ZH FUVS9P(4[2NC@)9+.$L4- \*P8P.I-&E C/ZF;*CEC:+40."2 M3&*[88-)SF@ !5KDRF0!UU)90*J%7#MC !S\M*N61 +(K:6%-F' !#=J** D M3AY 8XX*:-K A$D W3@SXJQ8\&IBK@MR>:^ , M.EXH@!).XMLHMC4:F .-!$)S39, 3(@A!A<&E&.A!Q*IQ84+9)G!+MXDD53 M6=)@ (XP HA#%05>^>P^$\*0I?X G"JJ18V>6 &! Q- \,RU6B8I@ Q:2" ! M#QEHH[)W+'@V DF(H0*%:R%" #E044*@3!'!"Z;:8E".# M)#(:V.^!.UY!X)57)KCA#@Y$M6& PR:(VH49B#)1@I)LH( $%$"*\0$4;#%W M(1CL&B.".,Y0X$+7TI#@#C4FX( 6$"98PPT%TN-@ C=^3R\".FA!H*P):+AC M [LFP.$.&A!X@R@37J'#MC,DF,.,$*V"8Z$)XG )H>8]D$H6!8;B5 (39*FA MK9?:.N,!V!7 RDHK YG2?R.#]#\!#I" !5Q2E?8G"S*@8 YT.,AO:C&'H=A! M?*BBP?X+RA?!H="A?;60Q1A<< ;(N.$%,6C7&& @!Q.@X52X1@XH M*,,D3(2A,Y!!#&((@VK:H!!9K"%IJ&#")NY0GJXPP05IV%H<8D #L,A&3#NC MP5!&4,&%J$$&<4@%#^&@$9QH1!4WF!,/(,+>"B8&QQF#2Z@@P-IL8:MV6&2=K $+?YRHXD,2K,6HI!% M?](0(8NXH2JV0 ,+RB"?^:B"G)K #B?42(LSL* R"P&:0BRA206^@19M",D@ M:V&)-2AG#B)2#AU<4(,>A3*9(4D%#EP 04[L+C:+"A@NIPPM$NA X#+1'77&B,CUH4A]5P@:IJ 05)T%% M.L!@!AWY/2YO?8*A%U3V M1]0=KFB4@USPIL0ENPUO]+W8?7-^-%!BJ$;9O=\GKAKDT."US MP:^#R:O>[N[WPN\U<8+W%];9KIC%+?Y?;5L;8QG/F,8UMO&-<9QC'>^8QSWV M,6%5[/YB(0^9R$,*!(SE2N(?%U;)$EZP71E[728OF!?#G;B;4-;Z-$F MUB!*6C 7T7PQ&QHTLC51F,&][^WKJ6!=ZOM"^K&*WBNCR;M7LU6TN;)&9-R7YA"[L9N8@$(\H!BY7N"5,JB #*3E(Q,$QD<^R]$F-H # M#BSQ#3DB+ -ZZ1$7,-RSJ)C $G=,@T*Q_,%S$/B9@6.C'EM" 7$H$ V$71D1B"(TM3, !)E3 1I3@P U$$!(R2'RM* !UKWAPH3$" T+JE &19RAIMC2!:6> /,/;(&K-B" M$UM3A49>$0%+$8 ER&Z82B-7PA%;8$*6UAG$Z!^Y@0(!L -.S*@)!/YXN!9EB(#@?/2"!]Q$#,)!P3X]0:BU2P0I*E 2([=-37LRMBCC,U Z+ M@PSU4142+^;%%M9,1$CN#'-3C!#?3'%CJ!%B9!(=ZN[5 1%?^-%3C!##+#)2P!,FY@4V3" US !![@ M0A:F##C@+R0@/6IA!-0@%2;@!5!@ S2" W[C N[ #A9@ L1D(6[@ FI OIP M&?& .%#@ E*A F1&%B0@$U"! F3 ZZ+K%4Q@ 49 %6!@ V9@!!Y (^(@C ^!@[USC!F@@#(2C]VH!!>) #?Z:XT?.8 +(P /. M0Q9( 1HH '2HP),0 8N0"8 -HH )0 MX%P4X/74Q /L(E!> .-N @74<2@PZC ^(#GH MJ.!P$9LP07*$B]J(09 X )B0DYPP.@FH0$D8#+( MH )PX KSJ0+@B@/Z2A8XP 56IGTZH2B-LN[(P"LO ._>H )&H 0XP0,D118F M00)DH")#P@-0P';"@ )HX +*Q?X%>@XGK'$$[ (5&L %9$ "=M-67B N59+.(Z M.P K/(!IKN)@3& "WD 6*H $8F # $05*C,&+D 5*F$"(L#>)F$"\E)J)L & M*&<^)L %).!"3C$54=3/_DVI/@2A7"(-(N !8*XE1J#NF" SPF N4K,6G$Y" M'N 5/ #OO',[E'$A2L1=%J[ZS"@3,@,$L%$4 L!$:, N2*,6/" WW&4R?(03 M'@XQ8/Y@(3@@-Z(C^5K*;#A 79C3-7)R."0 %?S$1^B@)PJ,6+PR.TT@%6Z@ M:90C#/:#X&IA#'1"-MKB ?;I%19@$S"J%D1 3&)@,AA@/SC #M"@[N"@(DR M.C9A -I%?HA"1"X #_X%(@X30R0 \$XD-W# +G)Q(3+@#E1A *SG:" BN!!# M3#J #BQA6&B*TV@@1YI((=0@,W@F)')5(3:A %(AFYBB(JI4.?1E?);B ?1G M ^J %0K@0G*U%LX@0N+T3D+B$A3#!29C3BTA G#J,<9 ! AB&%VP(5_@)EP# M%0C 1!Z #CKA1^?C 5C!#@A@@C)@(8YG(4J@4$:4+G1"%?X,H"3$0"?( "PP MJJ(0 "L8Q5UT;@QNPG9<"H*L5#4R05EBX#SN1R9*0@+F @5**PUZP@8RRC76 M(# L115L@62EJSNUU6.(900(H$ F(0-NH 0F@072+1J'XU 70@+*!P3VZ51D M9#\X04MI@'-HP$[80PHY00;F9R%&X#?*E19880S>L2=XTYM6C@%2L!)LXZ58M22< ML[Y>R#\REE43(5$%PS9> .\8("=K@ /"13DXH3@08XQ&8 T8I09B0&6Y;DS4 M)37\(Z V5C:BQC4VH0(@8@9*:_X3T. 59H!:R* &.&=K6($,9H $UN9*/>BT M1"0<':XP*+<#=(($T N(C&ZQ2]<().1C[C(XA!/@,RO$QNM=O(@ A!F)K-&$!IO0& MC%,Y"/XWGSZ8#%+!/92#/FI! O(B%:*W1L#K<$/B DKB 33-%FCV#+;C8SAA M#F8DG]3@ R>A<^W(/]; 3D*"!H0#!* EWHAS(VR !B3@/!C#2#/(#C*#-O/7 M=_^4.NI+#%!B#3XD).9T+"SB1-$VE(6LR3##(E A!B"#$Q#@,'#F-RJ! E(A M G" $RPA;CK7!&2F61XW=<>D)%S@+[8F#*C#-2[$2=6C<5OC-B9G%!N @RJ! M$PYM$+M4?NG6#AF[3 M(%-*VJ2O27,MF 5D0!3,=RY>0$L+IOEJX";F% TN8!,HX1(V@15:HA+* %> MSS6J6A9NH(./ S+\8BL6.A/F8C9N)JBV!N[ E%]Q1*>67Q3EU_@X!5P( R Y?(T4 +Z8P*<,(F\T^1< EU< M@@)D1F8#C (4Z22SHR1P9C): OX.%)HK[$ GV+8B7".2#@9+W>F.XZ !W. 5 MQ,!&-N"51D!(2U(OSH 3S+<_R* M^FJ!:*HG6D(&)U/,@$.&U,RN<. M%& _XJ!OYJ/QW" AA*H_4D$44D1@ ER#6F0#)/I*!C: $M+ '*# K 4!2SABQ6"$X9E'JFR+2QS(5A *E3B M)F3 :\>4#FU!!NXCXH(7!*B/%!A!&B!(BRB#@+C M$ G",7]Q(5Z@4%3A >8BFV1!#F4# 0B[ 8PU>F\@0KS\ L9H3I2# _8)!-6C M4#8 F$/65VK!!B)D!M35MO])1F6C 6Q!%FP=O#9$1,@W##8:0_2&+V0!!%9A M%6S##6S6*V0&>P<">+?&,@9"!B+$'?7BD7N.U74BV/,N)O[@2G%Y%"6@(SVB MG!(L0Y= ^;H9_K56M!;D(#1L "4R@0,XP ,H(.7(,NHX0"/4W 5X44P:0#%4 M@3HY@ 5"@A(D@ -H@ -D!@X4H#E.Y<-)@"2$:N7[MY6B9A 1P$14P6HX -4I M@<-]8@0FX!5B $MUZH4K(##M;3E,Q'XZ8 (L<)7VGX>S3*!\ ")3AA(QR%00E8J#B LT:M6"T2!3+1<M& MF%JT'#HD+OG8HRI+J4MS=9@:-E).8MVBB$V+ M,ZW+MCIRS00Z<4I5EV)#ONS;XV[2R3D%3]D)M*Q7#E%=\GW:=VK:*9=[M(Z< MM$KMP,7+YL@9:?+?SV.OLJ2*-*?=OC>Q3OR84_Q7BGVGLJ&89W'5 AYIZ3F$ M@R8.32 '5[24=UXMJ:52W'BD::*8*AW)\I@LE\2GDB8*(B4+AF[5]\ KG&!$ M&GP>G2:AN>4B MBFFFFB)UPP8F4*"&I&Y4@ )#FY[**"H5@ @EJJZ^"FNLL'+2 4\=+&DIC!X1 MPF>OOOX*;+!TM7JI+,0.]YRLRB[+;+/./ONG*IDVY>O.;+;[][[0&(NF'J M:F_!!A^,<,(*+\PPN_CZ"W'$$O[7)3"@(+Y(\+.RC(;8Q8S""=DJJHRLRBJ1 MD7RQ+"13UW#++K\,<\PR(Q8(P!/?C/.Y%:4AH; M]O"4^\0W3PE-/3-,"$% UL=D1'!![1T4 M M-9A0%1H <&ZS*Z !#XA ;]4N=PRTTP*#5:? 28@&&RC. U[0"34DH!8[J<4& MVE(#-EUF! RP@R8DL!$.,,$EA*M$ %P0!UFXH0%T2,T8+J )2TC@*!2TA'9J MD $+?F\-"*#%)";@F!$DZC(T*!J8!/@:.CP@%:E0!0E X+\1J$X4#4A4 K\( MQC"*\54/!%89&XA&P4C0)::3Q0,L43A5G(%-(S!!)4 6&26Z;P)+DX4HS,#' M2S @/9J8@)4>X)-:T(&/:C#=T]: 15N\D7*H<($,5($*-_XL0'Z92\G_7F.' M FP ;-OC8 $X< $)T*!Q8VRE*U\YQC.F<9:Y"UQ'TM!&"2A(%@V0(P!548,- M.,"+#AE!FBSQ %N480,RZ%0M*D&!JISP8JMXP&@J(8%:0!(IV[2%!"0BBPAL MH@0>F($+:#"&U#3Q-P HX1:8&)' +*V&)SWSJ,V\UHZ4_:;E&--13 M%KJ,XQF*IH8 (0 T'1'!1FKQ!@YHH@#QH40%GGE1AV3"D"F9 %5<<@%MFJXC M'6DD1Y#(%0E,SR9N261DYH>8$$8QFS;R'P#WB=.$%,4AD)N"@'C2T10T@6D-< M.-'$-R"%$F((0W/+H)@[?+06FP@54J3[$^!6=KO<[2ZS>IK9\)J+@)?J0%NR MYMWTJG>]KP2O>-\+K#4N1E'="9,;?"(T^OH&2JW*;Z (QE_$8"MF+ MX 0KV/Z]\(W8(7 6005+>,(4YBZ#&XQA/,D74^1]UH'AU9$/S[?")-:GB'DJ MWLUF6%@;+G$""79B2L58P3-F5H=='*9^KGC'OPJ$!%$!1X=0(CBRF(0L[K.I M:\F*2V'R$*9>$>1&68)CJ_$(*]Y !CI$ILBI404E8),(CT%+%G*($KP6H7EGL4)\+G9.**X6)+4T[B-X:;/ZDD)*KJ$*5M4 MXL:06;2C-'&'.]3!R(L2<9XQ5>6.W;E2%^:QI_NRLX[ 00$G(T!DAQH!6C3@ M$J,"--]" QTRB ?Z1J40#.""#"5R M0PB@2D=NT &'Q $ \4M)*DK YDN-P74>@8$$[O!J0.&: P]PG2I,< $*R*TJ M,8B#6SJP 0YX%#%IF("\[:#1>$N *) 9@2KB, %XCP"E'*D 270=*(2#R:0* M3\D9QK H590 -"[H:X?=, $/2."CFN# !B90[5J4X' OB*RN,-X!"6'++WCB':C[I*Q9:%?OKAZ%EI'8JS:H0NB\>?#@95V5CW&2 6 M&&QD2- Y4&0N80 X$C4^$Q!#+3KA .X6!R P &+1$6M@:HB1"0;P97&0 /SW MYX04 R@7T!8N( 8@ $?S5@$U, (-X']E-P(=<'PN, -O0W]"5@$;0$&A M @<9\(4200,+4 %480(>L $X("$L< 9O1 8 (>XP%H( &NYS4N MP4=M0A5XP #4(4CQP0D-@ H3 &ZJ00(+(%&R0 (E\(*UH DL( 8/<'HD< $F M\ (;H0D@( (;0"APP HY!$XL 3(!9P( ,R$/YZL_0&9&!-7;,!L6$" MPS<".. !#Z!<+Q(#D>@"T;4!() !#3)..% !(# 'AF@3$"9[!QDU TD\ !Z.9NMB #\>8"\1$&,O "$P "HJ5(#? -I$&7^$!D2(+ M*+ &\ )U0<#,!D?J&!T&\!O#O$&:7%4FC )-/586X%E$3 B=^ !8I Y(394 M]!..F=!K'E$&6P$'9= :@>,J# DL9$*)(!*8J *:^,0[78Z\68"M@""JP!2 MI9,X=_ -1F+-P "#V!K+O$5(/XP&I%! C81&2"P0J@PAQO 4L0)BG1A$_HA&MD P T 9P \0U>@O@?Y> "HB :$S.6:0 M !A! I&U(0]P%'<0 '. "L"H2),C"_/F BP% L"E "-7"V> %54 UA$)+1 M%@I@A\I)' P %A/[#?J>1"5)9"V+05^$4'0%P Z 1 R4@(1<@ MH1< 7/ZJ0 &LMGJD40'*!0(@0<&@ J4X&O5 8L.X0%' M40(/,#P30()5,0;]$P;U)&H9Q0H24)BR.*&(I H#9Z15 OU M"!O?M#1I=P8W]2=HH%AG *IW0%/?^2,,X0$JNAX>8!.J\ "M"7&;L "V, 8< M8)@X( L,4&25RD9ALB9+@P"A8@>*=42*85*P]@ H@ (5H/Y%DA&BEYH4;;$) MY1@ 9Q 7'&"'FH &W$9'@"H#( 2;P"AE+ Z]H_=. !J5 !4;='&3%ZXIH1 M ,0*%>H97Y8F;GR94J+E1M9 &,$ 'A.-&N_0 JU &<:@&;C J#!''R%" M:F&/'A ':E !::UM3 !)(&P,2 *"/ &5O4 &P$#,.@1[:-' M7 &+;A!MB6$##>!N=@"A1#H:'?X 7&Z !V]93V=P S70$J@@%!)Q P 4&7)P MBJI@I0YQ!MOH$11@"=44(!*0&A)@ML:2!EO1$21P!K@:'S7 -;3 I'&PC5BJ M"G2@!A.0*/.VIULQ!@^ W?0$9ZK4?TC?P[Q G;X&C=0%B8@O+4@ 8F@&I/[ M BSU FR9 &M@5170$,F1"I\"1U58%:ZZ(:1J M/(>6M@ S409*F A/@$V30 MJA+0O9O "0/@12, M]T*(AI"!Q=%!A(Z :XG(273/S3@ 7+@!F= ,DR-$6S MG7&!"@U "S7@ 7/@!F@ I*^! B @!VNP!AO0!JS #WJ!FVE"7!P \%V!U2W MP ,B _[5ZQ @$"HPD(,C6PDW8'(C.PF4( $,H*#[$U(U<&HU4!9B $!P$%*1 MD<)(\6 #B\1_L4; 4P-%QD3,+BU8 8QX!EI4 9G\ 82 M$0-;YQ 70!4>$"J1(0&H/Y<4J,6V:0&.' # M$A$'>749:."=9P$Y53H:%U"0'74)"ZP8)]0A>&PT9#!0$T$&N,H9-)"#$2 * M<-!&57L'F2 !,F '42S+#N$&H9<(,@$"!)5(W9H4POL"*Z0TQ%L+(I 3B(IO M)S. #[6G0US2L!$!J' '!,##Z6,3;H#-<&0' M"Q &OO$&%Y5U(27%G) *\^@^T=81F;"F-6(+%7 )(N!Z$7!PU9%,C+4&9) & M-81U'(3 4T0@R20#(M &4$T'.R=R< L'$< )*>(^(?4\9% 'E4H'( Q/S_;" MDF%K*&"'BI$!=T #-J$8&V 'EOY0 '0@ 2[EQ?Z3%C[,00"T!@R;$>R7$D>< MQ(V=%V('*"[ ,!%"W_I$P2U2RE-!U0G"VU!!DZ4OZ^!5R@A5W2 !Z?X"F>@ M&&5;"^3L/N 6 2W1LK\\QQ=% J$2VRGU(]E$ OS66B.[$9-@ "?I$$"+R$.; M33;@1)I@70[! 1]U!@JP ;NA %U8"QG@1+10*_&X3O/D2!VQ"1% '0B ;ZHP MEK <$QZ0?A-0%A'A$&H HW#KC52! XU5"Y.P2=%*&A/0W O";S1P6!Q+MA^U MD4B1"0L TF,%TAD0/Y*+$MVJ?IB;"A&PN?TA&5VH$9ZA&+PT":L0 9R!@QPA M 9UP5?Z*T0D(( LN0#\DX'^LO:=8] *D;5=R3;E]&L483=*G$UED<+<'+I.X MBA(PP- ;T0"IU,3=D$ #$@.*)2'NS4L2X0(7$ 84 M .K6%Z4I@0,HY ++.A'04P&G1@(-8 F9P !-1[,,T!*[COZ\X,:WT=P6",X1 MZHKHDF$&1IH3J2 2#IPFD5$&!> &FD!LS]0_LK !), $564T%>!N'<$!O3I[ M7^,"$; !U!$98@ 7V9Y^-81E$ -/(*$L !P+0!9$ #$U #Y)X<-5 !+/ " M1;, #(A$?9U W#;@$@(")! &$7 4E=MF<1 LPHV/C%L+V "S>D1&4 H MFC2)J\812D,#!)";%] !\8$&"Q!,CN06\%<+<_"E2/%&0)?.R><1G# !,C # M-(N18I !D<4Z\9&-7*&N=: +, $-3%4#P"B(U"I6*I-?4H#*#2'G<'>-+"R M+3@1%N<0:U B3("#A4!_2T+:/ZC"C'0YA>)6'Y8K7'Q; $@ A5P 1P &LA' M [AY&;R4X!_JN!RA&#@0 "! ^!EP^ M QW0 8MO[%8A 3Y\$$\C129X =2! M"@3@.IU0 2]0 Q&A57;YA6'@C(F7$F]@ /$<=#D'^QWP\3F. J?T<0_P9750 MDRQP ; _ F.@]F=@!WP4&1./ TKA]J>C .Y&3F(@ =DN*!X@^XFR2,X]>?BC M/S!U.C !!P5@$V30?Q[ >2D!=JD^L'.3:002*4B&9'=0!IR*"K61"K7A$7@ M$&0T<4I5J]:=,I,,UF)%!U4M5&K6J#*(29;!5)P,9J(HZU(M3JMJ6;HX4I9' MD 5K:?XJ2*=D!C@+:]&ZD\F6)8.R<-:2%>>,1ID<%ZK:R9/.F42V9*JB1(MG M):<&:56BN%"4RUITW*A2E4CG0CRB#-YX85#3&3E1:R4J6DOH3)] 4VF262O5 MI#N)\%9-E69KT*JH_%:5R0EO(CR3HF8J0T=MK4L757VL"UD6K4M.ORY=HZ:@ M4TIF$N7B'$R7=B/;Q):4S(0*5V6D2'O1XPI^-$]Y@ M9(.")U86A>9Z_ ;3:[UR@^:A+? ,HL.,G=R(03R#C!M)*?[,G*)EP+:H.^\. M2K"K[SZ>Y+ANDPJ76^@2,BI!Y;2%;+$#*#O,H,R@.LZ@3!4/53G.H,EJ$87$ M$0VBA!+4RK"CLEH. 61((HLT\D@DDU1R22:;=/))**.44W-..NLRLTX\*U-C@SS[]/-/ M0+<\XX$:T'0J#O("5731- /9HTE"J)1T4DHK=3)22Z&T$E YL^RT4YG4NA/0 M2=+ RM T09U3K4XY6<,-D60:U5,N.[5EUA)51>Y*7:_$U4X[>Q4O%9Q4[55. M864-54UA'Z/EUU6U[#4\/.) %O[+9+'5MK)K:=WR3CFAK?5*0A[-]%QTTU5W MW2,W9?1=>..5=UYZZ[7W7GSSU7=??NL2DEV Q9X8"3=[?=@91G-]MV%$:ZS MX8>Y=;A?71WN%R4>_;YYR.;Q7AHB;$,3ZU)8B6:UZ$Y.7"A3Z5:B(8X$/P8 M:M>6>3I4V00--UY]@WX\_0MH \P4I@B8)(/M MZP&CZ5,E&I"F-T2H2TY!@0W"UX!>28 .C/- ERS! -7AR2ERB,#S4$4"L.E* M*92H6F72\) 7S.![61K?X"3@@DQL@@P!6(X-7)"5#<[)$A*8"@+(P E.H* ! M2N& X&*6)Z70H"R=4L4"2%09"?P(2[)8P!VDYH(?.L4.!?YPBP+FD(I**( , MN#' &^H APIT4"8UF( ;7/" YWD !7%PP0:4HA0XCDYP,)"A!FMQAN*=R2D> MP &:*#"W+FG"#5K"@00,U("'D.$!:Y#! Z93B0*0S@0PB,$+ C C/#GJ@*MD M9;H2&*HWS "1\0D##?"PD#G,H R!$0,-O.B6&55B.7;01!AN(!8Y$(H\F; $ M'F3@!J4P,S<\2<,,6@B2&IS!#A5P"BIZ^4M-5((.,M#$*FY AHM8HB#$-":) M.!&&&B@$>IG@I$(RP8$17.(2%)!%_MZ3/CI(0 :J0(,+*/&"F A(!K/\T 24 ML@HRT$"+LD@##: I(!HXKRX0E?YH+53Q@@N9>&"2"[A>3DAPF@DLIY@V6%'TDH>; MVV3BEED-@TI8X=4@5L82-[A!WZ@# A!X415FF,$&;9&&-CW$FRR]P"\-\@K" M&E8-#SB#2K G _%,8@&U<$,%%G('QU6" 26AQ0*<"!$# (4#:W3*!Z.R (4H M)0XCT(0,TG"151Q'!A9L+&Z4L@DO0XEKB$<9=B ]Y@ RT0("'P%B+2B)@ M1;6(P23[1+)6YE>_4R+$*Q?B@A%4XKV;D, -W- --3B!A> PPLF0 M42 ' M;I@ ^6K@5!<42@%29<&#U[ %Q3KD 6H@1HD0#DR*( $8JC%"%Y0!P\PP2T- M"$,9+@>1"1AX FL\0P'&<(,'H" -%3B0F&JQ !"LP0426(D"U!!0'I$@ F<0 M0P$T80D*<, .EV#R!1)<"R,[90T-, $GW*" ,*A! ;8+ P?&*0*:08;)J9A M#=Y H M6P$:O*$!976#M=\0 2!Q8@+0J^,:)$"7,DS[!GRJP=,F0(<]U6'='L6VMLLJ M$SHL@ YKF(!E+6$X.+#B C* X^+"L 9;$(5#"@#X'Y4 <>J8N!PN(#!%Q # MNB@E!@=RRJVIVP"Q]JT2"Z"(4V)@@J'0X5:UN(#M-(.",V@"#2/ #AT4$(,U M< #E%*9OH2 NBP+((A,/(,-DW_Y0"QHHH QG0,!Q8> !/EJ;#@\8P8^4*JV00+(P/2\JN)4&5 #X'95AW'+ MPA85.,Y%PE""/^%WOX,GO)+\*R"*W(')+J <],J B@6HY :HD($,(;/9,#P- M>;5HP"UET0"Z5""V2CF#9T&2 %J86"EON$!\%$"+>#0^$ 6;=LEDT6+L6 MEJQ%'9A,@@0WP(NR>$!PY D"VXV@D;40 ?E<(&-+@/L-?-*$!#9V@1^=0?=D M, $7IW.!23HE$^"6HD$X 4(.@$T6Q[D!"%!S$:?,H"S0IH4<.B"35#" 1!D0 M7!M 0/Z"F)@!I[J$Q3&!-9* Y5"%") %,="]XUB#$:B%%<.>Q9D A9"!Q:F% M#:B:&%@B$5""B3A@W&+ =4*NBJD# V#.( M.[ =6;! ^O*S6D"#%/RA..B@=S,(%AB#*E()!)0#$JB%-!B!5, D@T! &;"] M'*R,2O@(6I@ QU*P [D!P+,+!D@%68B A^B$6ZH%%U@<"O BI0B#)K2+!4 % M69 ^M&X [FZT8(('." !:@ 'ADYBE *'' _,Y$%R]D8,F %E@ L!$/.MC# M*D(%.^ 3&?"Y._@\6AB!-L?Z2FM)SBLA(A5^Z M08CCA : OP8P,T+3GNGA$QOPP)+A3$(Q<5Y +JH0[J8@#1T M"C(HBUN1 $Y( Y2KA3"0@!

    40@Q&0 0E(@Q;[,A*PG34<"28C/E1HQ[ 1NS*8QS)X@4M0 !

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comp_0019.gif IMAGE begin 644 comp_0019.gif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

    +P1TLA ^

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

    #'3C7H WL/<(6 M5< $_VIM"UX QCH)@5HB,18"V**";B"!$]&A ?J%KK)RN(+C[;S)1@@@XW# MP$@LXH ;9J%5 X#/8T@4K8RR"9D, IQIW56. Y M!9#I[W X<'19H.&K9\!FR$W0A I<8A,3N%,#9K#Q%]3A[+VQQ! _P%9[E3W% MLGA )F+AOA3(?.TP8(T!P&,@#-(PL2A@1XH ,/&"L.8B!^67@ 6YJ(76,E4 H,E"#IHPU- M!5S!HAEX00[[J;E,L($U>PATFP,-T(CYD849R(%9@(!2B 7'FX4Y2*W?*PCC M0P0$)(@/V+,3")/>Z(#L2*J#.(6@.Z8TPP&I@H&:VPL628%ZZ:](P !X(P4W M()V=J[,;4*\5Y+@6!#6)$#6#4H( 4 (]F((,>#:92H*:B@(\6 ,FP*BJ6(,% MR(!# /X$#5@!0KBV/BB$/# DCH #;#""$@I)A" E3!#)I I%G@$/J!"+8P M:\,V;J/#.HP:;T,(#-B+"?@05PBT2FBJ@FN@+$(E5'B%#P@#4 &N"<$=G[,J M.) #P1FT2,@$@Z,$@RN($F #4CB4Z3 5@U,#4'$Z38P%!2@."&"74_@0.R@! M1$((%R&!WFB 7;$ 4EBP)'NT29.JIR.C#2N(.YB=,[ =6:B UQ #&DB!1,DM M64"%#ZD =C&(31@C69B "Y&%.4"WJT,(.""(6(" .8"#KT(#&GD ZS"AYNL- M32 D+3J%!>N-UMN(@E@%!E@%&&B,"<"/)DB!>72Z3-@@M/ZSDUW9! 5@"!:! M &QAIDP@N=Z N@0L"-CIK_^Z!';YD;R2 TR< 5>0@2P2N%A8R,0J ?5:CB^@ M!!NPG1JHJLQS.C7+)DSL@&:QEQJPK%=@ %-( 23K@$BS@, 0/\^R"/XIB)>\ MK/E!(=V:CC("? MLL/L9 OLK$,\/(@':)8$$#<%^(074I4&< SPM ,+Z(S+ @#AX!X)TH *, 4X M4("]V)M9D!\[> '2\246B00&H#@.. -22 Q."#)9)$D0H0XX #$S*L.:(PV M\"XV> #LF,4#(8&2,P@6F0, R"(,L $[\ +XN82VK ,%>(,V2 ".@($.L ,S M: #/2XP%> ,YT !31^#6(!$^00%\ 6X1[LD!M96(!]*0@I,@59< ,(P(X' M")!%^OZT&J .Z"#!Z"$-)!$,1 <#JB!._B"!$B#3%" VRB\&&4 3" .CB#S5J=&L* $[B#-)" )2T(#YB! M.R"_@%. =VQ+0&*#.>B 1STXLDF -T@Y/"J(6?" &+@#&4"W$K <,GT%5&B M""$//N. &%4 4@@#"XB$-I@ $GB%$UBS1_("") #3X4!.R@\ G.\,+ ##\"= M,( .! # 8BT!I@/$MPLODA6,Q" 9O&"!Y"#58" '( ##R D-D"WO?. %+ # M4'*%-L =>YD#!1 _#P"5:WTR@Q@!#Z@O!5C2@7P%.Z@E'O[;DVXQ !.@@Z_) MB-6P QR8 F9 0Q( 1,XRNEX 4-[@1J8A02@R^>:!;7T+T.#@1@X+0DH@1<0 MKU.:@"^P Q+ *_,ZB'&3 1^QK!C '2^H@#E@ P80,GLA.2^P@]4HB#<0@)L# MCH)] -_#*YC-TT0S ?@*38,(PD*8 A=PVB68 NQ4@@U 2FX"2G0B:0HA$)@ M A 0BD( !"58@HC1 Q>(@N%$@9EPF8AA A4X6Q98 RM< A! @:WH@R086T!8 M@KS5SK[U6^\TB$D9CB45DU4H!233D8*@A!@X 2RYA'H1$'LDA2:XA%@ @P=J M@T0Y!1PP 2_H#5( K2-IC>*P!/X9,($<0(6#0->!\0)H; ,WJ8]L2H$6<+CO MRRN#> 4O0(Q- (E(\!I30+):.8,YL$;GX ^$N ,36-1FH80 N1+).>&F 4Q@($T^ 0;. 4Z<+B' MP(%FD8R+(Z,DG8$3@%\[38$W^(RN \WD, /3$),36-'7V%P:LX06L(%"!1B$ MM!/RLOZ!)44$)).%/*6X2-B34\B!T-4B&D"$6!"#WEB%,N@-1'B!%-B5J%*# M.W@!'+E@$R 5J=.$2FBMJJ,Q.K!&*N&+WG %R&"6:[QC.XB%55B%XFC5@R"% M>I,3._EAA+ #&3 %*RT(.Q80>T/2T*@W30&8@9BK,.BMC* #1FD#>RL.ZA+@ MI)4%45.+0CB$53X$L%T+5N8*+CP$13"V@C*$528*0#"$7 :$55Z# #B975Z+ M6[Z)5NZ#7EYEKO"U7#X$7O;;9Z8:[GP+P#7E:K;F:S8(U&" .<+F;O;F;P;G MPLJ+0 Z+4X9GXFA++UJ((RZ(,^:'YF:&B6Z&>FYH-@OXFPX(:P%_:[ MZ X5*!;)Z$\+:8_N5,BIA!.P+83H:/'+:([N:(-H:9)N"([N"!9Y:96^:9BV M:)7VB)PN:8KSZ97N:9TNE:"NZ5)QB)NV8)N>:9[^M*.F:9E&:I]N:J>>Z9=F MZIT6OTB0@180 Z=,6A;9!!MX 1L0-*E.:J2F.(D Z1HXEYVN:I#V9JLQ";4H M";NN"V..FH>>Z+ZVPXJ>Y\ 6[,$F[,(V[,-&[,16[,5F[&O>9ZEQZ-&L"[[V MZ\JV[&X3":I&B(W6[,&^:;E>Z_[&_NC0]N;.!C73#DW4%NW59FVX'HFL_F;5 M'F?9#N?+MNW;GFC ;NW=YNW>]NW?!N[@%F[@EF;<-NZ@*N[+KNA7J*$VF.&) M\)HPD.[NS6Q3GH-;>>DYD 'G/8@XD&XPB->DI824_D'4G@6D-0CM;H$.?FV/ M( 6V8D:#6 7:9K(V.&N%$"BG$[\YJ&2KG@A48!$Z2!34IF]9F.^#V$2T/FJ' MF&&J?FYF+/"$B*NJ)L%FL0/JE@CF=NW"OFCQ:X,>?@/$>FE42(-\%@D-+Z3O MH._''JJT2.[CAG&_S>E03HX%"$N/D $&J('_28!^+6<6Z8!6\>C=4H,*.&.R M:B91]?Z=\I8%,#";"'>87C'Q&F@ +S ##- $S]MVL F4\ N?( (3/E!I F MCZ8N+1>H&IA?4SX%#%A24C5G%ED%"R"C6"B!_K;F.7]PAW %"T#4R/#S:V:1 M+_"MCM"$$(B%&%@RHPZ#0N=M-.$2!!S5:$#\6,1&C TSVB C:Z#[HT$.B"P4YB#&S\1.1 2 MT\@?+9*#QRR!-LB$.'!*,: 17[1@$0DQ4&$13(B#C'@L7K$73/#U>PE,ZG"X MZ)H#*3&-2^#).0"44Y"#L)P% *\#=LG,28#@!" C"Y@-7?Z'1M.(A%LAA6\? MN<3 =WT7/42 $F8A/S&A%-(74S@ M(3K8A$[=NU.(!3L0X$F8@_[*A#GH84F @#N(!:73A#B +WI'"%=XA146) &V M@V=U>'%AKD@@,'"7A3KH)HSO5-.P@X:)KSD0EP$[D1/9H=Z8!18>>NIHF/NQ M P*[GSN0DDB8@^4PC4S(B#@##3*:^.3@*E+0;Z*W"$R0WM1UZ\B@ R1->#DO M>WLAA7./C %#^H,8>\6=@TMG/CG@9D2@ Z?S^'PGH_%&5 (K^5CP@'BM>\10 M>M#H#>9VA;R/JCG(JN7PMV')"/X8M816-XA*V'J/\'11-_W39PMJ+K@'6%D+ M^-X) )57,($;P0#03+!+FQU-4%@VF9-6#%ELA $.R*(8H+>RRIT7L( '\@+7 MGX ].0$/<*):)$$.R($..&L]L9/$H$>7PP 8J(# X]!+*(\PZ'X+R YE/XT. MB WKES23#0%4E#0_F0 9D $2<(#B2*<7_1=+F/\2:( *!H@2##Y!%K5H<4)R;@>.&APBE9'#1.R$$19":0*1B$P!2&@84W ML5J$>(&A(*F,)T:XDN53%HX*)E) B"1+C(48%=[(.L&RTJF1)TCT]"#C020< M'93*F/XQHH$=62G,G)H XT0#+SYA5+1 218;#3,FJ#WH*D4##YEL<) 18D(F M69$JL*WAL^&;"C4X)#SQX(LL4AY*G, L0V&&174KO3PUJ>%2&5ED*B0XX2% M$K(T)2U1X85/-!9>6%#[IL,)#ZY@,/"<4D8*$K-($7:L\$7O23Y?\>X0Z56( M$S,L8$(80\*;4Q9(O,CH\,.)W*OH0(!@XR=Q&*5SI, 0(C($637.4WIM59:K M$BE>2-!DI[QA;+R&@4)S3$ : TR= EX*'I@B2PX>S/ '#]9V$8%*5AP@T,C MD*"A)1#V-0($!44X(5,$F(EV&*.2:9 M99IY)IIB@IDFFVVZ^2:<<:8)RY8_J4'"0@VTX9 "KH210FPG^'30#16$ 88- M&H3E 9%-G?%* B'1 <6KH"05BR8'"&+ [R$)"&#[)H%9#DC00TAT":(*) M!#Z9 L$J985D0L.RR* 0!##T] *>I A0ARPVF-!4&*X8\);$LJ#QGBQQ*$RK M0R'[Y+$LZOGD@1BR3&"42'3\] 8#/4U@F+BRO#"#3UZ\A\&-IR2)R@0A_51! M)*@D<*T%2C*@R2D'5/@*6*0P\(E##5QB!P&2^+3*!*3(F&X%DZR20):5,##+ M*Q.48J$K>,X4)T#U3^5DD!8-1 K]RD.R'=> M!>UV4(Q"!+)@U Y,H#DT2"J\T8!,TAA%0S\%8E:6RI20.!G1)J M#2WX9/Z&!BV?*HL)"C%@MR6U8D"'*0MLLC@!=Y2.BD\0D!*) &&1\L"/"NB= MAN\6-(I!$TKZ%$:J' !?E!V^RR*)!5I5)UG(J8 &/" "$ZA -JV)373:TD'0 M@*?$?:]PFH 2#F[P @CTY" VX,@-8""!3+SB 32P00XXH)JKG&!/B&" %VJ0 M P<4;1-?L &-$&(\H%!.@"1HU ENY)/UT2$,([B$M&95JX9D0@&O$ -=:H"# M!&3"#("BCAFB.$5-I$%0#I#5)>)S@AUB8EPG@%=*R <&&61B 3FH01,>8(9/ M$.L2NZ*CUWS"LU9U+!*[:L@9\#2!2B ,9R6HU2 +Z1,2M/ZA%.,BA00>Y*X8 MD> #P9)! TIQ(!O@( 0*,]<7 '60"F B#1*(80X4( E40, 4L=AD)Q4V@<^D MH&C$>1"RFD(6"1PD$[MJ4 YL, ,&O$(.#@B!%\B''@C [04A@X$8W!:L'$A M(0VYT]!B5(D*O$("A)3%)QX0BSDTX ->"(DFX?83"TAB8SVYP7DP90F M4H& M7W@#GLP%@S#8(8D.@<#W(J(Y!DRB4J^(A;]<4:F _FP"8(RA!""3.M"TBPYX M>@T.<%""LN%@=@TAE\ X!QI)K&)<,VC"*1@PS0IPR@032($6*$@1)I !0):@6A5-%N6D*,[4)8 M=+ 8/,96[MJA+-0PKB]X(!)BQ<0K,L&!29S*"\45ZR5>809!V&WR2 M"3$6S9 M"+"!P0Y6%=)> !E-3 !N8E!-$"M%/DR(<0:1J"QR96&*-Q ECQK6VPO4(I8R MD*(!=_CL)?1VD#8H3"05TE7A/J,)#CKD#1L\15F$[),*2*)2(;D!U6;A6(#9 MSYYP^*34S-!/6Y4%;C/@P!M($0+10" D2W:%*R3 4(>4&&$/.,,EA"LJ< >-F("R M^"MBPRWN!1YVW&X2H(4.<@8/Q&)=U<&=*C8"W.X M1/1P-(%UA9@499A>>&3Q 7C)@A(-T%LD&A"+H2[R1N:"PP,>% D -*Q5& C# M*4@!AP3L21*DBHS)Q,*!ADFBS9%I02S,@*<3W/H%L,F-!Q5&@NY*("1>L @$ M6":+&&1BR0VI1'PV\?!6DT(!8.B)'0Q@%.PLI )$@D!]BQR"6A5%1DD,01O6 M!TX'J+,"%4+#].Q@F!/$,PRL:OXX PYG!P$4W0%Z.T4+,OQ%6;0@GF7(+])2 MH!9-2$!O!FN*&,K:$TR8;D8^N4,-8L$!N\EB 04YR/H"TP(=YU@6%+#V#"@? MW")SX,CQD4&JFB42I#$ P\D[EVA.7@.JO9+8":C0*<"2TH)H@@&86#:9'5 = M!\34% K0U,G?C KA6ZAT!6D!Y=REE@HH#6$.8# %5AA]-!2M!A9IU?H.AX/H MSS+WN#;,O7!-"3K@S RGLL$)8J'TM[AM;OZ#@^^\?U2R6,#-3@PR>C2 W9#" M IQ"$QQ,A,C"#'"* MY K/F?+&@ '9R" E0')1B ^#1 =4P%99&P:(%028RR7( +IM";B9&PY^B0&56PZ:&R$H MUI90P@.\P"M0!WY80";$@DV4ANBU#.4T!!Q4P' PQJH]B$V4P 0P!9.0@ 50 MS29H0 H\C 1< @S4RD&800600!8VQ0Z-D85\D =H !I^QK0TP 1, +K\Q!FX MR 0(41LD@-[(PAZ6QHU8461X@">10$AXQ%08X5BL1O^Q".4,!JC 0"Q< @8T MQ"64C2N$0 7,67U,@ 4T@&P!4 E@ .Z!<(<3 NIREO@DT^TT"E40"R\P@B0 M$E P0$S)P'9,U"FL6@CPB(5X01K"0-_(0AI,0&D4C2NHH?XFK (P<@!$8(!R M#%V2D((%Z,UTA=DL]D0F6("YU$ O*DTRFD!F6,@KD$ KU4"2#!UDU <)C$0' MK:)/A$!,;6(LH ()A( GZ0T;3$!E9,O$34!U^(0&%!1( ,6M60"Q04 *;-2M M844+BR,(-*,0FQF/D-&,'N$98Y*1A M1*%K-,P<7(XLS('"-",'@$IU%,H)&$K0T)8L1&%I-(PKY$8(2*-3^40& 07D M<*4'Q$@6U80%* T<*&,%* 0=%/[9*5# *]Q!$M5!D9W!!X#!# "/3T1!F>3H$(IQF9+2*>\YFJ[P";'HG=.JG>?J$ M,I6F=I["L-4)I?GG0L!F+'";EI"G=\H">!YG\Q6H=?X$*AP$>"*HFPW<)!3D MST1"(/Z29X62PF?:([^:!-NPAT$5!O4FX46*6?2(8+"V1 MJ8Y&1B34 M(FRN B*$J'&2#WE6IQE<2@? M*9[FJ9[NZ0 =1!#Q*: &JJ .*J$6JJ'NZ77N*1U%Z*$6ZB1@@ G$HSHU*J7> MJ6Q6:JL5ZHSLR EH9Z/**:B&:@[2*::6JJG^1*+NZ2D8YZFVJJN^*JS&*E.E MJJQZ&R6$2(/6JJ[NJI:\ B5X:*7>H*@.*[$B$*GR*K(FJ_ZR+BNS-JNS/BNT M1JNWT>JA"FNQ7FL"\:"Y':NT=JNW?BNXAJNXCBNY0JNU8BNZINN8<.L0#9"Y M7$2YQJN\SBN]UJN]WNNGJJN^[JN7T*HF8, (O&M[2HL9=$ZFIJ"6H (N?E2B M4BN^/BS$1JS$3BS%NBF_7JQ@:>N;D.J0^9.61$)\0)AOU>EJLFK%GBS*IJS* MKFRWGBO&OBR<'BL2;49DQ "!A40D4 "+S%4;E$ )K,@ M'?VHSM)7UZ"!!,C!&SB TJQ" ZC& MQAF/*_YXC\,U1"0PP&JDH4T81@ND2P"GL JO,,MZ;P&_< '1*B6DRRG GQ?T MQ"?<2"18FQSL!W/*2%CX24C$'"H@[1#!RRDLZ"F( 6R4@6>R,!1'L133ZP 3 MJPL'UA5CL0&QJZQJ%"7,@0,(W12/,1F7<YT&\ MPAE,CM YK!GGL1[O,:56L1K_L9NP,1\/,B$7LKWZ\6!=;!H7L"#72:O@<9Y& MFR%/,B57$ M9AP$Y[BBC8$6+BC?QO(6L@J M8( '])6%@ %P56JKU,&MV2DIO$!(4%4"9YOW;-#))?._D0F9,P M0!<]>D\#Y L MGT* ML'TM*N6U/-JG-R#(M1/Y)**^M8I,.J6N,+A: E]ULDK=+0XCS3+*G(Y M;^MCRK.]P8:YA$$(X% '5% ,>$ '^(Q/Y @B!D8.J 4F4 49?@$&+,5-=T!. M/P\&= )K$(;V"%DJ!4B%F0.;$<)MLI,]L8FW$!,!0TEQ($=@D$LF(#>F (+ MQ@$.T,![]),'$$2K><'/I49(O/["#'1 !QA&?0SA*T26!Y2>+&""X'' !-#! M+)2 SPS,L/%9'A 0>323Y0A!<2(#-#TLM2 T!8B!U2$SXT?Y,0")D18)$2? M^WE "\@R28^VQ)+S20/RL=X% U1?&\^ \S2$&)83 C5#" *"!*]B!^]!18,"!M+2!0S%'"JR""=B *0Q+8 !?,I;"*92 M0!N$'UU"+'3 #E5 '+B""=2 0FL@. T.&PB &FB"+U7'3AD51B88=R@@5?PB M#DA7!Y#"*W# GI "!9"")@C &[C"'LK")$! B(R &,2"9ZSF? M]LO*+ @*!\01K$99(;P":4 '!5!PRH!1A@0-#"@0%H@I9;UW87R\ A1';)PFT'C5J4 M16#XU^X>A94K^5LTQ)_*@B5P# 04Y'4E3,,U !R\P1S(D89IUZYHF,"80!G@ MAR2TP0@(BD7[A 0HQRQ 0!C 01RD0 C$P@.L B64S0FDP!S 01@D@%@(T0N8 M@2;0(H[XSJC/P1N( 0)X*HS?.A7_\8QK\K'&P@UH &FV&O[JV8]<^40[>[H7 M@ $8H(%1' 0.K-P7A$&:-9P"=$XDG(JYG :F $&B($72/LI=(!,&-4++,NS MAT&TMT&XR\1>2R% KQ?8'42;ESM^$&0LF$+&F,'+J.#'1?NT-T0)L(HO:1BJ M+4Y\ +JXF,$7@($:7,*PF(NN@)/BI)B.F($72#J>M H%O$6EX("RHT%8D < M?,&R1 >Z)RW?A8RV]\A!?/C"G,#)PX&MXSK-DZMIC]NNTWB;^#)[\3A0I0H8 M.$\%U%4D9,E!P$'9Q 9^0,!OCT'#(4 @/@ E2$1%MTRJS(%JI$##(+T>BDQF MI4%\ '0%" QX*\D#Q(C6XT=U3?Z"".N[LN6O3ZB!<9Y ]*E!V7" ;(6!PJC! MY:R/U[S!)CS\XNS*)O#2M+1!8AB[H)2!:OS$Q@^,8ZX?PIR "82(!MT-D9Q MT;"ATCT/1Z4**B1SS8^^N-Z\SA]0SALKH,+ R[A5XWL!GHP*5#E -?I$"G" M%V #,Q"0MR*)6 " YQ A!S,[><^;"Q/CCT 4WB! M1*\<_&:D! 2FH L?SH MQ""C3LI L04\\/+"]2E"2A +(C!>QS$"^ ^!J0 N3]-#JSV_TB K4$ DR, MIZ#! UP\2%Q" T"\Q%5*".@C0)C1Y,"+EQ,.,*'Q("N6+%D/)#FD]*!�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

    SV -;E9D%B-B1 "1B!;"QQ+OZ0B!%L %J8$<3 MT08/D :G($::4$"D\ D&@!:NH##=4I,<\@*: <7A@DC4 (.MI8P&J/OUY9O M6:-[-XL@5%S,]08: $W6B0IGH%;5\1"8@#@&(16RX !T$P:A43?ZR!"D,'NA MJ1"9\A.98@+]: IQ@ D-D E]- &F11_'4@I%APGB0@HJ]!TK<3$E(#2NP "N MT (N2! !BLH09"R@%;$B4OZ '*]!YUT3BFT 8*< J2 M$ (D< DO0 DUT)7"\0(5,@M\E/Y&D%<:K!&E!&1#I, NO<[!G$&+Q"*0W<* M&# 2]H6',OJLT%I\-&JCU,I\=>(*US$+L6"L8# !,:!#,G *98 1A=$2XQ,> MKQ +91 :$B!-86 6L2 ?AL$0=M !)T!GET !A1$)%)!+3&D0=- > ,#,, > M;8&@FU".. !4!!H+VX:@0.6PG:$)+5 RI78:.Z$!;S +R*$):L"IPW(;K^$0 MA9$M). !,*!#..!Q'D,2?90"#(064^,&$NL99Y " H$#&T$!X!(+;X!+LH # M,# +@202\1$]M-:K73[?77R"@Z01[R1 U)C M$',1!D D$.\E$PU0:K9:AROWKO0Q'U@B"PUP/A5P"@O!6?W: @3&.YE@I#(1 M;QPP)"3 0'SQ!J=0N :!G?%Q+"E 8*8 IRD 1W(B U023)T#IQ0S)_YE+85A M"0_AAPU!%S(@I([[&B?P+S#@@C'B"H#[7QL! 2^: _ J"Z'T$4 5)+E(%Q^@ M3'60)&\P(IUQ/K/@ :_@5KQQ'"$#-JO0 &2J,W3Q"1,@$.>R/%XZ 7WSJ"CR M N!#=MCQ97&[O_QK>X)0MP"L=]('%JNC2OP $S8 >_6QA\-2<6@)(N<0D*@ -S8 (:(#X@&396(5;Q%B-E\@$] P8)D((+(#Y^55WAQ1L84 =">"PX %V< DC,(K]>\JH MG&D!O,J?-HM""0F29M 69G":*Q$+6V@0D1!49K 2 MWLAN-= S,%P*&$D*9A8#)R P!M'+,J". [$2K^ %,? &F0 CLF"5,B!-E" # M^',[0+-\D@7KR &)G "X_8< M;[ T[AS-'_$&D"4'[*$X,P#0P-<$)M $O)8&B,@1-\0R^%8#)9 #2':AXM,& M*9 ^!H$)#2V/6EAS! M?J=^/8G:A4H@J^W/MIJ)U[=A<-F?G[SRW;BK#^(UB#XU2%;UW21!CID M4B!!@78]U7Z-U'-KU8(=*+/XUX9]V(B=V,\7V(/=V/FCV)#=>VX;V90=K8SM MV(U=V)6]V9S=V9[]$9@=VH:BV9]=VJ9]VDA="(2@VH30VJZ]VJ\-"*W-VK/M MVK1MV[C]VKH-V[M]VZ_MV[P=W,)=V\0]W,6M)[L=W,!-V\"MV\W=W,=MVZ2- MVM1=W=8=HWN !WBP!]FMW=V]W=J]W=\-WN%=WMT]WN;MW>2]WM^-WN5-WN[] MWO#]WNT=WO5-W^HMW_.MW^?-WO;]W_*-WMRMW;,(3>)TX/X(GN *ON ,WN . M_N 0'N$2/N$47N$6?N$8GN$:ON$_N$@'N(B/N(D7N(:7@9C0 8JGN(J MWN)DP.(N'N,R#N,RON(U;N,S?N,O?N,TCN,Z[N,NWN,]GN,_/N0M;N1&#N0O M7G,';09.;@9G\.11[N13#N52_N14CN56CN55GN5(#NA\GNB0/NF5'NF&+NF8ONESWNB>+N?7'>JB/NJD M3MUDW8%J_8)D+=9J?>I?:->OSNO7=2WKJ-[7JIZ'L[Z"N%[K1[SKDRT0K'[K M+\CK:[W77JCKLL[5P][K8'WLML[LSM[JR+[LU'[JQ0[LT7[MN*[LP8[MNK[M MX-[MQ)[KXJ[MOC[MS=Z%R;[L/FCMY#[MYE[L[!ZRZ0[N\0[KZ)[M\B[N]7[N MZE[MT<[O^E[J!%_P!G_P")_P"K_P#-_P#O_P$!_Q$C_Q%%_Q%G_Q&)_Q&K_Q M'-_Q'O_Q(!_R(C_R)%_R)G_R*)_R*K_R+-_R+O_R,!_S,C_S-%_S-G_S.)_S @.K_S/-_S/O_S0!_T0C_T1%_T1G_T2)_T2K_T GRAPHIC 62 comp_0018.gif IMAGE begin 644 comp_0018.gif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

    !?@ MUZ-@ 0L S.@ 42M"Q*@ :.X#? *B- +?QO# @ '.@TAC,"2L &NP"YT M QP^RVT@ *0![= &NP ACPRA50QK/A"@$0 MA=$ LPT< 8,T [[ $'@ ,Q SL,(6$ S$ ()/@?2/0,,H "Q$ ,) MX 5X L FSO <6<'FA -^ZP 'W;1LXD.B?8.2\<0C(R@@M4 !.0 F4X <9 MP *FO0"!@ FZ3@E7@-J,P B4H-JE_;Y.P )1L $&&[J! M ,&QX I3=( ,-99_@&

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

    V=-$C !H$NL4"!CZ! M!8\#/MBE@@9 S>, #[**$X(3'" 5 0N<",""6Z!P(&! #@C% (NT$&!$/? M29=C\@P($*8A&H#@D<6!8%!# M(8!5/T$@!#04""$A4!#X0"&?!/X"A8$(3#CA@S?&5""67=J*\PZ0#&ZL+;<( M. .& %2ZE X UI+:IQL(X&"$$*+-B0,%;C@#AT,3 J$!#K[J)*M8%.AY%U@8 M^" 6!D8888 (G/Z)@1MF8&!MB^9 X8$\$C*L A1$O"6""T#2(*=7%-@EV#T^ MD0#<(-T,Z@,][D:YDP=T@<$$C]7210(]&(3CDRB7TN$3. +8HS//0@LD P9* M VV115);((,,*M@@D19D4V2^+ AX;3<6#, "$R@*@,(0+/R(@P(&#FG!@#]8 M6""1V*K/HH 7;L/N!02RP"2#"1AIOKSTWKM?O?G>X[]__]7#3R#L,Q[Q) (7 MNLL47/[:<@L)G,X&"(#%"AB@BQ,H0!.?,$$ 0#$"!)QE%YW@!"AF@+M;)& % M'PI15K*2!@W>:2TWT4."W/"),X0I*SA"B0<$MXL3) !E\6J4)D#!"0\DX!9F M",!<8M& 57TH VM(, M"/"1C]6!$\5RP]5T@0*>4"J/+/%0"HP($D9VI9>[&)0N;OYRECI<( 2 M3! !$*!,(5<12)Q X8H 3$&%NEB10*0("AP$H Z>(, '$ (#HS@F )Q "AH^ M<:Q$/B!G%H'! 5Y"@:9X\1,P&("8X+F EYC@ .[R0 -T00,"Y.$3&-&$-@E@ M@I4$S8P:H,!<*O E+4%CYYL2ULZ,0 =9&5G*. CSZXI3%Z-U 8$J( %+$ ! M<>G"; I00 !BD)!;F( #;G!# B@@(E*HK%M$E!'(GD#T0=0:W:$M9U,8DI%A38!0X:\Q,<< (K BG7!P13HX%H MX!41<&8,'.D!*QY(%YH(02?.^OXA#^KN$.51! FH1XG/O, )HF' 'S#!B$50 MP@GJHX0AK*>^YC$".()8Q/->$(@.1* #$W" (9[G! J( !,D6( ?%/$'!J@@ M"@6HW@L($ =%R$^ ]4%/>^)#P/_UUK>_'<\!._.)4>G,0+K@0P!J514,.*"I M(3@FB!:(@PB@9 !\**&'0"0BBTQA ''[F$8^Q@<=(*"I'_B 1MJ2@@%4*08 MT 0(;A5* * !%BB P-@2( L\.F1G57&+'3FE@^IF: \&TV,%)L>!LVJ-#V'$ M5D]/N(MM;>(3 &B#XP##1 N$ 2;" $$7A(H/>H"(F8Z0%X2P*Y8+&"FARR6 M13(U5OZ(,< ,:%B#0SIE8S7D^%+>!<4N1C& JZ: F1AX8BP.8(80@.4##X#% M+C@1@#2\4B,)(DD)&("0MDPA )L@8P0X0,$%C.)==^K*Q_($ !!XP%01>"H: M;H &$4.@H[K0&T-W<9,]A"( 2I%:&7.VBS-(0 ,F$$ =+KRO62H (5K3%M@L MX($/K&$7#P !2%: %?8) &PED!4G310E0;0('[,($%.JPZ 02 M"P>D,"0XT$,L:@:2@&%+(&?:Q)DW$8 [WW56%\! " \H@#\B:HV 5-%J>+ M;>5D)YR(12Q*S=4UQ0VH#CAC+!)0@EML41>=P/ 5UZ*+#/YRQA6:> DL&@B+ M$ KD)CF!T06X*I CX1D"81TK#B#D;((CD,/V3* !BB "/B# M1:B C C" #"M*%@ G@ TB )U $^5@$%6 "*@ X@ D2L UY"D/Z $ M*"!&0% $0 $K38 ME@,(@ $ @$3Z& "[!5AQA:7A%+5D2XLHKPC 1(OSP( )-\@"_"E .PR$5D M@ P)@5UP!088 B @%N*$P;X"Z?HFQ 28>(&?AKB_5+&0 XFH38EKY*@<:H M@P30@018G$4: K(RL:X(@5B"_X/ -^ 2A@0&?G(-7XAI=. .I7 $"R#(" M"($':(@/ 0"72 B,_(@4D0 0P"*7VI*$\ D\6@#%"P!F\0!YJ (4!( !&,M;&B&Z! )^(L*& SNZOCI @(4UD!D-"!." M9+V$X)P 4 "&("CP8BU":.!" X.D!FA M0*H+D !Y#+28J0 $S0$3BTKU? "'>!+UL@@Z6)6YV04: + 9J(H5& $ZB $, MV 4+\*0+@ $W& %=,8,*H(,S2(#& $6 M@ )!$/Z/*X"")XB")X "+%"$1?"#)WT!V@(L8.2Y%P!'0X@"U\H"*'#&VV ! M1I@/07 "$G""\/ X%H@"/X""/U $0( ")Y#2=%3'0!7406W'E;@%.*@!'*#" MM@"%-:#"D#@#&="G.I@#J=$$&E G-G 7-R F,1FJE52(.DB#:?*Q1OV(6W"# M&$ #%=0#-Y #G)HJ77"%,X@!.?")7:B#&:"#3G"#6]@[PYN#&"$-JB2D)@"&^"$.>"#/2,)5(U5;YD#-X"#&=*%45@#:/ZEBUX%B;J@OBXS M%!S <[(53C@5:7IA(5*"(NI51'Y!!O(,735!5Z @U5]%SB(@31P)CTH5I!H M5,X(V4O1EBK9A3D0D3I8 <,90QR8 96(A7T%"5=X W#)UC-8IT^(V97HUWNMDCX0JRL4B$UP /:,V832A+79 QJP :'D5]]S QO0 M@974!&45"$_P,8#5G3RP 1O0N%E#@QF0VFA37,@)5AN8MJF=@1O &DXP@QE M RC:!+\%B3STA%L0DTV 5DT81?Y=T-@S>(DZ^ C#,(-I:8LY@ $X^#RZ<(58 M6)M1:!1F^0@/>-0E-8\M%9[04 1&(%[AZ45#4 1*(-[\" 3+*@"?.UY#6 3& M2@1&2 T#8 P+4?BM=[3&-[A&9[Y6-ZJDP^K*\=U'-3T-<7V2,>?T9WWA=_X M?5\SF$?YM=_[Q5_[_9A$LH@*.,C\!> %F#\;8L<@*_XE8$!Z"!2'. &=N ' M!@EB@0 /&( 3V#<(QN ,=@M!U. .]N 'OH,T^&#XO04/L $^L $-H#Z0P"WR MN*W=.@WRQ8(H/8_RF(\K< *:LV$!.@WQX&$!,HT?!B#]H+KR3=\C1N+0<-_W M?$J1NT/*3ZS2[E@+'YB*+9B+G[BMM!7;.$J2EV:*=[B*WZ7 M+,ZH+V:++D[C2X%C-(;BE=@[9C'C2^&#-? V.6[CDIC@3A:M1'D.Y[C-39D.'9D2 8)-V9+2E:(?>,,-.YB-ZYD0>9D)F;@1(YB M+ZYD!F[B43YDW9GD.&YB2W8*-+ !CHW?]47BX>6?Z6T>0-6? FIA\T4/\DWB M8?Z?0AWA8T;F9%;F96;F9G;F9X;F:);F::9F +9E)!9F^,CF]1@@]N5F8@9G M=33F4_YC-B[G0E[E.3;DYX&FYX&N9UX.YZWS'W.$CV!.:*U[Z/489X*FZ(JVZ(O&Z(S6Z(WF M:(J^YH@>U/N1.JEC4D%%:)#NK4.8:-_3@1$P@:[PA,L4"#T6IL*U@1J8@BP& MA4WF%%#%%'P%"5[E5A#:!/:,0C=8S#.FL*LZ932X!4T@49U) RO6!'U"Y5.> M@[N]:D)V@U%4XX38A U<9X&0A5=XXW9>98%.:[J(53[^YW-[*C"N@1% @;4! MA4E)"#?(G3FPZ41=X8186E]#*S<0['>I"[/&SX1HU;9&$))@9ZF!!:=^ZU.V M9WL>5;=FY?CEJEMPZL[(-EW8W/ZQSNP&WA! "4W*1F=1/B(%_&I)1FUWGNS[ M_6B4_BU -<>3=@_:!N9A7F*0,,03J L)J(HY&-*$B !PJ0 32 ,S, .^LXB[ MZ:@U#H$Q #& M3@@JN0-&LXB#VK JO$"%P(P;\ !#$@@T\*3[#9J_[F :$ 52Y&\^=H4&$$.!. .XT ,.;N81 M$!,8&/[ #W:#"M#JC)[M0,7MJ7N/^&#>:]YFK!OB+==M;U:/WK:($W"V;W,% M/; K?A.3"W#O2TF!"A!Q(:^ $Z*VGM$*N!A#!*BH!^BC)DJ(.3BKH$G7B7,# M9H$%' B!().Q^L. 3[";VN64('.F6&@#3G #9W.3J#4##O"V.X # MHV:+NH"_47 #K %=6'>*(-.#57^)76!U78A:^/.644#6DA#V6Z=UK/&C3:"# MGQ*("I!O3H"^3=@K71B!2?D JR9D.I@<77@%CVQQ/(L!KOYZBY0Q@ULXM3$S MG81P #$&JI< !5J/W(2(6G2"!54?['1UA6(W5#I ]D_@*93QH]L+B1IQ])#8>!@X@5"0BEF# UMG=CI@ MV5ES UMG=$5FEH^?-EB(A5O0 ZD!!0_ @5BP 3/PEG2E=)\.B5WH [5M"T]P M@Y6$A5<0^KU @2K9 Z#N-%"("AP<= (W'-"]>*#*-C?@5URM/\!V@T"O987N M\EX69MLNZ7">\MU.WXGVQ+^0FJ"_P&S+-@O80%H1?.YJ"QI@;D"C"Q.H@W<* M@3K8@S,H;&])B HXL!%P@QD G/X1R(F7&(%$6J 0($0)X(-/T )8.JV< $/ MF($3H*@U@($[H',T@($%O2O5GP& -#$+P($1F*DVB ;B($&.)0U4'U"(=%; M&($5N $+"+8UB( 8@($'4+1ZRH,#*0$WR &EH*!)CX#+S9DV8*A/P !M'8M0 M<(#[BP <*/H(F!,76 $72A&V)#@1I<>"SA0K ")=)2& M&34PP/HPYR,&39HJV$ 1^*$N&&:0FFA*@0(:L* KU%CA 58L""MF6("AE ]M MX[= P$&*8<^F"J-/Z,I3X<2(H[K:/,!0YXP%&S <;-*%1H,.#[N3AA@Q(X6$ M3^X3?YC2_?L)>F"@W2XP<&:!&KHH)M\>#]!0V PR8!!#31+@@ ,&MS08H0,> MN<+!"C1(+)A'H4H<) M2GF'U"8(P-)&:1& HHL'FH!"@2X8!2 5)Y:*#+"7!\8BHL$MQR!U00P9'H!]61:48L M"DS*B:%ZA. 0 Y-^DAE(G&R*PAJ[.- )4BE\@H*>NIC1!BP(Y/%1!?I1=HL: M*""E)BP/-/2I1R!]\NT:MTBKR_XG#W":H&:)@I2'!$YJHL '5X:@@$8V17*F4: ?2!P 2F8,L0B-5 2G:)+ MK>XYYP;+KMQTA@0X\?' 41_ %?0N>]2!E 9]<.+ 475 MDTK5N/XD]-$7N6,@0\[(HXM*2K\]]]W+V*23KD]J6BBPW&'!+;S<P^&D.N^K5K\"E"PJ, E$?<<-&'/ * M.' G BF9P0=Q"MX MR:L"L7"![6:P @SD@8BZF(%0DF)&-,)O>02S@ D_ 9*ST?YD#Q&8'\%NP1/U MP>(6'Q *4>(7"^9U0@,><(X)T*8+6! 0!=<:I:20PI9 #A$D>QC>'2I@OT]< M@ \T@0$:;F$L7>R*>6V(@ ?>Y@I#7DIP "W=*&!3BSL M _.R#B=BP!CQ% R&-/@8UE!PQA&,X"&YP,$47O%(I-SA Z24&]T\@@/GG&TP M;925.RL BUW$PHYGVF >/L"+1YI!![%P0(2^>88^<&!%(?C,#$9F@S/HX0$V MB*%=DL*!B^R"#R&H0P0N^DP^:**A<3S#3%*PFZ-XH!%F^%P>DF>".>QB5SBA MPQG94])[_&B 1C&(/Z5S7.>]Y*ZI!WQ*!':F]Z,J/=4I5(UJ>!S MT@7(AI0&:.*52L& ^RZPNQ6YP0(G*($%(H"#-6Y& Q$(P2WJ1A,,<&X\%6 < M7\23KUO P$R\"YLN1K"I73P@%G40)5)@E10*Q,(-W)D##*#8D@P]K64P (6D M/F$07JS!7KI0@POGJ!D>CD 'H/C$*&+1"=&>@ [#0@H?DLB8&:R!!J\Q 0HV ML8L/@&(.5D6.0CW,6))L)"%YITD"8Q2 ,O8L=+ M?:IRE'H SV!P0VD3*7+% =[*F3.D9%"7:'$%8T\S95UH MK8=%YD2^!&R06,1T12-X30T^5X,S[*$DFGTQ[Q8,FA'DPM@:2,[A M%S&0($@8C*:Z:2-E>M0XBF/S^(" .<#B%3#@51W8B)0*?*8"??Y:T2TV"0,:W *H MFV3Q4;SS"EW( 0.F^00"]'!:3A3(G;>PP=8VP0!RN2$""]3%'/QIAJVY 01* MZ80#)N6& 8,K4.94>7H(4/#0/) M"0#U$*%@@#&N8( G<'""-BY&=.*1 $W=@(!;> "!1#3JZ!_2D@3A=6D6%FI1W=K&)5'KG*"!! PB. M,AJD[(%7OYS4 /6M%K:(^ $+Q/[9I'B"61$_TM8Z;X3H<.**"%PD%"$HH$QZ MK8%VZ*)RN_A$S'1Q M@Q+ H@Z_ @'F-?^I*Q>6/F:"Q04\0@=WZP($N]G%"38Q1*O4?BTS*-X,; "W M!8/B[TGQP EZ_0$=W"("MBQ^FOQHAA3HHA&)Y_(C;5"\/N[7(T&3IO<5L =- MF*H[IDJ#!XX2\H)Q10^>/6I22KT]49O:$$VM'JCM3ST?U;__2CW$53E)G5E M!80 ULV7E[')N\"?&6@5;%E>RV "'Q 7!UC !>1'@6 !A@@4I25!TR3 MBFQ;??Y,2AW$2E*LP05\@ W\'4XA!0Z(TB=LP)\0C >$ ;LAF1A M&USL 09XP RDP"T4WU$4GRZX@@9PQQET8*0E!2DP!$>%4C, 09$#+E@FP1J %XA10YH B<@)1T@N2E MX@7X%5+<0!M8TE&X ERE8 =:0!ZTAN"X @CL@H"<@!F,!OXPBH<0?@ &E&+M ME<@G\1, 4LCM(P&A( 'Z,K,%\G,%N]($L.F%.C ,G( E'D4C=",&? 9$TL0:? [K>&-[8"39 M>58,;(DK?,!.F P.F $*N!_9#0JT,2):K&3O: RF+0G]^9^,\ A3X9\A**7U M<%KV!$E1(HG\V9]1&DD -L]DP)]6;J6*+)V35%W\J,@8-H]7PE]96DQ(5^, 52;))0XIJ4J/ZE*X3*48D'+X1"U84*\X#"M3F$7HIE 2$% M+[QE4JQ*^*A2U2&%_=0E9,H"6J+E6"K%9:X('>YE9%:F*G7F?P&FDX FUBB3 M8C9/9D+F80[D::Z(8"H%JJUF7;XF5X*";"J%;6KE8R8%:>[)'IPE9*KE?[4F M5^Z":#9/+ AB4J3F5DYE56X/]> ?5&)/5%*E4SXG=BZE(5RE9W:G=WXG>(:G M*8KGBLC K6WE;I*G9Z:G>K:G>[YG7,"G>IJ G,FG??+>?4G?VJE8G>UZHAKIGAFZH M>OXG@/Z^2((F9?4DI5-=3XBF**:'N"*/*J(FJJ(N*J-ZYR$0@I%&3Z&@'^MR T 2HJHIJ MJAN ET^X#Y6)&PSD %<(UBCIP IT*D\(YZD6J[$>*[(FJ_YGRBJ"1N> 2I7U M@&F 6BE14E69SD (Y $4%HQ^N$XLV (:"OMG( ;[()\: (*B)RM*"N[MJN[ MOBNIJNJT,JB-.)6S0FN/;*F\,JOWH-J*? ($F,8:?"N@I,$,B([ NL()U,$= M_,HNO (#<$7#P2O%5JS%7NR2YFGVR*IT/BN!#BB7;MJ^9J>2UH&>F48G6("Y M_$I.?)0:5 ,H( +G H$!;D8:S.[BS/]JQ]:BR_ LFKSBF0!FV**FG& M(<4:W,H(K ':)&W+@ (*U(&2\>89MI[/9JW6;BW7.@G0\BNT_BBTRNK(6NM1 MG0 ,_$NV'$J^+04,>((;*$"\]?ZB!*#!)V#(+@C')L!%U_:MW_[MNY:MBBIE MJ-VIT8;H(?@KKL5@"GQ-+## 7<8@"C3$&A ?#+@)6O0&7V BX':NYW[NHGXM ML]KK=1[NI6JJ56P"S4KF47V""80JZ,:N[,ZNC8KNI4K5C4BKR,J([=I([WX/ M6RJ%#:3 ;<+?^M N\B:O\M+H[QKI_A5MEYKNT2XO]5:O]1YJ\SJOXP .=HDNCO4MFIC;1OD/HO@B;I #\P!$O, O/+@4?Z0DS\,BJ< O7L WW M[0N3;?_& M<:2R\1O?,1[7:!S+*1T;J1WG,2 'LH;N<1\7\I'\L2 GLB+W)R$_IP(;)1+7 M'R(O,B57\H="JB%G,G9.LB5WLB>C)?_5:;0"21$3Z5+.,:?-\2A7#Y<."2NK M,I&*+,W3W,XT_,^ZS,\^W- KS,Y7UHZ MGS,^F_,Z(_1"$[0\UW,W6X4]YW-"&W1!#XYI,$(B*()'?S1(A[1(CS1)E[1) MGS1*I[1*D_0BK+1+O[1)<_(GSS1-*X44/ %.Y[1.[S1/][1/_S10![50#S51 M%[51'S52XS1E.DD=K($;N$$;1+543W4;0+54/W540[569S55V8=^U5U-U7./U6G_U8#OV84-V8W<1\WWWW%UW7E[W M*&SW*)S"*& W>%NW=8^">)L$=YVLW>J?W>H).W=G.W=\MW M>]/W>,,W?L_W=OK_W=M]W>^>W@',W@+MW?0]X?!>X@N_W=A\X@2>X?IOW M@)\"AJG+]RE@-X9G>'MON'C_MX,'^(*K=X*/]X&+.(5W.(B#=XN[ HMK.'9+ M>(/W=X6G-XV?N$FD>(T[^(W;=X_+]X^GMXXC^(@_N(6;^)&C>(FK^)'7-)1' MN91/.957N95?.99GN99O.9=WN9=_.9B'N9B/.9F7N9F?.9JGN9JO.9NWN9N_ I.9S'N9S/.9W7N9W?.9[GN9[O.9_WN9__.: 'NJ /.J$7NJ$K:T #L! end GRAPHIC 63 comp_0017.gif IMAGE begin 644 comp_0017.gif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end GRAPHIC 64 comp_0022.gif IMAGE begin 644 comp_0022.gif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end GRAPHIC 65 comp_0021.gif IMAGE begin 644 comp_0021.gif M1TE&.#EA @/Z ?< 8" PH$! X*"PL'"!(*!1,-#! ' 1@1#A,/$!82$QH5 M%1X9&AL7&"$='B,?("8B(RDE)BHG*"TJ*S$M+BXM,C,O,#4R,SDU-CLW.#TZ M.S0T.T$]/CD[1$,_0#Y!3$5"0TE%1DI'2$U*2T!$3U%-3D1*5U)/4%524UE6 M5EI76%U:6TE07V%>7DQ49%)<;F)?8%ED>65B8VAF9FIG:&UJ:W!N;W)O<'5R M'UZ>X!^?P!4I@!:J0%7J !-HP!CK@9LLPAKL@YQM1EVN!AVN!-M MLR5\NS=\NUYK@F1N@F)OB&5SC&ITAVM[EH%_@"N!OC*#OG"!GG6(IWV2M'J/ ML#F*PC6'P4R5R$>2QE&6R%>;RT*.Q&NGT7&ATG6LU'ZPUF*BSE^@SH6"@XB& MAXF'B(V+C)".CY&/D)23DYB6EYF7F)R;FZ">GX*8O*&?H*2BHJBGIZFGJ*RK MJ["OK[&OL+6SM+BWM[FWN+NZN\"_OX6TXJ"_[<"_P)K"WY;!WIS$X:;)XZ?(YKS5Z;?2 MZ*7%]K3/Z\3#P\C'Q\C'R,O*R]#/S]#/T-/2T]C7U]C7V-S;V^#?W\+9Z\S? M[L#7ZN#?X,W@[]KI\]3D\<_B\.3CX^CGY^SL[.CGZ/#O[N/N]O#O\.[S^>?P M]_3T]/3X^_____7W^0 M M M M M "'Y! (?\+26UA9V5-86=I8VL-9V%M;6$] M,"XT-30U-0 L (#^@$ "/X 8X$:-0J2*5D(27T:-1#4086O$$I$:.I3 M+(H,/WT:**MB+%*07$D$!:KC1I*?2$DDA7+A)Y&R/CV*- NAJX4%2TV4=9,D M*)4\-S($]2FH2YT(2^$<]8G5R$>0+B9U"0IF+(T1C6:5Q0J24YL&)1*4*@L4 M5*FO3A(].'+AP)<(8T&:5#3NQHU(=Y8]RQ/2J)5>$\[\*HLIV<)+/VU%^(G0 MI,.?%D':^2K2Q9L9_^J-N>CQQ,B3)[JBR+I+HJN9E4I$FV,1/\A/H5)-MIF;ID)?RXQ(H,34DUA5)ZS!Z.-FO?SKV[ M]^_@P_Z+'T^^O/GSZ-.K7\]^/*LA0.(#B?*W2_P>0'P 4HL4 !1$IY '&3?CT(8&ONN_#&*^^\]-;;'BM"%/'(([=.^$4/ M8@P"R"#_]???3EX*$:LLC "R10]9#!Q+A:2X$L2ZL_HP"(5 ?#&(P+%% L@7 M0!#1,"M@)$K*(/H=:<4DCECQH$20] "%P$?X,,DH;'XLL$! 7 $S%S-KV87 MW.+Y("2,3*D2%D ,@D@0@#QRBA #$'$15D@:*0LI.0;!%N@P'HM$5?*

    S%M5>BY#,8KCM@Q!R]3 A M(S/W]_(B1O!0%!&%3H0Y&!\#LJAA11"2=ZT@$$$6*7O$3@QF M.(E 0JA0HTC>)"^P_5)%G0J"L4X)B?*2"A5B<+27SXA/U"8SG"?@!A"'L&# M+Y2B!_ZK^++U22-UPQ0I3$ C!9= $)1>A!24*9E4/%PD%?N(T/OO"*6KVB M!Z;@0@DG,B;M)40(0WC1+CAE$C\D@2)&Z[0D(ETXBB!$ M3S R" MX RG.,=)SG)N1X)%8 0CM&"$C=EG"$4H@A&*PL&)_+ +D/[@@:(NPK)<7D1+ M!TDC(&+Q0EEH"9Y%.(*E+B+%6%S$1!R" AA$8J(KJ-,*1HA-#J]0D TU(G!# M@*<1%%7110R""QE%8="R8 4(]6=C%WG3A'+T!49\80A*[-86\/:F4'T-"D,( M$ 5Y)@:,ON((<*-5^@XS"#!9R0B%C OFN,#2C=%I,K8C(2MLUHB3&Dζ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ˑ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�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�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end GRAPHIC 66 comp_0020.gif IMAGE begin 644 comp_0020.gif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end GRAPHIC 67 comp_0023.gif IMAGE begin 644 comp_0023.gif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�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

    4ZSM%"5@04).0"VY5"!O&% )!I9V%!3P:8A> MV,1'Q-. 0XCB !TA1 -*P8D("$H%'RG%&B PE#<\H!1MF%5;+*"24EB $'$H M$1J06 %0.6 HAX"/&&85(.&YIT$=H-8F5 ":J91!=Q%B! Q[)XI FH$$)W" M&THA@4R8 TG: 0%3M$)"23K%/Y<:$\<2G""";1 %'J,"R$6H"WB-$(%)># M!49I@H%XP02E8!CX@$@2"1!F#"!(2$508 (2& "#?!I# ^P@ H2 M11::R84,^I$:!Q3U!18P(!&9D$!;&B$!4>!Q)<24F1>^ ((2D3($CY*?U%Z% M@9&H(00B\ T$:E4&?[:E!%P@V$,(*@J"$>8$+4B("*C5%@H9%] .!+ZPA#7&0R1O*0 8RP:D8@/80$Y#T 4-QQ -0ZL!3K+2E1GD('H_7%D84L%&B M8$.#N# !,2B" W$(YT,40=H_E4 !B%#!!]B ANT]I!$_P_[D6MKR!@.8(1., MF)M[QH(#U>OL F8P!0:>P !S,@"%1;, #I7#- M*8X&20& -W5#5%E;R)#54HAA?%[@IR@:T(A%J%$A#CA%@W%,@<7-1PT'.$0I MQ@ ?," (!2 H12E(@ :]TB>S9VE@D?"XABF7H0.G8, =2+( -T'@(?D]Q1@D MT*D)\ D$0DB(&LYPE ;&:0-&P2A2)ID0$KYX$B3!8HZ'T@A-B^(!])&OU#R) MDM^YH7P#H8#%%$O'4SQ@)*6 L?XH%*"<>9["!2_YP!?B\.M,L/0#?FE A-+R M!@M,0 (A. DA#B4W+HAA Z+H1 5 PH8I\K/E:6UK.W9A? MH!!2^Y H3+!R$SP$#!;8 (02E!5SD2 #? +I1?S)A0K K ,D..BF$=JN"YC@ MY.*Y@ ="D$ZZO(40$R#!!D#P$,JFW40L[Q9]QL!V"KA MH D@,+T_DX # M'HCJ6C91>A,!IBFAS=D1A1N.)-X4'\*[$\J$VM( MK?0'(B!1*,(4K._)(1S;J-IO?_ESA3ZC"#%T]+^A?A Y1!LJ-'YO>PQ$XI#' M@*NQV"Z,FXH!M(H%?(HWD 3Z)9<28L&I(P*)$ ,S$ -? I(BH,+?#K'6, / MK(L-+$$3/$$43$$57$$6+(L1;$$8C$$7?$$9K$$;3)#=H/X+,7@I2\D^P&", M0H,($^@(#OB]XHBO95,]Z+ -$GP2]0F/(RP%,W@ B\B,NX@-47B4@.EXBQ,8 ML"\0)S?P%YEHBPGPC1?CA!&012[PIT,X@ ^@#3*" #!8!%4J8!2\)^$,(53^)E2X"Z2( AM@@LNT 4 MV("H,291C(@-((&=5":&9( 2" $2\ #J0C 16)P" T@2@,\/V 0Q^$XOX!,R MX("V* 0,D !WHPLW*)%O&0/]P)B>.*D/& E(FZ02,2VX8!Z8R( 3\ !M>L5" M6P3X" $R. ]2],25B#]>(<44.B)1513N@A77&]K, B$U&73""M1^D)12"$ MMWB(X%.4S40*3B $36@4B+B5AW"4"0Q.4.6$VB"$($D#H $5N.@MU?I-48$A6@E@\X@0]@ND3)! WH&$9H! L @0Q@J8:# TH@6& KX# $(T"4,H #Z8(,*V$>+H)T4V( &<"P,: /V 02 ML9T;;8HTR A%<($X^((2$ Q5DC83<-V'< .+:238XP05T#M1: $.((&;9=-I M60048(0R,$;:Z(DX ($^U!,5:P%][:#<, ,X((GC;0030!M#A,,XV!+49"ES M.YI/#=6ME,B9:$-10('4>@,00(%# (/)O%$N4 XQ" $7,,=#6(,U8(&=N C> MVX )$ &9:(0!!C\Z.P2,"X'%B8 04 ZQ2XCT@HA[%)07 M:P0NB"PO<(#AD !$^(0#F!+&/Z#:("^D"#*<,I^5*H4TA0,7&O#F* I/H""1""^SH%#"B$:K38 M! 2X'TYX #4(D8< T=:LN0O@"0DX$_I-B#2 YD48K,@<#H"<#A)0*%R[-?@H M@116@RUI:%B[GPT@@YDZ/!]BJ0E(81&(FK9(KMJ@@"+A F2%H0[B,V>3W_N8 MY?DIDOX3B)I0GAYRF4Z1ZN'!JC-.0#;WJ+SQ":(SD:TQ:0S=).K0R SQR8"H M;8^?]3IE@4 5X#S#L33QD!L0H(";%0.VFX#<. 0#V$P7<-.#NK4($(5-4&VT M0VN4N#R(DL97.06WEJ_6B,\*4-=,B( PH1F&V("3 ,@0"(&KB2_)JV028N4B MX80- !T),,8?1HD-.0&]*P,)R#PI+A^,)J@,,,P':+LM.T?-GN^Q( 0W*#\! M,3\Z5HY%<#'@,1Z]&+\)1+]0^;_@\4!=X:!&>0,\;+Y&.0GVPZ-#\,$'[0E1 M6"Q*K1\-N([@5 [VH]6>N ,$]SX'/P7V$X\V8!3F8SY.2/XMS++44*XYS/X- MMRB..&A#^L[QL?#MJ[ K\ALL\@8$V2$X0Z!)-1Q)&_FI^#2K&!R$[PM(R2* M[L-4OT N4-V5WNQ91[E90KA91I #&[':8[E40BB08VW6)$]S-7^#"?@ "J"6 MLM*R"Q"4+_"X"5@ISAT)$7A/#+@ Y6B$J=L E_T--]J\0@E+P N,+ E@!P%44 E0"# M!LF #F@+XUP?..2 B%$ WV@$!$J#7VL!1M#)A!C+H($[-"B%;B,)"+AQ [A* M-'!33V]VT7!1M'#KPJ@ W'0O+OZ(FH22"5&FVH3PXA!Q 2[X K,Y!:%NH#&I M (";Q3' NJ@QK8?8@)?U)-F9"R ,HA_##/,P';E; MPL/PYN6H:PX($VT&C,]A>,"H9\SP=QS<"U'(/#17"YQJ"]E#:S;Y'6"/$9# MJ0Q(:4-(;BK$7U5M(,(8V %: WVAK@=P 3F8"(6@@'=O R^F"RXX@='J]AC% M]SB<%JF(@.ZS\!%OC".^YJ-(5*8_A)Z]"D6HJ,@XXE-AF*W4$PQI 5P2>*,4S[! #BT-K^D#UWC!#! (A*8MN$6 5PZA-Q>'S1PL^&XI/N>[+43>JE M T)HL/[E,[(6N*>1 @,.X/2&"X&!UI44" $X*![(5 $06 ,T6!.+>(,X ,M M@8@P\( Q8$@+-S(64!$WB(-#@HAK98$/Z(A)T&CJ#0$AL!%%&($2>(/D#N5M MB8.1((3A\'L9NHY%,,Y;!!Y"( $16)I,*($(Z.')4 /)JP#"] #0B2GS&73J M[Z\@,-B *-,!TZ=8)!FC8(UIU)@>$/&0!B$"/XYF+C3@D*I-09( MB$EXZM2$"FG0*(CS"0*G4AY6'&+QX12C!F/<;&A0ZDV#-6LB8#@UXL0I"1C< MC$F0:=,#,&]")#B8,,X#-7$FB.'$ L*9@T/_ @XL>#!AP9O<* ),*(Y049R& M9DHH*M,I#8C="$4(A]#?R) 3EHKCQJ^H.(U.-7HL*O$FOYS>)$9(67;AVK9O MX\ZM>S=OP!,XEUT$I\)?#&ALDF@QM(0740P6B2J%P4P!6P,90$A8X 6?Y_[B5XBB+R*6)=;Q^".)@&]?V568@GHIBB MBBN&2$$A"4G R!.0M1^4#$!$EADUN4/"7!FG$D<%\;@PU!G[@W?47="JH,%15IYA 5D0,HB"> M!4&\PX%>2]2W")B&1?MJNN^_"&Z^D#0!';RD6L$!H!=$E](%RIWP@ MG@D:'))& XJ(\H 7AZP0 &=<3$""" [DFL I(E1[2@C5PO& ""9 ,(9-TJEP M"!<2B((&NTE:$$<<#+C!20)-98#"(5_TMP@#\'U@@"B;5/"!"1A,10)9$$!8 MEDLB8&#"!Q,\EM ;OQ(RP8YTR9NUUEMSG;47IYWR]2F92)3"; K&H2!$I7SA M00C ,4("!VB(P0B:C00ZJ"A4J@$L&A#Y%_,)6P[%B40G4':(L(%I,,8))"AC%W3 M7KOMM^->N 5K-.(%GK6%P$(C;C3@$6\/I WB&!PP<@@%BQ/F/"&-R)F[]==C M;_VFFN8FE%"'F!#""6!3*M0F+(0P@AR"@58;%XEM;U.)0X$VA@@AD#%_8%++ MV8*Y]&Z&Q##"; M OT/1''PP%!4 +W;U IW/X3, OYFDY 6I.IV$DB>)#6BV #TLO,7 MN9SF((>@S"9<>(I%Q($TJ#&D**8'F#L.QC]_490?_]((.2B*$!!@A)-0J*$B MGN(0B.BD351@@BT2J(@'400H&<$9(6)/!!(( 8%:=XI-K XAEY(D)^+ 228C86+ 3BWQ72083@>2=XE>E" $'0+ !3HA"( ]0!!H8$($OE$($ M&_B !1+SA1!X@ 1Y,@$')C C"W#@("?8@ D&=;$X62 #CWD#!3Y0 1R18 /V M)*9-Q/Y @F8-**0AR !ERH !$D0 #:+@0 ,VD D2)*AI'XC *441 @R$X -D M+.6 ).)#7B QUH"@;@)(&B>F$"":W :=88KPV@P0().L2%S%"!$%1 9!=( M7@941X$38(!*:'";!Q1A 0?0,@4 !<$'0&"!L_D4!&#-!.M.X($&4$D4(D@H M!CCI 15(( VBZ( '&OL_15S@ QD0P2E<@(+((>\4:_@ )RS@UP=0Z10M *J9 M (98-&CBI1KP4E\]\ #EL$ Y'X 3!C @3D_%00$,R&%@*&""$'X J40T%"X M0)8$L$ 4/?R L%K0I%.(@3A>2,"91+$ ,YR""^6*)R$XWSW;\P@BE)B@,9IG**,(P@GLQ2!)46T;H-)(@!^;L5"6-U M,L"H8$"9"=AR3LD 86VBC3JC#"$. +;K9> -ATC )Q2A'T8PX#298( CB'N( M[>1K;/+QR1T.XH98I0?$0Q%#VA)"B ;,F!"B2$#:",$ #6FK!%22P ?$Z:Y .)"@"G"P%HO$WE$5< ( J.&EC'@"V1$B@%*(:"J++,)6$W/40 MFPOM[;"JJA$T0C]AF,I!>J2KRE:K)UP8P786])<7#X4$Y=% I!FY@0J<@#.- M:!WK'M.(+[1 CN:P/I*<=8\>U1:;!K*&I2%:"]\0:$42$T$#J(K,&5@TRV8 M64RL-8$-L("3N@(G>%A0K99EKEB>$@4<,S7'P%R "VY80QR\(P%'_.7/@:[1 MH+U05%'$R#Y,U),B&B $0GQA0,X^Q0;<@.F$X#,#+7 #&^*0F$.@ 0T> 8,* MT# @#/ZP8.1&;[48,H"!4BP":J> ]2D@D!A11& 3)@@MI!!L:!0^ .6A#/8$ M/%(*"&2BWW^)0",RD71XVFX#6!PU%X@#A@H=1-P?(<1$2I&!$*SA$,1!0Y,2 M NY3"'E<+FC &4_Q!A<(F!,/<+=PW?" +S#,!:>H0(TG$(:1$\*9AQ0NOTMU M@IQGP@1F:)*N-*%BE(3@#20_TUE*I 84*$#'<+^]Q0>?N97!2P(T+.:NA^*& MFJ3=)A^H"0N&.@;BN*"HG-@D=.TKH2\P2&.GS,"I>"Y3>CG)UUW*7!S_X@@- M;"!M+K!O'*S$4H3,K!$/>'6"]NDD"$R"C\7!(7" =61)"/[\#"<\A@?\BPD, M" 2,TMLA#.7Q%P)QUU#$1"9$# JL0 0L @B4'P=@ M5QM,@ ADA)-(5@A(0+UM$5BAT$\YHOQ) E<0+5TUKZ$0()TAY-,0&*,B0B, M0:P45P)(0 0\@ 5,!M&@H3A) /[\4(!'9$(( )@%K! $Y1VE)<0)T. 8)"(% M@ %D&$""E ():( )M$!8,8E-,,(#D)$)>$%G<8 (3$"-C0T&5.-O;$($/(8C M!)MVD "UJ)>>#,4F: '? %Q :!?!4='D1^" LA(, *L$ %G$W6M,9@%$(B(<1M%8ZYJ$YC7,HF2(:B M/&1I4$8C.(9?/&3DP 9@1&08_=&EA))$#L7PC!(*K1 ^W9)04%C2H($IGD(G M\)4C\)50Q($,F4\I9(+(W%(#V![VC"1D=,8;7*!&_L4A> 0GB!E%1@XGR>0I M$,(;4/[E4&2E.)4"1G/!6UF;"&$:Y9(9I3/!1V"2VR"!505;V9*_ CG_)1! MMO$&EPQ(<2)$!RR";A[0<@[G4*3 =4:)Y3';IE#*^@@1><#7^5 6F4P<)8"S-- M0 N Y"^-Z1?,AB)D0ARX "@U D.* 1DXT+N! M 64PDRB<@3@U A>P 8P&!B%X0?Z?CLTB!(@4C@T7K$'H-%!"B,!EG<(=7",A MQ&F20$#)$(( >($;0$ &K$$+3$#[A&%E'<#?/("P? 'IJ4$"Z%A8*8+19->S M3HT89(((1"$G*, FH$!110 AW.0AL =T0("&30"6J@J=CD':E8("@, ;:-CEZ4@%J$<<4)X7)$HF-, ':$ F'((#K("R#A673( 9S.F5 M)8 *M/Y ^Q(?,36!'0 !I& KG+ Y'""Q59&:$7+*8# CFP?19; @'#!HA&7 M \3& )9!!C@&(\0%&+37064J+<%<)BQ"!(12J43 &^!3&(I" YS!5#Z3?@R% M"8A'@PX%!&S"&$R%"I"%%_ : .&/8($ )Z0!&?W=*:C!4$& \4C 2Q)082[' M"91"P%Z,<@3?+7$&!7"&.99!DVC XHAHVPZ%" 36V%#74%# 9A#'J)W-&!P M!E1 !,2<%X3?B&6"'!C/;^R8%/)1&8'94*2!KLP0GDSQ=,A1EL )K$8HVDK@$Y,$*$[@AW$AHH"QH\0 64 M "S>KAJ40AET[3ZAR19*(T)$7C"U!YK<2%DTPAH\K;[:+3Z)@7 Q%Y)@G!>( M0 G0R_;)Q1JB2;(8U:Z%0.>!&1OXVXN$QO8RT#@.!8!)"\]A$0F6BL;0KP1X M);:<4OX6%UGXGPE^$*9ZA,L5UTGM(40/X+E8 '4,;H&AM"L"-"5("9"E#;#86Q;>&, M?8!CA!+& MKM0D3N=AUP+()^C%VOV,2Z"87@K0 7F( )<(LHIV"HX$\7ZF//Y$E!")%3F.,"E?111U,?4 MU/&.9(("G$T(T)(*M-<*5(COQ %+1)/*%L+0B!83M0 9E0$#+"P#),8B),!0 M'6$2: [WH7\1!4.7/*8R!\3#"XI0! M9W""E?Q%&E#:&^1Q'%":"?)S\L@H QZ$9&?.<7 JSDUP %)'@XH !B8)52?$&E0 M!ER !9C ;*0!!F2 !YR&'&" !W@!>V4"")#&T(! "V3,+?X331F@ !<<0E'% M04^=P 7 ['[+YF&.T7?MS59RIM>5 L0ZN(,#$88.QD44SB'XVFY K(5'SO9X M>.&H9O:,.'-FJ&TL)_MD:(ISCTVT0 DH"G;RYF",>.U\ "A-D D^ (5R38TG M^(\#.0(%.;SX.&+*>((7N:0D^9 S>9,[N6PB22FH 2Q-2NZ(YQI6$L.6XH+51"I3IQ2BE0P2EM0HBU2YB/$.Q^ M" F0" (5SV9VS5]9'08 9HTG1 AIB"WE1B94 6 %C$N(I4 $2P0/+038^; M\QYS"L=Y0#A-@"9 )?TDOYI=!-+JJ6Y8%,O76 +?=,M5>9%1HZJ3U$< M* J_V,VP8:4U)$L)+"M'D4!8%1<&*")GM,\8 MM)?B;04%D( %T*\&H.?!BL4)"*--B$)(@4 %[&<%),0AE,H76$#"I\VTN4W7 M,<)3H^<&V)X V^($IA"P0^ M&@P^!JS0"2@"&30 !:1!?$C GR@"!R"D\?#]!H@ 5:Z @4XZ"U" "#Q&Y2,D M9Q ">4B "K@!!RC?.GN!;0)'Z- A99!!SIE -8\]B H&&% 6P+I$(URH(1 M#17D;" :(6BXC!\%Y))A#"OR#(ULUP1)"1!ZR_"C1)C!I 8A@K%@]%5_X#A@>(A\:8P0@G M1(8!!!H+ITZ-$7$* B-%$0@VDE!*Q<%3+C@1M'@18T:-&PEZL'#"! DN!%M\ M0.0@4RD.8DYEFL!(U(,UHM(T*/7!"T$,9421()&)$8-3)%2<>-#H$ $NG$200.AFTX4OG$2A M")&)$X4XIPAM-20ATRDO$@E6\+")# $WG"24*37A#=\*I>(0B+,) H=,-4_% M,8"&$QJ;BB0T.B5F:HL#:!J5&BF@9<67!2T MT2J\18),A#Q\&*GT%&!"#(1[8?Y0YM0A+BP"I0R0(D R"%AF((%&\ ML@BJ"@C9A*$-S*#J*0D<&4,"X;@X0)%%(-B@!4-(( Y"+B#H@S-: C ."$^A0+L- E6C %&X M<(NO!_Y8>$,4%L$X:)/2;H. $SFV.F4-"0*-XQ!.5O#@UD-*:40-->3HC%C/"!P-@,S L5RE O TNA"@PP,3"X59&* M1%'C!!M;G+A%#&@L[Q05#KC1*B^XX$*,16ICTZ(0Q(#* ^Q40 ''"%)]Z8,X M&J'NXS$*H4H- *EB9*H/PB@EU0H.60'+3"1@Y)0RT#2AA9:.3IJ#4RJ(#+PZ MW2(C1"&X(*.1$S;X^ O0++J /"NA(B$,-Q[P>.M&WICT2/[L&'G@E#?03'7A M%C+PPH4916E!A5*@6D0%#"2X<3;!/C@%,],V0G8,$)/C *433 M7V^H')L>@*]3B*!;7HA:2Q@@"A4T;1/L@1I7,*C!,D1M:J? @!M(PC)"Z,Q, MHD"-12XVPE/( 4(E^,+D6"B*-_YH+V6G: 2F*OB4!CCB#*T[Q89:D *"C&$O M#U0/1PBQ !2(8@*!88PH"*$I-D@ !!5( 52X,($0- MC5"'# E)U"C=@L0(G M*$6MB'("#)1"0!@1A0@T$ *A$80,RB&(%[SH(\&0"HJ9Z%$;+="3#(C@ Q/ M3P@T,((/4 _'TA#(_9UB%D1@@/ITI[D,."!#FR@(J,$#;V0#@DZ1 77]LC,'* $7,. 646S UZ@@'I.4 *"K&$!'X,,BS8A MQ=7EIA2A),@F?'F11L3!7QDY@1%7QXF:2HX0J4*:*,J($43(X7PQM2E.(U34 M31PLJ*= F@?2P(@XK,Y <2@C71A7GMS$P5IFVJ1%"$$(:IF/((K0ZDQ7)\B< MBB)2Y[-E+0^Q(S:X00V:L)]%4)6=K175#5P(*U^\H A%F&:-A"B%8@ER&8MH M9PQ%M8@HT, %-!2U%&;@@EG;A1\JI@HMG6535#-A"+[DYOX3:'!**91%D#=P MP3OEJ6P2R1J837 6$96+@V6!2I!#F :N+2D1;"\R6P?)!D=?X (BYMK4!=&/M @R;&B M\8 03,*MUR4J!#4BV1>2E[GK9VU[WOA>^ M\94OQ4J1J_FZ-Q/HQ4OZ#A'5C)Q/%+ZZ[WRA4N#_8LRZ"5;OBA;,H0.GK\$; M,3"%$E==!ZQE/[1*D?((I=&[Z0O(M*U(Q<&FB@_O.J7]S@5>F9()R !5G M=9L0P/0GAWB1!LQ:!B^88 2E^$DI6."!#6SN RP@005*0-2$U"T#&OA HNF9 M 1)4I!$?V(#%V'2"92ZL!!)@F2*\;8$*D*&Q&/JWE!(<@V&!21J$4ON @(, IQF!+,$"!!B)50J ,PL " - , M.D$,)N]VS 2?W$(,*D %2.Y&_.T4#*$"&D=PW 4$C 1&O(E>" $%*J "+F[[ M;O##)("$GJ)1$*(W-(4@2N $#B(.%J"QML(%EL@^1 $#C 0#VL!XI <,H@8" M.H'D6,C 3F")V* $-H$!_$4#6((!3X$,%J>BW* 1$B"4'N 0WJ#6L.,+1H @ MOL MC(A-%* 1KH(@Z$>5#@%!N/[M%+X 33X@NT! 7:!"$1"$"RJG B .!Q^Q MP]R 4:!*KRF%!; IU (*MX +S#(5C "TB 0B!"R9/2C;A"RK@"UK ,%1" M EK !1A Z!@ :;2-"YCM(C(AC;C@ >A$I+S _8"& 9Q"#(9):M!0 4* "T"* M($(@ [C N20"[9D&@-$F4: ]K/ [Y !2 2S8 E11!*$ZH!5@ FYD _8G M';U)*,2@ ;B@!21@@2"1'N5KKRQ"D!8KIA"'0M:J)<8 #18+$3(!<18K5=Y M#!3A8;(C$]: "][,OQR2MB:+# J+K"QK=:+*$1#G0@P! QAA1L['(2-#AX8O MM,R("_YX@DW08 RFCH0V 0WRB[,DT94R L8 >9R<39;8I3@8'5$H4\HI6E&D2!.P#8.B/ZS4.#W-* $8\6D MK(L3QL %;D2%)& -(&T,,"\WM.,VGR*HR@ _ZE(-&D$V&($+SE,1,B $.*LU M6[,%+ ,/B #ZJL!QF ,V.. /( +PHTN&H #"K1,A.#A0L"C,$ $),@!).V; MQ !K%(*7O" YU4 44(8+%L*;Z";DYHYN/("$:O #+HTI5. +(N ,1.$$' % M)H'0S&)TTN !*BM_2D$"-B VXB XN* !3"H.)D ,;K'X)& G[K,U%:$!R@@% M_)*SJN44%"")." G%N!*;_-)"8(!TT![#D&/YHZS-&!#RF#R,F(%&H 3UF K M!JD1*M!@F)+J"T# +$B(-P0G#J.#$SC5!.2 4K 07M)!8H":"A MTDK!]\PB/,+@ ]ZRL28 ! )##:!'$5#3#9X$$<]#APJ!$SY@$9HBCG2B#02' M1QF!ZD+)% H-S:A!42@!"@G.H;J: 3'#$SJ (@#J;"#-R"$C> ?6)B$QQ"LAB!HBJ !0)C,*-#-C[G.;4U MJ#B!$_X"HP0>55S+4A0J P^X5%R9R0( 0&P0P%48!/$<2^X U, P0\(!-.PC]"P&H1(4>I M@CFR8\]DZ!0H<0T@8!$XP02FPGLN=A1C@@U*00T,P*P:8/B PPN\X %81@4X M@!,VH0,:A 3N(F7-DA'X$P*S@P-""@VF[0)8@4R(/X#6@ J^F)_!E=E MY2C3V/0M.X%-.]1ZNS !YB "]B #QB!$UB!%YB!&]B!'QB" M(UB")YB"*]B"+QB#,[B 5^?..$16.YB#-:S \(R$PPB$/1C!J,+ 0EB%6]B% M0YB#2_B%1?@I9'B&9[B#6WB%45B'49B%[TR&<]B';3B'BYB'@9C"8'BZ8)B( MC]B'G7B'C7B';QB)I5*#K[C'X, -W. -N+B+NWB+N=B+M_B+R=B,P1B,Q7B, MUUB-SSB-Q5AJSSB,XUB.X7B.T[NXC.>8C>$8C=6XC_O8C->8CMN8C\.XD.V8 MC/'8C]MXD//8C0WYB_\XD/-8D06YDA]9CP?YD#&9DNNXDNFXD2%YCR.YCMFX MD_%8D=^8E#/YC]_8D%\9EF-9EF>9EFO9EF\9EW-9EW>9EWO9EW\9F(-9F(>9 MF(49BX^9QW[8B1U,F9>YF949FE/8F4V8FJ&XF@WSF:]9FZGXB:?9FZ-YF;]Y =F[,9G)4XG+-9G*VYFXTXG-YQ@(" #L! end XML 68 R1.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Document and Entity Information
    		 12 Months Ended
    Dec. 31, 2017
    shares
    Document Information [Line Items]  
    Document Type 6-K
    Amendment Flag false
    Document Period End Date Dec. 31, 2017
    Document Fiscal Year Focus 2017
    Document Fiscal Period Focus FY
    Trading Symbol NVS
    Entity Registrant Name NOVARTIS AG
    Entity Central Index Key 0001114448
    Current Fiscal Year End Date --12-31
    Entity Well-known Seasoned Issuer Yes
    Entity Current Reporting Status Yes
    Entity Voluntary Filers No
    Entity Filer Category Large Accelerated Filer
    Entity Common Stock, Shares Outstanding 2,317,456,499

    XML 69 R2.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Consolidated income statements
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2015
    USD ($)
    $ / shares
    Statement [line items]  
    Net sales to third parties from continuing operations $ 49,414
    Sales to discontinued segments 26
    Net sales from continuing operations 49,440
    Other revenues 947
    Cost of goods sold (17,404)
    Gross profit from continuing operations 32,983
    Marketing and Sales (11,772)
    Research and Development (8,935)
    General and Administration (2,475)
    Other income 2,049
    Other expense (2,873)
    Operating income from continuing operations 8,977
    Income from associated companies 266
    Interest expense (655)
    Other financial income and expense (454)
    Income before taxes from continuing operations 8,134
    Taxes (1,106)
    Net income from continuing operations 7,028
    Net income/loss from discontinued operations 10,766
    Net income 17,794
    Attributable to  
    Shareholders of Novartis AG 17,783
    Non-controlling interests $ 11
    Basic earnings per share [abstract]  
    Basic earnings per share, Continuing operations | $ / shares $ 2.92
    Basic earnings per share, Discontinued operations | $ / shares 4.48
    Total basic earnings per share | $ / shares 7.40
    Diluted earnings per share [abstract]  
    Diluted earnings per share, Continuing operations | $ / shares 2.88
    Diluted earnings per share, Discontinued operations | $ / shares 4.41
    Total diluted earnings per share | $ / shares $ 7.29
    XML 70 R3.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Consolidated statements of comprehensive income - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Statement [line items]      
    Net income $ 7,703 $ 6,698 $ 17,794
    Other comprehensive income to be eventually recycled into the consolidated income statement      
    Fair value adjustments on marketable securities, net of taxes 38 (113) 28
    Fair value adjustments on deferred cash flow hedges, net of taxes 12 15 20
    Total fair value adjustments on financial instruments, net of taxes 50 (98) 48
    Share of other comprehensive income of associates and joint ventures accounted for using equity method that may be reclassified to profit or loss, net of tax (37) 671 (48)
    Net investment hedge (237)    
    Currency translation effects 2,210 (2,391) (1,662)
    Total of items to eventually recycle 1,986 (1,818) (1,662)
    Other comprehensive income never to be recycled into the consolidated income statement      
    Actuarial gains/losses from defined benefit plans, net of taxes 851 (515) (147)
    Total comprehensive income 10,540 4,365 15,985
    Attributable to      
    Shareholders of Novartis AG 10,538 4,382 15,977
    Comprehensive income, attributable to non-controlling interests 2 (17) 8
    Continuing operations      
    Attributable to      
    Shareholders of Novartis AG $ 10,538 $ 4,382 5,238
    Discontinued operations      
    Attributable to      
    Shareholders of Novartis AG     $ 10,739
    XML 71 R4.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Consolidated balance sheets - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Non-current assets [abstract]    
    Property, plant and equipment $ 16,464 $ 15,641
    Goodwill 31,750 30,980
    Intangible assets other than goodwill 29,997 31,340
    Investments in associated companies 15,370 14,304
    Deferred tax assets 8,229 10,034
    Financial assets 2,243 2,196
    Other non-current assets 818 698
    Total non-current assets 104,871 105,193
    Current assets [abstract]    
    Inventories 6,867 6,255
    Current trade receivables 8,600 8,202
    Income tax receivable 202 156
    Marketable securities, commodities, time deposits and derivative financial instruments 625 770
    Cash and cash equivalents 8,860 7,007
    Other current assets 3,054 2,541
    Total current assets 28,208 24,931
    Total assets 133,079 130,124
    Equity [abstract]    
    Share capital 969 972
    Treasury shares (100) (76)
    Reserves 73,299 73,936
    Issued share capital and reserves attributable to Novartis AG shareholders 74,168 74,832
    Non-controlling interests 59 59
    Total equity 74,227 74,891
    Non-current liabilities [abstract]    
    Financial debts 23,224 17,897
    Deferred tax liabilities 5,168 6,657
    Provisions and other non-current liabilities 7,057 8,470
    Total non-current liabilities 35,449 33,024
    Current liabilities [abstract]    
    Trade payables 5,169 4,873
    Financial debts and derivative financial instruments 5,308 5,905
    Current income tax liabilities 1,723 1,603
    Provisions and other current liabilities 11,203 9,828
    Total current liabilities 23,403 22,209
    Total liabilities 58,852 55,233
    Total equity and liabilities $ 133,079 $ 130,124
    XML 72 R5.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Consolidated statements of changes in equity - USD ($)
    $ in Millions
    Total
    Equity attributable to owners of parent [member]
    Share capital
    Treasury shares
    Retained earnings
    Total value adjustments
    Non-controlling interests [member]
    Equity at beginning of period at Dec. 31, 2014 $ 70,844 $ 70,766 $ 1,001 $ (103) $ 72,433 $ (2,565) $ 78
    Net income 17,794 17,783     17,783   11
    Other comprehensive income (1,809) (1,806)     (48) (1,758) (3)
    Total comprehensive income 15,985 15,977     17,735 (1,758) 8
    Dividends (6,643) (6,643)     (6,643)    
    Purchase of treasury shares (6,119) (6,119)   (33) (6,086)    
    Reduction of share capital     (10) 15 (5)    
    Exercise of options and employee transactions 1,592 1,592   14 1,578    
    Equity-based compensation 815 815   6 809    
    Decrease of treasury share repurchase obligation under a share buyback trading plan 658 658     658    
    Changes in non-controlling interests (10)           (10)
    Fair value adjustments related to divestments         (100) 100  
    Total of other equity movements (9,707) (9,697) (10) 2 (9,789) 100 (10)
    Equity at end of period at Dec. 31, 2015 77,122 77,046 991 (101) 80,379 (4,223) 76
    Net income 6,698 6,712     6,712   (14)
    Other comprehensive income (2,333) (2,330)     671 (3,001) (3)
    Total comprehensive income 4,365 4,382     7,383 (3,001) (17)
    Dividends (6,475) (6,475)     (6,475)    
    Purchase of treasury shares (992) (992)   (7) (985)    
    Reduction of share capital     (19) 25 (6)    
    Exercise of options and employee transactions 214 214   2 212    
    Equity-based compensation 664 664   5 659    
    Impact of change in ownership of consolidated entities (7) (7)     (7)    
    Fair value adjustments related to divestments         (12) 12  
    Total of other equity movements (6,596) (6,596) (19) 25 (6,614) 12  
    Equity at end of period at Dec. 31, 2016 74,891 74,832 972 (76) 81,148 (7,212) 59
    Net income 7,703 7,703     7,703    
    Other comprehensive income 2,837 2,835     (37) 2,872 2
    Total comprehensive income 10,540 10,538     7,666 2,872 2
    Dividends (6,495) (6,495)     (6,495)    
    Purchase of treasury shares (5,574) (5,574)   (36) (5,538)    
    Reduction of share capital     (3) 5 (2)    
    Exercise of options and employee transactions 255 255   2 253    
    Equity-based compensation 612 612   5 607    
    Changes in non-controlling interests (2)           (2)
    Total of other equity movements (11,204) (11,202) (3) (24) (11,175)   (2)
    Equity at end of period at Dec. 31, 2017 $ 74,227 $ 74,168 $ 969 $ (100) $ 77,639 $ (4,340) $ 59
    XML 73 R6.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Consolidated cash flow statements - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Statement [line items]      
    Net income from continuing operations $ 7,703 $ 6,698 $ 7,028
    Reversal of non-cash items 7,058 8,437 9,070
    Dividends received from associated companies 987 899 432
    Interest received 97 43 34
    Interest paid (708) (723) (646)
    Other financial receipts     714
    Other financial payments (272) (155) (23)
    Taxes paid (1,611) (2,111) (2,454)
    Cash flows before working capital and provision changes from continuing operations 13,254 13,088 14,155
    Payments out of provisions and other net cash movements in non-current liabilities (877) (1,536) (1,207)
    Change in net current assets and other operating cash flow items 244 (77) (863)
    Cash flows from operating activities from continuing operations 12,621 11,475 12,085
    Cash flows used in operating activities from discontinued operations     (188)
    Total cash flows from operating activities 12,621 11,475 11,897
    Purchase of property, plant and equipment (1,696) (1,862) (2,367)
    Proceeds from sales of property, plant and equipment 92 161 237
    Purchase of intangible assets (1,050) (1,017) (1,138)
    Proceeds from sales of intangible assets 640 847 621
    Purchase of financial assets (468) (247) (264)
    Proceeds from sales of financial assets 330 247 166
    Purchase of other non-current assets (42) (149) (82)
    Proceeds from sales of other non-current assets 1   1
    Divestments of interests in associated companies 29    
    Acquisitions and divestments of businesses, net (784) (765) (16,507)
    Purchase of marketable securities and commodities (580) (530) (595)
    Proceeds from sales of marketable securities and commodities 549 622 262
    Cash flows used in investing activities from continuing operations (2,979) (2,693) (19,666)
    Cash flows used in/from investing activities from discontinued operations (140) (748) [1] 8,882 [2]
    Total cash flows used in/from investing activities (3,119) (3,441) (10,784)
    Dividends paid to shareholders of Novartis AG (6,495) (6,475) (6,643)
    Acquisition of treasury shares (5,490) (1,109) (6,071)
    Proceeds from exercise options and other treasury share transactions 252 214 1,581
    Proceeds from non-current financial debts 4,933 1,935 4,596
    Repayment of non-current financial debts (188) (1,696) (3,086)
    Change in current financial debts (755) 1,816 451
    Impact of change in ownership of consolidated entities 0 (6) 0
    Dividends paid to non-controlling interests and other financing cash flows 10 7 (4)
    Cash flows used in financing activities (7,733) (5,314) (9,176)
    Effect of exchange rate changes on cash and cash equivalents 84 (387) (286)
    Net change in cash and cash equivalents 1,853 2,333 (8,349)
    Cash and cash equivalents at beginning of period 7,007 4,674 13,023
    Cash and cash equivalents at end of period $ 8,860 $ 7,007 $ 4,674
    [1] In 2016, the total net tax payment amounted to USD 2,299 million, of which USD 188 million was included in the cash flows used in investing activities from discontinued operations.
    [2] In 2015, the total net tax payment amounted to USD 3,325 million, of which a refund of USD 94 million was included in the cash flows used in operating activities from discontinued operations, and a USD 965 million payment in the cash flows from investing activities of discontinued operations.
    XML 74 R7.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Consolidated cash flow statements (Parenthetical) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2016
    Dec. 31, 2015
    Statement [line items]    
    Income taxes (paid)/refund $ (2,299) $ (3,325)
    Income taxes refund/(paid), classified as operating activities (2,111) (2,454)
    Discontinued operations [member]    
    Statement [line items]    
    Income taxes (paid)/refund, classified as investing activities $ (188) (965)
    Income taxes refund/(paid), classified as operating activities   $ 94
    XML 75 R8.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Significant accounting policies
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Significant accounting policies
    1. Significant accounting policies
    The Novartis Group (Novartis or Group) is a multinational group of companies specializing in the research, development, manufacturing and marketing of a broad range of healthcare products led by innovative pharmaceuticals and also including eye care products and cost-saving generic pharmaceuticals. It is headquartered in Basel, Switzerland.
    The consolidated financial statements of the Group are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB). They are prepared in accordance with the historical cost convention except for items that are required to be accounted for at fair value.
    The Group’s financial year-end is December 31, which is also the annual closing date of the individual entities’ financial statements incorporated into the Group’s consolidated financial statements.
    The preparation of financial statements requires management to make certain estimates and assumptions, either at the balance sheet date or during the year that affect the reported amounts of assets and liabilities, including any contingent amounts, as well as of revenues and expenses. Actual outcomes and results could differ from those estimates and assumptions.
    Listed below are accounting policies of significance to Novartis or, in cases where IFRS provides alternatives, the option adopted by Novartis.
    Scope of consolidation
    The consolidated financial statements include all entities, including structured entities, over which Novartis AG, Basel, Switzerland, directly or indirectly has control (generally as a result of owning more than 50% of the entity’s voting interest). Consolidated entities are also referred to as “subsidiaries”.
    In cases where Novartis does not fully own a subsidiary, it has elected to value any remaining outstanding non-controlling interest at the time of acquiring control of the subsidiary at its proportionate share of the fair value of the net identified assets.
    The contribution of a business to an associate or joint venture is accounted for by applying the option under IFRS that permits the accounting for the retained interest of the business contributed at its net book value at the time of the contribution.
    Investments in associated companies (generally defined as investments in entities in which Novartis holds between 20% and 50% of voting shares or over which it otherwise has significant influence) and joint ventures are accounted for using the equity method, except for selected venture fund investments for which the Group has elected to apply the method of fair value through the consolidated income statement.
    Foreign currencies
    The consolidated financial statements of Novartis are presented in US dollars (USD). The functional currency of subsidiaries is generally the local currency of the respective entity. The functional currency used for the reporting of certain Swiss and foreign finance entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in these currencies.
    For subsidiaries not operating in hyperinflationary economies, the subsidiary’s results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates:
    • Income, expense and cash flows using for each month the average exchange rate with the US dollar values for each month being aggregated during the year.
    • Balance sheets using year-end exchange rates.
    • Resulting exchange rate differences are recognized in other comprehensive income.
    The only hyperinflationary economy applicable to Novartis is Venezuela. The financial statements of the major subsidiaries in this country are first adjusted for the effect of inflation, with any gain or loss on the net monetary position recorded in the related functional lines in the consolidated income statement and then translated into USD.
    Acquisition of assets
    Acquired assets are initially recognized on the balance sheet at cost if they meet the criteria for capitalization. If acquired as part of a business combination, the fair value of identified assets represents the cost for these assets. If separately acquired, the cost of the asset includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment when it is no longer used are included in their cost.
    Property, plant and equipment
    Property, plant and equipment are depreciated on a straight-line basis in the consolidated income statement over their estimated useful lives. Leasehold land is depreciated over the period of its lease, whereas freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset.
    Property, plant and equipment are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life.
    The following table shows the respective useful lives for property, plant and equipment:
    Useful life
    Buildings
    20 to 40 years
    Machinery and other equipment
    Machinery and equipment
    7 to 20 years
    Furniture and vehicles
    5 to 10 years
    Computer hardware
    3 to 7 years
    Government grants obtained for construction activities, including any related equipment, are deducted from the gross acquisition cost to arrive at the balance sheet carrying value of the related assets.
    Goodwill and intangible assets
    Goodwill
    Goodwill arises in a business combination and is the excess of the consideration transferred to acquire a business over the underlying fair value of the net identified assets acquired. It is allocated to groups of cash-generating units (CGUs) which are usually represented by the reported segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under “Other Expense” in the consolidated income statement.
    Intangible assets available-for-use
    Novartis has the following classes of available-for-use intangible assets: Currently marketed products; Marketing know-how; Technologies; Other intangible assets (including computer software) and the Alcon brand name.
    Currently marketed products represent the composite value of acquired intellectual property, patents, and distribution rights and product trade names.
    Marketing know-how represents the value attributable to the expertise acquired for marketing and distributing Alcon surgical products.
    Technologies represent identified and separable acquired know-how used in the research, development and production processes.
    Significant investments in internally developed and acquired computer software are capitalized and included in the “Other” category and amortized once available for use.
    The Alcon brand name is shown separately, as it is the only Novartis intangible asset that is available for use with an indefinite useful life. Novartis considers that it is appropriate that the Alcon brand name has an indefinite life since Alcon-branded products have a history of strong revenue and cash flow performance, and Novartis has the intent and ability to support the brand with spending to maintain its value for the foreseeable future.
    Except for the Alcon brand name, intangible assets available for use are amortized over their estimated useful lives on a straight-line basis and evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable. The Alcon brand name is not amortized, but evaluated for potential impairment annually.
    The following table shows the respective useful lives for available-for-use intangible assets and the location in the consolidated income statement in which the respective amortization and any potential impairment charge is recognized:




    Useful life
    Income statement location

    for amortization and

    impairment charges
    Currently marketed products
    5 to 20 years
    "Cost of goods sold"
    Marketing know-how
    25 years
    "Cost of goods sold"
    Technologies
    10 to 20 years



    "Cost of goods sold"

    or "Research

    and Development"
    Other (including

    computer software)
    3 to 7 years

    In the respective

    functional expense
    Alcon brand name
    Not amortized,

    indefinite useful life
    Not applicable

    Intangible assets not yet available-for-use
    Acquired research and development intangible assets, which are still under development and have accordingly not yet obtained marketing approval, are recognized as In-Process Research & Development (IPR&D).
    IPR&D is not amortized, but evaluated for potential impairment on an annual basis or when facts and circumstances warrant. Any impairment charge is recorded in the consolidated income statement under “Research & Development”. Once a project included in IPR&D has been successfully developed, it is transferred to the “Currently marketed products” category.
    Impairment of goodwill and intangible assets
    An asset is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value in use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates.
    Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGUs, and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset.
    The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group’s activities with regard to:
    • Amount and timing of projected future cash flows
    • Long-term sales forecasts for periods of up to 25 years
    • Actions of competitors (launch of competing products, marketing initiatives, etc.)
    • Sales erosion rates after the end of patent or other intellectual property rights protection and timing of the entry of generic competition
    • Outcome of R&D activities (compound efficacy, results of clinical trials, etc.)
    • Amount and timing of projected costs to develop IPR&D into commercially viable products
    • Probability of obtaining regulatory approval
    • Future tax rate
    • Appropriate royalty rate for the Alcon Brand name
    • Appropriate terminal growth rate
    • Appropriate discount rate
    Generally, for intangible assets with a definite useful life Novartis uses cash flow projections for the whole useful life of these assets. For goodwill and the Alcon brand name, Novartis generally utilizes cash flow projections for a five-year period based on management forecasts, with a terminal value based on cash flow projections usually in line with inflation rates for later periods. Probability-weighted scenarios are typically used.
    Discount rates used consider the Group’s estimated weighted average cost of capital, adjusted for specific country and currency risks associated with cash flow projections to approximate the weighted average cost of capital of a comparable market participant.
    Due to the above factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques.
    Impairment of associated companies accounted for at equity
    Novartis considers investments in associated companies for impairment evaluation whenever objective evidence indicates the net investment may be impaired, including when a quoted share price indicates a fair value less than the per-share balance sheet carrying value for the investment.
    If the recoverable amount of the investment is estimated to be lower than the balance sheet carrying amount an impairment charge is recognized for the difference in the consolidated income statement under “Income from associated companies”.
    Cash and cash equivalents, marketable securities, commodities and non-current financial assets
    Cash and cash equivalents include highly liquid investments with original maturities of three months or less, which are readily convertible to known amounts of cash. Bank overdrafts are usually presented within current financial debts on the consolidated balance sheet, except in cases where a right of offset has been agreed with a bank, which then allows for presentation on a net basis.
    Marketable securities are financial assets consisting principally of equity and debt securities as well as fund investments. Marketable securities held for short-term purposes are principally traded in liquid markets and are classified as marketable securities on the consolidated balance sheet. Marketable securities held for long-term strategic purposes are classified as non-current financial assets on the consolidated balance sheet.
    Marketable securities are initially recorded at fair value on their trade date, which is different from the settlement date when the transaction is ultimately effected. Quoted securities are re-measured at each reporting date to fair value based on current market prices. If the market for a financial asset is not active or no market is available, fair values are established using valuation techniques. The majority of non-quoted investments are valued initially at fair value through the established purchase price between a willing buyer and seller. Non-quoted investments are subsequently adjusted based on values derived from using discounted cash flow analysis or other pricing models. These investment values are what is known as “Level 3” in the fair value hierarchy.
    The Group has classified all its equity and quoted debt securities as well as fund investments as available-for-sale, as they are not acquired to generate profit from short-term fluctuations in price. Unrealized gains, except exchange gains related to quoted debt instruments, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are recognized in the consolidated income statement when the financial asset is sold, at which time the gain is transferred either to “Other financial income and expense”, for the marketable securities held for short-term non-strategic purposes, or to “Other income”, for all other equity securities and fund investments. Exchange gains related to quoted debt instruments are immediately recognized in the consolidated income statement under “Other financial income and expense”.
    A security is assessed for impairment when its market value at the balance sheet date is less than initial cost reduced by any previously recognized impairment. Impairments on equity securities, quoted debt securities and fund investments, and exchange rate losses on quoted debt securities in a foreign currency that are held for short-term non-strategic purposes are recorded in “Other financial income and expense”. Impairments are recorded for all other equity securities and other fund investments in “Other expense” in the consolidated income statement.
    Commodities include gold bullion or coins which are valued at the lower of cost or fair value using current market prices. The changes in fair value below cost are immediately recorded in “Other financial income and expense”.
    Other non-current financial assets, including loans held for long-term strategic purposes, are carried at amortized cost, which reflects the time value of money less any allowances for uncollectable amounts. For these financial assets, impairments and exchange rate losses are included in “Other expense” in the consolidated income statement and exchange rate gains and interest income using the effective interest rate method are included in “Other income” in the consolidated income statement.
    Derivative financial instruments
    Derivative financial instruments are initially recognized in the balance sheet at fair value and are re-measured to their current fair value at the end of each subsequent reporting period. The valuation of a forward exchange rate contract is based on the discounted cash flow model, using interest curves and spot rates at the reporting date as observable inputs.
    Options are valued based on a modified Black-Scholes model using volatility and exercise prices as major observable inputs.
    The Group utilizes derivative financial instruments for the purpose of hedging to reduce the volatility in the Group’s performance due to the exposure of various types of business risks. To mitigate these risks, the Group enters into certain derivative financial instruments. The risk reduction is obtained because the derivative’s value or cash flows are expected, wholly or partly, to offset changes in the value or cash flows of the recognized assets or liabilities. The overall strategy is aiming to mitigate the currency and interest exposure risk of positions that are contractually agreed and to partially mitigate the exposure risk of selected anticipated transactions.
    Certain derivative financial instruments meet the criteria for hedge accounting treatment. A prerequisite for obtaining this accounting-hedge relationship is extensive documentation on inception and proving on a regular basis that the economic hedge is effective for accounting purposes. Other derivative financial instruments do not meet the criteria to qualify for hedge accounting. Changes in the fair value of those derivative instruments are recognized immediately in “Other financial income and expense” in the consolidated income statement.
    In addition, the Group has designated certain long-term debt components as hedges of the translation risk arising on certain net investments in foreign operations. On consolidation, foreign currency differences arising on long-term debt designated as net investment hedges of a foreign operation are recognized in other comprehensive income and accumulated in currency translation effects, to the extent that the hedge is effective. The foreign currency differences arising from hedge ineffectiveness are recognized in the income statement in “Other financial income and expense”.
    When a hedged net investment is disposed of, the proportionate portion of the cumulative amount recognized in equity in relation to the hedged net investment is transferred to the income statement as an adjustment to the profit or loss on disposal.
    Inventories
    Inventory is valued at acquisition or production cost determined on a first-in first-out basis. This value is used for the “Cost of goods sold” in the consolidated income statement. Unsalable inventory is fully written off in the consolidated income statement under “Cost of goods sold”.
    Trade receivables
    Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as rebates, chargebacks and cash discounts.
    Provisions for doubtful trade receivables are established once there is an indication that it is likely that a loss will be incurred. These provisions represent the difference between the trade receivable’s carrying amount in the consolidated balance sheet and the estimated net collectible amount. Significant financial difficulties of a customer, such as probability of bankruptcy, financial reorganization, default or delinquency in payments are considered indicators that recovery of the trade receivable is doubtful. Charges for doubtful trade receivables are recognized in the consolidated income statement within “Marketing & Sales” expenses.
    Legal and environmental liabilities
    Novartis and its subsidiaries are subject to contingencies arising in the ordinary course of business such as patent litigation, environmental remediation liabilities and other product-related litigation, commercial litigation, and governmental investigations and proceedings. Provisions are recorded where a reliable estimate can be made of the probable outcome of legal or other disputes against the subsidiary.
    Contingent consideration
    In a business combination or divestment of a business, it is necessary to recognize contingent future payments to previous owners, representing contractually defined potential amounts as a liability or asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at their fair value, which is then re-measured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance and are adjusted for the probability of their likelihood of payment, and if material, are appropriately discounted to reflect the impact of time.
    Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in “Cost of goods sold” for currently marketed products and in “Research & Development” for IPR&D. Changes in contingent consideration assets are recognized in “Other income” or “Other expense”, depending on its nature.
    The effect of unwinding the discount over time is recognized for contingent liabilities in “Interest expense” and for contingent assets in “other financial income and expense” in the consolidated income statement.
    Defined benefit pension plans and other post-employment benefits
    The liability in respect of defined benefit pension plans and other post-employment benefits is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions where the associates are employed, while the net interest on the net defined benefit liability or asset is recognized as “Other expense” or “Other income”.
    Treasury shares
    Treasury shares are initially recorded at fair value on their trade date which is different from the settlement date, when the transaction is ultimately effected. Treasury shares are deducted from consolidated equity at their nominal value of CHF 0.50 per share. Differences between the nominal amount and the transaction price on purchases or sales of treasury shares with third parties, or the value of services received for the shares allocated to associates as part of share-based compensation arrangements, are recorded in “Retained earnings” in the consolidated statement of changes in equity.
    Revenue recognition
    Revenue
    Revenue is recognized on the sale of Novartis Group products and services and recorded as “Net sales” in the consolidated income statement when there is persuasive evidence that a sales arrangement exists; title, risks and rewards for the products are transferred to the customer; the price is determinable; and collectability is reasonably assured. When contracts contain customer acceptance provisions, sales are recognized upon the satisfaction of acceptance criteria. If products are stockpiled at the request of the customer, revenue is only recognized once the products have been inspected and accepted by the customer, and there is no right of return or replenishment on product expiry.
    Surgical equipment may be sold together with other products and services under a single contract. The total consideration is allocated to the separate elements based on their relative fair values. Revenue is recognized once the recognition criteria have been met for each element of the contract.
    For surgical equipment, in addition to cash and installment sales, revenue is recognized under finance and operating lease arrangements. Arrangements in which Novartis transfers substantially all the risks and rewards incidental to ownership to the customer are treated as finance lease arrangements. Revenue from finance lease arrangements is recognized at amounts equal to the fair values of the equipment, which approximate the present values of the minimum lease payments under the arrangements. As interest rates embedded in lease arrangements are approximately market rates, revenue under finance lease arrangements is comparable to revenue for outright sales. Finance income for arrangements in excess of twelve months is deferred and subsequently recognized based on a pattern that approximates the use of the effective interest method and recorded in “Other income”. Operating lease revenue for equipment rentals is recognized on a straight-line basis over the lease term.
    Provisions for rebates and discounts granted to government agencies, wholesalers, retail pharmacies, managed healthcare organizations and other customers are recorded as a deduction from revenue at the time the related revenues are recorded or when the incentives are offered. They are calculated on the basis of historical experience and the specific terms in the individual agreements.
    Provisions for refunds granted to healthcare providers under innovative pay-for-performance agreements are recorded as a revenue deduction at the time the related sales are recorded. They are calculated on the basis of historical experience and clinical data available for the product, as well as the specific terms in the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until such history is available.
    Cash discounts are offered to customers to encourage prompt payment and are recorded as revenue deductions.
    Following a decrease in the price of a product, we generally grant customers a “shelf stock adjustment” for their existing inventory for the involved product. Provisions for shelf stock adjustments, which are primarily relevant within the Sandoz Division, are determined at the time of the price decline or at the point of sale, if the impact of a price decline on the products sold can be reasonably estimated based on the customer’s inventory levels of the relevant product.
    When there is historical experience of Novartis agreeing to customer returns and Novartis can reasonably estimate expected future returns, a provision is recorded for estimated sales returns. In doing so, the estimated rate of return is applied, determined based on historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a re-sale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired.
    Provisions for revenue deductions are adjusted to actual amounts as rebates, discounts and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these sales deductions.
    Other revenue
    “Other revenue” includes royalty and profit sharing income and revenue from activities such as manufacturing services or other services rendered, to the extent such revenue is not recorded under net sales.
    Research & Development
    Internal Research & Development (R&D) costs are fully charged to “Research & Development” in the consolidated income statement in the period in which they are incurred. The Group considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland or Japan.
    Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&D, that is deemed to not transfer intellectual property to Novartis are expensed as internal R&D expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been achieved from a regulatory authority in a major market.
    Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are capitalized, as are payments for other assets, such as technologies to be used in R&D activities. If additional payments are made to the originator company to continue to perform R&D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&D services not resulting in an additional transfer of intellectual property rights to Novartis. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Novartis of additional intellectual property developed at the risk of the originator company. Subsequent internal R&D costs in relation to IPR&D and other assets are expensed, since the technical feasibility of the internal R&D activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market.
    Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval are capitalized and recognized as currently marketed products.
    Inventory produced ahead of regulatory approval is fully provisioned and the charge is included in “Other expense” in the consolidated income statement, as its ultimate use cannot be assured. If this inventory can be subsequently sold, the provision is released to “Other income” in the consolidated income statement either on approval by the appropriate regulatory authority or, exceptionally in Europe, on recommendation by the Committee for Medicinal Products for Human Use (CHMP), if approval is virtually certain.
    Share-based compensation
    Vested Novartis shares and American Depositary Receipts (ADRs) that are granted as compensation are valued at their market value on the grant date and are immediately expensed in the consolidated income statement.
    The fair values of unvested restricted shares, restricted share units (RSUs) and performance share units (PSUs) in Novartis shares and ADRs granted to associates as compensation are recognized as an expense over the related vesting period. The expense recorded in the consolidated income statement is included in the personnel expenses of the various functions where the associates are employed.
    Unvested restricted shares, restricted ADRs and RSUs are only conditional on the provision of services by the plan participant during the vesting period. They are valued using their fair value on the grant date. As RSUs do not entitle the holder to dividends the fair value is based on the Novartis share price at the grant date adjusted for the net present value of the dividends expected to be paid during the holding period. The fair value of these grants, after making adjustments for assumptions related to their forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period.
    PSUs are subject to certain performance criteria being achieved during the vesting period and require plan participants to provide services during the vesting period. PSUs granted under plans defined as “Long-Term Performance Plans” are subject to performance criteria based on Novartis internal performance metrics. The expense is determined taking into account assumptions concerning performance during the period against targets and expected forfeitures due to plan participants not meeting their service conditions. These assumptions are periodically adjusted. Any change in estimates for past services is recorded immediately as an expense or income in the consolidated income statement and amounts for future periods are expensed over the remaining vesting period. As a result, at the end of the vesting period, the total charge during the whole vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date.
    PSUs granted under the Long-Term Relative Performance Plan (LTRPP) are conditional on the provision of services by the plan participant during the vesting period as well as on the Total Shareholder Return (TSR) performance of Novartis relative to a specific peer group of companies over the vesting period. These performance conditions are based on variables that can be observed in the market. IFRS requires that these observations are taken into account in determining the fair value of these PSUs at the date of grant. Novartis has determined the fair value of these PSUs at the date of grant using a “Monte Carlo” simulation model. The total fair value of this grant is expensed on a straight-line basis over the vesting period. Adjustments to the number of equity instruments granted are only made if a plan participant does not fulfill the service conditions.
    If a plan participant leaves Novartis for reasons other than retirement, disability or death, then unvested restricted shares, restricted ADRs, RSUs and PSUs are forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Novartis Board of Directors, for example, in connection with a reorganization or divestment.
    Measuring the fair values of PSUs granted under the LTRPP, requires estimates. The Monte Carlo simulation used for determining the fair value of the PSUs related to the LTRPP requires as input parameters the probability of factors related to uncertain future events; the term of the award; the grant price of underlying shares or ADRs; expected volatilities; the expected correlation matrix of the underlying equity instruments with those of the peer group of companies and the risk-free interest rate.
    Government grants
    Grants from governments or similar organizations are recognized at their fair value when there is a reasonable assurance that the grant will be received and the Group will comply with all attached conditions.
    Government grants related to income are deferred and recognized in the consolidated income statement over the period necessary to match them with the related costs that they are intended to compensate.
    The accounting policy for property, plant and equipment describes the treatment of any related grants.
    Restructuring charges
    Restructuring provisions are recognized for the direct expenditures arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made.
    Charges to increase restructuring provisions are included in “Other expense” in the consolidated income statements. Corresponding releases are recorded in “Other income” in the consolidated income statement.
    Taxes
    Taxes on income are provided in the same periods as the revenues and expenses to which they relate and include any interest and penalties incurred during the period. Deferred taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax base of an asset or liability and its carrying value in the balance sheet prepared for consolidation purposes, except for those temporary differences related to investments in subsidiaries and associated companies, where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary’s retained earnings are only taken into account when a dividend has been planned.
    The estimated amounts for current and deferred tax assets or liabilities, including any amounts related to any uncertain tax positions, are based on currently known facts and circumstances. Tax returns are based on an interpretation of tax laws and regulations, and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made requiring payments of additional tax, interest or penalties. Inherent uncertainties exist in the estimates of the tax positions.
    Non-current assets held for sale
    Non-current assets are classified as assets held for sale when their carrying amount is to be recovered principally through a sale transaction and a sale is considered highly probable. They are stated at the lower of carrying amount and fair value less costs of disposal. Assets held for sale, included within a disposal group or discontinued operations are not depreciated or amortized.
    Status of adoption of significant new or amended IFRS standards or interpretations
    The adoption of new or amended standards and interpretations that are effective for the financial year beginning on January 1, 2017, did not have a material impact on the Group’s consolidated financial statements.
    The following new IFRS standards will, based on a Novartis analysis, be of significance to the Group, but have not yet been early adopted:
    IFRS 9 FINANCIAL INSTRUMENTS
    IFRS 9 Financial Instruments will substantially change the classification and measurement of financial instruments. The new standard requires impairments to be based on a forward-looking model, changes the approach to hedging financial exposures and related documentation, changes the recognition of certain fair value changes and amends disclosures requirements.
    The impairment of financial assets, including trade and lease receivables, will be assessed using an expected credit loss model rather than the current incurred loss model. Given the nature of Novartis’ financial assets, the Group does not expect a significant impact to our provisions for doubtful accounts or impairments from this change.
    The new hedge accounting model introduced by the standard requires hedge accounting relationships to be based upon the Group’s own risk management strategy and objectives, and to be discontinued only when the relationships no longer qualify for hedge accounting. Based on the impact of adoption assessment performed, Novartis expects that the existing hedge relationship will continue to be designated as such under the new hedge accounting requirements.
    The Group will implement the new standard on January 1, 2018 and will apply the modified retrospective method, which requires the recognition of the cumulative effect of initially applying IFRS 9, as at January 1, 2018, to retained earnings and not restate prior years.
    The most significant impact to the Group, upon adoption of IFRS 9, will be the treatment of the unrealized gains and losses from changes in fair value on certain of the Group’s financial instruments, which are classified as available-for-sale marketable securities and financial investments. The unrealized gains and losses (to the extent of previous recognized unrealized gains), which the Group currently recognizes in the consolidated statement of other comprehensive income, will in the future be recognized in the consolidated income statement. This approach will be applied to equity securities where the fair value through other comprehensive income irrevocable option will not be applied. If this accounting had been applied prior to January 1, 2018, the adoption date, the cumulative effect to be recorded as an increase to retained earnings, as at January 1, 2018, is estimated at USD 0.2 billion.
    IFRS 15 REVENUE FROM CONTRACTS WITH CUSTOMERS
    IFRS 15 Revenue from contracts with customers amends revenue recognition requirements and establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The standard replaces IAS 18 Revenue and IAS 11 Construction contracts and related interpretations.
    Results of our impact assessment:
    • The Group’s “Net sales” are derived from the sale of drug substances, vision care products, surgical equipment, other products and services, where control transfers to our customers and our performance obligations are satisfied at the time of shipment to or receipt of the products by the customer or when the services are performed. We do not expect IFRS 15 to significantly change the timing or amount of revenue recognized under these arrangements.
    • The Group’s “Other revenue” consists of royalty income from the out-licensing of intellectual property (IP), which is recognized as earned and from manufacturing services and other services, where revenue is recognized when control transfers to the third party and our performance obligations are satisfied. We do not expect IFRS 15 to significantly change the timing or amount of revenue recognized from these manufacturing and other services arrangements, nor from these royalty arrangements, as the standard’s royalty exception will apply for IP licenses.
    “Other revenue” also includes revenue from profit sharing arrangements with our collaboration partners. Furthermore, the Group receives milestone payments related to sale or out-licensing of IP. Novartis does not expect IFRS 15 to significantly change the timing or amount of revenue recognized under these arrangements.
    The Group will implement the new standard on January 1, 2018 and will apply the modified retrospective method, which requires the recognition of the cumulative effect of initially applying IFRS 15, as at January 1, 2018, to retained earnings and not restate prior years. However, since the results of the Group’s impact assessment indicates that IFRS 15 is not expected to significantly change the amount or timing of revenue recognition in 2017 or prior periods, an insignificant cumulative adjustment to increase retained earnings will be made.
    IFRS 16 LEASES
    IFRS 16 Leases substantially changes the financial statements as the majority of leases for which the company is the lessee will become on-balance sheet liabilities with corresponding right of use assets on the balance sheet. The standard replaces IAS 17 Leases and is effective on January 1, 2019. The current undiscounted operating lease commitments of USD 3.2 billion as of December 31, 2017, and disclosed in Note 27 provide, subject to the provision of the standard, an indicator of the impact of the implementation of IFRS 16 on the Group’s consolidated balance sheet.
    Upon adoption of the new standard, a portion of the annual operating lease costs, which is currently fully recognized as a functional expense, will be recorded as interest expense. In addition, the portion of the annual lease payments recognized in the cash flow statement as a reduction of the lease liability will be recognized as an outflow from financing activities, which currently are fully recognized as an outflow from operating activities. Given the leases involved and assuming the current low interest rate environment continues, the Group does not currently expect these effects to be significant.
    There are no other IFRS standards or interpretations not yet effective that would be expected to have a material impact on the Group.
    XML 76 R9.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Significant transactions
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Significant transactions
    2. Significant transactions
    Significant transactions in 2017
    Innovative Medicines – Acquisition of Ziarco Group Limited
    On January 20, 2017, Novartis acquired Ziarco Group Limited (Ziarco), a privately held company in the United Kingdom, focused on the development of novel treatments in dermatology. This acquisition adds a once-daily oral H4 receptor antagonist in development for atopic dermatitis, commonly known as eczema, to complement the Novartis dermatology portfolio and pipeline. The fair value of the total purchase consideration was USD 420 million. The amount consisted of an initial cash payment of USD 325 million and the net present value of the contingent consideration of USD 95 million, due to Ziarco shareholders, which they are eligible to receive upon the achievement of specified development milestones. The purchase price allocation resulted in net identifiable assets of USD 395 million and goodwill of USD 25 million. Results of operations since the date of acquisition were not material.
    Innovative Medicines – Acquisition of Encore Vision, Inc.
    On January 20, 2017, Novartis acquired Encore Vision, Inc. (Encore), a privately-held company in Fort Worth, Texas, in the United States, focused on the development of a novel treatment in presbyopia. The fair value of the total purchase consideration was USD 456 million. The amount consisted of an initial cash payment of USD 366 million and the net present value of the contingent consideration of USD 90 million, due to Encore shareholders, which they are eligible to receive upon the achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 389 million and goodwill of USD 67 million. Results of operations since the date of acquisition were not material.
    Significant transaction entered into in 2017 and closed in January 2018
    Innovative Medicines – Acquisition of ADVANCED ACCELERATOR APPLICATIONS, S.A.
    On October 30, 2017, Novartis entered into a binding memorandum of understanding with Advanced Accelerator Applications S.A., (AAA), a NASDAQ-listed company headquartered in Saint-Genis-Pouilly, France, under which Novartis agreed to commence a tender offer for 100% of the share capital of AAA subject to certain conditions. Novartis commenced the tender offer on December 7, 2017, to purchase all of the outstanding ordinary shares for a price of USD 41 per share and USD 82 per American Depositary Share (ADS), each representing two ordinary shares of AAA, which expired on January 19, 2018. The offer values AAAs equity at USD 3.9 billion, on a fully diluted basis. The transaction to acquire AAA is being funded mainly through external short- and long-term debt.
    As of the expiration of the tender offer, approximately 97% of the then outstanding fully diluted ordinary shares, including ordinary shares represented by ADSs, were validly tendered. On January 22, 2018, Novartis accepted and paid USD 3.9 billion for the ordinary shares, including ordinary shares represented by ADSs, tendered in the offer.
    On January 22, 2018 Novartis also commenced a subsequent offering period that will expire on January 31, 2018, unless extended.
    AAA is a radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicines, including Lutathera® (lutetium (177Lu) oxodotreotide), a first-in-class RLT product for neuroendocrine tumors (NETs) and a portfolio of diagnostic products. Radiopharmaceuticals, such as Lutathera®, are unique medicinal formulations containing radioisotopes, which are used clinically for both diagnosis and therapy.
    Significant transactions in 2016
    Alcon – Acquisition of Transcend Medical, Inc.
    On February 17, 2016, Alcon entered into an agreement to acquire Transcend Medical, Inc. (Transcend), a privately-held, US-based company focused on developing minimally-invasive surgical devices to treat glaucoma. The transaction closed on March 23, 2016, and the fair value of the total purchase consideration was USD 332 million. The amount consisted of an initial cash payment of USD 240 million and the net present value of contingent consideration of USD 92 million due to the Transcend shareholders, which they are eligible to receive upon the achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 294 million and goodwill of USD 38 million. The 2016 results of operations since the date of acquisition were not material.
    INNOVATIVE MEDICINES – ACQUISITION OF Reprixys PHARMACEUTICALs CORPORATION
    On November 18, 2016, Novartis acquired Reprixys Pharmaceuticals Corporation (Reprixys), a privately held, US-based company specializing in the development of therapeutics in certain hematologic and inflammatory disorders, following receipt of results of the SUSTAIN study. The previously held interest of 19% is adjusted to its fair value of USD 64 million through the consolidated income statement at acquisition date. This re-measurement resulted in a gain of USD 53 million.
    The fair value of the total purchase consideration for acquiring the 81% stake Novartis did not already own amounted to USD 268 million. The amount consisted of an initial cash payment of USD 194 million and the net present value of the contingent consideration of USD 74 million due to Reprixys shareholders, which they are eligible to receive upon the achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 332 million. No goodwill was recognized. The 2016 results of operations since the date of acquisition were not material.
    Significant transactions in 2015
    Portfolio transformation transactions
    Transaction with Eli Lilly and Company
    On January 1, 2015, Novartis closed its transaction with Eli Lilly and Company, USA (Lilly) announced in April 2014 to divest its Animal Health business for USD 5.4 billion in cash. This resulted in a pre-tax gain of USD 4.6 billion, which is recorded in operating income from discontinued operations.
    Transactions with GlaxoSmithKline plc
    On March 2, 2015, Novartis closed its transactions with GlaxoSmithKline plc, Great Britain (GSK) announced in April 2014, with the following consequences:
    Innovative Medicines – Acquisition of GSK oncology products
    Novartis acquired GSK’s oncology products and certain related assets for an aggregate cash consideration of USD 16.0 billion. Up to USD 1.5 billion of this cash consideration at the acquisition date is contingent on certain development milestones. The fair value of this potentially refundable consideration as at the acquisition date is USD 0.1 billion. In addition, under the terms of the agreement, Novartis is granted a right of first negotiation over the co-development or commercialization of GSK’s current and future oncology R&D pipeline, excluding oncology vaccines. The right of first negotiation is for a period of 12.5 years from the acquisition closing date. The purchase price allocation of the fair value of the consideration of USD 15.9 billion resulted in net identified assets of USD 13.5 billion and goodwill of USD 2.4 billion. In 2015, from the date of the acquisition the business generated net sales of USD 1.8 billion. Management estimates net sales for the entire year 2015 would have amounted to USD 2.1 billion had the oncology products been acquired at the beginning of the 2015 reporting period. The 2015 net results from operations on a reported basis since the acquisition date were not material.
    Vaccines – Divestment
    Novartis divested its Vaccines business (excluding its Vaccines influenza business) to GSK for up to USD 7.1 billion plus royalties. The USD 7.1 billion consists of USD 5.25 billion paid at closing and up to USD 1.8 billion in future milestone payments. The fair value of the contingent future milestones and royalties as at the acquisition date is USD 1.0 billion, resulting in a fair value of consideration received of USD 6.25 billion. Included in this amount is a USD 450 million milestone payment received in late March 2015. The sale of this business resulted in a pre-tax gain of USD 2.8 billion, which is recorded in operating income from discontinued operations.
    Novartis’s Vaccines influenza business was excluded from the GSK Vaccines business acquisition. However, GSK entered into a future option arrangement with Novartis in relation to the Vaccines influenza business, pursuant to which Novartis could have unilaterally required GSK to acquire the entire or certain parts of its Vaccines influenza business for consideration of up to USD 250 million (the Influenza Put Option) if the divestment to CSL Limited, Australia (CSL), discussed below, had not been completed. The option period was 18 months from the closing date of the GSK transaction, but terminated with the sale of the Vaccines influenza business to CSL on July 31, 2015. Novartis paid GSK a fee of USD 5 million in consideration for the grant of the Influenza Put Option.
    Consumer Health – Combination of Novartis OTC with GSK Consumer Healthcare
    Novartis and GSK agreed to create a combined consumer healthcare business through the combination between Novartis OTC and GSK Consumer Healthcare businesses. On March 2, 2015, a new entity, GlaxoSmithKline Consumer Healthcare Holdings Ltd. (GSK Consumer Healthcare) was formed via contribution of businesses from both Novartis and GSK. Novartis has a 36.5% interest in the newly created entity. Novartis has valued the contribution of 63.5% of its OTC Division in exchange for 36.5% of the GSK Consumer Healthcare business at fair value. Based on the estimates of fair values exchanged, an investment in an associated company of USD 7.6 billion was recorded. The resulting pre-tax gain, net of transaction related costs, of USD 5.9 billion is recorded in operating income from discontinued operations.
    Novartis has four of eleven seats on the GSK Consumer Healthcare Board of Directors. Furthermore, Novartis has customary minority rights and also exit rights at a pre-defined, market based pricing mechanism.
    The investment is accounted for using the equity method of accounting using estimated results for the last quarter of the year. Any differences between this estimate and actual results, when available, will be adjusted in the Group’s consolidated financial statements in the following year.
    Additional GSK related costs
    The GSK transaction resulted in USD 0.6 billion of additional transaction-related costs that were expensed, thereof USD 0.3 billion paid in 2015.
    Transaction with CSL
    On October 26, 2014, Novartis entered into an agreement with CSL to sell its Vaccines influenza business to CSL for USD 275 million. Entering into the separate divestment agreement with CSL resulted in the Vaccines influenza business being classified as a separate disposal group consisting of a group of cash generating units within the Vaccines Division, requiring the performance of a separate valuation of the Vaccines influenza business net assets. This triggered the recognition of an exceptional impairment charge in 2014 of USD 1.1 billion as the estimated net book value of the Vaccines influenza business net assets was above the USD 275 million consideration. The transaction with CSL was completed on July 31, 2015, resulting in a partial reversal of the impairment recorded in 2014 in the amount of USD 0.1 billion, which is included in operating income from discontinued operations.
    Other significant transactions in 2015
    Innovative Medicines – Acquisition of Spinifex Pharmaceuticals, Inc.
    On June 29, 2015, Novartis entered into an agreement to acquire Spinifex Pharmaceuticals, Inc. (Spinifex), a United States and Australia based, privately held development stage company, focused on developing a peripheral approach to treat neuropathic pain. The transaction closed on July 24, 2015, and the fair value of the total purchase consideration was USD 312 million. The amount consisted of an initial cash payment of USD 196 million and the net present value of the contingent consideration of USD 116 million due to previous Spinifex shareholders, which they are eligible to receive upon achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 263 million and goodwill of USD 49 million. The 2015 results of operations since the date of acquisition were not material.
    Innovative Medicines – Acquisition of Admune Therapeutics LLC
    On October 16, 2015, Novartis entered into an agreement to acquire Admune Therapeutics LLC (Admune), a US-based, privately held company, broadening Novartis’ pipeline of cancer immunotherapies. The fair value of the total purchase consideration amounted to USD 258 million. This amount consists of an initial cash payment of USD 140 million and the net present value of the contingent consideration of USD 118 million due to Admune’s previous owners, which they are eligible to receive upon the achievement of specified development and commercialization milestones. The purchase price allocation resulted in net identifiable assets of USD 258 million. No goodwill was recognized. The 2015 results of operations since the date of acquisition were not material.
    XML 77 R10.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Segmentation of key figures
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Segmentation of key figures
    3. Segmentation of key figures 2017, 2016 and 2015
    The businesses of Novartis are divided operationally on a worldwide basis into three identified reporting segments, Innovative Medicines, Sandoz and Alcon. In addition, we separately report Corporate activities.
    Reporting segments are presented in a manner consistent with the internal reporting to the chief operating decision maker, which is the Executive Committee of Novartis. The reporting segments are managed separately because they each research, develop, manufacture, distribute, and sell distinct products that require differing marketing strategies.
    The Executive Committee of Novartis is responsible for allocating resources and assessing the performance of the reporting segments.
    Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines. The Innovative Medicines Division is organized into two global business units: Novartis Oncology business unit, which consists of the global business franchises Oncology and Novartis Pharmaceuticals business unit, which consists of the global business franchises Ophthalmology, Neuroscience, Immunology and Dermatology, Respiratory, Cardio-Metabolic and Established Medicines.
    Sandoz develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. Sandoz is organized globally in three franchises: Retail Generics, Anti Infectives, and Biopharmaceuticals. In Retail Generics, Sandoz develops, manufactures and markets active ingredients and finished dosage forms of pharmaceuticals to third parties. Retail Generics includes the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmics, pain, and respiratory, as well as finished dosage form anti infectives sold to third parties. In Anti Infectives, Sandoz manufactures and supplies active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by Retail Generics and for sale to third party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein or other biotechnology based products, including biosimilars, and provides biotechnology manufacturing services to other companies.
    Alcon researches, discovers, develops, manufactures, distributes and sells eye care products. The Alcon Division is the global leader in eye care, with product offerings in eye care devices and vision care. The Alcon Division is organized globally in two global business franchises as follows: In Surgical, Alcon develops, manufactures, distributes and sells ophthalmic surgical equipment, instruments, disposable products and intraocular lenses. In Vision Care, Alcon develops, manufactures, distributes and sells contact lenses and lens care products.
    Income and expenses relating to Corporate include the costs of the Group headquarters and those of corporate coordination functions in major countries. In addition, Corporate includes other items of income and expense that are not attributable to specific segments, such as certain revenues from intellectual property rights, certain expenses related to post-employment benefits, environmental remediation liabilities, charitable activities, donations and sponsorships. Usually, no allocation of Corporate items is made to the segments. As a result, Corporate assets and liabilities principally consist of net liquidity (cash and cash equivalents, marketable securities less financial debts), investments in associated companies and current and deferred taxes and non-segment specific environmental remediation and post-employment benefit liabilities. Corporate also includes the Alcon brand name intangible asset as it is used to market products of the Alcon Division and products within the Ophthalmology business franchise of the Innovative Medicines Division.
    Our divisions are supported by the Novartis Institutes for BioMedical Research, Global Drug Development, Novartis Technical Operations and Novartis Business Services organizations.
    • The Novartis Institutes for BioMedical Research (NIBR) conducts research activities of the Innovative Medicines Division and also collaborates with Sandoz.
    • Global Drug Development organization was established in July 2016 and oversees all drug development activities for our Innovative Medicines Division and the biosimilars portfolio of our Sandoz Division.
    • Novartis Technical Operations organization was established in July 2016, to centralize management of our manufacturing operations across our Innovative Medicines and Sandoz Divisions.
    • Novartis Business Services (NBS) was established in January 2015 as a shared services organization and delivers business support services across the Group, such as information technology, real estate and facility services, procurement, product lifecycle services, human resources and financial reporting and accounting operations.
    Following the portfolio transformation transactions in 2015, described in Note 2, Novartis has separated the Group’s reported financial data into “continuing” operations and “discontinued” operations:
    Continuing operations comprise:
    • Innovative Medicines: innovative patent-protected prescription medicines
    • Sandoz: generic and biosimilar pharmaceuticals
    • Alcon: eye care devices and vision care
    • Corporate activities
    Discontinued operations comprise:
    • Vaccines: preventive human vaccines. Excluded are certain intellectual property rights and related other revenues of the Vaccines Division, which are now reported under Corporate activities.
    • Consumer Health: OTC (over-the-counter medicines) and Animal Health. These two divisions were managed separately. However, neither was material enough to the Group to be disclosed separately as a reporting segment.
    • Corporate: certain transactional and other expenses related to the portfolio transformation.
    The accounting policies mentioned in Note 1 are used in the reporting of segment results. Inter-segmental sales are made at amounts that are considered to approximate arm’s length transactions. The Executive Committee of Novartis evaluates segmental performance and allocates resources among the segments based on a number of measures including net sales, operating income and net operating assets. Segment net operating assets consist primarily of property, plant and equipment, intangible assets, goodwill, inventories and trade and other operating receivables less operating liabilities.
    Segmentation – Consolidated income statements
    Innovative Medicines
    Sandoz
    Alcon
    Corporate (including eliminations)
    Group
    (USD millions)
    2017
    2016
    2017
    2016
    2017
    2016
    2017
    2016
    2017
    2016
    Net sales to third parties
    33 025
    32 562
    10 060
    10 144
    6 024
    5 812
    49 109
    48 518
    Sales to other segments
    668
    624
    118
    104
    3
    – 789
    – 728
    Net sales
    33 693
    33 186
    10 178
    10 248
    6 027
    5 812
    – 789
    – 728
    49 109
    48 518
    Other revenues
    898
    815
    37
    37
    3
    4
    88
    62
    1 026
    918
    Cost of goods sold
    – 9 007
    – 9 331
    – 5 800
    – 5 971
    – 3 231
    – 3 092
    863
    874
    – 17 175
    – 17 520
    Gross profit
    25 584
    24 670
    4 415
    4 314
    2 799
    2 724
    162
    208
    32 960
    31 916
    Marketing & Sales
    – 9 089
    – 8 435
    – 1 811
    – 1 681
    – 1 961
    – 1 882
    – 12 861
    – 11 998
    Research & Development
    – 7 630
    – 7 709
    – 774
    – 814
    – 568
    – 516
    – 8 972
    – 9 039
    General & Administration
    – 986
    – 978
    – 315
    – 300
    – 383
    – 410
    – 452
    – 506
    – 2 136
    – 2 194
    Other income
    1 027
    1 091
    204
    185
    47
    48
    691
    603
    1 969
    1 927
    Other expense
    – 1 124
    – 1 213
    – 351
    – 259
    – 124
    – 96
    – 732
    – 776
    – 2 331
    – 2 344
    Operating income
    7 782
    7 426
    1 368
    1 445
    – 190
    – 132
    – 331
    – 471
    8 629
    8 268
    Income from associated companies
    – 1
    23
    6
    1 086
    697
    1 108
    703
    Interest expense
    – 777
    – 707
    Other financial income and expense
    39
    – 447
    Income before taxes
    8 999
    7 817
    Taxes
    – 1 296
    – 1 119
    Net income
    7 703
    6 698
    Attributable to:
    Shareholders of Novartis AG
    7 703
    6 712
    Non-controlling interests
    0
    – 14
    Included in net income are:
    Interest income
    110
    43
    Depreciation of property,

    plant & equipment


    – 916


    – 883


    – 270


    – 260


    – 217


    – 229


    – 117


    – 117


    – 1 520


    – 1 489
    Amortization of intangible assets
    – 2 291
    – 2 470
    – 447
    – 450
    – 942
    – 929
    – 10
    – 12
    – 3 690
    – 3 861
    Impairment charges on property,

    plant & equipment, net


    – 84


    – 93


    – 73


    – 2




    – 5




    – 2


    – 157


    – 102
    Impairment charges on intangible

    assets, net


    – 591


    – 522


    – 61


    – 65


    – 57


    – 4






    – 709


    – 591
    Impairment charges and fair value

    gains on financial assets, net


    – 42


    – 55






    – 29




    – 185


    – 77


    – 256


    – 132
    Additions to restructuring provisions
    – 122
    – 236
    – 61
    – 46
    – 8
    – 36
    – 3
    – 25
    – 194
    – 343
    Equity-based compensation of

    Novartis equity plans


    – 593


    – 582


    – 52


    – 47


    – 71


    – 53


    – 208


    – 164


    – 924


    – 846
     
     
    Innovative Medicines
    Sandoz
    Alcon
    Corporate (including eliminations)
    Group
    (USD millions)
    2016
    2015
    2016
    2015
    2016
    2015
    2016
    2015
    2016
    2015
    Net sales to third parties from

    continuing operations


    32 562


    33 345


    10 144


    10 070


    5 812


    5 999






    48 518


    49 414
    Sales to other segments
    624
    518
    104
    128
    – 728
    – 620
    26
    Net sales from continuing operations
    33 186
    33 863
    10 248
    10 198
    5 812
    5 999
    – 728
    – 620
    48 518
    49 440
    Other revenues
    815
    792
    37
    25
    4
    23
    62
    107
    918
    947
    Cost of goods sold
    – 9 331
    – 9 204
    – 5 971
    – 5 844
    – 3 092
    – 3 145
    874
    789
    – 17 520
    – 17 404
    Gross profit from continuing operations
    24 670
    25 451
    4 314
    4 379
    2 724
    2 877
    208
    276
    31 916
    32 983
    Marketing & Sales
    – 8 435
    – 8 430
    – 1 681
    – 1 679
    – 1 882
    – 1 663
    – 11 998
    – 11 772
    Research & Development
    – 7 709
    – 7 685
    – 814
    – 782
    – 516
    – 468
    – 9 039
    – 8 935
    General & Administration
    – 978
    – 1 031
    – 300
    – 346
    – 410
    – 450
    – 506
    – 648
    – 2 194
    – 2 475
    Other income
    1 091
    1 149
    185
    109
    48
    54
    603
    737
    1 927
    2 049
    Other expense
    – 1 213
    – 1 639
    – 259
    – 381
    – 96
    – 69
    – 776
    – 784
    – 2 344
    – 2 873
    Operating income from

    continuing operations


    7 426


    7 815


    1 445


    1 300


    – 132


    281


    – 471


    – 419


    8 268


    8 977
    Income from associated companies
    6
    2
    697
    264
    703
    266
    Interest expense
    – 707
    – 655
    Other financial income and expense
    – 447
    – 454
    Income before taxes from

    continuing operations


















    7 817


    8 134
    Taxes
    – 1 119
    – 1 106
    Net income from continuing operations
    6 698
    7 028
    Net income from discontinued operations
    10 766
    Net income
    6 698
    17 794
    Attributable to:
    Shareholders of Novartis AG
    6 712
    17 783
    Non-controlling interests
    – 14
    11
    Included in net income from continuing operations are:
    Interest income
    43
    33
    Depreciation of property,

    plant & equipment


    – 883


    – 839


    – 260


    – 277


    – 229


    – 237


    – 117


    – 117


    – 1 489


    – 1 470
    Amortization of intangible assets
    – 2 470
    – 2 384
    – 450
    – 450
    – 929
    – 912
    – 12
    – 9
    – 3 861
    – 3 755
    Impairment charges on property,

    plant & equipment, net


    – 93


    39


    – 2


    – 97


    – 5


    – 1


    – 2


    – 21


    – 102


    – 80
    Impairment charges on intangible

    assets, net


    – 522


    – 138


    – 65


    – 27


    – 4


    – 1






    – 591


    – 166
    Impairment charges and fair value

    gains on financial assets, net


    – 55


    – 32










    – 77


    – 72


    – 132


    – 104
    Additions to restructuring provisions
    – 236
    – 232
    – 46
    – 93
    – 36
    – 25
    – 25
    – 49
    – 343
    – 399
    Equity-based compensation of

    Novartis equity plans


    – 582


    – 620


    – 47


    – 53


    – 53


    – 66


    – 164


    – 164


    – 846


    – 903
    Segmentation – Consolidated balance sheets
    Innovative Medicines
    Sandoz
    Alcon
    Corporate (including eliminations)
    Group
    (USD millions)
    2017
    2016
    2017
    2016
    2017
    2016
    2017
    2016
    2017
    2016
    Total assets
    54 075
    51 911
    18 231
    17 611
    22 014
    22 970
    38 759
    37 632
    133 079
    130 124
    Total liabilities
    – 11 457
    – 10 007
    – 3 459
    – 3 168
    – 1 893
    – 2 520
    – 42 043
    – 39 538
    – 58 852
    – 55 233
    Total equity
    74 227
    74 891
    Net debt
    19 047
    16 025
    Net operating assets
    42 618
    41 904
    14 772
    14 443
    20 121
    20 450
    93 274
    90 916
    Included in assets and liabilities are:
    Total property, plant & equipment
    10 857
    10 410
    2 525
    2 374
    2 403
    2 163
    679
    694
    16 464
    15 641
    Additions to property,

    plant & equipment  1


    877


    996


    326


    316


    431


    396


    94


    127


    1 728


    1 835
    Total goodwill and intangible assets
    31 571
    31 630
    10 993
    10 774
    16 176
    16 914
    3 007
    3 002
    61 747
    62 320
    Additions to goodwill and

    intangible assets  1


    984


    865


    64


    45


    82


    63


    16


    5


    1 146


    978
    Total investment in associated

    companies


    41


    16


    7


    18






    15 322


    14 270


    15 370


    14 304
    Additions to investment in associated

    companies


    6


    4










    40


    37


    46


    41
    Cash and cash equivalents,

    marketable securities, commodities,

    time deposits and derivative

    financial instruments










































    9 485






    7 777






    9 485






    7 777
    Financial debts and derivative

    financial instruments














    28 532


    23 802


    28 532


    23 802
    Current income tax and deferred

    tax liabilities














    6 891


    8 260


    6 891


    8 260
     1  Excluding impact of business combinations
     
    The following table shows countries that accounted for more than 5% of at least one of the respective Group totals, as well as regional information for net sales for the years ended December 31, 2017, 2016 and 2015, and for selected non-current assets for the years ended December 31, 2017 and 2016:
    Net sales1
    Total of selected non-current assets2
    (USD millions)
    2017
    %
    2016
    %
    2015
    %
    2017
    %
    2016
    %
    Country
    Switzerland
    836
    2
    830
    2
    774
    2
    43 920
    47
    44 413
    48
    United States
    16 935
    34
    17 117
    35
    18 079
    37
    28 476
    30
    28 484
    31
    United Kingdom
    1 160
    2
    1 182
    2
    1 277
    3
    7 957
    9
    6 892
    7
    Germany
    3 690
    8
    3 634
    7
    3 262
    7
    3 128
    3
    2 733
    3
    France
    2 490
    5
    2 390
    5
    2 269
    5
    284
    199
    Japan
    3 177
    6
    3 267
    7
    3 163
    6
    148
    145
    Other
    20 821
    43
    20 098
    42
    20 590
    40
    9 668
    11
    9 399
    11
    Group
    49 109
    100
    48 518
    100
    49 414
    100
    93 581
    100
    92 265
    100
    Region
    Europe
    17 492
    36
    17 079
    35
    16 472
    33
    61 699
    66
    59 879
    65
    Americas
    20 899
    42
    20 998
    43
    22 414
    45
    29 113
    31
    29 831
    32
    Asia/Africa/Australasia
    10 718
    22
    10 441
    22
    10 528
    22
    2 769
    3
    2 555
    3
    Group
    49 109
    100
    48 518
    100
    49 414
    100
    93 581
    100
    92 265
    100
     
     1  Net sales from operations by location of third-party customer
     2  Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies
    The Group’s largest, second-largest and third-largest customers account for approximately 17%, 12% and 7% of net sales, respectively (2016: 16%, 12% and 6% respectively; 2015: 14%, 11% and 5% respectively). All segments had sales to these customers in 2017, 2016 and 2015. No other customer accounted for 5% or more of net sales in any year.
    The highest amounts of trade receivables outstanding were for these same three customers and amounted to 14%, 9% and 5%, respectively, of the trade receivables at December 31, 2017 (2016: 14%, 9% and 6% respectively).
    Innovative Medicines net sales by business franchise


    2017

    USD

    millions


    2016

    USD

    millions
    Change

    (2016

    to 2017)

    USD %


    2015

    USD

    millions
    Change

    (2015

    to 2016)

    USD %
    Oncology
    Gleevec/Glivec
    1 943
    3 323
    – 42
    4 658
    – 29
    Tasigna
    1 841
    1 739
    6
    1 632
    7
    Sandostatin
    1 612
    1 646
    – 2
    1 630
    1
    Afinitor/Votubia
    1 525
    1 516
    1
    1 607
    – 6
    Exjade/Jadenu
    1 059
    956
    11
    917
    4
    Tafinlar + Mekinist
    873
    672
    30
    453
    nm
    Promacta/Revolade
    867
    635
    37
    402
    nm
    Votrient
    808
    729
    11
    565
    nm
    Jakavi
    777
    581
    34
    410
    42
    Kisqali
    76
    0
    nm
    0
    nm
    Other
    893
    993
    – 10
    1 030
    – 4
    Total Oncology business unit
    12 274
    12 790
    – 4
    13 304
    – 4
    Ophthalmology
    Lucentis
    1 888
    1 835
    3
    2 060
    – 11
    Travoprost Group
    589
    619
    – 5
    631
    – 2
    Systane Group
    400
    377
    6
    380
    – 1
    Topical Olopatadine Group
    284
    335
    – 15
    457
    – 27
    Other
    2 207
    2 297
    – 4
    2 395
    – 4
    Total Ophthalmology
    5 368
    5 463
    – 2
    5 923
    – 8
    Immunology and Dermatology
    Cosentyx
    2 071
    1 128
    84
    261
    nm
    Neoral/Sandimmun(e)
    488
    515
    – 5
    570
    – 10
    Zortress/Certican
    414
    398
    4
    335
    19
    Ilaris
    402
    283
    42
    236
    20
    Myfortic
    378
    383
    – 1
    441
    – 13
    Other
    288
    308
    – 6
    294
    5
    Total Immunology and Dermatology
    4 041
    3 015
    34
    2 137
    41
    Neuroscience
    Gilenya
    3 185
    3 109
    2
    2 776
    12
    Other
    102
    124
    – 18
    141
    – 12
    Total Neuroscience
    3 287
    3 233
    2
    2 917
    11


    2017

    USD

    millions


    2016

    USD

    millions
    Change

    (2016

    to 2017)

    USD %


    2015

    USD

    millions
    Change

    (2015

    to 2016)

    USD %
    Respiratory
    Ultibro Breezhaler
    411
    363
    13
    260
    40
    Seebri Breezhaler
    151
    149
    1
    150
    – 1
    Onbrez Breezhaler
    112
    143
    – 22
    166
    – 14
    Subtotal COPD1 portfolio
    674
    655
    3
    576
    14
    Xolair  2
    920
    835
    10
    755
    11
    Other
    23
    31
    – 26
    37
    – 16
    Total Respiratory
    1 617
    1 521
    6
    1 368
    11
    Cardio-Metabolic
    Entresto
    507
    170
    198
    21
    nm
    Other
    17
    14
    21
    0
    nm
    Total Cardio-Metabolic
    524
    184
    185
    21
    nm
    Established Medicines
    Galvus
    1 233
    1 193
    3
    1 140
    5
    Exforge
    960
    926
    4
    1 047
    – 12
    Diovan/Co-Diovan
    957
    1 073
    – 11
    1 284
    – 16
    Voltaren/Cataflam
    465
    525
    – 11
    558
    – 6
    Exelon/Exelon Patch
    381
    444
    – 14
    728
    – 39
    Ritalin/Focalin
    236
    282
    – 16
    365
    – 23
    Other
    1 682
    1 913
    – 12
    2 553
    – 25
    Total Established Medicines
    5 914
    6 356
    – 7
    7 675
    – 17
    Total Pharmaceutical business unit
    20 751
    19 772
    5
    20 041
    – 1
    Total division net sales
    33 025
    32 562
    1
    33 345
    – 2
     1  Chronic obstructive pulmonary disease
     2  Net sales reflect Xolair sales for all indications (e.g., including Xolair SAA and Xolair CSU, which is managed by the Immunology and Dermatology franchise)
     
    nm = not meaningful
    The product portfolio of other segments is widely spread in 2017, 2016 and 2015.
    XML 78 R11.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Associated companies
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Associated companies
    4. Associated companies
    Net income statement effect
    Other comprehensive income effect
    Total comprehensive income effect
    (USD millions)
    2017
    2016
    2015
    2017
    2016
    2015
    2017
    2016
    2015
    Roche Holding AG, Switzerland
    456
    464
    343
    108
    – 39
    – 149
    564
    425
    194
    GlaxoSmithKline Consumer

    Healthcare Holdings Ltd., UK


    629


    234


    – 79


    – 145


    710


    – 4


    484


    944


    – 83
    Others
    23
    5
    2
    23
    5
    2
    Associated companies related to continuing operations
    1 108
    703
    266
    – 37
    671
    – 153
    1 071
    1 374
    113
    Novartis has significant investments in Roche Holding AG, Basel (Roche) and in GlaxoSmithKline Consumer Healthcare Holdings Ltd, Brentford, Middlesex, UK as well as certain other smaller investments that are accounted for as associated companies.
    Balance sheet value


    (USD millions)
    December 31,

    2017
    December 31,

    2016
    Roche Holding AG, Switzerland
    8 121
    7 644
    GlaxoSmithKline Consumer

    Healthcare Holdings Ltd., UK


    7 020


    6 448
    Others
    229
    212
    Total
    15 370
    14 304
    Roche Holding AG
    The Group’s holding in Roche voting shares was 33.3% at December 31, 2017, 2016 and 2015. This investment represents approximately 6.3% of Roche’s total outstanding voting and non-voting equity instruments at December 31, 2017, 2016 and 2015.
    Since full-year 2017 financial data for Roche is not available when Novartis produces its consolidated financial results, a survey of analyst estimates is used to estimate the Group’s share of Roche’s net income. Any differences between these estimates and actual results will be adjusted in the Group’s 2018 consolidated financial statements when available.
    The following tables show summarized financial information for Roche, including current values of fair value adjustments made at the time of the acquisition of the shares, for the year ended December 31, 2016 and for the six months ended June 30, 2017 (since full-year 2017 data is not yet available):


    (CHF billions)


    Current assets
    Non-current

    assets
    Current

    liabilities
    Non-current

    liabilities
    December 31, 2016
    28.7
    61.4
    22.6
    27.8
    June 30, 2017
    26.7
    56.9
    20.6
    26.0


    (CHF billions)




    Revenue




    Net income
    Other

    comprehen-

    sive income
    Total

    comprehen-

    sive income
    December 31, 2016
    50.6
    7.5
    0.7
    8.2
    June 30, 2017
    26.3
    4.4
    0.2
    4.6
    A purchase price allocation was performed on the basis of publicly available information at the time of acquisition of the investment. The December 31, 2017 balance sheet value allocation is as follows:


    (USD millions)
    December 31,

    2017
    Novartis share of Roche’s estimated net assets
    2 412
    Novartis share of re-appraised intangible assets
    673
    Implicit Novartis goodwill
    2 915
    Current value of share in net identifiable assets

    and goodwill


    6 000
    Accumulated equity accounting adjustments and translation effects less dividends received
    2 121
    Balance sheet value
    8 121
    The identified intangible assets principally relate to the value of currently marketed products and are amortized on a straight-line basis over their estimated average useful life of 20 years.
    In 2017, dividends received from Roche in relation to the distribution of its 2016 net income amounted to USD 438 million (2016: USD 433 million in relation to the distribution of its 2015 net income).
    The consolidated income statement effects from applying Novartis accounting principles for this investment in 2017, 2016 and 2015 are as follows:
    (USD millions)
    2017
    2016
    2015
    Novartis share of Roche's

    estimated current-year

    consolidated net income




    669




    678




    650
    Prior-year adjustment
    – 67
    – 68
    – 157
    Amortization of fair value adjustments relating to intangible assets, net of taxes of USD 42 million (2016: USD 42 million; 2015: USD 41 million)
    – 146
    – 146
    – 150
    Net income effect
    456
    464
    343
    The publicly quoted market value of the Novartis interest in Roche (SIX symbol: RO) at December 31, 2017, was USD 13.4 billion (2016: USD 12.4 billion).
    GlaxoSmithKline Consumer Healthcare Holdings Ltd.
    On March 2, 2015, Novartis closed its transactions with GlaxoSmithKline plc, Great Britain (GSK) announced in April 2014. As part of these transactions, Novartis and GSK agreed to create a combined consumer healthcare business through a combination between Novartis OTC and GSK Consumer Healthcare. On March 2, 2015, a new entity GlaxoSmithKline Consumer Healthcare Holdings Ltd (GSK Consumer Healthcare) was formed via the contribution of businesses from both Novartis and GSK.
    At December 31, 2017, 2016 and 2015, Novartis has a 36.5% interest in GSK Consumer Healthcare and four of eleven seats on the GSK Consumer Healthcare board of directors. Furthermore, Novartis has customary minority rights and also exit rights at a pre-defined, market-based pricing mechanism.
    The December 31, 2017 balance sheet value allocation is as follows:


    (USD millions)
    December 31,

    2017
    Novartis share of GSK Consumer Healthcare’s

    estimated net assets


    1 505
    Novartis share of re-appraised intangible assets
    3 852
    Implicit Novartis goodwill
    1 763
    Current value of share in net identifiable assets

    and goodwill


    7 120
    Accumulated equity accounting adjustments and translation effects less dividends received
    – 100
    Balance sheet value
    7 020
    The identified intangible assets principally relate to the value of the indefinite life GSK Consumer Healthcare intangible assets. The identified intangible assets with a definite life are amortized on a straight-line basis over their estimated average useful life of 20 years.
    At acquisition date, Novartis has valued the contribution of 63.5% of its OTC Division in exchange for 36.5% of the GSK Consumer Healthcare business at fair value. The retained interest in the OTC Division business contributed was accounted for at net book value at the time of contribution.
    The following tables show summarized financial information for GSK Consumer Healthcare, including current values of fair value adjustments made at the time of acquisition, for the year ended December 31, 2016, and for the nine months ended September 30, 2017 (interim unaudited), since full-year 2017 data is not yet available:


    (GBP billions)


    Current assets
    Non-current

    assets
    Current

    liabilities
    Non-current

    liabilities
    December 31, 2016
    4.0
    21.1
    3.1
    2.1
    September 30, 2017
    3.3
    20.6
    2.6
    2.0


    (GBP billions)




    Revenue




    Net income
    Other

    comprehen-

    sive income
    Total

    comprehen-

    sive income
    December 31, 2016
    6.5
    0.6
    1.6
    2.2
    September 30, 2017
    5.3
    0.6
    – 0.4
    0.2
    Since full-year 2017 financial data for GSK Consumer Healthcare is not available when Novartis produces its consolidated financial results, a projection of the latest internal management reporting is used to estimate the Group’s share of GSK Consumer Healthcare’s net result for the year. Any differences between this estimate and actual results will be adjusted in the Group’s 2018 consolidated financial statements when available.
    In 2017, dividends received from GSK Consumer Healthcare amounted to USD 544 million (2016: USD 463 million).
    The consolidated income statement effects from applying Novartis accounting principles for this investment in 2017, 2016 and 2015 are as follows:
    (USD millions)
    2017
    2016
    2015
    Novartis share of

    GSK Consumer Healthcare's

    estimated current-year

    consolidated net income






    589






    268






    – 17
    Prior-year adjustment
    47
    – 22
    Amortization of fair value adjustments relating to intangible assets and inventory, net of taxes of USD 1 million (2016: USD 2 million; 2015: USD 18 million)
    – 7
    – 12
    – 62
    Net income effect
    629
    234
    – 79
    XML 79 R12.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Interest expense and other financial income and expense
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Interest expense and other financial income and expense
    5. Interest expense and other financial income and expense
    Interest expense
    (USD millions)
    2017
    2016
    2015
    Interest expense
    – 758
    – 709
    – 669
    (Expense)/ income arising from discounting long-term liabilities
    – 19
    2
    14
    Total interest expense
    – 777
    – 707
    – 655
    Other financial income and expense
    (USD millions)
    2017
    2016
    2015
    Interest income
    110
    43
    33
    Dividend income
    1
    1
    1
    Net capital losses on

    available-for-sale securities


    – 1


    – 1


    – 8
    Income on forward contracts

    and options






    1
    Impairment of commodities

    and available-for-sale securities, net


    12


    7


    – 132
    Other financial expense
    – 25
    – 20
    – 23
    Monetary loss from hyperinflation

    accounting






    – 72
    Currency result, net
    – 58
    – 477
    – 254
    Total other financial income and expense
    39
    – 447
    – 454
    XML 80 R13.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Taxes
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Taxes
    6. Taxes
    Income before taxes
    (USD millions)
    2017
    2016
    2015
    Switzerland
    5 289
    3 110
    5 765
    Foreign
    3 710
    4 707
    2 369
    Income before taxes

    from continuing operations


    8 999


    7 817


    8 134
    Income before taxes from discontinued operations
    12 479
    Total income before taxes
    8 999
    7 817
    20 613
    Current and deferred income tax expense
    (USD millions)
    2017
    2016
    2015
    Switzerland
    – 462
    – 709
    – 317
    Foreign
    – 1 594
    – 1 418
    – 1 333
    Current income tax expense from continuing operations
    – 2 056
    – 2 127
    – 1 650
    Switzerland
    – 298
    765
    – 68
    Foreign
    1 058
    243
    612
    Deferred tax income from continuing operations
    760
    1 008
    544
    Income tax expense

    from continuing operations


    – 1 296


    – 1 119


    – 1 106
    Income tax expense from discontinued operations
    – 1 713
    Total income tax expense
    – 1 296
    – 1 119
    – 2 819
    Analysis of tax rate
    The main elements contributing to the difference between the Group’s overall applicable tax rate (which can change each year since it is calculated as the weighted average tax rate based on pre-tax income of each subsidiary) and the effective tax rate are:
    (As a percentage)
    2017
    2016
    2015
    Applicable tax rate
    14.5
    13.2
    12.4
    Effect of disallowed expenditures
    3.4
    3.5
    3.5
    Effect of utilization of tax losses

    brought forward from prior periods


    – 0.1


    – 0.2


    – 0.2
    Effect of income taxed at reduced rates
    – 0.2
    – 0.2
    – 0.3
    Effect of tax credits and allowances
    – 2.2
    – 2.8
    – 2.7
    Effect of release of

    contingent consideration liability


    – 1.2


    0.0


    0.0
    Effect of tax rate change

    on current and deferred

    tax assets and liabilities  1




    0.7




    0.2




    – 0.5
    Effect of write-off of deferred tax assets
    0.0
    0.5
    0.0
    Effect of write down and reversal of

    write-down of investments in subsidiaries


    – 1.1


    – 1.0


    – 0.9
    Effect of tax benefits expiring in 2017
    – 0.8
    – 0.5
    – 0.4
    Effect of non-deductible losses in Venezuela
    0.0
    1.3
    1.2
    Effect of prior year items
    1.2
    0.2
    1.0
    Effect of other items  2
    0.2
    0.1
    0.5
    Effective tax rate for continuing operations
    14.4
    14.3
    13.6
    Effective tax rate for discontinued operations
    13.7
    Effective tax rate
    14.4
    14.3
    13.7
     1  Included in 2017 is a 0.7% impact related to the revaluation of the deferred tax assets and liabities and a portion of current tax payables. This revaluation resulted from the US tax reform legislation enacted on December 22, 2017, refer to Note 11 for additional disclosures.
     2  Other items in 2016 (+0.1%) include one-time impacts for the deferred tax effects on the net assets of certain subsidiaries resulting from the change in their tax status (-6.2%), the changes in uncertain tax positions (+5.1%) and other items (+1.2%).
    Novartis has a substantial business presence in many countries and is therefore subject to different income and expense items that are non-taxable (permanent differences) or taxed at different rates in those tax jurisdictions. This results in a difference between our applicable tax rate and effective tax rate, as shown in the table above.
    The utilization of tax-loss carry-forwards lowered the tax charge by USD 7 million in 2017, and by USD 18 million and USD 15 million in 2016 and 2015, respectively.
    XML 81 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Earnings per share
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Earnings per share
    7. Earnings per share
    2017
    2016
    2015
    Net income attributable to shareholders of Novartis AG (USD millions)
    – Continuing operations
    7 703
    6 712
    7 025
    – Discontinued operations
    10 758
    – Total
    7 703
    6 712
    17 783
    Number of shares (in millions)
    Weighted average number of shares outstanding used in basic earnings per share
    2 346
    2 378
    2 403
    Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options
    25
    22
    35
    Weighted average number of shares in diluted earnings per share
    2 371
    2 400
    2 438
    Basic earnings per share (USD)
    – Continuing operations
    3.28
    2.82
    2.92
    – Discontinued operations
    4.48
    – Total
    3.28
    2.82
    7.40
    Diluted earnings per share (USD)
    – Continuing operations
    3.25
    2.80
    2.88
    – Discontinued operations
    4.41
    – Total
    3.25
    2.80
    7.29
    Basic earnings per share (EPS) is calculated by dividing net income attributable to shareholders of Novartis AG by the weighted average number of shares outstanding in a reporting period. This calculation excludes the average number of issued shares purchased by the Group and held as treasury shares.
    For diluted EPS, the weighted average number of shares outstanding is adjusted to assume the vesting of all restricted shares, restricted share units, and the conversion of all potentially dilutive shares arising from options on Novartis shares that have been issued.
    No options were excluded from the calculation of diluted EPS in 2017, 2016, or 2015, as all options were dilutive in all years.
    XML 82 R15.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Changes in consolidated statements of comprehensive income
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Changes in consolidated statements of comprehensive income
    8. Changes in consolidated statements of comprehensive income
    The consolidated statements of comprehensive income include the Group’s net income for the year as well as all other valuation adjustments recorded in the Group’s consolidated balance sheet but which under IFRS are not recorded in the consolidated income statement. These include fair value adjustments to financial instruments, actuarial gains or losses on defined benefit pension and other post-employment plans and currency translation effects, net of tax.
    The following table summarizes these value adjustments and currency translation effects attributable to Novartis shareholders:


    (USD millions)
    Fair value

    adjustments

    on marketable

    securities
    Fair value

    adjustments on

    deferred cash

    flow hedges
    Actuarial

    gains/(losses)

    from defined

    benefit plans


    Net

    investment

    hedge
    Cumulative

    currency

    translation

    effects




    Total value

    adjustments
    Value adjustments at January 1, 2015
    433
    – 38
    – 5 366
    2 406
    – 2 565
    Fair value adjustments on financial instruments
    28
    20
    48
    Net actuarial losses from defined benefit plans  1
    – 147
    – 147
    Currency translation effects  2
    – 1 659
    – 1 659
    Total value adjustments in 2015
    28
    20
    – 147
    – 1 659
    – 1 758
    Fair value adjustments related to divestments
    100
    100
    Value adjustments at December 31, 2015
    461
    – 18
    – 5 413
    747
    – 4 223
    Fair value adjustments on financial instruments
    – 113
    15
    – 98
    Net actuarial losses from defined benefit plans
    – 514
    – 514
    Currency translation effects
    – 2 389
    – 2 389
    Total value adjustments in 2016
    – 113
    15
    – 514
    – 2 389
    – 3 001
    Fair value adjustments related to divestments
    12
    12
    Value adjustments at December 31, 2016
    348
    – 3
    – 5 915
    – 1 642
    – 7 212
    Fair value adjustments on financial instruments
    38
    12
    50
    Net investment hedge
    – 237
    – 237
    Net actuarial gains from defined benefit plans
    851
    851
    Currency translation effects
    2 208
    2 208
    Total value adjustments in 2017
    38
    12
    851
    – 237
    2 208
    2 872
    Value adjustments at December 31, 2017
    386
    9
    – 5 064
    – 237
    566
    – 4 340
     1  Net actuarial gains of USD 10 million in 2015 were attributable to discontinued operations up to the respective divestment dates
     2  Currency translation losses of USD 29 million in 2015 were attributable to discontinued operations up to the respective divestment dates
    8.1) The 2017, 2016 and 2015 changes in the fair value of financial instruments were as follows:


    (USD millions)
    Fair value

    adjustments

    on marketable

    securities
    Fair value

    adjustments on

    deferred cash

    flow hedges






    Total
    Fair value adjustments at January 1, 2017
    348
    – 3
    345
    Changes in fair value:
    – Available-for-sale marketable securities
    11
    11
    – Available-for-sale financial investments
    47
    47
    Realized net gains transferred to the consolidated income statement:
    – Other financial assets sold
    – 109
    – 109
    Amortized net losses on cash flow hedges transferred to the consolidated income statement
    13
    13
    Impaired financial assets transferred to the consolidated income statement
    102
    102
    Deferred tax on above items  1
    – 13
    – 1
    – 14
    Fair value adjustments during the year
    38
    12
    50
    Fair value adjustments at December 31, 2017
    386
    9
    395
     1  Included in 2017 is a USD 18 million impact related to the revaluation of deferred tax liabilities on available-for-sale financial investments held in the US that were previously recognized through other comprehensive income. This revaluation resulted from the US tax reform legislation enacted on December 22, 2017, refer to Note 11 for additional disclosures.


    (USD millions)
    Fair value

    adjustments

    on marketable

    securities
    Fair value

    adjustments on

    deferred cash

    flow hedges






    Total
    Fair value adjustments at January 1, 2016
    461
    – 18
    443
    Changes in fair value:
    – Available-for-sale marketable securities
    1
    1
    – Available-for-sale financial investments
    – 87
    – 87
    Realized net gains transferred to the consolidated income statement:
    – Marketable securities sold
    – 1
    – 1
    – Other financial assets sold
    – 154
    – 154
    Amortized net losses on cash flow hedges transferred to the consolidated income statement
    16
    16
    Impaired financial assets transferred to the consolidated income statement
    131
    131
    Deferred tax on above items
    – 3
    – 1
    – 4
    Fair value adjustments during the year
    – 113
    15
    – 98
    Fair value adjustments at December 31, 2016
    348
    – 3
    345


    (USD millions)
    Fair value

    adjustments

    on marketable

    securities
    Fair value

    adjustments on

    deferred cash

    flow hedges






    Total
    Fair value adjustments at January 1, 2015
    433
    – 38
    395
    Changes in fair value:
    – Available-for-sale marketable securities
    – 130
    – 130
    – Available-for-sale financial investments
    80
    80
    – Associated companies’ movements in comprehensive income
    – 8
    – 8
    Realized net gains transferred to the consolidated income statement:
    – Marketable securities sold
    – 1
    – 1
    – Other financial assets sold
    – 103
    – 103
    Amortized net losses on cash flow hedges transferred to the consolidated income statement
    21
    21
    Impaired financial assets transferred to the consolidated income statement
    194
    194
    Deferred tax on above items
    – 4
    – 1
    – 5
    Fair value adjustments during the year
    28
    20
    48
    Fair value adjustments at December 31, 2015
    461
    – 18
    443
    8.2) In 2015, cumulative currency translation losses of USD 10 million were recycled through the income statement as a result of the divestments of subsidiaries. No currency translation losses or gains were recycled through the income statement in 2017 and 2016.
    8.3) Remeasurements from defined benefit plans arise as follows:
    (USD millions)
    2017
    2016
    2015
    Defined benefit pension plans before tax
    1 367
    – 667
    – 252
    Other post-employment benefit plans before tax
    76
    12
    168
    Taxation on above items  1
    – 592
    140
    – 63
    Total after tax
    851
    – 515
    – 147
    Attributable to:
    Shareholders of Novartis AG
    851
    – 514
    – 147
    Non-controlling interests
    – 1
     
     1  Included in 2017 is a USD -272 million impact related to the revaluation of deferred tax assets on US post-employment benefits that were previously recognized through other comprehensive income. This revaluation resulted from the US tax reform legislation enacted on December 22, 2017, refer to Note 11 for additional disclosures.
    XML 83 R16.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Property, plant and equipment
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Property, plant and equipment
    9. Property, plant & equipment
    The following table summarizes the movements of property, plant and equipment during 2017:


    (USD millions)




    Land




    Buildings


    Construction

    in progress
    Machinery

    & other

    equipment




    Total
    Cost
    January 1, 2017
    687
    13 113
    2 680
    14 816
    31 296
    Reclassifications  1
    5
    508
    – 1 617
    1 104
    Additions
    13
    104
    1 186
    425
    1 728
    Disposals and derecognitions  2
    – 23
    – 324
    – 71
    – 593
    – 1 011
    Currency translation effects
    38
    663
    190
    1 106
    1 997
    December 31, 2017
    720
    14 064
    2 368
    16 858
    34 010
    Accumulated depreciation
    January 1, 2017
    – 40
    – 5 436
    – 15
    – 10 164
    – 15 655
    Depreciation charge
    – 3
    – 510
    – 1 007
    – 1 520
    Accumulated depreciation on disposals and derecognitions  2
    6
    275
    34
    534
    849
    Impairment charge
    – 25
    – 58
    – 106
    – 189
    Reversal of impairment charge
    2
    30
    32
    Currency translation effects
    – 3
    – 287
    – 1
    – 772
    – 1 063
    December 31, 2017
    – 40
    – 5 983
    – 38
    – 11 485
    – 17 546
    Net book value at December 31, 2017
    680
    8 081
    2 330
    5 373
    16 464
    Net book value of property, plant & equipment under finance lease contracts
    78
    Commitments for purchases of property, plant & equipment
    318
    Capitalized borrowing costs
    9
     1  Reclassifications between various asset categories due to completion of plant and other equipment under construction.
     2  Derecognition of assets that are no longer used and are not considered to have a significant disposal value or other alternative use.
    The following table summarizes the movements of property, plant and equipment during 2016:


    (USD millions)




    Land




    Buildings


    Construction

    in progress
    Machinery

    & other

    equipment




    Total
    Cost
    January 1, 2016
    688
    12 857
    2 810
    15 093
    31 448
    Reclassifications  1
    4
    630
    – 1 226
    592
    Additions
    24
    176
    1 226
    409
    1 835
    Disposals and derecognitions  2
    – 8
    – 178
    – 19
    – 656
    – 861
    Currency translation effects
    – 21
    – 372
    – 111
    – 622
    – 1 126
    December 31, 2016
    687
    13 113
    2 680
    14 816
    31 296
    Accumulated depreciation
    January 1, 2016
    – 40
    – 5 188
    – 7
    – 10 231
    – 15 466
    Depreciation charge
    – 3
    – 530
    – 956
    – 1 489
    Accumulated depreciation on disposals and derecognitions  2
    5
    157
    1
    630
    793
    Impairment charge
    – 3
    – 47
    – 11
    – 61
    – 122
    Reversal of impairment charge
    6
    1
    13
    20
    Currency translation effects
    1
    166
    1
    441
    609
    December 31, 2016
    – 40
    – 5 436
    – 15
    – 10 164
    – 15 655
    Net book value at December 31, 2016
    647
    7 677
    2 665
    4 652
    15 641
    Net book value of property, plant & equipment under finance lease contracts
    81
    Commitments for purchases of property, plant & equipment
    223
    Capitalized borrowing costs
    9
     1  Reclassifications between various asset categories due to completion of plant and other equipment under construction.
     2  Derecognition of assets that are no longer used and are not considered to have a significant disposal value or other alternative use.
    XML 84 R17.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Goodwill and intangible assets
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Goodwill and intangible assets
    10. Goodwill and intangible assets
    The following table summarizes the movements of goodwill and intangible assets in 2017:
    Goodwill
    Intangible Assets other than Goodwill


    (USD millions)




    Total
    Acquired

    research &

    development


    Alcon

    brand name




    Technologies
    Currently

    marketed

    products


    Marketing

    know-how
    Other

    intangible

    assets




    Total
    Cost
    January 1, 2017
    31 381
    5 150
    2 980
    6 548
    33 007
    5 960
    1 492
    55 137
    Impact of business combinations
    94
    1 223
    1 223
    Reclassifications  1
    – 389
    175
    214
    Additions
    697
    5
    282
    162
    1 146
    Disposals and derecognitions  2
    – 353
    – 1
    – 328
    – 64
    – 746
    Currency translation effects
    704
    134
    86
    969
    48
    1 237
    December 31, 2017
    32 179
    6 462
    2 980
    6 638
    34 105
    5 960
    1 852
    57 997
    Accumulated amortization
    January 1, 2017
    – 401
    – 886
    – 3 637
    – 16 863
    – 1 430
    – 981
    – 23 797
    Reclassifications  1
    6
    – 6
    Amortization charge
    – 577
    – 2 571
    – 238
    – 304
    – 3 690
    Accumulated impairments on disposals

    and derecognitions2




    352






    317




    61


    730
    Impairment charge
    – 615
    – 92
    – 2
    – 709
    Currency translation effects
    – 28
    – 27
    – 54
    – 416
    – 37
    – 534
    December 31, 2017
    – 429
    – 1 170
    – 4 268
    – 19 631
    – 1 668
    – 1 263
    – 28 000
    Net book value at December 31, 2017
    31 750
    5 292
    2 980
    2 370
    14 474
    4 292
    589
    29 997
     1  Reclassifications between various asset categories as a result of product launches of acquired In-Process Research & Development and completion of software development.
     2  Derecognitions of assets that are no longer used or being developed and are not considered to have a significant disposal value or other alternative use.
    The following table summarizes the movements of goodwill and intangible assets in 2016:
    Goodwill
    Intangible Assets other than Goodwill


    (USD millions)




    Total
    Acquired

    research &

    development


    Alcon

    brand name




    Technologies
    Currently

    marketed

    products


    Marketing

    know-how
    Other

    intangible

    assets




    Total
    Cost
    January 1, 2016
    31 585
    4 119
    2 980
    6 563
    33 385
    5 960
    1 341
    54 348
    Impact of business combinations
    56
    690
    451
    1 141
    Reclassifications  1
    – 158
    6
    152
    Additions
    599
    223
    156
    978
    Disposals and derecognitions  2
    – 23
    – 464
    – 130
    – 617
    Currency translation effects
    – 260
    – 77
    – 15
    – 594
    – 27
    – 713
    December 31, 2016
    31 381
    5 150
    2 980
    6 548
    33 007
    5 960
    1 492
    55 137
    Accumulated amortization
    January 1, 2016
    – 411
    – 650
    – 3 070
    – 14 221
    – 1 192
    – 998
    – 20 131
    Reclassifications  1
    225
    – 225
    Amortization charge
    – 576
    – 2 926
    – 238
    – 121
    – 3 861
    Accumulated impairments on disposals

    and derecognitions2




    22






    390




    123


    535
    Impairment charge
    – 490
    – 96
    – 5
    – 591
    Currency translation effects
    10
    7
    9
    215
    20
    251
    December 31, 2016
    – 401
    – 886
    – 3 637
    – 16 863
    – 1 430
    – 981
    – 23 797
    Net book value at December 31, 2016
    30 980
    4 264
    2 980
    2 911
    16 144
    4 530
    511
    31 340
     1  Reclassifications between various asset categories as a result of product launches of acquired In-Process Research & Development and completion of software development.
     2  Derecognitions of assets that are no longer used or being developed and are not considered to have a significant disposal value or other alternative use.
    The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2017:
    Goodwill
    Intangible Assets other than Goodwill


    (USD millions)




    Total
    Acquired

    research &

    development


    Alcon

    brand name




    Technologies
    Currently

    marketed

    products


    Marketing

    know-how
    Other

    intangible

    assets




    Total
    Innovative Medicines
    15 237
    4 368
    9
    11 604
    353
    16 334
    Sandoz
    8 210
    625
    539
    1 589
    30
    2 783
    Alcon
    8 295
    291
    1 822
    1 281
    4 292
    195
    7 881
    Corporate
    8
    8
    2 980
    11
    2 999
    Net book value at December 31, 2017
    31 750
    5 292
    2 980
    2 370
    14 474
    4 292
    589
    29 997
    The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2016:
    Goodwill
    Intangible Assets other than Goodwill


    (USD millions)




    Total
    Acquired

    research &

    development


    Alcon

    brand name




    Technologies
    Currently

    marketed

    products


    Marketing

    know-how
    Other

    intangible

    assets




    Total
    Innovative Medicines
    15 010
    3 512
    11
    12 821
    276
    16 620
    Sandoz
    7 669
    613
    563
    1 904
    25
    3 105
    Alcon
    8 293
    139
    2 337
    1 419
    4 530
    196
    8 621
    Corporate
    8
    2 980
    14
    2 994
    Net book value at December 31, 2016
    30 980
    4 264
    2 980
    2 911
    16 144
    4 530
    511
    31 340
    The Innovative Medicines, Sandoz and Alcon Divisions’ cash generating units, to which goodwill are allocated, each comprise a group of smaller cash generating units. The valuation method of the recoverable amount of the cash generating units, to which goodwill is allocated, is based on the fair value less costs of disposal.
    The Alcon brand name is a Corporate asset with an indefinite life. The intangible asset is allocated to Corporate as it is used to market the Alcon-branded products of both the Alcon Division and the Ophthalmology business franchise of the Innovative Medicines Division. Net sales of these products together are the grouping of cash generating units, which is used to determine the recoverable amount. The valuation method is based on the fair value less costs of disposal.
    The following assumptions are used in the calculations:


    (As a percentage)
    Innovative

    Medicines


    Sandoz


    Alcon


    Corporate
    Terminal growth rate
    1.5
    2.0
    3.0
    2.6
    Discount rate (post-tax)
    7.0
    7.0
    7.0
    7.0
    The Alcon terminal growth rate assumption of 3% is higher than the expected inflation rate of the medical device industry, and more specifically the ophthalmic sub-segment of the industry. The growth rates are expected to exceed this long-term inflation rate, due to the impact of the demographic trend of the aging population to which Alcon’s products are prescribed is growing faster than the general population.
    The discount rates for all divisions consider the Group’s weighted average cost of capital, adjusted to approximate the weighted average cost of capital of a comparable market participant.
    The fair value less costs of disposal, for all groupings of cash generating units containing goodwill or indefinite life intangible assets, is reviewed for the impact of reasonably possible changes in key assumptions. In particular, we considered an increase in the discount rate, a decrease in the terminal growth rate and certain negative impacts on the forecasted cash flows. These reasonably possible changes in key assumptions did not indicate an impairment.
    Note 1, Significant accounting policies – Impairment of goodwill and intangible assets, provides additional disclosures on how the Group performs goodwill and intangible asset impairment testing.
    The following table shows the intangible asset impairment charges for 2017 and 2016:
    (USD millions)
    2017
    2016
    Innovative Medicines
    – 591
    – 522
    Sandoz
    – 61
    – 65
    Alcon
    – 57
    – 4
    Total
    – 709
    – 591
    XML 85 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Deferred tax assets and liabilities
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Deferred tax assets and liablities
    11. Deferred tax assets and liabilities


    (USD millions)


    Property,

    plant &

    equipment




    Intangible

    assets
    Pensions and

    other benefit

    obligations

    of associates






    Inventories


    Tax loss

    carry-

    forwards


    Other assets,

    provisions

    and accruals






    Total
    Gross deferred tax assets at January 1, 2017
    224
    1 331
    1 839
    4 160
    146
    2 597
    10 297
    Gross deferred tax liabilities at January 1, 2017
    – 629
    – 4 019
    – 358
    – 511
    – 1 403
    – 6 920
    Net deferred tax balance at January 1, 2017
    – 405
    – 2 688
    1 481
    3 649
    146
    1 194
    3 377
    At January 1, 2017
    – 405
    – 2 688
    1 481
    3 649
    146
    1 194
    3 377
    Credited/(charged) to income
    – 30
    1 279
    – 90
    – 304
    – 49
    – 46
    760
    Charged to equity
    – 101
    – 101
    Charged to other comprehensive income
    – 592
    – 69
    – 661
    Impact of business combinations
    – 322
    5
    – 317
    Other movements
    – 41
    33
    37
    – 14
    – 14
    2
    3
    Net deferred tax balance at December 31, 2017
    – 476
    – 1 698
    836
    3 331
    88
    980
    3 061
    Gross deferred tax assets at December 31, 2017
    137
    1 287
    1 090
    3 786
    97
    1 983
    8 380
    Gross deferred tax liabilities at December 31, 2017
    – 613
    – 2 985
    – 254
    – 455
    – 9
    – 1 003
    – 5 319
    Net deferred tax balance at December 31, 2017
    – 476
    – 1 698
    836
    3 331
    88
    980
    3 061
    After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction the balance amounts to:
    151
    Deferred tax assets at December 31, 2017
    8 229
    Deferred tax liabilities at December 31, 2017
    – 5 168
    Net deferred tax balance at December 31, 2017
    3 061
    Gross deferred tax assets at January 1, 2016
    216
    611
    1 730
    3 821
    62
    2 866
    9 306
    Gross deferred tax liabilities at January 1, 2016
    – 639
    – 3 962
    – 401
    – 565
    – 5
    – 1 132
    – 6 704
    Net deferred tax balance at January 1, 2016
    – 423
    – 3 351
    1 329
    3 256
    57
    1 734
    2 602
    At January 1, 2016
    – 423
    – 3 351
    1 329
    3 256
    57
    1 734
    2 602
    Credited/(charged) to income
    – 13
    1 057
    53
    373
    55
    – 517
    1 008
    Charged to equity
    – 44
    – 44
    Credited/(charged) to other comprehensive income
    140
    – 2
    138
    Impact of business combinations
    4
    – 400
    23
    37
    – 336
    Other movements
    27
    6
    – 41
    20
    11
    – 14
    9
    Net deferred tax balance at December 31, 2016
    – 405
    – 2 688
    1 481
    3 649
    146
    1 194
    3 377
    Gross deferred tax assets at December 31, 2016
    224
    1 331
    1 839
    4 160
    146
    2 597
    10 297
    Gross deferred tax liabilities at December 31, 2016
    – 629
    – 4 019
    – 358
    – 511
    – 1 403
    – 6 920
    Net deferred tax balance at December 31, 2016
    – 405
    – 2 688
    1 481
    3 649
    146
    1 194
    3 377
    After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction the balance amounts to:
    263
    Deferred tax assets at December 31, 2016
    10 034
    Deferred tax liabilities at December 31, 2016
    – 6 657
    Net deferred tax balance at December 31, 2016
    3 377
    The following table presents deferred tax assets and deferred tax liabilities, which are expected to have an impact on current taxes payable after more than twelve months:
    (USD billions)
    2017
    2016
    Expected to have an impact on current tax payable after more than 12 months
    – Deferred tax assets
    3.5
    4.8
    – Deferred tax liabilities
    4.4
    5.9
    For unremitted earnings retained by consolidated entities for reinvestment, no provision is made for income taxes that would be payable upon the distribution of these earnings. If these earnings were remitted, an income tax charge could result based on the tax statutes currently in effect.
    (USD billions)
    2017
    2016
    Unremitted earnings that have been retained

    by consolidated entities for reinvestment


    66


    63
    Temporary differences on which no deferred tax has been provided as they are permanent in nature related to:
    (USD billions)
    2017
    2016
    Investments in subsidiaries
    3
    2
    Goodwill from acquisitions
    – 29
    – 28
    The gross value of tax-loss carry-forwards that have, or have not, been capitalized as deferred tax assets, with their expiry dates is as follows:
    (USD millions)
    Not capitalized
    Capitalized
    2017 total
    One year
    37
    3
    40
    Two years
    64
    4
    68
    Three years
    87
    5
    92
    Four years
    26
    25
    51
    Five years
    67
    16
    83
    More than five years
    654
    1 671
    2 325
    Total
    935
    1 724
    2 659
    (USD millions)
    Not capitalized
    Capitalized
    2016 total
    One year
    21
    12
    33
    Two years
    30
    5
    35
    Three years
    50
    5
    55
    Four years
    75
    3
    78
    Five years
    73
    25
    98
    More than five years
    405
    1 913
    2 318
    Total
    654
    1 963
    2 617
    (USD millions)
    2017
    2016
    2015
    Tax losses carried forward

    that expired


    1


    19


    13
    Deferred tax assets related to taxable losses of relevant Group entities are recognized to the extent it is considered probable that future taxable profits will be available against which such losses can be utilized in the foreseeable future.
    On December 22, 2017, the US enacted tax reform legislation (Tax Cuts and Jobs Act), which among other provisions, reduced the US corporate tax rate from 35% to 21%, effective January 1, 2018. This required a revaluation of the deferred tax assets and liabilities and a portion of current tax payables to the newly enacted tax rates at the date of enactment.
    The following table shows the impact on the revaluation of deferred assets and liabilities and current income tax liabilities:


    (USD millions)
    Income

    statement


    Equity


    Total
    Deferred tax asset

    and liability revaluation






    Items previously recognized

    in consolidated income statement


    – 24




    – 24
    Items previously recognized

    in other comprehensive income  1




    – 254


    – 254
    Items previously recognized in retained earnings  2
    – 71
    – 71
    Total revaluation of deferred

    tax assets and liabilities


    – 24


    – 325


    – 349
    Total revaluation of current tax payables
    – 37
    – 37
    Total revaluation of deferred tax assets and liabilities and current income tax liabilities
    – 61
    – 325
    – 386
     1  Related to post-employment benefits and available for sale financial investments.
     2  Related to equity based compensation plans.
    The enacted US tax reform legislation includes a provision that requires the US parent company’s foreign subsidiaries’ unremitted earnings to be subject to an immediate toll tax on the qualifying amount of unremitted earnings (the deemed repatriated earnings). Previously, these earnings were taxable upon distribution to the US parent company. The toll tax amount owed is payable, without interest, in installments over an eight year period through 2024. Certain of the Group’s US subsidiaries are the parent company of non-US domiciled companies, and as a result, USD 70 million of deferred tax liabilities related to these entities’ unremitted earnings, the majority of which were recognized in the prior year, were reclassified to current income tax liabilities.
    XML 86 R19.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Financial and other non-current assets
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Financial and other non-current assets
    12. Financial and other non-current assets
    Financial assets
    (USD millions)
    2017
    2016
    Available-for-sale long-term

    financial investments


    1 275


    1 096
    Long-term receivables from customers
    197
    231
    Minimum lease payments

    from finance lease agreements


    122


    147
    Contingent consideration receivables  1
    394
    586
    Long-term loans, advances and security deposits
    255
    136
    Total financial assets
    2 243
    2 196
     1  Note 28 provides additional disclosures related to contingent considerations.
    Other non-current assets
    (USD millions)
    2017
    2016
    Deferred compensation plans
    484
    451
    Prepaid post-employment benefit plans
    133
    47
    Other non-current assets
    201
    200
    Total other non-current assets
    818
    698
    Minimum finance lease payments
    The following table shows the receivables of the gross investments in finance leases and the net present value of the minimum lease payments, as well as unearned finance income, related to surgical equipment lease arrangements. The finance income is recorded in “Other income”.
    2017
    2016


    (USD millions)
    Total

    future

    payments
    Unearned

    finance

    income


    Present

    value




    Provision
    Net

    book

    value
    Total

    future

    payments
    Unearned

    finance

    income


    Present

    value




    Provision
    Net

    book

    value
    Not later than one year  1
    83
    – 7
    76
    – 3
    73
    91
    – 5
    86
    – 2
    84
    Between one and five years
    180
    – 14
    166
    – 59
    107
    182
    – 16
    166
    – 37
    129
    Later than five years
    31
    – 2
    29
    – 14
    15
    63
    – 4
    59
    – 41
    18
    Total
    294
    – 23
    271
    – 76
    195
    336
    – 25
    311
    – 80
    231
     1  The current portion of the minimum lease payments is recorded in trade receivables or other current assets (to the extent not yet invoiced).
    XML 87 R20.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Inventories
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Inventories
    13. Inventories
    (USD millions)
    2017
    2016
    Raw material, consumables
    841
    705
    Work in progress
    2 957
    2 700
    Finished products
    3 069
    2 850
    Total inventories
    6 867
    6 255
    The following table shows the amount of inventory recognized as an expense in “Cost of goods sold” in the consolidated income statements:
    (USD billions)
    2017
    2016
    2015
    Cost of goods sold
    – 10.3
    – 10.3
    – 10.5
    The following table shows the recognized amount of inventory provisions and reversals of inventory provisions:
    (USD millions)
    2017
    2016
    2015
    Inventory provisions
    – 470
    – 283
    – 356
    Reversals of inventory provisions
    189
    67
    148
    The reversals mainly result from the release of products initially requiring additional quality control inspections and from the reassessment of inventory values manufactured prior to regulatory approval but for which approval was subsequently received.
    XML 88 R21.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Trade receivables
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Trade receivables
    14. Trade receivables
    (USD millions)
    2017
    2016
    Total gross trade receivables
    8 790
    8 364
    Provisions for doubtful trade receivables
    – 190
    – 162
    Total trade receivables, net
    8 600
    8 202
    The following table summarizes the movement in the provision for doubtful trade receivables:
    (USD millions)
    2017
    2016
    2015
    January 1
    – 162
    – 142
    – 156
    Impact of divestments
    12
    Provisions for doubtful trade receivables charged to the consolidated income statement
    – 119
    – 76
    – 68
    Utilization provisions for doubtful trade receivables
    12
    17
    39
    Reversal of provisions for doubtful trade receivables
    76
    37
    32
    Currency translation effects
    – 9
    2
    11
    December 31
    – 190
    – 162
    – 142
    The following sets forth the trade receivables that are not overdue as specified in the payment terms and conditions established with Novartis customers as well as an analysis of overdue amounts and related provisions for doubtful trade receivables:
    (USD millions)
    2017
    2016
    Not overdue
    7 758
    7 386
    Past due for not more than one month
    279
    262
    Past due for more than one month

    but less than three months


    230


    223
    Past due for more than three months

    but less than six months


    137


    185
    Past due for more than six months

    but less than one year


    137


    145
    Past due for more than one year
    249
    163
    Provisions for doubtful trade receivables
    – 190
    – 162
    Total trade receivables, net
    8 600
    8 202
    Trade receivable balances include sales to drug wholesalers, retailers, private health systems, government agencies, managed care providers, pharmacy benefit managers and government-supported healthcare systems. Novartis continues to monitor sovereign debt issues and economic conditions, particularly in Greece, Italy, Portugal, Spain, Brazil, Russia, Saudi Arabia and Turkey, and evaluates trade receivables in these countries for potential collection risks. The majority of the outstanding trade receivables from these closely monitored countries are due directly from local governments or from government-funded entities except for Russia, Brazil and Turkey, which are due from private entities. Deteriorating credit and economic conditions as well as other factors in these closely monitored countries have resulted in, and may continue to result in an increase in the average length of time that it takes to collect these trade receivables and may require Novartis to re-evaluate the collectability of these trade receivables in future periods.
    The following table shows the gross trade receivables balance from these closely monitored countries at December 31, 2017 and 2016, the amounts that are past due for more than one year and the related provisions that have been recorded:
    (USD millions)
    2017
    2016
    Total balance of gross trade

    receivables from closely

    monitored countries




    1 733




    1 717
    Past due for more than one year
    124
    82
    Provisions
    95
    63
    At December 31, 2017 amounts past due for more than one year are not significant in any of these countries on a standalone basis.
    Total trade receivables include amounts denominated in the following major currencies:
    (USD millions)
    2017
    2016
    US dollar (USD)
    3 451
    3 432
    Euro (EUR)
    1 533
    1 366
    Japanese yen (JPY)
    600
    567
    Chinese yuan (CNY)
    312
    264
    Russian ruble (RUB)
    268
    347
    Brazilian real (BRL)
    237
    222
    British pound (GBP)
    208
    160
    Australian dollar (AUD)
    165
    147
    Swiss franc (CHF)
    127
    135
    Canadian dollar (CAD)
    73
    97
    Other currencies
    1 626
    1 465
    Total trade receivables, net
    8 600
    8 202
    XML 89 R22.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Disclosure of marketable securities commodities deposits derivative instruments and cash
    15. Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents
    Marketable securities, commodities, time deposits and derivative financial instruments
    (USD millions)
    2017
    2016
    Debt securities
    328
    306
    Fund investments
    34
    31
    Total available-for-sale marketable securities
    362
    337
    Commodities
    106
    94
    Time deposits with original maturity more than 90 days
    125
    108
    Derivative financial instruments
    31
    230
    Accrued interest on debt securities and time deposits
    1
    1
    Total marketable securities, commodities, time deposits and derivative financial instruments
    625
    770
    The following table provides a breakdown of debt securities by currency:
    (USD millions)
    2017
    2016
    US dollar (USD)
    303
    284
    Euro (EUR)
    14
    12
    Japanese yen (JPY)
    11
    10
    Total debt securities
    328
    306
    Cash and cash equivalents
    (USD millions)
    2017
    2016
    Current accounts
    2 970
    1 912
    Time deposits and short-term investments with original maturity less than 90 days
    5 890
    5 095
    Total cash and cash equivalents
    8 860
    7 007
    XML 90 R23.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Other current assets
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Other current assets
    16. Other current assets
    (USD millions)
    2017
    2016
    VAT receivable
    717
    521
    Withholding tax recoverable
    93
    282
    Prepaid expenses
    – Third parties
    753
    692
    – Associated companies
    3
    5
    Receivables from associated companies
    8
    7
    Contingent consideration receivable  1
    450
    Other receivables and current assets
    1 030
    1 034
    Total other current assets
    3 054
    2 541
     1  Note 28 provides additional disclosures related to contingent consideration.
    XML 91 R24.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Equity
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Equity
    17. Equity
    The following table shows the movement in the share capital:


    (USD millions)


    Jan 1, 2015
    Movement

    in year


    Dec 31, 2015
    Movement

    in year


    Dec 31, 2016
    Movement

    in year


    Dec 31, 2017
    Share capital
    1 001
    – 10
    991
    – 19
    972
    – 3
    969
    Treasury shares
    – 103
    2
    – 101
    25
    – 76
    – 24
    – 100
    Outstanding share capital
    898
    – 8
    890
    6
    896
    – 27
    869
    The following table shows the movement in the shares:
    2017
    2016
    2015


    Number of outstanding shares

    (in millions)




    Note
    Total

    Novartis

    shares
    Total

    treasury

    shares
    Total

    outstanding

    shares
    Total

    Novartis

    shares
    Total

    treasury

    shares
    Total

    outstanding

    shares
    Total

    Novartis

    shares
    Total

    treasury

    shares
    Total

    outstanding

    shares
    Balance at beginning of year
    2 627.1
    – 253.0
    2 374.1
    2 677.0
    – 303.1
    2 373.9
    2 706.2
    – 307.6
    2 398.6
    Shares canceled for capital

    reduction  1




    – 10.3


    10.3




    – 49.9


    49.9




    – 29.2


    29.2


    Shares acquired to be held in

    Group Treasury  2


















    – 9.6


    – 9.6
    Shares acquired to be

    canceled  3






    – 66.2


    – 66.2




    – 10.3


    – 10.3




    – 49.9


    – 49.9
    Other share purchases  4
    – 3.8
    – 3.8
    – 2.6
    – 2.6
    – 4.1
    – 4.1
    Exercise of options

    and employee transactions  5


    17.6




    4.6


    4.6




    4.1


    4.1




    27.0


    27.0
    Equity-based compensation  5
    8.8
    8.8
    9.0
    9.0
    11.9
    11.9
    Total movements
    – 10.3
    – 46.3
    – 56.6
    – 49.9
    50.1
    0.2
    – 29.2
    4.5
    – 24.7
    Balance at end of year
    2 616.8
    – 299.3
    2 317.5
    2 627.1
    – 253.0
    2 374.1
    2 677.0
    – 303.1
    2 373.9
     1  Novartis reduced its share capital by cancelling shares which were repurchased on the SIX Swiss Exchange second trading line during previous years.
     2  Shares repurchased on the SIX Swiss Exchange first trading line
     3  For 2017 and 2016, shares repurchased on the SIX Swiss Exchange second trading line under the CHF 10 billion share buyback authority approved at the 2016 Annual General Meeting (AGM). For 2015, shares repurchased on the SIX Swiss Exchange second trading line under the CHF 10 billion share buyback authority approved at the 2008 Annual General Meeting (AGM).
     4  Shares acquired from employees, which were previously granted to them under the respective programs
     5  Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans
    17.1) The amount available for distribution as a dividend to shareholders is based on the available distributable retained earnings of Novartis AG determined in accordance with the legal provisions of the Swiss Code of Obligations.
    2017
    2016
    2015
    Dividend per share (in CHF)
    2.75
    2.70
    2.60
    Total dividend payment

    (in USD billion)


    6.5


    6.5


    6.6
    17.2) The following table summarizes the treasury shares movements:
    2017
    2016
    2015






    Note
    Number of

    outstanding

    shares

    (in millions)




    Equity impact

    USDm
    Number of

    outstanding

    shares

    (in millions)




    Equity impact

    USDm
    Number of

    outstanding

    shares

    (in millions)




    Equity impact

    USDm
    Shares acquired to be held in Group Treasury  1
    – 9.6
    – 897
    Shares acquired to be canceled  2
    – 66.2
    – 5 270
    – 10.3
    – 784
    – 49.9
    – 4 805
    Other share purchases  3
    – 3.8
    – 304
    – 2.6
    – 208
    – 4.1
    – 417
    Purchase of treasury shares
    – 70.0
    – 5 574
    – 12.9
    – 992
    – 63.6
    – 6 119
    Exercise of options and employee transactions  4
    17.6
    4.6
    255
    4.1
    214
    27.0
    1 592
    Equity-based compensation  5, 6
    8.8
    612
    9.0
    664
    11.9
    815
    Total
    – 56.6
    – 4 707
    0.2
    – 114
    – 24.7
    – 3 712
     1  Shares repurchased on the SIX Swiss Exchange first trading line
     2  For 2017 and 2016, shares repurchased on the SIX Swiss Exchange second trading line under the CHF 10 billion share buyback authority approved at the 2016 Annual General Meeting (AGM). For 2015, shares repurchased on the SIX Swiss Exchange second trading line under the CHF 10 billion share buyback authority approved at the 2008 Annual General Meeting (AGM).
     3  Shares acquired from employees, which were previously granted to them under the respective programs
     4  Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price reflecting the strike price of the options exercised.
     5  Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax deductible amounts exceeding the expense recognized in the income statement are credited to equity.
     6  Included in 2017 is a USD 71 million impact related to the revaluation of deferred tax assets on equity based compensation that were previously recognized through retained earnings. This revaluation resulted from the US tax reform legislation enacted on December 22, 2017, refer to Note 11 for additional disclosures.
    17.3) Changes in non-controlling interests represent the impact on the non-controlling interest of transactions with minority shareholders such as change in ownership percentage, dividend payments, and other equity transactions.
    17.4) In 2017, Novartis entered into an irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares on the second trading line under its up-to USD 5 billion share buyback, as well as to mitigate dilution from equity-based participation plans. The commitment under this arrangement is the expected purchases by the bank under such trading plan over a rolling 90-day period. As of December 31, 2017, this trading plan commitment was fully executed and expired, and as a consequence, there is no contingent liability related to this plan recognized.
    In 2014, Novartis entered into a similar irrevocable, non-discretionary arrangement with a bank to repurchase Novartis shares. The commitment under this arrangement reflected the expected purchases by the bank under such trading plan over a rolling 90-day period. In 2015, this trading plan was fully executed and expired, resulting in a decrease of USD 658 million in the repurchase obligation. As a consequence, there is no contingent liability related to this plan as of December 31, 2015 and December 31, 2016.
    17.5) The impact of change in ownership of consolidated entities represents the excess of the amount paid to non-controlling interest over their carrying value and equity allocation to non-controlling interest due to change in ownership percentage.
    17.6) At December 31, 2017, the market maker held 12 million written call options, originally issued as part of the share-based compensation for associates that have not yet been exercised. The weighted average exercise price of these options is USD 62.17 and they have contractual lives of 10 years, with remaining lives up to six years.
    XML 92 R25.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Non-current financial debt
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Non-current financial debt
    18. Non-current financial debt
    (USD millions)
    2017
    2016
    Straight bonds
    22 957
    17 285
    Liabilities to banks and other financial institutions  1
    539
    708
    Finance lease obligations
    87
    82
    Total, including current portion of non-current financial debt
    23 583
    18 075
    Less current portion of non-current financial debt
    – 359
    – 178
    Total non-current financial debts
    23 224
    17 897
     1  Average interest rate 0.3% (2016: 0.4%)
    Financial debts, including current financial debts, contain only general default covenants. The Group is in compliance with these covenants.
    The percentage of fixed-rate financial debt to total financial debt was 82% at December 31, 2017, and 76% at December 31, 2016.
    The average interest rate on total financial debt in 2017 was 2.6% (2016: 2.8%).
    The following table provides a breakdown of straight bonds:


    Coupon




    Currency


    Nominal

    amount


    Issuance

    year


    Maturity

    year




    Issuer




    Issue price
    2017

    (USD

    millions)
    2016

    (USD

    millions)
    5.125%
    USD
    3 000
    2009
    2019
    Novartis Securities Investment Ltd., Hamilton, Bermuda
    99.822%
    2 997
    2 995
    4.400%
    USD
    1 000
    2010
    2020
    Novartis Capital Corporation, New York, United States
    99.237%
    997
    996
    2.400%
    USD
    1 500
    2012
    2022
    Novartis Capital Corporation, New York, United States
    99.225%
    1 491
    1 490
    3.700%
    USD
    500
    2012
    2042
    Novartis Capital Corporation, New York, United States
    98.325%
    489
    489
    3.400%
    USD
    2 150
    2014
    2024
    Novartis Capital Corporation, New York, United States
    99.287%
    2 134
    2 132
    4.400%
    USD
    1 850
    2014
    2044
    Novartis Capital Corporation, New York, United States
    99.196%
    1 824
    1 823
    0.750%
    EUR
    600
    2014
    2021
    Novartis Finance S.A., Luxembourg, Luxembourg
    99.134%
    713
    625
    1.625%
    EUR
    600
    2014
    2026
    Novartis Finance S.A., Luxembourg, Luxembourg
    99.697%
    714
    627
    0.250%
    CHF
    500
    2015
    2025
    Novartis AG, Basel, Switzerland
    100.640%
    513
    491
    0.625%
    CHF
    550
    2015
    2029
    Novartis AG, Basel, Switzerland
    100.502%
    564
    539
    1.050%
    CHF
    325
    2015
    2035
    Novartis AG, Basel, Switzerland
    100.479%
    333
    318
    3.000%
    USD
    1 750
    2015
    2025
    Novartis Capital Corporation, New York, United States
    99.010%
    1 730
    1 728
    4.000%
    USD
    1 250
    2015
    2045
    Novartis Capital Corporation, New York, United States
    98.029%
    1 218
    1 217
    0.125%
    EUR
    1 250
    2016
    2023
    Novartis Finance S.A., Luxembourg, Luxembourg
    99.127%
    1 480
    1 299
    0.625%
    EUR
    500
    2016
    2028
    Novartis Finance S.A., Luxembourg, Luxembourg
    98.480%
    588
    516
    1.800%
    USD
    1 000
    2017
    2020
    Novartis Capital Corporation, New York, United States
    99.609%
    996
    2.400%
    USD
    1 000
    2017
    2022
    Novartis Capital Corporation, New York, United States
    99.449%
    993
    3.100%
    USD
    1 000
    2017
    2027
    Novartis Capital Corporation, New York, United States
    99.109%
    988
    0.000%
    EUR
    1 250
    2017
    2021
    Novartis Finance S.A., Luxembourg, Luxembourg
    99.133%
    1 480
    1.125%
    EUR
    600
    2017
    2027
    Novartis Finance S.A., Luxembourg, Luxembourg
    99.874%
    715
    Total straight bonds
    22 957
    17 285
    The following tables provide a breakdown of total non-current financial debt, including current portion by maturity and currency:
    Breakdown by maturity:
    (USD millions)
    2017
    2016
    2017
    178
    2018
    359
    345
    2019
    3 173
    3 168
    2020
    1 997
    1 000
    2021
    2 194
    628
    2022
    2 485
    2 442
    After 2022
    13 375
    10 314
    Total
    23 583
    18 075
    Breakdown by currency:
    (USD millions)
    2017
    2016
    US dollar (USD)
    15 945
    12 952
    Euro (EUR)
    5 695
    3 092
    Japanese yen (JPY)
    533
    683
    Swiss franc (CHF)
    1 410
    1 348
    Total
    23 583
    18 075
    The following table shows the comparison of balance sheet and fair value of total non-current financial debt, including current portion:


    (USD millions)
    2017

    Balance sheet
    2017

    Fair values
    2016

    Balance sheet
    2016

    Fair values
    Straight bonds
    22 957
    23 835
    17 285
    17 943
    Others
    626
    626
    790
    790
    Total
    23 583
    24 461
    18 075
    18 733
    The fair values of straight bonds are determined by quoted market prices. Other financial debts are recorded at notional amounts which are a reasonable approximation of the fair values.
    The following table shows the pledged assets:
    (USD millions)
    2017
    2016
    Total net book value of property,

    plant & equipment pledged as

    collateral for non-current financial debts




    84




    94
    XML 93 R26.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Provisions and other non-current liabilities
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Provisions and other non-current liabilities
    19. Provisions and other non-current liabilities
    (USD millions)
    2017
    2016
    Accrued liability for employee benefits:
    Defined benefit pension plans  1
    3 157
    4 490
    Other long-term employee benefits and deferred compensation
    625
    545
    Other post-employment benefits  1
    953
    1 005
    Environmental remediation provisions
    706
    708
    Provisions for product liabilities, governmental investigations and other legal matters
    230
    264
    Contingent consideration  2
    809
    840
    Other non-current liabilities
    577
    618
    Total provisions and other non-current liabilities
    7 057
    8 470
     
     1  Note 24 provides additional disclosures related to post-employment benefits.
     2  Note 28 provides additional disclosures related to contingent consideration.
    Novartis believes that its total provisions are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities in this area, Novartis may incur additional costs beyond the amounts provided. Management believes that such additional amounts, if any, would not be material to the Group’s financial condition but could be material to the results of operations or cash flows in a given period.
    Environmental remediation provisions
    The following table shows the movements in the environmental liability provisions:
    (USD millions)
    2017
    2016
    2015
    January 1
    773
    871
    923
    Cash payments
    – 46
    – 75
    – 52
    Releases
    – 153
    – 5
    Additions
    154
    1
    6
    Currency translation effects
    33
    – 24
    – 1
    December 31
    761
    773
    871
    Less current provision
    – 55
    – 65
    – 80
    Non-current environmental remediation provisions at December 31
    706
    708
    791
    The material components of the environmental remediation provisions consist of costs to sufficiently clean and refurbish contaminated sites to the extent necessary, and to treat, and where necessary, continue surveillance at sites where the environmental remediation exposure is less significant.
    A substantial portion of the environmental remediation provisions relate to the remediation of Basel regional landfills in the adjacent border areas in Switzerland, Germany and France. The provisions are re-assessed on a yearly basis and are adjusted as necessary.
    In the United States, Novartis has been named under federal legislation (the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended) as a potentially responsible party (PRP) in respect of certain sites. Novartis actively participates in, or monitors, the clean-up activities at the sites in which it is a PRP. The provision takes into consideration the number of other PRPs at each site as well as the identity and financial position of such parties in light of the joint and several nature of the liability.
    The expected timing of the related cash outflows as of December 31, 2017, is currently projected as follows:


    (USD millions)
    Expected

    cash outflows
    Due within two years
    164
    Due later than two years, but within five years
    241
    Due later than five years, but within ten years
    315
    Due after ten years
    41
    Total environmental remediation liability provisions
    761
    Provisions for product liabilities, governmental investigations and other legal matters
    Novartis has established provisions for certain product liabilities, governmental investigations and other legal matters where a potential cash outflow is probable and Novartis can make a reliable estimate of the amount of the outflow. These provisions represent the Group’s current best estimate of the total financial effect for the matters described below and for other less significant matters. Potential cash outflows reflected in a provision might be fully or partially off-set by insurance in certain circumstances.
    Novartis has not established provisions for potential damage awards for certain additional legal claims against its subsidiaries if Novartis currently believes that a payment is either not probable or cannot be reliably estimated. In total, these not-provisioned-for matters include more than 1 000 individual product liability cases and certain other legal matters. Plaintiffs’ alleged claims in these matters, which Novartis does not believe to be entirely remote but which do not fulfill the conditions for the establishment of provisions, currently aggregate to, according to Novartis’ current best belief, approximately USD 1.5 billion. In addition, in some of these matters there are claims for punitive or multiple (treble) damages, civil penalties and disgorgement of profits that in Novartis’ view are either wholly or partially unspecified or wholly or partially unquantifiable at present; the Group believes that information about these amounts claimed by plaintiffs generally is not meaningful for purposes of determining a reliable estimate of a loss that is probable or more than remote.
    A number of other legal matters are in such early stages or the issues presented are such that the Group has not made any provisions since it cannot currently estimate either a potential outcome or the amount of any potential losses. For these reasons, among others, the Group generally is unable to make a reliable estimate of possible loss with respect to such cases. It is therefore not practicable to provide information about the potential financial impact of those cases.
    There might also be cases for which the Group was able to make a reliable estimate of the possible loss or the range of possible loss, but the Group believes that publication of such information on a case-by-case basis would seriously prejudice the Group’s position in ongoing legal proceedings or in any related settlement discussions. Accordingly, in such cases, information has been disclosed with respect to the nature of the contingency, but no disclosure is provided as to an estimate of the possible loss or range of possible loss.
    Note 27 contains additional information on contingencies.
    Summary of significant legal proceedings
    The following is a summary of significant legal proceedings to which Novartis or its subsidiaries are a party or were a party and that concluded in 2017.
    Investigations and related litigations
    Southern District of New York (S.D.N.Y.) marketing practices investigation and litigation
    In 2013, the US government filed a civil complaint in intervention to an individual qui tam action against Novartis Pharmaceuticals Corporation (NPC) in the United States District Court (USDC) for the S.D.N.Y. The complaint, as subsequently amended, asserts federal False Claims Act (FCA) and common law claims with respect to speaker programs and other promotional activities for certain NPC cardiovascular medications ( Lotrel, Starlix and Valturna) allegedly serving as mechanisms to provide kickbacks to healthcare professionals (HCPs). It seeks damages, which according to the complaint are “substantial”, including treble damages and maximum civil penalties per claim, as well as disgorgement of Novartis profits from the alleged unlawful conduct. Also in 2013, New York State filed a civil complaint in intervention asserting similar claims. Neither government complaint in intervention adopted the individual relator’s claims with respect to off-label promotion of Valturna, which were subsequently dismissed with prejudice by the court. The individual relator continues to litigate the kickback claims on behalf of other states and municipalities. NPC vigorously contests the S.D.N.Y., New York State and individual claims, both as to alleged liability and amount of damages and penalties.
    S.D.N.Y. / Western District of New York healthcare fraud investigation
    In 2011, Alcon Laboratories, Inc. (ALI) received a subpoena from the United States Department of Health & Human Services relating to an investigation into allegations of healthcare fraud. The subpoena requests the production of documents relating to marketing practices, including the remuneration of healthcare providers, in connection with certain ALI products ( Vigamox, Nevanac, Omnipred, Econopred; surgical equipment). ALI is cooperating with this investigation.
    S.D.N.Y. gilenya marketing practices investigation
    In 2013, NPC received a civil investigative demand from the United States Attorney’s Office (USAO) for the S.D.N.Y. requesting the production of documents and information relating to marketing practices for Gilenya, including the remuneration of healthcare providers in connection therewith. In 2017, S.D.N.Y. and New York State declined to intervene in claims raised by an individual relator, which continue to be vigorously contested.
    GOVERNMENT GENERIC PRICING ANTITRUST INVESTIGATIONS, ANTITRUST CLASS ACTIONS
    In 2016 and 2017, Sandoz Inc. received subpoenas and interrogatories from the Antitrust Division of the US Department of Justice (DoJ) and from the Attorney General of the State of Connecticut requesting documents related to the marketing and pricing of generic pharmaceutical products sold by Sandoz Inc. and its subsidiaries, including Fougera Pharmaceuticals, Inc. (Fougera), and related communications with competitors. Sandoz Inc. is cooperating with these investigations, which it believes to be part of a broader inquiry into industry practice.
    Since the third quarter of 2016, Sandoz Inc. and Fougera have been sued alongside other generic pharmaceutical companies in more than 20 consolidated complaints by proposed classes of direct and indirect purchasers, and Attorneys General for 45 states, the District of Columbia and Puerto Rico have sought leave to file a complaint, alleging that defendants, including Sandoz, engaged in anti-competitive conduct with regard to the sales of various generic drugs and asserting violations of federal and state antitrust laws as well as consumer protection laws. Lek Pharmaceuticals d.d., Novartis AG and Novartis International AG were dismissed from the proceedings. The cases have been consolidated for pretrial purposes in the USDC for the Eastern District of Pennsylvania (E.D. Pa.) and the claims are being vigorously contested.
    District of Massachusetts (D. Mass.) charitable foundation investigation
    In 2016 and 2017, NPC received subpoenas from the USAO for the D. Mass. requesting documents related to NPC’s support of 501(c)(3) organizations that provide co-payment assistance to Medicare patients who are prescribed Novartis medicines, including the respective accounting and tax treatment, as well as related to pricing strategies for Gleevec, Tasigna, Zometa, and Gilenya. The requests are focused on potential violations of federal health care offenses, including the Anti-Kickback Statute, and FCA. NPC is cooperating with this investigation, which it believes to be part of a broader inquiry into industry practices.
    Asia/Russia investigation
    In 2017, Novartis Group companies, as well as present and former senior executives of Alcon, received document requests and subpoenas from the DoJ and the US Securities and Exchange Commission (SEC) requesting information concerning Alcon’s business practices in Asia and Russia and related accounting treatment, both before and after Alcon became part of the Novartis Group. Novartis is cooperating with this investigation.
    Lucentis/Avastin ® matters
    In connection with an investigation into whether Novartis Farma S.p.A., Novartis AG, F. Hoffmann-La Roche AG, Genentech Inc. and Roche S.p.A. colluded to artificially preserve the market positions of Avastin ® and Lucentis, in 2014 the Italian Competition Authority imposed a fine equivalent to USD 125 million on Novartis AG and Novartis Farma S.p.A. Novartis paid the fine, subject to the right to later claim recoupment, and is appealing before the Consiglio di Stato. In 2014 and 2015, the Italian Ministry of Health and the Lombardia region sent letters with payment requests for a total equivalent of approximately USD 1.5 billion in damages from Novartis and Roche entities based on the above allegations. In 2014, the French Competition Authority opened an investigation against Novartis Groupe France with respect to the French market for anti-vascular endothelial growth factor (VEGF) products indicated for the treatment of wet age-related macular degeneration (AMD). Novartis continues to vigorously contest all claims in Italy and France. Also, Novartis is challenging policies and regulations allowing off-label/unlicensed use and reimbursement for economic reasons in various countries, including in Italy and the UK.
    Japan investigation
    In 2015, a trial started against a former Novartis Pharma K.K. (NPKK) employee, and also NPKK under the dual liability concept in Japanese law, over allegations brought by the Tokyo District Public Prosecutor Office in two counts for alleged manipulation of data in sub-analysis publications of the Kyoto Heart Study regarding valsartan. The charges against NPKK are subject to a maximum total fine of JPY 4 million. In 2017, the Tokyo District Court issued a not-guilty ruling for both the former NPKK employee and NPKK. An appeal by the Tokyo District Public Prosecutor Office remains pending.
    south korea investigation
    In 2016, the Seoul Western District Prosecutor initiated a criminal investigation into, among other things, allegations that Novartis Korea utilized medical journals to provide inappropriate economic benefits to HCPs. A criminal trial is ongoing concerning allegations that Novartis Korea utilized medical journals to provide inappropriate economic benefits to HCPs. In addition, other authorities in South Korea, including the Korea Fair Trade Commission, the Ministry of Food and Drug Safety and the Ministry of Health and Welfare conducted investigations into Novartis Korea. Those investigations have led to total fines of approximately USD 53 million as well as sales and reimbursement suspensions on Novartis Korea products in 2017.
    greece investigation
    Novartis is investigating allegations of potentially inappropriate economic benefits in Greece to HCPs and others. Novartis Group companies in Greece are providing information to the Greek authorities related to these allegations. Novartis is also responding to a subpoena and document requests from the SEC and DoJ that it received in 2016 and 2017 in connection with such allegations and is cooperating with their investigation.
    Antitrust class actions
    contact lenses
    Since the first quarter of 2015, more than 50 putative class action complaints have been filed in several courts across the US naming contact-lens manufacturers, including ALI, and alleging violations of federal antitrust law as well as state antitrust, consumer protection and unfair competition laws of various states in connection with the sale of contact lenses. The cases have been consolidated in the Middle District of Florida by the Judicial Panel on Multidistrict Litigation and the claims are being vigorously contested.
    gleevec
    In 2015 and 2016, Novartis Group companies were sued in putative antitrust class actions in D. Mass. alleging delayed generic entry of Gleevec and seeking damages on behalf of direct and indirect purchasers of Gleevec. The motion to dismiss those actions was granted and plaintiffs have appealed. A similar class action was filed in 2018 in E.D. Pa. on behalf of direct purchasers of Gleevec. The claims are being vigorously contested.
    Enoxaparin
    In 2015, Sandoz and Momenta Pharmaceuticals were sued in a putative antitrust class action in federal court in Tennessee alleging that Momenta and Sandoz engaged in anticompetitive and unfair business conduct with regard to sales of enoxaparin, and the same allegations were made by Amphastar in a lawsuit filed in federal court in California and subsequently moved to federal court in Mass. (Sandoz, Momenta Pharmaceuticals and Amphastar are currently engaged in patent litigation concerning enoxaparin). The claims are being vigorously contested.
    Other matters
    Average Wholesale Price (AWP) litigation
    Lawsuits have been brought, the latest in February 2016, by various US state governmental entities and private parties against various pharmaceutical companies, including certain Sandoz entities and NPC, alleging that they fraudulently overstated the AWP that is or has been used by payors, including state Medicaid agencies, to calculate reimbursements to healthcare providers. NPC remains a defendant in an action brought by the state of Illinois and in a putative class action brought by private payors in New Jersey, and Sandoz remains a defendant in an individual action in Pennsylvania. The putative class action in Pennsylvania was dismissed in 2017. The claims are being vigorously contested.
    Reclast/ Aclasta product liability litigation
    NPC is a defendant in more than 20 US product liability actions involving Reclast and alleging atypical femur fracture injuries, most of which are in New Jersey state or federal court and in California state court coordinated with claims against other bisphosphonate manufacturers. The Canadian putative class action brought against numerous bisphosphonate manufacturers, including NPC, Novartis Pharmaceuticals Canada Inc. and Novartis International AG, in Quebec was discontinued in 2017. The claims are being vigorously contested.
    Taxotere® (docetaxel) product liability litigation
    Sandoz is a defendant in more than 1 000 US product liability actions involving Taxotere® (docetaxel), an oncology product, many of which have been transferred to Multidistrict Litigation in the Eastern District of Louisiana. The complaints allege that Sanofi, as innovator, and several 505(b)(2) NDA holders (including Sandoz) failed to warn of the risk of permanent alopecia/hair loss. The claims are being vigorously contested.
    Amiodarone product liability litigation
    Sandoz entities are named in more than 10 individual and multi-plaintiff US product liability cases involving amiodarone, a cardiac drug indicated to treat life-threatening arrhythmias that have not responded to other treatment. The complaints allege failure to warn, off-label promotion and failure to include medication guides to pharmacies. All claims are being vigorously contested.
    Oriel litigation
    In 2013, Shareholder Representative Services LLC filed a complaint in New York State Court against Sandoz Inc., two affiliates and two former officers of Sandoz AG asserting various common law and statutory contract, fraud and negligent misrepresentation claims arising out of Sandoz Inc.’s purchase of Oriel Therapeutics, Inc. In March 2015, the court dismissed all parties and claims but for a breach of contract claim against Sandoz Inc. Sandoz Inc. continues to vigorously contest the claim.
    Eye drop products consumer class actions
    Two putative consumer fraud class actions remain ongoing against Alcon and Sandoz in New Jersey and at the US Court of Appeals for the First Circuit after having been initially dismissed at the trial court level. They claim that Alcon’s and Sandoz’s eye drop products for glaucoma were unfairly designed so that the drop dosage is more than necessary and exceeds the capacity of the eye, leading to wastage and higher costs to patient consumers. The claims are being vigorously contested.
    IP Matters
    MIVS @ platform patent infringement litigation
    Johns Hopkins University filed a patent infringement lawsuit against Alcon alleging that the use of certain Alcon surgical products, principally by third parties, infringes a patent directed to certain methods of ocular surgery, and a trial is scheduled for February 2018. The claims are being vigorously contested.
    Concluded legal matters
    New York State pricing policy investigation
    In 2014, ALI received a civil subpoena from the New York State attorney general relating to an investigation into a unilateral pricing policy program. Novartis considers this matter concluded.
    Lucentis/Avastin ® matter in France
    Novartis’ appeals against a temporary recommendation of use and reimbursement of off-label Avastin ® for neovascular AMD by hospital ophthalmologists, in force since September 2015, as well as against the decree on which the recommendation is based, were rejected by the Supreme Court in 2016 and 2017.
    Solodyn ® antitrust class actions
    Since the third quarter of 2013, seventeen putative class action complaints and three other complaints had been filed against manufacturers of the brand drug Solodyn ® and its generic equivalent, including Sandoz Inc. The cases had been consolidated and transferred for pretrial purposes to the federal district court in Mass. The plaintiffs purported to represent direct and indirect purchasers of Solodyn ® branded products and asserted violations of federal and state antitrust laws, including allegations in connection with separate settlements by Medicis with each of the other defendants, including Sandoz Inc., of patent litigation relating to Solodyn ®. In 2017, all cases were resolved through settlement, the payment of which was not material to Novartis.
    Summary of product liability, governmental investigations and other legal matters provision movements
    (USD millions)
    2017
    2016
    2015
    January 1
    395
    1 194
    849
    Cash payments
    – 69
    – 811
    – 256
    Releases of provisions
    – 70
    – 239
    – 223
    Additions to provisions
    93
    243
    832
    Currency translation effects
    2
    8
    – 8
    December 31
    351
    395
    1 194
    Less current portion
    – 121
    – 131
    – 743
    Non-current product liabilities, governmental investigations and other legal matters provisions at December 31
    230
    264
    451
    Novartis believes that its total provisions for investigations, product liability, arbitration and other legal matters are adequate based upon currently available information. However, given the inherent difficulties in estimating liabilities, there can be no assurance that additional liabilities and costs will not be incurred beyond the amounts provided.
    XML 94 R27.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Current financial debt and derivative financial instruments
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Current financial debt and derivative financial instruments
    20. Current financial debt and derivative financial instruments
    (USD millions)
    2017
    2016
    Interest-bearing accounts of associates

    payable on demand  1


    1 822


    1 601
    Bank and other financial debt  2
    692
    836
    Commercial paper
    2 328
    3 174
    Current portion of non-current financial debt
    359
    178
    Fair value of derivative financial instruments
    107
    116
    Total current financial debt and derivative financial instruments
    5 308
    5 905
     1  Weighted average interest rate 0.5% (2016: 0.5%)
     2  Weighted average interest rate 7.0% (2016: 6.7%)
    The consolidated balance sheet amounts of current financial debt, other than the current portion of non-current financial debt, approximate the estimated fair value due to the short-term nature of these instruments.
    Details on commercial papers are provided in Note 28 – Liquidity risk.
    XML 95 R28.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Provisions and other current liabilities
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Provisions and other current liabilities
    21. Provisions and other current liabilities
    (USD millions)
    2017
    2016
    Taxes other than income taxes
    660
    547
    Restructuring provisions
    153
    222
    Accrued expenses for goods and services received but not invoiced
    977
    880
    Accruals for royalties
    586
    550
    Provisions for deductions from revenue
    4 672
    4 183
    Accruals for compensation and benefits including social security
    2 327
    1 993
    Environmental remediation liabilities
    55
    65
    Deferred income
    305
    287
    Provisions for product liabilities, governmental investigations and other legal matters  1
    121
    131
    Accrued share-based payments
    261
    199
    Contingent considerations  2
    44
    49
    Other payables
    1 042
    722
    Total provisions and other current liabilities
    11 203
    9 828
     
     1  Note 19 provides additional disclosures related to legal provisions.
     2  Note 28 provides additional disclosures related to contingent considerations.
    Provisions are based upon management’s best estimate and adjusted for actual experience. Such adjustments to the historic estimates have not been material.
    Provisions for deductions from revenue
    The following table shows the movement of the provisions for deductions from revenue:
    (USD millions)
    2017
    2016
    2015
    January 1
    4 183
    3 790
    3 533
    Impact of business combinations
    3
    Additions
    17 997
    16 622
    15 603
    Payments/utilizations
    – 17 452
    – 16 189
    – 15 218
    Changes in offset against

    gross trade receivables


    – 252


    10


    50
    Currency translation effects
    196
    – 50
    – 181
    December 31
    4 672
    4 183
    3 790
    Restructuring provisions movements
    (USD millions)
    2017
    2016
    2015
    January 1
    222
    260
    333
    Additions
    194
    343
    399
    Cash payments
    – 200
    – 260
    – 435
    Releases
    – 64
    – 66
    – 36
    Transfers
    – 7
    – 76
    Currency translation effects
    8
    21
    – 1
    December 31
    153
    222
    260
    In 2017, additions to provisions of USD 194 million were mainly related to the following reorganizations:
    • The Innovative Medicines Division’s Pharmaceuticals business unit adjusted a regional promotional model which led to a restructuring of the sales force. It also streamlined the above country operating model to facilitate an even higher external competition oriented focus. Furthermore, the development organization streamlined its activities to create efficiencies.
    • The Alcon Division continued initiatives to realign its operations to focus on the Surgical and Vision Care business after the Ophthalmic Pharmaceutical business transfer to the Innovative Medicines Division.
    • The Sandoz Division launched initiatives to focus resources to gain efficiencies.
    • Group-wide initiatives to streamline Novartis Technical Operations in the Innovative Medicines and Sandoz Divisions were launched.
    In 2016, additions to provisions of USD 343 million were mainly related to the following reorganizations:
    • The Innovative Medicines Division’s Pharmaceuticals business unit realigned its operations to improve its operating agility, to focus resources on key growth drivers. Furthermore, research realigned and focused its operations resulting in redundancies from the consolidation of certain research teams and the outsourcing of certain activities to qualified third party vendors.
    • The Alcon Division launched several initiatives to improve its efficiencies resulting in redundancies, as it realigned its operations to focus on its Surgical and Vision Care business franchises after the transfer of its Ophthalmic Pharmaceuticals business to Innovative Medicines division.
    • The Sandoz Division launched an initiative to reallocate resources to priority, high growth and higher profitability countries.
    • Various group-wide initiatives to simplify organizational structure, including the consolidation of manufacturing sites and support services.
    In 2015, additions to provisions of USD 399 million were mainly related to the following reorganizations:
    • The Innovative Medicines Division implemented a restructuring program targeted at efficiency gains in the business franchises, other than in Oncology. It also initiated initiatives related to the integration of the oncology business acquired from GSK.
    • The Alcon Division extended its initiative started in the prior year to realize productivity opportunities.
    • Various group-wide initiatives to simplify the organizational structure, mainly related to the manufacturing footprint and support services.
    XML 96 R29.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Details to the consolidated cash flow statements
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Details to the consolidated cash flow statements
    22. Details to the consolidated cash flow statements
    22.1) Adjustments for non-cash items from continuing operations
    (USD millions)
    2017
    2016
    2015
    Taxes
    1 296
    1 119
    1 106
    Depreciation, amortization and impairments on:
    Property, plant & equipment
    1 677
    1 591
    1 550
    Intangible assets
    4 399
    4 452
    3 921
    Financial assets  1
    256
    132
    104
    Income from associated companies
    – 1 108
    – 703
    – 266
    Gains on disposal and other adjustments on property, plant & equipment, intangible, financial and other

    non-current assets, net


    – 1 043


    – 935


    – 869
    Equity-settled compensation expense
    683
    671
    773
    Change in provisions and other non-current liabilities
    160
    956
    1 642
    Net financial expense
    738
    1 154
    1 109
    Total
    7 058
    8 437
    9 070
     1  Including unrealized fair value gains
    In 2015, the Group acquired property, plant and equipment of USD 85 million through finance lease contracts.
    22.2) Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations
    (USD millions)
    2017
    2016
    2015
    (Increase) in inventories
    – 247
    – 235
    – 482
    (Increase) in trade receivables
    – 204
    – 229
    – 513
    Increase/(Decrease) in trade payables
    58
    – 587
    378
    Change in other net current assets and other operating cash flow items
    637
    974
    – 246
    Total
    244
    – 77
    – 863
    22.3) Cash flows arising from acquisitions and divestments of businesses
    The following is a summary of the cash flow impact of acquisitions and divestments. The most significant transactions are described in Note 2.


    (USD millions)
    2017

    Acquisitions
    2017

    Divestments
    2016

    Acquisitions
    2016

    Divestments
    2015

    Acquisitions
    2015

    Divestments
    Property, plant & equipment
    25
    1 000
    Currently marketed products
    1
    – 451
    – 12 970
    646
    (Acquired)/divested research & development
    – 1 223
    – 690
    – 730
    13
    Technologies
    113
    Other intangible assets
    3
    – 15
    86
    Financial and other assets including deferred tax assets
    – 8
    – 39
    – 555
    40
    Inventories
    – 4
    893
    Trade receivables and other current assets
    34
    – 1
    – 3
    529
    Cash and cash equivalents
    – 20
    – 1
    – 25
    311
    Current and non-current financial debts
    – 601
    Trade payables and other liabilities including deferred tax liabilities
    326
    – 15
    372
    212
    – 841
    Net identifiable assets (acquired) or divested
    – 925
    48
    – 814
    – 14 086
    2 189
    Currency translation effects
    98
    Acquired/(divested) liquidity
    20
    1
    25
    – 479
    Fair value of previously held equity interests
    64
    Subtotal
    – 905
    48
    – 749
    – 14 061
    1 808
    Refinancing of intercompany financial debt, net
    578
    Goodwill
    – 94
    – 56
    – 2 438
    1 042
    Divestment gain
    7 401
    Taxes paid and other portfolio transformation related cash flows
    – 140
    – 748
    – 1 337
    Receivables and payables contingent consideration, net  1
    206
    84
    – 8
    – 519
    Other payments and deferred consideration, net
    – 36
    – 3
    – 44
    Deferred portion of sales price  2
    – 49
    Net cash flows
    – 829
    – 95
    – 765
    – 748
    – 16 507
    8 924
    Of which:
    Net cash flows used in/from discontinued operations
    – 140
    – 748
    8 924
    Net cash flows used in/from continuing operations
    – 829
    45
    – 765
    – 16 507
     1  The contingent consideration of the 2016 Transcend Medical, Inc. acquisition amounted to USD 92 million. Of this amount, USD 60 million has been paid in 2016.
     2  Divestments include USD 49 million proceeds for the divestment of the Animal Health business received in 2014.
    Notes 2 and 23 provide further information regarding acquisitions and divestments of businesses. All acquisitions were for cash.
    22.4) Cash flows from discontinued operations
    (USD millions)
    2017
    2016
    2015
    Cash flows used in operating activities
    – 188
    Purchase of property, plant & equipment
    – 41
    Proceeds from sales of property, plant & equipment
    1
    Purchase of financial and other non-current assets, net
    – 2
    Divestments of businesses  1
    – 140
    – 748
    8 924
    Cash flows used in/from investing activities
    – 140
    – 748
    8 882
    Total net cash flows used in/from discontinued operations
    – 140
    – 748
    8 694
     1  2017 includes payments related to the 2015 portfolio transformation transaction. 2016 includes mainly payments for capital gains taxes and other payments related to the 2015 portfolio transformation transaction. 2015 includes proceeds of USD 10 925 million reduced by USD 2 001 million, for payments of capital gains taxes, transaction-related costs and purchase price adjustments, related to the 2015 portfolio transformation transaction. See Note 2 for a description of the 2015 porfolio transformation transaction.
    22.5) Reconciliation of liabilities arising from financing activities


    (USD millions)






    Non-current

    financial

    debts










    Current

    financial

    debts and

    derivative

    financial

    instruments




















    Total
    January 1, 2017
    17 897
    5 905
    23 802
    Increase in non-current financial debts
    4 933
    4 933
    Repayment of non-current financial debts
    – 1
    – 187
    – 188
    Change in current financial debts
    – 755
    – 755
    Changes in fair values and other changes
    – 6
    – 140
    – 146
    Amortization of bonds discount
    16
    16
    Currency translation effects
    744
    126
    870
    Current portion of non-current financial debt
    – 359
    359
    December 31, 2017
    23 224
    5 308
    28 532
     
    XML 97 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Acquisitions of businesses
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Acquisition of businesses
    23. Acquisitions of businesses
    Fair value of assets and liabilities arising from acquisitions
    (USD millions)
    2017
    2016
    2015
    Currently marketed products
    451
    12 970
    Acquired research & development
    1 223
    690
    730
    Other intangible assets
    15
    Deferred tax assets
    8
    39
    555
    Inventories
    4
    Trade receivables and other current assets
    1
    3
    Cash and cash equivalents
    20
    1
    25
    Payables and other liabilities including deferred tax liabilities
    – 326
    – 372
    – 212
    Net identifiable assets acquired
    925
    814
    14 086
    Acquired liquidity
    – 20
    – 1
    – 25
    Goodwill
    94
    56
    2 438
    Net assets recognized as a result of business combinations
    999
    869
    16 499
    Note 2 details significant acquisition of businesses, which were Ziarco and Encore in 2017, were Transcend and Reprixys in 2016, and were the GSK Oncology products, Spinifex and Admune in 2015. The goodwill arising out of these acquisitions is attributable to buyer-specific synergies, the assembled workforce and the accounting for deferred tax liabilities on the acquired assets. No goodwill from 2017 is tax-deductible. Goodwill of USD 18 million from 2016 and of USD 2.4 billion from 2015 is tax deductible.
    XML 98 R31.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Post-employment benefits for associates
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Post-employment benefits for associates
    24. Post-employment benefits for associates
    Defined benefit plans
    In addition to the legally required social security schemes, the Group has numerous independent pension and other post-employment benefit plans. In most cases, these plans are externally funded in entities that are legally separate from the Group. For certain Group companies, however, no independent plan assets exist for the pension and other post-employment benefit obligations of associates. In these cases the related unfunded liability is included in the balance sheet. The defined benefit obligations (DBOs) of all major pension and other post-employment benefit plans are reappraised annually by independent actuaries. Plan assets are recognized at fair value. The major plans are based in Switzerland, the United States, the United Kingdom, Germany and Japan, which represent 94% of the Group’s total DBO for pension plans. Details of the plans in the two most significant countries of Switzerland and the United States are provided below.
    Swiss-based pension plans represent the most significant portion of the Group’s total DBO and plan assets. For the active insured members born on or after January 1, 1956, or having joined the plans after December 31, 2010, the benefits are partially linked to the contributions paid into the plan. Certain features of Swiss pension plans required by law preclude the plans being categorized as defined contribution plans. These factors include a minimum interest guarantee on retirement savings accounts, a pre-determined factor for converting the accumulated savings account balance into a pension and embedded death and disability benefits.
    All benefits granted under Swiss-based pension plans are vested, and Swiss legislation prescribes that the employer has to contribute a fixed percentage of an associate’s pay to an external pension fund. Additional employer contributions may be required whenever the plan’s statutory funding ratio falls below a certain level. The associate also contributes to the plan. The pension plans are run by separate legal entities, each governed by a Board of Trustees, that, for the principal plans, consists of representatives nominated by Novartis and the active insured associates. The Boards of Trustees are responsible for the plan design and asset investment strategy.
    In September 2017, the pension regulations in Switzerland were amended, which resulted in a change in accounting from defined benefit to defined contribution for a component of the Swiss pension plans. This change resulted in a reduction to the defined benefit pension plans liability and in a corresponding net pre-tax gain of USD 225 million (CHF 216 million).
    The United States pension plans represent the second largest component of the Group’s total DBO and plan assets. The principal plans (Qualified Plans) are funded, whereas plans providing additional benefits for executives (Restoration Plans) are unfunded. Employer contributions are required for Qualified Plans whenever the statutory funding ratio falls below a certain level. Furthermore, associates in the United States are covered under other post-employment benefit plans and post-retirement medical plans.
    The following tables are a summary of the funded and unfunded defined benefit obligation for pension and other post-employment benefit plans of associates at December 31, 2017 and 2016:
    Pension plans
    Other post-employment benefit plans
    (USD millions)
    2017
    2016
    2017
    2016
    Benefit obligation at January 1
    23 614
    23 402
    1 158
    1 132
    Current service cost
    422
    437
    34
    35
    Interest cost
    330
    390
    44
    48
    Past service costs and settlements
    – 1 226
    – 73
    – 10
    Administrative expenses
    27
    29
    Remeasurement losses arising from changes in financial assumptions
    11
    1 299
    32
    46
    Remeasurement (gains) arising from changes in demographic assumptions
    – 26
    – 7
    – 9
    – 26
    Experience-related remeasurement losses/(gains)
    47
    117
    – 87
    – 33
    Currency translation effects
    1 138
    – 896
    5
    7
    Benefit payments
    – 1 300
    – 1 250
    – 51
    – 51
    Contributions of associates
    207
    207
    Effect of acquisitions, divestments or transfers
    – 34
    – 41
    – 1
    Benefit obligation at December 31
    23 210
    23 614
    1 115
    1 158
    Fair value of plan assets at January 1
    19 225
    19 536
    153
    172
    Interest income
    236
    293
    5
    6
    Return on plan assets excluding interest income
    1 429
    742
    12
    – 1
    Currency translation effects
    909
    – 757
    Novartis Group contributions
    579
    542
    43
    27
    Contributions of associates
    207
    207
    Settlements
    – 995
    – 77
    Benefit payments
    – 1 300
    – 1 250
    – 51
    – 51
    Effect of acquisitions, divestments or transfers
    – 15
    – 11
    Fair value of plan assets at December 31
    20 275
    19 225
    162
    153
    Funded status
    – 2 935
    – 4 389
    – 953
    – 1 005
    Limitation on recognition of fund surplus at January 1
    – 54
    – 50
    Change in limitation on recognition of fund surplus (incl. exchange rate differences)
    – 30
    Interest income on limitation of fund surplus
    – 5
    – 4
    Limitation on recognition of fund surplus at December 31
    – 89
    – 54
    Net liability in the balance sheet at December 31
    – 3 024
    – 4 443
    – 953
    – 1 005
    The reconciliation of the net liability from January 1 to December 31 is as follows:
    Pension plans
    Other post-employment benefit plans
    (USD millions)
    2017
    2016
    2017
    2016
    Net liability at January 1
    – 4 443
    – 3 916
    – 1 005
    – 960
    Current service cost
    – 422
    – 437
    – 34
    – 35
    Net interest expense
    – 99
    – 101
    – 39
    – 42
    Administrative expenses
    – 27
    – 29
    Past service costs and settlements
    231
    – 4
    10
    Remeasurements
    1 397
    – 667
    76
    12
    Currency translation effects
    – 229
    139
    – 5
    – 7
    Novartis Group contributions
    579
    542
    43
    27
    Effect of acquisitions, divestments or transfers
    19
    30
    1
    Change in limitation on recognition of fund surplus
    – 30
    Net liability at December 31
    – 3 024
    – 4 443
    – 953
    – 1 005
    Amounts recognized in the consolidated balance sheet
    Prepaid benefit cost
    133
    47
    Accrued benefit liability
    – 3 157
    – 4 490
    – 953
    – 1 005
    The following table shows a breakdown of the DBO for pension plans by geography and type of member, and the breakdown of plan assets into the geographical locations in which they are held:
    2017
    2016


    (USD millions)


    Switzerland


    United States
    Rest of

    the world


    Total


    Switzerland


    United States
    Rest of

    the world


    Total
    Benefit obligation at December 31
    14 606
    3 788
    4 816
    23 210
    15 436
    3 783
    4 395
    23 614
    Thereof unfunded
    728
    499
    1 227
    739
    497
    1 236
    By type of member
    Active
    5 627
    796
    1 646
    8 069
    6 426
    891
    1 460
    8 777
    Deferred pensioners
    1 258
    1 646
    2 904
    831
    1 515
    2 346
    Pensioners
    8 979
    1 734
    1 524
    12 237
    9 010
    2 061
    1 420
    12 491
    Fair value of plan assets at December 31
    14 445
    2 400
    3 430
    20 275
    13 958
    2 282
    2 985
    19 225
    Funded status
    – 161
    – 1 388
    – 1 386
    – 2 935
    – 1 478
    – 1 501
    – 1 410
    – 4 389
    The following table shows the principal weighted average actuarial assumptions used for calculating defined benefit plans and other post-employment benefits of associates:
    Pension plans
    Other post-employment benefit plans
    2017
    2016
    2015
    2017
    2016
    2015
    Weighted average assumptions used to determine benefit obligations at December 31
    Discount rate
    1.5%
    1.4%
    1.8%
    3.7%
    4.2%
    4.4%
    Expected rate of pension increase
    0.5%
    0.4%
    0.4%
    Expected rate of salary increase
    2.8%
    2.2%
    2.9%
    Interest on savings account
    0.6%
    0.5%
    0.8%
    Current average life expectancy

    for a 65-year-old male in years


    22


    22


    21


    21


    21


    21
    Current average life expectancy

    for a 65-year-old female in years


    24


    24


    24


    23


    23


    23
    Changes in the aforementioned actuarial assumptions can result in significant volatility in the accounting for the Group’s pension plans in the consolidated financial statements. This can result in substantial changes in the Group’s other comprehensive income, long-term liabilities and prepaid pension assets.
    The DBO is significantly impacted by assumptions regarding the rate that is used to discount the actuarially determined post-employment benefit liability. This rate is based on yields of high-quality corporate bonds in the country of the plan. Decreasing corporate bond yields decrease the discount rate, so that the DBO increases and the funded status decreases.
    In Switzerland, an increase in the DBO due to lower discount rates is slightly offset by lower future benefits expected to be paid on the associate’s savings account where the assumption on interest accrued changes in line with the discount rate.
    The impact of decreasing interest rates on a plan’s assets is more difficult to predict. A significant part of the plan assets is invested in bonds. Bond values usually rise when interest rates decrease and may therefore partially compensate for the decrease in the funded status. Furthermore, pension assets also include significant holdings of equity instruments. Share prices tend to rise when interest rates decrease and therefore often counteract the negative impact of the rising defined benefit obligation on the funded status (although the correlation of interest rates with equities is not as strong as with bonds, especially in the short term).
    The expected rate for pension increases significantly affects the DBO of most plans in Switzerland, Germany and the United Kingdom. Such pension increases also decrease the funded status, although there is no strong correlation between the value of the plan assets and pension/inflation increases.
    Assumptions regarding life expectancy significantly impact the DBO. An increase in longevity increases the DBO. There is no offsetting impact from the plan assets, as no longevity bonds or swaps are held by the pension funds. Generational mortality tables are used where this data is available.
    The following table shows the sensitivity of the defined benefit pension obligation to the principal actuarial assumptions for the major plans in Switzerland, the United States, the United Kingdom, Germany and Japan on an aggregated basis:


    (USD millions)
    Change in 2017 year-end

    defined benefit pension obligation
    25 basis point increase in discount rate
    – 753
    25 basis point decrease in discount rate
    803
    1 year increase in life expectancy
    840
    25 basis point increase in rate of pension increase
    533
    25 basis point decrease in rate of pension increase
    – 138
    25 basis point increase of interest on savings account
    56
    25 basis point decrease of interest on savings account
    – 54
    25 basis point increase in rate of salary increase
    49
    25 basis point decrease in rate of salary increase
    – 50
    The healthcare cost trend rate assumptions used for other post-employment benefits are as follows:
    2017
    2016
    2015
    Healthcare cost trend rate

    assumed for next year


    6.5%


    7.0%


    7.5%
    Rate to which the cost trend

    rate is assumed to decline


    4.5%


    5.0%


    5.0%
    Year that the rate reaches

    the ultimate trend rate


    2025


    2022


    2022
    The following table shows the weighted average plan asset allocation of funded defined benefit pension plans at December 31, 2017 and 2016:
    Pension plans


    (as a percentage)
    Long-term

    target

    minimum
    Long-term

    target

    maximum




    2017




    2016
    Equity securities
    15
    40
    31
    31
    Debt securities
    20
    60
    35
    35
    Real estate
    5
    20
    15
    15
    Alternative investments
    0
    20
    15
    15
    Cash and other investments
    0
    15
    4
    4
    Total
    100
    100
    Cash and most of the equity and debt securities have a quoted market price in an active market. Real estate and alternative investments, which include hedge fund and private equity investments, usually do not have a quoted market price.
    The strategic allocation of assets of the different pension plans is determined with the objective of achieving an investment return that, together with the contributions paid by the Group and its associates, is sufficient to maintain reasonable control over the various funding risks of the plans. Based upon the market and economic environments, actual asset allocations may temporarily be permitted to deviate from policy targets. The asset allocation currently includes investments in shares of Novartis AG as per the below table:
    December 31,

    2017
    December 31,

    2016
    Investment in shares of Novartis AG
    Number of shares (in millions)
    11.0
    11.0
    Market Value (in USD billions)
    0.9
    0.8
    The weighted average duration of the defined benefit obligation is 14.6 years (2016: 14.5 years).
    The Group’s ordinary contribution to the various pension plans is based on the rules of each plan. Additional contributions are made whenever this is required by statute or law (i.e., usually when statutory funding levels fall below pre-determined thresholds). The only significant plans that are foreseen to require additional funding are those in the United Kingdom.
    The expected future cash flows in respect of pension and other post-employment benefit plans at December 31, 2017, were as follows:


    (USD millions)




    Pension plans
    Other post-

    employment

    benefit plans
    Novartis Group contributions
    2018 (estimated)
    395
    62
    Expected future benefit payments
    2018
    1 226
    63
    2019
    1 166
    65
    2020
    1 163
    67
    2021
    1 147
    68
    2022
    1 133
    69
    2023–2027
    5 534
    344
    Defined contribution plans
    In many subsidiaries, associates are covered by defined contribution plans. Contributions charged to the 2017 consolidated income statement for the defined contribution plans were:
    (USD millions)
    2017
    2016
    2015
    Contributions for defined contribution plans

    continuing operations


    406


    338


    359
    Contributions for defined contribution plans discontinued operations
    1
    XML 99 R32.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Equity-based participation plans for associates
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Equity-based participation plans for associates
    25. Equity-based participation plans for associates
    The expense related to all equity-based participation plans and the liabilities arising from equity-based payment transactions were as follows:
    (USD millions)
    2017
    2016
    2015
    Expense related to equity-based

    participation plans


    924


    846


    968
    of which continuing operations
    924
    846
    903
    of which discontinued operations
    65
    Liabilities arising from equity-based payment transactions
    261
    199
    209
    Equity-based participation plans can be separated into the following plans:
    Annual Incentive
    The Annual Incentive of the Novartis Group CEO and the other Executive Committee members is paid 50% in cash in February or March of the year following the performance period, and 50% in Novartis Restricted Shares (RSs) or Restricted Share Units (RSUs) that are granted in January of the year following the performance period, deferred and restricted for three years. In 2016, this was extended to Novartis Top Leaders (NTLs). The Annual Incentive payout for the NTLs is 70% in cash and 30% in Novartis RSs or RSUs. Each RS is entitled to voting rights and payment of dividends during the vesting period. Each RSU is equivalent to one Novartis share and is converted into one share at the vesting date. RSUs do not carry any dividend, dividend equivalent or voting rights. The executives in certain countries may elect to also receive their cash incentive partially or fully in shares or share units that will not be subject to vesting conditions.
    Share savings plans
    A number of associates in certain countries as well as certain key executives worldwide are encouraged to invest their Annual Incentive, and in the United Kingdom also their salary, in a share savings plan. Under the share savings plan, participants may elect to receive their Annual Incentive fully or partially in Novartis shares in lieu of cash. As a reward for their participation in the share savings plan, at no additional cost to the participant, Novartis matches their investments in shares after a holding period of three or five years.
    Novartis operates three share savings plans, and associates may only participate in one of the share savings plans in any given year:
    • In Switzerland, Employee Share Ownership Plan (ESOP) participants may choose to receive their Annual Incentive (i) 100% in shares, (ii) 50% in shares and 50% in cash or (iii) 100% in cash. After expiration of a three-year holding period for Novartis shares invested under the ESOP, participants will receive one matching share for every two invested shares. Associates eligible for the equity plan “Select” are not eligible to receive ESOP matching shares starting with the 2017 performance period onwards.
    • In the United Kingdom, associates can invest up to 10% of their monthly salary in shares (up to a maximum of GBP 150) and may also be invited to invest their net Annual Incentive in shares. Two invested shares are matched with one share with a holding period of three years. Starting with the 2017 performance period onwards, United Kingdom associates can only invest a maximum of 50% of their Annual Incentive in shares and this option is no longer offered to associates who are eligible for the equity plan “Select”.
    • The Leveraged Share Savings Plan (LSSP) was available to key executives for performance periods prior to 2016. At the participant’s election, the Annual Incentive was awarded partly or entirely in shares. The elected number of shares is subject to a holding period of five years. At the end of the holding period, Novartis will match the invested shares at a ratio of 1-to-1 (i.e. one share awarded for each invested share). In the United States both the LSSP award and the corresponding match are cash settled.
    Following the introduction of the new compensation programs in 2014, the Novartis Group CEO and the other Executive Committee members are no longer eligible to participate in the share savings plans. From the 2016 performance period onwards, the NTLs are also no longer eligible to participate in the share savings plans.
    Novartis equity plan “Select”
    The equity plan “Select” is a global equity incentive plan under which eligible associates may annually be awarded a grant subject to a three year vesting period. No awards are granted for performance ratings below a certain threshold. Executive Committee members are not eligible for participation in the equity plan “Select” effective from the performance period 2014, and the NTLs are not eligible to participate effective from the performance period 2016.
    The equity plan “Select” currently allows participants in Switzerland to choose the form of their equity compensation in RSs or RSUs. In all other jurisdictions, RSUs are typically granted. Until 2013, participants could also choose to receive part or the entire grant in the form of tradable share options.
    Tradable share options expire on their tenth anniversary from the grant date. Each tradable share option entitles the holder to purchase after vesting (and before the tenth anniversary from the grant date) one Novartis share at a stated exercise price that equals the closing market price of the underlying share at the grant date.
    Options under Novartis equity plan “Select” outside North America
    The following table shows the activity associated with the share options during the period. The weighted average prices in the table below are translated from Swiss francs into USD at historical rates.
    2017
    2016




    Options

    (millions)
    Weighted

    average

    exercise

    price (USD)




    Options

    (millions)
    Weighted

    average

    exercise

    price (USD)
    Options outstanding

    at January 1


    9.5


    59.4


    11.7


    59.9
    Sold or exercised
    – 2.1
    59.2
    – 2.2
    61.8
    Forfeited or expired
    Outstanding at December 31
    7.4
    59.5
    9.5
    59.4
    Exercisable at December 31
    7.4
    59.5
    9.5
    59.4
    All share options were granted at an exercise price that was equal to the closing market price of the Group’s shares at the grant date. The weighted average share price at the dates of sale or exercise was USD 80.1.
    The following table summarizes information about share options outstanding at December 31, 2017:
    Options outstanding


    Range of exercise prices (USD)


    Number

    outstanding

    (millions)
    Average

    remaining

    contractual

    life (years)
    Weighted

    average

    exercise

    price (USD)
    45–49
    0.7
    1.0
    46.7
    50–54
    1.1
    2.0
    54.6
    55–59
    2.7
    3.3
    57.6
    65–70
    2.9
    5.0
    66.1
    Total
    7.4
    3.6
    59.5
    Options under Novartis equity plan “Select” for North America
    The following table shows the activity associated with the American Depositary Receipts (ADR) options during the period:
    2017
    2016


    ADR

    options

    (millions)
    Weighted

    average

    exercise

    price (USD)


    ADR

    options

    (millions)
    Weighted

    average

    exercise

    price (USD)
    Options outstanding

    at January 1


    25.9


    59.9


    31.9


    60.2
    Sold or exercised
    – 5.6
    59.9
    – 6.0
    61.7
    Forfeited or expired
    Outstanding at December 31
    20.3
    59.9
    25.9
    59.9
    Exercisable at December 31
    20.3
    59.9
    25.9
    59.9
    All ADR options were granted at an exercise price that was equal to the closing market price of the ADRs at the grant date. The weighted average ADR price at the dates of sale or exercise was USD 79.9.
    The following table summarizes information about ADR options outstanding at December 31, 2017:
    ADR options outstanding


    Range of exercise prices (USD)


    Number

    outstanding

    (millions)
    Average

    remaining

    contractual

    life (years)
    Weighted

    average

    exercise

    price (USD)
    45–49
    1.8
    1.0
    46.4
    50–54
    2.1
    2.0
    53.7
    55–59
    8.0
    3.5
    58.0
    65–69
    8.4
    5.0
    66.1
    Total
    20.3
    3.7
    59.9
    Long-Term Performance Plan
    The Long-Term Performance Plan (LTPP) is an equity plan for the Novartis Group CEO, the other Executive Committee members and the NTLs. For the 2017 grant, the target incentive is 200% of base compensation for the Novartis Group CEO and ranges from 150% to 170% for other Executive Committee members. For the NTLs, the target incentive range is from 20% to 160% of base compensation.
    The awards of the LTPP are based on three-year performance objectives focused on financial and innovation measures. The financial measure is Novartis Cash Value Added (NCVA). The weighting of this measure is 75%. The NCVA target is approved by the Board of Directors.
    The innovation measure is based on a holistic approach under which divisional innovation targets are set at the beginning of the cycle, comprised of up to ten target milestones that represent the most important research and development project milestones for each division. The weighting of this measure is 25%. At the end of the performance period, the Research & Development Committee assists the Board of Directors and the Compensation Committee in evaluating performance against the innovation targets at the end of the cycle.
    Under the LTPP, participants are granted a target number of Performance Share Units (PSUs) at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. Payout is between 0% and 200% of target. PSUs granted under the LTPP do not carry voting rights, but do carry dividend equivalents that are paid in shares at the end of the performance period.
    Long-Term Relative Performance Plan
    The Long-Term Relative Performance Plan (LTRPP) is an equity plan for the Novartis Group CEO, other ECN members and NTLs. For the 2017 grant, the target incentive is 125% of base compensation for the Novartis Group CEO and ranges from 60% to 80% for other Executive Committee members. For the NTLs, the target incentive range is from 10% to 40% of base compensation. The LTRPP is based on the ranking of Novartis’ Total Shareholder Return (TSR) relative to a global healthcare peer group of 12 companies until 2016, and 15 companies from 2017, over rolling three-year performance periods. TSR in USD is calculated as price change of the Novartis share plus the dividend plus the re-investment return of the dividend amount, all translated to USD at the respective exchange rate, over the three-year performance period. The calculation is based on Bloomberg standard published TSR data, which is publicly available. The position in the peer group determines the payout range based on a payout matrix. Under the LTRPP, participants are also granted a target number of PSUs at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. Payout is between 0% and 200% of target. PSUs under the LTRPP do not carry voting rights, but do carry dividend equivalents that are paid in shares at the end of the performance period.
    Other share awards
    Selected associates, excluding the Executive Committee members, may exceptionally receive Special Share Awards of RSs or RSUs. These Special Share Awards provide an opportunity to reward outstanding achievements or exceptional performance, and aim to retain key contributors. They are based on a formal internal selection process, through which the individual performance of each candidate is thoroughly assessed at several management levels. Special Share Awards have a minimum three-year vesting period. In exceptional circumstances, Special Share Awards may be awarded to attract special expertise and new talents into the organization. These grants are consistent with market practice and Novartis’ philosophy to attract, retain and motivate best-in-class talents around the world.
    Worldwide, associates at different levels in the organization were awarded RSs and RSUs in 2017.
    In addition, in 2017, Board members received unrestricted shares as part of their regular compensation.
    Summary of non-vested share movements
    The table below provides a summary of non-vested share movements (RSs, RSUs and PSUs) for all plans:
    2017
    2016


    Number

    of shares

    in millions
    Weighted

    average fair

    value at grant

    date in USD


    Fair value at

    grant date in

    USD millions


    Number

    of shares

    in millions
    Weighted

    average fair

    value at grant

    date in USD


    Fair value at

    grant date in

    USD millions
    Non-vested shares at January 1
    21.0
    89.5
    1 880
    20.1
    87.1
    1 751
    Granted
    – Annual incentive
    1.3
    69.3
    90
    0.1
    73.8
    7
    – Share savings plans
    4.5
    69.4
    312
    4.4
    78.1
    344
    – Select North America
    4.5
    64.1
    288
    4.8
    72.4
    348
    – Select outside North America
    2.0
    65.3
    131
    1.6
    74.4
    119
    – Long-Term Performance Plan
    1.4
    71.5
    100
    1.2
    79.2
    95
    – Long-Term Relative Performance Plan
    0.4
    47.7
    19
    0.3
    58.5
    18
    – Other share awards
    1.3
    67.8
    88
    0.7
    65.8
    46
    Vested
    – 10.7
    78.2
    – 837
    – 10.4
    68.8
    – 716
    Forfeited
    – 1.8
    80.7
    – 145
    – 1.8
    73.1
    – 132
    Non-vested shares at December 31
    23.9
    80.6
    1 926
    21.0
    89.5
    1 880
    Alcon, Inc., equity plans granted to associates prior to the merger
    At the completion of the merger of Alcon, Inc. into Novartis on April 8, 2011, all awards outstanding under the Alcon equity plans were converted into awards based upon Novartis shares with a conversion factor of 3.0727 as defined in the Merger Agreement. The plans are fully vested.
    Share options entitle the recipient to purchase Novartis shares at the closing market price of the former Alcon, Inc., share on the day of grant divided by the conversion factor.
    Share-settled appreciation rights (SSAR) entitle the participant to receive, in the form of Novartis shares, the difference between the values of the former Alcon, Inc., share at the date of grant, converted into Novartis shares using the conversion factor, and the Novartis share price at the date of exercise.
    Both options and SSAR expire on their tenth anniversary. The last grant was made in 2009.
    The following table shows the activity associated with the converted Novartis share options and SSARs during 2017 and 2016:


    Number

    of options

    (millions)
    Weighted

    average

    exercise

    price (USD)


    Number of

    SSARs

    (millions)
    Weighted

    average

    exercise

    price (USD)
    Outstanding at

    January 1, 2016


    0.2


    36.8


    1.8


    36.6
    Exercised
    – 0.1
    37.6
    – 0.4
    38.9
    Outstanding at December 31, 2016
    0.1
    36.0
    1.4
    35.9
    Exercisable at December 31, 2016
    0.1
    36.0
    1.4
    35.9
    Outstanding at

    January 1, 2017


    0.1


    36.0


    1.4


    35.9
    Exercised
    – 0.6
    39.8
    Outstanding at December 31, 2017
    0.1
    33.7
    0.8
    33.0
    Exercisable at December 31, 2017
    0.1
    33.7
    0.8
    33.0
    XML 100 R33.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Transactions with related parties
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Transactions with related parties
    26. Transactions with related parties
    Genentech/Roche
    Novartis has two agreements with Genentech, Inc., United States, a subsidiary of Roche Holding AG which is indirectly included in the consolidated financial statements using equity accounting since Novartis holds 33.3% of the outstanding voting shares of Roche.
    LUCENTIS
    Novartis has licensed the exclusive rights to develop and market Lucentis outside the United States for indications related to diseases of the eye. As part of this agreement, Novartis paid Genentech/Roche an initial milestone and shared the cost for the subsequent development by making additional milestone payments upon the achievement of certain clinical development points and product approval. Novartis also pays royalties on the net sales of Lucentis products outside the United States. In 2017, Lucentis sales of USD 1.9 billion (2016: USD 1.8 billion, 2015: USD 2.1 billion) were recognized by Novartis.
    XOLAIR
    In February 2004, Novartis Pharma AG, Genentech, Inc., and Tanox, Inc., finalized a three-party collaboration to govern the development and commercialization of certain anti-IgE antibodies including Xolair and TNX-901. Under this agreement, all three parties co-developed Xolair. On August 2, 2007, Genentech, Inc. completed the acquisition of Tanox, Inc. and has taken over its rights and obligations. Novartis and Genentech/Roche are co-promoting Xolair in the United States where Genentech/Roche records all sales. Novartis records sales outside of the United States.
    Novartis markets Xolair and records all sales and related costs outside the United States as well as co-promotion costs in the US. Genentech/Roche and Novartis share the resulting profits from sales in the United States, Europe and other countries, according to agreed profit-sharing percentages. In 2017, Novartis recognized total sales of Xolair of USD 920 million (2016: USD 835 million, 2015: USD 755 million) including sales to them for the United States market.
    The net expense for royalties, cost sharing and profit sharing arising out of the Lucentis and Xolair agreements with Genentech/Roche totaled USD 33 million in 2017 (2016: USD 217 million, 2015: USD 309 million).
    Furthermore, Novartis has several patent license, supply and distribution agreements with Roche.
    Executive Officers and Non-Executive Directors Compensation
    During 2017, there were 11 Executive Committee members (“Executive Officers”), including those who stepped down during the year (14 members in 2016 and 11 members in 2015 also including those who stepped down).
    The total compensation for members of the Executive Committee and the 13 Non-Executive Directors (13 in 2016, 12 in 2015 including those who stepped down during the year) using the Group’s accounting policies for equity-based compensation and pension benefits was as follows:
    Executive Officers
    Non-Executive Directors
    Total
    (USD millions)
    2017
    2016
    2015
    2017
    2016
    2015
    2017
    2016
    2015
    Cash and other compensation
    18.4
    20.8
    17.1
    4.0
    4.0
    4.7
    22.4
    24.8
    21.8
    Post-employment benefits
    2.0
    2.2
    1.9
    2.0
    2.2
    1.9
    Equity-based compensation
    49.9
    46.2
    52.9
    4.8
    4.6
    4.4
    54.7
    50.8
    57.3
    Total
    70.3
    69.2
    71.9
    8.8
    8.6
    9.1
    79.1
    77.8
    81.0
    During 2017, there was an increase in the IFRS compensation expense for Executive Officers, mainly due to the pro-rata accelerated vesting of equity-based compensation, required by IFRS, for an ECN member who stepped down on December 31, 2017. This was partially offset by the reduction in the number of Executive Officers compared to 2016. The increase in the IFRS compensation expense for Non-Executive Directors was due to one additional Non-Executive Director appointed at the 2017 Annual General Meeting.
    During 2016, there was a decrease in the IFRS compensation expense for Executive Officers compared to 2015. This was mainly due to lower equity-based compensation expense attributable to lower performance factors, which was partially offset by higher benefits other than equity-based compensation resulting from the increase in the number of Executive Officers.
    The Annual Incentive award, which is fully included in equity-based compensation even when paid out in cash, is granted in January in the year following the reporting period.
    The disclosures on Board and Executive compensation required by the Swiss Code of Obligations and in accordance with the Swiss Ordinance against Excessive Compensation in Stock Exchange Listed Companies are shown in the Compensation Report.
    Transactions with former members of the Board of Directors
    During 2017, 2016 and 2015, the following payments (or waivers of claims) were made to former Board members or to “persons closely” linked to them:
    Currency
    2017
    2016
    2015
    Prof. Dr. Brody
    CHF
    0
    25 000
    100 000
    Prof. Dr. Zinkernagel
    CHF
    0
    50 000
    200 000
    Dr. Krauer
    CHF
    60 000
    60 000
    60 000
    Dr. Vasella
    CHF
    26 279
    0
    0
    USD
    0
    250 000
    250 000
    Prof. Dr. William R. Brody and Prof. Dr. Rolf M. Zinkernagel, who stepped down from the Board of Directors at the 2014 AGM, received in 2016 and 2015, delegated Board membership fees for their work on the Boards of the Novartis Institute for Tropical Diseases (Prof. Dr. Zinkernagel) and the Genomics Institute of the Novartis Research Foundation (Prof. Dr. Brody and Prof. Dr. Zinkernagel). No payments were made in 2017, as their respective mandates ended in 2016.
    Dr. Alex Krauer, Honorary Chairman, is entitled to an amount of CHF 60 000 for annual periods from one AGM to the next. This amount was fixed in 1998 upon his departure from the Board in 1999, and has not been revised since that date.
    In 2017, Dr. Daniel Vasella, Honorary Chairman, was paid CHF 26 279 for reimbursable costs under his agreement with the company. In 2016, Dr. Daniel Vasella received the contractual minimum compensation under an agreement which became effective on November 1, 2013 and ended in 2016. Under this agreement, Dr. Vasella was compensated at a rate of USD 25 000 per day, with an annual guaranteed minimum fee of USD 250 000. This amount was in line with compensation practices at other large companies when retired Chairmen or CEOs were retained in consulting agreements after leaving the board of directors.
    In 2014, Dr. Vasella exercised an option to acquire, at a future date, real estate in Risch, Zug, Switzerland. The real estate transaction closed in 2015 and Dr. Vasella acquired the Group assets from a consolidated entity for an arm’s length transaction price determined on the basis of two independent external assessments.
    Transactions with an Executive Officer prior to the start of employment
    As announced on September 24, 2015, Dr. James E. Bradner succeeded Dr. Mark Fishman as President of the Novartis Institutes for BioMedical Research (NIBR) and member of the Executive Committee of Novartis with effect from March 1, 2016. In 2015, a Novartis subsidiary acquired Dr. Bradner’s 10 million shares (7% interest) in a non-material entity for USD 10 million. The arm’s length transaction price was determined based on the most recent round of financing of this entity.
    The above disclosures related to Dr. Vasella and Dr. Bradner are made on a voluntary basis.
    XML 101 R34.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Commitments and contingencies
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Commitments and contingencies
    27. Commitments and contingencies
    Leasing commitments
    The Group has entered into various fixed-term operational leases, mainly for cars and real estate. As of December 31, 2017, the Group’s commitments with respect to these leases, including estimated payment dates, were as follows:
    (USD millions)
    2017
    2018
    309
    2019
    224
    2020
    161
    2021
    131
    2022
    123
    Thereafter
    2 221
    Total
    3 169
    Expense of current year
    337
    Research & Development and other intangible asset purchase commitments
    The Group has entered into long-term research and development agreements with various institutions which provide for potential milestone payments by Novartis that may be capitalized. As of December 31, 2017 the Group’s commitments to make payments under those agreements and other agreements to purchase intangible assets, and their estimated timing, were as follows:


    (USD millions)


    Research &

    Development

    commitments
    Other

    intangible asset

    purchase

    commitments






    Total
    2018
    780
    130
    910
    2019
    671
    671
    2020
    864
    864
    2021
    801
    801
    2022
    353
    353
    Thereafter
    837
    837
    Total
    4 306
    130
    4 436
    Other commitments
    The Group has entered into various purchase commitments for services and materials as well as for equipment in the ordinary course of business. These commitments are generally entered into at current market prices and reflect normal business operations.
    Contingencies
    Group companies have to observe the laws, government orders and regulations of the country in which they operate.
    A number of Novartis companies are, and will likely continue to be, subject to various legal proceedings and investigations that arise from time to time, including proceedings regarding product liability, sales and marketing practices, commercial disputes, employment, and wrongful discharge, antitrust, securities, health and safety, environmental, tax, international trade, privacy, and intellectual property matters. As a result, the Group may become subject to substantial liabilities that may not be covered by insurance and that could affect our business, financial position and reputation. While Novartis does not believe that any of these legal proceedings will have a material adverse effect on its financial position, litigation is inherently unpredictable and large judgments sometimes occur. As a consequence, Novartis may in the future incur judgments or enter into settlements of claims that could have a material adverse effect on its results of operations or cash flow.
    Governments and regulatory authorities around the world have been stepping up their compliance and law enforcement activities in recent years in key areas, including marketing practices, pricing, corruption, trade restrictions, embargo legislation, insider trading, antitrust, cyber security and data privacy. Further, when one government or regulatory authority undertakes an investigation, it is not uncommon for other governments or regulators to undertake investigations regarding the same or similar matters. Responding to such investigations is costly and requires an increasing amount of management’s time and attention. In addition, such investigations may affect our reputation, create a risk of potential exclusion from government reimbursement programs in the United States and other countries, and may lead to (or arise from) litigation. These factors have contributed to decisions by Novartis and other companies in the healthcare industry, when deemed in their interest, to enter into settlement agreements with governmental authorities around the world prior to any formal decision by the authorities or a court. Those government settlements have involved and may continue to involve, in current government investigations and proceedings, large cash payments, sometimes in the hundreds of millions of dollars or more, including the potential repayment of amounts allegedly obtained improperly and other penalties, including treble damages. In addition, settlements of government healthcare fraud cases often require companies to enter into corporate integrity agreements, which are intended to regulate company behavior for a period of years. Our affiliate Novartis Pharmaceuticals Corporation is a party to such an agreement, which will expire in 2020. Also, matters underlying governmental investigations and settlements may be the subject of separate private litigation.
    While provisions have been made for probable losses, which management deems to be reasonable or appropriate, there are uncertainties connected with these estimates.
    Note 19 contains additional information on these matters.
    A number of Group companies are involved in legal proceedings concerning intellectual property rights. The inherent unpredictability of such proceedings means that there can be no assurances as to their ultimate outcome. A negative result in any such proceeding could potentially adversely affect the ability of certain Novartis companies to sell their products, or require the payment of substantial damages or royalties.
    In the opinion of management, however, the outcome of these actions will not materially affect the Group’s financial position but could be material to the results of operations or cash flow in a given period.
    The Group’s potential environmental remediation liability is assessed based on a risk assessment and investigation of the various sites identified by the Group as at risk for environmental remediation exposure. The Group’s future remediation expenses are affected by a number of uncertainties. These uncertainties include, but are not limited to, the method and extent of remediation, the percentage of material attributable to the Group at the remediation sites relative to that attributable to other parties, and the financial capabilities of the other potentially responsible parties.
    Note 19 contains additional information on environmental liabilities.
    XML 102 R35.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Financial instruments - additional disclosures
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Disclosure of detailed information about financial instruments [text block]
    28. Financial instruments – additional disclosures
    (USD millions)
    Note
    2017 1
    2016 1
    Cash and cash equivalents
    15
    8 860
    7 007
    Financial assets - measured at fair value through other comprehensive income
    Available-for-sale marketable securities
    Debt securities
    15
    328
    306
    Fund investments
    15
    34
    31
    Total available-for-sale marketable securities
    362
    337
    Available-for-sale long-term financial investments
    Equity securities
    12
    1 109
    989
    Fund investments
    12
    166
    107
    Total available-for-sale long-term financial investments
    1 275
    1 096
    Total financial assets - measured at fair value through other comprehensive income
    1 637
    1 433
    Financial assets - measured at amortized costs
    Trade receivables, income tax receivables, and other current assets

    (excluding contingent consideration receivables and pre-payments)


    14/16


    10 650


    10 202
    Accrued interest on debt securities and time deposits
    15
    1
    1
    Time deposits with original maturity more than 90 days
    15
    125
    108
    Long-term loans and receivables from customers and finance lease, advances, security deposits
    12
    574
    514
    Total financial assets - measured at amortized costs
    11 350
    10 825
    Financial assets - measured at fair value through the consolidated income statement
    Associated companies at fair value through profit and loss
    216
    188
    Derivative financial instruments
    15
    31
    230
    Contingent consideration receivables
    12/16
    844
    586
    Total financial assets - measured at fair value through the consolidated income statement
    1 091
    1 004
    Total financial assets
    22 938
    20 269
    Financial liabilities - measured at amortized costs
    Current financial debt
    Interest-bearing accounts of associates payable on demand
    20
    1 822
    1 601
    Bank and other financial debt
    20
    692
    836
    Commercial paper
    20
    2 328
    3 174
    Current portion of non-current debt
    20
    359
    178
    Total current financial debt
    5 201
    5 789
    Non-current financial debt
    Straight bonds
    18
    22 957
    17 285
    Liabilities to banks and other financial institutions
    18
    539
    708
    Finance lease obligations
    18
    87
    82
    Current portion of non-current debt
    18
    – 359
    – 178
    Total non-current financial debt
    23 224
    17 897
    Trade payables
    5 169
    4 873
    Total financial liabilities - measured at amortized costs
    33 594
    28 559
    Financial liabilities - measured at fair value through the consolidated income statement
    Contingent consideration (see Note 19/21) and other financial liabilities
    924
    1 018
    Derivative financial instruments
    20
    107
    116
    Total financial liabilities - measured at fair value through the consolidated income statement
    1 031
    1 134
    Total financial liabilities
    34 625
    29 693
     
     1  Except for straight bonds (see Note 18), the carrying amount is a reasonable approximation of fair value.
    Derivative financial instruments
    The following tables show the contract or underlying principal amounts and fair values of derivative financial instruments analyzed by type of contract at December 31, 2017 and 2016. Contract or underlying principal amounts indicate the gross volume of business outstanding at the consolidated balance sheet date and do not represent amounts at risk. The fair values are determined by reference to market prices or standard pricing models that use observable market inputs at December 31, 2017 and 2016.
    Contract or underlying principal amount
    Positive fair values
    Negative fair values
    (USD millions)
    2017
    2016
    2017
    2016
    2017
    2016
    Currency-related instruments
    Forward foreign exchange rate contracts
    8 410
    8 220
    31
    230
    – 107
    – 116
    Total derivative financial instruments included in marketable securities and in current financial debts
    8 410
    8 220
    31
    230
    – 107
    – 116
    The following table shows by currency contract or underlying principal amount the derivative financial instruments at December 31, 2017 and 2016:
    2017
    (USD millions)
    EUR
    USD
    Other
    Total
    Currency-related instruments
    Forward foreign exchange rate contracts
    2 768
    4 361
    1 281
    8 410
    Total derivative financial instruments
    2 768
    4 361
    1 281
    8 410
    2016
    (USD millions)
    EUR
    USD
    JPY
    Other
    Total
    Currency-related instruments
    Forward foreign exchange rate contracts
    3 623
    3 427
    43
    1 127
    8 220
    Total derivative financial instruments
    3 623
    3 427
    43
    1 127
    8 220
    Derivative financial instruments effective for hedge accounting purposes
    At the end of 2017 and 2016, there were no open hedging instruments for anticipated transactions.
    Fair value by hierarchy
    As required by IFRS, financial assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. There are three hierarchical levels, based on an increasing amount of subjectivity associated with the inputs to derive fair valuation for these assets and liabilities, which are as follows:
    The assets carried at Level 1 fair value are equity and debt securities listed in active markets.
    The assets generally included in Level 2 fair value hierarchy are foreign exchange and interest rate derivatives and certain debt securities. Foreign exchange and interest rate derivatives are valued using corroborated market data. The liabilities generally included in this fair value hierarchy consist of foreign exchange and interest rate derivatives.
    Level 3 inputs are unobservable for the asset or liability. The assets generally included in Level 3 fair value hierarchy are various investments in hedge funds and unquoted equity security investments. Contingent consideration carried at fair value is included in this category.
    2017


    (USD millions)


    Level 1


    Level 2


    Level 3
    Valued at

    amortized cost


    Total
    Financial assets
    Debt securities
    303
    25
    328
    Fund investments
    34
    34
    Total available-for-sale marketable securities
    337
    25
    362
    Time deposits with original maturity more than 90 days
    125
    125
    Derivative financial instruments
    31
    31
    Accrued interest on debt securities
    1
    1
    Total marketable securities, time deposits and derivative financial instruments
    337
    56
    126
    519
    Available-for-sale financial investments
    672
    437
    1 109
    Fund investments
    166
    166
    Contingent consideration receivables
    394
    394
    Long-term loans and receivables from customers and finance lease, advances, security deposits
    574
    574
    Financial investments and long-term loans
    672
    997
    574
    2 243
    Associated companies at fair value through profit and loss
    28
    188
    216
    Contingent consideration receivables short-term
    450
    450
    Financial liabilities
    Contingent consideration payables
    – 852
    – 852
    Other financial liabilities
    – 72
    – 72
    Derivative financial instruments
    – 107
    – 107
    Total financial liabilities at fair value
    – 107
    – 924
    – 1 031
    2016


    (USD millions)


    Level 1


    Level 2


    Level 3
    Valued at

    amortized cost


    Total
    Financial assets
    Debt securities
    284
    22
    306
    Fund investments
    31
    31
    Total available-for-sale marketable securities
    315
    22
    337
    Time deposits with original maturity more than 90 days
    108
    108
    Derivative financial instruments
    230
    230
    Accrued interest on debt securities
    1
    1
    Total marketable securities, time deposits and derivative financial instruments
    315
    252
    109
    676
    Available-for-sale financial investments
    513
    476
    989
    Fund investments
    107
    107
    Contingent consideration receivables
    586
    586
    Long-term loans and receivables from customers and finance lease, advances, security deposits
    514
    514
    Financial investments and long-term loans
    513
    1 169
    514
    2 196
    Associated companies at fair value through profit and loss
    188
    188
    Financial liabilities
    Contingent consideration payables
    – 889
    – 889
    Other financial liabilities
    – 129
    – 129
    Derivative financial instruments
    – 116
    – 116
    Total financial liabilities at fair value
    – 116
    – 1 018
    – 1 134
    The analysis above includes all financial instruments including those measured at amortized cost or at cost.
    The change in carrying values associated with Level 3 financial instruments using significant unobservable inputs during the year ended December 31 are set forth below:
    2017


    (USD millions)
    Associated

    companies at

    fair value through

    profit and loss




    Fund

    investments
    Available-

    for-sale

    financial

    investments


    Contingent

    consideration

    receivables


    Contingent

    consideration

    payables


    Other

    financial

    liabilities
    January 1
    188
    107
    476
    586
    – 889
    – 129
    Fair value gains and other adjustments,

    including from divestments recognized

    in the consolidated income statement




    45








    32




    278




    362




    Fair value losses (including impairments and

    amortizations) and other adjustments recognized

    in the consolidated income statement




    – 34








    – 45








    – 193




    – 37
    Fair value adjustments recognized in the consolidated statement

    of comprehensive income




    45


    – 40






    Purchases
    37
    28
    113
    – 238
    Cash receipts and payments
    – 20
    106
    94
    Disposals
    – 19
    – 18
    – 52
    Reclassification
    – 29
    4
    – 47
    December 31
    188
    166
    437
    844
    – 852
    – 72
    Total of fair value gains and losses recognized

    in the consolidated income statement for assets

    and liabilities held at December 31, 2017




    11




    0




    – 13




    278




    169




    – 37
    2016


    (USD millions)
    Associated

    companies at

    fair value through

    profit and loss




    Fund

    investments
    Available-

    for-sale

    financial

    investments


    Contingent

    consideration

    receivables


    Contingent

    consideration

    payables


    Other

    financial

    liabilities
    January 1
    181
    94
    473
    550
    – 790
    – 315
    Fair value gains and other adjustments,

    including from divestments recognized

    in the consolidated income statement




    26








    1




    51








    3
    Fair value losses (including impairments and

    amortizations) and other adjustments recognized

    in the consolidated income statement




    – 28




    – 1




    – 24








    – 156




    Fair value adjustments recognized in the consolidated statement

    of comprehensive income




    14


    – 8






    Purchases
    41
    5
    122
    – 172
    Cash receipts and payments
    – 15
    229
    183
    Disposals
    – 3
    – 5
    – 18
    Reclassification
    – 29
    – 70
    December 31
    188
    107
    476
    586
    – 889
    – 129
    Total of fair value gains and losses recognized

    in the consolidated income statement for assets

    and liabilities held at December 31, 2016




    – 2




    – 1




    – 23




    51




    – 156




    3
    During 2017, there were several individually non-significant transfers of available-for-sale financial investments from Level 3 to Level 1 for USD 73 million (2016: USD 75 million) mainly due to Initial Public Offerings of the invested companies.
    Realized gains and losses associated with Level 3 available-for-sale marketable securities are recorded in the consolidated income statement under “Other financial income and expense” and realized gains and losses associated with Level 3 available-for-sale financial investments are recorded in the consolidated income statement under “Other income” or “Other expense”, respectively.
    If the pricing parameters for the Level 3 input were to change for associated companies at fair value through profit and loss, equity securities, fund investments and available-for-sale financial investments by 10% positively or negatively, this would change the amounts recorded in the 2017 consolidated statement of comprehensive income by USD 79 million.
    For the determination of the fair value of a contingent consideration various unobservable inputs are used. A change in these inputs might result in a significantly higher or lower fair value measurement. The inputs used are, among others, the probability of success, sales forecast and assumptions regarding the discount rate, timing and different scenarios of triggering events. The inputs are interrelated. The significance and usage of these inputs to each contingent consideration may vary due to differences in the timing and triggering events for payments or in the nature of the asset related to the contingent consideration.
    If the most significant parameters for the Level 3 input were to change by 10% positively or negatively, or where the probability of success (POS) is the most significant input parameter 10% were added or deducted from the applied probability of success, for contingent consideration payables, other financial liabilities and contingent consideration receivables, this would change the amounts recorded in the 2017 consolidated income statement by USD 333 million and USD 322 million, respectively.
    Nature and extent of risks arising from financial instruments
    Market risk
    Novartis is exposed to market risk, primarily related to foreign currency exchange rates, interest rates and the market value of the investments of liquid funds. The Group actively monitors and seeks to reduce, where it deems it appropriate to do so, fluctuations in these exposures. It is the Group’s policy and practice to enter into a variety of derivative financial instruments to manage the volatility of these exposures and to enhance the yield on the investment of liquid funds. It does not enter into any financial transactions containing a risk that cannot be quantified at the time the transaction is concluded. In addition, it does not sell short assets it does not have, or does not know it will have, in the future. The Group only sells existing assets or enters into transactions and future transactions (in the case of anticipatory hedges) that it confidently expects it will have in the future, based on past experience. In the case of liquid funds, the Group writes call options on assets it has, or writes put options on positions it wants to acquire and has the liquidity to acquire. The Group expects that any loss in value for these instruments generally would be offset by increases in the value of the underlying transactions.
    Foreign currency exchange rate risk
    The Group uses the US dollar as its reporting currency. As a result, the Group is exposed to foreign currency exchange movements, primarily in European, Japanese and emerging market currencies. Fluctuations in the exchange rates between the US dollar and other currencies can have a significant effect on both the Group’s results of operations, including reported sales and earnings, as well as on the reported value of our assets, liabilities and cash flows. This, in turn, may significantly affect the comparability of period-to-period results of operations.
    Because our expenditures in Swiss francs are significantly higher than our revenues in Swiss francs, volatility in the value of the Swiss franc can have a significant impact on the reported value of our earnings, assets and liabilities, and the timing and extent of such volatility can be difficult to predict. In addition, there is a risk that certain countries could take other steps that could significantly impact the value of their currencies.
    The Group is exposed to a potential adverse devaluation risk on its intercompany funding and total investment in certain subsidiaries operating in countries with exchange controls. The most significant foreign exchange losses (USD 0.3 billion) occurred in Venezuela in 2016. The net outstanding intercompany payable balance of Venezuela subsidiaries was not significant at December 31, 2017 and at December 31, 2016, due to reserves against the intercompany balances.
    The Group manages its global currency exposure by engaging in hedging transactions where management deems appropriate. Novartis may enter into various contracts that reflect the changes in the value of foreign currency exchange rates to preserve the value of assets, commitments and anticipated transactions. Novartis also uses forward contracts and foreign currency option contracts to hedge.
    Net investments in subsidiaries in foreign countries are long-term investments. Their fair value changes through movements of foreign currency exchange rates. The Group has designated a certain portion of its long-term euro-denominated straight bonds as hedges of the translation risk arising on certain of these net investments in foreign operations with euro functional currency. As of December 31, 2017, long-term financial debt with a carrying amount of EUR 1.8 billion (USD 2.2 billion) has been designated as a hedge instrument. During 2017, USD 237 million of unrealized loss was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge. The hedge remained effective since inception, and no amount was recognized in the consolidated income statement in 2017. During 2016 and 2015, the Group did not apply net investment hedge accounting.
    Commodity price risk
    The Group has only a very limited exposure to price risk related to anticipated purchases of certain commodities used as raw materials by the Group’s businesses. A change in those prices may alter the gross margin of a specific business, but generally by not more than 10% of the margin and thus below the Group’s risk management tolerance levels. Accordingly, the Group does not enter into significant commodity futures, forward and option contracts to manage fluctuations in prices of anticipated purchases.
    Interest rate risk
    The Group addresses its net exposure to interest rate risk mainly through the ratio of its fixed-rate financial debt to variable rate financial debt contained in its total financial debt portfolio. To manage this mix, Novartis may enter into interest rate swap agreements, in which it exchanges periodic payments based on a notional amount and agreed-upon fixed and variable interest rates.
    Equity risk
    The Group may purchase equities as investments of its liquid funds. As a policy, it limits its holdings in an unrelated company to less than 5% of its liquid funds. Potential investments are thoroughly analyzed. Call options are written on equities that the Group owns, and put options are written on equities that the Group wants to buy and for which cash is available.
    Credit risk
    Credit risks arise from the possibility that customers may not be able to settle their obligations as agreed. To manage this risk, the Group periodically assesses country and customer credit risk, assigns individual credit limits, and takes actions to mitigate credit risk where appropriate.
    The Group’s largest customer accounted for approximately 17% of net sales, and the second-largest and third-largest customers accounted for 12% and 7% of net sales, respectively (2016: 16%, 12% and 6%, respectively; 2015: 14%, 11% and 5%, respectively). No other customer accounted for 5% or more of net sales in either year.
    The highest amounts of trade receivables outstanding were for these same three customers and amounted to 14%, 9% and 5%, respectively, of the Group’s trade receivables at December 31, 2017 (2016: 14%, 9% and 6%, respectively). There is no other significant concentration of customer credit risk.
    Counterparty risk
    Counterparty risk encompasses issuer risk on marketable securities and money market instruments, credit risk on cash, time deposits and derivatives, as well as settlement risk for different instruments. Issuer risk is reduced by only buying securities that are at least A- rated. Counterparty credit risk and settlement risk are reduced by a policy of entering into transactions with counterparties (banks or financial institutions) that feature a strong credit rating. Exposure to these risks is closely monitored and kept within predetermined parameters. The limits are regularly assessed and determined based upon credit analysis, including financial statement and capital adequacy ratio reviews. In addition, reverse repurchasing agreements are contracted and Novartis has entered into credit support agreements with various banks for derivative transactions.
    The Group’s cash and cash equivalents are held with major regulated financial institutions, the three largest ones hold approximately 20.2%, 15.0% and 12.7%, respectively (2016: 16.5%, 6.9% and 6.7%, respectively).
    The Group does not expect any losses from non-performance by these counterparties and does not have any significant grouping of exposures to financial sector or country risk.
    Liquidity risk
    Liquidity risk is defined as the risk that the Group could not be able to settle or meet its obligations on time or at a reasonable price. Group Treasury is responsible for liquidity, funding and settlement management. In addition, liquidity and funding risks, and related processes and policies, are overseen by management. Novartis manages its liquidity risk on a consolidated basis according to business needs, tax, capital or regulatory considerations, if applicable, through numerous sources of financing in order to maintain flexibility. Management monitors the Group’s net debt or liquidity position through rolling forecasts on the basis of expected cash flows.
    Novartis has two United States commercial paper programs under which it can issue up to USD 9.0 billion in the aggregate of unsecured commercial paper notes. Novartis also has a Japanese commercial paper program under which it can issue up to JPY 150 billion (approximately USD 1.3 billion) of unsecured commercial paper notes. Commercial paper notes totaling USD 2.3 billion under these three programs were outstanding as per December 31, 2017 (2016: USD 3.2 billion). Novartis further has a committed credit facility of USD 6.0 billion, entered into on September 23, 2015. This credit facility is provided by a syndicate of banks and is intended to be used as a backstop for the United States commercial paper programs. It matures in September 2020 and was undrawn as per December 31, 2017 and December 31, 2016.
    The following table sets forth how management monitors net debt or liquidity based on details of the remaining contractual maturities of current financial assets and liabilities excluding trade receivables and payables as well as contingent considerations at December 31, 2017 and December 31, 2016:
    2017


    (USD millions)




    Due within

    one month
    Due later than

    one month

    but less than

    three months
    Due later than

    three months

    but less than

    one year
    Due later than

    one year

    but less than

    five years




    Due after

    five years






    Total
    Current assets
    Marketable securities and time deposits
    71
    72
    105
    181
    58
    487
    Commodities
    106
    106
    Derivative financial instruments and accrued interest
    7
    19
    6
    32
    Cash and cash equivalents
    4 260
    4 600
    8 860
    Total current financial assets
    4 338
    4 691
    111
    181
    164
    9 485
    Non-current liabilities
    Financial debt
    – 9 849
    – 13 375
    – 23 224
    Financial debt - undiscounted
    – 9 893
    – 13 519
    – 23 412
    Total non-current financial debt
    – 9 849
    – 13 375
    – 23 224
    Current liabilities
    Financial debt
    – 4 576
    – 169
    – 456
    – 5 201
    Financial debt - undiscounted
    – 4 576
    – 169
    – 456
    – 5 201
    Derivative financial instruments
    – 31
    – 48
    – 28
    – 107
    Total current financial debt
    – 4 607
    – 217
    – 484
    – 5 308
    Net debt
    – 269
    4 474
    – 373
    – 9 668
    – 13 211
    – 19 047
    2016


    (USD millions)




    Due within

    one month
    Due later than

    one month

    but less than

    three months
    Due later than

    three months

    but less than

    one year
    Due later than

    one year

    but less than

    five years




    Due after

    five years






    Total
    Current assets
    Marketable securities and time deposits
    32
    126
    110
    124
    53
    445
    Commodities
    94
    94
    Derivative financial instruments and accrued interest
    38
    102
    91
    231
    Cash and cash equivalents
    5 907
    1 100
    7 007
    Total current financial assets
    5 977
    1 328
    201
    124
    147
    7 777
    Non-current liabilities
    Financial debt
    – 5 141
    – 12 756
    – 17 897
    Financial debt - undiscounted
    – 5 155
    – 12 901
    – 18 056
    Total non-current financial debt
    – 5 141
    – 12 756
    – 17 897
    Current liabilities
    Financial debt
    – 5 099
    – 250
    – 440
    – 5 789
    Financial debt - undiscounted
    – 5 099
    – 250
    – 440
    – 5 789
    Derivative financial instruments
    – 15
    – 72
    – 29
    – 116
    Total current financial debt
    – 5 114
    – 322
    – 469
    – 5 905
    Net debt
    863
    1 006
    – 268
    – 5 017
    – 12 609
    – 16 025
    The consolidated balance sheet amounts of financial liabilities included in the above analysis are not materially different to the contractual amounts due on maturity. The positive and negative fair values on derivative financial instruments represent the net contractual amounts to be exchanged at maturity.
    The Group’s contractual undiscounted potential cash flows from derivative financial instruments to be settled on a gross basis are as follows:
    2017


    (USD millions)




    Due within

    one month
    Due later than

    one month

    but less than

    three months
    Due later than

    three months

    but less than

    one year












    Total
    Derivative financial instruments and accrued interest on derivative financial instruments
    Potential outflows in various currencies - from financial derivative liabilities
    – 953
    – 972
    – 2 824
    – 4 749
    Potential inflows in various currencies - from financial derivative assets
    928
    948
    2 778
    4 654
    2016


    (USD millions)




    Due within

    one month
    Due later than

    one month

    but less than

    three months
    Due later than

    three months

    but less than

    one year












    Total
    Derivative financial instruments and accrued interest on derivative financial instruments
    Potential outflows in various currencies - from financial derivative liabilities
    – 1 087
    – 1 246
    – 2 027
    – 4 360
    Potential inflows in various currencies - from financial derivative assets
    1 109
    1 287
    2 051
    4 447
    Other contractual liabilities that are not part of management’s monitoring of the net debt or liquidity consist of the following items:
    2017


    (USD millions)
    Due later than

    one month

    but less than

    three months
    Due later than

    three months

    but less than

    one year
    Due later than

    one year

    but less than

    five years




    Due after

    five years






    Total
    Contractual interest on non-current liabilities
    – 113
    – 507
    – 1 765
    – 3 859
    – 6 244
    Trade payables
    – 5 169
    – 5 169
    2016


    (USD millions)
    Due later than

    one month

    but less than

    three months
    Due later than

    three months

    but less than

    one year
    Due later than

    one year

    but less than

    five years




    Due after

    five years






    Total
    Contractual interest on non-current liabilities
    – 104
    – 433
    – 1 694
    – 4 015
    – 6 246
    Trade payables
    – 4 873
    – 4 873
    Capital risk management
    Novartis strives to maintain a strong credit rating. In managing its capital, Novartis focuses on maintaining a strong balance sheet. Moody’s rated the Group as Aa3 for long-term maturities and as P-1 for short-term maturities and Standard & Poor’s had a rating of AA- for long-term maturities and A-1+ for short-term maturities. Fitch had a long-term rating of AA and a short-term rating of F1+.
    The debt/equity ratio increased to 0.38:1 at December 31, 2017, compared to 0.32:1 at the beginning of the year.
    Value at risk
    The Group uses a value at risk (VAR) computation to estimate the potential ten-day loss in the fair value of its financial instruments.
    A ten-day period is used because of an assumption that not all positions could be undone in one day given the size of the positions. The VAR computation includes all financial assets and financial liabilities as set forth in the table on page 243, except trade receivables, income tax receivables and other current assets, contingent considerations, finance lease obligations, long-term loans and receivables from customers and finance lease, advances and security deposits and trade payables. 
    The VAR estimates are made assuming normal market conditions, using a 95% confidence interval. The Group uses a “Delta Normal” model to determine the observed interrelationships between movements in interest rates, stock markets and various currencies. These inter-relationships are determined by observing interest rate, stock market movements and forward foreign currency rate movements over a sixty-day period for the calculation of VAR amounts.
    The estimated potential ten-day loss in the fair value of the Group’s foreign currency positions (including foreign exchange translation risk), the estimated potential ten-day loss of its equity holdings, and the estimated potential ten-day loss in fair value of its interest rate sensitive instruments (primarily financial debt and investments of liquid funds under normal market conditions) as calculated in the VAR model are the following:
    (USD millions)
    2017
    2016
    All financial instruments
    498
    541
    Analyzed by components:
    Instruments sensitive to foreign

    currency exchange rates


    184


    222
    Instruments sensitive to equity

    market movements


    27


    26
    Instruments sensitive to interest rates
    242
    328
    The average, high, and low VAR amounts are as follows:
    2017
    (USD millions)
    Average
    High
    Low
    All financial instruments
    521
    560
    466
    Analyzed by components:
    Instruments sensitive to foreign

    currency exchange rates


    277


    352


    184
    Instruments sensitive to equity

    market movements


    28


    35


    21
    Instruments sensitive to

    interest rates


    282


    338


    219
    2016
    (USD millions)
    Average
    High
    Low
    All financial instruments
    402
    541
    316
    Analyzed by components:
    Instruments sensitive to foreign

    currency exchange rates


    203


    245


    147
    Instruments sensitive to equity

    market movements


    50


    99


    26
    Instruments sensitive to

    interest rates


    308


    407


    234
    The VAR computation is a risk analysis tool designed to statistically estimate the potential ten-day loss from adverse movements in foreign currency exchange rates, equity prices and interest rates under normal market conditions. The computation does not purport to represent actual losses in fair value on earnings to be incurred by the Group, nor does it consider the effect of favorable changes in market rates. The Group cannot predict actual future movements in such market rates and it does not claim that these VAR results are indicative of future movements in such market rates or are representative of any actual impact that future changes in market rates may have on the Group’s future results of operations or financial position.
    In addition to these VAR analyses, the Group uses stress testing techniques that aim to reflect a worst case scenario on the marketable securities that are monitored by Group Treasury. For these calculations, the Group uses the six-month period with the worst performance observed over the past twenty years in each category. For 2017 and 2016, the worst case loss scenario was calculated as follows:
    (USD millions)
    2017
    2016
    All financial instruments
    7
    6
    Analyzed by components:
    Instruments sensitive to foreign

    currency exchange rates




    Instruments sensitive to equity

    market movements




    Instruments sensitive to

    interest rates


    7


    6
    In the Group’s risk analysis, Novartis considered this worst case scenario acceptable as it could reduce income, but would not endanger the solvency or investment grade credit rating of the Group.
    XML 103 R36.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Discontinued operations
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Discontinued operations
    29. Discontinued operations
    Discontinued operations consolidated income statement segmentation
    2015


    (USD millions)




    Vaccines


    Consumer

    Health1
    Corporate

    (including

    eliminations)
    Total

    discontinued

    operations
    Net sales to third parties of discontinued operations
    145
    456
    601
    Sales to continuing segments
    18
    1
    19
    Net sales of discontinued operations
    163
    457
    620
    Other revenues
    18
    5
    23
    Cost of goods sold
    – 192
    – 184
    – 376
    Gross profit of discontinued operations
    – 11
    278
    267
    Marketing & Sales
    – 57
    – 187
    – 244
    Research & Development
    – 151
    – 30
    – 181
    General & Administration
    – 26
    – 32
    – 58
    Other income
    2 870
    10 558
    – 8
    13 420
    Other expense
    – 57
    – 14
    – 656
    – 727
    Operating income of discontinued operations
    2 568
    10 573
    – 664
    12 477
    Income from associated companies
    2
    2
    Income before taxes of discontinued operations
    12 479
    Taxes
    – 1 713
    Net income of discontinued operations
    10 766
     1  Consumer Health is the aggregation of the former OTC and Animal Health divisions.
    The following are included in net income from discontinued operations:
    (USD millions)
    2015
    Impairment charges on property, plant & equipment, net
    83
    Additions to restructuring provisions
    – 1
    Equity-based compensation of Novartis equity plans
    – 65
    XML 104 R37.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Events subsequent to the December 31 consolidated balance sheet date (Details)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Events subsequent to the December 31 consolidated balance sheet date
    30. Events subsequent to the December 31, 2017 consolidated balance sheet date
    Significant transaction closed in January 2018
    For significant transaction entered into in 2017 and closed in 2018, see Note 2.
    Dividend proposal for 2017 and approval of the Group’s 2017 consolidated financial statements
    On January 23, 2018, the Novartis AG Board of Directors proposed the acceptance of the 2017 consolidated financial statements of the Novartis Group for approval by the Annual General Meeting on March 2, 2018. Furthermore, also on January 23, 2018, the Board proposed a dividend of CHF 2.80 per share to be approved at the Annual General Meeting on March 2, 2018. If approved, total dividend payments would amount to approximately USD 6.7 billion (2016: USD 6.5billion) using the CHF/USD December 31, 2017 exchange rate.
    XML 105 R38.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Principal Group subsidiaries and associated companies
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Principal Group subsidiaries and associated companies
    31. Principal Group subsidiaries and associated companies
    The following table lists the principal subsidiaries controlled by Novartis and associated companies in which Novartis is deemed to have significant influence. It includes all subsidiaries and associated companies with Total assets or Net sales to third parties in excess of USD 25 million. The equity interest percentage shown in the table also represents the share in voting rights in those entities, except where explicitly noted.


    As at December 31, 2017
    Share

    capital 1
    Equity

    interest
    Algeria
    Société par actions SANDOZ
    Algiers
    DZD
    650.0
    m
    100%
    Argentina
    Novartis Argentina S.A.
    Buenos Aires
    ARS
    906.1
    m
    100%
    Alcon Laboratorios S.A.
    Buenos Aires
    ARS
    83.9
    m
    100%
    Australia
    Novartis Australia Pty Ltd
    North Ryde, NSW
    AUD
    2
    100%
    Novartis Pharmaceuticals Australia Pty Ltd
    North Ryde, NSW
    AUD
    3.8
    m
    100%
    Sandoz Pty Ltd
    North Ryde, NSW
    AUD
    11.6
    m
    100%
    Alcon Laboratories (Australia) Pty Ltd
    Frenchs Forest, NSW
    AUD
    2.6
    m
    100%
    Austria
    Novartis Austria GmbH
    Vienna
    EUR
    1.0
    m
    100%
    Novartis Pharma GmbH
    Vienna
    EUR
    1.1
    m
    100%
    Sandoz GmbH
    Kundl
    EUR
    32.7
    m
    100%
    EBEWE Pharma Ges.m.b.H Nfg. KG
    Unterach am Attersee
    EUR
    1.0
    m
    100%
    Bangladesh
    Novartis (Bangladesh) Limited
    Gazipur
    BDT
    162.5
    m
    60%
    Belgium
    N.V. Novartis Pharma S.A.
    Vilvoorde
    EUR
    7.1
    m
    100%
    N.V. Sandoz S.A.
    Vilvoorde
    EUR
    19.2
    m
    100%
    S.A. Alcon-Couvreur N.V.
    Puurs
    EUR
    110.6
    m
    100%
    N.V. Alcon S.A.
    Vilvoorde
    EUR
    141 856
    100%
    Bermuda
    Novartis Investment Ltd.
    Hamilton
    USD
    12 000
    100%
    Novartis Securities Investment Ltd.
    Hamilton
    CHF
    30 000
    100%
    Novartis Finance Services Ltd.
    Hamilton
    CHF
    20 000
    100%
    Novartis B2 Ltd.
    Hamilton
    USD
    12 000
    100%
    Novartis B3 Ltd.
    Hamilton
    USD
    106 400
    100%
    Triangle International Reinsurance Limited
    Hamilton
    CHF
    1.0
    m
    100%
    Trinity River Insurance Co Ltd.
    Hamilton
    USD
    370 000
    100%
    Brazil
    Novartis Biociências S.A.
    São Paulo
    BRL
    265.0
    m
    100%
    Sandoz do Brasil Indústria Farmacêutica Ltda.
    Cambé, PR
    BRL
    190.0
    m
    100%
    Canada
    Novartis Pharmaceuticals Canada Inc.
    Dorval, Quebec
    CAD
    13.0
    m
    100%
    Sandoz Canada Inc.
    Boucherville, Quebec
    CAD
    80.8
    m
    100%
    Alcon Canada Inc.
    Mississauga, Ontario
    CAD
    2 500
    100%
    CIBA Vision Canada Inc.
    Mississauga, Ontario
    CAD
    82 886
    100%
    Chile
    Novartis Chile S.A.
    Santiago de Chile
    CLP
    2.0
    bn
    100%
    Alcon Laboratorios Chile Ltd.
    Santiago de Chile
    CLP
    2.0
    bn
    100%
    China
    Beijing Novartis Pharma Co., Ltd.
    Beijing
    USD
    30.0
    m
    100%
    Novartis Pharmaceuticals (HK) Limited
    Hong Kong
    HKD
    200
    100%
    China Novartis Institutes for BioMedical Research Co., Ltd.
    Shanghai
    USD
    320.0
    m
    100%
    Suzhou Novartis Pharma Technology Co., Ltd.
    Changshu
    USD
    103.4
    m
    100%
    Shanghai Novartis Trading Ltd.
    Shanghai
    USD
    3.2
    m
    100%
    Sandoz (China) Pharmaceutical Co., Ltd.
    Zhongshan
    USD
    36.5
    m
    100%
    Alcon Hong Kong Limited
    Hong Kong
    HKD
    77 000
    100%
    Alcon (China) Ophthalmic Product Co., Ltd.
    Beijing
    USD
    60.0
    m
    100%
    Colombia
    Novartis de Colombia S.A.
    Santafé de Bogotá
    COP
    7.9
    bn
    100%
    Laboratorios Alcon de Colombia S.A.
    Santafé de Bogotá
    COP
    20.9
    m
    100%
    Croatia
    Sandoz d.o.o. farmaceutska industrija
    Zagreb
    HRK
    25.6
    m
    100%
    Czech Republic
    Novartis s.r.o.
    Prague
    CZK
    51.5
    m
    100%
    Sandoz s.r.o.
    Prague
    CZK
    44.7
    m
    100%
    Alcon Pharmaceuticals (Czech Republic) s.r.o.
    Prague
    CZK
    31.0
    m
    100%
    Denmark
    Novartis Healthcare A/S
    Copenhagen
    DKK
    14.0
    m
    100%
    Sandoz A/S
    Copenhagen
    DKK
    12.0
    m
    100%
    Alcon Nordic A/S
    Copenhagen
    DKK
    0.5
    m
    100%
    Ecuador
    Novartis Ecuador S.A.
    Quito
    USD
    4.0
    m
    100%
    Egypt
    Novartis Pharma S.A.E.
    Cairo
    EGP
    193.8
    m
    99.77%
    Sandoz Egypt Pharma S.A.E.
    New Cairo City
    EGP
    250 000
    100%
    Finland
    Novartis Finland Oy
    Espoo
    EUR
    459 000
    100%


    As at December 31, 2017
    Share

    capital 1
    Equity

    interest
    France
    Novartis Groupe France S.A.
    Rueil-Malmaison
    EUR
    103.0
    m
    100%
    Novartis Pharma S.A.S.
    Rueil-Malmaison
    EUR
    43.4
    m
    100%
    Sandoz S.A.S.
    Levallois-Perret
    EUR
    5.4
    m
    100%
    Laboratoires Alcon S.A.S.
    Rueil-Malmaison
    EUR
    12.9
    m
    100%
    Germany
    Novartis Deutschland GmbH
    Wehr
    EUR
    155.5
    m
    100%
    Novartis Business Services GmbH
    Wehr
    EUR
    25 000
    100%
    Novartis Pharma GmbH
    Nuremberg
    EUR
    25.6
    m
    100%
    Novartis Pharma Produktions GmbH
    Wehr
    EUR
    2.0
    m
    100%
    Sandoz International GmbH
    Holzkirchen
    EUR
    100 000
    100%
    1 A Pharma GmbH
    Oberhaching
    EUR
    26 000
    100%
    HEXAL AG
    Holzkirchen
    EUR
    93.7
    m
    100%
    Salutas Pharma GmbH
    Barleben
    EUR
    42.1
    m
    100%
    Aeropharm GmbH
    Rudolstadt
    EUR
    26 000
    100%
    Alcon Pharma GmbH
    Freiburg im Breisgau
    EUR
    512 000
    100%
    CIBA Vision GmbH
    Grosswallstadt
    EUR
    15.4
    m
    100%
    WaveLight GmbH
    Erlangen
    EUR
    6.6
    m
    100%
    Gibraltar
    Novista Insurance Limited
    Gibraltar City
    CHF
    130.0
    m
    100%
    Greece
    Novartis (Hellas) S.A.C.I.
    Metamorphosis/Athens
    EUR
    23.4
    m
    100%
    Alcon Laboratories Hellas- Commercial and Industrial S.A.
    Maroussi, Athens
    EUR
    5.7
    m
    100%
    Hungary
    Novartis Hungary Healthcare Limited Liability Company
    Budapest
    HUF
    545.6
    m
    100%
    Sandoz Hungary Limited Liability Company
    Budapest
    HUF
    883.0
    m
    100%
    India
    Novartis India Limited
    Mumbai
    INR
    140.7
    m
    73.4%
    Novartis Healthcare Private Limited
    Mumbai
    INR
    60.0
    m
    100%
    Sandoz Private Limited
    Mumbai
    INR
    32.0
    m
    100%
    Alcon Laboratories (India) Private Limited
    Bangalore
    INR
    1.1
    bn
    100%
    Indonesia
    PT. Novartis Indonesia
    Jakarta
    IDR
    7.7
    bn
    100%
    PT. CIBA Vision Batam
    Batam
    IDR
    11.9
    bn
    100%
    Ireland
    Novartis Ireland Limited
    Dublin
    EUR
    25 000
    100%
    Novartis Ringaskiddy Limited
    Ringaskiddy, County Cork
    EUR
    2.0
    m
    100%
    Alcon Laboratories Ireland Limited
    Cork City
    EUR
    541 251
    100%
    Israel
    Novartis Israel Ltd.
    Petach Tikva
    ILS
    1 000
    100%
    Optonol Ltd.
    Neve-Ilan
    ILS
    752 545
    100%
    Italy
    Novartis Farma S.p.A.
    Origgio
    EUR
    18.2
    m
    100%
    Sandoz S.p.A.
    Origgio
    EUR
    1.7
    m
    100%
    Sandoz Industrial Products S.p.A.
    Rovereto
    EUR
    2.6
    m
    100%
    Alcon Italia S.p.A.
    Milan
    EUR
    3.7
    m
    100%
    Japan
    Novartis Holding Japan K.K.
    Tokyo
    JPY
    10.0
    m
    100%
    Novartis Pharma K.K.
    Tokyo
    JPY
    6.0
    bn
    100%
    Ciba-Geigy Japan Limited
    Tokyo
    JPY
    8.5
    m
    100%
    Sandoz K.K.
    Tokyo
    JPY
    100.0
    m
    100%
    Alcon Japan Ltd.
    Tokyo
    JPY
    500.0
    m
    100%
    Luxembourg
    Novartis Investments S.à r.l.
    Luxembourg-Ville
    USD
    100.0
    m
    100%
    Novartis Finance S.A.
    Luxembourg-Ville
    USD
    100 000
    100%
    Malaysia
    Novartis Corporation (Malaysia) Sdn. Bhd.
    Kuala Lumpur
    MYR
    3.3
    m
    100%
    Alcon Laboratories (Malaysia) Sdn. Bhd.
    Petaling Jaya
    MYR
    1.0
    m
    100%
    CIBA Vision Johor Sdn. Bhd.
    Kuala Lumpur
    MYR
    10.0
    m
    100%
    Mexico
    Novartis Farmacéutica, S.A. de C.V.
    Mexico City
    MXN
    205.0
    m
    100%
    Sandoz, S.A. de C.V.
    Mexico City
    MXN
    468.2
    m
    100%
    Alcon Laboratorios, S.A. de C.V.
    Mexico City
    MXN
    5.9
    m
    100%
    Morocco
    Novartis Pharma Maroc SA
    Casablanca
    MAD
    80.0
    m
    100%
    Netherlands
    Novartis Netherlands B.V.
    Arnhem
    EUR
    1.4
    m
    100%
    Novartis Pharma B.V.
    Arnhem
    EUR
    4.5
    m
    100%
    Sandoz B.V.
    Almere
    EUR
    907 560
    100%
    Alcon Nederland B.V.
    Arnhem
    EUR
    18 151
    100%
    New Zealand
    Novartis New Zealand Ltd
    Auckland
    NZD
    820 000
    100%


    As at December 31, 2017
    Share

    capital 1
    Equity

    interest
    Norway
    Novartis Norge AS
    Oslo
    NOK
    1.5
    m
    100%
    Pakistan
    Novartis Pharma (Pakistan) Limited
    Karachi
    PKR
    3.9
    bn
    99.99%
    Panama
    Novartis Pharma (Logistics), Inc.
    Panama City
    USD
    10 000
    100%
    Alcon Centroamerica S.A.
    Panama City
    PAB
    1 000
    100%
    Philippines
    Novartis Healthcare Philippines, Inc.
    Manila
    PHP
    298.8
    m
    100%
    Sandoz Philippines Corporation
    Manila
    PHP
    30.0
    m
    100%
    Poland
    Novartis Poland Sp. z o.o.
    Warszawa
    PLN
    44.2
    m
    100%
    Sandoz Polska Sp. z o.o.
    Warszawa
    PLN
    25.6
    m
    100%
    Lek S.A.
    Strykow
    PLN
    11.4
    m
    100%
    Alcon Polska Sp. z o.o.
    Warszawa
    PLN
    750 000
    100%
    Portugal
    Novartis Portugal SGPS Lda.
    Porto Salvo
    EUR
    500 000
    100%
    Novartis Farma - Produtos Farmacêuticos S.A.
    Porto Salvo
    EUR
    2.4
    m
    100%
    Sandoz Farmacêutica Lda.
    Porto Salvo
    EUR
    499 900
    100%
    Alcon Portugal-Produtos e Equipamentos Oftalmológicos Lda.
    Porto Salvo
    EUR
    4.5
    m
    100%
    Romania
    Novartis Pharma Services Romania S.R.L.
    Bucharest
    RON
    3.0
    m
    100%
    Sandoz S.R.L.
    Targu-Mures
    RON
    105.2
    m
    100%
    Alcon Romania S.R.L.
    Bucharest
    RON
    10.8
    m
    100%
    Russian Federation
    Novartis Pharma LLC
    Moscow
    RUB
    20.0
    m
    100%
    Novartis Neva LLC
    St. Petersburg
    RUB
    1.3
    bn
    100%
    ZAO Sandoz
    Moscow
    RUB
    57.4
    m
    100%
    Alcon Farmacevtika LLC
    Moscow
    RUB
    44.1
    m
    100%
    Saudi Arabia
    Saudi Pharmaceutical Distribution Co. Ltd.
    Riyadh
    SAR
    26.8
    m
    75%
    Singapore
    Novartis (Singapore) Pte Ltd.
    Singapore
    SGD
    100 000
    100%
    Novartis Singapore Pharmaceutical Manufacturing Pte Ltd
    Singapore
    SGD
    45.0
    m
    100%
    Novartis Asia Pacific Pharmaceuticals Pte Ltd
    Singapore
    SGD
    39.0
    m
    100%
    Novartis Institute for Tropical Diseases Pte Ltd
    Singapore
    SGD
    2 004
    100%
    Alcon Pte Ltd
    Singapore
    SGD
    164 000
    100%
    Alcon Singapore Manufacturing Pte Ltd
    Singapore
    SGD
    101 000
    100%
    CIBA Vision Asian Manufacturing and Logistics Pte Ltd.
    Singapore
    SGD
    1.0
    m
    100%
    Slovakia
    Novartis Slovakia s.r.o.
    Bratislava
    EUR
    2.0
    m
    100%
    Slovenia
    Lek Pharmaceuticals d.d.
    Ljubjana
    EUR
    48.4
    m
    100%
    Sandoz Pharmaceuticals d.d.
    Ljubjana
    EUR
    1.5
    m
    100%
    South Africa
    Novartis South Africa (Pty) Ltd
    Midrand
    ZAR
    86.3
    m
    100%
    Sandoz South Africa (Pty) Ltd
    Kempton Park
    ZAR
    3.0
    m
    100%
    Alcon Laboratories (South Africa) (Pty) Ltd.
    Midrand
    ZAR
    201 820
    100%
    South Korea
    Novartis Korea Ltd.
    Seoul
    KRW
    24.5
    bn
    98.55%
    Sandoz Korea Ltd.
    Seoul
    KRW
    17.8
    bn
    100%
    Alcon Korea Ltd.
    Seoul
    KRW
    33.8
    bn
    100%
    Spain
    Novartis Farmacéutica S.A.
    Barcelona
    EUR
    63.0
    m
    100%
    Sandoz Farmacéutica S.A.
    Madrid
    EUR
    270 450
    100%
    Sandoz Industrial Products S.A.
    Les Franqueses del Vallés / Barcelona
    EUR
    9.3
    m
    100%
    Alcon Cusi S.A.
    Barcelona
    EUR
    11.6
    m
    100%
    Abadia Retuerta S.A.
    Sardón de Duero/Valladolid
    EUR
    6.0
    m
    100%
    Sweden
    Novartis Sverige AB
    Täby / Stockholm
    SEK
    5.0
    m
    100%
    Switzerland
    Novartis International AG
    Basel
    CHF
    10.0
    m
    100%
    Novartis Holding AG
    Basel
    CHF
    100.2
    m
    100%
    Novartis International Pharmaceutical Investment AG
    Basel
    CHF
    100 000
    100%
    Novartis Bioventures AG
    Basel
    CHF
    100 000
    100%
    Novartis Forschungsstiftung
    Basel
    --
    --
    100%
    Novartis Stiftung für Kaderausbildung
    Basel
    --
    --
    100%
    Novartis Mitarbeiterbeteiligungsstiftung
    Basel
    --
    --
    100%
    Novartis Stiftung für Mensch und Umwelt
    Basel
    --
    --
    100%
    Stiftung der Novartis AG für Erziehung, Ausbildung und Bildung
    Basel
    --
    --
    100%
    Novartis Pharma AG
    Basel
    CHF
    350.0
    m
    100%
    Novartis International Pharmaceutical AG
    Basel
    CHF
    100 000
    100%
    Novartis Pharma Services AG
    Basel
    CHF
    20.0
    m
    100%
    Novartis Pharma Schweizerhalle AG
    Muttenz
    CHF
    18.9
    m
    100%
    Novartis Pharma Stein AG
    Stein
    CHF
    251 000
    100%
    Novartis Pharma Schweiz AG
    Risch
    CHF
    5.0
    m
    100%
    Sandoz AG
    Basel
    CHF
    5.0
    m
    100%
    Sandoz Pharmaceuticals AG
    Risch
    CHF
    100 000
    100%
    Alcon Switzerland SA
    Risch
    CHF
    100 000
    100%
    Alcon Pharmaceuticals Ltd.
    Fribourg
    CHF
    200 000
    100%
    Roche Holding AG
    Basel
    CHF
    160.0
    m
    33/6 2


    As at December 31, 2017
    Share

    capital 1
    Equity

    interest
    Taiwan
    Novartis (Taiwan) Co., Ltd.
    Taipei
    TWD
    170.0
    m
    100%
    Thailand
    Novartis (Thailand) Limited
    Bangkok
    THB
    302.0
    m
    100%
    Alcon Laboratories (Thailand) Limited
    Bangkok
    THB
    228.1
    m
    100%
    Turkey
    Novartis Saglik, Gida ve Tarim Ürünleri Sanayi ve Ticaret A.S.
    Istanbul
    TRY
    98.0
    m
    100%
    Farmanova Saglik Hizmetleri Ltd. Sti.
    Istanbul
    TRY
    6.7
    m
    100%
    Sandoz Ilaç Sanayi ve Ticaret A.S.
    Istanbul
    TRY
    165.2
    m
    99.99%
    Sandoz Syntek Ilaç Hammaddeleri Sanayi ve Ticaret A.S.
    Istanbul
    TRY
    46.0
    m
    100%
    Sandoz Grup Saglik Ürünleri Ilaçlari Sanayi ve Ticaret A.S.
    Gebze - Kocaeli
    TRY
    50.0
    m
    100%
    Alcon Laboratuvarlari Ticaret A.S.
    Istanbul
    TRY
    25.2
    m
    100%
    United Arab Emirates
    Novartis Middle East FZE
    Dubai
    AED
    7.0
    m
    100%
    United Kingdom
    Novartis UK Limited
    Frimley/Camberley
    GBP
    25.5
    m
    100%
    Novartis Pharmaceuticals UK Limited
    Frimley/Camberley
    GBP
    5.4
    m
    100%
    Novartis Grimsby Limited
    Frimley/Camberley
    GBP
    250.0
    m
    100%
    Ziarco Group Limited
    Frimley/Camberley
    GBP
    3 904
    100%
    Sandoz Limited
    Frimley/Camberley
    GBP
    2.0
    m
    100%
    Alcon Eye Care UK Limited
    Frimley/Camberley
    GBP
    550 000
    100%
    Glaxosmithkline Consumer Healthcare Holdings Limited
    Brentford, Middlesex
    GBP
    100 000
    36.5%
    United States of America
    Novartis Corporation
    East Hanover, NJ
    USD
    72.2
    m
    100%
    Novartis Finance Corporation
    New York, NY
    USD
    1 000
    100%
    Novartis Capital Corporation
    New York, NY
    USD
    1
    100%
    Novartis Services, Inc.
    East Hanover, NJ
    USD
    1
    100%
    Novartis US Foundation
    New York, NY
    --
    --
    100%
    Novartis Pharmaceuticals Corporation
    East Hanover, NJ
    USD
    5.2
    m
    100%
    Novartis Institutes for BioMedical Research, Inc.
    Cambridge, MA
    USD
    1
    100%
    Corthera, Inc.
    San Mateo, CA
    USD
    1
    100%
    CoStim Pharmaceuticals Inc.
    Cambridge, MA
    USD
    1
    100%
    Encore Vision, Inc.
    New York, NY
    USD
    1
    100%
    Navigate BioPharma Services, Inc.
    Wilmington, NC
    USD
    100
    100%
    Reprixys Pharmaceuticals Corporation
    Oklahoma City, OK
    USD
    1
    100%
    Spinifex Pharmaceuticals, Inc.
    Wilmington, NC
    USD
    1
    100%
    Novartis Institute for Functional Genomics, Inc.
    San Diego, CA
    USD
    1 000
    100%
    Sandoz Inc.
    Princeton, NJ
    USD
    25 000
    100%
    Fougera Pharmaceuticals Inc.
    Melville, NY
    USD
    1
    100%
    Eon Labs, Inc.
    Princeton, NJ
    USD
    1
    100%
    Alcon Laboratories, Inc.
    Fort Worth, TX
    USD
    1 000
    100%
    Alcon Refractivehorizons, LLC
    Fort Worth, TX
    USD
    10
    100%
    Alcon Research, Ltd.
    Fort Worth, TX
    USD
    12.5
    100%
    Alcon Lensx, Inc.
    Aliso Viejo, CA
    USD
    1
    100%
    Alcon Laboratories Holding Corporation
    Fort Worth, TX
    USD
    10
    100%
    Novartis Vaccines and Diagnostics, Inc.
    Cambridge, MA
    USD
    3
    100%
    ClarVista Medical, Inc.
    Aliso Viejo, CA
    USD
    1
    100%
    Transcend Medical, Inc.
    Menlo Park, CA
    USD
    1
    100%
    Venezuela
    Novartis de Venezuela, S.A.
    Caracas
    VEF
    1.4
    m
    100%
    Alcon Pharmaceutical, C.A.
    Caracas
    VEF
    5.5
    m
    100%
    In addition, the Group is represented by subsidiaries and associated companies in the following countries: Bosnia/Herzegovina, Bulgaria, Dominican Republic, Guatemala, Kenya, Latvia, the Former Yugoslav Republic of Macedonia, Nigeria, Peru, Puerto Rico, Ukraine and Uruguay
     1  Share capital may not reflect the taxable share capital and does not include any paid-in surplus
     2  Approximately 33% of voting shares; approximately 6% of total net income and equity attributable to Novartis
    m = million; bn = billion
    XML 106 R39.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Significant accounting policies (Policies)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Scope of consolidation
    Scope of consolidation
    The consolidated financial statements include all entities, including structured entities, over which Novartis AG, Basel, Switzerland, directly or indirectly has control (generally as a result of owning more than 50% of the entity’s voting interest). Consolidated entities are also referred to as “subsidiaries”.
    In cases where Novartis does not fully own a subsidiary, it has elected to value any remaining outstanding non-controlling interest at the time of acquiring control of the subsidiary at its proportionate share of the fair value of the net identified assets.
    The contribution of a business to an associate or joint venture is accounted for by applying the option under IFRS that permits the accounting for the retained interest of the business contributed at its net book value at the time of the contribution.
    Investments in associated companies (generally defined as investments in entities in which Novartis holds between 20% and 50% of voting shares or over which it otherwise has significant influence) and joint ventures are accounted for using the equity method, except for selected venture fund investments for which the Group has elected to apply the method of fair value through the consolidated income statement.
    Foreign currencies
    Foreign currencies
    The consolidated financial statements of Novartis are presented in US dollars (USD). The functional currency of subsidiaries is generally the local currency of the respective entity. The functional currency used for the reporting of certain Swiss and foreign finance entities is USD instead of their respective local currencies. This reflects the fact that the cash flows and transactions of these entities are primarily denominated in these currencies.
    For subsidiaries not operating in hyperinflationary economies, the subsidiary’s results, financial position and cash flows that do not have USD as their functional currency are translated into USD using the following exchange rates:
    • Income, expense and cash flows using for each month the average exchange rate with the US dollar values for each month being aggregated during the year.
    • Balance sheets using year-end exchange rates.
    • Resulting exchange rate differences are recognized in other comprehensive income.
    The only hyperinflationary economy applicable to Novartis is Venezuela. The financial statements of the major subsidiaries in this country are first adjusted for the effect of inflation, with any gain or loss on the net monetary position recorded in the related functional lines in the consolidated income statement and then translated into USD.
    Acquisition of assets
    Acquisition of assets
    Acquired assets are initially recognized on the balance sheet at cost if they meet the criteria for capitalization. If acquired as part of a business combination, the fair value of identified assets represents the cost for these assets. If separately acquired, the cost of the asset includes the purchase price and any directly attributable costs for bringing the asset into the condition to operate as intended. Expected costs for obligations to dismantle and remove property, plant and equipment when it is no longer used are included in their cost.
    Property plant and equipment
    Property, plant and equipment
    Property, plant and equipment are depreciated on a straight-line basis in the consolidated income statement over their estimated useful lives. Leasehold land is depreciated over the period of its lease, whereas freehold land is not depreciated. The related depreciation expense is included in the costs of the functions using the asset.
    Property, plant and equipment are assessed for impairment whenever there is an indication that the balance sheet carrying amount may not be recoverable using cash flow projections for the useful life.
    The following table shows the respective useful lives for property, plant and equipment:
    Useful life
    Buildings
    20 to 40 years
    Machinery and other equipment
    Machinery and equipment
    7 to 20 years
    Furniture and vehicles
    5 to 10 years
    Computer hardware
    3 to 7 years
    Government grants obtained for construction activities, including any related equipment, are deducted from the gross acquisition cost to arrive at the balance sheet carrying value of the related assets.
    Goodwill
    Goodwill
    Goodwill arises in a business combination and is the excess of the consideration transferred to acquire a business over the underlying fair value of the net identified assets acquired. It is allocated to groups of cash-generating units (CGUs) which are usually represented by the reported segments. Goodwill is tested for impairment annually at the level of these groups of CGUs, and any impairment charges are recorded under “Other Expense” in the consolidated income statement.
    Intangible assets available-for-use
    Intangible assets available-for-use
    Novartis has the following classes of available-for-use intangible assets: Currently marketed products; Marketing know-how; Technologies; Other intangible assets (including computer software) and the Alcon brand name.
    Currently marketed products represent the composite value of acquired intellectual property, patents, and distribution rights and product trade names.
    Marketing know-how represents the value attributable to the expertise acquired for marketing and distributing Alcon surgical products.
    Technologies represent identified and separable acquired know-how used in the research, development and production processes.
    Significant investments in internally developed and acquired computer software are capitalized and included in the “Other” category and amortized once available for use.
    The Alcon brand name is shown separately, as it is the only Novartis intangible asset that is available for use with an indefinite useful life. Novartis considers that it is appropriate that the Alcon brand name has an indefinite life since Alcon-branded products have a history of strong revenue and cash flow performance, and Novartis has the intent and ability to support the brand with spending to maintain its value for the foreseeable future.
    Except for the Alcon brand name, intangible assets available for use are amortized over their estimated useful lives on a straight-line basis and evaluated for potential impairment whenever facts and circumstances indicate that their carrying value may not be recoverable. The Alcon brand name is not amortized, but evaluated for potential impairment annually.
    The following table shows the respective useful lives for available-for-use intangible assets and the location in the consolidated income statement in which the respective amortization and any potential impairment charge is recognized:




    Useful life
    Income statement location

    for amortization and

    impairment charges
    Currently marketed products
    5 to 20 years
    "Cost of goods sold"
    Marketing know-how
    25 years
    "Cost of goods sold"
    Technologies
    10 to 20 years



    "Cost of goods sold"

    or "Research

    and Development"
    Other (including

    computer software)
    3 to 7 years

    In the respective

    functional expense
    Alcon brand name
    Not amortized,

    indefinite useful life
    Not applicable

    Intangible assets not yet available-for-use
    Intangible assets not yet available-for-use
    Acquired research and development intangible assets, which are still under development and have accordingly not yet obtained marketing approval, are recognized as In-Process Research & Development (IPR&D).
    IPR&D is not amortized, but evaluated for potential impairment on an annual basis or when facts and circumstances warrant. Any impairment charge is recorded in the consolidated income statement under “Research & Development”. Once a project included in IPR&D has been successfully developed, it is transferred to the “Currently marketed products” category.
    Impairment of goodwill and intangible assets
    Impairment of goodwill and intangible assets
    An asset is considered impaired when its balance sheet carrying amount exceeds its estimated recoverable amount, which is defined as the higher of its fair value less costs of disposal and its value in use. Usually, Novartis applies the fair value less costs of disposal method for its impairment assessment. In most cases, no directly observable market inputs are available to measure the fair value less costs of disposal. Therefore, an estimate is derived indirectly and is based on net present value techniques utilizing post-tax cash flows and discount rates. In the limited cases where the value in use method would be applied, net present value techniques would be applied using pre-tax cash flows and discount rates.
    Fair value less costs of disposal reflects estimates of assumptions that market participants would be expected to use when pricing the asset or CGUs, and for this purpose, management considers the range of economic conditions that are expected to exist over the remaining useful life of the asset.
    The estimates used in calculating the net present values are highly sensitive and depend on assumptions specific to the nature of the Group’s activities with regard to:
    • Amount and timing of projected future cash flows
    • Long-term sales forecasts for periods of up to 25 years
    • Actions of competitors (launch of competing products, marketing initiatives, etc.)
    • Sales erosion rates after the end of patent or other intellectual property rights protection and timing of the entry of generic competition
    • Outcome of R&D activities (compound efficacy, results of clinical trials, etc.)
    • Amount and timing of projected costs to develop IPR&D into commercially viable products
    • Probability of obtaining regulatory approval
    • Future tax rate
    • Appropriate royalty rate for the Alcon Brand name
    • Appropriate terminal growth rate
    • Appropriate discount rate
    Generally, for intangible assets with a definite useful life Novartis uses cash flow projections for the whole useful life of these assets. For goodwill and the Alcon brand name, Novartis generally utilizes cash flow projections for a five-year period based on management forecasts, with a terminal value based on cash flow projections usually in line with inflation rates for later periods. Probability-weighted scenarios are typically used.
    Discount rates used consider the Group’s estimated weighted average cost of capital, adjusted for specific country and currency risks associated with cash flow projections to approximate the weighted average cost of capital of a comparable market participant.
    Due to the above factors, actual cash flows and values could vary significantly from forecasted future cash flows and related values derived using discounting techniques.
    Impairment of associated companies accounted for at equity
    Impairment of associated companies accounted for at equity
    Novartis considers investments in associated companies for impairment evaluation whenever objective evidence indicates the net investment may be impaired, including when a quoted share price indicates a fair value less than the per-share balance sheet carrying value for the investment.
    If the recoverable amount of the investment is estimated to be lower than the balance sheet carrying amount an impairment charge is recognized for the difference in the consolidated income statement under “Income from associated companies”.
    Cash and cash equivalents, marketable securities, commodities, derivative financial instruments and non-current financial assets
    Cash and cash equivalents, marketable securities, commodities and non-current financial assets
    Cash and cash equivalents include highly liquid investments with original maturities of three months or less, which are readily convertible to known amounts of cash. Bank overdrafts are usually presented within current financial debts on the consolidated balance sheet, except in cases where a right of offset has been agreed with a bank, which then allows for presentation on a net basis.
    Marketable securities are financial assets consisting principally of equity and debt securities as well as fund investments. Marketable securities held for short-term purposes are principally traded in liquid markets and are classified as marketable securities on the consolidated balance sheet. Marketable securities held for long-term strategic purposes are classified as non-current financial assets on the consolidated balance sheet.
    Marketable securities are initially recorded at fair value on their trade date, which is different from the settlement date when the transaction is ultimately effected. Quoted securities are re-measured at each reporting date to fair value based on current market prices. If the market for a financial asset is not active or no market is available, fair values are established using valuation techniques. The majority of non-quoted investments are valued initially at fair value through the established purchase price between a willing buyer and seller. Non-quoted investments are subsequently adjusted based on values derived from using discounted cash flow analysis or other pricing models. These investment values are what is known as “Level 3” in the fair value hierarchy.
    The Group has classified all its equity and quoted debt securities as well as fund investments as available-for-sale, as they are not acquired to generate profit from short-term fluctuations in price. Unrealized gains, except exchange gains related to quoted debt instruments, are recorded as a fair value adjustment in the consolidated statement of comprehensive income. They are recognized in the consolidated income statement when the financial asset is sold, at which time the gain is transferred either to “Other financial income and expense”, for the marketable securities held for short-term non-strategic purposes, or to “Other income”, for all other equity securities and fund investments. Exchange gains related to quoted debt instruments are immediately recognized in the consolidated income statement under “Other financial income and expense”.
    A security is assessed for impairment when its market value at the balance sheet date is less than initial cost reduced by any previously recognized impairment. Impairments on equity securities, quoted debt securities and fund investments, and exchange rate losses on quoted debt securities in a foreign currency that are held for short-term non-strategic purposes are recorded in “Other financial income and expense”. Impairments are recorded for all other equity securities and other fund investments in “Other expense” in the consolidated income statement.
    Commodities include gold bullion or coins which are valued at the lower of cost or fair value using current market prices. The changes in fair value below cost are immediately recorded in “Other financial income and expense”.
    Other non-current financial assets, including loans held for long-term strategic purposes, are carried at amortized cost, which reflects the time value of money less any allowances for uncollectable amounts. For these financial assets, impairments and exchange rate losses are included in “Other expense” in the consolidated income statement and exchange rate gains and interest income using the effective interest rate method are included in “Other income” in the consolidated income statement.
    Derivative financial instruments
    Derivative financial instruments are initially recognized in the balance sheet at fair value and are re-measured to their current fair value at the end of each subsequent reporting period. The valuation of a forward exchange rate contract is based on the discounted cash flow model, using interest curves and spot rates at the reporting date as observable inputs.
    Options are valued based on a modified Black-Scholes model using volatility and exercise prices as major observable inputs.
    The Group utilizes derivative financial instruments for the purpose of hedging to reduce the volatility in the Group’s performance due to the exposure of various types of business risks. To mitigate these risks, the Group enters into certain derivative financial instruments. The risk reduction is obtained because the derivative’s value or cash flows are expected, wholly or partly, to offset changes in the value or cash flows of the recognized assets or liabilities. The overall strategy is aiming to mitigate the currency and interest exposure risk of positions that are contractually agreed and to partially mitigate the exposure risk of selected anticipated transactions.
    Certain derivative financial instruments meet the criteria for hedge accounting treatment. A prerequisite for obtaining this accounting-hedge relationship is extensive documentation on inception and proving on a regular basis that the economic hedge is effective for accounting purposes. Other derivative financial instruments do not meet the criteria to qualify for hedge accounting. Changes in the fair value of those derivative instruments are recognized immediately in “Other financial income and expense” in the consolidated income statement.
    In addition, the Group has designated certain long-term debt components as hedges of the translation risk arising on certain net investments in foreign operations. On consolidation, foreign currency differences arising on long-term debt designated as net investment hedges of a foreign operation are recognized in other comprehensive income and accumulated in currency translation effects, to the extent that the hedge is effective. The foreign currency differences arising from hedge ineffectiveness are recognized in the income statement in “Other financial income and expense”.
    When a hedged net investment is disposed of, the proportionate portion of the cumulative amount recognized in equity in relation to the hedged net investment is transferred to the income statement as an adjustment to the profit or loss on disposal.
    Inventories
    Inventories
    Inventory is valued at acquisition or production cost determined on a first-in first-out basis. This value is used for the “Cost of goods sold” in the consolidated income statement. Unsalable inventory is fully written off in the consolidated income statement under “Cost of goods sold”.
    Trade receivables
    Trade receivables
    Trade receivables are initially recognized at their invoiced amounts, including any related sales taxes less adjustments for estimated revenue deductions such as rebates, chargebacks and cash discounts.
    Provisions for doubtful trade receivables are established once there is an indication that it is likely that a loss will be incurred. These provisions represent the difference between the trade receivable’s carrying amount in the consolidated balance sheet and the estimated net collectible amount. Significant financial difficulties of a customer, such as probability of bankruptcy, financial reorganization, default or delinquency in payments are considered indicators that recovery of the trade receivable is doubtful. Charges for doubtful trade receivables are recognized in the consolidated income statement within “Marketing & Sales” expenses.
    Legal and environmental liabilities
    Legal and environmental liabilities
    Novartis and its subsidiaries are subject to contingencies arising in the ordinary course of business such as patent litigation, environmental remediation liabilities and other product-related litigation, commercial litigation, and governmental investigations and proceedings. Provisions are recorded where a reliable estimate can be made of the probable outcome of legal or other disputes against the subsidiary.
    Contingent consideration
    Contingent consideration
    In a business combination or divestment of a business, it is necessary to recognize contingent future payments to previous owners, representing contractually defined potential amounts as a liability or asset. Usually for Novartis, these are linked to milestone or royalty payments related to certain assets and are recognized as a financial liability or financial asset at their fair value, which is then re-measured at each subsequent reporting date. These estimations typically depend on factors such as technical milestones or market performance and are adjusted for the probability of their likelihood of payment, and if material, are appropriately discounted to reflect the impact of time.
    Changes in the fair value of contingent consideration liabilities in subsequent periods are recognized in the consolidated income statement in “Cost of goods sold” for currently marketed products and in “Research & Development” for IPR&D. Changes in contingent consideration assets are recognized in “Other income” or “Other expense”, depending on its nature.
    The effect of unwinding the discount over time is recognized for contingent liabilities in “Interest expense” and for contingent assets in “other financial income and expense” in the consolidated income statement.
    Defined benefit pension plans and other post retirement benefits
    Defined benefit pension plans and other post-employment benefits
    The liability in respect of defined benefit pension plans and other post-employment benefits is the defined benefit obligation calculated annually by independent actuaries using the projected unit credit method. The current service cost for such post-employment benefit plans is included in the personnel expenses of the various functions where the associates are employed, while the net interest on the net defined benefit liability or asset is recognized as “Other expense” or “Other income”.
    Treasury Shares
    Treasury shares
    Treasury shares are initially recorded at fair value on their trade date which is different from the settlement date, when the transaction is ultimately effected. Treasury shares are deducted from consolidated equity at their nominal value of CHF 0.50 per share. Differences between the nominal amount and the transaction price on purchases or sales of treasury shares with third parties, or the value of services received for the shares allocated to associates as part of share-based compensation arrangements, are recorded in “Retained earnings” in the consolidated statement of changes in equity.
    Revenue
    Revenue recognition
    Revenue
    Revenue is recognized on the sale of Novartis Group products and services and recorded as “Net sales” in the consolidated income statement when there is persuasive evidence that a sales arrangement exists; title, risks and rewards for the products are transferred to the customer; the price is determinable; and collectability is reasonably assured. When contracts contain customer acceptance provisions, sales are recognized upon the satisfaction of acceptance criteria. If products are stockpiled at the request of the customer, revenue is only recognized once the products have been inspected and accepted by the customer, and there is no right of return or replenishment on product expiry.
    Surgical equipment may be sold together with other products and services under a single contract. The total consideration is allocated to the separate elements based on their relative fair values. Revenue is recognized once the recognition criteria have been met for each element of the contract.
    For surgical equipment, in addition to cash and installment sales, revenue is recognized under finance and operating lease arrangements. Arrangements in which Novartis transfers substantially all the risks and rewards incidental to ownership to the customer are treated as finance lease arrangements. Revenue from finance lease arrangements is recognized at amounts equal to the fair values of the equipment, which approximate the present values of the minimum lease payments under the arrangements. As interest rates embedded in lease arrangements are approximately market rates, revenue under finance lease arrangements is comparable to revenue for outright sales. Finance income for arrangements in excess of twelve months is deferred and subsequently recognized based on a pattern that approximates the use of the effective interest method and recorded in “Other income”. Operating lease revenue for equipment rentals is recognized on a straight-line basis over the lease term.
    Provisions for rebates and discounts granted to government agencies, wholesalers, retail pharmacies, managed healthcare organizations and other customers are recorded as a deduction from revenue at the time the related revenues are recorded or when the incentives are offered. They are calculated on the basis of historical experience and the specific terms in the individual agreements.
    Provisions for refunds granted to healthcare providers under innovative pay-for-performance agreements are recorded as a revenue deduction at the time the related sales are recorded. They are calculated on the basis of historical experience and clinical data available for the product, as well as the specific terms in the individual agreements. In cases where historical experience and clinical data are not sufficient for a reliable estimation of the outcome, revenue recognition is deferred until such history is available.
    Cash discounts are offered to customers to encourage prompt payment and are recorded as revenue deductions.
    Following a decrease in the price of a product, we generally grant customers a “shelf stock adjustment” for their existing inventory for the involved product. Provisions for shelf stock adjustments, which are primarily relevant within the Sandoz Division, are determined at the time of the price decline or at the point of sale, if the impact of a price decline on the products sold can be reasonably estimated based on the customer’s inventory levels of the relevant product.
    When there is historical experience of Novartis agreeing to customer returns and Novartis can reasonably estimate expected future returns, a provision is recorded for estimated sales returns. In doing so, the estimated rate of return is applied, determined based on historical experience of customer returns and considering any other relevant factors. This is applied to the amounts invoiced, also considering the amount of returned products to be destroyed versus products that can be placed back in inventory for resale. Where shipments are made on a re-sale or return basis, without sufficient historical experience for estimating sales returns, revenue is only recorded when there is evidence of consumption or when the right of return has expired.
    Provisions for revenue deductions are adjusted to actual amounts as rebates, discounts and returns are processed. The provision represents estimates of the related obligations, requiring the use of judgment when estimating the effect of these sales deductions.
    Other revenue
    “Other revenue” includes royalty and profit sharing income and revenue from activities such as manufacturing services or other services rendered, to the extent such revenue is not recorded under net sales.
    Research and development
    Research & Development
    Internal Research & Development (R&D) costs are fully charged to “Research & Development” in the consolidated income statement in the period in which they are incurred. The Group considers that regulatory and other uncertainties inherent in the development of new products preclude the capitalization of internal development expenses as an intangible asset until marketing approval from a regulatory authority is obtained in a major market such as the United States, the European Union, Switzerland or Japan.
    Payments made to third parties, such as contract research and development organizations in compensation for subcontracted R&D, that is deemed to not transfer intellectual property to Novartis are expensed as internal R&D expenses in the period in which they are incurred. Such payments are only capitalized if they meet the criteria for recognition of an internally generated intangible asset, usually when marketing approval has been achieved from a regulatory authority in a major market.
    Payments made to third parties to in-license or acquire intellectual property rights, compounds and products, including initial upfront and subsequent milestone payments, are capitalized, as are payments for other assets, such as technologies to be used in R&D activities. If additional payments are made to the originator company to continue to perform R&D activities, an evaluation is made as to the nature of the payments. Such additional payments will be expensed if they are deemed to be compensation for subcontracted R&D services not resulting in an additional transfer of intellectual property rights to Novartis. Such additional payments will be capitalized if they are deemed to be compensation for the transfer to Novartis of additional intellectual property developed at the risk of the originator company. Subsequent internal R&D costs in relation to IPR&D and other assets are expensed, since the technical feasibility of the internal R&D activity can only be demonstrated by the receipt of marketing approval for a related product from a regulatory authority in a major market.
    Costs for post-approval studies performed to support the continued registration of a marketed product are recognized as marketing expenses. Costs for activities that are required by regulatory authorities as a condition for obtaining marketing approval are capitalized and recognized as currently marketed products.
    Inventory produced ahead of regulatory approval is fully provisioned and the charge is included in “Other expense” in the consolidated income statement, as its ultimate use cannot be assured. If this inventory can be subsequently sold, the provision is released to “Other income” in the consolidated income statement either on approval by the appropriate regulatory authority or, exceptionally in Europe, on recommendation by the Committee for Medicinal Products for Human Use (CHMP), if approval is virtually certain.
    Share based compensation
    Share-based compensation
    Vested Novartis shares and American Depositary Receipts (ADRs) that are granted as compensation are valued at their market value on the grant date and are immediately expensed in the consolidated income statement.
    The fair values of unvested restricted shares, restricted share units (RSUs) and performance share units (PSUs) in Novartis shares and ADRs granted to associates as compensation are recognized as an expense over the related vesting period. The expense recorded in the consolidated income statement is included in the personnel expenses of the various functions where the associates are employed.
    Unvested restricted shares, restricted ADRs and RSUs are only conditional on the provision of services by the plan participant during the vesting period. They are valued using their fair value on the grant date. As RSUs do not entitle the holder to dividends the fair value is based on the Novartis share price at the grant date adjusted for the net present value of the dividends expected to be paid during the holding period. The fair value of these grants, after making adjustments for assumptions related to their forfeiture during the vesting period, is expensed on a straight-line basis over the respective vesting period.
    PSUs are subject to certain performance criteria being achieved during the vesting period and require plan participants to provide services during the vesting period. PSUs granted under plans defined as “Long-Term Performance Plans” are subject to performance criteria based on Novartis internal performance metrics. The expense is determined taking into account assumptions concerning performance during the period against targets and expected forfeitures due to plan participants not meeting their service conditions. These assumptions are periodically adjusted. Any change in estimates for past services is recorded immediately as an expense or income in the consolidated income statement and amounts for future periods are expensed over the remaining vesting period. As a result, at the end of the vesting period, the total charge during the whole vesting period represents the amount that will finally vest. The number of equity instruments that finally vest is determined at the vesting date.
    PSUs granted under the Long-Term Relative Performance Plan (LTRPP) are conditional on the provision of services by the plan participant during the vesting period as well as on the Total Shareholder Return (TSR) performance of Novartis relative to a specific peer group of companies over the vesting period. These performance conditions are based on variables that can be observed in the market. IFRS requires that these observations are taken into account in determining the fair value of these PSUs at the date of grant. Novartis has determined the fair value of these PSUs at the date of grant using a “Monte Carlo” simulation model. The total fair value of this grant is expensed on a straight-line basis over the vesting period. Adjustments to the number of equity instruments granted are only made if a plan participant does not fulfill the service conditions.
    If a plan participant leaves Novartis for reasons other than retirement, disability or death, then unvested restricted shares, restricted ADRs, RSUs and PSUs are forfeited, unless determined otherwise by the provision of the plan rules or by the Compensation Committee of the Novartis Board of Directors, for example, in connection with a reorganization or divestment.
    Measuring the fair values of PSUs granted under the LTRPP, requires estimates. The Monte Carlo simulation used for determining the fair value of the PSUs related to the LTRPP requires as input parameters the probability of factors related to uncertain future events; the term of the award; the grant price of underlying shares or ADRs; expected volatilities; the expected correlation matrix of the underlying equity instruments with those of the peer group of companies and the risk-free interest rate.
    Government grants
    Government grants
    Grants from governments or similar organizations are recognized at their fair value when there is a reasonable assurance that the grant will be received and the Group will comply with all attached conditions.
    Government grants related to income are deferred and recognized in the consolidated income statement over the period necessary to match them with the related costs that they are intended to compensate.
    The accounting policy for property, plant and equipment describes the treatment of any related grants.
    Restructuring charges
    Restructuring charges
    Restructuring provisions are recognized for the direct expenditures arising from the restructuring, where the plans are sufficiently detailed and where appropriate communication to those affected has been made.
    Charges to increase restructuring provisions are included in “Other expense” in the consolidated income statements. Corresponding releases are recorded in “Other income” in the consolidated income statement.
    Taxes
    Taxes
    Taxes on income are provided in the same periods as the revenues and expenses to which they relate and include any interest and penalties incurred during the period. Deferred taxes are determined using the comprehensive liability method and are calculated on the temporary differences that arise between the tax base of an asset or liability and its carrying value in the balance sheet prepared for consolidation purposes, except for those temporary differences related to investments in subsidiaries and associated companies, where the timing of their reversal can be controlled and it is probable that the difference will not reverse in the foreseeable future. Since the retained earnings are reinvested, withholding or other taxes on eventual distribution of a subsidiary’s retained earnings are only taken into account when a dividend has been planned.
    The estimated amounts for current and deferred tax assets or liabilities, including any amounts related to any uncertain tax positions, are based on currently known facts and circumstances. Tax returns are based on an interpretation of tax laws and regulations, and reflect estimates based on these judgments and interpretations. The tax returns are subject to examination by the competent taxing authorities, which may result in an assessment being made requiring payments of additional tax, interest or penalties. Inherent uncertainties exist in the estimates of the tax positions.
    Non-current assets held for sale
    Non-current assets held for sale
    Non-current assets are classified as assets held for sale when their carrying amount is to be recovered principally through a sale transaction and a sale is considered highly probable. They are stated at the lower of carrying amount and fair value less costs of disposal. Assets held for sale, included within a disposal group or discontinued operations are not depreciated or amortized.
    Status of adoption of significant new or amended IFRS standards or interpretations
    Status of adoption of significant new or amended IFRS standards or interpretations
    The adoption of new or amended standards and interpretations that are effective for the financial year beginning on January 1, 2017, did not have a material impact on the Group’s consolidated financial statements.
    The following new IFRS standards will, based on a Novartis analysis, be of significance to the Group, but have not yet been early adopted:
    IFRS 9 FINANCIAL INSTRUMENTS
    IFRS 9 Financial Instruments will substantially change the classification and measurement of financial instruments. The new standard requires impairments to be based on a forward-looking model, changes the approach to hedging financial exposures and related documentation, changes the recognition of certain fair value changes and amends disclosures requirements.
    The impairment of financial assets, including trade and lease receivables, will be assessed using an expected credit loss model rather than the current incurred loss model. Given the nature of Novartis’ financial assets, the Group does not expect a significant impact to our provisions for doubtful accounts or impairments from this change.
    The new hedge accounting model introduced by the standard requires hedge accounting relationships to be based upon the Group’s own risk management strategy and objectives, and to be discontinued only when the relationships no longer qualify for hedge accounting. Based on the impact of adoption assessment performed, Novartis expects that the existing hedge relationship will continue to be designated as such under the new hedge accounting requirements.
    The Group will implement the new standard on January 1, 2018 and will apply the modified retrospective method, which requires the recognition of the cumulative effect of initially applying IFRS 9, as at January 1, 2018, to retained earnings and not restate prior years.
    The most significant impact to the Group, upon adoption of IFRS 9, will be the treatment of the unrealized gains and losses from changes in fair value on certain of the Group’s financial instruments, which are classified as available-for-sale marketable securities and financial investments. The unrealized gains and losses (to the extent of previous recognized unrealized gains), which the Group currently recognizes in the consolidated statement of other comprehensive income, will in the future be recognized in the consolidated income statement. This approach will be applied to equity securities where the fair value through other comprehensive income irrevocable option will not be applied. If this accounting had been applied prior to January 1, 2018, the adoption date, the cumulative effect to be recorded as an increase to retained earnings, as at January 1, 2018, is estimated at USD 0.2 billion.
    IFRS 15 REVENUE FROM CONTRACTS WITH CUSTOMERS
    IFRS 15 Revenue from contracts with customers amends revenue recognition requirements and establishes principles for reporting information about the nature, amount, timing and uncertainty of revenue and cash flows arising from contracts with customers. The standard replaces IAS 18 Revenue and IAS 11 Construction contracts and related interpretations.
    Results of our impact assessment:
    • The Group’s “Net sales” are derived from the sale of drug substances, vision care products, surgical equipment, other products and services, where control transfers to our customers and our performance obligations are satisfied at the time of shipment to or receipt of the products by the customer or when the services are performed. We do not expect IFRS 15 to significantly change the timing or amount of revenue recognized under these arrangements.
    • The Group’s “Other revenue” consists of royalty income from the out-licensing of intellectual property (IP), which is recognized as earned and from manufacturing services and other services, where revenue is recognized when control transfers to the third party and our performance obligations are satisfied. We do not expect IFRS 15 to significantly change the timing or amount of revenue recognized from these manufacturing and other services arrangements, nor from these royalty arrangements, as the standard’s royalty exception will apply for IP licenses.
    “Other revenue” also includes revenue from profit sharing arrangements with our collaboration partners. Furthermore, the Group receives milestone payments related to sale or out-licensing of IP. Novartis does not expect IFRS 15 to significantly change the timing or amount of revenue recognized under these arrangements.
    The Group will implement the new standard on January 1, 2018 and will apply the modified retrospective method, which requires the recognition of the cumulative effect of initially applying IFRS 15, as at January 1, 2018, to retained earnings and not restate prior years. However, since the results of the Group’s impact assessment indicates that IFRS 15 is not expected to significantly change the amount or timing of revenue recognition in 2017 or prior periods, an insignificant cumulative adjustment to increase retained earnings will be made.
    IFRS 16 LEASES
    IFRS 16 Leases substantially changes the financial statements as the majority of leases for which the company is the lessee will become on-balance sheet liabilities with corresponding right of use assets on the balance sheet. The standard replaces IAS 17 Leases and is effective on January 1, 2019. The current undiscounted operating lease commitments of USD 3.2 billion as of December 31, 2017, and disclosed in Note 27 provide, subject to the provision of the standard, an indicator of the impact of the implementation of IFRS 16 on the Group’s consolidated balance sheet.
    Upon adoption of the new standard, a portion of the annual operating lease costs, which is currently fully recognized as a functional expense, will be recorded as interest expense. In addition, the portion of the annual lease payments recognized in the cash flow statement as a reduction of the lease liability will be recognized as an outflow from financing activities, which currently are fully recognized as an outflow from operating activities. Given the leases involved and assuming the current low interest rate environment continues, the Group does not currently expect these effects to be significant.
    There are no other IFRS standards or interpretations not yet effective that would be expected to have a material impact on the Group.
    XML 107 R40.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Significant accounting policies (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Respective Useful Lives of property, plant and equipment
    Useful life
    Buildings
    20 to 40 years
    Machinery and other equipment
    Machinery and equipment
    7 to 20 years
    Furniture and vehicles
    5 to 10 years
    Computer hardware
    3 to 7 years
    Respective Useful Lives of Available-for-Use Intangible Assets




    Useful life
    Income statement location

    for amortization and

    impairment charges
    Currently marketed products
    5 to 20 years
    "Cost of goods sold"
    Marketing know-how
    25 years
    "Cost of goods sold"
    Technologies
    10 to 20 years



    "Cost of goods sold"

    or "Research

    and Development"
    Other (including

    computer software)
    3 to 7 years

    In the respective

    functional expense
    Alcon brand name
    Not amortized,

    indefinite useful life
    Not applicable

    XML 108 R41.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Segmentation of key figures (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Segmentation - Consolidated income statements
    Innovative Medicines
    Sandoz
    Alcon
    Corporate (including eliminations)
    Group
    (USD millions)
    2017
    2016
    2017
    2016
    2017
    2016
    2017
    2016
    2017
    2016
    Net sales to third parties
    33 025
    32 562
    10 060
    10 144
    6 024
    5 812
    49 109
    48 518
    Sales to other segments
    668
    624
    118
    104
    3
    – 789
    – 728
    Net sales
    33 693
    33 186
    10 178
    10 248
    6 027
    5 812
    – 789
    – 728
    49 109
    48 518
    Other revenues
    898
    815
    37
    37
    3
    4
    88
    62
    1 026
    918
    Cost of goods sold
    – 9 007
    – 9 331
    – 5 800
    – 5 971
    – 3 231
    – 3 092
    863
    874
    – 17 175
    – 17 520
    Gross profit
    25 584
    24 670
    4 415
    4 314
    2 799
    2 724
    162
    208
    32 960
    31 916
    Marketing & Sales
    – 9 089
    – 8 435
    – 1 811
    – 1 681
    – 1 961
    – 1 882
    – 12 861
    – 11 998
    Research & Development
    – 7 630
    – 7 709
    – 774
    – 814
    – 568
    – 516
    – 8 972
    – 9 039
    General & Administration
    – 986
    – 978
    – 315
    – 300
    – 383
    – 410
    – 452
    – 506
    – 2 136
    – 2 194
    Other income
    1 027
    1 091
    204
    185
    47
    48
    691
    603
    1 969
    1 927
    Other expense
    – 1 124
    – 1 213
    – 351
    – 259
    – 124
    – 96
    – 732
    – 776
    – 2 331
    – 2 344
    Operating income
    7 782
    7 426
    1 368
    1 445
    – 190
    – 132
    – 331
    – 471
    8 629
    8 268
    Income from associated companies
    – 1
    23
    6
    1 086
    697
    1 108
    703
    Interest expense
    – 777
    – 707
    Other financial income and expense
    39
    – 447
    Income before taxes
    8 999
    7 817
    Taxes
    – 1 296
    – 1 119
    Net income
    7 703
    6 698
    Attributable to:
    Shareholders of Novartis AG
    7 703
    6 712
    Non-controlling interests
    0
    – 14
    Included in net income are:
    Interest income
    110
    43
    Depreciation of property,

    plant & equipment


    – 916


    – 883


    – 270


    – 260


    – 217


    – 229


    – 117


    – 117


    – 1 520


    – 1 489
    Amortization of intangible assets
    – 2 291
    – 2 470
    – 447
    – 450
    – 942
    – 929
    – 10
    – 12
    – 3 690
    – 3 861
    Impairment charges on property,

    plant & equipment, net


    – 84


    – 93


    – 73


    – 2




    – 5




    – 2


    – 157


    – 102
    Impairment charges on intangible

    assets, net


    – 591


    – 522


    – 61


    – 65


    – 57


    – 4






    – 709


    – 591
    Impairment charges and fair value

    gains on financial assets, net


    – 42


    – 55






    – 29




    – 185


    – 77


    – 256


    – 132
    Additions to restructuring provisions
    – 122
    – 236
    – 61
    – 46
    – 8
    – 36
    – 3
    – 25
    – 194
    – 343
    Equity-based compensation of

    Novartis equity plans


    – 593


    – 582


    – 52


    – 47


    – 71


    – 53


    – 208


    – 164


    – 924


    – 846
     
     
    Innovative Medicines
    Sandoz
    Alcon
    Corporate (including eliminations)
    Group
    (USD millions)
    2016
    2015
    2016
    2015
    2016
    2015
    2016
    2015
    2016
    2015
    Net sales to third parties from

    continuing operations


    32 562


    33 345


    10 144


    10 070


    5 812


    5 999






    48 518


    49 414
    Sales to other segments
    624
    518
    104
    128
    – 728
    – 620
    26
    Net sales from continuing operations
    33 186
    33 863
    10 248
    10 198
    5 812
    5 999
    – 728
    – 620
    48 518
    49 440
    Other revenues
    815
    792
    37
    25
    4
    23
    62
    107
    918
    947
    Cost of goods sold
    – 9 331
    – 9 204
    – 5 971
    – 5 844
    – 3 092
    – 3 145
    874
    789
    – 17 520
    – 17 404
    Gross profit from continuing operations
    24 670
    25 451
    4 314
    4 379
    2 724
    2 877
    208
    276
    31 916
    32 983
    Marketing & Sales
    – 8 435
    – 8 430
    – 1 681
    – 1 679
    – 1 882
    – 1 663
    – 11 998
    – 11 772
    Research & Development
    – 7 709
    – 7 685
    – 814
    – 782
    – 516
    – 468
    – 9 039
    – 8 935
    General & Administration
    – 978
    – 1 031
    – 300
    – 346
    – 410
    – 450
    – 506
    – 648
    – 2 194
    – 2 475
    Other income
    1 091
    1 149
    185
    109
    48
    54
    603
    737
    1 927
    2 049
    Other expense
    – 1 213
    – 1 639
    – 259
    – 381
    – 96
    – 69
    – 776
    – 784
    – 2 344
    – 2 873
    Operating income from

    continuing operations


    7 426


    7 815


    1 445


    1 300


    – 132


    281


    – 471


    – 419


    8 268


    8 977
    Income from associated companies
    6
    2
    697
    264
    703
    266
    Interest expense
    – 707
    – 655
    Other financial income and expense
    – 447
    – 454
    Income before taxes from

    continuing operations


















    7 817


    8 134
    Taxes
    – 1 119
    – 1 106
    Net income from continuing operations
    6 698
    7 028
    Net income from discontinued operations
    10 766
    Net income
    6 698
    17 794
    Attributable to:
    Shareholders of Novartis AG
    6 712
    17 783
    Non-controlling interests
    – 14
    11
    Included in net income from continuing operations are:
    Interest income
    43
    33
    Depreciation of property,

    plant & equipment


    – 883


    – 839


    – 260


    – 277


    – 229


    – 237


    – 117


    – 117


    – 1 489


    – 1 470
    Amortization of intangible assets
    – 2 470
    – 2 384
    – 450
    – 450
    – 929
    – 912
    – 12
    – 9
    – 3 861
    – 3 755
    Impairment charges on property,

    plant & equipment, net


    – 93


    39


    – 2


    – 97


    – 5


    – 1


    – 2


    – 21


    – 102


    – 80
    Impairment charges on intangible

    assets, net


    – 522


    – 138


    – 65


    – 27


    – 4


    – 1






    – 591


    – 166
    Impairment charges and fair value

    gains on financial assets, net


    – 55


    – 32










    – 77


    – 72


    – 132


    – 104
    Additions to restructuring provisions
    – 236
    – 232
    – 46
    – 93
    – 36
    – 25
    – 25
    – 49
    – 343
    – 399
    Equity-based compensation of

    Novartis equity plans


    – 582


    – 620


    – 47


    – 53


    – 53


    – 66


    – 164


    – 164


    – 846


    – 903
    Segmentation - Consolidated balance sheets
    Innovative Medicines
    Sandoz
    Alcon
    Corporate (including eliminations)
    Group
    (USD millions)
    2017
    2016
    2017
    2016
    2017
    2016
    2017
    2016
    2017
    2016
    Total assets
    54 075
    51 911
    18 231
    17 611
    22 014
    22 970
    38 759
    37 632
    133 079
    130 124
    Total liabilities
    – 11 457
    – 10 007
    – 3 459
    – 3 168
    – 1 893
    – 2 520
    – 42 043
    – 39 538
    – 58 852
    – 55 233
    Total equity
    74 227
    74 891
    Net debt
    19 047
    16 025
    Net operating assets
    42 618
    41 904
    14 772
    14 443
    20 121
    20 450
    93 274
    90 916
    Included in assets and liabilities are:
    Total property, plant & equipment
    10 857
    10 410
    2 525
    2 374
    2 403
    2 163
    679
    694
    16 464
    15 641
    Additions to property,

    plant & equipment  1


    877


    996


    326


    316


    431


    396


    94


    127


    1 728


    1 835
    Total goodwill and intangible assets
    31 571
    31 630
    10 993
    10 774
    16 176
    16 914
    3 007
    3 002
    61 747
    62 320
    Additions to goodwill and

    intangible assets  1


    984


    865


    64


    45


    82


    63


    16


    5


    1 146


    978
    Total investment in associated

    companies


    41


    16


    7


    18






    15 322


    14 270


    15 370


    14 304
    Additions to investment in associated

    companies


    6


    4










    40


    37


    46


    41
    Cash and cash equivalents,

    marketable securities, commodities,

    time deposits and derivative

    financial instruments










































    9 485






    7 777






    9 485






    7 777
    Financial debts and derivative

    financial instruments














    28 532


    23 802


    28 532


    23 802
    Current income tax and deferred

    tax liabilities














    6 891


    8 260


    6 891


    8 260
     1  Excluding impact of business combinations
     
    Net sales and total of selected non-current assets, by countries and regions
    Net sales1
    Total of selected non-current assets2
    (USD millions)
    2017
    %
    2016
    %
    2015
    %
    2017
    %
    2016
    %
    Country
    Switzerland
    836
    2
    830
    2
    774
    2
    43 920
    47
    44 413
    48
    United States
    16 935
    34
    17 117
    35
    18 079
    37
    28 476
    30
    28 484
    31
    United Kingdom
    1 160
    2
    1 182
    2
    1 277
    3
    7 957
    9
    6 892
    7
    Germany
    3 690
    8
    3 634
    7
    3 262
    7
    3 128
    3
    2 733
    3
    France
    2 490
    5
    2 390
    5
    2 269
    5
    284
    199
    Japan
    3 177
    6
    3 267
    7
    3 163
    6
    148
    145
    Other
    20 821
    43
    20 098
    42
    20 590
    40
    9 668
    11
    9 399
    11
    Group
    49 109
    100
    48 518
    100
    49 414
    100
    93 581
    100
    92 265
    100
    Region
    Europe
    17 492
    36
    17 079
    35
    16 472
    33
    61 699
    66
    59 879
    65
    Americas
    20 899
    42
    20 998
    43
    22 414
    45
    29 113
    31
    29 831
    32
    Asia/Africa/Australasia
    10 718
    22
    10 441
    22
    10 528
    22
    2 769
    3
    2 555
    3
    Group
    49 109
    100
    48 518
    100
    49 414
    100
    93 581
    100
    92 265
    100
     
     1  Net sales from operations by location of third-party customer
     2  Total of property, plant and equipment; goodwill; intangible assets; and investment in associated companies
    Net sales by business franchise


    2017

    USD

    millions


    2016

    USD

    millions
    Change

    (2016

    to 2017)

    USD %


    2015

    USD

    millions
    Change

    (2015

    to 2016)

    USD %
    Oncology
    Gleevec/Glivec
    1 943
    3 323
    – 42
    4 658
    – 29
    Tasigna
    1 841
    1 739
    6
    1 632
    7
    Sandostatin
    1 612
    1 646
    – 2
    1 630
    1
    Afinitor/Votubia
    1 525
    1 516
    1
    1 607
    – 6
    Exjade/Jadenu
    1 059
    956
    11
    917
    4
    Tafinlar + Mekinist
    873
    672
    30
    453
    nm
    Promacta/Revolade
    867
    635
    37
    402
    nm
    Votrient
    808
    729
    11
    565
    nm
    Jakavi
    777
    581
    34
    410
    42
    Kisqali
    76
    0
    nm
    0
    nm
    Other
    893
    993
    – 10
    1 030
    – 4
    Total Oncology business unit
    12 274
    12 790
    – 4
    13 304
    – 4
    Ophthalmology
    Lucentis
    1 888
    1 835
    3
    2 060
    – 11
    Travoprost Group
    589
    619
    – 5
    631
    – 2
    Systane Group
    400
    377
    6
    380
    – 1
    Topical Olopatadine Group
    284
    335
    – 15
    457
    – 27
    Other
    2 207
    2 297
    – 4
    2 395
    – 4
    Total Ophthalmology
    5 368
    5 463
    – 2
    5 923
    – 8
    Immunology and Dermatology
    Cosentyx
    2 071
    1 128
    84
    261
    nm
    Neoral/Sandimmun(e)
    488
    515
    – 5
    570
    – 10
    Zortress/Certican
    414
    398
    4
    335
    19
    Ilaris
    402
    283
    42
    236
    20
    Myfortic
    378
    383
    – 1
    441
    – 13
    Other
    288
    308
    – 6
    294
    5
    Total Immunology and Dermatology
    4 041
    3 015
    34
    2 137
    41
    Neuroscience
    Gilenya
    3 185
    3 109
    2
    2 776
    12
    Other
    102
    124
    – 18
    141
    – 12
    Total Neuroscience
    3 287
    3 233
    2
    2 917
    11


    2017

    USD

    millions


    2016

    USD

    millions
    Change

    (2016

    to 2017)

    USD %


    2015

    USD

    millions
    Change

    (2015

    to 2016)

    USD %
    Respiratory
    Ultibro Breezhaler
    411
    363
    13
    260
    40
    Seebri Breezhaler
    151
    149
    1
    150
    – 1
    Onbrez Breezhaler
    112
    143
    – 22
    166
    – 14
    Subtotal COPD1 portfolio
    674
    655
    3
    576
    14
    Xolair  2
    920
    835
    10
    755
    11
    Other
    23
    31
    – 26
    37
    – 16
    Total Respiratory
    1 617
    1 521
    6
    1 368
    11
    Cardio-Metabolic
    Entresto
    507
    170
    198
    21
    nm
    Other
    17
    14
    21
    0
    nm
    Total Cardio-Metabolic
    524
    184
    185
    21
    nm
    Established Medicines
    Galvus
    1 233
    1 193
    3
    1 140
    5
    Exforge
    960
    926
    4
    1 047
    – 12
    Diovan/Co-Diovan
    957
    1 073
    – 11
    1 284
    – 16
    Voltaren/Cataflam
    465
    525
    – 11
    558
    – 6
    Exelon/Exelon Patch
    381
    444
    – 14
    728
    – 39
    Ritalin/Focalin
    236
    282
    – 16
    365
    – 23
    Other
    1 682
    1 913
    – 12
    2 553
    – 25
    Total Established Medicines
    5 914
    6 356
    – 7
    7 675
    – 17
    Total Pharmaceutical business unit
    20 751
    19 772
    5
    20 041
    – 1
    Total division net sales
    33 025
    32 562
    1
    33 345
    – 2
     1  Chronic obstructive pulmonary disease
     2  Net sales reflect Xolair sales for all indications (e.g., including Xolair SAA and Xolair CSU, which is managed by the Immunology and Dermatology franchise)
     
    nm = not meaningful
    XML 109 R42.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Associated companies (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Schedule disclosing information related to associates
    Net income statement effect
    Other comprehensive income effect
    Total comprehensive income effect
    (USD millions)
    2017
    2016
    2015
    2017
    2016
    2015
    2017
    2016
    2015
    Roche Holding AG, Switzerland
    456
    464
    343
    108
    – 39
    – 149
    564
    425
    194
    GlaxoSmithKline Consumer

    Healthcare Holdings Ltd., UK


    629


    234


    – 79


    – 145


    710


    – 4


    484


    944


    – 83
    Others
    23
    5
    2
    23
    5
    2
    Associated companies related to continuing operations
    1 108
    703
    266
    – 37
    671
    – 153
    1 071
    1 374
    113
    Schedule disclosing information related to associates, balance sheet value
    Balance sheet value


    (USD millions)
    December 31,

    2017
    December 31,

    2016
    Roche Holding AG, Switzerland
    8 121
    7 644
    GlaxoSmithKline Consumer

    Healthcare Holdings Ltd., UK


    7 020


    6 448
    Others
    229
    212
    Total
    15 370
    14 304
    Roche Holding AG, Switzerland  
    Statement [line items]  
    Associates summarized financial information


    (CHF billions)


    Current assets
    Non-current

    assets
    Current

    liabilities
    Non-current

    liabilities
    December 31, 2016
    28.7
    61.4
    22.6
    27.8
    June 30, 2017
    26.7
    56.9
    20.6
    26.0


    (CHF billions)




    Revenue




    Net income
    Other

    comprehen-

    sive income
    Total

    comprehen-

    sive income
    December 31, 2016
    50.6
    7.5
    0.7
    8.2
    June 30, 2017
    26.3
    4.4
    0.2
    4.6
    Purchase price allocation associates


    (USD millions)
    December 31,

    2017
    Novartis share of Roche’s estimated net assets
    2 412
    Novartis share of re-appraised intangible assets
    673
    Implicit Novartis goodwill
    2 915
    Current value of share in net identifiable assets

    and goodwill


    6 000
    Accumulated equity accounting adjustments and translation effects less dividends received
    2 121
    Balance sheet value
    8 121
    Schedule disclosing information related to associates, net income effect
    (USD millions)
    2017
    2016
    2015
    Novartis share of Roche's

    estimated current-year

    consolidated net income




    669




    678




    650
    Prior-year adjustment
    – 67
    – 68
    – 157
    Amortization of fair value adjustments relating to intangible assets, net of taxes of USD 42 million (2016: USD 42 million; 2015: USD 41 million)
    – 146
    – 146
    – 150
    Net income effect
    456
    464
    343
    GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK  
    Statement [line items]  
    Associates summarized financial information


    (GBP billions)


    Current assets
    Non-current

    assets
    Current

    liabilities
    Non-current

    liabilities
    December 31, 2016
    4.0
    21.1
    3.1
    2.1
    September 30, 2017
    3.3
    20.6
    2.6
    2.0


    (GBP billions)




    Revenue




    Net income
    Other

    comprehen-

    sive income
    Total

    comprehen-

    sive income
    December 31, 2016
    6.5
    0.6
    1.6
    2.2
    September 30, 2017
    5.3
    0.6
    – 0.4
    0.2
    Purchase price allocation associates


    (USD millions)
    December 31,

    2017
    Novartis share of GSK Consumer Healthcare’s

    estimated net assets


    1 505
    Novartis share of re-appraised intangible assets
    3 852
    Implicit Novartis goodwill
    1 763
    Current value of share in net identifiable assets

    and goodwill


    7 120
    Accumulated equity accounting adjustments and translation effects less dividends received
    – 100
    Balance sheet value
    7 020
    Schedule disclosing information related to associates, net income effect
    (USD millions)
    2017
    2016
    2015
    Novartis share of

    GSK Consumer Healthcare's

    estimated current-year

    consolidated net income






    589






    268






    – 17
    Prior-year adjustment
    47
    – 22
    Amortization of fair value adjustments relating to intangible assets and inventory, net of taxes of USD 1 million (2016: USD 2 million; 2015: USD 18 million)
    – 7
    – 12
    – 62
    Net income effect
    629
    234
    – 79
    XML 110 R43.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Interest expense and other financial income and expense (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Interest expense
    (USD millions)
    2017
    2016
    2015
    Interest expense
    – 758
    – 709
    – 669
    (Expense)/ income arising from discounting long-term liabilities
    – 19
    2
    14
    Total interest expense
    – 777
    – 707
    – 655
    Other financial income and expense
    (USD millions)
    2017
    2016
    2015
    Interest income
    110
    43
    33
    Dividend income
    1
    1
    1
    Net capital losses on

    available-for-sale securities


    – 1


    – 1


    – 8
    Income on forward contracts

    and options






    1
    Impairment of commodities

    and available-for-sale securities, net


    12


    7


    – 132
    Other financial expense
    – 25
    – 20
    – 23
    Monetary loss from hyperinflation

    accounting






    – 72
    Currency result, net
    – 58
    – 477
    – 254
    Total other financial income and expense
    39
    – 447
    – 454
    XML 111 R44.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Taxes (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Income before taxes
    (USD millions)
    2017
    2016
    2015
    Switzerland
    5 289
    3 110
    5 765
    Foreign
    3 710
    4 707
    2 369
    Income before taxes

    from continuing operations


    8 999


    7 817


    8 134
    Income before taxes from discontinued operations
    12 479
    Total income before taxes
    8 999
    7 817
    20 613
    Current and deferred income tax expense
    (USD millions)
    2017
    2016
    2015
    Switzerland
    – 462
    – 709
    – 317
    Foreign
    – 1 594
    – 1 418
    – 1 333
    Current income tax expense from continuing operations
    – 2 056
    – 2 127
    – 1 650
    Switzerland
    – 298
    765
    – 68
    Foreign
    1 058
    243
    612
    Deferred tax income from continuing operations
    760
    1 008
    544
    Income tax expense

    from continuing operations


    – 1 296


    – 1 119


    – 1 106
    Income tax expense from discontinued operations
    – 1 713
    Total income tax expense
    – 1 296
    – 1 119
    – 2 819
    Analysis of tax rate
    (As a percentage)
    2017
    2016
    2015
    Applicable tax rate
    14.5
    13.2
    12.4
    Effect of disallowed expenditures
    3.4
    3.5
    3.5
    Effect of utilization of tax losses

    brought forward from prior periods


    – 0.1


    – 0.2


    – 0.2
    Effect of income taxed at reduced rates
    – 0.2
    – 0.2
    – 0.3
    Effect of tax credits and allowances
    – 2.2
    – 2.8
    – 2.7
    Effect of release of

    contingent consideration liability


    – 1.2


    0.0


    0.0
    Effect of tax rate change

    on current and deferred

    tax assets and liabilities  1




    0.7




    0.2




    – 0.5
    Effect of write-off of deferred tax assets
    0.0
    0.5
    0.0
    Effect of write down and reversal of

    write-down of investments in subsidiaries


    – 1.1


    – 1.0


    – 0.9
    Effect of tax benefits expiring in 2017
    – 0.8
    – 0.5
    – 0.4
    Effect of non-deductible losses in Venezuela
    0.0
    1.3
    1.2
    Effect of prior year items
    1.2
    0.2
    1.0
    Effect of other items  2
    0.2
    0.1
    0.5
    Effective tax rate for continuing operations
    14.4
    14.3
    13.6
    Effective tax rate for discontinued operations
    13.7
    Effective tax rate
    14.4
    14.3
    13.7
     1  Included in 2017 is a 0.7% impact related to the revaluation of the deferred tax assets and liabities and a portion of current tax payables. This revaluation resulted from the US tax reform legislation enacted on December 22, 2017, refer to Note 11 for additional disclosures.
     2  Other items in 2016 (+0.1%) include one-time impacts for the deferred tax effects on the net assets of certain subsidiaries resulting from the change in their tax status (-6.2%), the changes in uncertain tax positions (+5.1%) and other items (+1.2%).
    XML 112 R45.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Earnings per share (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Earnings per share
    2017
    2016
    2015
    Net income attributable to shareholders of Novartis AG (USD millions)
    – Continuing operations
    7 703
    6 712
    7 025
    – Discontinued operations
    10 758
    – Total
    7 703
    6 712
    17 783
    Number of shares (in millions)
    Weighted average number of shares outstanding used in basic earnings per share
    2 346
    2 378
    2 403
    Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options
    25
    22
    35
    Weighted average number of shares in diluted earnings per share
    2 371
    2 400
    2 438
    Basic earnings per share (USD)
    – Continuing operations
    3.28
    2.82
    2.92
    – Discontinued operations
    4.48
    – Total
    3.28
    2.82
    7.40
    Diluted earnings per share (USD)
    – Continuing operations
    3.25
    2.80
    2.88
    – Discontinued operations
    4.41
    – Total
    3.25
    2.80
    7.29
    XML 113 R46.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Changes in consolidated statements of comprehensive income (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Comprehensive income


    (USD millions)
    Fair value

    adjustments

    on marketable

    securities
    Fair value

    adjustments on

    deferred cash

    flow hedges
    Actuarial

    gains/(losses)

    from defined

    benefit plans


    Net

    investment

    hedge
    Cumulative

    currency

    translation

    effects




    Total value

    adjustments
    Value adjustments at January 1, 2015
    433
    – 38
    – 5 366
    2 406
    – 2 565
    Fair value adjustments on financial instruments
    28
    20
    48
    Net actuarial losses from defined benefit plans  1
    – 147
    – 147
    Currency translation effects  2
    – 1 659
    – 1 659
    Total value adjustments in 2015
    28
    20
    – 147
    – 1 659
    – 1 758
    Fair value adjustments related to divestments
    100
    100
    Value adjustments at December 31, 2015
    461
    – 18
    – 5 413
    747
    – 4 223
    Fair value adjustments on financial instruments
    – 113
    15
    – 98
    Net actuarial losses from defined benefit plans
    – 514
    – 514
    Currency translation effects
    – 2 389
    – 2 389
    Total value adjustments in 2016
    – 113
    15
    – 514
    – 2 389
    – 3 001
    Fair value adjustments related to divestments
    12
    12
    Value adjustments at December 31, 2016
    348
    – 3
    – 5 915
    – 1 642
    – 7 212
    Fair value adjustments on financial instruments
    38
    12
    50
    Net investment hedge
    – 237
    – 237
    Net actuarial gains from defined benefit plans
    851
    851
    Currency translation effects
    2 208
    2 208
    Total value adjustments in 2017
    38
    12
    851
    – 237
    2 208
    2 872
    Value adjustments at December 31, 2017
    386
    9
    – 5 064
    – 237
    566
    – 4 340
     1  Net actuarial gains of USD 10 million in 2015 were attributable to discontinued operations up to the respective divestment dates
     2  Currency translation losses of USD 29 million in 2015 were attributable to discontinued operations up to the respective divestment dates
    Fair value adjustments financial instruments reconciliation


    (USD millions)
    Fair value

    adjustments

    on marketable

    securities
    Fair value

    adjustments on

    deferred cash

    flow hedges






    Total
    Fair value adjustments at January 1, 2017
    348
    – 3
    345
    Changes in fair value:
    – Available-for-sale marketable securities
    11
    11
    – Available-for-sale financial investments
    47
    47
    Realized net gains transferred to the consolidated income statement:
    – Other financial assets sold
    – 109
    – 109
    Amortized net losses on cash flow hedges transferred to the consolidated income statement
    13
    13
    Impaired financial assets transferred to the consolidated income statement
    102
    102
    Deferred tax on above items  1
    – 13
    – 1
    – 14
    Fair value adjustments during the year
    38
    12
    50
    Fair value adjustments at December 31, 2017
    386
    9
    395
     1  Included in 2017 is a USD 18 million impact related to the revaluation of deferred tax liabilities on available-for-sale financial investments held in the US that were previously recognized through other comprehensive income. This revaluation resulted from the US tax reform legislation enacted on December 22, 2017, refer to Note 11 for additional disclosures.


    (USD millions)
    Fair value

    adjustments

    on marketable

    securities
    Fair value

    adjustments on

    deferred cash

    flow hedges






    Total
    Fair value adjustments at January 1, 2016
    461
    – 18
    443
    Changes in fair value:
    – Available-for-sale marketable securities
    1
    1
    – Available-for-sale financial investments
    – 87
    – 87
    Realized net gains transferred to the consolidated income statement:
    – Marketable securities sold
    – 1
    – 1
    – Other financial assets sold
    – 154
    – 154
    Amortized net losses on cash flow hedges transferred to the consolidated income statement
    16
    16
    Impaired financial assets transferred to the consolidated income statement
    131
    131
    Deferred tax on above items
    – 3
    – 1
    – 4
    Fair value adjustments during the year
    – 113
    15
    – 98
    Fair value adjustments at December 31, 2016
    348
    – 3
    345


    (USD millions)
    Fair value

    adjustments

    on marketable

    securities
    Fair value

    adjustments on

    deferred cash

    flow hedges






    Total
    Fair value adjustments at January 1, 2015
    433
    – 38
    395
    Changes in fair value:
    – Available-for-sale marketable securities
    – 130
    – 130
    – Available-for-sale financial investments
    80
    80
    – Associated companies’ movements in comprehensive income
    – 8
    – 8
    Realized net gains transferred to the consolidated income statement:
    – Marketable securities sold
    – 1
    – 1
    – Other financial assets sold
    – 103
    – 103
    Amortized net losses on cash flow hedges transferred to the consolidated income statement
    21
    21
    Impaired financial assets transferred to the consolidated income statement
    194
    194
    Deferred tax on above items
    – 4
    – 1
    – 5
    Fair value adjustments during the year
    28
    20
    48
    Fair value adjustments at December 31, 2015
    461
    – 18
    443
    Schedule of defined benefit plan amounts recognized in other comprehensive income
    (USD millions)
    2017
    2016
    2015
    Defined benefit pension plans before tax
    1 367
    – 667
    – 252
    Other post-employment benefit plans before tax
    76
    12
    168
    Taxation on above items  1
    – 592
    140
    – 63
    Total after tax
    851
    – 515
    – 147
    Attributable to:
    Shareholders of Novartis AG
    851
    – 514
    – 147
    Non-controlling interests
    – 1
     
     1  Included in 2017 is a USD -272 million impact related to the revaluation of deferred tax assets on US post-employment benefits that were previously recognized through other comprehensive income. This revaluation resulted from the US tax reform legislation enacted on December 22, 2017, refer to Note 11 for additional disclosures.
    XML 114 R47.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Property, plant and equipment (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Movements of property, plant and equipment


    (USD millions)




    Land




    Buildings


    Construction

    in progress
    Machinery

    & other

    equipment




    Total
    Cost
    January 1, 2017
    687
    13 113
    2 680
    14 816
    31 296
    Reclassifications  1
    5
    508
    – 1 617
    1 104
    Additions
    13
    104
    1 186
    425
    1 728
    Disposals and derecognitions  2
    – 23
    – 324
    – 71
    – 593
    – 1 011
    Currency translation effects
    38
    663
    190
    1 106
    1 997
    December 31, 2017
    720
    14 064
    2 368
    16 858
    34 010
    Accumulated depreciation
    January 1, 2017
    – 40
    – 5 436
    – 15
    – 10 164
    – 15 655
    Depreciation charge
    – 3
    – 510
    – 1 007
    – 1 520
    Accumulated depreciation on disposals and derecognitions  2
    6
    275
    34
    534
    849
    Impairment charge
    – 25
    – 58
    – 106
    – 189
    Reversal of impairment charge
    2
    30
    32
    Currency translation effects
    – 3
    – 287
    – 1
    – 772
    – 1 063
    December 31, 2017
    – 40
    – 5 983
    – 38
    – 11 485
    – 17 546
    Net book value at December 31, 2017
    680
    8 081
    2 330
    5 373
    16 464
    Net book value of property, plant & equipment under finance lease contracts
    78
    Commitments for purchases of property, plant & equipment
    318
    Capitalized borrowing costs
    9
     1  Reclassifications between various asset categories due to completion of plant and other equipment under construction.
     2  Derecognition of assets that are no longer used and are not considered to have a significant disposal value or other alternative use.
    The following table summarizes the movements of property, plant and equipment during 2016:


    (USD millions)




    Land




    Buildings


    Construction

    in progress
    Machinery

    & other

    equipment




    Total
    Cost
    January 1, 2016
    688
    12 857
    2 810
    15 093
    31 448
    Reclassifications  1
    4
    630
    – 1 226
    592
    Additions
    24
    176
    1 226
    409
    1 835
    Disposals and derecognitions  2
    – 8
    – 178
    – 19
    – 656
    – 861
    Currency translation effects
    – 21
    – 372
    – 111
    – 622
    – 1 126
    December 31, 2016
    687
    13 113
    2 680
    14 816
    31 296
    Accumulated depreciation
    January 1, 2016
    – 40
    – 5 188
    – 7
    – 10 231
    – 15 466
    Depreciation charge
    – 3
    – 530
    – 956
    – 1 489
    Accumulated depreciation on disposals and derecognitions  2
    5
    157
    1
    630
    793
    Impairment charge
    – 3
    – 47
    – 11
    – 61
    – 122
    Reversal of impairment charge
    6
    1
    13
    20
    Currency translation effects
    1
    166
    1
    441
    609
    December 31, 2016
    – 40
    – 5 436
    – 15
    – 10 164
    – 15 655
    Net book value at December 31, 2016
    647
    7 677
    2 665
    4 652
    15 641
    Net book value of property, plant & equipment under finance lease contracts
    81
    Commitments for purchases of property, plant & equipment
    223
    Capitalized borrowing costs
    9
     1  Reclassifications between various asset categories due to completion of plant and other equipment under construction.
     2  Derecognition of assets that are no longer used and are not considered to have a significant disposal value or other alternative use.
    XML 115 R48.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Goodwill and intangible assets (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Movements of goodwill and intangible assets
    Goodwill
    Intangible Assets other than Goodwill


    (USD millions)




    Total
    Acquired

    research &

    development


    Alcon

    brand name




    Technologies
    Currently

    marketed

    products


    Marketing

    know-how
    Other

    intangible

    assets




    Total
    Cost
    January 1, 2017
    31 381
    5 150
    2 980
    6 548
    33 007
    5 960
    1 492
    55 137
    Impact of business combinations
    94
    1 223
    1 223
    Reclassifications  1
    – 389
    175
    214
    Additions
    697
    5
    282
    162
    1 146
    Disposals and derecognitions  2
    – 353
    – 1
    – 328
    – 64
    – 746
    Currency translation effects
    704
    134
    86
    969
    48
    1 237
    December 31, 2017
    32 179
    6 462
    2 980
    6 638
    34 105
    5 960
    1 852
    57 997
    Accumulated amortization
    January 1, 2017
    – 401
    – 886
    – 3 637
    – 16 863
    – 1 430
    – 981
    – 23 797
    Reclassifications  1
    6
    – 6
    Amortization charge
    – 577
    – 2 571
    – 238
    – 304
    – 3 690
    Accumulated impairments on disposals

    and derecognitions2




    352






    317




    61


    730
    Impairment charge
    – 615
    – 92
    – 2
    – 709
    Currency translation effects
    – 28
    – 27
    – 54
    – 416
    – 37
    – 534
    December 31, 2017
    – 429
    – 1 170
    – 4 268
    – 19 631
    – 1 668
    – 1 263
    – 28 000
    Net book value at December 31, 2017
    31 750
    5 292
    2 980
    2 370
    14 474
    4 292
    589
    29 997
     1  Reclassifications between various asset categories as a result of product launches of acquired In-Process Research & Development and completion of software development.
     2  Derecognitions of assets that are no longer used or being developed and are not considered to have a significant disposal value or other alternative use.
    The following table summarizes the movements of goodwill and intangible assets in 2016:
    Goodwill
    Intangible Assets other than Goodwill


    (USD millions)




    Total
    Acquired

    research &

    development


    Alcon

    brand name




    Technologies
    Currently

    marketed

    products


    Marketing

    know-how
    Other

    intangible

    assets




    Total
    Cost
    January 1, 2016
    31 585
    4 119
    2 980
    6 563
    33 385
    5 960
    1 341
    54 348
    Impact of business combinations
    56
    690
    451
    1 141
    Reclassifications  1
    – 158
    6
    152
    Additions
    599
    223
    156
    978
    Disposals and derecognitions  2
    – 23
    – 464
    – 130
    – 617
    Currency translation effects
    – 260
    – 77
    – 15
    – 594
    – 27
    – 713
    December 31, 2016
    31 381
    5 150
    2 980
    6 548
    33 007
    5 960
    1 492
    55 137
    Accumulated amortization
    January 1, 2016
    – 411
    – 650
    – 3 070
    – 14 221
    – 1 192
    – 998
    – 20 131
    Reclassifications  1
    225
    – 225
    Amortization charge
    – 576
    – 2 926
    – 238
    – 121
    – 3 861
    Accumulated impairments on disposals

    and derecognitions2




    22






    390




    123


    535
    Impairment charge
    – 490
    – 96
    – 5
    – 591
    Currency translation effects
    10
    7
    9
    215
    20
    251
    December 31, 2016
    – 401
    – 886
    – 3 637
    – 16 863
    – 1 430
    – 981
    – 23 797
    Net book value at December 31, 2016
    30 980
    4 264
    2 980
    2 911
    16 144
    4 530
    511
    31 340
     1  Reclassifications between various asset categories as a result of product launches of acquired In-Process Research & Development and completion of software development.
     2  Derecognitions of assets that are no longer used or being developed and are not considered to have a significant disposal value or other alternative use.
    Allocation of net book values of goodwill and intangible assets by reporting segment
    Goodwill
    Intangible Assets other than Goodwill


    (USD millions)




    Total
    Acquired

    research &

    development


    Alcon

    brand name




    Technologies
    Currently

    marketed

    products


    Marketing

    know-how
    Other

    intangible

    assets




    Total
    Innovative Medicines
    15 237
    4 368
    9
    11 604
    353
    16 334
    Sandoz
    8 210
    625
    539
    1 589
    30
    2 783
    Alcon
    8 295
    291
    1 822
    1 281
    4 292
    195
    7 881
    Corporate
    8
    8
    2 980
    11
    2 999
    Net book value at December 31, 2017
    31 750
    5 292
    2 980
    2 370
    14 474
    4 292
    589
    29 997
    The following table summarizes the allocation of the net book values of goodwill and intangible assets by reporting segment at December 31, 2016:
    Goodwill
    Intangible Assets other than Goodwill


    (USD millions)




    Total
    Acquired

    research &

    development


    Alcon

    brand name




    Technologies
    Currently

    marketed

    products


    Marketing

    know-how
    Other

    intangible

    assets




    Total
    Innovative Medicines
    15 010
    3 512
    11
    12 821
    276
    16 620
    Sandoz
    7 669
    613
    563
    1 904
    25
    3 105
    Alcon
    8 293
    139
    2 337
    1 419
    4 530
    196
    8 621
    Corporate
    8
    2 980
    14
    2 994
    Net book value at December 31, 2016
    30 980
    4 264
    2 980
    2 911
    16 144
    4 530
    511
    31 340
    Assumptions used in the calculation of valuation


    (As a percentage)
    Innovative

    Medicines


    Sandoz


    Alcon


    Corporate
    Terminal growth rate
    1.5
    2.0
    3.0
    2.6
    Discount rate (post-tax)
    7.0
    7.0
    7.0
    7.0
    Intangible asset impairment charges
    (USD millions)
    2017
    2016
    Innovative Medicines
    – 591
    – 522
    Sandoz
    – 61
    – 65
    Alcon
    – 57
    – 4
    Total
    – 709
    – 591
    XML 116 R49.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Deferred tax assets and liabilities (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Schedule of Deferred Tax Assets and Liabilities


    (USD millions)


    Property,

    plant &

    equipment




    Intangible

    assets
    Pensions and

    other benefit

    obligations

    of associates






    Inventories


    Tax loss

    carry-

    forwards


    Other assets,

    provisions

    and accruals






    Total
    Gross deferred tax assets at January 1, 2017
    224
    1 331
    1 839
    4 160
    146
    2 597
    10 297
    Gross deferred tax liabilities at January 1, 2017
    – 629
    – 4 019
    – 358
    – 511
    – 1 403
    – 6 920
    Net deferred tax balance at January 1, 2017
    – 405
    – 2 688
    1 481
    3 649
    146
    1 194
    3 377
    At January 1, 2017
    – 405
    – 2 688
    1 481
    3 649
    146
    1 194
    3 377
    Credited/(charged) to income
    – 30
    1 279
    – 90
    – 304
    – 49
    – 46
    760
    Charged to equity
    – 101
    – 101
    Charged to other comprehensive income
    – 592
    – 69
    – 661
    Impact of business combinations
    – 322
    5
    – 317
    Other movements
    – 41
    33
    37
    – 14
    – 14
    2
    3
    Net deferred tax balance at December 31, 2017
    – 476
    – 1 698
    836
    3 331
    88
    980
    3 061
    Gross deferred tax assets at December 31, 2017
    137
    1 287
    1 090
    3 786
    97
    1 983
    8 380
    Gross deferred tax liabilities at December 31, 2017
    – 613
    – 2 985
    – 254
    – 455
    – 9
    – 1 003
    – 5 319
    Net deferred tax balance at December 31, 2017
    – 476
    – 1 698
    836
    3 331
    88
    980
    3 061
    After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction the balance amounts to:
    151
    Deferred tax assets at December 31, 2017
    8 229
    Deferred tax liabilities at December 31, 2017
    – 5 168
    Net deferred tax balance at December 31, 2017
    3 061
    Gross deferred tax assets at January 1, 2016
    216
    611
    1 730
    3 821
    62
    2 866
    9 306
    Gross deferred tax liabilities at January 1, 2016
    – 639
    – 3 962
    – 401
    – 565
    – 5
    – 1 132
    – 6 704
    Net deferred tax balance at January 1, 2016
    – 423
    – 3 351
    1 329
    3 256
    57
    1 734
    2 602
    At January 1, 2016
    – 423
    – 3 351
    1 329
    3 256
    57
    1 734
    2 602
    Credited/(charged) to income
    – 13
    1 057
    53
    373
    55
    – 517
    1 008
    Charged to equity
    – 44
    – 44
    Credited/(charged) to other comprehensive income
    140
    – 2
    138
    Impact of business combinations
    4
    – 400
    23
    37
    – 336
    Other movements
    27
    6
    – 41
    20
    11
    – 14
    9
    Net deferred tax balance at December 31, 2016
    – 405
    – 2 688
    1 481
    3 649
    146
    1 194
    3 377
    Gross deferred tax assets at December 31, 2016
    224
    1 331
    1 839
    4 160
    146
    2 597
    10 297
    Gross deferred tax liabilities at December 31, 2016
    – 629
    – 4 019
    – 358
    – 511
    – 1 403
    – 6 920
    Net deferred tax balance at December 31, 2016
    – 405
    – 2 688
    1 481
    3 649
    146
    1 194
    3 377
    After offsetting the following amount of deferred tax assets and liabilities within the same tax jurisdiction the balance amounts to:
    263
    Deferred tax assets at December 31, 2016
    10 034
    Deferred tax liabilities at December 31, 2016
    – 6 657
    Net deferred tax balance at December 31, 2016
    3 377
    Deferred tax assets/liabilities, expected to have impact on current taxes payable
    (USD billions)
    2017
    2016
    Expected to have an impact on current tax payable after more than 12 months
    – Deferred tax assets
    3.5
    4.8
    – Deferred tax liabilities
    4.4
    5.9
    Unremitted earnings retained by consolidated entities for reinvestment
    (USD billions)
    2017
    2016
    Unremitted earnings that have been retained

    by consolidated entities for reinvestment


    66


    63
    Temporary differences on which no deferred tax has been provided as they are permanent in nature related to:
    (USD billions)
    2017
    2016
    Investments in subsidiaries
    3
    2
    Goodwill from acquisitions
    – 29
    – 28
    Temporary differences on which no deferred tax assets have been provided
    (USD millions)
    Not capitalized
    Capitalized
    2017 total
    One year
    37
    3
    40
    Two years
    64
    4
    68
    Three years
    87
    5
    92
    Four years
    26
    25
    51
    Five years
    67
    16
    83
    More than five years
    654
    1 671
    2 325
    Total
    935
    1 724
    2 659
    (USD millions)
    Not capitalized
    Capitalized
    2016 total
    One year
    21
    12
    33
    Two years
    30
    5
    35
    Three years
    50
    5
    55
    Four years
    75
    3
    78
    Five years
    73
    25
    98
    More than five years
    405
    1 913
    2 318
    Total
    654
    1 963
    2 617
    Gross value of tax-loss carry-forwards
    (USD millions)
    2017
    2016
    2015
    Tax losses carried forward

    that expired


    1


    19


    13
    US Corporate tax rate, impact on the revaluation of deferred assets and liabilities and current income tax liabilities


    (USD millions)
    Income

    statement


    Equity


    Total
    Deferred tax asset

    and liability revaluation






    Items previously recognized

    in consolidated income statement


    – 24




    – 24
    Items previously recognized

    in other comprehensive income  1




    – 254


    – 254
    Items previously recognized in retained earnings  2
    – 71
    – 71
    Total revaluation of deferred

    tax assets and liabilities


    – 24


    – 325


    – 349
    Total revaluation of current tax payables
    – 37
    – 37
    Total revaluation of deferred tax assets and liabilities and current income tax liabilities
    – 61
    – 325
    – 386
     1  Related to post-employment benefits and available for sale financial investments.
     2  Related to equity based compensation plans.
    XML 117 R50.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Financial and other non-current assets (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Financial assets
    (USD millions)
    2017
    2016
    Available-for-sale long-term

    financial investments


    1 275


    1 096
    Long-term receivables from customers
    197
    231
    Minimum lease payments

    from finance lease agreements


    122


    147
    Contingent consideration receivables  1
    394
    586
    Long-term loans, advances and security deposits
    255
    136
    Total financial assets
    2 243
    2 196
     1  Note 28 provides additional disclosures related to contingent considerations.
    Other non-current assets
    (USD millions)
    2017
    2016
    Deferred compensation plans
    484
    451
    Prepaid post-employment benefit plans
    133
    47
    Other non-current assets
    201
    200
    Total other non-current assets
    818
    698
    Minimum finance lease payments
    2017
    2016


    (USD millions)
    Total

    future

    payments
    Unearned

    finance

    income


    Present

    value




    Provision
    Net

    book

    value
    Total

    future

    payments
    Unearned

    finance

    income


    Present

    value




    Provision
    Net

    book

    value
    Not later than one year  1
    83
    – 7
    76
    – 3
    73
    91
    – 5
    86
    – 2
    84
    Between one and five years
    180
    – 14
    166
    – 59
    107
    182
    – 16
    166
    – 37
    129
    Later than five years
    31
    – 2
    29
    – 14
    15
    63
    – 4
    59
    – 41
    18
    Total
    294
    – 23
    271
    – 76
    195
    336
    – 25
    311
    – 80
    231
     1  The current portion of the minimum lease payments is recorded in trade receivables or other current assets (to the extent not yet invoiced).
    XML 118 R51.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Inventories (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Inventories by class
    (USD millions)
    2017
    2016
    Raw material, consumables
    841
    705
    Work in progress
    2 957
    2 700
    Finished products
    3 069
    2 850
    Total inventories
    6 867
    6 255
    Amount of inventory recognized as an expense in cost of goods sold
    (USD billions)
    2017
    2016
    2015
    Cost of goods sold
    – 10.3
    – 10.3
    – 10.5
    Recognized amount of inventory provisions and reversals of inventory provision
    (USD millions)
    2017
    2016
    2015
    Inventory provisions
    – 470
    – 283
    – 356
    Reversals of inventory provisions
    189
    67
    148
    XML 119 R52.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Trade receivables (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Provisions for trade receivables
    (USD millions)
    2017
    2016
    Total gross trade receivables
    8 790
    8 364
    Provisions for doubtful trade receivables
    – 190
    – 162
    Total trade receivables, net
    8 600
    8 202
    Trade receivables provision movements
    (USD millions)
    2017
    2016
    2015
    January 1
    – 162
    – 142
    – 156
    Impact of divestments
    12
    Provisions for doubtful trade receivables charged to the consolidated income statement
    – 119
    – 76
    – 68
    Utilization provisions for doubtful trade receivables
    12
    17
    39
    Reversal of provisions for doubtful trade receivables
    76
    37
    32
    Currency translation effects
    – 9
    2
    11
    December 31
    – 190
    – 162
    – 142
    Overdue amounts and related provision
    (USD millions)
    2017
    2016
    Not overdue
    7 758
    7 386
    Past due for not more than one month
    279
    262
    Past due for more than one month

    but less than three months


    230


    223
    Past due for more than three months

    but less than six months


    137


    185
    Past due for more than six months

    but less than one year


    137


    145
    Past due for more than one year
    249
    163
    Provisions for doubtful trade receivables
    – 190
    – 162
    Total trade receivables, net
    8 600
    8 202
    Gross trade receivable from closely monitored countries
    (USD millions)
    2017
    2016
    Total balance of gross trade

    receivables from closely

    monitored countries




    1 733




    1 717
    Past due for more than one year
    124
    82
    Provisions
    95
    63
    Trade receivables denominated in other currencies
    (USD millions)
    2017
    2016
    US dollar (USD)
    3 451
    3 432
    Euro (EUR)
    1 533
    1 366
    Japanese yen (JPY)
    600
    567
    Chinese yuan (CNY)
    312
    264
    Russian ruble (RUB)
    268
    347
    Brazilian real (BRL)
    237
    222
    British pound (GBP)
    208
    160
    Australian dollar (AUD)
    165
    147
    Swiss franc (CHF)
    127
    135
    Canadian dollar (CAD)
    73
    97
    Other currencies
    1 626
    1 465
    Total trade receivables, net
    8 600
    8 202
    XML 120 R53.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Marketable securities, commodities, timedeposits, and derivative financial instruments
    (USD millions)
    2017
    2016
    Debt securities
    328
    306
    Fund investments
    34
    31
    Total available-for-sale marketable securities
    362
    337
    Commodities
    106
    94
    Time deposits with original maturity more than 90 days
    125
    108
    Derivative financial instruments
    31
    230
    Accrued interest on debt securities and time deposits
    1
    1
    Total marketable securities, commodities, time deposits and derivative financial instruments
    625
    770
    Debt securities, breakdown by currency
    (USD millions)
    2017
    2016
    US dollar (USD)
    303
    284
    Euro (EUR)
    14
    12
    Japanese yen (JPY)
    11
    10
    Total debt securities
    328
    306
    Cash and cash equivalents
    (USD millions)
    2017
    2016
    Current accounts
    2 970
    1 912
    Time deposits and short-term investments with original maturity less than 90 days
    5 890
    5 095
    Total cash and cash equivalents
    8 860
    7 007
    XML 121 R54.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Other current assets (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Other current assets
    (USD millions)
    2017
    2016
    VAT receivable
    717
    521
    Withholding tax recoverable
    93
    282
    Prepaid expenses
    – Third parties
    753
    692
    – Associated companies
    3
    5
    Receivables from associated companies
    8
    7
    Contingent consideration receivable  1
    450
    Other receivables and current assets
    1 030
    1 034
    Total other current assets
    3 054
    2 541
     1  Note 28 provides additional disclosures related to contingent consideration.
    XML 122 R55.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Equity (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Schedule disclosing information related to movement in the share capital


    (USD millions)


    Jan 1, 2015
    Movement

    in year


    Dec 31, 2015
    Movement

    in year


    Dec 31, 2016
    Movement

    in year


    Dec 31, 2017
    Share capital
    1 001
    – 10
    991
    – 19
    972
    – 3
    969
    Treasury shares
    – 103
    2
    – 101
    25
    – 76
    – 24
    – 100
    Outstanding share capital
    898
    – 8
    890
    6
    896
    – 27
    869
    Schedule disclosing information related to movement in the shares
    2017
    2016
    2015


    Number of outstanding shares

    (in millions)




    Note
    Total

    Novartis

    shares
    Total

    treasury

    shares
    Total

    outstanding

    shares
    Total

    Novartis

    shares
    Total

    treasury

    shares
    Total

    outstanding

    shares
    Total

    Novartis

    shares
    Total

    treasury

    shares
    Total

    outstanding

    shares
    Balance at beginning of year
    2 627.1
    – 253.0
    2 374.1
    2 677.0
    – 303.1
    2 373.9
    2 706.2
    – 307.6
    2 398.6
    Shares canceled for capital

    reduction  1




    – 10.3


    10.3




    – 49.9


    49.9




    – 29.2


    29.2


    Shares acquired to be held in

    Group Treasury  2


















    – 9.6


    – 9.6
    Shares acquired to be

    canceled  3






    – 66.2


    – 66.2




    – 10.3


    – 10.3




    – 49.9


    – 49.9
    Other share purchases  4
    – 3.8
    – 3.8
    – 2.6
    – 2.6
    – 4.1
    – 4.1
    Exercise of options

    and employee transactions  5


    17.6




    4.6


    4.6




    4.1


    4.1




    27.0


    27.0
    Equity-based compensation  5
    8.8
    8.8
    9.0
    9.0
    11.9
    11.9
    Total movements
    – 10.3
    – 46.3
    – 56.6
    – 49.9
    50.1
    0.2
    – 29.2
    4.5
    – 24.7
    Balance at end of year
    2 616.8
    – 299.3
    2 317.5
    2 627.1
    – 253.0
    2 374.1
    2 677.0
    – 303.1
    2 373.9
     1  Novartis reduced its share capital by cancelling shares which were repurchased on the SIX Swiss Exchange second trading line during previous years.
     2  Shares repurchased on the SIX Swiss Exchange first trading line
     3  For 2017 and 2016, shares repurchased on the SIX Swiss Exchange second trading line under the CHF 10 billion share buyback authority approved at the 2016 Annual General Meeting (AGM). For 2015, shares repurchased on the SIX Swiss Exchange second trading line under the CHF 10 billion share buyback authority approved at the 2008 Annual General Meeting (AGM).
     4  Shares acquired from employees, which were previously granted to them under the respective programs
     5  Shares delivered as a result of options being exercised and physical share deliveries related to equity-based participation plans
    Schedule disclosing information related to Dividend
    2017
    2016
    2015
    Dividend per share (in CHF)
    2.75
    2.70
    2.60
    Total dividend payment

    (in USD billion)


    6.5


    6.5


    6.6
    Schedule disclosing information related treasury shares movements
    2017
    2016
    2015






    Note
    Number of

    outstanding

    shares

    (in millions)




    Equity impact

    USDm
    Number of

    outstanding

    shares

    (in millions)




    Equity impact

    USDm
    Number of

    outstanding

    shares

    (in millions)




    Equity impact

    USDm
    Shares acquired to be held in Group Treasury  1
    – 9.6
    – 897
    Shares acquired to be canceled  2
    – 66.2
    – 5 270
    – 10.3
    – 784
    – 49.9
    – 4 805
    Other share purchases  3
    – 3.8
    – 304
    – 2.6
    – 208
    – 4.1
    – 417
    Purchase of treasury shares
    – 70.0
    – 5 574
    – 12.9
    – 992
    – 63.6
    – 6 119
    Exercise of options and employee transactions  4
    17.6
    4.6
    255
    4.1
    214
    27.0
    1 592
    Equity-based compensation  5, 6
    8.8
    612
    9.0
    664
    11.9
    815
    Total
    – 56.6
    – 4 707
    0.2
    – 114
    – 24.7
    – 3 712
     1  Shares repurchased on the SIX Swiss Exchange first trading line
     2  For 2017 and 2016, shares repurchased on the SIX Swiss Exchange second trading line under the CHF 10 billion share buyback authority approved at the 2016 Annual General Meeting (AGM). For 2015, shares repurchased on the SIX Swiss Exchange second trading line under the CHF 10 billion share buyback authority approved at the 2008 Annual General Meeting (AGM).
     3  Shares acquired from employees, which were previously granted to them under the respective programs
     4  Shares delivered as a result of options being exercised related to equity-based participation plans and the delivery of treasury shares. The average share price of the shares delivered was significantly below market price reflecting the strike price of the options exercised.
     5  Equity-settled share-based compensation is expensed in the consolidated income statement in accordance with the vesting period of the share-based compensation plans. The value for the shares and options granted is credited to consolidated equity over the respective vesting period. In addition, tax benefits arising from tax deductible amounts exceeding the expense recognized in the income statement are credited to equity.
     6  Included in 2017 is a USD 71 million impact related to the revaluation of deferred tax assets on equity based compensation that were previously recognized through retained earnings. This revaluation resulted from the US tax reform legislation enacted on December 22, 2017, refer to Note 11 for additional disclosures.
    XML 123 R56.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Non-current financial debt (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Disclosure of non-current portion of non-current borrowings by type
    (USD millions)
    2017
    2016
    Straight bonds
    22 957
    17 285
    Liabilities to banks and other financial institutions  1
    539
    708
    Finance lease obligations
    87
    82
    Total, including current portion of non-current financial debt
    23 583
    18 075
    Less current portion of non-current financial debt
    – 359
    – 178
    Total non-current financial debts
    23 224
    17 897
     1  Average interest rate 0.3% (2016: 0.4%)
    Disclosure of detailed information about borrowings


    Coupon




    Currency


    Nominal

    amount


    Issuance

    year


    Maturity

    year




    Issuer




    Issue price
    2017

    (USD

    millions)
    2016

    (USD

    millions)
    5.125%
    USD
    3 000
    2009
    2019
    Novartis Securities Investment Ltd., Hamilton, Bermuda
    99.822%
    2 997
    2 995
    4.400%
    USD
    1 000
    2010
    2020
    Novartis Capital Corporation, New York, United States
    99.237%
    997
    996
    2.400%
    USD
    1 500
    2012
    2022
    Novartis Capital Corporation, New York, United States
    99.225%
    1 491
    1 490
    3.700%
    USD
    500
    2012
    2042
    Novartis Capital Corporation, New York, United States
    98.325%
    489
    489
    3.400%
    USD
    2 150
    2014
    2024
    Novartis Capital Corporation, New York, United States
    99.287%
    2 134
    2 132
    4.400%
    USD
    1 850
    2014
    2044
    Novartis Capital Corporation, New York, United States
    99.196%
    1 824
    1 823
    0.750%
    EUR
    600
    2014
    2021
    Novartis Finance S.A., Luxembourg, Luxembourg
    99.134%
    713
    625
    1.625%
    EUR
    600
    2014
    2026
    Novartis Finance S.A., Luxembourg, Luxembourg
    99.697%
    714
    627
    0.250%
    CHF
    500
    2015
    2025
    Novartis AG, Basel, Switzerland
    100.640%
    513
    491
    0.625%
    CHF
    550
    2015
    2029
    Novartis AG, Basel, Switzerland
    100.502%
    564
    539
    1.050%
    CHF
    325
    2015
    2035
    Novartis AG, Basel, Switzerland
    100.479%
    333
    318
    3.000%
    USD
    1 750
    2015
    2025
    Novartis Capital Corporation, New York, United States
    99.010%
    1 730
    1 728
    4.000%
    USD
    1 250
    2015
    2045
    Novartis Capital Corporation, New York, United States
    98.029%
    1 218
    1 217
    0.125%
    EUR
    1 250
    2016
    2023
    Novartis Finance S.A., Luxembourg, Luxembourg
    99.127%
    1 480
    1 299
    0.625%
    EUR
    500
    2016
    2028
    Novartis Finance S.A., Luxembourg, Luxembourg
    98.480%
    588
    516
    1.800%
    USD
    1 000
    2017
    2020
    Novartis Capital Corporation, New York, United States
    99.609%
    996
    2.400%
    USD
    1 000
    2017
    2022
    Novartis Capital Corporation, New York, United States
    99.449%
    993
    3.100%
    USD
    1 000
    2017
    2027
    Novartis Capital Corporation, New York, United States
    99.109%
    988
    0.000%
    EUR
    1 250
    2017
    2021
    Novartis Finance S.A., Luxembourg, Luxembourg
    99.133%
    1 480
    1.125%
    EUR
    600
    2017
    2027
    Novartis Finance S.A., Luxembourg, Luxembourg
    99.874%
    715
    Total straight bonds
    22 957
    17 285
    Non-current financial debt including current portion by maturity
    (USD millions)
    2017
    2016
    2017
    178
    2018
    359
    345
    2019
    3 173
    3 168
    2020
    1 997
    1 000
    2021
    2 194
    628
    2022
    2 485
    2 442
    After 2022
    13 375
    10 314
    Total
    23 583
    18 075
    Non-current financial debt including current portion by currency
    (USD millions)
    2017
    2016
    US dollar (USD)
    15 945
    12 952
    Euro (EUR)
    5 695
    3 092
    Japanese yen (JPY)
    533
    683
    Swiss franc (CHF)
    1 410
    1 348
    Total
    23 583
    18 075
    Comparison of balance sheet and fair value of total non-current financial debt including current portion


    (USD millions)
    2017

    Balance sheet
    2017

    Fair values
    2016

    Balance sheet
    2016

    Fair values
    Straight bonds
    22 957
    23 835
    17 285
    17 943
    Others
    626
    626
    790
    790
    Total
    23 583
    24 461
    18 075
    18 733
    Collaerallized non-current financial debt and pledged assets
    (USD millions)
    2017
    2016
    Total net book value of property,

    plant & equipment pledged as

    collateral for non-current financial debts




    84




    94
    XML 124 R57.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Provisions and other non-current liabilities (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Disclosure of other provisions [text block]
    (USD millions)
    2017
    2016
    Accrued liability for employee benefits:
    Defined benefit pension plans  1
    3 157
    4 490
    Other long-term employee benefits and deferred compensation
    625
    545
    Other post-employment benefits  1
    953
    1 005
    Environmental remediation provisions
    706
    708
    Provisions for product liabilities, governmental investigations and other legal matters
    230
    264
    Contingent consideration  2
    809
    840
    Other non-current liabilities
    577
    618
    Total provisions and other non-current liabilities
    7 057
    8 470
     
     1  Note 24 provides additional disclosures related to post-employment benefits.
     2  Note 28 provides additional disclosures related to contingent consideration.
    Accrual for environmental loss contingencies [table text block]
    (USD millions)
    2017
    2016
    2015
    January 1
    773
    871
    923
    Cash payments
    – 46
    – 75
    – 52
    Releases
    – 153
    – 5
    Additions
    154
    1
    6
    Currency translation effects
    33
    – 24
    – 1
    December 31
    761
    773
    871
    Less current provision
    – 55
    – 65
    – 80
    Non-current environmental remediation provisions at December 31
    706
    708
    791
    Accrual for environmental loss contingencies, fiscal year maturity [table text block]


    (USD millions)
    Expected

    cash outflows
    Due within two years
    164
    Due later than two years, but within five years
    241
    Due later than five years, but within ten years
    315
    Due after ten years
    41
    Total environmental remediation liability provisions
    761
    Accrual for product liabilities government investigations other legal matters loss contingencies [table text block]
    (USD millions)
    2017
    2016
    2015
    January 1
    395
    1 194
    849
    Cash payments
    – 69
    – 811
    – 256
    Releases of provisions
    – 70
    – 239
    – 223
    Additions to provisions
    93
    243
    832
    Currency translation effects
    2
    8
    – 8
    December 31
    351
    395
    1 194
    Less current portion
    – 121
    – 131
    – 743
    Non-current product liabilities, governmental investigations and other legal matters provisions at December 31
    230
    264
    451
    XML 125 R58.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Current financial debt and derivative financial instruments (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Current financial debt and derivative instruments
    (USD millions)
    2017
    2016
    Interest-bearing accounts of associates

    payable on demand  1


    1 822


    1 601
    Bank and other financial debt  2
    692
    836
    Commercial paper
    2 328
    3 174
    Current portion of non-current financial debt
    359
    178
    Fair value of derivative financial instruments
    107
    116
    Total current financial debt and derivative financial instruments
    5 308
    5 905
     1  Weighted average interest rate 0.5% (2016: 0.5%)
     2  Weighted average interest rate 7.0% (2016: 6.7%)
    XML 126 R59.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Provisions and other current liabilities (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Provisions and other current liabilities
    (USD millions)
    2017
    2016
    Taxes other than income taxes
    660
    547
    Restructuring provisions
    153
    222
    Accrued expenses for goods and services received but not invoiced
    977
    880
    Accruals for royalties
    586
    550
    Provisions for deductions from revenue
    4 672
    4 183
    Accruals for compensation and benefits including social security
    2 327
    1 993
    Environmental remediation liabilities
    55
    65
    Deferred income
    305
    287
    Provisions for product liabilities, governmental investigations and other legal matters  1
    121
    131
    Accrued share-based payments
    261
    199
    Contingent considerations  2
    44
    49
    Other payables
    1 042
    722
    Total provisions and other current liabilities
    11 203
    9 828
     
     1  Note 19 provides additional disclosures related to legal provisions.
     2  Note 28 provides additional disclosures related to contingent considerations.
    Provisions for reduction of revenue
    (USD millions)
    2017
    2016
    2015
    January 1
    4 183
    3 790
    3 533
    Impact of business combinations
    3
    Additions
    17 997
    16 622
    15 603
    Payments/utilizations
    – 17 452
    – 16 189
    – 15 218
    Changes in offset against

    gross trade receivables


    – 252


    10


    50
    Currency translation effects
    196
    – 50
    – 181
    December 31
    4 672
    4 183
    3 790
    Restructuring provisions movements
    (USD millions)
    2017
    2016
    2015
    January 1
    222
    260
    333
    Additions
    194
    343
    399
    Cash payments
    – 200
    – 260
    – 435
    Releases
    – 64
    – 66
    – 36
    Transfers
    – 7
    – 76
    Currency translation effects
    8
    21
    – 1
    December 31
    153
    222
    260
    XML 127 R60.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Details to the consolidated cash flow statements (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Adjustments for non-cash items from continuing operations
    (USD millions)
    2017
    2016
    2015
    Taxes
    1 296
    1 119
    1 106
    Depreciation, amortization and impairments on:
    Property, plant & equipment
    1 677
    1 591
    1 550
    Intangible assets
    4 399
    4 452
    3 921
    Financial assets  1
    256
    132
    104
    Income from associated companies
    – 1 108
    – 703
    – 266
    Gains on disposal and other adjustments on property, plant & equipment, intangible, financial and other

    non-current assets, net


    – 1 043


    – 935


    – 869
    Equity-settled compensation expense
    683
    671
    773
    Change in provisions and other non-current liabilities
    160
    956
    1 642
    Net financial expense
    738
    1 154
    1 109
    Total
    7 058
    8 437
    9 070
     1  Including unrealized fair value gains
    Cash flows from changes in working capital and other operating items included in operating cash flow from continuing operations
    (USD millions)
    2017
    2016
    2015
    (Increase) in inventories
    – 247
    – 235
    – 482
    (Increase) in trade receivables
    – 204
    – 229
    – 513
    Increase/(Decrease) in trade payables
    58
    – 587
    378
    Change in other net current assets and other operating cash flow items
    637
    974
    – 246
    Total
    244
    – 77
    – 863
    Cash flows arising from acquisitions and divestments of businesses


    (USD millions)
    2017

    Acquisitions
    2017

    Divestments
    2016

    Acquisitions
    2016

    Divestments
    2015

    Acquisitions
    2015

    Divestments
    Property, plant & equipment
    25
    1 000
    Currently marketed products
    1
    – 451
    – 12 970
    646
    (Acquired)/divested research & development
    – 1 223
    – 690
    – 730
    13
    Technologies
    113
    Other intangible assets
    3
    – 15
    86
    Financial and other assets including deferred tax assets
    – 8
    – 39
    – 555
    40
    Inventories
    – 4
    893
    Trade receivables and other current assets
    34
    – 1
    – 3
    529
    Cash and cash equivalents
    – 20
    – 1
    – 25
    311
    Current and non-current financial debts
    – 601
    Trade payables and other liabilities including deferred tax liabilities
    326
    – 15
    372
    212
    – 841
    Net identifiable assets (acquired) or divested
    – 925
    48
    – 814
    – 14 086
    2 189
    Currency translation effects
    98
    Acquired/(divested) liquidity
    20
    1
    25
    – 479
    Fair value of previously held equity interests
    64
    Subtotal
    – 905
    48
    – 749
    – 14 061
    1 808
    Refinancing of intercompany financial debt, net
    578
    Goodwill
    – 94
    – 56
    – 2 438
    1 042
    Divestment gain
    7 401
    Taxes paid and other portfolio transformation related cash flows
    – 140
    – 748
    – 1 337
    Receivables and payables contingent consideration, net  1
    206
    84
    – 8
    – 519
    Other payments and deferred consideration, net
    – 36
    – 3
    – 44
    Deferred portion of sales price  2
    – 49
    Net cash flows
    – 829
    – 95
    – 765
    – 748
    – 16 507
    8 924
    Of which:
    Net cash flows used in/from discontinued operations
    – 140
    – 748
    8 924
    Net cash flows used in/from continuing operations
    – 829
    45
    – 765
    – 16 507
     1  The contingent consideration of the 2016 Transcend Medical, Inc. acquisition amounted to USD 92 million. Of this amount, USD 60 million has been paid in 2016.
     2  Divestments include USD 49 million proceeds for the divestment of the Animal Health business received in 2014.
    Cash flows from discontinued operations
    (USD millions)
    2017
    2016
    2015
    Cash flows used in operating activities
    – 188
    Purchase of property, plant & equipment
    – 41
    Proceeds from sales of property, plant & equipment
    1
    Purchase of financial and other non-current assets, net
    – 2
    Divestments of businesses  1
    – 140
    – 748
    8 924
    Cash flows used in/from investing activities
    – 140
    – 748
    8 882
    Total net cash flows used in/from discontinued operations
    – 140
    – 748
    8 694
     1  2017 includes payments related to the 2015 portfolio transformation transaction. 2016 includes mainly payments for capital gains taxes and other payments related to the 2015 portfolio transformation transaction. 2015 includes proceeds of USD 10 925 million reduced by USD 2 001 million, for payments of capital gains taxes, transaction-related costs and purchase price adjustments, related to the 2015 portfolio transformation transaction. See Note 2 for a description of the 2015 porfolio transformation transaction.
    Reconciliation of liabilities arising from financing activities


    (USD millions)






    Non-current

    financial

    debts










    Current

    financial

    debts and

    derivative

    financial

    instruments




















    Total
    January 1, 2017
    17 897
    5 905
    23 802
    Increase in non-current financial debts
    4 933
    4 933
    Repayment of non-current financial debts
    – 1
    – 187
    – 188
    Change in current financial debts
    – 755
    – 755
    Changes in fair values and other changes
    – 6
    – 140
    – 146
    Amortization of bonds discount
    16
    16
    Currency translation effects
    744
    126
    870
    Current portion of non-current financial debt
    – 359
    359
    December 31, 2017
    23 224
    5 308
    28 532
     
    XML 128 R61.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Acquisitions of businesses (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Fair value of assets and liabilities arising from acquisitions
    (USD millions)
    2017
    2016
    2015
    Currently marketed products
    451
    12 970
    Acquired research & development
    1 223
    690
    730
    Other intangible assets
    15
    Deferred tax assets
    8
    39
    555
    Inventories
    4
    Trade receivables and other current assets
    1
    3
    Cash and cash equivalents
    20
    1
    25
    Payables and other liabilities including deferred tax liabilities
    – 326
    – 372
    – 212
    Net identifiable assets acquired
    925
    814
    14 086
    Acquired liquidity
    – 20
    – 1
    – 25
    Goodwill
    94
    56
    2 438
    Net assets recognized as a result of business combinations
    999
    869
    16 499
    XML 129 R62.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Post-employment benefits for associates (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Summary of the funded and unfunded defined benefit obligation for pension and other post retirement benefit plans table
    Pension plans
    Other post-employment benefit plans
    (USD millions)
    2017
    2016
    2017
    2016
    Benefit obligation at January 1
    23 614
    23 402
    1 158
    1 132
    Current service cost
    422
    437
    34
    35
    Interest cost
    330
    390
    44
    48
    Past service costs and settlements
    – 1 226
    – 73
    – 10
    Administrative expenses
    27
    29
    Remeasurement losses arising from changes in financial assumptions
    11
    1 299
    32
    46
    Remeasurement (gains) arising from changes in demographic assumptions
    – 26
    – 7
    – 9
    – 26
    Experience-related remeasurement losses/(gains)
    47
    117
    – 87
    – 33
    Currency translation effects
    1 138
    – 896
    5
    7
    Benefit payments
    – 1 300
    – 1 250
    – 51
    – 51
    Contributions of associates
    207
    207
    Effect of acquisitions, divestments or transfers
    – 34
    – 41
    – 1
    Benefit obligation at December 31
    23 210
    23 614
    1 115
    1 158
    Fair value of plan assets at January 1
    19 225
    19 536
    153
    172
    Interest income
    236
    293
    5
    6
    Return on plan assets excluding interest income
    1 429
    742
    12
    – 1
    Currency translation effects
    909
    – 757
    Novartis Group contributions
    579
    542
    43
    27
    Contributions of associates
    207
    207
    Settlements
    – 995
    – 77
    Benefit payments
    – 1 300
    – 1 250
    – 51
    – 51
    Effect of acquisitions, divestments or transfers
    – 15
    – 11
    Fair value of plan assets at December 31
    20 275
    19 225
    162
    153
    Funded status
    – 2 935
    – 4 389
    – 953
    – 1 005
    Limitation on recognition of fund surplus at January 1
    – 54
    – 50
    Change in limitation on recognition of fund surplus (incl. exchange rate differences)
    – 30
    Interest income on limitation of fund surplus
    – 5
    – 4
    Limitation on recognition of fund surplus at December 31
    – 89
    – 54
    Net liability in the balance sheet at December 31
    – 3 024
    – 4 443
    – 953
    – 1 005
    Reconciliation of the net liability table
    Pension plans
    Other post-employment benefit plans
    (USD millions)
    2017
    2016
    2017
    2016
    Net liability at January 1
    – 4 443
    – 3 916
    – 1 005
    – 960
    Current service cost
    – 422
    – 437
    – 34
    – 35
    Net interest expense
    – 99
    – 101
    – 39
    – 42
    Administrative expenses
    – 27
    – 29
    Past service costs and settlements
    231
    – 4
    10
    Remeasurements
    1 397
    – 667
    76
    12
    Currency translation effects
    – 229
    139
    – 5
    – 7
    Novartis Group contributions
    579
    542
    43
    27
    Effect of acquisitions, divestments or transfers
    19
    30
    1
    Change in limitation on recognition of fund surplus
    – 30
    Net liability at December 31
    – 3 024
    – 4 443
    – 953
    – 1 005
    Amounts recognized in the consolidated balance sheet
    Prepaid benefit cost
    133
    47
    Accrued benefit liability
    – 3 157
    – 4 490
    – 953
    – 1 005
    Breakdown of the DBO for pension plans by geography and type of member and the breakdown of plan assets
    2017
    2016


    (USD millions)


    Switzerland


    United States
    Rest of

    the world


    Total


    Switzerland


    United States
    Rest of

    the world


    Total
    Benefit obligation at December 31
    14 606
    3 788
    4 816
    23 210
    15 436
    3 783
    4 395
    23 614
    Thereof unfunded
    728
    499
    1 227
    739
    497
    1 236
    By type of member
    Active
    5 627
    796
    1 646
    8 069
    6 426
    891
    1 460
    8 777
    Deferred pensioners
    1 258
    1 646
    2 904
    831
    1 515
    2 346
    Pensioners
    8 979
    1 734
    1 524
    12 237
    9 010
    2 061
    1 420
    12 491
    Fair value of plan assets at December 31
    14 445
    2 400
    3 430
    20 275
    13 958
    2 282
    2 985
    19 225
    Funded status
    – 161
    – 1 388
    – 1 386
    – 2 935
    – 1 478
    – 1 501
    – 1 410
    – 4 389
    Principal weighted average actuarial assumptions
    Pension plans
    Other post-employment benefit plans
    2017
    2016
    2015
    2017
    2016
    2015
    Weighted average assumptions used to determine benefit obligations at December 31
    Discount rate
    1.5%
    1.4%
    1.8%
    3.7%
    4.2%
    4.4%
    Expected rate of pension increase
    0.5%
    0.4%
    0.4%
    Expected rate of salary increase
    2.8%
    2.2%
    2.9%
    Interest on savings account
    0.6%
    0.5%
    0.8%
    Current average life expectancy

    for a 65-year-old male in years


    22


    22


    21


    21


    21


    21
    Current average life expectancy

    for a 65-year-old female in years


    24


    24


    24


    23


    23


    23
    The sensitivity of the defined benefit pension obligation to the principal actuarial assumptions


    (USD millions)
    Change in 2017 year-end

    defined benefit pension obligation
    25 basis point increase in discount rate
    – 753
    25 basis point decrease in discount rate
    803
    1 year increase in life expectancy
    840
    25 basis point increase in rate of pension increase
    533
    25 basis point decrease in rate of pension increase
    – 138
    25 basis point increase of interest on savings account
    56
    25 basis point decrease of interest on savings account
    – 54
    25 basis point increase in rate of salary increase
    49
    25 basis point decrease in rate of salary increase
    – 50
    The healthcare cost trend rate assumptions used for other post-employment benefits
    2017
    2016
    2015
    Healthcare cost trend rate

    assumed for next year


    6.5%


    7.0%


    7.5%
    Rate to which the cost trend

    rate is assumed to decline


    4.5%


    5.0%


    5.0%
    Year that the rate reaches

    the ultimate trend rate


    2025


    2022


    2022
    The weighted average plan asset allocation of funded defined benefit pension plans
    Pension plans


    (as a percentage)
    Long-term

    target

    minimum
    Long-term

    target

    maximum




    2017




    2016
    Equity securities
    15
    40
    31
    31
    Debt securities
    20
    60
    35
    35
    Real estate
    5
    20
    15
    15
    Alternative investments
    0
    20
    15
    15
    Cash and other investments
    0
    15
    4
    4
    Total
    100
    100
    Asset allocation, investments in shares of Novartis AG
    December 31,

    2017
    December 31,

    2016
    Investment in shares of Novartis AG
    Number of shares (in millions)
    11.0
    11.0
    Market Value (in USD billions)
    0.9
    0.8
    The expected future cash flows in respect of pension and other post- employment benefit plans


    (USD millions)




    Pension plans
    Other post-

    employment

    benefit plans
    Novartis Group contributions
    2018 (estimated)
    395
    62
    Expected future benefit payments
    2018
    1 226
    63
    2019
    1 166
    65
    2020
    1 163
    67
    2021
    1 147
    68
    2022
    1 133
    69
    2023–2027
    5 534
    344
    Defined contribution plans
    (USD millions)
    2017
    2016
    2015
    Contributions for defined contribution plans

    continuing operations


    406


    338


    359
    Contributions for defined contribution plans discontinued operations
    1
    XML 130 R63.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Equity-based participation plans for associates (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Expense related to all equity-based participation and liabilities arising from equity-based payment transactions
    (USD millions)
    2017
    2016
    2015
    Expense related to equity-based

    participation plans


    924


    846


    968
    of which continuing operations
    924
    846
    903
    of which discontinued operations
    65
    Liabilities arising from equity-based payment transactions
    261
    199
    209
    Schedule of unvested restricted stock units roll forward
    2017
    2016


    Number

    of shares

    in millions
    Weighted

    average fair

    value at grant

    date in USD


    Fair value at

    grant date in

    USD millions


    Number

    of shares

    in millions
    Weighted

    average fair

    value at grant

    date in USD


    Fair value at

    grant date in

    USD millions
    Non-vested shares at January 1
    21.0
    89.5
    1 880
    20.1
    87.1
    1 751
    Granted
    – Annual incentive
    1.3
    69.3
    90
    0.1
    73.8
    7
    – Share savings plans
    4.5
    69.4
    312
    4.4
    78.1
    344
    – Select North America
    4.5
    64.1
    288
    4.8
    72.4
    348
    – Select outside North America
    2.0
    65.3
    131
    1.6
    74.4
    119
    – Long-Term Performance Plan
    1.4
    71.5
    100
    1.2
    79.2
    95
    – Long-Term Relative Performance Plan
    0.4
    47.7
    19
    0.3
    58.5
    18
    – Other share awards
    1.3
    67.8
    88
    0.7
    65.8
    46
    Vested
    – 10.7
    78.2
    – 837
    – 10.4
    68.8
    – 716
    Forfeited
    – 1.8
    80.7
    – 145
    – 1.8
    73.1
    – 132
    Non-vested shares at December 31
    23.9
    80.6
    1 926
    21.0
    89.5
    1 880
    Select outside North America  
    Statement [line items]  
    Disclosure of number and weighted average remaining contractual life of outstanding share options
    2017
    2016




    Options

    (millions)
    Weighted

    average

    exercise

    price (USD)




    Options

    (millions)
    Weighted

    average

    exercise

    price (USD)
    Options outstanding

    at January 1


    9.5


    59.4


    11.7


    59.9
    Sold or exercised
    – 2.1
    59.2
    – 2.2
    61.8
    Forfeited or expired
    Outstanding at December 31
    7.4
    59.5
    9.5
    59.4
    Exercisable at December 31
    7.4
    59.5
    9.5
    59.4
    Disclosure of range of exercise prices of outstanding share options
    Options outstanding


    Range of exercise prices (USD)


    Number

    outstanding

    (millions)
    Average

    remaining

    contractual

    life (years)
    Weighted

    average

    exercise

    price (USD)
    45–49
    0.7
    1.0
    46.7
    50–54
    1.1
    2.0
    54.6
    55–59
    2.7
    3.3
    57.6
    65–70
    2.9
    5.0
    66.1
    Total
    7.4
    3.6
    59.5
    Select North America  
    Statement [line items]  
    Disclosure of number and weighted average remaining contractual life of outstanding share options
    2017
    2016


    ADR

    options

    (millions)
    Weighted

    average

    exercise

    price (USD)


    ADR

    options

    (millions)
    Weighted

    average

    exercise

    price (USD)
    Options outstanding

    at January 1


    25.9


    59.9


    31.9


    60.2
    Sold or exercised
    – 5.6
    59.9
    – 6.0
    61.7
    Forfeited or expired
    Outstanding at December 31
    20.3
    59.9
    25.9
    59.9
    Exercisable at December 31
    20.3
    59.9
    25.9
    59.9
    Disclosure of range of exercise prices of outstanding share options
    ADR options outstanding


    Range of exercise prices (USD)


    Number

    outstanding

    (millions)
    Average

    remaining

    contractual

    life (years)
    Weighted

    average

    exercise

    price (USD)
    45–49
    1.8
    1.0
    46.4
    50–54
    2.1
    2.0
    53.7
    55–59
    8.0
    3.5
    58.0
    65–69
    8.4
    5.0
    66.1
    Total
    20.3
    3.7
    59.9
    Alcon equity plans granted to associates prior merger  
    Statement [line items]  
    Schedule of share-based compensation, activity


    Number

    of options

    (millions)
    Weighted

    average

    exercise

    price (USD)


    Number of

    SSARs

    (millions)
    Weighted

    average

    exercise

    price (USD)
    Outstanding at

    January 1, 2016


    0.2


    36.8


    1.8


    36.6
    Exercised
    – 0.1
    37.6
    – 0.4
    38.9
    Outstanding at December 31, 2016
    0.1
    36.0
    1.4
    35.9
    Exercisable at December 31, 2016
    0.1
    36.0
    1.4
    35.9
    Outstanding at

    January 1, 2017


    0.1


    36.0


    1.4


    35.9
    Exercised
    – 0.6
    39.8
    Outstanding at December 31, 2017
    0.1
    33.7
    0.8
    33.0
    Exercisable at December 31, 2017
    0.1
    33.7
    0.8
    33.0
    XML 131 R64.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Transactions with related parties (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Executive Officers and Non-Executive Directors Compensation
    Executive Officers
    Non-Executive Directors
    Total
    (USD millions)
    2017
    2016
    2015
    2017
    2016
    2015
    2017
    2016
    2015
    Cash and other compensation
    18.4
    20.8
    17.1
    4.0
    4.0
    4.7
    22.4
    24.8
    21.8
    Post-employment benefits
    2.0
    2.2
    1.9
    2.0
    2.2
    1.9
    Equity-based compensation
    49.9
    46.2
    52.9
    4.8
    4.6
    4.4
    54.7
    50.8
    57.3
    Total
    70.3
    69.2
    71.9
    8.8
    8.6
    9.1
    79.1
    77.8
    81.0
    Transactions with former members of the Board of Directors
    Currency
    2017
    2016
    2015
    Prof. Dr. Brody
    CHF
    0
    25 000
    100 000
    Prof. Dr. Zinkernagel
    CHF
    0
    50 000
    200 000
    Dr. Krauer
    CHF
    60 000
    60 000
    60 000
    Dr. Vasella
    CHF
    26 279
    0
    0
    USD
    0
    250 000
    250 000
    XML 132 R65.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Commitments and contingencies (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Leasing commitments
    (USD millions)
    2017
    2018
    309
    2019
    224
    2020
    161
    2021
    131
    2022
    123
    Thereafter
    2 221
    Total
    3 169
    Expense of current year
    337
    Research and Development and other intangible purchase commitments


    (USD millions)


    Research &

    Development

    commitments
    Other

    intangible asset

    purchase

    commitments






    Total
    2018
    780
    130
    910
    2019
    671
    671
    2020
    864
    864
    2021
    801
    801
    2022
    353
    353
    Thereafter
    837
    837
    Total
    4 306
    130
    4 436
    XML 133 R66.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Financial instruments - additional disclosures (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Disclosure of financial assets and financial liabilities
    (USD millions)
    Note
    2017 1
    2016 1
    Cash and cash equivalents
    15
    8 860
    7 007
    Financial assets - measured at fair value through other comprehensive income
    Available-for-sale marketable securities
    Debt securities
    15
    328
    306
    Fund investments
    15
    34
    31
    Total available-for-sale marketable securities
    362
    337
    Available-for-sale long-term financial investments
    Equity securities
    12
    1 109
    989
    Fund investments
    12
    166
    107
    Total available-for-sale long-term financial investments
    1 275
    1 096
    Total financial assets - measured at fair value through other comprehensive income
    1 637
    1 433
    Financial assets - measured at amortized costs
    Trade receivables, income tax receivables, and other current assets

    (excluding contingent consideration receivables and pre-payments)


    14/16


    10 650


    10 202
    Accrued interest on debt securities and time deposits
    15
    1
    1
    Time deposits with original maturity more than 90 days
    15
    125
    108
    Long-term loans and receivables from customers and finance lease, advances, security deposits
    12
    574
    514
    Total financial assets - measured at amortized costs
    11 350
    10 825
    Financial assets - measured at fair value through the consolidated income statement
    Associated companies at fair value through profit and loss
    216
    188
    Derivative financial instruments
    15
    31
    230
    Contingent consideration receivables
    12/16
    844
    586
    Total financial assets - measured at fair value through the consolidated income statement
    1 091
    1 004
    Total financial assets
    22 938
    20 269
    Financial liabilities - measured at amortized costs
    Current financial debt
    Interest-bearing accounts of associates payable on demand
    20
    1 822
    1 601
    Bank and other financial debt
    20
    692
    836
    Commercial paper
    20
    2 328
    3 174
    Current portion of non-current debt
    20
    359
    178
    Total current financial debt
    5 201
    5 789
    Non-current financial debt
    Straight bonds
    18
    22 957
    17 285
    Liabilities to banks and other financial institutions
    18
    539
    708
    Finance lease obligations
    18
    87
    82
    Current portion of non-current debt
    18
    – 359
    – 178
    Total non-current financial debt
    23 224
    17 897
    Trade payables
    5 169
    4 873
    Total financial liabilities - measured at amortized costs
    33 594
    28 559
    Financial liabilities - measured at fair value through the consolidated income statement
    Contingent consideration (see Note 19/21) and other financial liabilities
    924
    1 018
    Derivative financial instruments
    20
    107
    116
    Total financial liabilities - measured at fair value through the consolidated income statement
    1 031
    1 134
    Total financial liabilities
    34 625
    29 693
     
     1  Except for straight bonds (see Note 18), the carrying amount is a reasonable approximation of fair value.
    Derivative financial instruments
    Contract or underlying principal amount
    Positive fair values
    Negative fair values
    (USD millions)
    2017
    2016
    2017
    2016
    2017
    2016
    Currency-related instruments
    Forward foreign exchange rate contracts
    8 410
    8 220
    31
    230
    – 107
    – 116
    Total derivative financial instruments included in marketable securities and in current financial debts
    8 410
    8 220
    31
    230
    – 107
    – 116
    Contract or underlying principal amount the derivative financial instruments, by currency
    2017
    (USD millions)
    EUR
    USD
    Other
    Total
    Currency-related instruments
    Forward foreign exchange rate contracts
    2 768
    4 361
    1 281
    8 410
    Total derivative financial instruments
    2 768
    4 361
    1 281
    8 410
    2016
    (USD millions)
    EUR
    USD
    JPY
    Other
    Total
    Currency-related instruments
    Forward foreign exchange rate contracts
    3 623
    3 427
    43
    1 127
    8 220
    Total derivative financial instruments
    3 623
    3 427
    43
    1 127
    8 220
    Fair value by hierarchy
    2017


    (USD millions)


    Level 1


    Level 2


    Level 3
    Valued at

    amortized cost


    Total
    Financial assets
    Debt securities
    303
    25
    328
    Fund investments
    34
    34
    Total available-for-sale marketable securities
    337
    25
    362
    Time deposits with original maturity more than 90 days
    125
    125
    Derivative financial instruments
    31
    31
    Accrued interest on debt securities
    1
    1
    Total marketable securities, time deposits and derivative financial instruments
    337
    56
    126
    519
    Available-for-sale financial investments
    672
    437
    1 109
    Fund investments
    166
    166
    Contingent consideration receivables
    394
    394
    Long-term loans and receivables from customers and finance lease, advances, security deposits
    574
    574
    Financial investments and long-term loans
    672
    997
    574
    2 243
    Associated companies at fair value through profit and loss
    28
    188
    216
    Contingent consideration receivables short-term
    450
    450
    Financial liabilities
    Contingent consideration payables
    – 852
    – 852
    Other financial liabilities
    – 72
    – 72
    Derivative financial instruments
    – 107
    – 107
    Total financial liabilities at fair value
    – 107
    – 924
    – 1 031
    2016


    (USD millions)


    Level 1


    Level 2


    Level 3
    Valued at

    amortized cost


    Total
    Financial assets
    Debt securities
    284
    22
    306
    Fund investments
    31
    31
    Total available-for-sale marketable securities
    315
    22
    337
    Time deposits with original maturity more than 90 days
    108
    108
    Derivative financial instruments
    230
    230
    Accrued interest on debt securities
    1
    1
    Total marketable securities, time deposits and derivative financial instruments
    315
    252
    109
    676
    Available-for-sale financial investments
    513
    476
    989
    Fund investments
    107
    107
    Contingent consideration receivables
    586
    586
    Long-term loans and receivables from customers and finance lease, advances, security deposits
    514
    514
    Financial investments and long-term loans
    513
    1 169
    514
    2 196
    Associated companies at fair value through profit and loss
    188
    188
    Financial liabilities
    Contingent consideration payables
    – 889
    – 889
    Other financial liabilities
    – 129
    – 129
    Derivative financial instruments
    – 116
    – 116
    Total financial liabilities at fair value
    – 116
    – 1 018
    – 1 134
    Reconciliation of changes in fair value measurement
    2017


    (USD millions)
    Associated

    companies at

    fair value through

    profit and loss




    Fund

    investments
    Available-

    for-sale

    financial

    investments


    Contingent

    consideration

    receivables


    Contingent

    consideration

    payables


    Other

    financial

    liabilities
    January 1
    188
    107
    476
    586
    – 889
    – 129
    Fair value gains and other adjustments,

    including from divestments recognized

    in the consolidated income statement




    45








    32




    278




    362




    Fair value losses (including impairments and

    amortizations) and other adjustments recognized

    in the consolidated income statement




    – 34








    – 45








    – 193




    – 37
    Fair value adjustments recognized in the consolidated statement

    of comprehensive income




    45


    – 40






    Purchases
    37
    28
    113
    – 238
    Cash receipts and payments
    – 20
    106
    94
    Disposals
    – 19
    – 18
    – 52
    Reclassification
    – 29
    4
    – 47
    December 31
    188
    166
    437
    844
    – 852
    – 72
    Total of fair value gains and losses recognized

    in the consolidated income statement for assets

    and liabilities held at December 31, 2017




    11




    0




    – 13




    278




    169




    – 37
    2016


    (USD millions)
    Associated

    companies at

    fair value through

    profit and loss




    Fund

    investments
    Available-

    for-sale

    financial

    investments


    Contingent

    consideration

    receivables


    Contingent

    consideration

    payables


    Other

    financial

    liabilities
    January 1
    181
    94
    473
    550
    – 790
    – 315
    Fair value gains and other adjustments,

    including from divestments recognized

    in the consolidated income statement




    26








    1




    51








    3
    Fair value losses (including impairments and

    amortizations) and other adjustments recognized

    in the consolidated income statement




    – 28




    – 1




    – 24








    – 156




    Fair value adjustments recognized in the consolidated statement

    of comprehensive income




    14


    – 8






    Purchases
    41
    5
    122
    – 172
    Cash receipts and payments
    – 15
    229
    183
    Disposals
    – 3
    – 5
    – 18
    Reclassification
    – 29
    – 70
    December 31
    188
    107
    476
    586
    – 889
    – 129
    Total of fair value gains and losses recognized

    in the consolidated income statement for assets

    and liabilities held at December 31, 2016




    – 2




    – 1




    – 23




    51




    – 156




    3
    Monitoring of net debt or liquidity based on contractual maturities
    2017


    (USD millions)




    Due within

    one month
    Due later than

    one month

    but less than

    three months
    Due later than

    three months

    but less than

    one year
    Due later than

    one year

    but less than

    five years




    Due after

    five years






    Total
    Current assets
    Marketable securities and time deposits
    71
    72
    105
    181
    58
    487
    Commodities
    106
    106
    Derivative financial instruments and accrued interest
    7
    19
    6
    32
    Cash and cash equivalents
    4 260
    4 600
    8 860
    Total current financial assets
    4 338
    4 691
    111
    181
    164
    9 485
    Non-current liabilities
    Financial debt
    – 9 849
    – 13 375
    – 23 224
    Financial debt - undiscounted
    – 9 893
    – 13 519
    – 23 412
    Total non-current financial debt
    – 9 849
    – 13 375
    – 23 224
    Current liabilities
    Financial debt
    – 4 576
    – 169
    – 456
    – 5 201
    Financial debt - undiscounted
    – 4 576
    – 169
    – 456
    – 5 201
    Derivative financial instruments
    – 31
    – 48
    – 28
    – 107
    Total current financial debt
    – 4 607
    – 217
    – 484
    – 5 308
    Net debt
    – 269
    4 474
    – 373
    – 9 668
    – 13 211
    – 19 047
    2016


    (USD millions)




    Due within

    one month
    Due later than

    one month

    but less than

    three months
    Due later than

    three months

    but less than

    one year
    Due later than

    one year

    but less than

    five years




    Due after

    five years






    Total
    Current assets
    Marketable securities and time deposits
    32
    126
    110
    124
    53
    445
    Commodities
    94
    94
    Derivative financial instruments and accrued interest
    38
    102
    91
    231
    Cash and cash equivalents
    5 907
    1 100
    7 007
    Total current financial assets
    5 977
    1 328
    201
    124
    147
    7 777
    Non-current liabilities
    Financial debt
    – 5 141
    – 12 756
    – 17 897
    Financial debt - undiscounted
    – 5 155
    – 12 901
    – 18 056
    Total non-current financial debt
    – 5 141
    – 12 756
    – 17 897
    Current liabilities
    Financial debt
    – 5 099
    – 250
    – 440
    – 5 789
    Financial debt - undiscounted
    – 5 099
    – 250
    – 440
    – 5 789
    Derivative financial instruments
    – 15
    – 72
    – 29
    – 116
    Total current financial debt
    – 5 114
    – 322
    – 469
    – 5 905
    Net debt
    863
    1 006
    – 268
    – 5 017
    – 12 609
    – 16 025
    Derivative financial instruments and accrued interest on derivative financial instruments
    2017


    (USD millions)




    Due within

    one month
    Due later than

    one month

    but less than

    three months
    Due later than

    three months

    but less than

    one year












    Total
    Derivative financial instruments and accrued interest on derivative financial instruments
    Potential outflows in various currencies - from financial derivative liabilities
    – 953
    – 972
    – 2 824
    – 4 749
    Potential inflows in various currencies - from financial derivative assets
    928
    948
    2 778
    4 654
    2016


    (USD millions)




    Due within

    one month
    Due later than

    one month

    but less than

    three months
    Due later than

    three months

    but less than

    one year












    Total
    Derivative financial instruments and accrued interest on derivative financial instruments
    Potential outflows in various currencies - from financial derivative liabilities
    – 1 087
    – 1 246
    – 2 027
    – 4 360
    Potential inflows in various currencies - from financial derivative assets
    1 109
    1 287
    2 051
    4 447
    Other contractual liabilities of the net debt or liquidity
    2017


    (USD millions)
    Due later than

    one month

    but less than

    three months
    Due later than

    three months

    but less than

    one year
    Due later than

    one year

    but less than

    five years




    Due after

    five years






    Total
    Contractual interest on non-current liabilities
    – 113
    – 507
    – 1 765
    – 3 859
    – 6 244
    Trade payables
    – 5 169
    – 5 169
    2016


    (USD millions)
    Due later than

    one month

    but less than

    three months
    Due later than

    three months

    but less than

    one year
    Due later than

    one year

    but less than

    five years




    Due after

    five years






    Total
    Contractual interest on non-current liabilities
    – 104
    – 433
    – 1 694
    – 4 015
    – 6 246
    Trade payables
    – 4 873
    – 4 873
    Ten day loss fair value VAR model
    (USD millions)
    2017
    2016
    All financial instruments
    498
    541
    Analyzed by components:
    Instruments sensitive to foreign

    currency exchange rates


    184


    222
    Instruments sensitive to equity

    market movements


    27


    26
    Instruments sensitive to interest rates
    242
    328
    Ten day loss fair value VAR model, average, high, and low VAR amounts
    2017
    (USD millions)
    Average
    High
    Low
    All financial instruments
    521
    560
    466
    Analyzed by components:
    Instruments sensitive to foreign

    currency exchange rates


    277


    352


    184
    Instruments sensitive to equity

    market movements


    28


    35


    21
    Instruments sensitive to

    interest rates


    282


    338


    219
    2016
    (USD millions)
    Average
    High
    Low
    All financial instruments
    402
    541
    316
    Analyzed by components:
    Instruments sensitive to foreign

    currency exchange rates


    203


    245


    147
    Instruments sensitive to equity

    market movements


    50


    99


    26
    Instruments sensitive to

    interest rates


    308


    407


    234
    Ten day loss fair value VAR model, worst case loss scenario
    (USD millions)
    2017
    2016
    All financial instruments
    7
    6
    Analyzed by components:
    Instruments sensitive to foreign

    currency exchange rates




    Instruments sensitive to equity

    market movements




    Instruments sensitive to

    interest rates


    7


    6
    XML 134 R67.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Discontinued operations (Tables) - Discontinued operations [member]
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Consolidated income statement segmentation
    2015


    (USD millions)




    Vaccines


    Consumer

    Health1
    Corporate

    (including

    eliminations)
    Total

    discontinued

    operations
    Net sales to third parties of discontinued operations
    145
    456
    601
    Sales to continuing segments
    18
    1
    19
    Net sales of discontinued operations
    163
    457
    620
    Other revenues
    18
    5
    23
    Cost of goods sold
    – 192
    – 184
    – 376
    Gross profit of discontinued operations
    – 11
    278
    267
    Marketing & Sales
    – 57
    – 187
    – 244
    Research & Development
    – 151
    – 30
    – 181
    General & Administration
    – 26
    – 32
    – 58
    Other income
    2 870
    10 558
    – 8
    13 420
    Other expense
    – 57
    – 14
    – 656
    – 727
    Operating income of discontinued operations
    2 568
    10 573
    – 664
    12 477
    Income from associated companies
    2
    2
    Income before taxes of discontinued operations
    12 479
    Taxes
    – 1 713
    Net income of discontinued operations
    10 766
     1  Consumer Health is the aggregation of the former OTC and Animal Health divisions.
    Expenses included in net income
    (USD millions)
    2015
    Impairment charges on property, plant & equipment, net
    83
    Additions to restructuring provisions
    – 1
    Equity-based compensation of Novartis equity plans
    – 65
    XML 135 R68.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Principal Group subsidiaries and associated companies (Tables)
    		 12 Months Ended
    Dec. 31, 2017
    Statement [line items]  
    Principal Group subsidiaries and associated companies


    As at December 31, 2017
    Share

    capital 1
    Equity

    interest
    Algeria
    Société par actions SANDOZ
    Algiers
    DZD
    650.0
    m
    100%
    Argentina
    Novartis Argentina S.A.
    Buenos Aires
    ARS
    906.1
    m
    100%
    Alcon Laboratorios S.A.
    Buenos Aires
    ARS
    83.9
    m
    100%
    Australia
    Novartis Australia Pty Ltd
    North Ryde, NSW
    AUD
    2
    100%
    Novartis Pharmaceuticals Australia Pty Ltd
    North Ryde, NSW
    AUD
    3.8
    m
    100%
    Sandoz Pty Ltd
    North Ryde, NSW
    AUD
    11.6
    m
    100%
    Alcon Laboratories (Australia) Pty Ltd
    Frenchs Forest, NSW
    AUD
    2.6
    m
    100%
    Austria
    Novartis Austria GmbH
    Vienna
    EUR
    1.0
    m
    100%
    Novartis Pharma GmbH
    Vienna
    EUR
    1.1
    m
    100%
    Sandoz GmbH
    Kundl
    EUR
    32.7
    m
    100%
    EBEWE Pharma Ges.m.b.H Nfg. KG
    Unterach am Attersee
    EUR
    1.0
    m
    100%
    Bangladesh
    Novartis (Bangladesh) Limited
    Gazipur
    BDT
    162.5
    m
    60%
    Belgium
    N.V. Novartis Pharma S.A.
    Vilvoorde
    EUR
    7.1
    m
    100%
    N.V. Sandoz S.A.
    Vilvoorde
    EUR
    19.2
    m
    100%
    S.A. Alcon-Couvreur N.V.
    Puurs
    EUR
    110.6
    m
    100%
    N.V. Alcon S.A.
    Vilvoorde
    EUR
    141 856
    100%
    Bermuda
    Novartis Investment Ltd.
    Hamilton
    USD
    12 000
    100%
    Novartis Securities Investment Ltd.
    Hamilton
    CHF
    30 000
    100%
    Novartis Finance Services Ltd.
    Hamilton
    CHF
    20 000
    100%
    Novartis B2 Ltd.
    Hamilton
    USD
    12 000
    100%
    Novartis B3 Ltd.
    Hamilton
    USD
    106 400
    100%
    Triangle International Reinsurance Limited
    Hamilton
    CHF
    1.0
    m
    100%
    Trinity River Insurance Co Ltd.
    Hamilton
    USD
    370 000
    100%
    Brazil
    Novartis Biociências S.A.
    São Paulo
    BRL
    265.0
    m
    100%
    Sandoz do Brasil Indústria Farmacêutica Ltda.
    Cambé, PR
    BRL
    190.0
    m
    100%
    Canada
    Novartis Pharmaceuticals Canada Inc.
    Dorval, Quebec
    CAD
    13.0
    m
    100%
    Sandoz Canada Inc.
    Boucherville, Quebec
    CAD
    80.8
    m
    100%
    Alcon Canada Inc.
    Mississauga, Ontario
    CAD
    2 500
    100%
    CIBA Vision Canada Inc.
    Mississauga, Ontario
    CAD
    82 886
    100%
    Chile
    Novartis Chile S.A.
    Santiago de Chile
    CLP
    2.0
    bn
    100%
    Alcon Laboratorios Chile Ltd.
    Santiago de Chile
    CLP
    2.0
    bn
    100%
    China
    Beijing Novartis Pharma Co., Ltd.
    Beijing
    USD
    30.0
    m
    100%
    Novartis Pharmaceuticals (HK) Limited
    Hong Kong
    HKD
    200
    100%
    China Novartis Institutes for BioMedical Research Co., Ltd.
    Shanghai
    USD
    320.0
    m
    100%
    Suzhou Novartis Pharma Technology Co., Ltd.
    Changshu
    USD
    103.4
    m
    100%
    Shanghai Novartis Trading Ltd.
    Shanghai
    USD
    3.2
    m
    100%
    Sandoz (China) Pharmaceutical Co., Ltd.
    Zhongshan
    USD
    36.5
    m
    100%
    Alcon Hong Kong Limited
    Hong Kong
    HKD
    77 000
    100%
    Alcon (China) Ophthalmic Product Co., Ltd.
    Beijing
    USD
    60.0
    m
    100%
    Colombia
    Novartis de Colombia S.A.
    Santafé de Bogotá
    COP
    7.9
    bn
    100%
    Laboratorios Alcon de Colombia S.A.
    Santafé de Bogotá
    COP
    20.9
    m
    100%
    Croatia
    Sandoz d.o.o. farmaceutska industrija
    Zagreb
    HRK
    25.6
    m
    100%
    Czech Republic
    Novartis s.r.o.
    Prague
    CZK
    51.5
    m
    100%
    Sandoz s.r.o.
    Prague
    CZK
    44.7
    m
    100%
    Alcon Pharmaceuticals (Czech Republic) s.r.o.
    Prague
    CZK
    31.0
    m
    100%
    Denmark
    Novartis Healthcare A/S
    Copenhagen
    DKK
    14.0
    m
    100%
    Sandoz A/S
    Copenhagen
    DKK
    12.0
    m
    100%
    Alcon Nordic A/S
    Copenhagen
    DKK
    0.5
    m
    100%
    Ecuador
    Novartis Ecuador S.A.
    Quito
    USD
    4.0
    m
    100%
    Egypt
    Novartis Pharma S.A.E.
    Cairo
    EGP
    193.8
    m
    99.77%
    Sandoz Egypt Pharma S.A.E.
    New Cairo City
    EGP
    250 000
    100%
    Finland
    Novartis Finland Oy
    Espoo
    EUR
    459 000
    100%


    As at December 31, 2017
    Share

    capital 1
    Equity

    interest
    France
    Novartis Groupe France S.A.
    Rueil-Malmaison
    EUR
    103.0
    m
    100%
    Novartis Pharma S.A.S.
    Rueil-Malmaison
    EUR
    43.4
    m
    100%
    Sandoz S.A.S.
    Levallois-Perret
    EUR
    5.4
    m
    100%
    Laboratoires Alcon S.A.S.
    Rueil-Malmaison
    EUR
    12.9
    m
    100%
    Germany
    Novartis Deutschland GmbH
    Wehr
    EUR
    155.5
    m
    100%
    Novartis Business Services GmbH
    Wehr
    EUR
    25 000
    100%
    Novartis Pharma GmbH
    Nuremberg
    EUR
    25.6
    m
    100%
    Novartis Pharma Produktions GmbH
    Wehr
    EUR
    2.0
    m
    100%
    Sandoz International GmbH
    Holzkirchen
    EUR
    100 000
    100%
    1 A Pharma GmbH
    Oberhaching
    EUR
    26 000
    100%
    HEXAL AG
    Holzkirchen
    EUR
    93.7
    m
    100%
    Salutas Pharma GmbH
    Barleben
    EUR
    42.1
    m
    100%
    Aeropharm GmbH
    Rudolstadt
    EUR
    26 000
    100%
    Alcon Pharma GmbH
    Freiburg im Breisgau
    EUR
    512 000
    100%
    CIBA Vision GmbH
    Grosswallstadt
    EUR
    15.4
    m
    100%
    WaveLight GmbH
    Erlangen
    EUR
    6.6
    m
    100%
    Gibraltar
    Novista Insurance Limited
    Gibraltar City
    CHF
    130.0
    m
    100%
    Greece
    Novartis (Hellas) S.A.C.I.
    Metamorphosis/Athens
    EUR
    23.4
    m
    100%
    Alcon Laboratories Hellas- Commercial and Industrial S.A.
    Maroussi, Athens
    EUR
    5.7
    m
    100%
    Hungary
    Novartis Hungary Healthcare Limited Liability Company
    Budapest
    HUF
    545.6
    m
    100%
    Sandoz Hungary Limited Liability Company
    Budapest
    HUF
    883.0
    m
    100%
    India
    Novartis India Limited
    Mumbai
    INR
    140.7
    m
    73.4%
    Novartis Healthcare Private Limited
    Mumbai
    INR
    60.0
    m
    100%
    Sandoz Private Limited
    Mumbai
    INR
    32.0
    m
    100%
    Alcon Laboratories (India) Private Limited
    Bangalore
    INR
    1.1
    bn
    100%
    Indonesia
    PT. Novartis Indonesia
    Jakarta
    IDR
    7.7
    bn
    100%
    PT. CIBA Vision Batam
    Batam
    IDR
    11.9
    bn
    100%
    Ireland
    Novartis Ireland Limited
    Dublin
    EUR
    25 000
    100%
    Novartis Ringaskiddy Limited
    Ringaskiddy, County Cork
    EUR
    2.0
    m
    100%
    Alcon Laboratories Ireland Limited
    Cork City
    EUR
    541 251
    100%
    Israel
    Novartis Israel Ltd.
    Petach Tikva
    ILS
    1 000
    100%
    Optonol Ltd.
    Neve-Ilan
    ILS
    752 545
    100%
    Italy
    Novartis Farma S.p.A.
    Origgio
    EUR
    18.2
    m
    100%
    Sandoz S.p.A.
    Origgio
    EUR
    1.7
    m
    100%
    Sandoz Industrial Products S.p.A.
    Rovereto
    EUR
    2.6
    m
    100%
    Alcon Italia S.p.A.
    Milan
    EUR
    3.7
    m
    100%
    Japan
    Novartis Holding Japan K.K.
    Tokyo
    JPY
    10.0
    m
    100%
    Novartis Pharma K.K.
    Tokyo
    JPY
    6.0
    bn
    100%
    Ciba-Geigy Japan Limited
    Tokyo
    JPY
    8.5
    m
    100%
    Sandoz K.K.
    Tokyo
    JPY
    100.0
    m
    100%
    Alcon Japan Ltd.
    Tokyo
    JPY
    500.0
    m
    100%
    Luxembourg
    Novartis Investments S.à r.l.
    Luxembourg-Ville
    USD
    100.0
    m
    100%
    Novartis Finance S.A.
    Luxembourg-Ville
    USD
    100 000
    100%
    Malaysia
    Novartis Corporation (Malaysia) Sdn. Bhd.
    Kuala Lumpur
    MYR
    3.3
    m
    100%
    Alcon Laboratories (Malaysia) Sdn. Bhd.
    Petaling Jaya
    MYR
    1.0
    m
    100%
    CIBA Vision Johor Sdn. Bhd.
    Kuala Lumpur
    MYR
    10.0
    m
    100%
    Mexico
    Novartis Farmacéutica, S.A. de C.V.
    Mexico City
    MXN
    205.0
    m
    100%
    Sandoz, S.A. de C.V.
    Mexico City
    MXN
    468.2
    m
    100%
    Alcon Laboratorios, S.A. de C.V.
    Mexico City
    MXN
    5.9
    m
    100%
    Morocco
    Novartis Pharma Maroc SA
    Casablanca
    MAD
    80.0
    m
    100%
    Netherlands
    Novartis Netherlands B.V.
    Arnhem
    EUR
    1.4
    m
    100%
    Novartis Pharma B.V.
    Arnhem
    EUR
    4.5
    m
    100%
    Sandoz B.V.
    Almere
    EUR
    907 560
    100%
    Alcon Nederland B.V.
    Arnhem
    EUR
    18 151
    100%
    New Zealand
    Novartis New Zealand Ltd
    Auckland
    NZD
    820 000
    100%


    As at December 31, 2017
    Share

    capital 1
    Equity

    interest
    Norway
    Novartis Norge AS
    Oslo
    NOK
    1.5
    m
    100%
    Pakistan
    Novartis Pharma (Pakistan) Limited
    Karachi
    PKR
    3.9
    bn
    99.99%
    Panama
    Novartis Pharma (Logistics), Inc.
    Panama City
    USD
    10 000
    100%
    Alcon Centroamerica S.A.
    Panama City
    PAB
    1 000
    100%
    Philippines
    Novartis Healthcare Philippines, Inc.
    Manila
    PHP
    298.8
    m
    100%
    Sandoz Philippines Corporation
    Manila
    PHP
    30.0
    m
    100%
    Poland
    Novartis Poland Sp. z o.o.
    Warszawa
    PLN
    44.2
    m
    100%
    Sandoz Polska Sp. z o.o.
    Warszawa
    PLN
    25.6
    m
    100%
    Lek S.A.
    Strykow
    PLN
    11.4
    m
    100%
    Alcon Polska Sp. z o.o.
    Warszawa
    PLN
    750 000
    100%
    Portugal
    Novartis Portugal SGPS Lda.
    Porto Salvo
    EUR
    500 000
    100%
    Novartis Farma - Produtos Farmacêuticos S.A.
    Porto Salvo
    EUR
    2.4
    m
    100%
    Sandoz Farmacêutica Lda.
    Porto Salvo
    EUR
    499 900
    100%
    Alcon Portugal-Produtos e Equipamentos Oftalmológicos Lda.
    Porto Salvo
    EUR
    4.5
    m
    100%
    Romania
    Novartis Pharma Services Romania S.R.L.
    Bucharest
    RON
    3.0
    m
    100%
    Sandoz S.R.L.
    Targu-Mures
    RON
    105.2
    m
    100%
    Alcon Romania S.R.L.
    Bucharest
    RON
    10.8
    m
    100%
    Russian Federation
    Novartis Pharma LLC
    Moscow
    RUB
    20.0
    m
    100%
    Novartis Neva LLC
    St. Petersburg
    RUB
    1.3
    bn
    100%
    ZAO Sandoz
    Moscow
    RUB
    57.4
    m
    100%
    Alcon Farmacevtika LLC
    Moscow
    RUB
    44.1
    m
    100%
    Saudi Arabia
    Saudi Pharmaceutical Distribution Co. Ltd.
    Riyadh
    SAR
    26.8
    m
    75%
    Singapore
    Novartis (Singapore) Pte Ltd.
    Singapore
    SGD
    100 000
    100%
    Novartis Singapore Pharmaceutical Manufacturing Pte Ltd
    Singapore
    SGD
    45.0
    m
    100%
    Novartis Asia Pacific Pharmaceuticals Pte Ltd
    Singapore
    SGD
    39.0
    m
    100%
    Novartis Institute for Tropical Diseases Pte Ltd
    Singapore
    SGD
    2 004
    100%
    Alcon Pte Ltd
    Singapore
    SGD
    164 000
    100%
    Alcon Singapore Manufacturing Pte Ltd
    Singapore
    SGD
    101 000
    100%
    CIBA Vision Asian Manufacturing and Logistics Pte Ltd.
    Singapore
    SGD
    1.0
    m
    100%
    Slovakia
    Novartis Slovakia s.r.o.
    Bratislava
    EUR
    2.0
    m
    100%
    Slovenia
    Lek Pharmaceuticals d.d.
    Ljubjana
    EUR
    48.4
    m
    100%
    Sandoz Pharmaceuticals d.d.
    Ljubjana
    EUR
    1.5
    m
    100%
    South Africa
    Novartis South Africa (Pty) Ltd
    Midrand
    ZAR
    86.3
    m
    100%
    Sandoz South Africa (Pty) Ltd
    Kempton Park
    ZAR
    3.0
    m
    100%
    Alcon Laboratories (South Africa) (Pty) Ltd.
    Midrand
    ZAR
    201 820
    100%
    South Korea
    Novartis Korea Ltd.
    Seoul
    KRW
    24.5
    bn
    98.55%
    Sandoz Korea Ltd.
    Seoul
    KRW
    17.8
    bn
    100%
    Alcon Korea Ltd.
    Seoul
    KRW
    33.8
    bn
    100%
    Spain
    Novartis Farmacéutica S.A.
    Barcelona
    EUR
    63.0
    m
    100%
    Sandoz Farmacéutica S.A.
    Madrid
    EUR
    270 450
    100%
    Sandoz Industrial Products S.A.
    Les Franqueses del Vallés / Barcelona
    EUR
    9.3
    m
    100%
    Alcon Cusi S.A.
    Barcelona
    EUR
    11.6
    m
    100%
    Abadia Retuerta S.A.
    Sardón de Duero/Valladolid
    EUR
    6.0
    m
    100%
    Sweden
    Novartis Sverige AB
    Täby / Stockholm
    SEK
    5.0
    m
    100%
    Switzerland
    Novartis International AG
    Basel
    CHF
    10.0
    m
    100%
    Novartis Holding AG
    Basel
    CHF
    100.2
    m
    100%
    Novartis International Pharmaceutical Investment AG
    Basel
    CHF
    100 000
    100%
    Novartis Bioventures AG
    Basel
    CHF
    100 000
    100%
    Novartis Forschungsstiftung
    Basel
    --
    --
    100%
    Novartis Stiftung für Kaderausbildung
    Basel
    --
    --
    100%
    Novartis Mitarbeiterbeteiligungsstiftung
    Basel
    --
    --
    100%
    Novartis Stiftung für Mensch und Umwelt
    Basel
    --
    --
    100%
    Stiftung der Novartis AG für Erziehung, Ausbildung und Bildung
    Basel
    --
    --
    100%
    Novartis Pharma AG
    Basel
    CHF
    350.0
    m
    100%
    Novartis International Pharmaceutical AG
    Basel
    CHF
    100 000
    100%
    Novartis Pharma Services AG
    Basel
    CHF
    20.0
    m
    100%
    Novartis Pharma Schweizerhalle AG
    Muttenz
    CHF
    18.9
    m
    100%
    Novartis Pharma Stein AG
    Stein
    CHF
    251 000
    100%
    Novartis Pharma Schweiz AG
    Risch
    CHF
    5.0
    m
    100%
    Sandoz AG
    Basel
    CHF
    5.0
    m
    100%
    Sandoz Pharmaceuticals AG
    Risch
    CHF
    100 000
    100%
    Alcon Switzerland SA
    Risch
    CHF
    100 000
    100%
    Alcon Pharmaceuticals Ltd.
    Fribourg
    CHF
    200 000
    100%
    Roche Holding AG
    Basel
    CHF
    160.0
    m
    33/6 2


    As at December 31, 2017
    Share

    capital 1
    Equity

    interest
    Taiwan
    Novartis (Taiwan) Co., Ltd.
    Taipei
    TWD
    170.0
    m
    100%
    Thailand
    Novartis (Thailand) Limited
    Bangkok
    THB
    302.0
    m
    100%
    Alcon Laboratories (Thailand) Limited
    Bangkok
    THB
    228.1
    m
    100%
    Turkey
    Novartis Saglik, Gida ve Tarim Ürünleri Sanayi ve Ticaret A.S.
    Istanbul
    TRY
    98.0
    m
    100%
    Farmanova Saglik Hizmetleri Ltd. Sti.
    Istanbul
    TRY
    6.7
    m
    100%
    Sandoz Ilaç Sanayi ve Ticaret A.S.
    Istanbul
    TRY
    165.2
    m
    99.99%
    Sandoz Syntek Ilaç Hammaddeleri Sanayi ve Ticaret A.S.
    Istanbul
    TRY
    46.0
    m
    100%
    Sandoz Grup Saglik Ürünleri Ilaçlari Sanayi ve Ticaret A.S.
    Gebze - Kocaeli
    TRY
    50.0
    m
    100%
    Alcon Laboratuvarlari Ticaret A.S.
    Istanbul
    TRY
    25.2
    m
    100%
    United Arab Emirates
    Novartis Middle East FZE
    Dubai
    AED
    7.0
    m
    100%
    United Kingdom
    Novartis UK Limited
    Frimley/Camberley
    GBP
    25.5
    m
    100%
    Novartis Pharmaceuticals UK Limited
    Frimley/Camberley
    GBP
    5.4
    m
    100%
    Novartis Grimsby Limited
    Frimley/Camberley
    GBP
    250.0
    m
    100%
    Ziarco Group Limited
    Frimley/Camberley
    GBP
    3 904
    100%
    Sandoz Limited
    Frimley/Camberley
    GBP
    2.0
    m
    100%
    Alcon Eye Care UK Limited
    Frimley/Camberley
    GBP
    550 000
    100%
    Glaxosmithkline Consumer Healthcare Holdings Limited
    Brentford, Middlesex
    GBP
    100 000
    36.5%
    United States of America
    Novartis Corporation
    East Hanover, NJ
    USD
    72.2
    m
    100%
    Novartis Finance Corporation
    New York, NY
    USD
    1 000
    100%
    Novartis Capital Corporation
    New York, NY
    USD
    1
    100%
    Novartis Services, Inc.
    East Hanover, NJ
    USD
    1
    100%
    Novartis US Foundation
    New York, NY
    --
    --
    100%
    Novartis Pharmaceuticals Corporation
    East Hanover, NJ
    USD
    5.2
    m
    100%
    Novartis Institutes for BioMedical Research, Inc.
    Cambridge, MA
    USD
    1
    100%
    Corthera, Inc.
    San Mateo, CA
    USD
    1
    100%
    CoStim Pharmaceuticals Inc.
    Cambridge, MA
    USD
    1
    100%
    Encore Vision, Inc.
    New York, NY
    USD
    1
    100%
    Navigate BioPharma Services, Inc.
    Wilmington, NC
    USD
    100
    100%
    Reprixys Pharmaceuticals Corporation
    Oklahoma City, OK
    USD
    1
    100%
    Spinifex Pharmaceuticals, Inc.
    Wilmington, NC
    USD
    1
    100%
    Novartis Institute for Functional Genomics, Inc.
    San Diego, CA
    USD
    1 000
    100%
    Sandoz Inc.
    Princeton, NJ
    USD
    25 000
    100%
    Fougera Pharmaceuticals Inc.
    Melville, NY
    USD
    1
    100%
    Eon Labs, Inc.
    Princeton, NJ
    USD
    1
    100%
    Alcon Laboratories, Inc.
    Fort Worth, TX
    USD
    1 000
    100%
    Alcon Refractivehorizons, LLC
    Fort Worth, TX
    USD
    10
    100%
    Alcon Research, Ltd.
    Fort Worth, TX
    USD
    12.5
    100%
    Alcon Lensx, Inc.
    Aliso Viejo, CA
    USD
    1
    100%
    Alcon Laboratories Holding Corporation
    Fort Worth, TX
    USD
    10
    100%
    Novartis Vaccines and Diagnostics, Inc.
    Cambridge, MA
    USD
    3
    100%
    ClarVista Medical, Inc.
    Aliso Viejo, CA
    USD
    1
    100%
    Transcend Medical, Inc.
    Menlo Park, CA
    USD
    1
    100%
    Venezuela
    Novartis de Venezuela, S.A.
    Caracas
    VEF
    1.4
    m
    100%
    Alcon Pharmaceutical, C.A.
    Caracas
    VEF
    5.5
    m
    100%
    In addition, the Group is represented by subsidiaries and associated companies in the following countries: Bosnia/Herzegovina, Bulgaria, Dominican Republic, Guatemala, Kenya, Latvia, the Former Yugoslav Republic of Macedonia, Nigeria, Peru, Puerto Rico, Ukraine and Uruguay
     1  Share capital may not reflect the taxable share capital and does not include any paid-in surplus
     2  Approximately 33% of voting shares; approximately 6% of total net income and equity attributable to Novartis
    m = million; bn = billion
    XML 136 R69.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Significant accounting policies (Details)
    		 12 Months Ended
    Dec. 31, 2017
    Buildings  
    Statement [line items]  
    Property, plant and equipment useful lives 20 to 40 years
    Machinery and other equipment  
    Statement [line items]  
    Property, plant and equipment useful lives 7 to 20 years
    Furniture and vehicles  
    Statement [line items]  
    Property, plant and equipment useful lives 5 to 10 years
    Computer equipment  
    Statement [line items]  
    Property, plant and equipment useful lives 3 to 7 years
    XML 137 R70.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Significant accounting policies (Details 2)
    		 12 Months Ended
    Dec. 31, 2017
    Currently marketed products [member] | Cost of sales [member]  
    Statement [line items]  
    Available for use intangible asset useful lives 5 to 20 years
    Marketing related intangible assets [member] | Cost of sales [member]  
    Statement [line items]  
    Available for use intangible asset useful lives 25 years
    Technology-based intangible assets [member] | Cost of sales or Research and Development [member]  
    Statement [line items]  
    Available for use intangible asset useful lives 10 to 20 years
    Other intangible assets [member]  
    Statement [line items]  
    Available for use intangible asset useful lives 3 to 7 years
    Brand names [member]  
    Statement [line items]  
    Available for use intangible asset useful lives Not amortized, indefinite useful life
    XML 138 R71.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Significant accounting policies (Details 3) - 12 months ended Dec. 31, 2017
    $ in Billions
    USD ($)
    SFr / shares
    Statement [line items]    
    Par value per share | SFr / shares   SFr 0.50
    Increase to retained earnings arising from first application of IFRS 9 $ 0.2  
    Undiscounted operating lease commitments $ 3.2  
    XML 139 R72.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Significant transactions
    		 12 Months Ended
    Jan. 20, 2017
    USD ($)
    Nov. 18, 2016
    USD ($)
    Mar. 23, 2016
    USD ($)
    Oct. 16, 2015
    USD ($)
    Jul. 31, 2015
    USD ($)
    Jul. 24, 2015
    USD ($)
    Mar. 02, 2015
    USD ($)
    year
    Jan. 01, 2015
    USD ($)
    Oct. 26, 2014
    USD ($)
    Dec. 31, 2017
    USD ($)
    Dec. 31, 2015
    USD ($)
    Jan. 22, 2018
    USD ($)
    Dec. 31, 2017
    SFr / shares
    Dec. 31, 2016
    USD ($)
    Disclosure of detailed information about business combination [line items]                            
    Identifiable assets acquired (liabilities assumed)                   $ 999,000,000 $ 16,499,000,000     $ 869,000,000
    Profit (loss) from discontinued operations                     10,766,000,000      
    Par value per share | SFr / shares                         SFr 0.50  
    Roche Holding AG, Switzerland                            
    Disclosure of detailed information about business combination [line items]                            
    Additional recognition, goodwill                   2,915,000,000        
    GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK                            
    Disclosure of detailed information about business combination [line items]                            
    Additional recognition, goodwill                   $ 1,763,000,000        
    GSK Oncology Products                            
    Disclosure of detailed information about business combination [line items]                            
    Consideration transferred, acquisition-date fair value             $ 15,900,000,000              
    Portion of consideration paid (received) consisting of cash and cash equivalents             (16,000,000,000)              
    Identifiable assets acquired (liabilities assumed)             13,500,000,000              
    Additional recognition, goodwill             2,400,000,000              
    Potentially refundable consideration from acquisition             1,500,000,000              
    Fair value of potentially refundable contingent consideration             $ 100,000,000              
    Contract right of first negotiation term | year             12.5              
    Revenue of acquiree since acquisition date             $ 1,800,000,000              
    Revenue of acquiree full year             $ 2,100,000,000              
    GSK Consumer Healthcare                            
    Disclosure of detailed information about business combination [line items]                            
    Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage             36.50%              
    Investments in subsidiaries, joint ventures and associates             $ 7,600,000,000              
    GSK Consumer Healthcare | GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK                            
    Disclosure of detailed information about business combination [line items]                            
    Interest exchanged             Novartis has valued the contribution of 63.5% of its OTC Division in exchange for 36.5% of the GSK Consumer Healthcare business at fair value.              
    Discontinued operations                            
    Disclosure of detailed information about business combination [line items]                            
    Consideration transferred, acquisition-date fair value                     10,925,000,000      
    Profit (loss) from discontinued operations                     10,766,000,000      
    Transaction related costs paid                     $ (2,001,000,000)      
    Discontinued operations | GSK Total Transaction                            
    Disclosure of detailed information about business combination [line items]                            
    Transaction related costs paid             $ (300,000,000)              
    Discontinued operations | Operating income [member] | GSK Consumer Healthcare                            
    Disclosure of detailed information about business combination [line items]                            
    Gain (loss) recognised as result of remeasuring to fair value equity interest in acquiree held by acquirer before business combination             5,900,000,000              
    Discontinued operations | Operating income [member] | GSK Total Transaction                            
    Disclosure of detailed information about business combination [line items]                            
    Transaction related costs             (600,000,000)              
    Subsidiaries [member] | Transcend Medical Inc.                            
    Disclosure of detailed information about business combination [line items]                            
    Consideration transferred, acquisition-date fair value     $ 332,000,000                      
    Portion of consideration paid (received) consisting of cash and cash equivalents     (240,000,000)                      
    Contingent liabilities recognised as of acquisition date     92,000,000                      
    Identifiable assets acquired (liabilities assumed)     294,000,000                      
    Additional recognition, goodwill     $ 38,000,000                      
    Subsidiaries [member] | Reprixys Pharmaceuticals Corporation                            
    Disclosure of detailed information about business combination [line items]                            
    Consideration transferred, acquisition-date fair value   $ 268,000,000                        
    Portion of consideration paid (received) consisting of cash and cash equivalents   (194,000,000)                        
    Contingent liabilities recognised as of acquisition date   74,000,000                        
    Identifiable assets acquired (liabilities assumed)   332,000,000                        
    Additional recognition, goodwill   $ 0                        
    Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage   19.00%                        
    Acquisition-date fair value of equity interest in acquiree held by acquirer immediately before acquisition date   $ 64,000,000                        
    Gain (loss) recognised as result of remeasuring to fair value equity interest in acquiree held by acquirer before business combination   $ 53,000,000                        
    Percentage of voting equity interests acquired   81.00%                        
    Subsidiaries [member] | Ziarco Group Limited                            
    Disclosure of detailed information about business combination [line items]                            
    Consideration transferred, acquisition-date fair value $ 420,000,000                          
    Portion of consideration paid (received) consisting of cash and cash equivalents (325,000,000)                          
    Contingent liabilities recognised as of acquisition date 95,000,000                          
    Identifiable assets acquired (liabilities assumed) 395,000,000                          
    Additional recognition, goodwill 25,000,000                          
    Subsidiaries [member] | Encore Vision, Inc.                            
    Disclosure of detailed information about business combination [line items]                            
    Consideration transferred, acquisition-date fair value 456,000,000                          
    Portion of consideration paid (received) consisting of cash and cash equivalents (366,000,000)                          
    Contingent liabilities recognised as of acquisition date 90,000,000                          
    Identifiable assets acquired (liabilities assumed) 389,000,000                          
    Additional recognition, goodwill $ 67,000,000                          
    Subsidiaries [member] | Eli Lilly and Company                            
    Disclosure of detailed information about business combination [line items]                            
    Portion of consideration paid (received) consisting of cash and cash equivalents               $ 5,400,000,000            
    Pre tax profit (loss) from divestment of business               $ 4,600,000,000            
    Subsidiaries [member] | GSK Vaccines                            
    Disclosure of detailed information about business combination [line items]                            
    Portion of consideration paid (received) consisting of cash and cash equivalents             5,250,000,000              
    Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations             7,100,000,000              
    Pre tax profit (loss) from divestment of business             2,800,000,000              
    Consideration transferred, divestment-date fair value             6,250,000,000              
    Potential receivable from divestment             1,800,000,000              
    Fair value of contingent consideration received             $ 1,000,000,000              
    Milestone payment already received             Included in this amount is a USD 450 million milestone payment received in late March 2015.              
    Future put option to sell business             Novartis’s Vaccines influenza business was excluded from the GSK Vaccines business acquisition. However, GSK entered into a future option arrangement with Novartis in relation to the Vaccines influenza business, pursuant to which Novartis could have unilaterally required GSK to acquire the entire or certain parts of its Vaccines influenza business for consideration of up to USD 250 million (the Influenza Put Option) if the divestment to CSL Limited, Australia (CSL), discussed below, had not been completed. The option period was 18 months from the closing date of the GSK transaction, but terminated with the sale of the Vaccines influenza business to CSL on July 31, 2015. Novartis paid GSK a fee of USD 5 million in consideration for the grant of the Influenza Put Option.              
    Payment put option             $ 5,000,000              
    Subsidiaries [member] | CSL                            
    Disclosure of detailed information about business combination [line items]                            
    Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations         $ 275,000,000                  
    Subsidiaries [member] | Spinifex                            
    Disclosure of detailed information about business combination [line items]                            
    Consideration transferred, acquisition-date fair value           $ 312,000,000                
    Portion of consideration paid (received) consisting of cash and cash equivalents           (196,000,000)                
    Contingent liabilities recognised as of acquisition date           116,000,000                
    Identifiable assets acquired (liabilities assumed)           263,000,000                
    Additional recognition, goodwill           $ 49,000,000                
    Subsidiaries [member] | Admune Theraputics                            
    Disclosure of detailed information about business combination [line items]                            
    Consideration transferred, acquisition-date fair value       $ 258,000,000                    
    Portion of consideration paid (received) consisting of cash and cash equivalents       (140,000,000)                    
    Contingent liabilities recognised as of acquisition date       118,000,000                    
    Identifiable assets acquired (liabilities assumed)       258,000,000                    
    Additional recognition, goodwill       $ 0                    
    Subsidiaries [member] | Advanced Accelerator Applications (AAA)                            
    Disclosure of detailed information about business combination [line items]                            
    Percentage of Share capital in tender offer                       100.00%    
    Cash offer per ordinary share                       $ 41    
    Cash offer per ADS                       $ 82    
    Number of ordinary share per ADS                       2    
    Value of equity                       $ 3,900,000,000    
    Percentage of share capital tendered at the expiration of the tender offer                       97.00%    
    Subsidiaries [member] | Discontinued operations | Operating income [member] | CSL                            
    Disclosure of detailed information about business combination [line items]                            
    Impairment loss                 $ 1,100,000,000          
    Reversal of impairment loss         $ 100,000,000                  
    XML 140 R73.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Segmentation of key figures (Details)
    		 12 Months Ended
    Dec. 31, 2017
    Disclosure of operating segments [line items]  
    Number of Reportable Segments 3
    Innovative Medicines  
    Disclosure of operating segments [line items]  
    Number of Business Units 2
    Sandoz  
    Disclosure of operating segments [line items]  
    Number of Franchises 3
    Alcon  
    Disclosure of operating segments [line items]  
    Number of Franchises 2
    Consumer Health  
    Disclosure of operating segments [line items]  
    Number of Business Units 2
    XML 141 R74.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Segmentation of key figures (Details 1) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 49,109 $ 48,518 $ 49,414
    Sales to other segments     26
    Net sales from continuing operations 49,109 48,518 49,440
    Other revenues 1,026 918 947
    Cost of goods sold (17,175) (17,520) (17,404)
    Gross profit from continuing operations 32,960 31,916 32,983
    Marketing and Sales (12,861) (11,998) (11,772)
    Research and Development (8,972) (9,039) (8,935)
    General and Administration (2,136) (2,194) (2,475)
    Other income 1,969 1,927 2,049
    Other expense (2,331) (2,344) (2,873)
    Operating income from continuing operations 8,629 8,268 8,977
    Income from associated companies 1,108 703 266
    Interest expense (777) (707) (655)
    Other financial income and expense 39 (447) (454)
    Income before taxes from continuing operations 8,999 7,817 8,134
    Taxes (1,296) (1,119) (1,106)
    Net income from continuing operations 7,703 6,698 7,028
    Net income/loss from discontinued operations     10,766
    Net income 7,703 6,698 17,794
    Attributable to      
    Shareholders of Novartis AG 7,703 6,712 17,783
    Non-controlling interests 0 (14) 11
    Operating segments [member] | Innovative Medicines      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations 33,025 32,562 33,345
    Sales to other segments 668 624 518
    Net sales from continuing operations 33,693 33,186 33,863
    Other revenues 898 815 792
    Cost of goods sold (9,007) (9,331) (9,204)
    Gross profit from continuing operations 25,584 24,670 25,451
    Marketing and Sales (9,089) (8,435) (8,430)
    Research and Development (7,630) (7,709) (7,685)
    General and Administration (986) (978) (1,031)
    Other income 1,027 1,091 1,149
    Other expense (1,124) (1,213) (1,639)
    Operating income from continuing operations 7,782 7,426 7,815
    Income from associated companies (1)    
    Operating segments [member] | Sandoz      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations 10,060 10,144 10,070
    Sales to other segments 118 104 128
    Net sales from continuing operations 10,178 10,248 10,198
    Other revenues 37 37 25
    Cost of goods sold (5,800) (5,971) (5,844)
    Gross profit from continuing operations 4,415 4,314 4,379
    Marketing and Sales (1,811) (1,681) (1,679)
    Research and Development (774) (814) (782)
    General and Administration (315) (300) (346)
    Other income 204 185 109
    Other expense (351) (259) (381)
    Operating income from continuing operations 1,368 1,445 1,300
    Income from associated companies 23 6 2
    Operating segments [member] | Alcon      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations 6,024 5,812 5,999
    Sales to other segments 3    
    Net sales from continuing operations 6,027 5,812 5,999
    Other revenues 3 4 23
    Cost of goods sold (3,231) (3,092) (3,145)
    Gross profit from continuing operations 2,799 2,724 2,877
    Marketing and Sales (1,961) (1,882) (1,663)
    Research and Development (568) (516) (468)
    General and Administration (383) (410) (450)
    Other income 47 48 54
    Other expense (124) (96) (69)
    Operating income from continuing operations (190) (132) 281
    Operating segments [member] | Corporate      
    Disclosure of operating segments [line items]      
    Sales to other segments (789) (728) (620)
    Net sales from continuing operations (789) (728) (620)
    Other revenues 88 62 107
    Cost of goods sold 863 874 789
    Gross profit from continuing operations 162 208 276
    General and Administration (452) (506) (648)
    Other income 691 603 737
    Other expense (732) (776) (784)
    Operating income from continuing operations (331) (471) (419)
    Income from associated companies $ 1,086 $ 697 $ 264
    XML 142 R75.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Segmentation of key figures (Details 2) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Disclosure of operating segments [line items]      
    Interest income $ 110 $ 43 $ 33
    Impairment charges and fair value gains on financial assets, net (256) (132) (104)
    Additions to restructuring provisions (194) (343) (399)
    Equity-based compensation of Novartis equity plans (924) (846) (968)
    Continuing operations      
    Disclosure of operating segments [line items]      
    Equity-based compensation of Novartis equity plans (924) (846) (903)
    Property, plant and equipment [member]      
    Disclosure of operating segments [line items]      
    Depreciation and amortisation expense (1,520) (1,489) (1,470)
    Impairment loss (reversal of impairment loss) recognised in profit or loss (157) (102) (80)
    Intangible assets and goodwill [member]      
    Disclosure of operating segments [line items]      
    Depreciation and amortisation expense (3,690) (3,861) (3,755)
    Impairment loss (reversal of impairment loss) recognised in profit or loss (709) (591) (166)
    Operating segments [member] | Innovative Medicines | Continuing operations      
    Disclosure of operating segments [line items]      
    Impairment charges and fair value gains on financial assets, net (42) (55) (32)
    Additions to restructuring provisions (122) (236) (232)
    Equity-based compensation of Novartis equity plans (593) (582) (620)
    Operating segments [member] | Innovative Medicines | Property, plant and equipment [member] | Continuing operations      
    Disclosure of operating segments [line items]      
    Depreciation and amortisation expense (916) (883) (839)
    Impairment loss (reversal of impairment loss) recognised in profit or loss (84) (93) 39
    Operating segments [member] | Innovative Medicines | Intangible assets and goodwill [member] | Continuing operations      
    Disclosure of operating segments [line items]      
    Depreciation and amortisation expense (2,291) (2,470) (2,384)
    Impairment loss (reversal of impairment loss) recognised in profit or loss (591) (522) (138)
    Operating segments [member] | Sandoz | Continuing operations      
    Disclosure of operating segments [line items]      
    Additions to restructuring provisions (61) (46) (93)
    Equity-based compensation of Novartis equity plans (52) (47) (53)
    Operating segments [member] | Sandoz | Property, plant and equipment [member] | Continuing operations      
    Disclosure of operating segments [line items]      
    Depreciation and amortisation expense (270) (260) (277)
    Impairment loss (reversal of impairment loss) recognised in profit or loss (73) (2) (97)
    Operating segments [member] | Sandoz | Intangible assets and goodwill [member] | Continuing operations      
    Disclosure of operating segments [line items]      
    Depreciation and amortisation expense (447) (450) (450)
    Impairment loss (reversal of impairment loss) recognised in profit or loss (61) (65) (27)
    Operating segments [member] | Alcon | Continuing operations      
    Disclosure of operating segments [line items]      
    Impairment charges and fair value gains on financial assets, net (29)    
    Additions to restructuring provisions (8) (36) (25)
    Equity-based compensation of Novartis equity plans (71) (53) (66)
    Operating segments [member] | Alcon | Property, plant and equipment [member] | Continuing operations      
    Disclosure of operating segments [line items]      
    Depreciation and amortisation expense (217) (229) (237)
    Impairment loss (reversal of impairment loss) recognised in profit or loss   (5) (1)
    Operating segments [member] | Alcon | Intangible assets and goodwill [member] | Continuing operations      
    Disclosure of operating segments [line items]      
    Depreciation and amortisation expense (942) (929) (912)
    Impairment loss (reversal of impairment loss) recognised in profit or loss (57) (4) (1)
    Operating segments [member] | Corporate | Continuing operations      
    Disclosure of operating segments [line items]      
    Impairment charges and fair value gains on financial assets, net (185) (77) (72)
    Additions to restructuring provisions (3) (25) (49)
    Equity-based compensation of Novartis equity plans (208) (164) (164)
    Operating segments [member] | Corporate | Property, plant and equipment [member] | Continuing operations      
    Disclosure of operating segments [line items]      
    Depreciation and amortisation expense (117) (117) (117)
    Impairment loss (reversal of impairment loss) recognised in profit or loss   (2) (21)
    Operating segments [member] | Corporate | Intangible assets and goodwill [member] | Continuing operations      
    Disclosure of operating segments [line items]      
    Depreciation and amortisation expense $ (10) $ (12) $ (9)
    XML 143 R76.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Segmentation of key figures (Details 3) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Dec. 31, 2014
    Disclosure of operating segments [line items]        
    Total assets $ 133,079 $ 130,124    
    Total liabilities (58,852) (55,233)    
    Total equity 74,227 74,891 $ 77,122 $ 70,844
    Net debt 19,047 16,025    
    Net operating assets 93,274 90,916    
    Property, plant and equipment 16,464 15,641    
    Additions to property, plant and equipment 1,728 1,835    
    Intangible assets and goodwill 61,747 62,320    
    Additions to intangible assets and goodwill 1,146 978    
    Investments in associated companies 15,370 14,304    
    Additions to investment in associated companies 46 41    
    Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments 9,485 7,777    
    Financial debts and derivative instruments 28,532 23,802    
    Current income tax and deferred tax liabilities 6,891 8,260    
    Operating segments [member] | Innovative Medicines        
    Disclosure of operating segments [line items]        
    Total assets 54,075 51,911    
    Total liabilities (11,457) (10,007)    
    Net operating assets 42,618 41,904    
    Property, plant and equipment 10,857 10,410    
    Additions to property, plant and equipment 877 996    
    Intangible assets and goodwill 31,571 31,630    
    Additions to intangible assets and goodwill 984 865    
    Investments in associated companies 41 16    
    Additions to investment in associated companies 6 4    
    Operating segments [member] | Sandoz        
    Disclosure of operating segments [line items]        
    Total assets 18,231 17,611    
    Total liabilities (3,459) (3,168)    
    Net operating assets 14,772 14,443    
    Property, plant and equipment 2,525 2,374    
    Additions to property, plant and equipment 326 316    
    Intangible assets and goodwill 10,993 10,774    
    Additions to intangible assets and goodwill 64 45    
    Investments in associated companies 7 18    
    Operating segments [member] | Alcon        
    Disclosure of operating segments [line items]        
    Total assets 22,014 22,970    
    Total liabilities (1,893) (2,520)    
    Net operating assets 20,121 20,450    
    Property, plant and equipment 2,403 2,163    
    Additions to property, plant and equipment 431 396    
    Intangible assets and goodwill 16,176 16,914    
    Additions to intangible assets and goodwill 82 63    
    Operating segments [member] | Corporate        
    Disclosure of operating segments [line items]        
    Total assets 38,759 37,632    
    Total liabilities (42,043) (39,538)    
    Property, plant and equipment 679 694    
    Additions to property, plant and equipment 94 127    
    Intangible assets and goodwill 3,007 3,002    
    Additions to intangible assets and goodwill 16 5    
    Investments in associated companies 15,322 14,270    
    Additions to investment in associated companies 40 37    
    Cash and cash equivalents, marketable securities, commodities, time deposits and derivative financial instruments 9,485 7,777    
    Financial debts and derivative instruments 28,532 23,802    
    Current income tax and deferred tax liabilities $ 6,891 $ 8,260    
    XML 144 R77.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Segmentation of key figures (Details 4) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 49,109 $ 48,518 $ 49,414
    Net sales (in % of total net sales) 100.00% 100.00% 100.00%
    Total of selected non-current assets $ 93,581 $ 92,265  
    Selected non-current assets (in % of total selected non-current assets) 100.00% 100.00%  
    Switzerland      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 836 $ 830 $ 774
    Net sales (in % of total net sales) 2.00% 2.00% 2.00%
    Total of selected non-current assets $ 43,920 $ 44,413  
    Selected non-current assets (in % of total selected non-current assets) 47.00% 48.00%  
    US      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 16,935 $ 17,117 $ 18,079
    Net sales (in % of total net sales) 34.00% 35.00% 37.00%
    Total of selected non-current assets $ 28,476 $ 28,484  
    Selected non-current assets (in % of total selected non-current assets) 30.00% 31.00%  
    UK      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 1,160 $ 1,182 $ 1,277
    Net sales (in % of total net sales) 2.00% 2.00% 3.00%
    Total of selected non-current assets $ 7,957 $ 6,892  
    Selected non-current assets (in % of total selected non-current assets) 9.00% 7.00%  
    Germany      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 3,690 $ 3,634 $ 3,262
    Net sales (in % of total net sales) 8.00% 7.00% 7.00%
    Total of selected non-current assets $ 3,128 $ 2,733  
    Selected non-current assets (in % of total selected non-current assets) 3.00% 3.00%  
    France      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 2,490 $ 2,390 $ 2,269
    Net sales (in % of total net sales) 5.00% 5.00% 5.00%
    Total of selected non-current assets $ 284 $ 199  
    Japan      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 3,177 $ 3,267 $ 3,163
    Net sales (in % of total net sales) 6.00% 7.00% 6.00%
    Total of selected non-current assets $ 148 $ 145  
    Other      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 20,821 $ 20,098 $ 20,590
    Net sales (in % of total net sales) 43.00% 42.00% 40.00%
    Total of selected non-current assets $ 9,668 $ 9,399  
    Selected non-current assets (in % of total selected non-current assets) 11.00% 11.00%  
    XML 145 R78.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Segmentation of key figures (Details 5) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 49,109 $ 48,518 $ 49,414
    Net sales (in % of total net sales) 100.00% 100.00% 100.00%
    Total of selected non-current assets $ 93,581 $ 92,265  
    Selected non-current assets (in % of total selected non-current assets) 100.00% 100.00%  
    Europe [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 17,492 $ 17,079 $ 16,472
    Net sales (in % of total net sales) 36.00% 35.00% 33.00%
    Total of selected non-current assets $ 61,699 $ 59,879  
    Selected non-current assets (in % of total selected non-current assets) 66.00% 65.00%  
    Americas [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 20,899 $ 20,998 $ 22,414
    Net sales (in % of total net sales) 42.00% 43.00% 45.00%
    Total of selected non-current assets $ 29,113 $ 29,831  
    Selected non-current assets (in % of total selected non-current assets) 31.00% 32.00%  
    Asia/Africa/Australasia [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 10,718 $ 10,441 $ 10,528
    Net sales (in % of total net sales) 22.00% 22.00% 22.00%
    Total of selected non-current assets $ 2,769 $ 2,555  
    Selected non-current assets (in % of total selected non-current assets) 3.00% 3.00%  
    XML 146 R79.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Segmentation of key figures (Details 6)
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Disclosure of major customers [line items]      
    Customers with net sales over five percent No other customer accounted for 5% or more of net sales in either year.    
    Largest customer [member]      
    Disclosure of major customers [line items]      
    Percentage of entity's revenue 17.00% 16.00% 14.00%
    Highest amount of trade receivables 14.00% 14.00%  
    Second largest customer [member]      
    Disclosure of major customers [line items]      
    Percentage of entity's revenue 12.00% 12.00% 11.00%
    Highest amount of trade receivables 9.00% 9.00%  
    Third largest customer [member]      
    Disclosure of major customers [line items]      
    Percentage of entity's revenue 7.00% 6.00% 5.00%
    Highest amount of trade receivables 5.00% 6.00%  
    XML 147 R80.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Segmentation of key figures (Details 7) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 49,109 $ 48,518 $ 49,414
    Operating segments [member] | Innovative Medicines      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 33,025 $ 32,562 33,345
    Net sales, change in % 1.00% (2.00%)  
    Operating segments [member] | Innovative Medicines | Oncology [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 12,274 $ 12,790 13,304
    Net sales, change in % (4.00%) (4.00%)  
    Operating segments [member] | Innovative Medicines | Oncology [member] | Gleevec/Glivec [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 1,943 $ 3,323 4,658
    Net sales, change in % (42.00%) (29.00%)  
    Operating segments [member] | Innovative Medicines | Oncology [member] | Tasigna [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 1,841 $ 1,739 1,632
    Net sales, change in % 6.00% 7.00%  
    Operating segments [member] | Innovative Medicines | Oncology [member] | Sandostatin [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 1,612 $ 1,646 1,630
    Net sales, change in % (2.00%) 1.00%  
    Operating segments [member] | Innovative Medicines | Oncology [member] | Afinitor/Votubia [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 1,525 $ 1,516 1,607
    Net sales, change in % 1.00% (6.00%)  
    Operating segments [member] | Innovative Medicines | Oncology [member] | Exjade/Jadenu [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 1,059 $ 956 917
    Net sales, change in % 11.00% 4.00%  
    Operating segments [member] | Innovative Medicines | Oncology [member] | Tafinlar + Mekinist [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 873 $ 672 453
    Net sales, change in % 30.00%    
    Operating segments [member] | Innovative Medicines | Oncology [member] | Promacta/Revolade [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 867 635 402
    Net sales, change in % 37.00%    
    Operating segments [member] | Innovative Medicines | Oncology [member] | Votrient [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 808 729 565
    Net sales, change in % 11.00%    
    Operating segments [member] | Innovative Medicines | Oncology [member] | Jakavi [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 777 $ 581 410
    Net sales, change in % 34.00% 42.00%  
    Operating segments [member] | Innovative Medicines | Oncology [member] | Kisqali [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 76 $ 0 0
    Operating segments [member] | Innovative Medicines | Oncology [member] | Other [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 893 $ 993 1,030
    Net sales, change in % (10.00%) (4.00%)  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 20,751 $ 19,772 20,041
    Net sales, change in % 5.00% (1.00%)  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 5,368 $ 5,463 5,923
    Net sales, change in % (2.00%) (8.00%)  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Lucentis [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 1,888 $ 1,835 2,060
    Net sales, change in % 3.00% (11.00%)  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Travoprost Group [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 589 $ 619 631
    Net sales, change in % (5.00%) (2.00%)  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Systane Group [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 400 $ 377 380
    Net sales, change in % 6.00% (1.00%)  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Topical Olopatadine Group [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 284 $ 335 457
    Net sales, change in % (15.00%) (27.00%)  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Ophthalmology [member] | Other [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 2,207 $ 2,297 2,395
    Net sales, change in % (4.00%) (4.00%)  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology and Dermatology [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 4,041 $ 3,015 2,137
    Net sales, change in % 34.00% 41.00%  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology and Dermatology [member] | Cosentyx [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 2,071 $ 1,128 261
    Net sales, change in % 84.00%    
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology and Dermatology [member] | Neoral/Sandimmun(e) [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 488 $ 515 570
    Net sales, change in % (5.00%) (10.00%)  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology and Dermatology [member] | Zortress/Certican [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 414 $ 398 335
    Net sales, change in % 4.00% 19.00%  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology and Dermatology [member] | Ilaris [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 402 $ 283 236
    Net sales, change in % 42.00% 20.00%  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology and Dermatology [member] | Myfortic [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 378 $ 383 441
    Net sales, change in % (1.00%) (13.00%)  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Immunology and Dermatology [member] | Other [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 288 $ 308 294
    Net sales, change in % (6.00%) 5.00%  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 3,287 $ 3,233 2,917
    Net sales, change in % 2.00% 11.00%  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Gilenya [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 3,185 $ 3,109 2,776
    Net sales, change in % 2.00% 12.00%  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Neuroscience [member] | Other [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 102 $ 124 141
    Net sales, change in % (18.00%) (12.00%)  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Respiratory [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 1,617 $ 1,521 1,368
    Net sales, change in % 6.00% 11.00%  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Xolair [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 920 $ 835 755
    Net sales, change in % 10.00% 11.00%  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | Other [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 23 $ 31 37
    Net sales, change in % (26.00%) (16.00%)  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | COPD [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 674 $ 655 576
    Net sales, change in % 3.00% 14.00%  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | COPD [member] | Ultibro Breezhaler [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 411 $ 363 260
    Net sales, change in % 13.00% 40.00%  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | COPD [member] | Seebri Breezhaler [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 151 $ 149 150
    Net sales, change in % 1.00% (1.00%)  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Respiratory [member] | COPD [member] | Onbrez Breezhaler [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 112 $ 143 166
    Net sales, change in % (22.00%) (14.00%)  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Cardio-Metabolic [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 524 $ 184 21
    Net sales, change in % 185.00%    
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Cardio-Metabolic [member] | Entresto [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 507 170 21
    Net sales, change in % 198.00%    
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Cardio-Metabolic [member] | Other [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 17 14 0
    Net sales, change in % 21.00%    
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 5,914 $ 6,356 7,675
    Net sales, change in % (7.00%) (17.00%)  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Galvus [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 1,233 $ 1,193 1,140
    Net sales, change in % 3.00% 5.00%  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Exforge [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 960 $ 926 1,047
    Net sales, change in % 4.00% (12.00%)  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Diovan/Co-Diovan [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 957 $ 1,073 1,284
    Net sales, change in % (11.00%) (16.00%)  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Voltaren/Cataflam [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 465 $ 525 558
    Net sales, change in % (11.00%) (6.00%)  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Exelon/Exelon Patch [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 381 $ 444 728
    Net sales, change in % (14.00%) (39.00%)  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Ritalin/Focalin [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 236 $ 282 365
    Net sales, change in % (16.00%) (23.00%)  
    Operating segments [member] | Innovative Medicines | Pharmaceutical [member] | Established Medicines [member] | Other [member]      
    Disclosure of operating segments [line items]      
    Net sales to third parties from continuing operations $ 1,682 $ 1,913 $ 2,553
    Net sales, change in % (12.00%) (25.00%)  
    XML 148 R81.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Associated companies (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Disclosure of associates [line items]      
    Net income statement effect $ 1,108 $ 703 $ 266
    Other comprehensive income effect (37) 671 (153)
    Total comprehensive income effect 1,071 1,374 113
    Roche Holding AG, Switzerland      
    Disclosure of associates [line items]      
    Net income statement effect 456 464 343
    Other comprehensive income effect 108 (39) (149)
    Total comprehensive income effect 564 425 194
    GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK      
    Disclosure of associates [line items]      
    Net income statement effect 629 234 (79)
    Other comprehensive income effect (145) 710 (4)
    Total comprehensive income effect 484 944 (83)
    Others      
    Disclosure of associates [line items]      
    Net income statement effect 23 5 2
    Total comprehensive income effect $ 23 $ 5 $ 2
    XML 149 R82.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Associated companies (Details 2) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Disclosure of associates [line items]    
    Balance sheet value $ 15,370 $ 14,304
    Roche Holding AG, Switzerland    
    Disclosure of associates [line items]    
    Balance sheet value 8,121 7,644
    GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK    
    Disclosure of associates [line items]    
    Balance sheet value 7,020 6,448
    Others    
    Disclosure of associates [line items]    
    Balance sheet value $ 229 $ 212
    XML 150 R83.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Associated companies (Details 3) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Roche Holding AG, Switzerland      
    Disclosure of associates [line items]      
    Proportion of voting rights held in associate 33.30% 33.30% 33.30%
    Proportion of ownership interest in associate 6.30% 6.30% 6.30%
    Available for use intangible asset useful lives 20    
    Dividends received $ 438 $ 433  
    Publicly quoted market value of the Novartis interest $ 13,400 $ 12,400  
    GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK      
    Disclosure of associates [line items]      
    Proportion of ownership interest in associate 36.50% 36.50% 36.50%
    Available for use intangible asset useful lives 20    
    Dividends received $ 544 $ 463  
    Contribution of business to joint venture     63.50%
    XML 151 R84.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Associated companies (Details 4) - USD ($)
    $ in Millions
    		 6 Months Ended 9 Months Ended 12 Months Ended
    Jun. 30, 2017
    Sep. 30, 2017
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Disclosure of associates [line items]          
    Current assets     $ 28,208 $ 24,931  
    Non-current assets     104,871 105,193  
    Current liabilities     23,403 22,209  
    Non-current liabilities     35,449 33,024  
    Profit (loss)     7,703 6,698 $ 17,794
    Other comprehensive income     2,837 (2,333) (1,809)
    Comprehensive income     $ 10,540 4,365 $ 15,985
    Roche Holding AG, Switzerland          
    Disclosure of associates [line items]          
    Current assets $ 26,700     28,700  
    Non-current assets 56,900     61,400  
    Current liabilities 20,600     22,600  
    Non-current liabilities 26,000     27,800  
    Revenue 26,300     50,600  
    Profit (loss) 4,400     7,500  
    Other comprehensive income 200     700  
    Comprehensive income $ 4,600     8,200  
    GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK          
    Disclosure of associates [line items]          
    Current assets   $ 3,300   4,000  
    Non-current assets   20,600   21,100  
    Current liabilities   2,600   3,100  
    Non-current liabilities   2,000   2,100  
    Revenue   5,300   6,500  
    Profit (loss)   600   600  
    Other comprehensive income   (400)   1,600  
    Comprehensive income   $ 200   $ 2,200  
    XML 152 R85.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Associated companies (Details 5) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Disclosure of associates [line items]    
    Balance sheet value $ 15,370 $ 14,304
    Roche Holding AG, Switzerland    
    Disclosure of associates [line items]    
    Novartis share of estimated net assets 2,412  
    Novartis share of re-appraised intangible assets 673  
    Implicit Novartis goodwill 2,915  
    Current value of share in net identifiable assets and goodwill 6,000  
    Accumulated equity accounting adjustments and translation effects less dividends received 2,121  
    Balance sheet value 8,121 7,644
    GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK    
    Disclosure of associates [line items]    
    Novartis share of estimated net assets 1,505  
    Novartis share of re-appraised intangible assets 3,852  
    Implicit Novartis goodwill 1,763  
    Current value of share in net identifiable assets and goodwill 7,120  
    Accumulated equity accounting adjustments and translation effects less dividends received (100)  
    Balance sheet value $ 7,020 $ 6,448
    XML 153 R86.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Associated companies (Details 6) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Disclosure of associates [line items]      
    Net income statement effect $ 1,108 $ 703 $ 266
    Roche Holding AG, Switzerland      
    Disclosure of associates [line items]      
    Novartis share of current year consolidated net income 669 678 650
    Prior year adjustment (67) (68) (157)
    Amortization of fair value adjustments relating to intangible assets (146) (146) (150)
    Net income statement effect 456 464 343
    Amortization of fair value adjustments relating to intangible assets tax 42 42 41
    GlaxoSmithKline Consumer Healthcare Holdings Ltd., UK      
    Disclosure of associates [line items]      
    Novartis share of current year consolidated net income 589 268 (17)
    Prior year adjustment 47 (22)  
    Amortization of fair value adjustments relating to intangible assets (7) (12) (62)
    Net income statement effect 629 234 (79)
    Amortization of fair value adjustments relating to intangible assets tax $ 1 $ 2 $ 18
    XML 154 R87.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Interest expense and other financial income and expense (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Interest expense [abstract]      
    Interest expense $ (758) $ (709) $ (669)
    Income/expense arising from discounting long-term liabilities (19) 2 14
    Interest expense $ (777) $ (707) $ (655)
    XML 155 R88.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Interest expense and other financial income and expense (Details 2) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Other financial income and expense [abstract]      
    Interest income $ 110 $ 43 $ 33
    Dividend income 1 1 1
    Net capital losses on available-for-sale securities (1) (1) (8)
    Income on forward contracts and options     1
    Impairment of commodities and available-for-sale securities, net 12 7 (132)
    Other financial expense (25) (20) (23)
    Monetary loss from hyperinflation     (72)
    Currency result, net (58) (477) (254)
    Total other financial income and expense $ 39 $ (447) $ (454)
    XML 156 R89.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Taxes (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Statement [line items]      
    Income before taxes from continuing operations $ 8,999 $ 7,817 $ 8,134
    Income loss before taxes from discontinued operations     12,479
    Total Income before taxes 8,999 7,817 20,613
    Switzerland      
    Statement [line items]      
    Income before taxes from continuing operations 5,289 3,110 5,765
    Foreign      
    Statement [line items]      
    Income before taxes from continuing operations $ 3,710 $ 4,707 $ 2,369
    XML 157 R90.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Taxes (Details 2) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Statement [line items]      
    Current income tax expense from continuing operations $ (2,056) $ (2,127) $ (1,650)
    Deferred income tax expense from continuing operations 760 1,008 544
    Income tax expense from continuing operations (1,296) (1,119) (1,106)
    Income tax expense from discontinued operations     (1,713)
    Total Income Tax Expense (1,296) (1,119) (2,819)
    Switzerland      
    Statement [line items]      
    Current income tax expense from continuing operations (462) (709) (317)
    Deferred income tax expense from continuing operations (298) 765 (68)
    Foreign      
    Statement [line items]      
    Current income tax expense from continuing operations (1,594) (1,418) (1,333)
    Deferred income tax expense from continuing operations $ 1,058 $ 243 $ 612
    XML 158 R91.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Taxes (Details 3) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Statement [line items]      
    Applicable tax rate 14.50% 13.20% 12.40%
    Effect of disallowed expenditures 3.40% 3.50% 3.50%
    Effect of utilization of tax losses brought forward from prior periods (0.10%) (0.20%) (0.20%)
    Effect of income taxed at reduced rates (0.20%) (0.20%) (0.30%)
    Effect of tax credits and allowances (2.20%) (2.80%) (2.70%)
    Effect of release of contingent consideration liability (1.20%) 0.00% 0.00%
    Effect of tax rate change on current and deferred tax assets and liabilities 0.70% 0.20% (0.50%)
    Effect of write off of deferred tax assets 0.00% 0.50% 0.00%
    Effect of write down and reversal of write down of investments in subsidiaries (1.10%) (1.00%) (0.90%)
    Effect of tax benefits expiring in 2017 (0.80%) (0.50%) (0.40%)
    Effect of non-deductible losses in Venezuela 0.00% 1.30% 1.20%
    Effect of prior year items 1.20% 0.20% 1.00%
    Effect of other items 0.20% 0.10% 0.50%
    Effective tax rate for continuing operations 14.40% 14.30% 13.60%
    Effective tax rate for discontinued operations     13.70%
    Effective tax rate 14.40% 14.30% 13.70%
    Effective income tax rate reconciliation change in uncertain tax positions   5.10%  
    Effective income tax rate reconciliation other adjustments   1.20%  
    Effective income tax rate reconciliation change in enacted tax rate   (6.20%)  
    Percentage impact of new tax law change in deferred tax assets and liabilities and current tax liabilities 0.70%    
    Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense $ 7 $ 18 $ 15
    XML 159 R92.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Earnings per share (Details)
    $ / shares in Units, shares in Millions, $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    USD ($)
    $ / shares
    shares
    Dec. 31, 2016
    USD ($)
    $ / shares
    shares
    Dec. 31, 2015
    USD ($)
    $ / shares
    shares
    Earnings per share [line items]      
    Profit/loss attributable to shareholders of Novartis AG | $ $ 7,703 $ 6,712 $ 17,783
    Weighted average number of shares outstanding used in the basic earnings per share | shares 2,346 2,378 2,403
    Adjustment for vesting of restricted shares, restricted share units and dilutive shares from options | shares 25 22 35
    Weighted average number of shares in diluted earnings per share | shares 2,371 2,400 2,438
    Basic earnings per share, Continuing operations $ 3.28 $ 2.82 $ 2.92
    Basic earnings per share, Discontinued operations     4.48
    Total basic earnings per share 3.28 2.82 7.40
    Diluted earnings per share, Continuing operations 3.25 2.80 2.88
    Diluted earnings per share, Discontinued operations     4.41
    Total diluted earnings per share $ 3.25 $ 2.80 $ 7.29
    Options excluded from the calculation 0 0 0
    Continuing operations [member]      
    Earnings per share [line items]      
    Profit/loss attributable to shareholders of Novartis AG | $ $ 7,703 $ 6,712 $ 7,025
    Discontinued operations [member]      
    Earnings per share [line items]      
    Profit/loss attributable to shareholders of Novartis AG | $     $ 10,758
    XML 160 R93.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Changes in consolidated statements of comprehensive income (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Changes in consolidated statements of comprehensive income [line items]      
    Fair value adjustments on financial instruments $ 50 $ (98) $ 48
    Net actuarial gains/losses from defined benefit plans 851 (515) (147)
    Net investment hedge (237)    
    Currency translation effects 2,210 (2,391) (1,662)
    Fair value adjustments on marketable securities      
    Changes in consolidated statements of comprehensive income [line items]      
    Value adjustments on comprehensive income at beginning of period 348 461 433
    Fair value adjustments on financial instruments 38 (113) 28
    Total value adjustments 38 (113) 28
    Value adjustments on comprehensive income at end of period 386 348 461
    Fair value adjustments on deferred cash flow hedges      
    Changes in consolidated statements of comprehensive income [line items]      
    Value adjustments on comprehensive income at beginning of period (3) (18) (38)
    Fair value adjustments on financial instruments 12 15 20
    Total value adjustments 12 15 20
    Value adjustments on comprehensive income at end of period 9 (3) (18)
    Actuarial gains/losses from defined benefit plans      
    Changes in consolidated statements of comprehensive income [line items]      
    Value adjustments on comprehensive income at beginning of period (5,915) (5,413) (5,366)
    Net actuarial gains/losses from defined benefit plans 851 (514) (147)
    Total value adjustments 851 (514) (147)
    Fair value adjustments related to divestments   12 100
    Value adjustments on comprehensive income at end of period (5,064) (5,915) (5,413)
    Other comprehensive income net of tax gains/losses on remeasurements of defined benefit plans related to discontinued operations     10
    Net investment hedge [member]      
    Changes in consolidated statements of comprehensive income [line items]      
    Net investment hedge (237)    
    Total value adjustments (237)    
    Value adjustments on comprehensive income at end of period (237)    
    Cumulative currency translation effects      
    Changes in consolidated statements of comprehensive income [line items]      
    Value adjustments on comprehensive income at beginning of period (1,642) 747 2,406
    Currency translation effects 2,208 (2,389) (1,659)
    Total value adjustments 2,208 (2,389) (1,659)
    Value adjustments on comprehensive income at end of period 566 (1,642) 747
    Other comprehensive income net of tax exchange differences on translation related to discontinued operations     29
    Total value adjustments      
    Changes in consolidated statements of comprehensive income [line items]      
    Value adjustments on comprehensive income at beginning of period (7,212) (4,223) (2,565)
    Fair value adjustments on financial instruments 50 (98) 48
    Net actuarial gains/losses from defined benefit plans 851 (514) (147)
    Net investment hedge (237)    
    Currency translation effects 2,208 (2,389) (1,659)
    Total value adjustments 2,872 (3,001) (1,758)
    Fair value adjustments related to divestments   12 100
    Value adjustments on comprehensive income at end of period $ (4,340) $ (7,212) $ (4,223)
    XML 161 R94.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Changes in consolidated statements of comprehensive income (Details 2) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Changes in consolidated statements of comprehensive income [line items]      
    Associated companies' movements in comprehensive income $ (37) $ 671 $ (153)
    Deferred tax on above items (661) 138  
    Fair value adjustments on financial instruments 50 (98) 48
    Impact of new tax law income tax relating to available-for-sale financia investments previously recognized through OCI 18    
    Fair value adjustments on marketable securities      
    Changes in consolidated statements of comprehensive income [line items]      
    Value adjustments on comprehensive income at beginning of period 348 461 433
    Available-for-sale marketable securities 11 1 (130)
    Available-for-sale financial investments 47 (87) 80
    Associated companies' movements in comprehensive income     (8)
    Marketable securities sold   (1) (1)
    Other financial assets sold (109) (154) (103)
    Impaired loss on financial assets transferred to the income statement 102 131 194
    Deferred tax on above items (13) (3) (4)
    Fair value adjustments on financial instruments 38 (113) 28
    Value adjustments on comprehensive income at end of period 386 348 461
    Fair value adjustments on deferred cash flow hedges      
    Changes in consolidated statements of comprehensive income [line items]      
    Value adjustments on comprehensive income at beginning of period (3) (18) (38)
    Amortized net losses on cash flow hedges transferred to the consolidated income statement 13 16 21
    Deferred tax on above items (1) (1) (1)
    Fair value adjustments on financial instruments 12 15 20
    Value adjustments on comprehensive income at end of period 9 (3) (18)
    Total fair value adjustments      
    Changes in consolidated statements of comprehensive income [line items]      
    Value adjustments on comprehensive income at beginning of period 345 443 395
    Available-for-sale marketable securities 11 1 (130)
    Available-for-sale financial investments 47 (87) 80
    Associated companies' movements in comprehensive income     (8)
    Marketable securities sold   (1) (1)
    Other financial assets sold (109) (154) (103)
    Amortized net losses on cash flow hedges transferred to the consolidated income statement 13 16 21
    Impaired loss on financial assets transferred to the income statement 102 131 194
    Deferred tax on above items (14) (4) (5)
    Fair value adjustments on financial instruments 50 (98) 48
    Value adjustments on comprehensive income at end of period $ 395 $ 345 $ 443
    XML 162 R95.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Changes in consolidated statements of comprehensive income (Details 3) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Comprehensive income [abstract]      
    Cumulative currency translation losses recycled throught income statement $ 0 $ 0 $ 10
    XML 163 R96.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Changes in consolidated statements of comprehensive income (Details 4) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Remeasurements from defined benefit plans [line items]      
    Defined benefit pension plans before tax $ 1,367 $ (667) $ (252)
    Other post-employment benefit plans before tax 76 12 168
    Taxation on above items (592) 140 (63)
    Remeasurements from defined benefit plans, total after tax 851 (515) $ (147)
    Impact of new tax law income tax relating to deferred tax assets on US post retirement previously recognized through OCI $ (272)    
    Non-controlling interests [member]      
    Remeasurements from defined benefit plans [line items]      
    Remeasurements from defined benefit plans, total after tax   $ (1)  
    XML 164 R97.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Property, plant and equipment (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Movements of property, plant and equipment [roll forward]    
    Property, plant and equipment at beginning of period $ 15,641  
    Additions 1,728 $ 1,835
    Property, plant and equipment at end of period 16,464 15,641
    Net book value of Property, plant and equipment under finance lease contracts 78 81
    Commitments for purchases of property, plant and equipment 318 223
    Capitalized borrowing costs 9 9
    Gross carrying amount    
    Movements of property, plant and equipment [roll forward]    
    Property, plant and equipment at beginning of period 31,296 31,448
    Additions 1,728 1,835
    Disposals and derecognitions (1,011) (861)
    Currency translation effects 1,997 (1,126)
    Property, plant and equipment at end of period 34,010 31,296
    Accumulated depreciation    
    Movements of property, plant and equipment [roll forward]    
    Property, plant and equipment at beginning of period (15,655) (15,466)
    Depreciation charge (1,520) (1,489)
    Accumulated depreciation on disposals and derecognitions 849 793
    Impairment charge (189) (122)
    Reversal of impairment charge 32 20
    Currency translation effects (1,063) 609
    Property, plant and equipment at end of period (17,546) (15,655)
    Land    
    Movements of property, plant and equipment [roll forward]    
    Property, plant and equipment at beginning of period 647  
    Property, plant and equipment at end of period 680 647
    Land | Gross carrying amount    
    Movements of property, plant and equipment [roll forward]    
    Property, plant and equipment at beginning of period 687 688
    Reclassifications 5 4
    Additions 13 24
    Disposals and derecognitions (23) (8)
    Currency translation effects 38 (21)
    Property, plant and equipment at end of period 720 687
    Land | Accumulated depreciation    
    Movements of property, plant and equipment [roll forward]    
    Property, plant and equipment at beginning of period (40) (40)
    Depreciation charge (3) (3)
    Accumulated depreciation on disposals and derecognitions 6 5
    Impairment charge   (3)
    Currency translation effects (3) 1
    Property, plant and equipment at end of period (40) (40)
    Buildings    
    Movements of property, plant and equipment [roll forward]    
    Property, plant and equipment at beginning of period 7,677  
    Property, plant and equipment at end of period 8,081 7,677
    Buildings | Gross carrying amount    
    Movements of property, plant and equipment [roll forward]    
    Property, plant and equipment at beginning of period 13,113 12,857
    Reclassifications 508 630
    Additions 104 176
    Disposals and derecognitions (324) (178)
    Currency translation effects 663 (372)
    Property, plant and equipment at end of period 14,064 13,113
    Buildings | Accumulated depreciation    
    Movements of property, plant and equipment [roll forward]    
    Property, plant and equipment at beginning of period (5,436) (5,188)
    Depreciation charge (510) (530)
    Accumulated depreciation on disposals and derecognitions 275 157
    Impairment charge (25) (47)
    Reversal of impairment charge   6
    Currency translation effects (287) 166
    Property, plant and equipment at end of period (5,983) (5,436)
    Construction in progress    
    Movements of property, plant and equipment [roll forward]    
    Property, plant and equipment at beginning of period 2,665  
    Property, plant and equipment at end of period 2,330 2,665
    Construction in progress | Gross carrying amount    
    Movements of property, plant and equipment [roll forward]    
    Property, plant and equipment at beginning of period 2,680 2,810
    Reclassifications (1,617) (1,226)
    Additions 1,186 1,226
    Disposals and derecognitions (71) (19)
    Currency translation effects 190 (111)
    Property, plant and equipment at end of period 2,368 2,680
    Construction in progress | Accumulated depreciation    
    Movements of property, plant and equipment [roll forward]    
    Property, plant and equipment at beginning of period (15) (7)
    Accumulated depreciation on disposals and derecognitions 34 1
    Impairment charge (58) (11)
    Reversal of impairment charge 2 1
    Currency translation effects (1) 1
    Property, plant and equipment at end of period (38) (15)
    Machinery and other equipment    
    Movements of property, plant and equipment [roll forward]    
    Property, plant and equipment at beginning of period 4,652  
    Property, plant and equipment at end of period 5,373 4,652
    Machinery and other equipment | Gross carrying amount    
    Movements of property, plant and equipment [roll forward]    
    Property, plant and equipment at beginning of period 14,816 15,093
    Reclassifications 1,104 592
    Additions 425 409
    Disposals and derecognitions (593) (656)
    Currency translation effects 1,106 (622)
    Property, plant and equipment at end of period 16,858 14,816
    Machinery and other equipment | Accumulated depreciation    
    Movements of property, plant and equipment [roll forward]    
    Property, plant and equipment at beginning of period (10,164) (10,231)
    Depreciation charge (1,007) (956)
    Accumulated depreciation on disposals and derecognitions 534 630
    Impairment charge (106) (61)
    Reversal of impairment charge 30 13
    Currency translation effects (772) 441
    Property, plant and equipment at end of period $ (11,485) $ (10,164)
    XML 165 R98.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Goodwill and intangible assets (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period $ 62,320  
    Additions 1,146 $ 978
    Intangible assets and goodwill at end of period 61,747 62,320
    Goodwill    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period 30,980  
    Intangible assets and goodwill at end of period 31,750 30,980
    Intangible Assets other than Goodwill    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period 31,340  
    Intangible assets and goodwill at end of period 29,997 31,340
    Acquired research and development [member]    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period 4,264  
    Intangible assets and goodwill at end of period 5,292 4,264
    Alcon brand name [member]    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period 2,980  
    Intangible assets and goodwill at end of period 2,980 2,980
    Technologies    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period 2,911  
    Intangible assets and goodwill at end of period 2,370 2,911
    Currently marketed products    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period 16,144  
    Intangible assets and goodwill at end of period 14,474 16,144
    Marketing know-how    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period 4,530  
    Intangible assets and goodwill at end of period 4,292 4,530
    Other intangible assets    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period 511  
    Intangible assets and goodwill at end of period 589 511
    Gross carrying amount [member] | Goodwill    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period 31,381 31,585
    Impact of business combinations 94 56
    Currency translation effects 704 (260)
    Intangible assets and goodwill at end of period 32,179 31,381
    Gross carrying amount [member] | Intangible Assets other than Goodwill    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period 55,137 54,348
    Impact of business combinations 1,223 1,141
    Additions 1,146 978
    Disposals and derecognitions (746) (617)
    Currency translation effects 1,237 (713)
    Intangible assets and goodwill at end of period 57,997 55,137
    Gross carrying amount [member] | Acquired research and development [member]    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period 5,150 4,119
    Impact of business combinations 1,223 690
    Reclassifications (389) (158)
    Additions 697 599
    Disposals and derecognitions (353) (23)
    Currency translation effects 134 (77)
    Intangible assets and goodwill at end of period 6,462 5,150
    Gross carrying amount [member] | Alcon brand name [member]    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period 2,980 2,980
    Intangible assets and goodwill at end of period 2,980 2,980
    Gross carrying amount [member] | Technologies    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period 6,548 6,563
    Additions 5  
    Disposals and derecognitions (1)  
    Currency translation effects 86 (15)
    Intangible assets and goodwill at end of period 6,638 6,548
    Gross carrying amount [member] | Currently marketed products    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period 33,007 33,385
    Impact of business combinations   451
    Reclassifications 175 6
    Additions 282 223
    Disposals and derecognitions (328) (464)
    Currency translation effects 969 (594)
    Intangible assets and goodwill at end of period 34,105 33,007
    Gross carrying amount [member] | Marketing know-how    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period 5,960 5,960
    Intangible assets and goodwill at end of period 5,960 5,960
    Gross carrying amount [member] | Other intangible assets    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period 1,492 1,341
    Reclassifications 214 152
    Additions 162 156
    Disposals and derecognitions (64) (130)
    Currency translation effects 48 (27)
    Intangible assets and goodwill at end of period 1,852 1,492
    Accumulated depreciation [member]    
    Disclosure of detailed information about intangible assets [line items]    
    Amortization charge (3,690) (3,861)
    Accumulated impairments on disposals and derecognitions 730 535
    Impairment charge (709) (591)
    Accumulated depreciation [member] | Goodwill    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period (401) (411)
    Currency translation effects (28) 10
    Intangible assets and goodwill at end of period (429) (401)
    Accumulated depreciation [member] | Intangible Assets other than Goodwill    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period (23,797) (20,131)
    Currency translation effects (534) 251
    Intangible assets and goodwill at end of period (28,000) (23,797)
    Accumulated depreciation [member] | Acquired research and development [member]    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period (886) (650)
    Reclassifications 6 225
    Accumulated impairments on disposals and derecognitions 352 22
    Impairment charge (615) (490)
    Currency translation effects (27) 7
    Intangible assets and goodwill at end of period (1,170) (886)
    Accumulated depreciation [member] | Technologies    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period (3,637) (3,070)
    Amortization charge (577) (576)
    Currency translation effects (54) 9
    Intangible assets and goodwill at end of period (4,268) (3,637)
    Accumulated depreciation [member] | Currently marketed products    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period (16,863) (14,221)
    Reclassifications (6) (225)
    Amortization charge (2,571) (2,926)
    Accumulated impairments on disposals and derecognitions 317 390
    Impairment charge (92) (96)
    Currency translation effects (416) 215
    Intangible assets and goodwill at end of period (19,631) (16,863)
    Accumulated depreciation [member] | Marketing know-how    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period (1,430) (1,192)
    Amortization charge (238) (238)
    Intangible assets and goodwill at end of period (1,668) (1,430)
    Accumulated depreciation [member] | Other intangible assets    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible assets and goodwill at beginning of period (981) (998)
    Amortization charge (304) (121)
    Accumulated impairments on disposals and derecognitions 61 123
    Impairment charge (2) (5)
    Currency translation effects (37) 20
    Intangible assets and goodwill at end of period $ (1,263) $ (981)
    XML 166 R99.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Goodwill and intangible assets (Details 2) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Disclosure of detailed information about intangible assets [line items]    
    Net book value $ 61,747 $ 62,320
    Operating segments [member] | Innovative Medicines    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 31,571 31,630
    Operating segments [member] | Sandoz    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 10,993 10,774
    Operating segments [member] | Alcon    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 16,176 16,914
    Operating segments [member] | Corporate    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 3,007 3,002
    Goodwill    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 31,750 30,980
    Goodwill | Operating segments [member] | Innovative Medicines    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 15,237 15,010
    Goodwill | Operating segments [member] | Sandoz    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 8,210 7,669
    Goodwill | Operating segments [member] | Alcon    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 8,295 8,293
    Goodwill | Operating segments [member] | Corporate    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 8 8
    Intangible Assets other than Goodwill    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 29,997 31,340
    Intangible Assets other than Goodwill | Operating segments [member] | Innovative Medicines    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 16,334 16,620
    Intangible Assets other than Goodwill | Operating segments [member] | Sandoz    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 2,783 3,105
    Intangible Assets other than Goodwill | Operating segments [member] | Alcon    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 7,881 8,621
    Intangible Assets other than Goodwill | Operating segments [member] | Corporate    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 2,999 2,994
    Acquired research and development [member]    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 5,292 4,264
    Acquired research and development [member] | Operating segments [member] | Innovative Medicines    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 4,368 3,512
    Acquired research and development [member] | Operating segments [member] | Sandoz    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 625 613
    Acquired research and development [member] | Operating segments [member] | Alcon    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 291 139
    Acquired research and development [member] | Operating segments [member] | Corporate    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 8  
    Alcon brand name [member]    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 2,980 2,980
    Alcon brand name [member] | Operating segments [member] | Corporate    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 2,980 2,980
    Technologies    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 2,370 2,911
    Technologies | Operating segments [member] | Innovative Medicines    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 9 11
    Technologies | Operating segments [member] | Sandoz    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 539 563
    Technologies | Operating segments [member] | Alcon    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 1,822 2,337
    Currently marketed products    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 14,474 16,144
    Currently marketed products | Operating segments [member] | Innovative Medicines    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 11,604 12,821
    Currently marketed products | Operating segments [member] | Sandoz    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 1,589 1,904
    Currently marketed products | Operating segments [member] | Alcon    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 1,281 1,419
    Marketing know-how    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 4,292 4,530
    Marketing know-how | Operating segments [member] | Alcon    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 4,292 4,530
    Other intangible assets    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 589 511
    Other intangible assets | Operating segments [member] | Innovative Medicines    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 353 276
    Other intangible assets | Operating segments [member] | Sandoz    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 30 25
    Other intangible assets | Operating segments [member] | Alcon    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value 195 196
    Other intangible assets | Operating segments [member] | Corporate    
    Disclosure of detailed information about intangible assets [line items]    
    Net book value $ 11 $ 14
    XML 167 R100.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Goodwill and intangible assets (Details 3) - Operating segments [member]
    Dec. 31, 2017
    Innovative Medicines  
    Disclosure of detailed information about intangible assets [line items]  
    Terminal Growth Rate 1.50%
    Discount Rate (post-tax) 7.00%
    Sandoz  
    Disclosure of detailed information about intangible assets [line items]  
    Terminal Growth Rate 2.00%
    Discount Rate (post-tax) 7.00%
    Alcon  
    Disclosure of detailed information about intangible assets [line items]  
    Terminal Growth Rate 3.00%
    Discount Rate (post-tax) 7.00%
    Corporate  
    Disclosure of detailed information about intangible assets [line items]  
    Terminal Growth Rate 2.60%
    Discount Rate (post-tax) 7.00%
    XML 168 R101.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Goodwill and intangible assets (Details 4) - Continuing operations - Operating segments [member] - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Disclosure of detailed information about intangible assets [line items]    
    Intangible asset impairment charges $ (709) $ (591)
    Description of growth rate The discount rates for all Divisions consider the Group’s weighted average cost of capital, adjusted to approximate the weighted average cost of capital of a comparable market participant.  
    Innovative Medicines    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible asset impairment charges $ (591) (522)
    Sandoz    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible asset impairment charges (61) (65)
    Alcon    
    Disclosure of detailed information about intangible assets [line items]    
    Intangible asset impairment charges $ (57) $ (4)
    XML 169 R102.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Deferred tax assets and liabilities (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Statement [line items]          
    Gross deferred tax assets     $ 8,380 $ 10,297 $ 9,306
    Gross deferred tax liabilities     (5,319) (6,920) (6,704)
    Net deferred tax balance $ 3,061 $ 2,602 3,061 3,377 2,602
    Movement in deferred tax balance [roll forward]          
    Net deferred tax balance at beginning of period 3,377 2,602      
    Credited/(charged) to income 760 1,008      
    Charged to equity (101) (44)      
    Credited/(charged) to other comprehensive income (661) 138      
    Impact of business combinations (317) (336)      
    Other movements 3 9      
    Net deferred tax balance at end of period 3,061 3,377      
    Offsetting of deferred tax assets and liabilities within the same tax jurisdiction     151 263  
    Deferred tax assets     8,229 10,034  
    Deferred tax liabilities     (5,168) (6,657)  
    Property, plant and equipment [member]          
    Statement [line items]          
    Gross deferred tax assets     137 224 216
    Gross deferred tax liabilities     (613) (629) (639)
    Net deferred tax balance (476) (423) (476) (405) (423)
    Movement in deferred tax balance [roll forward]          
    Net deferred tax balance at beginning of period (405) (423)      
    Credited/(charged) to income (30) (13)      
    Impact of business combinations   4      
    Other movements (41) 27      
    Net deferred tax balance at end of period (476) (405)      
    Intangible assets [member]          
    Statement [line items]          
    Gross deferred tax assets     1,287 1,331 611
    Gross deferred tax liabilities     (2,985) (4,019) (3,962)
    Net deferred tax balance (1,698) (3,351) (1,698) (2,688) (3,351)
    Movement in deferred tax balance [roll forward]          
    Net deferred tax balance at beginning of period (2,688) (3,351)      
    Credited/(charged) to income 1,279 1,057      
    Impact of business combinations (322) (400)      
    Other movements 33 6      
    Net deferred tax balance at end of period (1,698) (2,688)      
    Pensions and other benefit obligations of associates [member]          
    Statement [line items]          
    Gross deferred tax assets     1,090 1,839 1,730
    Gross deferred tax liabilities     (254) (358) (401)
    Net deferred tax balance 836 1,329 836 1,481 1,329
    Movement in deferred tax balance [roll forward]          
    Net deferred tax balance at beginning of period 1,481 1,329      
    Credited/(charged) to income (90) 53      
    Credited/(charged) to other comprehensive income (592) 140      
    Other movements 37 (41)      
    Net deferred tax balance at end of period 836 1,481      
    Inventories [member]          
    Statement [line items]          
    Gross deferred tax assets     3,786 4,160 3,821
    Gross deferred tax liabilities     (455) (511) (565)
    Net deferred tax balance 3,331 3,256 3,331 3,649 3,256
    Movement in deferred tax balance [roll forward]          
    Net deferred tax balance at beginning of period 3,649 3,256      
    Credited/(charged) to income (304) 373      
    Other movements (14) 20      
    Net deferred tax balance at end of period 3,331 3,649      
    Tax loss carryforwards [member]          
    Statement [line items]          
    Gross deferred tax assets     97 146 62
    Gross deferred tax liabilities     (9)   (5)
    Net deferred tax balance 88 57 88 146 57
    Movement in deferred tax balance [roll forward]          
    Net deferred tax balance at beginning of period 146 57      
    Credited/(charged) to income (49) 55      
    Impact of business combinations 5 23      
    Other movements (14) 11      
    Net deferred tax balance at end of period 88 146      
    Other assets, provisions and accruals [member]          
    Statement [line items]          
    Gross deferred tax assets     1,983 2,597 2,866
    Gross deferred tax liabilities     (1,003) (1,403) (1,132)
    Net deferred tax balance 980 1,734 $ 980 $ 1,194 $ 1,734
    Movement in deferred tax balance [roll forward]          
    Net deferred tax balance at beginning of period 1,194 1,734      
    Credited/(charged) to income (46) (517)      
    Charged to equity (101) (44)      
    Credited/(charged) to other comprehensive income (69) (2)      
    Impact of business combinations   37      
    Other movements 2 (14)      
    Net deferred tax balance at end of period $ 980 $ 1,194      
    XML 170 R103.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Deferred tax assets and liabilities (Details 2) - USD ($)
    $ in Billions
    Dec. 31, 2017
    Dec. 31, 2016
    Investments in subsidiaries [member]    
    Statement [line items]    
    Temporary differences on which no deferred tax has been provided as they are permanent in nature $ 3 $ 2
    Goodwill from acquisitions [member]    
    Statement [line items]    
    Temporary differences on which no deferred tax has been provided as they are permanent in nature $ (29) $ (28)
    XML 171 R104.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Deferred tax assets and liabilities (Details 3) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Statement [line items]      
    Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets $ 2,659 $ 2,617  
    Tax loss carryforwards expired 1 19 $ 13
    One year [member]      
    Statement [line items]      
    Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets 40 33  
    Two years [member]      
    Statement [line items]      
    Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets 68 35  
    Three years [member]      
    Statement [line items]      
    Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets 92 55  
    Four years [member]      
    Statement [line items]      
    Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets 51 78  
    Five years [member]      
    Statement [line items]      
    Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets 83 98  
    More than five years [member]      
    Statement [line items]      
    Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets 2,325 2,318  
    Capitalized [member]      
    Statement [line items]      
    Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets 1,724 1,963  
    Capitalized [member] | One year [member]      
    Statement [line items]      
    Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets 3 12  
    Capitalized [member] | Two years [member]      
    Statement [line items]      
    Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets 4 5  
    Capitalized [member] | Three years [member]      
    Statement [line items]      
    Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets 5 5  
    Capitalized [member] | Four years [member]      
    Statement [line items]      
    Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets 25 3  
    Capitalized [member] | Five years [member]      
    Statement [line items]      
    Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets 16 25  
    Capitalized [member] | More than five years [member]      
    Statement [line items]      
    Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets 1,671 1,913  
    Not capitalized [member]      
    Statement [line items]      
    Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets 935 654  
    Not capitalized [member] | One year [member]      
    Statement [line items]      
    Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets 37 21  
    Not capitalized [member] | Two years [member]      
    Statement [line items]      
    Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets 64 30  
    Not capitalized [member] | Three years [member]      
    Statement [line items]      
    Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets 87 50  
    Not capitalized [member] | Four years [member]      
    Statement [line items]      
    Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets 26 75  
    Not capitalized [member] | Five years [member]      
    Statement [line items]      
    Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets 67 73  
    Not capitalized [member] | More than five years [member]      
    Statement [line items]      
    Gross Value of tax loss carryforwards that have or nave not been capitalized as deferred tax assets $ 654 $ 405  
    XML 172 R105.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Deferred tax assets and liabilities (Details 4) - USD ($)
    $ in Billions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Statement [line items]    
    Deferred tax asset expected to have an impact on current taxes payable after more than 12 months $ 3.5 $ 4.8
    Deferred tax liabilities expected to have an impact on current taxes payable after more than 12 months 4.4 5.9
    Unremitted earnings retained by consolidated entities for reinvestment 66.0 63.0
    Provision for income taxes on unremitted earnings $ 0.0 $ 0.0
    XML 173 R106.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Deferred tax assets and liabilities (Details 5)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    USD ($)
    Deferred tax asset and liability valuation [abstract]  
    Items previously recognized in consolidated income statement $ (24)
    Items previously recognized in other comprehensive income (254)
    Items previously recognized in retained earnings (71)
    Total revaluation of deferred tax assets and liabilities (349)
    Total revaluation of current income tax liabilities (37)
    Total revaluation of deferred tax assets and liabilities and current income tax liabilities (386)
    Income statement [member]  
    Deferred tax asset and liability valuation [abstract]  
    Items previously recognized in consolidated income statement (24)
    Total revaluation of deferred tax assets and liabilities (24)
    Total revaluation of current income tax liabilities (37)
    Total revaluation of deferred tax assets and liabilities and current income tax liabilities (61)
    Equity [member]  
    Deferred tax asset and liability valuation [abstract]  
    Items previously recognized in other comprehensive income (254)
    Items previously recognized in retained earnings (71)
    Total revaluation of deferred tax assets and liabilities (325)
    Total revaluation of deferred tax assets and liabilities and current income tax liabilities $ (325)
    Impact of new tax law effective tax rate after implemetation of new law changes 21.00%
    Impact of new tax law tax on unremitted earnings period allowed for payment 8 years
    Impact of new tax law income tax relating to deferred tax assets on unremitted earnings $ 70
    XML 174 R107.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Financial and other non-current assets (Details) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Statement [line items]    
    Available-for-sale long-term financial investments $ 1,275 $ 1,096
    Long-term receivables from customers 197 231
    Minimum lease payments from finance lease agreements 122 147
    Contingent consideration receivables 394 586
    Long-term loans, advances and security deposits 255 136
    Total financial assets $ 2,243 $ 2,196
    XML 175 R108.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Financial and other non-current assets (Details 2) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Statement [line items]    
    Deferred compensation plans assets $ 484 $ 451
    Prepaid post-employment benefit plans assets 133 47
    Other non-current assets 201 200
    Total other non-current assets $ 818 $ 698
    XML 176 R109.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Financial and other non-current assets (Details 3) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Disclosure of finance lease and operating lease by lessor [line items]    
    Total future payments $ 294 $ 336
    Unearned interest income (23) (25)
    Minimum lease payments from finance lease agreements, at present value 271 311
    Provision (76) (80)
    Net book value 195 231
    Not later than one year    
    Disclosure of finance lease and operating lease by lessor [line items]    
    Total future payments 83 91
    Unearned interest income (7) (5)
    Minimum lease payments from finance lease agreements, at present value 76 86
    Provision (3) (2)
    Net book value 73 84
    Between one and five years    
    Disclosure of finance lease and operating lease by lessor [line items]    
    Total future payments 180 182
    Unearned interest income (14) (16)
    Minimum lease payments from finance lease agreements, at present value 166 166
    Provision (59) (37)
    Net book value 107 129
    Later than five years    
    Disclosure of finance lease and operating lease by lessor [line items]    
    Total future payments 31 63
    Unearned interest income (2) (4)
    Minimum lease payments from finance lease agreements, at present value 29 59
    Provision (14) (41)
    Net book value $ 15 $ 18
    XML 177 R110.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Inventories (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Inventory      
    Inventory $ 6,867 $ 6,255  
    Amount of inventory recognized as expense (10,300) (10,300) $ (10,500)
    Inventory provisions (470) (283) (356)
    Reversed inventory Provisions 189 67 $ 148
    Raw material, consumables      
    Inventory      
    Inventory 841 705  
    Work in progress      
    Inventory      
    Inventory 2,957 2,700  
    Finished products      
    Inventory      
    Inventory $ 3,069 $ 2,850  
    XML 178 R111.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Trade receivables (Details) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Dec. 31, 2014
    Disclosure of provision matrix [line items]        
    Total trade receivables, net $ 8,600 $ 8,202    
    Trade receivables [member]        
    Disclosure of provision matrix [line items]        
    Total trade receivables, net 8,600 8,202    
    Trade receivables [member] | Gross carrying amount [member]        
    Disclosure of provision matrix [line items]        
    Total trade receivables, net 8,790 8,364    
    Trade receivables [member] | Provision for doubtful receivable [member]        
    Disclosure of provision matrix [line items]        
    Total trade receivables, net $ (190) $ (162) $ (142) $ (156)
    XML 179 R112.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Trade receivables (Details 2) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Disclosure of provision matrix [line items]      
    Provisions at beginning of period $ 8,202    
    Provisions at end of period 8,600 $ 8,202  
    Trade receivables [member]      
    Disclosure of provision matrix [line items]      
    Provisions at beginning of period 8,202    
    Provisions at end of period 8,600 8,202  
    Trade receivables [member] | Provision for doubtful receivable [member]      
    Disclosure of provision matrix [line items]      
    Provisions at beginning of period (162) (142) $ (156)
    Impact of divestments 12    
    Provisions for doubtful trade receivables charged to the consolidated income statement (119) (76) (68)
    Utilization of reversal of provisions for doubtful trade receivables 12 17 39
    Reversal of provisions for doubtful trade receivables 76 37 32
    Currency translation effects (9) 2 11
    Provisions at end of period $ (190) $ (162) $ (142)
    XML 180 R113.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Trade receivables (Details 3) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Dec. 31, 2014
    Analysis of overdue amounts [line items]        
    Total trade receivables, net $ 8,600 $ 8,202    
    Trade receivables [member]        
    Analysis of overdue amounts [line items]        
    Total trade receivables, net 8,600 8,202    
    Trade receivables [member] | Current [member]        
    Analysis of overdue amounts [line items]        
    Total trade receivables, net 7,758 7,386    
    Trade receivables [member] | Not later than one month [member]        
    Analysis of overdue amounts [line items]        
    Total trade receivables, net 279 262    
    Trade receivables [member] | Later than one month and not later than three months [member]        
    Analysis of overdue amounts [line items]        
    Total trade receivables, net 230 223    
    Trade receivables [member] | Later than three months and not later than six months [member]        
    Analysis of overdue amounts [line items]        
    Total trade receivables, net 137 185    
    Trade receivables [member] | Later than six months and not later than one year [member]        
    Analysis of overdue amounts [line items]        
    Total trade receivables, net 137 145    
    Trade receivables [member] | Later than one year [member]        
    Analysis of overdue amounts [line items]        
    Total trade receivables, net 249 163    
    Trade receivables [member] | Provision for doubtful receivable [member]        
    Analysis of overdue amounts [line items]        
    Total trade receivables, net $ (190) $ (162) $ (142) $ (156)
    XML 181 R114.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Trade receivables (Details 4) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Disclosure of provision matrix [line items]    
    Total trade receivables, net $ 8,600 $ 8,202
    Trade receivables [member]    
    Disclosure of provision matrix [line items]    
    Total trade receivables, net 8,600 8,202
    Trade receivables [member] | USD    
    Disclosure of provision matrix [line items]    
    Total trade receivables, net 3,451 3,432
    Trade receivables [member] | EUR    
    Disclosure of provision matrix [line items]    
    Total trade receivables, net 1,533 1,366
    Trade receivables [member] | JPY    
    Disclosure of provision matrix [line items]    
    Total trade receivables, net 600 567
    Trade receivables [member] | CNY    
    Disclosure of provision matrix [line items]    
    Total trade receivables, net 312 264
    Trade receivables [member] | RUB    
    Disclosure of provision matrix [line items]    
    Total trade receivables, net 268 347
    Trade receivables [member] | BRL    
    Disclosure of provision matrix [line items]    
    Total trade receivables, net 237 222
    Trade receivables [member] | GBP    
    Disclosure of provision matrix [line items]    
    Total trade receivables, net 208 160
    Trade receivables [member] | AUD    
    Disclosure of provision matrix [line items]    
    Total trade receivables, net 165 147
    Trade receivables [member] | CHF    
    Disclosure of provision matrix [line items]    
    Total trade receivables, net 127 135
    Trade receivables [member] | CAD    
    Disclosure of provision matrix [line items]    
    Total trade receivables, net 73 97
    Trade receivables [member] | Others    
    Disclosure of provision matrix [line items]    
    Total trade receivables, net $ 1,626 $ 1,465
    XML 182 R115.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Trade receivables (Details 5) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Disclosure of provision matrix [line items]    
    Current trade receivables from closely monitored countries $ 1,733 $ 1,717
    Current trade receivables from closely monitored countries past due more than one year 124 82
    Current trade receivables from closely monitored countries past due more than one year, provisions recorded $ 95 $ 63
    XML 183 R116.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Statement [line items]    
    Debt securities $ 328 $ 306
    Fund investments 34 31
    Total available for sale marketable securities 362 337
    Commodities 106 94
    Time deposits with original maturity more than 90 days 125 108
    Derivative financial instruments 31 230
    Accrued interest on debt securities and time deposits 1 1
    Total marketable securities, commodities, time deposits and derivative financial instruments $ 625 $ 770
    XML 184 R117.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 2) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Dec. 31, 2014
    Statement [line items]        
    Current accounts $ 2,970 $ 1,912    
    Time deposits and short term investments with original maturity less than 90 days 5,890 5,095    
    Total cash and cash equivalents $ 8,860 $ 7,007 $ 4,674 $ 13,023
    XML 185 R118.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 3) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Statement [line items]    
    Debt securities denominated in other currencies $ 328 $ 306
    EUR    
    Statement [line items]    
    Debt securities denominated in other currencies 14 12
    JPY    
    Statement [line items]    
    Debt securities denominated in other currencies 11 10
    USD    
    Statement [line items]    
    Debt securities denominated in other currencies $ 303 $ 284
    XML 186 R119.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Other current assets (Details) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Statement [line items]    
    VAT Receivable $ 717 $ 521
    Withholding tax recoverable 93 282
    Prepaid expenses - third party 753 692
    Prepaid expenses - associated companies 3 5
    Receivables associated companies 8 7
    Contingent consideration receivable 450  
    Other receivables and current assets 1,030 1,034
    Total other current assets $ 3,054 $ 2,541
    XML 187 R120.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Equity (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Disclosure of classes of share capital [line items]      
    Share capital at beginning of period $ 972 $ 991 $ 1,001
    Treasury shares at beginning of period (76) (101) (103)
    Total outstanding share capital at beginning of period 896 890 898
    Share capital movement of period (3) (19) (10)
    Treasury shares movement of period (24) 25 2
    Total shares outstanding movement of period (27) 6 (8)
    Share capital at end of period 969 972 991
    Treasury shares at end of period (100) (76) (101)
    Total outstanding share capital at end of period $ 869 $ 896 $ 890
    XML 188 R121.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Equity (Details 2) - CHF (SFr)
    shares in Millions, SFr in Billions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Disclosure of classes of share capital [line items]      
    Number of shares outstanding at beginning of period 2,374.1 2,373.9 2,398.6
    Treasury shares acquired to be held     (9.6)
    Treasury shares acquired to be cancelled (66.2) (10.3) (49.9)
    Other share purchases (3.8) (2.6) (4.1)
    Exercise of options and employee transactions shares 4.6 4.1 27.0
    Equity based compensation shares 8.8 9.0 11.9
    Total movements (56.6) 0.2 (24.7)
    Number of shares outstanding at end of period 2,317.5 2,374.1 2,373.9
    Shares repurchased on the SIX Swiss Exchange second trading line under the share buyback authority approved SFr 10 SFr 10 SFr 10
    Total Novartis shares      
    Disclosure of classes of share capital [line items]      
    Number of shares outstanding at beginning of period 2,627.1 2,677.0 2,706.2
    Shares cancelled for capital reduction (10.3) (49.9) (29.2)
    Total movements (10.3) (49.9) (29.2)
    Number of shares outstanding at end of period 2,616.8 2,627.1 2,677.0
    Total treasury shares      
    Disclosure of classes of share capital [line items]      
    Number of shares outstanding at beginning of period (253.0) (303.1) (307.6)
    Shares cancelled for capital reduction 10.3 49.9 29.2
    Treasury shares acquired to be held     (9.6)
    Treasury shares acquired to be cancelled (66.2) (10.3) (49.9)
    Other share purchases (3.8) (2.6) (4.1)
    Exercise of options and employee transactions shares 4.6 4.1 27.0
    Equity based compensation shares 8.8 9.0 11.9
    Total movements (46.3) 50.1 4.5
    Number of shares outstanding at end of period (299.3) (253.0) (303.1)
    XML 189 R122.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Equity (Details 3)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    USD ($)
    Dec. 31, 2016
    USD ($)
    Dec. 31, 2015
    USD ($)
    Dec. 31, 2017
    SFr / shares
    Dec. 31, 2016
    SFr / shares
    Dec. 31, 2015
    SFr / shares
    Statement of changes in equity [abstract]            
    Dividends payable, amount per share | SFr / shares       SFr 2.75 SFr 2.70 SFr 2.60
    Dividends recognised as distributions to owners | $ $ 6,495 $ 6,475 $ 6,643      
    XML 190 R123.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Equity (Details 4) - USD ($)
    shares in Millions, $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Treasury shares acquired to be held     (9.6)
    Treasury shares acquired to be held, equity impact     $ (897)
    Treasury shares acquired to be cancelled (66.2) (10.3) (49.9)
    Treasury shares acquired for cancellation, equity impact $ (5,270) $ (784) $ (4,805)
    Other share purchases (3.8) (2.6) (4.1)
    Other share purchases, equity impact $ (304) $ (208) $ (417)
    Purchase of treasury shares (70.0) (12.9) (63.6)
    Purchase of treasury shares, equity impact $ (5,574) $ (992) $ (6,119)
    Exercise of options and employee transactions shares 4.6 4.1 27.0
    Exercise of options and employee transactions, equity impact $ 255 $ 214 $ 1,592
    Equity based compensation shares 8.8 9.0 11.9
    Equity-based compensation, equity impact $ 612 $ 664 $ 815
    Total number of outstanding treasury shares (56.6) 0.2 (24.7)
    Total equity impact of treasury share movements $ (4,707) $ (114) $ (3,712)
    Impact of new tax law income tax relating to revaluation of deferred tax assets on equity based compensation that were previously recognized through retained earnings $ 71    
    XML 191 R124.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Equity (Details 5)
    $ / shares in Units, Pure in Millions, $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    USD ($)
    year
    $ / shares
    Dec. 31, 2015
    USD ($)
    Statement of changes in equity [abstract]    
    Increase/decrease of treasury share repurchase obligation under a share buyback trading plan | $   $ 658
    Maximal amount of share buyback programm | $ $ 5,000  
    Written call options held by market maker 12  
    Written call options, contractual live | year 10  
    Written call options, contractual live, remaining | year 6  
    Written call options, weighted average exercise price | $ / shares $ 62.17  
    XML 192 R125.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Non-current financial debt (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Disclosure of components of non-current financial debts [line items]    
    Straight bonds $ 22,957 $ 17,285
    Liabilities to banks and other institutions 539 708
    Finance lease obligations 87 82
    Total including current portion of non-current financial debt 23,583 18,075
    Less current portion of non-current financial debt (359) (178)
    Total non-current financial debts $ 23,224 $ 17,897
    Average interest rate on loans received 0.30% 0.40%
    Ratio fixed rate financial debt to total financial debt 82.00% 76.00%
    Average interest rate on borrowings 2.60% 2.80%
    XML 193 R126.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Non-current financial debt (Details 2)
    € in Millions, SFr in Millions, $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    USD ($)
    Dec. 31, 2017
    CHF (SFr)
    Dec. 31, 2017
    EUR (€)
    Dec. 31, 2016
    USD ($)
    Disclosure of detailed information about borrowings [line items]        
    Straight bonds $ 22,957     $ 17,285
    5.125% USD 3 000 million bond 2009/2019 of Novaritis Securities Investment Ltd., Hamilton, Bermuda issued at 99.822% [member]        
    Disclosure of detailed information about borrowings [line items]        
    Borrowings, coupon 5.125% 5.125% 5.125%  
    Borrowings, original currency USD      
    Notional amount $ 3,000      
    Borrowings, issuance year 2009      
    Borrowings, maturity year 2019      
    Borrowings, issuer Novartis Securities Investment Ltd., Hamilton, Bermuda      
    Borrowings, issue price 99.822%      
    Straight bonds $ 2,997     2,995
    4.4% USD 1 000 million bond 2010/2020 of Novartis Capital Corporation, New York United States, issued at 99.237% [member]        
    Disclosure of detailed information about borrowings [line items]        
    Borrowings, coupon 4.40% 4.40% 4.40%  
    Borrowings, original currency USD      
    Notional amount $ 1,000      
    Borrowings, issuance year 2010      
    Borrowings, maturity year 2020      
    Borrowings, issuer Novartis Capital Corporation, New York, United States      
    Borrowings, issue price 99.237%      
    Straight bonds $ 997     996
    2.4% USD 1 500 million bond 2012/2022 of Novartis Capital Corporation, New York United States, issued at 99.225% [member]        
    Disclosure of detailed information about borrowings [line items]        
    Borrowings, coupon 2.40% 2.40% 2.40%  
    Borrowings, original currency USD      
    Notional amount $ 1,500      
    Borrowings, issuance year 2012      
    Borrowings, maturity year 2022      
    Borrowings, issuer Novartis Capital Corporation, New York, United States      
    Borrowings, issue price 99.225%      
    Straight bonds $ 1,491     1,490
    3.7% USD 500 million bond 2012/2042 of Novartis Capital Corporation, New York United States, issued at 98.325% [member]        
    Disclosure of detailed information about borrowings [line items]        
    Borrowings, coupon 3.70% 3.70% 3.70%  
    Borrowings, original currency USD      
    Notional amount $ 500      
    Borrowings, issuance year 2012      
    Borrowings, maturity year 2042      
    Borrowings, issuer Novartis Capital Corporation, New York, United States      
    Borrowings, issue price 98.325%      
    Straight bonds $ 489     489
    3.4% USD 2 150 million bond 2014/2024 of Novartis Capital Corporation, New York United States, issued at 99.287% [member]        
    Disclosure of detailed information about borrowings [line items]        
    Borrowings, coupon 3.40% 3.40% 3.40%  
    Borrowings, original currency USD      
    Notional amount $ 2,150      
    Borrowings, issuance year 2014      
    Borrowings, maturity year 2024      
    Borrowings, issuer Novartis Capital Corporation, New York, United States      
    Borrowings, issue price 99.287%      
    Straight bonds $ 2,134     2,132
    4.4% USD 1 850 million bond 2014/2044 of Novartis Capital Corporation, New York United States, issued at 99.196% [member]        
    Disclosure of detailed information about borrowings [line items]        
    Borrowings, coupon 4.40% 4.40% 4.40%  
    Borrowings, original currency USD      
    Notional amount $ 1,850      
    Borrowings, issuance year 2014      
    Borrowings, maturity year 2044      
    Borrowings, issuer Novartis Capital Corporation, New York, United States      
    Borrowings, issue price 99.196%      
    Straight bonds $ 1,824     1,823
    0.75% EUR 600 million bond 2014/2021 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.134% [member]        
    Disclosure of detailed information about borrowings [line items]        
    Borrowings, coupon 0.75% 0.75% 0.75%  
    Borrowings, original currency EUR      
    Notional amount | €     € 600  
    Borrowings, issuance year 2014      
    Borrowings, maturity year 2021      
    Borrowings, issuer Novartis Finance S.A., Luxembourg, Luxembourg      
    Borrowings, issue price 99.134%      
    Straight bonds $ 713     625
    1.625% EUR 600 million bond 2014/2026 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.697% [member]        
    Disclosure of detailed information about borrowings [line items]        
    Borrowings, coupon 1.625% 1.625% 1.625%  
    Borrowings, original currency EUR      
    Notional amount | €     € 600  
    Borrowings, issuance year 2014      
    Borrowings, maturity year 2026      
    Borrowings, issuer Novartis Finance S.A., Luxembourg, Luxembourg      
    Borrowings, issue price 99.697%      
    Straight bonds $ 714     627
    0.25% CHF 500 million bond 2015/2025 of Novartis AG Basel Switzerland, issued at 100.64% [member]        
    Disclosure of detailed information about borrowings [line items]        
    Borrowings, coupon 0.25% 0.25% 0.25%  
    Borrowings, original currency CHF      
    Notional amount | SFr   SFr 500    
    Borrowings, issuance year 2015      
    Borrowings, maturity year 2025      
    Borrowings, issuer Novartis AG, Basel, Switzerland      
    Borrowings, issue price 100.64%      
    Straight bonds $ 513     491
    0.625% CHF 550 million bond 2015/2029 of Novartis AG Basel Switzerland, issued at 100.502% [member]        
    Disclosure of detailed information about borrowings [line items]        
    Borrowings, coupon 0.625% 0.625% 0.625%  
    Borrowings, original currency CHF      
    Notional amount | SFr   SFr 550    
    Borrowings, issuance year 2015      
    Borrowings, maturity year 2029      
    Borrowings, issuer Novartis AG, Basel, Switzerland      
    Borrowings, issue price 100.502%      
    Straight bonds $ 564     539
    1.050% CHF 325 million bond 2015/2035 of Novartis AG Basel Switzerland, issued at 100.479% [member]        
    Disclosure of detailed information about borrowings [line items]        
    Borrowings, coupon 1.05% 1.05% 1.05%  
    Borrowings, original currency CHF      
    Notional amount | SFr   SFr 325    
    Borrowings, issuance year 2015      
    Borrowings, maturity year 2035      
    Borrowings, issuer Novartis AG, Basel, Switzerland      
    Borrowings, issue price 100.479%      
    Straight bonds $ 333     318
    3.0% USD 1 750 million bond 2015/2025 of Novartis Capital Corporation, New York United States, issued at 99.010% [member]        
    Disclosure of detailed information about borrowings [line items]        
    Borrowings, coupon 3.00% 3.00% 3.00%  
    Borrowings, original currency USD      
    Notional amount $ 1,750      
    Borrowings, issuance year 2015      
    Borrowings, maturity year 2025      
    Borrowings, issuer Novartis Capital Corporation, New York, United States      
    Borrowings, issue price 99.01%      
    Straight bonds $ 1,730     1,728
    4.0% USD 1 250 million bond 2015/2045 of Novartis Capital Corporation, New York United States, issued at 98.029% [member]        
    Disclosure of detailed information about borrowings [line items]        
    Borrowings, coupon 4.00% 4.00% 4.00%  
    Borrowings, original currency USD      
    Notional amount $ 1,250      
    Borrowings, issuance year 2015      
    Borrowings, maturity year 2045      
    Borrowings, issuer Novartis Capital Corporation, New York, United States      
    Borrowings, issue price 98.029%      
    Straight bonds $ 1,218     1,217
    0.125% EUR 1 250 million bond 2016/2023 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 99.127% [member]        
    Disclosure of detailed information about borrowings [line items]        
    Borrowings, coupon 0.125% 0.125% 0.125%  
    Borrowings, original currency EUR      
    Notional amount | €     € 1,250  
    Borrowings, issuance year 2016      
    Borrowings, maturity year 2023      
    Borrowings, issuer Novartis Finance S.A., Luxembourg, Luxembourg      
    Borrowings, issue price 99.127%      
    Straight bonds $ 1,480     1,299
    0.625% EUR 500 million bond 2016/2028 of Novartis Finance S.A. Luxembourg, Luxembourg, issued at 98.48% [member]        
    Disclosure of detailed information about borrowings [line items]        
    Borrowings, coupon 0.625% 0.625% 0.625%  
    Borrowings, original currency EUR      
    Notional amount | €     € 500  
    Borrowings, issuance year 2016      
    Borrowings, maturity year 2028      
    Borrowings, issuer Novartis Finance S.A., Luxembourg, Luxembourg      
    Borrowings, issue price 98.48%      
    Straight bonds $ 588     $ 516
    1.800% USD 1'000 million 2017/2020 of Novartis Capital Corporation, New York, United States, issued at 99.609% [member]        
    Disclosure of detailed information about borrowings [line items]        
    Borrowings, coupon 1.80% 1.80% 1.80%  
    Borrowings, original currency USD      
    Notional amount $ 1,000      
    Borrowings, issuance year 2017      
    Borrowings, maturity year 2020      
    Borrowings, issuer Novartis Capital Corporation, New York, United States      
    Borrowings, issue price 99.609%      
    Straight bonds $ 996      
    2.400% USD 1'000 million 2017/2022 of Novartis Capital Corporation, New York, United States, issued at 99.449% [member]        
    Disclosure of detailed information about borrowings [line items]        
    Borrowings, coupon 2.40% 2.40% 2.40%  
    Borrowings, original currency USD      
    Notional amount $ 1,000      
    Borrowings, issuance year 2017      
    Borrowings, maturity year 2022      
    Borrowings, issuer Novartis Capital Corporation, New York, United States      
    Borrowings, issue price 99.449%      
    Straight bonds $ 993      
    3.100% USD 1'000 million 2017/2027 of Novartis Capital Corporation, New York, United States, issued at 99.109% [member]        
    Disclosure of detailed information about borrowings [line items]        
    Borrowings, coupon 3.10% 3.10% 3.10%  
    Borrowings, original currency USD      
    Notional amount $ 1,000      
    Borrowings, issuance year 2017      
    Borrowings, maturity year 2027      
    Borrowings, issuer Novartis Capital Corporation, New York, United States      
    Borrowings, issue price 99.109%      
    Straight bonds $ 988      
    0.000% EUR 1'250 million 2017/2021 of Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.133% [member]        
    Disclosure of detailed information about borrowings [line items]        
    Borrowings, coupon 0.00% 0.00% 0.00%  
    Borrowings, original currency EUR      
    Notional amount | €     € 1,250  
    Borrowings, issuance year 2017      
    Borrowings, maturity year 2021      
    Borrowings, issuer Novartis Finance S.A., Luxembourg, Luxembourg      
    Borrowings, issue price 99.133%      
    Straight bonds $ 1,480      
    1.125% EUR 600 million 2017/2027 of Novartis Finance S.A., Luxembourg, Luxembourg, issued at 99.874% [member]        
    Disclosure of detailed information about borrowings [line items]        
    Borrowings, coupon 1.125% 1.125% 1.125%  
    Borrowings, original currency EUR      
    Notional amount | €     € 600  
    Borrowings, issuance year 2017      
    Borrowings, maturity year 2027      
    Borrowings, issuer Novartis Finance S.A., Luxembourg, Luxembourg      
    Borrowings, issue price 99.874%      
    Straight bonds $ 715      
    XML 194 R127.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Non-current financial debt (Details 3) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Borrowings $ 23,583 $ 18,075
    Not later than one year [member]    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Borrowings 359 178
    Later than one year and not later than two years [member]    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Borrowings 3,173 345
    Later than two years and not later than three years [member]    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Borrowings 1,997 3,168
    Later than three years and not later than four years [member]    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Borrowings 2,194 1,000
    Later than four years and not later than five years [member]    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Borrowings 2,485 628
    Later than five years and not later than six years [member]    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Borrowings   2,442
    Later than five years [member]    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Borrowings $ 13,375  
    Later than six years [member]    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Borrowings   $ 10,314
    XML 195 R128.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Non-current financial debt (Details 4) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Borrowings $ 23,583 $ 18,075
    USD    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Borrowings 15,945 12,952
    EUR    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Borrowings 5,695 3,092
    JPY    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Borrowings 533 683
    CHF    
    Disclosure of maturity analysis for non-derivative financial liabilities [line items]    
    Borrowings $ 1,410 $ 1,348
    XML 196 R129.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Non-current financial debt (Details 5) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Disclosure of fair value measurement of liabilities [line items]    
    Straight bonds $ 22,957 $ 17,285
    Total 23,583 18,075
    Balance sheet    
    Disclosure of fair value measurement of liabilities [line items]    
    Straight bonds 22,957 17,285
    Others 626 790
    Total 23,583 18,075
    Fair values    
    Disclosure of fair value measurement of liabilities [line items]    
    Straight bonds 23,835 17,943
    Others 626 790
    Total $ 24,461 $ 18,733
    XML 197 R130.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Non-current financial debt (Details 6) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Disclosure of the collateralized non-current financial debt and pledged assets [line items]    
    Total net book value of property, plant and equipment pledged as collateral for non-current financial debts $ 84 $ 94
    XML 198 R131.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Provisions and other non-current liabilities (Details) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Disclosure of other provisions [line items]      
    Defined benefit pension plans $ 3,157 $ 4,490  
    Other long-term employee benefits and deferred compensation 625 545  
    Other post-employment benefits 953 1,005  
    Environmental remediation provisions 706 708 $ 791
    Product liability, government investigations, other legal matters provisions 230 264 $ 451
    Contingent consideration 809 840  
    Other non-current liabilities 577 618  
    Total provisions and other non-current liabilities $ 7,057 $ 8,470  
    XML 199 R132.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Provisions and other non-current liabilities (Details 2) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Environmental provision [roll forward]      
    Environmental liabilities provision at beginning of period $ 773 $ 871 $ 923
    Cash payments (46) (75) (52)
    Releases (153)   (5)
    Additions 154 1 6
    Currency translation effects 33 (24) (1)
    Environmental liabilities provision at end of period 761 773 871
    Less current provision (55) (65) (80)
    Non-current environmental remediation provisions at end of period $ 706 $ 708 $ 791
    XML 200 R133.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Provisions and other non-current liabilities (Details 3) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Dec. 31, 2014
    Environmental provision, fiscal year maturity [abstract]        
    Due within two years $ 164      
    Due later than two years, but within five years 241      
    Due later than five years, but within ten years 315      
    Due after ten years 41      
    Total environmental remediation liability provisions $ 761 $ 773 $ 871 $ 923
    XML 201 R134.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Provisions and other non-current liabilities (Details 4)
    ¥ in Millions, $ in Millions
    Dec. 31, 2017
    USD ($)
    Dec. 31, 2017
    JPY (¥)
    Dec. 31, 2016
    Dec. 31, 2014
    USD ($)
    Disclosure of other provisions [line items]        
    Product liability contingency, loss exposure not accrued, number of cases 1,000 1,000    
    Product liability contingency, loss exposure not accrued, best estimate $ 1,500      
    Solodyn [member]        
    Disclosure of other provisions [line items]        
    Description of nature of obligation contingent liabilities, number of putative cases referred to court 17 17    
    Description of nature of obligation contingent liabilities, number of other cases referred to court 3 3    
    Italy | Lucentis [member]        
    Disclosure of other provisions [line items]        
    Estimated financial effect of contingent liabilities, maximum fine       $ 1,500
    Italy | NAG and Novartis Pharma SpA [member] | Lucentis [member]        
    Disclosure of other provisions [line items]        
    Estimated financial effect of contingent liabilities       $ 125
    Japan | Novartis Pharma K.K. [member]        
    Disclosure of other provisions [line items]        
    Estimated financial effect of contingent liabilities, maximum fine | ¥   ¥ 4    
    US | Sandoz [member]        
    Disclosure of other provisions [line items]        
    Description of nature of obligation contingent liabilities, number of putative cases referred to court 1 1    
    Description of nature of obligation contingent liabilities, number of states with alleged violations 45 45    
    Description of nature of obligation contingent liabilities, number of cases still pending 20 20    
    US | Sandoz [member] | Taxotere [member]        
    Disclosure of other provisions [line items]        
    Product liability contingency, loss exposure not accrued, number of cases 1,000 1,000    
    US | Sandoz [member] | Amiodarone [member]        
    Disclosure of other provisions [line items]        
    Product liability contingency, loss exposure not accrued, number of cases 10 10    
    US | NPC and others [member] | Reclast/Aclasta [member]        
    Disclosure of other provisions [line items]        
    Product liability contingency, loss exposure not accrued, number of cases 20 20    
    US | Alcon [member] | Contact Lenses [member]        
    Disclosure of other provisions [line items]        
    Description of nature of obligation contingent liabilities, number of putative cases referred to court     50  
    US | Others associates [member]        
    Disclosure of other provisions [line items]        
    Description of nature of obligation contingent liabilities, number of putative cases referred to court 2 2    
    South Korea        
    Disclosure of other provisions [line items]        
    Estimated financial effect of contingent liabilities, maximum fine $ 53      
    XML 202 R135.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Provisions and other non-current liabilities (Details 5) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Product liability, government investigations, other legal matters provisions [roll forward]      
    Product liabilities government investigations other legal matters provisions at beginning of period $ 395 $ 1,194 $ 849
    Cash payments (69) (811) (256)
    Releases (70) (239) (223)
    Additions 93 243 832
    Currency translation effects 2 8 (8)
    Product liabilities government investigations other legal matters provisions at end of period 351 395 1,194
    Less current provision (121) (131) (743)
    Non-current product liabilities, governmental investigations and other legal matters provisions at end of period $ 230 $ 264 $ 451
    XML 203 R136.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Current financial debt and derivative financial instruments (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Current financial debt and derivative financial instruments [line items]    
    Interest bearning accounts of associates payable on demand $ 1,822 $ 1,601
    Bank and other financial debt 692 836
    Commercial Papers 2,328 3,174
    Current portion of non-current financial debt 359 178
    Fair value of derivative financial instruments 107 116
    Total current financial debt and derivative financial instruments $ 5,308 $ 5,905
    Weighted average interest rate, associates 0.50% 0.50%
    Weighted average interest rate on Bank and other financial debt 7.00% 6.70%
    XML 204 R137.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Provisions and other current liabilities (Details) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Provisions and other current liabilities [line items]      
    Taxes other than income taxes $ 660 $ 547  
    Restructuring provisions 153 222  
    Accrued expenses for goods and services received but not invoiced 977 880  
    Accruals for royalties 586 550  
    Provisions for deductions from revenue 4,672 4,183  
    Accurals for compensation and benefits including social security 2,327 1,993  
    Environmental remediation liabilities 55 65 $ 80
    Deferred income 305 287  
    Provisions for product liabilities, governmental investigations and other legal matters 121 131 743
    Accrued share-based payments 261 199 $ 209
    Contingent considerations 44 49  
    Other payables 1,042 722  
    Total provisions and other current liabilities $ 11,203 $ 9,828  
    XML 205 R138.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Provisions and other current liabilities (Details 2) - Deductions from revenue - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Provisions for deductions from revenue [roll forward]      
    Provision at beginning of period $ 4,183 $ 3,790 $ 3,533
    Impact of business combinations     3
    Additions 17,997 16,622 15,603
    Payments/utilizations (17,452) (16,189) (15,218)
    Changes in offset against gross trade receivables (252) 10 50
    Currency translation effects 196 (50) (181)
    Provision at end of period $ 4,672 $ 4,183 $ 3,790
    XML 206 R139.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Provisions and other current liabilities (Details 3) - Restructuring provision - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Restructuring provisions movements [roll forward]      
    Provision at beginning of period $ 222 $ 260 $ 333
    Additions 194 343 399
    Cash payments (200) (260) (435)
    Releases (64) (66) (36)
    Transfers (7) (76)  
    Currency translation effects 8 21 (1)
    Provision at end of period $ 153 $ 222 $ 260
    XML 207 R140.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Details to the consolidated cash flow statements (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Statement [line items]      
    Income tax expense from continuing operations $ 1,296 $ 1,119 $ 1,106
    Depreciation, amortization and impairments on:      
    Income from associated companies (1,108) (703) (266)
    Gains on disposal of property, plant and equipment, intangible, financial and other non-current assets, net (1,043) (935) (869)
    Equity-based and settled compensation expense 683 671 773
    Change in provisions and other non-current liabilities 160 956 1,642
    Net financial expense 738 1,154 1,109
    Adjustments to reconcile profit (loss) 7,058 8,437 9,070
    Acquisitions through finance lease contracts property plant and equipment     85
    Property, plant and equipment      
    Depreciation, amortization and impairments on:      
    Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss 1,677 1,591 1,550
    Intangible assets      
    Depreciation, amortization and impairments on:      
    Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss 4,399 4,452 3,921
    Financial assets impaired [member]      
    Depreciation, amortization and impairments on:      
    Adjustments for depreciation and amortisation expense and impairment loss (reversal of impairment loss) recognised in profit or loss $ 256 $ 132 $ 104
    XML 208 R141.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Details to the consolidated cash flow statements (Details 2) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Statement [line items]      
    (Increase) in inventories $ (247) $ (235) $ (482)
    (Increase) in trade receivables (204) (229) (513)
    (Decrease)/Increase in trade payables 58 (587) 378
    Change in other net current assets and other operating cash flow items 637 974 (246)
    Total $ 244 $ (77) $ (863)
    XML 209 R142.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Details to the consolidated cash flow statements (Details 3) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Statement [line items]      
    Net cash flows $ (784) $ (765) $ (16,507)
    Acquisitions      
    Statement [line items]      
    Currently marketed products   (451) (12,970)
    (Acquired)/divested research and development (1,223) (690) (730)
    Other intangible assets     (15)
    Financial and other assets including deferred tax assets (8) (39) (555)
    Inventories   (4)  
    Trade receivables and other current assets   (1) (3)
    Cash and cash equivalents (20) (1) (25)
    Trade payables and other liabilities including deferred tax liabilities 326 372 212
    Net identifiable assets (acquired) or divested (925) (814) (14,086)
    Acquired/(divested) liquity 20 1 25
    Fair value of previously held equity interests   64  
    Subtotal (905) (749) (14,061)
    Goodwill (94) (56) (2,438)
    Receivables and payables contingent consideration, net 206 84 (8)
    Other payments and deferred consideration, net (36) (44)  
    Net cash flows (829) (765) (16,507)
    Acquisitions | Continuing operations      
    Statement [line items]      
    Net cash flows (829) (765) (16,507)
    Divestments      
    Statement [line items]      
    Property, plant and equipment 25   1,000
    Currently marketed products 1   646
    (Acquired)/divested research and development     13
    Technologies     113
    Other intangible assets 3   86
    Financial and other assets including deferred tax assets     40
    Inventories     893
    Trade receivables and other current assets 34   529
    Cash and cash equivalents     311
    Current and non-current financial debts     (601)
    Trade payables and other liabilities including deferred tax liabilities (15)   (841)
    Net identifiable assets (acquired) or divested 48   2,189
    Currency translation effects     98
    Acquired/(divested) liquity     (479)
    Subtotal 48   1,808
    Refinancing of intercompany financial debt, net     578
    Goodwill     1,042
    Divestment gain     7,401
    Taxes paid and other portfolio transformation related cash flows (140) (748) (1,337)
    Receivables and payables contingent consideration, net     (519)
    Other payments and deferred consideration, net (3)    
    Deferred portion of sales price     (49)
    Net cash flows (95) (748) 8,924
    Divestments | Continuing operations      
    Statement [line items]      
    Net cash flows 45    
    Divestments | Discontinued operations      
    Statement [line items]      
    Net cash flows $ (140) $ (748) $ 8,924
    XML 210 R143.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Details to the consolidated cash flow statements (Details 3, Parenthetical) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2016
    Dec. 31, 2015
    Transcend Medical Inc.    
    Disclosure of detailed information about business combination [line items]    
    Contingent consideration arrangements and indemnification assets recognised as of acquisition date $ 92  
    Contingent consideration paid $ 60  
    Animal health [member]    
    Disclosure of detailed information about business combination [line items]    
    Proceeds from sale of business   $ 49
    XML 211 R144.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Details to the consolidated cash flow statements (Details 4) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Statement [line items]      
    Cash flows used in operating activities from discontinued operations     $ (188)
    Purchase of property, plant and equipment $ (1,696) $ (1,862) (2,367)
    Proceeds from sales of property, plant and equipment 92 161 237
    Cash flows used in/from investing activities from discontinued operations (140) (748) [1] 8,882 [2]
    Discontinued operations      
    Statement [line items]      
    Cash flows used in operating activities from discontinued operations     (188)
    Purchase of property, plant and equipment     (41)
    Proceeds from sales of property, plant and equipment     1
    Purchase of financial and other non-current assets, net     (2)
    Divestments of businesses (140) (748) 8,924
    Cash flows used in/from investing activities from discontinued operations (140) (748) 8,882
    Total net cash flows used in/from discontinued operations $ (140) $ (748) 8,694
    Consideration transferred, acquisition-date fair value     10,925
    Transaction related costs paid     $ 2,001
    [1] In 2016, the total net tax payment amounted to USD 2,299 million, of which USD 188 million was included in the cash flows used in investing activities from discontinued operations.
    [2] In 2015, the total net tax payment amounted to USD 3,325 million, of which a refund of USD 94 million was included in the cash flows used in operating activities from discontinued operations, and a USD 965 million payment in the cash flows from investing activities of discontinued operations.
    XML 212 R145.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Details to the consolidated cash flow statements (Details 5) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Statement [line items]      
    Financial debts and derivative instruments at beginning of period $ 23,802    
    Proceeds from non-current financial debts 4,933 $ 1,935 $ 4,596
    Repayment of non-current financial debts (188) (1,696) (3,086)
    Change in current financial debts (755) 1,816 $ 451
    Changes in fair values and other changes (146)    
    Amortization of bonds discount 16    
    Currency translation effects 870    
    Financial debts and derivative instruments at end of period 28,532 23,802  
    Non-current financial debts [member]      
    Statement [line items]      
    Financial debts and derivative instruments at beginning of period 17,897    
    Proceeds from non-current financial debts 4,933    
    Repayment of non-current financial debts (1)    
    Changes in fair values and other changes (6)    
    Amortization of bonds discount 16    
    Currency translation effects 744    
    Current portion of non-current financial debt (359)    
    Financial debts and derivative instruments at end of period 23,224 17,897  
    Current financial debts and derivative financial instruments [member]      
    Statement [line items]      
    Financial debts and derivative instruments at beginning of period 5,905    
    Repayment of non-current financial debts (187)    
    Change in current financial debts (755)    
    Changes in fair values and other changes (140)    
    Currency translation effects 126    
    Current portion of non-current financial debt 359    
    Financial debts and derivative instruments at end of period $ 5,308 $ 5,905  
    XML 213 R146.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Acquisitions of businesses (Details) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Amounts recognised as of acquisition date for each major class of assets acquired and liabilities assumed [line items]      
    Currently marketed products   $ 451 $ 12,970
    Acquired research and development $ 1,223 690 730
    Other intangible assets     15
    Deferred tax assets 8 39 555
    Inventories   4  
    Trade receivables and other current assets   1 3
    Cash and cash equivalents 20 1 25
    Payables and other liabilities including deferred tax liabilities (326) (372) (212)
    Net identifiable assets acquired 925 814 14,086
    Acquired liquidity (20) (1) (25)
    Goodwill 94 56 2,438
    Net assets recognized as a result of business combinations 999 869 16,499
    Goodwill expected to be deductible for tax purposes $ 0 $ 18 $ 2,400
    XML 214 R147.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Post-employment benefits for associates (Details)
    SFr in Millions, $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    USD ($)
    Dec. 31, 2017
    CHF (SFr)
    Disclosure of defined benefit plans [line items]    
    Concentration of major plans, geographic The major plans are based in Switzerland, the United States, the United Kingdom, Germany and Japan, which represent 94% of the Group’s total DBO for pension plans. The major plans are based in Switzerland, the United States, the United Kingdom, Germany and Japan, which represent 94% of the Group’s total DBO for pension plans.
    Description of plan amendments, curtailments and settlements In September 2017, the pension regulations in Switzerland were amended, which resulted in a change in accounting from defined benefit to defined contribution for a component of the Swiss pension plans. This change resulted in a reduction to the defined benefit pension plans liability and in a corresponding net pre-tax gain of USD 225 million (CHF 216 million). In September 2017, the pension regulations in Switzerland were amended, which resulted in a change in accounting from defined benefit to defined contribution for a component of the Swiss pension plans. This change resulted in a reduction to the defined benefit pension plans liability and in a corresponding net pre-tax gain of USD 225 million (CHF 216 million).
    Net Pre-tax curtailment gain (loss) $ 225 SFr 216
    XML 215 R148.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Post-employment benefits for associates (Details 2) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Defined benefit plan, change in benefit obligation [roll forward]      
    Benefit obligation at beginning of period $ 23,614    
    Benefit obligation at end of period 23,210 $ 23,614  
    Defined benefit plan, change in fair value of plan assets [roll forward]      
    Fair value of plan assets at beginning of period 19,225    
    Fair value of plan assets at end of period 20,275 19,225  
    Funded status (2,935) (4,389)  
    Pension plans      
    Defined benefit plan, change in benefit obligation [roll forward]      
    Benefit obligation at beginning of period 23,614 23,402  
    Current service cost 422 437  
    Interest cost 330 390  
    Past service cost and settlements (1,226) (73)  
    Administrative expenses 27 29  
    Remeasurement losses/(gains) arising from changes in financial assumptions 11 1,299  
    Remeasurement (gains) arising from changes in demographic assumptions (26) (7)  
    Experience-related remeasurement losses/(gains) 47 117  
    Currency translation effects 1,138 (896)  
    Benefit payments (1,300) (1,250)  
    Contributions of associates 207 207  
    Effect of acquisitions, divestments or transfers (34) (41)  
    Benefit obligation at end of period 23,210 23,614  
    Defined benefit plan, change in fair value of plan assets [roll forward]      
    Fair value of plan assets at beginning of period 19,225 19,536  
    Interest income 236 293  
    Return on plan assets excluding interest income 1,429 742  
    Currency translation effects 909 (757)  
    Novartis Group contributions 579 542  
    Contributions of associates 207 207  
    Settlements (995) (77)  
    Benefit payments (1,300) (1,250)  
    Effect of acquisitions, divestments or transfers (15) (11)  
    Fair value of plan assets at end of period 20,275 19,225  
    Funded status (2,935) (4,389)  
    Defined benefit plan, change in limitation on recognition of fund surplus [roll forward]      
    Limitation on recognition of fund surplus at beginning of period (54) (50)  
    Change in limitation on recognition of fund surplus (incl. exchange rate differences) (30)    
    Interest income on limitation of fund surplus (5) (4)  
    Limitation on recognition of fund surplus at end of period (89) (54)  
    Net liability in the balance sheet at end of period (3,024) (4,443) $ (3,916)
    Other post-employment benefit plans      
    Defined benefit plan, change in benefit obligation [roll forward]      
    Benefit obligation at beginning of period 1,158 1,132  
    Current service cost 34 35  
    Interest cost 44 48  
    Past service cost and settlements (10)    
    Remeasurement losses/(gains) arising from changes in financial assumptions 32 46  
    Remeasurement (gains) arising from changes in demographic assumptions (9) (26)  
    Experience-related remeasurement losses/(gains) (87) (33)  
    Currency translation effects 5 7  
    Benefit payments (51) (51)  
    Effect of acquisitions, divestments or transfers (1)    
    Benefit obligation at end of period 1,115 1,158  
    Defined benefit plan, change in fair value of plan assets [roll forward]      
    Fair value of plan assets at beginning of period 153 172  
    Interest income 5 6  
    Return on plan assets excluding interest income 12 (1)  
    Novartis Group contributions 43 27  
    Benefit payments (51) (51)  
    Fair value of plan assets at end of period 162 153  
    Funded status (953) (1,005)  
    Defined benefit plan, change in limitation on recognition of fund surplus [roll forward]      
    Net liability in the balance sheet at end of period $ (953) $ (1,005) $ (960)
    XML 216 R149.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Post-employment benefits for associates (Details 3) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Amounts recognized in the consolidated balance sheet [abstract]    
    Prepaid benefit cost $ 133 $ 47
    Pension plans    
    Defined benefit plan, change in net liability [roll forward]    
    Net liability at beginning of period (4,443) (3,916)
    Current service cost (422) (437)
    Net interest expense (99) (101)
    Administrative expenses (27) (29)
    Past service cost and settlements 231 (4)
    Remeasurements 1,397 (667)
    Currency translation effects (229) 139
    Novartis Group contributions 579 542
    Effect of acquisitions, divestments or transfers 19 30
    Change in limitation on recognition of fund surplus (incl. exchange rate differences) (30)  
    Net liability at end of period (3,024) (4,443)
    Amounts recognized in the consolidated balance sheet [abstract]    
    Prepaid benefit cost 133 47
    Accrued benefit liability (3,157) (4,490)
    Other post-employment benefit plans    
    Defined benefit plan, change in net liability [roll forward]    
    Net liability at beginning of period (1,005) (960)
    Current service cost (34) (35)
    Net interest expense (39) (42)
    Past service cost and settlements 10  
    Remeasurements 76 12
    Currency translation effects (5) (7)
    Novartis Group contributions 43 27
    Effect of acquisitions, divestments or transfers 1  
    Net liability at end of period (953) (1,005)
    Amounts recognized in the consolidated balance sheet [abstract]    
    Accrued benefit liability $ (953) $ (1,005)
    XML 217 R150.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Post-employment benefits for associates (Details 4) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Disclosure of net defined benefit liability (asset) [line items]    
    Defined benefit obligation, at present value $ 23,210 $ 23,614
    Plan assets, at fair value 20,275 19,225
    Funded status (2,935) (4,389)
    Unfunded    
    Disclosure of net defined benefit liability (asset) [line items]    
    Defined benefit obligation, at present value 1,227 1,236
    Active    
    Disclosure of net defined benefit liability (asset) [line items]    
    Defined benefit obligation, at present value 8,069 8,777
    Deferred pensioners    
    Disclosure of net defined benefit liability (asset) [line items]    
    Defined benefit obligation, at present value 2,904 2,346
    Pensioners    
    Disclosure of net defined benefit liability (asset) [line items]    
    Defined benefit obligation, at present value 12,237 12,491
    Switzerland    
    Disclosure of net defined benefit liability (asset) [line items]    
    Defined benefit obligation, at present value 14,606 15,436
    Plan assets, at fair value 14,445 13,958
    Funded status (161) (1,478)
    Switzerland | Active    
    Disclosure of net defined benefit liability (asset) [line items]    
    Defined benefit obligation, at present value 5,627 6,426
    Switzerland | Pensioners    
    Disclosure of net defined benefit liability (asset) [line items]    
    Defined benefit obligation, at present value 8,979 9,010
    US    
    Disclosure of net defined benefit liability (asset) [line items]    
    Defined benefit obligation, at present value 3,788 3,783
    Plan assets, at fair value 2,400 2,282
    Funded status (1,388) (1,501)
    US | Unfunded    
    Disclosure of net defined benefit liability (asset) [line items]    
    Defined benefit obligation, at present value 728 739
    US | Active    
    Disclosure of net defined benefit liability (asset) [line items]    
    Defined benefit obligation, at present value 796 891
    US | Deferred pensioners    
    Disclosure of net defined benefit liability (asset) [line items]    
    Defined benefit obligation, at present value 1,258 831
    US | Pensioners    
    Disclosure of net defined benefit liability (asset) [line items]    
    Defined benefit obligation, at present value 1,734 2,061
    Rest of the world    
    Disclosure of net defined benefit liability (asset) [line items]    
    Defined benefit obligation, at present value 4,816 4,395
    Plan assets, at fair value 3,430 2,985
    Funded status (1,386) (1,410)
    Rest of the world | Unfunded    
    Disclosure of net defined benefit liability (asset) [line items]    
    Defined benefit obligation, at present value 499 497
    Rest of the world | Active    
    Disclosure of net defined benefit liability (asset) [line items]    
    Defined benefit obligation, at present value 1,646 1,460
    Rest of the world | Deferred pensioners    
    Disclosure of net defined benefit liability (asset) [line items]    
    Defined benefit obligation, at present value 1,646 1,515
    Rest of the world | Pensioners    
    Disclosure of net defined benefit liability (asset) [line items]    
    Defined benefit obligation, at present value $ 1,524 $ 1,420
    XML 218 R151.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Post-employment benefits for associates (Details 5)
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Pension plans      
    Disclosure of defined benefit plans [line items]      
    Discount rate 1.50% 1.40% 1.80%
    Expected rate of pension increase 0.50% 0.40% 0.40%
    Expected rate of salary increase 2.80% 2.20% 2.90%
    Interest on savings account 0.60% 0.50% 0.80%
    Current life expectancy for a 65-year-old male 22 years 22 years 21 years
    Current life expectancy for a 65-year-old female 24 years 24 years 24 years
    Other post-employment benefit plans      
    Disclosure of defined benefit plans [line items]      
    Discount rate 3.70% 4.20% 4.40%
    Current life expectancy for a 65-year-old male 21 years 21 years 21 years
    Current life expectancy for a 65-year-old female 23 years 23 years 23 years
    XML 219 R152.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Post-employment benefits for associates (Details 6)
    $ in Millions
    Dec. 31, 2017
    USD ($)
    Discount rate | 25 basis point change  
    Disclosure of sensitivity analysis for actuarial assumptions [line items]  
    Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption $ (753)
    Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption 803
    Life expectancy | 1 year increase  
    Disclosure of sensitivity analysis for actuarial assumptions [line items]  
    Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption 840
    Rate of pension increase | 25 basis point change  
    Disclosure of sensitivity analysis for actuarial assumptions [line items]  
    Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption 533
    Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption (138)
    Interest on savings account | 25 basis point change  
    Disclosure of sensitivity analysis for actuarial assumptions [line items]  
    Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption 56
    Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption (54)
    Salary increase | 25 basis point change  
    Disclosure of sensitivity analysis for actuarial assumptions [line items]  
    Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption 49
    Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption $ (50)
    XML 220 R153.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Post-employment benefits for associates (Details 7) - Other post-employment benefit plans
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Disclosure of defined benefit plans [line items]      
    Healthcare cost trend rate assumed for next year 6.50% 7.00% 7.50%
    Rate to which the cost trend rate is assumed to decline 4.50% 5.00% 5.00%
    Year that the rate reaches the ultimate trend rate 2025 2022 2022
    XML 221 R154.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Post-employment benefits for associates (Details 8) - Pension plans - USD ($)
    shares in Millions, $ in Billions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Disclosure of defined benefit plans [line items]    
    Defined benefit plan, plan asset allocations 100.00% 100.00%
    Shares held by defined benefit plan 11.0 11.0
    Value of shares held by defined benefit plan $ 0.9 $ 0.8
    Weighted average duration of defined benefit obligation years 14 years 7 months 7 days 14 years 6 months 1 day
    Equity securities    
    Disclosure of defined benefit plans [line items]    
    Defined benefit plan, target plan asset allocations range minimum 15.00%  
    Defined benefit plan, target plan asset allocations range maximum 40.00%  
    Defined benefit plan, plan asset allocations 31.00% 31.00%
    Debt securities    
    Disclosure of defined benefit plans [line items]    
    Defined benefit plan, target plan asset allocations range minimum 20.00%  
    Defined benefit plan, target plan asset allocations range maximum 60.00%  
    Defined benefit plan, plan asset allocations 35.00% 35.00%
    Real estate    
    Disclosure of defined benefit plans [line items]    
    Defined benefit plan, target plan asset allocations range minimum 5.00%  
    Defined benefit plan, target plan asset allocations range maximum 20.00%  
    Defined benefit plan, plan asset allocations 15.00% 15.00%
    Alternative investments    
    Disclosure of defined benefit plans [line items]    
    Defined benefit plan, target plan asset allocations range minimum 0.00%  
    Defined benefit plan, target plan asset allocations range maximum 20.00%  
    Defined benefit plan, plan asset allocations 15.00% 15.00%
    Cash and other investments    
    Disclosure of defined benefit plans [line items]    
    Defined benefit plan, target plan asset allocations range minimum 0.00%  
    Defined benefit plan, target plan asset allocations range maximum 15.00%  
    Defined benefit plan, plan asset allocations 4.00% 4.00%
    XML 222 R155.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Post-employment benefits for associates (Details 9)
    $ in Millions
    Dec. 31, 2017
    USD ($)
    Pension plans  
    Novartis Group contributions  
    Contributions, next fiscal year (estimated) $ 395
    Pension plans | Not later than one year [member]  
    Expected future benefit payments  
    Expected future benefit payment 1,226
    Pension plans | Later than one year and not later than two years [member]  
    Expected future benefit payments  
    Expected future benefit payment 1,166
    Pension plans | Later than two years and not later than three years [member]  
    Expected future benefit payments  
    Expected future benefit payment 1,163
    Pension plans | Later than three years and not later than four years [member]  
    Expected future benefit payments  
    Expected future benefit payment 1,147
    Pension plans | Later than four years and not later than five years [member]  
    Expected future benefit payments  
    Expected future benefit payment 1,133
    Pension plans | Later than five years and not later than ten years [member]  
    Expected future benefit payments  
    Expected future benefit payment 5,534
    Other post-employment benefit plans  
    Novartis Group contributions  
    Contributions, next fiscal year (estimated) 62
    Other post-employment benefit plans | Not later than one year [member]  
    Expected future benefit payments  
    Expected future benefit payment 63
    Other post-employment benefit plans | Later than one year and not later than two years [member]  
    Expected future benefit payments  
    Expected future benefit payment 65
    Other post-employment benefit plans | Later than two years and not later than three years [member]  
    Expected future benefit payments  
    Expected future benefit payment 67
    Other post-employment benefit plans | Later than three years and not later than four years [member]  
    Expected future benefit payments  
    Expected future benefit payment 68
    Other post-employment benefit plans | Later than four years and not later than five years [member]  
    Expected future benefit payments  
    Expected future benefit payment 69
    Other post-employment benefit plans | Later than five years and not later than ten years [member]  
    Expected future benefit payments  
    Expected future benefit payment $ 344
    XML 223 R156.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Post-employment benefits for associates (Details 10) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Continuing operations      
    Defined contribution pension and other post-retirement plans disclosure [line items]      
    Post-employment benefit expense, defined contribution plans $ 406 $ 338 $ 359
    Discontinued operations      
    Defined contribution pension and other post-retirement plans disclosure [line items]      
    Post-employment benefit expense, defined contribution plans     $ 1
    XML 224 R157.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Equity-based participation plans for associates (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Disclosure of terms and conditions of share-based payment arrangement [line items]      
    Expense from share-based payment transactions with employees $ 924 $ 846 $ 968
    Liabilities from share-based payment transactions 261 199 209
    Continuing operations      
    Disclosure of terms and conditions of share-based payment arrangement [line items]      
    Expense from share-based payment transactions with employees $ 924 $ 846 903
    Discontinued operations      
    Disclosure of terms and conditions of share-based payment arrangement [line items]      
    Expense from share-based payment transactions with employees     $ 65
    XML 225 R158.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Equity-based participation plans for associates (Details 2)
    		 12 Months Ended
    Dec. 31, 2017
    Annual incentive  
    Disclosure of terms and conditions of share-based payment arrangement [line items]  
    Description of share-based payment arrangement The Annual Incentive of the Novartis Group CEO and the other Executive Committee members is paid 50% in cash in February or March of the year following the performance period, and 50% in Novartis Restricted Shares (RSs) or Restricted Share Units (RSUs) that are granted in January of the year following the performance period, deferred and restricted for three years. In 2016, this was extended to Novartis Top Leaders (NTLs). The Annual Incentive payout for the NTLs is 70% in cash and 30% in Novartis RSs or RSUs. Each RS is entitled to voting rights and payment of dividends during the vesting period. Each RSU is equivalent to one Novartis share and is converted into one share at the vesting date. RSUs do not carry any dividend, dividend equivalent or voting rights. The executives in certain countries may elect to also receive their cash incentive partially or fully in shares or share units that will not be subject to vesting conditions.
    Share savings plans  
    Disclosure of terms and conditions of share-based payment arrangement [line items]  
    Description of share-based payment arrangement A number of associates in certain countries as well as certain key executives worldwide are encouraged to invest their Annual Incentive, and in the United Kingdom also their salary, in a share savings plan. Under the share savings plan, participants may elect to receive their Annual Incentive fully or partially in Novartis shares in lieu of cash. As a reward for their participation in the share savings plan, at no additional cost to the participant, Novartis matches their investments in shares after a holding period of three or five years.
    Employee Share Ownership Plan (ESOP)  
    Disclosure of terms and conditions of share-based payment arrangement [line items]  
    Description of share-based payment arrangement In Switzerland, Employee Share Ownership Plan (ESOP) participants may choose to receive their Annual Incentive (i) 100% in shares, (ii) 50% in shares and 50% in cash or (iii) 100% in cash. After expiration of a three-year holding period for Novartis shares invested under the ESOP, participants will receive one matching share for every two invested shares. Associates eligible for the equity plan “Select” are not eligible to receive ESOP matching shares starting with the 2017 performance period onwards.
    UK Share Savings Plan  
    Disclosure of terms and conditions of share-based payment arrangement [line items]  
    Description of share-based payment arrangement In the United Kingdom, associates can invest up to 10% of their monthly salary in shares (up to a maximum of GBP 150) and may also be invited to invest their net Annual Incentive in shares. Two invested shares are matched with one share with a holding period of three years. Starting with the 2017 performance period onwards, United Kingdom associates can only invest a maximum of 50% of their Annual Incentive in shares and this option is no longer offered to associates who are eligible for the equity plan “Select”.
    Leveraged Share Savings Plan (LSSP)  
    Disclosure of terms and conditions of share-based payment arrangement [line items]  
    Description of share-based payment arrangement The Leveraged Share Savings Plan (LSSP) was available to key executives for performance periods prior to 2016. At the participant’s election, the Annual Incentive was awarded partly or entirely in shares. The elected number of shares is subject to a holding period of five years. At the end of the holding period, Novartis will match the invested shares at a ratio of 1-to-1 (i.e. one share awarded for each invested share). In the United States both the LSSP award and the corresponding match are cash settled.
    Select  
    Disclosure of terms and conditions of share-based payment arrangement [line items]  
    Description of share-based payment arrangement The equity plan “Select” is a global equity incentive plan under which eligible associates may annually be awarded a grant subject to a three year vesting period. No awards are granted for performance ratings below a certain threshold. Executive Committee members are not eligible for participation in the equity plan “Select” effective from the performance period 2014, and the NTLs are not eligible to participate effective from the performance period 2016. The equity plan “Select” currently allows participants in Switzerland to choose the form of their equity compensation in RSs or RSUs. In all other jurisdictions, RSUs are typically granted. Until 2013, participants could also choose to receive part or the entire grant in the form of tradable share options. Tradable share options expire on their tenth anniversary from the grant date. Each tradable share option entitles the holder to purchase after vesting (and before the tenth anniversary from the grant date) one Novartis share at a stated exercise price that equals the closing market price of the underlying share at the grant date.
    Long-Term Performance Plan  
    Disclosure of terms and conditions of share-based payment arrangement [line items]  
    Description of share-based payment arrangement The Long-Term Performance Plan (LTPP) is an equity plan for the Novartis Group CEO, the other Executive Committee members and the NTLs. For the 2017 grant, the target incentive is 200% of base compensation for the Novartis Group CEO and ranges from 150% to 170% for other Executive Committee members. For the NTLs, the target incentive range is from 20% to 160% of base compensation. The awards of the LTPP are based on three-year performance objectives focused on financial and innovation measures. The financial measure is Novartis Cash Value Added (NCVA). The weighting of this measure is 75%. The NCVA target is approved by the Board of Directors. The innovation measure is based on a holistic approach under which divisional innovation targets are set at the beginning of the cycle, comprised of up to ten target milestones that represent the most important research and development project milestones for each division. The weighting of this measure is 25%. At the end of the performance period, the Research & Development Committee assists the Board of Directors and the Compensation Committee in evaluating performance against the innovation targets at the end of the cycle. Under the LTPP, participants are granted a target number of Performance Share Units (PSUs) at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. Payout is between 0% and 200% of target. PSUs granted under the LTPP do not carry voting rights, but do carry dividend equivalents that are paid in shares at the end of the performance period.
    Long-Term Relative Performance Plan  
    Disclosure of terms and conditions of share-based payment arrangement [line items]  
    Description of share-based payment arrangement The Long-Term Relative Performance Plan (LTRPP) is an equity plan for the Novartis Group CEO, other ECN members and NTLs. For the 2017 grant, the target incentive is 125% of base compensation for the Novartis Group CEO and ranges from 60% to 80% for other Executive Committee members. For the NTLs, the target incentive range is from 10% to 40% of base compensation. The LTRPP is based on the ranking of Novartis’ Total Shareholder Return (TSR) relative to a global healthcare peer group of 12 companies until 2016, and 15 companies from 2017, over rolling three-year performance periods. TSR in USD is calculated as price change of the Novartis share plus the dividend plus the re-investment return of the dividend amount, all translated to USD at the respective exchange rate, over the three-year performance period. The calculation is based on Bloomberg standard published TSR data, which is publicly available. The position in the peer group determines the payout range based on a payout matrix. Under the LTRPP, participants are also granted a target number of PSUs at the beginning of every performance period, which are converted into unrestricted Novartis shares after the performance period. Payout is between 0% and 200% of target. PSUs under the LTRPP do not carry voting rights, but do carry dividend equivalents that are paid in shares at the end of the performance period.
    Special share awards  
    Disclosure of terms and conditions of share-based payment arrangement [line items]  
    Description of share-based payment arrangement Selected associates, excluding the Executive Committee members, may exceptionally receive Special Share Awards of RSs or RSUs. These Special Share Awards provide an opportunity to reward outstanding achievements or exceptional performance, and aim to retain key contributors. They are based on a formal internal selection process, through which the individual performance of each candidate is thoroughly assessed at several management levels. Special Share Awards have a minimum three-year vesting period. In exceptional circumstances, Special Share Awards may be awarded to attract special expertise and new talents into the organization. These grants are consistent with market practice and Novartis’ philosophy to attract, retain and motivate best-in-class talents around the world. Worldwide, associates at different levels in the organization were awarded RSs and RSUs in 2017. In addition, in 2017, Board members received unrestricted shares as part of their regular compensation.
    Alcon equity plans granted to associates prior merger  
    Disclosure of terms and conditions of share-based payment arrangement [line items]  
    Description of share-based payment arrangement At the completion of the merger of Alcon, Inc. into Novartis on April 8, 2011, all awards outstanding under the Alcon equity plans were converted into awards based upon Novartis shares with a conversion factor of 3.0727 as defined in the Merger Agreement. The plans are fully vested. Share options entitle the recipient to purchase Novartis shares at the closing market price of the former Alcon, Inc., share on the day of grant divided by the conversion factor. Share-settled appreciation rights (SSAR) entitle the participant to receive, in the form of Novartis shares, the difference between the values of the former Alcon, Inc., share at the date of grant, converted into Novartis shares using the conversion factor, and the Novartis share price at the date of exercise. Both options and SSAR expire on their tenth anniversary. The last grant was made in 2009.
    XML 226 R159.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Equity-based participation plans for associates (Details 3) - Select outside North America
    Pure in Millions
    		 12 Months Ended
    Dec. 31, 2017
    USD ($)
    Dec. 31, 2016
    USD ($)
    Dec. 31, 2017
    USD ($)
    year
    Dec. 31, 2016
    USD ($)
    Disclosure of number and weighted average exercise prices of share options [roll forward]        
    Number of share options outstanding at beginning of period 9.5 11.7    
    Weighted average exercise price of share options outstanding at beginning of period $ 59.4 $ 59.9    
    Number of share options exercised or sold (2.1) (2.2)    
    Weighted average exercise price of share options exercised or sold $ 59.2 $ 61.8    
    Number of share options outstanding at end of period 7.4 9.5    
    Weighted average exercise price of share options outstanding at end of period $ 59.5 $ 59.4    
    Number of share options exercisable     7.4 9.5
    Weighted average exercise price of share options exercisable     $ 59.5 $ 59.4
    Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]        
    Exercise price of outstanding share options     $ 80.1  
    Number of share options outstanding in share-based payment arrangement 7.4 11.7 7.4 9.5
    Weighted average remaining contractual life of outstanding share options | year     3.6  
    Weighted average exercise price of share options outstanding in share-based payment arrangement $ 59.5 $ 59.9 $ 59.5 $ 59.4
    45-49        
    Disclosure of number and weighted average exercise prices of share options [roll forward]        
    Number of share options outstanding at end of period 0.7      
    Weighted average exercise price of share options outstanding at end of period $ 46.7      
    Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]        
    Number of share options outstanding in share-based payment arrangement 0.7   0.7  
    Weighted average remaining contractual life of outstanding share options | year     1.0  
    Weighted average exercise price of share options outstanding in share-based payment arrangement $ 46.7   $ 46.7  
    50-54        
    Disclosure of number and weighted average exercise prices of share options [roll forward]        
    Number of share options outstanding at end of period 1.1      
    Weighted average exercise price of share options outstanding at end of period $ 54.6      
    Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]        
    Number of share options outstanding in share-based payment arrangement 1.1   1.1  
    Weighted average remaining contractual life of outstanding share options | year     2.0  
    Weighted average exercise price of share options outstanding in share-based payment arrangement $ 54.6   $ 54.6  
    55-59        
    Disclosure of number and weighted average exercise prices of share options [roll forward]        
    Number of share options outstanding at end of period 2.7      
    Weighted average exercise price of share options outstanding at end of period $ 57.6      
    Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]        
    Number of share options outstanding in share-based payment arrangement 2.7   2.7  
    Weighted average remaining contractual life of outstanding share options | year     3.3  
    Weighted average exercise price of share options outstanding in share-based payment arrangement $ 57.6   $ 57.6  
    65-70        
    Disclosure of number and weighted average exercise prices of share options [roll forward]        
    Number of share options outstanding at end of period 2.9      
    Weighted average exercise price of share options outstanding at end of period $ 66.1      
    Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]        
    Number of share options outstanding in share-based payment arrangement 2.9   2.9  
    Weighted average remaining contractual life of outstanding share options | year     5.0  
    Weighted average exercise price of share options outstanding in share-based payment arrangement $ 66.1   $ 66.1  
    XML 227 R160.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Equity-based participation plans for associates (Details 4) - Select North America
    Pure in Millions
    		 12 Months Ended
    Dec. 31, 2017
    USD ($)
    Dec. 31, 2016
    USD ($)
    Dec. 31, 2017
    USD ($)
    year
    Dec. 31, 2016
    USD ($)
    Disclosure of number and weighted average exercise prices of share options [roll forward]        
    Number of share options outstanding at beginning of period 25.9 31.9    
    Weighted average exercise price of share options outstanding at beginning of period $ 59.9 $ 60.2    
    Number of share options exercised or sold (5.6) (6.0)    
    Weighted average exercise price of share options exercised or sold $ 59.9 $ 61.7    
    Number of share options outstanding at end of period 20.3 25.9    
    Weighted average exercise price of share options outstanding at end of period $ 59.9 $ 59.9    
    Number of share options exercisable     20.3 25.9
    Weighted average exercise price of share options exercisable     $ 59.9 $ 59.9
    Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]        
    Exercise price of outstanding share options     $ 79.9  
    Number of share options outstanding in share-based payment arrangement 20.3 31.9 20.3 25.9
    Weighted average remaining contractual life of outstanding share options | year     3.7  
    Weighted average exercise price of share options outstanding in share-based payment arrangement $ 59.9 $ 60.2 $ 59.9 $ 59.9
    45-49        
    Disclosure of number and weighted average exercise prices of share options [roll forward]        
    Number of share options outstanding at end of period 1.8      
    Weighted average exercise price of share options outstanding at end of period $ 46.4      
    Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]        
    Number of share options outstanding in share-based payment arrangement 1.8   1.8  
    Weighted average remaining contractual life of outstanding share options | year     1.0  
    Weighted average exercise price of share options outstanding in share-based payment arrangement $ 46.4   $ 46.4  
    50-54        
    Disclosure of number and weighted average exercise prices of share options [roll forward]        
    Number of share options outstanding at end of period 2.1      
    Weighted average exercise price of share options outstanding at end of period $ 53.7      
    Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]        
    Number of share options outstanding in share-based payment arrangement 2.1   2.1  
    Weighted average remaining contractual life of outstanding share options | year     2.0  
    Weighted average exercise price of share options outstanding in share-based payment arrangement $ 53.7   $ 53.7  
    55-59        
    Disclosure of number and weighted average exercise prices of share options [roll forward]        
    Number of share options outstanding at end of period 8.0      
    Weighted average exercise price of share options outstanding at end of period $ 58.0      
    Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]        
    Number of share options outstanding in share-based payment arrangement 8.0   8.0  
    Weighted average remaining contractual life of outstanding share options | year     3.5  
    Weighted average exercise price of share options outstanding in share-based payment arrangement $ 58.0   $ 58.0  
    65-69        
    Disclosure of number and weighted average exercise prices of share options [roll forward]        
    Number of share options outstanding at end of period 8.4      
    Weighted average exercise price of share options outstanding at end of period $ 66.1      
    Disclosure of number and weighted average remaining contractual life of outstanding share options [abstract]        
    Number of share options outstanding in share-based payment arrangement 8.4   8.4  
    Weighted average remaining contractual life of outstanding share options | year     5.0  
    Weighted average exercise price of share options outstanding in share-based payment arrangement $ 66.1   $ 66.1  
    XML 228 R161.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Equity-based participation plans for associates (Details 5) - Non-vested shares granted [member]
    Pure in Millions
    		 12 Months Ended
    Dec. 31, 2017
    USD ($)
    Dec. 31, 2016
    USD ($)
    Schedule of unvested restricted stock units [roll forward]    
    Number of shares at beginning of period 21.0 20.1
    Weighted average fair value at grante date at beginning of period $ 89.5 $ 87.1
    Fair value at grante date at beginning of period $ 1,880,000,000 $ 1,751,000,000
    Vested, number of shares (10.7) (10.4)
    Vested, weighted average fair value at grante date $ 78.2 $ 68.8
    Vested, fair value at grante date $ (837,000,000) $ (716,000,000)
    Forfeited, number of shares (1.8) (1.8)
    Forfeited, weighted average fair value at grante date $ 80.7 $ 73.1
    Forfeited, fair value at grante date $ (145,000,000) $ (132,000,000)
    Number of shares at end of period 23.9 21.0
    Weighted average fair value at grante date at end of period $ 80.6 $ 89.5
    Fair value at grante date at end of period $ 1,926,000,000 $ 1,880,000,000
    Annual incentive    
    Schedule of unvested restricted stock units [roll forward]    
    Granted, number of shares 1.3 0.1
    Granted, weighted average fair value at grante date $ 69.3 $ 73.8
    Granted, fair value at grante date $ 90,000,000 $ 7,000,000
    Share savings plans    
    Schedule of unvested restricted stock units [roll forward]    
    Granted, number of shares 4.5 4.4
    Granted, weighted average fair value at grante date $ 69.4 $ 78.1
    Granted, fair value at grante date $ 312,000,000 $ 344,000,000
    Select North America    
    Schedule of unvested restricted stock units [roll forward]    
    Granted, number of shares 4.5 4.8
    Granted, weighted average fair value at grante date $ 64.1 $ 72.4
    Granted, fair value at grante date $ 288,000,000 $ 348,000,000
    Select outside North America    
    Schedule of unvested restricted stock units [roll forward]    
    Granted, number of shares 2.0 1.6
    Granted, weighted average fair value at grante date $ 65.3 $ 74.4
    Granted, fair value at grante date $ 131,000,000 $ 119,000,000
    Long-Term Performance Plan    
    Schedule of unvested restricted stock units [roll forward]    
    Granted, number of shares 1.4 1.2
    Granted, weighted average fair value at grante date $ 71.5 $ 79.2
    Granted, fair value at grante date $ 100,000,000 $ 95,000,000
    Long-Term Relative Performance Plan    
    Schedule of unvested restricted stock units [roll forward]    
    Granted, number of shares 0.4 0.3
    Granted, weighted average fair value at grante date $ 47.7 $ 58.5
    Granted, fair value at grante date $ 19,000,000 $ 18,000,000
    Other share awards    
    Schedule of unvested restricted stock units [roll forward]    
    Granted, number of shares 1.3 0.7
    Granted, weighted average fair value at grante date $ 67.8 $ 65.8
    Granted, fair value at grante date $ 88,000,000 $ 46,000,000
    XML 229 R162.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Equity-based participation plans for associates (Details 6)
    Pure in Millions
    		 12 Months Ended
    Dec. 31, 2017
    USD ($)
    Dec. 31, 2016
    USD ($)
    Alcon, Inc., equity plan, converted, Novartis share options [member]    
    Disclosure of number and weighted average exercise prices of share options [roll forward]    
    Number of share options outstanding at beginning of period 0.1 0.2
    Weighted average exercise price of share options outstanding at beginning of period $ 36.0 $ 36.8
    Number of share options exercised   (0.1)
    Weighted average exercise price of share options exercised   $ 37.6
    Number of share options outstanding at end of period 0.1 0.1
    Weighted average exercise price of share options outstanding at end of period $ 33.7 $ 36.0
    Number of share options exercisable 0.1 0.1
    Weighted average exercise price of share options exercisable $ 33.7 $ 36.0
    Alcon, Inc., equity plan, converted, Share-settled appreciation rights (SSAR) [member]    
    Disclosure of number and weighted average exercise prices of share options [roll forward]    
    Number of share options outstanding at beginning of period 1.4 1.8
    Weighted average exercise price of share options outstanding at beginning of period $ 35.9 $ 36.6
    Number of share options exercised (0.6) (0.4)
    Weighted average exercise price of share options exercised $ 39.8 $ 38.9
    Number of share options outstanding at end of period 0.8 1.4
    Weighted average exercise price of share options outstanding at end of period $ 33.0 $ 35.9
    Number of share options exercisable 0.8 1.4
    Weighted average exercise price of share options exercisable $ 33.0 $ 35.9
    XML 230 R163.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Transactions with related parties (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Disclosure of transactions between related parties [line items]      
    Net sales to third parties from continuing operations $ 49,109 $ 48,518 $ 49,414
    Executive Commitee members 11 14 11
    Non-executive directors 13 13 12
    Roche Holding AG [member]      
    Disclosure of transactions between related parties [line items]      
    Proportion of voting rights held in associate 33.30% 33.30% 33.30%
    Genentech / Roche [member]      
    Disclosure of transactions between related parties [line items]      
    Net expense, royalties cost sharing and profit sharing $ (33) $ (217) $ (309)
    Number of contracts with related parties 2    
    Genentech / Roche [member] | Lucentis [member]      
    Disclosure of transactions between related parties [line items]      
    Net sales to third parties from continuing operations $ 1,900 1,800 2,100
    Genentech / Roche [member] | Xolair [member]      
    Disclosure of transactions between related parties [line items]      
    Net sales to third parties from continuing operations $ 920 $ 835 $ 755
    XML 231 R164.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Transactions with related parties (Details 2) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Disclosure of transactions between related parties [line items]      
    Benefits other than equity-based compensation $ 22.4 $ 24.8 $ 21.8
    Post-employment benefits 2.0 2.2 1.9
    Equity-based compensation 54.7 50.8 57.3
    Total 79.1 77.8 81.0
    Key management personnel of entity or parent [member]      
    Disclosure of transactions between related parties [line items]      
    Benefits other than equity-based compensation 18.4 20.8 17.1
    Post-employment benefits 2.0 2.2 1.9
    Equity-based compensation 49.9 46.2 52.9
    Total 70.3 69.2 71.9
    Non-Executive Director [member]      
    Disclosure of transactions between related parties [line items]      
    Benefits other than equity-based compensation 4.0 4.0 4.7
    Equity-based compensation 4.8 4.6 4.4
    Total $ 8.8 $ 8.6 $ 9.1
    XML 232 R165.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Transactions with related parties (Details 3)
    		 12 Months Ended
    Dec. 31, 2017
    USD ($)
    Dec. 31, 2017
    CHF (SFr)
    Dec. 31, 2016
    USD ($)
    Dec. 31, 2016
    CHF (SFr)
    Dec. 31, 2015
    USD ($)
    shares
    Dec. 31, 2015
    CHF (SFr)
    shares
    Disclosure of transactions between related parties [line items]            
    Key management personnel compensation $ 79,100,000   $ 77,800,000   $ 81,000,000  
    Key management personnel of entity or parent [member]            
    Disclosure of transactions between related parties [line items]            
    Key management personnel compensation 70,300,000   69,200,000   71,900,000  
    Prof. Dr. Brody [member]            
    Disclosure of transactions between related parties [line items]            
    Key management personnel compensation | SFr   SFr 0   SFr 25,000   SFr 100,000
    Prof. Dr. Zinkernagel [member]            
    Disclosure of transactions between related parties [line items]            
    Key management personnel compensation | SFr   0   50,000   200,000
    Dr. Alex Krauer [member]            
    Disclosure of transactions between related parties [line items]            
    Key management personnel compensation | SFr   60,000   60,000   60,000
    Dr. Daniel Vasella [member]            
    Disclosure of transactions between related parties [line items]            
    Key management personnel compensation $ 0 SFr 26,279 250,000 SFr 0 $ 250,000 SFr 0
    Key management personnel compensation, daily rate     25,000      
    Key management personnel compensation, annual guaranteed minimum     $ 250,000      
    Dr. James Bradner [member]            
    Disclosure of transactions between related parties [line items]            
    Key management personnel compensation, shares acquired | shares         10,000,000 10,000,000
    Key management personnel compensation, shares acquired, price         $ 10,000,000  
    Key management personnel compensation, ownership interest acquired         7.00% 7.00%
    XML 233 R166.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Commitments and contingencies (Details)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    USD ($)
    Schedule for commitments under fixed term operating leases [line items]  
    Leasing commitments $ 3,169
    Expense of current year 337
    Not later than one year  
    Schedule for commitments under fixed term operating leases [line items]  
    Leasing commitments 309
    Later than one year and not later than two years [member]  
    Schedule for commitments under fixed term operating leases [line items]  
    Leasing commitments 224
    Later than two years and not later than three years [member]  
    Schedule for commitments under fixed term operating leases [line items]  
    Leasing commitments 161
    Later than three years and not later than four years [member]  
    Schedule for commitments under fixed term operating leases [line items]  
    Leasing commitments 131
    Later than four years and not later than five years [member]  
    Schedule for commitments under fixed term operating leases [line items]  
    Leasing commitments 123
    Later than five years  
    Schedule for commitments under fixed term operating leases [line items]  
    Leasing commitments $ 2,221
    XML 234 R167.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Commitments and contingencies (Details 2)
    $ in Millions
    Dec. 31, 2017
    USD ($)
    Schedule for commitments under research and development and other intangible asset purchase [line items]  
    Commitments under long-term research and development agreements $ 4,306
    Other intangible asset purchase commitments 130
    Total 4,436
    Not later than one year  
    Schedule for commitments under research and development and other intangible asset purchase [line items]  
    Commitments under long-term research and development agreements 780
    Other intangible asset purchase commitments 130
    Total 910
    Later than one year and not later than two years [member]  
    Schedule for commitments under research and development and other intangible asset purchase [line items]  
    Commitments under long-term research and development agreements 671
    Total 671
    Later than two years and not later than three years [member]  
    Schedule for commitments under research and development and other intangible asset purchase [line items]  
    Commitments under long-term research and development agreements 864
    Total 864
    Later than three years and not later than four years [member]  
    Schedule for commitments under research and development and other intangible asset purchase [line items]  
    Commitments under long-term research and development agreements 801
    Total 801
    Later than four years and not later than five years [member]  
    Schedule for commitments under research and development and other intangible asset purchase [line items]  
    Commitments under long-term research and development agreements 353
    Total 353
    Later than five years  
    Schedule for commitments under research and development and other intangible asset purchase [line items]  
    Commitments under long-term research and development agreements 837
    Total $ 837
    XML 235 R168.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Financial instruments - additional disclosures (Details) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Disclosure of financial assets [line items]    
    Financial assets $ 22,938 $ 20,269
    Cash and cash equivalents [member]    
    Disclosure of financial assets [line items]    
    Financial assets 8,860 7,007
    Financial assets at fair value, class [member] | Financial assets at fair value through other comprehensive income, category [member]    
    Disclosure of financial assets [line items]    
    Financial assets 1,637 1,433
    Financial assets at fair value, class [member] | Financial assets at fair value through other comprehensive income, category [member] | Available-for-sale marketable securities [member]    
    Disclosure of financial assets [line items]    
    Financial assets 362 337
    Financial assets at fair value, class [member] | Financial assets at fair value through other comprehensive income, category [member] | Available-for-sale marketable securities [member] | Debt securities [member]    
    Disclosure of financial assets [line items]    
    Financial assets 328 306
    Financial assets at fair value, class [member] | Financial assets at fair value through other comprehensive income, category [member] | Available-for-sale marketable securities [member] | Fund investments [member]    
    Disclosure of financial assets [line items]    
    Financial assets 34 31
    Financial assets at fair value, class [member] | Financial assets at fair value through other comprehensive income, category [member] | Available-for-sale long-term financial investments [member]    
    Disclosure of financial assets [line items]    
    Financial assets 1,275 1,096
    Financial assets at fair value, class [member] | Financial assets at fair value through other comprehensive income, category [member] | Available-for-sale long-term financial investments [member] | Equity securities [member]    
    Disclosure of financial assets [line items]    
    Financial assets 1,109 989
    Financial assets at fair value, class [member] | Financial assets at fair value through other comprehensive income, category [member] | Available-for-sale long-term financial investments [member] | Fund investments [member]    
    Disclosure of financial assets [line items]    
    Financial assets 166 107
    Financial assets at fair value, class [member] | Financial assets at fair value through profit or loss, category [member]    
    Disclosure of financial assets [line items]    
    Financial assets 1,091 1,004
    Financial assets at fair value, class [member] | Financial assets at fair value through profit or loss, category [member] | Contingent consideration receivables [member]    
    Disclosure of financial assets [line items]    
    Financial assets 844 586
    Financial assets at fair value, class [member] | Financial assets at fair value through profit or loss, category [member] | Associated companies at fair value through profit and loss [member]    
    Disclosure of financial assets [line items]    
    Financial assets 216 188
    Financial assets at fair value, class [member] | Financial assets at fair value through profit or loss, category [member] | Derivative financial instruments [member]    
    Disclosure of financial assets [line items]    
    Financial assets 31 230
    Financial assets at amortised cost, class [member] | Financial assets at amortised cost, category [member]    
    Disclosure of financial assets [line items]    
    Financial assets 11,350 10,825
    Financial assets at amortised cost, class [member] | Financial assets at amortised cost, category [member] | Trade receivables and other current assets excluding pre-payments [member]    
    Disclosure of financial assets [line items]    
    Financial assets 10,650 10,202
    Financial assets at amortised cost, class [member] | Financial assets at amortised cost, category [member] | Accrued interest on debt securities and time deposits [member]    
    Disclosure of financial assets [line items]    
    Financial assets 1 1
    Financial assets at amortised cost, class [member] | Financial assets at amortised cost, category [member] | Time deposits with original maturity more than 90 days [member]    
    Disclosure of financial assets [line items]    
    Financial assets 125 108
    Financial assets at amortised cost, class [member] | Financial assets at amortised cost, category [member] | Long-term loans and receivables from customers and finance lease, advances, security deposits [member]    
    Disclosure of financial assets [line items]    
    Financial assets $ 574 $ 514
    XML 236 R169.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Financial instruments - additional disclosures (Details 2) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Disclosure of financial liabilities [line items]    
    Financial liabilities $ 34,625 $ 29,693
    Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member]    
    Disclosure of financial liabilities [line items]    
    Financial liabilities 33,594 28,559
    Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Current financial debt [member]    
    Disclosure of financial liabilities [line items]    
    Financial liabilities 5,201 5,789
    Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Current financial debt [member] | Interest bearning accounts of associates payable on demand [member]    
    Disclosure of financial liabilities [line items]    
    Financial liabilities 1,822 1,601
    Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Current financial debt [member] | Bank and other financial debt [member]    
    Disclosure of financial liabilities [line items]    
    Financial liabilities 692 836
    Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Current financial debt [member] | Commercial paper [member]    
    Disclosure of financial liabilities [line items]    
    Financial liabilities 2,328 3,174
    Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Current financial debt [member] | Current portion of non-current debt [member]    
    Disclosure of financial liabilities [line items]    
    Financial liabilities 359 178
    Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Non-current financial debt [member]    
    Disclosure of financial liabilities [line items]    
    Financial liabilities 23,224 17,897
    Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Non-current financial debt [member] | Current portion of non-current debt [member]    
    Disclosure of financial liabilities [line items]    
    Financial liabilities 359 178
    Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Non-current financial debt [member] | Straight bonds [member]    
    Disclosure of financial liabilities [line items]    
    Financial liabilities 22,957 17,285
    Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Non-current financial debt [member] | Liabilities to banks and other financial institutions [member]    
    Disclosure of financial liabilities [line items]    
    Financial liabilities 539 708
    Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Non-current financial debt [member] | Finance lease obligations [member]    
    Disclosure of financial liabilities [line items]    
    Financial liabilities 87 82
    Financial liabilities at amortised cost, class [member] | Financial liabilities at amortised cost, category [member] | Trade payables [member]    
    Disclosure of financial liabilities [line items]    
    Financial liabilities 5,169 4,873
    Financial liabilities at fair value, class [member] | Financial liabilities at fair value through profit or loss, category [member]    
    Disclosure of financial liabilities [line items]    
    Financial liabilities 1,031 1,134
    Financial liabilities at fair value, class [member] | Financial liabilities at fair value through profit or loss, category [member] | Contingent consideration and other financial liabilities [member]    
    Disclosure of financial liabilities [line items]    
    Financial liabilities 924 1,018
    Financial liabilities at fair value, class [member] | Financial liabilities at fair value through profit or loss, category [member] | Derivative financial instruments [member]    
    Disclosure of financial liabilities [line items]    
    Financial liabilities $ 107 $ 116
    XML 237 R170.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Financial instruments - additional disclosures (Details 3) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Contract or underlying principal amout [member]    
    Disclosure of derivative financial instruments [line items]    
    Derivative financial instruments $ 8,410 $ 8,220
    Positive fair values [member]    
    Disclosure of derivative financial instruments [line items]    
    Derivative financial instruments 31 230
    Negative fair values [member]    
    Disclosure of derivative financial instruments [line items]    
    Derivative financial instruments (107) (116)
    Derivative financial instruments, at fair value currency related [member] | Contract or underlying principal amout [member]    
    Disclosure of derivative financial instruments [line items]    
    Derivative financial instruments, forward foreign exchange rate contracts 8,410 8,220
    Derivative financial instruments, at fair value currency related [member] | Positive fair values [member]    
    Disclosure of derivative financial instruments [line items]    
    Derivative financial instruments, forward foreign exchange rate contracts 31 230
    Derivative financial instruments, at fair value currency related [member] | Negative fair values [member]    
    Disclosure of derivative financial instruments [line items]    
    Derivative financial instruments, forward foreign exchange rate contracts $ (107) $ (116)
    XML 238 R171.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Financial instruments - additional disclosures (Details 4) - Contract or underlying principal amout [member] - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Disclosure of derivative financial instruments [line items]    
    Derivative financial instruments $ 8,410 $ 8,220
    EUR    
    Disclosure of derivative financial instruments [line items]    
    Derivative financial instruments 2,768 3,623
    USD    
    Disclosure of derivative financial instruments [line items]    
    Derivative financial instruments 4,361 3,427
    JPY    
    Disclosure of derivative financial instruments [line items]    
    Derivative financial instruments   43
    Others    
    Disclosure of derivative financial instruments [line items]    
    Derivative financial instruments 1,281 1,127
    Derivative financial instruments, at fair value currency related [member]    
    Disclosure of derivative financial instruments [line items]    
    Derivative financial instruments, forward foreign exchange rate contracts 8,410 8,220
    Derivative financial instruments, at fair value currency related [member] | EUR    
    Disclosure of derivative financial instruments [line items]    
    Derivative financial instruments, forward foreign exchange rate contracts 2,768 3,623
    Derivative financial instruments, at fair value currency related [member] | USD    
    Disclosure of derivative financial instruments [line items]    
    Derivative financial instruments, forward foreign exchange rate contracts 4,361 3,427
    Derivative financial instruments, at fair value currency related [member] | JPY    
    Disclosure of derivative financial instruments [line items]    
    Derivative financial instruments, forward foreign exchange rate contracts   43
    Derivative financial instruments, at fair value currency related [member] | Others    
    Disclosure of derivative financial instruments [line items]    
    Derivative financial instruments, forward foreign exchange rate contracts $ 1,281 $ 1,127
    XML 239 R172.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Financial instruments - additional disclosures (Details 5) - Recurring fair value measurement [member] - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Marketable securities, time deposits and derivative financial instruments [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value $ 519 $ 676
    Marketable securities, time deposits and derivative financial instruments [member] | Debt securities    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 328 306
    Marketable securities, time deposits and derivative financial instruments [member] | Fund investments [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 34 31
    Marketable securities, time deposits and derivative financial instruments [member] | Total available-for-sale marketable securities [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 362 337
    Marketable securities, time deposits and derivative financial instruments [member] | Time deposits with original maturity more than 90 days [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 125 108
    Marketable securities, time deposits and derivative financial instruments [member] | Derivative financial instruments [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 31 230
    Marketable securities, time deposits and derivative financial instruments [member] | Accrued interest on debt securities and time deposits [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 1 1
    Financial investments and long-term loans [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 2,243 2,196
    Financial investments and long-term loans [member] | Fund investments [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 166 107
    Financial investments and long-term loans [member] | Available-for-sale financial investments [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 1,109 989
    Financial investments and long-term loans [member] | Contingent consideration receivables [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 394 586
    Financial investments and long-term loans [member] | Long-term loans and receivables from customers and finance lease, advances, security deposits [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 574 514
    Associated companies at fair value through profit and loss [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 216 188
    Contingent consideration receivables short-term [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 450  
    Level 1 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 337 315
    Level 1 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Debt securities    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 303 284
    Level 1 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Fund investments [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 34 31
    Level 1 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Total available-for-sale marketable securities [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 337 315
    Level 1 of fair value hierarchy [member] | Financial investments and long-term loans [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 672 513
    Level 1 of fair value hierarchy [member] | Financial investments and long-term loans [member] | Available-for-sale financial investments [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 672 513
    Level 1 of fair value hierarchy [member] | Associated companies at fair value through profit and loss [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 28  
    Level 2 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 56 252
    Level 2 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Debt securities    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 25 22
    Level 2 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Total available-for-sale marketable securities [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 25 22
    Level 2 of fair value hierarchy [member] | Marketable securities, time deposits and derivative financial instruments [member] | Derivative financial instruments [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 31 230
    Level 3 of fair value hierarchy [member] | Financial investments and long-term loans [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 997 1,169
    Level 3 of fair value hierarchy [member] | Financial investments and long-term loans [member] | Fund investments [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 166 107
    Level 3 of fair value hierarchy [member] | Financial investments and long-term loans [member] | Available-for-sale financial investments [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 437 476
    Level 3 of fair value hierarchy [member] | Financial investments and long-term loans [member] | Contingent consideration receivables [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 394 586
    Level 3 of fair value hierarchy [member] | Associated companies at fair value through profit and loss [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 188 188
    Level 3 of fair value hierarchy [member] | Contingent consideration receivables short-term [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 450  
    Valued at amortized cost [member] | Marketable securities, time deposits and derivative financial instruments [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 126 109
    Valued at amortized cost [member] | Marketable securities, time deposits and derivative financial instruments [member] | Time deposits with original maturity more than 90 days [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 125 108
    Valued at amortized cost [member] | Marketable securities, time deposits and derivative financial instruments [member] | Accrued interest on debt securities and time deposits [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 1 1
    Valued at amortized cost [member] | Financial investments and long-term loans [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value 574 514
    Valued at amortized cost [member] | Financial investments and long-term loans [member] | Long-term loans and receivables from customers and finance lease, advances, security deposits [member]    
    Disclosure of fair value measurement of assets [line items]    
    Financial assets, at fair value $ 574 $ 514
    XML 240 R173.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Financial instruments - additional disclosures (Details 6) - Recurring fair value measurement [member] - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Disclosure of fair value measurement of liabilities [line items]    
    Financial liabilities, at fair value $ (1,031) $ (1,134)
    Contingent consideration payables [member]    
    Disclosure of fair value measurement of liabilities [line items]    
    Financial liabilities, at fair value (852) (889)
    Other financial liabilities [member]    
    Disclosure of fair value measurement of liabilities [line items]    
    Financial liabilities, at fair value (72) (129)
    Derivative financial instruments [member]    
    Disclosure of fair value measurement of liabilities [line items]    
    Financial liabilities, at fair value (107) (116)
    Level 2 of fair value hierarchy [member]    
    Disclosure of fair value measurement of liabilities [line items]    
    Financial liabilities, at fair value (107) (116)
    Level 2 of fair value hierarchy [member] | Derivative financial instruments [member]    
    Disclosure of fair value measurement of liabilities [line items]    
    Financial liabilities, at fair value (107) (116)
    Level 3 of fair value hierarchy [member]    
    Disclosure of fair value measurement of liabilities [line items]    
    Financial liabilities, at fair value (924) (1,018)
    Level 3 of fair value hierarchy [member] | Contingent consideration payables [member]    
    Disclosure of fair value measurement of liabilities [line items]    
    Financial liabilities, at fair value (852) (889)
    Level 3 of fair value hierarchy [member] | Other financial liabilities [member]    
    Disclosure of fair value measurement of liabilities [line items]    
    Financial liabilities, at fair value $ (72) $ (129)
    XML 241 R174.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Financial instruments - additional disclosures (Details 7) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Associated companies at fair value through profit and loss [member]    
    Disclosure of derivative financial instruments [line items]    
    Fair value measurement, carrying value, level 3, at beginning of period $ 188 $ 181
    Fair value gains and other adjustments including from divestments recognized in the consolidated income statement 45 26
    Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement (34) (28)
    Purchases fair value measurement assets 37 41
    Disposals fair value measurement assets (19) (3)
    Reclassification fair value measurement assets (29) (29)
    Fair value measurement, carrying value, level 3, at end of period 188 188
    Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end 11 (2)
    Fund investments [member]    
    Disclosure of derivative financial instruments [line items]    
    Fair value measurement, carrying value, level 3, at beginning of period 107 94
    Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement   (1)
    Fair value adjustments recognized in the consolidated statement of comprehensive income 45 14
    Purchases fair value measurement assets 28 5
    Disposals fair value measurement assets (18) (5)
    Reclassification fair value measurement assets 4  
    Fair value measurement, carrying value, level 3, at end of period 166 107
    Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end 0 (1)
    Available-for-sale financial investments [member]    
    Disclosure of derivative financial instruments [line items]    
    Fair value measurement, carrying value, level 3, at beginning of period 476 473
    Fair value gains and other adjustments including from divestments recognized in the consolidated income statement 32 1
    Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement (45) (24)
    Fair value adjustments recognized in the consolidated statement of comprehensive income (40) (8)
    Purchases fair value measurement assets 113 122
    Disposals fair value measurement assets (52) (18)
    Reclassification fair value measurement assets (47) (70)
    Fair value measurement, carrying value, level 3, at end of period 437 476
    Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end (13) (23)
    Contingent consideration receivables [member]    
    Disclosure of derivative financial instruments [line items]    
    Fair value measurement, carrying value, level 3, at beginning of period 586 550
    Fair value gains and other adjustments including from divestments recognized in the consolidated income statement 278 51
    Cash receipts and payments fair value measurement assets (20) (15)
    Fair value measurement, carrying value, level 3, at end of period 844 586
    Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end 278 51
    Contingent consideration payables [member]    
    Disclosure of derivative financial instruments [line items]    
    Fair value measurement, carrying value, level 3, at beginning of period (889) (790)
    Fair value gains and other adjustments including from divestments recognized in the consolidated income statement 362  
    Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement (193) (156)
    Purchases fair value measurement assets (238) (172)
    Cash receipts and payments fair value measurement assets 106 229
    Fair value measurement, carrying value, level 3, at end of period (852) (889)
    Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end 169 (156)
    Other financial liabilities [member]    
    Disclosure of derivative financial instruments [line items]    
    Fair value measurement, carrying value, level 3, at beginning of period (129) (315)
    Fair value gains and other adjustments including from divestments recognized in the consolidated income statement   3
    Fair value losses (including impairments and amortizations) and other adjustments recognized in the consolidated income statement (37)  
    Cash receipts and payments fair value measurement assets 94 183
    Fair value measurement, carrying value, level 3, at end of period (72) (129)
    Total fair value gains and (losses) recognized in the consolidated income statement for assets and liabilities held at period end $ (37) $ 3
    XML 242 R175.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Financial instruments - additional disclosures (Details 8) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Maturity of net debt [line items]    
    Current financial assets $ 9,485 $ 7,777
    Non-current financial debts (23,224) (17,897)
    Current financial debt (5,308) (5,905)
    Net debt (19,047) (16,025)
    Marketable securities and time deposits [member]    
    Maturity of net debt [line items]    
    Current financial assets 487 445
    Commodities [member]    
    Maturity of net debt [line items]    
    Current financial assets 106 94
    Deriviative financial instruments and accrued interest [member]    
    Maturity of net debt [line items]    
    Current financial assets 32 231
    Cash and cash equivalents [member]    
    Maturity of net debt [line items]    
    Current financial assets 8,860 7,007
    Financial debt [member]    
    Maturity of net debt [line items]    
    Non-current financial debts (23,224) (17,897)
    Current financial debt (5,201) (5,789)
    Financial debt - undiscounted [member]    
    Maturity of net debt [line items]    
    Non-current financial debts (23,412) (18,056)
    Current financial debt (5,201) (5,789)
    Derivative financial instruments [member]    
    Maturity of net debt [line items]    
    Current financial debt (107) (116)
    Not later than one month [member]    
    Maturity of net debt [line items]    
    Current financial assets 4,338 5,977
    Current financial debt (4,607) (5,114)
    Net debt (269) 863
    Not later than one month [member] | Marketable securities and time deposits [member]    
    Maturity of net debt [line items]    
    Current financial assets 71 32
    Not later than one month [member] | Deriviative financial instruments and accrued interest [member]    
    Maturity of net debt [line items]    
    Current financial assets 7 38
    Not later than one month [member] | Cash and cash equivalents [member]    
    Maturity of net debt [line items]    
    Current financial assets 4,260 5,907
    Not later than one month [member] | Financial debt [member]    
    Maturity of net debt [line items]    
    Current financial debt (4,576) (5,099)
    Not later than one month [member] | Financial debt - undiscounted [member]    
    Maturity of net debt [line items]    
    Current financial debt (4,576) (5,099)
    Not later than one month [member] | Derivative financial instruments [member]    
    Maturity of net debt [line items]    
    Current financial debt (31) (15)
    Later than one month and not later than three months [member]    
    Maturity of net debt [line items]    
    Current financial assets 4,691 1,328
    Current financial debt (217) (322)
    Net debt 4,474 1,006
    Later than one month and not later than three months [member] | Marketable securities and time deposits [member]    
    Maturity of net debt [line items]    
    Current financial assets 72 126
    Later than one month and not later than three months [member] | Deriviative financial instruments and accrued interest [member]    
    Maturity of net debt [line items]    
    Current financial assets 19 102
    Later than one month and not later than three months [member] | Cash and cash equivalents [member]    
    Maturity of net debt [line items]    
    Current financial assets 4,600 1,100
    Later than one month and not later than three months [member] | Financial debt [member]    
    Maturity of net debt [line items]    
    Current financial debt (169) (250)
    Later than one month and not later than three months [member] | Financial debt - undiscounted [member]    
    Maturity of net debt [line items]    
    Current financial debt (169) (250)
    Later than one month and not later than three months [member] | Derivative financial instruments [member]    
    Maturity of net debt [line items]    
    Current financial debt (48) (72)
    Later than three month and not later than twelve months [member]    
    Maturity of net debt [line items]    
    Current financial assets 111 201
    Current financial debt (484) (469)
    Net debt (373) (268)
    Later than three month and not later than twelve months [member] | Marketable securities and time deposits [member]    
    Maturity of net debt [line items]    
    Current financial assets 105 110
    Later than three month and not later than twelve months [member] | Deriviative financial instruments and accrued interest [member]    
    Maturity of net debt [line items]    
    Current financial assets 6 91
    Later than three month and not later than twelve months [member] | Financial debt [member]    
    Maturity of net debt [line items]    
    Current financial debt (456) (440)
    Later than three month and not later than twelve months [member] | Financial debt - undiscounted [member]    
    Maturity of net debt [line items]    
    Current financial debt (456) (440)
    Later than three month and not later than twelve months [member] | Derivative financial instruments [member]    
    Maturity of net debt [line items]    
    Current financial debt (28) (29)
    Between one and five years    
    Maturity of net debt [line items]    
    Current financial assets 181 124
    Non-current financial debts (9,849) (5,141)
    Net debt (9,668) (5,017)
    Between one and five years | Marketable securities and time deposits [member]    
    Maturity of net debt [line items]    
    Current financial assets 181 124
    Between one and five years | Financial debt [member]    
    Maturity of net debt [line items]    
    Non-current financial debts (9,849) (5,141)
    Between one and five years | Financial debt - undiscounted [member]    
    Maturity of net debt [line items]    
    Non-current financial debts (9,893) (5,155)
    Later than five years    
    Maturity of net debt [line items]    
    Current financial assets 164 147
    Non-current financial debts (13,375) (12,756)
    Net debt (13,211) (12,609)
    Later than five years | Marketable securities and time deposits [member]    
    Maturity of net debt [line items]    
    Current financial assets 58 53
    Later than five years | Commodities [member]    
    Maturity of net debt [line items]    
    Current financial assets 106 94
    Later than five years | Financial debt [member]    
    Maturity of net debt [line items]    
    Non-current financial debts (13,375) (12,756)
    Later than five years | Financial debt - undiscounted [member]    
    Maturity of net debt [line items]    
    Non-current financial debts $ (13,519) $ (12,901)
    XML 243 R176.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Financial instruments - additional disclosures (Details 9) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Derivative financial instruments and accrued interest on derivative financial instruments [line items]    
    Potential outflows in various currencies - from financial derivative liabilities $ (4,749) $ (4,360)
    Potential inflows in various currencies - from financial derivative assets 4,654 4,447
    Not later than one month [member]    
    Derivative financial instruments and accrued interest on derivative financial instruments [line items]    
    Potential outflows in various currencies - from financial derivative liabilities (953) (1,087)
    Potential inflows in various currencies - from financial derivative assets 928 1,109
    Later than one month and not later than three months [member]    
    Derivative financial instruments and accrued interest on derivative financial instruments [line items]    
    Potential outflows in various currencies - from financial derivative liabilities (972) (1,246)
    Potential inflows in various currencies - from financial derivative assets 948 1,287
    Later than three month and not later than twelve months [member]    
    Derivative financial instruments and accrued interest on derivative financial instruments [line items]    
    Potential outflows in various currencies - from financial derivative liabilities (2,824) (2,027)
    Potential inflows in various currencies - from financial derivative assets $ 2,778 $ 2,051
    XML 244 R177.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Financial instruments - additional disclosures (Details 10) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Derivative financial instruments and accrued interest on derivative financial instruments [line items]    
    Contractual interest on non-current liabilities $ (6,244) $ (6,246)
    Trade payables and commitment for repurchase of own shares (5,169) (4,873)
    Later than one month and not later than three months [member]    
    Derivative financial instruments and accrued interest on derivative financial instruments [line items]    
    Contractual interest on non-current liabilities (113) (104)
    Trade payables and commitment for repurchase of own shares (5,169) (4,873)
    Later than three month and not later than twelve months [member]    
    Derivative financial instruments and accrued interest on derivative financial instruments [line items]    
    Contractual interest on non-current liabilities (507) (433)
    Between one and five years    
    Derivative financial instruments and accrued interest on derivative financial instruments [line items]    
    Contractual interest on non-current liabilities (1,765) (1,694)
    Later than five years    
    Derivative financial instruments and accrued interest on derivative financial instruments [line items]    
    Contractual interest on non-current liabilities $ (3,859) $ (4,015)
    XML 245 R178.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Financial instruments - additional disclosures (Details 11) - USD ($)
    $ in Millions
    Dec. 31, 2017
    Dec. 31, 2016
    Ten day loss fair value VAR model [line items]    
    All financial instruments $ 498 $ 541
    Instruments sensitive to foreign currency exchange rates 184 222
    Instruments sensitive to equity market movements 27 26
    Instruments sensitive to interest rates 242 328
    Average    
    Ten day loss fair value VAR model [line items]    
    All financial instruments 521 402
    Instruments sensitive to foreign currency exchange rates 277 203
    Instruments sensitive to equity market movements 28 50
    Instruments sensitive to interest rates 282 308
    High    
    Ten day loss fair value VAR model [line items]    
    All financial instruments 560 541
    Instruments sensitive to foreign currency exchange rates 352 245
    Instruments sensitive to equity market movements 35 99
    Instruments sensitive to interest rates 338 407
    Low    
    Ten day loss fair value VAR model [line items]    
    All financial instruments 466 316
    Instruments sensitive to foreign currency exchange rates 184 147
    Instruments sensitive to equity market movements 21 26
    Instruments sensitive to interest rates 219 234
    Worst case loss scenario    
    Ten day loss fair value VAR model [line items]    
    All financial instruments 7 6
    Instruments sensitive to interest rates $ 7 $ 6
    XML 246 R179.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Financial instruments - additional disclosures (Details 12)
    $ in Millions, € in Billions, ¥ in Billions
    		 12 Months Ended
    Dec. 31, 2017
    USD ($)
    Dec. 31, 2016
    USD ($)
    Dec. 31, 2017
    EUR (€)
    Dec. 31, 2017
    JPY (¥)
    Dec. 31, 2015
    USD ($)
    Disclosure of derivative financial instruments [line items]          
    Transfers out of Level 3 of fair value hierarchy, assets $ 73 $ 75      
    Amount of change in OCI when pricing parameters for level 3 change more than 10% 79        
    Amount of change in OCI when most significant parameters for level 3 change more than 10% 333        
    Amount of change in OCI when POS for level 3 change more than 10% 322        
    Most significant foreign exchange losses   300      
    Long-term financial debt with a carrying amount $ 2,200   € 1.8    
    Maximum margin percentage impact of commodity price change 10.00%        
    Maximum holding in unrelated company 5.00%        
    Unrealized loss was recognized in other comprehensive income and accumulated in currency translation effects in relation with this net investment hedge $ 237        
    Net investment hedge recognized in the income statement 0        
    Borrowings commercial paper maximum borrowing amount $ 2,300 3,200      
    Borrowings commercial paper, number of programs 3   3 3  
    Borrowings credit facility committed $ 6,000 $ 6,000     $ 6,000
    Debt/equity ratio 0.38:1 0.32:1      
    VAR estimate confidence interval 95.00%   95.00% 95.00%  
    US commercial paper programs [member]          
    Disclosure of derivative financial instruments [line items]          
    Borrowings commercial paper maximum borrowing amount $ 9,000        
    Borrowings commercial paper, number of programs 2   2 2  
    JP commercial paper programs [member]          
    Disclosure of derivative financial instruments [line items]          
    Borrowings commercial paper maximum borrowing amount $ 1,300     ¥ 150  
    Borrowings commercial paper, number of programs 1   1 1  
    Largest financial institution [member]          
    Counterparty risk [abstract]          
    Percentage of entity's cash and cash equivalents held with financial institution 20.20% 16.50%      
    Second largest financial institution [member]          
    Counterparty risk [abstract]          
    Percentage of entity's cash and cash equivalents held with financial institution 15.00% 6.90%      
    Third largest financial institution [member]          
    Counterparty risk [abstract]          
    Percentage of entity's cash and cash equivalents held with financial institution 12.70% 6.70%      
    XML 247 R180.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Financial instruments - additional disclosures (Details 13)
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Disclosure of major customers [line items]      
    Customers with net sales over five percent No other customer accounted for 5% or more of net sales in either year.    
    Largest customer [member]      
    Disclosure of major customers [line items]      
    Percentage of entity's revenue 17.00% 16.00% 14.00%
    Highest amount of trade receivables 14.00% 14.00%  
    Second largest customer [member]      
    Disclosure of major customers [line items]      
    Percentage of entity's revenue 12.00% 12.00% 11.00%
    Highest amount of trade receivables 9.00% 9.00%  
    Third largest customer [member]      
    Disclosure of major customers [line items]      
    Percentage of entity's revenue 7.00% 6.00% 5.00%
    Highest amount of trade receivables 5.00% 6.00%  
    XML 248 R181.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Discontinued operations (Details) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Statement [line items]      
    Net sales to third parties of discontinued operations $ 49,109 $ 48,518 $ 49,414
    Net sales of discontinued operations 49,109 48,518 49,440
    Other revenues 1,026 918 947
    Cost of goods sold (17,175) (17,520) (17,404)
    Gross profit of discontinued operations 32,960 31,916 32,983
    Marketing and Sales (12,861) (11,998) (11,772)
    Research and Development (8,972) (9,039) (8,935)
    General and Administration (2,136) (2,194) (2,475)
    Other income 1,969 1,927 2,049
    Other expense (2,331) (2,344) (2,873)
    Income from associated companies $ 1,108 $ 703 266
    Income loss before taxes from discontinued operations     12,479
    Net income from discontinued operations     10,766
    Discontinued operations [member]      
    Statement [line items]      
    Net sales to third parties of discontinued operations     601
    Sales to continuing segments     19
    Net sales of discontinued operations     620
    Other revenues     23
    Cost of goods sold     (376)
    Gross profit of discontinued operations     267
    Marketing and Sales     (244)
    Research and Development     (181)
    General and Administration     (58)
    Other income     13,420
    Other expense     (727)
    Operating income/loss of discontinued operations     12,477
    Income from associated companies     2
    Income loss before taxes from discontinued operations     12,479
    Income tax expense of discontinued operations     (1,713)
    Net income from discontinued operations     10,766
    Discontinued operations [member] | Vaccines      
    Statement [line items]      
    Net sales to third parties of discontinued operations     145
    Sales to continuing segments     18
    Net sales of discontinued operations     163
    Other revenues     18
    Cost of goods sold     (192)
    Gross profit of discontinued operations     (11)
    Marketing and Sales     (57)
    Research and Development     (151)
    General and Administration     (26)
    Other income     2,870
    Other expense     (57)
    Operating income/loss of discontinued operations     2,568
    Income from associated companies     2
    Discontinued operations [member] | Consumer Health      
    Statement [line items]      
    Net sales to third parties of discontinued operations     456
    Sales to continuing segments     1
    Net sales of discontinued operations     457
    Other revenues     5
    Cost of goods sold     (184)
    Gross profit of discontinued operations     278
    Marketing and Sales     (187)
    Research and Development     (30)
    General and Administration     (32)
    Other income     10,558
    Other expense     (14)
    Operating income/loss of discontinued operations     10,573
    Discontinued operations [member] | Corporate      
    Statement [line items]      
    Other income     (8)
    Other expense     (656)
    Operating income/loss of discontinued operations     $ (664)
    XML 249 R182.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Discontinued operations (Details 2) - USD ($)
    $ in Millions
    		 12 Months Ended
    Dec. 31, 2017
    Dec. 31, 2016
    Dec. 31, 2015
    Statement [line items]      
    Equity-based compensation of Novartis equity plans $ (924) $ (846) $ (968)
    Restructuring provision      
    Statement [line items]      
    Additional provisions, other provisions 194 343 399
    Property, plant and equipment [member]      
    Statement [line items]      
    Impairment (loss) reversal of impairment loss recognised in profit or loss $ (157) $ (102) (80)
    Discontinued operations [member]      
    Statement [line items]      
    Equity-based compensation of Novartis equity plans     (65)
    Discontinued operations [member] | Restructuring provision      
    Statement [line items]      
    Additional provisions, other provisions     (1)
    Discontinued operations [member] | Property, plant and equipment [member]      
    Statement [line items]      
    Impairment (loss) reversal of impairment loss recognised in profit or loss     $ 83
    XML 250 R183.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Events subsequent to the December 31 consolidated balance sheet date (Details)
    $ in Billions
    		 12 Months Ended
    Dec. 31, 2017
    USD ($)
    Dec. 31, 2017
    SFr / shares
    Dec. 31, 2016
    USD ($)
    Statement [line items]      
    Dividends proposed | $ $ 6.7   $ 6.5
    Subsequent Event [member]      
    Statement [line items]      
    Dividends proposed, cash per share | SFr / shares   SFr 2.80  
    XML 251 R184.htm IDEA: XBRL DOCUMENT v3.8.0.1
    Principal Group subsidiaries and associated companies (Details) - 12 months ended Dec. 31, 2017
    ₨ in Millions, ¥ in Millions, VEF in Millions, TWD in Millions, TRY in Millions, THB in Millions, SEK in Millions, SAR in Millions, RUB in Millions, RON in Millions, PHP in Millions, NOK in Millions, MYR in Millions, MXN in Millions, MAD in Millions, HUF in Millions, HRK in Millions, DZD in Millions, DKK in Millions, CZK in Millions, COP in Millions, BRL in Millions, BDT in Millions, ARS in Millions, AED in Millions, ₩ in Billions, PKR in Billions, IDR in Billions, CLP in Billions
    USD ($)
    CHF (SFr)
    EUR (€)
    JPY (¥)
    DZD
    ARS
    AUD
    BDT
    BRL
    CAD
    CLP
    HKD
    COP
    HRK
    CZK
    DKK
    EGP
    HUF
    INR (₨)
    IDR
    ILS (₪)
    MYR
    MXN
    MAD
    NZD
    NOK
    PKR
    PAB
    PHP
    PLN
    RON
    RUB
    SAR
    SGD
    ZAR
    KRW (₩)
    SEK
    TWD
    THB
    TRY
    AED
    GBP (£)
    VEF
    Disclosure of subsidiaries [line items]                                                                                      
    Principal group companies materiality of assets or sales to third parties | $ $ 25,000,000                                                                                    
    Subsidiaries [member] | Societe par actions SANDOZ, Algiers [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Société par actions SANDOZ                                                                                    
    Principal place of business of subsidiary Algiers                                                                                    
    Country of incorporation of subsidiary Algeria                                                                                    
    Share/paid-in capital | DZD         DZD 650.0                                                                            
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Argentina S.A., Buenos Aires [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Argentina S.A.                                                                                    
    Principal place of business of subsidiary Buenos Aires                                                                                    
    Country of incorporation of subsidiary Argentina                                                                                    
    Share/paid-in capital | ARS           ARS 906.1                                                                          
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Laboratorios S.A., Buenos Aires [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Laboratorios S.A.                                                                                    
    Principal place of business of subsidiary Buenos Aires                                                                                    
    Country of incorporation of subsidiary Argentina                                                                                    
    Share/paid-in capital | ARS           ARS 83.9                                                                          
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Australia Pty Ltd, North Ryde, NSW [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Australia Pty Ltd                                                                                    
    Principal place of business of subsidiary North Ryde, NSW                                                                                    
    Country of incorporation of subsidiary Australia                                                                                    
    Share/paid-in capital | AUD             AUD 2                                                                        
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Pharmaceuticals Australia Pty Ltd, North Ryde, NSW [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Pharmaceuticals Australia Pty Ltd                                                                                    
    Principal place of business of subsidiary North Ryde, NSW                                                                                    
    Country of incorporation of subsidiary Australia                                                                                    
    Share/paid-in capital | AUD             3,800,000                                                                        
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz Pty Ltd, North Ryde, NSW [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz Pty Ltd                                                                                    
    Principal place of business of subsidiary North Ryde, NSW                                                                                    
    Country of incorporation of subsidiary Australia                                                                                    
    Share/paid-in capital | AUD             11,600,000                                                                        
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Laboratories (Australia) Pty Ltd, Frenchs Forest, NSW [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Laboratories (Australia) Pty Ltd                                                                                    
    Principal place of business of subsidiary Frenchs Forest, NSW                                                                                    
    Country of incorporation of subsidiary Australia                                                                                    
    Share/paid-in capital | AUD             AUD 2,600,000                                                                        
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Austria GmbH, Vienna [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Austria GmbH                                                                                    
    Principal place of business of subsidiary Vienna                                                                                    
    Country of incorporation of subsidiary Austria                                                                                    
    Share/paid-in capital     € 1,000,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Pharma GmbH, Vienna [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Pharma GmbH                                                                                    
    Principal place of business of subsidiary Vienna                                                                                    
    Country of incorporation of subsidiary Austria                                                                                    
    Share/paid-in capital     1,100,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz GmbH, Kundl [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz GmbH                                                                                    
    Principal place of business of subsidiary Kundl                                                                                    
    Country of incorporation of subsidiary Austria                                                                                    
    Share/paid-in capital     32,700,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | EBEWE Pharma Ges.m.b.H Nfg. KG, Unterach am Attersee [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary EBEWE Pharma Ges.m.b.H Nfg. KG                                                                                    
    Principal place of business of subsidiary Unterach am Attersee                                                                                    
    Country of incorporation of subsidiary Austria                                                                                    
    Share/paid-in capital     1,000,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis (Bangladesh) Limited, Gazipur [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis (Bangladesh) Limited                                                                                    
    Principal place of business of subsidiary Gazipur                                                                                    
    Country of incorporation of subsidiary Bangladesh                                                                                    
    Share/paid-in capital | BDT               BDT 162.5                                                                      
    Proportion of ownership interest in subsidiary 60.00%                                                                                    
    Proportion of voting rights held in subsidiary 60.00%                                                                                    
    Subsidiaries [member] | N.V. Novartis Pharma S.A., Vilvoorde [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary N.V. Novartis Pharma S.A.                                                                                    
    Principal place of business of subsidiary Vilvoorde                                                                                    
    Country of incorporation of subsidiary Belgium                                                                                    
    Share/paid-in capital     7,100,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | N.V. Sandoz S.A., Vilvoorde [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary N.V. Sandoz S.A.                                                                                    
    Principal place of business of subsidiary Vilvoorde                                                                                    
    Country of incorporation of subsidiary Belgium                                                                                    
    Share/paid-in capital     19,200,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | S.A. Alcon-Couvreur N.V., Puurs [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary S.A. Alcon-Couvreur N.V.                                                                                    
    Principal place of business of subsidiary Puurs                                                                                    
    Country of incorporation of subsidiary Belgium                                                                                    
    Share/paid-in capital     110,600,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | N.V. Alcon S.A., Vilvoorde [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary N.V. Alcon S.A.                                                                                    
    Principal place of business of subsidiary Vilvoorde                                                                                    
    Country of incorporation of subsidiary Belgium                                                                                    
    Share/paid-in capital     141,856                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Investment Ltd., Hamilton [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Investment Ltd.                                                                                    
    Principal place of business of subsidiary Hamilton                                                                                    
    Country of incorporation of subsidiary Bermuda                                                                                    
    Share/paid-in capital | $ $ 12,000                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Securities Investment Ltd., Hamilton [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Securities Investment Ltd.                                                                                    
    Principal place of business of subsidiary Hamilton                                                                                    
    Country of incorporation of subsidiary Bermuda                                                                                    
    Share/paid-in capital | SFr   SFr 30,000                                                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Finance Services Ltd., Hamilton [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Finance Services Ltd.                                                                                    
    Principal place of business of subsidiary Hamilton                                                                                    
    Country of incorporation of subsidiary Bermuda                                                                                    
    Share/paid-in capital | SFr   20,000                                                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis B2 Ltd., Hamilton [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis B2 Ltd.                                                                                    
    Principal place of business of subsidiary Hamilton                                                                                    
    Country of incorporation of subsidiary Bermuda                                                                                    
    Share/paid-in capital | $ $ 12,000                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis B3 Ltd., Hamilton [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis B3 Ltd.                                                                                    
    Principal place of business of subsidiary Hamilton                                                                                    
    Country of incorporation of subsidiary Bermuda                                                                                    
    Share/paid-in capital | $ $ 106,400                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Triangle International Reinsurance Limited, Hamilton [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Triangle International Reinsurance Limited                                                                                    
    Principal place of business of subsidiary Hamilton                                                                                    
    Country of incorporation of subsidiary Bermuda                                                                                    
    Share/paid-in capital | SFr   1,000,000                                                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Trinity River Insurance Co Ltd., Hamilton [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Trinity River Insurance Co Ltd.                                                                                    
    Principal place of business of subsidiary Hamilton                                                                                    
    Country of incorporation of subsidiary Bermuda                                                                                    
    Share/paid-in capital | $ $ 370,000                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Biociencias S.A., Sao Paulo [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Biociências S.A.                                                                                    
    Principal place of business of subsidiary São Paulo                                                                                    
    Country of incorporation of subsidiary Brazil                                                                                    
    Share/paid-in capital | BRL                 BRL 265.0                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz do Brasil Industria Farmaceutica Ltda., Cambe, PR [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz do Brasil Indústria Farmacêutica Ltda.                                                                                    
    Principal place of business of subsidiary Cambé, PR                                                                                    
    Country of incorporation of subsidiary Brazil                                                                                    
    Share/paid-in capital | BRL                 BRL 190.0                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Pharmaceuticals Canada Inc., Dorval, Quebec [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Pharmaceuticals Canada Inc.                                                                                    
    Principal place of business of subsidiary Dorval, Quebec                                                                                    
    Country of incorporation of subsidiary Canada                                                                                    
    Share/paid-in capital | CAD                   CAD 13,000,000                                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz Canada Inc., Boucherville, Quebec [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz Canada Inc.                                                                                    
    Principal place of business of subsidiary Boucherville, Quebec                                                                                    
    Country of incorporation of subsidiary Canada                                                                                    
    Share/paid-in capital | CAD                   80,800,000                                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Canada Inc., Mississauga, Ontario [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Canada Inc.                                                                                    
    Principal place of business of subsidiary Mississauga, Ontario                                                                                    
    Country of incorporation of subsidiary Canada                                                                                    
    Share/paid-in capital | CAD                   2,500                                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | CIBA Vision Canada Inc., Mississauga, Ontario [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary CIBA Vision Canada Inc.                                                                                    
    Principal place of business of subsidiary Mississauga, Ontario                                                                                    
    Country of incorporation of subsidiary Canada                                                                                    
    Share/paid-in capital | CAD                   CAD 82,886                                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Chile S.A., Santiago de Chile [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Chile S.A.                                                                                    
    Principal place of business of subsidiary Santiago de Chile                                                                                    
    Country of incorporation of subsidiary Chile                                                                                    
    Share/paid-in capital | CLP                     CLP 2.0                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Laboratorios Chile Ltd., Santiago de Chile [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Laboratorios Chile Ltd.                                                                                    
    Principal place of business of subsidiary Santiago de Chile                                                                                    
    Country of incorporation of subsidiary Chile                                                                                    
    Share/paid-in capital | CLP                     CLP 2.0                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Beijing Novartis Pharma Co., Ltd., Beijing [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Beijing Novartis Pharma Co., Ltd.                                                                                    
    Principal place of business of subsidiary Beijing                                                                                    
    Country of incorporation of subsidiary China                                                                                    
    Share/paid-in capital | $ $ 30,000,000                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Pharmaceuticals (HK) Limited, Hong Kong [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Pharmaceuticals (HK) Limited                                                                                    
    Principal place of business of subsidiary Hong Kong                                                                                    
    Country of incorporation of subsidiary China                                                                                    
    Share/paid-in capital | HKD                       HKD 200                                                              
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | China Novartis Institutes for BioMedical Research Co., Ltd., Shanghai [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary China Novartis Institutes for BioMedical Research Co., Ltd.                                                                                    
    Principal place of business of subsidiary Shanghai                                                                                    
    Country of incorporation of subsidiary China                                                                                    
    Share/paid-in capital | $ $ 320,000,000                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Suzhou Novartis Pharma Technology Co., Ltd., Changshu [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Suzhou Novartis Pharma Technology Co., Ltd.                                                                                    
    Principal place of business of subsidiary Changshu                                                                                    
    Country of incorporation of subsidiary China                                                                                    
    Share/paid-in capital | $ $ 103,400,000                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Shanghai Novartis Trading Ltd., Shanghai [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Shanghai Novartis Trading Ltd.                                                                                    
    Principal place of business of subsidiary Shanghai                                                                                    
    Country of incorporation of subsidiary China                                                                                    
    Share/paid-in capital | $ $ 3,200,000                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz (China) Pharmaceutical Co., Ltd., Zhongshan [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz (China) Pharmaceutical Co., Ltd.                                                                                    
    Principal place of business of subsidiary Zhongshan                                                                                    
    Country of incorporation of subsidiary China                                                                                    
    Share/paid-in capital | $ $ 36,500,000                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Hong Kong Limited, Hong Kong [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Hong Kong Limited                                                                                    
    Principal place of business of subsidiary Hong Kong                                                                                    
    Country of incorporation of subsidiary China                                                                                    
    Share/paid-in capital | HKD                       HKD 77,000                                                              
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon (China) Ophthalmic Product Co., Ltd., Beijing [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon (China) Ophthalmic Product Co., Ltd.                                                                                    
    Principal place of business of subsidiary Beijing                                                                                    
    Country of incorporation of subsidiary China                                                                                    
    Share/paid-in capital | $ $ 60,000,000                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis de Colombia S.A., Santafe de Bogota [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis de Colombia S.A.                                                                                    
    Principal place of business of subsidiary Santafé de Bogotá                                                                                    
    Country of incorporation of subsidiary Colombia                                                                                    
    Share/paid-in capital | COP                         COP 7,900.0                                                            
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Laboratorios Alcon de Colombia S.A., Santafe de Bogota [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Laboratorios Alcon de Colombia S.A.                                                                                    
    Principal place of business of subsidiary Santafé de Bogotá                                                                                    
    Country of incorporation of subsidiary Colombia                                                                                    
    Share/paid-in capital | COP                         COP 20.9                                                            
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz d.o.o. farmaceutska industrija, Zagreb [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz d.o.o. farmaceutska industrija                                                                                    
    Principal place of business of subsidiary Zagreb                                                                                    
    Country of incorporation of subsidiary Croatia                                                                                    
    Share/paid-in capital | HRK                           HRK 25.6                                                          
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis s.r.o., Prague [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis s.r.o.                                                                                    
    Principal place of business of subsidiary Prague                                                                                    
    Country of incorporation of subsidiary Czech Republic                                                                                    
    Share/paid-in capital | CZK                             CZK 51.5                                                        
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz s.r.o., Prague [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz s.r.o.                                                                                    
    Principal place of business of subsidiary Prague                                                                                    
    Country of incorporation of subsidiary Czech Republic                                                                                    
    Share/paid-in capital | CZK                             44.7                                                        
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Pharmaceuticals (Czech Republic) s.r.o., Prague [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Pharmaceuticals (Czech Republic) s.r.o.                                                                                    
    Principal place of business of subsidiary Prague                                                                                    
    Country of incorporation of subsidiary Czech Republic                                                                                    
    Share/paid-in capital | CZK                             CZK 31.0                                                        
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Healthcare A/S, Copenhagen [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Healthcare A/S                                                                                    
    Principal place of business of subsidiary Copenhagen                                                                                    
    Country of incorporation of subsidiary Denmark                                                                                    
    Share/paid-in capital | DKK                               DKK 14.0                                                      
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz A/S, Copenhagen [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz A/S                                                                                    
    Principal place of business of subsidiary Copenhagen                                                                                    
    Country of incorporation of subsidiary Denmark                                                                                    
    Share/paid-in capital | DKK                               12.0                                                      
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Nordic A/S, Copenhagen [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Nordic A/S                                                                                    
    Principal place of business of subsidiary Copenhagen                                                                                    
    Country of incorporation of subsidiary Denmark                                                                                    
    Share/paid-in capital | DKK                               DKK 0.5                                                      
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Ecuador S.A., Quito [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Ecuador S.A.                                                                                    
    Principal place of business of subsidiary Quito                                                                                    
    Country of incorporation of subsidiary Ecuador                                                                                    
    Share/paid-in capital | $ $ 4,000,000                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Pharma S.A.E., Cairo [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Pharma S.A.E.                                                                                    
    Principal place of business of subsidiary Cairo                                                                                    
    Country of incorporation of subsidiary Egypt                                                                                    
    Share/paid-in capital | EGP                                 EGP 193,800,000                                                    
    Proportion of ownership interest in subsidiary 99.77%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz Egypt Pharma S.A.E., New Cairo City [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz Egypt Pharma S.A.E.                                                                                    
    Principal place of business of subsidiary New Cairo City                                                                                    
    Country of incorporation of subsidiary Egypt                                                                                    
    Share/paid-in capital | EGP                                 EGP 250,000                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Finland Oy, Espoo [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Finland Oy                                                                                    
    Principal place of business of subsidiary Espoo                                                                                    
    Country of incorporation of subsidiary Finland                                                                                    
    Share/paid-in capital     459,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Groupe France S.A., Rueil-Malmaison [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Groupe France S.A.                                                                                    
    Principal place of business of subsidiary Rueil-Malmaison                                                                                    
    Country of incorporation of subsidiary France                                                                                    
    Share/paid-in capital     103,000,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Pharma S.A.S., Rueil-Malmaison [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Pharma S.A.S.                                                                                    
    Principal place of business of subsidiary Rueil-Malmaison                                                                                    
    Country of incorporation of subsidiary France                                                                                    
    Share/paid-in capital     43,400,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz S.A.S., Levallois-Perret [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz S.A.S.                                                                                    
    Principal place of business of subsidiary Levallois-Perret                                                                                    
    Country of incorporation of subsidiary France                                                                                    
    Share/paid-in capital     5,400,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Laboratoires Alcon S.A.S., Rueil-Malmaison [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Laboratoires Alcon S.A.S.                                                                                    
    Principal place of business of subsidiary Rueil-Malmaison                                                                                    
    Country of incorporation of subsidiary France                                                                                    
    Share/paid-in capital     12,900,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Deutschland GmbH, Wehr [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Deutschland GmbH                                                                                    
    Principal place of business of subsidiary Wehr                                                                                    
    Country of incorporation of subsidiary Germany                                                                                    
    Share/paid-in capital     155,500,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Pharma GmbH, Nuremberg [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Pharma GmbH                                                                                    
    Principal place of business of subsidiary Nuremberg                                                                                    
    Country of incorporation of subsidiary Germany                                                                                    
    Share/paid-in capital     25,600,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Pharma Produktions GmbH, Wehr [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Pharma Produktions GmbH                                                                                    
    Principal place of business of subsidiary Wehr                                                                                    
    Country of incorporation of subsidiary Germany                                                                                    
    Share/paid-in capital     2,000,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Pharma GmbH, Freiburg im Breisgau [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Pharma GmbH                                                                                    
    Principal place of business of subsidiary Freiburg im Breisgau                                                                                    
    Country of incorporation of subsidiary Germany                                                                                    
    Share/paid-in capital     512,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | WaveLight GmbH, Erlangen [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary WaveLight GmbH                                                                                    
    Principal place of business of subsidiary Erlangen                                                                                    
    Country of incorporation of subsidiary Germany                                                                                    
    Share/paid-in capital     6,600,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | CIBA Vision GmbH, Grosswallstadt [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary CIBA Vision GmbH                                                                                    
    Principal place of business of subsidiary Grosswallstadt                                                                                    
    Country of incorporation of subsidiary Germany                                                                                    
    Share/paid-in capital     15,400,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz International GmbH, Holzkirchen [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz International GmbH                                                                                    
    Principal place of business of subsidiary Holzkirchen                                                                                    
    Country of incorporation of subsidiary Germany                                                                                    
    Share/paid-in capital     100,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | 1 A Pharma GmbH, Oberhaching [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary 1 A Pharma GmbH                                                                                    
    Principal place of business of subsidiary Oberhaching                                                                                    
    Country of incorporation of subsidiary Germany                                                                                    
    Share/paid-in capital     26,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Salutas Pharma GmbH, Barleben [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Salutas Pharma GmbH                                                                                    
    Principal place of business of subsidiary Barleben                                                                                    
    Country of incorporation of subsidiary Germany                                                                                    
    Share/paid-in capital     42,100,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | HEXAL AG, Holzkirchen [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary HEXAL AG                                                                                    
    Principal place of business of subsidiary Holzkirchen                                                                                    
    Country of incorporation of subsidiary Germany                                                                                    
    Share/paid-in capital     93,700,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Aeropharm GmbH, Rudolstadt [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Aeropharm GmbH                                                                                    
    Principal place of business of subsidiary Rudolstadt                                                                                    
    Country of incorporation of subsidiary Germany                                                                                    
    Share/paid-in capital     26,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Business Services GmbH, Wehr [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Business Services GmbH                                                                                    
    Principal place of business of subsidiary Wehr                                                                                    
    Country of incorporation of subsidiary Germany                                                                                    
    Share/paid-in capital     25,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novista Insurance Limited, Gibraltar City [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novista Insurance Limited                                                                                    
    Principal place of business of subsidiary Gibraltar City                                                                                    
    Country of incorporation of subsidiary Gibraltar                                                                                    
    Share/paid-in capital | SFr   130,000,000                                                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis (Hellas) S.A.C.I., Metamorphosis/Athens [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis (Hellas) S.A.C.I.                                                                                    
    Principal place of business of subsidiary Metamorphosis/Athens                                                                                    
    Country of incorporation of subsidiary Greece                                                                                    
    Share/paid-in capital     23,400,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Laboratories Hellas Commercial and Industrial S.A., Maroussi, Athens [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Laboratories Hellas- Commercial and Industrial S.A.                                                                                    
    Principal place of business of subsidiary Maroussi, Athens                                                                                    
    Country of incorporation of subsidiary Greece                                                                                    
    Share/paid-in capital     5,700,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Hungary Healthcare Limited Liability Company, Budapest [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Hungary Healthcare Limited Liability Company                                                                                    
    Principal place of business of subsidiary Budapest                                                                                    
    Country of incorporation of subsidiary Hungary                                                                                    
    Share/paid-in capital | HUF                                   HUF 545.6                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz Hungary Limited Liability Company, Budapest [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz Hungary Limited Liability Company                                                                                    
    Principal place of business of subsidiary Budapest                                                                                    
    Country of incorporation of subsidiary Hungary                                                                                    
    Share/paid-in capital | HUF                                   HUF 883.0                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis India Limited, Mumbai [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis India Limited                                                                                    
    Principal place of business of subsidiary Mumbai                                                                                    
    Country of incorporation of subsidiary India                                                                                    
    Share/paid-in capital | ₨                                     ₨ 140.7                                                
    Proportion of ownership interest in subsidiary 73.40%                                                                                    
    Proportion of voting rights held in subsidiary 73.00%                                                                                    
    Subsidiaries [member] | Novartis Healthcare Private Limited, Mumbai [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Healthcare Private Limited                                                                                    
    Principal place of business of subsidiary Mumbai                                                                                    
    Country of incorporation of subsidiary India                                                                                    
    Share/paid-in capital | ₨                                     60.0                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz Private Limited, Mumbai [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz Private Limited                                                                                    
    Principal place of business of subsidiary Mumbai                                                                                    
    Country of incorporation of subsidiary India                                                                                    
    Share/paid-in capital | ₨                                     32.0                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Laboratories (India) Private Limited, Bangalore [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Laboratories (India) Private Limited                                                                                    
    Principal place of business of subsidiary Bangalore                                                                                    
    Country of incorporation of subsidiary India                                                                                    
    Share/paid-in capital | ₨                                     ₨ 1,100.0                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | PT. Novartis Indonesia, Jakarta [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary PT. Novartis Indonesia                                                                                    
    Principal place of business of subsidiary Jakarta                                                                                    
    Country of incorporation of subsidiary Indonesia                                                                                    
    Share/paid-in capital | IDR                                       IDR 7.7                                              
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | PT. CIBA Vision Batam, Batam [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary PT. CIBA Vision Batam                                                                                    
    Principal place of business of subsidiary Batam                                                                                    
    Country of incorporation of subsidiary Indonesia                                                                                    
    Share/paid-in capital | IDR                                       IDR 11.9                                              
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Ireland Limited, Dublin [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Ireland Limited                                                                                    
    Principal place of business of subsidiary Dublin                                                                                    
    Country of incorporation of subsidiary Ireland                                                                                    
    Share/paid-in capital     25,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Ringaskiddy Limited, Ringaskiddy, County Cork [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Ringaskiddy Limited                                                                                    
    Principal place of business of subsidiary Ringaskiddy, County Cork                                                                                    
    Country of incorporation of subsidiary Ireland                                                                                    
    Share/paid-in capital     2,000,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Laboratories Ireland Limited, Cork City [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Laboratories Ireland Limited                                                                                    
    Principal place of business of subsidiary Cork City                                                                                    
    Country of incorporation of subsidiary Ireland                                                                                    
    Share/paid-in capital     541,251                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Israel Ltd., Petach Tikva [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Israel Ltd.                                                                                    
    Principal place of business of subsidiary Petach Tikva                                                                                    
    Country of incorporation of subsidiary Israel                                                                                    
    Share/paid-in capital | ₪                                         ₪ 1,000                                            
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Optonol Ltd., Neve-Ilan [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Optonol Ltd.                                                                                    
    Principal place of business of subsidiary Neve-Ilan                                                                                    
    Country of incorporation of subsidiary Israel                                                                                    
    Share/paid-in capital | ₪                                         ₪ 752,545                                            
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Farma S.p.A., Origgio [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Farma S.p.A.                                                                                    
    Principal place of business of subsidiary Origgio                                                                                    
    Country of incorporation of subsidiary Italy                                                                                    
    Share/paid-in capital     18,200,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz S.p.A., Origgio [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz S.p.A.                                                                                    
    Principal place of business of subsidiary Origgio                                                                                    
    Country of incorporation of subsidiary Italy                                                                                    
    Share/paid-in capital     1,700,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz Industrial Products S.p.A., Rovereto [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz Industrial Products S.p.A.                                                                                    
    Principal place of business of subsidiary Rovereto                                                                                    
    Country of incorporation of subsidiary Italy                                                                                    
    Share/paid-in capital     2,600,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Italia S.p.A., Milan [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Italia S.p.A.                                                                                    
    Principal place of business of subsidiary Milan                                                                                    
    Country of incorporation of subsidiary Italy                                                                                    
    Share/paid-in capital     3,700,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Holding Japan K.K., Tokyo [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Holding Japan K.K.                                                                                    
    Principal place of business of subsidiary Tokyo                                                                                    
    Country of incorporation of subsidiary Japan                                                                                    
    Share/paid-in capital | ¥       ¥ 10.0                                                                              
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Pharma K.K., Tokyo [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Pharma K.K.                                                                                    
    Principal place of business of subsidiary Tokyo                                                                                    
    Country of incorporation of subsidiary Japan                                                                                    
    Share/paid-in capital | ¥       6,000.0                                                                              
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Ciba-Geigy Japan Limited, Tokyo [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Ciba-Geigy Japan Limited                                                                                    
    Principal place of business of subsidiary Tokyo                                                                                    
    Country of incorporation of subsidiary Japan                                                                                    
    Share/paid-in capital | ¥       8.5                                                                              
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz K.K., Tokyo [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz K.K.                                                                                    
    Principal place of business of subsidiary Tokyo                                                                                    
    Country of incorporation of subsidiary Japan                                                                                    
    Share/paid-in capital | ¥       100.0                                                                              
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Japan Ltd., Tokyo [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Japan Ltd.                                                                                    
    Principal place of business of subsidiary Tokyo                                                                                    
    Country of incorporation of subsidiary Japan                                                                                    
    Share/paid-in capital | ¥       ¥ 500.0                                                                              
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Investments S.a r.l., Luxembourg-Ville [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Investments S.à r.l.                                                                                    
    Principal place of business of subsidiary Luxembourg-Ville                                                                                    
    Country of incorporation of subsidiary Luxembourg                                                                                    
    Share/paid-in capital | $ $ 100,000,000                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Finance S.A., Luxembourg-Ville [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Finance S.A.                                                                                    
    Principal place of business of subsidiary Luxembourg-Ville                                                                                    
    Country of incorporation of subsidiary Luxembourg                                                                                    
    Share/paid-in capital | $ $ 100,000                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Corporation (Malaysia) Sdn. Bhd., Kuala Lumpur [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Corporation (Malaysia) Sdn. Bhd.                                                                                    
    Principal place of business of subsidiary Kuala Lumpur                                                                                    
    Country of incorporation of subsidiary Malaysia                                                                                    
    Share/paid-in capital | MYR                                           MYR 3.3                                          
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Laboratories (Malaysia) Sdn. Bhd., Petaling Jaya [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Laboratories (Malaysia) Sdn. Bhd.                                                                                    
    Principal place of business of subsidiary Petaling Jaya                                                                                    
    Country of incorporation of subsidiary Malaysia                                                                                    
    Share/paid-in capital | MYR                                           1.0                                          
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | CIBA Vision Johor Sdn. Bhd., Kuala Lumpur [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary CIBA Vision Johor Sdn. Bhd.                                                                                    
    Principal place of business of subsidiary Kuala Lumpur                                                                                    
    Country of incorporation of subsidiary Malaysia                                                                                    
    Share/paid-in capital | MYR                                           MYR 10.0                                          
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Farmaceutica, S.A. de C.V., Mexico City [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Farmacéutica, S.A. de C.V.                                                                                    
    Principal place of business of subsidiary Mexico City                                                                                    
    Country of incorporation of subsidiary Mexico                                                                                    
    Share/paid-in capital | MXN                                             MXN 205.0                                        
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz, S.A. de C.V., Mexico City [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz, S.A. de C.V.                                                                                    
    Principal place of business of subsidiary Mexico City                                                                                    
    Country of incorporation of subsidiary Mexico                                                                                    
    Share/paid-in capital | MXN                                             468.2                                        
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Laboratorios, S.A. de C.V., Mexico City [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Laboratorios, S.A. de C.V.                                                                                    
    Principal place of business of subsidiary Mexico City                                                                                    
    Country of incorporation of subsidiary Mexico                                                                                    
    Share/paid-in capital | MXN                                             MXN 5.9                                        
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Pharma Maroc SA, Casablanca [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Pharma Maroc SA                                                                                    
    Principal place of business of subsidiary Casablanca                                                                                    
    Country of incorporation of subsidiary Morocco                                                                                    
    Share/paid-in capital | MAD                                               MAD 80.0                                      
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Netherlands B.V., Arnhem [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Netherlands B.V.                                                                                    
    Principal place of business of subsidiary Arnhem                                                                                    
    Country of incorporation of subsidiary Netherlands                                                                                    
    Share/paid-in capital     1,400,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Pharma B.V., Arnhem [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Pharma B.V.                                                                                    
    Principal place of business of subsidiary Arnhem                                                                                    
    Country of incorporation of subsidiary Netherlands                                                                                    
    Share/paid-in capital     4,500,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz B.V., Almere [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz B.V.                                                                                    
    Principal place of business of subsidiary Almere                                                                                    
    Country of incorporation of subsidiary Netherlands                                                                                    
    Share/paid-in capital     907,560                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Nederland B.V., Arnhem [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Nederland B.V.                                                                                    
    Principal place of business of subsidiary Arnhem                                                                                    
    Country of incorporation of subsidiary Netherlands                                                                                    
    Share/paid-in capital     18,151                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis New Zealand Ltd, Auckland [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis New Zealand Ltd                                                                                    
    Principal place of business of subsidiary Auckland                                                                                    
    Country of incorporation of subsidiary New Zealand                                                                                    
    Share/paid-in capital | NZD                                                 NZD 820,000                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Norge AS, Oslo [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Norge AS                                                                                    
    Principal place of business of subsidiary Oslo                                                                                    
    Country of incorporation of subsidiary Norway                                                                                    
    Share/paid-in capital | NOK                                                   NOK 1.5                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Pharma (Pakistan) Limited, Karachi [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Pharma (Pakistan) Limited                                                                                    
    Principal place of business of subsidiary Karachi                                                                                    
    Country of incorporation of subsidiary Pakistan                                                                                    
    Share/paid-in capital | PKR                                                     PKR 3.9                                
    Proportion of ownership interest in subsidiary 99.99%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Pharma (Logistics), Inc., Panama City [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Pharma (Logistics), Inc.                                                                                    
    Principal place of business of subsidiary Panama City                                                                                    
    Country of incorporation of subsidiary Panama                                                                                    
    Share/paid-in capital | $ $ 10,000                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Centroamerica S.A., Panama City [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Centroamerica S.A.                                                                                    
    Principal place of business of subsidiary Panama City                                                                                    
    Country of incorporation of subsidiary Panama                                                                                    
    Share/paid-in capital | PAB                                                       PAB 1,000                              
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Healthcare Philippines, Inc., Manila [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Healthcare Philippines, Inc.                                                                                    
    Principal place of business of subsidiary Manila                                                                                    
    Country of incorporation of subsidiary Philippines                                                                                    
    Share/paid-in capital | PHP                                                         PHP 298.8                            
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz Philippines Corporation, Manila [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz Philippines Corporation                                                                                    
    Principal place of business of subsidiary Manila                                                                                    
    Country of incorporation of subsidiary Philippines                                                                                    
    Share/paid-in capital | PHP                                                         PHP 30.0                            
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Poland Sp. z o.o., Warszawa [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Poland Sp. z o.o.                                                                                    
    Principal place of business of subsidiary Warszawa                                                                                    
    Country of incorporation of subsidiary Poland                                                                                    
    Share/paid-in capital | PLN                                                           PLN 44,200,000                          
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz Polska Sp. z o.o., Warszawa [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz Polska Sp. z o.o.                                                                                    
    Principal place of business of subsidiary Warszawa                                                                                    
    Country of incorporation of subsidiary Poland                                                                                    
    Share/paid-in capital | PLN                                                           25,600,000                          
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Lek S.A., Strykow [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Lek S.A.                                                                                    
    Principal place of business of subsidiary Strykow                                                                                    
    Country of incorporation of subsidiary Poland                                                                                    
    Share/paid-in capital | PLN                                                           11,400,000                          
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Polska Sp. z o.o., Warszawa [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Polska Sp. z o.o.                                                                                    
    Principal place of business of subsidiary Warszawa                                                                                    
    Country of incorporation of subsidiary Poland                                                                                    
    Share/paid-in capital | PLN                                                           PLN 750,000                          
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Portugal SGPS Lda., Porto Salvo [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Portugal SGPS Lda.                                                                                    
    Principal place of business of subsidiary Porto Salvo                                                                                    
    Country of incorporation of subsidiary Portugal                                                                                    
    Share/paid-in capital     500,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Farma - Produtos Farmaceuticos S.A., Porto Salvo [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Farma - Produtos Farmacêuticos S.A.                                                                                    
    Principal place of business of subsidiary Porto Salvo                                                                                    
    Country of incorporation of subsidiary Portugal                                                                                    
    Share/paid-in capital     2,400,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz Farmaceutica Lda., Porto Salvo [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz Farmacêutica Lda.                                                                                    
    Principal place of business of subsidiary Porto Salvo                                                                                    
    Country of incorporation of subsidiary Portugal                                                                                    
    Share/paid-in capital     499,900                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Portugal-Produtos e Equipamentos Oftalmologicos Lda., Porto Salvo [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Portugal-Produtos e Equipamentos Oftalmológicos Lda.                                                                                    
    Principal place of business of subsidiary Porto Salvo                                                                                    
    Country of incorporation of subsidiary Portugal                                                                                    
    Share/paid-in capital     4,500,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Pharma Services Romania S.R.L., Bucharest [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Pharma Services Romania S.R.L.                                                                                    
    Principal place of business of subsidiary Bucharest                                                                                    
    Country of incorporation of subsidiary Romania                                                                                    
    Share/paid-in capital | RON                                                             RON 3.0                        
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz S.R.L., Targu-Mures [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz S.R.L.                                                                                    
    Principal place of business of subsidiary Targu-Mures                                                                                    
    Country of incorporation of subsidiary Romania                                                                                    
    Share/paid-in capital | RON                                                             105.2                        
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Romania S.R.L., Bucharest [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Romania S.R.L.                                                                                    
    Principal place of business of subsidiary Bucharest                                                                                    
    Country of incorporation of subsidiary Romania                                                                                    
    Share/paid-in capital | RON                                                             RON 10.8                        
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Pharma LLC, Moscow [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Pharma LLC                                                                                    
    Principal place of business of subsidiary Moscow                                                                                    
    Country of incorporation of subsidiary Russian Federation                                                                                    
    Share/paid-in capital | RUB                                                               RUB 20.0                      
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Neva LLC, St. Petersburg [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Neva LLC                                                                                    
    Principal place of business of subsidiary St. Petersburg                                                                                    
    Country of incorporation of subsidiary Russian Federation                                                                                    
    Share/paid-in capital | RUB                                                               1,300.0                      
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | ZAO Sandoz, Moscow [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary ZAO Sandoz                                                                                    
    Principal place of business of subsidiary Moscow                                                                                    
    Country of incorporation of subsidiary Russian Federation                                                                                    
    Share/paid-in capital | RUB                                                               57.4                      
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Farmacevtika LLC, Moscow [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Farmacevtika LLC                                                                                    
    Principal place of business of subsidiary Moscow                                                                                    
    Country of incorporation of subsidiary Russian Federation                                                                                    
    Share/paid-in capital | RUB                                                               RUB 44.1                      
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Saudi Pharmaceutical Distribution Co. Ltd., Riyadh [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Saudi Pharmaceutical Distribution Co. Ltd.                                                                                    
    Principal place of business of subsidiary Riyadh                                                                                    
    Country of incorporation of subsidiary Saudi Arabia                                                                                    
    Share/paid-in capital | SAR                                                                 SAR 26.8                    
    Proportion of ownership interest in subsidiary 75.00%                                                                                    
    Proportion of voting rights held in subsidiary 75.00%                                                                                    
    Subsidiaries [member] | Novartis (Singapore) Pte Ltd., Singapore [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis (Singapore) Pte Ltd.                                                                                    
    Principal place of business of subsidiary Singapore                                                                                    
    Country of incorporation of subsidiary Singapore                                                                                    
    Share/paid-in capital | SGD                                                                   SGD 100,000                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Singapore Pharmaceutical Manufacturing Pte Ltd, Singapore [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Singapore Pharmaceutical Manufacturing Pte Ltd                                                                                    
    Principal place of business of subsidiary Singapore                                                                                    
    Country of incorporation of subsidiary Singapore                                                                                    
    Share/paid-in capital | SGD                                                                   45,000,000                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Asia Pacific Pharmaceuticals Pte Ltd, Singapore [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Asia Pacific Pharmaceuticals Pte Ltd                                                                                    
    Principal place of business of subsidiary Singapore                                                                                    
    Country of incorporation of subsidiary Singapore                                                                                    
    Share/paid-in capital | SGD                                                                   39,000,000                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Institute for Tropical Diseases Pte Ltd, Singapore [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Institute for Tropical Diseases Pte Ltd                                                                                    
    Principal place of business of subsidiary Singapore                                                                                    
    Country of incorporation of subsidiary Singapore                                                                                    
    Share/paid-in capital | SGD                                                                   2,004                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Pte Ltd, Singapore [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Pte Ltd                                                                                    
    Principal place of business of subsidiary Singapore                                                                                    
    Country of incorporation of subsidiary Singapore                                                                                    
    Share/paid-in capital | SGD                                                                   164,000                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Singapore Manufacturing Pte Ltd, Singapore [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Singapore Manufacturing Pte Ltd                                                                                    
    Principal place of business of subsidiary Singapore                                                                                    
    Country of incorporation of subsidiary Singapore                                                                                    
    Share/paid-in capital | SGD                                                                   101,000                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | CIBA Vision Asian Manufacturing and Logistics Pte Ltd., Singapore [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary CIBA Vision Asian Manufacturing and Logistics Pte Ltd.                                                                                    
    Principal place of business of subsidiary Singapore                                                                                    
    Country of incorporation of subsidiary Singapore                                                                                    
    Share/paid-in capital | SGD                                                                   SGD 1,000,000                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Slovakia s.r.o., Bratislava [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Slovakia s.r.o.                                                                                    
    Principal place of business of subsidiary Bratislava                                                                                    
    Country of incorporation of subsidiary Slovakia                                                                                    
    Share/paid-in capital     2,000,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Lek Pharmaceuticals d.d., Ljubjana [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Lek Pharmaceuticals d.d.                                                                                    
    Principal place of business of subsidiary Ljubjana                                                                                    
    Country of incorporation of subsidiary Slovenia                                                                                    
    Share/paid-in capital     48,400,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz Pharmaceuticals d.d., Ljubjana [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz Pharmaceuticals d.d.                                                                                    
    Principal place of business of subsidiary Ljubjana                                                                                    
    Country of incorporation of subsidiary Slovenia                                                                                    
    Share/paid-in capital     1,500,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis South Africa (Pty) Ltd, Midrand [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis South Africa (Pty) Ltd                                                                                    
    Principal place of business of subsidiary Midrand                                                                                    
    Country of incorporation of subsidiary South Africa                                                                                    
    Share/paid-in capital | ZAR                                                                     ZAR 86,300,000                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz South Africa (Pty) Ltd, Kempton Park [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz South Africa (Pty) Ltd                                                                                    
    Principal place of business of subsidiary Kempton Park                                                                                    
    Country of incorporation of subsidiary South Africa                                                                                    
    Share/paid-in capital | ZAR                                                                     3,000,000                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Laboratories (South Africa) (Pty) Ltd., Midrand [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Laboratories (South Africa) (Pty) Ltd.                                                                                    
    Principal place of business of subsidiary Midrand                                                                                    
    Country of incorporation of subsidiary South Africa                                                                                    
    Share/paid-in capital | ZAR                                                                     ZAR 201,820                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Korea Ltd., Seoul [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Korea Ltd.                                                                                    
    Principal place of business of subsidiary Seoul                                                                                    
    Country of incorporation of subsidiary South Korea                                                                                    
    Share/paid-in capital | ₩                                                                       ₩ 24.5              
    Proportion of ownership interest in subsidiary 98.55%                                                                                    
    Proportion of voting rights held in subsidiary 99.00%                                                                                    
    Subsidiaries [member] | Sandoz Korea Ltd., Seoul [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz Korea Ltd.                                                                                    
    Principal place of business of subsidiary Seoul                                                                                    
    Country of incorporation of subsidiary South Korea                                                                                    
    Share/paid-in capital | ₩                                                                       17.8              
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Korea Ltd., Seoul [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Korea Ltd.                                                                                    
    Principal place of business of subsidiary Seoul                                                                                    
    Country of incorporation of subsidiary South Korea                                                                                    
    Share/paid-in capital | ₩                                                                       ₩ 33.8              
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Farmaceutica S.A., Barcelona [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Farmacéutica S.A.                                                                                    
    Principal place of business of subsidiary Barcelona                                                                                    
    Country of incorporation of subsidiary Spain                                                                                    
    Share/paid-in capital     63,000,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz Farmaceutica S.A., Madrid [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz Farmacéutica S.A.                                                                                    
    Principal place of business of subsidiary Madrid                                                                                    
    Country of incorporation of subsidiary Spain                                                                                    
    Share/paid-in capital     270,450                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz Industrial Products S.A., Barcelona [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz Industrial Products S.A.                                                                                    
    Principal place of business of subsidiary Les Franqueses del Vallés / Barcelona                                                                                    
    Country of incorporation of subsidiary Spain                                                                                    
    Share/paid-in capital     9,300,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Cusi S.A., Barcelona [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Cusi S.A.                                                                                    
    Principal place of business of subsidiary Barcelona                                                                                    
    Country of incorporation of subsidiary Spain                                                                                    
    Share/paid-in capital     11,600,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Abadia Retuerta S.A., Sardon de Duero/Valladolid [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Abadia Retuerta S.A.                                                                                    
    Principal place of business of subsidiary Sardón de Duero/Valladolid                                                                                    
    Country of incorporation of subsidiary Spain                                                                                    
    Share/paid-in capital     € 6,000,000                                                                                
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Sverige AB, Stockholm [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Sverige AB                                                                                    
    Principal place of business of subsidiary Täby / Stockholm                                                                                    
    Country of incorporation of subsidiary Sweden                                                                                    
    Share/paid-in capital | SEK                                                                         SEK 5.0            
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis International AG, Basel [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis International AG                                                                                    
    Principal place of business of subsidiary Basel                                                                                    
    Country of incorporation of subsidiary Switzerland                                                                                    
    Share/paid-in capital | SFr   10,000,000                                                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Holding AG, Basel [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Holding AG                                                                                    
    Principal place of business of subsidiary Basel                                                                                    
    Country of incorporation of subsidiary Switzerland                                                                                    
    Share/paid-in capital | SFr   100,200,000                                                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis International Pharmaceutical Investment AG, Basel [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis International Pharmaceutical Investment AG                                                                                    
    Principal place of business of subsidiary Basel                                                                                    
    Country of incorporation of subsidiary Switzerland                                                                                    
    Share/paid-in capital | SFr   100,000                                                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Bioventures AG, Basel [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Bioventures AG                                                                                    
    Principal place of business of subsidiary Basel                                                                                    
    Country of incorporation of subsidiary Switzerland                                                                                    
    Share/paid-in capital | SFr   100,000                                                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Forschungsstiftung, Basel [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Forschungsstiftung                                                                                    
    Principal place of business of subsidiary Basel                                                                                    
    Country of incorporation of subsidiary Switzerland                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Stiftung fuer Kaderausbildung, Basel [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Stiftung für Kaderausbildung                                                                                    
    Principal place of business of subsidiary Basel                                                                                    
    Country of incorporation of subsidiary Switzerland                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Mitarbeiterbeteiligungsstiftung, Basel [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Mitarbeiterbeteiligungsstiftung                                                                                    
    Principal place of business of subsidiary Basel                                                                                    
    Country of incorporation of subsidiary Switzerland                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Stiftung fuer Mensch und Umwelt, Basel [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Stiftung für Mensch und Umwelt                                                                                    
    Principal place of business of subsidiary Basel                                                                                    
    Country of incorporation of subsidiary Switzerland                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Stiftung der Novartis AG fuer Erziehung, Ausbildung und Bildung, Basel [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Stiftung der Novartis AG für Erziehung, Ausbildung und Bildung                                                                                    
    Principal place of business of subsidiary Basel                                                                                    
    Country of incorporation of subsidiary Switzerland                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Pharma AG, Basel [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Pharma AG                                                                                    
    Principal place of business of subsidiary Basel                                                                                    
    Country of incorporation of subsidiary Switzerland                                                                                    
    Share/paid-in capital | SFr   350,000,000                                                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis International Pharmaceutical AG, Basel [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis International Pharmaceutical AG                                                                                    
    Principal place of business of subsidiary Basel                                                                                    
    Country of incorporation of subsidiary Switzerland                                                                                    
    Share/paid-in capital | SFr   100,000                                                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Pharma Services AG, Basel [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Pharma Services AG                                                                                    
    Principal place of business of subsidiary Basel                                                                                    
    Country of incorporation of subsidiary Switzerland                                                                                    
    Share/paid-in capital | SFr   20,000,000                                                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Pharma Schweizerhalle AG, Muttenz [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Pharma Schweizerhalle AG                                                                                    
    Principal place of business of subsidiary Muttenz                                                                                    
    Country of incorporation of subsidiary Switzerland                                                                                    
    Share/paid-in capital | SFr   18,900,000                                                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Pharma Stein AG, Stein [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Pharma Stein AG                                                                                    
    Principal place of business of subsidiary Stein                                                                                    
    Country of incorporation of subsidiary Switzerland                                                                                    
    Share/paid-in capital | SFr   251,000                                                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Pharma Schweiz AG, Risch [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Pharma Schweiz AG                                                                                    
    Principal place of business of subsidiary Risch                                                                                    
    Country of incorporation of subsidiary Switzerland                                                                                    
    Share/paid-in capital | SFr   5,000,000                                                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz AG, Basel [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz AG                                                                                    
    Principal place of business of subsidiary Basel                                                                                    
    Country of incorporation of subsidiary Switzerland                                                                                    
    Share/paid-in capital | SFr   5,000,000                                                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz Pharmaceuticals AG, Risch [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz Pharmaceuticals AG                                                                                    
    Principal place of business of subsidiary Risch                                                                                    
    Country of incorporation of subsidiary Switzerland                                                                                    
    Share/paid-in capital | SFr   100,000                                                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Switzerland SA, Risch [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Switzerland SA                                                                                    
    Principal place of business of subsidiary Risch                                                                                    
    Country of incorporation of subsidiary Switzerland                                                                                    
    Share/paid-in capital | SFr   100,000                                                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Pharmaceuticals Ltd., Fribourg [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Pharmaceuticals Ltd.                                                                                    
    Principal place of business of subsidiary Fribourg                                                                                    
    Country of incorporation of subsidiary Switzerland                                                                                    
    Share/paid-in capital | SFr   200,000                                                                                  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Roche Holding AG, Basel [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Roche Holding AG                                                                                    
    Principal place of business of subsidiary Basel                                                                                    
    Country of incorporation of subsidiary Switzerland                                                                                    
    Share/paid-in capital | SFr   SFr 160,000,000                                                                                  
    Proportion of ownership interest in subsidiary 5.50%                                                                                    
    Proportion of voting rights held in subsidiary 33.33%                                                                                    
    Subsidiaries [member] | Novartis (Taiwan) Co., Ltd., Taipei [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis (Taiwan) Co., Ltd.                                                                                    
    Principal place of business of subsidiary Taipei                                                                                    
    Country of incorporation of subsidiary Taiwan                                                                                    
    Share/paid-in capital | TWD                                                                           TWD 170.0          
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis (Thailand) Limited, Bangkok [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis (Thailand) Limited                                                                                    
    Principal place of business of subsidiary Bangkok                                                                                    
    Country of incorporation of subsidiary Thailand                                                                                    
    Share/paid-in capital | THB                                                                             THB 302.0        
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Laboratories (Thailand) Limited, Bangkok [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Laboratories (Thailand) Limited                                                                                    
    Principal place of business of subsidiary Bangkok                                                                                    
    Country of incorporation of subsidiary Thailand                                                                                    
    Share/paid-in capital | THB                                                                             THB 228.1        
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Saglik, Gida ve Tarim Urunleri Sanayi ve Ticaret A.S., Istanbul [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Saglik, Gida ve Tarim Ürünleri Sanayi ve Ticaret A.S.                                                                                    
    Principal place of business of subsidiary Istanbul                                                                                    
    Country of incorporation of subsidiary Turkey                                                                                    
    Share/paid-in capital | TRY                                                                               TRY 98.0      
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Farmanova Saglik Hizmetleri Ltd. Sti., Istanbul [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Farmanova Saglik Hizmetleri Ltd. Sti.                                                                                    
    Principal place of business of subsidiary Istanbul                                                                                    
    Country of incorporation of subsidiary Turkey                                                                                    
    Share/paid-in capital | TRY                                                                               6.7      
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz Syntek Ilac Hammaddeleri Sanayi ve Ticaret A.S., Istanbul [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz Syntek Ilaç Hammaddeleri Sanayi ve Ticaret A.S.                                                                                    
    Principal place of business of subsidiary Istanbul                                                                                    
    Country of incorporation of subsidiary Turkey                                                                                    
    Share/paid-in capital | TRY                                                                               46.0      
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz Ilac Sanayi ve Ticaret A.S., Istanbul [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz Ilaç Sanayi ve Ticaret A.S.                                                                                    
    Principal place of business of subsidiary Istanbul                                                                                    
    Country of incorporation of subsidiary Turkey                                                                                    
    Share/paid-in capital | TRY                                                                               165.2      
    Proportion of ownership interest in subsidiary 99.99%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz Grup Saglik Urunleri Ilaclari Sanayi ve Ticaret A.S., Gebze - Kocaeli [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz Grup Saglik Ürünleri Ilaçlari Sanayi ve Ticaret A.S.                                                                                    
    Principal place of business of subsidiary Gebze - Kocaeli                                                                                    
    Country of incorporation of subsidiary Turkey                                                                                    
    Share/paid-in capital | TRY                                                                               50.0      
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Laboratuvarlari Ticaret A.S., Istanbul [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Laboratuvarlari Ticaret A.S.                                                                                    
    Principal place of business of subsidiary Istanbul                                                                                    
    Country of incorporation of subsidiary Turkey                                                                                    
    Share/paid-in capital | TRY                                                                               TRY 25.2      
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Middle East FZE, Dubai [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Middle East FZE                                                                                    
    Principal place of business of subsidiary Dubai                                                                                    
    Country of incorporation of subsidiary United Arab Emirates                                                                                    
    Share/paid-in capital | AED                                                                                 AED 7.0    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis UK Limited, Frimley/Camberley [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis UK Limited                                                                                    
    Principal place of business of subsidiary Frimley/Camberley                                                                                    
    Country of incorporation of subsidiary United Kingdom                                                                                    
    Share/paid-in capital | £                                                                                   £ 25,500,000  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Pharmaceuticals UK Limited, Frimley/Camberley [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Pharmaceuticals UK Limited                                                                                    
    Principal place of business of subsidiary Frimley/Camberley                                                                                    
    Country of incorporation of subsidiary United Kingdom                                                                                    
    Share/paid-in capital | £                                                                                   5,400,000  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Grimsby Limited, Frimley/Camberley [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Grimsby Limited                                                                                    
    Principal place of business of subsidiary Frimley/Camberley                                                                                    
    Country of incorporation of subsidiary United Kingdom                                                                                    
    Share/paid-in capital | £                                                                                   250,000,000  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Ziarco Group Limited, Frimley/Camberley [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Ziarco Group Limited                                                                                    
    Principal place of business of subsidiary Frimley/Camberley                                                                                    
    Country of incorporation of subsidiary United Kingdom                                                                                    
    Share/paid-in capital | £                                                                                   3,904  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz Limited, Frimley/Camberley [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz Limited                                                                                    
    Principal place of business of subsidiary Frimley/Camberley                                                                                    
    Country of incorporation of subsidiary United Kingdom                                                                                    
    Share/paid-in capital | £                                                                                   2,000,000  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Eye Care UK Limited, Frimley/Camberley [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Eye Care UK Limited                                                                                    
    Principal place of business of subsidiary Frimley/Camberley                                                                                    
    Country of incorporation of subsidiary United Kingdom                                                                                    
    Share/paid-in capital | £                                                                                   550,000  
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Glaxosmithkline Consumer Healthcare Holdings Limited, Brentford, Middlesex [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Glaxosmithkline Consumer Healthcare Holdings Limited                                                                                    
    Principal place of business of subsidiary Brentford, Middlesex                                                                                    
    Country of incorporation of subsidiary United Kingdom                                                                                    
    Share/paid-in capital | £                                                                                   £ 100,000  
    Proportion of ownership interest in subsidiary 36.50%                                                                                    
    Proportion of voting rights held in subsidiary 37.00%                                                                                    
    Subsidiaries [member] | Novartis Corporation, East Hanover, NJ [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Corporation                                                                                    
    Principal place of business of subsidiary East Hanover, NJ                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 72,200,000                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Finance Corporation, New York, NY [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Finance Corporation                                                                                    
    Principal place of business of subsidiary New York, NY                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 1,000                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Capital Corporation, New York, NY [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Capital Corporation                                                                                    
    Principal place of business of subsidiary New York, NY                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 1                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Services, Inc., East Hanover, NJ [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Services, Inc.                                                                                    
    Principal place of business of subsidiary East Hanover, NJ                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 1                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis US Foundation, New York, NY [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis US Foundation                                                                                    
    Principal place of business of subsidiary New York, NY                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Pharmaceuticals Corporation, East Hanover, NJ [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Pharmaceuticals Corporation                                                                                    
    Principal place of business of subsidiary East Hanover, NJ                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 5,200,000                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Institutes for BioMedical Research, Inc., Cambridge, MA [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Institutes for BioMedical Research, Inc.                                                                                    
    Principal place of business of subsidiary Cambridge, MA                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 1                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Corthera, Inc., San Mateo, CA [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Corthera, Inc.                                                                                    
    Principal place of business of subsidiary San Mateo, CA                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 1                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | CoStim Pharmaceuticals Inc., Cambridge, MA [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary CoStim Pharmaceuticals Inc.                                                                                    
    Principal place of business of subsidiary Cambridge, MA                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 1                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Encore Vision, Inc., New York, NY [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Encore Vision, Inc.                                                                                    
    Principal place of business of subsidiary New York, NY                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 1                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Navigate BioPharma Services, Inc., Wilmington, NC [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Navigate BioPharma Services, Inc.                                                                                    
    Principal place of business of subsidiary Wilmington, NC                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 100                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Reprixys Pharmaceuticals Corporation, Oklahoma City, OK [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Reprixys Pharmaceuticals Corporation                                                                                    
    Principal place of business of subsidiary Oklahoma City, OK                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 1                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Spinifex Pharmaceuticals, Inc., Wilmington, NC [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Spinifex Pharmaceuticals, Inc.                                                                                    
    Principal place of business of subsidiary Wilmington, NC                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 1                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Institute for Functional Genomics, Inc., San Diego, CA [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Institute for Functional Genomics, Inc.                                                                                    
    Principal place of business of subsidiary San Diego, CA                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 1,000                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Sandoz Inc., Princeton, NJ [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Sandoz Inc.                                                                                    
    Principal place of business of subsidiary Princeton, NJ                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 25,000                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Fougera Pharmaceuticals Inc., Melville, NY [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Fougera Pharmaceuticals Inc.                                                                                    
    Principal place of business of subsidiary Melville, NY                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 1                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Eon Labs, Inc., Princeton, NJ [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Eon Labs, Inc.                                                                                    
    Principal place of business of subsidiary Princeton, NJ                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 1                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Laboratories, Inc., Fort Worth, TX [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Laboratories, Inc.                                                                                    
    Principal place of business of subsidiary Fort Worth, TX                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 1,000                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Refractivehorizons, LLC, Fort Worth, TX [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Refractivehorizons, LLC                                                                                    
    Principal place of business of subsidiary Fort Worth, TX                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 10                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Research, Ltd., Fort Worth, TX [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Research, Ltd.                                                                                    
    Principal place of business of subsidiary Fort Worth, TX                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 12.5                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Lensx, Inc., Aliso Viejo, CA [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Lensx, Inc.                                                                                    
    Principal place of business of subsidiary Aliso Viejo, CA                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 1                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Laboratories Holding Corporation, Fort Worth, TX [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Laboratories Holding Corporation                                                                                    
    Principal place of business of subsidiary Fort Worth, TX                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 10                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis Vaccines and Diagnostics, Inc., Cambridge, MA [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis Vaccines and Diagnostics, Inc.                                                                                    
    Principal place of business of subsidiary Cambridge, MA                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 3                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | ClarVista Medical, Inc., Aliso Viejo, CA [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary ClarVista Medical, Inc.                                                                                    
    Principal place of business of subsidiary Aliso Viejo, CA                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 1                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Transcend Medical, Inc., Menlo Park, CA [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Transcend Medical, Inc.                                                                                    
    Principal place of business of subsidiary Menlo Park, CA                                                                                    
    Country of incorporation of subsidiary USA                                                                                    
    Share/paid-in capital | $ $ 1                                                                                    
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Novartis de Venezuela, S.A., Caracas [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Novartis de Venezuela, S.A.                                                                                    
    Principal place of business of subsidiary Caracas                                                                                    
    Country of incorporation of subsidiary Venezuela                                                                                    
    Share/paid-in capital | VEF                                                                                     VEF 1.4
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    Subsidiaries [member] | Alcon Pharmaceutical, C.A., Caracas [member]                                                                                      
    Disclosure of subsidiaries [line items]                                                                                      
    Name of subsidiary Alcon Pharmaceutical, C.A.                                                                                    
    Principal place of business of subsidiary Caracas                                                                                    
    Country of incorporation of subsidiary Venezuela                                                                                    
    Share/paid-in capital | VEF                                                                                     VEF 5.5
    Proportion of ownership interest in subsidiary 100.00%                                                                                    
    Proportion of voting rights held in subsidiary 100.00%                                                                                    
    EXCEL 252 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 253 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 254 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 256 FilingSummary.xml IDEA: XBRL DOCUMENT 3.8.0.1 html 1772 809 1 true 558 0 false 48 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://novartis.com/20171231/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Consolidated income statements Sheet http://novartis.com/20171231/role/StatementOfIncome Consolidated income statements Statements 2 false false R3.htm 1002000 - Statement - Consolidated statements of comprehensive income Sheet http://novartis.com/20171231/role/StatementOfComprehensiveIncome Consolidated statements of comprehensive income Statements 3 false false R4.htm 1003000 - Statement - Consolidated balance sheets Sheet http://novartis.com/20171231/role/BalanceSheet Consolidated balance sheets Statements 4 false false R5.htm 1004000 - Statement - Consolidated statements of changes in equity Sheet http://novartis.com/20171231/role/StatementOfChangesInEquity Consolidated statements of changes in equity Statements 5 false false R6.htm 1005000 - Statement - Consolidated cash flow statements Sheet http://novartis.com/20171231/role/StatementsOfCashFlow Consolidated cash flow statements Statements 6 false false R7.htm 1005010 - Statement - Consolidated cash flow statements (Parenthetical) Sheet http://novartis.com/20171231/role/StatementsOfCashFlowParenthetical Consolidated cash flow statements (Parenthetical) Statements 7 false false R8.htm 2100100 - Disclosure - Significant accounting policies Sheet http://novartis.com/20171231/role/DisclosureSummaryOfSignificantAccountingPolicies Significant accounting policies Notes 8 false false R9.htm 2100200 - Disclosure - Significant transactions Sheet http://novartis.com/20171231/role/DisclosureSignificantTransactions Significant transactions Notes 9 false false R10.htm 2100300 - Disclosure - Segmentation of key figures Sheet http://novartis.com/20171231/role/DisclosureSegmentationOfKeyFigures Segmentation of key figures Notes 10 false false R11.htm 2100400 - Disclosure - Associated companies Sheet http://novartis.com/20171231/role/DisclosureAssociatedCompanies Associated companies Notes 11 false false R12.htm 2100500 - Disclosure - Interest expense and other financial income and expense Sheet http://novartis.com/20171231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpense Interest expense and other financial income and expense Notes 12 false false R13.htm 2100600 - Disclosure - Taxes Sheet http://novartis.com/20171231/role/DisclosureTaxes Taxes Notes 13 false false R14.htm 2100700 - Disclosure - Earnings per share Sheet http://novartis.com/20171231/role/DisclosureEarningsPerShare Earnings per share Notes 14 false false R15.htm 2100800 - Disclosure - Changes in consolidated statements of comprehensive income Sheet http://novartis.com/20171231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncome Changes in consolidated statements of comprehensive income Notes 15 false false R16.htm 2100900 - Disclosure - Property, plant and equipment Sheet http://novartis.com/20171231/role/DisclosurePropertyPlantAndEquipment Property, plant and equipment Notes 16 false false R17.htm 2101000 - Disclosure - Goodwill and intangible assets Sheet http://novartis.com/20171231/role/DisclosureGoodwillAndIntangibleAssets Goodwill and intangible assets Notes 17 false false R18.htm 2101100 - Disclosure - Deferred tax assets and liabilities Sheet http://novartis.com/20171231/role/DisclosureDeferredTaxAssetsAndLiabilities Deferred tax assets and liabilities Notes 18 false false R19.htm 2101200 - Disclosure - Financial and other non-current assets Sheet http://novartis.com/20171231/role/DisclosureFinancialAndOtherNoncurrentAssets Financial and other non-current assets Notes 19 false false R20.htm 2101300 - Disclosure - Inventories Sheet http://novartis.com/20171231/role/DisclosureInventories Inventories Notes 20 false false R21.htm 2101400 - Disclosure - Trade receivables Sheet http://novartis.com/20171231/role/DisclosureTradeReceivables Trade receivables Notes 21 false false R22.htm 2101500 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents Sheet http://novartis.com/20171231/role/DisclosureMarketableSecurities Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents Notes 22 false false R23.htm 2101600 - Disclosure - Other current assets Sheet http://novartis.com/20171231/role/DisclosureOtherCurrentAssets Other current assets Notes 23 false false R24.htm 2101700 - Disclosure - Equity Sheet http://novartis.com/20171231/role/DisclosureEquity Equity Notes 24 false false R25.htm 2101800 - Disclosure - Non-current financial debt Sheet http://novartis.com/20171231/role/DisclosureNonCurrentFinancialDebt Non-current financial debt Notes 25 false false R26.htm 2101900 - Disclosure - Provisions and other non-current liabilities Sheet http://novartis.com/20171231/role/DisclosureProvisionsAndOtherNonCurrentLiabilities Provisions and other non-current liabilities Notes 26 false false R27.htm 2102000 - Disclosure - Current financial debt and derivative financial instruments Sheet http://novartis.com/20171231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstruments Current financial debt and derivative financial instruments Notes 27 false false R28.htm 2102100 - Disclosure - Provisions and other current liabilities Sheet http://novartis.com/20171231/role/DisclosureProvisionsAndOtherCurrentLiabilities Provisions and other current liabilities Notes 28 false false R29.htm 2102200 - Disclosure - Details to the consolidated cash flow statements Sheet http://novartis.com/20171231/role/DisclosureDetailsConsolidatedCashFlowStatements Details to the consolidated cash flow statements Notes 29 false false R30.htm 2102300 - Disclosure - Acquisitions of businesses Sheet http://novartis.com/20171231/role/DisclosureAcquisitionsOfBusinesses Acquisitions of businesses Notes 30 false false R31.htm 2102400 - Disclosure - Post-employment benefits for associates Sheet http://novartis.com/20171231/role/DisclosurePostEmploymentBenefitsForAssociates Post-employment benefits for associates Notes 31 false false R32.htm 2102500 - Disclosure - Equity-based participation plans for associates Sheet http://novartis.com/20171231/role/DisclosureEquityBasedParticipationPlansForAssociates Equity-based participation plans for associates Notes 32 false false R33.htm 2102600 - Disclosure - Transactions with related parties Sheet http://novartis.com/20171231/role/DisclosureTransactionsWithRelatedParties Transactions with related parties Notes 33 false false R34.htm 2102700 - Disclosure - Commitments and contingencies Sheet http://novartis.com/20171231/role/DisclosureCommitmentsAndContingencies Commitments and contingencies Notes 34 false false R35.htm 2102800 - Disclosure - Financial instruments - additional disclosures Sheet http://novartis.com/20171231/role/DisclosureFinancialInstrumentsAdditionalDisclosures Financial instruments - additional disclosures Notes 35 false false R36.htm 2102900 - Disclosure - Discontinued operations Sheet http://novartis.com/20171231/role/DisclosureDiscontinuedOperations Discontinued operations Notes 36 false false R37.htm 2103000 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date (Details) Sheet http://novartis.com/20171231/role/DisclosureSubsequentEvents Events subsequent to the December 31 consolidated balance sheet date (Details) Details 37 false false R38.htm 2103100 - Disclosure - Principal Group subsidiaries and associated companies Sheet http://novartis.com/20171231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompanies Principal Group subsidiaries and associated companies Uncategorized 38 false false R39.htm 2200100 - Disclosure - Significant accounting policies (Policies) Sheet http://novartis.com/20171231/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Significant accounting policies (Policies) Uncategorized 39 false false R40.htm 2300100 - Disclosure - Significant accounting policies (Tables) Sheet http://novartis.com/20171231/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Significant accounting policies (Tables) Uncategorized 40 false false R41.htm 2300300 - Disclosure - Segmentation of key figures (Tables) Sheet http://novartis.com/20171231/role/DisclosureSegmentationOfKeyFiguresTables Segmentation of key figures (Tables) Uncategorized 41 false false R42.htm 2300400 - Disclosure - Associated companies (Tables) Sheet http://novartis.com/20171231/role/DisclosureAssociatedCompaniesTables Associated companies (Tables) Uncategorized 42 false false R43.htm 2300500 - Disclosure - Interest expense and other financial income and expense (Tables) Sheet http://novartis.com/20171231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseTables Interest expense and other financial income and expense (Tables) Uncategorized 43 false false R44.htm 2300600 - Disclosure - Taxes (Tables) Sheet http://novartis.com/20171231/role/DisclosureTaxesTables Taxes (Tables) Uncategorized 44 false false R45.htm 2300700 - Disclosure - Earnings per share (Tables) Sheet http://novartis.com/20171231/role/DisclosureEarningsPerShareTables Earnings per share (Tables) Uncategorized 45 false false R46.htm 2300800 - Disclosure - Changes in consolidated statements of comprehensive income (Tables) Sheet http://novartis.com/20171231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeTables Changes in consolidated statements of comprehensive income (Tables) Uncategorized 46 false false R47.htm 2300900 - Disclosure - Property, plant and equipment (Tables) Sheet http://novartis.com/20171231/role/DisclosurePropertyPlantAndEquipmentTables Property, plant and equipment (Tables) Uncategorized 47 false false R48.htm 2301000 - Disclosure - Goodwill and intangible assets (Tables) Sheet http://novartis.com/20171231/role/DisclosureGoodwillAndIntangibleAssetsTables Goodwill and intangible assets (Tables) Uncategorized 48 false false R49.htm 2301100 - Disclosure - Deferred tax assets and liabilities (Tables) Sheet http://novartis.com/20171231/role/DisclosureDeferredTaxAssetsAndLiabilitiesTables Deferred tax assets and liabilities (Tables) Uncategorized 49 false false R50.htm 2301200 - Disclosure - Financial and other non-current assets (Tables) Sheet http://novartis.com/20171231/role/DisclosureFinancialAndOtherNoncurrentAssetsTables Financial and other non-current assets (Tables) Uncategorized 50 false false R51.htm 2301300 - Disclosure - Inventories (Tables) Sheet http://novartis.com/20171231/role/DisclosureInventoriesTables Inventories (Tables) Uncategorized 51 false false R52.htm 2301400 - Disclosure - Trade receivables (Tables) Sheet http://novartis.com/20171231/role/DisclosureTradeReceivablesTables Trade receivables (Tables) Uncategorized 52 false false R53.htm 2301500 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Tables) Sheet http://novartis.com/20171231/role/DisclosureMarketableSecuritiesTables Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Tables) Uncategorized 53 false false R54.htm 2301600 - Disclosure - Other current assets (Tables) Sheet http://novartis.com/20171231/role/DisclosureOtherCurrentAssetsTables Other current assets (Tables) Uncategorized 54 false false R55.htm 2301700 - Disclosure - Equity (Tables) Sheet http://novartis.com/20171231/role/DisclosureEquityTables Equity (Tables) Uncategorized 55 false false R56.htm 2301800 - Disclosure - Non-current financial debt (Tables) Sheet http://novartis.com/20171231/role/DisclosureNonCurrentFinancialDebtTables Non-current financial debt (Tables) Uncategorized 56 false false R57.htm 2301900 - Disclosure - Provisions and other non-current liabilities (Tables) Sheet http://novartis.com/20171231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesTables Provisions and other non-current liabilities (Tables) Uncategorized 57 false false R58.htm 2302000 - Disclosure - Current financial debt and derivative financial instruments (Tables) Sheet http://novartis.com/20171231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsTables Current financial debt and derivative financial instruments (Tables) Uncategorized 58 false false R59.htm 2302100 - Disclosure - Provisions and other current liabilities (Tables) Sheet http://novartis.com/20171231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesTables Provisions and other current liabilities (Tables) Uncategorized 59 false false R60.htm 2302200 - Disclosure - Details to the consolidated cash flow statements (Tables) Sheet http://novartis.com/20171231/role/DisclosureDetailsConsolidatedCashFlowStatementsTables Details to the consolidated cash flow statements (Tables) Uncategorized 60 false false R61.htm 2302300 - Disclosure - Acquisitions of businesses (Tables) Sheet http://novartis.com/20171231/role/DisclosureAcquisitionsOfBusinessesTables Acquisitions of businesses (Tables) Uncategorized 61 false false R62.htm 2302400 - Disclosure - Post-employment benefits for associates (Tables) Sheet http://novartis.com/20171231/role/DisclosurePostEmploymentBenefitsForAssociatesTables Post-employment benefits for associates (Tables) Uncategorized 62 false false R63.htm 2302500 - Disclosure - Equity-based participation plans for associates (Tables) Sheet http://novartis.com/20171231/role/DisclosureEquityBasedParticipationPlansForAssociatesTables Equity-based participation plans for associates (Tables) Uncategorized 63 false false R64.htm 2302600 - Disclosure - Transactions with related parties (Tables) Sheet http://novartis.com/20171231/role/DisclosureTransactionsWithRelatedPartiesTables Transactions with related parties (Tables) Uncategorized 64 false false R65.htm 2302700 - Disclosure - Commitments and contingencies (Tables) Sheet http://novartis.com/20171231/role/DisclosureCommitmentsAndContingenciesTables Commitments and contingencies (Tables) Uncategorized 65 false false R66.htm 2302800 - Disclosure - Financial instruments - additional disclosures (Tables) Sheet http://novartis.com/20171231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresTables Financial instruments - additional disclosures (Tables) Uncategorized 66 false false R67.htm 2302900 - Disclosure - Discontinued operations (Tables) Sheet http://novartis.com/20171231/role/DisclosureDiscontinuedOperationsTables Discontinued operations (Tables) Uncategorized 67 false false R68.htm 2303100 - Disclosure - Principal Group subsidiaries and associated companies (Tables) Sheet http://novartis.com/20171231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesTables Principal Group subsidiaries and associated companies (Tables) Uncategorized 68 false false R69.htm 2400100 - Disclosure - Significant accounting policies (Details) Sheet http://novartis.com/20171231/role/DisclosureSignificantAccountingPoliciesDetails Significant accounting policies (Details) Uncategorized 69 false false R70.htm 2400101 - Disclosure - Significant accounting policies (Details 2) Sheet http://novartis.com/20171231/role/DisclosureSignificantAccountingPoliciesDetails2 Significant accounting policies (Details 2) Uncategorized 70 false false R71.htm 2400102 - Disclosure - Significant accounting policies (Details 3) Sheet http://novartis.com/20171231/role/DisclosureSignificantAccountingPoliciesDetails3 Significant accounting policies (Details 3) Uncategorized 71 false false R72.htm 2400200 - Disclosure - Significant transactions Sheet http://novartis.com/20171231/role/DisclosureSignificantTransactionsDetails Significant transactions Uncategorized 72 false false R73.htm 2400300 - Disclosure - Segmentation of key figures (Details) Sheet http://novartis.com/20171231/role/DisclosureSegmentationOfKeyFiguresDetails Segmentation of key figures (Details) Uncategorized 73 false false R74.htm 2400301 - Disclosure - Segmentation of key figures (Details 1) Sheet http://novartis.com/20171231/role/DisclosureSegmentationOfKeyFiguresDetails1 Segmentation of key figures (Details 1) Uncategorized 74 false false R75.htm 2400302 - Disclosure - Segmentation of key figures (Details 2) Sheet http://novartis.com/20171231/role/DisclosureSegmentationOfKeyFiguresDetails2 Segmentation of key figures (Details 2) Uncategorized 75 false false R76.htm 2400303 - Disclosure - Segmentation of key figures (Details 3) Sheet http://novartis.com/20171231/role/DisclosureSegmentationOfKeyFiguresDetails3 Segmentation of key figures (Details 3) Uncategorized 76 false false R77.htm 2400304 - Disclosure - Segmentation of key figures (Details 4) Sheet http://novartis.com/20171231/role/DisclosureSegmentationOfKeyFiguresDetails4 Segmentation of key figures (Details 4) Uncategorized 77 false false R78.htm 2400305 - Disclosure - Segmentation of key figures (Details 5) Sheet http://novartis.com/20171231/role/DisclosureSegmentationOfKeyFiguresDetails5 Segmentation of key figures (Details 5) Uncategorized 78 false false R79.htm 2400306 - Disclosure - Segmentation of key figures (Details 6) Sheet http://novartis.com/20171231/role/DisclosureSegmentationOfKeyFiguresDetails6 Segmentation of key figures (Details 6) Uncategorized 79 false false R80.htm 2400307 - Disclosure - Segmentation of key figures (Details 7) Sheet http://novartis.com/20171231/role/DisclosureSegmentationOfKeyFiguresDetails7 Segmentation of key figures (Details 7) Uncategorized 80 false false R81.htm 2400400 - Disclosure - Associated companies (Details) Sheet http://novartis.com/20171231/role/DisclosureAssociatedCompaniesDetails Associated companies (Details) Uncategorized 81 false false R82.htm 2400401 - Disclosure - Associated companies (Details 2) Sheet http://novartis.com/20171231/role/DisclosureAssociatedCompaniesDetails2 Associated companies (Details 2) Uncategorized 82 false false R83.htm 2400402 - Disclosure - Associated companies (Details 3) Sheet http://novartis.com/20171231/role/DisclosureAssociatedCompaniesDetails3 Associated companies (Details 3) Uncategorized 83 false false R84.htm 2400403 - Disclosure - Associated companies (Details 4) Sheet http://novartis.com/20171231/role/DisclosureAssociatedCompaniesDetails4 Associated companies (Details 4) Uncategorized 84 false false R85.htm 2400404 - Disclosure - Associated companies (Details 5) Sheet http://novartis.com/20171231/role/DisclosureAssociatedCompaniesDetails5 Associated companies (Details 5) Uncategorized 85 false false R86.htm 2400405 - Disclosure - Associated companies (Details 6) Sheet http://novartis.com/20171231/role/DisclosureAssociatedCompaniesDetails6 Associated companies (Details 6) Uncategorized 86 false false R87.htm 2400500 - Disclosure - Interest expense and other financial income and expense (Details) Sheet http://novartis.com/20171231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails Interest expense and other financial income and expense (Details) Uncategorized 87 false false R88.htm 2400501 - Disclosure - Interest expense and other financial income and expense (Details 2) Sheet http://novartis.com/20171231/role/DisclosureInterestExpenseAndOtherFinancialIncomeExpenseDetails2 Interest expense and other financial income and expense (Details 2) Uncategorized 88 false false R89.htm 2400600 - Disclosure - Taxes (Details) Sheet http://novartis.com/20171231/role/DisclosureTaxesDetails Taxes (Details) Uncategorized 89 false false R90.htm 2400601 - Disclosure - Taxes (Details 2) Sheet http://novartis.com/20171231/role/DisclosureTaxesDetails2 Taxes (Details 2) Uncategorized 90 false false R91.htm 2400602 - Disclosure - Taxes (Details 3) Sheet http://novartis.com/20171231/role/DisclosureTaxesDetails3 Taxes (Details 3) Uncategorized 91 false false R92.htm 2400700 - Disclosure - Earnings per share (Details) Sheet http://novartis.com/20171231/role/DisclosureEarningsPerShareDetails Earnings per share (Details) Uncategorized 92 false false R93.htm 2400800 - Disclosure - Changes in consolidated statements of comprehensive income (Details) Sheet http://novartis.com/20171231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails Changes in consolidated statements of comprehensive income (Details) Uncategorized 93 false false R94.htm 2400801 - Disclosure - Changes in consolidated statements of comprehensive income (Details 2) Sheet http://novartis.com/20171231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails2 Changes in consolidated statements of comprehensive income (Details 2) Uncategorized 94 false false R95.htm 2400802 - Disclosure - Changes in consolidated statements of comprehensive income (Details 3) Sheet http://novartis.com/20171231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails3 Changes in consolidated statements of comprehensive income (Details 3) Uncategorized 95 false false R96.htm 2400803 - Disclosure - Changes in consolidated statements of comprehensive income (Details 4) Sheet http://novartis.com/20171231/role/DisclosureChangesInConsolidatedStatementsOfComprehensiveIncomeDetails4 Changes in consolidated statements of comprehensive income (Details 4) Uncategorized 96 false false R97.htm 2400900 - Disclosure - Property, plant and equipment (Details) Sheet http://novartis.com/20171231/role/DisclosurePropertyPlantAndEquipmentDetails Property, plant and equipment (Details) Uncategorized 97 false false R98.htm 2401000 - Disclosure - Goodwill and intangible assets (Details) Sheet http://novartis.com/20171231/role/DisclosureGoodwillAndIntangibleAssetsDetails Goodwill and intangible assets (Details) Uncategorized 98 false false R99.htm 2401001 - Disclosure - Goodwill and intangible assets (Details 2) Sheet http://novartis.com/20171231/role/DisclosureGoodwillAndIntangibleAssetsDetails2 Goodwill and intangible assets (Details 2) Uncategorized 99 false false R100.htm 2401002 - Disclosure - Goodwill and intangible assets (Details 3) Sheet http://novartis.com/20171231/role/DisclosureGoodwillAndIntangibleAssetsDetails3 Goodwill and intangible assets (Details 3) Uncategorized 100 false false R101.htm 2401003 - Disclosure - Goodwill and intangible assets (Details 4) Sheet http://novartis.com/20171231/role/DisclosureGoodwillAndIntangibleAssetsDetails4 Goodwill and intangible assets (Details 4) Uncategorized 101 false false R102.htm 2401100 - Disclosure - Deferred tax assets and liabilities (Details) Sheet http://novartis.com/20171231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails Deferred tax assets and liabilities (Details) Uncategorized 102 false false R103.htm 2401101 - Disclosure - Deferred tax assets and liabilities (Details 2) Sheet http://novartis.com/20171231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails2 Deferred tax assets and liabilities (Details 2) Uncategorized 103 false false R104.htm 2401102 - Disclosure - Deferred tax assets and liabilities (Details 3) Sheet http://novartis.com/20171231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails3 Deferred tax assets and liabilities (Details 3) Uncategorized 104 false false R105.htm 2401103 - Disclosure - Deferred tax assets and liabilities (Details 4) Sheet http://novartis.com/20171231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails4 Deferred tax assets and liabilities (Details 4) Uncategorized 105 false false R106.htm 2401104 - Disclosure - Deferred tax assets and liabilities (Details 5) Sheet http://novartis.com/20171231/role/DisclosureDeferredTaxAssetsAndLiabilitiesDetails5 Deferred tax assets and liabilities (Details 5) Uncategorized 106 false false R107.htm 2401200 - Disclosure - Financial and other non-current assets (Details) Sheet http://novartis.com/20171231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails Financial and other non-current assets (Details) Uncategorized 107 false false R108.htm 2401201 - Disclosure - Financial and other non-current assets (Details 2) Sheet http://novartis.com/20171231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails2 Financial and other non-current assets (Details 2) Uncategorized 108 false false R109.htm 2401202 - Disclosure - Financial and other non-current assets (Details 3) Sheet http://novartis.com/20171231/role/DisclosureFinancialAndOtherNoncurrentAssetsDetails3 Financial and other non-current assets (Details 3) Uncategorized 109 false false R110.htm 2401300 - Disclosure - Inventories (Details) Sheet http://novartis.com/20171231/role/DisclosureInventoriesDetails Inventories (Details) Uncategorized 110 false false R111.htm 2401400 - Disclosure - Trade receivables (Details) Sheet http://novartis.com/20171231/role/DisclosureTradeReceivablesDetails Trade receivables (Details) Uncategorized 111 false false R112.htm 2401401 - Disclosure - Trade receivables (Details 2) Sheet http://novartis.com/20171231/role/DisclosureTradeReceivablesDetails2 Trade receivables (Details 2) Uncategorized 112 false false R113.htm 2401402 - Disclosure - Trade receivables (Details 3) Sheet http://novartis.com/20171231/role/DisclosureTradeReceivablesDetails3 Trade receivables (Details 3) Uncategorized 113 false false R114.htm 2401403 - Disclosure - Trade receivables (Details 4) Sheet http://novartis.com/20171231/role/DisclosureTradeReceivablesDetails4 Trade receivables (Details 4) Uncategorized 114 false false R115.htm 2401404 - Disclosure - Trade receivables (Details 5) Sheet http://novartis.com/20171231/role/DisclosureTradeReceivablesDetails5 Trade receivables (Details 5) Uncategorized 115 false false R116.htm 2401500 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details) Sheet http://novartis.com/20171231/role/DisclosureMarketableSecuritiesDetails Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details) Uncategorized 116 false false R117.htm 2401501 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 2) Sheet http://novartis.com/20171231/role/DisclosureMarketableSecuritiesDetails2 Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 2) Uncategorized 117 false false R118.htm 2401502 - Disclosure - Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 3) Sheet http://novartis.com/20171231/role/DisclosureMarketableSecuritiesDetails3 Marketable securities, commodities, time deposits, derivative financial instruments and cash and cash equivalents (Details 3) Uncategorized 118 false false R119.htm 2401600 - Disclosure - Other current assets (Details) Sheet http://novartis.com/20171231/role/DisclosureOtherCurrentAssetsDetails Other current assets (Details) Uncategorized 119 false false R120.htm 2401700 - Disclosure - Equity (Details) Sheet http://novartis.com/20171231/role/DisclosureEquityDetails Equity (Details) Uncategorized 120 false false R121.htm 2401701 - Disclosure - Equity (Details 2) Sheet http://novartis.com/20171231/role/DisclosureEquityDetails2 Equity (Details 2) Uncategorized 121 false false R122.htm 2401702 - Disclosure - Equity (Details 3) Sheet http://novartis.com/20171231/role/DisclosureEquityDetails3 Equity (Details 3) Uncategorized 122 false false R123.htm 2401703 - Disclosure - Equity (Details 4) Sheet http://novartis.com/20171231/role/DisclosureEquityDetails4 Equity (Details 4) Uncategorized 123 false false R124.htm 2401704 - Disclosure - Equity (Details 5) Sheet http://novartis.com/20171231/role/DisclosureEquityDetails5 Equity (Details 5) Uncategorized 124 false false R125.htm 2401800 - Disclosure - Non-current financial debt (Details) Sheet http://novartis.com/20171231/role/DisclosureNonCurrentFinancialDebtDetails Non-current financial debt (Details) Uncategorized 125 false false R126.htm 2401801 - Disclosure - Non-current financial debt (Details 2) Sheet http://novartis.com/20171231/role/DisclosureNonCurrentFinancialDebtDetails2 Non-current financial debt (Details 2) Uncategorized 126 false false R127.htm 2401802 - Disclosure - Non-current financial debt (Details 3) Sheet http://novartis.com/20171231/role/DisclosureNonCurrentFinancialDebtDetails3 Non-current financial debt (Details 3) Uncategorized 127 false false R128.htm 2401803 - Disclosure - Non-current financial debt (Details 4) Sheet http://novartis.com/20171231/role/DisclosureNonCurrentFinancialDebtDetails4 Non-current financial debt (Details 4) Uncategorized 128 false false R129.htm 2401804 - Disclosure - Non-current financial debt (Details 5) Sheet http://novartis.com/20171231/role/DisclosureNonCurrentFinancialDebtDetails5 Non-current financial debt (Details 5) Uncategorized 129 false false R130.htm 2401805 - Disclosure - Non-current financial debt (Details 6) Sheet http://novartis.com/20171231/role/DisclosureNonCurrentFinancialDebtDetails6 Non-current financial debt (Details 6) Uncategorized 130 false false R131.htm 2401900 - Disclosure - Provisions and other non-current liabilities (Details) Sheet http://novartis.com/20171231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails Provisions and other non-current liabilities (Details) Uncategorized 131 false false R132.htm 2401901 - Disclosure - Provisions and other non-current liabilities (Details 2) Sheet http://novartis.com/20171231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails2 Provisions and other non-current liabilities (Details 2) Uncategorized 132 false false R133.htm 2401902 - Disclosure - Provisions and other non-current liabilities (Details 3) Sheet http://novartis.com/20171231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails3 Provisions and other non-current liabilities (Details 3) Uncategorized 133 false false R134.htm 2401903 - Disclosure - Provisions and other non-current liabilities (Details 4) Sheet http://novartis.com/20171231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails4 Provisions and other non-current liabilities (Details 4) Uncategorized 134 false false R135.htm 2401904 - Disclosure - Provisions and other non-current liabilities (Details 5) Sheet http://novartis.com/20171231/role/DisclosureProvisionsAndOtherNonCurrentLiabilitiesDetails5 Provisions and other non-current liabilities (Details 5) Uncategorized 135 false false R136.htm 2402000 - Disclosure - Current financial debt and derivative financial instruments (Details) Sheet http://novartis.com/20171231/role/DisclosureCurrentFinancialDebtAndDerivativeFinancialInstrumentsDetails Current financial debt and derivative financial instruments (Details) Uncategorized 136 false false R137.htm 2402100 - Disclosure - Provisions and other current liabilities (Details) Sheet http://novartis.com/20171231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails Provisions and other current liabilities (Details) Uncategorized 137 false false R138.htm 2402101 - Disclosure - Provisions and other current liabilities (Details 2) Sheet http://novartis.com/20171231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails2 Provisions and other current liabilities (Details 2) Uncategorized 138 false false R139.htm 2402102 - Disclosure - Provisions and other current liabilities (Details 3) Sheet http://novartis.com/20171231/role/DisclosureProvisionsAndOtherCurrentLiabilitiesDetails3 Provisions and other current liabilities (Details 3) Uncategorized 139 false false R140.htm 2402200 - Disclosure - Details to the consolidated cash flow statements (Details) Sheet http://novartis.com/20171231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails Details to the consolidated cash flow statements (Details) Uncategorized 140 false false R141.htm 2402201 - Disclosure - Details to the consolidated cash flow statements (Details 2) Sheet http://novartis.com/20171231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails2 Details to the consolidated cash flow statements (Details 2) Uncategorized 141 false false R142.htm 2402202 - Disclosure - Details to the consolidated cash flow statements (Details 3) Sheet http://novartis.com/20171231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails3 Details to the consolidated cash flow statements (Details 3) Uncategorized 142 false false R143.htm 2402202 - Disclosure - Details to the consolidated cash flow statements (Details 3, Parenthetical) Sheet http://novartis.com/20171231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails3Parenthetical Details to the consolidated cash flow statements (Details 3, Parenthetical) Uncategorized 143 false false R144.htm 2402203 - Disclosure - Details to the consolidated cash flow statements (Details 4) Sheet http://novartis.com/20171231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails4 Details to the consolidated cash flow statements (Details 4) Uncategorized 144 false false R145.htm 2402204 - Disclosure - Details to the consolidated cash flow statements (Details 5) Sheet http://novartis.com/20171231/role/DisclosureDetailsConsolidatedCashFlowStatementsDetails5 Details to the consolidated cash flow statements (Details 5) Uncategorized 145 false false R146.htm 2402300 - Disclosure - Acquisitions of businesses (Details) Sheet http://novartis.com/20171231/role/DisclosureAcquisitionsOfBusinessesDetails Acquisitions of businesses (Details) Uncategorized 146 false false R147.htm 2402400 - Disclosure - Post-employment benefits for associates (Details) Sheet http://novartis.com/20171231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails Post-employment benefits for associates (Details) Uncategorized 147 false false R148.htm 2402401 - Disclosure - Post-employment benefits for associates (Details 2) Sheet http://novartis.com/20171231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails2 Post-employment benefits for associates (Details 2) Uncategorized 148 false false R149.htm 2402402 - Disclosure - Post-employment benefits for associates (Details 3) Sheet http://novartis.com/20171231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails3 Post-employment benefits for associates (Details 3) Uncategorized 149 false false R150.htm 2402403 - Disclosure - Post-employment benefits for associates (Details 4) Sheet http://novartis.com/20171231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails4 Post-employment benefits for associates (Details 4) Uncategorized 150 false false R151.htm 2402404 - Disclosure - Post-employment benefits for associates (Details 5) Sheet http://novartis.com/20171231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails5 Post-employment benefits for associates (Details 5) Uncategorized 151 false false R152.htm 2402405 - Disclosure - Post-employment benefits for associates (Details 6) Sheet http://novartis.com/20171231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails6 Post-employment benefits for associates (Details 6) Uncategorized 152 false false R153.htm 2402406 - Disclosure - Post-employment benefits for associates (Details 7) Sheet http://novartis.com/20171231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails7 Post-employment benefits for associates (Details 7) Uncategorized 153 false false R154.htm 2402407 - Disclosure - Post-employment benefits for associates (Details 8) Sheet http://novartis.com/20171231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails8 Post-employment benefits for associates (Details 8) Uncategorized 154 false false R155.htm 2402408 - Disclosure - Post-employment benefits for associates (Details 9) Sheet http://novartis.com/20171231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails9 Post-employment benefits for associates (Details 9) Uncategorized 155 false false R156.htm 2402409 - Disclosure - Post-employment benefits for associates (Details 10) Sheet http://novartis.com/20171231/role/DisclosurePostEmploymentBenefitsForAssociatesDetails10 Post-employment benefits for associates (Details 10) Uncategorized 156 false false R157.htm 2402500 - Disclosure - Equity-based participation plans for associates (Details) Sheet http://novartis.com/20171231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails Equity-based participation plans for associates (Details) Uncategorized 157 false false R158.htm 2402501 - Disclosure - Equity-based participation plans for associates (Details 2) Sheet http://novartis.com/20171231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails2 Equity-based participation plans for associates (Details 2) Uncategorized 158 false false R159.htm 2402502 - Disclosure - Equity-based participation plans for associates (Details 3) Sheet http://novartis.com/20171231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails3 Equity-based participation plans for associates (Details 3) Uncategorized 159 false false R160.htm 2402503 - Disclosure - Equity-based participation plans for associates (Details 4) Sheet http://novartis.com/20171231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails4 Equity-based participation plans for associates (Details 4) Uncategorized 160 false false R161.htm 2402504 - Disclosure - Equity-based participation plans for associates (Details 5) Sheet http://novartis.com/20171231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails5 Equity-based participation plans for associates (Details 5) Uncategorized 161 false false R162.htm 2402505 - Disclosure - Equity-based participation plans for associates (Details 6) Sheet http://novartis.com/20171231/role/DisclosureEquityBasedParticipationPlansForAssociatesDetails6 Equity-based participation plans for associates (Details 6) Uncategorized 162 false false R163.htm 2402600 - Disclosure - Transactions with related parties (Details) Sheet http://novartis.com/20171231/role/DisclosureTransactionsWithRelatedPartiesDetails Transactions with related parties (Details) Uncategorized 163 false false R164.htm 2402601 - Disclosure - Transactions with related parties (Details 2) Sheet http://novartis.com/20171231/role/DisclosureTransactionsWithRelatedPartiesDetails2 Transactions with related parties (Details 2) Uncategorized 164 false false R165.htm 2402602 - Disclosure - Transactions with related parties (Details 3) Sheet http://novartis.com/20171231/role/DisclosureTransactionsWithRelatedPartiesDetails3 Transactions with related parties (Details 3) Uncategorized 165 false false R166.htm 2402700 - Disclosure - Commitments and contingencies (Details) Sheet http://novartis.com/20171231/role/DisclosureCommitmentsAndContingenciesDetails Commitments and contingencies (Details) Uncategorized 166 false false R167.htm 2402701 - Disclosure - Commitments and contingencies (Details 2) Sheet http://novartis.com/20171231/role/DisclosureCommitmentsAndContingenciesDetails2 Commitments and contingencies (Details 2) Uncategorized 167 false false R168.htm 2402800 - Disclosure - Financial instruments - additional disclosures (Details) Sheet http://novartis.com/20171231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails Financial instruments - additional disclosures (Details) Uncategorized 168 false false R169.htm 2402801 - Disclosure - Financial instruments - additional disclosures (Details 2) Sheet http://novartis.com/20171231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails2 Financial instruments - additional disclosures (Details 2) Uncategorized 169 false false R170.htm 2402802 - Disclosure - Financial instruments - additional disclosures (Details 3) Sheet http://novartis.com/20171231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails3 Financial instruments - additional disclosures (Details 3) Uncategorized 170 false false R171.htm 2402803 - Disclosure - Financial instruments - additional disclosures (Details 4) Sheet http://novartis.com/20171231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails4 Financial instruments - additional disclosures (Details 4) Uncategorized 171 false false R172.htm 2402804 - Disclosure - Financial instruments - additional disclosures (Details 5) Sheet http://novartis.com/20171231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails5 Financial instruments - additional disclosures (Details 5) Uncategorized 172 false false R173.htm 2402805 - Disclosure - Financial instruments - additional disclosures (Details 6) Sheet http://novartis.com/20171231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails6 Financial instruments - additional disclosures (Details 6) Uncategorized 173 false false R174.htm 2402806 - Disclosure - Financial instruments - additional disclosures (Details 7) Sheet http://novartis.com/20171231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails7 Financial instruments - additional disclosures (Details 7) Uncategorized 174 false false R175.htm 2402807 - Disclosure - Financial instruments - additional disclosures (Details 8) Sheet http://novartis.com/20171231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails8 Financial instruments - additional disclosures (Details 8) Uncategorized 175 false false R176.htm 2402808 - Disclosure - Financial instruments - additional disclosures (Details 9) Sheet http://novartis.com/20171231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails9 Financial instruments - additional disclosures (Details 9) Uncategorized 176 false false R177.htm 2402809 - Disclosure - Financial instruments - additional disclosures (Details 10) Sheet http://novartis.com/20171231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails10 Financial instruments - additional disclosures (Details 10) Uncategorized 177 false false R178.htm 2402810 - Disclosure - Financial instruments - additional disclosures (Details 11) Sheet http://novartis.com/20171231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails11 Financial instruments - additional disclosures (Details 11) Uncategorized 178 false false R179.htm 2402811 - Disclosure - Financial instruments - additional disclosures (Details 12) Sheet http://novartis.com/20171231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails12 Financial instruments - additional disclosures (Details 12) Uncategorized 179 false false R180.htm 2402812 - Disclosure - Financial instruments - additional disclosures (Details 13) Sheet http://novartis.com/20171231/role/DisclosureFinancialInstrumentsAdditionalDisclosuresDetails13 Financial instruments - additional disclosures (Details 13) Uncategorized 180 false false R181.htm 2402900 - Disclosure - Discontinued operations (Details) Sheet http://novartis.com/20171231/role/DisclosureDiscontinuedOperationsDetails Discontinued operations (Details) Uncategorized 181 false false R182.htm 2402901 - Disclosure - Discontinued operations (Details 2) Sheet http://novartis.com/20171231/role/DisclosureDiscontinuedOperationsDetails2 Discontinued operations (Details 2) Uncategorized 182 false false R183.htm 2403000 - Disclosure - Events subsequent to the December 31 consolidated balance sheet date (Details) Sheet http://novartis.com/20171231/role/DisclosureSubsequentEventsDetails Events subsequent to the December 31 consolidated balance sheet date (Details) Uncategorized 183 false false R184.htm 2403100 - Disclosure - Principal Group subsidiaries and associated companies (Details) Sheet http://novartis.com/20171231/role/DisclosurePrincipalGroupSubsidiariesAndAssociatedCompaniesDetails Principal Group subsidiaries and associated companies (Details) Uncategorized 184 false false All Reports Book All Reports nvs-20171231.xml nvs-20171231.xsd nvs-20171231_cal.xml nvs-20171231_def.xml nvs-20171231_lab.xml nvs-20171231_pre.xml http://xbrl.sec.gov/currency/2017-01-31 http://xbrl.sec.gov/country/2017-01-31 http://xbrl.ifrs.org/taxonomy/2016-03-31/ifrs-full http://xbrl.sec.gov/dei/2014-01-31 true true ZIP 258 0001370368-18-000005-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001370368-18-000005-xbrl.zip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�LR_6,-1!;A+<;=OG>'V8M5U0TEIG4*L>=-:SX*5.N-5>S M)5/=?(8G]=6,9@#]4A9BW-@>K(U['C:WDV#:]8-FU9K*1K-QC*2YFV$K)#%L MFJVK;;0MJ:%@=U.NXK-@M6)J,YW/Q,(5MD5? M>UM47=H831'>5QE;(2=[/&Q,;U\E,J/#+S4W\2FNWMF&9-NL(+?LJ??0#\N. M)M"?RP+5+6RS>#Y*:3\*QX%!!=SO*[2F&D?S1AR411FWJP>> M2%K>8[KI;9;Q"9]SI;@-RA[* 41S(=B=<(3??UUNJW4T65SY[B@2L MQ>ZD[6^SP,U,IA>QRT:VS][TL<_V_D_,Q;=(!UIKW>TTY#.QN-.\.WVWB#AF]4]F@+TLRAW M6H K?-/"/LRC:U3U:.[=/D;#SM?;<2T?>I+:HZG1%&1,NV&G./VDV3=RL5]; M(ZI.*9IQJ.IL>9RC]M,.,C&R-8RVMZCS*.],A;C'AZT N2I&&Y[U4MO-T_D^ M[SO_YNL847"E>34ON-TLF73[VQ%$]W9,T;UI$=W;K19=@_MCV!1J4/%HX8D] M'"N[&==$1'WG89.:1Y1^:78VE/Z63]LMWJ]AX]^P\M&TH*]O;3<1F,JJ[V1@ M6ON(JE":$+JHPFY6,!!77S//M/81E:%D '92ANTV#\W$]>Y9E>'=F,KP=I R MO-MJ93 Y*.F[2)C5/>(I3&F),#V%V?+E(?%EQ\[M*^F&R0[]0>&;[?6.%MCW MIFPJ)JUG_..8937B8!?,V2Z?05YRT]I'.XKOK0,[%[N)N(;M'8VK'\TP&* . MNPVDN<#Z6@?F]8^H$24+H:-&[ P%(YGUW4F:US^B3I3VDEUU8KNWDUI.QR-8 MBQ45C68>5AS3ZN;V=L9@??Z, M-<4OF;J';@ ]GW'HGR%W\2JK&FTBKHB$3!O<\Y(6_Q.S&Z^D'?W#%RN^9_.U M](0/_[2Y$@_0A0\\%_'F^2H(\^?BPJTS>B9_P<1@#\S9]K2>5=(=-,\W5#C: M3$]!:7;+2(VPARTD336.MI30T)_=.M4H[KY^A,8J1U2ADNO@]51HR[T0#1+O MZWAHK')$)2KY&EY1B;;;;7$EW6C_DKA[3OA=WUS'=;6-9C?_6E["KC(NJ501 M;&AVF^6:.?*]5K;E;1;Q++CSP+B!BD\Q=?'06^,UM8UE +ZM&-MA2WM> MTO2>+_?\)=\[X19?W7&U]_80Y5WSSM >_K;;6S;88(.\6\UUCN;@ZF3=[3Q1 M?1?I0:HPI,6Q%&5DXV"G2K2 @(HT6"D#F3N*L5VY>[E(=]/$^E< M?:2=X-/Y4> )EWM>;YG75C>:G"M>9,XVNB?G>W=)L]LLV6OI^:>KM2,WN @> M<1)\$0]OL/;(.:1Y/WNXIQ#>W_R!,&]NXB#O;F4N&%MXB'K1:^ MP=P[Z."V0P.CG> .F.)WA[D-D_,@16BI=#3A=YKW=^(VFZ:'30'&]8^F!/T7 M@YU&&$[:PSP^75H8;?<_:%W8DHW@6'K1UQW4J8D1-:/D%^JL&5ON(NH@N+YA M!)V:&%$W2C$%W75CNR,,ZFR_86M(6ZVC:4!'DW*W4AC9? ,-"/,&1M.#(5;E M3BFZR*RW]="AA1'5HFP\=%2+;;<=C,76VW3HT,*(BE&V'+HJQG8;#N9BZQNF MV*6%$16C%++863&V.W[17&Q]8QF[M#"B8I3B&CLKQG8'.9J+K6_ 8Y<61E2, M4O!C9\78[DA(<[']\NR*\.7P8KQZTXQ MC,3VX=D5X\.8BO'K8,7XL%,,([$='CR[9D 3(ZK&A\&J<7BPU;IQJYC-;[C% MQ8,^1Q[ZZ'-==:-=JZEP4NA&]U3:ZLX=T2B-WH^QUU4WHG#+[[+7"W>[G9 U MTAA7MF.*MG0842_:G6 SHA@4S%13V5B12X9BW<4HE00QDCS'2S)K(LF= $LS M9%]'?FUU(\ZX):]]PV*ZW?[Y&FGT=<;75C>B<$N>]P;A;KF/70G7$FOF?%0R M6..E/F$+I@3'N*QD@VH?R]6:N4/NA75L9JRI^VUEH&C$S)[F1E\KC-G106#) M7ABOD$8<[93$7'H#;YGT:FPLJVTTA=E9=CV$.302O5]K8ZT\(^K.;K.G./:C MOL$?0#5KKG3U0QTU+96.YG_]4';79)O>DTG;.Z>-@62>0]IC"KLT[MN$O1-U M22R#S(;&*LK?\UPAE5 F/=^O<7+9;+=)P^CK.)%LY9M[RS)&/,VB+ M9U. ]?7_=&MCM%G\3=DI%*_,4;J97(H9_8#8''C:\Q*F=CZC[A+L>Y[:K8T1 MM:1TR-I?2[;[#+:+!'O;^YW:&%%+RN9_;RW9\GU!!PF^@)*,J2-E@Z.OCNPT MI$U\PW87'5H8;;,QBG[L=B%FPGM.Q1AOCS*"2NPTP=!DO&:8 V#)?0&]\!(V M:KY!H@;K?^[EV-SJB67&%ZNXUNG\=[XY$POXN7=*U;KJQIH^#BJR'V0;Q>P' M]WRS-P_;W6;1CG?T_9RGVP<5@4F3W>%U/MWUDKD+[IV[V4DXG7RGN*!G[O0:;QO_NL^38VF"Q7/8D4,[0DW/\=G9G88\E:6*Z!%MK998\JYB=*' M,9XC17)U[:,%+U;XM2N3'KF9%SAVF9)U5YW^*Q#^Y@BZTKY&R>)!/K9P[3!W ME+2Z'1H8;0_QOB*_NF;C1Z2Q]]991O;6R,DNRVXV?#%Y0?*K\)9F+;FD?FI/W85^[F]8^F M A56PEGE,SD_[K&$D[VT2[9:'^IV:(-\BRV5CN5.[+CYVWD.J_=NPQ)G/WOX MJNF.<"?>GONU84^?]V]P- 49=9NX4R/S'=W(;R\TM3&6L@S=.^[4H],>;Y"& M=&YFM'/*X1O*G9ZT;@*'WG1NKWHT?>BSR]QI0)?MX"!EZ-K*:'HQ>.NY4Y*& M[>*P"*BV6LZ\"]W%-U5N&P>FVW_^NW#F&]&=A/MM# >^TSR@Q=%T9.2] MZ$Z3!LFU][//0YH<49?*[T$/UZ4MC[T>(-J^USH&-3FB-I6"YL;0INV^[S% MM'VOD@UJ=[90%Y?H,"7IWLYH MP=UC^%YWJM)#A'V-Y1X-C:@L)1.YK[)LN5W<68I]K>$>#8VH+B4;N+>Z;+?A MVUF*?WNFRW9=M9BGUSS.DNQ[R-:/1H:45U*;VGU5I?M?E.KLQ3[/JW5HZ$1 MU:7TPE9O==GNE[8Z2['O@UL]&AI174KO;O56E^U^?ZLY,FWPNRT&=8^F%/W" MWG;.-T-!#7B9R:3R$=6@ZITF0S78:D:P&O+]F4OF(BE#U&INI(FRWP\PX M1G78"M&YF=&48X18V-W*H?A'*>U'X3@3USZ'RMV%N',PNI$/SBYJ4O-HI[T' MY:DB;E^?]8J$ S0A^2Z#J+F4^GK236H>4?XEU[FI_/_RGO)__[=_VQL2$-_7 M;FRM=L20^-+H-PF)WW);L44^?>?]UFI'%'MIT!N)?;MG_!;Y])WN6ZL=4>RE MWP;;SINN>%>+Y.^ M-GM3C2-*N;1+:Y;R=MOI]3+I:Z(WU3BBE$N;LF8I;[=97B^3OA9Y4XTC2KFT M!VN6\G9;X?4RZ6N -]4XHI1+6ZYF*6^WT=WMJEM?BZQK*Z/YV"L>Y.UUHV[+ MK;=N\NMKT75M940M*5EY_;1DNZV_;O+K:Q%V;65$+2E9B?VT9+NMQV[RZVM1 M=FUE1"TI69G]M&2[K<]N\NMKD79M940M*5FI_;1DNZW7,/YZ4"SY>$^N_%)W M*W\GH1%RW(Z=Y+A66KM\DTF?CY$@8_0D*0V"VP5'%GI]6+Z*\;?CO]3EHMAM MM"LZ?ECZB/&WR;_4I8;8;8 K.GY8-H?QMZ^_U&5JV.Z-:9IZ;3J/7^GM_PCP MK+6V4>1Y>'#P_N 0U\&D0+ M#/L>DG9O9T1=*1V3]M65[3XH[2K#OI=MNKO>SHBZ4DK[UU=7MCOK7U<9'AZ\D+) 0R-J MRX>QM.7P8*SB:Y_=PNUV_)WS.E>+V+7L*T\%-7'N\RPJFM8]VT'Q8 M==@8\K#GLZ_N)I1#1\3"%7-A,=>?6)8,7%^XBVOI"&OX'3BSND<+ M(CFLR$*70%P(/P L7Q4,EC_ M]@/P*GR^^F'/U[S"/U?2!9&KS3G\C !^^*D:=A:B'2C=05F,89,QQ!-IZ=4' M.#X%%?,WY]#+:J5+3:(R,3Y#VC[@H#"H=QNTX1*]XOZ1E/=?F!/PZ1P$!L7] M#;Y;X&.,SQI;^NS:7(4K-+_@,$B/I:MK2P0]N!8Z\D^":?1UBQA@Z5<#AM_\ M;0EM*BNXX^=]A-N3;YA+='M>B??LE^?3R3:VRU-*JBPXD&)]T3U]RY_\(T=: M]YDIQ9"\.\*W?_/C\N/*YMQ]@')2X5J9IITH3"9M1&0D-K.6W X<&.@QRYOH M;F*UR#K0$Y19CM>BK(H?RQD/># \VH0U-.1@_15JOMS%^;=!1BLC:": M*,G! DM$># Q86[S1E0-A.1 E=;^RB\$5Y)3IERHW[OF:K9DBA\Q3UBPO)\( M)_#1 ]&\L'0M_JKK3*$3TL5^.K^4#_$UG8:<_Z6.&%8%I+HA2SNOUN(R$QT(7-'?"X5LLB]Z@FMG8R2ND:V+TZSD9,VD<'ITQJ, M15Z-LD]=%:.SF,-2-W&8B2@K<+()J?!W+$%7ME@.M)DTV+TI&<5/SN(7Y-NNZ M:W%*RG[+5VNIF-J\Q6'ARDQF0%QP[TUMWSQP&&#, ^<"_B;5SBN:/= #ZZ%TO"H 3-Y8$(S M"98H?"CM'KMT3->Z*'7/"?1UCTIP&T@G?I3!;T@7]FB#T')_ M%B@7FE9HRG_A8+\XO. %;Z2@XOZ^9.J>HXBB5[2+RIR'9$Q-!5[D+W$V(>?< M!E/##JPBKG8R*H#"[6,:EA!Y+/-'E$TD! \L*]DMGB@U$U$1S['T8&:;L=)D M4/6!(--3!98H9\I::A?C W>D-L1KP;06H *RZ$XK19#4?7Z]+5@>0#=/(@%? M85N G;'O?^J".?#(E)U$O:$S-#RNRD\0+93/&2F7H+7YW1"PJ2<_#RWW.VT@ M26!/S'&( &4BW T9PH5LISXNA6A#3_CQ3+&W[',:X9\%IV$X0G-Z7S.+5@4 MCO58QV&'QZF/V)4)2#/2[MC>(<\6L/^\T+XJ:'4ZGU(NGX/BPD 5N [6 M(J\@I -K I)@BXA;\< C[ILFJ6Y%R$/%(ZJ0=6X;@ZTM](IP\W;B=;AS2ZZ- M1%HXO7/$(N0VXWHI[%)ZEJ5CXR=AX-4!B8(@TZ!8%]+SCIE2FWEHO1:X;Z1X M/ACCV.\*KZN<\/#/VR6PM%AJW4J"[3)K8WPRNM&+9,8 'E;+B]B+O:\1@8$ M;*)7K?6X^*OPEP*#\V9,[PC^'BCAV<(*Q1#M_$:KCL[%HF&GQL6]\6BU47$- MA!:4'@;G;M:0*L^"S614YL3X= 6MJ(GUKT!X^J)H 4\K%14X1^$<,5MR[M_" M%*9ED'79-A&0<]A6,IN73#,)%;$=Z-Y2[4U7Q.SFES_*8[_3*+U2Z?.IRY"_//DKDJVC]%G\E MP^Y2<5[%PHMP$G<"$Q=#6"Q_ZJ9'%MR[9AM$ M-)G[N",-17SXYE*Z_K+*Q3]6O:^YK^W6DYE-YS/TY[BU$^_5SZ[B*^$#QOCF MY@UF[W&Y?;3)OG!SBEE5H$?.I+KA(MGZQ=TWO!KB_90DT-'ACM$1*F[TR\@3 M]V>G(G3<(]G+%LF9?SEM4.0":KBIT:4PF=#T3@ :[_]V*DTJM+,21$.\>9<" M5(%62Z@5KEDQJJ OA2M6P2J;"PJ6,^W3:X?>I3"A4%LML>.F.:R1@LQ$5>:R MX<)@,]VS2J?%AFX_T9CJ;A&X;N(V,S#FN[WK2 =%;2CC+NKJ4G\)Q8 3*,Z,AF;W;U@Z!-IO&X MU9-9DT:&V&Q^C%L_)1.M!=JM6'$[@J?CY&.$5:G$JXV"9VV!4E?JD1)*&R^ M/3"GOE,,:6E;2V$*G2VS3&SHB6T'K# M[_R4M1/NRA4,+QUT4%H[C$BI1)"$2[R5.Y8M_$;N2#8._3IW,Z[@*/+@1CI. M=!4D/7HQ)7^!*S&];70=>[J ZM!'*^PH +5B&V) 2&A9N\G8STDA!M$*^E!RVM':D]3E%H<05:MOA@ M(3W KOY(Z&)/.E]B@"AF!HUBBVKL4V-R2L9FF6O/&%\%)2&G*<9W\G\%4/84 M8]^A6'9MK_U*;I4O<\KS(15-!%2B0@H\-@(@QSSN,H6?[,)CPZ(JK949*4GG M1P/KC4X-PW*$9H8L]YD\9+<*EE9F56]F.A4A*=\:MAME:U"&J%PCEVWB_,'= M:,XME'6M-0B[9STD-: +EN8AW[,B2H9/%D^Z=[J6"LME?SJ22LE'#'DYVF#M M[:?,PZJCVDGA$VF8\BCS3)4,,H#:>Z9''52[(Y5H;AB,8/8]8T+%T<<2MIW= M^J*];U^N:;J=#XQQQ1Q]NZ@&)'3'-UX5T%SX,ZP1?@JC"G]Q> M@LYQ=JN95AN450BM[5<#N7'2"TUIA RNA?+8B///'O'P@EF4"3V7;RNZMSAU M3_B*N4E@2[^B=$9+<9<-C6CN:[:"S?[J;N6I+*A=(>3FBKZ%R4T378&49H@A M%5!1A0M\VCB7(@#FN"OI)[_/Q%-%8H'NQ:@<+YL"(PL@JW7X;BKZLWQT:'7P M9S7-:2/4246YQX!5._<-K9#T?-@77.,<.4:EE(VJNGG_&*\;AHD.8O1Q]W0K M0L>(FKS;?_/^]//-X?N#@TM@"\]WI&N_.3CX\.;@\&=< Q^8\H4711[.]B?[ M%\$3S*4R4(OT;^>>%X"8_0\?]G]Y_TM^*G[F-JC,YP#SW>?9R>%! >7AP1OX MOQ1E%-]X+!5FD\0ZK_CC/Z6Z_^P"E[9^K,3+8'WSMMR?S]X0F4Y]$V(MJL[A M&\#Z9@#6-^\+G?H"#9'IU+?[OP#6*JCO>D/]=?]MJ4^?OQU"78KJ\P;T9T2L MH#Z_%@?_"S1$IE.CB>[7(M9W@/5=?ZR''WZNGE&?LR$RG7H JR>LQC\71R5@ M?7/89S$^?/NNT)W/V@29CCS<__E-+9LW/'XJC_7G;(-.5!V A'G\Z*ZT4 M[P'E^Q3EY.,1\[@S>Q3^-Z[ S+=C8& ,[?]<5L-Q:R7473^'R(KS%2+[8(KL M_<&;4H>-72^9+CO"A">VNL#.]^^5 :H&/72Z;+WNX?X*+X2Y4R MO.^_*,(^I632/'M#9#KU78CU3076=[VQ_KH/P[-DTCQ[0V0Z]6#_,/0PE-#^ M#"KTMI?%\::X%#]S(X0Z,S0Y2LLFPORU.\Q?]]_]6K7./%<3K]>1!3=B&IY_ MP3$*(89?\3N9BR\I;]>8NC18Z8>K@C3_:Q-!=Q3&;UF-\%Q._KI_SDT;@VNA MH>.V34+'CS:7G*%77E]V9QX8&IGKNNUDY.[M-K!&(21"D9RO%]T2Z%J,"N()';" $4"?(9MH72'3?/VETF'I3KM:*+W&H M/$3OL%YQ7V>UKPHQRDTZW%^7 MA"8!6ON9.*[BTX(P4)5>A#8ZQ0=,V(&REO@A>0)3!Z).].>C #!;]R!*O-:% MN6G2F+S1ZZ7]:L8-MP.MS--Y-OE+.AG4?2:N(,FB-K'_#*+'\VXX1@#8.(LE M#^J5%L%V>N+(X\S@TP"6KR1'4?(T+*QJF'8Q>7_SW$WM[ZA$2KZ?KHJL:L2JTH/C]P26V6/#:R# M=@?%N90B^T&,$73[KA+)-..MW+T?&?3-ZC,_?S[.1M,8A* MQZ3%1UV@XEZ:C#5]!_?"M_<_L95P?"C&U2JP6<:K^^N;XKG:2[5&T/6)G**& MGH I4_8A%KY2B3>.$USHH5UP5]1\H^)Y2=;ZT(E0>,&SYB,5YO7$:7'7O@23 MP4*/AU5X([.!@ J(&91\VGC7L!*LF,6! 6#4RQRP%=+X&9-3 ?B'8,J2NLD+ ML<)3PCRBAN]4()R"_BO^1:]/)26K^TB&>4=< "\;G3<0GQ$IO"S<\)T*A(^S MWZ?0RXY<;,!.P#U^\8WV!@)"(+XPRQ(N+S-?^D"(:8'*DS.UL(5<_Y46+>*OU)A=V*O I?? M@G7&UKB:%@9G_>>7 =!^4GT4>#AUX#,M=]';#S.?KR?6OP)8D_"?H=\\OL!] M[NI/BO/K\#"=+5)3>YRZGO%DO__=MK([\+CD^6NZ(-FQ/)D8C:X83I_6#@/9 M2[5I3 \UH"Y">:*RB#)J/IW'0Z%9*=J+D-&#./6+F>2JTX,-K(-2LK04@'YS M.CDXB@Z4J_%W+40)\ W'> +TYBZBQ1(V7SV\ VOYM6P MC9PFR!G*11_-;28NP&5M I,]4^&)7@RJ#?^ FFAV3>C).,88$NGYMV#8 MV#=XM:&M(XS+T80]<:!Z%MHT.%R;LBMW+D43,CXH;?GI(M;XS'WW8H2V.E&( M++Z#OG"%AT?TN0T,GJK!J#UEUO*2_2F5/LM/K)UPGV\7K!X]&KT[J59)T7V"P,$^?=RTZ?SKTS2@UD>XK MO(GP"!PV=$(S">U(L&OI0UU@W3N;&SX/7!MYS3T#7'"&)$ZT'@6)AYY&_K]( MB(KSL\!Q,(]DX9I*)0%M,8>W:F+7=F1'I,ZN_.N+VCB)!NTWGN0.'EC'7[># MPF#0)6R9TGMZ8W1:3;W$1U$><AOE)+);5 M73BLPN^T[\+ XS$ZK5--?YG>.N/\FHF:F"GDW?',B]QJ[_W7)T)[HFN2Z&;SLO8I#6?B>MS#>-9S6TFH1-K;W*P M7/**="U$.9WPQ+)4P)PSJ6[9$_>2I3P,PM:_1>#2O7B'$J^IR8;@N7TC-\Q! MH44O2F2O%56!-RU!4E\#J;M9,%0.X MSRNZ!O(7%TV+T)%U6PQ%A:2[%:%R$2:7];WHWVF(HFJ@ M)1,^U<2O:I2C!'OZP)4=\.AH M"2RHR$!,!5D-NTJ6P-P^4S50-"BDMLG>9]85!CX!5TKVI!ZES#"PAYK!/BXN#43E, MSIW-I70%++JX!0[0=Y$Q,?N5)7T.U0?3-?/\DX!?PH^XDYRZ/'N:,6J-E-QC MH)^66#-'-SP#3H0M&'(/BUORS&%T3;)V51AO0\HB8",JDNCJ6+KFX5A4OJ&"T=&/V1RX5BZZ6PDEG6 MB/3U7)DFF^;2!8'TC/**^Q^A?R^DY\&Z<"MA4?&9<')YS@:4IS/MW'!?A.EF M$0"6RB;=K?U*+M=NF=/"^*O_3F4.R=Q$R/->]8$*TWHC>2T]J!23>F(EV1LW MA9PMAL2D\^.6AWU\V(AG5O630X&*^*%=,7OG[1*86BRSU\O/B],ER EOG M;8JOZ4<9HDUZ:,3ZB"M1>0*9<=\/F_!2^/7S31TY<=P]YXDF80^=@]KJIF/- ME;4@SJ=:FDI2G'1!:&2>JLB:+_"E+-'.CU*DE'%WHFV(C1]R].[C0_Y?AH M4_2AUGPCYT$M\EEPW=5]I>*(_.SB;;UB_M[2KU38U<\.%/JX\!L55F%P<@63 M8S022UG$&[Y3@5#'.F&6TVP>%8FLTC"9_)3:M= +3Z0F(?:EK#QI.A.=K&8Z MCVWPJ3MC#YAY'U;+[+.> ^MXQ?R@C89%BN9"S'F(!RR7S27+A$]U*=''D(BY M?A6D9WS5&6M2YC71YD=V01BY":GF&Y5):]MZ&%F#(4K7=<6?_#,P-UDNS\C@6JB:9NU0;B5,*0X4 MZ=L7V0HH=P-*J@;)#6.&!6XOL1^#IYXHXO!B WTE"!@@\7QDD% M:K&T$9$)/RY/ +=,+;B?#(-T;(3I72Z%*U;!JGX",2Y/>4IM \&>AG5"4OZ% M.J'SB0IP7L5]/>(::CI"_LK%8@D;WU\4R%8<(J%[2=<6"6[NN/5AVQ&)Z^B/*7*L>IBYSM,1!7Z:KM MB/5142.SG.!E*[2%FJHJ9-: &,%9X(-L\CAJIH_NI:F(N0W J;YOP556M1\* QOM9'E[0RKV/DXF:-HE''[]:TK>U>ZF(J3.H M3U5T@F%FTA+3JY/I'Q-G(4K'SH:T5':9^5>5\!ZC=RL+<5NX MR3QSY.,,M_Q:SYMR*O6JA4RVI8G]9Q!MHL^DNI*N!6SKE3_-?1M L]$3Y;4I M:D:HAU+*FEAX(?=Q.K2O4MT#ANC*?6Q(I:^W(]QS%^_PZ+PT\>]Q9=UZ]'59 M("F,FK??\$F$-!8U^SQD2\\.KX]D-R$>G*%".7.[DZ89%B0%/#/KAL'LR9P[ MXPO\0]=0 [YG84H=$-VQS S\*^['24FK0'/A7 M6)/3N2X29B8=0-=B=.RSZN?MR;YMGW^UON#0K_Y&AW6UQL0MO,AU\6?2U_Q3 M\T /<=S1@=U:.=$G,=*=BM"^N)VD9XZFO3;L'>AI T^-!#FV:[O^9?MZA+3KZ/]P MY["MF@8^_A'E^-SHNY*.+GXZGW,K-4F[%:&]])2PQ.\8AG+$5S#UXR:UV.OI MOS/@V60+BC]@NE=G\XD[=N%UE]J>Z%#!]]8UL/G"C:<-3< *B*R'RV*]XFLU ML/7SUW:F8XS[\AE;I-_YVFR#[?X1O@<8FB;N(KJ;8.DLJ9O$8CGA=_Y5>CC4 MOSC];LEI2/Q29*T*90B^,VCI$AKGU$-WU]F3V<0:2'0;'#M^,FP,'/*-5@XW !4EI0,,CV#A^GR(Z^< MEYO<2Y_(<*XY6R>NQ'R_)]$W+41DT)P^P1Y!((_A"ZZXFD9A4?PV?3'3R\/K M7(H.7KT]Q-SX^OT)#JQBB0*\%J+G0S/&"Z]-DUON@6TS4MHV=#4&/!()9SU= MW@!U30G:X"MF2LUX#F\;$:'G9Y)HJFSP1QJG-YWC:%1\B>U]=D4N!7>;9O2MAF:GZ)GSKF@' M1T$0&Z-YU[PTH?= KV Q>.)6@'?S8YTN/H[60$'ET#[_(%C38V'D6+\(\$JT M* 0;E'ZEPN[_2 <6TSRSA=\H!T5<\?@]F!NY80[&-^%5,QS J!XNOF@,"UWT M[V0,="U%QWO[$59NU^?6$I;D_<^S25YRM5^IJ!MV[(DZ4M(NY/:K^D"+Z3^$ M>X]I3Q;%UPOK/U,!<*(F#G_Z7;& %X9ZY1YDS:,3)IQ--F55MR*T'5;M M6":N&S#G8\!@6^YS;A?2[PRI@)"CJQU&WCMI#K]4CHSGO9WWZ2-FR5Z*=1R] MU1U^4Q6OF)JGZNBXHX:&F[B53]S#R@-,9[+*4#KG/S_X] MRE%9U*I93X)8H@"F3]Q>F(%N*4D%=I*W-TQ=H6^UEE/(U^1P-BM#!>IQL K0 MJ?S Z_W,A7B1+B7(P.PQ$952(@VMA'1.F#A,$_.+HT\LG9\R:1*3?:N*'I P1UQ;BCK<"QYF!;7[X6XO3KT#XE@W#2#91K2"6V54.^,V9JC=:X'\@3#&3S#!:^^'!7(V0R"5P$R M-W'M0C+L./I97[KQHCB'*!"ZZHGC4:NDLC'0>=TQB6^6\7?OWWTHA!FTDE&1 M?"6G[P_>OS, E".C#>C]>Q,)YO;7O/2 B?Z"?NQ'>M_!K M*F+[K>3"\>;4K="2N <,:8F/O)S.=X'?IR"=DY1;Z3.G>)@]\<-,_#HX7,8^ M$ZW'2^G8I33W0RNA8CEI)S^&FZ;NH6/IPN80K)\<@&A36'%$T*?T]P _G,3T MXQ;V9 TJ;847D6YP!^W-9I,;\\[H4!>5KNEWMV38S12*<4)7,DG"FD,4_<.%^@+&%.64KXCG!L%U)6__U%B;R$[Z6GHCR@"D1!J-4 MW6-. LY>HB7:ZI[+!YG'4]%AQM2T08>!E8;%8/J(Y<+Q=9+83'GAB]P"Y8U8NL_ MD[-F*U@MWIVL)Z BCM- R77AZ9#";U18G:R W&+%_7[Q5S+L>H)-YLC;)$ * MA\$/!=X;25X/2&'*_"062[P_I/-Z8 8W9O-,XM4833L9F6M'%]I<]X^AUV$Y M*]REK/M(1;%FF(/&;H303$(%R.U2J&8K MLX3T+TXI4THSBDUBD(#A&*V%?7K#J)[OIEM@9ZK])D>;^/W&,P727@JO)NW2 M:+51[2*PM27ZH7G'<6-8CA+LE.59L%HQA9FR,AOH))=[S6.V?4M3ZH(X"Z,^ MC9TXT$)X_2'!5HV]>S%"^90^.NQ)SE;"7_[NP"#-/RYH,14G(O(N_(*;N5=) M*FN]WI5ZJ8@J]JQ57ZFPWVFX]1JC%,^9S 9:MV'Y,CB'AZ.$9\3S4V!MA;=P M874M.(H:"&A'VD2^O.B5H##YO%OYY! 86:7'9GH6IMTE$\L*+YWSZ,DJ^ $M M33PRR 13N';Y)OH%&%K)PP#A?C=-T_$,]=+Q0C:\2YW-'YMHCC'Y2TX0_0\/ MHPD@&A#_Y$PE+U07YH@:$N*'HS"/2X4\IYJ:3/65GXCCF:SPG9AO87*<>57Z MD/ RDKNXE>>NS]R%2.:RU-LXJ [:DZ".[)VZ8_33.%71F>JR>\T3J%\X.(&)U'M53O846I]O1M1Y?54!0P#J4[=!Z&DB_6$F6N25XTL M4;?!ZUV:TN;6%,09* %S<#*]9#X>MMX6?_(2+I+@#-*KY^'UT9R+\@ET;/ MYS;JW2CMN#"*PC7L#-"Z>3YFFO] MMQ(B(THJL/(=__OOQ3COFJ]DV"^^;'!%\#F#J^OC^-9B8=*O_$*&[4CX5\?5 M2I'Y_658;K=K"D;N)K5:-VC$GCZM]=[S2OK:,.9VF))C.C_.OD$YN)8^UI%P M?;[@ZOEMO\[HCF!O$/O\>W=1H9*7LA_;NR,YS4C.J4+7+&8>C1\CSFR:+MD3 M9A0'XJ0O!M5 IR-.N&XD<:0BSLGVA968HD5_SKP=4"X'@ W<92T M/):!2ET_SU?_,XZWE^O#,(KYF3JPJ?*_1._I@Q7OJ_"7$\*%>- @4 M.=S_]>#@\^SD\.#@X!+8 NHW!X>_O#EXSJ/7^FL.28;H1Y" ;C M)-6*"V5A_WO"PS_/70QF@CV?D@YJ1/1(7>*?Z$!//.X0T\1H_Z=^W.D\?9A/ MNT23D-A3V/YF,RYT+_::4W&\>S'4T;..[H>:(&VIXH6O\_7.Y%'GOF_.E0SW/V"?# [OCQ3(R M^$^?+"= ]W/T[Y. W\K/[J/0/FGL6/L>727TU M<>W) Q.:^SEL?%DV159E:K@^5=#N'MB!1=(.;[)H&:/O/D"1A[?2,QIC3DYH MA@W/K#,O!C_=@+%U@VDU+.&$B5)CP^PS="=8,,(%JFM,BI9%/T9%KY@VI4>W MZ,/5C/^D2T]4E/V^P,>B/'49+A0131]E*-7P$BO,^"GS,?GB'$!T?8Q!WPO" M$[YTNN!V>7)Y^6:)&[UM'0(+ME:P$P&ZB&\K8\=D+I^.U._#FZ'CAXRSJ>"1 M5#957<7OY'+497G,NR4KOU!Q3$Y!F1RYV!2R1!1_I<)N&!!L<6C98DZ>Z9IO M5%A/O!=9S2[^2$ZM$P8+L>:EGZET\_EJ%;A:><.4L2OF5RAX*Q45.%<\4-*S M!$[LA7#HJB]4V+[AWEH D52%CJ_Z0(7I8Z9L(2\Q'[-T1.'24=U'*LR?>NC: M%=X2\^%7/IK>2$$%1A3@?2V5/X=^EMG)LN8;N3FSR&=AF:K[2D4$Q]/KDX+N M9W^APF9T"_"C(^HN"!8^46'\EGEB4;I;5_B1"K,SYMK2PRCXXE77B@]4F)[ M;E/ $O-%^L%=*15PS4^M?S MB^I=\Y4*^S KP][!9S?\03K0PZ4YN_HK%?:GZZ6_9,ZJ:B]7^8D*XS *%9BP M!74I_4J%W;^S>_8@\LP6?J/"ZN_"^Q=S"KP6?Z3";)CU(;2,JC)6ECY18?Q6 ML0>YAHV8KYLMS'HU'ZDP/]O@N2^OX+SR"Q6V;^4:/3Q31ZZ9SVQ1B:"-B J8 M8^E!NKF98T:ZPLZL]"L5=C\*A[N;PE:A^",59C\[OKA3 M\DAQ_@U,N^);#O6?J0"8<7ZG1!W_M5^IL#]U[Q3_5L=^[5+PSSS/-=^HL/Y% M.CY3W#T&TV[NL%5Q]UCSE0K[IT_D#W5/W1'AKZ0'Q-3[4IL*'O?V)JW.,KZ-LS,7\ MXSVJ(!20EP&2QE9Z&1SAB2FWY,+-1^#U*DDG^F1B@4"4?JN<,V4M-;%[T+@*^B8IY8IE2F^@U M>>]VR?Q/[(%/%?[W2OI''%<#?0$>GP:9>)D75?,!ZL]3-?%0MN-PV&*B(QUL M;VTR 61A3-\-MS:6 ZB6P.]BZ1>>%4C\%F/41+RWZB+RBK'FF0=H,,UQ+D1W M8!W?:0]=LM)CUVT=4EV$SJ*17+: ">)$!G?^/'#2ISA+IT@FM/1OO]\6'AS% MRTW'CO2XL[F4^G 5\U)'SP>FUU$P_%K9Z9,MH]7VBKG>S/Q%/ MV1WX2(*7C/0;*]%:EXS;VL_$YZ@PQ4C$[J5\R"UC=1^)8ZH11A%=.QFA[8CF M$&PPZ!H'K :8.B-V;SB>"(HT8[X19:],"KKBD7'=*GU#8A-R7111[=?GXW^X M61YF>XAOT^<@Q C2.TIFM(04W:U0/VLCF>V^E^BY%F20T:8:9)?LN M<<(DPL7"K?!SX558]'4U=X!1>=I[PVI@A=6EC>@[@HC7FNWP7"]OV<7$&I@EX)AY2]@_SQWY>,6?_-M'B1!;AGI[X>]H M$#2AN@ 36=TNF1M#.PI\S&LJ0!T>>+^>,JOSK]:!";8$[2UW!W9@8YU_D0Z< MS!%LWZXJEJ8S.1M\J^O?J5M_LAU_O5[T-R!\%*-T;8!1^B%@FMB MU!K_\IU7]G2,72FAT[ZO,%J6L#FH. .:>)[$Z-YT[3 EIG,"UL#QU#UB[GW\ M/&SEV5_OTM_C>5G\D@?>6TN/7TR)2>T@T^BS."("8ZVB#-7ZG8/*4+4&8J/< M.\L-RC"XX^=]-GX]47JQ#D8BR3QU5XW4H YM#49XY,(BAQ24^(70#E\!U - M1ILU)P^:SJCU /[8Z*EBYG<\G4/0<++FEW9#P+A&S7W?,:V*O/W0CM+K[EUE*G8&U<92H[KE]1VMVAE^.!"C6P#MH= ME.PE8]LEA'?N1N^BE.[==>R\9ZR?=L>BK\;%A+P=.ZQ'.=H=4;R(5-@0]M*J MD>NDW8%H:0) _ --JP?FX+ZRJZTQL!+B!P>QX-W,VU8Y-UE/VVR4"HGW7>76 MM<^ [%\''7_>Q!4KYGSBS/$+^4,JOU"^SP^["8MSVTL?R8O?S,CLW.HIZ$^* MN/WV/H-ZG;L9Y=)>ET3!O!03KXEK.':8Y\'6'=4T.F%Q%Q-\YRA_O?0E6Z3= M^9,5>N*_A:E8YD?2M;WXH;QDM#22$)\1\^<-TWG-$E!8*PS(Z%&?2Q)P(O>OB>&1+^RQ THRP^8 KL@ M\[[C1($YZ2YTGA;]]B"8A@A7Z;>HHDD/X 6KM38B3?OO19HBKH#GKH6Y$/@) M#_^,LF0EX*,XOOC51PRY:0"=NNI&KG4;>C&GG*/62,>XKG:V%5\^:Z2ADN/P M*%2;V9)S'2R6>T"T^ANYE\.*?!8>$JW[2D4$85*7-%-;(:UMW5H W\9DH\Q%5??/F%!Z(QM9===*HK7FVK@)*0R; M_N6I=,$)4#_H/6HFNRR&R58L!X:T5*#IQKSI/(WET.M5)IXU:Q4:4Y.S$]LY M+_C)S>FIB%(;(O'Y;(6-4OI$A?%X13WB3+GZM$R?)>&Y%]T5<^W" M@TX#*J#2";67@(H[FC8R*H#P9((K9.^:K8LO_M1]),-\[;%?622&M%2@S>!7 MO(RFSVT+STA5?J+">/9ZD<1QX)4& JZT$6M%*ZUG82K@LZ;C],Z)[XD6=MPM M1%3 U&P<2Q*I79V'5$"E$S!DPI%>H/ATWFPT'FVPSO2@.W=';7@UY.[H-<*X MPBTGH$A_R1JH_8J2LU8[PNBP VDH3&9@-&IQ9N\8IV:(#K6Z[,,,:J'2'57L M7X/*66(-NY*5-G2S0Z #/3F]-^&]:LDS+$%%I/$,/%6?75B[G(UV#&>8+EJ8 MYO14(%ZC,PL'7SS,"G)K^$X%PA5?L"8(#=^I0# W#BZ$JY=VK[M=D2WZ MGL M^@;K-(,P6S:H7]]NYCY*.EAQ\)Z$4)IU@UE%WW%/31^X@HV$]B+%)WG69AI& MS)CU45L5="(:NNP@8AR#MR)U%9';C.B'.<)+W,A8>MZ7/1,+G^EL *QY+_AD MGZ%B*NM.U2-\^G G//+B MDR"..YTC(2^Y+2Q\F23,-G,L]R]\>W^&NYXE$P5)CE 1Y9O'-6'=5]R/]X$G M8C[G:-RG5_6Z%J)]PZ.(YMQ-7$"7^E5&W58V*"8."0UCW^MZI4<]=':1L!4.+[T@7FSW 0+W7V;,\O=4#OTE3@SYAKRV]M&II:("1X^7Z7KI+YFS$O>U@ SHJ$ *QT8= MD-JO5-@_/3K]>AKI#??V5_MW^Y^NYHO]WS]6P3&FI@(O'AE'8&$XS.;>\D)@ M@@'[(_LFUH&J'D>MU&3@[7_9SP_^V?YD_XMP'J14=B%7ABDQ%7#(G9X(CF7P MH'B@$,!U$*ABF%\['15(R)EFM45,#324H(2S6PN6)B(R8*)AD;IN4Y\2;FD_ ML95P?.E63Q?&I:C!+=CMQ\QE-H-MW/Z)5 _,^4? [[AE9/*W%*4"/)PF$EXO MA>?!_V?!@DU=V$.B1Z-DAAB14P%X?'XT^1*^KVN,LF,9*E##>25E^4@&UI*K M!^"/5VEN!WHJ$./!=KP4#L<9%##X@BWD"=<_50_-5FHJ\ J[9QERKEV(33B[ M%Z,"^(B+/X6[R,^AD=_RR+2SJ6HP)T% MWY8RR+.?I"??1++2'DYO&11FI%Y%R0"/W/PQ_W@I#_2Q_BBA2P$J(/5<$^M> MHP(;49*"I8]V$B>+%;WHT#0==2]&!7"T^"/K^1DFXON/I<11QMQ*FZ%#,5J M3_8E_-]9S+EW#Y:/K9V>?[(_V$+QNRJ\'4I1@9MLQ?85L'ZMV"*HL8XJ*:C MT .LN+7ZANE-^3JXAP-WZE B-7GU J8+17N]?X1"%]6 M*UDM%34XJ5/Z=/^8"56#IYZ,"J!0A4X7F[6?9?:*/VI^CS'%4(7.F16@ C(6 MQYEP'6!_NCGUUK)&9#4TU*#H1OF9TDGV0 (W 1?.)9BY3'AUSE_#,M2@IFHV M,X)I0$\%8NP:$HI[R4%*,\IN1:@ 34]69OL7_($YC@1!X1M5?K7UU$1(!52L M<">X\["6.&W@\?E7OJPYK&TBI 8J#="XPG X8++1#59-2!.4]@/9L>(/)XI+NX"M3A?'<'?O 4+*NQ[(W(J +^R M!WZ!"8"0WU/E8)1I8>)O)J$")#VA0S:A:<][A$G<\YE=O,=B0DD%5K@LZ6QG MKB9E#G+]23K?[H6REM4[,R-Z*A _G?[/Y&+RL192PW!+:OFA38B*F!@$17 MV;GK!7I'%\"8^ M3 ;%%!V=BU$!7 J4#R&D>1,GF%P]/&1@#B*[9,"?YXFJ?ABM-BK=DP@VV'8\F6=^.<9<1/!?=5^-M&MA*N!+UDU>9,ASV0SN6H@*V$0M/<6X@S$U MUV#.6LM;C&SH6(8*U,2PE0X&OOZ=P6[D]_W?]V_E_:9F0#634@,6.LQ:(-4140&C M![_N<)R:*X T$5 !$8Z0&DG4?:3"?"9J)(ZJN B>@$L9J,47O*]3&V721D\- M(MAE:QD27S*';6#?-+/=_:.EO?][ #]?H26]3 ME1:@@IP*Q=#4+Q^()/][_LG_)GX15$?K6K0@5H&E$ M33,Z SHJD/+K,SK,K=GDF'G ',RJC1E'ZHFI@;OBF' *-\;>$=ZS5^ZR^,BN M&2DU8*$@VC#54E&!$P:1<8,!KC9UA6H@*V.B0+^4UMUDKX^Q 3P5B,L@D3O&S M]?X?TWVY_Y4I[QM[K#,7FVFI0 M#7:7CW;-F7":$5$!%*F: RHB2"JP+?J\O M-OAJ7=AL'_\M9\QYJ/.@MM.3@QA>'XI" MXF^@)1?/5F[V+_:/ @L^U@8S=2I)!;:>%TQ0FA!2 17[,I#+6Z86P66@BAG2 M6VBH0"D8B!?'E]*SBK-'&Q$5,%J'HFP-#[ZXK\-C0$<%TA^3::A)53CJ/E)A M/MT*/V 7SWQT2W/EX6V9NDUS R456#,6V"*?8.)$X/GKG>8ERHAR(S;,7A8G MA1XEJCTDI-!1Z82(6D(2?[]O[%G\'=GZR8 M_=>0E@JT>$]EB,Z),YW[C,G"J5;6&A@H4K6A- M.)H(J("(@D$:4#124($1ND,#3^"&_X@IBSNR\E6!>AHJ4.JCVVJ1=2M"!>CD MCMF"W7 _X,H/757(X: MY)#;1G35)#2!Q$Y0 T!UI$2!6<10 MO-V*4 $:6B]& ,U(J0#[Z+ GZ0&ORWM'N/Q8NEZPXBJ-3XV\05Z\*"IH9BZ5 M'4ZT'G_*HQ^Q/BI=5'$_$=>73\S%B]E7_ZP>R:W4U.!%MTTS?%_QQW]*=5^' MT*0 -9#';"U\?.[&%*1) 6H@BZ^F=-+;KH6I@3]WP_8YOE)_A DB; 1R U,+ M4]828^QQ-E;"7O#+29V+N%<=9+L"4)P%KA6ZO#]R5ZZBVR.P5IT(OI#';1W1 MI09JW?"%619>09BX]HE@"U^!*:_@0EY<7']<' M$_#OU>$JU214@)SJJL SO3W)'OX!=7.0ZE: ",WT2 MY@MW^;> .SH\Z!AO-K.:7-HMM%2@51S1'==!,Z2E BUY.$5(2W#7$F%J\QF3 MURRHNYC?1DP%7/2BJCQ2S!-.$J%WEA$.K%%,V\>5Z2&Z%J4"/!U?Q]*1JSO! MXB?IV9R?\"-Y)XM9A+L5H0(TF[M(C[P.B'N6I0(]W?8^<,_'.F PLIM]QRQ? MFWDQ:H"S8[ ]"53G4B3AZIAB7V91A,FZVJXK=RY-!7YTNS^\;!T#.#W]5R#6 M#&N4WG3N,V<%(W:!<)KN;H]4%Y6N"=>FW%+4 -Z8F@J\NA%;$WYO3DX%8%DB MX2LIMBI&VQM14H&5N.;8PA'W'X7-OO!;IL3JLPIV^(]1:J+2 M+=%^VV&6,?YN16@!_:B"=2BW6%B( R-X*K!\Y'??^._28MRI?*AC>&54.B<\ M?Q3,P5,*%6B[:V+;(CRD.!&>Y4@O4'P2E4]< =W+=8=\^#?29?[ M3&T&HJZ2?0'V1U G[X9;Z=@+"9\3^\\@VI)%F+XAIMNECDS! M2W7,Y_;,A_\BT72.;VHICH^JB0=^[EIRQ9.A,W*EQ#4))L*U]."W=J4Q(R6D M'R VAWF>F,-2IT_\6B%V*O%22 U6AYA-/>%-7#LWOJO4-E3/1'G/I IA8=GH MX;GP@4*[-"Z>IXW75)N\P7$I78&^+7& .9?,#Y2&;S"6-%,]G:G:%H>YA# $K,VY%^@?C M\U:L^ F'V5[XA5.:+@6H;"'PA55I:U;S8*H^4&'Z!*@?<*0\\,JMC&M/+ M* MV/JFU2<0X+F[\$_;F2?OKAD3L/X1>O>%;4JRP5Z'H8=1A%4[>Y1&F5>,X&7L"? MT7_C<2U]J R8GP;^W)&/8 9\85!#X!T'2N$9.??.E%QEADF,.V,]QMTX6FVT M_2$)S'.W(\K\/F>$>N@8[&,/H9S-^ER5OX!!.]CIF-F=I/"NP(372N)7#,-. M)>AHT"UW3]@FY_KZ,KFYE#9W1 M><5_P:[$P A_$VZ1+^6#9F=8'];5^!?LO'C!&*YXQ9KH+#1?I?+\8^9QG&-G M%G?1ZLIOF)I)GF]?--PX!::7-]SB8JT-HVNVT>)J][KW*4A'IN$0U0[=:PR^ ML,0ZO$$:Q6*$WZ^A=V?0AN7##L43-K_"NQV3\ VD0G3^B!52V4=WQ31>[Y#N MEO#)=KR)EW#M?50,O4"W$G1=PM0'<]@UU*DNN5IP51&?UZ\\E2Z864MN!PZ? MSC_KP%INWW T%BU]N"JM^\^N\+T;Z3A@3SPRE1Q(]2E(Q>U>I\13?+QSAB^I M3)!CSTSU:TN]GHP+2X-FKF01E7[M)1[][LS( 7G<3Z.\/W&\_YL/LZO__C)= MWFZ"?54"4TL>,\>9KK%U?=!Z%)N2[#YC<1B1]I&-@(D(YISG1I;Q.ER 5B/ MJTSX_:"ZX:@D,!,9P\N6((SS*VP2ES!G3QZX8@M^^L25)3P.:Y;5(,J64MWQ MOD,@>D9Z 3=NH& O[/%VT]B(DO9F4*_%-WP=(;E6%F\W0^1WM\'D:^P(_ KG\#5HH%QDEV6]N!OJC8J1ILRH<9,#Y@_!PWM'N?A!^WB P M(WVUS;O!(,6)[PXM2W2I<-?3?3-1"CUVV,K11F,,3=",,^9*NE^T\7WN7NL6 MDYDJ9^6-7C7M<[K>F*/-V_B=V5 Q\0C5WI"?2R]?62E?H2=A;IYS\2R=V5@U M'2=?5BLY%3=,F>-<)H9+Y@9SW%K@,AN",8;> MO2)JG3+Q!+MF%H:%%U*+&'5%]^+4.B";(>X6K+CH,4S8BW"S+NA3 95."%]/ M2-@S'@D]RE&!?'Q^-/FBK5C473?'NP[]7PB=(Z]Y%AQ<"Y7N"*_!M\J:NE0K M\L39,#/I<"6>28?/G&I\G8M2 3Y;"U?,^5-%7JBOPEF!P# !UG'A(FW'0E3 MGKH6R" <=\AL3>K;=C(J@,J)5W"V^,16P@$)M"5IJ:2E!BU*LASGYFS'9U* M&LBC-^VX:FC(07EK *6:A@J48W''/G*QV/R=K9D;3>&W\GY3B$#M MOW1>Z/MZ8'T-U+KA2,@'J"!0+6_O-=!1@P2[!\]:!N[" S[F/ORE 5<;,35P ME\)GZ@Z=(?!?GPM'+ R1=BI)!;9.SN,"@C!/R2?Q;<5]S%2B]P*^J$GQTKT8 M%3=DAJ&RA31LG4M1@?L%]@:6SSI [52""LSDX:;9F0Q<.XQ% M:WYMHIF4"K!C#)SCBD7Y_R]AHU=*\-Q"0P<*3 RKBHU<[=, G4I0@7G%'L0" M1 +>OX]W>:-;O=B5 #?\+423YN&UTRF]PY;0LN8J'+Z>QYW[])4X!\[3,$& M'E.LVJ%IVI2,W9B:"KQ;Q5S/XJZ=8?B2NXZ\9NJ^B,Z4F XXP=R%PW,[C1LN M7 ^*PLX^6@2KMYA]"Q,"[\*0NA$/7)W'3!_+^CUUEP)40"8'89$5?A9P]3NS M8;4,O#OAV,TFO7$IRG!A ,(.[+-K?UX])P #*4:W QZB(3*?HW).S#4Q+]YAO$L;FBMDVK\D\>AM\K26J7?O9 M57R%4=+V*5,8]>W=& <88 ME(M>4:DV:8J["6@1:H[K@>EU+#V@^BBE[^ MX6#%81[)*H+V;GR>9BAU*C3H>;"AL;F^%?N C&$ZEF/H NYLHLR"&&H'\%6< M,;#4:<.KH=0IF"4K33EWI#B[M^6C"W-/E%^@1G,Z%Z,$>A: V:,VT_FMTO<^ M-CK.TDMBZJLQ=RY%"?+G6>R X=$MB7AUOEV"(C\P)XC21\9+?-7Z#O^*%O/D M;H63?BWUV$LW2JG#BUDYLX 43):P*4M30<%N!-]?3/.4EKIRO.HH=5)ZV5@+ M?N) &[I,YC6@UAG&Y6C" MC@RX&^ZP\/Z]XX3A[G>E&]N%>2,=%[D".@V&=FPR_29S:P>^ @>41)&U$I/$ M,GBR\03]5GU^;*P>MA<1ZM! M1H4;JB+JE"7;;+O4OSJJG30PNWICCXU8-]7N>Y:LE@.&^@@M4NUJ?>TMEYDA M635@@[;D90UK[\P1ZJ3:76TI-AO[I4OA[[ #HEP7G\1BJ:_//,*'U'"K%4PJ! M1^E84SQG;I(8@_[E7S%'1U,GX';N2H+M; >P>P,&PR=[SMT;OA!I MR.9<@D M)"D>\66VM)LOL<>N^"Q@UT*D<^A'3DJP4A\!SP5[S*!+CI/0$UGWTEO<*V-4 M1#SY01-$[3 !D=U*S%X /.ET-9&55?M2W*@U_B5Z#QGQ8(.I%K!%4L>Z-6Z? M" 43B[.)LQEWZS_C.K^W'@31X_$,/^'AG^=N!G\R)^E)JK;'NM7Q_?=0\7BE MM(@/K.-[ZZ'0F9.3>O/!5 9OYMF&9ZB73NJ6$-Q%=,(R>1(%V(4O1@\XV&*% M\[?4-NPSIR'+"]YN,+9$D;, *CZ>16QL%/<3!4[G 3 MMH>3]=J)7A&=SL_/;F8?,L"'U$$[VV/V(;/I6N^5W,4%PL7']D1XMIDH?(B/:%]E/MV*[#2MF"/]V>" JX5?\!GNIQ,[.#M$M MEM/C M\R8CZ#D:HST3F?1"2=NF[N?9M?1\F)E%>"0V7I>/T1B=F;"$./0?X0,LH3]I M,O>Y BILP(_6,"!.QGJ]]=FG)CHNN!(<^"](NA0]':8[Q-B?1VZ?215%6]3V M2N=J^NA*C(_N\"QUP- A6%7A]S^S508M9F!GWI+(9NR\73+_*U>\82(J&JU= M^O]%N:*=(GAB 59\L0JCJD(,45*GR .3W>]VJ39<;^/41&A5.I)A(]N&+6 MN?@^-SX7+)BC'U2/U$7-P' !@_IV*508W98Q-0=70WL.T*[D<["EW06>TL3O M!%1LLHPH:8.]X1YGP#9H[0E_X([4>@O_,N^%856\XE1BH HP3^I':/#*U<2- M8CQA9LS$;2;*8$9+:#Z(+_G$&T2P@[\NN8L/?6 \(%. "\8TXKE P;X-"2^E MXOBZ^.%!,D^.4!&A?KF$C<-,P!HX%Q;H1_389OS(9GAJ&T,WI*4]"5Q(=P'R MR3Y*?>=_%?YR:O484>!%=KB*K.<[:3;)2\X MOI-4"-W+$9J./J^A@,X[,G4_2<=&&SS<7&FIAP98DCJ91\1-;1 M6,#WIYASS:".2_8D5L$J^9Z?E[H7(R1FG$/#3=H-DF9O6>9_?IE'?-J%]&5R M'-B)QNRW$9%V+;?I4V3W!#Y69&<>D.M3D/;4FT&D MJSACEC[9#XUYF%@JH-<2TCG!UA>TN5K#UG2#KUX78]H:OK_>6UH5CT/CX0W\ M@1,%C"O<6N%#D[C4YR+\(_X2='U*D@E2_,)=&W9:F:B#W"_DH@U"[@IY.?._ M48DNN,"8,,^OTH \_R:$5$#-\+J6;0S-G)P*0.UE,\9G3/UZ42,&!^L*O>!A MN*R^3Z#DZD3$IGX:&I#Z+HWI23NF4IY/P+)*;E%,Y[?29TXNFE[O!T3P_B M-9T8/2V\-.M5\2BVD9+._J8RWT+V(5BF% OC08#AQBP-3:6,;.WE!K7NXD[GBOCZ(G#YP=09L1\%RB1J;T;[ ;-5;@8%KW,6=.?+1 M^ZRO$&7/KO%D+J.OB97#O6.'>9Z8"\RZ%+I(^+4 G2BH_G91 M)G&HG1R$0W=DXU"]B17%X9Y)]1F#D$-WWB7WE]*&G@6SBSTENXX7;)#.--6Z MD'BSI50^GCD5'Q/H7I#,M=K0?O/ (G("&U_ED*O;)3]FCA4X+&ORF1#V$2;H M#%^ B3+R\:F ;O=!3R)+=>(HSNQ-*)/4(&PGH_):/::PRWEQ8;%?*+8JO%3? M3D;%4?#W:R- [60O VB H_XJ0$ZG\YCS5@=]10$Z(ZLFSJ(0@S \<*-7A80V MH77Q*--9[U"6YJ)T5M*)_8 V#X8%8$9W?%(V<]7)FTP*CWMTH*.V5KXN$&YY9C-;#J?I_A,B<$*/Y(?.>E3\KC M9(31V#T*-G?,NH_6YE5B21J1$EJ?3KAG*;$.8_4GKAOH1Y6@+C!\T[B/1AHR MI\_QD(@W_9]=D88&UWVD8U)A*GLWT,G;T>T3/0Z0C5>/+8&"TZA/03)'YU'+MGF",,I M$T_?K>?\47T@^3RMYRE2QS9J0O9(28 M'05&-S_T;2 \.1$*ZPI3#I6?"NA2X,4R /;?CX0;#-A:82[ETZ>UB%Z^Q#2B M'78JYM6\1"SE&)?RDH"#:^FC0<,O;SVDSV#3DY1, M7$:CF[LJKJ-36>([ ;#KP9[Z%FE]@FQB_QE$1TZ9E&;Y*<3+K#S#JR&T@XCB MB"]A7A3N=2GW!SHU)28GQBM8/#1$<[NESD7I) &(^(_N-IS77H0PH'N]"=-@ M58GGM/P+4^D03]8- \+1-/>_?D*<[$.?',=)<_MQFKW'CNW6=YW*QU':?>NA24CBE@)T0(9R2+,?SC]]\G5Z? M?/_-/__[/__CIR+'?_[(__.0E.@5FX1+\>/'UXNJ6OUX>OKT]/3F^8$6;PB= MG[Y[^_;]:3OZ=3/\^6C\TWLQ^NR''WXX%7_=#BUSV4 &]NST?S_??DD7:)F< MY+BL$ISR#Y3YCZ7XY2U)DXK3HL;K5>\(_M-).^R$_^KD[-W)^[,WSV7VFG'C MU:M7-4,H*= ]FKWB_WZ]O]E^%)/'A%9Y^28E2P;R[+NS=^_/3OFHT\N\3 M2 MKBFZH^0QYWPOSW$VJ1:(?EI3BG!UFR9%7.2HO497D1;+58%>GWJC[A-9+O-JR3[-4?E$<,54BJG6#H%W MVE09P I$39>5YV6)*F/)*"$$POP2S1#[:#9-GNO/,@XZ*)@9N%"ZM4B8_,L; MS%2A)$6>)17*OE3LOT)')C.F,"N*%@B7^2.Z8?9LB4P)]?"-8!(57^GB]2DI M%]<%>=KAUPSZUD"P%E !4/@^"(7O U-XGOY[S>PTWZF8*EVLRQPCMIR,EZ,F MG$!4'.\VOQ+D8M:EP[*RHNNN'ZR_GZG- _V8<>"O0%L<_G5AZ.#I#Q\?>!?NBS0$)QCN?E':)?%@DU-LR* M^5ZQOD@*'@'^LD"H4B#X(!G:CTN:%.FZ$*'D6_9S,YY_TQ:M^EOHN4(X0VT8 M>?N]@J1[Z#??$''I?$9+$9RNDF>"R7+#O_:/D[?O3]CW9NNB^(./V/W?24KH M'[LA@GKQ>S%B+P;9(E'_NTC\'Z8AK@AN\"/#BU!F^R7 MJF'_\"#18U)P?T]F;08'0B&GF[S9^4A]JT)C-!3"Z@C>>571_&$MO(TIF3QA M1-G1_B[A!$CHTY\$B\Q>4F!O&PQS\_;HWK>E#(RT$='[ M2"+2(B7R!E.6:YX&6^554LBV&-G?(2\3K05!E,3%E8K80.Y1B>BC=..7_AVF MSV4NE0'BXDIE2E'"SK<;<:B5B44^P-EBG0 1S!!Y<25SG#7M/]=*!D'Q4H;Q M-T8\EB&6(4KT9!#?2='1I,%Q,,WP@$PTJ &P&QX>IX8EI#L%IK &5@FQH0^$ M<9XFSQT$FU_VF^G!X3 / 6JQZ=,&8,7M[(+)HM.;!7/C&K:$Q))*'5$>)2O8 M+_Z0%HAI;5"&,V$N)RUI6%$:=W$UCO=>V71_D$TZ#.;R&<1X+VJE%D?DX^H@ M#4#UBBV%%:+5YJY(,"^]X*2LEO)-5CD6IH;UIFJ($5EQY?0S(=E37LBB;8=_ M@NF>JJ0@IR)V(JU*\#Q_*%"-L]@JIHL$#TA#>P[T_5,N)D/R8LOO$97B!MAY MFI(UKE!V3>C7,L?SVF1_1M6"9#U)4H.9-K+\%H L+8B$$FQ1)U258VVD]H_H M4M,D"]19<#CI[;,>Y+OH\M$@"41H1:^4Z\Q%&!_&BIXF?8+."?H"C?BK"XLKLZ(:Y M1$R]8VPD$WX9J38:!3E@Y#$"-VQ'@CXZ!!F'>5MUF1]$XA]X1ZEB)E2 M=BSKW] '!MMYPA]BFB9=HD#X6E.:9&B'X8#7U3?23D+O $AHF*+8Q3D,MS8' M<)=L!()3(G[]9;U:%3FB\IH=@WF@/>L84 I.NLEP(18V&DC-=K$BS#CVLQ!Y/G:K/%'F;T^#T.!F:WR(WP=RB,? MT_)B7:',T9PY0(%BT 9(,",8ME'309QX$BIHS=8V;4YP8!HW?TI@:.#&\R6U M^R#H^I/2*,SY(P/(/W)-Z)>DD'Y5HE(FT\#81_10=7JP_((*6=I\8!3,I6 D M"J)))(1*0;6L!L?!+$ZQD98&F=91V.LUSM2,'A@%,[QMPV8ED7!"0R-8 .)/L58F)N1@?0T*8Q=?E??71],3O4/@KD'&0A)15I< MZ7Q9$%HQ!)>7:$7*O"I_)=6G(BG+?):C[+Q4=V&QA !STS.0JQ/=^H4ZX7- M!C3SQQ1(YC6%?0RQFP[M^]Z!WH X4AYT!HR?H^ :*&-JY]=0#I:C]'R*Y8\I M<"9]8HE ;'KJVJ4T!K^TA.Q5O9YUD3T1NN+M*= M \7B1+]#,.:5-^6V;B0\H)<_MF?9&:%E(M52X[DP3Q_:@K6D%XJ ;TDB+F4*4^8EO7SI^:0;@41/"K\Z7RWH5B!A3_,-K=Q9'R [KW2K3$!2"M MLZ-'_[*6SAR8IUDM$1K2:!W#NZ-HE>09?ST+';Z>-6P3#&?"],:U9&%%:93= MQ-]K/ BH&2Y1)3C>I>L$"WKKKT]@>;^@:#V)#C=#"-ELH>:Y&F($4B^[8)0 M2IYX.=U03NUX%.#]R$!02@)!7-B[8T@RFB>S6X+G2J'I3P*\CYDL-D-ZP56. MJ*XDZTR &5V>5VTN&$[P)5HF6-Z3R1H* MS&"2J:R<&3"B5]G[O"44!_&.$N: \X)V@XLN^I.@.(X[C ?)@>T,2O D=@*) MNQ/M8ZM]!<5D&DPG45> \"_,[?"]X!DTWGEB4&)'HZ"O,.4Z.A)<#XE0Y,0) M:LC@6R9S=08:8.O-@;[(CB4B76U*"F,?F!.*)K,=SET_YQQG_R(YKGYC+L:: M.46F#3[] X=YM--0BE"L ) :V'<]#X-C,L<4[J)6K5BBH R .)I$:HW=)U+* MFHP/#X1YZ-989#IDQ970SY1?[A642,0B^2O,]KG&"Z:7,@ +YAX](N8+]RV3 M@S_#M& R_A(5$7%YWZ#$%8A?C9O,>'-SF</@*EM>[;6AX]=TFA^)FW^"K0XNL5NC:;D M*W[*<<:/S#.1?5_C:H)W#^1*U-1B-I1JF'@'\"!KK ]9XB@H2#$^!8T'?[YZ M3HMUMCOR^*'=J,C1 R;]^NA.7[3^.3:&$UQCG5'2F"/F_)(B.G=KMX_XJJSP2S]44W=[Q[F?SPKSL%YB5O"W$J:00D M0K8++!(\1Y?Y;,9L*B.2_7)*$UP6;?L6,F>G9)3=X/J$/:$])X=HH0_AW M]"R4P0\C[%V)Y2K)Z5+T_"C9ESO-\-BV>6AX=NWHF [+7 AW:';W)X)'C_0D MZXW^V.FJ[5&Y=:6&8PB'HVR$&/[]43T9*LD"(YO+_#'/F)>J"/ <#;,Z8;Z% M)YX>P@#D/!HJ-!QVUXK#LQ$23WJ"&:;*X:S+/SC!UX0^)33C@3J:I!6WIY/5 M<(F*SB28$4W-W<:0RBA!S%\)EC5[ !JN'+Q[;7K'>DRTF17L[3LA^2O,(*.$ MP41!@K5=Z5Q^G9*+!/]9MF$BWG$DK]9]ML5L(DS[TL]H&^KB;KC=EFG#E^T5 M(V'>W.X7E18Y(]K\[3WL*"+^%.:R&5P6KRP5HZ_ M@B(<"=W3LG@)@M=N$> #',SK0R&5!'Z[ 0D=-_@1E;XV%$-@,)-W'NAJ>_ZR MC:0%5@,Z3_^]SNMT$-]6+G,.M_&G+M9ECA'/&'1?_Y%\&I)&U4V'&)&BD_&J M*MO:*T90?9=[0@]>N)S,ZB)9QC_!2#UBCUH1CO!-F*<%?_HY,B.MS_%WE*0( M95WT#M+CYDKD#2;,>\O^E,0SH^*:*PDQ-[AB;G_^4""/JF0)%&;Y0U!=P!PBR;"*-$KER"HT#-9\P]JG_RP["4<^ZR/>"\N+#1$0_^)W^IP^Q($[Q(6,@;W8L)"WI3D18:% M&A??W#X,3/1P8[%KH*^>>8?^$C5U$&V4?DI14J[I1O2A$T662=JGT#[ O9@@ MP9!D)/N?&S_B*O0-3CF:Z!+5_]Y@[7>!3:?"W/2,J>BW:,H%#>MZES>ZK7RZ M6#%KCW0#;^-Z-9NAM)K,VIKZ^Z1"=>*6UV+KKG('*#"K?6P5P)D10-(/=XEX M"*N<$I%BH2AX\B'L%X$V#PJ0>QB#C_:9AS5EZX(Y01X2#HZ@W"OZH:N$'PY% M#NEM:?"05W"%!?6R00B5>[!,07?/=6@7._1/M3( X<_+H6L:5 R)*__MK=J[),^FI#YQ_4(*QGV>\DSH M@='2RP9XA&J7)0K>(<#./GCG"QSCL7NM?/!6I>Z4%U-?8)A+4=,I.>4%A"PVAFE%M?R%^N4IX5+:]D31YPLQ6+/(5^Q7;@DB19VQ+R=I8 MF"R-90?!KB(?J-UUX@&XC+PDPJ^Q3-T N0>0 *F##U8 R';.*&M<'?8EV_?/([H7^*>Z:KO$J*O$%_O,4>LGK"L1&6JZI[9E-,W5L,_DL;Y.?X-W[L1PAP._@($^ MWN1/_"'89:T4@2\$=K1DE*N'(S?_W3:?X/[;%!?H'J7;_7E* MNJV"6YH-V&0#]F5972L*-5>:F7)!JA6.P2WU3AXYWM;O3^Z](ZCP.J$MC"&$ M%9*SMPZP]YF]QNSW[#C!;[.T+>TNT8R=@[(+A-G_5+R.P\8IL?T$3+?%08?\ M,"1ZMK-Y4E">USSX(]!HFEJ&?:3 7LVUGSN9L9_K:$43Q+DFE/$3#]YF]0X; MYLV0&-N])>NLXVJBPJJIY)2@-9GMRG#.2I>N$(9P^UK MF>-Y79[Q&54+DG$>?4XVEHXW(*RC&J"8WI'JVO)Z-I1#_5-M#;JOA'A+%V?S& 6E./^ES5=%>N28YKFS$YR)&569& 8%%(X M3DVOW.HZR>EO2;&6': &Q\%T?P?93[3)LM[:;O-E7@D$)^T[4>*'V?4:9PUR MTO6@/PUH#M!D21-;JO4#,R.4GUM0K+8.D2N-]TB8/!3YO&9L=<=V7+8W]9D* MLXG.X9

      /E<\RP]5'?B?]#F MDI(O9$&&E4;T0H$9#PNA# H6P-<#0BM^ [8^-B+D9"&4T.PV[- !B3!ZH<6* M*%MZ4_)X@[OU\'MO_!Q'4)J-_EN[C=ZHG*BNV)PFSZ@,F+;Q\!4H7L#?+/D5 MOY[+FEI%(-V;3EK''5PQ$_.E#E*H]:GY19CN*71%,V*N=Z73H;ZMZ.Y'DE%I M6DH6YL,PG>)8*AB2QU&\JCIM!/3UV_J!U>;ZBV0E2/_NHV1\7955@K,U=%7G<,9+TJ% MCI GAC*POX7>5=8!K@^. ^INF?%:@\*XRU>Y8FT6:;3,GZ8QU53Z$:LNCJ\7 MDO9&>>FW7Q$FRBUTXL:HV&>CUT$XRM3 M*.7_%7[,*<$<AL*1]K^NU;0U"2K=,M3IN? MF4-)!0+-C?NZ *2LES2:,Y>] M !GX/&M*Y'<>I$32VG-@/E)K*3U#J@'<8-%U1,/XGN%?B'79&LWZK4 ]S'WP MF [W8)WZ389_X'Z.;JY(A2$5_)'/&X'^=D9K(_SW=I9&.5D"5!<-1VH\H]]M MDM5MB^44LI,'US-&<3[+D^V+)4WS^$P685<.]F"$FW5;;#XG]$_$*[MKX9:' M3ZOL D7GC$D=EETFE;1M@E? ,$VQAH1(.&Y86]<6R7M4(@9D(0)%CZ@@JWH- MNPD^ '28EE5?^L%8XA:]JXPJ,-C:=@MS#] M 849.]27I6].Q%W \C=YC5UR>R@P(Y &_KSL)IW HM6" M]PO=1M3?AR\/,ESZ(7@2)3C1!"&Z=[7:?J^[.UO-H/=^X]'R=PW[&;9M+MZC MK+Y ^@A[-"P4[S2AZEBY>LRGUAR8P0I]]$D(<=FG2-U#)RK%#/4)F'$+8T4( MRQ[G,%8-W#VZHM*24;X',S)BK#(C\LK>,T/I I."S >] )56.$"!&1 QEK4S M!\:*8JI$Z0,S&4JK4F"5\?ZM.-OV 9[,ZGX0 MS(5&E"'?%T\<]^-P Y,C\X&X:)R_M=%/CXZZJ&?#C3\"D;875&0V]L(0%MS8(A!UL&.H3#EB!N_B,=,@.^:THD0=>8:R"W90G;7/ MLT]F K>4+%<)WFQC%9?HH6+X]*PG!T@AW(^?"\D+6($DY-@0^.Q>1]^OJ M>0_+8)8''/=/JZV3VW<[4"IX6Q >L!<]]^Z2O-/;C%8S4N1$K,,9H?7R;MJL M;U_SEIU\'$'YZ-74G#-$#<)>NP&E#$RG>L"V_00S[2O&-LZNG#\3P7LJE7]>5/FU?J#HOFXM8>'Z>5OECW\WCP%^">=P,372O"#U#[ 07F)Y :GO#LKDV_][PV69YRUF>,'(,QSB"?:B&\UBGO3C?GQ M*4*9($/8+!Z*[[F'8'[@#0 =;E+%61U(8*8YY0",-U(YL>8Z-/['8=<4^U"Q M6#R-;.O6-%TPR^_7Q'D#"K1/O%?3YIE9UA9MA\A1D?4N*%V'"_E!PD$K/,)W MOK_RDA3$.]_B=Q0X8%+#!5^G&&-P,*N5@KOIEGR*#K4[AAO]&!<^V;9 M=JG>X+*B:X%:7PK:$HR'9._>"V@BLW.>_=^Z]G,F6(*7A 1K&#"/Q/;D*%Z; MTQ=I7*O\-WO*-;SU#JY1X1]JC:=M5\^IL/>7^6R&>(J:T]C)4EMHERY(F%&5 MX-IDQA[8VO,+RN8\5L1K'O#V '^#KPEE,L*#[J1WV#"OV@?7)TL^14H*'=P> M9CXV_/?3)$VE-@+]@5K"WK%0\CA,7>3-LN0U9,-C8;J::ED0(_KBVN)])'L[ M6 T- QKMLY23XLK!>%;M^#JU__-P [Y)^5\]\Z?>4,F^1MA1IZI??TMP3S;# M="X4&]5E[*\$S[;AN3[EUYL TUIIXDZ<9&J?CI-^;[K(:7;'5HCTKJ_F%)BG M2A_BZ*,U:"S$J0>J=:K2>"T7URYMW_TF3:- M*3!/069",*/56@K=+VAMI'H38*;RS21@0JDU_W_/J\6"%+RM5+W*^!M#_)L2 MUBO'PNR_9<9U32+M-W%YX?9.V,8/4O9.A=DMRW OL*(Y3M*.+)=YU99.;Q%/ M=T&5=SX/([NO?65 MJ]3;SN SBE"?2DY\\E>;A3+>I.V:?Y=$\2V%J"#I'0? M<(8&\PSB@S#B)F8WG\I4DF$%%OZ4XE%@IJR(8N>.WV[M?;C5H[T[3U.Z3HIK M0L7U'O'=Z2+!=2!>_*Y_YS2?##W\HO'4L=XLF$;0A #B)N.X@8 O"T*KQB97 M=)U6:\J\ANT2D\A6K%J:;5VO40 M7T#9/=DD!<>@N2AK( JCR2\KQ*.2C 7I<5?:/9JM<58.V%%M]Z3>' M6N-?5G1I0 H&U,9=5&W>O?9H]78V[3DP.ZU;B-.08B!V\A;-A?+Q&Z#,O1W< MV?0GP>RG[F(I-4GV'9YO<\MUFP?]V+Q\GGM+-RARL2 ;0C5M@U[32T<10#D< MYM[&'HKTU%3:7[2LGZ[;UI+]S--HN'Z,3%S8F]<%L0(%L:@_)WR![Q;TP*;F M'[B53$&&2T+Q)NZR[1 LVB,L$HH>DA)E3;,B4;N?I((R!N1,HC2V(*Q4 V00 MQHT#.KF&Y@_\/QPP^\W_ U!+ P04 " #C1CA,&UL[+W;DMLXLBCZ?B+./TST?EA/OI3=[FZO M6+-WJ&[NZK&M.E7E[C/G98)%0A+'%*$&R7)IOOX I"Z4A#M (NEF[!UKVB4@ MF3'ZQ>__-?_ M^=__]__U/UF:?_UO]G\>HP+]C4[*B_J??_]A49:K_W[UZMNW;R^?'TGV$I/Y MJS>O7[]]M1W]PV8X^S4I=Q/:@]^]:G[<#3T!_>UM/?;L_?OWK^I?=T.+E#>0 M CU[]?]^^G@?+] R>I'F11GE,<.E2/^[J/_X$<=1R$=P1FZ0[._L?_]S^VB.GR)2IL7+&"\I MR+.?S]Z\/7O%1KVZ3(LXPT5%T"U)\SA=1=D'@JO5??58I$D:D105DSR9% 6. MTZA$R05>KJ*<_O42E5&:%93:^ML+@F9__R%_*EYL/\#0^U^)+_CE>H7^_D.1 M+E<9^N&5-ZJOTYS*+(VR&RH]4BU17A:3)$F9T*)L/VZ+SMD;;8+M07=$ZWTZ MS]-9&D=Y^4"BO(ABAHJQ(/7 0)'7V^[D];8_>4WB&%=Y22WF+<[2>+\\],DS M@A:0(OT%9@2M(XHNT0P1@I*'Z)G:,%0R8_8QC1[3C.K-#HMWVC09P@N]RAZB MQPSIFPY+N!U1>?5GE9;K<[JI)K=L--N=&":W&;5JUYCL-B53,FT!=T0G9W,U M)$@)(;0>^M? 7G3/4*-ZPH$[Y M;+S=\:<%MXV6=-B AD*KOM-E#QH*K3]V1^N/T&C5=]/L04.A]:?N:/T)&JW= MD0K%_]F&I&?=1;MGT&A]W1VMKX'1^KXS4M\#H_27SBC]!1BE/W=&Z<\=4]K. M^OV1EHL[E+'0L+:8YC;7"%K0+([G) XP?=1W"*PA Z%4W\VSA@R$4GWGW1HR M$$J[2_-W'9&9XM/= 537<;8I/IT1VG6>"A?E%86)UPR3YA 14 A?H6U@IJ5R<",0UT MBWI]%-/9>56D.:*.BO'"TX0#0$[Z^X,5U.XRWD\I*YMA'N2T7"!R45'',B]/ MO4E] FV AJ>O"_+@4*>_J=L [8V^SS@78J-O*2WA@J"R(R([IG'_Z9TK=8D> MC<_5],#T<:IF=ZC6)X:FYRI]QUTMK8P;F3:I#&O?7!.@5[K.HXQ59-XO$"H5 M&#]RAG95!87FS(FH3Q:FLW^@]74ZMTH,Z@(*0X;SE+H$ M!^EF?24W@!6,&OWMS@!6,&KT%Z !K>"0&0EVOOJJ9@0M)D[["F8$+0I-Y M!E8;6/#[/!UZ 4.JR3(YJ+(LT.KS+,L$,7V38P45 (6=$-@U??2_ M,&LC4J%DND(D:G>V,1"9%I@0-/@A 8*6&6YS%C![E8\I.1I 0DK'KUR"2,11 M%F#N&.BGWBQ@!J?.H'#6'&9PZ@SN.-L #4Z?_FU?"YC!J=,OY+. &9PZ_52X M!N N,[KH,QZHQJ7?+F !T)S9]3V7&UH[):I M /2+M[YA5 'H%V^CO+440+]X&^6FI0#ZQ=L5[?"[B:F1-878\]U>TY:?6F " MWIQT+GL.5?.LUA.?.A=(VYSU#("&>=6MKL^9\'*9EDWGBYSZ-G4O;)3'Y@M% M&U)7E'!ND%)$+A&A&T29/G&[?9C2Z/Z-?F_B&M*G!:6;>VC3F=8A9B$:WQ56 MYN>LA=;D(#>R]9U"33B=WTG4Y35G2F<:L3T]U^K%72@G!M$$_3!2$TX0*O1S MB9IP@E"A'QIKP@E"A7Z@K FGJTKMZK% ?U;TZU=/-F4'BOF0O!OCPEP/'^G? M3S4OO]:'%8P:C\3TO)ZL%U(XGOM@-L3UW^W"#[/;N.XR7:\&_B-G^HM"/C]P M]QZ+;JFZ$ -39M$=51=B1Y1]BLA7^B4:F=\C^GVK9F(:,/K'7E_)=(#TC[^^ M*ND Z1%_PV21&D2/N#MAW3&^[,#?4$16 WO!VP#CT#F7[5J(> MO%!4^:.G\[IEG4<93/HY&\$+2I7^5FP(+RA5)G=HC.!U52D1/=N4H_!F]8"A M0>$);U8/&%HAV%_<*'R3V":(5 +KB)Z;G.5T,#%W*X4SP]@,X_M"!M#ZOUMN M2(TVI.ZJ+?@/KIH7\>C Z>J>$IG]ZEO32]$GXZIS/K M4B*"BO+J>87R FT]PU:6DAVU;WXUMC_6L#O+L"^7$5E/9U*[;MH%S0)H4/JV M_^N9PF.PW>^'-CMAV#W0U^X7;M_SL>.%VNO<=[F>]S?KG:V//L_Z;AJ>*>9WOP.9(BR>*L8U(O$6W;,>R_6;4DSE\D:!95V9'UVTS_]NW;RQV(-Z]?OZL!)N4+]M\;Y 5PNL08 M+Z,T=T?X (QW?!<4((FK1_1B]TE+E"60_'.Y9LJ+)5H^(F++8AX,[YA&66:) M7VNF7QN X[IB@[D$U$Z6ZYM\ALFR[C>AL@$:4\6XTJ67YO45C8_TGYOA#"5? M6#>?1L\ERA.4_-!\>_?Y#,<\0=1"*%#\B* MK1/ZN81]\CJ+YAR^742G37.XX"TZ_A:'" M$G*ZYO@U=<6C[)\H(M?T+S);+AAIP?4?87!=2E _?&\$K\=YSE@+WK^#Q'LA M25UQG]WLI_'Q_7KYB#,.Q[F_6W#YI[!?HZ6/ ,N M&V;!YY_#\EE-3;?LOJ!X$I9U2]#S/]!:R&_!. N&_P*!X5)RNN+XKN)_NVF( MO1354 N^OP_+=SV*NE7V/U"6_2/'W_)[%!4X1\E-451[PDZ47C'>)N!Y#4'[ MM>CJV.XTZG"'5IBP[#B[PLSU8'2&VP@B<.BI3U:W1F1]G6:(B 4@ M&&?#^<"QJ08]W;*\_N(%-7US3,0;+G>4#;L#!ZA*:CJV,WBYQ/E]B>.O]7%6 M,:W*HHQRYMR*K8W&)!M1!(Y:38GK5C*WU6.6QM<9CDJA(#AC;/@>.&)5T-)B M\_^\.J*"POQJ=FAQ?)+SMCFP8 /=#R;2&2EJP&7TC'.\7#,Y__3B]5LJWE>S M*LO^Q4;L_^M%C,F_]D-J#:C_7H^XB A94ZV;+-D1^:<#3K=]8,Y@PPJR>+6'>\Z4R(MV@M&$T$I-EF M>&,+J>JH[,F).OW#O[;U-&NA=@E&F&F3_-L">7-_AR-6/GI8@VMA#SU!,1XV;0%M.?H.C*:>H816OPZK(<;UQ7;3YL(CR;4VRQ%H8S82B6#L3 MK<1?M3<9 8"CHI;X8P>IAU7Q#PC/2;1:L$?U)@1%8H.H& E%A4_0%&BJ=!P< MA92CB0U$$U;/>)=/A*JF'@Q%VWB8"A1.-12.SBDQQ69BLO;*V8G9=';UO$HE MCKEXD ??O U<(%?1$#CR%&*(]3AH+;_SB 9M,;I?(%0^4+M42N-WC=$>),K] MBD"TRK%P9*Q&%1MRV381WG2"B6N[^O/N7[4@6BGQ[=__-2YV6)-M#@D3=F-MUX/[(V,$15,2$&F,]Y),X7Y' MF%I1CH8C:!UDL3&W [N%\SE!?J ,.(_R1.(5JL9"<0H_125K8RN#WHMHE9:1.%&C,1J*6G%15>5A1&/A*)P:56PH*NM- M[:C_-;LA(U0!#A:JHDOMI1@6#5M'M42ZB/O9RB*QYZ)PSFJ7S%K\!0YVM*!> \5JM1K#L7+ HGFMZR9O8R[*:QA.A:.0QIAC*^F& M5=^ZOFG_9+909:7CH*AINSQY^P:XN@";,Q*.$JH0Q=KB 9+2YSUZIT[MJV>! MTT$>RBIM5,T!J)=*E(]3_[JB#'QW)2K*RPHU%YL%8A..@2,F,8J8,P">&"X9 MKU!RCG+Z'R6[0"(V%LJQ4$P$!U&!ABE&PM$S%:+82$362?OI8Y;.ZY#P?"T] M^I,/])">/_Z 0,"R87"D*\42ZW/46JX7"W:]Y":?Q&5%'>DHFQ1%M5Q)RY6T MY_BH/A-_2[3EZ\V HP.Z"&,K[@?.39XB*BA$E-L M)B8@85%3B*\.A'CCH.C;$9*J8.=T%!PMDR%Y'-"(16*]W]VA,FV.KYF/)/5D M5$,][&ZGGQ!=7)4.A"-=!9[8A+/6,I[$?U9ID38&C!UL[%*,DJU';XH'F8L_ M)=Q!="; T0%-?+$-YT&=2)Q7!8VYBN("+Q_37'' :CP7RM[#PU14 *<8"D=' ME9CR3QQTI1;8]6FZJJ5L"[U#=7^<6_9LA? D26\"'.EIXLN7X>$$>-(S0%=L M7M1$ACY[1)[26**LRK%0U)2#J.A81CX2CB*J$,5&(@JK<\=]4U@7.],..\(Y M4'10V%JFA;EI5QW!5#A::HRYH)..0KJ@W)G[YO&L"^HXXRQ-:A>Z;I&J7=*E M!P"*8@O1%6W].N/AJ+ >NH+R+1-)AE7B#:IB)>4/ *:$"IV#K6)$N;=Z,)1]^O16F;J+M_8< M.+JGCS(VDR \I=P^MFBDG/Q)8)2T50ADHJ<&TP"IJ@G6$FV5B=1Z*_Q <+5J M(]8<3>K81-.I/E(4RD^*,A9&$^'HCB'>V$4R]NY4J_LZ.PC4:H9_.M"'6W7T M 8T6^,?#X,A>BB6G\;V(HT!VM$8']3##A:J(OP\<:E%A\H MO=351Z!Z>.(-ZUTX&X8&ZF#+5S^_N3M.FXY;DM(_K>CWZA=G-=1(>[*/C)_& M1T7)0,.I<-3%&/-CU3&4D+4^72*2/D5E^H0XG_[,7BQ K,1P^Q=)EP\'.!ZT MS/#[PL8>UE#@Z)X+$=B;- .?>>T[38M.B?@CX(A1A.#)BR&M@? $H1/##R>= M:9#%!!_5*S'%6M()W")$O0JX[QPIUHS35G2S7$6QQKM=DF'>L1!HJW@0'#V5 MX(AU.6GM'OV.\@03H0QY/WN070-6(+/3'^'(BH,;5G&J)9O_>76$\4?ZS\U/ MG%\V8 ZPS_$3N[9:O(SQ\M66L:]J_%F/Z@RS9<_N%^9EG4^X1&649D>L1,\E M11N)Y4:4$_0^+J$;W8*15G MX4L1Q4IN6B_Z'4S)%3GNB/X7XD'?;0[K^#? ),B[,^TN^O:);K&LQU/Q@>!" M[/?I3NF+K34S7RP/OLWAZ1%RQUS5(L:=S7]@\O4FOR68NC2%+J.5DRQ8_28< MJS7)<6$6PODQA'#T:8&Q9EJ6FK-03NSXD0#Z"MZO(I*SQT6I[:FO]SE% M\-_]BV(]]NHXDHLH_R =!RG_($<4.P@+2,X MI>5'7!23LB3I8U4R#!_P]%M.??[I[#8B+:X=WHXTF C#OFJ+S8:XL'+\ Z7S M!0W))C14B^:H)H^W%J7C8!A1;2EIT!)ZG\LJ5GQV-9NAN-RT2MJT<9GFGRM& M_W0V)4F:1V0ME)D+&!@)(&V1NI,:."9)_ET55"5UEZ/6>!AY(FT9&M 45ECG M49'&6[*8L=^2=DV)YGG2' %:P[ 0ZKN 0G6D$["@^1ZWJ:CE4"R$_1-48>M0 M"E3<)D)U$-W/$$4'24#U+H\21]/K ,5"J+^$]HI<* 4M;FT#[ 3'0N3OX8H< MOA&6$& F6I<4PFN8$O14;+2)BZZ>XZQ*4,+TXF&!+J(LKK):(3B,UIYCP^Z0 M*1M#P@)4:]]7RR4-6FE0NW\A9A+'["XD*T'!61J?G$T[57"S5JMU]E-TA,D? MX*&&>P?X1%R\KY_*=&CY8 DI6,WJT(9ZJZ!4,[54].IYE44YD\U:<%KC# ]& MOE@M5H_$!KD_4B*"BG)3"S?)DVFY0*1U5Y;.1IM?1\,T&J9@ANE(4_4MD'KB M$$V-+E4!;,I#]#PZ,:.M"&HKV*Y%]=#$2HBG#-,^J.@)8!F.0[G12(Q&HE7/U9I:NVOH[F830/O?L00JW4 M]RE,0 S%D+C1%\"Z[%Z0S9/C!V-'^S+:EY#Y#-'KQ4:Y#0,@0[0Q-A0&L#*7 M:(8(00D-N'9XMMJ-C99FM#3!+$U+-TU.;E33AFA-]&@*<@XCN)H\VHK15O3J ME>STT,0+D4T:HIW0H0AL_LJK.GL2"_7UYC<5X]%FJ21 MAG5Q@S08D^.#3-@RI_\?46/5M/Z*UP\DRHNF&L]- XS@PKC5Z*X/%D3#UH[M MDY87>/F8YM&F?M-%+S0APK@4Z:X11N3"U@7;A+M'L#"N6;IKA5-B'J!J:"9& M[:' N(KI+GB3U*B9'Z[Z\DF>]BE*,^:@SC"I"O1 '>9S^J&O%G(S!0WCJJ6[ M,.WH[DW"GW'Y3U1V*&>]#\"XG>E?VB;4=R?SY2I*":-K.I,I"[$_V]2)YB@..4/39#WL@":)(*6_K-NU7T+_*>O2Y@@%Q@=9>XFDC8LGX@ M4;*[6W:'8I0^,9_&<&>]9/"L1$^R&2?!I6P MQ=VT*9G7/-B_U)@G^[_[< 4"!U"[1IO^CJQ^A@&4C?) 914U*88M^\X1/\SM[F"2ON/V$ M',#8"!QD4E%-)'19%XABN& MU"GV&=Z>8FFT / ,VD8G0"8<[0B'K2>U07N, M"I3<1NNZ-HJ51D2QAX("4] V>@(R#6E'.&P]^8"?$,D9,1\H,:5-PDD$PJ;& M"&1Z44X@;/E>TOUNN4P+%B33OU-31X71O+:>)W=HT81"]1]\I1Y\?=)&?T F M*_TR!+:^Z38:<0!CHQ<@4Y=&'4D ROHSSN/F =LF=3(EEVFQPD64?2"X6A47 M641U?I:RIT5_11D[GKN/,DP$.*X?KJ4B MB;+):D5ICYHQG]$WRL,\B4A"2:_;@*T(*L4MDSOY@(TVA4^4>B8?[ V@^F;( M>/_',AK[SN__<-E,O32V--(G]*5 U#!]I/]52#I\U-^6%?SX 3B4BSP^J?4M MPW8)(?WAI+#,4I)68(=R$<<_S4'NE!OT]AVWC''+,&/SD7HI[8C6^*$8? -B MK!G,6ZUL$]'DM\WTH=AG>]H"V.&ZV15 I" M<\90+G\;D1-@8^,^;3[N<>,>I\_F>(&2*D/3V;$NU:]8,HO3O*&F7/J.D(:R M)WHA,X"ID&?"1ILQV@QM-MOGI+_3Y+-KEAE )^[1"HQ6P(S-[6Z-G_!3#;^P M;U+@#FTHUL(;J?9Q759SB?+B,RK/,?[Z>Y15J#C^;+3O]"V-^=RA#24.]T:J MO>B*HEHVS^Q^*5@:X/"!W>F,853_IU1D]E &$[J[DNAR+-/6AGTSB0L:)D#+%281 M65^F,_IUE,>HF.9_+-)X\1F?(/1K](3.$6H*Z1.--%D7X(?B/G5'>^ 2XI9' MSZ'Q2UX5-5T?,26,Z?#N+Q>48/7M^0[ #\6-ZXYV+X&OPD!MRYT?,%/F3='S MIGMT69^HWD;K6JU59J._CX9S+,Z<-JHWW2OGF4P[^Y"*%YW]DA.T3$N*R_8$ MXPZ5E!$H.5]?T' )9VG"^MU=Y66->7UC.KP-:[LZ9(2U M4GRYO\"$651VKET?;V_5DL;*=^AI&R#O=9NGV*RG3:/%NYJ$K.6B210ER/>' M$C '9$Z02NE=6[TQP!X#;-L >ZM&Z]V^JAU1ZTT=7@AM0I<7]V*R9'?A6A_> MM,#Y#[-0DWQ3KW:37^!BTW"YN,>9.G#N[!M#B9X[9H 7X;?0.,9PWVJ@[D+P MA$@1905O@)$J=/C%(<;(G;,CQ)5;V4W;2^9&9Y;^0G/Z 7]*[5,%*)$T0\QQ%*FA4W\U4@5GPY6[K&@CW[N MRX/8\OE%8UY.V7W*4*S".BRSSW%9XB4U<0P_(<\EHV X;USV8DWDPTK@ :]4 M[!<-@>%DR7@OQSPLX^N.*M+[[(*MQFQB3T+RL!O8T!56A$)$A4M)!WM$CC3.+(J@?#B)4-.:M+5N#-'R]758F(>L=0C(1Q M]&$H(RV:[%/'8X;>$G'C?D^=82GP<"PYN@$0>&V MK!@))H"3LUPD%X@.4Y67K$7G)5ZF<9J)LU6*D3 ,O8KCV("6L(*YQ@2E\[S! M-)7%&]*!,*(X3;'HD#*ZKW\!]Y7Z6[.T9'7*NX9*_*2?:!0,:Z1U&UY. C@Y M,->S?I:O0LF4>B["5M[&[::QYJ395X+OKT#:R,)F.@QSH_,*DBUM87>%XS[#FJ(TF3:46,R< M)NN%=/PI#0X[5N];C1($)WIVS#W[3+ MF>0):W+Y+6*]F?B[I.ZLH7@BQB1IZ\U/PBS1) M(Y;W4DG($:R%['X)+CLO-/N3ZCG**9_J?F8IH?N;CLA$ MIQLX>M#-!VP4)-S+F1V1;[W=3.C>%LTW^*1/VP!1,]MK,=M&7&$J<&QI\RT+ M[2(UJ_DV\@C2%\^!NL I)C[B^@)T$560P%J+#D"^#2=8UO&RY?&U;@JY-__- M*G.F=N=\).3 \6J7=%/3+\K/.1TA[);.[K2,??+05]BJWY<\1H2UE*6C;G&1 MBK8';S!M[%"0C)AGBJTW=AT\:N^P%318"E $QD9F0=)H[D1V*J:MNESE4=W4 M6[A;N .S$5F0[)DO4GUEI'=HH&12WK%-"27US6>U,5=.'=#IOP5=OB1PAS(4 M%6@Z:Z*E.<64]3I/DXU_OFU4S7OTPA64U>E3> E9TNDOSZR1E)0YP]HY32>_ MZ!:1F'*&!A>;INBSS^@;\\"B;UL+HWB.8=\8G4W;_YU#8_%"X.6B8D+2@BY I]BU!3RFNBFS-GG*HF^SN7YYYV#XW,R6<1VH.DPI=_@H+C(Q-B6VH Q80K I0/:=8=5 O['$M!/_.GFKH>&U/?6U/CX>! MTZ0<'(57D=2#P=S?4_)>(B.OUY)N=H\*4<^L7;D@Y++F#!AED!K\PQ9D6;-[ M^Q TVXLF\9]5NLDIB2^D:DV <>]%G]DF5(TW[OX"%=?[4P*.Y\5.Q 7/@MX4 M=SLOCB-=GV!A=NV6^:0;KP?J\&7(>9:RX]WZ!4/E 4%1*^J@KQT(YP')^ M+U7D^_H%#,EG]DP9-M(8Z[V."U_'8J+:)664<:>4Q*W MJ1"-@;%]Z# ):U%BS<7/N-1AI&P8#'?7@)=J8JS9^4\4D;K>(B5KP78E&@+I M@8]NS*Z<! 8VRID#X=]7I5VFB,&6\@[[N\P+*B$)UB)O/W!W#?, M8(KS!/P!, REFF4R[.UY1G]#"JX)AL!H0J'!-RG^UIR[QA61,TXP L:;$FJ^ M2=&W9UOZI- WP0@8=V,UV"9#WYIMGUB'T464J]FG&&G!Q@XJ$-5LU")C3'MZ M2WMVD:S0OUT8(@?X@5!2?H^R"NU*D2\B0M;7F'R+2%)0[2M_C9[0E+#_2Z.3 MDQ#CPV*X.P;G32H/%8I5C-4%S]CMC0F^::4+M]7%:'B-EHS#":S$I&M M\W#VYA/ESD+1.='K)V $X$;=%3N@WX?D6S:D6_EW\*&A;+%]<,%:%UCUX3(M M*2)7$6'WX8H[MI?D*#E?LPIOG*5)Q'[-RQKM^DYXNBM1X0C=$T08F0^-U^Q\ MDFLMQEN"GU*68J7@][9Q&&77N MZDMDGW$>-^: YXJ.[MWHWDDV^5:N0:E8#Y3Z*VNVS<2CC&MWCY@FB6/I4':^>5UF4,SGP M^A,8SQWB#FQ & @+,CKAHQTQ8[- AV0^A>Z4H2QX,WI K//-,>RXT,>%WJO# ML%'"NNYADB1- RL4H_3I8.,Y?5]0-6,HML*('&NC_$=:+A8X2YJND>R2(NLD MRE^7RK%#";0U"=$N0PMR"K31CUN"5E&:;+JC% ^+E"2WU-#[ZEK%_PS=&W"< MLC/ "[Q<13F_G9/Q7!BUNK:\5Q)F+836NM?CO-X$]:G:;4./FGK:_M&N? M):S,TYUBP><@G4#-Z GK'[0]U<\XGQTFL!6QA'B"A:B"= UH<:S[3_=8I0F M7[0K.7GS@K:->_W=X,+#TG"JE:$,T.'2CJX <>:GB'RE@27%Z![%%>'T)1Q# MS#'$U#RTXN@2=0Z6.-G4D:]8PJ+UI+1)D7[_YC0[%*?7'" MWH>FMFYC\J[^K.C7,RT)FTP;2MK-G":'ZR"/Y5XAS@F*OK)71,_7C0,!::! M'I>56!/_GKA]]>6.P]W67V'X 3)V80'./7'PM]M_O M8RPPG%B !=*M'-*O*./WRA>.@F$A]#(&4A)Z,AA?[B\Y#&[]%8;_J6$P3G"& MY6V.:971E(ZF=!"FU*\<6#18W$>9M'"H'=\:3!M*VQ]SFK0+V,,44>^/:2%9O_L% M)F6)R');Q<+>E\BBHDAG*6NFJ4Z/6D(82C6V$WFA/8R3\W]AO;!R[%"JNC4) M"2N9&^H3$U24^U)5CDC$@X92MJVB $Y-O7J!:(RV<M38M]'=#I;G=0 MD"[8"X]X!Z8'UUA[,28)3-F\;1K+;FZAO*BO)MQF45Y(]F"M&<.)^PW(L6;S MYN[-+2XH#JL,URV)SE%.V5#*V6TXO5[H3'1+"J MKQ_F\_H/Y^N/J"@PT7GTV!P0I (A1TJP2NAA[=QD/B=HSB[@L[L5YU&>B)\4 M4XX%4VO$Y38VHB*L6#[C\B-%D;#G%%0/@"K'PO"GU7S'1O2$%= QAM0:M/%6 MO\]G!P"&CZXM2A?F V(#BO-+SFU6#E*-O@U[^E,53(U MF 5C!_8G66/2P\I7TJ5]?P@W80V+"K3IML@+P>VAP-C-_1T&KOVE4:]3^=Y.DOC*"\? M2)074DP'&BS-EIFM 4P!9]Q?EP4PVK71U,P MFH+ Z1NJB8XC6Q(BT ,:$9TF4/;E&4S.:&ANO0ZEL[;YOFJZ( M$\PA6A0/!(>P,WBY3,M=K]%M2^1X;#$\6A-;:R)6*6WC80!BD+;"F+X0J8WJ ML4!_5A3)JZ?1NQCM0=! IE'!R:QD;VZL,&$+YI9NK3C1#V>,8 S1K%@0",OE M<&JF,>"24[ZIBAH;S"V6?:&L(-?I,TH>$%D>9M$+H3EU! 6I8M29EK%F M=*P9'6M&_VHUHP_?L%/)*'\^C'H57Q6C,AJ!"'>+XC'F% '=0E)#$#!*4LQ% M;$4F%"GOD#RN:<85T16S(0P8M2X6C"K MP,OJKFJ'U/!R(A[ P3#5/A7%'U<"6_9-$>=]1=$\K&G&\SPM6&>SS7.V/&-O M/AN&_?>I"M9, )FQM6QM]!=*V=ZA@OH!\:(N"7A"&5Y)S[^< TD7:M#R9BL M'9.U8[)V3-:.R=HQ63LF:V%*>4S6CLG:,5D[)FMA!>L#2-;R Z )Q;O.>-HF M;8W!?D_)6W/BU4E<[9#;6DF.O_@1YW/V:L#NRSO\.:I@/AE&2-.%%&UY82VY MNG?F35Y&^3RE^G!;T8]$13MEQI&8_B08,4L7DC+E@;6$!!ANVIZ:BLX#-!A! M2AL-)]/XAA7]!O3V:0H,/UPB;9GH]/\$BVI \_1!0GZTY\$(TW;R<:I37U8 7.(;'4\X0A7 M;P*,Q*Q?P9I0'E:HW ?8Y&+5G0(C=^M7L&:T\T3;U_N4?NG^ Z7S18F2R1,B MT1SMGE.D3N#>&_3DS1M]JZ67%C@Z!:.2[TWS\RC_NDU6<'NXZ2&N %BO!%6)\H$^NU_X[+O1^XC'=<1GON(QW M7,8[+H[YK%/P1Y^]3Y]-;ZUH08!Q(.IPF<6 2BAK,,0-I Y.GEN9LA:OSTCHKTWJJ,)W9=X%T'F7K(BVN,6MCE$B+:62'$MY@R_-4O0>W M'="%Y7H2.D/J1J_HB-H+W+YU0^MHVS-E5JUS ![M=;=PNE"E !4L\E3XCQXK M69K/Q*(L-N]G^RVK0/'+.7YZ%6^@UO3O_E4C]^+UV=;P;/_^KTF6;?!@[=6!-_4^-OR>TO]Y<<[K;^"F/SE;$+"W#NB8-77^XX'&S] M%4A*5\W!$YQ[XN!OM__D<+#U5R 94S4'3W#NB8,7OU[SS/G^KT!RD6H.GN"L M[>1TD533P'F&R.'89P^2_ M0IC\D\S6V&DCFKOBN0N*6'=]@>MFP? M..GN==[@#Z[$O1LN<-:X1[6R/K,2?+*XP$^(%;>N]QAR%,9B-CSOQ[N,K;D2 MUD-BIS;C"/G$75R!.ENS1D0H]$=ZBW$IS/#L,(,"-00PI * M;"%[ZUU0\A5A8D1[#IAS#EU>JEGOM6SF(B)DG>;SYBEU:A67K)76[NM['1+G MJ.P@P'!%]-F,/5#KOD3V\-F>UWQ<8Y5H3(/A$1C+PYQ$.)DPI5'6#1?- 0TZ M+K0@EQ, VFSLH8\I\D3<>8[S*PP;ZT=T0O*LC6I]J"*(,CC\U1D.PXCZ8;@^ MO:%7A5A3[H M[A+;8"@J[Y(.A!+FBAFO;'HDGP$I@-5%&>M++JRI:K 2NNN\G\'$KPKN8A4) M$#@_*9M^#TQ[M@T?IK/;B,B:,9E.A>%T<06!72@**\#&\[N(5FD994)9249! M$HL!Z[$F86&E\T!JUV5=MTX1YR-DPV"XSK;R45,65D!W["@A1\E5TS%?+"+Y M0!C.LZV0=&@+*R86;N&\I$R@GYMOFXN*I:4U'M+*$G4ZT28CK'S$'JDL56

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

      <=W'4 MZFVFZ+)+3_[.6=K+?LU;)31K-?Y8X.I=,YRX9T"HAN0-L [BIM M.H<11[#7ONW6 Y1@G98G^8 4\ZSM/&>',4>X-SQG50TTC:"_-[2-D-E^(W-] MX Z/K]-9WU9S/J=1NLN,#SAN(]MS&I[UYWK^@-9YM!'H#4\^NP\9LCR#BI,M M]_:9YI@"33(],S#;;.XXU0;[\QP5"@' KNM45Y"#[4X'JK/UJS? Q7B-KFM=P2$0J'G]BNT MLF%VPP#XFE4'KYPW.H_67>:+P');6:+S,*T_._0+O%Z@CH#7MK[%=NB0!1I6 MQ&RY?^@\7CW+ TT#)ID@F:"I\/4"=QZ'?'2S7TXRJ7UCUI%-?-\MOXGOV.$% M6]L7FJ,MK-G,U5Q(S>^;-8*\$"K2&4"6%9UNJQSPB%TVV9BF1X@NM%="]/?G1EH']/\+@BYL^3H,RVY4'Y&]R%>XFI:>.U M4U!/&6OP7$7<^U&384^-KNX'J=K3<"+W:\M]I0'& PAS-#=)PM#>9Z41[IG M^572% ]1TLH:0<_8X4PESUA_B&&-(:Q9VF::(A;J$9?9ELM,'5_HLM6&W]BD M;BRRK R%'AR93Z')R5^%OI2A<^;'2$#3<,FFX7),FQ*?89+-B$XM72:C#K2; M[Q"@'M0;KMF+II6!,!"V:9YQ2?0>R[N\*8-"1?GD@@B@6R=TIX6&A&/-A .\ M@W=K4PW "W@M23)>4"GB$_TC\O%5[,!U]W#M_Z;1@)!1+)]1 &[ ;4?Z %)! MJC6Y0B/.I4I$N1LB[333 #LO..00J^<0@![0VYU;@& 0;&W.<22R=B,)>_>4 M@%[3T#LW.F0=JV<=P![8VYYW@&$P;$+F,5^%+T5>3@H]3L[F?4[S"VT$ZK8M MDJM$OMRIY UV7V T/$K#TVHSQV@3*#;V/G4#UO9O$;9.WK1N.)2-NF?>:'B/ MQTA[V'#D;K^GY:.^91F+X;W4N*'>3L';4T4W#O*H_-(T> K2>.S:2DJ$?B[J M*PX=6N\:R'V7>X. C^(O3X;G,(W%[S0M%)(_'_D5QP[-=P[FWHN^0=!']9>F MPW.4QJ,7/9#GST=^Q:%#\UT#N>^2;Q#P4?SER? 4I?$R328^"G[-ZP06DZU2 MN(#X]B#NI-SO1%BAPKI46&<+DVN5ZN_,'\N Y7K(RBU?NN4EVXG8RK><+[AN MEL>.'JJP[&8+P,H<6+U?'E;O=P2KU\#*6E@9=5['.A9XGF@C;D5WL1R\(@G/ MTC3\'L6QX[!:>.78X'HV"+3,@I9#5@BTS(*6,W9X&B4B"?H[D>L7G'>Z(E(R M=!Q4:[]K/W&AV-NL$V2!CHG0,5=SALXEKPB=X9>YC9W)*R4'6E-W M _*LV*V W3(=U8V+?(=+&M::U&_,DJ**&GUQC,+^G_+\$I_DYAQPN7TUXTM MOO(%ET.-@&IC.7**PIR1W,0B++M(8[3>0AMH8R9MS/6:B18QM($VIM#&X,)P M?=*\O&E=RMA?=:[%F=D#N4O&4!#;1!F_7<8,QICA,>829B,5#2[C%&<,<1G' MZQE( VD%I;:\$$F-).J(^*,4<=YV&T*35XH[[7(ZU%Y< M[;B_3/D-\-P!GE%>.9&-;WM6#NS5MV7-NYWMWC0N8<]W=EY$XBZ*=44L1[.N MSVDR^(3G>V*.Y9W]/?)9%][/P.9?M5/EW=H(F3I0)1/UKWGHG>GZ_-2Y_MFJ M<&*.93Y^UAD3I] U)VU'>@R6'DLRK 5RJA$S=N]U_\X^' A6R(^Z?WB$4@UTR"2N;P6JA'TJMYFX_/QU;\;<4O' M\6E.>P2ES:B5Z"@'^F4#OZKJ%G;0=DU1$8;C%,7O\F M)KAUB'\?BVR?%57"ZA3Z1_- H _T38"^19EJ)?OF,92?F_^$.98RIW)L??<.2 ) M<) U'>2Z+51'!++(RSLPX)+#7%HVU/@+%($B1E#$-?=IBB1,_X9 SA!H?D!] M=Q+@#MQQA66;P7+D / ^CAFNN,M!HC M<=:Y^_@UDDDBX(^E_%D04=]]!, #>)QAZ08P/'&&)],#BB\ =^".*U1JYD(/ MZ^DQ/9"^NP#P!MZH_@0M3@Y/_GDR,%*9[7?V[_8_?KYO[7\Z@R96TZ1:8'UW M!> /_'&-E3M(AR)IQ2*46?LBZD2Y#,_$WU&W4-#&4MI4"ZSOK@'\@3^NL;QK M['_='^W=E3=/?HWBAS15H80UMK*F2ER]]PS #_AQC.4=H]_O@RRND&5F/'$( MP [8<83YTWAZ*'OKB(_2XD')0I6C?%T4;-YI+4\6A=1W7P#R0!YWJ)Q"]<:5 M#,H%FLP+I^^N -2!.FY0:9KN)>87>;C_472B.$\3J&(K52J$U7MW /I '[=8 MQ2V:,BA4[\ IR.,D>:H%& >!#M !5]F0J_0/))1-J1ZB0&8PR"$&+8PM7@() M( $.LMZ]%J_ABT-\F19.? *H W7Z\]2B2B//A?QC=2\+519C0WN7H0[EG-GI3C[[A^0 W+43@X''2?1C]U$ M#U*=/XWP44J&Y@:1JL469X$$D '6:^#%:5!)),@$KTSU)LBO19%G$(<2XE3 M*:Z^.P?@!_PXQDH[DQ^GATID47R>A/WC0$Z'SK35]BSVCX0>3BAD*856B++O M;@(Q($:MQ'#-:6:1/4P+C53U$,6QA$56LZAJ:'WW%"@ !7"/E=RCOW?8\_!>1EFF M_R.*EKA*].5$-))M94[%R/KN'1 N <*SC'T?EAXVM4Q@#V.,B>9<+KNX= M!:B FVQDON2H'<6RO^!!OTBTTF/9>PCR6$J>:H'UW4& /_#'-5;K7EV(NU2) M/-7?VA_FV"/2RRY M^TKIQ5?==MX6<2<*KE4:%D'.,DMWN%,]PO@'A( 0K#[>V.KC8WF4QFGG+A)/ M-Y^*>WDL#].[-!>0R%(2+1%=WQT%(D $G&0-)QF^U[1GWC#)12:M$F;?O05J M0 W<9@LS\L?[J?Z_YW-ILF_BZ;":_XA_BY:2=Y#)4C(M%V#?'08Z0(<:Z.": MJSR5BY=\R:-_(;G&G1Q+6.,":%:+LNV= #(A1*S%<#H22 MC>91VI5)6[0D=T[9RJ J8?7=2X ^T,P.,,%9NK)ZW';CX\LI_E]][@ M'NG70QE+*5,YMKZ[!22 !#C(FK7%:93$>JRO'D^R;DJ>92M?YH73=Y\ ZD = M-ZA$D3.5%EUYJD02R-)Q;PH9Q9H@E] MW*+/HM#B(E "N >:^S848[KA7P0<9SJP9;Z@W(X8REG%L;4=[\ ]( >AUAR M=_)(R?[>O.17#M%FB>CZ[AH0 2+@)!LY,:G(-3;+^:2SSMW'?\JV@C:6TF9A M3'UW#4 /Z'&()1WBL,BB1&994ZJ'*) 9C'&$,?,#BU< ?^"/:ZPU UZ.Z>=" M]8:.0XQM9\S,F.(5@![0XQ KD*5W&/JW7,>"S,HMRLR,+&X! 2 SK'B^JAS M_4DJ$>6XBK@W2&F@,N-G*W.JAM9W[X "4 #W6&WOV8/&2RUWI4>L M+8)VE%"AVTJ8^0'UW2F .W#'%1;2Y./)_S0N&FP1!K&;(@HKY[ 8 '\#A#E?)9JK1;CFDYI#=%F,;Z*D)N M2;65)G/CZ;LK '; CB-4/SB^'-93):.[0K7..X?Z7UE+%-#%5KI4BZSW+@$! M( #.L;QS')T?-KY&90S*T3U3:99]%S$YEM6<61Q4W_T"V -[7**R2_Q3/,B+ MJ-7.RX$]4;%(."S87I[,B:;OO@#0 3I.,/\&H4C_[O,D*WJ[M%]$G2B7X5ET MIT2LK^!^EG8Y4023B1A*> M)V&1Y4K_48;A4JBTR+((?EG-K\T$WGOPH=9W9 M#H1Z*CTO(G$7Q?I=.AY=D3P>%J'H:AQ!-TOIME[ ?7&:TUS?[@\U#--$9I'X4WS3 M#PCH8RE]%L;4=QAZCN$"_;V1R*7'1Z_P51["7*['CB#( =L.,(U1:- M*!F+)!P49,?%71RQ0Y&M3%D<5-^] =@#>UQB:9>XB9*6R+Y%8?BT>GGHD:.T M2,I5S.H;#+*<04O%&2^!')"C9G*XYCB3TT8CIEX.,+OA64RFI>+KN\- !LC M[I";ZG1E2LCX(@_WKV4N@O9M].V!J4);J5,AJKZ[!\ '^#C%$DYQU]8?X)GV0 M2N;PQ6Z^5 LO/@$5H )NLNY:I_-K!2UI_BJY(/NU_VK]-OSV21]G*E I1]=T; #[ QRE6<(KK=CG! U5.(.@!VPXPAS27(4W8DS&;4>>S8[N'T$GMC,DT4A]=T7@#R0QQV6F*HC=;*= M'U/CZ+L/ &[ C>)/FV[KNV@>0@RKB3$SEKXK/R 'Y#C PD.!GP/>W! D4@ *XQQKN<92J;KGMH8[&I8C%8Q:)9ICL'[;#_4^%?N"BZ'0+!8TLI]$R M8<95H ;4J)4:KKG-Q :[XR-=[IT8]Y8G/[(EIJV,6B'*OGL-Q( 8M1+#-:=Y M.:'PS[2=*A(V=UA4-;2^>PH4@ *XQ_K[S@:RR#4:RM;CL3S:_[I_*7]$07H4 M<=*+M01:+L"^.PET@ XUT,$U5WG:_A'B.$.<12'UW3F /)#''59I :<9K'&( M-4M$UW?/@ @0 2?9V'Y4ET*E0;-Q)#)Q%XLD8/K05NI4BJOO[@'X 3^.L:)C M?)9Y6ZKRR//L4!MR0R4:H5#&DXG9;6^DQ/9"^NP#P!MZH_O2)NL\R[)=8)$?6TV-^0'UW > . MW'&%)5JJW_\M13FR%WG8*()OY3_ABJ5J34")H1[#% 0V@ 2ZR M$1>Y2%MZA*- HR#8OQ:)Z AN&'*&/W.CBX] !(B DZPWHWVDWZ52T=%?V]\% M!>Y8SYUJ@?7=/X _\,>VLJ> MI>+KNX= !LBPZPW'Y*6:]2: MW?U_7^VG^_\4*OM;?(EZCL$A?R6SEEU,S5X[?T.P2QE"#3PNB[$P!MH(W:3RX$(3=RBA\+8^J[ M#P!Z0(]#+#W'H/)"OZ1Y=MV\",5^^7?:%/$#=[G:RIFJH?7=+Z %, ]UC]? M^UJE89&GPX?/]D^%@DC.$&FY0.,LT -ZU$X/UURG/SLT?,8YZ9H3-*H66-]= M!?@#?UQCU;F0?B'XY-$G)W\545>4 Y5F5_>YB#MIG+9*QX943I!J$V'WW7&@ M#M0QG#JNN=7H)C%-J1ZB0&8W:4"64JPY8/LNQ-! M"VA1(RU<+(P MIK[[ J ']#C$:CNT7QQ=IEG O5;6$F5N/'UW!L .V'&$RH=E/I1#VLSWKV4N M5797J!9,L9PILX.*-P![8(]+5'2)?S>N^@T[4BBK&3(UCKY[ > &W"C^M+;J M8"GS0QY]HWZVGA^+0NJ[#P!Y((\[5%R,4811OP\WN-,E/HZR7$5W1;EY_%&Z M?Y&'^S?1HPC;D,=2\BP?9-\=!%I BQIIX9K+//7SFE'2$MU4R>M / M_'&-I5WC0GX;6Q!QO!_N7_RGN/N/2""-K:2I$E;?'0/H WW<8H4S06"->ZRI M&%G?/0,"0 "<8YWN5%KD[<:]TL-[G3]>Y.%E%"H]]/#&4MY4"ZSOO@'\@3^N ML>H9A.-C^TEVNGF:7 OU#>)82IRJH?7=.: %, ]5E\%?"'N4B7RM(SIQ%#O MDW[93:%E0^R[FT )*%$3)5QSEZ?*[U.JI.BM8Y-I$4,;2VDS+YR^NP90!^JX M084R'8(X09#9P?3="8 Y,,<%YI?7L,,)=LR,I>\> ,@!.0ZPH%0^'5I'UMQO M[!\*%<@X98&@M52I&%G?W0$"0 "<8^4.TOC@7HI014S&V7,51D44PQ@7&S NG M[UX!U($Z;C"?(G="!_!&YH54>:]::PH5ILFQ/-:/I%]%'(LPC:G)[67-UDF1U4' +8 WM<8DF7^)CJP4M:$,4-HDP+)\X MU($Z;K!L\C2Z<^\+'""0&P1:/M@X"32!)L;0Q%47.HS2!_W>0FD,0"(G2#0K MI#@*D ?RGKG#.O? IDJ#L4A:6:;AE>M_0!87R#(WKC!FG1GSP7B>%E)]$J%4 MHLCNHCB$.HY0IUJ X= :'+J,]"^_DY$N!.]D+J,X:F%!KO&H>I#ATH;\Z%(' M)VA_2<(OG>\RSN&1"SRJ%F XM,H=NH.A/9;J:;0;9^4XGZB_(UFFSXUG[]># M?DB:9S^MUHXY3%NO&]UO^=.5LYM&)W1E.HA"E@%X I[YD05#P'X !^G6-4I@O9W&?TM55O$L6R<719Y+I._ M(8X;Q)D779P#(D $G&133I++*&F<]?X'UKC!FHF0XAE 'LCC#JNF5XVSFTBC M$[*X098I0<4A@#VPQR66.C>'=JW=_)@21=]] & #;)1^@A"C4_\9B9$+_)@7 M5'P V -[7&*9T\^:WZ/\;ZEB/Y.'^ MJ8KNTD*U8(O-;%D86#P"^ -_7&-)U[A)-1;9J]T)ILR,I>_> ,@!.0ZP8"'& MK8B^B^0HW2_-5?_1E1$DL90D"V/JNR, >D"/0RSK$&T1E>VZBZ@3Y3(\%$GK M6_H-OMC.ESEAQ2> /M#'+9:=A[@0=ZD2>5K&$^XXQ9VEXNN[?T &R("C;*C^ M:(I6''T[BT+Q5=[J"'>^J"*)]>]HBD0\1OI!C14E\\9^<_^\9/U=09_75F:M M'W3?O0?:0!N#:>.:2YV6*Q02/?S]H?\8_=V1>3GB91NRF4=PRW9N+1EAW_T' M0D (G&5C=P2>QR(@8W./1$M$UW='@0@0 2=9VTF:C_JCOI4#_5%T.B(,Y8S" M\+;X.Q;PR@E>K1-T? ?:0!MC:>.F2YVIHMNO*Y]:EV448C%U],_DW=_R4QH( M&;. TV[&K1EWO KR0![#R>.:8PTO RD>A"H'G-:$.^1:*KZ^.Q!D@ S40!M: M\W89A6$L3T26G_[[Y+BX$V1HMO)F44A]]PT@#^1QAZ6H\N738)WYJ8HZL7P\ M$N7PZ7_ &,L9LR"R> 4$@ XQYJG33UOJ :/7.71E[-I4Z'WW("@$A2RAD&ON]337=92J;GDSD(Y6N<3[8[DEG%2? M_P6Q+"56M<#Z[CS '_CC&BN[QFF4B"200X/\67[_5ZJ^P1SKF;,PMG@')( $ M.,AZ=8?H1KF((8^#Y%D86QP$$D "'&2]$\6D>H@"J:,?[%.[NT2=!9'%/2 M!/#:.=;9=:)YFA9)2+;E%&/F1!6V;'2W"69,'*704G$F!X,5LJ40YJ4R27^L>D1U#(5@K-"Z?O;@+4@3INL( BS3SJC)6!I%>N M$*9J<'$*: -<)$57>0D"5(EOT9E(,J!90+2=LXLB*CO?@'@ 3S.4*6A*QZB MEOX%AU':-^#A-4#_C.).E+3R-/E\!'$L)T,, >KCF.LUNI $A?TSI)I*\ M.<"FI>+KN\= !LA ';/IU<&GJ3HMDJ!T;A&?R23M1$$V6/-P',D62UCL9=3J MP?;=:Z )-#&()JZY4/]HCG)$KU64!+(T]C_ACZ7\F1--WWT$H -TG& .04[3 MHB65F%+S7.'UW M"J .U'&#Q8J11?_@ @0 2=9UTGZNXE=Y"')ESN\ MF1-4? /8 WM<8JDNE0[ C[*,:\11EGZ-Y']82&@Y6>:$%(< \D >=UBEB?LQ MU:.8M(9NM"2]P;@!_PXQHH=K6/Y52;R[T+& MHKG?T'6<$H'(X(REG*D25M_] N@#?=QB^=GVT?OSCZ",]92I$E;?W0+H WW< M8N 6>V]&07L4BRR3V=7]M4H?>H=U34'VC;PODC![?HGMZ)YQT<-@GG[)-4CI MV]U(Z=YK<&$^+D9TYMWR.O-N:SHSZLM R2XH&659H[IT )@L ]/[Y<'T?G?5 M,F@R'DT[*20G$F.$QBYHO-\=-,B-[8+&NQVUGT;;/_W?GXWTGLZ3)'T0Y384 MO2G0Q3H<:27CR5Q%U MRY&:-@FF Y!'21$EK=[-(EG0_UN&5_HS>CM-3(-DN2J"O% :(6/5#YRRFE/SBMW908=4B[.9TM_3 M. I[03S/96<*\@=!3EI/Z<'4Q1K.UU'3AVH8C#,&:K.DH*I;8]X*U(-Z)R?8 MZE9ZEWHCQD*>3HU1.@_F/< \*C_2[>QOB24=0?U(HW/DTK8"ZZV1#+4'^V#? M0]4W8*[AY4WCS< :2.K@0H\5.K2S0V+3G(=9,K.NQK(Z9S5O1^%0.!0.A2.# M\T/?W)@\0=*LW$#)SA*SN%1SD9"@92H:2V:]D9&2VZACK M-WQ;O^&8=)*9H6@H&HJ&HKF1H5FO/ZRNJ$&)C*W,S%K/8%%>@PZ@ ^@ V8#E M*D"?V&_>U]V9-=?Q76,Z?0?G^@Y65OKF,MZ]'!_.PWD3.$\^SUI[=\JA_YS#JG3 A MTT%?M]*#>3?;J/0J7<(^>WVRHLG8.^"KPKE1%#%8RL^[D=4HX43-V)J!_9FJ.YMBF 7304#DS M5(X>&L)FD+#114/+Z*,A90Y(&9TTE(Q>FKEJ9E8OS3'Q]%W1K%<@NE\U:)&Q MN0S])E]U@$S$N4P$[X?S](0-(+RQ=D\7UB.VTS7UF^ST*8>X?C[,]9,D'-\V M@]K;31+47N!&B0:^?O_KB5TBGIYQ!=UN9)>F [J.%,X?##N1,YD.X1H2$W\0 M[$Q?C^99?4B>LW?LF4Q;2G3;42#BAI*BC[X@+9)+U0VUM& )>2\!-[E87KC;*Q/;T@C-Y%& A'22"!"&KEF&@E&/$LC";@_ M:>2?U\[&^L]KTLA-I)% A#02B)!&KIE&@A'/TD@"[FP:^70#R%7>ENJH-RB1 M_?>7S@AZ>3O(M LENUPANP0Y=2'']J03Y+"YPHJY*-"IYZ9!TU)4<.#VS:-/ M\1T>D1O9>MX_Z>GYDZ(\=,K.N)=AG7%]_9@/7QPIZGB*"D1,@(C1N2@0,0$B M9B>=8*0FC-2571+P^@-N6AK9Z.CO"H2E!<3":(]>'JGDJJDD,"&=!"8&P,2- ME!*<>)A6$G3/4LLL$HW[H@B!26.!0/QQJ63AZ*?Z3JB-]]:G.[4>1<"%42V;YTY-V8N!E_<7DE?9! M,/4RR6CG+AH%->:@QMPTMC)FFE)_3.@)VPIF% M7T7@Q&'(%<=N^#3!>2.W"*G+_;C)\Q1'AQU>&,>+\C#*0@O71RGBO T[=LJ. M:8,/1PSDB"/GW5I'CZ4.X_6,&6.\$$H]EH'ME+=]-X*@Z!2Q_MKP6':5#*)> MW/23*H^R_K^3\+S3%9$JQTK_<:;2+!O[E DB37G1-!8=Q2++9'9U?Y[D(FE% M=[%LZ =T;/7WI&GX/8KC*1\^>,9ZEFTI%,.TG!F(S7*R:B!'?MI(&&D!.T?: MYY4]P5]%I&1X(S-]94&[]!3Y(..T6_XZ6&PABWN+F"J$%58[Q^J1=XV_N+>A MS&U;)'BTQ>Q^>4_%^$)SYVC^7-/V+RM^O!3JF]2_^EJE81'D]C=(?61VKUJ> M'U&X[!R71][5D_#Q=T!F"\G\\IXY,87.;M/Y5@;M)(W3UN.=R&0(L9TB=J7H M0O'YF_XZP'+*:2?H7$_57,N=GRY0D :VLYPTK8$-1]?E:*PO]E"))/PL.O8O MP/"6DU/"" <-YR %J>/,-+0@A;!,[L!2$R=W8.::S.R'3W_FC>S]:&S4$8)6 M"RP\-9RG3*DZR5"CIE0A)TL4(:IE2Q1W0MK:ES0,?>[+FYEK,8*KTF^+Q#/C/;XSRU#9WO@>8UV#:=:"+T MK]WAM5$=;"A=%Z5I;CO"8FZT]XNX3%>YSFC#)JS,I;H)4]/8-*0VUZ:]62'" M?#.\M'B^&9XRVP1;+9MM@K0L^8"IIB[Y@)W,[$)2.V9VX2KSM+#4X'E:",KD M#62URJMFV+3=(,CYIBU]SMU;G9N-17IQ.P61^\TO^D4K@6OB:';[-Y5R!M)^[QU5.PG? M04(:@[#2\!XG+*7EZC,KS>@>PT*:V7#3JKX\E&6: )Z:.>,!-YF @:(VS"7! M5*:VX*BQLW30DTE#J&K=_.?V:#NR1=G>@7.+[_=V/O=["SH M!FV9+G66QZ9-E\)K^L10VI4^,6RF((;:'A3$$)W&-.1VJ#$-H5EB!;4=7V)E M+LDGIJS'UA(80HW MS2],H2QSNO#4S#E=N,F]/U#4LGM_8"I3K'#4K"E6Z,E2)ZAJW5*G>FA;RRU[ MG%IN##^-/LVF=B*Z?N\LYY;#3#?F06$JW^9QV&YV:CD=[GH4M_)KLI>$8R8$:F#O!]/9NTP[#SK;V5J$ MWM[2>_F.&22WNGL'U[WE>L46)@2WKIT*J;TE==4.(*RVL!L)K^'U$BU9.&YY M>QB^PW-M+2_(;&C'6_?J$R3&T8[V-?V MC<:TLJ&N*]UKW[A+PQKVNMFC]I?)M*5AM>6=Z-[-KSYRUV>*#@4=AEK7A_:, MLK2AH;";76C/B$P3&CZ[UX/VC,2TH"'N]O;D@+^[X.]F=@2!QA[1V.")),\( MS#P2W'5R&LE;'C.+!*?MGD0Z2E4WU>^U?N/821R.7=IF8>_;O)6/3#5\,@GJ M,G\%E9>D\I0-PZ&NJ]1=87=XJ%HW50WN5T%;6F1PV)V^%7RF5>8OM[=QZ!G[ M[-35BK:91NN*G4G;Z5APIH'A?2VO">UFRPF"&W[8&S2OR[=94 W;=W+^'A3? MO9.SW!I:;_L .WA=EW4[TZ*&V<:?*0C+ZV*YDXUK&.]QQ]S?77]\IFS-F_M8 MP%+#^^*^T996.#1VMOOM&YEI>,-I)WO3[1M[:5[#7U?[U?YR MF18UO+:^*^WM)B(^D[3>O4(LX*CA/6G/2$M+&A*[VI'VC,HTI&&TB_UHSVA, M.QKJKD9=MK4VA\%L:PV179I6\HS"S"K!7DWO3RJNU0V5YB5AS882C.'E8_N:'QK_)CK63]7:-?'>C_ M/'_V\W-C;Y)ZM)_?,D*HIVBKM,_E7H MAT\>]'_=/G9';X@9?=I.@/=NY9AZG8/;/*9=)!I\OO?Q7P>S$YMFU$ITB *= M0ITG#S++>VP[3W0.F@:1_@VC!<%-JE'P,=4CJM7ES$X@#0 M_6ILO=][\VHKV2] L1THZ\O0"+HV*D._76X,7&>Q^)$V.U'>_A1'B2S3B:(C MU47'I1X%^VT["E;QS*K3*!&)'KKX7'^U*EZZ7J-W M9R@1RAL9R.A!W,4.[7@YZ_)'[H28>O&U@*7V5BYPL0^]<&$JO? MMI-8'>]I]B69",I>RMY1\V+O]=Z?1?SXOZ&,2K"]W7O]CX,/%[(EXI/>Y8Y. M\#0OIK;/9@2MK+&C,!(JDE,TF#LR2YW,]VT'5SV/J$I'LK$'E#.'Q40N0M$GG2Z^3 MKKXG4F7MJ LVJXX/*-T%2K]\0CF7&1=0N0M47L@'74>T9 @X5Q@>,+H+C'Y. M'\H_L_[SY>@W92P#2Q=&;1JB\T<'A.Y$1=.D=2M5YUJJ^U1UA*Y-T=!*@P,^ M=XG/WC9-9<\$G*XX2.!U)SVFKBS7,/0^J/%=J-#Z"_?: MGR?!_DM*E9WIU^8RO$U?%D)47.E<='U Z[Y;%IQ5*'9U['+AUH;1A:ER)H1XE4C_Y!:^S2 M@=;ZT'IRUM-")5%>Z.0E";_*=A2XM/1V 2YTGL,RBOZ,TRW4N+ES2QDJCN;-3 2HML)L( [S9 M/&\J;N8/?2K39W=;\L.BNEDTVN:J=#[5BDRZ4O..3?.'84,MLUV=/K4LS>:' M"OIMB7YS=GCTD1YK;'@)!%>$X//VP![C;GP, -OHS79GS4_5[K+3+YR\H7>9 M&^.\O9EZY@U4>,R.YHZK;'&NP%IMDC2Y@%)>G$XXO%+-Y_N\4V$ M#\46)R23%J/__( ?=Q4X5[&<4)>AB.7V^R-AOL G.@GF[P__)+P9/M'IS3?_ M(MDE^$2G-U\^/A'>#)_H]N;O))KA$YW>?'7S3'@S?*+;FQ^_DM[\^+7;I+TD MH0&?Z/;FKP^D-W]]Z/3FW_]!HAD^T8WF,9'F<4>:'_]!HOGQ']UH_A?IS?") M;K/['Z0WPRCTES$#[1 M+?+_!TF"\(EN;[Z\(KWY\JK;FW\GV0WX1+ZO?D[ M"6?X1*W-7T@S!3[1ZW-OY.T#C[1[ 3G=[\ MQRTIDH%/M'LS2CRNI'_'U,P21;QO/C__C;ZVV^V8P6NY[M1]'__3[L15]3MTI,/>39+ MRJ]945R!69:#Y_C7(5$-.R1?0/:2QV^OR22>7^80$%SMWS(M\X_Q[ 8NV"?) M?-,X;<<9RK3ML77A_^TWSPZC4?6___M_&FGMR\YAZUI>##F6-1+#D"U(0H'O M"6&(FIW/\*7)2[KB:M=.LUD\@2CQT.M;%W[<8!2HJFY=^+$=GYD]P'2CP+\N.VZZC$M!@_[ENV0DR3[,]((5I)?MP:C92:1 1' M[KEN?VH/G]YE4%A&'(%5FZ@M!]U1N7IL][4^H:5E1[70\O#='4[\[;?1)\OU:BFAPY?W&[T& M.GY\Q^8YODT4#NTEL)%3(Y@%/<)Y)*O%R/'TYY*H?.*Y7#\%^NC@!20P1RN'@'\5A4DO\#AT=FU9+H.E+\F\8]DGI0?/:5KX:7;>GC.#+3PZGL+ M#"4Y('ML-AR<< Z?\VQQ_8K:G-ZE+(+[T2@XZ8@P8S&EK8TVG':3W*EK8^A/ M!VQF U1'RGL+%JV+#>,QI;"-D3SZ5G:K]^%_HIB!702>O_&SKZ>P<*0WY$4@8RUB1PLG&0T8*V- M@8F$L'8%4@ 7B 5<3R8YINJ6=A6!"^5PX[ BJ=6Z 6=EN!+51KYN?Z+NLW2Z M7?VOUHUWZ2-X@3$%!^]!&)$#G2T\B(5;<$F@E.Q%L %Z*TI/9@LNI_^S7#?- M^)SENU( U'LUR?*'JF=$ST#":DI7M". /Q?]XDF%^&BA1B/F?*R:%>V_"7W[ M$4!*)W!=4JU1KD#Y$X#TL"H4^J##_:">EJ2[C8):P^2\17SM\>:\ MN@UD=4/BZI7)^V8/I\^F^8E-L[5GIQB0/94M-M=<1P4ZR9MPCL^>SKX''4Y0 M&C12VO* _[+_762. 0+2EKJG1A:VDFL)2U(L-"!3N#+X3-WB[<8>=Q[\!/M MV<0_-QF?HUP -$J;!!]>;E,(;(5?[_F EH*^3<]-G00Z-BH/ MNQ-#$T2) M]7RA 94>5-)A3,RY9'5 /54$^;@EX"Y=!?KCG%A@4Z_5Q?JYHXK>DS?6M#M^ M-CH&EY8EY2 Y;&P,G]^T-&Y5VF[C#O_JB,JF+_##JHTM>J3R9>NY,_XQ3UY6 M ?UXMNM?VTIQHH$HSN[.AG?XQ:SUV39GY X+@+6=O([S_&.6Y?L7 Q/.*@]L MLJRBO>HI.,1[LIHYDTF^A#RW/+VM."*MSU!PH7]U!WCZ\IS=E6!1P-5!_@*F MXWSEG\'T)H'>NYQ_/&>K.W#5$JXULAK1H>5.%%"2V=HMK[8O0E?H92E:4(UG ME5S0'W+PBIS5>YLTK7POZ$7V,6H=6540L?ZS!=?F16%\2-SXF$G"CAUT9 _< M@-7/Y]<\6[Z\7BWA\@9 OYPM?J#^V$@">]-R6X9724FU2/K"L?'SHS>GJJ+7 M-YK"K'6UA*M]UQ,>C*Y/G>'>5DW';]E[==>7P)G4;YGN;NU.?]:4A:BGL:GW M&AD.1OS"%R<8-F*T:WK+'38>G9?X0P>F=YQK:X8/P2ZPYF;GX^]!22QU/]Q& M%NYN+0<3G> HE\5=[P1WJ!Z#_-R<-<(EJQ5AE])'.4&(22XJPDM7_Q*IJXV] M/8,5A9A&I;RX(_2.=4(F$X&B!$BX[<;VA3U)OE0^>UIQ.PHQV0)E6.5GSVT/ ML_6F'-^4AMWU=!!F9PNO 6_]3?UH),7V$#**CM4'_=;K"^F6WPV:MUV;%R9" M^>P;O_L1IM!,&58Y[K>%CLHR[EQ+XCC-FZ]JL-4Y?13JH*W]]SHC7'3-GT]B MH1)NT[)%^FD\F\'?T88FIEE '<@_D_(U29]?P5-<[83^?9DGQ329E)@CJ'3D M6UYMYX,132R66H?-5P5X.-L2N/;OQE]/S^9;&%V5SB''U%2 *\!5AF':Y%1H MJRR^KO[+Q]0P*,-4_ZV+T!=J50@+1>BN!*>H)!ARWY&R()9BTIV(/'^D,LO/ MNKNXFDH%.:(/1G<[U4H-#H/.R!K.NT1N)_D[/PYU#40P48M%!\^Z:4J=U)8C8;8YJ5#VN M2[S=BS-?/$Y7*N 0-R<9=#F0*F'"Z'6BF6@?'8QYU.7(KH3E!L:J:'D 5AZ(]3;5N&-*FD)'K)##I!FU.2\NP8S;NAWME6*O#Z_E M'0Q('/Y*L/K_Z6?'A18]HH)%?L2628]JRAA>OPJ PWG=T-KN^F,ESU+]3U1)Z3 M)^\[V&S(H:D<$V_+?5SACH :.1E6W1WU.BG*GUF.G; \3)980Q20S8?JTY(*?S MV#?;JX4Q=_6@FS7_?$TFK_?9X9!WQ:[ B4-/A_7U7W?I_CWE1'V,M@T5CZ3> MGTL9R'6RQ)VQLP>%'25RFZ $76]U.8'AV/H*P#; 76R6K@.!CEKM^H$7<@8/ MF<\O.?3C?\3S)1C/]KWZY[57?WZ-R]_C=S#.T7_OL_(*@/0Z?DO*>)[\&TPO MBR.CV]P6=P/-50Q#_ EX>@6@?,Y!7$W.&GAPL+V!5I!M/T3O&L]N?[TE^4?= MAP<>(UXY]_9NBS=HTT7(-SIRE/ _(9 M8,Q&&ON.TIX+9&S[*C)"*[.%#Q6OJ?\Z6>6N@;=\ MW6GFTZ%\SC.?"JEZ,\EA(L5MXB?O[2VL;UQ^QXE/@[)U!N:5#5+A&61">$W\ M;UD.(-$IG0'PSF =RL4"=(+;\H,S<&UL,;.= B4^SH;&[2>"\ MD>8,\W!#GS8SGTHASP(J-?;8/#/YS2Z;@.E/A]59@*7$3EM@H!:RUW86T2PC ME1QN@8V(V4^3R@S.0BWE;[@-.&'<:OK38!69Z2]ZTVWO".YY8RYLVRVRSL+R MLMYXLXQMZ+CU-N1]]7Y3G#13_2'/5-+VFR6N'@OSWLTA]/PUTB><,&:](D,=VH5)!M-Y3 ]MYA6HD2 M=]V3K#,D4"H ).E[D5@(OJ'&U[8D"G]C>9 &* M<7H\0@^IK*FF&(P]A22,^]"XGBFS>_ 33:GXY]X$ZW]MTS9.70WS-9M4[98. MVF*@US^54.BM6\O6NP7W94$4&@HRQ? *FB99USI6K&Y::I=H;(U)ERML!(*C M"9\,;NSBH ;UHFZ6G$C 1T%6#]N3WZ6M.W\I8.TIJ)>,04?U/RC05QP B]N M)(67-8';L&C[*AD*7>_YTX=Z 1@HP JT;>E+716P7:_2Z6Z]U]"]5H2(_68[ MWI,C!;'B9-OT!(K <^A+XOEV-H,Q 8P.4?P M;G*A<"GYE"ORTJ6U<-;&HB- MG_MJQ,,R!_OPV' Q^\FV3@!#37X#%/"_N(7Q \B3;'HYGV<_P12NHQ_B#V(* MI!L(OSV$_QQ]&]V9!"&&S);0<3-?A%H1L!;Q. M<%Q#(I)TB=KJOH%\U:B[SZZ9'>&O3R0.RIQ0XD::A;N#0@ZII*TU:\0(5>)N M[Z$)(JBAC;NTY,26;6,3ZA8W() :KOCM&N4W7W[0#A7RE34CW/SD! SQ:@C? M:]<)O!;9/()WD"X!:FG[%,_!>(::W!;/KTD^?8AS-\#ZF:+ JHGD+\G MD\,&NG, AYM\F\V[V VETE98Z=X5K[TY?U=XJ&]QUV MCTZS]QA%/]_ -)F@NUT/BKHV-[Y^AW ?G%.<9//LI94/MB*WME=.1IJ95 X[ M&QNYU Z0VASELEERP/!R0@QWC9!.K5TN1I] UF^^5C@^.!>)!$ZDADDSXL'F,T>^ M;$M&&Q(,4338=G&.K<;,,:;MU-P)9,\=.L$\Q>DT*]!F1#HHX6!GC\5Q]C"= M+FW(RTRQ(,53[XL&"DQA0R=JXI-+!DSR$ZX5S.$LA/EO^1 ME!6+):F5;H#% ]VXL@_"D\GEW\D MQ?_&\V$)!N?^.19U,)TG9R(/"8*@]"=&$$JL3JHFWYN'ABZ,,-)EQ_^LQ!+Q M% N_M% M:Q I8EX& K*JMN'0R6H+,/;*3F?$T3KT<9+:PJRJ'M/%(%^7:/!$R_#CX37. M%_$$+,MD$L\/OO4YC]/):U* NC3?7LO7>+Z@:-$7ZE([8D1)$J6>%8Y&KL03 M1XYLHTN[0CS@K"G MCZ*,4V#$VGANC..BAVUS5"--HC0=GD<#.#:/-J)MDW*2W@&/NNFTD2MYRH:: M9IV,<-L%3;IEGK(WA,=XGKW%93Q-C(2;L\:A*B4P1K!L[;*>.W=&RM1; _IE MI(R,J9:XGB*+(F.Q><]E6WJ?HC,KQQ828MD\N_2;\GKQ\HP4,M$BJR(C%4>ZL0]<['@*IP<7Y5B<",.* [75_( ]=G)1M4*!=V. M= F9-)&MR*0Y>Y-V8MJ$LJ<-74!WG17P>Q^_SB26NULLEFDE3PC(#8!?+RE. M-004OARCS:,8\;:WR[XLLTPGTGN0 MY?$<74R?(&YOC6C)^XW:'-\VPJ46KF"79 [2C_A, M(L%[L,RS8I* = ):N3 KY.C"F ;V1I#-@AQI>7N7D2IA<:9=E9"1:&.D$P2: MU@89N1*JJZ7/5),H8SU;+6T*JXTT6TC35B2G;43+VORBN@'IC=3,GA2'.:MK MT8\1;KM9JUC4=&Y2P:42[%"5.Q^,-* T'"4+E\]--)ID9\Y-+-C2%1+,-I._S,OF19UMREHL5:I:C )(40!'S=L!D&ES-SMH_ ? C3XP>L+4+EJ=+Q&CDST7^KI853D89^#@%_<[Z&TW@XQ8T M#1>-.O P#$IT :'<*DY_Y.#?1A$8VP5+F]HM(W\NX:*6^46C#)R\@JW<7JU1 M!2EVP=>T -^H R?+8$D_'FR$V&].^X$JM\X8V5'+SC--%/03)#XEI]P6KI$B M[73T5#V?:$1)/R%5BVQ((>Y_9_,X.=O MGEB1C;'/#?3A8J1XFDIAJK#,KO3Z%-K5DY'EZB@:J+$B,W64Z277;%3S# Z24,]7FN,-C#@.+E:6C MR#EO(UC&EA=MO9EVX9K+%7M+EAH3UMAB'E/6DCYESUHHV'UKGL>:32J63AB> MK62\]"23==Y[@+19@OCJ_(W4!G;LL&D1JY3*.5(D5C"S[RG(3]DDWG4:P/02+,;S6ITB[GI5&JN2[3"197I,& MX6A\E?>C1I[MY&E:0 ]$N-B5C"U])6-V&KC,6]GNU$BA6E;R[*!_[FF;+MXL M5-*=G:%PL,N[4/K-NF>0B1[N$NU+/']?GDM,<%M K"LS\Z MVQNTC#Q;R-.*M.S;8(3;;G-6N2."1K!,9JVKR":%,MR.%M(UPN1ECZ<6[J[6(CV3;1T\C5M)C>R+=M M/;WT[G-T@KU)(*[I=;;Z:>3;['8]7:H$C%BIS'*@92K*")G2-FM7-& D3+5# MH,HNJ;'6G">R]),_=/+](YN7,?SJ=5S&LWF\,!)NOC+2Y]B8A>G$-8*E$JQG M*])QQTC91%I&QGUFLJ?H,4\C9]9S6?XQ:]I4)9AGZ>J_#W$Y>34B;N[O$NIR MW:*1+&4<[2JR'C9BYAUO:;AA:(1,,Y<#6]. RPB:>C8[D>S93"?BQZ2,YTGZ M.9N@'T:^A%ZF'$MWF,Y<(U8:L88<;Z'D%VL9&>NV\T ;:!D)TZR%>>X\\(RR MC)3IYK$M_7@*G7S/L7M YSH GZ? MSGMD?J!H^N9*E4]PT/7BH) R=T>S:%6M"')$#PN MR5R,7$6N.1J8]3@118HHC]?5C! -@FK@J:6R9.63GF!5%"[[ZT/3>EW#-)GQRWDSXABBX02?]Y^[_+I/PX1.1N'Y';='KAU)FXSA9O M68K8&,]6;SA&XZXHEF!Z';^A6H)6Z\"FG(ASR;)>77K*#S M#;SFI14$(69>[J@42#\;_56)HQY*;&$JCU>1!&T6R MH'>_@R,O@!(Z M=N%B)N0IBD5R)L(U6(&G*/<','QGSJ#M-JAH- M:,8=3$PECR-YQD(1*3)RSUX4!,KRV,,P=!/<3?*>3$$Z+1[B9*K$Q/-]%V/B M:G2*98*-WG%FB_G@#\M\\AH78#RKIPF8PTN?A< MY$^1*XVM3JH_"C'1BW*L M,9H0EH4)&S@SRYZD52X2U;8F63J>51^M,X',@>^29ZRE3+%DBN>C2^+14Y*3 M+K.$FK+++)"VE0" .YD57#^@!Y@B=&$T7>V,*3#A:F7/)\@4ST>7V;270E"* M%S93):Q[+T[1/H(;L/IY$/T\@K=-6/1CGKQ47_Z>3D%^67U\M83O MGOP%)]04JL##/%9#S?QZ\T76/&J$'J,8?J!X*LKU7;K+#^VGAU1*0UW4UQQM M66#.-&0?KOREA]K;<"LL-. '&D H@7<26 MNVO;K.M2I1G+(!BYK$LWQ5K'@#GY),0L&Q/N]"O=M 0E4R#MQZ3WKW/L0#ZC M;(8Z#/5R\)A:8-:5F^)4[)@7OM5N[3@3X1D<["$1%;CG$6?;FZH.M;G5JG+3 M(F/>@R95C4;@X.KOY3$DSU8H(D0V%L)U0EQB2 T6>_GK;N6H%-6!HKRU&V J MIEF5.,H+"_FRQ7SP;J5Q'>"E3T)@-)UOP9\@S8]"C)"4XXS-=(@BW"*)+Z_, M*>I<(]@!=OJJS5HM#)]:1R'3_>*P!80BG'2KS:;AA$UIFQ A*5'$)TB(MJ4K MMVQLMZU&B2[!GO>GLDO]G)#))J .4)0]] 14;,J+^7U7 '?L:-C%/8>E3,^O M>;9\>=WNKZZP>$W>MHO4N_1I^:-(IDF<)Z!X?HW+F^P^@V05RWEYEZ*D\7AV MO5K=*J%ZF%4$7ZXUQYC1YMY9HZXD-NPJ\P3-W(MZ_"6K#E&9O&T?.#J6YXA8 MP%[@CE&RK#$2LS#"M7^0RT2G.>?[N!UA\9P(G4_*B(S1]B@,MS&E*4QYXT%! MRRH9$48I"EH7VO"CND,.C7E)DB"[$UH6KN^6 -)%;+@&-L[6B)8+H\C>#1T% MF.FQA^JUK@]M6;,E:"$;X-JI]BXXDUC^2<5.IZ(604&3@UG2<2W64<6RV2'. M3\IGG4%.,U1Y64;066T>/8\!;CG36.'LIYAE)&)*JH-%.2$45Q_4&O*@S>V%##IO"7V[%2-04F] MQOB1V&TG5T2!!^Z );N]:#%G$_@618@JJ+(LW $QJ8PP*GFPH/GB6\\AR59Q MX:4%F/0*WVZS5T3QAL^X Y 0$X-MBR:6ZF[;TKXC VXA[98<5[I,6%5M6#[C M^AI%:S9.[1'>@W(\>XY_7;['R1S!.,OR(IZ#STD:IY,DGE\6!>@5O.%RKSVI M$F6CGL +LT#K!E?<9S^#O=^GV_-A="LD R4LZ?@-Y MW'>3Y<*FJ>NCIHR6Y=M?DRJG<9/,9G QDD[@*&FUNS/OFT^W;5SO[+X$"66P M14M 7'MKO7@DWOWA^QUB:58\HNG^9S*?OF^>_Q$E:H!>@B? (%E5Z%"Q6":,;,$-IQRN0PG^4Z%JC/CXF]#H8 M)5KZI/)/U'&ORQ):+PB(JN]V"#3Z0D!;UDTL+\?EGUO48M/205(HU_%Q^X8< M""%?T(GKGMB-DJ:D>C^QM3P5T$0 3_K)XF[9/5<: V0U"=HURI7%P>'N25HF MZ1*N]>!B\"8I)JO?P72WM#G>3ME]:?<4VU,K\O13(CP:*+]$=#Q;==UA@0[^ MN7:3*\!MA_,&Z,36:I_\10O4"NW;\*,@]W"M >!+ MI_6=P7;5EJ%6_%].RF6<)_%\M>SZG&<+S$*KW6$?Q_>UXOUZN5BB?. [6+UF M\K&7(KR=S<"DY8%==Z07XSR+MFS/][J#P6'G5Z(QM-7>$Y=J*'>%&OICPW$^ ML:I,D)8GE.6-I"0@5<:6I]%7$NR>&Y-20HD+R\?5VFJVIZN.7G)$$]GCF@IW M">14C56H&5,:$U91BJZH\'&K.B/"Q5[K# A7*QQXK(P+FY[RLF;/WAFS;BWU MF>0*9'H9UZ^5P$K(E,CU)Q>6[/2@-,_AN9;LU+ <'Q'47:;R?',]TFG;/92 MPZD6B;9P_T2?BCDP%MATMY26-QQL>,XH5N>NI-522O-'N)M69.>L9&++4TN5 M!+OGZ0PY"T[;";5/$*JCESS1Y+"F5RE<42?3H5*@HBLJ?!RKSHAPL=@Z \+3 M#D/+8C'"2,:UDPQ3A#TOW622+Y#I9AQ7=H9,KCNYD)TDD^)9'NE6V50))?N< MDC+ALC)9-H4"93TQX>)&]86C?\2K+^\\W).^: BZ.[@G0"S24U*]BN2SO5+] M1Z01[RQ3T2/?U8AS-BY!<299V7Y/=I<"56Q\[7X5]IEVVD7QWKXFKON/VB]YMGRY;5<4?)4 MP@&0J/MUUJOI6W]B#C,JM7ODPUR4U7TO_%,_!.*]HI;J9 MON6=-/N$- S5$Q:B <'H)"=8" IJ8SK)4N#2E:P.5XT2J:I2/M3=Y:"^>1* M7K4K4#WYL,PGKW%!2 V)7,R$^TO18SJ[,R%S;*'FP_;YL2%U=*&3W^+'!LO1 M;W^!?)(4Z$[?M]6M,>GT=O$VSSX J#:]XBKZ*UHD@ 4N0_9UA(X#+IQK1[#0 M-:.E&N_ZD2QR75C++"O!O"B:JZ***V@?IZCB < 'T7-*6;YP/\1H))@%7XJ1 M(])JU;8T!'"F&D$"+8YE16)9XT-1]?MFRXV#O6"VO["E41SM'6-HGS'MY"$W M1:S,AI2]!R&%^D[B]D86:^+)@0/C$27O4DBAOMNBP&-->PO UOVB3P_*8%=; M8&V";_F;\$ODOKW(3%04.1(X;%&78 6>!,)$.A/;MP-+'QX[*IB'*685P6,+ M%0M<*? +=&&VC[O-7ED>NU97.7+DV$;%G(B6M,IUEMGDKT?PMLXF/^392QXO M+I?E:Y8G_P;3RT6V3$N+PLQ>__ZY1EVT=Z?+UF&W&Y4YF;7)JC2A-F]"_\R3 ML@3I=3R?KU-KJ%#AZF-U!OA;_!?(*83^L,Q!2\C'.\CC M%[#)"S[DR81XF+!>\OJPWD"IS2'[;[_Y]B M:2A=K7%W%(Z0T$^1=S ,!46/8!$G*5T@A2'-;TG9=K@=B=_B7^@]*P5=VZJK MY<>/>/+76HL77:NKHUV#MXT:MAAM1]I-\IY,03HM'N(/=(YT]:V- M'9Q%-J M9W\*O!5IS:.QHNK0!#;0-1)*E]V6+I^2KN;2K.I ;\\3'U%MSZ+%>"3BJIJ] MJE2C2D^2:22=U=_LJC22B!N5.:7$(WE!Z*I"*DGP;CCR^M**V=&OGN@MN7[O!'R#J5#9_C$A6T0GJ"SY(M MB_G'(YAD+RE:WJY;-SR",D8-0F[C'"TRB"?!FZ$(:IWPU.+L,+D$%R^SI$3] M+/KUS@B""'.X>_?VKN.2S@;[$::!Y^EA5T#V/00"[IFGL0\(T"3%L'3'./CL,3!O(O)Y-5WQXPO0%O.62M,I3P0]3%:_7O M=(I, O7W(X?P[>L@"/#AQY!F:S; M!QN947A&&^,9:7$U*3O,A8.0KI$+LF<]#U M$\OK>U!BVM4/ &-Q'MYIGZ2D1-O(4&@TX/L8*V8DJ88D>ZQ]=ZV[C5A5$RMM MXAB3Q3"B%!"31%'[?9F>R+<&DW (5_>IT3;^V-2&'%;"&+3Y99S!P&E."M?NVVL M![I&1'R=@!UX1E*R)-5]7>6X1FI:>';/2(J/WP_=B"FP>^G2+1WHA-KZ9&(! MZ4M7Y];&.?K[(" 6O>+ U<3UA-M(3\X1$%R*R8A2$Z]T@=^A,^+CM$0-<4=S MV:+]"-Y!#OW<>'9&N$O=VC@6*3,9&.&*MXD.)HMD!"K.2CHB)]1 RT:42/WA M-GA,\8\J4J1X3=R55>N=(NY -MVR A3R-)N)*X:7:O"'#5" M$?=L:BX5"AJ\*,0W?3.P"W/ON--.1@*\LZJ6&V)V.,X.=Q),@>=BTL_"8>)9 M_A*JX'AX6_IP%&*6$3JPV:>B'99=E?51/Y _*V M3W]/IR#_G*3HEH"O*#[>W)K2MX%QK>%^/TH.!;=WL4TZO6R->D<[:QZW=C)35EW*?C4[;;M^-Q A= M(:%3]K9KOPFJ6;/RP0FVK4O&M?W4MAGRX*1(MTS&70]D9*F*+'NT;<.Z5R-9 M521+U[1\A,G8:M"T?'!2:^LA,9D%I?KY#DXPE$[/R$AX4V73G LW 6N!G:1I6:2*OL' M)P*Z4C,WM*2<&%$,=E*IF1W)04E*0=XYGS =(.*TOGTLD!B@DNB3B[K2JD95.BRW+B$T3#[]WRLS( MBFT $.Q.'&MTZX=R(,M=!6ITS\ )4>WX MFETC/W[)!FSYEXX702B'O& WADFX:7ZUQP ERF!I;,2KKGCI"GXPRP8C4I'> M#W>IML[7\2@'O[@UN#F1H+08Z=+WN((&(TUUI,DTBC&"54>P=(TT7"--::&+ MC^MB8DX.J1*.R"J9'A[BE$5@KG-&9R@4=?(7EI0+8@8H ]J::5NZ_\SROW9V MMC7E=H2[_D8TZ%V)7Y,N$W=HUI+B%4R_9-FT/>7.R,W-))@?: M26U+?([*2AC;QL75#6,CJSN>[3VPVV:[+&Y_O8&T #?+'-KG!VAMLL[WM(4H M]>S@)@(M!5PY:,17%QYL$@\>#QYV9C)/X(HP^YG"66SUN-=OLWS"JG)]% :T M$(,NW'73_*AIDB&RS+CC?>VHV=M?/WJ^A[0LW)FYIK&8T46TB1AK+(8P@A M MW)U=-)2MQWK.XRF LQ4D[_&/>8N@04*NB+;)SVH=!L/;NVJ!7BUFCM]ZR'FK M^#V(<-8/#R4CQ!7K\",>

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